PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	D'Assoro, AB; Busby, R; Acu, ID; Quatraro, C; Reinholz, MM; Farrugia, DJ; Schroeder, MA; Allen, C; Stivala, F; Galanis, E; Salisbury, JL				D'Assoro, A. B.; Busby, R.; Acu, I. D.; Quatraro, C.; Reinholz, M. M.; Farrugia, D. J.; Schroeder, M. A.; Allen, C.; Stivala, F.; Galanis, E.; Salisbury, J. L.			Impaired p53 function leads to centrosome amplification, acquired ER alpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts	ONCOGENE			English	Article						cell cycle; estrogen independence; mitosis; tumor progression	CELL-CYCLE PROGRESSION; CHROMOSOME INSTABILITY; DIFFERENTIAL REGULATION; GENOMIC INSTABILITY; ENDOCRINE THERAPY; ESTROGEN; RECEPTOR; EXPRESSION; MDM2; OVEREXPRESSION	In this study, we establish an MCF-7 xenograft model that mimics the progression of human breast carcinomas typified by loss of p53 integrity, development of centrosome amplification, acquired estrogen receptor (ER alpha) heterogeneity, overexpression of Mdm2 and metastatic spread from the primary tumor to distant organs. MCF-7 cells with abrogated p53 function (vMCF-7D(np53)) maintained nuclear ERa expression and normal centrosome characteristics in vitro. However, following mitogen stimulation, they developed centrosome amplification and a higher frequency of aberrant mitotic spindles. Centrosome amplification was dependent on cdk2/cyclin activity since treatment with the small molecule inhibitor SU9516 suppressed centriole reduplication. In contrast to the parental MCF-7 cells, when introduced into nude mice as xenografts, tumors derived from the vMCF-7(DNp53) cell line developed a strikingly altered phenotype characterized by increased tumor growth, higher tumor histopathology grade, centrosome amplification, loss of nuclear ERa expression, increased expression of Mdm-2 oncoprotein and resistance to the antiestrogen tamoxifen. Importantly, while MCF-7 xenografts did not develop distant metastases, primary tumors derived from vMCF-7(DNp53) cells gave rise to lung metastases. Taken together, these observations indicate that abrogation of p53 function and consequent deregulation of the G1/S cell cycle transition leads to centrosome amplification responsible for breast cancer progression.	[D'Assoro, A. B.; Busby, R.; Acu, I. D.; Quatraro, C.; Farrugia, D. J.; Salisbury, J. L.] Mayo Clin, Coll Med, Tumor Biol Program, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Allen, C.; Galanis, E.] Mayo Clin, Coll Med, Dept Mol Med, Rochester, MN 55905 USA; [Reinholz, M. M.] Mayo Clin, Coll Med, Dept Lab Med & Expt Pathol, Rochester, MN 55905 USA; [D'Assoro, A. B.] Univ Catania, Dept Biomed Sci, Catania, Italy	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Catania	Salisbury, JL (corresponding author), Mayo Clin, Coll Med, Tumor Biol Program, Dept Biochem & Mol Biol, Guggenheim 14,200 1st St SW, Rochester, MN 55905 USA.	Salisbury@mayo.edu	Farrugia, Daniel/E-4752-2015	Salisbury, Jeffrey/0000-0001-9257-4578	NCI NIH HHS [R01 CA072836-09, CA72836, R01 CA072836, BC022276] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; Bindels EMJ, 2002, ONCOGENE, V21, P8158, DOI 10.1038/sj.onc.1206012; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Calaf GM, 2006, INT J ONCOL, V28, P285; Caldon CE, 2006, J CELL BIOCHEM, V97, P261, DOI 10.1002/jcb.20690; Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; D'Assoro AB, 2001, MARC MALPIG SYMP SER, V7, P103; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Duensing A, 2007, ONCOGENE, V26, P6280, DOI 10.1038/sj.onc.1210456; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing A, 2006, CELL CYCLE, V5, P2899, DOI 10.4161/cc.5.24.3567; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1; Glass AG, 2007, JNCI-J NATL CANCER I, V99, P1152, DOI 10.1093/jnci/djm059; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Hasegawa K, 2006, CLIN CANCER RES, V12, P1868, DOI 10.1158/1078-0432.CCR-05-1803; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Ingle JN, 2004, CLIN CANCER RES, V10, p362S, DOI 10.1158/1078-0432.CCR-031200; Joe AK, 2005, ANTICANCER RES, V25, P273; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Knippschild U, 1996, ONCOGENE, V12, P1755; Kurokawa H, 2000, CANCER RES, V60, P5887; Kurokawa H, 2003, CLIN CANCER RES, V9, p511S; Kurokawa L, 2001, CLIN CANCER RES, V7, p4436S; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lewis JS, 2005, ONCOL RES, V15, P113, DOI 10.3727/096504005776367924; Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Mawson A, 2005, MOL CELL ENDOCRINOL, V229, P161, DOI 10.1016/j.mce.2004.08.002; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Medina D, 2003, CANCER RES, V63, P1067; Sluder G, 2000, CURR TOP DEV BIOL, V49, P267; Span PN, 2003, ONCOGENE, V22, P4898, DOI 10.1038/sj.onc.1206818; Suizu F, 2006, MOL CELL BIOL, V26, P1463, DOI 10.1128/MCB.26.4.1463-1479.2006; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Turbin DA, 2006, MODERN PATHOL, V19, P69, DOI 10.1038/modpathol.3800484	49	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3901	3911		10.1038/onc.2008.18	http://dx.doi.org/10.1038/onc.2008.18			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264135	Green Accepted			2022-12-28	WOS:000257089000002
J	Nittka, S; Bohm, C; Zentgraf, H; Neumaier, M				Nittka, S.; Boehm, C.; Zentgraf, H.; Neumaier, M.			The CEACAM1-mediated apoptosis pathway is activated by CEA and triggers dual cleavage of CEACAM1	ONCOGENE			English	Article						CEACAM1; apoptosis; CEA; caspases	CELL-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN FAMILY; BILIARY GLYCOPROTEIN CD66A; C-CAM; COLORECTAL CARCINOMAS; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; HUMAN COLON; EXPRESSION; MEMBERS	Marked reduction in apoptosis is a hallmark of early colon tumour growth and the vast majority of these tumours exhibit a loss of expression of the glycoprotein carcinoembryonic-antigen-related cell adhesion molecule 1 (CEACAM1). We recently reported that the CEACAM1 functions as a mediator of apoptosis implicating this cell surface protein in early tumour development. However, the mechanistic involvement of CEACAM1 in cell death pathways is unclear. Here, we show that apoptosis triggers cleavage of the long form of CEACAM1 (CEACAM1-4L) at intracellular and extracellular sites in Jurkat cells and HEK293 cells. Signalling through CEACAM1 leads to caspase activation including caspase-1 and -3 and also involves non-caspase proteases. Moreover, we provide evidence that the naturally occurring CEACAM family member CEA is an inducer of CEACAM1-mediated apoptosis in HT29 colon cancer cells, an effect that depends on the abundance of CEACAM1 on the cell surface. Together, our results demonstrate that the CEACAM1-dependent cell death pathway involves dual cleavage of CEACAM1 and caspase activation and can be activated by CEA.	[Nittka, S.; Neumaier, M.] Univ Heidelberg, Inst Clin Chem, Univ Hosp Mannheim, D-68167 Mannheim, Germany; [Boehm, C.; Zentgraf, H.] German Canc Res Ctr, Dept Appl Tumor Virol, D-6900 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Neumaier, M (corresponding author), Univ Heidelberg, Inst Clin Chem, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	michael.neumaier@ikc.ma.uni-heidelberg.de						BARANOV V, 1994, CANCER RES, V54, P3305; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BRUMMER J, 1995, ONCOGENE, V11, P1649; Charbonneau J, 1999, CELL ADHES COMMUN, V7, P233, DOI 10.3109/15419069909010805; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; Frangsmyr L, 1999, TUMOR BIOL, V20, P277, DOI 10.1159/000030075; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; Hilbi H, 1998, J BIOL CHEM, V273, P32895, DOI 10.1074/jbc.273.49.32895; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; Houde C, 2003, J BIOL CHEM, V278, P16929, DOI 10.1074/jbc.M301842200; Huang J, 1999, J CELL SCI, V112, P4193; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kunath T, 1995, ONCOGENE, V11, P2375; Liu KB, 2003, J IMMUNOL, V170, P6329, DOI 10.4049/jimmunol.170.12.6329; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; PAXTON RJ, 1987, P NATL ACAD SCI USA, V84, P920, DOI 10.1073/pnas.84.4.920; RONCUCCI L, 1991, HUM PATHOL, V22, P287, DOI 10.1016/0046-8177(91)90163-J; Singer BB, 2000, CANCER RES, V60, P1236; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Watt SM, 2001, BLOOD, V98, P1469, DOI 10.1182/blood.V98.5.1469	29	23	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3721	3728		10.1038/sj.onc.1211033	http://dx.doi.org/10.1038/sj.onc.1211033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18278069				2022-12-28	WOS:000256659300009
J	Goda, AE; Yoshida, T; Horinaka, M; Yasuda, T; Shiraishi, T; Wakada, M; Sakai, T				Goda, A. E.; Yoshida, T.; Horinaka, M.; Yasuda, T.; Shiraishi, T.; Wakada, M.; Sakai, T.			Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole	ONCOGENE			English	Article						dipyridamole; TRAIL; DR5; survivin; D-type cyclins; cdk6	APOPTOSIS-INDUCING LIGAND; DEATH RECEPTOR 5/TRAIL-R2; METHOTREXATE CYTOTOXICITY; IN-VITRO; SURVIVIN; TUMOR; PROLIFERATION; ACTIVATION; INHIBITION; CASPASE-3	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has emerged as an attractive cytokine that selectively targets cancer cells, however its efficacy has been challenged by a number of resistance mechanisms. Therefore, the current study investigated the potential of dipyridamole to enhance TRAIL efficacy and the probable underlying mechanisms. Dipyridamole dramatically sensitized p53-mutant human cancer cell lines: SW480, MG63 and DU145, to the antitumor activity of TRAIL, as evidenced by enabling TRAIL to efficiently cleave initiator and executioner caspases. Although dipyridamole upregulated both DR4 and DR5 and increased their cell surface expression, RNA interference revealed a preferential dependence on DR5. Moreover, dipyridamole inhibited survivin expression and its important consequences were confirmed by small interfering RNA. Mechanistically, dipyridamole induced transcriptional shutdown of survivin expression accompanying G(1) arrest that was characterized by downregulation of D-type cyclins and cdk6. In addition, a transcriptional mechanism powered by CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) induction was responsible for DR5 upregulation by dipyridamole. Importantly, dipyridamole-induced enhancement of TRAIL efficacy and alterations of protein expression were independent of either protein kinase A or protein kinase G. In conclusion, findings of the present study described novel mechanisms of dipyridamole action and highlighted its promising use as a potential enhancer of TRAIL efficacy.	[Goda, A. E.; Yoshida, T.; Horinaka, M.; Yasuda, T.; Wakada, M.; Sakai, T.] Kyoto Prefectural Univ Med, Dept Mol Targeting Canc Prevent, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan; [Goda, A. E.] Tanta Univ, Dept Pharmacol & Toxicol, Fac Pharm, Tanta, Egypt; [Yasuda, T.; Shiraishi, T.] Kyoto Prefectural Univ Med, Dept Urol, Grad Sch Med Sci, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Egyptian Knowledge Bank (EKB); Tanta University; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Dept Mol Targeting Canc Prevent, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp	Goda, Ahmed/AAA-4688-2020	Goda, Ahmed/0000-0001-8200-6104				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Azuhata T, 2006, J PEDIATR SURG, V41, P1431, DOI 10.1016/j.jpedsurg.2006.04.020; Carlo-Stella C, 2007, CLIN CANCER RES, V13, P2313, DOI 10.1158/1078-0432.CCR-06-2774; CLARKE WR, 1994, PULM PHARMACOL, V7, P81, DOI 10.1006/pulp.1994.1009; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Hung KY, 2001, KIDNEY INT, V60, P872, DOI 10.1046/j.1523-1755.2001.060003872.x; Kappler M, 2004, CANCER GENE THER, V11, P186, DOI 10.1038/sj.cgt.7700677; Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200; KENNEDY DG, 1986, BIOCHEM PHARMACOL, V35, P3053, DOI 10.1016/0006-2952(86)90385-0; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Ren YG, 2004, MOL BIOL CELL, V15, P5064, DOI 10.1091/mbc.e04-03-0184; Rodrigues M, 2004, BRAZ J MED BIOL RES, V37, P591, DOI 10.1590/S0100-879X2004000400017; Saito S, 2003, BIOCHEM BIOPH RES CO, V311, P17, DOI 10.1016/j.bbrc.2003.09.161; SALZMAN EW, 1972, ANN NY ACAD SCI, V201, P61, DOI 10.1111/j.1749-6632.1972.tb16287.x; SATO S, 1993, ANTI-CANCER DRUG DES, V8, P289; Shiraishi T, 2005, CANCER RES, V65, P6364, DOI 10.1158/0008-5472.CAN-05-0312; Thompson KL, 2003, TOXICOL SCI, V74, P260, DOI 10.1093/toxsci/kfg113; Van Geelen CMM, 2004, DRUG RESIST UPDATE, V7, P345, DOI 10.1016/j.drup.2004.11.002; VANMOUWERIK TJ, 1987, BIOCHEM PHARMACOL, V36, P809, DOI 10.1016/0006-2952(87)90168-7; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yoshida T, 2005, CANCER RES, V65, P5662, DOI 10.1158/0008-5472.CAN-05-0693; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Yoshida T, 2007, MOL CANCER RES, V5, P615, DOI 10.1158/1541-7786.MCR-06-0045; Zhang M, 2006, J EXP CLIN CANC RES, V25, P391; Zhuplatov SB, 2006, BASIC CLIN PHARMACOL, V99, P431, DOI 10.1111/j.1742-7843.2006.pto_516.x	35	22	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3435	3445		10.1038/sj.onc.1211008	http://dx.doi.org/10.1038/sj.onc.1211008			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193086				2022-12-28	WOS:000256309900008
J	Achour, M; Jacq, X; Ronde, P; Alhosin, M; Charlot, C; Chataigneau, T; Jeanblanc, M; Macaluso, M; Giordano, A; Hughes, AD; Schini-Kerth, VB; Bronner, C				Achour, M.; Jacq, X.; Ronde, P.; Alhosin, M.; Charlot, C.; Chataigneau, T.; Jeanblanc, M.; Macaluso, M.; Giordano, A.; Hughes, A. D.; Schini-Kerth, V. B.; Bronner, C.			The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression	ONCOGENE			English	Article						ICBP90; DNMT1; methylation; UHRF1; vascular endothelial growth factor; yeast two-hybrid system	UBIQUITIN LIGASE ACTIVITY; ESTROGEN-RECEPTOR-ALPHA; CCAAT-BINDING-PROTEIN; GROWTH-FACTOR GENE; DNA METHYLTRANSFERASE-1; BREAST-CANCER; CELL-CYCLE; DOWN-REGULATION; DNA-METHYLTRANSFERASE-1 DNMT1; G1/S TRANSITION	Inverted CCAAT box-binding protein of 90 kDa (ICBP90) is over-expressed in several types of cancer, including breast, prostate and lung cancers. In search for proteins that interact with the set and ring-associated (SRA) domain of ICBP90, we used the two-hybrid system and screened a placental cDNA library. Several clones coding for a new domain of DNMT1 were found. The interaction, between the ICBP90 SRA domain and the DNMT1 domain, has been confirmed with purified proteins by glutathione-S-transferase pull-down experiments. We checked whether ICBP90 and DNMT1 are present in the same macromolecular complexes in Jurkat cells and immortalized human vascular smooth muscle cells (HVTs-SM1). Coimmunoprecipitation experiments showed that ICBP90 and DNMT1 are present in the same molecular complex, which was further confirmed by co-localization experiments as assessed by immunocytochemistry. Downregulation of ICBP90 and DNMT1 decreased VEGF gene expression, a major pro-angiogenic factor, whereas those of p16(INK4A) gene and RB1 gene were significantly enhanced. Together, these results indicate that DNMT1 and ICBP90 are involved in VEGF gene expression, possibly via an interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 and an upregulation of p16(INK4A). They further suggest a new role of ICBP90 in the relationship between histone ubiquitination and DNA methylation in the context of tumoral angiogenesis and tumour suppressor genes silencing.	[Achour, M.; Ronde, P.; Alhosin, M.; Charlot, C.; Chataigneau, T.; Jeanblanc, M.; Schini-Kerth, V. B.; Bronner, C.] Univ Louis Pasteur Strasbourg 1, CNRS, UMR 7175, Dept Pharmacol & Pharmacochim,Fac Pharm,Inst Gilb, F-67401 Illkirch Graffenstaden, France; [Jacq, X.] Hybrigen, Paris, France; [Macaluso, M.; Giordano, A.] Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Macaluso, M.; Giordano, A.] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; [Hughes, A. D.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Natl Heart & Lung Inst, Clin Pharmacol, London SW7 2AZ, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; Imperial College London	Bronner, C (corresponding author), Univ Louis Pasteur Strasbourg 1, CNRS, UMR 7175, Dept Pharmacol & Pharmacochim,Fac Pharm,Inst Gilb, 74 Route Rhin,BP 60024, F-67401 Illkirch Graffenstaden, France.	Christian.Bronner@pharma.u-strasbg.fr	高, 雨莉/HGU-8187-2022; Hughes, Alun D/C-6636-2009; Alhosin, Mahmoud/H-8101-2017; Hughes, Alun David/N-3781-2013; Alhosin, Mahmoud/AAD-5782-2020; Bronner, Christian/R-8488-2016; Giordano, Antonio/F-1927-2010	Hughes, Alun David/0000-0001-5432-5271; Alhosin, Mahmoud/0000-0003-2147-1445; Bronner, Christian/0000-0002-3101-9279; Giordano, Antonio/0000-0002-5959-016X; ACHOUR, Mayada/0000-0003-1044-824X				Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003; Caracciolo V, 2006, ONCOGENE, V25, P5294, DOI 10.1038/sj.onc.1209681; Chen Dao-Rong, 2006, Ai Zheng, V25, P308; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Crnogorac-Jurcevic T, 2005, GASTROENTEROLOGY, V129, P1454, DOI 10.1053/j.gastro.2005.08.012; Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gabellini C, 2006, ONCOGENE, V25, P5326, DOI 10.1038/sj.onc.1209631; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Hopfner R, 2002, ANTICANCER RES, V22, P3165; Hopfner R, 2000, CANCER RES, V60, P121; Hsieh JK, 2000, ARTERIOSCL THROM VAS, V20, P973, DOI 10.1161/01.ATV.20.4.973; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878; Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194; Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lorenzato M, 2005, HUM PATHOL, V36, P1101, DOI 10.1016/j.humpath.2005.07.016; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Macaluso M, 2007, CANCER RES, V67, P7731, DOI 10.1158/0008-5472.CAN-07-1476; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; Miki K, 2000, ONCOL RES, V12, P335, DOI 10.3727/096504001108747783; Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200; Mortusewicz O, 2005, P NATL ACAD SCI USA, V102, P8905, DOI 10.1073/pnas.0501034102; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Naumann K, 2005, EMBO J, V24, P1418, DOI 10.1038/sj.emboj.7600604; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Oak MH, 2005, J NUTR BIOCHEM, V16, P1, DOI 10.1016/j.jnutbio.2004.09.004; Oba-Shinjo SM, 2005, MOL BRAIN RES, V140, P25, DOI 10.1016/j.molbrainres.2005.06.015; Ohta T, 2004, ONCOGENE, V23, P2079, DOI 10.1038/sj.onc.1207371; Papait R, 2007, MOL BIOL CELL, V18, P1098, DOI 10.1091/mbc.E06-09-0874; Peng DF, 2006, CARCINOGENESIS, V27, P1160, DOI 10.1093/carcin/bgi361; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; Schaaf GJ, 2005, FASEB J, V19, P404, DOI 10.1096/fj.04-2104fje; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631; Uemura T, 2000, CELL STRUCT FUNCT, V25, P149, DOI 10.1247/csf.25.149; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Vallbohmer D, 2006, CLIN LUNG CANCER, V8, P39, DOI 10.3816/CLC.2006.n.031; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743	53	128	134	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2187	2197		10.1038/sj.onc.1210855	http://dx.doi.org/10.1038/sj.onc.1210855			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17934516				2022-12-28	WOS:000254621300009
J	Llobet, D; Eritja, N; Encinas, M; Llecha, N; Yeramian, A; Pallares, J; Sorolla, A; Gonzalez-Tallada, FJ; Matias-Guiu, X; Dolcet, X				Llobet, D.; Eritja, N.; Encinas, M.; Llecha, N.; Yeramian, A.; Pallares, J.; Sorolla, A.; Gonzalez-Tallada, F. J.; Matias-Guiu, X.; Dolcet, X.			CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells	ONCOGENE			English	Article						endometrial carcinoma; apoptosis; death receptor; casein kinase 2; FLIP	PROTEIN-KINASE CK2; LIGAND-MEDIATED APOPTOSIS; C-FLIP; CANCER-CELLS; DEATH RECEPTORS; DOWN-REGULATION; TUMOR-CELLS; SIGNALING COMPLEX; MOLECULAR-CLONING; PROSTATE-CANCER	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has emerged as a promising antineoplastic agent because of its ability to selectively kill tumoral cells. However, some cancer cells are resistant to TRAIL-induced apoptosis. We have previously demonstrated that in endometrial carcinoma cells such resistance is caused by elevated FLICE-inhibitory protein (FLIP) levels. The present study focuses on the mechanisms by which FLIP could be modulated to sensitize endometrial carcinoma cells to TRAIL-induced apoptosis. We find that inhibition of casein kinase (CK2) sensitizes endometrial carcinoma cells to TRAIL-and Fas-induced apoptosis. CK2 inhibition correlates with a reduction of FLIP protein, suggesting that CK2 regulates resistance to TRAIL and Fas by controlling FLIP levels. FLIP downregulation correlates with a reduction of mRNA and is prevented by addition of the MG-132, suggesting that CK2 inhibition results in a proteasome-mediated degradation of FLIP. Consistently, forced expression of FLIP restores resistance to TRAIL and Fas. Moreover, knockdown of either FADD or caspase-8 abrogates apoptosis triggered by inhibition of CK2, indicating that CK2 sensitization requires formation of functional DISC. Finally, because of the possible role of both TRAIL and CK2 in cancer therapy, we demonstrate that CK2 inhibition sensitizes primary endometrial carcinoma explants to TRAIL apoptosis. In conclusion, we demonstrate that CK2 regulates endometrial carcinoma cell sensitivity to TRAIL and Fas by regulating FLIP levels.	[Llobet, D.; Eritja, N.; Llecha, N.; Yeramian, A.; Pallares, J.; Sorolla, A.; Matias-Guiu, X.; Dolcet, X.] IRBLleida, Inst Recerca Biomed Lleida, Oncol Pathol Grp, Hosp Univ Arnau de Vilanova,Lab Recerca Biomed, Lleida 25198, Spain; [Encinas, M.] IRBLleida, Inst Recerca Biomed Lleida, Cell Signaling & Apoptosis Grp, Lleida 25198, Spain; [Gonzalez-Tallada, F. J.] IRBLleida, Inst Recerca Biomed Lleida, Dept Gynecol, Lleida 25198, Spain	Institut de Recerca Biomedica - IRB Lleida; University Hospital Arnau de Vilanova; Institut de Recerca Biomedica - IRB Lleida; Institut de Recerca Biomedica - IRB Lleida	Dolcet, X (corresponding author), IRBLleida, Inst Recerca Biomed Lleida, Oncol Pathol Grp, Hosp Univ Arnau de Vilanova,Lab Recerca Biomed, Av Rovira Roure 80, Lleida 25198, Spain.	dolcet@cmb.udl.es	Encinas, Mario/B-5600-2009; Eritja, Nuria/M-1347-2015; yeramian, andree/B-5936-2009; Llobet-Navas, David/AAT-4676-2021; matias-guiu, xavier/C-3039-2009; Llobet-Navas, David/B-5660-2009; Dolcet, Xavi/B-5665-2009; Pallares, Judit/A-6635-2010; Sorolla Bardaji, Anabel/C-6614-2011; Eritja Sanchez, Nuria/C-4465-2011; Sorolla, Anabel/E-2546-2012; Yeramian, Andree/P-6724-2019; Eritja, Núria/S-3700-2019	Encinas, Mario/0000-0003-3509-7431; Eritja, Nuria/0000-0003-1018-6649; yeramian, andree/0000-0002-9569-6316; matias-guiu, xavier/0000-0002-7201-6605; Llobet-Navas, David/0000-0003-1443-7003; Dolcet, Xavi/0000-0003-1921-0449; Sorolla, Anabel/0000-0001-8238-8763; Eritja, Núria/0000-0003-2131-7915				Ahmad KA, 2005, ANTI-CANCER DRUG, V16, P1037, DOI 10.1097/00001813-200511000-00001; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Dolcet X, 2005, LAB INVEST, V85, P885, DOI 10.1038/labinvest.3700286; Dolcet X, 2006, J BIOL CHEM, V281, P22118, DOI 10.1074/jbc.M601350200; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Dutton A, 2004, P NATL ACAD SCI USA, V101, P6611, DOI 10.1073/pnas.0400765101; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Izeradjene K, 2005, ONCOGENE, V24, P2050, DOI 10.1038/sj.onc.1208397; Izeradjene K, 2004, CLIN CANCER RES, V10, P6650, DOI 10.1158/1078-0432.CCR-04-0576; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Korkolopoulou P, 2004, UROLOGY, V63, P1198, DOI 10.1016/j.urology.2004.01.007; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee SH, 2003, APMIS, V111, P309, DOI 10.1034/j.1600-0463.2003.1110203.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Liu X, 2006, CANCER RES, V66, P11115, DOI 10.1158/0008-5472.CAN-06-2471; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Palacios C, 2006, CANCER RES, V66, P8858, DOI 10.1158/0008-5472.CAN-06-0808; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Poukkula M, 2005, J BIOL CHEM, V280, P27345, DOI 10.1074/jbc.M504019200; Ravi R, 2002, CANCER RES, V62, P4180; Rippo MR, 2004, ONCOGENE, V23, P7753, DOI 10.1038/sj.onc.1208051; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; Son YG, 2007, CANCER RES, V67, P8274, DOI 10.1158/0008-5472.CAN-07-0407; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang GX, 2006, CANCER RES, V66, P2242, DOI 10.1158/0008-5472.CAN-05-2772; Wang GX, 2005, MOL CELL BIOCHEM, V274, P77, DOI 10.1007/s11010-005-3077-1; Wang GX, 2005, MOL CELL BIOCHEM, V274, P201, DOI 10.1007/s11010-005-2952-0; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498	52	43	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2513	2524		10.1038/sj.onc.1210924	http://dx.doi.org/10.1038/sj.onc.1210924			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982483				2022-12-28	WOS:000255057000001
J	Wang, Q; Sun, Z; Yang, HS				Wang, Q.; Sun, Z.; Yang, H-S			Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells	ONCOGENE			English	Article						Pdcd4; invasion; beta-catenin; AP-1; E-cadherin; stably knockdown	E-CADHERIN EXPRESSION; INITIATION-FACTOR 4A; RECEPTOR U-PAR; NF-KAPPA-B; TRANSFORMATION SUPPRESSOR; AP-1 TRANSACTIVATION; CANCER; CARCINOGENESIS; TUMORIGENESIS; TRANSLATION	Programmed cell death 4 (Pdcd4) is a tumor suppressor that inhibits neoplastic transformation and tumor invasion. Tissue microarray analysis showed that Pdcd4 expression is downregulated in colon adenocarcinoma and carcinoma relative to adjacent normal tissues. To address the issue of whether reduced Pdcd4 expression is sufficient to promote tumor progression, we knocked down Pdcd4 expression in colon tumor HT29 cells using pdcd4 short hairpin RNA (shRNA). Pdcd4 knockdown results in a. broblast-like transition, while the control cells (expressing LacZ shRNA) remain as clumped similar to the parental cells. In addition, expression of pdcd4 shRNA in HT29 cells promotes invasion. In an effort to characterize the molecular mechanism underlying these observations, we discovered that knockdown of Pdcd4 results in reduction of E-cadherin expression, and accumulation of active beta-catenin in the nucleus. The active beta-catenin binds with T-cell factor 4 (Tcf4) and activates beta-catenin/Tcf-dependent transcription. Furthermore, Pdcd4 knockdown dramatically increases AP-1-dependent transcription. Thus, the mechanism by which reduced Pdcd4 expression promotes invasion appears to involve the activation of beta-catenin/Tcf and AP-1-dependent transcription.	[Wang, Q.; Sun, Z.; Yang, H-S] Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY 40536 USA; [Yang, H-S] Univ Kentucky, Coll Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Yang, HS (corresponding author), Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY 40536 USA.	hyang3@uky.edu	Yang, Hsin-Sheng/AAF-6793-2020; Yang, Hsin-Sheng/A-6419-2008	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036				Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bonome T, 2005, CANCER RES, V65, P10602, DOI 10.1158/0008-5472.CAN-05-2240; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gao F, 2007, ONCOL REP, V17, P123; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; Kemler R, 1992, Semin Cell Biol, V3, P149; KINSELLA AR, 1994, CLIN EXP METASTAS, V12, P335, DOI 10.1007/BF01753841; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Laufs S, 2006, CELL CYCLE, V5, P1760; Lee S, 2006, ONCOL REP, V16, P747; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Matsuhashi S, 2007, EXP DERMATOL, V16, P179, DOI 10.1111/j.1600-0625.2006.00531.x; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Portereiko MF, 2006, PLANT CELL, V18, P1862, DOI 10.1105/tpc.106.040824; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VANAKEN J, 1993, PATHOL RES PRACT, V189, P975; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634	33	132	138	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1527	1535		10.1038/sj.onc.1210793	http://dx.doi.org/10.1038/sj.onc.1210793			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828298				2022-12-28	WOS:000253815800004
J	Engelmann, A; Speidel, D; Bornkamm, GW; Deppert, W; Stocking, C				Engelmann, A.; Speidel, D.; Bornkamm, G. W.; Deppert, W.; Stocking, C.			Gadd45 beta is a pro-survival factor associated with stress-resistant tumors	ONCOGENE			English	Article						B-cell lymphoma; MYC; p53; Bcl-x(L); retroviral insertional mutagenesis; stress-resistance	NF-KAPPA-B; MYC TRANSGENIC MICE; CELL-DEATH; INDUCED APOPTOSIS; INSERTIONAL MUTAGENESIS; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; GROWTH-ARREST; IDENTIFICATION; FIBROBLASTS	Tumors that acquire resistance against death stimuli constitute a severe problem in the context of cancer therapy. To determine genetic alterations that favor the development of stress-resistant tumors in vivo, we took advantage of polyclonal tumors generated after retroviral infection of newborn E lambda-MYC mice, in which the retroviral integration acts as a mutagen to enhance tumor progression. Tumor cells were cultivated ex vivo and exposed to gamma-irradiation prior to their transplantation into syngenic recipients, thereby providing a strong selective pressure for pro-survival mutations. Secondary tumors developing from stress-resistant tumor stem cells were analysed for retroviral integration sites to reveal candidate genes whose dysregulation confer survival. In addition to the gene encoding the antiapoptotic Bcl-x(L) protein, we identified the gadd45b locus to be a novel common integration site in these tumors, leading to enhanced expression. In accord with a thus far undocumented role of Gadd45 beta in tumorigenesis, we showed that NIH3T3 cells overexpressing Gadd45 beta form tumors in NOD/SCID mice. Interestingly and differently to other known 'classical' antiapoptotic factors, high Gadd45b levels did not protect against MYC-, UV- or gamma-irradiation-induced apoptosis, but conferred a strong and specific survival advantage to serum withdrawal.	[Engelmann, A.; Speidel, D.; Deppert, W.; Stocking, C.] Heinrich Pette Inst, D-20206 Hamburg, Germany; [Bornkamm, G. W.] GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, Munich, Germany	Heinrich Pette Institute; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Stocking, C (corresponding author), Heinrich Pette Inst, POB 201652, D-20206 Hamburg, Germany.	stocking@hpi.uni-hamburg.de	Speidel, Daniel/I-4244-2012					Baxter EW, 1996, J VIROL, V70, P2095, DOI 10.1128/JVI.70.4.2095-2100.1996; Bernier J, 2004, NAT REV CANCER, V4, P737, DOI 10.1038/nrc1451; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Das S, 2005, J BIOL CHEM, V280, P23748, DOI 10.1074/jbc.M412837200; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Gupta M, 2005, ONCOGENE, V24, P7170, DOI 10.1038/sj.onc.1208847; Gupta M, 2006, J BIOL CHEM, V281, P17552, DOI 10.1074/jbc.M600950200; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Kues Wilfried A., 2002, Cloning and Stem Cells, V4, P231, DOI 10.1089/15362300260339511; Leicht M, 2003, MOL CELL BIOCHEM, V251, P119, DOI 10.1023/A:1025446302759; Liebermann DA, 2002, ONCOGENE, V21, P3391, DOI 10.1038/sj.onc.1205312; Lindsten T, 2003, J NEUROSCI, V23, P11112; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Paddenberg R, 2001, EUR J CELL BIOL, V80, P366, DOI 10.1078/0171-9335-00166; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Simm A, 1997, J CELL SCI, V110, P819; Speidel D, 2006, ONCOGENE, V25, P940, DOI 10.1038/sj.onc.1209126; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101	38	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1429	1438		10.1038/sj.onc.1210772	http://dx.doi.org/10.1038/sj.onc.1210772			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17891184				2022-12-28	WOS:000253548200010
J	Wendt, MK; Cooper, AN; Dwinell, MB				Wendt, M. K.; Cooper, A. N.; Dwinell, M. B.			Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells	ONCOGENE			English	Article						chemokine; DNA hypermethylation; cancer; metastasis; CXCR4	CHEMOKINE RECEPTOR CXCR4; BREAST-CANCER; FACTOR-I; DOWN-REGULATION; HOST-DEFENSE; TUMOR-GROWTH; EXPRESSION; GENE; HYPERMETHYLATION; ACTIVATION	Expression of the chemokine receptor CXCR4 has been linked with increased metastasis and decreased clinical prognosis in breast cancer. The current paradigm dictates that CXCR4 fosters carcinoma cell metastasis along a chemotactic gradient to organs expressing the ligand CXCL12. The present study asked if alterations in autocrine CXCR4 signaling via dysregulation of CXCL12 in mammary carcinoma cells modulated their metastatic potential. While CXCR4 was consistently detected, expression of CXCL12 characteristic of human mammary epithelium was silenced by promoter hypermethylation in breast cancer cell lines and primary mammary tumors. Stable re-expression of functional CXCL12 in ligand null cells increased orthotopic primary tumor growth in the mammary fat-pad model of tumorigenesis. Those data parallel increased carcinoma cell proliferation measured in vitro with little-to-no-impact on apoptosis. Moreover, re-expression of autocrine CXCL12 markedly reduced metastatic lung invasion assessed using in vivo bioluminescence imaging following tail vein injection. Consistent with those data, decreased metastasis reflected diminished intracellular calcium signaling and chemotactic migration in response to exogenous CXCL12 independent of changes in CXCR4 express ion. Together these data suggest that an elevated migratory signaling response to ectopic CXCL12 contributes to the metastatic potential of CXCR4-expressing mammary carcinoma cells, subsequent to epigenetic silencing of autocrine CXCL12.	[Wendt, M. K.; Cooper, A. N.; Dwinell, M. B.] Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Dwinell, MB (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mdwinell@mcw.edu		Wendt, Mike/0000-0002-3665-7413				Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003; Baylin SB, 2005, COLD SH Q B, V70, P427, DOI 10.1101/sqb.2005.70.010; Brauweiler A, 2007, J IMMUNOL, V178, P3353, DOI 10.4049/jimmunol.178.6.3353; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Dewan MZ, 2006, BIOMED PHARMACOTHER, V60, P273, DOI 10.1016/j.biopha.2006.06.004; Ellison G, 2002, J CLIN PATHOL-MOL PA, V55, P294, DOI 10.1136/mp.55.5.294; Garcia-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hesselgesser J, 1998, J IMMUNOL, V160, P877; Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026; Kimura R, 2003, GENES IMMUN, V4, P356, DOI 10.1038/sj.gene.6363978; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Moyer RA, 2007, LAB INVEST, V87, P807, DOI 10.1038/labinvest.3700595; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, P NATL ACAD SCI USA, V93, P14726, DOI 10.1073/pnas.93.25.14726; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8; Schrader AJ, 2002, BRIT J CANCER, V86, P1250, DOI 10.1038/sj.bjc.6600221; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Smith JM, 2005, AM J PHYSIOL-GASTR L, V288, pG316, DOI 10.1152/ajpgi.00208.2004; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Ueda Y, 2006, CANCER RES, V66, P5665, DOI 10.1158/0008-5472.CAN-05-3579; Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	34	94	97	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1461	1471		10.1038/sj.onc.1210751	http://dx.doi.org/10.1038/sj.onc.1210751			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724466				2022-12-28	WOS:000253548200013
J	Kurban, G; Duplan, E; Ramlal, N; Hudon, V; Sado, Y; Ninomiya, Y; Pause, A				Kurban, G.; Duplan, E.; Ramlal, N.; Hudon, V.; Sado, Y.; Ninomiya, Y.; Pause, A.			Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2	ONCOGENE			English	Article						VHL; collagen IV; extracellular matrix; renal cell carcinoma	FIBRONECTIN MATRIX; REGULATE HIF; TUMORIGENESIS; ANGIOGENESIS; INHIBITION; THERAPY; DISEASE; COMPLEX; GENE; IV	Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene predisposes to vascular tumor formation in several organs. VHL regulates two evolutionary conserved pathways: the targeting of hydroxylated hypoxia-inducible factor-alpha (HIF-alpha) for proteasomal degradation and the remodeling of extracellular matrix (ECM). The biochemical mechanisms of the ECM assembly pathway remain poorly defined. Here, we provide evidence supporting a biochemical role for VHL in ECM assembly. We show that VHL directly binds to the collagen IV alpha 2 (COL4A2) chain and that this interaction is necessary for its assembly into the ECM. The VHL-COL4A2 interaction is dependent on endoplasmic reticulum (ER)mediated COL4A2 hydroxylation and independent of cytosolic, hypoxia regulated HIF-alpha-modifying enzymes. We find that the N-terminal tail of COL4A2 protrudes from the ER lumen into the cytosol where it is bound by VHL. Failure of VHL to interact with COL4A2 correlates with loss of collagen IV network formation in vitro and collagen IV remodeling in vivo. Our data suggest a HIF-alpha-independent role for the VHL-COL4A2 interaction in suppression of angiogenic tumor formation through collagen IV network assembly.	[Kurban, G.; Duplan, E.; Ramlal, N.; Hudon, V.; Pause, A.] McGill Univ, Dept Biochem, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; [Sado, Y.] Shigei Med Res Inst, Div Immunol, Okayama, Japan; [Ninomiya, Y.] Okayama Univ, Dept Mol Biol & Biochem, Grad Sch Med, Okayama, Japan	McGill University; Okayama University	Pause, A (corresponding author), McGill Univ, Dept Biochem, McGill Canc Ctr, McIntyre Bldg,3655 Sir William Osler Promenade,Ro, Montreal, PQ H3G 1Y6, Canada.	arnim.pause@mcgill.ca	Duplan, Eric/AAK-8224-2020	Duplan, Eric/0000-0002-1348-1507				Barry RE, 2004, TRENDS MOL MED, V10, P466, DOI 10.1016/j.molmed.2004.07.008; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esteban-Barragan MA, 2002, CANCER RES, V62, P2929; Grosfeld A, 2007, J BIOL CHEM, V282, P13264, DOI 10.1074/jbc.M611648200; Handsley MM, 2005, INT J CANCER, V115, P849, DOI 10.1002/ijc.20945; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Soder S, 2004, BIOCHEM BIOPH RES CO, V325, P276, DOI 10.1016/j.bbrc.2004.10.034; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Zimmer M, 2004, MOL CANCER RES, V2, P89	21	60	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					1004	1012		10.1038/sj.onc.1210709	http://dx.doi.org/10.1038/sj.onc.1210709			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700531				2022-12-28	WOS:000252946300012
J	Kauffmann, A; Rosselli, F; Lazar, V; Winnepenninckx, V; Mansuet-Lupo, A; Dessen, P; van den Oord, JJ; Spatz, A; Sarasin, A				Kauffmann, A.; Rosselli, F.; Lazar, V.; Winnepenninckx, V.; Mansuet-Lupo, A.; Dessen, P.; van den Oord, J. J.; Spatz, A.; Sarasin, A.			High expression of DNA repair pathways is associated with metastasis in melanoma patients	ONCOGENE			English	Article						melanoma; metastasis; DNA repair; microarray	TOPOISOMERASE-II; CUTANEOUS MELANOMA; P53 MUTATIONS; DAMAGE; CARCINOMA; GENETICS; CELLS; FOXM1	We have identified a gene-profile signature for human primary malignant melanoma associated with metastasis to distant sites and poor prognosis. We analyse the differential gene expression by looking at whole biological pathways rather than individual genes. Among the most significant pathways associated with progression to metastasis, we found the DNA replication (P = 10(-14)) and the DNA repair pathways (P = 10(-16)). We concentrated our analysis on DNA repair and found that 48 genes of this category, among a list of 234 genes, are associated with metastatic progression. These genes belong essentially to the pathways allowing recovery of stalled replication forks due to spontaneous blockage or induced DNA lesions. Because almost all these differentially expressed repair genes were overexpressed in primary tumors with bad prognosis, we speculate that primary melanoma cells that will metastasize try to replicate in a fast and error-free mode. In contrast to the progression from melanocytes to primary melanoma, genetic stability appears to be necessary for a melanoma cell to give rise to distant metastasis. This overexpression of repair genes explains nicely the extraordinary resistance of metastatic melanoma to chemo- and radio-therapy. Our results may open a new avenue for the discovery of drugs active on human metastatic melanoma.	[Kauffmann, A.; Rosselli, F.; Dessen, P.; Sarasin, A.] Inst Gustave Roussy, CNRS, Lab Genomes & Canc, FRE2939,PR2, F-94805 Villejuif, France; [Kauffmann, A.; Rosselli, F.; Dessen, P.; Sarasin, A.] Univ Paris Sud, Orsay, France; [Lazar, V.] Inst Gustave Roussy, Unit Funct Genom, F-94805 Villejuif, France; [Winnepenninckx, V.] Univ Hosp Maastricht, Dept Pathol, Maastricht, HX, Netherlands; [Mansuet-Lupo, A.; Spatz, A.] Inst Gustave Roussy, Dept Biopathol, F-94805 Villejuif, France; [van den Oord, J. J.] Katholieke Univ Leuven, Dept Morphol & Mol Pathol, Louvain, Belgium	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Maastricht University; Maastricht University Medical Centre (MUMC); UNICANCER; Gustave Roussy; KU Leuven	Sarasin, A (corresponding author), Inst Gustave Roussy, CNRS, Lab Genomes & Canc, FRE2939,PR2, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	sarasin@igr.fr	Lazar, Vladimir/AAV-2087-2020; SPATZ, ALAN/B-8645-2009; Filippo, Rosselli/AAO-6393-2020; Lazar, Vladimir/AAQ-2086-2020	SPATZ, ALAN/0000-0003-3020-1420; Filippo, Rosselli/0000-0003-1080-5745; 				Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622; Bastian BC, 2003, AM J PATHOL, V163, P1765, DOI 10.1016/S0002-9440(10)63536-5; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bradshaw PS, 2005, NAT GENET, V37, P193, DOI 10.1038/ng1506; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061; EDER JP, 1995, CANCER RES, V55, P6109; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Halazonetis TD, 2004, DNA REPAIR, V3, P1057, DOI 10.1016/j.dnarep.2004.03.036; Hamid T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-3; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P678, DOI 10.1093/jnci/93.9.678; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Munoz P, 2005, NAT GENET, V37, P1063, DOI 10.1038/ng1633; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; SCHUUR ER, 1995, CELL GROWTH DIFFER, V6, P219; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Spatz A, 2001, CANCER RES, V61, P2480; Stary A, 2002, BIOCHIMIE, V84, P49, DOI 10.1016/S0300-9084(01)01358-X; Thompson JF, 2005, LANCET, V365, P687, DOI 10.1016/S0140-6736(05)17951-3; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang L, 2002, ENVIRON MOL MUTAGEN, V39, P348, DOI 10.1002/em.10072; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Warters RL, 2005, J INVEST DERMATOL, V124, P807, DOI 10.1111/j.0022-202X.2005.23674.x; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103	32	195	198	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					565	573		10.1038/sj.onc.1210700	http://dx.doi.org/10.1038/sj.onc.1210700			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17891185				2022-12-28	WOS:000252674900001
J	Fadloun, A; Kobi, D; Delacroix, L; Dembele, D; Michel, I; Lardenois, A; Tisserand, J; Losson, R; Mengus, G; Davidson, I				Fadloun, A.; Kobi, D.; Delacroix, L.; Dembele, D.; Michel, I.; Lardenois, A.; Tisserand, J.; Losson, R.; Mengus, G.; Davidson, I.			Retinoic acid induces TGF beta-dependent autocrine fibroblast growth	ONCOGENE			English	Article						TAF4; transcription regulation; CTGF; MBD1; ENPP1/PC-1	LIVER STELLATE CELLS; TREATED HL-60 CELLS; TFIID COMPLEX; INCREASES SUSCEPTIBILITY; EMBRYONAL CARCINOMA; TARGET GENES; EXPRESSION; DIFFERENTIATION; PROTEIN; TRANSCRIPTION	To evaluate the role of murine TFIID subunit TAF4 in activation of cellular genes by all-trans retinoic acid (T-RA), we have characterized the T-RA response of taf4(lox/-) and taf4(-/-) embryonic fibroblasts. T-RA regulates almost 1000 genes in taf4(lox/-) cells, but less than 300 in taf4(-/-) cells showing that TAF4 is required for T-RA regulation of most, but not all cellular genes. We further show that T-RA-treated taf4(lox/-) cells exhibit transforming growth factor (TGF) beta-dependent autocrine growth and identify a set of genes regulated by loss of TAF4 and by T-RA corresponding to key mediators of the TGF beta signalling pathway. T-RA rapidly and potently induces expression of connective tissue growth factor (CTGF) via a conserved DR2 type response element in its proximal promoter leading to serum-free autocrine growth. These results highlight the role of TAF4 as a cofactor in the cellular response to T-RA and identify the genetic programme of a novel cross talk between the T-RA and TGFb pathways that leads to deregulated cell growth.	[Fadloun, A.; Kobi, D.; Delacroix, L.; Dembele, D.; Michel, I.; Lardenois, A.; Tisserand, J.; Losson, R.; Mengus, G.; Davidson, I.] Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, ULP,UMR7104, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Davidson, I (corresponding author), Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, ULP,UMR7104, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France.	irwin@titus.u-strasbg.fr	Dembélé, Doulaye/O-6513-2017; Lardenois, Aurélie/AAA-8961-2020	Dembélé, Doulaye/0000-0003-3879-6940; Delacroix, Laurence/0000-0003-3440-5359; Davidson, Irwin/0000-0001-5533-1171; MENGUS, Gabrielle/0000-0002-2844-1778				Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bohnsack BL, 2004, GENE DEV, V18, P1345, DOI 10.1101/gad.1184904; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Cao ZH, 2003, BLOOD, V101, P498, DOI 10.1182/blood-2002-05-1549; Cerignoli F, 2002, CANCER RES, V62, P1196; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Eifert C, 2006, MOL REPROD DEV, V73, P796, DOI 10.1002/mrd.20444; Falender AE, 2005, GENE DEV, V19, P794, DOI 10.1101/gad.1290105; FALK LA, 1991, BLOOD, V77, P1248; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; GLICK AB, 1991, DEVELOPMENT, V111, P1081; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Grob P, 2006, STRUCTURE, V14, P511, DOI 10.1016/j.str.2005.11.020; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Harris Thomas M, 2002, Funct Integr Genomics, V2, P105, DOI 10.1007/s10142-002-0062-6; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Kizawa H, 2005, NAT GENET, V37, P138, DOI 10.1038/ng1496; Koda H, 1996, BIOCHEM BIOPH RES CO, V221, P565, DOI 10.1006/bbrc.1996.0636; Krig SR, 2002, TOXICOL SCI, V68, P102, DOI 10.1093/toxsci/68.1.102; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2003, BIOCHEM CELL BIOL, V81, P355, DOI 10.1139/O03-069; Lee YJ, 2000, FEBS LETT, V472, P230, DOI 10.1016/S0014-5793(00)01461-7; Leurent C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; Matangkasombut O, 2004, ADV PROTEIN CHEM, V67, P67; Mengus G, 2005, EMBO J, V24, P2753, DOI 10.1038/sj.emboj.7600748; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Meyre D, 2005, NAT GENET, V37, P863, DOI 10.1038/ng1604; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; Nugent P, 1998, J CELL PHYSIOL, V177, P36, DOI 10.1002/(SICI)1097-4652(199810)177:1<36::AID-JCP4>3.0.CO;2-F; Nunes I, 1996, CANCER RES, V56, P495; Okuno M, 1997, HEPATOLOGY, V26, P913, DOI 10.1002/hep.510260417; Okuno M, 2002, FRONT BIOSCI-LANDMRK, V7, pD204, DOI 10.2741/okuno; Pendaries V, 2003, ONCOGENE, V22, P8212, DOI 10.1038/sj.onc.1206913; ROBERTS AB, 1992, CANCER SURV, V14, P205; Sanders SL, 2000, J BIOL CHEM, V275, P13895, DOI 10.1074/jbc.275.18.13895; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Thuault S, 2002, J BIOL CHEM, V277, P45510, DOI 10.1074/jbc.M206556200; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; Wei Y, 2002, DIFFERENTIATION, V70, P204, DOI 10.1046/j.1432-0436.2002.700409.x; Yu Q, 2000, GENE DEV, V14, P163	53	16	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					477	489		10.1038/sj.onc.1210657	http://dx.doi.org/10.1038/sj.onc.1210657			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637747				2022-12-28	WOS:000252426100008
J	Wang, RF; Miyahara, Y; Wang, HY				Wang, R-F; Miyahara, Y.; Wang, H. Y.			Toll-like receptors and immune regulation: implications for cancer therapy	ONCOGENE			English	Review						toll-like receptors; tumor immunology; cancer immunotherapy; immune tolerance; innate immunity; regulatory T cells	SINGLE-STRANDED RNA; GROWTH-FACTOR-BETA; SUPPRESSOR T-CELLS; NF-KAPPA-B; RIG-I; ADAPTER PROTEIN; ANTIVIRAL RESPONSES; DENDRITIC CELLS; INNATE; INFLAMMATION	Toll-like receptors (TLRs) function as pathogen pattern recognition molecules that sensor and initiate innate and adaptive immune responses against microbes and cancer cells. Recognition of pathogen-derived ligands by TLRs expressed on many types of cells, including dendritic cells and T cells, triggers the nuclear factor (NF)-kappa B and type-1 interferon pathways, leading to the production of proinflammatory cytokines that are essential in stimulating CD4(+) T cells to differentiate to T helper (Th) 1, Th2 Th17 and regulatory T (Treg) cells. Recent studies indicate that Treg cells play a critical role in suppressing immune responses and inducing immune tolerance to cancer and infectious diseases. Of particular interest, the human TLR8 signaling pathway is essential for reversing the suppressive function of Treg cells. Thus, TLRs regulate cancer immunity and tolerance through innate immune responses mediated by Treg, dendritic and other immune cells. In this review, we focus on the current understanding of TLRs and Treg cells with emphasis on their roles in cancer immunity. Related information on non-TLR immune receptors will be briefly discussed.	[Wang, R-F; Miyahara, Y.; Wang, H. Y.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Wang, R-F; Miyahara, Y.; Wang, H. Y.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Wang, R-F; Miyahara, Y.; Wang, H. Y.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Wang, RF (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, ALKEK Bldg,N1120, Houston, TX 77030 USA.	Rongfuw@bcm.tmc.edu						Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Baldridge JR, 2004, EXPERT OPIN BIOL TH, V4, P1129, DOI 10.1517/14712598.4.7.1129; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crellin NK, 2005, J IMMUNOL, V175, P8051, DOI 10.4049/jimmunol.175.12.8051; Crozat K, 2004, P NATL ACAD SCI USA, V101, P6835, DOI 10.1073/pnas.0401347101; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Fehervari Z, 2004, INT IMMUNOL, V16, P1769, DOI 10.1093/intimm/dxh178; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; FRANCOIS BJ, 2003, NAT REV IMMUNOL, V3, P189; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hamilton SE, 2006, NAT IMMUNOL, V7, P475, DOI 10.1038/ni1326; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Hu JW, 2006, CANCER RES, V66, P8887, DOI 10.1158/0008-5472.CAN-05-3448; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jackson DC, 2004, P NATL ACAD SCI USA, V101, P15440, DOI 10.1073/pnas.0406740101; Jahrsdorfer B, 2005, J LEUKOCYTE BIOL, V77, P378, DOI 10.1189/jlb.0604373; Jahrsdorfer B, 2005, CLIN CANCER RES, V11, P1490, DOI 10.1158/1078-0432.CCR-04-1890; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; KINIWA Y, 2007, IN PRESS CLIN CANC; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Kubo T, 2004, J IMMUNOL, V173, P7249, DOI 10.4049/jimmunol.173.12.7249; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Lin RT, 2006, J VIROL, V80, P6072, DOI 10.1128/JVI.02495-05; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997; MARINON F, 2006, NATURE, V440, P237; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Netea MG, 2004, J IMMUNOL, V172, P3712, DOI 10.4049/jimmunol.172.6.3712; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Peng G, 2007, IMMUNITY, V27, P334, DOI 10.1016/j.immuni.2007.05.020; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Roncarolo MG, 2000, CURR OPIN IMMUNOL, V12, P676, DOI 10.1016/S0952-7915(00)00162-X; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Salaun B, 2006, J IMMUNOL, V176, P4894, DOI 10.4049/jimmunol.176.8.4894; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Stockfleth E, 2003, BRIT J DERMATOL, V149, P53, DOI 10.1046/j.0366-077X.2003.05626.x; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; Sun JL, 2005, JNCI-J NATL CANCER I, V97, P525, DOI 10.1093/jnci/dji070; Sun Xing Cai, 2004, BMC Physiol, V4, P8, DOI 10.1186/1472-6793-4-8; Sutmuller RPM, 2006, TRENDS IMMUNOL, V27, P387, DOI 10.1016/j.it.2006.06.005; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Tabiasco J, 2006, J IMMUNOL, V177, P8708, DOI 10.4049/jimmunol.177.12.8708; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Ting JPY, 2005, ANNU REV IMMUNOL, V23, P387, DOI 10.1146/annurev.immunol.23.021704.115616; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102; Wang HY, 2007, CURR OPIN IMMUNOL, V19, P217, DOI 10.1016/j.coi.2007.02.004; Wang HY, 2005, J IMMUNOL, V174, P2661, DOI 10.4049/jimmunol.174.5.2661; Wang YJ, 2004, PROTEOMICS, V4, P20, DOI 10.1002/pmic.200300549; WANG ZK, 2001, MAT PHYS MECH, V4, P22; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Woo EY, 2001, CANCER RES, V61, P4766; Xu JF, 2005, CANCER EPIDEM BIOMAR, V14, P2563, DOI 10.1158/1055-9965.EPI-05-0356; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yuan XP, 2006, CANCER RES, V66, P2630, DOI 10.1158/0008-5472.CAN-05-1682; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	108	106	118	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					181	189		10.1038/sj.onc.1210906	http://dx.doi.org/10.1038/sj.onc.1210906			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176599				2022-12-28	WOS:000252163600004
J	van Gent, DC; van der Burg, M				van Gent, D. C.; van der Burg, M.			Non-homologous end-joining, a sticky affair	ONCOGENE			English	Review						DNA repair; V(D)J recombination; DNA double-strand break repair; severe combined immuno-deficiency; DNA damage response; chromosomal instability	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; DNA-LIGASE-IV; SEVERE COMBINED IMMUNODEFICIENCY; INCREASED GENOMIC INSTABILITY; COMBINED IMMUNE-DEFICIENCY; ARTEMIS GENE-MUTATIONS; LEAKY SCID PHENOTYPE; V(D)J RECOMBINATION; CATALYTIC SUBUNIT	Rejoining of broken chromosomes is crucial for cell survival and prevention of malignant transformation. Most mammalian cells rely primarily on the non-homologous end-joining pathway of DNA double-strand break (DSB) repair to accomplish this task. This review focuses both on the core non-homologous end-joining machinery, which consists of DNA-dependent protein kinase and the ligase IV/XRCC4 complex, and on accessory factors that facilitate rejoining of a subset of the DSBs. We discuss how the ATM protein kinase and the Mre11/Rad50/Nbs1 complex might function in DSB repair and what role ionizing radiation-induced foci may play in this process.	[van Gent, D. C.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Cell Biol & Genet, NL-3000 CA Rotterdam, Netherlands; [van der Burg, M.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Gent, DC (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Cell Biol & Genet, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.vangent@erasmusmc.nl		van Gent, Dik C./0000-0003-1473-8148				Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Burma S, 2006, DNA REPAIR, V5, P1042, DOI 10.1016/j.dnarep.2006.05.026; Capp JP, 2007, NUCLEIC ACIDS RES, V35, P3551, DOI 10.1093/nar/gkm243; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Costantini S, 2007, DNA REPAIR, V6, P712, DOI 10.1016/j.dnarep.2006.12.007; Cui XP, 2005, MOL CELL BIOL, V25, P10842, DOI 10.1128/MCB.25.24.10842-10852.2005; Darroudi F, 2007, MUTAT RES-FUND MOL M, V615, P111, DOI 10.1016/j.mrfmmm.2006.11.029; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Digweed M, 1999, BIOESSAYS, V21, P649, DOI 10.1002/(SICI)1521-1878(199908)21:8<649::AID-BIES4>3.0.CO;2-O; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2007, MOL CELL BIOL, V27, P1581, DOI 10.1128/MCB.01962-06; Drouet J, 2005, J BIOL CHEM, V280, P7060, DOI 10.1074/jbc.M410746200; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Goodarzi AA, 2006, EMBO J, V25, P3880, DOI 10.1038/sj.emboj.7601255; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Gu JF, 2007, NUCLEIC ACIDS RES, V35, P5755, DOI 10.1093/nar/gkm579; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Hsu HL, 2002, DNA REPAIR, V1, P225, DOI 10.1016/S1568-7864(01)00018-0; Iliakis G, 2004, CYTOGENET GENOME RES, V104, P14, DOI 10.1159/000077461; Jung D, 2006, ANNU REV IMMUNOL, V24, P541, DOI 10.1146/annurev.immunol.23.021704.115830; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kabotyanski EB, 1998, NUCLEIC ACIDS RES, V26, P5333, DOI 10.1093/nar/26.23.5333; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Kobayashi N, 2003, HUM GENET, V112, P348, DOI 10.1007/s00439-002-0897-x; Koch CA, 2004, EMBO J, V23, P3874, DOI 10.1038/sj.emboj.7600375; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; LEE K, 2001, J ARTIFICIAL LIFE RO, V4, P182; Lee Y, 2007, NEUROSCIENCE, V145, P1365, DOI 10.1016/j.neuroscience.2006.07.026; Li LY, 2002, J IMMUNOL, V168, P6323, DOI 10.4049/jimmunol.168.12.6323; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Ma YM, 2005, J BIOL CHEM, V280, P33839, DOI 10.1074/jbc.M507113200; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; McKinnon PJ, 2004, EMBO REP, V5, P772, DOI 10.1038/sj.embor.7400210; Meek K, 2007, MOL CELL BIOL, V27, P3881, DOI 10.1128/MCB.02366-06; Modesti M, 2003, J MOL BIOL, V334, P215, DOI 10.1016/j.jmb.2003.09.031; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Nikjoo H, 1998, INT J RADIAT BIOL, V73, P355, DOI 10.1080/095530098142176; Noordzij JG, 2003, BLOOD, V101, P1446, DOI 10.1182/blood-2002-01-0187; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Ristic D, 2003, NUCLEIC ACIDS RES, V31, P5229, DOI 10.1093/nar/gkg729; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schatz DG, 2004, IMMUNOL REV, V200, P5, DOI 10.1111/j.0105-2896.2004.00173.x; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Slijepcevic P, 2006, DNA REPAIR, V5, P1299, DOI 10.1016/j.dnarep.2006.05.038; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Spagnolo L, 2006, MOL CELL, V22, P511, DOI 10.1016/j.molcel.2006.04.013; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Taylor AMR, 2004, DNA REPAIR, V3, P1219, DOI 10.1016/j.dnarep.2004.04.009; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Tsai CJ, 2007, P NATL ACAD SCI USA, V104, P7851, DOI 10.1073/pnas.0702620104; Uematsu N, 2007, J CELL BIOL, V177, P219, DOI 10.1083/jcb.200608077; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; van Heemst D, 2004, DNA REPAIR, V3, P43, DOI 10.1016/j.dnarep.2003.09.004; VANDERBURG M, 2007, IN PRESS EUR J IMMUN; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; Verkaik NS, 2002, EUR J IMMUNOL, V32, P701, DOI 10.1002/1521-4141(200203)32:3<701::AID-IMMU701>3.0.CO;2-T; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; Weterings E, 2003, NUCLEIC ACIDS RES, V31, P7238, DOI 10.1093/nar/gkg889; WU PY, 2007, IN PRESS J BIOL CHEM; Xu XZ, 2003, FASEB J, V17, P1842, DOI 10.1096/fj.03-0310com; Yan CT, 2007, NATURE, V449, P478, DOI 10.1038/nature06020; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Zha S, 2007, P NATL ACAD SCI USA, V104, P4518, DOI 10.1073/pnas.0611734104; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	117	123	124	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2007	26	56					7731	7740		10.1038/sj.onc.1210871	http://dx.doi.org/10.1038/sj.onc.1210871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066085				2022-12-28	WOS:000251537900003
J	Iwasaki, H; Akashi, K				Iwasaki, H.; Akashi, K.			Hematopoietic developmental pathways: on cellular basis	ONCOGENE			English	Review						hematopoietic stem cell; lineage commitment; transcription factor; leukemic stem cell	ACUTE MYELOGENOUS LEUKEMIA; MYELOID LINEAGE COMMITMENT; STEM-CELLS; BONE-MARROW; LONG-TERM; DENDRITIC CELLS; INTERLEUKIN-7 RECEPTOR; COMMITTED PROGENITOR; FLT3 LIGAND; CORD BLOOD	To elucidate the molecular mechanisms underlying normal and malignant hematopoietic development, it is critical to identify developmental intermediates for each lineage downstream of hematopoietic stem cells. Recent advances in prospective isolation of hematopoietic stem and progenitor cells, and effficient xenogeneic transplantation systems have provided a detailed developmental map in both mouse and human hematopoiesis, demonstrating that surface phenotypes of mouse stem - progenitor cells and their human counterparts are considerably different. Here, we summarize the phenotype and functional properties and their differences of hematopoietic stem and progenitor cell populations between mouse and human.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Kyushu Univ Hosp, Ctr Cellular & Mol Med, Fukuoka 812, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kyushu University	Akashi, K (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.	Koichi_akashi@dfci.harvard.edu						Adolfsson J, 2001, IMMUNITY, V15, P659, DOI 10.1016/S1074-7613(01)00220-5; Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Akashi K, 2005, CELL, V121, P160, DOI 10.1016/j.cell.2005.04.005; Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Allman D, 2003, NAT IMMUNOL, V4, P168, DOI 10.1038/ni878; Arinobu Y, 2005, P NATL ACAD SCI USA, V102, P18105, DOI 10.1073/pnas.0509148102; ARINOBU Y, 2007, IN PRESS CELL STEM C; Back J, 2005, EXP HEMATOL, V33, P395, DOI 10.1016/j.exphem.2004.12.010; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bhandoola A, 2006, NAT REV IMMUNOL, V6, P117, DOI 10.1038/nri1778; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; D'Amico A, 2003, J EXP MED, V198, P293, DOI 10.1084/jem.20030107; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Forsberg EC, 2006, CELL, V126, P415, DOI 10.1016/j.cell.2006.06.037; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; Gilliland DG, 2002, SEMIN HEMATOL, V39, P6, DOI 10.1053/shem.2002.36921; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Gotze KS, 1998, BLOOD, V91, P1947, DOI 10.1182/blood.V91.6.1947.1947_1947_1958; Gounari F, 2002, NAT IMMUNOL, V3, P489, DOI 10.1038/ni778; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; Hao QL, 2001, BLOOD, V97, P3683, DOI 10.1182/blood.V97.12.3683; Heyworth C, 2002, EMBO J, V21, P3770, DOI 10.1093/emboj/cdf368; Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Igarashi H, 2001, BLOOD, V97, P2680, DOI 10.1182/blood.V97.9.2680; Igarashi H, 2002, IMMUNITY, V17, P117, DOI 10.1016/S1074-7613(02)00366-7; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Ishikawa F, 2003, LEUKEMIA, V17, P960, DOI 10.1038/sj.leu.2402878; ISHIKAWA F, 2007, IN PRESS BLOOD; Iwama A, 1998, NUCLEIC ACIDS RES, V26, P3034, DOI 10.1093/nar/26.12.3034; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Iwasaki H, 2003, IMMUNITY, V19, P451, DOI 10.1016/S1074-7613(03)00242-5; Iwasaki H, 2005, J EXP MED, V201, P1891, DOI 10.1084/jem.20050548; Iwasaki H, 2006, GENE DEV, V20, P3010, DOI 10.1101/gad.1493506; Iwasaki H, 2007, IMMUNITY, V26, P726, DOI 10.1016/j.immuni.2007.06.004; Jaiswal S, 2003, P NATL ACAD SCI USA, V100, P10002, DOI 10.1073/pnas.1633833100; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Jordan CT, 2002, LEUKEMIA, V16, P559, DOI 10.1038/sj.leu.2402446; Karsunky H, 2003, J EXP MED, V198, P305, DOI 10.1084/jem.20030323; Kiyoi H, 1999, BLOOD, V93, P3074; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Krueger A, 2007, IMMUNITY, V26, P105, DOI 10.1016/j.immuni.2006.12.004; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Kuwata N, 1999, J IMMUNOL, V163, P6355; Lai AY, 2006, J EXP MED, V203, P1867, DOI 10.1084/jem.20060697; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399; Martin CH, 2003, NAT IMMUNOL, V4, P866, DOI 10.1038/ni965; McKenna HJ, 2000, BLOOD, V95, P3489, DOI 10.1182/blood.V95.11.3489; Miyamoto T, 2002, DEV CELL, V3, P137, DOI 10.1016/S1534-5807(02)00201-0; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Okuno Y, 2002, P NATL ACAD SCI USA, V99, P6246, DOI 10.1073/pnas.092027799; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Perry SS, 2006, J IMMUNOL, V177, P2880, DOI 10.4049/jimmunol.177.5.2880; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Randall TD, 1996, BLOOD, V87, P4057, DOI 10.1182/blood.V87.10.4057.bloodjournal87104057; Rappold I, 1997, BLOOD, V90, P111; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rosnet O, 1996, LEUKEMIA, V10, P238; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Schwarz BA, 2004, NAT IMMUNOL, V5, P953, DOI 10.1038/ni1101; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Sitnicka E, 2002, IMMUNITY, V17, P463, DOI 10.1016/S1074-7613(02)00419-3; Sitnicka E, 2003, BLOOD, V102, P881, DOI 10.1182/blood-2002-06-1694; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Umland O, 2007, J IMMUNOL, V178, P4147, DOI 10.4049/jimmunol.178.7.4147; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Walsh JC, 2002, IMMUNITY, V17, P665, DOI 10.1016/S1074-7613(02)00452-1; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Ye M, 2003, IMMUNITY, V19, P689, DOI 10.1016/S1074-7613(03)00299-1; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	100	70	74	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6687	6696		10.1038/sj.onc.1210754	http://dx.doi.org/10.1038/sj.onc.1210754			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934478				2022-12-28	WOS:000250147000002
J	Laulajainen, M; Muranen, T; Carpen, O; Gronholm, M				Laulajainen, M.; Muranen, T.; Carpen, O.; Groenholm, M.			Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton	ONCOGENE			Unspecified	Article						NF2; merlin; PKA; phosphorylation; actin	NEUROFIBROMATOSIS TYPE-2; P21-ACTIVATED KINASE; SCHWANN-CELLS; GROWTH; EZRIN; GENE; MEMBRANE; INHIBITION; PRODUCT; BINDING	Mutations in the neuro. bromatosis 2 tumor suppressor gene (NF2) encoding merlin (moesin-ezrin-radixin like-protein) induce tumors of the nervous system. Merlin localizes to the cell membrane where it links the actin cytoskeleton to membrane proteins. Cell proliferation is regulated by merlin in many cell types, but merlin's tumor suppressor function still remains unclear. Phosphorylation has been suggested to regulate merlin's activity. The C-terminal serine 518 is phosphorylated both by p21-activated kinases (PAKs) and protein kinase A (PKA). In this work, we identify a novel PKA phosphorylation site, serine 10, in the N terminus of merlin. We show that a non-phosphorylatable form of serine 10 (S10A) affects cellular morphology. Regulation of this site also influences actin cytoskeleton organization and dynamics in vivo, as merlin S10A reduces the amount of cellular F-actin and merlin S10D stabilizes F-actin. laments. By using a wound-healing assay and live cell imaging, we demonstrate that dephosphorylation of serine 10 leads to defects in migration, possibly through altered ability of the cells to form lamellipodia. This study suggests a role for merlin in mediating PKA-induced changes of the actin cytoskeleton.	[Laulajainen, M.; Muranen, T.; Carpen, O.; Groenholm, M.] Univ Helsinki, Dept Pathol, Helsinki 14, Finland; [Carpen, O.] Univ Turku, Dept Pathol, Turku, Finland; Univ Turku, Cent Hosp, FIN-20520 Turku, Finland	University of Helsinki; University of Turku; University of Turku	Laulajainen, M (corresponding author), Univ Helsinki, Dept Pathol, Haartmaninkatu 8,PL 63, Helsinki 14, Finland.	minja.laulajainen@helsinki.fi	Gronholm, Mikaela/B-4225-2010; Muranen, Taru/AAM-9349-2021	Gronholm, Mikaela/0000-0002-2378-8924; Muranen, Taru/0000-0003-4158-9002				Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Bai Y, 2007, ONCOGENE, V26, P836, DOI 10.1038/sj.onc.1209849; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; Bohling T, 1996, AM J PATHOL, V148, P367; Brault E, 2001, J CELL SCI, V114, P1901; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; Giovannini M, 2000, GENE DEV, V14, P1617; Golovnina K, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-69; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 2003, J BIOL CHEM, V278, P41167, DOI 10.1074/jbc.M306149200; Gronholm M, 1999, J CELL SCI, V112, P895; Hotulainen P, 2006, J CELL BIOL, V173, P383, DOI 10.1083/jcb.200511093; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Kim HA, 1997, J NEUROSCI RES, V49, P236; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Manent J, 2003, J NEUROSCI METH, V123, P167, DOI 10.1016/S0165-0270(02)00349-7; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muranen T, 2007, HUM MOL GENET, V16, P1742, DOI 10.1093/hmg/ddm122; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Shimizu T, 2002, J BIOL CHEM, V277, P10332, DOI 10.1074/jbc.M109979200; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Thaxton C, 2007, MOL CELL NEUROSCI, V34, P231, DOI 10.1016/j.mcn.2006.11.003; Trofatter J A, 1993, Cell, V75, P826; Turunen O, 1998, BBA-PROTEIN STRUCT M, V1387, P1, DOI 10.1016/S0167-4838(98)00103-4; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Zhou RH, 2003, J BIOL CHEM, V278, P35651, DOI 10.1074/jbc.M303416200	40	35	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3233	3243		10.1038/sj.onc.1210988	http://dx.doi.org/10.1038/sj.onc.1210988			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18071304				2022-12-28	WOS:000256111400002
J	He, Q; Luo, X; Jin, W; Huang, Y; Reddy, MVR; Reddy, EP; Sheikh, MS				He, Q.; Luo, X.; Jin, W.; Huang, Y.; Reddy, M. V. R.; Reddy, E. P.; Sheikh, M. S.			Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP	ONCOGENE			English	Article						COX-2 inhibitors; TRAIL; death receptor 5; prostate cancer; colon cancer	ENDOPLASMIC-RETICULUM STRESS; INDUCED APOPTOSIS; CYCLOOXYGENASE-2; CANCER; ADENOCARCINOMAS; CARCINOMA; CELLS; SULINDAC; PATHWAY; COLON	Cyclooxygenase-2 (COX-2) inhibitors are promising anticancer agents but their long-term use at high doses is associated with adverse cardiovascular events. The molecular mechanisms underlying the anticancer or toxic cardiovascular effects of COX-2 inhibitors remain unknown. Here we report that COX-2-selective celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 (DR5) and cooperate with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), the ligand for DR5, to induce apoptosis in COX-2-positive and -negative cancer cells. We also show that both agents engage GADD153/CHOP to transcriptionally upregulate DR5 expression; GADD153/CHOP is a C/EBP homologous transcription factor implicated in cellular stress response and apoptosis. Based on our results, we propose that (1) these agents appear to mediate their effects, at least in part, by engaging GADD153/CHOP to activate DR5-dependent apoptotic pathway and (2) their regulation of GADD153/CHOP and DR5 expression appears to occur independent of their COX2 inhibitory effects. Our results also indicate that ON09310 is generally more potent than celecoxib and, at lower concentration, strongly cooperates with TRAIL to induce apoptosis. Taken together, our findings form the basis for future in-depth studies to further explore the utility of TRAIL and/or agonistic anti-DR5 antibodies in combination with low-dose COX-2 inhibitors as a rational approach for cancer prevention and treatment.	[He, Q.; Luo, X.; Jin, W.; Huang, Y.; Sheikh, M. S.] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; [Reddy, M. V. R.; Reddy, E. P.] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@upstate.edu	Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA109820, R01CA086945] Funding Source: NIH RePORTER; NCI NIH HHS [CA 109820, CA86945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hida T, 1998, CANCER RES, V58, P3761; Huang Y, 2001, CANCER RES, V61, P6918; HUANG Y, 2006, TOXICOL APPL PH 1216; Liu XG, 2004, JNCI-J NATL CANCER I, V96, P1769, DOI 10.1093/jnci/djh322; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; REDDY EP, 2002, Patent No. 6376519423; Ristimaki A, 1997, CANCER RES, V57, P1276; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wilson KT, 1998, CANCER RES, V58, P2929; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Zimmermann KC, 1999, CANCER RES, V59, P198	18	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2656	2660		10.1038/sj.onc.1210894	http://dx.doi.org/10.1038/sj.onc.1210894			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17968315				2022-12-28	WOS:000255057000015
J	Subramanian, S; Lui, WO; Lee, CH; Espinosa, I; Nielsen, TO; Heinrich, MC; Corless, CL; Fire, AZ; van de Rijn, M				Subramanian, S.; Lui, W. O.; Lee, C. H.; Espinosa, I.; Nielsen, T. O.; Heinrich, M. C.; Corless, C. L.; Fire, A. Z.; van de Rijn, M.			MicroRNA expression signature of human sarcomas	ONCOGENE			English	Article						miRNA; microarrays; sarcoma	GENE-EXPRESSION; KIT; MUTATIONS; TUMORS; REGIONS; MDM2; RNAS	MicroRNAs (miRNAs) are similar to 22 nucleotide-long noncoding RNAs involved in several biological processes including development, differentiation and proliferation. Recent studies suggest that knowledge of miRNA expression patterns in cancer may have substantial value for diagnostic and prognostic determinations as well as for eventual therapeutic intervention. We performed comprehensive analysis of miRNA expression profiles of 27 sarcomas, 5 normal smooth muscle and 2 normal skeletal muscle tissues using microarray technology and/or small RNA cloning approaches. The miRNA expression profiles are distinct among the tumor types as demonstrated by an unsupervised hierarchical clustering, and unique miRNA expression signatures were identified in each tumor class. Remarkably, the miRNA expression patterns suggested that two of the sarcomas had been misdiagnosed and this was confirmed by reevaluation of the tumors using histopathologic and molecular analyses. Using the cloning approach, we also identified 31 novel miRNAs or other small RNA effectors in the sarcomas and normal skeletal muscle tissues examined. Our data show that different histological types of sarcoma have distinct miRNA expression patterns, reflecting the apparent lineage and differentiation status of the tumors. The identification of unique miRNA signatures in each tumor type may indicate their role in tumorigenesis and may aid in diagnosis of soft tissue sarcomas.	[Subramanian, S.; Lui, W. O.; Lee, C. H.; Espinosa, I.; Fire, A. Z.; van de Rijn, M.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; [Lee, C. H.; Nielsen, T. O.] Univ British Columbia, Gen Pathol Evaluat Ctr, Vancouver, BC V5Z 1M9, Canada; [Heinrich, M. C.] Oregon Hlth & Sci Univ, Div Hematol Oncol, Portland, OR 97201 USA; [Corless, C. L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA; [Fire, A. Z.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Stanford University; University of British Columbia; Oregon Health & Science University; Oregon Health & Science University; Stanford University	van de Rijn, M (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, 300 Pasteur Dr,L-235, Stanford, CA 94305 USA.	mrijn@stanford.edu	Heinrich, Michael/AAC-6745-2019; Lui, Weng-Onn/G-6703-2013; Lui, Weng-Onn/X-5957-2019	Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473; Subramanian, Subbaya/0000-0002-2544-480X; Fire, Andrew/0000-0001-6217-8312; Heinrich, Michael/0000-0003-3790-0478; van de Rijn, Matt/0000-0002-1909-9739	NCI NIH HHS [CA112270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Baer C, 2004, INT J CANCER, V110, P687, DOI 10.1002/ijc.20171; Binh MBN, 2005, AM J SURG PATHOL, V29, P1340, DOI 10.1097/01.pas.0000170343.09562.39; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; ESPINOSA I, 2007, IN PRESS AM J SURG; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Fletcher JA, 2007, CURR OPIN GENET DEV, V17, P3, DOI 10.1016/j.gde.2006.12.010; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; HE L, 2004, NAT REV GENET, V5, P522; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Michael MZ, 2003, MOL CANCER RES, V1, P882; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Politz JCR, 2006, P NATL ACAD SCI USA, V103, P18957, DOI 10.1073/pnas.0609466103; Pretto D, 2006, ONCOGENE, V25, P3661, DOI 10.1038/sj.onc.1209413; Shimada S, 2006, HUM PATHOL, V37, P1123, DOI 10.1016/j.humpath.2006.04.010; Subramanian S, 2004, ONCOGENE, V23, P7780, DOI 10.1038/sj.onc.1208056; WEISS SW, 2001, SOFT TISSUE TUMORS; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	31	185	213	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					2015	2026		10.1038/sj.onc.1210836	http://dx.doi.org/10.1038/sj.onc.1210836			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922033				2022-12-28	WOS:000254359100006
J	Xiao, W; Zhang, Q; Habermacher, G; Yang, X; Zhang, AY; Cai, X; Hahn, J; Liu, J; Pins, M; Doglio, L; Dhir, R; Gingrich, J; Wang, Z				Xiao, W.; Zhang, Q.; Habermacher, G.; Yang, X.; Zhang, A-y; Cai, X.; Hahn, J.; Liu, J.; Pins, M.; Doglio, L.; Dhir, R.; Gingrich, J.; Wang, Z.			U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia	ONCOGENE			English	Article						U19/Eaf2; lung adenocarcinoma; B-cell lymphoma; hepatocellular carcinoma; prostate cancer; tumor suppressor	ELONGATION-FACTOR ELL; TUMOR-SUPPRESSOR; VASCULAR TUMORS; FACTOR-2 EAF2; CAJAL BODY; GENE; POLYMERASE; MLL; INACTIVATION; EXPRESSION	Upregulated gene 19 (U19)/ELL-associated factor 2 (Eaf2) is a potential human tumor suppressor that exhibits frequent allelic loss and downregulation in high-grade prostate cancer. U19/Eaf2, along with its homolog Eaf1, has been reported to regulate transcriptional elongation via interaction with the eleven-nineteen lysine-rich leukemia (ELL) family of proteins. To further explore the tumor-suppressive effects of U19/Eaf2, we constructed and characterized a murine U19/Eaf2-knockout model. Homozygous or heterozygous deletion of U19/Eaf2 resulted in high rates of lung adenocarcinoma, B-cell lymphoma, hepato cellular carcinoma and prostate intraepithelial neoplasia. Within the mouse prostate, U19/Eaf2 defficiency enhanced cell proliferation and increased epithelial cell size. The knockout mice also exhibited cardiac cell hypertrophy. These data indicate a role for U19/Eaf2 in growth suppression and cell size control as well as argue for U19/Eaf2 as a novel tumor suppressor in multiple mouse tissues. The U19/Eaf2 knockout mouse also provides a unique animal model for three important cancers: lung adenocarcinoma, B-cell lymphoma and hepatocellular carcinoma.	[Zhang, A-y; Liu, J.; Gingrich, J.; Wang, Z.] Univ Pittsburgh, Dept Urol, Shadyside Med Ctr, Inst Canc,Sch Med, Pittsburgh, PA 15232 USA; [Xiao, W.; Zhang, Q.; Habermacher, G.; Zhang, A-y; Cai, X.; Hahn, J.; Wang, Z.] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; [Xiao, W.] Chinese Acad Sci, Inst Hydrobiol, Wuhan, Peoples R China; [Yang, X.; Pins, M.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Yang, X.; Pins, M.; Wang, Z.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Doglio, L.; Wang, Z.] Northwestern Univ, Feinberg Sch Med, Ctr Genet Med, Chicago, IL 60611 USA; [Dhir, R.] Univ Pittsburgh, Sch Med, Dept Pathol, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; Feinberg School of Medicine; Chinese Academy of Sciences; Institute of Hydrobiology, CAS; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, Z (corresponding author), Univ Pittsburgh, Dept Urol, Shadyside Med Ctr, Inst Canc,Sch Med, Suite G40,5200 Ctr Ave, Pittsburgh, PA 15232 USA.	wangz2@upmc.edu	Xiao, Wuhan/GLU-7352-2022	Gingrich, Jeffrey/0000-0002-4516-2893	NATIONAL CANCER INSTITUTE [R01CA120386, P50CA090386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051193, R37DK051193] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90386, R01 CA120386, P50 CA090386-06A25083, P50 CA090386, R01 CA120386-03] Funding Source: Medline; NIDDK NIH HHS [R01 DK51193, R01 DK051193, R37 DK051193-14, R37 DK051193] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cioce M, 2005, ANNU REV CELL DEV BI, V21, P105, DOI 10.1146/annurev.cellbio.20.010403.103738; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Gall JG, 2003, NAT REV MOL CELL BIO, V4, P975, DOI 10.1038/nrm1262; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kong SE, 2005, P NATL ACAD SCI USA, V102, P10094, DOI 10.1073/pnas.0503017102; Li M, 2003, DEV DYNAM, V228, P273, DOI 10.1002/dvdy.10367; Luo RT, 2001, MOL CELL BIOL, V21, P5678, DOI 10.1128/MCB.21.16.5678-5687.2001; Ma WB, 2003, CANCER RES, V63, P5320; Maurus D, 2005, EMBO J, V24, P1181, DOI 10.1038/sj.emboj.7600603; Mitani K, 2000, BIOCHEM BIOPH RES CO, V279, P563, DOI 10.1006/bbrc.2000.3970; Polak PE, 2003, MOL BIOL CELL, V14, P1517, DOI 10.1091/mbc.E02-07-0394; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; Simone F, 2003, BLOOD, V101, P2355, DOI 10.1182/blood-2002-06-1664; Simone F, 2001, BLOOD, V98, P201, DOI 10.1182/blood.V98.1.201; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wang Z, 1997, P NATL ACAD SCI USA, V94, P12999, DOI 10.1073/pnas.94.24.12999; Xiao WH, 2003, CANCER RES, V63, P4698; Zhu N, 1999, CANCER RES, V59, P1896	26	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1536	1544		10.1038/sj.onc.1210786	http://dx.doi.org/10.1038/sj.onc.1210786			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873910	Green Accepted			2022-12-28	WOS:000253815800005
J	Ingram, WJ; Mccue, KI; Tran, TH; Hallahan, AR; Wainwright, BJ				Ingram, W. J.; McCue, K. I.; Tran, T. H.; Hallahan, A. R.; Wainwright, B. J.			Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling	ONCOGENE			English	Article						Sonic Hedgehog; Hes1; Notch; C3H/10T1/2; MNS70; gene expression profiling	GENE-EXPRESSION; HUMAN HOMOLOG; CELL DIFFERENTIATION; MICROARRAY ANALYSIS; NEURAL DEVELOPMENT; IDENTIFICATION; GROWTH; ROLES; MEDULLOBLASTOMAS; CERULOPLASMIN	Aberrant regulation of signalling mechanisms that normally orchestrate embryonic development, such as the Hedgehog, Wnt and Notch pathways, is a common feature of tumorigenesis. In order to better understand the neoplastic events mediated by Hedgehog signalling, we identified over 200 genes regulated by Sonic Hedgehog in multipotent mesodermal cells. Widespread crosstalk with other developmental signalling pathways is evident, suggesting a complex network of interactions that challenges the often over-simplistic representation of these pathways as simple linear entities. Hes1, a principal effector of the Notch pathway, was found to be a target of Sonic Hedgehog in both C3H/10T1/2 mesodermal and MNS70 neural cells. Desert Hedgehog also elicited a strong Hes1 response. While Smoothened function was found necessary for upregulation of Hes1 in response to Sonic Hedgehog, the mechanism does not require gamma-secretase-mediated cleavage of Notch receptors, and appears to involve transcription factors other than RBP-J kappa. Thus, we have defined a novel mechanism for Hes1 regulation in stem-like cells that is independent of canonical Notch signalling.	[Ingram, W. J.; McCue, K. I.; Tran, T. H.; Wainwright, B. J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Ingram, W. J.; Hallahan, A. R.] Univ Queensland, Royal Childrens Hosp, Dept Paediat & Child Hlth, Brisbane, Qld, Australia	University of Queensland; Royal Children's Hospital Brisbane; University of Queensland	Wainwright, BJ (corresponding author), Univ Queensland, Inst Mol Biosci, Bldg 80,St Lucia Campus, Brisbane, Qld 4072, Australia.	b.wainwright@imb.uq.edu.au	Hallahan, Andrew R/F-1757-2010; Ingram, Wendy J/F-7317-2010	Ingram, Wendy J/0000-0002-7063-1081; Wainwright, Brandon/0000-0003-0406-2092				Alexandre C, 1999, DEVELOPMENT, V126, P5689; Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Baonza A, 2001, DEVELOPMENT, V128, P3889; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Borzillo GV, 2005, CURR TOP MED CHEM, V5, P147, DOI 10.2174/1568026053507732; CHAKRABORTY PK, 1984, ACTA MED OKAYAMA, V38, P315; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Dakubo GD, 2006, J NEURO-ONCOL, V79, P221, DOI 10.1007/s11060-006-9132-2; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Fu WM, 2003, DEVELOPMENT, V130, P5229, DOI 10.1242/dev.00764; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hansson EM, 2004, SEMIN CANCER BIOL, V14, P320, DOI 10.1016/j.semcancer.2004.04.011; Hays R, 1999, DEVELOPMENT, V126, P2891; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jia J, 2006, CELL MOL LIFE SCI, V63, P1249, DOI 10.1007/s00018-005-5519-z; Johansson FK, 2005, ONCOGENE, V24, P3896, DOI 10.1038/sj.onc.1208553; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kageyama R, 2005, EXP CELL RES, V306, P343, DOI 10.1016/j.yexcr.2005.03.015; Kappler R, 2004, ONCOGENE, V23, P8785, DOI 10.1038/sj.onc.1208133; Kappler R, 2004, INT J ONCOL, V25, P113; Kato M, 2001, BIOCHEM BIOPH RES CO, V289, P472, DOI 10.1006/bbrc.2001.5976; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; KUNAPULI SP, 1987, LIFE SCI, V40, P2225, DOI 10.1016/0024-3205(87)90057-9; Kwon C, 2004, DEVELOPMENT, V131, P2681, DOI 10.1242/dev.01127; Li XM, 2002, MICROCIRCULATION, V9, P13, DOI 10.1038/sj.mn.7800118; Lowndes SA, 2004, ONCOL RES, V14, P529, DOI 10.3727/0965040042707952; McGlinn E, 2005, MECH DEVELOP, V122, P1218, DOI 10.1016/j.mod.2005.06.012; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; Nakagawa Y, 1996, DEVELOPMENT, V122, P2449; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pathi S, 2001, MECH DEVELOP, V106, P107, DOI 10.1016/S0925-4773(01)00427-0; Pietsch T, 1997, CANCER RES, V57, P2085; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Shawber C, 1996, DEVELOPMENT, V122, P3765; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Varela AS, 1997, CANCER LETT, V121, P139, DOI 10.1016/S0304-3835(97)00340-6; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532; Yokota N, 2004, ONCOGENE, V23, P3444, DOI 10.1038/sj.onc.1207475; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399	62	129	135	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1489	1500		10.1038/sj.onc.1210767	http://dx.doi.org/10.1038/sj.onc.1210767			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17873912				2022-12-28	WOS:000253548200016
J	Lagadec, C; Adriaenssens, E; Toillon, RA; Chopin, V; Romon, R; Van Coppenolle, F; Hondermarck, H; Le Bourhis, X				Lagadec, C.; Adriaenssens, E.; Toillon, R. A.; Chopin, V.; Romon, R.; Van Coppenolle, F.; Hondermarck, H.; Le Bourhis, X.			Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells	ONCOGENE			English	Article						breast cancer; tamoxifen; TRAIL; apoptosis; tumor xenograft	KAPPA-B; DEATH; MECHANISMS; RECEPTORS; THERAPY; ALPHA	Tamoxifen (TAM), is widely used as a single agent in adjuvant treatment of breast cancer. Here, we investigated the effects of TAM in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in estrogen receptor-alpha (ER-alpha)-positive and -negative breast cancer cells. We showed that cotreatment with TAM and TRAIL synergistically induced apoptosis regardless of ER-alpha status. By contrast, cotreatment did not affect the viability of normal breast epithelial cells. Cotreatment with TAM and TRAIL in breast cancer cells decreased the levels of antiapoptotic proteins including FLIPs and Bcl-2, and enhanced the levels of proapoptotic proteins such as FADD, caspase 8, tBid, Bax and caspase 9. Furthermore, cotreatment-induced apoptosis was efficiently reduced by FADD- or Bid-siRNA, indicating the implication of both extrinsic and intrinsic pathways in synergistic apoptosis induction. Importantly, cotreatment totally arrested tumor growth in an ER-alpha-negative MDA-MB-231 tumor xenograft model. The abrogation of tumor growth correlated with enhanced apoptosis in tumor tissues. Our findings raise the possibility to use TAM in combination with TRAIL for breast cancers, regardless of ER-alpha status.	[Lagadec, C.; Adriaenssens, E.; Toillon, R. A.; Chopin, V.; Romon, R.; Hondermarck, H.; Le Bourhis, X.] Univ Sci & Tech Lille Flandres Artois, IFR147, INSERM, ERI 8,JE2488, F-59655 Villeneuve Dascq, France; Univ Sci & Tech Lille Flandres Artois, IFR147, INSERM, U800, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Le Bourhis, X (corresponding author), Univ Sci & Tech Lille Flandres Artois, IFR147, INSERM, ERI 8,JE2488, F-59655 Villeneuve Dascq, France.	xuefen.lebourhis@univ-lille1.fr	Toillon, Robert-Alain/Q-2286-2018; Le+Bourhis, Xuefen/AAL-5141-2021; Lagadec, chann/E-4250-2010	Toillon, Robert-Alain/0000-0001-5483-2118; Lagadec, chann/0000-0002-5182-2069				Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Chopin V, 2004, EXP CELL RES, V298, P560, DOI 10.1016/j.yexcr.2004.04.038; Duiker EW, 2006, EUR J CANCER, V42, P2233, DOI 10.1016/j.ejca.2006.03.018; Gelmann EP, 1997, SEMIN ONCOL, V24, pS65; Grambihler A, 2003, J BIOL CHEM, V278, P26831, DOI 10.1074/jbc.M303229200; Hawkins RA, 2000, BREAST, V9, P96, DOI 10.1054/brst.2000.0140; JORDAN VC, 1992, CANCER, V70, P977; Kallio A, 2005, APOPTOSIS, V10, P1395, DOI 10.1007/s10495-005-2137-z; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; McClay EF, 2000, BRIT J CANCER, V83, P16; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Nazarewicz RR, 2007, CANCER RES, V67, P1282, DOI 10.1158/0008-5472.CAN-06-3099; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Yanamadala V, 2007, J BIOL CHEM, V282, P24352, DOI 10.1074/jbc.M702804200	17	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1472	1477		10.1038/sj.onc.1210749	http://dx.doi.org/10.1038/sj.onc.1210749			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17767197				2022-12-28	WOS:000253548200014
J	Neise, D; Graupner, V; Gillissen, BF; Daniel, PT; Schulze-Osthoff, K; Janicke, RU; Essmann, F				Neise, D.; Graupner, V.; Gillissen, B. F.; Daniel, P. T.; Schulze-Osthoff, K.; Jaenicke, R. U.; Essmann, F.			Activation of the mitochondrial death pathway is commonly mediated by a preferential engagement of Bak	ONCOGENE			English	Article						apoptosis; Bak; Bax; Bcl-2; caspase; cytochrome c	BCL-2 FAMILY-MEMBERS; BH3 MIMETIC ABT-737; INDUCED APOPTOSIS; CELL-DEATH; BH3-ONLY PROTEINS; INTERCHAIN PROTEOLYSIS; CANCER CELLS; X-L; CASPASE-3; MCL-1	Among the members of the Bcl-2 family, the multidomain proteins Bax and Bak are crucial for the activation of mitochondria. However, it is still unclear whether they act in a unique and distinct manner or whether they exhibit redundant functions. To systematically investigate their activation on a single-cell level, we established MCF-7 cell lines stably expressing GFP-fusion variants of these proteins. We found that MCF-7/GFP-Bak cells showed an increased sensitivity to apoptosis induction by staurosporine, actinomycin D, TRAIL and overexpression of Puma compared to GFP-Bax-expressing cells. Independently of the death stimulus used, oligomerization of endogenous and exogenous Bak was mostly detected prior to an activation of Bax, whereas cells displaying oligomerized Bax in the absence of Bak clusters were not observed. In addition, activation of Bax but not Bak was attenuated by a caspase inhibitor. Consistent with this, caspase-3-deficient MCF-7 cells displayed a significantly reduced activation of endogenous Bax than caspase-3-proficient MCF-7 cells. Thus, our data strongly suggest that diverse apoptotic stimuli preferentially engage the Bak pathway, whereas the triggering of Bax occurs, at least partially, downstream of mitochondrial caspase activation, most likely constituting a positive feedback loop for the amplication of the death signal.	[Neise, D.; Graupner, V.; Schulze-Osthoff, K.; Jaenicke, R. U.; Essmann, F.] Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, NRW, Germany; [Gillissen, B. F.; Daniel, P. T.] Univ Med Ctr, Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany	Heinrich Heine University Dusseldorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Essmann, F (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, NRW, Germany.	essmann@uni-duesseldorf.de	Essmann, Frank/ABG-7409-2020; Schulze-Osthoff, Klaus/N-9025-2013	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adams KW, 2007, J BIOL CHEM, V282, P6192, DOI 10.1074/jbc.M610643200; Blanc C, 2000, CANCER RES, V60, P4386; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Dansen TB, 2006, J BIOL CHEM, V281, P10890, DOI 10.1074/jbc.M513655200; Essmann F, 2004, CANCER RES, V64, P7065, DOI 10.1158/0008-5472.CAN-04-1082; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Han J, 2004, LEUKEMIA, V18, P1671, DOI 10.1038/sj.leu.2403496; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kepp O, 2007, EMBO J, V26, P825, DOI 10.1038/sj.emboj.7601533; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Letai A, 2005, J CLIN INVEST, V115, P2648, DOI 10.1172/JCI26250; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lindenboim L, 2005, CELL DEATH DIFFER, V12, P713, DOI 10.1038/sj.cdd.4401638; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lomonosova E, 2002, J VIROL, V76, P11283, DOI 10.1128/JVI.76.22.11283-11290.2002; Lucken-Ardjomande S, 2005, J CELL SCI, V118, P473, DOI 10.1242/jcs.01654; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Murphy BM, 2004, J BIOL CHEM, V279, P36916, DOI 10.1074/jbc.M402039200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Pardo J, 2006, J CELL BIOL, V174, P509, DOI 10.1083/jcb.200604044; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Pop C, 2006, MOL CELL, V22, P269, DOI 10.1016/j.molcel.2006.03.009; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Shimazu T, 2007, GENE DEV, V21, P929, DOI 10.1101/gad.1522007; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	51	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1387	1396		10.1038/sj.onc.1210773	http://dx.doi.org/10.1038/sj.onc.1210773			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724463				2022-12-28	WOS:000253548200005
J	Delys, L; Detours, V; Franc, B; Thomas, G; Bogdanova, T; Tronko, M; Libert, F; Dumont, JE; Maenhaut, C				Delys, L.; Detours, V.; Franc, B.; Thomas, G.; Bogdanova, T.; Tronko, M.; Libert, F.; Dumont, J. E.; Maenhaut, C.			Gene expression and the biological phenotype of papillary thyroid carcinomas	ONCOGENE			English	Article						cancer; thyroid; microarrays; molecular phenotype	GROWTH-FACTOR RECEPTOR; CANCER; INVASION; MECHANISMS; PROFILES; REVEALS; BRAF; OVEREXPRESSION; METASTASIS; MIGRATION	The purpose of this paper is to correlate the molecular phenotype of papillary thyroid carcinoma (PTC) to their biological pathology. We hybridized 26 PTC on microarrays and showed that nearly 44% of the transcriptome was regulated in these tumors. We then combined our data set with two published PTC microarray studies to produce a platform- and study-independent list of PTC-associated genes. We further confirmed the mRNA regulation of 15 genes from this list by quantitative reverse transcription PCR. Analysis of this list with statistical tools led to several conclusions: (1) there is a change in cell population with an increased expression of genes involved in the immune response, reflecting lymphocyte infiltration in the tumor compared to the normal tissue. (2) The c-jun N-terminal kinase pathway is activated by overexpression of its components. ( 3) The activation of ERKK1/2 by genetic alterations is supplemented by activation of the epidermal growth factor but not of the insulin-like growth factor signaling pathway. (4) There is a downregulation of immediate early genes. (5) We observed an overexpression of many proteases in accordance with tumor remodeling, and suggested a probable role of S100 proteins and annexin A2 in this process. (6) Numerous overexpressed genes favor the hypothesis of a collective migration mode of tumor cells.	[Delys, L.; Detours, V.; Libert, F.; Dumont, J. E.; Maenhaut, C.] Univ Libre Bruxelles, Inst Interdisciplinary Res, Sch Med, Brussels, Belgium; [Franc, B.] Univ Versailles St Quentin Yvelines, Serv Anat & Cytol Pathol, Fac Med Paris Ile France Ouest, Hop Ambroise Pare APHP, Boulogne, France; [Thomas, G.] Singleton Hosp, S W Wales Canc Inst, Swansea Clin Sch, Swansea SA2 8QA, W Glam, Wales; [Bogdanova, T.; Tronko, M.] Kiev Endocrinol & Metab Res Inst, Kiev, Ukraine	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Singleton Hospital; National Academy of Medical Sciences of Ukraine; V. P. Komissarenko Institute of Endocrinology & Metabolism of the National Academy of Medical Science of Ukraine	Delys, L (corresponding author), Free Univ Brussels, Inst Interdisciplinary Res, Sch Med, Campus Erasme,Route Lennik 808, B-1070 Brussels, Belgium.	laurent.delys@ulb.ac.be; cmaenhau@ulb.ac.be	Tronko, Mykola/AAQ-3327-2021	Tronko, Mykola/0000-0001-7421-0981; Bogdanova, Tetiana/0000-0001-5119-0236				Albert L, 2003, J CELL PHYSIOL, V195, P168, DOI 10.1002/jcp.10252; Baris O, 2005, ONCOGENE, V24, P4155, DOI 10.1038/sj.onc.1208578; Borrello MG, 2005, P NATL ACAD SCI USA, V102, P14825, DOI 10.1073/pnas.0503039102; Ciampi R, 2005, ENDOCR PATHOL, V16, P163, DOI 10.1385/EP:16:3:163; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Detours V, 2005, BRIT J CANCER, V92, P1545, DOI 10.1038/sj.bjc.6602521; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Fluge O, 2006, THYROID, V16, P161; Fluge O, 2000, INT J CANCER, V87, P763, DOI 10.1002/1097-0215(20000915)87:6<763::AID-IJC1>3.0.CO;2-T; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Haugen DRF, 1996, CANCER RES, V56, P1184; Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099; HOELTING T, 1994, J CLIN ENDOCR METAB, V79, P401, DOI 10.1210/jc.79.2.401; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; LiVolsi VA, 2004, WHO CLASSIFICATION T, P57; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Mitsiades CS, 2006, J CLIN ENDOCR METAB, V91, P3662, DOI 10.1210/jc.2006-0055; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Pavlidis P, 2003, BIOINFORMATICS, V19, P1620, DOI 10.1093/bioinformatics/btg227; Powell DJ, 2003, J IMMUNOL, V170, P861, DOI 10.4049/jimmunol.170.2.861; Prasad ML, 2005, MODERN PATHOL, V18, P48, DOI 10.1038/modpathol.3800235; Semov A, 2005, J BIOL CHEM, V280, P20833, DOI 10.1074/jbc.M412653200; Shin E, 2004, YONSEI MED J, V45, P306, DOI 10.3349/ymj.2004.45.2.306; Sid B, 2006, INT J BIOCHEM CELL B, V38, P1729, DOI 10.1016/j.biocel.2006.04.005; Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P1251, DOI 10.3748/wjg.v11.i9.1251; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Wattel S, 2005, ONCOGENE, V24, P6902, DOI 10.1038/sj.onc.1208849; Zou M, 2005, BRIT J CANCER, V93, P1277, DOI 10.1038/sj.bjc.6602856	42	62	68	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7894	7903		10.1038/sj.onc.1210588	http://dx.doi.org/10.1038/sj.onc.1210588			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17621275				2022-12-28	WOS:000252163500007
J	Demuth, I; Digweed, M				Demuth, I.; Digweed, M.			The clinical manifestation of a defective response to DNA double-strand breaks as exemplified by Nijmegen breakage syndrome	ONCOGENE			English	Review						immunodeficiency; lymphoma; haploinsufficient tumor suppressor	CLASS-SWITCH RECOMBINATION; GERMLINE 657DEL5 MUTATION; SYNDROME GENE NBS1; CHROMOSOMAL INSTABILITY; DEPENDENT PHOSPHORYLATION; TARGETED DISRUPTION; ATM ACTIVATION; INCREASED RISK; MRE11 COMPLEX; CANCER	The autosomal recessive genetic disorder Nijmegen breakage syndrome (NBS) was first described in 1981 in patients living in Nijmegen, Holland. NBS patients display a characteristic facial appearance, microcephaly and a range of symptoms including immunodeficiency, increased cancer risk and growth retardation. In addition, NBS patient cells were found to have elevated levels of chromosomal damage and to be sensitive to ionizing irradiation (IR). This radiosensitivity had fatal consequences in some undiagnosed patients. The most dangerous DNA lesion caused by IR is considered to be the double-strand break (DSB) and indeed, NBS patient cells are sensitive to all mutagens that produce DSBs directly or indirectly. We discuss here our current understanding of how a deficiency in DSB repair manifests as the particular symptom complex of NBS.	Charite Univ Med Berlin, Inst Humangenet, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Digweed, M (corresponding author), Charite Univ Med Berlin, Inst Humangenet, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	martin.digweed@charite.de	Demuth, Ilja/ABD-5352-2021	Demuth, Ilja/0000-0002-4340-2523				Buslov KG, 2005, INT J CANCER, V114, P585, DOI 10.1002/ijc.20765; Carlomagno F, 1999, GENE CHROMOSOME CANC, V25, P393, DOI 10.1002/(SICI)1098-2264(199908)25:4<393::AID-GCC12>3.0.CO;2-8; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen WE, 2005, WIREL NETW MOB COMP, V1, P3; Cherry SM, 2007, CURR BIOL, V17, P373, DOI 10.1016/j.cub.2006.12.048; Chrzanowska KH, 2006, INT J CANCER, V118, P1269, DOI 10.1002/ijc.21439; Cybulski C, 2004, CANCER RES, V64, P1215, DOI 10.1158/0008-5472.CAN-03-2502; Debniak T, 2003, MELANOMA RES, V13, P365, DOI 10.1097/00008390-200308000-00005; Demuth I, 2004, HUM MOL GENET, V13, P2385, DOI 10.1093/hmg/ddh278; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Difilippantonio S, 2007, J EXP MED, V204, P1003, DOI 10.1084/jem.20070319; Dumon-Jones V, 2003, CANCER RES, V63, P7263; Frappart PO, 2005, NAT MED, V11, P538, DOI 10.1038/nm1228; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gorski B, 2003, INT J CANCER, V106, P379, DOI 10.1002/ijc.11231; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Kracker S, 2005, P NATL ACAD SCI USA, V102, P1584, DOI 10.1073/pnas.0409191102; Kruger L, 2007, CARCINOGENESIS, V28, P107, DOI 10.1093/carcin/bgl126; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lian GW, 2006, CURR OPIN PEDIATR, V18, P614, DOI 10.1097/MOP.0b013e328010542d; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Meyer P, 2007, MELANOMA RES, V17, P109, DOI 10.1097/CMR.0b013e3280dec638; O'Driscoll M, 2007, AM J HUM GENET, V81, P77, DOI 10.1086/518696; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223; Porcedda P, 2006, DNA REPAIR, V5, P904, DOI 10.1016/j.dnarep.2006.05.002; Powers JT, 2004, MOL CANCER RES, V2, P203; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Resnick IB, 2003, AM J MED GENET A, V120A, P174, DOI 10.1002/ajmg.a.20188; Rhee JG, 2007, INT J RADIAT ONCOL, V67, P273, DOI 10.1016/j.ijrobp.2006.09.019; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Seemanova E, 2006, Cas Lek Cesk, V145, P201; Seemanova E, 2006, Cas Lek Cesk, V145, P138; SEEMANOVA E, 1990, MUTAT RES, V238, P321, DOI 10.1016/0165-1110(90)90024-6; Seemanova E, 2006, J MED GENET, V43, P218, DOI 10.1136/jmg.2005.035287; SEEMANOVA E, 2004, CSL PEDIAT, V59, P242; Stanulla M, 2000, BRIT J HAEMATOL, V109, P117, DOI 10.1046/j.1365-2141.2000.01973.x; Steffen J, 2004, INT J CANCER, V111, P67, DOI 10.1002/ijc.20239; Steffen J, 2006, INT J CANCER, V119, P472, DOI 10.1002/ijc.21853; Steffen J, 2006, INT J CANCER, V119, P2970, DOI 10.1002/ijc.22280; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stracker TH, 2007, NATURE, V447, P218, DOI 10.1038/nature05740; TAYLOR GM, 2001, CANCER RES, V61, P3570; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 2001, CANCER RES, V61, P3570; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; Yeo TC, 2000, MOL IMMUNOL, V37, P1131, DOI 10.1016/S0161-5890(01)00026-8; Yuan LX., 2001, ACTA AGRON SINICA, V27, P149, DOI 10.3321/j.issn:0496-3490.2001.02.003; Zhang Y, 2007, TOXICOL LETT, V171, P50, DOI 10.1016/j.toxlet.2007.04.006; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	54	54	55	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2007	26	56					7792	7798		10.1038/sj.onc.1210876	http://dx.doi.org/10.1038/sj.onc.1210876			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066092				2022-12-28	WOS:000251537900010
J	Fischer, U; Meese, E				Fischer, U.; Meese, E.			Glioblastoma multiforme: the role of DSB repair between genotype and phenotype	ONCOGENE			English	Review						gene amplification; XRCC6BP1; temozolomide	COMPARATIVE GENOMIC HYBRIDIZATION; HEMATOPOIETIC STEM-CELLS; KINASE CATALYTIC SUBUNIT; GENE AMPLIFICATION; PROTEIN-KINASE; MALIGNANT GLIOMA; DNA-REPAIR; SECONDARY GLIOBLASTOMA; FRAGILE SITES; EXPRESSION	Glioblastoma is the most frequent primary brain tumor in adults. The average survival time of less than 1 year did not improve notably over the last three decades. The dismal prognosis of glioblastoma patients is largely due to the striking radioresistance of this tumor. Here, we attempt a combined view on the genetics, the repair mechanisms and the radioresistance of glioblastoma. Specifically, we address the role of DNA-PKcs and the novel potential end-joining factor KUB3 in maintaining the radioresistant phenotype, the interrelationship between genetic lesions and repair mechanisms, and new perspectives that emerge from the identification of glioblastoma stem cells.	Univ Saarland, Dept Human Genet, D-66421 Homburg, Germany	Saarland University	Meese, E (corresponding author), Univ Saarland, Dept Human Genet, Bldg 60, D-66421 Homburg, Germany.	hgemee@uniklinik-saarland.de	Meese, Eckart Ulrich/ABD-1983-2021					ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Clarke MF, 2004, NATURE, V432, P281, DOI 10.1038/432281a; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202; Dibiase SJ, 2000, CANCER RES, V60, P1245; FISCHER U, 1994, EUR J CANCER, V30A, P1124, DOI 10.1016/0959-8049(94)90470-7; Fischer U, 2001, GLIA, V36, P1, DOI 10.1002/glia.1090; Friedman HS, 1997, CANCER RES, V57, P2933; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kasten U, 1999, RADIAT RES, V151, P532, DOI 10.2307/3580029; Koschny R, 2002, CANCER GENET CYTOGEN, V135, P147, DOI 10.1016/S0165-4608(01)00650-1; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Maher EA, 2006, CANCER RES, V66, P11502, DOI 10.1158/0008-5472.CAN-06-2072; McClintock B, 1941, GENETICS, V26, P234; Mondello C, 2001, CANCER RES, V61, P4520; MULERIS M, 1994, ONCOGENE, V9, P2717; Munnia A, 2001, ONCOGENE, V20, P4853, DOI 10.1038/sj.onc.1204650; Nijnik A, 2007, NATURE, V447, P686, DOI 10.1038/nature05875; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Otomo T, 2004, J RADIAT RES, V45, P53, DOI 10.1269/jrr.45.53; Raderschall E, 2002, J CELL SCI, V115, P153; Rattray AJ, 2005, GENE DEV, V19, P1390, DOI 10.1101/gad.1315805; Reifenberger G, 1996, CANCER RES, V56, P5141; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Roos WP, 2007, ONCOGENE, V26, P186, DOI 10.1038/sj.onc.1209785; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Ruano Y, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-39; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; SCHROCK E, 1994, AM J PATHOL, V144, P1203; Schwartz M, 2005, GENE DEV, V19, P2715, DOI 10.1101/gad.340905; Shen HX, 1998, BBA-GEN SUBJECTS, V1381, P131, DOI 10.1016/S0304-4165(98)00020-8; Short SC, 2007, NEURO-ONCOLOGY, V9, P404, DOI 10.1215/15228517-2007-030; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Slack A, 2006, PLOS GENET, V2, P385, DOI 10.1371/journal.pgen.0020048; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2007, J CLIN ONCOL, V25, P4127, DOI 10.1200/JCO.2007.11.8554; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Tanaka H, 2005, NAT GENET, V37, P320, DOI 10.1038/ng1515; Virsik-Kopp P, 2003, INT J RADIAT BIOL, V79, P61, DOI 10.1080/0955300021000038644; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165	46	24	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7809	7815		10.1038/sj.onc.1210878	http://dx.doi.org/10.1038/sj.onc.1210878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066094				2022-12-28	WOS:000251537900012
J	Xu, Y				Xu, Y.			Induction of genetic instability by gain-of-function p53 cancer mutants	ONCOGENE			English	Review						p53 cancer mutants; gain-of-function; genetic stability; chromosomal translocation; ATM	P53-INDEPENDENT APOPTOTIC PATHWAYS; EMBRYONIC STEM-CELLS; LI-FRAUMENI-SYNDROME; DNA-DAMAGE; TUMOR SUPPRESSION; ATM ACTIVATION; P53-DEPENDENT APOPTOSIS; TRANSCRIPTION-FACTOR; WILD-TYPE; REPLICATIVE SENESCENCE	p53 plays critical roles in tumor suppression and the loss of its function is required for cancer progression. In this context, the p53 gene is the most commonly mutated tumor suppressor gene in human cancers. The majority of the p53 gene mutations in human cancers are missense mutations, leading to the expression of the full-length mutant p53 protein in cancer cells. In addition to the loss of tumor suppression activity, p53 cancer mutants gain new oncogenic activities to promote tumorigenesis and drug resistance. Recent studies have identified a novel gain-of-function of p53 cancer mutants in inducing genetic instability by inactivating critical tumor suppressors such as ATM. Genetic instability is a common mechanism by which cancer cells efficiently accumulate genetic mutations to promote their growth, survival and metastatic potential. Therefore, this gain-of-function of p53 cancer mutants could play important roles in tumorigenesis and drug resistance of various types of human cancers. In addition, because many cancer therapies such as radiation therapy suppress or kill cancer cells by activating ATM-dependent responses to DNA double-stranded break damage, elucidation of this gain-of-function of p53 cancer mutants will have important implications on cancer therapy.	Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X	NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER; NCI NIH HHS [CA94254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albor A, 1998, CANCER RES, V58, P2091; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Goldie JH, 2001, CANCER METAST REV, V20, P63, DOI 10.1023/A:1013164609041; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gudkov AV, 2003, CANCER BIOL THER, V2, P444, DOI 10.4161/cbt.2.4.480; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hergenhahn M, 2004, CELL CYCLE, V3, P738; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kang J, 2005, MOL CELL BIOL, V25, P661, DOI 10.1128/MCB.25.2.661-670.2005; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Li Y, 2007, ONCOGENE, V26, P2220, DOI 10.1038/sj.onc.1210311; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Murphy ME, 2003, CANCER BIOL THER, V2, P381, DOI 10.4161/cbt.2.4.439; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Taubert H, 1996, CANCER RES, V56, P4134; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vega FJ, 1997, BRIT J CANCER, V76, P44, DOI 10.1038/bjc.1997.334; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Weisz L, 2007, ONCOGENE, V26, P2202, DOI 10.1038/sj.onc.1210294; Woerner Stefan M., 2006, Cancer Biomarkers, V2, P69; Xu Y, 2006, NAT REV IMMUNOL, V6, P261, DOI 10.1038/nri1804; Xu Y, 2005, CELL CYCLE, V4, P363, DOI 10.4161/cc.4.3.1529; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724; Zhang YM, 2006, DNA REPAIR, V5, P1282, DOI 10.1016/j.dnarep.2006.05.020	87	42	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3501	3507		10.1038/sj.onc.1211023	http://dx.doi.org/10.1038/sj.onc.1211023			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223686				2022-12-28	WOS:000256468500001
J	Dong, W; Arpin, C; Accardi, R; Gissmann, L; Sylla, BS; Marvel, J; Tommasino, M				Dong, W.; Arpin, C.; Accardi, R.; Gissmann, L.; Sylla, B. S.; Marvel, J.; Tommasino, M.			Loss of p53 or p73 in human papillomavirus type 38 E6 and E7 transgenic mice partially restores the UV-activated cell cycle checkpoints	ONCOGENE			English	Article						HPV38; transgenic mice; Delta Np73; UV irradiation; cell cycle checkpoints	SPONTANEOUS TUMORS; SKIN; PROTEINS; CANCER	We have previously shown that human keratinocytes expressing E6 and E7 from the cutaneous human papillomavirus (HPV) type 38 have high levels of a specific form of p53, which in turn activate the transcription of Delta Np73 gene. Expression of HPV38 E6 and E7 in mouse skin also promotes p53 and Delta Np73 accumulation. Interestingly, keratinocytes of these mice do not undergo cell cycle arrest after skin ultraviolet (UV) irradiation. Here, we provide several lines of evidence that Delta Np73 expression and lack of the UV response are directly linked. Loss of p53 gene in HPV38E6/E7 transgenic mice abolished Delta Np73 expression and partially restored the UV-activated cell cycle checkpoints. Similarly, loss of p73, and consequently Delta Np73, led to restoration of the p53 pathways. In fact, keratinocytes of p73(-/-) HPV38 E6/E7 transgenic mice upon UV irradiation express high levels of p21(WAF1) and are cell cycle arrested. Thus, HPV38 E6 and E7, via Delta Np73 accumulation, are able to alter the regulation of cell cycle checkpoints activated by UV radiation. These data suggest that UV and HPV may cooperate in skin carcinogenesis.	[Dong, W.; Accardi, R.; Sylla, B. S.; Tommasino, M.] WHO, Int Agcy Res Canc, Infect & Canc Biol Grp, F-69008 Lyon, France; [Arpin, C.; Marvel, J.] INSERM, U851, Lyon, France; [Arpin, C.; Marvel, J.] BioSci Lyon Gerland, IFR128, Lyon, France; [Arpin, C.; Marvel, J.] Univ Lyon 1, F-69622 Villeurbanne, France; [Gissmann, L.] Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany	World Health Organization; International Agency for Research on Cancer (IARC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Helmholtz Association; German Cancer Research Center (DKFZ)	Tommasino, M (corresponding author), WHO, Int Agcy Res Canc, Infect & Canc Biol Grp, F-69008 Lyon, France.	tommasino@iarc.fr	marvel, jacqueline/H-8638-2014; Gissmann, Lutz/H-4688-2011; Arpin, Christophe/M-3862-2014	marvel, jacqueline/0000-0001-6241-459X; Arpin, Christophe/0000-0003-0915-5554				Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Akgul B, 2005, CANCER RES, V65, P2216, DOI 10.1158/0008-5472.CAN-04-1952; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dong W, 2005, J VIROL, V79, P14899, DOI 10.1128/JVI.79.23.14899-14908.2005; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Michel A, 2006, J VIROL, V80, P11153, DOI 10.1128/JVI.00954-06; Pfister Herbert, 2003, J Natl Cancer Inst Monogr, P52; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	12	16	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2923	2928		10.1038/sj.onc.1210944	http://dx.doi.org/10.1038/sj.onc.1210944			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18026133				2022-12-28	WOS:000255502500013
J	Song, MS; Song, SJ; Kim, SJ; Nakayama, K; Nakayama, KI; Lim, DS				Song, M. S.; Song, S. J.; Kim, S. J.; Nakayama, K.; Nakayama, K. I.; Lim, D-S			Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G(1)-S transition	ONCOGENE			English	Article						Skp2; RASSF1A; cyclin D-Cdk4; ubiquitination; G(1)-S transition	ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE; HUMAN CANCERS; PROTEIN; GENE; PROGRESSION; LIGASE; TRANSCRIPTION; ACCUMULATION; DESTRUCTION	The tumor suppressor RASSF1A is inactivated in many human cancers and is implicated in regulation of microtubule stability, cell cycle progression and apoptosis. However, the precise mechanisms of RASSF1A action and their regulation remain unclear. Here we show that Skp2, an oncogenic subunit of the Skp1-Cul1-F-box ubiquitin ligase complex, interacts with, ubiquitinates, and promotes the degradation of RASSF1A at the G1-S transition of the cell cycle. This Skp2-dependent destruction of RASSF1A requires phosphorylation of the latter on serine-203 by cyclin D-cyclin-dependent kinase 4. Interestingly, mutation of RASSF1A-phosphorylation site Ser(203) to alanine results in a delay in cell cycle progression from G(1) to S phase. Moreover, enforced expression of Skp2 abolishes the inhibitory effect of RASSF1A on cell proliferation. Finally, the delay in G(1)-S progression after Skp2 removal is normalized by depletion of RASSF1A. These findings suggest that the Skp2-mediated degradation of RASSF1A plays an important role in cell proliferation and survival.	[Song, M. S.; Song, S. J.; Kim, S. J.; Lim, D-S] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Nakayama, K.] Tohoku Univ, Grad Sch Med, Ctr Translat & Adv Anim Res Human Dis, Div Dev Genet, Sendai, Miyagi 980, Japan; [Nakayama, K. I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan	Korea Advanced Institute of Science & Technology (KAIST); Tohoku University; Kyushu University	Lim, DS (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Guseong D, Taejon 305701, South Korea.	daesiklim@kaist.ac.kr	Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555				Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bashir T, 2003, ADV CANCER RES, V88, P101, DOI 10.1016/S0065-230X(03)88305-7; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harper JW, 2002, TRENDS CELL BIOL, V12, P104, DOI 10.1016/S0962-8924(01)02238-3; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Pagano M, 2003, CANCER CELL, V4, P251, DOI 10.1016/S1535-6108(03)00243-5; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; RONG R, 2007, ONCOGENE; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tommasi S, 2005, CANCER RES, V65, P92; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	34	49	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3176	3185		10.1038/sj.onc.1210971	http://dx.doi.org/10.1038/sj.onc.1210971			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071316				2022-12-28	WOS:000255897600010
J	Takano, S; Yoshitomi, H; Togawa, A; Sogawa, K; Shida, T; Kimura, F; Shimizu, H; Tomonaga, T; Nomura, F; Miyazaki, M				Takano, S.; Yoshitomi, H.; Togawa, A.; Sogawa, K.; Shida, T.; Kimura, F.; Shimizu, H.; Tomonaga, T.; Nomura, F.; Miyazaki, M.			Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells	ONCOGENE			English	Article						apolipoprotein C-1; pancreatic cancer; SELDI-TOF MS; serum marker; apoptosis	GENE-EXPRESSION; PROTEOMIC PATTERNS; PROTEIN EXPRESSION; SERUM; IDENTIFICATION; PROLIFERATION; CARCINOMA; PATHWAY; MARKERS; SURFACE	Pancreatic cancer still remains one of the most lethal diseases and establishment of new therapy is needed. The purpose of this study is to find novel factors involved in pancreatic cancer progression by proteomic approach. We compared pre- and postoperative serum protein pro. ling obtained from pancreatic cancer patients who had curative pancreatectomy using surface-enhanced laser desorption ionization time-of-flight mass spectrometry. The peak intensity levels of both 6630 and 6420 Da were significantly higher in the preoperative serum than in the postoperative serum (P < 0.002). Sequential amino acid analysis identified these proteins to be apolipoprotein C-1 (ApoC-1). The high level of ApoC-1 in preoperative serum significantly correlated with poor prognosis. Furthermore, ApoC-1 was abundantly expressed in pancreas neoplastic epithelium, and was detected in the culture medium of the pancreatic cancer cell line in vitro, which suggests that cancer cells secrete ApoC-1. Inhibition of ApoC-1 expression by short interfering RNA suppressed cell proliferation and induced apoptosis of pancreatic cancer cells. The specific expression of ApoC-1 and its role in preventing from spontaneous apoptosis in pancreatic cancer cells suggest that ApoC-1 contributes to the aggressiveness of pancreatic cancer and will be useful as a new therapeutic target.	[Takano, S.; Yoshitomi, H.; Togawa, A.; Shida, T.; Kimura, F.; Shimizu, H.; Miyazaki, M.] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chuo Ku, Chiba 2608670, Japan; [Takano, S.; Sogawa, K.; Tomonaga, T.; Nomura, F.] Chiba Univ, Grad Sch Med, Dept Mol Diag, Chiba 2608670, Japan	Chiba University; Chiba University	Yoshitomi, H (corresponding author), Chiba Univ, Grad Sch Med, Dept Gen Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	yoshitomi@faculty.chiba-u.jp	Yoshitomi, Hideyuki/AAN-8812-2020	Yoshitomi, Hideyuki/0000-0003-2911-8056				Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chen X, 2006, CANCER RES, V66, P11323, DOI 10.1158/0008-5472.CAN-06-1536; Chen YC, 2005, CANCER RES, V65, P331; Ehmann M, 2007, PANCREAS, V34, P205, DOI 10.1097/01.mpa.0000250128.57026.b2; FADOK VA, 1992, J IMMUNOL, V148, P2207; Ferrone CR, 2006, J CLIN ONCOL, V24, P2897, DOI 10.1200/JCO.2005.05.3934; Goncalves A, 2006, ONCOGENE, V25, P981, DOI 10.1038/sj.onc.1209131; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P91, DOI 10.1016/S0002-9440(10)64353-2; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; Melle C, 2005, GASTROENTEROLOGY, V129, P66, DOI 10.1053/j.gastro.2005.05.014; Mitsuhashi N, 2003, HEPATOLOGY, V37, P1105, DOI 10.1053/jhep.2003.50204; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Mutaguchi K, 2003, CANCER RES, V63, P7717; Nomura F, 2004, PROTEOMICS, V4, P1187, DOI 10.1002/pmic.200300674; Paradis V, 2005, HEPATOLOGY, V41, P40, DOI 10.1002/hep.20505; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Rhodes JM, 1999, ANN ONCOL, V10, P118, DOI 10.1023/A:1008369626649; Rosty C, 2002, CANCER RES, V62, P1868; Ryu B, 2001, CANCER RES, V61, P1833; Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008; SCHAEFER EJ, 1978, J LIPID RES, V19, P667; Shida T, 2006, CANCER BIOL THER, V5, P1530, DOI 10.4161/cbt.5.11.3458; Sobin LH., 2002, INT UNION CANC UICC, V6; Tomonaga T, 2004, CLIN CANCER RES, V10, P2007, DOI 10.1158/1078-0432.CCR-03-0321; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; Wroblewski MS, 2006, FEBS J, V273, P4707, DOI 10.1111/j.1742-4658.2006.05473.x; Xiao Z, 2005, MOL CELL ENDOCRINOL, V230, P95, DOI 10.1016/j.mce.2004.10.010; Xiao Z, 2001, CANCER RES, V61, P6029; Yu KH, 2005, J PROTEOME RES, V4, P1742, DOI 10.1021/pr050174l	32	56	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2008	27	20					2810	2822		10.1038/sj.onc.1210951	http://dx.doi.org/10.1038/sj.onc.1210951			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037960				2022-12-28	WOS:000255502500002
J	Lehnert, S; Gotz, C; Kartarius, S; Schafer, B; Montenarh, M				Lehnert, S.; Goetz, C.; Kartarius, S.; Schaefer, B.; Montenarh, M.			Protein kinase CK2 interacts with the splicing factor hPrp3p	ONCOGENE			English	Article						protein kinase CK2; hPrp3p; splicing factor; phosphorylation; protein -protein interaction	CARBOXYL-TERMINAL DOMAIN; RNA-POLYMERASE-II; DOMINANT RETINITIS-PIGMENTOSA; BETA-SUBUNIT; CASEIN KINASE-2; CYCLIN-H; PHOSPHORYLATION; EXPRESSION; SUBSTRATE; BINDING	Numerous signalling pathways in cells are influenced by the ubiquitous Ser/ Thr protein kinase CK2. Protein kinase CK2 is composed of two regulatory beta-subunits and two catalytic alpha- or alpha'- subunits. Several of the known CK2 substrates are proteins known to regulate transcriptional events. Here, we describe that protein kinase CK2 interacts with the splicing factor hPrp3p, which is important for the assembly of the spliceosome. In a two-hybrid screen hPrp3p is exclusively bound to the catalytic alpha- or alpha'- subunits of CK2 but not to the regulatory beta-subunit. The interaction was confirmed by coimmunoprecipitation experiments in vitro and in vivo. Moreover, both proteins colocalized in nuclear speckles which is typical for splicing factor compartments within the nucleus. Phosphorylation experiments revealed that hPrp3p is also a substrate of protein kinase CK2. The main phosphorylation site was mapped to C- terminal residues. In vitro and in vivo splicing assays showed that the splicing activity is significantly influenced by the CK2 - hPrp3p interaction. Thus, these data showed that CK2 is involved in the regulation of RNA processing.	[Lehnert, S.; Goetz, C.; Kartarius, S.; Schaefer, B.; Montenarh, M.] Univ Saarland, D-66421 Homburg, Germany	Saarland University	Montenarh, M (corresponding author), Univ Saarland, Gebaude 44, D-66421 Homburg, Germany.	Montenarh@uks.eu	Montenarh, Mathias/AAB-6689-2020					Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; BURNETT G, 1954, J BIOL CHEM, V211, P969; Cabrejos ME, 2004, J CELL BIOCHEM, V93, P2, DOI 10.1002/jcb.20209; Chakarova CF, 2002, HUM MOL GENET, V11, P87, DOI 10.1093/hmg/11.1.87; Faust M, 1999, FEBS LETT, V462, P51, DOI 10.1016/S0014-5793(99)01492-1; Faust M, 2002, BIOCHEM BIOPH RES CO, V269, P6; Gonzalez-Santos JM, 2002, J BIOL CHEM, V277, P23764, DOI 10.1074/jbc.M111461200; Gotz C, 2005, MOL CELL BIOCHEM, V274, P181, DOI 10.1007/s11010-005-2950-2; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; Guerra B, 1998, ACTA CRYSTALLOGR D, V54, P143, DOI 10.1107/S0907444997010184; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Krempler A, 2005, CELL MOL LIFE SCI, V62, P1379, DOI 10.1007/s00018-005-5023-5; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; Li MF, 1999, J MOL BIOL, V293, P1067, DOI 10.1006/jmbi.1999.3207; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Liu SB, 2006, RNA, V12, P1418, DOI 10.1261/rna.55406; Maita H, 2004, EXP CELL RES, V300, P283, DOI 10.1016/j.yexcr.2004.07.029; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; Messenger MM, 2002, J BIOL CHEM, V277, P23054, DOI 10.1074/jbc.M200111200; Palancade B, 2002, J BIOL CHEM, V277, P36061, DOI 10.1074/jbc.M205192200; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Schneider E, 2002, ONCOGENE, V21, P5031, DOI 10.1038/sj.onc.1205690; SCHNEIDER HR, 1988, BIOCHEM BIOPH RES CO, V156, P1390, DOI 10.1016/S0006-291X(88)80786-1; Schuster N, 1999, FEBS LETT, V447, P160, DOI 10.1016/S0014-5793(99)00273-2; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Trembley JH, 2005, MOL CELL BIOL, V25, P1446, DOI 10.1128/MCB.25.4.1446-1457.2005; Trembley JH, 2003, J BIOL CHEM, V278, P2265, DOI 10.1074/jbc.M207518200	35	18	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2390	2400		10.1038/sj.onc.1210882	http://dx.doi.org/10.1038/sj.onc.1210882			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	18026141				2022-12-28	WOS:000254844900004
J	Tsutsumi, S; Scroggins, B; Koga, F; Lee, MJ; Trepel, J; Felts, S; Carreras, C; Neckers, L				Tsutsumi, S.; Scroggins, B.; Koga, F.; Lee, M-J; Trepel, J.; Felts, S.; Carreras, C.; Neckers, L.			A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion	ONCOGENE			English	Article						heat shock protein 90; cell motility; cancer metastasis; molecularly targeted small molecules	FOCAL ADHESION KINASE; CANCER CELLS; METASTASIS; MIGRATION; MELANOMA; EXPRESSION; GELDANAMYCIN; PHENOTYPES; SELECTION; ACTIN	Heat shock protein 90 ( Hsp90) is a molecular chaperone that maintains function of numerous intracellular signaling nodes utilized by cancer cells for proliferation and survival. Hsp90 is also detected on the plasma membrane of tumor cells and its expression has been suggested to correlate with metastatic potential. Given the abundance and diverse functions of the intracellular pool of this protein, the precise contribution of cell surface Hsp90 to cell motility and tumor metastasis remains to be determined. In this study we utilized the small molecule DMAG- N- oxide, a novel cell- impermeable Hsp90 inhibitor, to specifically examine the role of cell surface Hsp90 in cell motility. We observed that, while not affecting intracellular Hsp90 function, DMAG- N- oxide significantly retarded tumor cell migration and integrin/extracellular matrix- dependent cytoskeletal reorganization. Concomitant with these findings, targeting cell surface Hsp90 significantly inhibited tumor cell motility and invasion in vitro, and had a dramatic impact on melanoma cell lung colonization in vivo. These data indicate that cell surface Hsp90 plays an important role in modulating cancer cell migration that is independent of the function of the intracellular Hsp90 pool, and that small molecule inhibitors of surface Hsp90 may provide a new approach to targeting the metastatic phenotype.	[Tsutsumi, S.; Scroggins, B.; Koga, F.; Neckers, L.] NCI, NIH, Urol Oncol Branch, Bethesda, MD 20892 USA; [Lee, M-J; Trepel, J.] NCI, Med Oncol Branch, Bethesda, MD 20892 USA; [Felts, S.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA; [Felts, S.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA; [Carreras, C.] Kosan Biosci, Hayward, CA USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; Mayo Clinic; Bristol-Myers Squibb; Kosan Biosciences, Inc.	Neckers, L (corresponding author), NCI, NIH, Urol Oncol Branch, 9000 ROckville Pike,Bldg 10-CRC,1-5940, Bethesda, MD 20892 USA.	len@helix.nih.gov	, Fumitaka/AAO-2957-2021; KOGA, Fumitaka/AAM-8739-2021; Koga, Fumitaka/AAO-4655-2021; Koga, Fumitaka/AAO-2779-2021	, Fumitaka/0000-0001-7888-0085; KOGA, Fumitaka/0000-0001-7888-0085; 	Intramural NIH HHS [Z01 SC006659-25, Z01 SC010074-12] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC011032, ZIASC010074, ZICSC006743, Z01SC006659] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlander SJH, 2006, J BIOL CHEM, V281, P2989, DOI 10.1074/jbc.M508687200; Banerjee S, 2005, ADV MATER, V17, P17, DOI 10.1002/adma.200401340; Becker B, 2004, EXP DERMATOL, V13, P27, DOI 10.1111/j.0906-6705.2004.00114.x; BRUNSON KW, 1978, NATURE, V272, P543, DOI 10.1038/272543a0; Cranmer LD, 2005, MELANOMA RES, V15, P325, DOI 10.1097/00008390-200510000-00002; Entschladen F, 2004, LANCET ONCOL, V5, P254, DOI 10.1016/S1470-2045(04)01431-7; ERKELLERYUKSEL FM, 1992, J AUTOIMMUN, V5, P803, DOI 10.1016/0896-8411(92)90194-U; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Fidler IJ, 1999, CANCER CHEMOTH PHARM, V43, pS3, DOI 10.1007/s002800051091; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Heath Elisabeth I, 2005, Clin Prostate Cancer, V4, P138, DOI 10.3816/CGC.2005.n.024; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Neckers Len, 2005, Expert Opin Emerg Drugs, V10, P137, DOI 10.1517/14728214.10.1.137; Nguyen DM, 2000, ANN THORAC SURG, V70, P1853, DOI 10.1016/S0003-4975(00)01810-5; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Sidera K, 2004, J BIOL CHEM, V279, P45379, DOI 10.1074/jbc.M405486200; Solit DB, 2002, CLIN CANCER RES, V8, P986; Stellas D, 2007, CLIN CANCER RES, V13, P1831, DOI 10.1158/1078-0432.CCR-06-1585; Tian ZQ, 2004, BIOORGAN MED CHEM, V12, P5317, DOI 10.1016/j.bmc.2004.07.053; Wehrle-Haller B, 2003, INT J BIOCHEM CELL B, V35, P39, DOI 10.1016/S1357-2725(02)00071-7; Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x	29	130	140	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2478	2487		10.1038/sj.onc.1210897	http://dx.doi.org/10.1038/sj.onc.1210897			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968312	Green Accepted			2022-12-28	WOS:000254844900012
J	Loveridge, CJ; MacDonald, ADH; Thoms, HC; Dunlop, MG; Stark, LA				Loveridge, C. J.; MacDonald, A. D. H.; Thoms, H. C.; Dunlop, M. G.; Stark, L. A.			The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappa B	ONCOGENE			English	Article						chemoprevention; colon cancer; aspirin; cell adhesion; nucleolus; cell death	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSCRIPTIONAL REGULATION; EXPRESSION; APOPTOSIS; CHEMOPREVENTION; ICAM-1; CELLS; GENE; RELA	Understanding the mechanisms that underlie the antitumour activity of non-steroidal anti-inflammatory drugs (NSAIDs) against colorectal cancer will allow the development of more effective and specific chemopreventative agents. Modulation of the NF-kappa B pathway has been implicated as a key effector of the antitumour effect of aspirin, but the effects of non-aspirin NSAIDs on this pathway have yet to be fully defined. Here, we demonstrate that sulindac, sulindac sulfone and indomethacin activate the NF-kappa B pathway in colorectal cancer cells, as determined by western blot analysis of cytoplasmic levels of I kappa B alpha and immunocytochemical analysis of nuclear NF-kappa B/RelA. Furthermore, we show that all of these NSAIDs induce nucleolar translocation of the RelA subunit of NF-kappa B. Using RelA deleted for the previously described nucleolar localization signal, we demonstrate that this response is causally involved in the apoptotic effects of these agents. Finally, we demonstrate that NSAID-mediated nucleolar translocation of RelA is associated with downregulation of NF-kappa B-driven transcription and of the NF-kappa B target gene, ICAM-1. These data identify nucleolar translocation of RelA and the associated repression of the NF-kappa B-driven transcription as a central molecular mechanism of NSAID-mediated growth inhibition and apoptosis. As well as providing new understanding of the molecular determinants of RelA function, these findings also have relevance to the development of novel chemotherapeutic and chemopreventative agents.	Univ Edinburgh, Canc Res Ctr, Colon Canc Genet Grp, Sch Clin & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Stark, LA (corresponding author), Univ Edinburgh, Edinburgh Canc Res Ctr, Colon Canc Genet Grp, MRC,Human Genet Unit,Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland.	lesley.stark@hgu.mrc.ac.uk	Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851; Loveridge, Carolyn/0000-0002-6237-8661	Cancer Research UK [C48/A6361, C20658/A6656, C348/A3758] Funding Source: Medline; Medical Research Council [MC_U127527198] Funding Source: Medline; MRC [MC_U127527198] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BRANDLI DW, 1991, CLIN PHARMACOL THER, V50, P650, DOI 10.1038/clpt.1991.203; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Din FVN, 2004, BRIT J CANCER, V91, P381, DOI 10.1038/sj.bjc.6601913; DIPPOLD W, 1993, GUT, V34, P1593, DOI 10.1136/gut.34.11.1593; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Gardner SH, 2004, BRIT J CANCER, V91, P153, DOI 10.1038/sj.bjc.6601901; Grau MV, 2006, BASIC CLIN PHARMACOL, V98, P281, DOI 10.1111/j.1742-7843.2006.pto_294.x; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Stark LA, 2005, MOL CELL BIOL, V25, P5985, DOI 10.1128/MCB.25.14.5985-6004.2005; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Stark LA, 2007, CARCINOGENESIS, V28, P968, DOI 10.1093/carcin/bgl220; Sun YJ, 2005, MOL CANCER THER, V4, P51; Thoms HC, 2007, CANCER RES, V67, P1660, DOI 10.1158/0008-5472.CAN-06-1038; Vainer B, 2006, SCAND J GASTROENTERO, V41, P318, DOI 10.1080/00365520510024241; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	19	48	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2648	2655		10.1038/sj.onc.1210891	http://dx.doi.org/10.1038/sj.onc.1210891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	18059344				2022-12-28	WOS:000255057000014
J	Zhu, S; Bjorge, JD; Cheng, HC; Fujita, DJ				Zhu, S.; Bjorge, J. D.; Cheng, H. C.; Fujita, D. J.			Decreased CHK protein levels are associated with Src activation in colon cancer cells	ONCOGENE			English	Article						cHK; src; colon cancer	HOMOLOGOUS KINASE CHK; LYN TYROSINE KINASE; COLORECTAL-CANCER; BREAST-CANCER; GENETIC PATHWAYS; FOCAL ADHESIONS; CSK; EXPRESSION; FAMILY; BRAIN	Src activation has been associated with colon cancers but the mechanism underlying Src activation is largely unknown. Csk-homologous kinase (CHK) can inhibit the kinase activity of certain Src kinase family members in vitro by phosphorylating the C-terminal tyrosine and by a non-catalytic mechanism. CHK was previously reported to be expressed primarily in brain and hematopoietic cells. We report herein that CHK is also expressed in normal colon cell lines. Furthermore, CHK protein levels are significantly decreased in various colon cancer cell lines and the decrease correlates with the increased specific activity of Src in these cell lines, while the level of the other Src inhibitory kinase, C-terminal Src kinase, is not significantly changed. CHK is also expressed in normal colon tissues but its expression level is decreased in colon cancer tissues collected from the same patients. Immuno- fluorescence microscopy shows that CHK colocalizes with Src in normal colon FHC cells. Overexpression of CHK in colon cancer cells results in inactivation of Src without phosphorylating Y530 at its C-terminus. In addition, CHK suppresses anchorage-independent cell growth and cell invasion of colon cancer cells. These results reveal a potentially important role for CHK in Src activation and tumorigenicity in colon cancer cells.	[Zhu, S.; Bjorge, J. D.; Fujita, D. J.] Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; [Zhu, S.; Bjorge, J. D.; Fujita, D. J.] Univ Calgary, So Alberta Canc Res Inst, Calgary, AB T2N 4N1, Canada; [Cheng, H. C.] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic 3052, Australia	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Melbourne	Fujita, DJ (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	dfujita@ucalgary.ca	Zhu, Shudong/A-1741-2011	Cheng, Heung-Chin/0000-0002-4965-7148				AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Bougeret C, 2001, J BIOL CHEM, V276, P33711, DOI 10.1074/jbc.M104209200; Cam WR, 2001, CANCER, V92, P61, DOI 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D; Chong YP, 2004, J BIOL CHEM, V279, P20752, DOI 10.1074/jbc.M309865200; Chong YP, 2006, J BIOL CHEM, V281, P32988, DOI 10.1074/jbc.M602951200; CHOW LML, 1994, ONCOGENE, V9, P3437; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; ERSHLER MA, 1995, FEBS LETT, V375, P50, DOI 10.1016/0014-5793(95)01154-7; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Hirao A, 1998, J BIOL CHEM, V273, P10004, DOI 10.1074/jbc.273.16.10004; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; Ilyas M, 1999, EUR J CANCER, V35, P1986, DOI 10.1016/S0959-8049(99)00298-1; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Isozumi T, 1997, ACTA NEUROPATHOL, V93, P438, DOI 10.1007/s004010050637; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kim S, 2002, J BIOL CHEM, V277, P36465, DOI 10.1074/jbc.M206018200; Kim SO, 2004, CANCER-AM CANCER SOC, V101, P1018, DOI 10.1002/cncr.20442; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KRUEGER JG, 1980, P NATL ACAD SCI-BIOL, V77, P4142, DOI 10.1073/pnas.77.7.4142; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; KUO SS, 1994, J NEUROSCI RES, V38, P705, DOI 10.1002/jnr.490380613; Levin Victor A, 2004, Cancer Treat Res, V119, P89; Nakayama Y, 2005, EXP CELL RES, V304, P570, DOI 10.1016/j.yexcr.2004.11.027; SAKANO S, 1994, ONCOGENE, V9, P1155; Samokhvalov I, 1997, BIOCHEM MOL BIOL INT, V43, P115; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Trubert CL, 1997, EUR J HISTOCHEM, V41, P169; WATANABE N, 1995, JPN J CLIN ONCOL, V25, P5; Yamaguchi N, 2001, J CELL SCI, V114, P1631; ZHU S, 2007, IN PRESS CANC RES, V67; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	41	13	15	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2027	2034		10.1038/sj.onc.1210838	http://dx.doi.org/10.1038/sj.onc.1210838			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17934522				2022-12-28	WOS:000254359100007
J	Park, HJ; Wang, Z; Costa, RH; Tyner, A; Lau, LF; Raychaudhuri, P				Park, H. J.; Wang, Z.; Costa, R. H.; Tyner, A.; Lau, L. F.; Raychaudhuri, P.			An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle	ONCOGENE			English	Article						FoxM1; cell cycle regulation; FoxM1-inhibitory domain; transforming activity	TRANSCRIPTION FACTOR TRIDENT; S-PHASE; HEPATOCYTE ENTRY; FACTOR HFH-11B; LIVER; TRANSACTIVATION; PROLIFERATION; PROGRESSION; CARCINOMAS; EXPRESSION	The FoxM1 transcription factor plays critical roles in the expression of genes that are essential for cell proliferation. FoxM1 null or depleted cells fail to progress through mitosis, as expression of several mitotic genes depends upon FoxM1. The transcriptional activity of FoxM1 is stimulated by cyclin-cdk-mediated phosphorylation at a site within the transcriptional activation domain. Here, we characterize the role of an N-terminal inhibitory domain in the transcriptional activity of FoxM1. Deletion of the N-terminal 232 amino-acid residues increases the transcriptional and transforming activities of FoxM1. Moreover, while the activity of the full-length FoxM1 is stimulated by growth factors, the activity of the N-terminal deletion mutant is constitutively high in all phases of the cell cycle. The N-terminal deletion also eliminates the requirement for cyclin-cdk to activate FoxM1. We provide evidence that the N-terminal domain interacts with the C-terminal half of the transcription factor to attenuate its transcriptional activity. Moreover, the N-terminal fragment inhibits the transcriptional activity of FoxM1 in G(1)/S cells, but not in G(2)/M cells. Our results suggest that cyclin-cdk phosphorylates FoxM1 to counteract the inhibition by the N-terminal domain to fully activate FoxM1 in G(2)/M phase.	[Park, H. J.; Wang, Z.; Costa, R. H.; Tyner, A.; Lau, L. F.; Raychaudhuri, P.] Univ Illinois, Coll Med, Dept Biochem & Mol Genet M C 669, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet M C 669, 900 S Ashland Ave, Chicago, IL 60607 USA.	pradip@uic.edu		Lau, Lester/0000-0002-4364-2914; Tyner, Angela/0000-0001-7448-8625	NCI NIH HHS [R01 CA100035, CA46565, R01 CA046565, R01 CA124488, CA124488, R01 CA124488-02, R01 CA100035-04, CA100035] Funding Source: Medline; NIA NIH HHS [R01 AG021842, R01 AG021842-05] Funding Source: Medline; NIDDK NIH HHS [R01 DK044525, R01 DK054687-09, DK044525, R01 DK054687] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565, R01CA124488, R01CA100035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687, R55DK044525, R01DK044525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Wang XH, 2001, HEPATOLOGY, V33, P1404, DOI 10.1053/jhep.2001.24666; Wierstra I, 2006, BIOCHEM BIOPH RES CO, V348, P99, DOI 10.1016/j.bbrc.2006.07.008; Wierstra I, 2006, BIOL CHEM, V387, P949, DOI 10.1515/BC.2006.119; Wierstra I, 2006, BIOL CHEM, V387, P963, DOI 10.1515/BC.2006.120; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626	20	58	60	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1696	1704		10.1038/sj.onc.1210814	http://dx.doi.org/10.1038/sj.onc.1210814			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891172	Green Submitted, Green Accepted			2022-12-28	WOS:000253962100005
J	Iwakuma, T; Tochigi, Y; Van Pelt, CS; Caldwell, LC; Terzian, T; Parant, JM; Chau, GP; Koch, JG; Eischen, CM; Lozano, G				Iwakuma, T.; Tochigi, Y.; Van Pelt, C. S.; Caldwell, L. C.; Terzian, T.; Parant, J. M.; Chau, G. P.; Koch, J. G.; Eischen, C. M.; Lozano, G.			Mtbp haploinsufficiency in mice increases tumor metastasis	ONCOGENE			English	Article						Mdm2; p53; MrpL13	MAMMALIAN MITOCHONDRIAL RIBOSOME; EMBRYONIC LETHALITY; S PHASE; MDM2; P53; EXPRESSION; SPECTRUM; RESCUE; SUPPRESSION; PROTEINS	Mdm2 inhibits the function of the p53 tumor suppressor. Mdm2 is overexpressed in many tumors with wild-type p53 suggesting an alternate mechanism of loss of p53 activity in tumors. An Mdm2-binding protein (MTBP) was identified using a yeast two-hybrid screen. In tissue culture, MTBP inhibits Mdm2 self-ubiquitination, leading to stabilization of Mdm2 and increased degradation of p53. To address the role of MTBP in the regulation of the p53 pathway in vivo, we deleted the Mtbp gene in mice. Homozygous disruption of Mtbp resulted in early embryonic lethality, which was not rescued by loss of p53. Mtbp(+/-) mice were not tumor prone. When mice were sensitized for tumor development by p53 heterozygosity, we found that the Mtbp(+/-)p53(+/-) mice developed significantly more metastatic tumors (18.2%) as compared to p53(+/-) mice (2.6%). Results of in vitro migration and invasion assays support the in vivo findings. Downmodulation of Mtbp in osteosarcoma cells derived from p53(+/-) mice resulted in increased invasiveness, and overexpression of Mtbp in Mtbp(+/-)p53(+/-) osteosarcoma cells inhibited invasiveness. These results suggest that MTBP is a metastasis suppressor. These results advance our understanding of the cellular roles of MTBP and raise the possibility that MTBP is a novel therapeutic target for metastasis.	[Iwakuma, T.; Terzian, T.; Parant, J. M.; Chau, G. P.; Koch, J. G.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA; [Iwakuma, T.; Tochigi, Y.] Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA USA; [Van Pelt, C. S.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med, Houston, TX USA; [Koch, J. G.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Eischen, C. M.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA	University of Texas System; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Vanderbilt University	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	tiwaku@lsuhsc.edu; gglozano@mdanderson.org		Chau, Gilda/0000-0002-7907-3290	NATIONAL CANCER INSTITUTE [R01CA098139] Funding Source: NIH RePORTER; NCI NIH HHS [CA098139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; BARTEK J, 1991, ONCOGENE, V6, P1699; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brady M, 2005, MOL CELL BIOL, V25, P545, DOI 10.1128/MCB.25.2.545-553.2005; Che G, 2006, NEOPLASMA, V53, P530; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Finch RA, 2002, CANCER RES, V62, P3221; Iwakuma T, 2004, ONCOGENE, V23, P7644, DOI 10.1038/sj.onc.1207793; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jee BK, 2006, BIOCHEM BIOPH RES CO, V342, P655, DOI 10.1016/j.bbrc.2006.01.153; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LEVINE AJ, 2004, CELL, V69, pS67; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; Lozano G, 2005, J PATHOL, V205, P206, DOI 10.1002/path.1704; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; PURDIE CA, 1994, ONCOGENE, V9, P603; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Suzuki T, 2001, J BIOL CHEM, V276, P21724, DOI 10.1074/jbc.M100432200; TSUKADA T, 1993, ONCOGENE, V8, P3313; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991	34	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1813	1820		10.1038/sj.onc.1210827	http://dx.doi.org/10.1038/sj.onc.1210827			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906694				2022-12-28	WOS:000254150600001
J	Averous, J; Fonseca, BD; Proud, CG				Averous, J.; Fonseca, B. D.; Proud, C. G.			Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1	ONCOGENE			English	Article						rapamycin; translation initiation; 4E-BP1; cell cycle; cancer	CAP-BINDING PROTEIN; MESSENGER-RNA; TRANSLATION INITIATION; MAMMALIAN TARGET; AMINO-ACIDS; C-MYC; RAPAMYCIN; PHOSPHORYLATION; MEDIATE; EIF-4E	There is currently substantial interest in the regulation of cell function by mammalian target of rapamycin ( mTOR), especially effects linked to the rapamycin-sensitive mTOR complex 1 ( mTORC1). Rapamycin induces G(1) arrest and blocks proliferation of many tumor cells, suggesting that the inhibition of mTORC1 signaling may be useful in cancer therapy. In MCF7 breast adenocarcinoma cells, rapamycin decreases levels of cyclin D1, without affecting cytoplasmic levels of its mRNA. In some cell - types, rapamycin does not affect cyclin D1 levels, whereas the starvation for leucine ( which impairs mTORC1 signaling more profoundly than rapamycin) does. This pattern correlates with the behavior of eukaryotic initiation factor 4E-binding protein 1 ( 4E-BP1, an mTORC1 target that regulates translation initiation). siRNA-mediated knockdown of 4E-BP1 abrogates the effect of rapamycin on cyclin D1 expression and increases the polysomal association of the cyclin D1 mRNA. Our data identify 4E-BP1 as a key regulator of cyclin D1 expression, indicate that this effect is not mediated through the changes in cytoplasmic levels of cyclin D1 mRNA and suggest that, in some cell types, interfering with the amino acid input to mTORC1, rather than using rapamycin, may inhibit proliferation.	[Averous, J.; Fonseca, B. D.; Proud, C. G.] Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Proud, CG (corresponding author), Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	cgpr@interchange.ubc.ca		Proud, Christopher/0000-0003-0704-6442				ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Averous J, 2006, ONCOGENE, V25, P6423, DOI 10.1038/sj.onc.1209887; Averous J, 2005, FEBS LETT, V579, P2609, DOI 10.1016/j.febslet.2005.03.077; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gingras AC, 2001, GENE DEV, V15, P2852; Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hizli AA, 2006, J BIOL CHEM, V281, P14596, DOI 10.1074/jbc.M601959200; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Jiang H, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-2; Kimball SR, 2006, J NUTR, V136, p227S, DOI 10.1093/jn/136.1.227S; Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	30	141	142	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1106	1113		10.1038/sj.onc.1210715	http://dx.doi.org/10.1038/sj.onc.1210715			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17724476				2022-12-28	WOS:000253136700010
J	Muerkoster, SS; Rausch, AV; Isberner, A; Minkenberg, J; Blaszczuk, E; Witt, M; Folsch, UR; Schmitz, F; Schafer, H; Arlt, A				Mueerkoester, S. Sebens; Rausch, A. V.; Isberner, A.; Minkenberg, J.; Blaszczuk, E.; Witt, M.; Foelsch, U. R.; Schmitz, F.; Schaefer, H.; Arlt, A.			The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition	ONCOGENE			English	Article						early-response gene; gastrin receptor; loss of function mutation; apoptosis; colon cancer	EARLY-RESPONSE GENE; GLYCINE-EXTENDED GASTRIN; COLON-CANCER; CARCINOMA CELLS; TRANSGENIC MICE; MOUSE MODEL; CRYPT FOCI; IN-VIVO; PROGASTRIN; RECEPTORS	Addressing the puzzling role of amidated gastrin(17) ( G17) and the gastrin/ CCKB/ CCK2 receptor in colorectal carcinogenesis, we analysed potential candidate genes involved in G17-dependent NF-kappa B inhibition and apoptosis. The colorectal carcinoma cell line Colo320 over-expressing the wild-type CCK2 receptor ( Colo320wt) underwent G17-induced apoptosis along with suppressed NF-kappa B activation and decreased expression of the antiapoptotic NF-kappa B target genes cIAP1 and cIAP2, whereas G17 was without effect on Colo320 cells expressing a CCK2 receptor bearing a loss of function mutation ( Colo320mut). Gene microarray analysis revealed an elevated expression of the stress response gene IEX-1 in G17-treated Colo320wt but not Colo320mut cells. Quantitative real-time PCR and conventional RT-PCR confirmed this G17-dependent increase of IEX-1 expression in Colo320wt cells. If these cells were subjected to IEX-1 knockdown by small interfering RNA transfection, the apoptosis-inducing effect of G17 was abolished. Moreover, tumor necrosis factor alpha (TNF alpha)- or 5-FU-induced apoptosis that is greatly enhanced by G17 treatment in Colo320wt cells was prevented if IEX-1 expression was repressed. Under these conditions of blocked IEX-1 expression, the NF-kappa B activity remained unaffected by G17, in particular in Colo320wt cells co-treated with TNF alpha and also the suppressive effect of G17 on cIAP1 and cIAP2 expression was not observed anymore if IEX-1 expression was blocked. Conversely, IEX-1 overexpression in Colo320mut cells caused an increase of basal and TNF alpha- or 5-FU-induced apoptosis, an effect not further triggered by G17 treatment. Using a xenograft tumor model in severe combined immune deficiency mice, we could show that experimental systemic hypergastrinemia induced by the administration of omeprazole led to enhanced apoptosis as well as to a marked increase of IEX-1 expression in Colo320wt tumors, but not in Colo320mut tumors. These observations indicate that the proapoptotic effect of G17 on human colon cancer cells expressing the wild-type CCK2 receptor is mediated by IEX-1, which modulates NF-kappa B-dependent antiapoptotic protection and thereby exerts tumor-suppressive potential.	[Mueerkoester, S. Sebens; Rausch, A. V.; Isberner, A.; Minkenberg, J.; Blaszczuk, E.; Witt, M.; Foelsch, U. R.; Schmitz, F.; Schaefer, H.; Arlt, A.] Univ Hosp Schleswig Holstein, Dept Med 1, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany; [Schmitz, F.] Klinikum Hildesheim, Dept Med 2, Hildesheim, Germany	University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), Univ Hosp Schleswig Holstein, Dept Med 1, Lab Mol Gastroenterol & Hepatol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Arlt, Alexander/G-7308-2019; Sebens, Susanne/C-1222-2010; Schäfer, Heiner/C-1055-2011; Schmitz, Frank/ABB-6798-2021	Arlt, Alexander/0000-0002-6160-1059; 				Ahmed S, 2004, FEBS LETT, V556, P199, DOI 10.1016/S0014-5793(03)01408-X; Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Arlt A, 2003, ONCOGENE, V22, P3343, DOI 10.1038/sj.onc.1206524; Arlt A, 2007, BIOCHEM J, V402, P367, DOI 10.1042/BJ20061072; Baldwin GS, 1998, GUT, V42, P581, DOI 10.1136/gut.42.4.581; Clerc P, 1997, INT J CANCER, V72, P931, DOI 10.1002/(SICI)1097-0215(19970917)72:6<931::AID-IJC2>3.0.CO;2-Q; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Cobb S, 2002, GASTROENTEROLOGY, V123, P516, DOI 10.1053/gast.2002.34754; Copps J, 2007, PEPTIDES, V28, P632, DOI 10.1016/j.peptides.2006.10.008; Corcoran JA, 2006, J VIROL, V80, P9720, DOI 10.1128/JVI.01216-06; Dilley WG, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-9; Dockray GJ, 1996, PHYSIOL REV, V76, P767, DOI 10.1152/physrev.1996.76.3.767; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu YH, 2004, CANCER RES, V64, P7748, DOI 10.1158/0008-5472.CAN-04-1827; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; Kondratyev AD, 1996, CANCER RES, V56, P1498; Muerkoster S, 2005, GASTROENTEROLOGY, V129, P952, DOI 10.1053/j.gastro.2005.06.059; Nambiar PR, 2004, CANCER RES, V64, P6394, DOI 10.1158/0008-5472.CAN-04-0933; Osawa Y, 2003, J IMMUNOL, V170, P4053, DOI 10.4049/jimmunol.170.8.4053; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; PINSON DM, 1995, GASTROENTEROLOGY, V108, P1068, DOI 10.1016/0016-5085(95)90204-X; Rooman I, 2001, GASTROENTEROLOGY, V121, P940, DOI 10.1053/gast.2001.27998; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1996, CANCER RES, V56, P2641; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Schmidt WE, 2004, GASTROENTEROLOGY, V126, P606, DOI 10.1053/j.gastro.2003.12.017; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Shen L, 2006, J BIOL CHEM, V281, P15304, DOI 10.1074/jbc.M600054200; Siddheshwar RK, 2001, GUT, V48, P47, DOI 10.1136/gut.48.1.47; Singh P, 2007, ONCOGENE, V26, P425, DOI 10.1038/sj.onc.1209798; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; Till A, 2005, J BIOL CHEM, V280, P5994, DOI 10.1074/jbc.M411541200; Watson SA, 2001, CANCER RES, V61, P625; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Yu HG, 2005, CELL SIGNAL, V17, P1505, DOI 10.1016/j.cellsig.2005.03.009	40	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1122	1134		10.1038/sj.onc.1210728	http://dx.doi.org/10.1038/sj.onc.1210728			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704804				2022-12-28	WOS:000253136700012
J	Mizumachi, T; Suzuki, S; Naito, A; Carcel-Trullols, J; Evans, TT; Spring, PM; Oridate, N; Furuta, Y; Fukuda, S; Higuchi, M				Mizumachi, T.; Suzuki, S.; Naito, A.; Carcel-Trullols, J.; Evans, T. T.; Spring, P. M.; Oridate, N.; Furuta, Y.; Fukuda, S.; Higuchi, M.			Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells	ONCOGENE			English	Article						docetaxel; drug resistance; head and neck cancer; mitochondrial DNA; Fo-ATPase	BREAST-CANCER; OXIDATIVE STRESS; REACTIVE OXYGEN; P-GLYCOPROTEIN; APOPTOSIS; EXPRESSION; DEATH; DETERMINES; CARCINOMA; SYNTHASE	Docetaxel is one of the most effective chemotherapeutic agents against cancer; nevertheless, some patients develop resistance. Unfortunately, their causes and mechanisms remain unknown. We created docetaxel-resistant DRHEp2 from human laryngeal cancer HEp2 and investigated the roles of mitochondrial DNA (mtDNA) and reactive oxygen species (ROS) on docetaxel resistance. DRHEp2 had greatly increased mtDNA content. Reduction of mtDNA content in DRHEp2 by ethidium bromide treatment reduced the resistance. These results indicate the possible roles of mtDNA-coded enzymes in mitochondrial respiratory chain (MRC) in resistant mechanisms. Oligomycin A, an Fo-ATPase inhibitor, eliminated docetaxel resistance in DRHEp2; in contrast, inhibitors of other MRC did not. RNA interference targeted to Fo-ATPase d-subunit restored docetaxel-induced cytotoxicity to DRHEp2. These results indicate the roles of Fo-ATPase for resistant mechanisms. Docetaxel induced ROS generation in HEp2 but not in DRHEp2 and antioxidant pyrrolidine dithiocarbamate eliminated docetaxel-induced cytotoxicity, suggesting roles of ROS in docetaxel-induced cell death. Furthermore, inhibition of Fo-ATPase by Oligomycin A induced docetaxel-mediated ROS generation in DRHEp2. Taken together, DRHEp2 acquired docetaxel resistance through increasing Fo-ATPase, which led to diminish docetaxel-induced ROS generation and subsequently inhibited cell death. In conclusion, mtDNA plays an important role in developing docetaxel resistance through the reduction of ROS generation by regulating Fo-ATPase.	[Mizumachi, T.; Suzuki, S.; Naito, A.; Carcel-Trullols, J.; Evans, T. T.; Higuchi, M.] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; [Mizumachi, T.; Suzuki, S.; Oridate, N.; Furuta, Y.; Fukuda, S.] Hokkaido Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sapporo, Hokkaido, Japan; [Spring, P. M.] Univ Arkansas Med Sci, Dept Otolaryngol Head & Neck Surg, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; Hokkaido University; University of Arkansas System; University of Arkansas Medical Sciences	Higuchi, M (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham St,Slot 516, Little Rock, AR 72205 USA.	mhiguchi@uams.edu	Fukuda, Satoshi/A-8433-2012; Suzuki, Seigo/G-5378-2012; Oridate, Nobuhiko/ABC-4116-2020; Oridate, Nobuhiko/G-5365-2012; Mizumachi, Takatsugu/G-5479-2012	Oridate, Nobuhiko/0000-0002-6968-3028; 	NCI NIH HHS [R01 CA100846, R01 CA100846-04, R01 CA100846-01A1, R01 CA100846-02, R01 CA100846-06, R01 CA100846-05, R01 CA100846-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; Alexandre J, 2006, INT J CANCER, V119, P41, DOI 10.1002/ijc.21685; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BISSERY MC, 1995, ANTI-CANCER DRUG, V6, P339, DOI 10.1097/00001813-199506000-00001; Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918; Caporossi D, 2003, FREE RADICAL BIO MED, V35, P1355, DOI 10.1016/j.freeradbiomed.2003.08.008; Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9; Cavalli LR, 1997, CELL GROWTH DIFFER, V8, P1189; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2; Higuchi M, 2006, ONCOGENE, V25, P1437, DOI 10.1038/sj.onc.1209190; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Iwao-Koizumi K, 2005, J CLIN ONCOL, V23, P422, DOI 10.1200/JCO.2005.09.078; Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434; Kim SJ, 2005, CLIN CANCER RES, V11, P8425, DOI 10.1158/1078-0432.CCR-05-0449; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kirkland RA, 2007, EXP NEUROL, V204, P458, DOI 10.1016/j.expneurol.2006.09.013; Lee CF, 2005, ANN NY ACAD SCI, V1042, P246, DOI 10.1196/annals.1338.027; Li YC, 2004, CHEMOTHERAPY, V50, P55, DOI 10.1159/000077803; Lievre A, 2005, J CLIN ONCOL, V23, P3517, DOI 10.1200/JCO.2005.07.044; Liu B, 2001, J SURG RES, V99, P179, DOI 10.1006/jsre.2001.6126; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Qian W, 2005, AM J PHYSIOL-CELL PH, V289, pC1466, DOI 10.1152/ajpcell.00265.2005; Santamaria G, 2006, CARCINOGENESIS, V27, P925, DOI 10.1093/carcin/bgi315; Schaaf GJ, 2002, FREE RADICAL RES, V36, P835, DOI 10.1080/1071576021000005267; Schrijvers D, 2005, CURR OPIN ONCOL, V17, P218, DOI 10.1097/01.cco.0000158735.91723.0e; Shalli K, 2005, FASEB J, V19, P1299, DOI 10.1096/fj.04-3178fje; Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; WILS P, 1994, BIOCHEM PHARMACOL, V48, P1528, DOI 10.1016/0006-2952(94)90580-0; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3	30	50	54	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					831	838		10.1038/sj.onc.1210681	http://dx.doi.org/10.1038/sj.onc.1210681			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17637738	Green Accepted			2022-12-28	WOS:000252884500012
J	Ogawa, E; Okuyama, R; Ikawa, S; Nagoshi, H; Egawa, T; Kurihara, A; Yabuki, M; Tagami, H; Obinata, M; Aiba, S				Ogawa, E.; Okuyama, R.; Ikawa, S.; Nagoshi, H.; Egawa, T.; Kurihara, A.; Yabuki, M.; Tagami, H.; Obinata, M.; Aiba, S.			P51/p63 inhibits ultraviolet B-induced apoptosis via Akt activation	ONCOGENE			English	Article						p51/p63; p53; apoptosis; UV; epidermis	SKIN-CANCER; P53 HOMOLOG; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; DOWN-REGULATION; P63; PATHWAY; DELTA-NP63-ALPHA; TRANSCRIPTION; DEGRADATION	The epidermis must be protected against excess apoptotic cell death in response to ultraviolet-B (UV-B) irradiation. p53 is known to be critical for this protection. Although the p53 family member Delta Np51B/Delta Np63a (an N terminal-deleted form of p51/p63) is abundantly expressed in keratinocytes, its contribution to UV-B-dependent apoptosis is largely unknown. We found that, after a transient increase, Delta Np51B is downregulated in UV-B-irradiated keratinocytes undergoing apoptosis, whereas p53 is upregulated with delayed kinetics. Furthermore, the reduction of Delta Np51B by small interfering RNAs augmented UV- B-dependent apoptosis in keratinocytes, indicating that Delta Np51B blocks keratinocyte apoptosis. Although the exogenous expression of Delta Np51B in keratinocytes did not further block the UV-B-dependent apoptosis, to our surprise the expression of TAp51B (an isoform with a full NH2-terminal transactivation domain that is structurally and functionally similar to p53) decreased apoptosis significantly. The blockade of keratinocyte apoptosis by the p51 was dependent on the phosphorylation of Akt, resulting in the activation of a survival pathway. Thus, in addition to its indispensable roles in epithelial development, p51 acts in adult cells to protect the epidermis against UV-B irradiation by preventing excess depletion of keratinocytes.	[Ogawa, E.; Okuyama, R.; Egawa, T.; Tagami, H.; Aiba, S.] Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Ikawa, S.; Nagoshi, H.; Kurihara, A.; Yabuki, M.; Obinata, M.] Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Ikawa, S.; Nagoshi, H.; Kurihara, A.; Yabuki, M.] Tohoku Univ, Interdisciplinary Res Ctr, Aoba Ku, Sendai, Miyagi 9808574, Japan	Tohoku University; Tohoku University; Tohoku University	Okuyama, R (corresponding author), Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	rokuyama@mail.tains.tohoku.ac.jp	井川, 俊太郎/L-5911-2015					Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CUI R, 2005, BIOCH BIOPHYS RES CO; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Koster MI, 2006, CANCER RES, V66, P3981, DOI 10.1158/0008-5472.CAN-06-0027; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Liefer KM, 2000, CANCER RES, V60, P4016; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mills AA, 2006, CURR OPIN GENET DEV, V16, P38, DOI 10.1016/j.gde.2005.12.001; Okuyama R, 2007, ONCOGENE, V26, P4478, DOI 10.1038/sj.onc.1210235; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Papoutsaki M, 2005, ONCOGENE, V24, P6970, DOI 10.1038/sj.onc.1208835; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wang HQ, 2003, J BIOL CHEM, V278, P45737, DOI 10.1074/jbc.M300574200; Westfall MD, 2005, CELL CYCLE, V4, P710, DOI 10.4161/cc.4.5.1685; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	26	20	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					848	856		10.1038/sj.onc.1210682	http://dx.doi.org/10.1038/sj.onc.1210682			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653081				2022-12-28	WOS:000252884500014
J	Cuenin, S; Tinel, A; Janssens, S; Tschopp, J				Cuenin, S.; Tinel, A.; Janssens, S.; Tschopp, J.			p53-induced protein with a death domain (PIDD) isoforms differentially activate nuclear factor-kappaB and caspase-2 in response to genotoxic stress	ONCOGENE			English	Article						PIDD; DNA repair; NF-kappa B; caspase-2	DNA-DAMAGE; B ACTIVATION; INDUCED APOPTOSIS; MITOCHONDRIA; NEMO; ATM	Cellsres pond to DNA damage in a complex way and the fate of damaged cells depends on the balance between pro-and antiapoptotic signals. This is of crucial importance in cancer as genotoxic stress is implied both in oncogenesis and in classical tumor therapies. p53-induced protein with a death domain (PIDD), initially described as a p53-inducible gene, is one of the molecular switches able to activate a survival or apoptotic program. Two isoforms of PIDD, PIDD ( isoform 1) and LRDD ( isoform 2), have already been reported and we describe here a third isoform. These three isoforms are differentially expressed in tissues and cell lines. Genotoxic stress only affects PIDD isoform 3 mRNA levels, whereas isoforms 1 and 2 mRNA levels remain unchanged. All isoforms are capable of activating nuclear factor-kappaB in response to genotoxic stress, but only isoform 1 interacts with RIP-associated ICH-1/CED-3 homologous protein with a death domain and activates caspase-2. Isoform 2 counteracts the pro-apoptotic function of isoform 1, whereas isoform 3 enhances it. Thus, the differential splicing of PIDD mRNA leads to the formation of at least three proteins with antagonizing/agonizing functions, thereby regulating cell fate in response to DNA damage.	[Cuenin, S.; Tinel, A.; Janssens, S.; Tschopp, J.] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne	Tschopp, J (corresponding author), Univ Lausanne, Dept Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	jurg.tschopp@unil.ch	Janssens, Sophie/HHN-1756-2022					Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Campbell KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-101; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hay RT, 2004, NAT CELL BIOL, V6, P89, DOI 10.1038/ncb0204-89; Ho WC, 2005, CANCER RES, V65, P4273, DOI 10.1158/0008-5472.CAN-04-3494; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Katzenberger RJ, 2006, MOL CELL BIOL, V26, P9256, DOI 10.1128/MCB.01125-06; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458; Pick R, 2006, BIOCHEM BIOPH RES CO, V349, P1329, DOI 10.1016/j.bbrc.2006.08.176; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinel A, 2007, EMBO J, V26, P197, DOI 10.1038/sj.emboj.7601473; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049	21	48	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					387	396		10.1038/sj.onc.1210635	http://dx.doi.org/10.1038/sj.onc.1210635			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637755				2022-12-28	WOS:000252256000015
J	Callen, E; Nussenzweig, MC; Nussenzweig, A				Callen, E.; Nussenzweig, M. C.; Nussenzweig, A.			Breaking down cell cycle checkpoints and DNA repair during antigen receptor gene assembly	ONCOGENE			English	Review						DNA repair; cell cycle checkpoints; class-switching; V(D)J recombination; ATM; lymphoma	CLASS-SWITCH RECOMBINATION; GENOMIC INSTABILITY; V(D)J RECOMBINATION; CHROMOSOME-ABERRATIONS; REGION RECOMBINATION; ATM; ACTIVATION; ADAPTATION; RADIATION; 53BP1	Double-strand breaks (DSBs) are intermediates in several physiological processes including V(D)J and class switch recombination. They are also potent substrates for chromosomal translocations that arise as by-products of antigen receptor gene assembly in lymphocytes. ATM is one among several key proteins involved in the detection, signaling and repair of DNA breaks. Despite redundancies in DSB signaling pathways, it has recently been demonstrated that ATM deficient lymphocytes can survive and proliferate several generations in vitro and in vivo despite harboring terminally deleted chromosomes produced by V(D)J recombination. In this review, we discuss how two complementary genome maintenance functions mediated by ATM prevent lymphocytes from adapting to persistent DNA damage.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rockefeller University; Howard Hughes Medical Institute	Callen, E (corresponding author), NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.	callene@mail.nih.gov	Nussenzweig, Michel/AAE-7292-2019					AWA A A, 1978, Journal of Radiation Research, V19, P126, DOI 10.1269/jrr.19.126; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bertoni F, 1999, GENE CHROMOSOME CANC, V26, P176, DOI 10.1002/(SICI)1098-2264(199910)26:2<176::AID-GCC11>3.3.CO;2-V; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Callen E, 2007, CELL, V130, P63, DOI 10.1016/j.cell.2007.06.016; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Huang CY, 2007, J EXP MED, V204, P1371, DOI 10.1084/jem.20061460; Jankovic M, 2007, NAT IMMUNOL, V8, P801, DOI 10.1038/ni1498; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; KANO Y, 1984, CANCER RES, V44, P3706; Kaye JA, 2004, CURR BIOL, V14, P2096, DOI 10.1016/j.cub.2004.10.051; Kracker S, 2005, P NATL ACAD SCI USA, V102, P1584, DOI 10.1073/pnas.0409191102; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Lumsden JM, 2004, J EXP MED, V200, P1111, DOI 10.1084/jem.20041074; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Matei IR, 2007, BLOOD, V109, P1887, DOI 10.1182/blood-2006-05-020917; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; NORMAN A, 1966, BLOOD-J HEMATOL, V27, P706, DOI 10.1182/blood.V27.5.706.706; Nussenzweig A, 2007, CELL, V131, P223, DOI 10.1016/j.cell.2007.10.005; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petiniot LK, 2000, P NATL ACAD SCI USA, V97, P6664, DOI 10.1073/pnas.97.12.6664; Ramiro AR, 2006, CANCER RES, V66, P7837, DOI 10.1158/0008-5472.CAN-06-0863; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Reina-San-Martin B, 2004, J EXP MED, V200, P1103, DOI 10.1084/jem.20041162; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Reina-San-Martin B, 2007, EUR J IMMUNOL, V37, P235, DOI 10.1002/eji.200636789; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SASAKI MS, 1967, NATURE, V214, P502, DOI 10.1038/214502a0; Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563; Spruill MD, 1996, MUTAT RES-FUND MOL M, V356, P135, DOI 10.1016/0027-5107(95)00218-9; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Vacchio MS, 2007, P NATL ACAD SCI USA, V104, P6323, DOI 10.1073/pnas.0611222104; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Yan CT, 2007, NATURE, V449, P478, DOI 10.1038/nature06020; Yoo HY, 2007, J BIOL CHEM, V282, P17501, DOI 10.1074/jbc.M701770200; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9	57	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7759	7764		10.1038/sj.onc.1210873	http://dx.doi.org/10.1038/sj.onc.1210873			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066088				2022-12-28	WOS:000251537900006
J	O'Connor, MJ; Martin, NMB; Smith, GCM				O'Connor, M. J.; Martin, N. M. B.; Smith, G. C. M.			Targeted cancer therapies based on the inhibition of DNA strand break repair	ONCOGENE			English	Review						DNA-PK; ATM; PARP; CHK1; CHK2	DEPENDENT PROTEIN-KINASE; HUMAN POLYNUCLEOTIDE KINASE; 3-KINASE RELATED KINASES; SMALL-MOLECULE INHIBITOR; ADP-RIBOSE POLYMERASE; POLY(ADP-RIBOSE) POLYMERASE; RADIOSENSITIZING AGENT; SELECTIVE INHIBITOR; SYNTHETIC LETHALITY; ATM ACTIVATION	Both DNA double- and single-strand break repair are highly coordinated processes utilizing signal transduction cascades and post-translational modifications such as phosphorylation, acetylation and ADP ribosylation. 'Drugable' targets within these networks have been identified that could potentially lead to novel therapeutic approaches within the oncology arena. Key regulators within these signalling cascades, such as DNA-dependent protein kinase, ataxia-telangiectasia mutated, checkpoint kinase 1 (CHK1), checkpoint kinase 2 (CHK2) and poly( ADPribose) polymerase, use either ATP or nicotinamide adenine dinucleotide for their enzymatic functions and are therefore readily accessible to small molecule inhibition at their catalytic sites. A range of highly potent and selective inhibitors of these DNA damage response pathways has now been identified through drug discovery efforts, with candidate molecules either approaching or already in clinical trials. This review will describe the small molecule inhibitors and drug discovery activities that focus on DNA break repair, along with the therapeutic rationale behind chemosensitization and the concept of synthetic lethality. We will also describe the emerging clinical data coming from this exciting new approach to targeted cancer therapy.	KuDOS Pharmaceut Ltd, Cambridge CB4 0PE, England	AstraZeneca	Smith, GCM (corresponding author), KuDOS Pharmaceut Ltd, 410 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0PE, England.	gcmsmith@kudospharma.co.uk						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Abrahamsson PA, 2004, EUR UROL SUPPL, V3, P3, DOI 10.1016/j.eursup.2004.09.001; Albertella MR, 2005, CANCER RES, V65, P9799, DOI 10.1158/0008-5472.CAN-05-1095; Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Arienti KL, 2005, J MED CHEM, V48, P1873, DOI 10.1021/jm0495935; Austen B, 2005, BLOOD, V106, P3175, DOI 10.1182/blood-2004-11-4516; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bonicalzi ME, 2005, CELL MOL LIFE SCI, V62, P739, DOI 10.1007/s00018-004-4505-1; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Carlessi L, 2007, MOL CANCER THER, V6, P935, DOI 10.1158/1535-7163.MCT-06-0567; Chalmers A, 2004, INT J RADIAT ONCOL, V58, P410, DOI 10.1016/j.ijrobp.2003.09.053; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Curtin Nicola J., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S146239940500904X; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; De Soto JA, 2006, INT J BIOL SCI, V2, P179; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fedier A, 2004, INT J ONCOL, V24, P1039; FONG PC, 2006, J CLIN ONCOL, V24, pA3022; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hardcastle IR, 2005, J MED CHEM, V48, P7829, DOI 10.1021/jm050444b; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hay T, 2005, CANCER RES, V65, P10145, DOI 10.1158/0008-5472.CAN-05-1186; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hollick JJ, 2007, J MED CHEM, V50, P1958, DOI 10.1021/jm061121y; Hu HY, 2004, J BIOL CHEM, V279, P39736, DOI 10.1074/jbc.M402842200; Ismail IH, 2004, ONCOGENE, V23, P873, DOI 10.1038/sj.onc.1207303; Izzard RA, 1999, CANCER RES, V59, P2581; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; Janetka JW, 2007, CURR OPIN DRUG DISC, V10, P473; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Karimi-Busheri F, 2007, CANCER RES, V67, P6619, DOI 10.1158/0008-5472.CAN-07-0480; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kennedy RD, 2007, J CLIN INVEST, V117, P1440, DOI 10.1172/JCI31245; Kennedy RD, 2006, J CLIN ONCOL, V24, P3799, DOI 10.1200/JCO.2005.05.4171; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Krokan HE, 2007, DNA REPAIR, V6, P397, DOI 10.1016/j.dnarep.2006.10.007; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu Lili, 2004, Curr Opin Investig Drugs, V5, P623; LUCCHESI JC, 1968, GENETICS, V59, P37; Lynch HT, 1999, J MED GENET, V36, P801; Madhusudan S, 2005, NUCLEIC ACIDS RES, V33, P4711, DOI 10.1093/nar/gki781; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McCabe N, 2005, CANCER BIOL THER, V4, P934, DOI 10.4161/cbt.4.9.2141; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; PLUMMER R, 2006, J CLIN ONCOL, V24, pA8013; PLUMMER R, 2005, J CLIN ONCOL ASCO AN, V23, pA3065; POWELL SN, 1995, CANCER RES, V55, P1643; Ratnam K, 2007, CLIN CANCER RES, V13, P1383, DOI 10.1158/1078-0432.CCR-06-2260; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496; Shinohara ET, 2005, CANCER RES, V65, P4987, DOI 10.1158/0008-5472.CAN-04-4250; Shiobara M, 2001, J GASTROEN HEPATOL, V16, P338, DOI 10.1046/j.1440-1746.2001.02378.x; Smith G.C.M., 2003, HDB CELL SIGNALING, V1, P557; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; TOMODA T, 1991, AM J HEMATOL, V37, P223, DOI 10.1002/ajh.2830370402; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Won JJ, 2006, NAT CHEM BIOL, V2, P369, DOI 10.1038/nchembio800; Yang S, 2005, MOL CANCER THER, V4, P1923, DOI 10.1158/1535-7163.MCT-05-0229; YAP TA, 2007, J CLIN ONCOL ASCO 1, V25, pA3529; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	84	115	122	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7816	7824		10.1038/sj.onc.1210879	http://dx.doi.org/10.1038/sj.onc.1210879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066095				2022-12-28	WOS:000251537900013
J	Rice, KL; Hormaeche, I; Licht, JD				Rice, K. L.; Hormaeche, I.; Licht, J. D.			Epigenetic regulation of normal and malignant hematopoiesis	ONCOGENE			English	Review						hematopoiesis; epigenetics; histone code; methylation; leukemia; acetylation	ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; ACUTE MYELOID-LEUKEMIA; HISTONE ACETYLTRANSFERASE ACTIVITY; POLYCOMB GROUP PROTEINS; DOMAIN-CONTAINING GENE; T-CELL LYMPHOMA; PML-RAR-ALPHA; DNA METHYLATION; ARGININE METHYLATION	The molecular processes governing hematopoiesis involve the interplay between lineage- specific transcription factors and a series of epigenetic tags, including DNA methylation and covalent histone tail modifications, such as acetylation, methylation, phosphorylation, SUMOylation and ubiquitylation. These post- translational modifications, which collectively constitute the 'histone code', are capable of affecting chromatin structure and gene transcription and are catalysed by opposing families of enzymes, allowing the developmental potential of hematopoietic stem cells to be dynamically regulated. The essential role of these enzymes in regulating normal blood development is highlighted by the finding that members from all families of chromatin regulators are targets for dysregulation in many hematological malignancies, and that patterns of histone modification are globally affected in cancer as well as the regulatory regions of specific oncogenes and tumor suppressors. The discovery that these epigenetic marks can be reversed by compounds targeting aberrant transcription factor/ co- activator/ co- repressor interactions and histone- modifying activities, provides the basis for an exciting field in which the epigenome of cancer cells may be manipulated with potential therapeutic benefits.	Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Licht, JD (corresponding author), Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Lurie 5-123,303 E Super St, Chicago, IL 60611 USA.	j-licht@northwestern.edu	Licht, Jonathan/AAL-9184-2020; Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369; 	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; ALLIS CD, 1980, CELL, V20, P55; Ambros V, 2007, DEVELOPMENT, V134, P1635, DOI 10.1242/dev.002006; Angrand PO, 2001, GENOMICS, V74, P79, DOI 10.1006/geno.2001.6524; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Balint BL, 2005, IMMUNOBIOLOGY, V210, P141, DOI 10.1016/j.imbio.2005.05.009; Balint BL, 2005, MOL CELL BIOL, V25, P5648, DOI 10.1128/MCB.25.13.5648-5663.2005; Bao N, 2004, DEV CELL, V7, P653, DOI 10.1016/j.devcel.2004.10.003; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; Belinsky SA, 2003, CANCER RES, V63, P7089; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Blobel GA, 2002, J LEUKOCYTE BIOL, V71, P545; Bottardi S, 2007, CELL CYCLE, V6, P1035, DOI 10.4161/cc.6.9.4208; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Breuer RHJ, 2004, NEOPLASIA, V6, P736, DOI 10.1593/neo.04160; Bruserud O, 2006, EXPERT OPIN THER TAR, V10, P51, DOI 10.1517/14728222.10.1.51; Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Canote R, 2002, ONCOL REP, V9, P57; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288-1296.2006; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Cebrian A, 2006, CARCINOGENESIS, V27, P1661, DOI 10.1093/carcin/bgi375; Chen HM, 2004, SER REMOTE SENS, V3, P3, DOI 10.1142/9789812702630_0001; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548; Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Daser A, 2005, SEMIN CANCER BIOL, V15, P175, DOI 10.1016/j.semcancer.2005.01.007; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Douglas J, 2005, EUR J HUM GENET, V13, P150, DOI 10.1038/sj.ejhg.5201298; DOVER GJ, 1992, NEW ENGL J MED, V327, P569; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Ernst P, 2002, CURR OPIN HEMATOL, V9, P282, DOI 10.1097/00062752-200207000-00004; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Esteller M, 2003, CLIN IMMUNOL, V109, P80, DOI 10.1016/S1521-6616(03)00208-0; Fan HY, 2003, MOL CELL, V11, P1311, DOI 10.1016/S1097-2765(03)00192-8; Fatemi M, 2006, J CELL SCI, V119, P3033, DOI 10.1242/jcs.03099; Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286; Forneris F, 2006, J BIOL CHEM, V281, P35289, DOI 10.1074/jbc.M607411200; Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Ge YZ, 2004, J BIOL CHEM, V279, P25447, DOI 10.1074/jbc.M312296200; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998; Gray SG, 2005, J BIOL CHEM, V280, P28507, DOI 10.1074/jbc.M413687200; Grewal SIS, 2007, NATURE, V447, P399, DOI 10.1038/nature05914; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Huo XF, 2005, J CELL MOL MED, V9, P103, DOI 10.1111/j.1582-4934.2005.tb00340.x; Ikegami K, 2007, GENES CELLS, V12, P1, DOI 10.1111/j.1365-2443.2006.01029.x; Ivascu C, 2007, INT J BIOCHEM CELL B, V39, P1523, DOI 10.1016/j.biocel.2007.02.006; Jaju RJ, 2001, BLOOD, V98, P1264, DOI 10.1182/blood.V98.4.1264; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kapoor A, 2005, FEBS LETT, V579, P5889, DOI 10.1016/j.febslet.2005.08.039; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kim DY, 2005, LEUKEMIA LYMPHOMA, V46, P1061, DOI 10.1080/10428190500102589; Kim KC, 2003, CANCER RES, V63, P7619; Kishigami S, 2006, DEV BIOL, V289, P195, DOI 10.1016/j.ydbio.2005.10.026; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863; Langst G, 2001, MOL CELL, V8, P1085, DOI 10.1016/S1097-2765(01)00397-5; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004; Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Levings PP, 2002, EUR J BIOCHEM, V269, P1589, DOI 10.1046/j.1432-1327.2002.02797.x; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mahadevan D, 2005, MOL CANCER THER, V4, P1867, DOI 10.1158/1535-7163.MCT-05-0146; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mukherjee S, 2004, NAT GENET, V36, P1331, DOI 10.1038/ng1473; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; O'Geen H, 2007, PLOS GENET, V3, P916, DOI 10.1371/journal.pgen.0030089; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; OSTLER KR, IN PRESS ONCOGENE; Ouaissi M, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/13474; Pahlich S, 2006, BBA-PROTEINS PROTEOM, V1764, P1890, DOI 10.1016/j.bbapap.2006.08.008; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Park DJ, 2003, BLOOD, V102, P3727, DOI 10.1182/blood-2003-02-0412; Pastural E, 2007, ONCOGENE, V26, P1586, DOI 10.1038/sj.onc.1209959; Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Qian C, 2006, CELL MOL LIFE SCI, V63, P2755, DOI 10.1007/s00018-006-6274-5; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reed-Inderbitzin E, 2006, ONCOGENE, V25, P5777, DOI 10.1038/sj.onc.1209591; Richie ER, 2002, ONCOGENE, V21, P299, DOI 10.1038/sj.onc.1205051; Rosati R, 2002, BLOOD, V99, P3857, DOI 10.1182/blood.V99.10.3857; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rozman M, 2004, GENE CHROMOSOME CANC, V40, P140, DOI 10.1002/gcc.20022; Sanchez C, 2007, MOL CELL PROTEOMICS, V6, P820, DOI 10.1074/mcp.M600275-MCP200; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Santillan DA, 2006, CANCER RES, V66, P10032, DOI 10.1158/0008-5472.CAN-06-2597; Saunthararajah Y, 2004, SEMIN HEMATOL, V41, P11, DOI 10.1053/j.seminhematol.2004.08.003; Schaefer CB, 2007, SCIENCE, V316, P398, DOI 10.1126/science.1137544; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Singh M, 2007, EXP HEMATOL, V35, P48, DOI 10.1016/j.exphem.2006.09.001; Sirulnik A, 2003, BEST PRACT RES CL HA, V16, P387, DOI 10.1016/S1521-6926(03)00062-8; Smallwood A, 2007, GENE DEV, V21, P1169, DOI 10.1101/gad.1536807; Spannhoff A, 2007, J MED CHEM, V50, P2319, DOI 10.1021/jm061250e; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6; Steele JC, 2006, BRIT J CANCER, V95, P1202, DOI 10.1038/sj.bjc.6603369; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Stopka T, 2005, EMBO J, V24, P3712, DOI 10.1038/sj.emboj.7600834; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tan CP, 2006, MOL CELL BIOL, V26, P7224, DOI 10.1128/MCB.00473-06; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; van Doorn R, 2005, J CLIN ONCOL, V23, P3886, DOI 10.1200/JCO.2005.11.353; van Haelst MM, 2005, AM J MED GENET A, V139A, P40, DOI 10.1002/ajmg.a.30973; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Verdone Loredana, 2006, Briefings in Functional Genomics & Proteomics, V5, P209, DOI 10.1093/bfgp/ell028; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Vitoux D, 2007, INT J BIOCHEM CELL B, V39, P1063, DOI 10.1016/j.biocel.2007.01.028; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100; Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012; Yang MJ, 2007, BIOCHEMISTRY-US, V46, P8058, DOI 10.1021/bi700664y; Yoon YS, 2007, MOL CELL BIOL, V27, P3499, DOI 10.1128/MCB.02170-06; Zayed A, 2007, LEUKEMIA LYMPHOMA, V48, P489, DOI 10.1080/10428190601136163; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhou J, 2006, P NATL ACAD SCI USA, V103, P9238, DOI 10.1073/pnas.0603324103; Zhu J, 2001, BLOOD, V98, P2563, DOI 10.1182/blood.V98.8.2563; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	177	110	112	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6697	6714		10.1038/sj.onc.1210755	http://dx.doi.org/10.1038/sj.onc.1210755			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934479				2022-12-28	WOS:000250147000003
J	Lafon, A; Chang, CS; Scott, EM; Jacobson, SJ; Pillus, L				Lafon, A.; Chang, C. S.; Scott, E. M.; Jacobson, S. J.; Pillus, L.			MYST opportunities for growth control: yeast genes illuminate human cancer gene functions	ONCOGENE			English	Review						chromatin; transcription; Saccharomyces cerevisiae; silencing	HISTONE ACETYLTRANSFERASE COMPLEX; CHROMATIN-REMODELING COMPLEXES; H2A VARIANT HTZ1; SACCHAROMYCES-CEREVISIAE; SILENCING PROTEIN; H4 ACETYLATION; NUA4; INTERACTS; FAMILY; RECRUITMENT	The MYST family of histone acetyltransferases ( HATs) was initially dfined by human genes with disease connections and by yeast genes identified for their role in epigenetic transcriptional silencing. Since then, many new MYST genes have been discovered through genetic and genomic approaches. Characterization of the complexes through which MYST proteins act, regions of the genome to which they are targeted and biological consequences when they are disrupted, all deepen the connections of MYST proteins to development, growth control and human cancers. Many of the insights into MYST family function have come from studies in model organisms. Herein, we review functions of two of the founding MYST genes, yeast SAS2 and SAS3, and the essential yeast MYST ESA1. Analysis of these genes in yeast has de. fined roles for MYST proteins in transcriptional activation and silencing, and chromatin-mediated boundary formation. They have further roles in DNA damage repair and nuclear integrity. The observation that MYST protein complexes share subunits with other HATs, histone deacetylases and other key nuclear proteins, many with connections to human cancers, strengthens the idea that coordinating distinct chromatin modi. cations is critical for regulation.	Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Pillus, L (corresponding author), Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, Moores Canc Ctr, La Jolla, CA 92093 USA.	lpillus@ucsd.edu						Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Altaf M, 2007, MUTAT RES-FUND MOL M, V618, P81, DOI 10.1016/j.mrfmmm.2006.09.009; Anafi M, 2000, MOL ENDOCRINOL, V14, P718, DOI 10.1210/me.14.5.718; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Babiarz JE, 2006, GENE DEV, V20, P700, DOI 10.1101/gad.1386306; Baker SP, 2007, ONCOGENE, V26, P5329, DOI 10.1038/sj.onc.1210603; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Bittner CB, 2004, EUKARYOT CELL, V3, P976, DOI 10.1128/EC.3.4.976-983.2004; BORRESEN B, 1996, P 10 INT S MOLT SALT, V7, P11; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown K, 2003, J BIOL CHEM, V278, P39402, DOI 10.1074/jbc.M307832200; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Choy JS, 2002, MOL CELL BIOL, V22, P8215, DOI 10.1128/MCB.22.23.8215-8225.2002; Choy JS, 2001, J BIOL CHEM, V276, P43653, DOI 10.1074/jbc.M102531200; Clarke AS, 2006, MOL BIOL CELL, V17, P1744, DOI 10.1091/mbc.E05-07-0613; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Dziak R, 2003, J BIOL CHEM, V278, P27372, DOI 10.1074/jbc.M301110200; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149; Gomez EB, 2005, MOL CELL BIOL, V25, P8887, DOI 10.1128/MCB.25.20.8887-8903.2005; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Howe L, 2002, MOL CELL BIOL, V22, P5047, DOI 10.1128/MCB.22.14.5047-5053.2002; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Iizuka M, 2006, MOL CELL BIOL, V26, P1098, DOI 10.1128/MCB.26.3.1098-1108.2006; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Jacobson S, 2004, MOL CELL BIOL, V24, P6029, DOI 10.1128/MCB.24.13.6029-6039.2004; John S, 2000, GENE DEV, V14, P1196; Kabani M, 2005, BIOCHEM BIOPH RES CO, V332, P398, DOI 10.1016/j.bbrc.2005.04.158; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Keogh MC, 2006, GENE DEV, V20, P660, DOI 10.1101/gad.1388106; Keogh MC, 2005, CELL, V123, P593, DOI 10.1016/j.cell.2005.10.025; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Krogan NJ, 2004, P NATL ACAD SCI USA, V101, P13513, DOI 10.1073/pnas.0405753101; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Le Masson I, 2003, MOL CELL BIOL, V23, P6086, DOI 10.1128/MCB.23.17.6086-6102.2003; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Liu Y, 2000, MOL GEN GENET, V262, P1132, DOI 10.1007/PL00008656; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; Martin DGE, 2006, MOL CELL BIOL, V26, P3018, DOI 10.1128/MCB.26.8.3018-3028.2006; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Nishikawa J, 1999, TOXICOL APPL PHARM, V154, P76, DOI 10.1006/taap.1998.8557; Nourani A, 2004, EMBO J, V23, P2597, DOI 10.1038/sj.emboj.7600230; Nourani A, 2003, J BIOL CHEM, V278, P19171, DOI 10.1074/jbc.C300036200; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Ogryzko VV, 2001, CELL MOL LIFE SCI, V58, P683, DOI 10.1007/PL00000892; Olaharski AJ, 2005, PLOS GENET, V1, P689, DOI 10.1371/journal.pgen.0010077; Ooi SL, 2006, TRENDS GENET, V22, P56, DOI 10.1016/j.tig.2005.11.003; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; Panchenko MV, 2004, J BIOL CHEM, V279, P56032, DOI 10.1074/jbc.M410487200; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Selleck W, 2005, MOL CELL BIOL, V25, P5535, DOI 10.1128/MCB.25.13.5535-5542.2005; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Shia WJ, 2006, GENE DEV, V20, P2507, DOI 10.1101/gad.1439206; Shia WJ, 2005, J BIOL CHEM, V280, P11987, DOI 10.1074/jbc.M500276200; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Smith JS, 1998, GENETICS, V149, P1205; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; SUTTON WS, 1903, BIOL BULL, V4, P5; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taverna SD, 2006, MOL CELL, V24, P785, DOI 10.1016/j.molcel.2006.10.026; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Troke PJF, 2006, BIOCHEM SOC SYMP, V73, P23; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Xu EY, 1999, GENETICS, V153, P25; Xu EY, 1999, GENETICS, V153, P13; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zhang HY, 2004, MOL CELL BIOL, V24, P9424, DOI 10.1128/MCB.24.21.9424-9436.2004; Zhang WZ, 2006, J BIOL CHEM, V281, P18059, DOI 10.1074/jbc.M601903200; Zhang YM, 2006, DNA REPAIR, V5, P1282, DOI 10.1016/j.dnarep.2006.05.020; Zhou MI, 2002, J BIOL CHEM, V277, P39887, DOI 10.1074/jbc.M205040200; Zong HL, 2005, FEBS LETT, V579, P3579, DOI 10.1016/j.febslet.2005.05.039	119	46	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5373	5384		10.1038/sj.onc.1210606	http://dx.doi.org/10.1038/sj.onc.1210606			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694079				2022-12-28	WOS:000248674300006
J	Jiemjit, A; Fandy, TE; Carraway, H; Bailey, KA; Baylin, S; Herman, JG; Gore, SD				Jiemjit, A.; Fandy, T. E.; Carraway, H.; Bailey, K. A.; Baylin, S.; Herman, J. G.; Gore, S. D.			p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage	ONCOGENE			English	Article; Proceedings Paper	96th Annual Meeting of the American-Association-for-Cancer-Research	APR 16-20, 2005	Anaheim, CA	Amer Assoc Canc Res		decitabine; apoptosis; DNA methyltransferase inhibitors; histone deacetylase inhibitors; epigenetics; p21	HISTONE DEACETYLASE INHIBITION; ACUTE MYELOID-LEUKEMIA; 5-AZA-2'-DEOXYCYTIDINE DECITABINE; HEMATOPOIETIC MALIGNANCIES; FUNDAMENTAL ROLE; GENE-EXPRESSION; CANCER-CELLS; METHYLATION; DEMETHYLATION; APOPTOSIS	Decitabine (DAC) and 5-azacitidine have recently been approved for the treatment of myelodysplastic syndrome. The pharmacodynamic effects of DAC and 5-azacitidine outside their known activity as inhibitors of DNA methyltransferases (DNMTs) require further investigation. The purpose of this study was to investigate the effect of DAC on the expression of p21(WAF1/CIP1), a gene with a putative CpG island surrounding its promoter region. Promoter methylation analysis of p21(WAF1/CIP1) in leukemia cells revealed the absence of CpG methylation. However, DAC upregulated p21(WAF1/CIP1) expression in a dose-dependent manner (ED(50) = 103.34 nM) and induced G2/M cell cycle arrest in leukemia cells. Sequential application of DAC followed by different histone deacetylase inhibitors induced expression of p21(WAF1/CIP1) synergistically. Upregulation of p21(WAF1/CIP1) paralleled DAC-induced apoptosis (ED50 = 153 nM). Low doses of DAC induced gamma-H2AX expression (ED(50) =16.5 nM) and upregulated p21(WAF1/CIP1) in congenic HCT 116 colon cancer cells in a DNMT-independent and p53-dependent fashion. Inhibition of p53 transactivation by pifithrin-alpha or the kinase activity of ATM by either the specific ATM inhibitor KU-5593 or caffeine abrogated p21(WAF1/CIP1) upregulation, indicating that DAC upregulation of p21(WAF1/CIP1) was p53- and ATM-dependent in leukemia cells. In conclusion, DAC upregulates p21(WAF1/CIP1) in DNMT-independent manner via the DNA damage/ATM/p53 axis.	[Jiemjit, A.; Fandy, T. E.; Carraway, H.; Bailey, K. A.; Baylin, S.; Herman, J. G.; Gore, S. D.] Sidney Kimmel Comprehens Canc Ctr John Hopkins, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Gore, SD (corresponding author), Sidney Kimmel Comprehens Canc Ctr John Hopkins, 1650 Orleans St, Baltimore, MD 21231 USA.	gorest@jhmi.edu	Carraway, Hetty/AAR-4977-2020; Bailey, Kayleen/G-7716-2018	Carraway, Hetty/0000-0001-5241-3614; Bailey, Kayleen/0000-0002-8193-642X	NCI NIH HHS [R01 CA125635, L30 CA111124-01, P30 CA006973, K24CA111717, L30 CA111124, K24 CA111717, P30 CA06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973, K24CA111717, R01CA125635] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brakensiek K, 2005, LEUKEMIA RES, V29, P1357, DOI 10.1016/j.leukres.2005.04.012; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHOU TC, 1977, J BIOL CHEM, V252, P6438; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Galm O, 2004, LEUKEMIA, V18, P1687, DOI 10.1038/sj.leu.2403434; Gartel AL, 2005, LEUKEMIA RES, V29, P1237, DOI 10.1016/j.leukres.2005.04.023; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Ju R, 2003, CANCER RES, V63, P2891; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; KASTAN MB, 1991, CANCER RES, V51, P6304; Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schmelz K, 2005, LEUKEMIA, V19, P103, DOI 10.1038/sj.leu.2403552; Schmelz K, 2005, INT J CANCER, V114, P683, DOI 10.1002/ijc.20797; Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010; Tamm I, 2005, ANN HEMATOL, V84, P47, DOI 10.1007/s00277-005-0013-0; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970	33	76	80	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3615	3623		10.1038/sj.onc.1211018	http://dx.doi.org/10.1038/sj.onc.1211018			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223691	Green Accepted			2022-12-28	WOS:000256468500013
J	Ramsey, CS; Yeung, F; Stoddard, PB; Li, D; Creutz, CE; Mayo, MW				Ramsey, C. S.; Yeung, F.; Stoddard, P. B.; Li, D.; Creutz, C. E.; Mayo, M. W.			Copine-I represses NF-kappa B transcription by endoproteolysis of p65	ONCOGENE			English	Article						NF-kappa B; copine-I; endoproteolysis; p65; transcription; repressor	PHOSPHOLIPID-BINDING PROTEINS; DEPENDENT TRANSCRIPTION; KINASE ALPHA; SUBUNIT; FAMILY; DOMAIN; PHOSPHORYLATION; ACETYLATION; SURVIVAL; DNA	Nuclear factor-kappa B (NF-kappa B) is a dynamic transcription factor that regulates important biological processes involved in cancer initiation and progression. Identifying regulators that control the half-life of NF-kappa B is important to understanding molecular processes that control the duration of transcriptional responses. In this study we identify copine-I, a calcium phospholipid-binding protein, as a novel repressor that physically interacts with p65 to inhibit NF-kappa B transcription. Knockdown of copine-I by siRNA increases tumor necrosis factor alpha-stimulated NF-kappa B transcription, while copine-I expression blocks endogenous transcription. Copine-I abolishes NF-kappa B transcription by inducing endoprotease processing of the N-terminus of p65, a process antagonized by I kappa B alpha. Copine-I stimulates endoproteolysis of p65 within a conserved region that is required for base-specific contact with DNA. p65 proteins lacking the N-terminus fail to bind to DNA and act as dominant-negative molecules that inhibit NF-kappa B transcription. Our work provides evidence that copine-I regulates the half-life of NF-kappa B transcriptional responses through a novel mechanism that involves endoproteolysis of the p65 protein.	[Ramsey, C. S.; Yeung, F.; Stoddard, P. B.; Li, D.; Mayo, M. W.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Creutz, C. E.] Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Mayo, MW (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Box 800733, Charlottesville, VA 22908 USA.	mwm3y@virginia.edu			NCI NIH HHS [R01CA095644, R01CA104397] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095644, R01CA104397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; BALDWIN AS, 1996, ANNU REV IMMUNOL, V14, P681; Burstein E, 2005, J BIOL CHEM, V280, P22222, DOI 10.1074/jbc.M501928200; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393; David A, 2003, J LEUKOCYTE BIOL, V74, P551, DOI 10.1189/jlb.1202624; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kang KH, 2001, J BIOL CHEM, V276, P24638, DOI 10.1074/jbc.M101291200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim TM, 2005, CLIN CANCER RES, V11, P79; Kurosawa S, 2000, J IMMUNOL, V165, P4697, DOI 10.4049/jimmunol.165.8.4697; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lin L, 1996, MOL CELL BIOL, V16, P2248; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Maitra R, 2003, BIOCHEM BIOPH RES CO, V303, P842, DOI 10.1016/S0006-291X(03)00445-5; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; Preston GA, 2002, J AM SOC NEPHROL, V13, P2840, DOI 10.1097/01.ASN.0000034911.03334.C3; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Tomsig JL, 2004, BIOCHEM J, V378, P1089, DOI 10.1042/BJ20031654; Tomsig JL, 2003, J BIOL CHEM, V278, P10048, DOI 10.1074/jbc.M212632200; Tomsig JL, 2002, CELL MOL LIFE SCI, V59, P1467, DOI 10.1007/s00018-002-8522-7; Tomsig JL, 2000, BIOCHEMISTRY-US, V39, P16163, DOI 10.1021/bi0019949; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	42	33	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3516	3526		10.1038/sj.onc.1211030	http://dx.doi.org/10.1038/sj.onc.1211030			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212740				2022-12-28	WOS:000256468500003
J	Ropero, S; Ballestar, E; Alaminos, M; Arango, D; Schwartz, S; Esteller, M				Ropero, S.; Ballestar, E.; Alaminos, M.; Arango, D.; Schwartz, S., Jr.; Esteller, M.			Transforming pathways unleashed by a HDAC2 mutation in human cancer	ONCOGENE			English	Article						histone; HDAC2; deacetylase; epigenetics; chromatin	HISTONE MODIFICATIONS; ACETYLATION; EXPRESSION; EPIGENOMICS; BINDING	Although disruption of histone modi. cation patterns is a common hallmark of human cancer, our knowledge of the mechanistic role of histone-modifying enzymes in its generation is very limited. We have recently identified an inactivating mutation in the histone deacetylase-2 (HDAC2) in sporadic carcinomas with microsatellite instability and in tumors arising in individuals with hereditary nonpolyposis colorectal cancer syndrome. Since HDAC2 seems to be a central player in epigenetic gene repression, we wondered whether HDAC2-truncating mutations conferred a particular expression signature on these cancer cells. Using unsupervised clustering analysis in microsatellite-unstable colorectal cancer cell lines, we have found that HDAC2 mutant cells (RKO and Co115) show a characteristically different expression microarray signature from HDAC2 wild-type cells (HCT-116, SW48, HCT-15 and LoVo). HDAC2 mutant cells exhibit upregulation of tumor-promoting genes, such as those of tyrosine kinases, mediators of cell cycle progression and angiogenic factors. The overexpression of these genes is associated with a loss of HDAC2 recruitment and a gain of histone H4 hyperacetylation in their particular 5'-end promoters, as observed by chromatin immunoprecipitation. Transfection of wild-type HDAC2 in mutant cells reverted this epigenetic pattern by repressing the transforming genes in association with HDAC2 promoter occupancy. These results suggest a role for HDAC2 mutations in human tumorigenesis through the derepression of key genes from multiple cellular transformation pathways.	[Ropero, S.; Ballestar, E.; Esteller, M.] Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Madrid 28029, Spain; [Alaminos, M.] Univ Granada, Dept Histol, Granada, Spain; [Alaminos, M.] Hosp Clin Fdn, Granada, Spain; [Alaminos, M.; Arango, D.] Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona, Catalonia, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); University of Granada; Hospital Universitari Vall d'Hebron	Esteller, M (corresponding author), Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	ALAMINOS, MIGUEL/N-9960-2016; Schwartz, Simo/H-7776-2012; Arango, Diego/M-5667-2016; Ballestar, Esteban/ABG-8561-2020; Esteller, Manel/L-5956-2014; Arango, Diego/AFW-0125-2022	ALAMINOS, MIGUEL/0000-0003-4876-2672; Arango, Diego/0000-0003-2953-3284; Esteller, Manel/0000-0003-4490-6093; Arango, Diego/0000-0003-2953-3284; Schwartz, Simo/0000-0001-8297-7971; Ballestar, Esteban/0000-0002-1400-2440	Direct For Biological Sciences [0757780] Funding Source: National Science Foundation	Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))		Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Dopazo J, 1997, J MOL EVOL, V44, P226, DOI 10.1007/PL00006139; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fahrner JA, 2002, CANCER RES, V62, P7213; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Montgomery RL, 2007, GENE DEV, V21, P1790, DOI 10.1101/gad.1563807; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	18	25	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					4008	4012		10.1038/onc.2008.31	http://dx.doi.org/10.1038/onc.2008.31			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264134				2022-12-28	WOS:000257089000012
J	Reinbold, M; Luo, JL; Nedelko, T; Jerchow, B; Murphy, ME; Whibley, C; Wei, Q; Hollstein, M				Reinbold, M.; Luo, J-L; Nedelko, T.; Jerchow, B.; Murphy, M. E.; Whibley, C.; Wei, Q.; Hollstein, M.			Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72	ONCOGENE			English	Article						lung cancer; mutation hotspot; embryonic broblasts; senescence; polymorphism	LUNG-CANCER; POLYMORPHIC VARIANTS; MURINE FIBROBLASTS; GENE-MUTATIONS; DNA-DAMAGE; HOT-SPOTS; TRANSVERSIONS; INHIBITION; HOTSPOTS; ADDUCTS	Codon 72 of human p53 gene is polymorphic, encoding arginine or proline. Here we report construction of a human p53 knock-in (Hupki) mouse encoding the codon 72(pro) variant. The new strain was crossed with the original Hupki mice (codon 72(arg/arg)) to obtain primary embryonic fibroblasts polymorphic at codon 72 or homozygous for codon 72(pro). The fibroblasts, cultured under standard conditions, immortalized within 12 weeks and acquired p53 mutations similarly to Hupki codon 72(arg/arg) cells investigated previously. Sequencing of human p53 exons 4-9 in immortalized cultures revealed missense mutations found repeatedly in human tumours. In cell lines ensuing from benzo(a) pyrene-treated cultures the combined p53 mutation pattern from experiments with the 3 codon 72 genotypes showed a predominance of strand-biased G to T transversions (18 of 36 mutations), and mutations recurring at smokers' lung tumour hotspot codons 157 and 273, supporting involvement of tobacco carcinogens in shaping the mutation signature in lung cancers of smokers. Mutations in cell lines from unexposed cultures did not cluster at these codons and G to T transversions were uncommon (2 of 52 mutations) (Fisher's exact test P < 0.0001). Most mutations (13/16) in cell lines derived from cells polymorphic at codon 72 were found on the proline allele, with loss of the arginine allele.	[Whibley, C.; Hollstein, M.] Univ Leeds, Fac Med & Hlth, LIGHT Labs, Leeds LS2 9JT, W Yorkshire, England; [Reinbold, M.; Nedelko, T.; Wei, Q.; Hollstein, M.] German Canc Res Ctr, Dept Genet Alternat Carcinogenesis, D-6900 Heidelberg, Germany; [Luo, J-L] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Jerchow, B.] Max Delbruck Ctr, Berlin, Germany; [Murphy, M. E.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	University of Leeds; Helmholtz Association; German Cancer Research Center (DKFZ); University of California System; University of California San Diego; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Fox Chase Cancer Center	Hollstein, M (corresponding author), Univ Leeds, Fac Med & Hlth, LIGHT Labs, Clarendon Way, Leeds LS2 9JT, W Yorkshire, England.	m.hollstein@leeds.ac.uk		Jerchow, Boris-Alexander/0000-0002-7031-8730; Murphy, Maureen/0000-0001-7644-7296	NATIONAL CANCER INSTITUTE [R01CA102184] Funding Source: NIH RePORTER; Cancer Research UK Funding Source: Medline; NCI NIH HHS [R01 CA102184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Chen JX, 1998, CANCER RES, V58, P2070; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Feng ZH, 2006, P NATL ACAD SCI USA, V103, P15404, DOI 10.1073/pnas.0607031103; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hu YC, 2005, CLIN CANCER RES, V11, P2502, DOI 10.1158/1078-0432.CCR-04-1913; Liu Zhipei, 2007, Genet Eng (N Y), V28, P45, DOI 10.1007/978-0-387-34504-8_3; Liu ZP, 2005, CANCER RES, V65, P2583, DOI 10.1158/0008-5472.CAN-04-3675; Liu ZP, 2004, P NATL ACAD SCI USA, V101, P2963, DOI 10.1073/pnas.0308607101; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Nelson HH, 2005, CARCINOGENESIS, V26, P1770, DOI 10.1093/carcin/bgi125; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pfeifer GP, 2003, MUTAT RES-FUND MOL M, V526, P39, DOI 10.1016/S0027-5107(03)00013-7; Pietsch EC, 2006, ONCOGENE, V25, P1602, DOI 10.1038/sj.onc.1209367; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Szymanowska A, 2006, LUNG CANCER, V52, P9, DOI 10.1016/j.lungcan.2005.12.007; Thomas M, 1999, MOL CELL BIOL, V19, P1092; vom Brocke J, 2006, CARCINOGENESIS, V27, P2141, DOI 10.1093/carcin/bg1101; Zienolddiny S, 2001, BRIT J CANCER, V84, P226, DOI 10.1054/bjoc.2000.1528	29	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2008	27	19					2788	2794		10.1038/sj.onc.1210932	http://dx.doi.org/10.1038/sj.onc.1210932			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998932	Green Accepted			2022-12-28	WOS:000255259500014
J	Hasskarl, J; Mern, DS; Munger, K				Hasskarl, J.; Mern, D. S.; Muenger, K.			Interference of the dominant negative helix-loop-helix protein ID1 with the proteasomal subunit S5A causes centrosomal abnormalities	ONCOGENE			English	Article						ID1; centrosome; S5A; proteasome; cancer	CELL-CYCLE; RETINOBLASTOMA PROTEIN; MITOTIC DEFECTS; DNA-BINDING; DEGRADATION; ID-1; DUPLICATION; CANCER; DIFFERENTIATION; SENESCENCE	The inhibitor of DNA-binding (ID) proteins are dominant-negative inhibitors of basic helix-loop-helix transcription factors that have multiple functions d uring development and cellular differentiation. High-level expression of some ID family members has been observed in human malignancies, and in some cases was correlated with poor clinical prognosis. Ectopic ID1 expression extends the life span of primary human epithelial cells, inhibits cellular differentiation and induces centrosome duplication errors, thus suggesting that ID1 may have oncogenic activities. ID1 can bind to the proteasomal subunit S5A/Rpn10, but the biological consequences of the interaction have not been studied in detail. Here, we show that ID1' s ability to induce supernumerary centrosomes correlates with S5A binding. Similar to ID1, a fraction of the S5A protein localizes to centrosomal structures. Furthermore, partial depletion of S5A by RNA interference causes accumulation of cells with supernumerary centrosomes. These results are consistent with the model that ID1 dysregulates centrosome homeostasis at least in part by interfering with S5A activities at the centrosome.	[Hasskarl, J.; Mern, D. S.] Univ Freiburg, Med Ctr, Div Hematol & Oncol, D-79106 Freiburg, Freiburg Im Bre, Germany; [Muenger, K.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA	University of Freiburg; Harvard University; Brigham & Women's Hospital	Hasskarl, J (corresponding author), Univ Freiburg, Med Ctr, Div Hematol & Oncol, Hugstetter Str 55,Med 1, D-79106 Freiburg, Freiburg Im Bre, Germany.	jens.hasskarl@uniklinik-freiburg.de	Hasskarl, Jens/E-8980-2011	Shenegelegn Mern, Demissew/0000-0001-5893-981X; Munger, Karl/0000-0003-3288-9935	NCI NIH HHS [R01 CA066980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Berse M, 2004, J MOL BIOL, V343, P361, DOI 10.1016/j.jmb.2004.08.043; Bloom J, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-5; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; D'Assoro AB, 2001, MARC MALPIG SYMP SER, V7, P103; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Duensing S, 2001, CANCER RES, V61, P2356; Duensing Stefan, 2003, Mol Cancer, V2, P30, DOI 10.1186/1476-4598-2-30; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Fraidenraich D, 2004, SCIENCE, V306, P247, DOI 10.1126/science.1102612; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hara E, 1996, DEV GENET, V18, P161; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HASSKARL J, 2004, ONCOGENE, V63, P476; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Stavropoulou V, 2005, CANCER RES, V65, P1361, DOI 10.1158/0008-5472.CAN-04-2085; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Szlanka T, 2003, J CELL SCI, V116, P1023, DOI 10.1242/jcs.00332; Tang J, 2002, LAB INVEST, V82, P1073, DOI 10.1097/01.LAB.0000022223.65962.3A; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Wigley WC, 1999, J CELL BIOL, V145, P481; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	44	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1657	1664		10.1038/sj.onc.1210808	http://dx.doi.org/10.1038/sj.onc.1210808			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891176				2022-12-28	WOS:000253962100001
J	Nieto-Miguel, T; Gajate, C; Gonzalez-Camacho, F; Mollinedo, F				Nieto-Miguel, T.; Gajate, C.; Gonzalez-Camacho, F.; Mollinedo, F.			Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy	ONCOGENE			English	Article						Hsp90; JNK; lipid rafts; apoptosis; edelfosine; alkyl-lysophospholipid	HUMAN LEUKEMIC-CELLS; FAS/CD95 DEATH RECEPTOR; REGULATES AKT KINASE; COLON-CANCER CELLS; ET-18-OCH3 EDELFOSINE; INDUCED APOPTOSIS; HEAT-SHOCK-PROTEIN-90 FUNCTION; SELECTIVE INDUCTION; CYCLE ARREST; TUMOR-CELLS	Heat shock protein 90 (Hsp90) is a survival signaling chaperone and a cancer chemotherapeutic target. However, we have found that inhibitors of Hsp90 diminished the apoptotic response induced in leukemic cells by the antitumor alkyl-lysophospholipid analog edelfosine, which acts through lipid raft reorganization. Edelfosine treatment recruited Hsp90, c-Jun N-terminal kinase (JNK) and apoptotic molecules in lipid rafts, but not the JNK regulators apoptosis signal-regulating kinase 1 (ASK1) and Daxx, or the survival signaling molecules extracellular signal-regulated kinase (ERK) and Akt. Following edelfosine treatment, Hsp90 bound to JNK in lipid rafts and Hsp90-JNK clusters were identified at the plasma membrane by immunoelectron microscopy. Hsp90 inhibition reduced JNK protein level in lipid rafts and turned proapoptotic persistent JNK activation into a transient response in edelfosine-treated cells. Decrease in edelfosine-induced JNK activation and apoptosis by Hsp90 inhibition was prevented through proteasome inhibition, suggesting that Hsp90 inhibition diminishes apoptosis by promoting JNK protein degradation. Expression of ASK1 dominant negative mutant did not affect JNK activation and apoptosis following edelfosine treatment. These data indicate that lipid raft-recruited JNK is ASK1-independent and becomes a novel Hsp90 client protein. Our results reveal a new chaperoning role of Hsp90 on JNK-mediated apoptosis following its recruitment in lipid rafts.	[Nieto-Miguel, T.; Gajate, C.; Gonzalez-Camacho, F.; Mollinedo, F.] Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, E-37007 Salamanca, Spain; [Gajate, C.] Hosp Univ Salamanca, Unidad Invest, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca	Mollinedo, F (corresponding author), Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	fmollin@usal.es	2008, Ibsal/A-1268-2012; González-Camacho, Fernando/P-1610-2014; Nieto Miguel, Teresa/L-1496-2016	Gajate, Consuelo/0000-0003-0604-6459; Nieto Miguel, Teresa/0000-0002-8374-5379; Gonzalez-Camacho, Fernando/0000-0003-3175-9004				Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chiosis G, 2001, BIOORG MED CHEM LETT, V11, P909, DOI 10.1016/S0960-894X(01)00099-3; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Gajate C, 2000, CANCER RES, V60, P2651; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood-2006-04-016824; Georgakis GV, 2006, CLIN CANCER RES, V12, P584, DOI 10.1158/1078-0432.CCR-05-1194; George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Mollinedo F, 2003, J IMMUNOL, V170, P1034, DOI 10.4049/jimmunol.170.2.1034; Mollinedo F, 1997, CANCER RES, V57, P1320; Mollinedo F, 2004, CURR MED CHEM, V11, P3163, DOI 10.2174/0929867043363703; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; MOLLINEDO F, 1994, BIOCHEM J, V302, P325, DOI 10.1042/bj3020325; Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.drup.2006.04.002; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nieto-Miguel T, 2006, J BIOL CHEM, V281, P14833, DOI 10.1074/jbc.M511251200; Ruiter GA, 1999, CANCER RES, V59, P2457; Solit DB, 2003, CANCER RES, V63, P2139; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; van der Luit AH, 2002, J BIOL CHEM, V277, P39541, DOI 10.1074/jbc.M203176200; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zaremberg V, 2005, J BIOL CHEM, V280, P38047, DOI 10.1074/jbc.M502849200; Zhang H, 2004, J BIOL CHEM, V279, P19457, DOI 10.1074/jbc.M311377200; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024	32	44	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1779	1787		10.1038/sj.onc.1210816	http://dx.doi.org/10.1038/sj.onc.1210816			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891170				2022-12-28	WOS:000253962100013
J	Lau, LMS; Nugent, JK; Zhao, X; Irwin, MS				Lau, L. M. S.; Nugent, J. K.; Zhao, X.; Irwin, M. S.			HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function	ONCOGENE			English	Article						Nutlin; p73; HDM2; apoptosis; p53	MOLECULE MDM2 ANTAGONISTS; SQUAMOUS-CELL CARCINOMA; CENTRAL DOMAIN; P53 PATHWAY; MUTANT P53; IN-VIVO; APOPTOSIS; FAMILY; SITE; P63	Nutlin-3, a small molecule inhibitor, activates p53 by disrupting p53-HDM2 association. In this study, we found that Nutlin-3 suppressed cell growth and induced apoptosis in the absence of wild-type p53, suggesting a p53-independent mechanism for Nutlin-3-induced cell death. Like p53, its homolog p73 transactivates proapoptotic genes and induces cell death. Since HDM2, a key negative regulator of p53, also binds to and inhibits p73, we asked whether p73 could mediate Nutlin-3-induced apoptosis. We demonstrate that Nutlin-3 inhibits endogenous binding between the proapoptotic p73 isoform TAp73 alpha and HDM2 in p53-null cells. Dissociation of p73 and HDM2 leads to increased p73 transcriptional activity with up regulation of p73 target genes noxa, puma and p21,as well as enhanced apoptosis. p73 knockdown by siRNA results in rescue of Nutlin-3-treated cells, indicating that Nutlin-3-induced apoptosis is, at least in part, p73 dependent. In addition, Nutlin-3 treatment increases TAp73 alpha protein levels with prolongation of p73 half-life. These results provide the first evidence that Nutlin-3 disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73 and thus, provides a rationale for the use of Nutlin-3 in the large number of human tumors in which p53 is inactivated.	[Lau, L. M. S.; Zhao, X.; Irwin, M. S.] Univ Toronto, Div Hematol Oncol, Dept Paediat, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Lau, L. M. S.; Nugent, J. K.; Irwin, M. S.] Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Irwin, M. S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; [Irwin, M. S.] Univ Toronto, Inst Med Sci, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Irwin, MS (corresponding author), Univ Toronto, Div Hematol Oncol, Dept Paediat, Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	meredith.irwin@sickkids.ca	Lau, Loretta MS/B-1565-2008	Lau, Loretta MS/0000-0002-3172-0970				Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2004, CELL CYCLE, V3, P319; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kulikov R, 2006, J BIOL CHEM, V281, P28575, DOI 10.1074/jbc.M513311200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LaRusch GA, 2007, CANCER RES, V67, P450, DOI 10.1158/0008-5472.CAN-06-2710; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Ma JH, 2006, BIOCHEMISTRY-US, V45, P9238, DOI 10.1021/bi060661u; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; VanderBorght A, 2006, ONCOGENE, V25, P6672, DOI 10.1038/sj.onc.1209667; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Watson IR, 2006, J BIOL CHEM, V281, P34096, DOI 10.1074/jbc.M603654200; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	30	147	153	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					997	1003		10.1038/sj.onc.1210707	http://dx.doi.org/10.1038/sj.onc.1210707			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700533				2022-12-28	WOS:000252946300011
J	Nardi, V; Raz, T; Cao, X; Wu, CJ; Stone, RM; Cortes, J; Deininger, MWN; Church, G; Zhu, J; Daley, GQ				Nardi, V.; Raz, T.; Cao, X.; Wu, C. J.; Stone, R. M.; Cortes, J.; Deininger, M. W. N.; Church, G.; Zhu, J.; Daley, G. Q.			Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors	ONCOGENE			English	Article						mutations detection; solid-phase PCR; drug resistance	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; DASATINIB BMS-354825; DOMAIN MUTATIONS; IMATINIB; RECOMMENDATIONS; MUTAGENESIS	Resistance to molecularly targeted chemotherapy, and the development of novel agents that are active against resistant forms of target proteins create the need for a sensitive and quantitative assay to monitor drug-resistant mutations in patients to guide treatment and assess response. Here, we describe an application of the polymerase colony (polony) method to identify and quantify known point mutations in the BCR-ABL oncogene in patients with chronic myelogenous leukemia who evolve resistance to ABL kinase inhibitors. The assay can detect mutations with a sensitivity of 10(-4), quantify the burden of drug-resistant cells, and simultaneously monitor the dynamics of several coexisting mutations. As a proof of concept, we analysed blood samples from three patients undergoing therapy with ABL kinase inhibitors and found that the patients' response to therapy correlated with our molecular monitoring. We were also able to detect mutations emerging in patients long before clinical relapse. Therefore, the polony assay could be applied to a larger patient sample to assess the utility of early mutation detection in patient-specific treatment decisions. Finally, this methodology could be a valuable research tool to shed light on the natural behavior of mutations pre-existing kinase inhibitors therapy and either disappearing over time or slowly taking over.	[Cao, X.; Zhu, J.] Duke Univ, Inst Genome Sci & Policy, Dept Cell Biol, Durham, NC 27708 USA; [Nardi, V.; Raz, T.; Daley, G. Q.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Biol Chem & Mol Pharmacol,Div Hematol Oncol, Boston, MA 02115 USA; [Wu, C. J.; Stone, R. M.] Childrens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Deininger, M. W. N.] Oregon Hlth & Sci Univ, Inst Canc, Div Hematol Oncol, Portland, OR 97201 USA; [Cortes, J.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA; [Church, G.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Duke University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Oregon Health & Science University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School	Zhu, J (corresponding author), Duke Univ, Inst Genome Sci & Policy, Dept Cell Biol, 2353A CIEMAS,101 Sci Dr, Durham, NC 27708 USA.	jun.zhu@duke.edu; george.daley@childrens.harvard.edu		Cortes, Jorge/0000-0002-8636-1071; church, george/0000-0001-6232-9969	NCI NIH HHS [F32-CA101505, R01 CA86691] Funding Source: Medline; NHLBI NIH HHS [T32 HL066987-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA101505] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL066987] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Baccarani M, 2006, BLOOD, V108, P1809, DOI 10.1182/blood-2006-02-005686; Bradeen HA, 2006, BLOOD, V108, P2332, DOI 10.1182/blood-2006-02-004580; Butz J, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-11; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Diehl F, 2006, NAT METHODS, V3, P551, DOI 10.1038/NMETH898; Hughes T, 2006, BLOOD, V108, P28, DOI 10.1182/blood-2006-01-0092; Kang HY, 2006, HAEMATOLOGICA, V91, P659; KANTARJIAN HM, 2006, BLOOD, V18, P18; Li M, 2006, NAT METHODS, V3, P95, DOI 10.1038/NMETH850; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Mitra RD, 2003, P NATL ACAD SCI USA, V100, P5926, DOI 10.1073/pnas.0936399100; Mitra RD, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e34; Quintas-Cardama A, 2007, BLOOD, V109, P497, DOI 10.1182/blood-2006-07-035493; Soverini S, 2004, CLIN CHEM, V50, P1205, DOI 10.1373/clinchem.2004.031112; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; Willis SG, 2005, BLOOD, V106, P2128, DOI 10.1182/blood-2005-03-1036; ZHAM M, 2006, P NATL ACAD SCI USA, V103, P9244; Zhang K, 2006, NAT GENET, V38, P382, DOI 10.1038/ng1741; Zhu J, 2003, SCIENCE, V301, P836, DOI 10.1126/science.1085792	21	20	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					775	782		10.1038/sj.onc.1210698	http://dx.doi.org/10.1038/sj.onc.1210698			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17684485				2022-12-28	WOS:000252884500006
J	Downs, JA				Downs, J. A.			Chromatin structure and DNA double-strand break responses in cancer progression and therapy	ONCOGENE			English	Review						chromatin; DNA repair; genome stability; linker histone; H2A; H2AX; HMGB	HISTONE DEACETYLASE INHIBITOR; TELOMERE MAINTENANCE; H2AX PHOSPHORYLATION; GENOMIC INSTABILITY; IONIZING-RADIATION; DAMAGE RESPONSE; REPAIR PROTEINS; HUMAN TUMOR; RECOMBINATION; CELLS	Defects in the detection and repair of DNA double-strand breaks (DSBs) have been causatively linked to tumourigenesis. Moreover, inhibition of DNA damage responses (DDR) can increase the efficacy of cancer therapies that rely on generation of damaged DNA. DDR must occur within the context of chromatin, and there have been significant advances in recent years in understanding how the modulation and manipulation of chromatin contribute to this activity. One particular covalent modification of a histone variant-the phosphorylation of H2AX-has been investigated in great detail and has been shown to have important roles in DNA DSB responses and in preventing tumourigenesis. These studies are reviewed here in the context of their relevance to cancer therapy and diagnostics. In addition, there is emerging evidence for contributions by proteins involved in mediating higher order structure to DNA DSB responses. The contributions of a subset of these proteins-linker histones and high-mobility group box (HMGB) proteins-to DDR and their potential significance in tumourigenesis are discussed.	Univ Sussex, MRC Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Sussex	Downs, JA (corresponding author), Univ Sussex, MRC Genome Damage & Stabil Ctr, Sci Pk Rd, Brighton BN1 9RQ, E Sussex, England.	j.a.downs@sussex.ac.uk		Downs, Jessica/0000-0002-6600-849X				Alami R, 2003, P NATL ACAD SCI USA, V100, P5920, DOI 10.1073/pnas.0736105100; Ausio J, 2000, BIOESSAYS, V22, P873, DOI 10.1002/1521-1878(200010)22:10<873::AID-BIES1>3.3.CO;2-I; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bergeron S, 2005, J BIOL CHEM, V280, P31314, DOI 10.1074/jbc.M503063200; Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Costelloe T, 2006, EXP CELL RES, V312, P2677, DOI 10.1016/j.yexcr.2006.06.031; Cowell IG, 2005, BIOCHEM PHARMACOL, V71, P13, DOI 10.1016/j.bcp.2005.09.029; Dai Y, 2005, MOL CELL BIOL, V25, P4413, DOI 10.1128/MCB.25.11.4413-4425.2005; Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532; Downs JA, 2003, MOL CELL, V11, P1685, DOI 10.1016/S1097-2765(03)00197-7; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Funayama R, 2006, J CELL BIOL, V175, P869, DOI 10.1083/jcb.200604005; Gallmeier E, 2005, CARCINOGENESIS, V26, P1811, DOI 10.1093/carcin/bgi132; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harvey AC, 2004, MOL MICROBIOL, V53, P771, DOI 10.1111/j.1365-2958.2004.04195.x; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; HASHIMOTO H, 2007, IN PRESS DNA REPAIR; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Kao J, 2006, CURR CANCER DRUG TAR, V6, P197, DOI 10.2174/156800906776842957; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Lavin MF, 2006, EMBO REP, V7, P154, DOI 10.1038/sj.embor.7400629; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Madhusudan S, 2005, CANCER TREAT REV, V31, P603, DOI 10.1016/j.ctrv.2005.09.006; Mahrhofer H, 2006, INT J RADIAT ONCOL, V64, P573, DOI 10.1016/j.ijrobp.2005.09.037; Meng LH, 2005, CANCER RES, V65, P5337, DOI 10.1158/0008-5472.CAN-05-0003; Michor F, 2005, PHILOS T R SOC B, V360, P631, DOI 10.1098/rstb.2004.1617; Morrison AJ, 2005, CELL CYCLE, V4, P568; Munshi A, 2006, MOL CANCER THER, V5, P1967, DOI 10.1158/1535-7163.MCT-06-0022; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nagaki S, 1998, BIOCHEM BIOPH RES CO, V246, P137, DOI 10.1006/bbrc.1998.8589; Neumann AA, 2002, NAT REV CANCER, V2, P879, DOI 10.1038/nrc929; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Qian XZ, 2006, MOL CANCER THER, V5, P2086, DOI 10.1158/1535-7163.MCT-06-0111; Qvarnstrom OF, 2004, RADIOTHER ONCOL, V72, P311, DOI 10.1016/j.radonc.2004.07.009; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Raucci A, 2007, AUTOIMMUNITY, V40, P285, DOI 10.1080/08916930701356978; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Reeves R, 2005, DNA REPAIR, V4, P926, DOI 10.1016/j.dnarep.2005.04.010; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Stros M, 2000, EUR J BIOCHEM, V267, P4088, DOI 10.1046/j.1432-1327.2000.01450.x; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741; Ueda T, 2002, BBA-MOL CELL RES, V1593, P77, DOI 10.1016/S0167-4889(02)00332-4; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Williams RS, 2007, BIOCHEM CELL BIOL, V85, P509, DOI 10.1139/O07-069; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yamakov V, 2002, NAT MATER, V1, P45, DOI 10.1038/nmat700; Yoshida K, 2004, CANCER RES, V64, P4131, DOI 10.1158/0008-5472.CAN-03-2566; Yu T, 2006, DNA REPAIR, V5, P935, DOI 10.1016/j.dnarep.2006.05.040	67	29	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7765	7772		10.1038/sj.onc.1210874	http://dx.doi.org/10.1038/sj.onc.1210874			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066089				2022-12-28	WOS:000251537900007
J	Lo, YH; Wu, CC; Shih, HM; Lai, MZ				Lo, Y-H; Wu, C-C; Shih, H-M; Lai, M-Z			Selective activation of NFAT by promyelocytic leukemia protein	ONCOGENE			English	Article						PML; NFAT; CBP; tumor suppressor; transcription activation	ALPHA-INDUCED APOPTOSIS; T-CELLS; NUCLEAR-BODIES; KAPPA-B; DNA-DAMAGE; PML GENE; TRANSCRIPTION; DAXX; COACTIVATOR; EXPRESSION	Promyelocytic leukemia (PML) protein is a tumor suppressor with complicated action mechanisms not yet fully understood. In this study, we found that the nuclear factor of activated T cell ( NFAT) is an unexpected partner of PML: PML specifically enhanced the transcription activation of NFAT. In PML-null mouse embryonic fibroblasts, no transcription activity of NFAT could be detected. There was a selective requirement of PML isoform in NFAT activation: PML-I and PML-VI, but not PML-IV, increased NFAT transactivation. PML specifically promoted the expression of many, but not all, NFAT-targeted genes. We found a specific binding of PML to NFATc. The interaction of PML with NFATc in vivo was further confirmed by chromatin immunoprecipitation and DNA affinity precipitation assay analysis. The unexpected coupling of PML with NFAT reveals a novel mechanism underlying the diverse physiological functions of PML.	[Lo, Y-H; Wu, C-C; Lai, M-Z] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; [Lo, Y-H; Lai, M-Z] Natl Yang Ming Univ, Grad Inst Microbiol & Immunol, Taipei 112, Taiwan; [Shih, H-M] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Lai, M-Z] Natl Taiwan Univ, Sch Med, Grad Inst Immunol, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Taiwan University	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	mblai@imb.sinica.edu.tw	Shih, Hsiu-Ming/S-7023-2018; Lai, Ming-Zong/AAA-4408-2021	Lai, Ming-Zong/0000-0002-3237-4803				Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bruno S, 2003, BLOOD, V101, P3514, DOI 10.1182/blood-2002-11-3335; Buschbeck M, 2007, ONCOGENE, V26, P3415, DOI 10.1038/sj.onc.1210128; Cairo S, 2005, ONCOGENE, V24, P2195, DOI 10.1038/sj.onc.1208338; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Crowder C, 2005, BLOOD, V105, P1280, DOI 10.1182/blood-2004-04-1614; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; GODDARD AD, 1995, MAMM GENOME, V6, P732, DOI 10.1007/BF00354296; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Ho HY, 1997, EUR J IMMUNOL, V27, P222, DOI 10.1002/eji.1830270133; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin DY, 2004, MOL CELL BIOL, V24, P10529, DOI 10.1128/MCB.24.24.10529-10541.2004; Lin DY, 2003, J BIOL CHEM, V278, P15958, DOI 10.1074/jbc.M300387200; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Moller A, 2003, CANCER RES, V63, P4310; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wu CC, 2003, MOL CELL BIOL, V23, P6442, DOI 10.1128/MCB.23.18.6442-6454.2003; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Wu WS, 2002, ONCOGENE, V21, P3925, DOI 10.1038/sj.onc.1205491; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	40	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3821	3830		10.1038/onc.2008.2	http://dx.doi.org/10.1038/onc.2008.2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246125				2022-12-28	WOS:000256904700006
J	Alsheich-Bartok, O; Haupt, S; Alkalay-Snir, I; Saito, S; Appella, E; Haupt, Y				Alsheich-Bartok, O.; Haupt, S.; Alkalay-Snir, I.; Saito, S.; Appella, E.; Haupt, Y.			PML enhances the regulation of p53 by CK1 in response to DNA damage	ONCOGENE			English	Article						PML; CK1; p53; Mdm2; threonine 18 phosphorylation	ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEAR-BODIES; PROTEIN-KINASE; HUMAN CANCERS; PHOSPHORYLATION; MDM2; BINDING; UBIQUITINATION; DEGRADATION; INHIBITOR	In response to stress, p53 is accumulated and activated to induce appropriate growth inhibitory responses. This requires the release of p53 from the constraints of its negative regulators Mdm2 and Mdm4. A key event in this dissociation is the phosphorylation of p53 at threonine residue (Thr18) within the Mdm2/4-binding domain. Casein kinase 1 (CK1) plays a major role in this phosphorylation. The promyelocytic leukemia protein (PML) regulates certain modi. cations of p53 in response to DNA damage. Here, we investigated the role of PML in the regulation of Thr18 phosphorylation. We found that PML enhances Thr18 phosphorylation of endogenous p53 in response to stress. On DNA damage, CK1 accumulates in the cell, with a proportion concentrated in the nucleus together with p53 and PML. Furthermore, CK1 interacts with endogenous p53 and PML, and this interaction is enhanced by genotoxic stress. Inhibition of CK1 impairs the protection of p53 by PML from Mdm2-mediated degradation. Our findings support a role for PML in the regulation of p53 by CK1. We propose that following DNA damage, PML facilitates Thr18 phosphorylation by recruiting p53 and CK1 into PML nuclear bodies, thereby protecting p53 from inhibition by Mdm2, leading to p53 activation.	[Alsheich-Bartok, O.; Haupt, S.; Alkalay-Snir, I.; Haupt, Y.] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Dept Immunol, IL-91120 Jerusalem, Israel; [Saito, S.; Appella, E.] NCI, Cell Biol Lab, Ctr Canc Res, Natl Inst Hlth, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Haupt, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Dept Immunol, IL-91120 Jerusalem, Israel.	haupt@md.huji.ac.il		Haupt, Ygal/0000-0001-5925-0096	NATIONAL CANCER INSTITUTE [ZIABC005599, Z01BC005599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Maritzen T, 2003, EUR J CELL BIOL, V82, P369, DOI 10.1078/0171-9335-00323; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Salomoni P, 2002, NAT CELL BIOL, V4, pE152, DOI 10.1038/ncb0602-e152; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Soubeyrand S, 2004, EUR J BIOCHEM, V271, P3776, DOI 10.1111/j.1432-1033.2004.04319.x; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Wang ZG, 1998, SCIENCE, V279, P1547; Wolff S, 2006, FEBS LETT, V580, P6477, DOI 10.1016/j.febslet.2006.10.068; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020	30	52	54	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3653	3661		10.1038/sj.onc.1211036	http://dx.doi.org/10.1038/sj.onc.1211036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18246126				2022-12-28	WOS:000256659300002
J	Hartl, B; Zeller, T; Blanchette, P; Kremmer, E; Dobner, T				Haertl, B.; Zeller, T.; Blanchette, P.; Kremmer, E.; Dobner, T.			Adenovirus type 5 early region 1B 55-kDa oncoprotein can promote cell transformation by a mechanism independent from blocking p53-activated transcription	ONCOGENE			English	Article						E1B-55K; Mre11; PML-NBs; cytoplasmic perinuclear body; CRM1	P53 TUMOR-SUPPRESSOR; E1B 55-KILODALTON ONCOPROTEIN; GENE-EXPRESSION; NUCLEAR EXPORT; MESSENGER-RNAS; PROTEIN; E4ORF6; 1B; PHOSPHORYLATION; REPRESSION	Inhibition of p53-activated transcription is an integral part of the mechanism by which early region 1B 55K oncoprotein (E1B-55K) from adenovirus type 5 (Ad5) contributes to complete cell transformation in combination with Ad E1A. In addition, more recent data suggest that the mode of action of the Ad protein during transformation may involve additional functions and other protein interactions. In the present study, we performed a comprehensive mutational analysis to assign further transforming functions of Ad5 E1B-55K to distinct domains within the viral polypeptide. Results from these studies show that the functions required for transformation are encoded within several patches of the 55K primary sequence, including several clustered cysteine and histidine residues, some of which match the consensus for zinc fingers. In addition, two amino-acid substitutions (C454S/C456S) created a 55K mutant protein, which had substantially reduced transforming activity. Interestingly, the same mutations neither affected binding to p53 nor inhibition of p53-mediated transactivation. Therefore, an activity necessary for efficient transformation of primary rat cells can be separated from functions required for inhibition of p53-stimulated transcription. Our data indicate that this activity is linked to the ability of the Ad5 protein to bind to components of the Mre11/Rad50/NBS1 DNA double-strand break repair complex, and/or its ability to assemble multiprotein aggregates in the cytoplasm and nucleus of transformed rat cells. These results introduce a new function for Ad5 E1B-55K and suggest that the viral protein contributes to cell transformation through p53 transcription-dependent and-independent pathways.	[Haertl, B.; Dobner, T.] Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Virol, D-20251 Hamburg, Germany; [Zeller, T.] Geneart Biopk, Regensburg, Germany; [Blanchette, P.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Kremmer, E.] GSF Inst Mol Immunol, Munich, Germany	Heinrich Pette Institute; McGill University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Dobner, T (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Virol, Martinistr 52, D-20251 Hamburg, Germany.	thomas.dobner@hpi.uni-hamburg.de						ANDERSON CW, 1984, J VIROL, V50, P387, DOI 10.1128/JVI.50.2.387-396.1984; Barral PM, 2005, FEBS LETT, V579, P2752, DOI 10.1016/j.febslet.2005.03.095; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Boivin D, 1999, J VIROL, V73, P1245, DOI 10.1128/JVI.73.2.1245-1253.1999; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Budhu AS, 2005, CELL CYCLE, V4, P1510, DOI 10.4161/cc.4.11.2187; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Carter CC, 2003, VIROLOGY, V315, P224, DOI 10.1016/S0042-6822(03)00526-9; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Flint SJ, 2005, VIROLOGY, V337, P7, DOI 10.1016/j.virol.2005.04.007; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Florin L, 2004, J VIROL, V78, P5546, DOI 10.1128/JVI.78.11.5546-5553.2004; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gabler S, 1998, J VIROL, V72, P7960, DOI 10.1128/JVI.72.10.7960-7971.1998; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; Greenberg RA, 2005, CURR MOL MED, V5, P213, DOI 10.2174/1566524053586590; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Hutton FG, 2000, ONCOGENE, V19, P452, DOI 10.1038/sj.onc.1203316; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kindsmuller K, 2007, P NATL ACAD SCI USA, V104, P6684, DOI 10.1073/pnas.0702158104; Koch P, 2001, CANCER RES, V61, P5941; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Liao DQ, 1999, VIROLOGY, V254, P11, DOI 10.1006/viro.1998.9512; Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005; Lober C, 2002, J GEN VIROL, V83, P2047, DOI 10.1099/0022-1317-83-8-2047; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NEVELS M, 2007, ADENOVIRUS METHODS P, P187; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; Wan YP, 2004, CHINESE MED J-PEKING, V117, P753; Wendt J, 2006, ONCOGENE, V25, P972, DOI 10.1038/sj.onc.1209031; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	51	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3673	3684		10.1038/sj.onc.1211039	http://dx.doi.org/10.1038/sj.onc.1211039			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212738				2022-12-28	WOS:000256659300004
J	Baird, SK; Aerts, JL; Eddaoudi, A; Lockley, M; Lemoine, NR; McNeish, IA				Baird, S. K.; Aerts, J. L.; Eddaoudi, A.; Lockley, M.; Lemoine, N. R.; McNeish, I. A.			Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer	ONCOGENE			English	Article						adenovirus; ovarian cancer; apoptosis; autophagy; necrosis	INDUCED APOPTOSIS; AUTOPHAGY; PROTEIN; INHIBITION; RB; 3-METHYLADENINE; BIOLUMINESCENCE; PATHWAYS; GENES; ADP	Oncolytic adenoviral mutants have considerable activity in ovarian cancer. However, the mechanisms by which they induce cell death remain uncertain. dl922-947, which contains a 24 bp deletion in E1A CR2, is more potent than both E1A wild-type adenoviruses and the E1B-55K deletion mutant dl1520 (Onyx-015). We investigated the mode of death induced by three E1A CR2-deleted replicating adenoviruses in models of ovarian cancer and also the importance of E3 11.6 (adenovirus death protein) in determining this mode of death. Ovarian cancer cells were infected with dl922-947 (E3 11.6(+)) and dlCR2 (E3 11.6(-)). We also generated dlCR2 tSmac, which also encodes the gene for processed Smac/DIABLO. Classical apoptosis does not occur in adenoviral cell death and there is no role for mitochondria. Expression of Smac/DIABLO does not enhance cytotoxicity nor increase apoptotic features. A role for cathepsins and lysosomal membrane permeability was excluded. Autophagy is induced, but is not the mode of death and may act as a cell survival mechanism. There is no evidence of pure necrosis, while the presence of E3 11.6 does not modulate the mode or extent of cell death. Thus, E1A CR2-deleted oncolytic adenoviral cytotoxicity in ovarian cancer may de. ne a novel mode of programmed cell death.	[Baird, S. K.; Aerts, J. L.; Lockley, M.; Lemoine, N. R.; McNeish, I. A.] John Vane Sci Ctr, Barts & London Queen Marys Sch Med, Inst Canc, Canc Res UK Clin Ctr,Ctr Mol Oncol, London EC1M 6BQ, England; [Eddaoudi, A.] Canc Res UK London Res Inst, FACS Lab, London, England	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK	McNeish, IA (corresponding author), John Vane Sci Ctr, Barts & London Queen Marys Sch Med, Inst Canc, Canc Res UK Clin Ctr,Ctr Mol Oncol, Charterhouse Sq, London EC1M 6BQ, England.	iain.mcneish@cancer.org.uk	Aerts, Joeri/J-6957-2014	Aerts, Joeri/0000-0002-9902-3696; McNeish, Iain/0000-0002-9387-7586; lockley, michelle/0000-0002-9281-5789; Eddaoudi, Ayad/0000-0001-5272-6426	MRC [G0601891, G84/6553] Funding Source: UKRI; Cancer Research UK [A4119, C9423/A4119] Funding Source: Medline; Medical Research Council [G84/6553, G0601891, G0601891(82080)] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abou El Hassan MAI, 2004, J VIROL, V78, P12243, DOI 10.1128/JVI.78.22.12243-12251.2004; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495; Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; Castino R, 2002, INT J CANCER, V97, P775, DOI 10.1002/ijc.10139; Cereghetti GM, 2006, ONCOGENE, V25, P4717, DOI 10.1038/sj.onc.1209605; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Ito H, 2006, JNCI-J NATL CANCER I, V98, P625, DOI 10.1093/jnci/djj161; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Leyton J, 2006, CANCER RES, V66, P9178, DOI 10.1158/0008-5472.CAN-06-1539; Lockley M, 2006, CANCER RES, V66, P989, DOI 10.1158/0008-5472.CAN-05-2691; McNeish IA, 2003, EXP CELL RES, V286, P186, DOI 10.1016/S0014-4827(03)00073-9; McNeish IA, 2001, CANCER GENE THER, V8, P308, DOI 10.1038/sj.cgt.7700305; Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Stroikin Y, 2004, EUR J CELL BIOL, V83, P583, DOI 10.1078/0171-9335-00433; Subramanian T, 2006, J VIROL, V80, P2000, DOI 10.1128/JVI.80.4.2000-2012.2006; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Terman A, 2003, EXP GERONTOL, V38, P863, DOI 10.1016/S0531-5565(03)00114-1; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; Yaginuma Y, 1997, EXP CELL RES, V233, P233, DOI 10.1006/excr.1997.3560; Ying BL, 2003, VIROLOGY, V313, P224, DOI 10.1016/S0042-6822(03)00287-3; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	37	61	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3081	3090		10.1038/sj.onc.1210977	http://dx.doi.org/10.1038/sj.onc.1210977			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071311	Green Accepted			2022-12-28	WOS:000255897600001
J	Vecchi, M; Confalonieri, S; Nuciforo, P; Vigano, MA; Capra, M; Bianchi, M; Nicosia, D; Bianchi, F; Galimberti, V; Viale, G; Palermo, G; Riccardi, A; Campanini, R; Daidone, MG; Pierotti, MA; Pece, S; Di Fiore, P				Vecchi, M.; Confalonieri, S.; Nuciforo, P.; Vigano, M. A.; Capra, M.; Bianchi, M.; Nicosia, D.; Bianchi, F.; Galimberti, V.; Viale, G.; Palermo, G.; Riccardi, A.; Campanini, R.; Daidone, M. G.; Pierotti, M. A.; Pece, S.; Di Fiore, P. P.			Breast cancer metastases are molecularly distinct from their primary tumors	ONCOGENE			English	Article						gene profiling; breast cancer; metastases	LYMPH-NODE METASTASES; GENE-EXPRESSION; LUNG METASTASIS; SOLID TUMORS; CELLS; MASPIN; GROWTH; MICROENVIRONMENT; PROGRESSION; LACTOFERRIN	Metastases have been widely thought to arise from rare, selected, mutation-bearing cells in the primary tumor. Recently, however, it has been proposed that breast tumors are imprinted ab initio with metastatic ability. Thus, there is a debate over whether 'phenotypic' disease progression is really associated with 'molecular' progression. We pro. led 26 matched primary breast tumors and lymph node metastases and identified 270 probesets that could discriminate between the two categories. We then used an independent cohort of breast tumors (81 samples) and unmatched distant metastases (32 samples) to validate and re. ne this list down to a 126-probeset list. A representative subset of these genes was subjected to analysis by in situ hybridization, on a third independent cohort (57 primary breast tumors and matched lymph node metastases). This not only confirmed the expression pro. le data, but also allowed us to establish the cellular origin of the signals. One-third of the analysed representative genes (4 of 11) were expressed by the epithelial component. The four epithelial genes alone were able to discriminate primary breast tumors from their metastases. Finally, engineered alterations in the expression of two of the epithelial genes (SERPINB5 and LTF) modified cell motility in vitro, in accordance with a possible causal role in metastasis. Our results show that breast cancer metastases are molecularly distinct from their primary tumors.	[Vecchi, M.; Confalonieri, S.; Nuciforo, P.; Vigano, M. A.; Capra, M.; Bianchi, M.; Nicosia, D.; Bianchi, F.; Galimberti, V.; Viale, G.; Pierotti, M. A.; Pece, S.; Di Fiore, P. P.] Ist Europeo Oncol, Fdn Ist FIRC Oncol Mol, IFOM, I-20139 Milan, Italy; [Viale, G.; Pece, S.; Di Fiore, P. P.] Univ Milan, Dipartimento Med Chirurg Odontoiatria, I-20122 Milan, Italy; [Palermo, G.; Riccardi, A.; Campanini, R.] Univ Bologna, Dept Phys, I-40126 Bologna, Italy; [Daidone, M. G.; Pierotti, M. A.] Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan; University of Bologna; Fondazione IRCCS Istituto Nazionale Tumori Milan	Di Fiore, P (corresponding author), Ist Europeo Oncol, Fdn Ist FIRC Oncol Mol, IFOM, Via Adamello 16, I-20139 Milan, Italy.	pierpaolo.difiore@ifom-ieo-campus.it	Confalonieri, Stefano/AAQ-6786-2020; Viale, Giuseppe/AAE-8921-2019; Pece, Salvatore/B-9609-2013; Vecchi, Manuela/L-3502-2017; GALIMBERTI, Viviana Enrica/AAS-3963-2020; Di Fiore, Pier Paolo/K-2130-2012; Bianchi, Fabrizio/B-5995-2017; Daidone, Maria Grazia/E-9232-2017; Bianchi, Fabrizio/W-7037-2019; Capra, Maria/AAM-8054-2020; Pierotti, Marco Alessandro/AAC-4728-2022; Nuciforo, Paolo/Q-2885-2019	Confalonieri, Stefano/0000-0001-6886-9851; Pece, Salvatore/0000-0003-1764-3929; Vecchi, Manuela/0000-0002-2750-9160; GALIMBERTI, Viviana Enrica/0000-0002-5036-7439; Di Fiore, Pier Paolo/0000-0002-2252-0950; Bianchi, Fabrizio/0000-0001-7412-8638; Daidone, Maria Grazia/0000-0002-4786-1321; Bianchi, Fabrizio/0000-0001-7412-8638; Pierotti, Marco Alessandro/0000-0002-7431-8332; Nuciforo, Paolo/0000-0003-1380-0990; vigano, maria alessandra/0000-0003-2009-0384	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Beltran A, 2007, ONCOGENE, V26, P2791, DOI 10.1038/sj.onc.1210072; BEZAULT J, 1994, CANCER RES, V54, P2310; Capra M, 2006, CANCER RES, V66, P8147, DOI 10.1158/0008-5472.CAN-05-3489; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Feng YM, 2007, BREAST CANCER RES TR, V103, P319, DOI 10.1007/s10549-006-9385-7; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Gangnus R, 2004, CLIN CANCER RES, V10, P3457, DOI 10.1158/1078-0432.CCR-03-0818; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hao XS, 2004, CANCER-AM CANCER SOC, V100, P1110, DOI 10.1002/cncr.20095; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lamelas M L, 2000, Int J Surg Investig, V2, P285; Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reddy KB, 2001, ONCOGENE, V20, P6538, DOI 10.1038/sj.onc.1204796; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; Schedin P, 2004, BREAST CANCER RES, V6, P93, DOI 10.1186/bcr772; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Shi HY, 2001, CANCER RES, V61, P6945; Suzuki M, 2007, MOL ONCOL, V1, P172, DOI 10.1016/j.molonc.2007.03.005; Ushida Y, 1998, CANCER LETT, V134, P141, DOI 10.1016/S0304-3835(98)00249-3; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Weigelt B, 2005, BRIT J CANCER, V93, P924, DOI 10.1038/sj.bjc.6602794; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	41	95	98	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2148	2158		10.1038/sj.onc.1210858	http://dx.doi.org/10.1038/sj.onc.1210858			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952122				2022-12-28	WOS:000254621300005
J	Kfoury, Y; Nasr, R; Favre-Bonvin, A; El-Sabban, M; Renault, N; Giron, ML; Setterblad, N; El Hajj, H; Chiari, E; Mikati, AG; Hermine, O; Saib, A; de The, H; Pique, C; Bazarbachi, A				Kfoury, Y.; Nasr, R.; Favre-Bonvin, A.; El-Sabban, M.; Renault, N.; Giron, M-L; Setterblad, N.; El Hajj, H.; Chiari, E.; Mikati, A. G.; Hermine, O.; Saib, A.; de The, H.; Pique, C.; Bazarbachi, A.			Ubiquitylated Tax targets and binds the IKK signalosome at the centrosome	ONCOGENE			English	Article						NF-kappa B; I kappa B kinase; centrosome; HTLV-I; Tax; ubiquitin	T-CELL LEUKEMIA; NF-KAPPA-B; VIRUS TYPE-1 TAX; I TAX; ACTIVATION; PROTEIN; UBIQUITINATION; ONCOPROTEIN; KINASE; AMPLIFICATION	Constitutive activation of the NF-kappa B pathway by the Tax oncoprotein plays a crucial role in the proliferation and transformation of HTLV-I infected T lymphocytes. We have previously shown that Tax ubiquitylation on C-terminal lysines is critical for binding of Tax to I kappa B kinase (IKK) and its subsequent activation. Here, we report that ubiquitylated Tax is not associated with active cytosolic IKK subunits, but binds endogenous IKK-alpha, -beta, -gamma, targeting them to the centrosome. K63-ubiquitylated Tax colocalizes at the centrosome with IKK-gamma, while K48-ubiquitylated Tax is stabilized upon proteasome inhibition. Altogether, these results support a model in which K63-ubiquitylated Tax activates IKK in a centrosome-associated signalosome, leading to the production of Tax-free active cytoplasmic IKK. These observations highlight an unsuspected link between Tax-induced IKK activation and the centrosome.	[Kfoury, Y.; Nasr, R.; El Hajj, H.; Mikati, A. G.; Bazarbachi, A.] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon; [Nasr, R.; Renault, N.; Giron, M-L; Saib, A.; de The, H.] CNRS, UMR 7151, Lab Associe Comite Paris Ligue Canc, Paris, France; [Favre-Bonvin, A.; Chiari, E.; Pique, C.] Univ Paris 05, Univ Paris 07, CNRS,Fac Med Rene Descartes,UMR 7151, Inst Cochin,Dept Biol Cellulaire,UMR3,INSERM U567, Paris, France; [El-Sabban, M.] Amer Univ Beirut, Dept Human Morphol, Beirut, Lebanon; [Giron, M-L] Inst Univ Hematol IFR105, Imagery Dept, Paris, France; [Hermine, O.] Hop Necker Enfants Malad, Dept Hematol, Paris, France; [Hermine, O.] CNRS, UMR 8603, Paris, France	American University of Beirut; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; American University of Beirut; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Bazarbachi, A (corresponding author), Amer Univ Beirut, Med Ctr, Dept Internal Med, Hamra St,POB 1136044, Beirut, Lebanon.	bazarbac@aub.edu.lb	Pique, Claudine/O-6088-2017; Nasr, Rihab/AAF-1606-2020; Hermine, Olivier/Q-7072-2018; setterblad, niclas/GSN-1756-2022	Pique, Claudine/0000-0001-8690-2440; Hermine, Olivier/0000-0003-2574-3874; Bazarbachi, Ali/0000-0002-7171-4997; Mikati, Mohamad/0000-0003-0363-8715; Nasr, Rihab/0000-0003-1166-4999				Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Cheng TS, 2006, LIFE SCI, V78, P1114, DOI 10.1016/j.lfs.2005.06.021; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Ching YP, 2006, NAT CELL BIOL, V8, P717, DOI 10.1038/ncb1432; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Harhaj NS, 2007, J BIOL CHEM, V282, P4185, DOI 10.1074/jbc.M611031200; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128/MCB.25.23.10391-10406.2005; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961; Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200; Nitta T, 2006, CANCER SCI, V97, P836, DOI 10.1111/j.1349-7006.2006.00254.x; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Pumfery A, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-50; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384	20	57	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1665	1676		10.1038/sj.onc.1210804	http://dx.doi.org/10.1038/sj.onc.1210804			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891179				2022-12-28	WOS:000253962100002
J	Khaleque, M; Bharti, A; Gong, J; Gray, PJ; Sachdev, V; Ciocca, DR; Stati, A; Fanelli, M; Calderwood, SK				Khaleque, Ma; Bharti, A.; Gong, J.; Gray, P. J.; Sachdev, V.; Ciocca, D. R.; Stati, A.; Fanelli, M.; Calderwood, S. K.			Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1	ONCOGENE			English	Article						heat shock factor; metastasis; associated protein	METASTASIS-ASSOCIATED PROTEIN-1; C-FOS; GENE; CANCER; EXPRESSION; PHOSPHORYLATION; 14-3-3-EPSILON; CHAPERONES; COMPLEXES; APOPTOSIS	Heat shock factor 1 (HSF1), the transcriptional activator of the heat shock genes, is increasingly implicated in cancer. We have shown that HSF1 binds to the corepressor metastasis-associated protein 1 (MTA1) in vitro and in human breast carcinoma samples. HSF1-MTA1 complex formation was strongly induced by the transforming ligand heregulin and complexes incorporated a number of additional proteins including histone deacetylases (HDAC1 and 2) and Mi2 alpha, all components of the NuRD corepressor complex. These complexes were induced to assemble on the chromatin of MCF7 breast carcinoma cells and associated with the promoters of estrogen-responsive genes. Such HSF1 complexes participate in repression of estrogen-dependent transcription in breast carcinoma cells treated with heregulin and this effect was inhibited by MTA1 knockdown. Repression of estrogen-dependent transcription may contribute to the role of HSF1 in cancer.	[Khaleque, Ma; Gray, P. J.; Calderwood, S. K.] Harvard Univ, Sch Med, Dept Radiat Oncol, BIDMC, Boston, MA 02215 USA; [Khaleque, Ma] NS Univ, Dept Biochem, Dhaka, Bangladesh; [Bharti, A.; Gong, J.; Sachdev, V.; Calderwood, S. K.] Boston Univ, Dept Med, Mendoza, Argentina; [Ciocca, D. R.; Stati, A.; Fanelli, M.] Inst Expt Med & Biol Cuyo, Lab Oncol, Mendoza, Argentina	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dept Radiat Oncol, BIDMC, 21-27 Burlington Ave,5th Floor, Boston, MA 02215 USA.	scalderw@bidmc.harvard.edu		Khaleque, Md Abdul/0000-0002-6873-9165	NATIONAL CANCER INSTITUTE [R01CA077465] Funding Source: NIH RePORTER; NCI NIH HHS [CA077465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bewick M, 1999, BONE MARROW TRANSPL, V24, P377, DOI 10.1038/sj.bmt.1701907; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Gago G, 2006, J BACTERIOL, V188, P477, DOI 10.1128/JB.188.2.477-486.2006; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Jones EL, 2004, INT J HYPERTHER, V20, P835, DOI 10.1080/02656730410001721807; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Neubauer BL, 2003, CANCER RES, V63, P6056; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Toh Y, 2000, J EXP CLIN CANC RES, V19, P105; Wang XZ, 2006, J BIOL CHEM, V281, P782, DOI 10.1074/jbc.M505822200; Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Xie Y, 2003, J BIOL CHEM, V278, P4687, DOI 10.1074/jbc.M210189200; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200	24	77	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1886	1893		10.1038/sj.onc.1210834	http://dx.doi.org/10.1038/sj.onc.1210834			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17922035				2022-12-28	WOS:000254150600008
J	Lee, JA; Park, JE; Lee, DH; Park, SG; Myung, PK; Park, BC; Cho, S				Lee, J. A.; Park, J. E.; Lee, D. H.; Park, S. G.; Myung, P. K.; Park, B. C.; Cho, S.			G(1) to S phase transition protein 1 induces apoptosis signal-regulating kinase 1 activation by dissociating 14-3-3 from ASK1	ONCOGENE			English	Article						apoptosis; apoptosis signal-regulating kinase 1; G(1) to S phase transition 1; mitogen-activated protein kinase	BINDING PROTEIN; TRANSLATION TERMINATION; CELL-DEATH; PROLIFERATION; THIOREDOXIN; INHIBITOR; STRESS; DAXX	Apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinase kinase kinase family, plays a critical role in mediating apoptosis signals initiated by a variety of death stimuli such as hydrogen peroxide and tumor necrosis factor-a. Owing to its critical role in inducing apoptosis, the activity of ASK1 is tightly regulated by various mechanisms such as post-translational modi. cations and protein-protein interactions. Here we describe the identification of G(1) to S phase transition protein 1 (GSPT1), which is associated with protein translation, as a regulator of ASK1. GSPT1 interacts with ASK1 and enhances ASK1-induced apoptotic activity through the activation of caspase-3. In vitro kinase assay data show that GSPT1 enhances ASK1 autophosphorylation and its kinase activity. Cell cycle-dependent GSPT1 induction and small interfering RNA analyses show that ASK1 autophosphorylation is dependent on the expression level of endogenous GSPT1 in cells. GSPT1 inhibits the binding of ASK1 to the 14-3-3 protein, an ASK1 inhibitor, while GSPT1 has no effect on the interaction between ASK1 and TRAF2, a C-terminal-binding activator of ASK1. Thus, our results reveal a novel role of GSPT1 in the regulation of ASK1-mediated apoptosis.	[Park, J. E.; Lee, D. H.; Park, S. G.; Park, B. C.] Korea Res Inst Biosci & Biotechnol, Translat Res Ctr, Proteome Res Lab, Taejon 305600, South Korea; [Lee, J. A.; Cho, S.] Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea; [Lee, J. A.; Cho, S.] Chung Ang Univ, Res Inst Translat Syst Biom, Seoul, South Korea; [Myung, P. K.] Chungnam Natl Univ, Coll Pharm, Taejon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chung Ang University; Chung Ang University; Chungnam National University	Park, BC (corresponding author), Korea Res Inst Biosci & Biotechnol, Translat Res Ctr, Proteome Res Lab, POB 115 Yusong, Taejon 305600, South Korea.	parkbc@kribb.re.kr; sycho@cau.ac.kr						[Anonymous], 1999, HYBRID RICE; Bell R, 2004, EJC SUPPL, V2, P1, DOI 10.1016/J.EJCSUP.2004.01.001; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chauvin C, 2005, MOL CELL BIOL, V25, P5801, DOI 10.1128/MCB.25.14.5801-5811.2005; Cho SY, 2004, J BIOL CHEM, V279, P16050, DOI 10.1074/jbc.M305758200; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Malta-Vacas J, 2005, J CLIN PATHOL, V58, P621, DOI 10.1136/jcp.2004.021774; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	23	22	23	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1297	1305		10.1038/sj.onc.1210740	http://dx.doi.org/10.1038/sj.onc.1210740			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17700517				2022-12-28	WOS:000253407000012
J	Foijer, F; Simonis, M; van Vliet, M; Wessels, L; Kerkhoven, R; Sorger, PK; Riele, HT				Foijer, F.; Simonis, M.; van Vliet, M.; Wessels, L.; Kerkhoven, R.; Sorger, P. K.; Riele, H. te			Oncogenic pathways impinging on the G(2)-restriction point	ONCOGENE			English	Article						mitogenic signaling; G2 restriction point; retinoblastoma gene family; expression profiling; c-MYC; RAS	DNA-DAMAGE; MITOGEN REQUIREMENT; RESTRICTION POINT; KINASE-ACTIVITY; G(1) CONTROL; CELL; CYCLE; INHIBITOR; P21; PHOSPHORYLATION	In the absence of mitogenic stimuli, cells normally arrest in G(1/0), because they fail to pass the G(1)-restriction point. However, abrogation of the G(1)-restriction point ( by loss of the retinoblastoma gene family) reveals a second-restriction point that arrests cells in G(2). Serum-starvation-induced G(2) arrest is effectuated through inhibitory interactions of p27(KIP1) and p21(CIP1) with cyclins A and B1 and can be reversed through mitogen re-addition. In this study, we have investigated the pathways that allow cell cycle re-entry from this G(2) arrest. We provide evidence that recovery from G(2) arrest depends on the rat sarcoma viral oncogene ( RAS) and phosphatidylinositol-3 kinase pathways and show that oncogenic hits, such as overexpression of c-MYC or mutational activation of RAS can abrogate the G(2)-restriction point. Together, our results provide new mechanistic insight into multistep carcinogenesis.	[Foijer, F.; van Vliet, M.; Wessels, L.; Riele, H. te] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; [Foijer, F.; Sorger, P. K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA; [Simonis, M.; Kerkhoven, R.] Netherlands Canc Inst, Cent Microarray Facil, NL-1066 CX Amsterdam, Netherlands; [van Vliet, M.; Wessels, L.] Delft Univ Technol, Fac Elect Engn Math & Comp Sci, Delft, Netherlands	Netherlands Cancer Institute; Harvard University; Harvard Medical School; Netherlands Cancer Institute; Delft University of Technology	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.t.riele@nki.nl		Sorger, Peter/0000-0002-3364-1838; Foijer, Floris/0000-0003-0989-3127				Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; D'Abaco GM, 2002, J CELL SCI, V115, P4607, DOI 10.1242/jcs.00161; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Foijer F, 2005, CANCER CELL, V8, P455, DOI 10.1016/j.ccr.2005.10.021; Foijer F, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-8; Foijer F, 2006, CELL CYCLE, V5, P831, DOI 10.4161/cc.5.8.2687; Guo QM, 2000, CANCER RES, V60, P5922; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARPER JW, 1993, CELL, V75, P805; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Theodosiou A, 2002, GENOME BIOL, V3; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhu HY, 2005, J BIOL CHEM, V280, P29282, DOI 10.1074/jbc.M407352200	41	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1142	1154		10.1038/sj.onc.1210724	http://dx.doi.org/10.1038/sj.onc.1210724			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700522				2022-12-28	WOS:000253136700014
J	Brookes, MJ; Boult, J; Roberts, K; Cooper, BT; Hotchin, NA; Matthews, G; Iqbal, T; Tselepis, C				Brookes, M. J.; Boult, J.; Roberts, K.; Cooper, B. T.; Hotchin, N. A.; Matthews, G.; Iqbal, T.; Tselepis, C.			A role for iron in Wnt signalling	ONCOGENE			English	Article						Wnt; E-cadherin; iron; colon	COLORECTAL-CANCER RISK; C-MYC; COLON-CANCER; E-CADHERIN; HEME IRON; CARCINOGENESIS; GENE; APC; IDENTIFICATION; ACTIVATION	There is an emerging body of evidence implicating iron in carcinogenesis and in particular colorectal cancer, but whether this involves Wnt signalling, a major oncogenic signalling pathway has not been studied. We aimed to determine the effect of iron loading on Wnt signalling using mutant APC (Caco-2 and SW480) and wild-type APC (HEK-293 and human primary. broblasts) containing cell lines. Elevating cellular iron levels in Caco-2 and SW480 cells caused increased Wnt signalling as indicated by increased TOPFLASH reporter activity, increased mRNA expression of two known targets, c-myc and Nkd1, and increased cellular proliferation. In contrast wild-type APC and beta-catenin-containing lines, HEK-293 and human primary. broblasts were not responsive to iron loading. This was verified in SW480 cells that no longer induced iron-mediated Wnt signalling when transfected with wild-type APC. The cell line LS174T, wild type for APC but mutant for beta-catenin, was also responsive suggesting that the role of iron is to regulate beta-catenin. Furthermore, we show that E-cadherin status has no influence on iron-mediated Wnt signalling. We thus speculate that excess iron could exacerbate tumorigenesis in the background of APC loss, a common finding in cancers.	[Brookes, M. J.; Boult, J.; Roberts, K.; Iqbal, T.; Tselepis, C.] Univ Birmingham, CRUK Inst Canc Studies, Birmingham B32 1NX, W Midlands, England; [Brookes, M. J.; Cooper, B. T.] City Hosp, Birmingham, W Midlands, England; [Hotchin, N. A.] Univ Birmingham, Sch Biosci, Birmingham B32 1NX, W Midlands, England; [Matthews, G.] Univ Birmingham, Dept Med Sci, Birmingham B32 1NX, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham	Tselepis, C (corresponding author), Univ Birmingham, CRUK Inst Canc Studies, Vincent Dr, Birmingham B32 1NX, W Midlands, England.	c.tselepis@bham.ac.uk	Brookes, Matthew/ABE-6952-2020	Brookes, Matthew/0000-0002-8782-0292; iqbal, tariq/0000-0002-6681-9882; Hotchin, Neil/0000-0002-1844-7607				Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brookes MJ, 2006, GUT, V55, P1449, DOI 10.1136/gut.2006.094060; Chao A, 2005, JAMA-J AM MED ASSOC, V293, P172, DOI 10.1001/jama.293.2.172; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Habel ME, 2006, BIOCHEM BIOPH RES CO, V341, P1309, DOI 10.1016/j.bbrc.2006.01.097; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ilsley JNM, 2004, NUTR CANCER, V49, P162, DOI 10.1207/s15327914nc4902_7; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Latunde-Dada GO, 2006, TRENDS BIOCHEM SCI, V31, P182, DOI 10.1016/j.tibs.2006.01.005; Lee DH, 2004, JNCI-J NATL CANCER I, V96, P403, DOI 10.1093/jnci/djh047; Maines MD, 2005, BIOCHEM BIOPH RES CO, V338, P568, DOI 10.1016/j.bbrc.2005.08.121; Mainous AG, 2005, ANN FAM MED, V3, P131, DOI 10.1370/afm.283; Miranda E, 2006, BRIT J CANCER, V95, P1101, DOI 10.1038/sj.bjc.6603337; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Munro SB, 1995, EXP MOL PATHOL, V62, P118, DOI 10.1006/exmp.1995.1013; Nelson RL, 2001, NUTR REV, V59, P140, DOI 10.1111/j.1753-4887.2001.tb07002.x; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Norat T, 2005, J NATL CANCER I, V97, P906, DOI 10.1093/jnci/dji164; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Oates PS, 2006, WORLD J GASTROENTERO, V12, P4281, DOI 10.3748/wjg.v12.i27.4281; Orsulic S, 1999, J CELL SCI, V112, P1237; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Penman GA, 2005, J CELL SCI, V118, P4741, DOI 10.1242/jcs.02589; Pierre F, 2003, CARCINOGENESIS, V24, P1683, DOI 10.1093/carcin/bgg130; Rao AS, 2005, EUR J ENDOCRINOL, V153, P929, DOI 10.1530/eje.1.02038; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Seril DN, 2002, DIGEST DIS SCI, V47, P1266, DOI 10.1023/A:1015362228659; Shaheen NJ, 2003, JNCI-J NATL CANCER I, V95, P154, DOI 10.1093/jnci/95.2.154; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; Uzel C, 1998, SEMIN HEMATOL, V35, P27; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; YOUNG GP, 1990, J GASTROEN HEPATOL, V5, P194, DOI 10.1111/j.1440-1746.1990.tb01824.x	38	98	101	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					966	975		10.1038/sj.onc.1210711	http://dx.doi.org/10.1038/sj.onc.1210711			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700530				2022-12-28	WOS:000252946300008
J	Veverka, V; Crabbe, T; Bird, I; Lennie, G; Muskett, FW; Taylor, RJ; Carr, MD				Veverka, V.; Crabbe, T.; Bird, I.; Lennie, G.; Muskett, F. W.; Taylor, R. J.; Carr, M. D.			Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR	ONCOGENE			English	Article						mTOR; FRB; rapamycin; phosphatidic acid; NMR	N-TERMINAL DOMAIN; MAMMALIAN TARGET; TISSUE INHIBITOR; BINDING PARTNER; RAPAMYCIN MTOR; PROTEIN; CANCER; TOR; PATHWAY; GROWTH	The mammalian target of rapamycin (mTOR) is a large, multidomain protein kinase, which plays a central role in the regulation of cell growth and has recently emerged as an essential target of survival signals in many types of human cancer cells. Here, we report the solution structures of complexes formed between the FKBP12-rapamycin binding (FRB) domain of mTOR and phosphatidic acid, an important cellular activator of the kinase, and between the FRB domain and a novel inhibitor (HTS-1). The overall structure of the FRB domain is very similar to that seen in the ternary complex formed with FKBP12 and the immunosuppressive drug rapamycin; however, there are significant changes within the rapamycin-binding site with important consequences for rational drug design. The surface of the FRB domain contains a number of distinctive features that have previously escaped attention, including a potential new regulatory site on the opposite face to that involved in the binding of rapamycin, which displays the features expected for a specific binding site for a small molecule. The interaction sites for phosphatidic acid and HTS-1 were found to closely match the site responsible for rapamycin binding. In addition, the structures determined for the FRB phosphatidic acid and FRB-HTS-1 complexes revealed a striking similarity between the conformations of buried portions of the ligands and that seen for the rapamycin backbone in contact with the domain. Our findings further highlight the importance of the FRB domain in small molecule-mediated regulation of mTOR, demonstrate the ability to identify novel inhibitors of mTOR that bind tightly to the rapamycin-binding site in the absence of FKBP12, and identify a potential new regulatory site that may be exploited in the design of new anticancer drugs.	[Veverka, V.; Muskett, F. W.; Carr, M. D.] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; [Crabbe, T.; Bird, I.; Lennie, G.; Taylor, R. J.] UCB R&D, Slough, Berks, England	University of Leicester	Carr, MD (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg, Leicester LE1 9HN, Leics, England.	mdc12@le.ac.uk	Ward, Stephen/AAE-4341-2020; Veverka, Vaclav/P-5251-2019; Veverka, Vaclav/G-9174-2014	Veverka, Vaclav/0000-0003-3782-5279; Veverka, Vaclav/0000-0003-3782-5279; Carr, Mark/0000-0002-3939-0996	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Annis DA, 2004, INT J MASS SPECTROM, V238, P77, DOI 10.1016/j.ijms.2003.11.022; Avila-Flores A, 2005, J BIOL CHEM, V280, P10091, DOI 10.1074/jbc.M412296200; Banaszynski LA, 2005, J AM CHEM SOC, V127, P4715, DOI 10.1021/ja043277y; Bianco RB, 2006, EUR J CANCER, V42, P290, DOI 10.1016/j.ejca.2005.07.034; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Choi Jai-Pil, 1996, EUROPEAN J POLITICAL, V12, P273, DOI DOI 10.1016/0176-2680(95)00017-8; DELANO WL, 2002, PYMOL MOL GRAPHICS; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; Hancock JF, 2007, NAT CELL BIOL, V9, P615, DOI 10.1038/ncb0607-615; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; Koharudin LMI, 2003, J MAGN RESON, V163, P228, DOI 10.1016/S1090-7807(03)00149-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leone M, 2006, BIOCHEMISTRY-US, V45, P10294, DOI 10.1021/bi060976+; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Mor A, 2007, NAT CELL BIOL, V9, P713, DOI 10.1038/ncb1592; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Thomas GV, 2006, CURR OPIN GENET DEV, V16, P78, DOI 10.1016/j.gde.2005.12.003; Veverka V, 2006, J BIOMOL NMR, V36, P3, DOI 10.1007/s10858-005-4324-1; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594	43	118	126	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					585	595		10.1038/sj.onc.1210693	http://dx.doi.org/10.1038/sj.onc.1210693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684489				2022-12-28	WOS:000252674900003
J	Attard, G; Clark, J; Ambroisine, L; Fisher, G; Kovacs, G; Flohr, P; Berney, D; Foster, CS; Fletcher, A; Gerald, WL; Moller, H; Reuter, V; De Bono, JS; Scardino, P; Cuzick, J; Cooper, CS				Attard, G.; Clark, J.; Ambroisine, L.; Fisher, G.; Kovacs, G.; Flohr, P.; Berney, D.; Foster, C. S.; Fletcher, A.; Gerald, W. L.; Moller, H.; Reuter, V.; De Bono, J. S.; Scardino, P.; Cuzick, J.; Cooper, C. S.		Transatlantic Prostate Grp	Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer	ONCOGENE			English	Article						prostate cancer; ERG gene; ERG gene break point; Gleason score; prognosis	INTEROBSERVER REPRODUCIBILITY; RADICAL PROSTATECTOMY; GLEASON; CARCINOMA; PATHOLOGISTS; GENE; MEN	New predictive markers for managing prostate cancer are urgently required because of the highly variable natural history of this disease. At the time of diagnosis, Gleason score provides the gold standard for assessing the aggressiveness of prostate cancer. However, the recent discovery of TMPRSS2 fusions to the ERG gene in prostate cancer raises the possibility of using alterations at the ERG locus as additional mechanism-based prognostic indicators. Fluorescence in situ hybridization (FISH) assays were used to assess ERG gene status in a cohort of 445 prostate cancers from patients who had been conservatively managed. The FISH assays detected separation of 50 (labelled green) and 30 ( labelled red) ERG sequences, which is a consequence of the TMPRSS2-ERG fusion, and additionally identify interstitial deletion of genomic sequences between the tandemly located TMPRSS2 and ERG gene sequences on chromosome 21. Cancers lacking ERG alterations exhibited favourable cause-specific survival (90% survival at 8 years). We identify a novel category of prostate cancers, characterized by duplication of the fusion of TMPRSS2 to ERG sequences together with interstitial deletion of sequences 50 to ERG (called '2 + Edel'), which by comparison exhibited extremely poor cause-specific survival (hazard ratio 6.10, 95% confidence ratio = 3.33-11.15, P < 0.001, 25% survival at 8 years). In multivariate analysis, '2 + Edel' provided significant prognostic information (P = 0.003) in addition to that provided by Gleason score and prostate-specific antigen level at diagnosis. Other individual categories of ERG alteration were associated with intermediate or good prognosis. We conclude that determination of ERG gene status, including duplication of the fusion of TMPRSS2 to ERG sequences in 2 + Edel, allows strati. cation of prostate cancer into distinct survival categories.	[Attard, G.; Flohr, P.; Fletcher, A.; Cooper, C. S.] Inst Canc Res, Male Urolog Canc Res Ctr, Sutton SM2 5NG, Surrey, England; [Attard, G.; De Bono, J. S.] Royal Marsden NHS Trust Fdn Hosp, Surrey, England; [Ambroisine, L.; Cuzick, J.] Univ London, Wolfson Inst Prevent Med, London, England; [Kovacs, G.] Heidelberg Univ, Fac Med, Mol Oncol Lab, Heidelberg, Germany; [Foster, C. S.] Royal Liverpool Hosp, Dept Pathol, London, England; [Gerald, W. L.; Reuter, V.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Moller, H.] Kings Coll London, Canc Registry, London, England; [Scardino, P.] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY USA	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Queen Mary University London; Ruprecht Karls University Heidelberg; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; Memorial Sloan Kettering Cancer Center; University of London; King's College London; Memorial Sloan Kettering Cancer Center	Cooper, CS (corresponding author), Inst Canc Res, Male Urolog Canc Res Ctr, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	Colin.Cooper@icr.ac.uk		Attard, Gerhardt/0000-0002-4811-7983; de Bono, Johann S/0000-0002-2034-595X; Berney, Daniel/0000-0001-5474-8696; Moller, Henrik/0000-0001-8200-5929	NATIONAL CANCER INSTITUTE [P50CA092629] Funding Source: NIH RePORTER; MRC [G0501019] Funding Source: UKRI; Medical Research Council [G0501019] Funding Source: Medline; NCI NIH HHS [P50 CA092629-07, P50 CA092629] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adolfsson J, 1997, UROLOGY, V50, P722, DOI 10.1016/S0090-4295(97)00320-8; Albertsen PC, 2005, J NATL CANCER I, V97, P1248, DOI 10.1093/jnci/dji248; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; Allsbrook WC, 2001, HUM PATHOL, V32, P74, DOI 10.1053/hupa.2001.21134; Allsbrook WC, 2001, HUM PATHOL, V32, P81, DOI 10.1053/hupa.2001.21135; Bill-Axelson A, 2005, NEW ENGL J MED, V352, P1977, DOI 10.1056/NEJMoa043739; Bostwick D G, 1999, Semin Urol Oncol, V17, P222; Chism DB, 2003, INT J RADIAT ONCOL, V56, P1241, DOI 10.1016/S0360-3016(03)00268-2; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Cox D. R., 1984, ANAL SURVIVAL DATA; Cuzick J, 2006, BRIT J CANCER, V95, P1186, DOI 10.1038/sj.bjc.6603411; DEMICHELIS F, 2007, ONCOGENE; Foster CS, 2000, PROSTATE, P4; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Foster CS, 2000, SCAND J UROL NEPHROL, V34, P19, DOI 10.1080/003655900750169284; Hermans KG, 2006, CANCER RES, V66, P10658, DOI 10.1158/0008-5472.CAN-06-1871; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; Lambros MBK, 2006, LAB INVEST, V86, P398, DOI 10.1038/labinvest.3700390; Melia J, 2006, HISTOPATHOLOGY, V48, P644, DOI 10.1111/j.1365-2559.2006.02393.x; NAM RK, 2007, CANC BIOL THER; Oyama T, 2005, ARCH PATHOL LAB MED, V129, P1004; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Smith EB, 2002, CANCER-AM CANCER SOC, V94, P2282, DOI 10.1002/cncr.10457; Soller MJ, 2006, GENE CHROMOSOME CANC, V45, P717, DOI 10.1002/gcc.20329; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; van der Kwast TH, 2006, INT J CANCER, V118, P2538, DOI 10.1002/ijc.21667; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Yao SL, 2002, J NATL CANCER I, V94, P958; Yoshimoto M, 2006, NEOPLASIA, V8, P465, DOI 10.1593/neo.06283	33	348	370	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					253	263		10.1038/sj.onc.1210640	http://dx.doi.org/10.1038/sj.onc.1210640			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637754	Green Accepted			2022-12-28	WOS:000252256000001
J	Morimoto, K; Satoh-Yamaguchi, K; Hamaguchi, A; Inoue, Y; Takeuchi, M; Okada, M; Ikeda, W; Takai, Y; Imai, T				Morimoto, K.; Satoh-Yamaguchi, K.; Hamaguchi, A.; Inoue, Y.; Takeuchi, M.; Okada, M.; Ikeda, W.; Takai, Y.; Imai, T.			Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs	ONCOGENE			English	Article						Necl-5; poliovirus receptor; CD226; cancer cell; platelet; metastasis	IMMUNOGLOBULIN SUPERFAMILY; ADHESION; POLIOVIRUS; MIGRATION; DNAM-1; MEMBER; CD155; IDENTIFICATION; PROLIFERATION; INHIBITION	Necl-5 is an immunoglobulin (Ig)-like molecule that was originally identified as a poliovirus receptor and is often upregulated in cancer cells. We recently found that it colocalizes with integrin alpha(v)beta(3) at the leading edges of moving cells and enhances growth factor-induced cell movement and proliferation. Upon cell-cell contact, Necl-5 is removed from the cell surface by its trans-interaction with the cell adhesion molecule nectin-3, resulting in reduced cell movement and proliferation. Here, we investigated the role of Necl-5 in the interaction of cancer cells with platelets. Necl-5 was upregulated in CT26 cells, a colon adenocarcinoma cell line. When CT26 cells were injected into the tail vein of mice, they were arrested in the pulmonary vessels by adhering to platelets and subsequently metastasized to the lungs. Overexpression of Necl-5 in CT26 cells enhanced this metastasis, while inhibition of the trans-interaction of Necl-5 with CD226 by an anti-Necl-5 monoclonal antibody reduced the metastasis. Depletion of platelets by treatment with a rabbit anti-mouse platelet serum reduced the Necl-5-enhanced metastasis in mice. Thus, the trans-interaction of upregulated Necl-5 in cancer cells with its counter-receptor in platelets, probably CD226, is critical for efficient metastasis of cancer cells to the lungs.	[Morimoto, K.; Satoh-Yamaguchi, K.; Hamaguchi, A.; Inoue, Y.; Takeuchi, M.; Okada, M.; Imai, T.] KAN Res Inst Ic, Kobe MI R&D Ctr, Kobe, Hyogo 6500047, Japan; [Ikeda, W.; Takai, Y.] Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka, Japan	KAN Research Institute; Osaka University	Imai, T (corresponding author), KAN Res Inst Ic, Kobe MI R&D Ctr, 6-7-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	imai@kan.eisai.co.jp	Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Chadeneau C, 1996, INT J CANCER, V68, P817; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; CRISSMAN JD, 1988, CANCER RES, V48, P4065; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; Fujito T, 2005, J CELL BIOL, V171, P165, DOI 10.1083/jcb.200501090; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hirota T, 2005, ONCOGENE, V24, P2229, DOI 10.1038/sj.onc.1208409; Ikeda W, 2004, J BIOL CHEM, V279, P18015, DOI 10.1074/jbc.M312969200; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Im JH, 2004, CANCER RES, V64, P8613, DOI 10.1158/0008-5472.CAN-04-2078; Kakunaga S, 2004, J BIOL CHEM, V279, P36419, DOI 10.1074/jbc.M406340200; Kato Y, 2003, J BIOL CHEM, V278, P51599, DOI 10.1074/jbc.M309935200; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Kojima H, 2003, J BIOL CHEM, V278, P36748, DOI 10.1074/jbc.M300702200; Martin-Villar E, 2006, J CELL SCI, V119, P4541, DOI 10.1242/jcs.03218; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Nash GF, 2002, LANCET ONCOL, V3, P425, DOI 10.1016/S1470-2045(02)00789-1; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Sherrington PD, 1997, J BIOL CHEM, V272, P21735, DOI 10.1074/jbc.272.35.21735; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; Sloan KE, 2005, CANCER RES, V65, P10930, DOI 10.1158/0008-5472.CAN-05-1890; Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-73; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822	31	53	58	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					264	273		10.1038/sj.onc.1210645	http://dx.doi.org/10.1038/sj.onc.1210645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637752				2022-12-28	WOS:000252256000002
J	Huang, B; Zhao, J; Unkeless, JC; Feng, ZH; Xiong, H				Huang, B.; Zhao, J.; Unkeless, J. C.; Feng, Z. H.; Xiong, H.			TLR signaling by tumor and immune cells: a double-edged sword	ONCOGENE			English	Review						TLR signaling; tumor; endogenous ligand	TOLL-LIKE RECEPTORS; MOBILITY GROUP BOX-1; HEAT-SHOCK PROTEINS; DOUBLE-STRANDED-RNA; LUNG-CANCER CELLS; NF-KAPPA-B; ENDOGENOUS LIGANDS; SEQUENCE VARIANTS; DENDRITIC CELLS; CUTTING EDGE	The tumor cell signaling pathways that trigger the uncontrolled proliferation, resistance to apoptosis, metastasis and escape from immune surveillance are partially understood. Toll-like receptors (TLRs), which recognize a variety of pathogen-associated molecular patterns, are centrally involved in the initiation of the innate and adaptive immune responses. However, recent evidence shows that functional TLRs are also expressed on a wide variety of tumors suggesting that TLRs may play important roles in tumor biology. Activation of tumor cell TLRs not only promotes tumor cell proliferation and resistance to apoptosis, but also enhances tumor cell invasion and metastasis by regulating metalloproteinases and integrins. Moreover, the activation of TLR signaling in tumor cells induces the synthesis of proinflammatory factors and immunosuppressive molecules, which enhance the resistance of tumor cells to cytotoxic lymphocyte attack and lead to immune evasion. Thus, the neoplastic process may usurp TLR signaling pathways to advance cancer progression, which suggests that targeting tumor TLR signaling pathways may open novel therapeutic avenues.	[Unkeless, J. C.; Xiong, H.] Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA; [Huang, B.; Feng, Z. H.] Tongji Med Coll, Dept Biochem & Mol Biol, Wuhan, Peoples R China; [Zhao, J.] Tongji Med Coll, Dept Gynecol & Obstet, Wuhan, Peoples R China	Icahn School of Medicine at Mount Sinai; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Xiong, H (corresponding author), Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA.	tjhuangbo@yahoo.com; huabao.xiong@mssm.eduor			NIDDK NIH HHS [P01 DK72201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK072201] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abiko Y, 1999, CANCER LETT, V143, P37, DOI 10.1016/S0304-3835(99)00171-8; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Andersen MH, 2006, J INVEST DERMATOL, V126, P32, DOI 10.1038/sj.jid.5700001; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Beg AA, 2002, TRENDS IMMUNOL, V23, P509, DOI 10.1016/S1471-4906(02)02317-7; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Bohnhorst J, 2006, LEUKEMIA, V20, P1138, DOI 10.1038/sj.leu.2404225; Boule MW, 2004, J EXP MED, V199, P1631, DOI 10.1084/jem.20031942; Camilo R, 2006, HUM PATHOL, V37, P542, DOI 10.1016/j.humpath.2005.12.019; Chen YC, 2005, CANCER RES, V65, P11771, DOI 10.1158/0008-5472.CAN-05-2078; Cheng I, 2007, CANCER EPIDEM BIOMAR, V16, P352, DOI 10.1158/1055-9965.EPI-06-0429; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Craft N, 2005, J IMMUNOL, V175, P1983, DOI 10.4049/jimmunol.175.3.1983; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Deane JA, 2006, J IMMUNOL, V177, P6573, DOI 10.4049/jimmunol.177.10.6573; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Droemann D, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-1; Ehlers M, 2007, TRENDS IMMUNOL, V28, P74, DOI 10.1016/j.it.2006.12.006; Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953; Ganz T, 1997, SEMIN HEMATOL, V34, P343; Gotte M, 2006, CANCER RES, V66, P10233, DOI 10.1158/0008-5472.CAN-06-1464; Gratas C, 1998, CANCER RES, V58, P2057; Guillot L, 2002, J IMMUNOL, V168, P5989, DOI 10.4049/jimmunol.168.12.5989; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; Hassan F, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-281; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067; Iino N, 2007, CELL TISSUE RES, V328, P355, DOI 10.1007/s00441-006-0343-9; Ilvesaro JM, 2007, PROSTATE, V67, P774, DOI 10.1002/pros.20562; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jego G, 2006, LEUKEMIA, V20, P1130, DOI 10.1038/sj.leu.2404226; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Khazaie K, 2006, SEMIN CANCER BIOL, V16, P124, DOI 10.1016/j.semcancer.2005.11.006; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lee JW, 2007, MOL CARCINOGEN, V46, P941, DOI 10.1002/mc.20325; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Liu HY, 2006, P NATL ACAD SCI USA, V103, P7048, DOI 10.1073/pnas.0601554103; Liu Y, 2007, INT J CANCER, V121, P184, DOI 10.1002/ijc.22644; Lizee G, 2006, CLIN CANCER RES, V12, P4794, DOI 10.1158/1078-0432.CCR-06-0944; Marshak-Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957; Mellor AL, 2005, J IMMUNOL, V175, P5601, DOI 10.4049/jimmunol.175.9.5601; Merrell MA, 2006, MOL CANCER RES, V4, P437, DOI 10.1158/1541-7786.MCR-06-0007; Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002; Molteni M, 2006, CANCER LETT, V235, P75, DOI 10.1016/j.canlet.2005.04.006; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Nieters A, 2006, GENES IMMUN, V7, P615, DOI 10.1038/sj.gene.6364337; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Ohara T, 2006, INT J MOL MED, V18, P59; Okamoto M, 2006, J IMMUNOTHER, V29, P78, DOI 10.1097/01.cji.0000192106.32206.30; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pashenkov M, 2006, J CLIN ONCOL, V24, P5716, DOI 10.1200/JCO.2006.07.9129; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; Roelofs MF, 2006, J IMMUNOL, V176, P7021, DOI 10.4049/jimmunol.176.11.7021; Rouas-Freiss N, 2003, SEMIN CANCER BIOL, V13, P325, DOI 10.1016/S1044-579X(03)00023-3; Ru LB, 2005, ARTHRITIS RHEUM-US, V52, P2936, DOI 10.1002/art.21238; Rybarczyk BJ, 2000, CANCER RES, V60, P2033; Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004; Schmausser B, 2005, INT J MED MICROBIOL, V295, P179, DOI 10.1016/j.ijmm.2005.02.009; Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Sioud M, 2006, TRENDS MOL MED, V12, P167, DOI 10.1016/j.molmed.2006.02.004; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Song C, 2006, CANCER BIOL THER, V5, P1285, DOI 10.4161/cbt.5.10.3304; Sun JL, 2005, JNCI-J NATL CANCER I, V97, P525, DOI 10.1093/jnci/dji070; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; Szczepanski M, 2007, EUR ARCH OTO-RHINO-L, V264, P525, DOI 10.1007/s00405-006-0215-7; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Tsan MF, 2007, J ENDOTOXIN RES, V13, P6, DOI 10.1177/0968051907078604; Vicari AP, 2002, SEMIN CANCER BIOL, V12, P33, DOI 10.1006/scbi.2001.0400; Wang HY, 2007, CURR OPIN IMMUNOL, V19, P217, DOI 10.1016/j.coi.2007.02.004; Wang JH, 2003, J IMMUNOL, V170, P795, DOI 10.4049/jimmunol.170.2.795; Whitmore MM, 2004, CANCER RES, V64, P5850, DOI 10.1158/0008-5472.CAN-04-0063; Whitmore MM, 2001, CANCER IMMUNOL IMMUN, V50, P503, DOI 10.1007/s002620100227; Wingender G, 2006, EUR J IMMUNOL, V36, P12, DOI 10.1002/eji.200535602; Wu JD, 2004, J CLIN INVEST, V114, P560, DOI 10.1172/JCI200422206; Xu QB, 2002, ARTERIOSCL THROM VAS, V22, P1547, DOI 10.1161/01.ATV.0000029720.59649.50; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zheng SL, 2004, CANCER RES, V64, P2918, DOI 10.1158/0008-5472.CAN-03-3280; Zhou XX, 2006, CANCER EPIDEM BIOMAR, V15, P862, DOI 10.1158/1055-9965.EPI-05-0874	102	276	312	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					218	224		10.1038/sj.onc.1210904	http://dx.doi.org/10.1038/sj.onc.1210904			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176603				2022-12-28	WOS:000252163600008
J	Phillips, ER; McKinnon, PJ				Phillips, E. R.; McKinnon, P. J.			DNA double-strand break repair and development	ONCOGENE			English	Review						DNA repair; double-strand breaks; ATM; NHEJ; development	ONCOGENE-INDUCED SENESCENCE; SEVERE COMBINED IMMUNODEFICIENCY; ATM-DEPENDENT PHOSPHORYLATION; EARLY EMBRYONIC LETHALITY; HEMATOPOIETIC STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; HUMAN GENETIC-DISEASE; LEAKY SCID PHENOTYPE; LIGASE IV DEFICIENCY; END-JOINING FACTORS	Normal development of an organism requires the ability to respond to DNA damage. A particularly deleterious lesion is a DNA double-strand break (DSB). The cellular response to DNA DSBs occurs via an integrated sensing and signaling network that maintains genomic stability. The outcomes of defective DNA DSB repair are related to the developmental stage of an organism, and often show striking tissue specificity. Many human diseases are associated with deficiencies in DNA DSB repair and can be characterized by neuropathology, immune deficiency, growth retardation or predisposition to cancer. This review will focus on the requirements of the DNA DSB response that function to maintain homeostasis during mammalian development.	St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	McKinnon, PJ (corresponding author), St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.mckinnon@stjude.org						Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Brown EJ, 2000, GENE DEV, V14, P397; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Callen E, 2007, CELL, V130, P63, DOI 10.1016/j.cell.2007.06.016; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; D'Andrea AD, 2003, GENE DEV, V17, P1933, DOI 10.1101/gad.1128303; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dibiase SJ, 2000, CANCER RES, V60, P1245; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Difilippantonio S, 2007, J EXP MED, V204, P1003, DOI 10.1084/jem.20070319; Digweed M, 2004, DNA REPAIR, V3, P1207, DOI 10.1016/j.dnarep.2004.03.004; Dornan D, 2006, SCIENCE, V313, P1122, DOI 10.1126/science.1127335; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Frappart PO, 2007, EMBO J, V26, P2732, DOI 10.1038/sj.emboj.7601703; Frappart PO, 2006, NEUROMOL MED, V8, P495, DOI 10.1385/NMM:8:4:495; Frappart PO, 2005, NAT MED, V11, P538, DOI 10.1038/nm1228; Friedberg EC, 2006, DNA REPAIR, V5, P189, DOI 10.1016/j.dnarep.2005.09.009; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Girard PM, 2004, HUM MOL GENET, V13, P2369, DOI 10.1093/hmg/ddh274; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Holcomb VB, 2006, ONCOGENE, V25, P7159, DOI 10.1038/sj.onc.1209704; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jeggo P, 2002, DNA REPAIR, V1, P771, DOI 10.1016/S1568-7864(02)00096-4; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; Lee Y, 2007, NEUROSCIENCE, V145, P1365, DOI 10.1016/j.neuroscience.2006.07.026; Lee Y, 2002, CANCER RES, V62, P6395; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McKinnon PJ, 2007, ANNU REV GENOM HUM G, V8, P37, DOI 10.1146/annurev.genom.7.080505.115648; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; McKinnon PJ, 2004, EMBO REP, V5, P772, DOI 10.1038/sj.embor.7400210; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nijnik A, 2007, NATURE, V447, P686, DOI 10.1038/nature05875; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; O'Driscoll M, 2004, DNA REPAIR, V3, P1227, DOI 10.1016/j.dnarep.2004.03.025; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Offit K, 2003, JNCI-J NATL CANCER I, V95, P1548, DOI 10.1093/jnci/djg072; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Perrault R, 2004, J CELL BIOCHEM, V92, P781, DOI 10.1002/jcb.20104; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Revy P, 2006, CURR OPIN ALLERGY CL, V6, P416, DOI 10.1097/01.all.0000246623.72365.43; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Rosenthal N, 2007, NAT CELL BIOL, V9, P993, DOI 10.1038/ncb437; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Shivji MKK, 2004, DNA REPAIR, V3, P835, DOI 10.1016/j.dnarep.2004.03.008; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stracker TH, 2007, NATURE, V447, P218, DOI 10.1038/nature05740; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Thacker J, 2004, DNA REPAIR, V3, P1081, DOI 10.1016/j.dnarep.2004.04.012; Thacker J, 2003, DNA REPAIR, V2, P655, DOI 10.1016/S1568-7864(03)00062-4; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Ward I, 2004, CURR TOP DEV BIOL, V63, P1, DOI 10.1016/S0070-2153(04)63001-8; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Windhofer F, 2007, INT J RADIAT ONCOL, V68, P1462, DOI 10.1016/j.ijrobp.2007.04.038; Wyman C, 2004, DNA REPAIR, V3, P827, DOI 10.1016/j.dnarep.2004.03.037; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yan CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI 10.1073/pnas.0601938103; Yoo HY, 2007, J BIOL CHEM, V282, P17501, DOI 10.1074/jbc.M701770200; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	147	38	41	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2007	26	56					7799	7808		10.1038/sj.onc.1210877	http://dx.doi.org/10.1038/sj.onc.1210877			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066093				2022-12-28	WOS:000251537900011
J	Van Etten, RA				Van Etten, R. A.			Aberrant cytokine signaling in leukemia	ONCOGENE			English	Review						tyrosine kinase; kinase inhibitor; leukemia stem cell	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ABL TYROSINE KINASE; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; INTERNAL TANDEM DUPLICATION; MARROW TRANSPLANT MODEL; DNA-BINDING ACTIVITY; BCR-ABL	Abnormalities of cytokine and growth factor signaling pathways are characteristic of all forms of leukemia: lymphoid and myeloid, acute and chronic. In normal hematopoietic cells, cytokines provide the stimulus for proliferation, survival, self- renewal, differentiation and functional activation. In leukemic cells, these pathways are usurped to subserve critical parts of the malignant program. In this review, our current knowledge of leukemic cell cytokine signaling will be summarized, and some speculations on the significance and implications of these insights will be advanced. A better understanding of aberrant cytokine signaling in leukemia should provide additional targets for the rational therapy of these diseases.	Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Div Hematol Oncol, Boston, MA 02111 USA	Tufts Medical Center; Tufts Medical Center	Van Etten, RA (corresponding author), Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA.	rvanetten@tufts-nemc.org			NATIONAL CANCER INSTITUTE [R01CA090576, R01CA105043] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA105043, CA090576, R01 CA090576, CA105043] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Baxter EJ, 2002, HUM MOL GENET, V11, P1391, DOI 10.1093/hmg/11.12.1391; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Benekli M, 2002, BLOOD, V99, P252, DOI 10.1182/blood.V99.1.252; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; De Keersmaecker K, 2005, BLOOD, V105, P4849, DOI 10.1182/blood-2004-12-4897; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Eisterer W, 2005, LEUKEMIA, V19, P435, DOI 10.1038/sj.leu.2403649; Emanuel PD, 2000, BLOOD, V95, P639, DOI 10.1182/blood.V95.2.639; Fiedler W, 2003, BLOOD, V102, P2763, DOI 10.1182/blood-2002-10-2998; Giles FJ, 2005, CURR MOL MED, V5, P653, DOI 10.2174/156652405774641034; Gilliland DG, 2002, CANCER CELL, V1, P417, DOI 10.1016/S1535-6108(02)00081-8; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gururajan M, 2007, J IMMUNOL, V178, P111, DOI 10.4049/jimmunol.178.1.111; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Haferlach T, 1997, BRIT J HAEMATOL, V97, P99, DOI 10.1046/j.1365-2141.1997.9662656.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Jaiswal S, 2003, P NATL ACAD SCI USA, V100, P10002, DOI 10.1073/pnas.1633833100; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jones AV, 2004, CELL MOL LIFE SCI, V61, P2912, DOI 10.1007/s00018-004-4272-z; Jones AV, 2005, BLOOD, V106, P2162, DOI 10.1182/blood-2005-03-1320; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kelly LM, 2002, P NATL ACAD SCI USA, V99, P8283, DOI 10.1073/pnas.122233699; Klion AD, 2003, BLOOD, V101, P4660, DOI 10.1182/blood-2003-01-0006; Kottaridis PD, 2002, BLOOD, V100, P2393, DOI 10.1182/blood-2002-02-0420; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kralovics R, 2006, BLOOD, V108, P1377, DOI 10.1182/blood-2005-11-009605; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Le DT, 2004, BLOOD, V103, P4243, DOI 10.1182/blood-2003-08-2650; Lee JW, 2004, LEUKEMIA, V18, P170, DOI 10.1038/sj.leu.2403201; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Lunghi P, 2003, LEUKEMIA, V17, P1783, DOI 10.1038/sj.leu.2403032; Macdonald D, 2002, ACTA HAEMATOL-BASEL, V107, P101, DOI 10.1159/000046639; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Milella M, 2002, BLOOD, V99, P3461, DOI 10.1182/blood.V99.9.3461; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Million RP, 2000, BLOOD, V96, P664; Nakao M, 1996, LEUKEMIA, V10, P1911; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Pardanani A, 2003, BLOOD, V102, P3093, DOI 10.1182/blood-2003-05-1627; Pardanani AD, 2006, BLOOD, V108, P3472, DOI 10.1182/blood-2006-04-018879; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Pulford K, 2004, CELL MOL LIFE SCI, V61, P2939, DOI 10.1007/s00018-004-4275-9; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Roumiantsev S, 2004, CANCER CELL, V5, P287, DOI 10.1016/S1535-6108(04)00053-4; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Scherr M, 2006, BLOOD, V107, P3279, DOI 10.1182/blood-2005-08-3087; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Scott LM, 2005, BLOOD, V106, P2920, DOI 10.1182/blood-2005-05-2087; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shannon K, 1995, Curr Opin Hematol, V2, P305; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Smith BD, 2004, BLOOD, V103, P3669, DOI 10.1182/blood-2003-11-3775; Smith KM, 2003, MOL CELL, V12, P27, DOI 10.1016/S1097-2765(03)00274-0; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Steensma DP, 2006, LEUKEMIA, V20, P971, DOI 10.1038/sj.leu.2404206; Steensma DP, 2005, BLOOD, V106, P1207, DOI 10.1182/blood-2005-03-1183; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; Stover EH, 2006, P NATL ACAD SCI USA, V103, P8078, DOI 10.1073/pnas.0601192103; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Tartaglia M, 2004, CURR OPIN HEMATOL, V11, P44, DOI 10.1097/00062752-200401000-00007; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Thorington Richard W. Jr., 2002, Journal of Mammalian Evolution, V9, P99; Trowbridge JJ, 2006, P NATL ACAD SCI USA, V103, P14134, DOI 10.1073/pnas.0604568103; Ugo V, 2004, EXP HEMATOL, V32, P179, DOI 10.1016/j.exphem.2003.11.003; Van Etten R A, 2001, Curr Oncol Rep, V3, P228; Van Etten RA, 2004, CANCER CELL, V6, P547, DOI 10.1016/j.ccr.2004.12.004; Van Etten RA, 2004, LEUKEMIA RES, V28, pS21, DOI 10.1016/j.leukres.2003.10.005; Van Etten RA, 2003, CURR BIOL, V13, pR608, DOI 10.1016/S0960-9822(03)00528-1; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Wadleigh M, 2005, BLOOD, V105, P22, DOI 10.1182/blood-2003-11-3896; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Walz C, 2006, GENE CHROMOSOME CANC, V45, P950, DOI 10.1002/gcc.20359; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Wang L, 2007, BLOOD; WeberNordt RM, 1996, BLOOD, V88, P809; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Wossning T, 2006, J EXP MED, V203, P2829, DOI 10.1084/jem.20060967; Wu JH, 2004, CANCER RES, V64, P6461, DOI 10.1158/0008-5472.CAN-04-0866; Xia Z, 1998, CANCER RES, V58, P3173; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xu Q, 2005, BLOOD, V106, P4261, DOI 10.1182/blood-2004-11-4468; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Ye D, 2006, BLOOD, V107, P4917, DOI 10.1182/blood-2005-10-4110; Yu CR, 2002, CANCER RES, V62, P188; Zaleskas VM, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000018; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220; Zheng R, 2004, BLOOD, V103, P267, DOI 10.1182/blood-2003-06-1969	139	70	70	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	47					6738	6749		10.1038/sj.onc.1210758	http://dx.doi.org/10.1038/sj.onc.1210758			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934482	Green Accepted, Green Published			2022-12-28	WOS:000250147000006
J	Botlagunta, M; Vesuna, F; Mironchik, Y; Raman, A; Lisok, A; Winnard, P; Mukadam, S; Van Diest, P; Chen, JH; Farabaugh, P; Patel, AH; Raman, V				Botlagunta, M.; Vesuna, F.; Mironchik, Y.; Raman, A.; Lisok, A.; Winnard, P., Jr.; Mukadam, S.; Van Diest, P.; Chen, J. H.; Farabaugh, P.; Patel, A. H.; Raman, V.			Oncogenic role of DDX3 in breast cancer biogenesis	ONCOGENE			English	Article						DDX3; breast cancer; BPDE	BOX RNA HELICASE; MAMMARY EPITHELIAL-CELLS; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; TOBACCO-SMOKE; DIOL-EPOXIDE; DNA-DAMAGE; IN-VITRO; EXPRESSION; TRANSFORMATION	Benzo[a] pyrene diol epoxide (BPDE), the active metabolite of benzo[a] pyrene present in tobacco smoke, is a major cancer-causing compound. To evaluate the effects of BPDE on human breast epithelial cells, we exposed an immortalized human breast cell line, MCF 10A, to BPDE and characterized the gene expression pattern. Of the differential genes expressed, we found consistent activation of DDX3, a member of the DEAD box RNA helicase family. Overexpression of DDX3 in MCF 10A cells induced an epithelial-mesenchymal- like transformation, exhibited increased motility and invasive properties, and formed colonies in soft-agar assays. Besides the altered phenotype, MCF 10A-DDX3 cells repressed E-cadherin expression as demonstrated by both immunoblots and by E-cadherin promoter-reporter assays. In addition, an in vivo association of DDX3 and the E-cadherin promoter was demonstrated by chromatin immunoprecipitation assays. Collectively, these results demonstrate that the activation of DDX3 by BPDE, can promote growth, proliferation and neoplastic transformation of breast epithelial cells.	[Botlagunta, M.; Vesuna, F.; Mironchik, Y.; Lisok, A.; Winnard, P., Jr.; Mukadam, S.] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [Raman, A.] Univ Maryland, Dept Biol, Baltimore, MD 21201 USA; [Van Diest, P.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Chen, J. H.] Tzu Chi Univ, Dept Life Sci, Hualien, Taiwan; [Patel, A. H.] Arvind Patel Inst Virol, Glasgow G11, Lanark, Scotland; [Raman, V.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Utrecht University; Utrecht University Medical Center; Tzu Chi University; Johns Hopkins University	Raman, V (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, 720 Rutlands Ave,340 Traylor Bldg, Baltimore, MD 21205 USA.	vraman2@jhmi.edu	Botlagunta, Mahendran/R-5140-2018; Vesuna, Farhad/G-3179-2010	Botlagunta, Mahendran/0000-0002-0490-2832; Vesuna, Farhad/0000-0002-0356-5096; Farabaugh, Philip/0000-0002-5658-7141	Medical Research Council [MC_U130184144] Funding Source: Medline; NCI NIH HHS [R01 CA097226] Funding Source: Medline; MRC [MC_U130184144] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA097226] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelhaleem M, 2005, CLIN BIOCHEM, V38, P499, DOI 10.1016/j.clinbiochem.2005.01.010; Boffetta P, 2006, INT J CANCER, V119, P884, DOI 10.1002/ijc.21903; Bonner MR, 2005, CANCER CAUSE CONTROL, V16, P683, DOI 10.1007/s10552-005-1906-x; Burdick AD, 2006, CARCINOGENESIS, V27, P2331, DOI 10.1093/carcin/bgl083; Caruso JA, 2001, MUTAT RES-FUND MOL M, V473, P85, DOI 10.1016/S0027-5107(00)00140-8; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Duriseti S, 2006, NEOPLASIA, V8, P250, DOI 10.1593/neo.05766; Huang JS, 2004, BIOCHEM BIOPH RES CO, V315, P950, DOI 10.1016/j.bbrc.2004.01.151; Jeffy BD, 2002, CANCER RES, V62, P113; Jung JW, 2007, EUR J CANCER, V43, P1214, DOI 10.1016/j.ejca.2007.01.034; KROLEWSKI B, 1988, TERATOGEN CARCIN MUT, V8, P127, DOI 10.1002/tcm.1770080302; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; Marchetti A, 1996, ONCOGENE, V12, P1319; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Mei JX, 2003, BREAST CANCER RES TR, V79, P95, DOI 10.1023/A:1023326121951; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; Norsa'adah B., 2005, SMJ Singapore Medical Journal, V46, P698; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Parkin D M, 1992, IARC Sci Publ, P45; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; PHILLIPS PH, 1991, AM J EPIDEMIOL, V133, P757, DOI 10.1093/oxfordjournals.aje.a115954; Pirkle James L., 1996, JAMA (Journal of the American Medical Association), V275, P1233, DOI 10.1001/jama.275.16.1233; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Sasco AJ, 2001, APMIS, V109, P321, DOI 10.1034/j.1600-0463.2001.090501.x; Sekiguchi T, 2007, BIOCHEM BIOPH RES CO, V356, P668, DOI 10.1016/j.bbrc.2007.03.038; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; Wang AJ, 2003, CARCINOGENESIS, V24, P225, DOI 10.1093/carcin/24.2.225; Whitbread AK, 2006, BIOL CHEM, V387, P707, DOI 10.1515/BC.2006.089; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; YANG DJ, 1992, P NATL ACAD SCI USA, V89, P2237, DOI 10.1073/pnas.89.6.2237; Yang LQ, 2007, J BIOL CHEM, V282, P16811, DOI 10.1074/jbc.M610488200; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yokoyama K, 2003, INT J ONCOL, V22, P891; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	41	156	163	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3912	3922		10.1038/onc.2008.33	http://dx.doi.org/10.1038/onc.2008.33			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264132	Green Accepted			2022-12-28	WOS:000257089000003
J	Chang, CL; Hong, E; Lao-Sirieix, P; Fitzgerald, RC				Chang, C-L; Hong, E.; Lao-Sirieix, P.; Fitzgerald, R. C.			A novel role for the retinoic acid-catabolizing enzyme CYP26A1 in Barrett's associated adenocarcinoma	ONCOGENE			English	Article						vitamin A; oesophageal adenocarcinoma; proliferation; invasion; bile acids	VITAMIN-A; RECEPTOR-GAMMA; HUMAN BREAST; IN-VITRO; EXPRESSION; CANCER; METABOLISM; GROWTH; DIFFERENTIATION; INHIBITION	Vitamin A deficiency is associated with carcinogenesis, and upregulation of CYP26A1, a major retinoic acid (RA)-catabolizing enzyme, has recently been shown in cancer. We have previously demonstrated alterations of RA biosynthesis in Barrett's oesophagus, the precursor lesion to oesophageal adenocarcinoma. The aims of this study were to determine CYP26A1 expression levels and functional effects in Barrett's associated carcinogenesis. Retinoic acid response element reporter cells were used to determine RA levels in non-dysplastic and dysplastic Barrett's cell lines and endoscopic biopsies. CYP26A1 expression levels, with or without induction by RA and lithocholic acid, were determined by quantitative reverse transcriptase-PCR (RT-PCR) and immunohistochemistry. CYP26A1 promoter activity was determined by a luciferase reporter construct. CYP26A1 was stably over-expressed in GihTERT cells, which were evaluated for gene-expression changes (pathway array and quantitative RT-PCR), cellular proliferation (cytometric DNA pro. le and colorimetric assay) and invasion (in vitro matrigel assay) with or without the CYP inhibitor ketaconazole. RA levels decreased progressively with the degree of dysplasia (P < 0.05) and were inversely correlated with CYP26A1 gene levels and activity (P < 0.01). CYP26A1 expression was increased synergistically by RA and lithocholic acid (P < 0.05). Overexpression of CYP26A1 led to induction of c-Myc, epidermal growth factor receptor and matrix metalloproteinase 3 as well as downregulation of tissue inhibitor metalloproteinase 1 and 3. Functional effects of CYP26A1 overexpression were increased proliferation (P < 0.01) and invasion in vitro (P < 0.01), which were inhibited by ketaconazole. Overexpression of CYP26A1 causes intracellular RA depletion and drives the cell into a highly proliferative and invasive state with induction of other known oncogenes.	[Chang, C-L; Hong, E.; Lao-Sirieix, P.; Fitzgerald, R. C.] MRC, Hutchison Res Ctr, Canc Cell Unit, Cambridge CB2 2XZ, England; [Chang, C-L] Mackay Mem Hosp, Dept Obstet & Gynecol, Taipei, Taiwan	Mackay Memorial Hospital	Fitzgerald, RC (corresponding author), MRC, Hutchison Res Ctr, Canc Cell Unit, Cambridge CB2 2XZ, England.	rcf@hutchison-mrc.cam.ac.uk	Chang, Chih-Long/AAJ-8784-2020	Chang, Chih-Long/0000-0003-3981-9366; Fitzgerald, Rebecca/0000-0002-3434-3568	Medical Research Council [MC_U105365007] Funding Source: Medline; MRC [MC_U105365007] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abu-Abed SS, 1998, J BIOL CHEM, V273, P2409, DOI 10.1074/jbc.273.4.2409; Avidan B, 2002, AM J GASTROENTEROL, V97, P1930, DOI 10.1111/j.1572-0241.2002.05902.x; Bancewicz J, 2002, LANCET, V359, P1727; Bax DA, 2005, J SURG ONCOL, V92, P89, DOI 10.1002/jso.20353; BERTRAM JS, 1993, ANN NY ACAD SCI, V686, P161, DOI 10.1111/j.1749-6632.1993.tb39170.x; Bigg HF, 2000, EUR J BIOCHEM, V267, P4150, DOI 10.1046/j.1432-1327.2000.01459.x; Brabender J, 2004, ONCOGENE, V23, P4780, DOI 10.1038/sj.onc.1207663; Chang CL, 2007, GUT, V56, P906, DOI 10.1136/gut.2006.097915; Downie D, 2005, CLIN CANCER RES, V11, P7369, DOI 10.1158/1078-0432.CCR-05-0466; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Hormi-Carver K, 2007, AM J PHYSIOL-GASTR L, V292, pG18, DOI 10.1152/ajpgi.00237.2006; Klamt F, 2003, MUTAT RES-GEN TOX EN, V539, P117, DOI 10.1016/S1383-5718(03)00155-4; Liu T, 2005, BRIT J CANCER, V93, P310, DOI 10.1038/sj.bjc.6602700; Lord RVN, 2001, SURGERY, V129, P267, DOI 10.1067/msy.2001.110856; Loudig O, 2005, BIOCHEM J, V392, P241, DOI 10.1042/BJ20050874; Niederreither K, 2002, NAT GENET, V31, P84, DOI 10.1038/ng876; Osanai M, 2005, MOL PHARMACOL, V67, P1808, DOI 10.1124/mol.104.005769; Palanca-Wessels MCA, 2003, CARCINOGENESIS, V24, P1183, DOI 10.1093/carcin/bgg076; Patel JB, 2004, J MED CHEM, V47, P6716, DOI 10.1021/jm0401457; Pohl H, 2005, J NATL CANCER I, V97, P142, DOI 10.1093/jnci/dji024; Radominska-Pandya A, 2002, BIOCHEMISTRY-US, V41, P4883, DOI 10.1021/bi0121151; Reifen R, 1998, INT J MOL MED, V1, P579; SAFFIOTTI U, 1967, CANCER-AM CANCER SOC, V20, P857, DOI 10.1002/1097-0142(1967)20:5&lt;857::AID-CNCR2820200545&gt;3.0.CO;2-3; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Schoenermark MP, 1999, ANN NY ACAD SCI, V878, P466, DOI 10.1111/j.1749-6632.1999.tb07703.x; Shelton DN, 2006, CANCER RES, V66, P7571, DOI 10.1158/0008-5472.CAN-06-1067; SMITH AH, 1991, AM J EPIDEMIOL, V133, P661, DOI 10.1093/oxfordjournals.aje.a115941; Van Heusden J, 2002, BRIT J CANCER, V86, P605, DOI 10.1038/sj.bjc.6600056; WALD N, 1980, LANCET, V2, P813; Webster RP, 1996, IN VIVO, V10, P113; Winters C, 1987, GASTROENTEROLOGY, V92, P118, DOI 10.1016/0016-5085(87)90847-X; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; WOUTERS W, 1992, CANCER RES, V52, P2841; Yung BYM, 2004, FEBS LETT, V578, P211, DOI 10.1016/j.febslet.2004.08.089	34	26	27	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					2951	2960		10.1038/sj.onc.1210969	http://dx.doi.org/10.1038/sj.onc.1210969			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059332				2022-12-28	WOS:000255681700002
J	Melchor, L; Honrado, E; Garcia, MJ; Alvarez, S; Palacios, J; Osorio, A; Nathanson, KL; Benitez, J				Melchor, L.; Honrado, E.; Garcia, M. J.; Alvarez, S.; Palacios, J.; Osorio, A.; Nathanson, K. L.; Benitez, J.			Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes	ONCOGENE			English	Article						hereditary breast cancer; BRCA1; BRCA2; BRCAX; array-CGH; breast cancer subtypes	MOLECULAR PORTRAITS; TISSUE MICROARRAY; COPY NUMBER; BRCA2 GENES; EXPRESSION; TUMORS; CARCINOMAS; MUTATIONS; PROFILES; CLASSIFICATION	Five breast cancer subtypes have been described in sporadic breast cancer (SBC) using expression arrays: basal-like, ERBB2, normal breast-like, luminal A and B. These molecular subtypes show different genomic aberration patterns (GAPs). Recently, our group described these breast cancer subtypes in 50 non-BRCA1/2 familial tumors using immunohistochemistry assays. We extended this study to the other classes of familial breast cancer (FBC), including 62 tumors (18 BRCA1, 16 BRCA2 and 28 non-BRCA1/2), with the same panel of 25 immunohistochemical (IHC) markers and histological grade obtaining a similar classification. We combined these data with results generated by a 1Mb BAC array-based CGH study to evaluate the genomic aberrations of each group. We found that BRCA1-related tumors are preferentially basal-like, whereas non-BRCA1/2 familial tumors are mainly luminal A subtype. We described distinct GAPs related to each IHC subtype. Basal tumors had a greater number of gains/losses, while luminal B tumors had more high-level DNA amplifications. Our data are similar to those obtained in SBC studies, highlighting the existence of distinct genetic pathways of tumor evolution, common to both SBC and FBC.	[Melchor, L.; Honrado, E.; Garcia, M. J.; Osorio, A.; Benitez, J.] Ctr Biomed Res Rare Dis CIBERER, Spanish Natl Canc Ctr CNIO, Human Canc Genet Program, Human Genet Grp, Madrid 28029, Spain; [Alvarez, S.] Spanish Natl Canc Ctr CNIO, Human Canc Genet Program, Mol Cytogenet Grp, Madrid, Spain; [Palacios, J.] Spanish Natl Canc Ctr CNIO, Mol Pathol Program, Breast & Gynecol Grp, Madrid, Spain; [Nathanson, K. L.] Univ Penn, Dept Med, Div Med Genet, Philadelphia, PA 19104 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); University of Pennsylvania	Benitez, J (corresponding author), Ctr Biomed Res Rare Dis CIBERER, Spanish Natl Canc Ctr CNIO, Human Canc Genet Program, Human Genet Grp, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	jbenitez@cnio.es	García, María J/G-1361-2016; Osorio, Ana/I-4324-2014; Melchor, Lorenzo/H-7221-2015; Palacios, Jose/AAV-3765-2020	García, María J/0000-0002-2236-9912; Osorio, Ana/0000-0001-8124-3984; Melchor, Lorenzo/0000-0002-5322-2817; Nathanson, Katherine/0000-0002-6740-0901; Honrado Franco, Emiliano/0000-0001-5668-4083				Adem C, 2004, GENE CHROMOSOME CANC, V41, P1, DOI 10.1002/gcc.20057; Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Alvarez S, 2005, CLIN CANCER RES, V11, P1146; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Diez O, 2003, HUM MUTAT, V22, P301, DOI 10.1002/humu.10260; ELSHEIKH S, 2007, BREAST CANC RES TREA; Greshock J, 2004, GENOME RES, V14, P179; Grushko TA, 2002, CANCER RES, V62, P1481; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; Herrero J, 2003, NUCLEIC ACIDS RES, V31, P3461, DOI 10.1093/nar/gkg591; Honrado E, 2005, J CLIN ONCOL, V23, P7503, DOI 10.1200/JCO.2005.01.3698; Honrado E, 2005, MODERN PATHOL, V18, P1305, DOI 10.1038/modpathol.3800453; Honrado E, 2007, MODERN PATHOL, V20, P1298, DOI 10.1038/modpathol.3800969; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Lacroix M, 2005, BREAST CANCER RES TR, V89, P297, DOI 10.1007/s10549-004-2172-4; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; MELCHOR L, IN PRESS CLIN CANC R; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Oldenburg RA, 2006, CLIN CANCER RES, V12, P1693, DOI 10.1158/1078-0432.CCR-05-2230; Osorio A, 2000, BRIT J CANCER, V82, P1266, DOI 10.1054/bjoc.1999.1089; Palacios J, 2003, CLIN CANCER RES, V9, P3606; Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Reis JS, 2006, MODERN PATHOL, V19, P999, DOI 10.1038/modpathol.3800621; Rodriguez-Pinilla SM, 2007, J CLIN PATHOL, V60, P1017, DOI 10.1136/jcp.2006.043869; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Staff S, 2003, CANCER RES, V63, P4978; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tischkowitz MD, 2006, CELL CYCLE, V5, P963, DOI 10.4161/cc.5.9.2713; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876; van Beers EH, 2005, CANCER RES, V65, P822; Vaquerizas JM, 2005, NUCLEIC ACIDS RES, V33, pW616, DOI 10.1093/nar/gki500; Vaquerizas JM, 2004, BIOINFORMATICS, V20, P3656, DOI 10.1093/bioinformatics/bth401; Vincent-Salomon A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1666; Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yehiely F, 2006, TRENDS MOL MED, V12, P537, DOI 10.1016/j.molmed.2006.09.004	44	63	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3165	3175		10.1038/sj.onc.1210975	http://dx.doi.org/10.1038/sj.onc.1210975			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071313				2022-12-28	WOS:000255897600009
J	Nowacki, S; Skowron, M; Oberthuer, A; Fagin, A; Voth, H; Brors, B; Westermann, F; Eggert, A; Hero, B; Berthold, F; Fischer, M				Nowacki, S.; Skowron, M.; Oberthuer, A.; Fagin, A.; Voth, H.; Brors, B.; Westermann, F.; Eggert, A.; Hero, B.; Berthold, F.; Fischer, M.			Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma	ONCOGENE			English	Article						CADM1; neuroblastoma; tumor suppressor; outcome assessment (health care); cell proliferation; disease progression	LACTATE-DEHYDROGENASE RELEASE; PROMOTER METHYLATION; ADHESION MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; STAGE NEUROBLASTOMA; CERVICAL-CANCER; LUNG-CANCER; TSLC1 GENE; IN-SILICO; CARCINOMA	Cell adhesion molecule 1 (CADM1) is a putative tumour suppressor gene, which is downregulated in many solid tumours. In neuroblastoma, loss of CADM1 expression has recently been found in disseminated tumours with adverse outcome, prompting us to investigate its role in neuroblastoma tumour progression. Oligonucleotide-microarray analysis of 251 neuroblastoma specimens demonstrated that CADM1 downregulation is associated with unfavourable prognostic markers like disseminated stage 4, age > 18 months, MYCN amplification and chromosome 11q alterations (P < 0.001 each). Furthermore, low CADM1 expression was signficantly correlated with unfavourable gene expression-based classification (P < 0.001) and adverse patient outcome (P < 0.001). Bisulphite sequencing and genetic analysis of 18 primary neuroblastomas suggested that neither haploinsufficiency nor hypermethylation is regularly involved in CADM1 gene silencing in neuroblastoma, which is in contrast to results obtained in other malignancies. In addition, no mutations disrupting the CADM1 reading frame were found in 25 primary neuroblastomas. Over-expression of CADM1 in neuroblastoma cells resulted in significant reduction of proliferation, viability and colony formation in soft agar. Collectively, our results suggest that downregulation of CADM1 tumour suppressor gene expression is a critical event in neuroblastoma pathogenesis resulting in tumour progression and unfavourable patient outcome.	[Nowacki, S.; Skowron, M.; Oberthuer, A.; Voth, H.; Hero, B.; Berthold, F.; Fischer, M.] Univ Cologne, Childrens Hosp, Dept Pediat Oncol & Hematol, D-50924 Cologne, Germany; [Brors, B.] German Canc Res Ctr, Dept Theoret Bioinformat B080, D-6900 Heidelberg, Germany; [Fagin, A.; Eggert, A.] Univ Hosp Essen, Dept Pediat Oncol & Hematol, Essen, Germany; [Westermann, F.] German Canc Res Ctr, Dept Tumor Genet B030, D-6900 Heidelberg, Germany	University of Cologne; Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ)	Fischer, M (corresponding author), Univ Cologne, Childrens Hosp, Dept Pediat Oncol & Hematol, Kerpener St 62, D-50924 Cologne, Germany.	matthias.fischer@uk-koeln.de	Westermann, Frank/F-7509-2013; Brors, Benedikt/E-5620-2013; Eggert, Angelika/AAE-6907-2022	Brors, Benedikt/0000-0001-5940-3101; Eggert, Angelika/0000-0003-3476-8184				Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; CICCARONE V, 1989, CANCER RES, V49, P219; De Preter K, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r84; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; Ehrlich M, 2006, ONCOGENE, V25, P2636, DOI 10.1038/sj.onc.1209145; Fischer M, 2006, CLIN CANCER RES, V12, P5118, DOI 10.1158/1078-0432.CCR-06-0985; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Heller G, 2007, BREAST CANCER RES TR, V103, P283, DOI 10.1007/s10549-006-9377-7; Houshmandi SS, 2006, NEUROLOGY, V67, P1863, DOI 10.1212/01.wnl.0000244472.56198.84; Ito A, 2003, BLOOD, V101, P2601, DOI 10.1182/blood-2002-07-2265; Ito T, 2003, CANCER RES, V63, P6320; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Katoh M, 2004, ONCOL REP, V12, P429; Katoh M, 2003, INT J ONCOL, V23, P1213; Kikuchi S, 2006, CANCER-AM CANCER SOC, V106, P1751, DOI 10.1002/cncr.21800; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Li JD, 2005, GYNECOL ONCOL, V96, P150, DOI 10.1016/j.ygyno.2004.08.050; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; Mao XL, 2004, ONCOGENE, V23, P5632, DOI 10.1038/sj.onc.1207756; Mertens F, 1997, CANCER RES, V57, P2765; Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x; Naishiro Y, 2005, ONCOGENE, V24, P3141, DOI 10.1038/sj.onc.1208517; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Oberthuer A, 2004, CLIN CANCER RES, V10, P4307, DOI 10.1158/1078-0432.CCR-03-0813; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Ojeda SR, 2006, ENDOCRINOLOGY, V147, P1166, DOI 10.1210/en.2005-1136; RACHER AJ, 1990, CYTOTECHNOLOGY, V3, P301, DOI 10.1007/BF00365494; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Surace EI, 2004, J NEUROPATH EXP NEUR, V63, P1015, DOI 10.1093/jnen/63.10.1015; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Waha A, 2003, J NEUROPATH EXP NEUR, V62, P1192, DOI 10.1093/jnen/62.11.1192; Wakayama T, 2003, BIOL REPROD, V68, P1755, DOI 10.1095/biolreprod.102.012344; Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P668, DOI 10.1001/archotol.132.6.668	40	39	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3329	3338		10.1038/sj.onc.1210996	http://dx.doi.org/10.1038/sj.onc.1210996			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084322				2022-12-28	WOS:000256111400011
J	Zwerner, JP; Joo, J; Warner, KL; Christensen, L; Hu-Lieskovan, S; Triche, TJ; May, WA				Zwerner, J. P.; Joo, J.; Warner, K. L.; Christensen, L.; Hu-Lieskovan, S.; Triche, T. J.; May, W. A.			The EWS/FLI1 oncogenic transcription factor deregulates GLI1	ONCOGENE			English	Article						Ewing's sarcoma; EWS/FLI1; GLI1; Hedgehog; Ewing family tumors	HEDGEHOG SIGNALING PATHWAY; DNA-BINDING; SONIC HEDGEHOG; EWINGS-SARCOMA; FUSION PROTEIN; TARGET GENES; GROWTH-FACTOR; SELF-RENEWAL; STEM-CELLS; PDGF-C	Ewing family tumors ( EFT), classically Ewing's sarcoma and peripheral primitive neuroectodermal tumor, share a common class of tumor-specific fusion genes thought to be key mediators of tumor biology. Here we demonstrate that the most common Ewing's fusion, EWS/FLI1, produces transcriptional upregulation of GLI1 and its direct transcriptional target PATCHED1 in a model transformation system. This deregulation of GLI1 is common to other EWS/ets chimera and depends on the functional transcriptional regulatory domains. Inhibition of GLI1 via RNAi or via overexpression of endogenous inhibitors results in a reduction of EWS/FLI1 transformation activity. Activation of GLI1 appears to occur in a Hedgehog- independent fashion as blockade of Hedgehog signaling has only a modest effect on EFT cells. We present evidence that EWS/FLI1 upregulation of cMYC may play a role in the upregulation of GLI1 in EWS/ FLI1-transformed NIH3T3 cells. Finally, we demonstrate that observations made in a model transformation system translate to an Ewing cellular background. EFT cell lines express GLI1 and PATCHED and this expression is EWS/ FLI1 dependent. Inhibition of GLI1 expression via RNAi results in reduced anchorage-independent growth in an EFT cell line. GLI1 appears to be a transcriptionally deregulated target of EWS/FLI1 that mediates a portion of its tumorigenic phenotype.	[Joo, J.; Warner, K. L.; Christensen, L.; May, W. A.] Univ So Calif, Childrens Hosp Los Angeles, Saban Res Inst, Dept Pediat,Div Hematol Oncol, Los Angeles, CA 90027 USA; [Zwerner, J. P.] Stanford Univ, Sch Med, Dept Dermatol, Palo Alto, CA 94304 USA; [Hu-Lieskovan, S.; Triche, T. J.] Univ So Calif, Childrens Hosp Los Angeles, Saban Res Inst, Dept Pathol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Stanford University; Children's Hospital Los Angeles; University of Southern California	May, WA (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Saban Res Inst, Dept Pediat,Div Hematol Oncol, 4650 Sunset Blvd Mail Stop 54, Los Angeles, CA 90027 USA.	wmay@chla.usc.edu			NCI NIH HHS [R01 CA090666, CA90666] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090666] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Aparicio LMA, 2007, CLIN TRANSL ONCOL, V9, P66, DOI 10.1007/s12094-007-0015-6; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BACCI G, 1982, CANCER-AM CANCER SOC, V48, P1561, DOI 10.1002/1097-0142(19820415)49:8<1561::AID-CNCR2820490808>3.0.CO;2-K; Bailey EC, 2002, J BIOL CHEM, V277, P33632, DOI 10.1074/jbc.M202203200; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BOYER CW, 1967, CANCER, V20, P1602, DOI 10.1002/1097-0142(196710)20:10<1602::AID-CNCR2820201006>3.0.CO;2-H; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621; Hepker J, 1997, DEVELOPMENT, V124, P549; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Koch A, 2004, NEUROPATH APPL NEURO, V30, P532, DOI 10.1111/j.1365-2990.2004.00560.x; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Lauth M, 2007, ONCOGENE, V26, P5163, DOI 10.1038/sj.onc.1210321; Lazar A, 2006, ARCH PATHOL LAB MED, V130, P1199; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lokker NA, 2002, CANCER RES, V62, P3729; Marigo V, 1996, DEVELOPMENT, V122, P1225; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Pizzo PA, 2005, PRINCIPLES PRACTICE; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Stein U, 1999, CANCER RES, V59, P1890; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Teitell MA, 1999, LAB INVEST, V79, P1535; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Zhou JX, 2006, HUM REPROD, V21, P1698, DOI 10.1093/humrep/del086; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	47	92	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3282	3291		10.1038/sj.onc.1210991	http://dx.doi.org/10.1038/sj.onc.1210991			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084326				2022-12-28	WOS:000256111400007
J	Cai, DH; Wang, D; Keefer, J; Yeamans, C; Hensley, K; Friedman, AD				Cai, D. H.; Wang, D.; Keefer, J.; Yeamans, C.; Hensley, K.; Friedman, A. D.			C/EBP alpha: AP-1 leucine zipper heterodimers bind novel DNA elements, activate the PU.1 promoter and direct monocyte lineage commitment more potently than C/EBP alpha homodimers or AP-1	ONCOGENE			English	Article						C/EBP alpha; C-jun; PU.1; myeloid	COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTORS; MYELOID PROGENITORS; COILED-COIL; C-JUN; DIFFERENTIATION; SPECIFICITY; FOS; DIMERIZATION; MACROPHAGE	The basic-region leucine zipper (BR-LZ or bZIP) transcription factors dimerize via their LZ domains to position the adjacent BRs for DNA binding. Members of the C/EBP, AP-1 and CREB/ATF bZIP subfamilies form homodimeric or heterodimeric complexes with other members of the same subset and bind-specific DNA motifs. Here we demonstrate that C/EBP alpha also zippers with AP-1 proteins and that this interaction allows contact with novel DNA elements and induction of monocyte lineage commitment in myeloid progenitors. A leucine zipper swap: gel shift assay demonstrates that C/EBP alpha zippers with c-Jun, JunB or c-Fos, but not with c-Maf or MafB. To evaluate activities of specific homodimers or heterodimers we utilized LZs with acid (LZE) or basic (LZK) residues in their salt bridge positions. C/EBP alpha LZE: C/EBP alpha LZK preferentially binds a C/EBP site, c-JunLZE: c-FosLZK an AP-1 site and C/EBP alpha LZE: c-JunLZK a hybrid element identified as TTGCGTCAT by oligonucleotide selection. In murine myeloid progenitors, C/EBP alpha:c-Jun or C/EBP alpha:c-Fos LZE: LZK heterodimers induce monocyte lineage commitment with markedly increased potency compared with C/EBP alpha or c-Jun homodimers or c-Jun: c-Fos heterodimers, demonstrating a positive functional consequence of C/EBP: AP-1 bZIP subfamily interaction. C/EBP alpha:cJun binds and activates the endogenous PU.1 promoter, providing one mechanism for induction of monopoiesis by this complex.	[Cai, D. H.; Wang, D.; Keefer, J.; Yeamans, C.; Hensley, K.; Friedman, A. D.] Johns Hopkins Univ, Sch Med, Div Pediat Oncol, Baltimore, MD 21231 USA	Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Oncol, CRB I,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	afriedm2@jhmi.edu			NHLBI NIH HHS [R01 HL082948, R01 HL082948-01, R01 HL082948-02, R01 HL082948-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Gombart AF, 2007, J LEUKOCYTE BIOL, V81, P1535, DOI 10.1189/jlb.0806516; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963; Hegde SP, 1999, BLOOD, V94, P1578, DOI 10.1182/blood.V94.5.1578.417k18_1578_1589; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wang D, 2006, BLOOD, V108, P1223, DOI 10.1182/blood-2005-12-008763; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Yeamans C, 2007, BLOOD, V110, P3136, DOI 10.1182/blood-2007-03-080291; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006	22	68	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2772	2779		10.1038/sj.onc.1210940	http://dx.doi.org/10.1038/sj.onc.1210940			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18026136	Green Accepted			2022-12-28	WOS:000255259500012
J	Ferreira, BI; Alonso, J; Carrillo, J; Acquadro, F; Largo, C; Suela, J; Teixeira, MR; Cerveira, N; Molares, A; Gomez-Lopez, G; Pestana, A; Sastre, A; Garcia-Miguel, P; Cigudosa, JC				Ferreira, B. I.; Alonso, J.; Carrillo, J.; Acquadro, F.; Largo, C.; Suela, J.; Teixeira, M. R.; Cerveira, N.; Molares, A.; Gomez-Lopez, G.; Pestana, A.; Sastre, A.; Garcia-Miguel, P.; Cigudosa, J. C.			Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma	ONCOGENE			English	Article						Ewing's sarcoma; arrayCGH; expression profile; genomic instability	TUMORS; HYBRIDIZATION; TRANSLOCATION; PREDICTION; FUSION	Ewing's sarcoma (ES) is characterized by specific chromosome translocations, the most common being t(11; 22)(q24; q12). Additionally, other type of genetic abnormalities may occur and be relevant for explaining the variable tumour biology and clinical outcome. We have carried out a high-resolution array CGH and expression profiling on 25 ES tumour samples to characterize the DNA copy number aberrations (CNA) occurring in these tumours and determine their association with gene-expression profiles and clinical outcome. CNA were observed in 84% of the cases. We observed a median number of three aberrations per case. Besides numerical chromosome changes, smaller aberrations were found and defined at chromosomes 5p, 7q and 9p. All CNA were compiled to define the smallest overlapping regions of imbalance (SORI). A total of 35 SORI were delimited. Bioinformatics analyses were conducted to identify subgroups according to the pattern of genomic instability. Unsupervised and supervised clustering analysis (using SORI as variables) segregated the tumours in two distinct groups: one genomically stable (<= 3 CNA) and other genomically unstable (> 3 CNA). The genomic unstable group showed a statistically significant shorter overall survival and was more refractory to chemotherapy. Expression pro. le analysis revealed significant differences between both groups. Genes related with chromosome segregation, DNA repair pathways and cell-cycle control were upregulated in the genomically unstable group. This report elucidates, for the first time, data about genomic instability in ES, based on CNA and expression pro. ling, and shows that a genomically unstable group of Ewing's tumours is correlated with a significant poor prognosis.	[Ferreira, B. I.; Acquadro, F.; Largo, C.; Suela, J.; Cigudosa, J. C.] CNIO, Mol Cytogenet Grp, Madrid 28089, Spain; [Ferreira, B. I.; Acquadro, F.; Largo, C.; Suela, J.; Cigudosa, J. C.] CIBERER, Madrid, Spain; [Alonso, J.; Carrillo, J.; Pestana, A.] UAM, CSIC, Inst Invest Biomed A Sols, Dept Biol Mol & Celular Canc, Madrid, Spain; [Teixeira, M. R.; Cerveira, N.] Portuguese Oncol Inst & Biomed Sci Inst ICBAS, Dept Genet, Oporto, Portugal; [Molares, A.; Gomez-Lopez, G.] Hosp Rebullon, CHUVI, Fdn Biomed, Vigo, Pontevedra, Spain; [Gomez-Lopez, G.] CNIO, Unidad Bioinformat, Madrid, Spain; [Sastre, A.; Garcia-Miguel, P.] Hosp Infantil La Paz, Unidad Oncohematol Infantil, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Universidade do Porto; Complexo Hospitalario Universitario de Vigo; Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz	Cigudosa, JC (corresponding author), CNIO, Mol Cytogenet Grp, 3 C Melchor Fernandez Almagro, Madrid 28089, Spain.	jalonso@iib.uam.es; jccigudosa@cnio.es	Molares-Vila, Alberto/AAA-3140-2021; García, Jaime Carrillo/AAC-5144-2020; Gomez-Lopez, Gonzalo/D-9123-2016; Teixeira, Manuel AC/AAZ-7251-2020; Cigudosa, Juan C/E-4105-2016; SUELA, JAVIER/K-3968-2016; Alonso, Javier/B-6012-2013; Teixeira, Manuel António Rodrigues/E-4885-2011	Gomez-Lopez, Gonzalo/0000-0002-4146-0551; Teixeira, Manuel AC/0000-0002-1959-0624; Alonso, Javier/0000-0002-6287-8391; Teixeira, Manuel António Rodrigues/0000-0002-4896-5982; ferreira, Bibiana/0000-0003-4772-9395; Cerveira, Nuno/0000-0001-5098-3840; Carrillo Garcia, Jaime/0000-0002-2861-3015				Armengol G, 1997, BRIT J CANCER, V75, P1403, DOI 10.1038/bjc.1997.242; AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; Bandres E, 2005, J PEDIAT HEMATOL ONC, V27, P537, DOI 10.1097/01.mph.0000184576.38835.e2; Blaveri E, 2005, CLIN CANCER RES, V11, P7012, DOI 10.1158/1078-0432.CCR-05-0177; Brisset S, 2001, CANCER GENET CYTOGEN, V130, P57, DOI 10.1016/S0165-4608(01)00454-X; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Eilers PHC, 2005, BIOINFORMATICS, V21, P1146, DOI 10.1093/bioinformatics/bti148; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Mendiola M, 2006, INT J CANCER, V118, P1381, DOI 10.1002/ijc.21578; MUGNERET F, 1988, CANCER GENET CYTOGEN, V32, P239, DOI 10.1016/0165-4608(88)90286-5; Ohali A, 2004, ONCOGENE, V23, P8997, DOI 10.1038/sj.onc.1208060; Ozaki T, 2001, GENE CHROMOSOME CANC, V32, P164, DOI 10.1002/gcc.1178; Pinkel D, 2005, ANNU REV GENOM HUM G, V6, P331, DOI 10.1146/annurev.genom.6.080604.162140; Rouveirol C, 2006, BIOINFORMATICS, V22, P849, DOI 10.1093/bioinformatics/btl004; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thompson PM, 2001, CANCER RES, V61, P679; Ushigome U, 2002, PATHOLOGY GENETICS T, P298; Wu W, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-309; Zielenska M, 2001, CANCER, V91, P2156, DOI 10.1002/1097-0142(20010601)91:11<2156::AID-CNCR1244>3.0.CO;2-I	21	45	61	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2084	2090		10.1038/sj.onc.1210845	http://dx.doi.org/10.1038/sj.onc.1210845			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17952124				2022-12-28	WOS:000254359100013
J	Sahay, S; Pannucci, NL; Mahon, GM; Rodriguez, PL; Megjugorac, NJ; Kostenko, EV; Ozer, HL; Whitehead, IP				Sahay, S.; Pannucci, N. L.; Mahon, G. M.; Rodriguez, P. L.; Megjugorac, N. J.; Kostenko, E. V.; Ozer, H. L.; Whitehead, I. P.			The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation	ONCOGENE			English	Article						chronic myelogenous leukemia; p210 Bcr-Abl; RhoA; RhoGEF domain; transformation	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; POSITIVE HUMAN LEUKEMIAS; ADAPTER PROTEIN; ONCOGENE; FAMILY; ONCOPROTEIN; SEQUENCES; INTERACTS; GROWTH	The BCR-ABL oncogene encodes an in-frame fusion protein containing N-terminal sequences derived from Bcr and C-terminal sequences derived from Abl. Bcr contains a centrally located Rho-specific guanine nucleotide exchange factor (RhoGEF) domain that is retained within p210 Bcr-Abl. Although this domain is subject to autoinhibition in the context of Bcr, here we show that it is constitutively activated in p210 Bcr-Abl. p210 Bcr-Abl can stimulate RhoA activation independently of its tyrosine kinase activity, and mutations within the RhoGEF domain that are predicted to eliminate RhoGEF activity inhibit RhoA activation. The RhoGEF mutant of p210 Bcr-Abl does not affect the tyrosine kinase activity of the molecule, nor the ability of p210 Bcr-Abl to interact with XPB through the RhoGEF domain. Despite retaining normal levels of tyrosine kinase activity, the RhoGEF mutant of p210 Bcr-Abl is impaired in transforming activity as measured by anchorage-independent growth. However, the mutant is still able to confer the phenotype of growth factor independence in myeloid cells, suggesting that some, but not all parameters of p210 Bcr-Abl transformation, are dependent upon a catalytically active RhoGEF domain. Collectively, these observations identify a gain-of-function activity attributable to the RhoGEF domain of p210 Bcr-Abl that is required to support the transformed phenotype.	[Sahay, S.; Pannucci, N. L.; Mahon, G. M.; Rodriguez, P. L.; Megjugorac, N. J.; Kostenko, E. V.; Ozer, H. L.; Whitehead, I. P.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Univ Hosp Canc Ctr, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Whitehead, IP (corresponding author), UMDNJ, NJMS Canc Ctr H Level, Dept Microbiol & Mol Genet, 205 S Orange Ave, Newark, NJ USA.	whiteip@umdnj.edu			NATIONAL CANCER INSTITUTE [R01CA097066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004821] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA097066, CA097066, R01 CA097066-05A1] Funding Source: Medline; NIA NIH HHS [AG04821, R01 AG004821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Harnois T, 2003, ONCOGENE, V22, P6445, DOI 10.1038/sj.onc.1206626; Korus M, 2002, ONCOGENE, V21, P4601, DOI 10.1038/sj.onc.1205678; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Mahon GM, 2003, CURR BIOL, V13, P437, DOI 10.1016/S0960-9822(03)00090-3; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Olabisi OO, 2006, CANCER RES, V66, P6250, DOI 10.1158/0008-5472.CAN-06-0536; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; TENHOEVE J, 1994, CANCER RES, V54, P2563; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	24	27	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					2064	2071		10.1038/sj.onc.1210841	http://dx.doi.org/10.1038/sj.onc.1210841			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922031	Green Accepted			2022-12-28	WOS:000254359100011
J	Kao, CJ; Chiang, YJ; Chen, PH; Lin, KR; Hwang, PI; Yang-Yen, HF; Yen, JJY				Kao, C-J; Chiang, Y-J; Chen, P-H; Lin, K-R; Hwang, P-I; Yang-Yen, H-F; Yen, J. J-Y			CBAP interacts with the un-liganded common beta-subunit of the GM-CSF/IL-3/IL-5 receptor and induces apoptosis via mitochondrial dysfunction	ONCOGENE			English	Article						apoptosis; cytokine deprivation; mitochondrial dysfunction; cytokine receptor	COLONY-STIMULATING FACTOR; GM-CSF; SIGNAL-TRANSDUCTION; EXPRESSION CLONING; JAK2; CHAIN; ERYTHROPOIETIN; PROLIFERATION; REQUIRES; REGION	The cytoplasmic domain of the common beta-chain (beta c) of the granulocyte-macrophage-colony-stimulating factor (GM-CSF)/interleukin-3 (IL-3)/IL-5 receptor contains a membrane proximal region that is sufficient to mediate ligand-dependent mitogenic activity. Within this region two motifs, designated as box 1 and box 2, are highly conserved among members of the cytokine receptor superfamily. Whereas box 1 is required for the recruitment and phosphorylation of Janus kinase-2, the function of box 2 remains largely unknown. Here, we report the identification of a novel transmembrane protein (common beta-chain associated protein (CBAP)) which directly associated with beta c via the box 2 motif. Interestingly, such an association only occurred in the absence of GM-CSF in vivo. Ectopic overexpression of CBAP triggered apoptosis of factor-dependent cells via mitochondrial dysfunction, which could be inhibited by Bcl-2 overexpression. Reduced expression of endogenous CBAP by small interfering RNA did not interfere GM-CSF-activated signaling molecules, but such treatment significantly inhibited apoptosis induced by GM-CSF deprivation, but not other death stimuli. Domain mapping studies indicated that one apoptogenic domain of CBAP correlated with its ability to interact with beta c. Taken together, these results suggest that CBAP modulates GM-CSF-deprivation-induced apoptosis possibly via a novel mechanism involving interaction with an un-liganded beta c molecule.	[Kao, C-J; Chiang, Y-J; Chen, P-H; Lin, K-R; Yen, J. J-Y] Acad Sinica, Inst Biomed Sci, Agr Biotechnol Res Ctr, Taipei 11529, Taiwan; [Kao, C-J; Yen, J. J-Y] Natl Taiwan Univ, Sch Med, Inst Mol Med, Taipei 10764, Taiwan; [Hwang, P-I] Acad Sinica, Bioinformat Core Lab, Agr Biotechnol Res Ctr, Taipei 11529, Taiwan; [Yang-Yen, H-F] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan; Academia Sinica - Taiwan	Yen, JJY (corresponding author), Acad Sinica, Inst Biomed Sci, Agr Biotechnol Res Ctr, 128 Sec 2,Yen Jiou Yuan Rd, Taipei 11529, Taiwan.	bmjyen@ibms.sinica.edu.tw	Yen, Jeffrey Jong-Young/Q-5134-2018; Chen, Ping-Hung/AAN-6443-2020; Lin, Kuo-Ray/V-6333-2019; Yang-Yen, Hsin-Fang/ABA-5808-2021	Yen, Jeffrey Jong-Young/0000-0001-6299-1995; Chen, Ping-Hung/0000-0002-7156-0510; Yang-Yen, Hsin-Fang/0000-0001-9048-4800				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Drachman JG, 2002, J BIOL CHEM, V277, P23544, DOI 10.1074/jbc.M201120200; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Huang HM, 1999, BLOOD, V93, P2569, DOI 10.1182/blood.V93.8.2569.408k08_2569_2577; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Lee SF, 1999, MOL CELL BIOL, V19, P7399; MIURA O, 1993, BLOOD, V81, P1739; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	15	7	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1397	1403		10.1038/sj.onc.1210778	http://dx.doi.org/10.1038/sj.onc.1210778			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828305				2022-12-28	WOS:000253548200006
J	Lee, OH; Xu, J; Fueyo, J; Alonso, MM; Liu, D; Martin, V; Jiang, H; Piao, Y; Liu, TJ; Gomez-Manzano, C				Lee, O-H; Xu, J.; Fueyo, J.; Alonso, M. M.; Liu, D.; Martin, V.; Jiang, H.; Piao, Y.; Liu, T. J.; Gomez-Manzano, C.			Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas	ONCOGENE			English	Article						Tie2; angiopoietin-2; HIF-1 alpha; VEGF; gliomas	RECEPTOR TYROSINE KINASE; VESSEL FORMATION; ANGIOGENESIS; TIE2; INTEGRIN; CANCER; CELLS; ADHESION; MATRIX; RAT	Angiogenesis is thought to depend on a perfectly coordinated balance between endogenous-positive and negative regulatory factors. Of these factors, the vascular endothelial growth factor (VEGF) and angiopoietins (Angs) seem to play an essential role. Recently, we reported the expression of the Ang-natural receptor, Tie2, in neoplastic astrocytic cells within gliomas. Because of the VEGF/Ang2 functional partnership together with the presence of Tie2 in gliomas, we hypothesized a role of Ang2 on the modulation of VEGF levels in these tumors. We examined the effect of Ang2 on VEGF expression in a panel of glioma cells, which showed that Ang2 inhibited VEGF expression at both mRNA and protein levels in Tie2-expressing cells, but not in Tie2-negative cells. VEGF promoter analysis showed that Ang2 regulated VEGF expression at the transcriptional level in relation to a decrease in HIF-1 alpha expression and HIF-DNA-binding activity. Tie2 silencing by siRNA rescued the Ang2-mediated downmodulation of VEGF, suggesting an essential role for Tie2 in this regulatory loop. To our knowledge, this is the first report on the role of Ang2/Tie2 in the regulation of HIF-1 alpha/VEGF expression, providing additional evidence of the intrinsic coordination that occurs among these factors during angiogenesis.	[Lee, O-H; Xu, J.; Fueyo, J.; Alonso, M. M.; Liu, D.; Martin, V.; Jiang, H.; Piao, Y.; Liu, T. J.; Gomez-Manzano, C.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Neurooncol, Unit 1002, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Gomez-Manzano, C (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Neurooncol, Unit 1002, 1515 Holcombe Blvd, Houston, TX 77030 USA.	cmanzano@mdanderson.org	MARTIN, VANESA/A-7312-2012; Alonso, Marta M/AAI-9457-2020	MARTIN, VANESA/0000-0001-6923-2529; Alonso, Marta M/0000-0002-7520-7351; Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA083127] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA83127, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Goede V, 1998, LAB INVEST, V78, P1385; Gomez-Manzano C, 2003, ANN NEUROL, V53, P109, DOI 10.1002/ana.10396; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hu B, 2006, CANCER RES, V66, P775, DOI 10.1158/0008-5472.CAN-05-1149; Kukk E, 1997, BRIT J HAEMATOL, V98, P195, DOI 10.1046/j.1365-2141.1997.1732989.x; Lee OH, 2006, MOL CANCER RES, V4, P915, DOI 10.1158/1541-7786.MCR-06-0184; Lee OH, 2006, NEOPLASIA, V8, P419, DOI 10.1593/neo.06109; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loureiro RMB, 2005, CYTOKINE GROWTH F R, V16, P77, DOI 10.1016/j.cytogfr.2005.01.005; Machein MR, 2004, AM J PATHOL, V165, P1557, DOI 10.1016/S0002-9440(10)63413-X; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Shirakawa K, 2002, INT J CANCER, V99, P344, DOI 10.1002/ijc.10336; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Wang J, 2005, BIOCHEM BIOPH RES CO, V337, P386, DOI 10.1016/j.bbrc.2005.09.051; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	18	15	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1310	1314		10.1038/sj.onc.1210731	http://dx.doi.org/10.1038/sj.onc.1210731			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704802				2022-12-28	WOS:000253407000014
J	Ji, Y; Shah, S; Soanes, K; Islam, MN; Hoxter, B; Biffo, S; Heslip, T; Byers, S				Ji, Y.; Shah, S.; Soanes, K.; Islam, M. N.; Hoxter, B.; Biffo, S.; Heslip, T.; Byers, S.			Eukaryotic initiation factor 6 selectively regulates Wnt signaling and beta-catenin protein synthesis	ONCOGENE			English	Article						beta-catenin; eIF6; wnt; wingless; Drosophila; APC	SACCHAROMYCES-CEREVISIAE HOMOLOG; C-MYC; TRANSLATION; APC; PHOSPHORYLATION; UBIQUITINATION; P27(BBP); ADHESION; COMPLEX; BINDING	Eukaryotic initiation factor 6 ( eIF6), an essential protein important in ribosome biosynthesis and assembly, was identified as an interacting partner of the beta-catenin C terminus in the yeast two-hybrid assay. Independent studies identified Drosophila eIF6 ( DeIF6) in a genetic screen designed to detect new genes involved in the regulation of the Wnt/Wg ( wingless) pathway. Ectopic expression of DeIF6 in wing discs results in a Wg phenotype. Expression of eIF6 in adenomatous polyposis coli ( APC)-mutant colon cancer cells, which express high levels of active beta-catenin, showed that eIF6 selectively inhibits the Wnt pathway at the level of beta-catenin protein independently of proteasomal degradation. Incorporation of radiolabeled amino acids into beta-catenin was selectively decreased in cells that overexpressed eIF6. A similar inverse relationship of the two proteins was observed in the APC(min/+) mouse intestine, in which beta-catenin levels are very high. Taken together these data reveal a link between eIF6 and Wnt signaling, perhaps at the level of ribosome recycling on beta-catenin mRNA.	[Ji, Y.; Shah, S.; Islam, M. N.; Hoxter, B.; Byers, S.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; [Biffo, S.] DIBIT HSR, Mol Histol Unit, Milan, Italy; [Soanes, K.; Heslip, T.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada	Georgetown University; University of Calgary	Byers, S (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, E415 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	byerss@georgetown.edu	Ji, Yun/B-7245-2009; Waldmann, Thomas/AAT-5972-2021	Ji, Yun/0000-0001-6340-7009; Waldmann, Thomas/0000-0003-4500-6660; biffo, stefano/0000-0002-3780-1050				Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Basu U, 2003, MOL CELL BIOL, V23, P6187, DOI 10.1128/MCB.23.17.6187-6199.2003; Basu U, 2001, MOL CELL BIOL, V21, P1453, DOI 10.1128/MCB.21.5.1453-1462.2001; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Biffo S, 1997, J BIOL CHEM, V272, P30314, DOI 10.1074/jbc.272.48.30314; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chendrimada TP, 2007, NATURE, V447, P823, DOI 10.1038/nature05841; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Donadini A, 2001, GENE, V266, P35, DOI 10.1016/S0378-1119(01)00370-5; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Greaves S, 1999, GENETICS, V153, P1753; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Sanvito F, 1999, J CELL BIOL, V144, P823, DOI 10.1083/jcb.144.5.823; Si K, 1999, MOL CELL BIOL, V19, P1416; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wood LC, 1999, J BIOL CHEM, V274, P11653, DOI 10.1074/jbc.274.17.11653	30	30	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					755	762		10.1038/sj.onc.1210667	http://dx.doi.org/10.1038/sj.onc.1210667			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17667944				2022-12-28	WOS:000252884500004
J	Li, ZG; Yang, J; Vazquez, ES; Rose, D; Vakar-Lopez, F; Mathew, P; Lopez, A; Logothetis, CJ; Lin, SH; Navone, NM				Li, Z. G.; Yang, J.; Vazquez, E. S.; Rose, D.; Vakar-Lopez, F.; Mathew, P.; Lopez, A.; Logothetis, C. J.; Lin, S-H; Navone, N. M.			Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone	ONCOGENE			English	Article						WNT; WNT7b; prostate cancer; bone metastases; osteoblasts; DKK1	METASTASES; OSTEOBLASTS; DICKKOPF-1; PROTEINS; HEDGEHOG; CATENIN; LESIONS	The tendency of prostate cancer to produce osteoblastic bone metastases suggests that cancer cells and osteoblasts interact in ways that contribute to cancer progression. To identify factors that mediate these interactions, we compared gene expression patterns between two bone-derived prostate cancer cell lines that produce osteoblastic (MDA PCa 2b) or osteolytic lesions (PC-3). Both cell lines expressed Wnt ligands, including WNT7b, a canonical Wnt implicated in osteogenesis. PC-3 cells expressed 50 times more Dickkopf-1 (DKK1), an inhibitor of Wnt pathways, than did MDA PCa 2b cells. Evaluation of the functional role of these factors (in cocultures of prostate cancer cells with primary mouse osteoblasts (PMOs) or in bone organ cultures) showed that MDA PCa 2b cells activated Wnt canonical signaling in PMOs and that DKK1 blocked osteoblast proliferation and new bone formation induced by MDA PCa 2b cells. MDA PCa 2b cells did not induce bone formation in calvaria from mice lacking the Wnt co-receptor Lrp5. In human specimens, WNT7b was not expressed in normal prostate but was expressed in areas of high-grade prostate intraepithelial neoplasia, in three of nine primary prostate tumor specimens and in 16 of 38 samples of bone metastases from prostate cancer. DKK1 was not expressed in normal or cancerous tissue but was expressed in two of three specimens of osteolytic bone metastases (P = 0.0119). We conclude that MDA PCa 2b induces new bone formation through Wnt canonical signaling, that LRP5 mediates this effect, and that DKK1 is involved in the balance between bone formation and resorption that determines lesion phenotype.	[Li, Z. G.; Yang, J.; Rose, D.; Mathew, P.; Logothetis, C. J.; Navone, N. M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, Houston, TX 77230 USA; [Vazquez, E. S.] Univ Buenos Aires, CONICET, Sch Sci, Dept Biol Chem, RA-1053 Buenos Aires, DF, Argentina; [Vakar-Lopez, F.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77230 USA; [Lopez, A.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77230 USA; [Lin, S-H] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77230 USA	University of Texas System; UTMD Anderson Cancer Center; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Navone, NM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 1515 Holcombe Blvd,POB 301439, Houston, TX 77230 USA.	nnavone@mdanderson.org	; Vazquez, Elba/D-5134-2019	Lopez, Adriana/0000-0001-9169-800X; Vazquez, Elba/0000-0002-0460-0236	NATIONAL CANCER INSTITUTE [R01CA096797, R01CA111479, P50CA090270] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA111479, R01CA096797, P50CA90270] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; COOK GB, 1968, J UROLOGY, V99, P87, DOI 10.1016/S0022-5347(17)62647-8; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802; Ferrari SL, 2005, CURR OPIN LIPIDOL, V16, P207, DOI 10.1097/01.mol.0000162326.62419.e4; Fizazi K, 2003, CLIN CANCER RES, V9, P2587; Freshney RI, 1994, CULTURE ANIMAL CELLS; GARRETT R, 2003, METHODS MOL MED, P183; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008-5472.CAN-05-1317; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kolpakova E, 2005, DEV CELL, V8, P626, DOI 10.1016/j.devcel.2005.04.008; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; YANG BC, 2001, J E CHINA NORMAL U N, V1, P61; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	27	53	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					596	603		10.1038/sj.onc.1210694	http://dx.doi.org/10.1038/sj.onc.1210694			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17700537				2022-12-28	WOS:000252674900004
J	Shih, JW; Tsai, Y; Chao, CH; Lee, YHW				Shih, J-W; Tsai, Y.; Chao, C-H; Lee, Y-H Wu			Candidate tumor suppressor DDX3 RNA helicase specifically represses cap-dependent translation by acting as an eIF4E inhibitory protein	ONCOGENE			English	Article						cap-dependent translation; HCVIRES; DEAD box RNA helicase; DDX3; eIF4E inhibitory protein; tumor suppressor	HEPATITIS-C VIRUS; MESSENGER-RNA; CORE PROTEIN; EUKARYOTIC TRANSLATION; CELL-GROWTH; BINDING-PROTEIN; INITIATION; TRANSFORMATION; REQUIREMENT; EXPRESSION	DDX3 is a human RNA helicase with plethoric functions. Our previous studies have indicated that DDX3 is a transcriptional regulator and functions as a tumor suppressor. In this study, we use a bicistronic reporter to demonstrate that DDX3 specifically represses cap-dependent translation but enhances hepatitis C virus internal ribosome entry site-mediated translation in vivo in a helicase activity-independent manner. To elucidate how DDX3 modulates translation, we identified translation initiation factor eukaryotic initiation factor 4E (eIF4E) as a DDX3-binding partner. Interestingly, DDX3 utilizes a consensus eIF4E-binding sequence YIPPHLR to interact with the functionally important dorsal surface of eIF4E in a similar manner to other eIF4E-binding proteins. Furthermore, cap affinity chromatography analysis suggests that DDX3 traps eIF4E in a translationally inactive complex by blocking interaction with eIF4G. Point mutations within the consensus eIF4E-binding motif in DDX3 impair its ability to bind eIF4E and result in a loss of DDX3's regulatory effects on translation. All these features together indicate that DDX3 is a new member of the eIF4E inhibitory proteins involved in translation initiation regulation. Most importantly, this DDX3-mediated translation regulation also confers the tumor suppressor function on DDX3. Altogether, this study demonstrates regulatory roles and action mechanisms for DDX3 in translation, cell growth and likely viral replication.	[Shih, J-W; Tsai, Y.; Chao, C-H; Lee, Y-H Wu] Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Sect 2, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Sect 2, 155 Li Nong St, Taipei 112, Taiwan.	yhwulee@ym.edu.tw	Shih, Jing-Wen/J-4555-2017	Shih, Jing-Wen/0000-0002-0417-9015; Lee Wu, Yan-Hwa/0000-0001-7299-7354; Chao, Chi-Hong/0000-0001-9890-4902				Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; Ferraiuolo MA, 2005, J CELL BIOL, V170, P913, DOI 10.1083/jcb.200504039; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hwang LH, 1998, BIOCHEM BIOPH RES CO, V252, P455, DOI 10.1006/bbrc.1998.9673; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kao CF, 2004, ONCOGENE, V23, P2472, DOI 10.1038/sj.onc.1207368; Linder P, 2003, BIOL CELL, V95, P157, DOI 10.1016/S0248-4900(03)00032-7; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Niessing D, 2002, GENE DEV, V16, P2576, DOI 10.1101/gad.240002; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Park SH, 1998, CYTOGENET CELL GENET, V81, P178, DOI 10.1159/000015022; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rousseau D, 1996, ONCOGENE, V13, P2415; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Svitkin YV, 2005, MOL CELL BIOL, V25, P10556, DOI 10.1128/MCB.25.23.10556-10565.2005; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; YANG HS, 2004, NAT STRUCT MOL BIOL, V23, P26; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	38	130	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					700	714		10.1038/sj.onc.1210687	http://dx.doi.org/10.1038/sj.onc.1210687			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667941				2022-12-28	WOS:000252674900014
J	Fanelli, M; Caprodossi, S; Ricci-Vitiani, L; Porcellini, A; Tomassoni-Ardori, F; Amatori, S; Andreoni, F; Magnani, M; De Maria, R; Santoni, A; Minucci, S; Pelicci, PG				Fanelli, M.; Caprodossi, S.; Ricci-Vitiani, L.; Porcellini, A.; Tomassoni-Ardori, F.; Amatori, S.; Andreoni, F.; Magnani, M.; De Maria, R.; Santoni, A.; Minucci, S.; Pelicci, P. G.			Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment	ONCOGENE			English	Article						glioblastoma; DNA methyltransferases; DNA methylation; brain tumor; stem cells	CHROMOSOME INSTABILITY; DNMT3B; HYPOMETHYLATION; GENE; OVEREXPRESSION; FEATURES; REGIONS; CANCER; 3B	Cancer is generally characterized by loss of CG dinucleotides methylation resulting in a global hypomethylation and the consequent genomic instability. The major contribution to the general decreased methylation levels seems to be due to demethylation of heterochromatin repetitive DNA sequences. In human immunodeficiency, centromeric instability and facial anomalies syndrome, demethylation of pericentromeric satellite 2 DNA sequences has been correlated to functional mutations of the de novo DNA methyltransferase 3b (DNMT3b), but the mechanism responsible for the hypomethylated status in tumors is poorly known. Here, we report that human glioblastoma is affected by strong hypomethylation of satellite 2 pericentromeric sequences that involves the stem cell compartment. Concomitantly with the integrity of the DNMTs coding sequences, we report aberrations in DNA methyltrasferases expression showing upregulation of the DNA methyltransferase 1 (DNMT1) and downregulation of the de novo DNA methyltransferase 3a (DNMT3a). Moreover, we show that DNMT3a is the major de novo methyltransferase expressed in normal neural progenitor cells (NPCs) and its forced re-expression is sufficient to partially recover the methylation levels of satellite 2 repeats in glioblastoma cell lines. Thus, we speculate that DNMT3a decreased expression may be involved in the early post-natal inheritance of an epigenetically altered NPC population that could be responsible for glioblastoma development later in adult life.	[Fanelli, M.; Caprodossi, S.; Tomassoni-Ardori, F.; Amatori, S.; Andreoni, F.; Magnani, M.] Univ Urbino, Ctr Biotechnol, Mol Pathol Lab, I-61032 Urbino, Italy; [Caprodossi, S.; Minucci, S.; Pelicci, P. G.] European Inst Oncol, Dept Expt Oncol, Milan, Italy; [Ricci-Vitiani, L.; De Maria, R.] Inst Sup Sanita, Dept Hematol, Rome, Italy; [Porcellini, A.; Santoni, A.] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy; [Porcellini, A.; Santoni, A.] INM Neuromed, Dept Expt Med & Pathol, Rome, Italy	University of Urbino; IRCCS European Institute of Oncology (IEO); Istituto Superiore di Sanita (ISS); Sapienza University Rome; IRCCS Neuromed	Fanelli, M (corresponding author), Univ Urbino, Ctr Biotechnol, Mol Pathol Lab, Via Campanella 1, I-61032 Urbino, Italy.	mirco.fanelli@uniurb.it	Porcellini, Antonio/AAC-6097-2019; Ricci Vitiani, Lucia/J-8320-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; De Maria, Ruggero/S-6385-2019; Fanelli, Mirco/F-2665-2011; Porcellini, Antonio/E-1900-2011; Minucci, Saverio/J-9669-2012; santoni, angela/K-8997-2016; feng, jian/G-9313-2011; Francesca, Andreoni/G-7505-2012; Magnani, Mauro/A-1919-2008	Ricci Vitiani, Lucia/0000-0001-7336-5615; De Maria, Ruggero/0000-0003-2255-0583; Fanelli, Mirco/0000-0002-9649-8661; Porcellini, Antonio/0000-0001-6882-9518; santoni, angela/0000-0003-1206-7731; Francesca, Andreoni/0000-0002-4857-8210; Amatori, Stefano/0000-0003-3988-3480; Tomassoni Ardori, Francesco/0000-0002-8824-3693; Magnani, Mauro/0000-0001-6456-6626				Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Baeza N, 2003, ACTA NEUROPATHOL, V106, P479, DOI 10.1007/s00401-003-0748-4; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Blanc JL, 2004, J NEURO-ONCOL, V68, P275, DOI 10.1023/B:NEON.0000033385.37098.85; Calogero A, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-1; Caprodossi S, 2005, MOL BIOTECHNOL, V30, P231, DOI 10.1385/MB:30:3:231; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feng J, 2005, J NEUROSCI RES, V79, P734, DOI 10.1002/jnr.20404; Gao YX, 2004, CLIN CHIM ACTA, V349, P173, DOI 10.1016/j.cccn.2004.07.006; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hassan KMA, 2001, HUM GENET, V109, P452; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Kang ES, 2001, BIOCHEM BIOPH RES CO, V289, P862, DOI 10.1006/bbrc.2001.6057; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PROSSER J, 1986, J MOL BIOL, V187, P145, DOI 10.1016/0022-2836(86)90224-X; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Tsuda H, 2002, AM J PATHOL, V161, P859, DOI 10.1016/S0002-9440(10)64246-0; Vilain A, 1999, FEBS LETT, V460, P231, DOI 10.1016/S0014-5793(99)01358-7; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	30	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					358	365		10.1038/sj.onc.1210642	http://dx.doi.org/10.1038/sj.onc.1210642			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17653095				2022-12-28	WOS:000252256000012
J	Jeggo, P; Lobrich, M				Jeggo, P. A.; Loebrich, M.			DNA double-strand breaks: their cellular and clinical impact? Introduction	ONCOGENE			English	Editorial Material							REPAIR; RECOMBINATION; MUTATIONS; ARTEMIS; PATHWAY; COMPLEX; ATM		Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Tech Univ Darmstadt, Darmstadt, Germany	University of Sussex; Technical University of Darmstadt	Jeggo, P (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	p.a.jeggo@sussex.ac.uk; lobrich@bio.tu-darmstadt.de			Medical Research Council [G0500897] Funding Source: Medline; MRC [G0500897] Funding Source: UKRI; Medical Research Council [G0300662B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Lobrich M, 2005, P NATL ACAD SCI USA, V102, P8984, DOI 10.1073/pnas.0501895102; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451	13	183	189	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7717	7719		10.1038/sj.onc.1210868	http://dx.doi.org/10.1038/sj.onc.1210868			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066083				2022-12-28	WOS:000251537900001
J	Karagianni, P; Wong, J				Karagianni, P.; Wong, J.			HDAC3: taking the SMRT-N-CoRrect road to repression	ONCOGENE			English	Review						HDAC3; SMRT; N-CoR; corepressor complex; histone deacetylation; repression and cancer	NUCLEAR RECEPTOR-COREPRESSOR; THYROID-HORMONE RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; HUMAN HISTONE DEACETYLASE; PML-RAR-ALPHA; CO-REPRESSOR; TRANSCRIPTIONAL REPRESSION; KAPPA-B; FUSION PROTEIN	Known histone deacetylases ( HDACs) are divided into different classes, and HDAC3 belongs to Class I. Through forming multiprotein complexes with the corepressors SMRT and N-CoR, HDAC3 regulates the transcription of a plethora of genes. A growing list of nonhistone substrates extends the role of HDAC3 beyond transcriptional repression. Here, we review data on the composition, regulation and mechanism of action of the SMRT/N-CoR-HDAC3 complexes and provide several examples of nontranscriptional functions, to illustrate the wide variety of physiological processes affected by this deacetylase. Furthermore, we discuss the implication of HDAC3 in cancer, focusing on leukemia. We conclude with some thoughts about the potential therapeutic efficacies of HDAC3 activity modulation.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Wong, J (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	jmweng@bio.ecnu.edu.cn		Wong, Jiemin/0000-0002-5311-842X	NIDDK NIH HHS [DK58679] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058679] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alenghat T, 2006, EMBO J, V25, P3966, DOI 10.1038/sj.emboj.7601280; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Atsumi A, 2006, BIOCHEM BIOPH RES CO, V345, P1471, DOI 10.1016/j.bbrc.2006.05.047; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bartling B, 2005, LUNG CANCER-J IASLC, V49, P145, DOI 10.1016/j.lungcan.2005.02.006; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cho YS, 2005, GENOMICS, V86, P606, DOI 10.1016/j.ygeno.2005.07.007; Chuang HC, 2006, NUCLEIC ACIDS RES, V34, P1459, DOI 10.1093/nar/gkl048; Codina A, 2005, P NATL ACAD SCI USA, V102, P6009, DOI 10.1073/pnas.0500299102; Cowger JJM, 2006, BIOCHEMISTRY-US, V45, P13150, DOI 10.1021/bi060562g; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; ERICKSON P, 1992, BLOOD, V80, P1825; Escaffit F, 2007, MOL CELL BIOL, V27, P554, DOI 10.1128/MCB.00869-06; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Foglietti C, 2006, J BIOL CHEM, V281, P17968, DOI 10.1074/jbc.M511945200; Frank R, 1995, ONCOGENE, V11, P2667; Fu JHJ, 2007, MOL CELL BIOL, V27, P4641, DOI 10.1128/MCB.00857-06; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gao ZG, 2006, J BIOL CHEM, V281, P4540, DOI 10.1074/jbc.M507784200; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2000, GENE DEV, V14, P1048; Guenther MG, 2002, GENE DEV, V16, P3130, DOI 10.1101/gad.1037502; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Guidez F, 2000, BLOOD, V96, P2557; Hartman HB, 2005, EMBO REP, V6, P445, DOI 10.1038/sj.embor.7400391; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hoogeveen AT, 2002, ONCOGENE, V21, P6703, DOI 10.1038/sj.onc.1205882; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang EY, 2000, GENE DEV, V14, P45; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jepsen K, 2002, J CELL SCI, V115, P689; Jeyakumar M, 2007, J BIOL CHEM, V282, P9312, DOI 10.1074/jbc.M609009200; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin X.-Q., 2002, CO COMP SCI, V2; Johnson CA, 2002, J BIOL CHEM, V277, P9590, DOI 10.1074/jbc.M107942200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kao HY, 2000, GENE DEV, V14, P55; Karagiannis TC, 2007, LEUKEMIA, V21, P61, DOI 10.1038/sj.leu.2404464; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Li D, 2005, J BIOL CHEM, V280, P26941, DOI 10.1074/jbc.M500463200; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Li Y, 2006, GENE DEV, V20, P2566, DOI 10.1101/gad.1455006; Liby P, 2006, FOLIA BIOL-PRAGUE, V52, P21; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Longworth MS, 2006, ONCOGENE, V25, P4495, DOI 10.1038/sj.onc.1209473; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Monte M, 2006, P NATL ACAD SCI USA, V103, P11160, DOI 10.1073/pnas.0510834103; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Narita N, 2005, ONCOGENE, V24, P7346, DOI 10.1038/sj.onc.1208879; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Peng YC, 2001, MOL CELL BIOL, V21, P5913, DOI 10.1128/MCB.21.17.5913-5924.2001; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Pijnappel WWMP, 2001, GENE DEV, V15, P2991, DOI 10.1101/gad.207401; Racanicchi S, 2005, EMBO J, V24, P1232, DOI 10.1038/sj.emboj.7600593; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rowley J D, 1982, Natl Cancer Inst Monogr, V60, P17; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Smith WL, 1997, ACAD RADIOL, V4, P657, DOI 10.1016/S1076-6332(05)80273-9; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takami Y, 2000, J BIOL CHEM, V275, P16191, DOI 10.1074/jbc.M908066199; Tanaka Tomoyuki, 1997, Leukemia (Basingstoke), V11, P299; Thevenet L, 2004, EMBO J, V23, P3336, DOI 10.1038/sj.emboj.7600352; Uchida H, 1997, J IMMUNOL, V158, P2251; Vermeulen M, 2004, MOL CELL BIOL, V24, P2364, DOI 10.1128/MCB.24.6.2364-2372.2004; Vermeulen M, 2006, MOL CELL BIOL, V26, P5226, DOI 10.1128/MCB.00440-06; VIDALI G, 1978, P NATL ACAD SCI USA, V75, P2239, DOI 10.1073/pnas.75.5.2239; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Wang L, 1998, EUR T ELECTR POWER, V8, P21, DOI 10.1002/etep.4450080105; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Xia Y, 2007, MOL CELL, V25, P219, DOI 10.1016/j.molcel.2007.01.005; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Yin L, 2005, MOL ENDOCRINOL, V19, P1452, DOI 10.1210/me.2005-0057; Yoon HG, 2005, MOL CELL BIOL, V25, P324, DOI 10.1128/MCB.25.1.324-335.2005; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zeng LF, 2006, J CELL BIOL, V174, P1059, DOI 10.1083/jcb.200605113; Zhang DZ, 2005, MOL CELL BIOL, V25, P6404, DOI 10.1128/MCB.25.15.6404-6414.2005; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004	125	170	177	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5439	5449		10.1038/sj.onc.1210612	http://dx.doi.org/10.1038/sj.onc.1210612			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694085				2022-12-28	WOS:000248674300012
J	Kump, E; Ji, J; Wernli, M; Hausermann, P; Erb, P				Kump, E.; Ji, J.; Wernli, M.; Haeusermann, P.; Erb, P.			Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis	ONCOGENE			English	Article						Gli2; cFlip; apoptosis; basal cell carcinoma; gene silencing	HEDGEHOG SIGNALING PATHWAY; SKIN-CANCER; HUMAN EPIDERMIS; TUMOR-GROWTH; IN-VIVO; ACTIVATION; EXPRESSION; PROTEINS; INHIBITION; PROMOTER	Mutations in the Hedgehog signaling pathway is responsible for the formation of various cancers, including some forms of basal cell carcinoma (BCC). Uncontrolled Hedgehog signaling leads to overexpression of the zinc finger Gli transcription factors, among which Gli2 plays a central role. We found that high Gli2 expression induced the concomitant high expression of the caspase 8 inhibitor, cFlip, and thereby counteracts death-ligand-mediated apoptosis. By investigating the cFlip promoter, Gli2 binding sites were identified and confirmed. Gli2 gene silencing by RNA interference broke the apoptosis resistance via cFlip downregulation. The direct functional connection between Gli2 and cFlip was not only demonstrated in a keratinocytic cell line but also in BCC tissue. As cFlip and Bcl-2 are highly expressed in BCCs, as a consequence of high Gli2 expression, this may explain the marked resistance of the tumor to the extrinsic and intrinsic apoptotic pathway. We could now demonstrate that Gli2 gene silencing in BCC tissues made the tumor sensitive to TRAIL ( tumor necrosis factor-related apoptosis-inducing ligand)- mediated cell death by downregulating cFlip. As Gli2 silencing does not only downregulate cFlip, but also Bcl-2, Gli2 could be a key target for a novel therapeutic approach in tumors with dysregulated Hedgehog signaling.	[Kump, E.; Ji, J.; Wernli, M.; Erb, P.] Univ Basel, Dept Biomed, Inst Med Microbiol, CH-4003 Basel, Switzerland; [Haeusermann, P.] Univ Basel Hosp, Dept Dermatol, CH-4031 Basel, Switzerland	University of Basel; University of Basel	Erb, P (corresponding author), Univ Basel, Dept Biomed, Inst Med Microbiol, Peterspl 10, CH-4003 Basel, Switzerland.	peter.erb@unibas.ch						Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Bachmann F, 2001, J INVEST DERMATOL, V117, P59, DOI 10.1046/j.0022-202x.2001.01380.x; Bai CB, 2002, DEVELOPMENT, V129, P4753; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; Callahan CA, 2001, CURR OPIN GENET DEV, V11, P541, DOI 10.1016/S0959-437X(00)00230-6; Cohen MM, 2003, AM J MED GENET A, V123A, P5, DOI 10.1002/ajmg.a.20495; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Daya-Grosjean L, 2005, CANCER LETT, V225, P181, DOI 10.1016/j.canlet.2004.10.003; Delehedde M, 1999, CANCER, V85, P1514, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1514::AID-CNCR12>3.3.CO;2-H; Diepgen TL, 2002, BRIT J DERMATOL, V146, P1, DOI 10.1046/j.1365-2133.146.s61.2.x; Eichberger T, 2004, J INVEST DERMATOL, V122, P1180, DOI 10.1111/j.0022-202X.2004.22505.x; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Erb P, 2005, IMMUNOL LETT, V100, P68, DOI 10.1016/j.imlet.2005.06.008; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Igney FH, 2005, CANCER IMMUNOL IMMUN, V54, P1127, DOI 10.1007/s00262-005-0680-7; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ji J, 2005, GENE THER, V12, P678, DOI 10.1038/sj.gt.3302453; Ji J, 2008, INT J CANCER, V122, P50, DOI 10.1002/ijc.23023; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Miller KL, 2006, CARCINOGENESIS, V27, P1670, DOI 10.1093/carcin/bgi376; Nguyen V, 2005, DEVELOPMENT, V132, P3267, DOI 10.1242/dev.01905; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Park HL, 2000, DEVELOPMENT, V127, P1593; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Trisciuoglio D, 2005, J CELL PHYSIOL, V205, P414, DOI 10.1002/jcp.20413; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	33	46	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3856	3864		10.1038/onc.2008.5	http://dx.doi.org/10.1038/onc.2008.5			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264131				2022-12-28	WOS:000256904700009
J	Kwei, KA; Kim, YH; Girard, L; Kao, J; Pacyna-Gengelbach, M; Salari, K; Lee, J; Choi, YL; Sato, M; Wang, P; Hernandez-Boussard, T; Gazdar, AF; Petersen, I; Minna, JD; Pollack, JR				Kwei, K. A.; Kim, Y. H.; Girard, L.; Kao, J.; Pacyna-Gengelbach, M.; Salari, K.; Lee, J.; Choi, Y-L; Sato, M.; Wang, P.; Hernandez-Boussard, T.; Gazdar, A. F.; Petersen, I.; Minna, J. D.; Pollack, J. R.			Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer	ONCOGENE			English	Article						TITF1; lineage-specific oncogene; genomic profiling; lung cancer; TTF-1; NKX2-1	TRANSCRIPTION FACTOR-I; COPY NUMBER ALTERATION; GENE-EXPRESSION; BREAST-CANCER; PROSTATE-CANCER; REVEALS; ADENOCARCINOMAS; AMPLIFICATION; DEPENDENCY; MICROARRAY	Lung cancer is a leading cause of cancer death, where the amplification of oncogenes contributes to tumorigenesis. Genomic pro. ling of 128 lung cancer cell lines and tumors revealed frequent focal DNA amplification at cytoband 14q13.3, a locus not amplified in other tumor types. The smallest region of recurrent amplification spanned the homeobox transcription factor TITF1 (thyroid transcription factor 1; also called NKX2-1), previously linked to normal lung development and function. When amplified, TITF1 exhibited increased expression at both the RNA and protein levels. Small interfering RNA (siRNA)mediated knockdown of TITF1 in lung cancer cell lines with amplification led to reduced cell proliferation, manifested by both decreased cell-cycle progression and increased apoptosis. Our findings indicate that TITF1 amplification and overexpression contribute to lung cancer cell proliferation rates and survival and implicate TITF1 as a lineage-specific oncogene in lung cancer.	[Pollack, J. R.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Girard, L.; Sato, M.; Gazdar, A. F.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Pacyna-Gengelbach, M.; Petersen, I.] Univ Hosp Charite, Inst Pathol, Berlin, Germany; [Salari, K.; Hernandez-Boussard, T.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Choi, Y-L] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol, Seoul, South Korea; [Wang, P.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98195 USA	Stanford University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Stanford University; Sungkyunkwan University (SKKU); Samsung Medical Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Pollack, JR (corresponding author), Stanford Univ, Sch Med, Dept Pathol, CCSR-3245A,269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu	Sato, MITSUO/I-7280-2014	Sato, MITSUO/0000-0001-5458-9576	NATIONAL CANCER INSTITUTE [R01CA097139, P50CA070907, T32CA009151] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA070907-11, R01 CA097139-02, T32 CA009151-31, T32 CA009151, P50 CA070907-10, R01 CA97139, T32 CA09151, R01 CA097139, P50CA70907, P50 CA070907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kao J, 2006, GENE CHROMOSOME CANC, V45, P761, DOI 10.1002/gcc.20339; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Lechner JF, 2001, RADIAT RES, V155, P235, DOI 10.1667/0033-7587(2001)155[0235:PCDTMA]2.0.CO;2; Miccadei S, 2002, MOL ENDOCRINOL, V16, P837, DOI 10.1210/me.16.4.837; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Puglisi F, 1999, MODERN PATHOL, V12, P318; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Tan DF, 2003, HUM PATHOL, V34, P597, DOI 10.1016/S0046-8177(03)00180-1; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tian JM, 2006, CANCER RES, V66, P10399, DOI 10.1158/0008-5472.CAN-06-1564; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013; Travis WD., 2004, TRAVIS WB WHO CLASSI; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010	31	154	160	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3635	3640		10.1038/sj.onc.1211012	http://dx.doi.org/10.1038/sj.onc.1211012			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212743	Green Accepted			2022-12-28	WOS:000256468500015
J	Tao, WJ; Lin, H; Sun, T; Samanta, AK; Arlinghaus, R				Tao, W. J.; Lin, H.; Sun, T.; Samanta, A. K.; Arlinghaus, R.			BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor	ONCOGENE			English	Article						BCR-ABL; interleukin-3 receptor; leukemia; oncogenic transformation	TYROSINE PHOSPHORYLATION; MYELOID-LEUKEMIA; CELLS; JAK2; P210; ACTIVATION; INHIBITOR; BCR/ABL; GROWTH; MYC	Oncogenic transformation of hematopoietic cells by the Bcr-Abl oncoprotein directly involves the activation Jak2 tyrosine kinase and the Stat5 transcription factor. Both proteins are normally linked to the interleukin (IL)-3/granulocyte- macrophage colony-stimulating factor receptors for growth and survival. Since fibroblastic cells are not targets of BCR-ABL-induced oncogenesis, we determined whether forced expression of the IL-3 receptor would allow oncogenic transformation of NIH 3T3 fibroblasts known to be resistant to transformation by BCR-ABL. NIH 3T3 cells transduced with the human IL-3 receptor alpha and beta chains were highly susceptible to oncogenic transformation by expression of BCR-ABL. Forced expression of both receptor chains but not either one alone allowed efficient foci formation of NIH 3T3 cells expressing BCR-ABL (triple positive cells), and these cells formed colonies in soft agar, whereas BCR-ABL+ NIH 3T3 cells lacking IL-3 receptor expression did not. Signaling studies indicate that the BCR-ABL/IL-3 receptor+ NIH 3T3 cells utilize the Gab2/PI-3 kinase pathway activated by Jak2, and the Stat5 pathway activated separately by Bcr-Abl, whereas BCR-ABL+ NIH 3T3 cells lacking the IL-3 receptor do not utilize the Jak2 pathway, but still maintain activation of Stat5. The Bcr-Abl kinase inhibitor imatinib mesylate (1 mu M) and two Jak2 kinase inhibitors strongly inhibited agar colony formation and the activation of Gab2 caused by Jak2. All of these findings indicate that Bcr-Abl oncoprotein requires the IL-3 receptor/Jak2/Stat5 pathways for oncogenic transformation of NIH 3T3 fibroblasts.	[Tao, W. J.; Lin, H.; Sun, T.; Samanta, A. K.; Arlinghaus, R.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, 7435 Fannin St,Unit 951, Houston, TX 77054 USA.	rarlingh@mdanderson.org			NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [CA49639, P01 CA049639-09A10019, P01 CA049639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; GROFFEN J, 1993, LEUKEMIA LYMPHOMA, V11, P19, DOI 10.3109/10428199309047857; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Miyamoto N, 2001, LEUKEMIA, V15, P1758, DOI 10.1038/sj.leu.2402260; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Sandberg EM, 2005, J MED CHEM, V48, P2526, DOI 10.1021/jm049470k; SIRARD C, 1994, BLOOD, V83, P1575; Watanabe Sumiko, 1997, Leukemia (Basingstoke), V11, P76; WilsonRawls J, 1996, CANCER RES, V56, P3426; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; YOKOTA T, 1993, LEUKEMIA, V7, pS102	16	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3194	3200		10.1038/sj.onc.1210979	http://dx.doi.org/10.1038/sj.onc.1210979			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071309	Green Accepted			2022-12-28	WOS:000255897600012
J	Tao, Y; Zhang, P; Girdler, F; Frascogna, V; Castedo, M; Bourhis, J; Kroemer, G; Deutsch, E				Tao, Y.; Zhang, P.; Girdler, F.; Frascogna, V.; Castedo, M.; Bourhis, J.; Kroemer, G.; Deutsch, E.			Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152	ONCOGENE			English	Article						cell cycle; checkpoints; AZD1152 Aurora-B; ionizing radiation; p53	SPINDLE ASSEMBLY CHECKPOINT; MITOTIC CATASTROPHE; DNA-DAMAGE; P53; APOPTOSIS; PHOSPHORYLATION; DIVISION; VX-680; GROWTH; DEATH	Overexpression of the Aurora-B kinase correlates with oncogenic transformation and poor prognosis. We evaluated the effects of the bona. de Aurora-B kinase inhibitor AZD1152 on tumor responses to ionizing radiation (IR). When p53(wt) HCT116 and A549 cells were pretreated with AZD1152-HQPA prior to IR, additive effects were observed. Interestingly, more pronounced tumoricidal effects were observed in p53-deficient HCT116 and HT29 cells, as well as A549 cells treated with the p53 inhibitor cyclic pifithrin-a. In vivo studies on xenografted mice confirmed enhanced tumor growth delay after the combination of IR plus AZD1152-IR as compared to IR alone. Again, this effect was more pronounced with p53(-/-) HCT116 and p53-mutant xenografts. The AZD1152-mediated radiosensitization was mimicked by knockdown of Aurora-B with a short interference RNA or by inhibition of Aurora-B by transfection with an inducible kinase-dead Aurora-B. The radiosensitizing effect of AZD1152 was lost in CHK2(-/-) and 14-3-3(-/-) HCT116 cells. Altogether, these data indicate that AZD1152 can radiosensitize tumor cell lines in vitro and in vivo, the fact that these effects are exacerbated in p53-deficient cancer cells is of potential interest for further clinical development.	[Tao, Y.; Zhang, P.; Frascogna, V.; Bourhis, J.; Deutsch, E.] Inst Gustave Roussy, PRI, Lab UPRES Radiosensit Tumors & Normal Tissues EA2, F-94805 Villejuif, France; [Tao, Y.; Bourhis, J.; Kroemer, G.] Univ Paris 11, Le Kremlin Bicetre, France; [Tao, Y.] Fu Dan Hosp, Canc Hosp, Shanghai, Peoples R China; [Girdler, F.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Castedo, M.; Kroemer, G.] INSERM, U848, Villejuif, France; [Tao, Y.; Zhang, P.; Frascogna, V.; Castedo, M.; Bourhis, J.; Kroemer, G.; Deutsch, E.] Inst Gustave Roussy, Villejuif, France	UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Fudan University; University of Manchester; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Deutsch, E (corresponding author), Inst Gustave Roussy, PRI, Lab UPRES Radiosensit Tumors & Normal Tissues EA2, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	deutsch@igr.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405; deutsch, eric/0000-0002-8223-3697; Bourhis, Jean/0000-0001-5162-1171; Zhang, Ping/0000-0002-3043-8738; tao, yungan/0000-0002-6916-5263				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2005, ONCOGENE, V24, P5005, DOI 10.1038/sj.onc.1208752; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gadea BB, 2005, MOL BIOL CELL, V16, P1305, DOI 10.1091/mbc.E04-10-0891; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Girdler F, 2006, J CELL SCI, V119, P3664, DOI 10.1242/jcs.03145; Gizatullin F, 2006, CANCER RES, V66, P7668, DOI 10.1158/0008-5472.CAN-05-3353; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Milas L, 1999, SEMIN RADIAT ONCOL, V9, P12; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Wilkinson RW, 2007, CLIN CANCER RES, V13, P3682, DOI 10.1158/1078-0432.CCR-06-2979; Zhang P, 2006, ONCOGENE, V25, P7758, DOI 10.1038/sj.onc.1209744; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	31	77	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3244	3255		10.1038/sj.onc.1210990	http://dx.doi.org/10.1038/sj.onc.1210990			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084327				2022-12-28	WOS:000256111400003
J	Colo, GP; Rubio, MF; Nojek, IM; Werbajh, SE; Echeverria, PC; Alvarado, CV; Nahmod, VE; Galigniana, MD; Costas, MA				Colo, G. P.; Rubio, M. F.; Nojek, I. M.; Werbajh, S. E.; Echeverria, P. C.; Alvarado, C. V.; Nahmod, V. E.; Galigniana, M. D.; Costas, M. A.			The p160 nuclear receptor co-activator RAC3 exerts an anti-apoptotic role through a cytoplasmatic action	ONCOGENE			English	Article						apoptosis; NF-kappa B; peroxides; nuclear receptor co-activators; MAP kinases	NF-KAPPA-B; TRANSCRIPTIONAL COACTIVATOR; EXPRESSION; AIB1; PROTEIN; BREAST; ACTIVATION; PATHWAY; GROWTH; STRESS	The p160 nuclear receptor co- activators represent a family of molecules, which are recruited by steroid nuclear receptors as well as other transcription factors that are overexpressed in several tumors. We investigated the role of one member of this family on the sensitivity of cells to apoptosis. We observed that overexpression of the RAC3 ( receptor- associated co- activator- 3) p160 co- activator inhibits hydrogen peroxide- induced cell death in human embryonic kidney 293 ( HEK293) cells. The mechanism involves the activation of anti- apoptotic pathways mediated through enhanced nuclear factor kappa B ( NF-kappa B) activity, inhibition of caspase- 9 activation, diminished apoptotic- inducing factor ( AIF) nuclear localization and a change in the activation pattern of several kinases, including an increase in both AKT and p38 kinase activities, and inhibition of ERK2. Moreover, RAC3 has been found associated with a protein complex containing AIF, Hsp90 and dynein, suggesting a role for the coactivator in the cytoplasmatic nuclear transport of these proteins associated with cytoskeleton. These results demonstrate that there are several molecular pathways that could be affected by their overexpression, including those not restricted to steroid regulation or the nuclear action of co- activators, which results in diminished sensitivity to apoptosis. Furthermore, this could represent one mechanism by which co- activators contribute to tumor development.	[Colo, G. P.; Rubio, M. F.; Nojek, I. M.; Werbajh, S. E.; Echeverria, P. C.; Alvarado, C. V.; Nahmod, V. E.; Costas, M. A.] Univ Buenos Aires, CONICET, Argentine Natl Res Council, Inst Invest Med Alfredo Lanari IDIM,Lab Biol Mol, Buenos Aires, DF, Argentina; [Galigniana, M. D.] Fdn Inst Leloir, Lab Receptores Nucl & Arquitectura Nucl, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Leloir Institute	Costas, MA (corresponding author), Univ Buenos Aires, CONICET, Argentine Natl Res Council, Inst Invest Med Alfredo Lanari IDIM,Lab Biol Mol, Combatientes Malvinas 3150,Cuerpo 2-Piso 1, Buenos Aires, DF, Argentina.	mcostas@lanari.fmed.uba.ar	Echeverria, Pablo Christian/A-9098-2010	Echeverria, Pablo Christian/0000-0003-1367-9692; Costas, Monica/0000-0002-4773-3389; GALIGNIANA, MARIO/0000-0002-9130-8574; Alvarado, Cecilia/0000-0003-3147-747X	FIC NIH HHS [R03TW007162-01A2] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW007162] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cavarretta ITR, 2002, MOL ENDOCRINOL, V16, P253, DOI 10.1210/me.16.2.253; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; Costas MA, 2000, BBA-MOL CELL RES, V1499, P122, DOI 10.1016/S0167-4889(00)00113-0; Coste A, 2006, EMBO J, V25, P2453, DOI 10.1038/sj.emboj.7601106; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Franco D, 2002, CELL DEATH DIFFER, V9, P1090, DOI 10.1038/sj.cdd.4401074; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Glaeser M, 2001, HORM METAB RES, V33, P121, DOI 10.1055/s-2001-14938; Glass CK, 2000, GENE DEV, V14, P121; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Iwase H, 2003, BREAST CANCER RES TR, V80, P339, DOI 10.1023/A:1024916126532; Katoh I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200; Kultz D, 1998, J EXP BIOL, V201, P3015; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; ONATE SA, 1995, SCIENCE, V270, P1354; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Park BG, 2005, TOXICOLOGY, V215, P115, DOI 10.1016/j.tox.2005.07.003; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rubio MF, 2006, ONCOGENE, V25, P1367, DOI 10.1038/sj.onc.1209176; Sakakura C, 2000, INT J CANCER, V89, P217; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yan J, 2006, ACTA PHARMACOL SIN, V27, P387, DOI 10.1111/j.1745-7254.2006.00315.x; Zhang L, 2001, CELL DEATH DIFFER, V8, P528, DOI 10.1038/sj.cdd.4400838; Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003	50	45	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2430	2444		10.1038/sj.onc.1210900	http://dx.doi.org/10.1038/sj.onc.1210900			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968310				2022-12-28	WOS:000254844900008
J	Scian, MJ; Carchman, EH; Mohanraj, L; Stagliano, KER; Anderson, MAE; Deb, D; Crane, BM; Kiyono, T; Windle, B; Deb, SP; Deb, S				Scian, M. J.; Carchman, E. H.; Mohanraj, L.; Stagliano, K. E. R.; Anderson, M. A. E.; Deb, D.; Crane, B. M.; Kiyono, T.; Windle, B.; Deb, S. P.; Deb, S.			Wild-type p53 and p73 negatively regulate expression of proliferation related genes	ONCOGENE			English	Article						wild-type p53; transcriptional repression; cell cycle; DNA replication; microarray analysis	P53-MEDIATED TRANSCRIPTIONAL REPRESSION; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; DNA-DAMAGE; INDUCED APOPTOSIS; G(2)/M PROMOTERS; VIRAL PROMOTERS; PROTEIN; IDENTIFICATION; MODULATION	When normal cells come under stress, the wild-type (WT) p53 level increases resulting in the regulation of gene expression responsible for growth arrest or apoptosis. Here we show that elevated levels of WT p53 or its homologue, p73, inhibit expression of a number of cell cycle regulatory and growth promoting genes. Our analysis also identified a group of genes whose expression is differentially regulated by WT p53 and p73. We have infected p53-null H1299 human lung carcinoma cells with recombinant adenoviruses expressing WT p53, p73 or beta-galactosidase, and have undertaken microarray hybridization analyses to identify genes whose expression pro. le is altered by p53 or p73. Quantitative real-time PCR verified the repression of E2F5, centromere protein A and E, minichromosome maintenance proteins (MCM)-2, -3, -5, -6 and -7 and human CDC25B after p53 expression. 5-Fluorouracil treatment of col on carcinoma HCT116 cells expressing WT p53 results in a reduction of the cyclin B2 protein level suggesting that DNA damage may indeed cause repression of the se genes. Transient transcriptional assays verified that WT p53 repressed promoters of a number of these genes. Interestingly, a gain-of-function p53 mutant instead upregulated a number of the se promoters in transient transfection. Using promoter deletion mutants of MCM-7 we have found that WT p53-mediated repression needs a minimal promoter that contains a single E2F site and surrounding sequences. However, a single E2F site cannot be significantly repressed by WT p53. Many of the genes identified are also repressed by p21. Thus, our work shows that WT p53 and p73 repress a number of growth-related genes and that in many instances this repression may be through the induction of p21.	[Scian, M. J.; Carchman, E. H.; Mohanraj, L.; Stagliano, K. E. R.; Anderson, M. A. E.; Deb, D.; Crane, B. M.; Deb, S. P.; Deb, S.] Virginia Commonwealth Univ, Goodwin Res Lab, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Scian, M. J.; Carchman, E. H.; Mohanraj, L.; Stagliano, K. E. R.; Anderson, M. A. E.; Deb, D.; Crane, B. M.; Deb, S. P.; Deb, S.] Virginia Commonwealth Univ, Goodwin Res Lab, Massey Canc Ctr, Richmond, VA 23298 USA; [Kiyono, T.] Natl Canc Ctr, Res Inst, Div Virol, Tokyo 104, Japan; [Windle, B.] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Center - Japan; Virginia Commonwealth University	Deb, S (corresponding author), Virginia Commonwealth Univ, Goodwin Res Lab, Dept Biochem & Mol Biol, 401 Coll St, Richmond, VA 23298 USA.	sdeb@vcu.edu	Kiyono, Tohru/H-5834-2011	Anderson, Michelle/0000-0003-1510-2942	NATIONAL CANCER INSTITUTE [R01CA074172, F31CA097520, R01CA070712] Funding Source: NIH RePORTER; NCI NIH HHS [CA70712, CA74172, F31-CA97520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldaz CM, 2002, ONCOGENE, V21, P6366, DOI 10.1038/sj.onc.1205816; Altschmied J, 1997, BIOTECHNIQUES, V23, P436, DOI 10.2144/97233bm19; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Basile V, 2006, J BIOL CHEM, V281, P2347, DOI 10.1074/jbc.M507712200; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chae HD, 2005, EXP MOL MED, V37, P488, DOI 10.1038/emm.2005.60; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Deb D, 2002, ONCOGENE, V21, P176, DOI 10.1038/sj/onc/1205035; Deb D, 2001, INT J ONCOL, V18, P401; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Ichimiya S, 2001, MED PEDIATR ONCOL, V36, P42, DOI 10.1002/1096-911X(20010101)36:1<42::AID-MPO1011>3.0.CO;2-K; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Korner K, 2001, J BIOL CHEM, V276, P9662, DOI 10.1074/jbc.M008696200; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kubicka S, 1999, J BIOL CHEM, V274, P32137, DOI 10.1074/jbc.274.45.32137; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Maeda Y, 2006, BIOCHEM J, V400, P303, DOI 10.1042/BJ20060614; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 2003, MOL CANCER RES, V1, P1001; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Prives C, 1999, J PATHOL, V187, P112; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Scoumanne A, 2006, CANCER RES, V66, P6271, DOI 10.1158/0008-5472.CAN-06-0121; Sengupta S, 2005, ONCOGENE, V24, P1738, DOI 10.1038/sj.onc.1208380; Senoo M, 2001, BIOCHEM BIOPH RES CO, V286, P628, DOI 10.1006/bbrc.2001.5429; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; Stagliano Katherine E Roth, 2003, Methods Mol Biol, V234, P73; Stanelle J, 2003, CARDIOVASC RES, V59, P512, DOI 10.1016/S0008-6363(03)00392-4; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Tannapfel A, 2000, DIGEST DIS SCI, V45, P317, DOI 10.1023/A:1005412626515; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Thibault C, 2001, INT REV NEUROBIOL, V48, P219, DOI 10.1016/S0074-7742(01)48017-2; Urist M, 2002, CANCER CELL, V1, P311, DOI 10.1016/S1535-6108(02)00064-8; Valerie E, 1999, UROLOGY, V54, P1082, DOI 10.1016/S0090-4295(99)00311-8; Van Bodegom D, 2006, J BIOL CHEM, V281, P31234, DOI 10.1074/jbc.M606510200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Zhang LL, 2000, CANCER RES, V60, P3655; Zhao R, 2000, COLD SPRING HARB SYM, V65, P475, DOI 10.1101/sqb.2000.65.475	69	60	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2583	2593		10.1038/sj.onc.1210898	http://dx.doi.org/10.1038/sj.onc.1210898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982488				2022-12-28	WOS:000255057000008
J	Mahanivong, C; Chen, HM; Yee, SW; Pan, ZK; Dong, Z; Huang, S				Mahanivong, C.; Chen, H. M.; Yee, S. W.; Pan, Z. K.; Dong, Z.; Huang, S.			Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; LPA; uPA; NF-kappa B	GROWTH-FACTOR EXPRESSION; EPITHELIAL-CELLS; RECEPTOR; TUMOR; BCL10; LYSOPHOSPHOLIPIDS; PHOSPHORYLATION; PROGRESSION; INDUCTION; SECRETION	We reported previously that a signaling pathway consisting of G(i)-Ras-NF-kappa B mediates lysophosphatidic acid (LPA)-induced urokinase plasminogen activator (uPA) upregulation in ovarian cancer cells. However, it is not clear what signaling components link Ras to nuclear factor (NF)-kappa B for this LPA-induced event. In the present study, we found that treatment of protein kinase C (PKC) inhibitors including conventional PKC (cPKC) inhibitor Go6976 abolished LPA-induced uPA upregulation in ovarian cancer cell lines tested, indicating the importance of cPKC activity in this LPA-induced event. Indeed, LPA stimulation led to the activation of PKC alpha and Ras-PKC alpha interaction. Although constitutively active mutants of PKC alpha (a cPKC), PKC theta (a novel PKC (nPKC)) and PKC zeta (an atypical PKC (aPKC)) were all able to activate NF-kappa B and upregulate uPA expression, only dominant-negative PKCa mutant attenuated LPA-induced NF-kappa B activation and uPA upregulation. These results suggest that PKCa, rather than PKC isoforms in other PKC classes, participates in LPA-induced NF-kappa B activation and uPA upregulation in ovarian cancer cells. To determine the signaling components downstream of PKC alpha mediating LPA-induced uPA upregulation, we showed that forced expression of dominant-negative CARMA3 or silencing CARMA3, Bcl10 and MALT1 with specific siRNAs diminished these LPA-induced events. Furthermore, we demonstrated that PKC alpha/CARMA3 signaling axis is important in LPA-induced ovarian cancer cell in vitro invasion.	[Mahanivong, C.; Chen, H. M.; Yee, S. W.; Huang, S.] Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Pan, Z. K.] Med Univ Ohio, Dept Med Microbiol & Immunol, Toledo, OH USA; [Dong, Z.] Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Huang, S (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	shuang@mcg.edu		Yee, Sook Wah/0000-0001-8121-8746	NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043524] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093926, R01 CA93926] Funding Source: Medline; NIAID NIH HHS [R01 AI043524, R01 AI043524-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Birgbauer E, 2006, CELL MOL LIFE SCI, V63, P2695, DOI 10.1007/s00018-006-6155-y; Corbalan-Garcia S, 2006, BBA-MOL CELL BIOL L, V1761, P633, DOI 10.1016/j.bbalip.2006.04.015; Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; Do TV, 2007, MOL CANCER RES, V5, P121, DOI 10.1158/1541-7786.MCR-06-0319; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fischer K, 1998, FEBS LETT, V438, P101, DOI 10.1016/S0014-5793(98)01279-4; Fishman DA, 2001, CANCER RES, V61, P3194; Grabiner BC, 2007, GENE DEV, V21, P984, DOI 10.1101/gad.1502507; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Klemm S, 2007, P NATL ACAD SCI USA, V104, P134, DOI 10.1073/pnas.0608388103; Konecny G, 2001, CLIN CANCER RES, V7, P1743; LaVallie ER, 2006, J BIOL CHEM, V281, P24124, DOI 10.1074/jbc.M601905200; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Matsumoto R, 2005, IMMUNITY, V23, P575, DOI 10.1016/j.immuni.2005.10.007; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Murthi P, 2004, GYNECOL ONCOL, V92, P80, DOI 10.1016/j.ygyno.2003.09.016; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Perletti GP, 1996, ONCOGENE, V12, P847; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; SCHMALFELDT B, 1995, CANCER RES, V55, P3958; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Suzuki M, 2004, J BIOL CHEM, V279, P14899, DOI 10.1074/jbc.M313130200; Tanyi JL, 2003, CANCER RES, V63, P1073; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wang DH, 2007, P NATL ACAD SCI USA, V104, P145, DOI 10.1073/pnas.0601894104; Wang P, 2007, GYNECOL ONCOL, V104, P714, DOI 10.1016/j.ygyno.2006.10.016; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719	33	63	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1273	1280		10.1038/sj.onc.1210746	http://dx.doi.org/10.1038/sj.onc.1210746			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724468	Green Accepted			2022-12-28	WOS:000253407000009
J	Yoshida, K; Ozaki, T; Furuya, K; Nakanishi, M; Kikuchi, H; Yamamoto, H; Ono, S; Koda, T; Omura, K; Nakagawara, A				Yoshida, K.; Ozaki, T.; Furuya, K.; Nakanishi, M.; Kikuchi, H.; Yamamoto, H.; Ono, S.; Koda, T.; Omura, K.; Nakagawara, A.			ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin	ONCOGENE			English	Article						apoptosis; ATM; cisplatin; IKK; p73; ubiquitination	B-KINASE-ALPHA; MICE LACKING; LIVER DEGENERATION; KAPPA; PHOSPHORYLATION; ACTIVATION; SUBUNIT; SKIN	I kappa B kinase ( IKK) complex plays an important role in the regulation of signaling pathway that activates nuclear factor-kappa-B (NF-kappa B). Recently, we reported that cisplatin ( CDDP) treatment causes a remarkable nuclear accumulation of IKK-alpha in association with stabilization and activation of p73. However, underlying mechanisms of CDDP-induced nuclear accumulation of IKK-alpha are elusive. Here, we found that ataxia-telangiectasia mutated ( ATM) is one of upstream mediators of IKK-alpha during CDDP-induced apoptosis. In response to CDDP, ATM was phosphorylated at Ser-1981, which was accompanied with nuclear accumulation of IKK-alpha in HepG2 cells, whereas CDDP treatment had undetectable effects on IKK-alpha in ATM-deficient cells. Indirect immuno fluorescence experiments demonstrated that phosphorylated form of ATM colocalizes with nuclear IKK-alpha in response to CDDP. In vitro kinase assay indicated that ATM phosphorylates IKK-alpha at Ser-473. Moreover, IKK-alpha-deficient MEFs displayed CDDP-resistant phenotype as compared with wild-type MEFs. Taken together, our present results suggest that ATM-mediated phosphorylation of nuclear IKK-alpha, which stabilizes p73, is one of the main apoptotic pathways in response to CDDP.	[Yoshida, K.; Ozaki, T.; Furuya, K.; Nakanishi, M.; Kikuchi, H.; Yamamoto, H.; Nakagawara, A.] Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Yoshida, K.; Omura, K.] Tokyo Med & Dent Univ, Dept Oral & Maxillofacial Surg, Tokyo, Japan; [Ono, S.; Koda, T.] Hisamitsu Pharmaceut Co Inc, Res Ctr Funct Genom, Chiba, Japan	Chiba Cancer Center; Tokyo Medical & Dental University (TMDU); Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Furuya K, 2007, J BIOL CHEM, V282, P18365, DOI 10.1074/jbc.M610522200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Saito H, 2002, GYNECOL OBSTET INVES, V53, P46, DOI 10.1159/000049424; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576	21	41	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1183	1188		10.1038/sj.onc.1210722	http://dx.doi.org/10.1038/sj.onc.1210722			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700524				2022-12-28	WOS:000253136700019
J	Veeck, J; Chorovicer, M; Naami, A; Breuer, E; Zafrakas, M; Bektas, N; Durst, M; Kristiansen, G; Wild, PJ; Hartmann, A; Knuechel, R; Dahl, E				Veeck, J.; Chorovicer, M.; Naami, A.; Breuer, E.; Zafrakas, M.; Bektas, N.; Duerst, M.; Kristiansen, G.; Wild, P. J.; Hartmann, A.; Knuechel, R.; Dahl, E.			The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation	ONCOGENE			English	Article						inter-alpha-trypsin inhibitor heavy chain ( ITIH); breast cancer; prognostic marker; predictive marker; tumour invasion; metastasis	ALPHA-TRYPSIN INHIBITOR; FACTOR-STIMULATED GENE-6; SHAP-HYALURONAN COMPLEX; TUMOR-SUPPRESSOR GENES; DNA METHYLATION; HEAVY-CHAIN; OVARIAN-CANCER; FAMILY; BINDING; TISSUE	Inter-alpha-trypsin inhibitors (ITIs) are protease inhibitors stabilizing the extracellular matrix. ITIs consist of one light (bikunin) and two heavy chains (ITIHs). We have recently characterized ITIH5, a novel member of the ITIH gene family, and showed that its messenger RNA is lost in a high proportion of breast tumours. In the present study, an ITIH5-specific polyclonal antibody was generated, validated with western blot and used for immunohistochemical analysis on a tissue microarray; ITIH5 was strongly expressed in epithelial cells of normal breast (n = 11/15), while it was lost or strongly reduced in 42% (92/217) of invasive breast cancers. ITIH5 expression in invasive carcinomas was associated with positive expression of oestrogen receptor (P = 0.008) and histological grade (P = 0.024). Correlation of ITIH5 expression with clinical outcome revealed that patients with primary tumours retaining abundant ITIH5 expression had longer recurrence-free survival (RFS; P = 0.037) and overall survival (OS; P = 0.044), compared to those with reduced expression (mean RFS: 102 vs 78 months; mean OS: 120 vs 105 months). Methylation-specific PCR analysis frequently showed strong methylation of the ITIH5 promoter in primary breast tumours (41%, n = 109) and breast cancer cell lines (n = 6). Methylation was significantly associated with mRNA loss (P<0.001; n = 39), and ITIH5 expression was induced after treatment of tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine. Moreover, ITIH5 promoter methylation was significantly associated with reduced OS (P = 0.008). The cellular function of ITIH5 was evaluated by forced expression of a full-length ITIH5 complementary DNA in the breast cancer cell line MDA-MB-231, which does not endogenously express ITIH5. ITIH5-expressing clones showed a 40% reduced proliferation rate compared to mock-transfected cells. Overall, these data show that promoter methylation-mediated loss of ITIH5 expression is associated with unfavourable outcome in breast cancer patients, and thus ITIH5 could be used as a prognostic marker, although this marker is not multivariate independent due to its close association with ER expression. Our data indicate that ITIH5 is a candidate class II tumour suppressor gene and could be involved in tumour progression, invasion and metastasis, as its absence is associated with increased proliferation rates and a prognostic value indicating poor clinical outcome.	[Veeck, J.; Chorovicer, M.; Naami, A.; Breuer, E.; Zafrakas, M.; Bektas, N.; Knuechel, R.; Dahl, E.] Rhein Westfal TH Aachen, Univ Hosp Aachen, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany; [Duerst, M.] Univ Jena, Dept Gynecol & Obstet, Jena, Germany; [Kristiansen, G.] Univ Med Berlin, Inst Pathol, Berlin, Germany; [Wild, P. J.] Univ Zurich, Inst Pathol, Zurich, Switzerland; [Hartmann, A.] Univ Regensburg, Inst Pathol, Regensburg, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; University of Regensburg	Dahl, E (corresponding author), Rhein Westfal TH Aachen, Univ Hosp Aachen, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	, Zafrakas-M/ABA-8487-2021; Veeck, Jürgen/B-9256-2008	Veeck, Jürgen/0000-0002-2952-6159				Atmani F, 1999, UROL RES, V27, P57, DOI 10.1007/s002400050089; Bachman KE, 1999, CANCER RES, V59, P798; Balduyck M, 2000, J LAB CLIN MED, V135, P188, DOI 10.1067/mlc.2000.104462; Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x; Bourguignon J, 1999, J HISTOCHEM CYTOCHEM, V47, P1625, DOI 10.1177/002215549904701214; CHEN L, 1994, J BIOL CHEM, V269, P28282; Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687; Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Esteller M, 1999, CANCER RES, V59, P67; Fujita Y, 2004, J HUM GENET, V49, P24, DOI 10.1007/s10038-003-0101-8; GRAFF JR, 1995, CANCER RES, V55, P5195; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Himmelfarb M, 2004, CANCER LETT, V204, P69, DOI 10.1016/j.canlet.2003.09.011; HUANG L, 1993, J BIOL CHEM, V268, P26725; Janssen U, 2001, KIDNEY INT, V60, P126, DOI 10.1046/j.1523-1755.2001.00779.x; Jessen TE, 2003, REPRODUCTION, V125, P27, DOI 10.1530/rep.0.1250027; KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361; Onda H, 1999, J CEREBR BLOOD F MET, V19, P1279, DOI 10.1097/00004647-199911000-00013; Paris S, 2002, INT J CANCER, V97, P615, DOI 10.1002/ijc.10120; Pineiro M, 2004, INFECT IMMUN, V72, P3777, DOI 10.1128/IAI.72.7.3777-3782.2004; REMMELE W, 1987, PATHOLOGE, V8, P138; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Sanggaard KW, 2005, J BIOL CHEM, V280, P11936, DOI 10.1074/jbc.M409016200; Shao GZ, 2006, CANCER RES, V66, P4566, DOI 10.1158/0008-5472.CAN-05-2130; Sobin L., 1997, UICC TNM CLASSIFICAT, P184; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; YONEDA M, 1990, J BIOL CHEM, V265, P5247; Zhang Z, 2004, CANCER RES, V64, P5882, DOI 10.1158/0008-5472.CAN-04-0746; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	39	64	68	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					865	876		10.1038/sj.onc.1210669	http://dx.doi.org/10.1038/sj.onc.1210669			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653090				2022-12-28	WOS:000252884500016
J	Lee, KC; Goh, WLP; Xu, M; Kua, N; Lunny, D; Wong, JS; Coomber, D; Vojtesek, B; Lane, EB; Lane, DP				Lee, K-C; Goh, W. L. P.; Xu, M.; Kua, N.; Lunny, D.; Wong, J. S.; Coomber, D.; Vojtesek, B.; Lane, E. B.; Lane, D. P.			Detection of the p53 response in zebrafish embryos using new monoclonal antibodies	ONCOGENE			English	Article						zebrafish; p53; monoclonal antibody; immunohistochemistry; p53-activating agents	DANIO-RERIO; MUTANT P53; GENE; EXPRESSION; MUTATIONS; PROTEIN; IDENTIFICATION; ACTIVATION; INDUCTION; NEOPLASIA	The zebrafish has many advantages as a vertebrate model organism and has been extensively used in the studies of development. Its potential as a model in which to study tumour suppressor and oncogene function is now being realized. Whilst in situ hybridization of mRNA has been well developed in this species to study gene expression, antibody probes are in short supply. We have, therefore, generated a panel of anti-zebrafish p53 monoclonal antibodies and used these to study the p53 response in zebrafish embryos. By immunohistochemistry, we show that the exposure of zebrafish embryos to p53-activating agents such as R-roscovitine and c-irradiation results in the accumulation of p53 protein in the gut epithelium, liver and pancreas. A combination of R-roscovitine and gamma-irradiation results in massive p53 induction, not only in the pharyngeal arches, gut region and liver but also in brain tissues. Induction of apoptosis and expression of p53 response genes are seen in regions that correspond to sites of p53 protein accumulation. In contrast, although zebrafish tp53(M214K) mutant embryos showed a similar accumulation of p53 protein, a complete lack of a downstream p53-dependent response was observed. In this system the p53 gene is identified as a p53-responsive gene itself. Our results demonstrate that zebrafish p53 protein can readily be induced in embryos and detected using these new antibody tools, which will increase the usefulness of zebrafish as a model in compound-based screening for novel drugs in cancer research.	[Lee, K-C; Goh, W. L. P.; Xu, M.; Kua, N.; Wong, J. S.; Coomber, D.; Vojtesek, B.; Lane, D. P.] Inst Mol & Cell Biol, Control Pathway Lab P53, Proteos 138673, Singapore; [Lunny, D.; Lane, E. B.] Med Biol Inst, Epithelial Biol Programme, Proteos, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Lane, DP (corresponding author), Inst Mol & Cell Biol, Control Pathway Lab P53, 61 Biopolis Dr, Proteos 138673, Singapore.	d.p.lane@imcb.a-star.edu.sg	Lane, David P/C-4920-2008; Lee, Kian-Chung/AAP-9059-2021	Lane, David/0000-0003-0551-3545				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; BARTEK J, 1990, ONCOGENE, V5, P893; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Chen J, 2005, GENE DEV, V19, P2900, DOI 10.1101/gad.1366405; Cheng R, 1997, MOL MAR BIOL BIOTECH, V6, P88; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARLOW E, 1988, ANTIBODIES LAB MANUA, P186; HARLOW E, 1999, USING ANTIBODIES LAB, P395; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Jowett T, 1999, METHOD CELL BIOL, V59, P63; KASTAN MB, 1991, CANCER RES, V51, P6304; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kotala V, 2001, CELL MOL LIFE SCI, V58, P1333, DOI 10.1007/PL00000944; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lu WG, 2001, ONCOGENE, V20, P3206, DOI 10.1038/sj.onc.1204412; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nickels A, 1997, J CLIN PATHOL, V50, P654, DOI 10.1136/jcp.50.8.654; Nusslein-Volhard C., 2002, ZEBRAFISH PRACTICAL; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Ribas J, 2006, EXP CELL RES, V312, P2394, DOI 10.1016/j.yexcr.2006.04.021; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Spitsbergen Jan M., 2003, Toxicologic Pathology, V31, P62, DOI 10.1080/01926230309774; Spitsbergen JM, 2000, TOXICOL PATHOL, V28, P716, DOI 10.1177/019262330002800512; STANTON MF, 1965, JNCI-J NATL CANCER I, V34, P117, DOI 10.1093/jnci/34.1.117; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Sutcliffe JE, 2004, FEBS LETT, V567, P86, DOI 10.1016/j.febslet.2004.03.122; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Zhao L, 2003, MOL CANCER RES, V1, P195	41	56	57	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					629	640		10.1038/sj.onc.1210695	http://dx.doi.org/10.1038/sj.onc.1210695			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684488				2022-12-28	WOS:000252674900007
J	Yang, F; Strand, DW; Rowley, DR				Yang, F.; Strand, D. W.; Rowley, D. R.			Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma	ONCOGENE			English	Article						transforming growth factor-beta; fibroblast growth factor; prostate cancer; stroma; angiogenesis	MOUSE MODEL; EXPRESSION; ANGIOGENESIS; RECEPTOR; INDUCTION; FGF; GROWTH-FACTOR-BETA-1; SECRETION; PHENOTYPE; FIBROSIS	Transforming growth factor-beta (TGF-beta) is overexpressed at sites of wound repair and in most adenocarcinomas including prostate cancer. In stromal tissues, TGF-beta regulates cell proliferation, phenotype and matrix synthesis. To address mechanisms of TGF-beta action in cancer-associated reactive stroma, we developed prostate stromal cells null for TGF-beta receptor II (T beta RII) or engineered to express a dominant-negative Smad3 to attenuate TGF-beta signaling. The differential reactive stroma (DRS) xenograft model was used to evaluate altered stromal TGF-beta signaling on LNCaP tumor progression. LNCaP xenograft tumors constructed with TbRII null or dominant-negative Smad3 stromal cells exhibited a significant reduction in mass and microvessel density relative to controls. Additionally, decreased cellular fibroblast growth factor-2 (FGF-2) immunostaining was associated with attenuated TGF-beta signaling in stroma. In vitro, TGF-b stimulated stromal FGF-2 expression and release. However, stromal cells with attenuated TGF-b signaling were refractory to TGF-beta-stimulated FGF-2 expression and release. Re-expression of FGF-2 in these stromal cells in DRS xenografts resulted in restored tumor mass and microvessel density. In summary, these data show that TGF-beta signaling in reactive stroma is angiogenic and tumor promoting and that this effect is mediated in part through a TbRII/Smad3-dependent upregulation of FGF-2 expression and release.	[Yang, F.; Strand, D. W.; Rowley, D. R.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Rowley, DR (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,325D, Houston, TX 77030 USA.	drowley@bcm.tmc.edu	Strand, Douglas/A-1702-2011; Strand, Douglas/K-4003-2019	Strand, Douglas/0000-0002-0746-927X	NCI NIH HHS [P50-CA58204, U54-CA126568, UO1-CA84296, R01-CA058093] Funding Source: Medline; NIDDK NIH HHS [R01-DK045909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA126568, R01CA058093, P50CA058204, U01CA084296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Backhaus R, 2004, J CELL SCI, V117, P1727, DOI 10.1242/jcs.01027; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bonniaud P, 2004, J IMMUNOL, V173, P2099, DOI 10.4049/jimmunol.173.3.2099; Butter S, 2001, EUR J PHARMACOL, V422, P47, DOI 10.1016/S0014-2999(01)01072-X; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; COFFEY RJ, 1986, CANCER RES, V46, P1164; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dow JK, 2000, UROLOGY, V55, P800, DOI 10.1016/S0090-4295(00)00457-X; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EASTHAM JA, 1995, LAB INVEST, V73, P628; Fukabori Y, 1997, Int J Urol, V4, P597, DOI 10.1111/j.1442-2042.1997.tb00316.x; Giri D, 1999, CLIN CANCER RES, V5, P1063; Hayashi T, 2004, CLIN CANCER RES, V10, P7540, DOI 10.1158/1078-0432.CCR-04-0632; Huss WJ, 2003, PROSTATE, V54, P8, DOI 10.1002/pros.10163; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Peehl DM, 1998, PROSTATE, V35, P125, DOI 10.1002/(SICI)1097-0045(19980501)35:2<125::AID-PROS6>3.0.CO;2-I; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Polnaszek N, 2003, CANCER RES, V63, P5754; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; ROWLEY DR, 2007, TRANSFORMING GROWTH; Sakko AJ, 2001, CANCER RES, V61, P926; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Story MT, 1996, PROSTATE, V28, P219; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Tuxhorn JA, 2002, CANCER RES, V62, P3298; Uchiyama-Tanaka Y, 2002, KIDNEY INT, V62, P799, DOI 10.1046/j.1523-1755.2002.00537.x; Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008-5472.CAN-05-1702	37	67	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					450	459		10.1038/sj.onc.1210663	http://dx.doi.org/10.1038/sj.onc.1210663			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637743				2022-12-28	WOS:000252426100005
J	Friedman, AD				Friedman, A. D.			Normal and malignant hematopoiesis - Introduction	ONCOGENE			English	Editorial Material									Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21218 USA	Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21218 USA.								0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	47					6686	6686		10.1038/sj.onc.1210753	http://dx.doi.org/10.1038/sj.onc.1210753			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934477				2022-12-28	WOS:000250147000001
J	Aufsatz, W; Stoiber, T; Rakic, B; Naumann, K				Aufsatz, W.; Stoiber, T.; Rakic, B.; Naumann, K.			Arabidopsis histone deacetylase 6: a green link to RNA silencing	ONCOGENE			English	Review						RNA silencing; cytosine methylation; histone deacetylation; epigenetics; Arabidopsis; transcriptional gene silencing	DIRECTED DNA METHYLATION; SMALL INTERFERING RNA; DOUBLE-STRANDED-RNA; GROUP PROTEIN EZH2; DE-NOVO; FUNCTIONAL DIVERSIFICATION; CHROMATIN-STRUCTURE; GENE-EXPRESSION; BINDING DOMAIN; ABSCISIC-ACID	Epigenetic reprogramming is at the base of cancer initiation and progression. Generally, genome-wide reduction in cytosine methylation contrasts with the hypermethylation of control regions of functionally well-established tumor suppressor genes and many other genes whose role in cancer biology is not yet clear. While insight into mechanisms that induce aberrant cytosine methylation in cancer cells is just beginning to emerge, the initiating signals for analogous promoter methylation in plants are well documented. In Arabidopsis, the silencing of promoters requires components of the RNA interference machinery and promoter double-stranded RNA ( dsRNA) to induce a repressive chromatin state that is characterized by cytosine methylation and histone deacetylation catalysed by the RPD3-type histone deacetylase AtHDA6. Similar mechanisms have been shown to occur in fission yeast and mammals. This review focuses on the connections between cytosine methylation, dsRNA and AtHDA6- controlled histone deacetylation during promoter silencing in Arabidopsis and discusses potential mechanistic similarities of these silencing events in cancer and plant cells.	Austrian Acad Sci, Gregor Mendel Inst Mol Plant Biol, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Gregor Mendel Institute of Molecular Plant Biology (GMI)	Aufsatz, W (corresponding author), Austrian Acad Sci, Gregor Mendel Inst Mol Plant Biol, Dr Bohr Gasse 3, A-1030 Vienna, Austria.	werner.aufsatz@gmi.oeaw.ac.at						Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Aravind L., 1998, SCIENCE, V280, P1167, DOI DOI 10.1126/SCIENCE.280.5367.1167A; Aufsatz W, 2004, PLANT MOL BIOL, V54, P793, DOI 10.1007/s11103-004-0179-1; Aufsatz W, 2002, EMBO J, V21, P6832, DOI 10.1093/emboj/cdf663; Aufsatz W, 2002, P NATL ACAD SCI USA, V99, P16499, DOI 10.1073/pnas.162371499; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Benhamed M, 2006, PLANT CELL, V18, P2893, DOI 10.1105/tpc.106.043489; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cao XF, 2002, CURR BIOL, V12, P1138, DOI 10.1016/S0960-9822(02)00925-9; Cao XF, 2003, CURR BIOL, V13, P2212, DOI 10.1016/j.cub.2003.11.052; Castanotto D, 2005, MOL THER, V12, P179, DOI 10.1016/j.ymthe.2005.03.003; Chan SWL, 2005, NAT REV GENET, V6, P351, DOI 10.1038/nrg1601; Chan SWL, 2004, SCIENCE, V303, P1336, DOI 10.1126/science.1095989; Chang S, 2005, J BIOL CHEM, V280, P796, DOI 10.1074/jbc.M409053200; Chen ZJ, 1997, GENE DEV, V11, P2124, DOI 10.1101/gad.11.16.2124; Cigan AM, 2005, PLANT J, V43, P929, DOI 10.1111/j.1365-313X.2005.02492.x; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; De Marzo AM, 1999, CANCER RES, V59, P3855; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Earley K, 2006, GENE DEV, V20, P1283, DOI 10.1101/gad.1417706; Fahrner JA, 2002, CANCER RES, V62, P7213; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Furner IJ, 1998, GENETICS, V149, P651; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Grimaud C, 2006, CELL, V124, P957, DOI 10.1016/j.cell.2006.01.036; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2000, GENE DEV, V14, P1021; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herr AJ, 2005, SCIENCE, V308, P118, DOI 10.1126/science.1106910; Holst CR, 2003, CANCER RES, V63, P1596; Huettel B, 2006, EMBO J, V25, P2828, DOI 10.1038/sj.emboj.7601150; Jacobsen SE, 2000, CURR BIOL, V10, P179, DOI 10.1016/S0960-9822(00)00324-9; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kanno T, 2005, NAT GENET, V37, P761, DOI 10.1038/ng1580; Kanno T, 2004, CURR BIOL, V14, P801, DOI 10.1016/j.cub.2004.04.037; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Kim DH, 2006, NAT STRUCT MOL BIOL, V13, P793, DOI 10.1038/nsmb1142; Klimov Dmitry, 2006, Journal of Bioinformatics and Computational Biology, V4, P515, DOI 10.1142/S0219720006001795; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Lawrence RJ, 2004, MOL CELL, V13, P599, DOI 10.1016/S1097-2765(04)00064-4; Li CF, 2006, CELL, V126, P93, DOI 10.1016/j.cell.2006.05.032; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875; Lippman Z, 2003, PLOS BIOL, V1, P420, DOI 10.1371/journal.pbio.0000067; Long JA, 2006, SCIENCE, V312, P1520, DOI 10.1126/science.1123841; Lu C, 2005, SCIENCE, V309, P1567, DOI 10.1126/science.1114112; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; Martienssen RA, 2005, TRENDS GENET, V21, P450, DOI 10.1016/j.tig.2005.06.005; Mathieu O, 2004, J CELL SCI, V117, P4881, DOI 10.1242/jcs.01479; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Melquist S, 2003, GENE DEV, V17, P2036, DOI 10.1101/gad.1081603; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Murfett J, 2001, PLANT CELL, V13, P1047, DOI 10.1105/tpc.13.5.1047; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Nicolai M, 2006, PLANT PHYSIOL, V141, P663, DOI 10.1104/pp.106.079418; Onodera Y, 2005, CELL, V120, P613, DOI 10.1016/j.cell.2005.02.007; Pandey R, 2002, NUCLEIC ACIDS RES, V30, P5036, DOI 10.1093/nar/gkf660; Pontes O, 2006, CELL, V126, P79, DOI 10.1016/j.cell.2006.05.031; Pontier D, 2005, GENE DEV, V19, P2030, DOI 10.1101/gad.348405; Probst AV, 2004, PLANT CELL, V16, P1021, DOI 10.1105/tpc.018754; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Song CP, 2006, PLANT MOL BIOL, V60, P241, DOI 10.1007/s11103-005-3880-9; Song CP, 2005, PLANT CELL, V17, P2384, DOI 10.1105/tpc.105.033043; Sridha S, 2006, PLANT J, V46, P124, DOI 10.1111/j.1365-313X.2006.02678.x; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tian L, 2003, GENETICS, V165, P399; Tian L, 2001, P NATL ACAD SCI USA, V98, P200, DOI 10.1073/pnas.011347998; Ting AH, 2005, NAT GENET, V37, P906, DOI 10.1038/ng1611; Tran RK, 2005, CURR BIOL, V15, P154, DOI 10.1016/j.cub.2005.01.008; Ueno Y, 2007, PLANT CELL, V19, P445, DOI 10.1105/tpc.106.042325; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Verdel A, 2005, FEBS LETT, V579, P5872, DOI 10.1016/j.febslet.2005.08.083; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wassenegger M, 2000, PLANT MOL BIOL, V43, P203, DOI 10.1023/A:1006479327881; Weinberg MS, 2006, RNA, V12, P256, DOI 10.1261/rna.2235106; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wu KQ, 2000, PLANT J, V22, P19, DOI 10.1046/j.1365-313x.2000.00711.x; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Xu CR, 2005, P NATL ACAD SCI USA, V102, P14469, DOI 10.1073/pnas.0503143102; Zemach A, 2007, TRENDS PLANT SCI, V12, P80, DOI 10.1016/j.tplants.2006.12.004; Zhang XY, 2006, CELL, V126, P1189, DOI 10.1016/j.cell.2006.08.003; Zhao YD, 2003, SCIENCE, V301, P1107, DOI 10.1126/science.1084161; Zhou CH, 2005, PLANT CELL, V17, P1196, DOI 10.1105/tpc.104.028514; Zhou CH, 2004, PLANT J, V38, P715, DOI 10.1111/j.1365-313X.2004.02083.x; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695; Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929	112	36	38	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5477	5488		10.1038/sj.onc.1210615	http://dx.doi.org/10.1038/sj.onc.1210615			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694088				2022-12-28	WOS:000248674300015
J	Yang, XJ; Seto, E				Yang, X-J; Seto, E.			HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention	ONCOGENE			English	Editorial Material						lysine acetylation; histone acetylase; histone deacetylase; signaling; tubulin	HISTONE DEACETYLASE INHIBITORS; ACETYL-COA SYNTHETASE; LYSINE-ACETYLATION; DNA-DAMAGE; MONOCLONAL-ANTIBODIES; H4 ACETYLTRANSFERASE; TRANSCRIPTION FACTOR; DOSAGE COMPENSATION; MODIFYING ENZYMES; SODIUM-BUTYRATE	Acetylation of the epsilon-amino group of a lysine residue was first discovered with histones in 1968, but the responsible enzymes, histone acetyltransferases and deacetylases, were not identified until the mid-1990s. In the past decade, knowledge about this modi. cation has exploded, with targets rapidly expanding from histones to transcription factors and other nuclear proteins, and then to cytoskeleton, metabolic enzymes, and signaling regulators in the cytoplasm. Thus, protein lysine acetylation has emerged as a major post-translational modi. cation to rival phosphorylation. In this issue of Oncogene, 19 articles review various aspects of the enzymes governing lysine acetylation, especially about their intimate links to cancer. To introduce the articles, we highlight here four central themes: ( i) multisubunit enzymatic complexes; ( ii) non-histone substrates in diverse cellular processes; ( iii) interplay of lysine acetylation with other regulatory mechanisms, such as noncoding RNA-mediated gene silencing and activation; and (iv) novel therapeutic strategies and preventive measures to combat cancer and other human diseases.	McGill Univ, Mol Oncol Grp, Dept Med, Ctr Hlth,RVH, Montreal, PQ H3A 1A1, Canada; Univ S Florida, H Lee Moffitt Canc Ctr, Mol Oncol Program, Tampa, FL 33682 USA	McGill University; Royal Victoria Hospital; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Yang, XJ (corresponding author), McGill Univ, Mol Oncol Grp, Dept Med, Ctr Hlth,RVH, Room H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	xiang-jiao.yang@mcgill.ca; ed.seto@mofitt.org						ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; Ahn SH, 2006, MOL CELL, V24, P211, DOI 10.1016/j.molcel.2006.09.008; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Aufsatz W, 2007, ONCOGENE, V26, P5477, DOI 10.1038/sj.onc.1210615; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Baker SP, 2007, ONCOGENE, V26, P5329, DOI 10.1038/sj.onc.1210603; Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; Belfield JL, 2006, J BIOL CHEM, V281, P27724, DOI 10.1074/jbc.M601485200; Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Boyault C, 2007, ONCOGENE, V26, P5468, DOI 10.1038/sj.onc.1210614; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Brush MH, 2004, J BIOL CHEM, V279, P7685, DOI 10.1074/jbc.M310997200; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chen Y, 2007, MOL CELL PROTEOMICS, V6, P812, DOI 10.1074/mcp.M700021-MCP200; Chinenov Y, 2002, TRENDS BIOCHEM SCI, V27, P115, DOI 10.1016/S0968-0004(02)02058-3; COHEN T, 2004, SCI STIKE; Collins SR, 2007, NATURE, V446, P806, DOI 10.1038/nature05649; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Driscoll R, 2007, SCIENCE, V315, P649, DOI 10.1126/science.1135862; Druesne N, 2004, CARCINOGENESIS, V25, P1227, DOI 10.1093/carcin/bgh123; Earley K, 2006, GENE DEV, V20, P1283, DOI 10.1101/gad.1417706; GERSHEY EL, 1968, J BIOL CHEM, V243, P5018; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Goodman RH, 2000, GENE DEV, V14, P1553; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Han JH, 2007, SCIENCE, V315, P653, DOI 10.1126/science.1133234; HANSEN JC, 1992, TRENDS BIOCHEM SCI, V17, P187, DOI 10.1016/0968-0004(92)90264-A; Hodawadekar SC, 2007, ONCOGENE, V26, P5528, DOI 10.1038/sj.onc.1210619; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ivanov D, 2002, CURR BIOL, V12, P323, DOI 10.1016/S0960-9822(02)00681-4; Iwabata H, 2005, PROTEOMICS, V5, P4653, DOI 10.1002/pmic.200500042; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Karagianni P, 2007, ONCOGENE, V26, P5439, DOI 10.1038/sj.onc.1210612; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lafon A, 2007, ONCOGENE, V26, P5373, DOI 10.1038/sj.onc.1210606; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li Y, 2006, GENE DEV, V20, P2566, DOI 10.1101/gad.1455006; Lin WC, 2006, CURR OPIN GENET DEV, V16, P137, DOI 10.1016/j.gde.2006.02.002; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lucchesi JC, 2005, ANNU REV GENET, V39, P615, DOI 10.1146/annurev.genet.39.073003.094210; Marchion D, 2007, EXPERT REV ANTICANC, V7, P583, DOI 10.1586/14737140.7.4.583; Martin M, 2007, ONCOGENE, V26, P5450, DOI 10.1038/sj.onc.1210613; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mejat A, 2005, NAT NEUROSCI, V8, P313, DOI 10.1038/nn1408; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mittal R, 2006, P NATL ACAD SCI USA, V103, P18574, DOI 10.1073/pnas.0608995103; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mujtaba S, 2007, ONCOGENE, V26, P5521, DOI 10.1038/sj.onc.1210618; Mukherjee S, 2006, SCIENCE, V312, P1211, DOI 10.1126/science.1126867; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Nicolas E, 2007, NAT STRUCT MOL BIOL, V14, P372, DOI 10.1038/nsmb1239; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okamoto M, 2004, TRENDS ENDOCRIN MET, V15, P21, DOI 10.1016/j.tem.2003.11.002; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PHILLIPS DM, 1963, BIOCHEM J, V87, P258, DOI 10.1042/bj0870258; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; Rasheed WK, 2007, EXPERT OPIN INV DRUG, V16, P659, DOI 10.1517/13543784.16.5.659; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; SHAHBAZIN MD, 2007, ANN REV BIOCH, V76; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; STERNER R, 1979, J BIOL CHEM, V254, P1577; Straub T, 2007, NAT REV GENET, V8, P47, DOI 10.1038/nrg2013; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tahiliani M, 2007, NATURE, V447, P601, DOI 10.1038/nature05823; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Toleman C, 2004, J BIOL CHEM, V279, P53665, DOI 10.1074/jbc.M410406200; Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552; Tsubota T, 2007, MOL CELL, V25, P703, DOI 10.1016/j.molcel.2007.02.006; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; van der Linden AM, 2007, EMBO J, V26, P358, DOI 10.1038/sj.emboj.7601479; Vaquero A, 2007, ONCOGENE, V26, P5505, DOI 10.1038/sj.onc.1210617; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; Xhemalce B, 2007, J BIOL CHEM, V282, P15040, DOI 10.1074/jbc.M701197200; Xie HW, 2007, J PROTEOME RES, V6, P2019, DOI 10.1021/pr060691j; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yamada T, 2005, MOL CELL, V20, P173, DOI 10.1016/j.molcel.2005.10.002; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 2007, ONCOGENE, V26, P5408, DOI 10.1038/sj.onc.1210609; Yang XJ, 2007, EMBO REP, V8, P556, DOI 10.1038/sj.embor.7400977; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zaratiegui M, 2007, CELL, V128, P763, DOI 10.1016/j.cell.2007.02.016; Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	138	703	747	5	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5310	5318		10.1038/sj.onc.1210599	http://dx.doi.org/10.1038/sj.onc.1210599			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694074				2022-12-28	WOS:000248674300001
J	Oxmann, D; Held-Feindt, J; Stark, AM; Hattermann, K; Yoneda, T; Mentlein, R				Oxmann, D.; Held-Feindt, J.; Stark, A. M.; Hattermann, K.; Yoneda, T.; Mentlein, R.			Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype	ONCOGENE			English	Article						breast cancer; metastasis; brain; tumor invasion; growth factor receptor	DIFFERENTIAL EXPRESSION; BRAIN-SEEKING; TGF-BETA; COMPLEX; CD105	Endoglin is a cell-surface adhesion protein as well as a coreceptor for transforming growth factor-beta (TGF-beta). It is located on endothelial and few other cells, but also found on certain tumor cells. Brain metastatic breast tumor cells derived from the MDA-MB-231 cell line heavily express endoglin in contrast to the corresponding parental ones. To clarify whether this determines their invasive phenotype, we compared their biological properties with endoglin-silenced brain-metastatic cells, low-expressing parental cells and these transfected with L- and S-endoglins, isoforms transducing or lacking TGF-beta signals. All L-endoglin-overexpressing cells were characterized by numerous invadopodia where endoglin was preferentially localized. Endoglin-expression resulted in elevated levels of the matrix metalloproteinases (MMP-1 and MMP-19) and downregulation of the plasminogen activator inhibitor-1. In Boyden-chamber and wound-healing assays, endoglin-overexpressing cells showed a considerably higher migration and chemotaxis to TGF-beta. In 3D spheroid confrontation assays between breast tumor cells and TGF-beta-secreting glioma cells, high L-endoglin-expressing cells invaded into the glioma-spheroids whereas low-endoglin-expressing cells dissociated in the culture; invasion was blocked by TGF-beta antibodies. In contrast to parental cells, endoglin-overexpressing cells invaded deeply into mouse brain slices. Thus, endoglin expression on tumor cells enhances their invasive character by formation of invadopodia, extracellular proteolysis, chemotaxis and migration.	[Oxmann, D.; Hattermann, K.; Mentlein, R.] Univ Kiel, Dept Anat, D-24098 Kiel, Germany; [Held-Feindt, J.; Stark, A. M.] Univ Klinikum Schleswig Holstein, Dept Neurosurg, Kiel, Germany; [Yoneda, T.] Univ Texas Hlth Sci Ctr San Antonio, Div Endocrinol & Metab, San Antonio, TX 78229 USA	University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Texas System; University of Texas Health San Antonio	Mentlein, R (corresponding author), Univ Kiel, Dept Anat, Olshausenstr 40, D-24098 Kiel, Germany.	rment@anat.uni-kiel.de	Mentlein, Rolf/B-1613-2010; Hattermann, Kirsten/E-8043-2010; Held-Feindt, Janka/E-4690-2010	Mentlein, Rolf/0000-0002-6350-3911; 				Andre F, 2006, ANN ONCOL, V17, P945, DOI 10.1093/annonc/mdl053; Beck IM, 2007, J INVEST DERMATOL, V127, P1107, DOI 10.1038/sj.jid.5700674; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Djonov V, 2001, J PATHOL, V195, P147, DOI 10.1002/path.927; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; Forstreuter F, 2002, J NEUROIMMUNOL, V132, P93, DOI 10.1016/S0165-5728(02)00315-6; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Held-Feindt J, 2003, J NEURO-ONCOL, V63, P117, DOI 10.1023/A:1023943405292; Kousidou OC, 2004, ANTICANCER RES, V24, P4025; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Ludwig A, 2005, J NEUROCHEM, V93, P1293, DOI 10.1111/j.1471-4159.2005.03123.x; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; Mentlein R, 2004, J NEURO-ONCOL, V67, P9, DOI 10.1023/B:NEON.0000021737.89357.cc; Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273; Palmieri D, 2007, CANCER RES, V67, P4190, DOI 10.1158/0008-5472.CAN-06-3316; Postiglione L, 2005, INT J ONCOL, V26, P1193; Stark AM, 2005, NEUROSURG REV, V28, P115, DOI 10.1007/s10143-004-0364-3; Stark AM, 2007, J NEURO-ONCOL, V81, P39, DOI 10.1007/s11060-006-9207-0; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486	26	60	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3567	3575		10.1038/sj.onc.1211025	http://dx.doi.org/10.1038/sj.onc.1211025			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223685				2022-12-28	WOS:000256468500008
J	Lee, DY; Sugden, B				Lee, D. Y.; Sugden, B.			The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy	ONCOGENE			English	Article						autophagy; EBV; LMP1	EPSTEIN-BARR-VIRUS; MEMBRANE-PROTEIN 1; LATENT MEMBRANE-PROTEIN-1; GROWTH TRANSFORMATION; NUCLEAR ANTIGEN; LMP1; PROLIFERATION; ASSOCIATION; RECEPTOR; CD40	Epstein-Barr virus (EBV) is a herpes virus that is associated with several human cancers. Infection of B cells by EBV leads to their induction and maintenance of proliferation and requires the oncogene, latent membrane protein 1 (LMP1). LMP1 signals in a ligand-independent manner and is expressed at widely different levels in cells of a single clone. It is this unusual distribution that allows LMP1 to stimulate multiple, distinct pathways. Average levels of LMP1 induce proliferation while high levels induce cytostasis and inhibition of protein synthesis. These inhibitory pathways are induced by the six transmembrane domains of LMP1. We uncovered a novel function encoded by transmembrane domains 3-6 of LMP1; they induce autophagy in a dose-dependent manner and thus, modify the physiology of their host. Cells that express low levels of LMP1 display early stages of autophagy, autophagosomes; those that express high levels of this oncogene display late stages of autophagy, autolysosomes. Inhibition of autophagy in EBV-positive cells leads to an accumulation of LMP1 and a decreased ability to form colonies. These results indicate that LMP1's induction of autophagy contributes to its own regulation and that of its host cell.	[Lee, D. Y.; Sugden, B.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Sugden, B (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	sugden@oncology.wisc.edu			NCI NIH HHS [P30 CA014520, CA070723] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bornkamm GW, 2001, PHILOS T R SOC B, V356, P437, DOI 10.1098/rstb.2000.0781; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dirmeier U, 2005, ONCOGENE, V24, P1711, DOI 10.1038/sj.onc.1208367; Dirmeier U, 2003, CANCER RES, V63, P2982; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Humme S, 2003, P NATL ACAD SCI USA, V100, P10989, DOI 10.1073/pnas.1832776100; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kaykas A, 2002, J VIROL, V76, P11551, DOI 10.1128/JVI.76.22.11551-11560.2002; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KNUTSON JC, 1987, ANAL BIOCHEM, V164, P44, DOI 10.1016/0003-2697(87)90365-4; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Lam N, 2004, J VIROL, V78, P1657, DOI 10.1128/JVI.78.4.1657-1664.2004; Lam N, 2003, CELL SIGNAL, V15, P9, DOI 10.1016/S0898-6568(02)00083-9; Lee J, 2007, J VIROL, V81, P9121, DOI 10.1128/JVI.00136-07; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Neuhierl B, 2002, P NATL ACAD SCI USA, V99, P15036, DOI 10.1073/pnas.232381299; Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200; Tassa A, 2003, BIOCHEM J, V376, P577, DOI 10.1042/BJ20030826; Taylor GS, 2006, J IMMUNOL, V177, P3746, DOI 10.4049/jimmunol.177.6.3746; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023	36	114	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2833	2842		10.1038/sj.onc.1210946	http://dx.doi.org/10.1038/sj.onc.1210946			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037963				2022-12-28	WOS:000255502500004
J	Menges, CW; McCance, DJ				Menges, C. W.; McCance, D. J.			Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA(2) receptor	ONCOGENE			English	Article						Raf-MEK1; Ras; PI3; AKT; kinase; EphA(2) receptor	TYROSINE KINASE; PROTEIN-KINASE; CYCLE ARREST; AKT; DIFFERENTIATION; CELLS; P21(CIP1); GROWTH; PROLIFERATION; ANGIOGENESIS	The Raf-mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)-AKT pathways are two downstream effectors of the small GTPase Ras. Although both pathways are positively regulated by Ras, the Raf-MAPK and PI3K-AKT pathways have been shown to control opposing functions within the cell, suggesting a need for cross-talk regulation. The PI3K -AKT pathway can inhibit the Raf-MAPK pathway directly during processes such as muscle differentiation. Here we describe the ability of the Raf-MAPK pathway to negatively regulate the PI3K-AKT pathway during cellular arrest. Constitutive activation of Raf or methyl ethyl ketone 1 (MEK1) leads to inhibition of AKT and cellular arrest. Furthermore, we show that activation of Raf-MEK1 signaling causes negative feedback inhibition of Ras through the ephrin receptor EphA(2). EphA(2)-mediated negative feedback inhibition is required for Raf-induced AKT inhibition and cell cycle arrest, therefore establishing the inhibition of the Ras-PI3K-AKT pathway as a necessary event for the Raf-MEK1-regulated cellular arrest.	[Menges, C. W.; McCance, D. J.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Menges, C. W.] Univ Rochester, Sch Med, Dept Biochem, Rochester, NY USA; [Menges, C. W.] Univ Rochester, Sch Med, Dept Biophys, Rochester, NY USA; [McCance, D. J.] Univ Rochester, Sch Med, Dept Microbiol, Rochester, NY USA; [McCance, D. J.] Univ Rochester, Sch Med, Dept Immunol, Rochester, NY USA; [McCance, D. J.] Univ Rochester, Sch Med, James P Wilmot Canc Ctr, Rochester, NY USA	Queens University Belfast; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	McCance, DJ (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, MBC Bldg, Belfast BT9 7BL, Antrim, North Ireland.	d.mccance@qub.ac.uk			NIAID NIH HHS [R01 AI 30798] Funding Source: Medline; NIDCR NIH HHS [R01 DE015935] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015935] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Cheng N, 2002, MOL CANCER RES, V1, P2; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cichowski K, 2003, GENE DEV, V17, P449, DOI 10.1101/gad.1054703; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; Holt KH, 1996, MOL CELL BIOL, V16, P577; Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495; Laprise P, 2004, J CELL PHYSIOL, V199, P32, DOI 10.1002/jcp.10432; Lawlor MA, 2001, J CELL SCI, V114, P2903; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Thrash BR, 2006, J BIOL CHEM, V281, P12155, DOI 10.1074/jbc.M512116200; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	28	72	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2934	2940		10.1038/sj.onc.1210957	http://dx.doi.org/10.1038/sj.onc.1210957			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18059341				2022-12-28	WOS:000255502500015
J	Bennett, HL; Brummer, T; Jeanes, A; Yap, AS; Daly, RJ				Bennett, H. L.; Brummer, T.; Jeanes, A.; Yap, A. S.; Daly, R. J.			Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis	ONCOGENE			English	Article						tyrosine kinase; signal transduction; E-cadherin; cell-cell adhesion; cell invasion	DOCKING PROTEIN GAB2; E-CADHERIN; SIGNALING PATHWAY; ACTIVATION; PHOSPHORYLATION; PROLIFERATION; ADHESION; ROLES; AKT; DEPHOSPHORYLATION	The Gab2 docking protein is a target of several oncogenic protein tyrosine kinases and potentiates activation of the Ras/extracellular signal regulated kinase and phosphatidylinositol 3-kinase (PI3-kinase) pathways. Since Gab2 is phosphorylated by c-Src, and both proteins are over-expressed in breast cancers, we have determined the biological consequences of their co-expression in the immortalized human mammary epithelial cell line MCF-10A. While overexpression of c-Src did not affect acinar morphogenesis or growth factor dependence in three-dimensional culture, c-Src co-operated with Gab2 to promote epidermal growth factor (EGF)-independent acinar growth. In contrast, expression of v-Src or the activated mutant c-SrcY527F led to a spectrum of aberrant phenotypes ranging from spheroids with incomplete luminal clearance to highly disrupted, dispersed structures. Gab2 co-expression shifted the phenotypic distribution towards the dispersed phenotype, an effect not observed with a Gab2 mutant unable to bind the p85 subunit of PI3-kinase (Gab2 Delta p85). In v-Src-expressing cells, Gab2, but not Gab2 Delta p85, significantly decreased E-cadherin adhesive strength without altering its surface expression. Gab2 associated with E-cadherin in the presence and absence of v-Src, indicating that the ability of Gab2 to weaken the strength of cell-cell contacts may reflect enhanced activation of PI3-kinase at adherens junctions. Gab2 also increased migration and invasion of these cells in transwell assays, but these effects were p85-independent. Overall, these findings demonstrate a novel mechanism whereby Gab2 may promote metastatic spread and indicate that Gab2 may play several roles during breast cancer progression.	[Bennett, H. L.; Brummer, T.; Daly, R. J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; [Jeanes, A.; Yap, A. S.] Univ Queensland, Inst Mol Biosci, Queensland, Australia	Garvan Institute of Medical Research; University of Queensland	Daly, RJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	r.daly@garvan.org.au	Daly, Roger J/C-8179-2009; Jeanes, Angela/D-9770-2011; Brummer, Tilman/B-6218-2016; Brummer, Tilman/AAA-9428-2020; Yap, Alpha S./J-1554-2014	Jeanes, Angela/0000-0003-0717-6298; Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905; Yap, Alpha S./0000-0002-1038-8956; Daly, Roger/0000-0002-5739-8027				Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; BRIEHER WM, 1994, J CELL BIOL, V126, P519, DOI 10.1083/jcb.126.2.519; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Gonzalez L, 2006, J BIOL CHEM, V281, P20851, DOI 10.1074/jbc.M601570200; Grille SJ, 2003, CANCER RES, V63, P2172; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Guan KL, 2000, J BIOL CHEM, V275, P27354; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; JANES PW, 1994, ONCOGENE, V9, P3601; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Kotelevets L, 2001, J CELL BIOL, V155, P1129, DOI 10.1083/jcb.200105109; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Mege RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Nyga R, 2005, BIOCHEM J, V390, P359, DOI 10.1042/BJ20041523; Pang JH, 2005, J BIOL CHEM, V280, P3043, DOI 10.1074/jbc.M412148200; Podar K, 2004, J BIOL CHEM, V279, P21658, DOI 10.1074/jbc.M305783200; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Shewan AM, 2005, MOL BIOL CELL, V16, P4531, DOI 10.1091/mbc.E05-04-0330; SHORE EM, 1991, J BIOL CHEM, V266, P19672; Verma S, 2004, J BIOL CHEM, V279, P34062, DOI 10.1074/jbc.M404814200; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203; Wang FM, 2005, BREAST CANCER RES TR, V89, P5, DOI 10.1007/s10549-004-1002-z; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Yamasaki S, 2001, J BIOL CHEM, V276, P45175, DOI 10.1074/jbc.M105384200; Yu M, 2006, J IMMUNOL, V176, P2421, DOI 10.4049/jimmunol.176.4.2421; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351	44	33	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2693	2704		10.1038/sj.onc.1210928	http://dx.doi.org/10.1038/sj.onc.1210928			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998934				2022-12-28	WOS:000255259500004
J	Weiss, C; Faust, D; Schreck, I; Ruff, A; Farwerck, T; Melenberg, A; Schneider, S; Oesch-Bartlomowicz, B; Zatloukalova, J; Vondracek, J; Oesch, F; Dietrich, C				Weiss, C.; Faust, D.; Schreck, I.; Ruff, A.; Farwerck, T.; Melenberg, A.; Schneider, S.; Oesch-Bartlomowicz, B.; Zatloukalova, J.; Vondracek, J.; Oesch, F.; Dietrich, C.			TCDD deregulates contact inhibition in rat liver oval cells via Ah receptor, JunD and cyclin A	ONCOGENE			English	Article						aryl hydrocarbon receptor; contact inhibition; cell cycle control; JunD; cyclin A; liver oval cells	ARYL-HYDROCARBON RECEPTOR; C-JUN; EPITHELIAL-CELLS; DIOXIN RECEPTOR; TUMOR PROMOTION; GROWTH ARREST; PROLIFERATION; EXPRESSION; HEPATOCYTES; APOPTOSIS	The aryl hydrocarbon receptor (AhR) is a transcription factor involved in physiological processes, but also mediates most, if not all, toxic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Activation of the AhR by TCDD leads to its dimerization with aryl hydrocarbon nuclear translocator (ARNT) and transcriptional activation of several phase I and II metabolizing enzymes. However, this classical signalling pathway so far failed to explain the pleiotropic hazardous effects of TCDD, such as developmental toxicity and tumour promotion. Thus, there is an urgent need to de. ne genetic programmes orchestrated by AhR to unravel its role in physiology and toxicology. Here we show that TCDD treatment of rat liver oval cells leads to induction of the transcription factor JunD, resulting in transcriptional upregulation of the proto-oncogene cyclin A which finally triggers a release from contact inhibition. Ectopic expression of cyclin A in confluent cultures overcomes G(1) arrest, indicating that increased cyclin A levels are indeed sufficient to bypass contact inhibition. Functional interference with AhR-, but not with ARNT, abolished TCDD-induced increase in JunD and cyclin A and prevented loss of contact inhibition. In summary, we have discovered a novel AhR- dependent and probably ARNT-independent signalling pathway involving JunD and cyclin A, which mediates TCDD-induced deregulation of cell cycle control.	[Schreck, I.; Schneider, S.] Res Ctr Karlsruhe, Inst Genet & Toxicol, D-76344 Eggenstein Leopoldshafen, Germany; [Weiss, C.; Faust, D.; Ruff, A.; Farwerck, T.; Melenberg, A.; Oesch-Bartlomowicz, B.; Oesch, F.; Dietrich, C.] Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; [Zatloukalova, J.; Vondracek, J.] Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic	Helmholtz Association; Karlsruhe Institute of Technology; Johannes Gutenberg University of Mainz; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Dietrich, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacherstr 67, D-55131 Mainz, Germany.	carsten.weiss@itg.fzk.de; cdietric@uni-mainz.de	Vondracek, Jan/J-3037-2012; Weiss, Carsten/I-1811-2013; Prochazkova, Jirina/D-4403-2015; Oesch, Franz/AAA-8746-2020	Vondracek, Jan/0000-0003-4071-1969; Weiss, Carsten/0000-0002-5380-3208; Prochazkova, Jirina/0000-0003-2738-8546; 				ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; [Anonymous], 1997, IARC Monogr Eval Carcinog Risks Hum, V69, P1; Bock KW, 2005, BIOCHEM PHARMACOL, V69, P1403, DOI 10.1016/j.bcp.2005.02.004; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Chramostova K, 2004, TOXICOL APPL PHARM, V196, P136, DOI 10.1016/j.taap.2003.12.008; Coleman WB, 1997, AM J PATHOL, V151, P353; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Dietrich C, 2003, INT J CANCER, V103, P435, DOI 10.1002/ijc.10830; Dietrich C, 2002, TOXICOL APPL PHARM, V183, P117, DOI 10.1006/taap.2002.9475; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Dumble ML, 2002, CARCINOGENESIS, V23, P435, DOI 10.1093/carcin/23.3.435; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; Faust D, 2005, ONCOGENE, V24, P7941, DOI 10.1038/sj.onc.1208948; FOX TR, 1993, CANCER RES, V53, P2265; Hailey JR, 2005, TOXICOL PATHOL, V33, P165, DOI 10.1080/01926230590888324; HEBERT CD, 1990, CARCINOGENESIS, V11, P1335, DOI 10.1093/carcin/11.8.1335; Heit I, 2001, ONCOGENE, V20, P5143, DOI 10.1038/sj.onc.1204657; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; Hushka DR, 1995, MUTAT RES-FUND MOL M, V333, P89, DOI 10.1016/0027-5107(95)00135-2; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Libbrecht L, 2000, J HEPATOL, V33, P76, DOI 10.1016/S0168-8278(00)80162-2; Ma Q, 1996, MOL CELL BIOL, V16, P8878; Marlowe JL, 2005, J CELL BIOCHEM, V96, P1174, DOI 10.1002/jcb.20656; MASON GGF, 1994, J BIOL CHEM, V269, P4438; Moennikes O, 2004, CANCER RES, V64, P4707, DOI 10.1158/0008-5472.CAN-03-0875; Munzel P, 1996, CARCINOGENESIS, V17, P197, DOI 10.1093/carcin/17.2.197; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; PITOT HC, 1980, CANCER RES, V40, P3616; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; Shafritz DA, 2002, J HEPATOL, V36, P552, DOI 10.1016/S0168-8278(02)00013-2; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; STEINBERG P, 1994, LAB INVEST, V71, P700; STINCHCOMBE S, 1995, CARCINOGENESIS, V16, P1271, DOI 10.1093/carcin/16.6.1271; TSAO MS, 1987, AM J PATHOL, V127, P168; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; Tuomisto J., 2005, TOXICOL APPL PHARM, V207, pS2; Vondracek J, 2005, TOXICOL SCI, V83, P53, DOI 10.1093/toxsci/kfi009; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Weiss C, 2005, ONCOGENE, V24, P4975, DOI 10.1038/sj.onc.1208679; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; Worner W, 1996, CANCER RES, V56, P1272	50	72	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2198	2207		10.1038/sj.onc.1210859	http://dx.doi.org/10.1038/sj.onc.1210859			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952121				2022-12-28	WOS:000254621300010
J	Yin, X; DeWille, JW; Hai, T				Yin, X.; DeWille, J. W.; Hai, T.			A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development	ONCOGENE			English	Article						ATF3; transcriptional regulation; cancer cell dichotomy; cell motility; breast cancer; adaptive response	ACTIVATING TRANSCRIPTION FACTOR-3; RNA-POLYMERASE-II; BREAST-CANCER; BETA; CELLS; EXPRESSION; IDENTIFICATION; AMPLIFICATION; METASTASIS; SUPPRESSOR	Activating transcription factor 3 (ATF3) is a member of the ATF/cyclic AMP response element-binding family of transcription factors. We present evidence that ATF3 has a dichotomous role in cancer development. By both gain- and loss-of-function approaches, we found that ATF3 enhances apoptosis in the untransformed MCF10A mammary epithelial cells, but protects the aggressive MCF10CA1a cells and enhances its cell motility. Array analyses indicated that ATF3 upregulates the expression of several genes in the tumor necrosis factor pathway in the MCF10A cells but upregulates the expression of several genes implicated in tumor metastasis, including TWIST1, fibronectin (FN)-1, plasminogen activator inhibitor-1, urokinase-type plasminogen activator, caveolin-1 and Slug, in the MCF10CA1a cells. We present evidence that ATF3 binds to the endogenous promoters and regulates the transcription of the TWIST1, FN-1, Snail and Slug genes. Furthermore, conditioned medium experiments indicated that ATF3 has a paracrine/autocrine effect, consistent with its upregulation of genes encoding secreted factors. Finally, ATF3 gene copy number is > 2 in similar to 80% of the breast tumors examined (N = 48) and its protein level is elevated in similar to 50% of the tumors. These results provided a correlative argument that it is advantageous for the malignant cancer cells to express ATF3, consistent with its oncogenic roles suggested by the MCF10CA1a cell data.	[Yin, X.; Hai, T.] Ohio State Univ, Neurobiotechnol Ctr, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; [Yin, X.; DeWille, J. W.; Hai, T.] Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; [Yin, X.; Hai, T.] Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA; [DeWille, J. W.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Hai, T (corresponding author), Ohio State Univ, Neurobiotechnol Ctr, Dept Mol & Cellular Biochem, 174 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	hai.2@osu.edu	Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NATIONAL CANCER INSTITUTE [R01CA118306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059605, R01DK064938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS045758] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA118306] Funding Source: Medline; NIDDK NIH HHS [R01 DK059605, R01 DK064938] Funding Source: Medline; NINDS NIH HHS [P30-NS045758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albertson DG, 2003, BREAST CANCER RES TR, V78, P289, DOI 10.1023/A:1023025506386; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Ameri K, 2007, ONCOGENE, V26, P284, DOI 10.1038/sj.onc.1209781; Baek SJ, 2004, CARCINOGENESIS, V25, P2425, DOI 10.1093/carcin/bgh255; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; Bottone FG, 2003, J BIOL CHEM, V278, P25790, DOI 10.1074/jbc.M301002200; Bottone FG, 2005, MOL CANCER THER, V4, P693, DOI 10.1158/1535-7163.MCT-04-0337; Cheng CH, 2003, MOL CELL BIOL, V23, P1961, DOI 10.1128/MCB.23.6.1961-1967.2003; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HAI T, 2006, GENE EXPRESSION REGU, P322; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ishiguro T, 1996, CANCER RES, V56, P875; Ishiguro T, 2000, JPN J CANCER RES, V91, P833, DOI 10.1111/j.1349-7006.2000.tb01021.x; Ishiguro T, 2000, ONCOL RES, V12, P343, DOI 10.3727/096504001108747792; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Loeb LA, 2001, CANCER RES, V61, P3230; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Lu D, 2007, BIOCHEM J, V401, P559, DOI 10.1042/BJ20061081; Mallory JC, 2005, MOL PHARMACOL, V68, P1747, DOI 10.1124/mol.105.016519; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Pauletti G, 1996, ONCOGENE, V13, P63; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rooney PH, 1999, BRIT J CANCER, V80, P862, DOI 10.1038/sj.bjc.6690433; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; SOULE HD, 1990, CANCER RES, V50, P6075; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Yamaguchi K, 2006, CANCER RES, V66, P2376, DOI 10.1158/0008-5472.CAN-05-1987; Yan CH, 2005, MOL CANCER THER, V4, P233; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5	38	157	160	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2118	2127		10.1038/sj.onc.1210861	http://dx.doi.org/10.1038/sj.onc.1210861			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952119				2022-12-28	WOS:000254621300002
J	Zhu, JH; Chen, R; Yi, W; Cantin, GT; Fearns, C; Yang, Y; Yates, JR; Lee, JD				Zhu, J-H; Chen, R.; Yi, W.; Cantin, G. T.; Fearns, C.; Yang, Y.; Yates, J. R., III; Lee, J-D			Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling	ONCOGENE			English	Article						PTPN13; Her2; dephosphorylation; invasion and negative feedback	HUMAN-BREAST-CANCER; TUMOR-SUPPRESSOR; GROWTH; CELLS; NEU; METASTASIS; MUTATIONS; CARCINOMA; DISEASE; GENE	Deregulated Her2/ErbB2 receptor tyrosine kinase drives tumorigenesis and tumor progression in a variety of human tissues. Her2 transmits oncogenic signals through phosphorylation of its cytosolic domain. To study innate cellular mechanisms for containing Her2 oncogenic phosphorylation, a siRNA phosphatase library was screened for cellular phosphatase(s) that enhance phosphorylation in the signaling motif of Her2 after knockdown. We found that silencing protein tyrosine phosphatase PTPN13 significantly augmented growth factor-induced phosphorylation of the Her2 signaling domain and promoted the invasiveness of Her2-deregulated cancer cells. In addition, we discovered that growth factor-induced phosphorylation of PTPN13 was essential for the dephosphorylation of Her2 suggesting a negative feedback mechanism induced by growth factor to inhibit cellular Her2 activity through PTPN13. Importantly, we showed that PTPN13 mutations previously reported in human tumors significantly reduced the phosphatase activity of PTPN13, and consequently elevated the oncogenic potential of Her2 and the invasiveness of Her2-overexpressing human cancer cells. Taken together, these results suggest that cellular PTPN13 inhibits Her2 activity by dephosphorylating the signal domain of Her2 and plays a role in attenuating invasiveness and metastasis of Her2 overactive tumors.	[Zhu, J-H; Chen, R.; Yi, W.; Fearns, C.; Lee, J-D] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; [Cantin, G. T.; Yates, J. R., III] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Yang, Y.] Johnson & Johnson Pharmaceut Res & Dev, San Diego, CA USA	Scripps Research Institute; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, IMM-12,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jdlee@scripps.edu	Zhu, Jian-Hong/E-3927-2010	Zhu, Jian-Hong/0000-0001-9412-8264	NATIONAL CANCER INSTITUTE [R01CA114059, R01CA079871] Funding Source: NIH RePORTER; NCI NIH HHS [CA114059, CA079871] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200; Cantin GT, 2006, J PROTEOME RES, V5, P127, DOI 10.1021/pr050270m; Engelman JA, 2006, CLIN CANCER RES, V12, p4372S, DOI 10.1158/1078-0432.CCR-06-0795; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Gensler M, 2004, J BIOL CHEM, V279, P12110, DOI 10.1074/jbc.M309527200; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hayes DF, 2002, SEMIN ONCOL, V29, P231, DOI 10.1053/sonc.2002.32899; Inazawa J, 1996, GENOMICS, V31, P240, DOI 10.1006/geno.1996.0039; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Menard S, 2004, CELL MOL LIFE SCI, V61, P2965, DOI 10.1007/s00018-004-4277-7; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tartaglia M, 2005, EUR J MED GENET, V48, P81, DOI 10.1016/j.ejmg.2005.03.001; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; Yeh SH, 2006, CLIN CANCER RES, V12, P1097, DOI 10.1158/1078-0432.CCR-05-1383	27	55	55	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2525	2531		10.1038/sj.onc.1210922	http://dx.doi.org/10.1038/sj.onc.1210922			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982484				2022-12-28	WOS:000255057000002
J	Caramel, J; Medjkane, S; Quignon, F; Delattre, O				Caramel, J.; Medjkane, S.; Quignon, F.; Delattre, O.			The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors	ONCOGENE			English	Article						SNF5/INI1; rhabdoid tumor suppressor; differentiation; SWI/SNF; adipocyte	CHROMATIN-REMODELING COMPLEX; SWI/SNF COMPLEX; BETA ISOFORM; CELL-CYCLE; SNF5; HSNF5/INI1; SUPPRESSOR; MUTATIONS; TRANSCRIPTION; BINDING	ATP-dependent SWI/SNF chromatin remodeling complexes regulate cell-cycle and play critical roles in a variety of differentiation pathways. The core subunit SNF5/INI1 is a tumor suppressor that is inactivated in a highly aggressive childhood cancer of unknown cellular origin, termed malignant rhabdoid tumor (MRT). The highly undifferentiated phenotype of this tumor suggests that the loss-of-function of hSNF5/INI1 impairs specific differentiation programs of the MRT parental cell. Based on the hypothesis that these programs might be reinitialized upon hSNF5/INI1 re-expression in MRTs, we show that some MRT cell lines can differentiate toward the adipogenic lineage. We further show that the knock down of the SNF5/INI1 subunit abrogates adipocyte differentiation of murine 3T3-L1 preadipocytes and of human mesenchymal stem cells. Finally, we provide evidence that hSNF5/INI1 cooperates with C/EBP beta and PPAR gamma 2 transcriptional regulators to activate the expression of adipocyte-specific genes. These data indicate that not only the ATPase subunit of the SWI/SNF complex, but also SNF5/INI1 is required for adipocyte differentiation. They further show that MRT cell lines harbor an adipogenic differentiation potential and that the tumor suppressor role of the SNF5/INI1 subunit may rely on its ability to regulate the balance between cell proliferation and differentiation.	[Caramel, J.; Medjkane, S.; Quignon, F.; Delattre, O.] Inst Curie, INSERM, U830, Sect Rech,Unite Genet & Biol Canc, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite	Delattre, O (corresponding author), Inst Curie, INSERM, U830, Sect Rech,Unite Genet & Biol Canc, 26 Rue Ulm, F-75248 Paris 05, France.	olivier.delattre@curie.fr	Quignon, Frédérique/P-4249-2017	Medjkane, Souhila/0000-0001-7973-7707; Caramel, Julie/0000-0002-8883-918X; delattre, olivier/0000-0002-8730-2276				Albanese P, 2006, EUR J CANCER, V42, P2326, DOI 10.1016/j.ejca.2006.03.028; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Chai JJ, 2007, CANCER RES, V67, P3002, DOI 10.1158/0008-5472.CAN-06-4207; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Dennis JE, 2002, STEM CELLS, V20, P205, DOI 10.1634/stemcells.20-3-205; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Hata K, 2005, MOL CELL BIOL, V25, P1971, DOI 10.1128/MCB.25.5.1971-1979.2005; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kashiwagi M, 2007, DEVELOPMENT, V134, P1571, DOI 10.1242/dev.001750; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Krabbe C, 2005, APMIS, V113, P831, DOI 10.1111/j.1600-0463.2005.apm_3061.x; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lee MC, 2002, NEUROPATHOLOGY, V22, P252, DOI 10.1046/j.1440-1789.2002.00458.x; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Medjkane S, 2004, CANCER RES, V64, P3406, DOI 10.1158/0008-5472.CAN-03-3004; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Saladin R, 1999, CELL GROWTH DIFFER, V10, P43; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	40	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2035	2044		10.1038/sj.onc.1210847	http://dx.doi.org/10.1038/sj.onc.1210847			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922027				2022-12-28	WOS:000254359100008
J	Banjac, A; Perisic, T; Sato, H; Seiler, A; Bannai, S; Weiss, N; Kolle, P; Tschoep, K; Issels, RD; Daniel, PT; Conrad, M; Bornkamm, GW				Banjac, A.; Perisic, T.; Sato, H.; Seiler, A.; Bannai, S.; Weiss, N.; Koelle, P.; Tschoep, K.; Issels, R. D.; Daniel, P. T.; Conrad, M.; Bornkamm, G. W.			The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death	ONCOGENE			English	Article						cystine-glutamate exchange; glutathione metabolism; lipid peroxidation; redox regulation; system x(c)(-)	CYSTINE TRANSPORT ACTIVITY; BURKITT-LYMPHOMA CELLS; THIOREDOXIN REDUCTASE; GLUTATHIONE SYNTHESIS; GLUTAMATE TOXICITY; APOPTOSIS; INDUCTION; FIBROBLASTS; METABOLISM; INHIBITION	The glutathione-dependent system is one of the key systems regulating cellular redox balance, and thus cell fate. Cysteine, typically present in its oxidized form cystine in the extracellular space, is regarded as the rate-limiting substrate for glutathione (GSH) synthesis. Cystine is transported into cells by the highly specific amino-acid antiporter system x(c)(-). Since Burkitt's Lymphoma (BL) cells display limited uptake capacity for cystine, and are thus prone to oxidative stress-induced cell death, we stably expressed the substrate-specific subunit of system x(c)(-), xCT, in HH514 BL cells. xCT-overexpressing cells became highly resistant to oxidative stress, particularly upon GSH depletion. Contrary to previous predictions, the increase of intracellular cysteine did not affect the cellular GSH pool, but concomitantly boosted extracellular cysteine concentrations. Even though cells were depleted of bulk GSH, xCT overexpression maintained cellular integrity by protecting against lipid peroxidation, a very early event in cell death progression. Our results show that system x(c)(-) protects against oxidative stress not by elevating intracellular GSH levels, but rather creates a reducing extracellular environment by driving a highly efficient cystine/cysteine redox cycle. Our findings show that the cystine/cysteine redox cycle by itself must be viewed as a discrete major regulator of cell survival.	[Banjac, A.; Seiler, A.; Conrad, M.; Bornkamm, G. W.] GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumor Genet, Munich, Germany; [Perisic, T.; Seiler, A.] Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 305, Japan; [Weiss, N.; Koelle, P.] Univ Munich, Med Poliklin Innnenstadt, D-8000 Munich, Germany; [Tschoep, K.; Issels, R. D.] Univ Munich, GSF, Klin Kooperat Grp Hyperthermie, Med Clin 3, Munich, Germany; [Daniel, P. T.] Humboldt Univ, Med Klin Schwerpunkt Hamatol & Onkol, Berlin, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Tsukuba; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Humboldt University of Berlin	Conrad, M (corresponding author), GSF, Res Ctr, Inst Clin Mol Biol & Tumor Genet, Marchioninistr 25, D-81377 Munich, Germany.	marcus.conrad@gsf.de	Conrad, Marcus/E-8792-2015	Conrad, Marcus/0000-0003-1140-5612; Issels, Rolf/0000-0002-3494-6561				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; BANNAI S, 1989, J BIOL CHEM, V264, P18480; BANNAI S, 1982, J CELL PHYSIOL, V112, P265, DOI 10.1002/jcp.1041120216; Brielmeier M, 1998, NUCLEIC ACIDS RES, V26, P2082, DOI 10.1093/nar/26.9.2082; BROOME JD, 1973, J EXP MED, V138, P574, DOI 10.1084/jem.138.3.574; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; DROGE W, 1991, AM J MED, V91, P140; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; FALK MH, 1993, INT J CANCER, V55, P485, DOI 10.1002/ijc.2910550327; FalK MH, 1998, INT J CANCER, V75, P620, DOI 10.1002/(SICI)1097-0215(19980209)75:4<620::AID-IJC21>3.0.CO;2-B; Feussner A, 1997, EUR J CLIN CHEM CLIN, V35, P687; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; Hattori H, 2005, BIOCHEM BIOPH RES CO, V337, P464, DOI 10.1016/j.bbrc.2005.09.076; ISHII T, 1987, J CELL PHYSIOL, V133, P330, DOI 10.1002/jcp.1041330217; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Jonas CR, 2002, FREE RADICAL BIO MED, V33, P1499, DOI 10.1016/S0891-5849(02)01081-X; Kuppner MC, 2003, BLOOD, V102, P3668, DOI 10.1182/blood-2003-05-1408; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; Melino G, 2005, CELL DEATH DIFFER, V12, P1155, DOI 10.1038/sj.cdd.4401740; METCALF D, 1976, J IMMUNOL, V116, P635; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nicotera P, 2004, ONCOGENE, V23, P2757, DOI 10.1038/sj.onc.1207559; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; NOVOGRODSKY A, 1979, P NATL ACAD SCI USA, V76, P4932, DOI 10.1073/pnas.76.10.4932; Okita C, 2004, BIOTECHNIQUES, V36, P418, DOI 10.2144/04363ST01; Okuno S, 2003, BRIT J CANCER, V88, P951, DOI 10.1038/sj.bjc.6600786; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; Sipos K, 2002, J BIOL CHEM, V277, P26944, DOI 10.1074/jbc.M200677200; Sonoda Y, 2004, BBA-MOL CELL BIOL L, V1683, P22, DOI 10.1016/j.bbalip.2004.04.002; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Ye ZC, 1999, CANCER RES, V59, P4383	42	193	201	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1618	1628		10.1038/sj.onc.1210796	http://dx.doi.org/10.1038/sj.onc.1210796			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828297	Bronze			2022-12-28	WOS:000253815800014
J	Gort, EH; van Haaften, G; Verlaan, I; Groot, AJ; Plasterk, RHA; Shvarts, A; Suijkerbuijk, KPM; van Laar, T; van der Wall, E; Raman, V; van Diest, PJ; Tijsterman, M; Vooijs, M				Gort, E. H.; van Haaften, G.; Verlaan, I.; Groot, A. J.; Plasterk, R. H. A.; Shvarts, A.; Suijkerbuijk, K. P. M.; van Laar, T.; van der Wall, E.; Raman, V.; van Diest, P. J.; Tijsterman, M.; Vooijs, M.			The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2 alpha	ONCOGENE			English	Article						hypoxia; HIF-2 alpha; TWIST1; C. elegans; cancer	ENDOTHELIAL GROWTH-FACTOR; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; C-ELEGANS; TRANSCRIPTIONAL RESPONSE; FUNCTIONAL-ANALYSIS; DROSOPHILA EMBRYO; FACTOR-1 HIF-1; UP-REGULATION; FACTOR-I	Hypoxia-inducible factors (HIFs) are highly conserved transcription factors that play a crucial role in oxygen homeostasis. Intratumoral hypoxia and genetic alterations lead to HIF activity, which is a hallmark of solid cancer and is associated with poor clinical outcome. HIF activity is regulated by an evolutionary conserved mechanism involving oxygen-dependent HIF alpha protein degradation. To identify novel components of the HIF pathway, we performed a genome-wide RNA interference screen in Caenorhabditis elegans, to suppress HIF-dependent phenotypes, like egg-laying defects and hypoxia survival. In addition to hif-1 (HIF alpha) and aha-1 (HIF beta), we identified hlh-8, gska-3 and spe-8. The hlh-8 gene is homologous to the human oncogene TWIST1. We show that TWIST1 expression in human cancer cells is enhanced by hypoxia in a HIF-2 alpha-dependent manner. Furthermore, intronic hypoxia response elements of TWIST1 are regulated by HIF-2 alpha, but not HIF-1 alpha. These results identify TWIST1 as a direct target gene of HIF-2 alpha, which may provide insight into the acquired metastatic capacity of hypoxic tumors.	[Gort, E. H.; Verlaan, I.; Groot, A. J.; Shvarts, A.; Suijkerbuijk, K. P. M.; van Laar, T.; van Diest, P. J.; Vooijs, M.] Univ Med Ctr Utrecht, Dept Pathol, NL-3508 GA Utrecht, Netherlands; [van Haaften, G.; Plasterk, R. H. A.; Tijsterman, M.] Ctr Biomed Genet, Hubrecht Lab, Utrecht, Netherlands; [van der Wall, E.] Univ Med Ctr Utrecht, Dept Med Oncol, NL-3508 GA Utrecht, Netherlands; [Raman, V.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA	Utrecht University; Utrecht University Medical Center; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Johns Hopkins University	Vooijs, M (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3508 GA Utrecht, Netherlands.	m.vooijs@umcutrecht.nl	van Haaften, Gijs/G-7832-2012; Tijsterman, Marcel/H-5663-2018; Vooijs, Marc/K-3522-2019	van Haaften, Gijs/0000-0003-3033-0329; Tijsterman, Marcel/0000-0001-8465-9002; Suijkerbuijk, Karijn/0000-0003-3604-5430				Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Corsi AK, 2002, DEVELOPMENT, V129, P2761; Dekanty A, 2005, J CELL SCI, V118, P5431, DOI 10.1242/jcs.02648; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erbel PJA, 2003, P NATL ACAD SCI USA, V100, P15504, DOI 10.1073/pnas.2533374100; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gort EH, 2006, ONCOGENE, V25, P6123, DOI 10.1038/sj.onc.1209643; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harfe BD, 1998, GENE DEV, V12, P2623, DOI 10.1101/gad.12.16.2623; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kress S, 1998, J CANCER RES CLIN, V124, P315, DOI 10.1007/s004320050175; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Padilla PA, 2002, MOL BIOL CELL, V13, P1473, DOI 10.1091/mbc.01-12-0594; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ravi R, 2000, GENE DEV, V14, P34; Salem Y, 2005, CELL SIGNAL, V17, P341, DOI 10.1016/j.cellsig.2004.08.001; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shen C, 2005, J BIOL CHEM, V280, P20580, DOI 10.1074/jbc.M501894200; Shen C, 2003, ANN NY ACAD SCI, V995, P191, DOI 10.1111/j.1749-6632.2003.tb03222.x; Shen C, 2006, GENETICS, V174, P1205, DOI 10.1534/genetics.106.063594; Shibata T, 1998, INT J RADIAT ONCOL, V42, P913, DOI 10.1016/S0360-3016(98)00298-3; SZYMANSKI P, 1995, EMBO J, V14, P2229, DOI 10.1002/j.1460-2075.1995.tb07217.x; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; To KKW, 2005, J BIOL CHEM, V280, P38102, DOI 10.1074/jbc.M504342200; TRENT C, 1983, GENETICS, V104, P619; van Haaften G, 2004, P NATL ACAD SCI USA, V101, P12992, DOI 10.1073/pnas.0403131101; Vaupel P, 2005, TRANSFUS CLIN BIOL, V12, P5, DOI 10.1016/j.tracli.2004.11.005; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wilkie AOM, 2001, NAT REV GENET, V2, P458, DOI 10.1038/35076601; Woelfle U, 2003, CANCER RES, V63, P5679; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	54	107	117	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1501	1510		10.1038/sj.onc.1210795	http://dx.doi.org/10.1038/sj.onc.1210795			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873906				2022-12-28	WOS:000253815800001
J	Jiang, Y; Prunier, C; Howe, PH				Jiang, Y.; Prunier, C.; Howe, P. H.			The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin	ONCOGENE			English	Article						disabled-2 (Dab2); axin; wnt; beta-catenin; differentiation	BETA-CATENIN; NEGATIVE REGULATOR; ENDOCYTOSIS; PROTEIN; DOMAIN; MOUSE; PHOSPHORYLATION; MECHANISM; PATHWAY; ADAPTER	beta-Catenin-mediated Wnt signaling is essential in embryonic development and in adult tissues. Recent studies have demonstrated that Axin not only plays an important inhibitory role in coordinating beta-catenin degradation, but is itself degraded by the low-density-lipoprotein receptor-related protein (LRP) 5/6 Wnt co-receptor. Here, we demonstrate that the endocytic adaptor molecule Disabled-2 (Dab2), which we have previously demonstrated to act as an inhibitor of beta-catenin signaling, interacts with Axin and prevents its interaction with and degradation by the LRP5 co-receptor, thereby increasingits half-life and stabilization. Dab2 levels induced during retinoic acid-induced differentiation of F9, or during transforming growth factor-beta-induced epithelial-mesenchymal transdifferentiation of mouse mammary epithelial cells result in the stabilization of Axin and concomitant inhibition of beta-catenin signaling. Ectopic expression of Dab2 in F9 cells as well as in transformed cell lines results in increased Axin expression and attenuation of Wnt-mediated signaling. We conclude that Dab2 may play an important role in the maintenance of the differentiated state and restrain Wnt- mediated proliferation through its association with and modulation of Axin.	[Jiang, Y.; Howe, P. H.] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; [Prunier, C.] Hop St Antoine, INSERM, U673, F-75571 Paris, France	Cleveland Clinic Foundation; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Howe, PH (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Canc Biol, NB4, Cleveland, OH 44195 USA.	howep@ccf.org	Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273	NCI NIH HHS [R01 CA080095, R01 CA055536-18, R01 CA055536, CA80095, CA55536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055536, R01CA055536, R01CA080095] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BILIC J, 2007, J CELL SCI, V119, P395; Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826; Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; HERBER B, 1994, ONCOGENE, V9, P1295; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; KAKIMURA DM, 2001, TRAFFIC, V7, P324; Kleeff J, 2002, DIS COLON RECTUM, V45, P1242, DOI 10.1007/s10350-004-6399-2; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Lickert H, 2005, DEVELOPMENT, V132, P2599, DOI 10.1242/dev.01842; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Prunier C, 2004, GROWTH FACTORS, V22, P141, DOI 10.1080/08977190410001720860; Shibamoto S, 2004, EXP CELL RES, V292, P11, DOI 10.1016/j.yexcr.2003.08.009; Shibamoto S, 1998, GENES CELLS, V3, P659; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; WILES MV, 1988, DEVELOPMENT, V104, P403; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003; Yu A, 2007, DEV CELL, V12, P129, DOI 10.1016/j.devcel.2006.10.015; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	41	40	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1865	1875		10.1038/sj.onc.1210829	http://dx.doi.org/10.1038/sj.onc.1210829			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17922036	Green Accepted			2022-12-28	WOS:000254150600006
J	Fennell, DA; Chacko, A; Mutti, L				Fennell, D. A.; Chacko, A.; Mutti, L.			BCL-2 family regulation by the 20S proteasome inhibitor bortezomib	ONCOGENE			English	Review						mitochondria; proteasome; BAX; BAK; BIM; NOXA	PRO-APOPTOTIC PROTEIN; MANTLE-CELL LYMPHOMA; CYTOCHROME-C RELEASE; BH3 MIMETIC ABT-737; BIM MESSENGER-RNA; BH3-ONLY PROTEIN; ENDOPLASMIC-RETICULUM; MITOCHONDRIAL DYSFUNCTION; KAPPA-B; CASPASE ACTIVATION	Bortezomib (Velcade, PS341) was licensed in 2003 as a first-in-class 20S proteasome inhibitor indicated for treatment of multiple myeloma, and is currently being evaluated clinically in a range of solid tumours. The mechanisms underlying its cancer cell toxicity are complex. A growing body of evidence suggests proteasome inhibition-dependent regulation of the BCL-2 family is a critical requirement. In particular, the stabilization of BH3-only proteins BIK, NOXA and BIM, appear to be essential for effecting BAX- and BAK-dependent cell death. These mechanisms are reviewed and the implications for favourable novel drug interactions are highlighted.	[Fennell, D. A.; Chacko, A.] Queens Univ Belfast, Thorac Oncol Res Grp, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [Mutti, L.] Med Gen Lab Oncol Clin, Vercelli, Italy	Queens University Belfast	Fennell, DA (corresponding author), City Hosp, No Ireland Canc Ctr, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.fennell@qub.ac.uk	Mutti, Luciano/A-3545-2011	Mutti, Luciano/0000-0002-1578-2637				Abrams MT, 2004, J BIOL CHEM, V279, P55809, DOI 10.1074/jbc.M411767200; Adachi M, 2005, CELL DEATH DIFFER, V12, P192, DOI 10.1038/sj.cdd.4401529; Adams J, 1999, CANCER RES, V59, P2615; Adams J, 1998, BIOORG MED CHEM LETT, V8, P333, DOI 10.1016/S0960-894X(98)00029-8; Adams KW, 2007, J BIOL CHEM, V282, P6192, DOI 10.1074/jbc.M610643200; An JB, 2004, MOL CANCER THER, V3, P727; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Anan A, 2006, HEPATOLOGY, V43, P335, DOI 10.1002/hep.21036; Anderson KC, 2005, SEMIN HEMATOL, V42, pS3, DOI 10.1053/j.seminhematol.2005.10.001; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; BOYD JM, 1995, ONCOGENE, V11, P1921; Bross PF, 2004, CLIN CANCER RES, V10, P3954, DOI 10.1158/1078-0432.CCR-03-0781; Brunelle JK, 2007, MOL CELL BIOL, V27, P1222, DOI 10.1128/MCB.01535-06; Campas C, 2006, EXP HEMATOL, V34, P1663, DOI 10.1016/j.exphem.2006.07.008; Canfield SE, 2006, MOL CANCER THER, V5, P2043, DOI 10.1158/1535-7163.MCT-05-0437; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Concannon CG, 2007, ONCOGENE, V26, P1681, DOI 10.1038/sj.onc.1209974; Coquelle A, 2006, CELL DEATH DIFFER, V13, P873, DOI 10.1038/sj.cdd.4401881; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duechler M, 2005, EUR J HAEMATOL, V74, P407, DOI 10.1111/j.1600-0609.2004.00406.x; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fahy BN, 2005, CANCER CHEMOTH PHARM, V56, P46, DOI 10.1007/s00280-004-0944-5; Fanucchi MP, 2006, J CLIN ONCOL, V24, P5025, DOI 10.1200/JCO.2006.06.1853; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Hideshima T, 2001, CANCER RES, V61, P3071; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Kabore AF, 2006, APOPTOSIS, V11, P1175, DOI 10.1007/s10495-006-8048-9; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Landowski TH, 2005, CANCER RES, V65, P3828, DOI 10.1158/0008-5472.CAN-04-3684; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LeBlanc R, 2002, CANCER RES, V62, P4996; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Ling YH, 2003, J BIOL CHEM, V278, P33714, DOI 10.1074/jbc.M302559200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; MacLaren AP, 2001, CELL DEATH DIFFER, V8, P210, DOI 10.1038/sj.cdd.4400801; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Matsui H, 2007, MOL CELL, V25, P99, DOI 10.1016/j.molcel.2006.12.007; MAURER F, 1906, HDB VERGLEICHENDEN 1, V3, P1; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Mori S, 2004, CANCER-AM CANCER SOC, V100, P1673, DOI 10.1002/cncr.20164; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Mortenson MM, 2005, LUNG CANCER, V49, P163, DOI 10.1016/j.lungcan.2005.01.006; Nawrocki ST, 2004, MOL CANCER THER, V3, P59; Nencioni A, 2005, CLIN CANCER RES, V11, P4259, DOI 10.1158/1078-0432.CCR-04-2496; Nencioni A, 2005, BLOOD, V105, P3255, DOI 10.1182/blood-2004-10-3984; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nikrad M, 2005, MOL CANCER THER, V4, P443; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pagano M, 2003, CANCER CELL, V4, P251, DOI 10.1016/S1535-6108(03)00243-5; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Perez-Galan P, 2007, BLOOD, V109, P4441, DOI 10.1182/blood-2006-07-034173; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qin JZ, 2006, CANCER RES, V66, P9636, DOI 10.1158/0008-5472.CAN-06-0747; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Tong T, 2005, MOL CELL BIOL, V25, P4488, DOI 10.1128/MCB.25.11.4488-4500.2005; Tong Y, 2001, MOL CANCER THER, V1, P95; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Warr MR, 2005, FEBS LETT, V579, P5603, DOI 10.1016/j.febslet.2005.09.028; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Witters LM, 2007, ONCOL REP, V17, P465; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yasuda M, 1999, CANCER RES, V59, P533; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zhang LZ, 2004, J BIOL CHEM, V279, P20858, DOI 10.1074/jbc.M310643200; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu HB, 2005, CANCER BIOL THER, V4, P781, DOI 10.4161/cbt.4.7.1897; Zhu HB, 2005, ONCOGENE, V24, P4993, DOI 10.1038/sj.onc.1208683	128	126	132	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1189	1197		10.1038/sj.onc.1210744	http://dx.doi.org/10.1038/sj.onc.1210744			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17828309				2022-12-28	WOS:000253407000001
J	Eckert, A; Bock, BC; Tagscherer, KE; Haas, TL; Grund, K; Sykora, J; Herold-Mende, C; Ehemann, V; Hollstein, M; Chneiweiss, H; Wiestler, OD; Walczak, H; Roth, W				Eckert, A.; Boeck, B. C.; Tagscherer, K. E.; Haas, T. L.; Grund, K.; Sykora, J.; Herold-Mende, C.; Ehemann, V.; Hollstein, M.; Chneiweiss, H.; Wiestler, O. D.; Walczak, H.; Roth, W.			The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway	ONCOGENE			English	Article						apoptosis; brain tumors; PEA-15/PED; glucose; MAP kinases; ERK1/2	DEATH EFFECTOR DOMAIN; CANCER-CELLS; CYTOPLASMIC SEQUESTRATION; INTEGRIN ACTIVATION; GLIOMA-CELLS; IN-VITRO; PED/PEA-15; EXPRESSION; ASTROCYTES; PHOSPHOPROTEIN	PEA-15 ( phosphoprotein enriched in astrocytes 15 kDa) is a death effector domain-containing protein, which is involved in the regulation of apoptotic cell death. Since PEA-15 is highly expressed in cells of glia l origin, we studied the role of PEA-15 in human malignant brain tumors. Immunohistochemical analysis of PEA-15 expression shows strong immunoreactivity in astrocytomas and glioblastomas. Phosphorylation of PEA-15 at Ser(116) is found in vivo in perinecrotic areas in glioblastomas and in vitro after glucose deprivation of glioblastoma cells. Overexpression of PEA-15 induces a marked resistance against glucose deprivation-induced apoptosis, whereas small interfering RNA (siRNA)-mediated downregulation of endogenous PEA-15 results in the sensitization to glucose withdrawal-mediated cell death. This antiapoptotic activity of PEA-15 under low glucose conditions depends on its phosphorylation at Ser116. Moreover, siRNA-mediated knockdown of PEA-15 abolishes the tumorigenicity of U87MG glioblastoma cells in vivo. PEA-15 regulates the level of phosphorylated extracellular-regulated kinase ( ERK) 1/ 2 in glioblastoma cells and the PEA-15-dependent protection from glucose deprivation-induced cell death requires ERK1/2 signaling. PEA-15 transcriptionally upregulates the Glucose Transporter 3, which is abrogated by the inhibition of ERK1/2 phosphorylation. Taken together, our findings suggest that Ser(116)-phosphorylated PEA-15 renders glioma cells resistant to glucose deprivation-mediated cell death as encountered in poor microenvironments, for example in perinecrotic areas of glioblastomas.	[Eckert, A.; Boeck, B. C.; Tagscherer, K. E.; Haas, T. L.; Grund, K.; Sykora, J.; Wiestler, O. D.; Walczak, H.; Roth, W.] German Canc Res Ctr, Div Apoptosis Regulat, D-69120 Heidelberg, Germany; [Herold-Mende, C.] Univ Heidelberg, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Ehemann, V.; Roth, W.] Univ Heidelberg, Inst Pathol, D-6900 Heidelberg, Germany; [Hollstein, M.] German Canc Res Ctr, Dept Genet Alterat Carcinogenesis, D-69120 Heidelberg, Germany; [Chneiweiss, H.] INSERM, U752, Paris, France	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Institut National de la Sante et de la Recherche Medicale (Inserm)	Roth, W (corresponding author), German Canc Res Ctr, Div Apoptosis Regulat, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	W.Roth@dkfz.de	Walczak, Henning/AAV-2214-2020; Tagscherer, Katrin/AAS-3809-2021; herve, chneiweiss/Q-6818-2019	Walczak, Henning/0000-0002-6312-4591; Tagscherer, Katrin/0000-0002-0657-6399; herve, chneiweiss/0000-0001-7675-5061; Haas, Tobias/0000-0003-2336-0263				ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Bartholomeusz C, 2006, ONCOGENE, V25, P79, DOI 10.1038/sj.onc.1209014; Boulos S, 2007, NEUROBIOL DIS, V25, P54, DOI 10.1016/j.nbd.2006.08.012; Chou FL, 2003, J BIOL CHEM, V278, P52587, DOI 10.1074/jbc.M309322200; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; Dong G, 2001, CANCER RES, V61, P4797; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Formisano P, 2005, ONCOGENE, V24, P7012, DOI 10.1038/sj.onc.1208871; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Hao CH, 2001, CANCER RES, V61, P1162; Karcher S, 2006, INT J CANCER, V118, P2182, DOI 10.1002/ijc.21648; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Krueger J, 2005, MOL BIOL CELL, V16, P3552, DOI 10.1091/mbc.E04-11-1007; Kubes M, 1998, J NEUROCHEM, V71, P1307; Nelson DA, 2004, GENE DEV, V18, P2095, DOI 10.1101/gad.1204904; NISHIOKA T, 1992, CANCER RES, V52, P3972; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Renault-Mihara F, 2006, MOL BIOL CELL, V17, P5141, DOI 10.1091/mbc.E05-11-1072; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Sharif A, 2004, NEUROSCIENCE, V126, P263, DOI 10.1016/j.neuroscience.2004.02.039; Song JH, 2006, J NEUROSCI, V26, P3299, DOI 10.1523/JNEUROSCI.5572-05.2006; Stassi G, 2005, CANCER RES, V65, P6668, DOI 10.1158/0008-5472.CAN-04-4009; Todaro M, 2006, CANCER RES, V66, P1491, DOI 10.1158/0008-5472.CAN-05-2514; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; Vigliotta G, 2004, MOL CELL BIOL, V24, P5005, DOI 10.1128/MCB.24.11.5005-5015.2004; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Ziegler A, 2001, CANCER RES, V61, P5595	37	44	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1155	1166		10.1038/sj.onc.1210732	http://dx.doi.org/10.1038/sj.onc.1210732			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700518				2022-12-28	WOS:000253136700015
J	Scavelli, C; Nico, B; Cirulli, T; Ria, R; Di Pietro, G; Mangieri, D; Bacigalupo, A; Mangialardi, G; Coluccia, AML; Caravita, T; Molica, S; Ribatti, D; Dammacco, F; Vacca, A				Scavelli, C.; Nico, B.; Cirulli, T.; Ria, R.; Di Pietro, G.; Mangieri, D.; Bacigalupo, A.; Mangialardi, G.; Coluccia, A. M. L.; Caravita, T.; Molica, S.; Ribatti, D.; Dammacco, F.; Vacca, A.			Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma	ONCOGENE			English	Article						basic fibroblast growth factor; macrophages; multiple myeloma; vascular endothelial growth factor; vasculogenesis	ENDOTHELIAL GROWTH-FACTOR; IN-VITRO; PROGENITOR CELLS; PERIPHERAL-BLOOD; HUMAN MONOCYTES; FACTOR VEGF; STEM-CELLS; ANGIOGENESIS; EXPRESSION; NEOVASCULARIZATION	Bone marrow macrophages of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies of undetermined significance (MGUS) and benign anemia (controls) were stimulated for 7 days with vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and analysed for the expression of endothelial cell (EC) markers by reverse transcription (RT) - PCR, real- time RT - PCR, western blot and immunofluorescence. Their vasculogenic ability was investigated in vitro in a Matrigel assay and in vivo on bone marrow biopsies through dual immunofluorescence and confocal laser microscopy. Active MM macrophages exposed to VEGF and bFGF acquired EC markers and formed capillary-like structures mimicking paired bone marrow ECs (multiple myeloma patient-derived endothelial cells, MMECs), with major responsiveness compared to macrophages from nonactive MM, MGUS or controls. Bone marrow biopsies of active MM harbored 'mosaic' vessels, being formed by MMECs, EC-like macrophages and macrophages themselves. These figures were rare in nonactive MM and absent in MGUS or controls. Our data indicate that macrophages contribute to build neovessels in active MM through vasculogenic mimicry, and this ability proceeds parallel to progression of the plasma cell tumors. Macrophages may be a target for the MM antivascular treatment.	[Scavelli, C.; Cirulli, T.; Ria, R.; Di Pietro, G.; Mangialardi, G.; Coluccia, A. M. L.; Dammacco, F.; Vacca, A.] Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, I-70124 Bari, Italy; [Nico, B.; Mangieri, D.] Univ Bari, Sch Med, Dept Human Anat & Histol, I-70124 Bari, Italy; [Bacigalupo, A.] San Martino Hosp, Dept Hematooncol, Genoa, Italy; [Caravita, T.] Univ Roma Tor Vergata, Sch Med, Dept Hematol, S Eugenio Hosp, Rome, Italy; [Molica, S.] Azienda Osped Pugliese Ciaccio, Dept Med Oncol, Catanzaro, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Genoa; IRCCS AOU San Martino IST; Sant'Eugenio Hospital; University of Rome Tor Vergata	Vacca, A (corresponding author), Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, Piazzi Giulio Cesare 11, I-70124 Bari, Italy.	a.vacca@dimo.uniba.it	Caravita, Tommaso/O-8929-2019; Dammacco, Franco/ABG-5728-2020; Vacca, Angelo/AAC-9558-2022; Ria, Roberto/I-4263-2015	Dammacco, Franco/0000-0003-2149-5471; Vacca, Angelo/0000-0002-4567-8216; Mangieri, Domenica/0000-0001-7350-9383; Ria, Roberto/0000-0002-1515-0090; Mangieri, Domenica/0000-0003-4871-1701	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Anghelina M, 2004, STEM CELLS DEV, V13, P665, DOI 10.1089/scd.2004.13.665; Anghelina M, 2006, AM J PATHOL, V168, P529, DOI 10.2353/ajpath.2006.050255; Anghelina M, 2006, J CELL MOL MED, V10, P708, DOI 10.2755/jcmm010.003.21; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BARONI CD, 1987, HISTOPATHOLOGY, V11, P1029; Bellamy WT, 1999, CANCER RES, V59, P728; Bender AT, 2004, CELL SIGNAL, V16, P365, DOI 10.1016/j.cellsig.2003.08.009; Bender CM, 1998, CANCER RES, V58, P95; Cavallaro U, 2006, EXP CELL RES, V312, P659, DOI 10.1016/j.yexcr.2005.09.019; Conejo-Garcia JR, 2005, BLOOD, V105, P679, DOI 10.1182/blood-2004-05-1906; Di Raimondo F, 2000, HAEMATOLOGICA, V85, P800; Dome B, 2007, AM J PATHOL, V170, P1, DOI 10.2353/ajpath.2007.060302; DURIE BGM, 1986, SEMIN ONCOL, V13, P300; Fehrenbach H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-60; Fernandez E, 2000, Gac Sanit, V14, P287; Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fujiyama S, 2003, CIRC RES, V93, P980, DOI 10.1161/01.RES.0000099245.08637.CE; Gendron RL, 1996, DEV BIOL, V177, P332, DOI 10.1006/dbio.1996.0167; GOTO F, 1993, LAB INVEST, V69, P508; Guidolin D, 2004, MICROVASC RES, V67, P117, DOI 10.1016/j.mvr.2003.11.002; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Kerjaschki D, 2006, NAT MED, V12, P230, DOI 10.1038/nm1340; Kumar S, 2004, BLOOD, V104, P1159, DOI 10.1182/blood-2003-11-3811; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Maruyama K, 2007, AM J PATHOL, V170, P1178, DOI 10.2353/ajpath.2007.060018; Moldovan NI, 2000, CIRC RES, V87, P378; Moldovan NI, 2005, STEM CELLS DEV, V14, P111, DOI 10.1089/scd.2005.14.111; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Rajkumar SV, 1999, LEUKEMIA, V13, P469, DOI 10.1038/sj.leu.2401336; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Ribatti D, 2006, ONCOGENE, V25, P4257, DOI 10.1038/sj.onc.1209456; RISAU W, 1988, DEVELOPMENT, V102, P471; Schmeisser A, 2001, CARDIOVASC RES, V49, P671, DOI 10.1016/S0008-6363(00)00270-4; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Vacca A, 2005, J CLIN ONCOL, V23, P5334, DOI 10.1200/JCO.2005.03.723; Vacca A, 1999, BLOOD, V93, P3064; Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood-2003-04-1338; Zhang H, 2005, BLOOD, V105, P3286, DOI 10.1182/blood-2004-06-2101; Zhao Y, 2003, P NATL ACAD SCI USA, V100, P2426, DOI 10.1073/pnas.0536882100	45	112	117	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					663	674		10.1038/sj.onc.1210691	http://dx.doi.org/10.1038/sj.onc.1210691			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667938				2022-12-28	WOS:000252674900010
J	Roses, RE; Xu, M; Koski, GK; Czerniecki, BJ				Roses, R. E.; Xu, M.; Koski, G. K.; Czerniecki, B. J.			Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer	ONCOGENE			English	Review						cancer; immunotherapy; Toll-like receptor; radiation	HUMAN DENDRITIC CELLS; ENHANCES TUMOR RESPONSE; TOTAL-BODY IRRADIATION; HEAT-SHOCK PROTEINS; CD8(+) T-CELLS; NF-KAPPA-B; IMMUNE-RESPONSE; GAMMA-IRRADIATION; MOUSE MODEL; MEDIATED REGRESSION	The identification of pathogen-associated molecular patterns, conserved microbial structures that act on Toll-like receptors, has led to a novel avenue of investigation aimed at developing a new generation of cancer immunotherapies. Ligation of Toll-like receptors results in the induction of robust immune responses that may be directed against tumor-associated antigens. Recent data suggest that such strategies may result in enhanced antitumor immunity. Nonetheless, as clinically effective immunotherapy for cancer remains a somewhat distant goal, attention has shifted toward multimodality approaches to cancer therapy, sometimes combining novel immune interventions and conventional treatments. The traditional view of radiation therapy as immunosuppressive has now been challenged, prompting a re-evaluation of its potential as an adjunct to immunotherapy. Radiation therapy can enhance the expression of tumor-associated antigens, induce immune-mediated targeting of tumor stroma, and diminish regulatory T cell activity. Recent evidence suggests that radiation therapy may also activate effectors of innate immunity through TLR-dependent mechanisms, thereby augmenting the adaptive immune response to cancer. In this paper, we will review evidence for enhanced tumor-directed immunity resulting from radiation exposure and early promising data suggesting synergistic effects of radiation and TLR-targeted immunotherapies.	[Roses, R. E.; Xu, M.; Czerniecki, B. J.] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Koski, G. K.] Cleveland Clin Fdn, Surg Res Ctr, Cleveland, OH 44195 USA	University of Pennsylvania; Pennsylvania Medicine; Cleveland Clinic Foundation	Czerniecki, BJ (corresponding author), Hosp Univ Penn, Dept Surg, 4 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	brian.czerniecki@uphs.upenn.edu			NCI NIH HHS [R01-CA096997-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096997] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acker JC, 1998, RADIAT RES, V149, P350, DOI 10.2307/3579697; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Ambach A, 2004, MOL IMMUNOL, V40, P1307, DOI 10.1016/j.molimm.2004.01.002; Antony PA, 2005, J IMMUNOL, V174, P2591, DOI 10.4049/jimmunol.174.5.2591; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Bourquin C, 2006, INT J CANCER, V118, P2790, DOI 10.1002/ijc.21681; Cao MD, 2004, CELL BIOL INT, V28, P223, DOI 10.1016/j.cellbi.2003.12.006; Cao ZA, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-11; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Chakraborty M, 2003, J IMMUNOL, V170, P6338, DOI 10.4049/jimmunol.170.12.6338; Chakravarty PK, 1999, CANCER RES, V59, P6028; Chakravarty PK, 2006, ONCOLOGY-BASEL, V70, P245, DOI 10.1159/000096288; Chiang CS, 2000, CANCER GENE THER, V7, P1172, DOI 10.1038/sj.cgt.7700217; COLE S, 1986, J INVEST DERMATOL, V87, P608, DOI 10.1111/1523-1747.ep12455853; Czerniecki BJ, 2007, CANCER RES, V67, P1842, DOI 10.1158/0008-5472.CAN-06-4038; Demaria S, 2005, CLIN CANCER RES, V11, P728; Demaria S, 2005, INT J RADIAT ONCOL, V63, P655, DOI 10.1016/j.ijrobp.2005.06.032; Demaria S, 2004, INT J RADIAT ONCOL, V58, P862, DOI 10.1016/j.ijrobp.2003.09.012; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; DUNN PL, 1991, J LEUKOCYTE BIOL, V49, P388, DOI 10.1002/jlb.49.4.388; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Hallahan DE, 1999, RADIAT RES, V152, P6, DOI 10.2307/3580044; Hallahan DE, 1998, CANCER RES, V58, P5216; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HAREYAMA M, 1991, CANCER, V67, P2269, DOI 10.1002/1097-0142(19910501)67:9<2269::AID-CNCR2820670910>3.0.CO;2-Z; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Hashimoto S, 1999, RADIAT RES, V151, P717, DOI 10.2307/3580211; HAUSER SH, 1993, CANCER RES, V53, P1952; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hong JH, 1999, INT J RADIAT BIOL, V75, P1421, DOI 10.1080/095530099139287; Ina Y, 2005, INT J RADIAT BIOL, V81, P721, DOI 10.1080/09553000500519808; ISHIHARA H, 1995, J RADIAT RES, V36, P112, DOI 10.1269/jrr.36.112; JAMES RFL, 1989, TRANSPLANTATION, V47, P929, DOI 10.1097/00007890-198906000-00001; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kim KW, 2004, INT J CANCER, V109, P685, DOI 10.1002/ijc.20036; Kochling J, 2003, CLIN CANCER RES, V9, P3142; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Liao YP, 2004, J IMMUNOL, V173, P2462, DOI 10.4049/jimmunol.173.4.2462; Liu HM, 1998, BLOOD, V92, P3730, DOI 10.1182/blood.V92.10.3730.422k20_3730_3736; Lohr F, 2000, MOL THER, V2, P195, DOI 10.1006/mthe.2000.0114; Macagno A, 2007, TRENDS IMMUNOL, V28, P227, DOI 10.1016/j.it.2007.03.008; Mason KA, 2005, CLIN CANCER RES, V11, P361; McBride WH, 2004, RADIAT RES, V162, P1, DOI 10.1667/RR3196; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Merrick A, 2005, BRIT J CANCER, V92, P1450, DOI 10.1038/sj.bjc.6602518; Milas L, 2004, CANCER RES, V64, P5074, DOI 10.1158/0008-5472.CAN-04-0926; Miller GM, 2003, ONCOLOGY-BASEL, V65, P229, DOI 10.1159/000074476; NEMOTO K, 1995, J RADIAT RES, V36, P125, DOI 10.1269/jrr.36.125; Nikitina EY, 2001, INT J CANCER, V94, P825, DOI 10.1002/1097-0215(20011215)94:6<825::AID-IJC1545>3.0.CO;2-5; NORTH RJ, 1986, J EXP MED, V164, P1652, DOI 10.1084/jem.164.5.1652; Paulos CM, 2007, J CLIN INVEST, V117, P2197, DOI 10.1172/JCI32205; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Scheffer SR, 2003, INT J CANCER, V103, P205, DOI 10.1002/ijc.10777; SCHREIBER RD, 2004, CANC IMMUN S1, V5, P1; Seetharam S, 1999, INT J ONCOL, V15, P769; Shi YH, 2007, CANCER RES, V67, P1823, DOI 10.1158/0008-5472.CAN-06-2381; Shigematsu A, 2007, J RADIAT RES, V48, P51, DOI 10.1269/jrr.06048; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; van Duin D, 2006, TRENDS IMMUNOL, V27, P49, DOI 10.1016/j.it.2005.11.005; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; WASSERMAN J, 1989, B NEW YORK ACAD MED, V65, P36; WEICHSELBAUM RR, 1994, CANCER RES, V54, P4266; Wesa A, 2007, J IMMUNOTHER, V30, P75, DOI 10.1097/01.cji.0000211316.15278.6e; Wrzesinski C, 2007, J CLIN INVEST, V117, P492, DOI 10.1172/JCI30414; Xu SW, 2006, SURGERY, V140, P170, DOI 10.1016/j.surg.2006.03.006; Xu SW, 2003, J IMMUNOL, V171, P2251, DOI 10.4049/jimmunol.171.5.2251; Zhang B, 2007, J EXP MED, V204, P49, DOI 10.1084/jem.20062056	75	71	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					200	207		10.1038/sj.onc.1210909	http://dx.doi.org/10.1038/sj.onc.1210909			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176601				2022-12-28	WOS:000252163600006
J	Bartek, J; Bartkova, J; Lukas, J				Bartek, J.; Bartkova, J.; Lukas, J.			DNA damage signalling guards against activated oncogenes and tumour progression	ONCOGENE			English	Review						DNA damage response; oncogenes; cellular senescence; cancer progression; DNA damage threshold; genetic instability	CELL-CYCLE CHECKPOINTS; INDUCED SENESCENCE; HUMAN TUMORIGENESIS; ATM ACTIVATION; PATHWAY; CANCER; P53; REPLICATION; INSTABILITY; TELOMERES	DNA damage response (DDR), the guardian of genomic integrity, emerges as an oncogene-inducible biological barrier against progression of cancer beyond its early stages. Recent evidence from both cell culture and animal models as well as analyses of clinical specimens show that activation of numerous oncogenes and loss of some tumour suppressors result in DNA replication stress and DNA damage that alarm the cellular DDR machinery, a multifaceted response orchestrated by the ATR-Chk1 and ATM-Chk2 kinase signalling pathways. Such activation of the DDR network leads to cellular senescence or death of oncogene-transformed cells, resulting in delay or prevention of tumorigenesis. At the same time, the ongoing chronic DDR activation creates selective pressure that eventually favours outgrowth of malignant clones with genetic or epigenetic defects in the genome maintenance machinery, such as aberrations in the ATM-Chk2-p53 cascade and other DDR components. Furthermore, the executive DDR machinery is shared by at least two anticancer barriers, as both the oncogene-induced DNA replication stress and telomere shortening impact the cell fate decisions through convergence on DNA damage signalling. In this study, we highlight recent advances in this rapidly evolving area of cancer research, with particular emphasis on mechanistic insights, emerging issues of special conceptual significance and discussion of major remaining challenges and implications of the concept of DDR as a tumorigenesis barrier for experimental and clinical oncology.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Danish Canc Soc, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Danish Cancer Society	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	jb@cancer.dk	Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BARTKOVA J, 2007, J ANDROL, V30, P282; BARTKOVA J, 2007, ONCOGENE; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Branzei D, 2005, CURR OPIN CELL BIOL, V17, P568, DOI 10.1016/j.ceb.2005.09.003; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fan C, 2006, BBA-MOL CELL RES, V1763, P1090, DOI 10.1016/j.bbamcr.2006.08.026; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985; Frame FM, 2006, ONCOGENE, V25, P3258, DOI 10.1038/sj.onc.1209352; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Powers JT, 2004, MOL CANCER RES, V2, P203; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Reimann M, 2007, BLOOD, V110, P2996, DOI 10.1182/blood-2007-02-075614; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147	34	415	430	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7773	7779		10.1038/sj.onc.1210881	http://dx.doi.org/10.1038/sj.onc.1210881			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066090				2022-12-28	WOS:000251537900008
J	Wickrema, A; Crispino, JD				Wickrema, A.; Crispino, J. D.			Erythroid and megakaryocytic transformation	ONCOGENE			English	Review						AMKL; erythroleukemia; myeloproliferative diseases; GATA1; RUNX1; Fli-1; friend virus	ACUTE MEGAKARYOBLASTIC LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE JAK2; ZINC-FINGER PROTEIN; DOWN-SYNDROME; GENE-EXPRESSION; MYELODYSPLASTIC SYNDROME; AML1/PEBP2-ALPHA-B GENE; ACTIVATING MUTATION	Red blood cells and megakaryocytes arise from a common precursor, the megakaryocyte- erythroid progenitor and share many regulators including the transcription factors GATA- 1 and GFI- 1B and signaling molecules such as JAK2 and STAT5. These lineages also share the distinction of being associated with rare, but aggressive malignancies that have very poor prognoses. In this review, we will briefly summarize features of normal development of red blood cells and megakaryocytes and also highlight events that lead to their leukemic transformation. It is clear that much more work needs to be done to improve our understanding of the unique biology of these leukemias and to pave the way for novel targeted therapeutics.	Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA; Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA	Northwestern University; University of Chicago	Crispino, JD (corresponding author), Northwestern Univ, Div Hematol Oncol, 303 E Sup St,Lurie 5-11, Chicago, IL 60611 USA.	j-crispino@northwestern.edu		Crispino, John/0000-0002-8182-8306	NCI NIH HHS [R01 CA101774-05, R01 CA101774] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101774] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelhaleem M, 2007, LEUKEMIA, V21, P352, DOI 10.1038/sj.leu.2404503; Al-Ahmari A, 2006, BRIT J HAEMATOL, V133, P646, DOI 10.1111/j.1365-2141.2006.06097.x; Al-Kasim F, 2002, J PEDIAT HEMATOL ONC, V24, P9, DOI 10.1097/00043426-200201000-00004; Andrews NC, 1998, INT J BIOCHEM CELL B, V30, P429, DOI 10.1016/S1357-2725(97)00135-0; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; Barnard DR, 2007, PEDIATR BLOOD CANCER, V49, P17, DOI 10.1002/pbc.20951; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bernstein J, 2000, LEUKEMIA, V14, P216, DOI 10.1038/sj.leu.2401639; Blair DG, 2000, ONCOGENE, V19, P6472, DOI 10.1038/sj.onc.1204046; Bourquin JP, 2006, P NATL ACAD SCI USA, V103, P3339, DOI 10.1073/pnas.0511150103; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Carpinelli MR, 2004, P NATL ACAD SCI USA, V101, P6553, DOI 10.1073/pnas.0401496101; CARROLL A, 1991, BLOOD, V78, P748; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Chang AN, 2002, P NATL ACAD SCI USA, V99, P9237, DOI 10.1073/pnas.142302099; Chen FL, 2000, CURR BIOL, V10, P943, DOI 10.1016/S0960-9822(00)00625-4; Chen Z, 2007, BLOOD, V109, P1451, DOI 10.1182/blood-2006-08-038901; CHUNG SW, 1989, P NATL ACAD SCI USA, V86, P7957, DOI 10.1073/pnas.86.20.7957; Cramer EM, 1997, BLOOD, V89, P2336, DOI 10.1182/blood.V89.7.2336; Crispino JD, 2005, SEMIN CELL DEV BIOL, V16, P137, DOI 10.1016/j.semcdb.2004.11.002; Drexler HG, 2004, LEUKEMIA RES, V28, P1243, DOI 10.1016/j.leukres.2004.03.022; Drissen R, 2005, MOL CELL BIOL, V25, P5205, DOI 10.1128/MCB.25.12.5205-5214.2005; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Elmaagacli AH, 2007, BRIT J HAEMATOL, V136, P212, DOI 10.1111/j.1365-2141.2006.06407.x; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Fang C, 1998, VIROLOGY, V252, P46, DOI 10.1006/viro.1998.9453; Freyssinier JM, 1999, BRIT J HAEMATOL, V106, P912; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; Frohling S, 2005, J CLIN ONCOL, V23, P6285, DOI 10.1200/JCO.2005.05.010; Gamis AS, 2005, PEDIATR BLOOD CANCER, V44, P13, DOI 10.1002/pbc.20207; Garcon L, 2005, BLOOD, V105, P1448, DOI 10.1182/blood-2003-11-4068; Ge YB, 2004, CANCER RES, V64, P728, DOI 10.1158/0008-5472.CAN-03-2456; Ghinassi B, 2007, BLOOD, V109, P1460, DOI 10.1182/blood-2006-07-030726; Giarratana MC, 2005, NAT BIOTECHNOL, V23, P69, DOI 10.1038/nbt1047; Goerttler PS, 2005, BRIT J HAEMATOL, V129, P138, DOI 10.1111/j.1365-2141.2005.05416.x; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Gu TL, 2007, BLOOD, V110, P323, DOI 10.1182/blood-2006-10-052282; HANCOCK V, 1993, BRIT J HAEMATOL, V85, P692, DOI 10.1111/j.1365-2141.1993.tb03210.x; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; ITO E, 1995, BRIT J HAEMATOL, V90, P607, DOI 10.1111/j.1365-2141.1995.tb05591.x; Izraeli S, 2006, HEMATOL ONCOL, V24, P3, DOI 10.1002/hon.758; Jacobs-Helber SM, 2003, BLOOD, V101, P524, DOI 10.1182/blood-2001-11-0084; Jaffe E.S., 2001, PATHOLOGY GENETICS T, VVolume 3; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jelinek J, 2005, BLOOD, V106, P3370, DOI 10.1182/blood-2005-05-1800; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kirito K, 2002, INT J HEMATOL, V75, P51, DOI 10.1007/BF02981979; Kiritoa K, 2006, CURR OPIN HEMATOL, V13, P151, DOI 10.1097/01.moh.0000219660.03657.4b; Kosmider O, 2005, CANCER CELL, V8, P467, DOI 10.1016/j.ccr.2005.11.009; Koury MJ, 2002, CURR OPIN HEMATOL, V9, P93, DOI 10.1097/00062752-200203000-00002; KOURY MJ, 1984, J CELL PHYSIOL, V121, P526, DOI 10.1002/jcp.1041210311; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kuhl C, 2005, MOL CELL BIOL, V25, P8592, DOI 10.1128/MCB.25.19.8592-8606.2005; Lange B, 2000, BRIT J HAEMATOL, V110, P512, DOI 10.1046/j.1365-2141.2000.02027.x; Lange BJ, 1998, BLOOD, V91, P608; Langebrake C, 2006, HAEMATOLOGICA, V91, P1473; Lannutti BJ, 2006, ONCOGENE, V25, P3316, DOI 10.1038/sj.onc.1209351; Lannutti BJ, 2003, EXP HEMATOL, V31, P1268, DOI 10.1016/j.exphem.2003.09.009; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Li Z, 2005, NAT GENET, V37, P613, DOI 10.1038/ng1566; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Lulli V, 2006, CELL DEATH DIFFER, V13, P1064, DOI 10.1038/sj.cdd.4401811; Ma XY, 2007, MOL CELL BIOL, V27, P3056, DOI 10.1128/MCB.01339-06; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj.onc.1205230; McLean TW, 1996, BLOOD, V88, P4252; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; Michiels JJ, 1997, HAEMATOLOGICA, V82, P452; MICHIELS JJ, 2002, SEM VASC MED, V1, P1; Muntean AG, 2005, BLOOD, V106, P1223, DOI 10.1182/blood-2005-02-0551; Muntean AG, 2007, BLOOD, V109, P5199, DOI 10.1182/blood-2006-11-059378; Muntean AG, 2006, LEUKEMIA LYMPHOMA, V47, P986, DOI 10.1080/10428190500485810; Nelson ME, 2006, LEUKEMIA LYMPHOMA, V47, P177, DOI 10.1080/10428190500301348; Ney PA, 2000, BLOOD, V96, P3675, DOI 10.1182/blood.V96.12.3675.h8003675_3675_3680; NUCIFORA G, 1995, BLOOD, V86, P1; Oki Y, 2006, BLOOD, V107, P880, DOI 10.1182/blood-2005-06-2450; Osato M, 2005, CRIT REV EUKAR GENE, V15, P217, DOI 10.1615/CritRevEukarGeneExpr.v15.i3.40; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Osawa M, 2002, BLOOD, V100, P2769, DOI 10.1182/blood-2002-01-0182; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Pagano L, 2002, LEUKEMIA, V16, P1622, DOI 10.1038/sj.leu.2402618; Pang LY, 2006, BLOOD, V108, P2198, DOI 10.1182/blood-2006-04-019760; Pardanani AD, 2006, BLOOD, V108, P3472, DOI 10.1182/blood-2006-04-018879; Park S, 2002, LEUKEMIA, V16, P1399, DOI 10.1038/sj.leu.2402549; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Phillips JD, 2007, BLOOD, V109, P2618, DOI 10.1182/blood-2006-06-022848; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Putz G, 2006, ONCOGENE, V25, P929, DOI 10.1038/sj.onc.1209136; Raffel GD, 2007, P NATL ACAD SCI USA, V104, P6001, DOI 10.1073/pnas.0609041104; Rainis L, 2005, CANCER RES, V65, P7596, DOI 10.1158/0008-5472.CAN-05-0147; Raslova H, 2003, BLOOD, V101, P541, DOI 10.1182/blood-2002-05-1553; Raslova H, 2007, BLOOD, V109, P3225, DOI 10.1182/blood-2006-07-037838; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; Rietveld LEG, 2001, ONCOGENE, V20, P3100, DOI 10.1038/sj.onc.1204335; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Rubnitz JE, 2007, CANCER, V109, P157, DOI 10.1002/cncr.22385; Saleque S, 2002, GENE DEV, V16, P301, DOI 10.1101/gad.959102; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SOTIROV N, 1981, J NATL CANCER I, V66, P1143, DOI 10.1093/jnci/66.6.1143; Steensma DP, 2006, LEUKEMIA, V20, P971, DOI 10.1038/sj.leu.2404206; Steensma DP, 2006, BLOOD, V107, P1733, DOI 10.1182/blood-2005-09-3646; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Szalai G, 2006, CELL MOL LIFE SCI, V63, P2460, DOI 10.1007/s00018-006-6190-8; Tallman MS, 2000, BLOOD, V96, P2405; Teal HE, 2006, ONCOGENE, V25, P2433, DOI 10.1038/sj.onc.1209288; Tilbrook PA, 2001, CANCER RES, V61, P2453; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tubman VN, 2007, BLOOD, V109, P3297, DOI 10.1182/blood-2006-02-004101; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Vannucchi AM, 2002, BLOOD, V100, P1123, DOI 10.1182/blood-2002-06-1913; Vyas P, 1999, BLOOD, V93, P2867; Vyas P, 2007, CURR OPIN PEDIATR, V19, P9, DOI 10.1097/MOP.0b013e328013e7b2; Vyas P, 2006, EARLY HUM DEV, V82, P767, DOI 10.1016/j.earlhumdev.2006.09.016; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; WICKREMA A, 1991, BLOOD, V78, P2269, DOI 10.1182/blood.V78.9.2269.bloodjournal7892269; Wiellette EL, 1999, DEVELOPMENT, V126, P5373; XU Z, 2003, J DISTANCE ED TECHNO, V1, P1; Yamashita N, 2005, BRIT J HAEMATOL, V131, P495, DOI 10.1111/j.1365-2141.2005.05793.x; Yanagida M, 2005, ONCOGENE, V24, P4477, DOI 10.1038/sj.onc.1208675; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200; Zipursky A, 2003, BRIT J HAEMATOL, V120, P930, DOI 10.1046/j.1365-2141.2003.04229.x	130	38	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6803	6815		10.1038/sj.onc.1210763	http://dx.doi.org/10.1038/sj.onc.1210763			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934487				2022-12-28	WOS:000250147000011
J	Xu, WS; Parmigiani, RB; Marks, PA				Xu, W. S.; Parmigiani, R. B.; Marks, P. A.			Histone deacetylase inhibitors: molecular mechanisms of action	ONCOGENE			English	Review						histone deacetylase; histone deacetylase inhibitor; apoptosis; mitotic cell death; senescence; angiogenesis	SUBEROYLANILIDE HYDROXAMIC ACID; HUMAN LEUKEMIA-CELLS; 2 CATALYTIC DOMAINS; DEPENDENT APOPTOSIS; LYSINE-ACETYLATION; TRANSFORMED-CELLS; HDAC INHIBITORS; GENE-EXPRESSION; IN-VITRO; CANCER	This review focuses on the mechanisms of action of histone deacetylase ( HDAC) inhibitors ( HDACi), a group of recently discovered 'targeted' anticancer agents. There are 18 HDACs, which are generally divided into four classes, based on sequence homology to yeast counterparts. Classical HDACi such as the hydroxamic acid-based vorinostat ( also known as SAHA and Zolinza) inhibits classes I, II and IV, but not the NAD(+)- dependent class III enzymes. In clinical trials, vorinostat has activity against hematologic and solid cancers at doses well tolerated by patients. In addition to histones, HDACs have many other protein substrates involved in regulation of gene expression, cell proliferation and cell death. Inhibition of HDACs causes accumulation of acetylated forms of these proteins, altering their function. Thus, HDACs are more properly called 'lysine deacetylases.' HDACi induces different phenotypes in various transformed cells, including growth arrest, activation of the extrinsic and/or intrinsic apoptotic pathways, autophagic cell death, reactive oxygen species ( ROS)-induced cell death, mitotic cell death and senescence. In comparison, normal cells are relatively more resistant to HDACi- induced cell death. The plurality of mechanisms of HDACi- induced cell death reflects both the multiple substrates of HDACs and the heterogeneous patterns of molecular alterations present in different cancer cells.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Marks, PA (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	PaulA_Marks@mskcc.org	PARMIGIANI, RAPHAEL B/A-7475-2014	PARMIGIANI, RAPHAEL B/0000-0001-8360-3584	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA08748-41] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almenara J, 2002, LEUKEMIA, V16, P1331, DOI 10.1038/sj.leu.2402535; Anders M W, 1994, Adv Pharmacol, V27, P431, DOI 10.1016/S1054-3589(08)61042-X; Aoyagi S, 2005, TRENDS CELL BIOL, V15, P565, DOI 10.1016/j.tcb.2005.09.003; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Boyault C, 2006, EMBO J, V25, P3357, DOI 10.1038/sj.emboj.7601210; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Brush MH, 2004, J BIOL CHEM, V279, P7685, DOI 10.1074/jbc.M310997200; Bug G, 2005, CANCER, V104, P2717, DOI 10.1002/cncr.21589; Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Butler LM, 2000, CANCER RES, V60, P5165; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Chavez-Blanco A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-22; Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200; Chung YM, 2001, ANTICANCER RES, V21, P1129; Cimini D, 2003, MOL BIOL CELL, V14, P3821, DOI 10.1091/mbc.E03-01-0860; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Dowling M, 2005, CANCER BIOL THER, V4, P197, DOI 10.4161/cbt.4.2.1441; Duvic M, 2006, BRIT J CANCER, V95, pS13, DOI 10.1038/sj.bjc.6603465; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Fath DM, 2006, J BIOL CHEM, V281, P13612, DOI 10.1074/jbc.M600456200; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Garber K, 2007, NAT BIOTECHNOL, V25, P17, DOI 10.1038/nbt0107-17; Glaser KB, 2006, LEUKEMIA RES, V30, P651, DOI 10.1016/j.leukres.2005.10.016; Glaser KB, 2003, MOL CANCER THER, V2, P151; GLICK RD, 1999, CANCER RES, V59, P4692; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gray SG, 2004, INT J ONCOL, V24, P773; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541; Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Iwabata H, 2005, PROTEOMICS, V5, P4653, DOI 10.1002/pmic.200500042; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Kim DK, 2003, J MED CHEM, V46, P5745, DOI 10.1021/jm030377q; Kim MS, 2003, CANCER RES, V63, P7291; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X; LIANG D, 2007, ANTIOXID REDOX SIGN, V9, P25; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Lindemann RK, 2007, P NATL ACAD SCI USA, V104, P8071, DOI 10.1073/pnas.0702294104; Lucas DM, 2004, LEUKEMIA, V18, P1207, DOI 10.1038/sj.leu.2403388; Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024; Marchion DC, 2005, CLIN CANCER RES, V11, P8467, DOI 10.1158/1078-0432.CCR-05-1073; Marks PA, 2005, EXPERT OPIN INV DRUG, V14, P1497, DOI 10.1517/13543784.14.12.1497; Marks PA, 1996, INT J HEMATOL, V63, P1; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Miller TA, 2003, J MED CHEM, V46, P5097, DOI 10.1021/jm0303094; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Mitsiades N, 2003, BLOOD, V101, P4055, DOI 10.1182/blood-2002-11-3514; Munster PN, 2001, CANCER RES, V61, P8492; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Nimmanapalli R, 2003, BLOOD, V101, P3236, DOI 10.1182/blood-2002-08-2675; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Peart MJ, 2003, CANCER RES, V63, P4460; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Robbins AR, 2005, CELL CYCLE, V4, P717, DOI 10.4161/cc.4.5.1690; Rosato RR, 2004, EXPERT OPIN INV DRUG, V13, P21, DOI 10.1517/eoid.13.1.21.25283; Rosato RR, 2006, MOL PHARMACOL, V69, P216, DOI 10.1124/mol.105.017145; Rosato RR, 2005, EXPERT OPIN THER TAR, V9, P809, DOI 10.1517/14728222.9.4.809; Rosato RR, 2003, CANCER RES, V63, P3637; Rosato RR, 2001, INT J ONCOL, V19, P181; Ruefli AA, 2002, INT J CANCER, V99, P292, DOI 10.1002/ijc.10327; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sasakawa Y, 2002, BIOCHEM PHARMACOL, V64, P1079, DOI 10.1016/S0006-2952(02)01261-3; Sasakawa Y, 2005, BIOCHEM PHARMACOL, V69, P603, DOI 10.1016/j.bcp.2004.11.008; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Solit DB, 2006, CURR TOP MED CHEM, V6, P1205, DOI 10.2174/156802606777812068; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Stadler WM, 2006, CLIN GENITOURIN CANC, V5, P57, DOI 10.3816/CGC.2006.n.018; Sutheesophon K, 2005, J CELL PHYSIOL, V203, P387, DOI 10.1002/jcp.20235; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Tan J, 2006, J BIOL CHEM, V281, P10508, DOI 10.1074/jbc.M512719200; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Wang LG, 2004, ONCOGENE, V23, P5175, DOI 10.1038/sj.onc.1207654; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Xu WS, 2006, P NATL ACAD SCI USA, V103, P15540, DOI 10.1073/pnas.0607518103; Xu WS, 2005, CANCER RES, V65, P7832, DOI 10.1158/0008-5472.CAN-04-4608; Yoshida M, 2003, CURR MED CHEM, V10, P2351, DOI 10.2174/0929867033456602; Zhang XD, 2004, MOL CANCER THER, V3, P425; Zhang Y, 2006, J BIOL CHEM, V281, P2401, DOI 10.1074/jbc.C500241200; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102; Zou H, 2006, BIOCHEM BIOPH RES CO, V341, P45, DOI 10.1016/j.bbrc.2005.12.144	115	1163	1208	5	247	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5541	5552		10.1038/sj.onc.1210620	http://dx.doi.org/10.1038/sj.onc.1210620			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694093				2022-12-28	WOS:000248674300020
J	Espinosa, JM				Espinosa, J. M.			Mechanisms of regulatory diversity within the p53 transcriptional network	ONCOGENE			English	Review						p21; ASPP; HZF; hCAS; serine 46; lysine 120	RNA-POLYMERASE-II; IN-VIVO; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; TUMOR-SUPPRESSOR; BINDING-SITES; GENE-EXPRESSION; MESSENGER-RNAS; CORE PROMOTER; TARGET GENES	p53 is arguably the most intensively studied protein to date, yet there is much that we ignore about its function as a transcription factor. The p53-dependent transcriptional program is remarkably flexible, as it varies with the nature of p53-activating stimuli, the cell type and the duration of the activation signal. This flexibility may allow cells to mount alternative responses to p53 activation, such as cell cycle arrest or apoptosis. Here, I organize the available data into two alternative models to explain how this regulatory diversity is achieved.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Espinosa, JM (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	joaquin.espinosa@colorado.edu			NCI NIH HHS [R01 CA117907, R01-CA117907, R01 CA117907-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA117907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brunkhorst A, 2004, BIOCHEM BIOPH RES CO, V325, P574, DOI 10.1016/j.bbrc.2004.10.078; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Das S, 2007, CELL, V130, P624, DOI 10.1016/j.cell.2007.06.013; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Donner AJ, 2007, CELL CYCLE, V6, P2594, DOI 10.4161/cc.6.21.4893; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; Efeyan A, 2007, CANCER RES, V67, P7350, DOI 10.1158/0008-5472.CAN-07-0200; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fei PW, 2002, CANCER RES, V62, P7316; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Horvath MM, 2007, PLOS GENET, V3, P1284, DOI 10.1371/journal.pgen.0030127; Jett SD, 2000, J MOL BIOL, V299, P585, DOI 10.1006/jmbi.2000.3759; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Loncle N, 2007, EMBO J, V26, P1045, DOI 10.1038/sj.emboj.7601566; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Luecke HF, 2005, GENE DEV, V19, P1116, DOI 10.1101/gad.1297105; Mattia M, 2007, MOL CELL BIOL, V27, P1309, DOI 10.1128/MCB.01520-06; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; Moll UM, 2004, MOL CANCER RES, V2, P371; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Perez CA, 2007, ONCOGENE, V26, P7363, DOI 10.1038/sj.onc.1210561; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shi LF, 2005, J BIOL CHEM, V280, P18981, DOI 10.1074/jbc.M411034200; Shu LM, 2006, GENE DEV, V20, P2961, DOI 10.1101/gad.1463306; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tanaka T, 2007, CELL, V130, P638, DOI 10.1016/j.cell.2007.08.001; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; van de Peppel J, 2005, MOL CELL, V19, P511, DOI 10.1016/j.molcel.2005.06.033; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vives V, 2006, GENE DEV, V20, P1262, DOI 10.1101/gad.374006; Vives V, 2006, CELL CYCLE, V5, P2187, DOI 10.4161/cc.5.19.3266; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang G, 2005, MOL CELL, V17, P683, DOI 10.1016/j.molcel.2005.02.010; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang XP, 2004, DALTON T, P1787, DOI 10.1039/b405981f; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zhao RB, 2000, GENE DEV, V14, P981; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	77	85	86	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4013	4023		10.1038/onc.2008.37	http://dx.doi.org/10.1038/onc.2008.37			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18278067	Green Accepted			2022-12-28	WOS:000257325100001
J	Gouyer, V; Fontaine, D; Dumont, P; de Wever, O; Fontayne-Devaud, H; Leteurtre, E; Truant, S; Delacour, D; Drobecq, H; Kerckaert, JP; de Launoit, Y; Bracke, M; Gespach, C; Desseyn, JL; Huet, G				Gouyer, V.; Fontaine, D.; Dumont, P.; de Wever, O.; Fontayne-Devaud, H.; Leteurtre, E.; Truant, S.; Delacour, D.; Drobecq, H.; Kerckaert, J-P; de launoit, Y.; Bracke, M.; Gespach, C.; Desseyn, J-L; Huet, G.			Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells	ONCOGENE			English	Article						mucinous differentiation; CXCR4; CKB; GRB10; CSPG4/NG2; BMP-7	PROSTATE-CANCER; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; PLASMINOGEN-ACTIVATOR; TISSUE INHIBITOR; OVARIAN-CANCER; EXPRESSION; GROWTH; GENE; PROGRESSION	From the conditioned medium of the human colon carcinoma cells, HT-29 5M21 ( CM-5M21), expressing a spontaneous invasive phenotype, tumor-associated trypsin inhibitor ( TATI) was identified and characterized by proteomics, cDNA microarray approaches and functional analyses. Both CM-5M21 and recombinant TATI, but not the K18Y-TATI mutant at the protease inhibitor site, trigger collagen type I invasion by several human adenoma and carcinoma cells of the colon and breast, through phosphoinositide-3-kinase, protein kinase C and Rho-GTPases/Rho kinase-dependent pathways. Conversely, the proinvasive action of TATI in parental HT29 cells was alleviated by the TATI antibody PSKAN2 and the K18Y-TATI mutant. Stable expression of K18Y-TATI in HT-29 5M21 cells downregulated tumor growth, angiogenesis and the expression of several metastasis-related genes, including CSPG4 ( 13.8-fold), BMP-7 ( 9.7-fold), the BMP antagonist CHORDIN ( 5.2-fold), IGFBP-2 and IGF2 ( 9.6- and 4.6-fold). Accordingly, ectopic expression of KY-TATI inhibited the development of lung metastases from HT-29 5M21 tumor xenografts in immunodeficient mice. These findings identify TATI as an autocrine transforming factor potentially involved in early and late events of colon cancer progression, including local invasion of the primary tumor and its metastatic spread. Targeting TATI, its molecular partners and effectors may bring novel therapeutic applications for high-grade human solid tumors in the digestive and urogenital systems.	[Gouyer, V.; Fontaine, D.; Fontayne-Devaud, H.; Leteurtre, E.; Truant, S.; Kerckaert, J-P; Desseyn, J-L; Huet, G.] Ctr Rech Jean Pierre Aubert, INSERM, U837, Fac Med, F-59045 Lille, France; [Gouyer, V.; Fontaine, D.; Dumont, P.; Fontayne-Devaud, H.; Leteurtre, E.; Truant, S.; Drobecq, H.; Kerckaert, J-P; de launoit, Y.; Desseyn, J-L; Huet, G.] NW Canceropole, Lille, France; [Gouyer, V.; Leteurtre, E.; Truant, S.; Huet, G.] CHRU, Lille, France; [Dumont, P.; Drobecq, H.; de launoit, Y.] Inst Biol Lille, UMR 8161, Lille, France; [de Wever, O.; Bracke, M.] Ghent Univ Hosp, Expt Cancerol Lab, Ghent, Belgium; [Delacour, D.] Univ Marburg, Dept Cell Biol & Cell Pathol, Marburg, Germany; [Gespach, C.] INSERM, U673, Paris, France; [Gespach, C.] Univ Paris 06, Hop St Antoine, Fac Med, Lab Mol & Clin Oncol Solid Tumors, Paris, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Ghent University; Ghent University Hospital; Philipps University Marburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Huet, G (corresponding author), Ctr Rech Jean Pierre Aubert, INSERM, U837, Fac Med, Pl Verdun, F-59045 Lille, France.	huet@lille.inserm.fr	Gouyer, Valérie/R-4984-2018; Desseyn, Jean-Luc/M-5070-2018; de wever, olivier/J-3094-2013	Gouyer, Valérie/0000-0002-4223-7060; Desseyn, Jean-Luc/0000-0001-6876-8049; de wever, olivier/0000-0002-5453-760X; Drobecq, Herve/0000-0002-4081-1575; de Launoit, Yvan/0000-0003-1837-9808				Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Antila R, 2006, GYNECOL ONCOL, V101, P97, DOI 10.1016/j.ygyno.2005.09.046; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Balasubramani M, 2006, CANCER RES, V66, P763, DOI 10.1158/0008-5472.CAN-05-3771; BARTELT DC, 1977, ARCH BIOCHEM BIOPHYS, V179, P189, DOI 10.1016/0003-9861(77)90103-5; Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chirco R, 2006, CANCER METAST REV, V25, P99, DOI 10.1007/s10555-006-7893-x; Delacour D, 2005, J CELL BIOL, V169, P491, DOI 10.1083/jcb.200407073; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Fountoulakis M, 1998, ELECTROPHORESIS, V19, P1819, DOI 10.1002/elps.1150191046; Gouyer V, 2005, CANCER-AM CANCER SOC, V103, P1676, DOI 10.1002/cncr.20965; Grijelmo C, 2007, CELL SIGNAL, V19, P1722, DOI 10.1016/j.cellsig.2007.03.008; Harbeck N, 2007, CRIT REV CL LAB SCI, V44, P179, DOI 10.1080/10408360601040970; Hu KM, 2007, IMMUNOL LETT, V113, P19, DOI 10.1016/j.imlet.2007.07.004; HUHTALA ML, 1982, J BIOL CHEM, V257, P13713; Janicke F, 2001, J NATL CANCER I, V93, P913, DOI 10.1093/jnci/93.12.913; KAZAL LA, 1948, J AM CHEM SOC, V70, P3034, DOI 10.1021/ja01189a060; Kebache S, 2007, J BIOL CHEM, V282, P21873, DOI 10.1074/jbc.M611066200; KIKUCHI N, 1989, J BIOCHEM-TOKYO, V106, P1059, DOI 10.1093/oxfordjournals.jbchem.a122964; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Le Floch N, 2004, FASEB J, V18, P144, DOI 10.1096/fj.04-2373fje; Lee YC, 2007, EUR J CANCER, V43, P736, DOI 10.1016/j.ejca.2006.11.020; Lesuffleur T, 1998, INT J CANCER, V76, P383, DOI 10.1002/(SICI)1097-0215(19980504)76:3<383::AID-IJC16>3.3.CO;2-M; Loberg RD, 2007, CANCER RES, V67, P9417, DOI 10.1158/0008-5472.CAN-07-1286; Louvet C, 2000, ANTI-CANCER DRUG, V11, P579, DOI 10.1097/00001813-200008000-00010; Makagiansar IT, 2007, J CELL BIOL, V178, P155, DOI 10.1083/jcb.200612084; McCarthy K, 1999, INT J CANCER, V84, P44, DOI 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.3.CO;2-G; Monti P, 2003, CANCER RES, V63, P7451; Nguyen QD, 2005, ONCOGENE, V24, P8240, DOI 10.1038/sj.onc.1208990; Nyberg P, 2006, EXP CELL RES, V312, P1219, DOI 10.1016/j.yexcr.2005.12.024; OHMACHI Y, 1993, INT J CANCER, V55, P728, DOI 10.1002/ijc.2910550505; Paju A, 2006, CRIT REV CL LAB SCI, V43, P103, DOI 10.1080/10408360500523852; Paju A, 2004, CLIN CANCER RES, V10, P4761, DOI 10.1158/1078-0432.CCR-0204-03; Paju A, 2007, EUR UROL, V52, P1670, DOI 10.1016/j.eururo.2007.01.096; Poole CJ, 2006, NEW ENGL J MED, V355, P1851, DOI 10.1056/NEJMoa052084; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Stenman UH, 2002, CLIN CHEM, V48, P1206; Truant S, 2003, INT J CANCER, V104, P683, DOI 10.1002/ijc.11011; TURPEINEN U, 1988, BIOCHEM J, V254, P911, DOI 10.1042/bj2540911; van der Zee M, 2006, P NATL ACAD SCI USA, V103, P16307, DOI 10.1073/pnas.0605154103; Xuan JA, 2006, CANCER RES, V66, P3611, DOI 10.1158/0008-5472.CAN-05-2983; Yan RL, 2007, INT J CANCER, V121, P2301, DOI 10.1002/ijc.22933; Yang JB, 2004, J CELL BIOL, V165, P881, DOI 10.1083/jcb.200403174; Yasuda T, 1998, J BIOL CHEM, V273, P34413, DOI 10.1074/jbc.273.51.34413; YASUDA T, 1993, GENE, V131, P275	50	51	57	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4024	4033		10.1038/onc.2008.42	http://dx.doi.org/10.1038/onc.2008.42			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18317448				2022-12-28	WOS:000257325100002
J	Bonnomet, A; Polette, M; Strumane, K; Gilles, C; Dalstein, V; Kileztky, C; Berx, G; van Roy, F; Birembaut, P; Nawrocki-Raby, B				Bonnomet, A.; Polette, M.; Strumane, K.; Gilles, C.; Dalstein, V.; Kileztky, C.; Berx, G.; van Roy, F.; Birembaut, P.; Nawrocki-Raby, B.			The E-cadherin-repressed hNanos1 gene induces tumor cell invasion by upregulating MT1-MMP expression	ONCOGENE			English	Article						hNanos1; E-cadherin; MT1-MMP; cancer; cell invasion	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; GERMLINE STEM-CELLS; MESSENGER-RNA; POSTERIOR DETERMINANT; DROSOPHILA GERMLINE; NANOS; PUMILIO; COMPLEX; CANCER; ADHESION	In this study, we examined the role of the E-cadherin-repressed gene human Nanos1 (hNanos1) in tumor invasion process. First, our in vivo study revealed that hNanos1 mRNAs were overexpressed in invasive lung carcinomas. Moreover, hNanos1 was co-localized with MT1-MMP (membrane type 1-matrix metalloproteinase) in E-cadherin-negative invasive lung tumor clusters. Using an inducible Tet-on system, we showed that induction of hNanos1 expression in DLD1 cells increased their migratory and invasive abilities in a three-dimensional migration and in a modified Boyden chamber assay. Accordingly, we demonstrated that hNanos1 upregulated MT1-MMP expression at the mRNA and protein levels. Inversely, using an RNA interference strategy to inhibit hNanos1 expression in invasive Hs578T, BT549 and BZR cancer cells, we observed a downregulation of MT1-MMP mRNA and protein and concomitantly a decrease of the invasive capacities of tumor cells in a modified Boyden chamber assay. Taken together, our results demonstrate that hNanos1, by regulating MT1-MMP expression, plays an important role in the acquisition of invasive properties by epithelial tumor cells.	[Bonnomet, A.; Polette, M.; Dalstein, V.; Kileztky, C.; Birembaut, P.; Nawrocki-Raby, B.] Univ Reims, Histol Lab, CHU Maison Blanche, IFR 53,INSERM UMRS 514, F-51100 Reims, France; [Bonnomet, A.; Gilles, C.] Univ Liege, CHU Sart Tilman, Lab Dev & Tumor Biol, Liege, Belgium; [Strumane, K.; Berx, G.; van Roy, F.] Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; [Strumane, K.] Leiden Univ, Med Ctr, Dept IHB, Leiden, Netherlands	CHU de Reims; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; University of Liege; Flanders Institute for Biotechnology (VIB); Ghent University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Nawrocki-Raby, B (corresponding author), Univ Reims, Histol Lab, CHU Maison Blanche, IFR 53,INSERM UMRS 514, 45 Rue Cognacq Jay, F-51100 Reims, France.	beatrice.raby@univ-reims.fr	POLETTE, Myriam/P-5147-2016; van Roy, Frans M/C-6123-2009; BIREMBAUT, Philippe/P-5210-2016; DALSTEIN, Véronique/P-5250-2016; Raby, Beatrice/P-5666-2016	van Roy, Frans M/0000-0003-4358-1039; Raby, Beatrice/0000-0002-3163-8619; BONNOMET, Arnaud/0000-0002-4933-3338; Berx, Geert/0000-0001-5770-2458; POLETTE, Myriam/0000-0001-8173-3246				Ara T, 2000, CANCER LETT, V157, P115, DOI 10.1016/S0304-3835(00)00494-8; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bhat KM, 1999, GENETICS, V151, P1479; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Deshpande G, 1999, CELL, V99, P271, DOI 10.1016/S0092-8674(00)81658-X; Edwards TA, 2001, CELL, V105, P281, DOI 10.1016/S0092-8674(01)00318-X; Forbes A, 1998, DEVELOPMENT, V125, P679; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GILLES C, 2004, RISE FALL EPITHELIAL, P1; Hatzfeld M, 2005, EUR J CELL BIOL, V84, P205, DOI 10.1016/j.ejcb.2004.12.016; Hazgui S, 2005, AM J PHYSIOL-CELL PH, V289, pC1547, DOI 10.1152/ajpcell.00319.2005; Hlubek F, 2004, INT J CANCER, V108, P321, DOI 10.1002/ijc.11522; Jaruzelska J, 2003, DEV GENES EVOL, V213, P120, DOI 10.1007/s00427-003-0303-2; Kitadai Y, 1996, AM J PATHOL, V149, P1541; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; Luo J, 1999, CANCER RES, V59, P3552; Mareel M, 1996, J CELL BIOCHEM, V61, P524; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Nawrocki-Raby B, 2003, AM J PATHOL, V163, P653, DOI 10.1016/S0002-9440(10)63692-9; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Polette M, 1998, CLIN EXP METASTAS, V16, P105; Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801; Strumane K, 2006, CANCER RES, V66, P10007, DOI 10.1158/0008-5472.CAN-05-3096; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204	34	26	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3692	3699		10.1038/sj.onc.1211035	http://dx.doi.org/10.1038/sj.onc.1211035			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223680				2022-12-28	WOS:000256659300006
J	Hsieh, SH; Ying, NW; Wu, MH; Chiang, WF; Hsu, CL; Wong, TY; Jin, YT; Hong, TM; Chen, YL				Hsieh, S. H.; Ying, N. W.; Wu, M. H.; Chiang, W. F.; Hsu, C. L.; Wong, T. Y.; Jin, Y. T.; Hong, T. M.; Chen, Y. L.			Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells	ONCOGENE			English	Article						galectin-1; neuropilin-1; endothelial cells; oral cancer	BREAST-CANCER; GROWTH-FACTOR; EXPRESSION; RECEPTORS; FIBRONECTIN; DIFFERENTIATION; SUSCEPTIBILITY; GLYCOSYLATION; ANGIOGENESIS; PROGRESSION	Galectin-1 (Gal-1), a homodimeric prototype of the galectins with a single carbohydrate-recognition domain, was recently identified as being overexpressed in tumor-associated capillary endothelial cells. The role of Gal-1 in endothelial cellular functions and the mechanism of action of Gal-1 remain unknown. Neuropilin-1 (NRP1) is a neuronal receptor that mediates repulsive growth cone guidance, and NRP1 functions in endothelial cells as a coreceptor (with vascular endothelial growth factor receptors (VEGFRs)) for VEGF(165). In this study, we found that Gal-1 was overexpressed in the tumor-associated endothelial cells of oral squamous cell carcinomas (P<0.001). Gal-1 increased the proliferation and adhesion of endothelial cells, and enhanced cell migration in combination with VEGF165. Surprisingly, Gal-1 selectively bound NRP1 via the carbohydrate-recognition domain, but did not bind VEGFR-1, VEGFR-2 or VEGFR-3. The Gal-1-NRP1 interaction mediated the migration and adhesion of endothelial cells. The binding of Gal-1 to NRP1 enhanced VEGFR-2 phosphorylation and stimulated the activation of the mitogen activated protein (MAP) kinases SAPK1/JNK (stress activated protein kinase-1/c-Jun NH2-terminal kinase). These findings show, for the first time, that Gal-1 can directly bind to NRP1 on endothelial cells, and can promote the NRP1/VEGFR-2-mediated signaling pathway as well as NRP1-mediated biological activities.	[Hsieh, S. H.; Ying, N. W.; Wong, T. Y.; Jin, Y. T.; Chen, Y. L.] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan 70101, Taiwan; [Wu, M. H.; Chen, Y. L.] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Chiang, W. F.] Chi Mei Med Ctr, Oral Maxillofacial Sect, Tainan, Taiwan; [Hsu, C. L.] Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Taipei 10591, Taiwan; [Wong, T. Y.] Natl Taiwan Univ, Coll Med, NTU Ctr Gen Med, Taipei 10764, Taiwan	National Cheng Kung University; National Cheng Kung University; Chi Mei Hospital; Chang Gung Memorial Hospital; National Taiwan University	Chen, YL (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Oral Med, 1 Univ Rd, Tainan 70101, Taiwan.	htm@gate.sinica.edu.tw; yuhling@mail.ncku.edu.tw	Chiang, Wei-Fan/L-6537-2019; Chen, Yuh-Ling/AAS-7957-2021	Chiang, Wei-Fan/0000-0002-9240-1404; 				Camby I, 2006, GLYCOBIOLOGY, V16, p137R, DOI 10.1093/glycob/cwl025; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; CHIANG WF, 2007, ORAL ONCOL IN PRESS; Clausse N, 1999, Angiogenesis, V3, P317, DOI 10.1023/A:1026584523789; Elola MT, 2005, J BIOMED SCI, V12, P13, DOI 10.1007/s11373-004-8169-5; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fischer C, 2005, J BIOL CHEM, V280, P37266, DOI 10.1074/jbc.M411580200; Fons P, 2004, J CELL PHYSIOL, V200, P351, DOI 10.1002/jcp.20076; Gaudet AD, 2005, CURR DRUG TARGETS, V6, P419, DOI 10.2174/1389450054021864; Glinsky VV, 2000, CANCER RES, V60, P2584; GU MJ, 1994, J CELL SCI, V107, P175; He J, 2006, LAB INVEST, V86, P578, DOI 10.1038/labinvest.3700420; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Jung EJ, 2007, INT J CANCER, V120, P2331, DOI 10.1002/ijc.22434; Kadri T, 2005, STEM CELLS DEV, V14, P204, DOI 10.1089/scd.2005.14.204; Konigsberg W, 2001, THROMB HAEMOSTASIS, V86, P757, DOI 10.1055/s-0037-1616129; Murga M, 2005, BLOOD, V105, P1992, DOI 10.1182/blood-2004-07-2598; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; OZEKI Y, 1995, GLYCOBIOLOGY, V5, P255, DOI 10.1093/glycob/5.2.255; Parsons-Wingerter P, 2005, AM J PATHOL, V167, P193, DOI 10.1016/S0002-9440(10)62965-3; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; Rabinovich GA, 2005, BRIT J CANCER, V92, P1188, DOI 10.1038/sj.bjc.6602493; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Shintani Y, 2006, EMBO J, V25, P3045, DOI 10.1038/sj.emboj.7601188; Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; Valenzuela HF, 2007, CANCER RES, V67, P6155, DOI 10.1158/0008-5472.CAN-05-4431; van den Brule FA, 2001, J PATHOL, V193, P80, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH730>3.0.CO;2-2	30	163	170	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3746	3753		10.1038/sj.onc.1211029	http://dx.doi.org/10.1038/sj.onc.1211029			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223683				2022-12-28	WOS:000256659300012
J	Wagner, S; Carpentier, I; Rogov, V; Kreike, M; Ikeda, F; Lohr, F; Wu, CJ; Ashwell, JD; Dotsch, V; Dikic, I; Beyaert, R				Wagner, S.; Carpentier, I.; Rogov, V.; Kreike, M.; Ikeda, F.; Loehr, F.; Wu, C-J; Ashwell, J. D.; Doetsch, V.; Dikic, I.; Beyaert, R.			Ubiquitin binding mediates the NF-kappa B inhibitory potential of ABIN proteins	ONCOGENE			English	Article						ABIN; NF-kappa B; ubiquitin; TNF; protein-protein interaction	ADENOVIRAL GENE-TRANSFER; A20-BINDING INHIBITOR; NEMO/IKK-GAMMA; KINASE COMPLEX; ACTIVATION; ALPHA; A20; IKK; RIP	Deregulated nuclear factor kappa B (NF-kappa B) activation plays an important role in inflammation and tumorigenesis. ABIN proteins have been characterized as negative regulators of NF-kappa B signaling. However, their mechanism of NF-kappa B inhibition remained unclear. With the help of a yeast two-hybrid screen, we identified ABIN proteins as novel ubiquitin-interacting proteins. The minimal ubiquitin-binding domain (UBD) corresponds to the ABIN homology domain 2 (AHD2) and is highly conserved in ABIN-1, ABIN-2 and ABIN-3. Moreover, this region is also present in NF-kappa B essential modulator/I kappa B kinase gamma (NEMO/IKK gamma) and the NEMO-like protein optineurin, and is therefore termed UBD in ABIN proteins and NEMO (UBAN). Nuclear magnetic resonance studies of the UBAN domain identify it as a novel type of UBD, with the binding surface on ubiquitin being significantly different from the binding surface of other UBDs. ABIN-1 specifically binds ubiquitinated NEMO via a bipartite interaction involving its UBAN and NEMO-binding domain. Mutations in the UBAN domain led to a loss of ubiquitin binding and impaired the NF-kappa B inhibitory potential of ABINs. Taken together, these data illustrate an important role for ubiquitin binding in the negative regulation of NF-kappa B signaling by ABINs and identify UBAN as a novel UBD.	[Carpentier, I.; Kreike, M.; Beyaert, R.] Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium; [Carpentier, I.; Kreike, M.; Beyaert, R.] Univ Ghent, Dept Mol Biol, Zwijnaarde, Belgium; [Wagner, S.; Ikeda, F.; Dikic, I.] Univ Frankfurt, Sch Med, Inst Biochem 2, Frankfurt, Germany; [Rogov, V.; Loehr, F.; Doetsch, V.] Univ Frankfurt, Inst Biophys Chem, Frankfurt, Germany; [Rogov, V.] Russian Acad Sci, Inst Prot Res, Pushchino 142292, Russia; [Wu, C-J; Ashwell, J. D.] NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Goethe University Frankfurt; Goethe University Frankfurt; Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Beyaert, R (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technologiepk 927, B-9052 Ghent, Belgium.	ivan.dikic@biochem2.de; rudi.beyaert@dmbr.ugent.be	Doetsch, Volker/D-5697-2011; Ikeda, Fumiyo/AAD-3770-2020; Dikic, Ivan/O-4650-2015; Beyaert, Rudi/B-2589-2009; Wagner, Sebastian/B-9056-2012	Ikeda, Fumiyo/0000-0003-0407-2768; Dikic, Ivan/0000-0001-8156-9511; Dotsch, Volker/0000-0001-5720-212X; Beyaert, Rudi/0000-0002-5704-582X	NATIONAL CANCER INSTITUTE [ZIABC010779, Z01BC010779] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agou F, 2004, J BIOL CHEM, V279, P54248, DOI 10.1074/jbc.M406423200; Calzado MA, 2007, CURR MED CHEM, V14, P367, DOI 10.2174/092986707779941113; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; El Bakkouri K, 2005, J BIOL CHEM, V280, P17938, DOI 10.1074/jbc.M413588200; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Liu WK, 2004, BIOCHEM J, V378, P867, DOI 10.1042/BJ20031736; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; Shambharkar PB, 2007, EMBO J, V26, P1794, DOI 10.1038/sj.emboj.7601622; Shembade N, 2007, EMBO J, V26, P3910, DOI 10.1038/sj.emboj.7601823; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Weaver BK, 2007, MOL CELL BIOL, V27, P4603, DOI 10.1128/MCB.00223-07; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wullaert A, 2005, HEPATOLOGY, V42, P381, DOI 10.1002/hep.20785; Wullaert A, 2007, J BIOL CHEM, V282, P81, DOI 10.1074/jbc.M607481200; Wullaert A, 2006, TRENDS IMMUNOL, V27, P533, DOI 10.1016/j.it.2006.09.003; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zhu G, 2007, CURR BIOL, V17, P1438, DOI 10.1016/j.cub.2007.07.041	21	176	186	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3739	3745		10.1038/sj.onc.1211042	http://dx.doi.org/10.1038/sj.onc.1211042			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212736				2022-12-28	WOS:000256659300011
J	Cuende, J; Moreno, S; Bolanos, JP; Almeida, A				Cuende, J.; Moreno, S.; Bolanos, J. P.; Almeida, A.			Retinoic acid downregulates Rae1 leading to APC(Cdh1) activation and neuroblastoma SH-SY5Y differentiation	ONCOGENE			English	Article						retinoic acid; Rae1; Cdh1; Skp2; p27; neuroblastoma	ANAPHASE-PROMOTING COMPLEX; CDK INHIBITOR P27; CELL-CYCLE EXIT; POSTMITOTIC NEURONS; AXONAL GROWTH; S-PHASE; DEGRADATION; P27(KIP1); SKP2; PHOSPHORYLATION	In neuroblastoma cells, retinoic acid induces cell cycle arrest and differentiation through degradation of the F-box protein, Skp2, and stabilization of cyclin-dependent kinase inhibitor, p27. However, the mechanism responsible for retinoic acid-mediated Skp2 destabilization is unknown. Since Skp2 is degraded by anaphase-promoting complex (APC)(Cdh1), here we studied whether retinoic acid promotes differentiation of human SH-SY5Y neuroblastoma cells by modulating Cdh1. We found that retinoic acid induced the nuclear accumulation of Cdh1 that paralleled Skp2 destabilization and p27 accumulation. The mRNA and protein abundance of Rae1-a nuclear export factor that limits APC(Cdh1) activity in mitosis decreased upon retinoic acid-induced inhibition of neuroblastoma cell proliferation. Furthermore, either Rae1 overexpression or Cdh1 inhibition promoted Skp2 accumulation, p27 destabilization and prevented retinoic acid-induced cell cycle arrest and differentiation. Conversely, inhibition of Rae1 accelerated retinoic acid-induced differentiation. Thus, retinoic acid downregulates Rae1, hence facilitating APC(Cdh1)-mediated Skp2 degradation leading to the arrest of cell cycle progression and neuroblastoma differentiation.	[Cuende, J.; Almeida, A.] Hosp Univ Salamanca, Unidad Invest, Inst Estudios Ciencias Salud Castilla & Leon, Salamanca 37007, Spain; [Cuende, J.; Bolanos, J. P.; Almeida, A.] Univ Salamanca, Inst Neurociencias Castilla & Leon, Dept Bioquim & Biol Mol, E-37008 Salamanca, Spain; [Moreno, S.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37008 Salamanca, Spain	University of Salamanca; University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Almeida, A (corresponding author), Hosp Univ Salamanca, Unidad Invest, Inst Estudios Ciencias Salud Castilla & Leon, Paseo San Vicente 58-182, Salamanca 37007, Spain.	aaparra@usal.es	ALMEIDA, ANGELES/B-4727-2017; 2008, Ibsal/A-1268-2012; Bolaños, Juan Pedro/M-9518-2019; Moreno, Sergio/K-3671-2014	ALMEIDA, ANGELES/0000-0003-0485-8904; Bolaños, Juan Pedro/0000-0002-3949-6862; Moreno, Sergio/0000-0002-8039-1413				Almeida A, 2005, J NEUROSCI, V25, P8115, DOI 10.1523/JNEUROSCI.1143-05.2005; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Blower MD, 2005, CELL, V121, P223, DOI 10.1016/j.cell.2005.02.016; Borriello A, 2006, CANCER RES, V66, P4240, DOI 10.1158/0008-5472.CAN-05-2759; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Clagett-Dame M, 2006, J NEUROBIOL, V66, P739, DOI 10.1002/neu.20241; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jeganathan KB, 2005, NATURE, V438, P1036, DOI 10.1038/nature04221; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Maden M, 2002, NAT REV NEUROSCI, V3, P843, DOI 10.1038/nrn963; Matthay M A, 1999, Chest, V116, p119S; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Zancai P, 2005, ONCOGENE, V24, P2483, DOI 10.1038/sj.onc.1208458	27	49	50	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3339	3344		10.1038/sj.onc.1210987	http://dx.doi.org/10.1038/sj.onc.1210987			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18212744				2022-12-28	WOS:000256111400012
J	Helton, ES; Zhang, J; Chen, X				Helton, E. S.; Zhang, J.; Chen, X.			The proline-rich domain in p63 is necessary for the transcriptional and apoptosis-inducing activities of TAp63	ONCOGENE			English	Article						p53 family; p63; transcription; cell cycle; apoptosis	TARGET GENES; P53 FAMILY; MOUSE MODELS; TUMOR-CELLS; DELTA-NP63-ALPHA; IDENTIFICATION; HOMOLOG; ARREST; MUTANT; LIMB	p63 shares considerable sequence identity with p53, especially in its DNA-binding, activation and tetramerization domains. When the upstream promoter is used for p63 expression, three major transactivation p63 (TAp63) isoforms (alpha, beta and gamma) are produced. p63 is also expressed from an alternate promoter located in intron 3, producing three major Delta Np63 isoforms. Recent studies demonstrated that p63 has the potential to function as a tumor suppressor or an oncoprotein. To further address this, we generated cell lines that inducibly express each TAp63 isoform. We showed that TAp63 isoforms are capable of inducing p53-responsive genes, inhibiting cell proliferation and promoting apoptosis. Interestingly, we discovered that both the activation domain (residues 1-59) and the proline-rich domain (residues 67-127) are required for TAp63 transcriptional activity. Likewise, TAp63 beta(Delta PRD), deleted of residues 60-133, possessed a greatly attenuated ability to induce endogenous target genes and promote apoptosis, but retained the ability to inhibit cell proliferation when expressed in stable, inducible cell lines. TAp63 beta(Delta PRD) also functioned as a dominant negative to wild-type p63 beta in a dose-dependent manner. Furthermore, the loss of function seen with deletion of the proline-rich domain was not due to a DNA-binding defect, as TAp63 beta(Delta PRD) was found to strongly bind endogenous promoters using chromatin immunoprecipitation assay. Finally, mutational analysis revealed that a PXXP motif at residues 124-127 contributes to the transcriptional activity of TAp63. Altogether, our findings suggest that TAp63 transcriptional activity can be regulated by modification(s) of, or protein interactions with, the p63 proline-rich domain.	[Helton, E. S.; Zhang, J.; Chen, X.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Ctr Comparat Oncol, Davis, CA 95616 USA	University of California System; University of California Davis	Chen, X (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Ctr Comparat Oncol, 2128 Tupper Hall, Davis, CA 95616 USA.	xbchen@ucdavis.edu			NATIONAL CANCER INSTITUTE [R01CA102188] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102188, R01 CA102188-07, CA102188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 2005, MUTAT RES-FUND MOL M, V576, P4, DOI 10.1016/j.mrfmmm.2004.08.022; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Boyle JM, 1998, BRIT J CANCER, V77, P2181, DOI 10.1038/bjc.1998.364; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Edwards SJ, 2003, ONCOGENE, V22, P4517, DOI 10.1038/sj.onc.1206726; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Phang BH, 2007, ONCOGENE, V26, P2964, DOI 10.1038/sj.onc.1210112; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	24	23	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2843	2850		10.1038/sj.onc.1210948	http://dx.doi.org/10.1038/sj.onc.1210948			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037962	Green Accepted			2022-12-28	WOS:000255502500005
J	Howarth, KD; Blood, KA; Ng, BL; Beavis, JC; Chua, Y; Cooke, SL; Raby, S; Ichimura, K; Collins, VP; Carter, NP; Edwards, PAW				Howarth, K. D.; Blood, K. A.; Ng, B. L.; Beavis, J. C.; Chua, Y.; Cooke, S. L.; Raby, S.; Ichimura, K.; Collins, V. P.; Carter, N. P.; Edwards, P. A. W.			Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that break in cancer-relevant genes	ONCOGENE			English	Article						breast cancer; chromosome rearrangements; microarrays	COMPARATIVE GENOMIC HYBRIDIZATION; POLYCYSTIC KIDNEY-DISEASE; CHROMOSOME REARRANGEMENT; CYTOGENETIC ANALYSIS; COLORECTAL CANCERS; MYELOID-LEUKEMIA; DNA MICROARRAYS; PROSTATE-CANCER; GAMMA-HEREGULIN; FUSION GENES	Chromosome translocations in the common epithelial cancers are abundant, yet little is known about them. They have been thought to be almost all unbalanced and therefore dismissed as mostly mediating tumour suppressor loss. We present a comprehensive analysis by array painting of the chromosome translocations of breast cancer cell lines HCC1806, HCC1187 and ZR-75-30. In array painting, chromosomes are isolated by flow cytometry, amplified and hybridized to DNA microarrays. A total of 200 breakpoints were identified and all were mapped to 1Mb resolution on bacterial artificial chromosome (BAC) arrays, then 40 selected breakpoints, including all balanced breakpoints, were further mapped on tiling-path BAC arrays or to around 2 kb resolution using oligonucleotide arrays. Many more of the translocations were balanced at 1Mb resolution than expected, either reciprocal (eight in total) or balanced for at least one participating chromosome (19 paired breakpoints). Second, many of the breakpoints were at genes that are plausible targets of oncogenic translocation, including balanced breaks at CTCF, EP300/p300 and FOXP4. Two gene fusions were demonstrated, TAX1BP1-AHCY and RIF1-PKD1L1. Our results support the idea that chromosome rearrangements may play an important role in common epithelial cancers such as breast cancer.	[Howarth, K. D.; Blood, K. A.; Beavis, J. C.; Chua, Y.; Cooke, S. L.; Raby, S.; Edwards, P. A. W.] Univ Cambridge, Hutchison MRC Res Ctr, Dept Pathol, Cambridge CB2 0XZ, England; [Ng, B. L.; Carter, N. P.] Wellcome Trust Sanger, Cambridge, England; [Ichimura, K.; Collins, V. P.] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Cambridge CB2 0XZ, England	University of Cambridge; Wellcome Trust Sanger Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Edwards, PAW (corresponding author), Univ Cambridge, Hutchison MRC Res Ctr, Dept Pathol, Hills Rd, Cambridge CB2 0XZ, England.	pawe1@cam.ac.uk	Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374	Cancer Research UK [A4392] Funding Source: Medline; Wellcome Trust [077008] Funding Source: Medline; Breast Cancer Now [2005NOV68] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Breast Cancer Now		Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Adeyinka A, 2000, INT J MOL MED, V5, P235; Alsop AE, 2006, CANCER GENET CYTOGEN, V164, P97, DOI 10.1016/j.cancergencyto.2005.09.011; Barlund M, 2002, GENE CHROMOSOME CANC, V35, P311, DOI 10.1002/gcc.10121; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Chin KT, 2007, CANCER RES, V67, P1072, DOI 10.1158/0008-5472.CAN-06-3053; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas P, 2005, PFLUG ARCH EUR J PHY, V451, P264, DOI 10.1007/s00424-005-1431-5; Dorssers LCJ, 1997, INT J CANCER, V72, P700, DOI 10.1002/(SICI)1097-0215(19970807)72:4<700::AID-IJC24>3.0.CO;2-D; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; ENGEL LW, 1978, CANCER RES, V38, P3352; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Fiegler H, 2003, J MED GENET, V40, P664, DOI 10.1136/jmg.40.9.664; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Gribble SM, 2007, J MED GENET, V44, P51, DOI 10.1136/jmg.2006.044909; Gribble SM, 2005, J MED GENET, V42, P8, DOI 10.1136/jmg.2004.024141; Grigorova M, 2005, CANCER GENET CYTOGEN, V162, P1, DOI 10.1016/j.cancergencyto.2005.03.007; Hahn Y, 2004, P NATL ACAD SCI USA, V101, P13257, DOI 10.1073/pnas.0405490101; Huang AL, 2006, NATURE, V442, P934, DOI [10.1038/nature05084, 10.1038/nature050084]; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Ichimura K, 2006, ONCOGENE, V25, P1261, DOI 10.1038/sj.onc.1209156; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Krzywinski M, 2004, NUCLEIC ACIDS RES, V32, P3651, DOI 10.1093/nar/gkh700; Liu XF, 1999, ONCOGENE, V18, P7110, DOI 10.1038/sj.onc.1203136; McMullan TFW, 2002, HUM GENET, V110, P244, DOI 10.1007/s00439-002-0679-5; Mehra R, 2007, MODERN PATHOL, V20, P538, DOI 10.1038/modpathol.3800769; Mitelman F, 2005, GENE CHROMOSOME CANC, V43, P350, DOI 10.1002/gcc.20212; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Morris JS, 1997, GENE CHROMOSOME CANC, V20, P120, DOI 10.1002/(SICI)1098-2264(199710)20:2<120::AID-GCC3>3.0.CO;2-5; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Ng BL, 2006, CYTOM PART A, V69A, P1028, DOI 10.1002/cyto.a.20330; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Persson K, 1999, GENE CHROMOSOME CANC, V25, P115, DOI 10.1002/(SICI)1098-2264(199906)25:2<115::AID-GCC7>3.0.CO;2-2; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Roschke AV, 2003, CANCER RES, V63, P8634; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Seng TJ, 2005, GENE CHROMOSOME CANC, V43, P181, DOI 10.1002/gcc.20181; Shillingford JM, 2006, P NATL ACAD SCI USA, V103, P5466, DOI 10.1073/pnas.0509694103; Silverman J, 2004, GENE DEV, V18, P2108, DOI 10.1101/gad.1216004; Sinclair PB, 2000, BLOOD, V95, P738, DOI 10.1182/blood.V95.3.738.003k21_738_743; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Theodorou V, 2007, NAT GENET, V39, P759, DOI 10.1038/ng2034; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Yuasa T, 2002, GENOMICS, V79, P376, DOI 10.1006/geno.2002.6719	55	49	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3345	3359		10.1038/sj.onc.1210993	http://dx.doi.org/10.1038/sj.onc.1210993			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084325	Green Accepted			2022-12-28	WOS:000256111400013
J	Sirvent, A; Leroy, C; Boureux, A; Simon, V; Roche, S				Sirvent, A.; Leroy, C.; Boureux, A.; Simon, V.; Roche, S.			The Src-like adaptor protein regulates PDGF-induced actin dorsal ruffles in a c-Cbl-dependent manner	ONCOGENE			English	Article						SLAP; Src; PDGF; Cbl; DNA synthesis; F-actin assembly	RECEPTOR TYROSINE KINASES; DNA-SYNTHESIS; NEGATIVE REGULATION; FIBROBLASTS; MITOGENESIS; EXPRESSION; THYMOCYTES; MIGRATION; BINDING; SLAP	The Src-like adaptor protein (SLAP) belongs to the subfamily of adapter proteins that negatively regulate cellular signalling initiated by tyrosine kinases. SLAP has a unique, myristylated N-terminus, followed by SH3 and SH2 domains with high homology to Src family tyrosine kinases (SFK) and a unique C-terminal tail, which is important for c-Cbl binding. We have previously shown that SLAP negatively regulates platelet-derived growth factor (PDGF)-induced mitogenesis in fibroblasts and we now report that it regulates F-actin assembly for dorsal ruffles formation. c-Cbl mediated SLAP inhibition towards actin remodelling. Moreover, SLAP enhanced PDGF-induced c-Cbl phosphorylation by SFK. In contrast, SLAP mitogenic inhibition was not mediated by c-Cbl, but it rather involved a competitive mechanism with SFK for PDGF-receptor (PDGFR) association and mitogenic signalling. Accordingly, phosphorylation of the Src mitogenic substrates Stat3 and Shc were reduced by SLAP. Thus, we concluded that SLAP regulates PDGFR signalling by two independent mechanisms: a competitive mechanism for PDGF-induced Src mitogenic signalling and a non-competitive mechanism for dorsal ruffles formation mediated by c-Cbl.	[Roche, S.] Univ Montpellier 1, CNRS, CRBM, UMR5237, F-34293 Montpellier 05, France; Univ Montpellier 2, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier	Roche, S (corresponding author), Univ Montpellier 1, CNRS, CRBM, UMR5237, 1919 Route Mende, F-34293 Montpellier 05, France.	serge.roche@crbm.cnrs.fr		roche, serge/0000-0003-3413-3859				Boureux A, 2005, J CELL SCI, V118, P3717, DOI 10.1242/jcs.02491; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Myers MD, 2006, NAT IMMUNOL, V7, P57, DOI 10.1038/ni1291; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Reddi AL, 2007, J BIOL CHEM, V282, P29336, DOI 10.1074/jbc.M701797200; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Scaife RM, 2003, J CELL SCI, V116, P463, DOI 10.1242/jcs.00244; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Swaminathan G, 2007, ONCOGENE, V26, P4095, DOI 10.1038/sj.onc.1210184; Teckchandani AM, 2005, EXP CELL RES, V307, P247, DOI 10.1016/j.yexcr.2005.03.010; Veracini L, 2006, J CELL SCI, V119, P2921, DOI 10.1242/jcs.03015	19	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3494	3500		10.1038/sj.onc.1211011	http://dx.doi.org/10.1038/sj.onc.1211011			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193084	Green Submitted, Bronze			2022-12-28	WOS:000256309900015
J	Ushmorov, A; Hogarty, MD; Liu, X; Knauss, H; Debatin, KM; Beltinger, C				Ushmorov, A.; Hogarty, M. D.; Liu, X.; Knauss, H.; Debatin, K. M.; Beltinger, C.			N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells	ONCOGENE			English	Article						N-myc; bcl-2; survivin; FLIP(L); neuroblastoma	ADVANCED-STAGE NEUROBLASTOMA; NEURO-BLASTOMA CELLS; ANTI-APOPTOSIS GENE; C-MYC; CASPASE-8 EXPRESSION; MEDIATED APOPTOSIS; ONCOLOGY GROUP; AMPLIFICATION; SURVIVIN; ACTIVATION	N-myc has proapoptotic functions, yet it acts as an oncogene in neuroblastoma. Thus, antiapoptotic mechanisms have to be operative in neuroblastoma cells that antagonize the proapoptotic effects of N-myc. We conditionally activated N-myc in SH-EP neuroblastoma cells subjected to the trophic stress of serum or nutrient deprivation while changing the expression of Bcl-2, survivin and FLIPL, antiapoptotic molecules often over-expressed in poor prognosis neuroblastomas. Bcl-2 protected SH-EP cells from death during nutritional deprivation by activating energetically advantageous oxidative phosphorylation. N-myc overrode the metabolic protection provided by Bcl-2-induced oxidative phosphorylation by reestablishing the glycolytic phenotype and attenuated the antiapoptotic effect of Bcl-2during metabolic stress. Survivin partially antagonized the growth suppressive function of N-myc in SH-EP neuroblastoma cells during serum deprivation whereas FLIPL did not. These findings advance our understanding of the functions of N-myc in neuroblastoma cells.	[Ushmorov, A.; Knauss, H.; Debatin, K. M.; Beltinger, C.] Univ Childrens Hosp, D-89075 Ulm, Germany; [Hogarty, M. D.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Beltinger, C (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	christian.beltinger@uniklinik-ulm.de	Ushmorov, Alexey/AAI-6445-2020; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Ushmorov, Alexey/0000-0003-3724-7253				Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CASTLE VP, 1993, AM J PATHOL, V143, P1543; Chan HSL, 1997, CLIN CANCER RES, V3, P1699; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Cohn SL, 2000, J CLIN ONCOL, V18, P3604, DOI 10.1200/JCO.2000.18.21.3604; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Eggert A, 2001, CANCER RES, V61, P1314; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Fischer M, 2005, J MOL DIAGN, V7, P89, DOI 10.1016/S1525-1578(10)60013-X; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 2006, CANCER RES, V66, P10016, DOI 10.1158/0008-5472.CAN-05-4079; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048; Hogarty MD, 2003, CANCER LETT, V197, P173, DOI 10.1016/S0304-3835(03)00103-4; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kim YH, 2003, MOL CELLS, V16, P67; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; LIU X, 2007, ONCOGENE, V27; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Matthay KK, 2000, J CLIN ONCOL, V18, P3591, DOI 10.1200/JCO.2000.18.21.3591; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Miller MA, 2006, J PEDIAT HEMATOL ONC, V28, P412, DOI 10.1097/01.mph.0000212937.00287.e5; NAKAGAWARA A, 1990, CANCER RES, V50, P3043; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; Papas KK, 1999, FEBS LETT, V446, P338, DOI 10.1016/S0014-5793(99)00240-9; Poulaki V, 2001, CANCER RES, V61, P4864; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; ROSS RA, 1983, J NATL CANCER I, V71, P741; Roth W, 2004, VITAM HORM, V67, P189; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SLAVC I, 1990, CANCER RES, V50, P1459; Song JX, 2005, IMMUNITY, V22, P621, DOI 10.1016/j.immuni.2005.03.012; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tang XX, 2006, CANCER RES, V66, P2826, DOI 10.1158/0008-5472.CAN-05-0854; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E	58	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3424	3434		10.1038/sj.onc.1211017	http://dx.doi.org/10.1038/sj.onc.1211017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193081				2022-12-28	WOS:000256309900007
J	Daubon, T; Chasseriau, J; El Ali, A; Rivet, J; Kitzis, A; Constantin, B; Bourmeyster, N				Daubon, T.; Chasseriau, J.; El Ali, A.; Rivet, J.; Kitzis, A.; Constantin, B.; Bourmeyster, N.			Differential motility of p190(bcr-abl)- and p210(bcr-abl)-expressing cells: respective roles of Vav and Bcr-Abl GEFs	ONCOGENE			English	Article						amoeboid; Bcr-Abl; motility; Rho; Vav	CHRONIC MYELOGENOUS LEUKEMIA; GTP-BINDING PROTEIN; TYROSINE PHOSPHORYLATION; ACTIVATION; MIGRATION; TRANSFORMATION; ASSOCIATION; EXPRESSION; ONCOGENE; ADHESION	The chimeric oncogene Bcr-Abl is known to induce autonomous motility of leukemicc ells. We show here that p210(bcr-abl) responsible for chronic myelogenous leukemia induces an amoeboid type of motility while p190(bcr-abl), associated with acute lymphoid leukemia, induces a rolling type of motility. We previously reported that p210(bcr-abl) activates RhoA and Rac1, while p190(bcr-abl) although devoid of a Dbl-homology (DH) domain activates Rac1, but not RhoA. We investigated the regulation of GDP/GTP exchange factor (GEF) activities in the Bcr-Abl complex. For that purpose, different GEF activity mutants of Vav and of Bcr-Abl were constructed and stably transfected in Ba/F3 cells. Using these mutants, we demonstrate that RhoA is exclusively activated by the DH domain of p210(bcr-abl), while Rac1 activation is mostly due to Vav. Inhibition of Rac1 by Vav GEF mutant leads to immobilization of cells. Vav depletion using shRNA also induces immobilization of cells and suppression of GTP-bound Rac1. RhoA inactivation induces the specific loss of amoeboid movements. These results suggest that Rac1 activation by Vav triggers the motility of Bcr-Abl-expressing Ba/F3 cells, while the specific amoeboid mode of motility induced by p210(bcr-abl) is a consequence of RhoA activation.	[Daubon, T.; Chasseriau, J.; El Ali, A.; Kitzis, A.; Constantin, B.; Bourmeyster, N.] Univ Poitiers, CNRS, Inst Phys & Biol Cellulaires, UMR 6187,Fac Sci, F-86021 Poitiers, France; [Rivet, J.; Kitzis, A.; Bourmeyster, N.] CHU Poitiers, LGCM, Poitiers, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; CHU Poitiers; Universite de Poitiers	Bourmeyster, N (corresponding author), Univ Poitiers, CNRS, Inst Phys & Biol Cellulaires, UMR 6187,Fac Sci, 40 Ave Recteur Pineau,BP 577, F-86021 Poitiers, France.	n.bourmeyster@chu-poitiers.fr	Constantin, Bruno/AAH-6463-2021	ElAli, Ayman/0000-0002-4048-6039; DAUBON, Thomas/0000-0002-0319-7617; Bourmeyster, Nicolas/0000-0002-9563-5142; Constantin, Bruno/0000-0003-1668-581X				Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; Bhatia R, 1999, EXP HEMATOL, V27, P1384, DOI 10.1016/S0301-472X(99)00084-3; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Harnois T, 2003, ONCOGENE, V22, P6445, DOI 10.1038/sj.onc.1206626; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Marvaud JC, 2002, J BIOL CHEM, V277, P43659, DOI 10.1074/jbc.M207828200; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; Unwin RD, 2005, J BIOL CHEM, V280, P6316, DOI 10.1074/jbc.M410598200; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340	27	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2673	2685		10.1038/sj.onc.1210933	http://dx.doi.org/10.1038/sj.onc.1210933			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18059343	Green Published			2022-12-28	WOS:000255259500002
J	Johnson, J; Lagowski, J; Lawson, S; Liu, Y; Kulesz-Martin, M				Johnson, J.; Lagowski, J.; Lawson, S.; Liu, Y.; Kulesz-Martin, M.			P73 expression modulates p63 and Mdm2 protein presence in complex with p53 family-specific DNA target sequence in squamous cell carcinogenesis	ONCOGENE			English	Article						p73; squamous cell carcinoma; keratinocyte; p53 family interplay	TRANSCRIPTIONAL ACTIVITY; ACTIVATION; CARCINOMA; CANCER; ANTAGONISTS; ISOFORMS; DOMAIN; DEATH; FORMS	The expression of p73 and p63 isoforms is frequently deregulated in human epithelial tumors. We previously showed that loss of p73 protein expression associates with malignant conversion in vivo and ionizing radiation (IR) resistance in vitro in a clonal model of mouse epidermal carcinogenesis. Here we show that loss of endogenous p73 expression in squamous cell carcinoma (SCC) cells and tumors was concomitant with preferential DNA binding of the inhibitory Delta Np63 alpha isoform and reduction of transcriptionally active p63 gamma isoforms binding to a p21 promoter sequence in vitro. Reconstitution of TAp73 alpha in malignant cells increased the steady state DNA-binding capabilities of the endogenous transcriptionally active TAp63 gamma and Delta Np63 gamma isoforms, correlating with restoration of tumor suppression but not IR sensitivity. Loss of p73 in malignant cells also coincided with increased presence of p53 family inhibitor Mdm2 in p53-specific DNA-bound complexes, whereas reconstitution of TAp73 alpha expression resulted in exclusion of Mdm2 from these complexes. These results suggest a dual mechanism for TAp73 alpha to foster tumor suppression through enhancement of the DNA-binding activity of p63 gamma isoforms, and through inhibition of transcriptional repressors Mdm2 or DNp63a.	[Johnson, J.; Lagowski, J.; Lawson, S.; Liu, Y.; Kulesz-Martin, M.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97239 USA; [Johnson, J.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; [Kulesz-Martin, M.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Kulesz-Martin, M (corresponding author), Oregon Hlth & Sci Univ, Dept Dermatol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	kuleszma@ohsu.edu			NCI NIH HHS [CA98893, 1-T32-CA106195, CA98577, CA69533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098577, T32CA106195, P30CA069533, R01CA098893] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2000, ONCOGENE, V19, P831, DOI 10.1038/sj.onc.1203311; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Cui Rutao, 2005, Biochem Biophys Res Commun, V336, P339; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Goldschneider D, 2003, CANCER LETT, V197, P99, DOI 10.1016/S0304-3835(03)00089-2; Gu JJ, 2001, CANCER RES, V61, P6703; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Johnson J, 2007, CANCER RES, V67, P7723, DOI 10.1158/0008-5472.CAN-07-1195; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; King KE, 2006, CARCINOGENESIS, V27, P53, DOI 10.1093/carcin/bgi200; Knights CD, 2003, J BIOL CHEM, V278, P52890, DOI 10.1074/jbc.M300279200; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KULESZMARTIN MF, 1988, CARCINOGENESIS, V9, P171, DOI 10.1093/carcin/9.1.171; Liu G, 2005, J BIOL CHEM, V280, P20111, DOI 10.1074/jbc.M413889200; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu YG, 2001, CANCER RES, V61, P5402; Liu YG, 2004, CANCER BIOL THER, V3, P1102, DOI 10.4161/cbt.3.11.1189; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Moll UM, 2004, MOL CANCER RES, V2, P371; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Rocco JW, 2006, CELL CYCLE, V5, P936, DOI 10.4161/cc.5.9.2716; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	35	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2008	27	19					2780	2787		10.1038/sj.onc.1210941	http://dx.doi.org/10.1038/sj.onc.1210941			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18026135				2022-12-28	WOS:000255259500013
J	Thaxton, C; Lopera, J; Bott, M; Fernandez-Valle, C				Thaxton, C.; Lopera, J.; Bott, M.; Fernandez-Valle, C.			Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways	ONCOGENE			English	Article						nerve; merlin; beta 1 integrin; ErbB2; Cdc42	MERLIN; PAXILLIN; ACTIVATION; RECEPTORS; ADHESION; LOCALIZATION; MYELINATION; ASSOCIATION; EXPRESSION; GENE	Mutations in the neuro. bromatosis type 2 (NF2) gene cause formation of schwannomas and other tumors in the nervous system. The NF2 protein, Schwannomin/Merlin, is a cytoskeleton-associated tumor suppressor regulated by phosphorylation at serine 518 (S518). Unphosphorylated Schwannomin restricts cell proliferation in part by inhibiting Rac- and p21-activated kinase (Pak). In a negative-feedback loop, Pak phosphorylates Schwannomin inactivating its ability to inhibit Pak. Little is known about receptor mechanisms that promote Pak activity and Schwannomin phosphorylation. Here we demonstrate in primary Schwann cells (SCs) that Schwannomin is rapidly phosphorylated on S518 by Pak following laminin-1 binding to b1 integrin, and by protein kinase A following neuregulin-1b (NRG1b) binding to ErbB2/ErbB3 receptors. These receptors, together with phosphorylated Schwannomin, P-Pak, Cdc42 and paxillin are enriched at the distal tips of SC processes, and can be isolated as a complex using b1 integrin antibody. Dual stimulation with laminin-1 and NRG1 beta does not synergistically increase Schwannomin phosphorylation because ErbB2 kinase partially antagonizes integrin-dependent activation of Pak. These results identify two parallel, but interactive pathways that inactivate the tumor suppressor activity of Schwannomin to allow proliferation of subconfluent SCs. Moreover, they identify ErbB2, ErbB3 and beta 1 integrins as potential therapeutic targets for NF2.	[Thaxton, C.; Lopera, J.; Bott, M.; Fernandez-Valle, C.] Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	State University System of Florida; University of Central Florida	Fernandez-Valle, C (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA.	cfernand@mail.ucf.edu		Thaxton, Courtney/0000-0002-6733-369X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034499] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS034499] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Chen LM, 2000, J NEUROSCI, V20, P3776, DOI 10.1523/JNEUROSCI.20-10-03776.2000; Chen ZL, 2003, J CELL BIOL, V163, P889, DOI 10.1083/jcb.200307068; Chernousov MA, 2000, HISTOL HISTOPATHOL, V15, P593, DOI 10.14670/HH-15.593; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Dubovy P, 1999, Gen Physiol Biophys, V18 Suppl 1, P63; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; Garratt AN, 2000, BIOESSAYS, V22, P987, DOI 10.1002/1521-1878(200011)22:11<987::AID-BIES5>3.0.CO;2-5; Hansen MR, 2004, OTOL NEUROTOL, V25, P155, DOI 10.1097/00129492-200403000-00013; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Iacovelli J, 2007, GLIA, V55, P1638, DOI 10.1002/glia.20578; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kim HA, 1997, J NEUROSCI RES, V49, P236; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lee JW, 2004, MOL CELLS, V17, P188; LOTTI LV, 1992, EXP CELL RES, V202, P274, DOI 10.1016/0014-4827(92)90075-J; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Monje PV, 2006, GLIA, V53, P649, DOI 10.1002/glia.20330; Okada T, 2007, TRENDS CELL BIOL, V17, P222, DOI 10.1016/j.tcb.2007.03.006; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Rosenbaum C, 1997, EXP NEUROL, V148, P604, DOI 10.1006/exnr.1997.6696; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Scoles DR, 2005, BIOCHEM BIOPH RES CO, V335, P385, DOI 10.1016/j.bbrc.2005.07.083; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Taylor AR, 2003, GLIA, V41, P94, DOI 10.1002/glia.10170; Thaxton C, 2007, MOL CELL NEUROSCI, V34, P231, DOI 10.1016/j.mcn.2006.11.003; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Turner CE, 2000, J CELL SCI, V113, P4139; Utermark T, 2003, BRAIN PATHOL, V13, P352; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yang DR, 2005, J CELL BIOL, V168, P655, DOI 10.1083/jcb.200411158	39	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2705	2715		10.1038/sj.onc.1210923	http://dx.doi.org/10.1038/sj.onc.1210923			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998937				2022-12-28	WOS:000255259500005
J	Leal, JFM; Fominaya, J; Cascon, A; Guijarro, MV; Blanco-Aparicio, C; Lleonart, M; Castro, ME; Cajal, SRY; Robledo, M; Beach, DH; Carnero, A				Leal, J. F. M.; Fominaya, J.; Cascon, A.; Guijarro, M. V.; Blanco-Aparicio, C.; Lleonart, M.; Castro, M. E.; Ramon y Cajal, S.; Robledo, M.; Beach, D. H.; Carnero, A.			Cellular senescence bypass screen identifies new putative tumor suppressor genes	ONCOGENE			English	Article						senescence; genetic screening; tumor suppressor; p53; BRF1; Csn2	COP9 SIGNALOSOME; CANCER-THERAPY; HUMAN-CELLS; P53; ACCUMULATION; DEGRADATION; P16(INK4A); DISRUPTION; HALLMARKS; ABSENCE	Senescence is a mechanism that limits cellular lifespan and constitutes a barrier against cellular immortalization. To identify new senescence regulatory genes that might play a role in tumorigenesis, we have designed and performed a large-scale antisense-based genetic screen in primary mouse embryo. broblasts (MEFs). Out of this screen, we have identified five different genes through which loss of function partially bypasses senescence. These genes belong to very different biochemical families: csn2 (component of the Cop9 signalosome), aldose reductase (a metabolic enzyme) and brf1 (subunit of the RNA polymerase II complex), S-adenosyl homocysteine hydrolase and Bub1. Inactivation, at least partial, of these genes confers resistance to both p53- and p16INK4a-induced proliferation arrest. Furthermore, such inactivation inhibits p53 but not E2F1 transcriptional activity and impairs DNA-damage-induced transcription of p21. Since the aim of the screen was to identify new regulators of tumorigenesis, we have tested their inactivation in human tumors. We have found, either by northern blot or quantitative reverse transcriptase-PCR analysis, that the expression of three genes, Csn2, Aldose reductase and Brf1, is lost at different ratios in tumors of different origins. These genes are located at common positions of loss of heterogeneity (15q21.2, 7q35 and 14q32.33); therefore, we have measured genomic losses of these specific genes in different tumors. We have found that Csn2 and Brf1 also show genomic losses of one allele in different tumors. Our data suggest that the three genes identified in the genome-wide loss-of-function genetic screen are putative tumor suppressors located at 15q21.2; 7q35 and 14q32.33.	[Leal, J. F. M.; Fominaya, J.; Guijarro, M. V.; Blanco-Aparicio, C.; Castro, M. E.; Carnero, A.] CNIO, Expt Therapeut Programme, Madrid 28029, Spain; [Cascon, A.; Robledo, M.] CNIO, Mol Pathol Programme, Madrid 28029, Spain; [Lleonart, M.; Ramon y Cajal, S.] Hosp Valle De Hebron, Dept Patol, Barcelona, Spain; [Beach, D. H.] Ctr Cutaneous Biol, Inst Cell & Mol Sci, London, England	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitari Vall d'Hebron; University of London; Queen Mary University London	Carnero, A (corresponding author), CNIO, Expt Therapeut Programme, C Melchor Fernandez Almagro 3, Madrid 28029, Spain.	acarnero@cnio.es	IBIS, CANCER/P-3323-2015; Leal, Juan F Martinez/N-6328-2013; LLeonart, Matilde E./Q-2662-2019; Ramon y Cajal, Santiago/H-4955-2016; Blanco-Aparicio, Carmen/I-3162-2015; Espinosas, Maribel/H-8083-2012; Robledo, Mercedes/O-2230-2013; Cascon, Alberto/G-3160-2014	Leal, Juan F Martinez/0000-0002-7538-0875; LLeonart, Matilde E./0000-0002-6196-7405; Ramon y Cajal, Santiago/0000-0002-3867-1390; Blanco-Aparicio, Carmen/0000-0002-3249-6595; Robledo, Mercedes/0000-0001-6256-5902; Cascon, Alberto/0000-0003-2119-891X; Carnero, Amancio/0000-0003-4357-3979	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Carnero A, 2004, ONCOGENE, V23, P6006, DOI 10.1038/sj.onc.1207839; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eichhorn K, 2001, J BIOL CHEM, V276, P21158, DOI 10.1074/jbc.M102295200; Greider Carol W., 2004, Cell, VS116, pS83, DOI 10.1016/S0092-8674(04)00053-4; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Lefrancois-Martinez AM, 2004, J CLIN ENDOCR METAB, V89, P3010, DOI 10.1210/jc.2003-031830; Lleonart ME, 2006, ONCOL REP, V16, P603; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Yoneda-Kato N, 2005, EMBO J, V24, P1739, DOI 10.1038/sj.emboj.7600656	31	41	44	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					1961	1970		10.1038/sj.onc.1210846	http://dx.doi.org/10.1038/sj.onc.1210846			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17968325				2022-12-28	WOS:000254359100001
J	Barbetti, V; Gozzini, A; Rovida, E; Morandi, A; Spinelli, E; Fossati, G; Mascagni, P; Lubbert, M; Dello Sbarba, P; Santini, V				Barbetti, V.; Gozzini, A.; Rovida, E.; Morandi, A.; Spinelli, E.; Fossati, G.; Mascagni, P.; Luebbert, M.; Dello Sbarba, P.; Santini, V.			Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells	ONCOGENE			English	Article						AML; AML1/ETO; HDAC inhibitors; gene expression	ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; TRANSCRIPTION FACTORS; FUSION PARTNER; HEPATOMA-CELLS; RETINOIC ACID; IN-VITRO; APOPTOSIS; TARGET; ACETYLATION	We analysed the in vitro effects of a new hydroxamate derivative, ITF2357, on AML cells. ITF2357 potently induced histone acetylation. ITF2357 0.1 mu M blocked proliferation and induced apoptosis in AML1/ETO-positive Kasumi-1 cells, while AML1/ETO-negative HL60, THP1 and NB4 cell lines were sensitive only to 1 mu M ITF2357. Apoptosis was induced by 0.1 mu M ITF2357 in AML1/ETO-positive primary blasts and U937-A/E cells induced to express AML1/ETO, but not in U937-A/E cells non-expressing AML1/ETO. In Kasumi-1 cells 0.1 mu M ITF2357 induced AML1/ETO degradation through a caspase-dependent mechanism. ITF2357 0.1 mu M also determined DNMT1 efflux from, and p300 influx to, the nucleus. Moreover, 0.1 mu M ITF2357 determined local H4 acetylation and release of DNMT1, HDAC1 and AML1/ETO, paralleled by recruitment of p300 to the IL-3 gene promoter. ITF2357 treatment, however, did not induce re-expression of IL-3 gene. Accordingly, the methylation level of IL-3 promoter, as well as of several other genes, was unmodified. In conclusion, ITF2357 emerged as an antileukaemic agent very potent on AML cells, and on AML1/ETO-positive cells in particular. More relevantly, clearly emerged from our results that ITF2357 could be an ideal agent to treat AML subtypes presenting AML1/ETO fusion protein which determine HDAC involvement in leukaemogenesis.	[Gozzini, A.; Spinelli, E.; Santini, V.] Univ Florence, UF Ematol, AOU Careggi, I-50134 Florence, Italy; [Barbetti, V.; Rovida, E.; Morandi, A.; Dello Sbarba, P.] Univ Florence, Dipartimento Patol Oncol Sperimentali, I-50134 Florence, Italy; [Luebbert, M.] Univ Freiburg, Dept Med, D-7800 Freiburg, Germany; [Fossati, G.; Mascagni, P.] Italfarmaco SpA, Milan, Italy	University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; University of Freiburg; Italfarmaco	Santini, V (corresponding author), Univ Florence, UF Ematol, AOU Careggi, Viale GB Morgagni 85, I-50134 Florence, Italy.	santini@unifi.it	Rovida, Elisabetta/F-3565-2015; Dello Sbarba, Persio/AAX-9887-2020; SANTINI, VALERIA/AAL-3135-2020	Rovida, Elisabetta/0000-0002-5949-3239; SANTINI, VALERIA/0000-0002-5439-2172; Morandi, Andrea/0000-0002-9222-5332				Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; Altucci L, 2005, CANCER RES, V65, P8754, DOI 10.1158/0008-5472.CAN-04-3569; Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020; ASOU H, 1991, BLOOD, V77, P2031; Atsumi A, 2006, BIOCHEM BIOPH RES CO, V345, P1471, DOI 10.1016/j.bbrc.2006.05.047; Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gozzini A, 2003, CANCER RES, V63, P8955; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; KLISOVIC MI, 2003, LEUKEMIA, V350; Leoni F, 2005, MOL MED, V11, P1, DOI 10.2119/2006-00005.Dinarello; Liu SJ, 2007, J PHARMACOL EXP THER, V321, P953, DOI 10.1124/jpet.106.118406; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lu Y, 2006, LEUKEMIA, V20, P987, DOI 10.1038/sj.leu.2404218; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mrozek K, 2001, J CLIN ONCOL, V19, P2482, DOI 10.1200/JCO.2001.19.9.2482; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pasqualucci L, 2003, LEUKEMIA LYMPHOMA, V44, pS5, DOI 10.1080/10428190310001621588; Pathil A, 2006, HEPATOLOGY, V43, P425, DOI 10.1002/hep.21054; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Santini V, 2007, CURR DRUG METAB, V8, P383, DOI 10.2174/138920007780655397; Tan J, 2006, J BIOL CHEM, V281, P10508, DOI 10.1074/jbc.M512719200; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang L, 2007, CELL DEATH DIFFER, V14, P306, DOI 10.1038/sj.cdd.4401996; Yang G, 2007, ONCOGENE, V26, P91, DOI 10.1038/sj.onc.1209760	33	38	41	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1767	1778		10.1038/sj.onc.1210820	http://dx.doi.org/10.1038/sj.onc.1210820			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891169				2022-12-28	WOS:000253962100012
J	Campanero, MR; Herrero, A; Calvo, V				Campanero, M. R.; Herrero, A.; Calvo, V.			The histone deacetylase inhibitor trichostatin A induces GADD45 gamma expression via Oct and NF-Y binding sites	ONCOGENE			English	Article						GADD45 gamma; HDAC inhibitor; TSA; Oct; NF-Y	TRANSCRIPTION FACTORS OCT-1; GROWTH-ARREST; CELL-GROWTH; P53-INDEPENDENT INDUCTION; GENOTOXIC STRESS; CANCER CELLS; GENE GADD45; DNA-DAMAGE; PROMOTER; RECRUITMENT	The GADD45 gamma protein is a potential tumor suppressor whose expression is reduced in several tumors. However, very little is known about the regulation of its expression. We have determined that the most relevant region of its promoter lies between nucleotides -112 and -54, relative to the transcription start site. Putative Oct and NF-Y elements were found in this region and factors belonging to these families interacted with these elements in vitro and with the promoter in vivo. Mutation of these elements reduced the basal activity of the promoter, suggesting that both sites are essential for basal expression. These factors interact with chromatin modifying proteins and we found that histone deacetylase 1 or silencing mediator for retinoid and thyroid hormone receptor overexpression reduced the basal activity of the promoter. In contrast, forced expression of the histone acetylase protein PCAF or cell treatment with the HDAC inhibitor trichostatin A increased GADD45 gamma mRNA levels and induced GADD45 gamma promoter activity through its Oct and NF-Y elements. Moreover, ectopic expression of a dominant-negative version of NF-YA strongly inhibited trichostatin A-induced activation of the promoter. Our data strongly suggest that inhibition of deacetylase activity could potentially be used for treatment of tumors where GADD45 gamma expression is reduced.	[Herrero, A.; Calvo, V.] Univ Autonoma Madrid, Fac Med, CSIC, E-28029 Madrid, Spain; [Campanero, M. R.] Univ Autonoma Madrid, Inst Invest Biomed, CSIC, Madrid, Spain; [Herrero, A.; Calvo, V.] Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Calvo, V (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Arzobiospo Morcillo 4, E-28029 Madrid, Spain.	vcalvo@iib.uam.es	HERRERO, ANA/GOV-3351-2022; Campanero, Miguel R/A-4052-2013; Calvo, Victor/L-5024-2014	HERRERO, ANA/0000-0001-8065-2225; Campanero, Miguel R/0000-0003-1410-8621; Calvo, Victor/0000-0002-5913-7058				Balliet AG, 2003, DNA CELL BIOL, V22, P457, DOI 10.1089/104454903322247334; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Brockman JL, 2005, MOL CELL ENDOCRINOL, V239, P45, DOI 10.1016/j.mce.2005.04.006; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Chung HK, 2003, J CLIN ENDOCR METAB, V88, P3913, DOI 10.1210/jc.2002-022031; Constance CM, 1996, MOL CELL BIOL, V16, P3878; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; HINKLEY C, 1992, MOL CELL BIOL, V12, P4400, DOI 10.1128/MCB.12.10.4400; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jiang F, 2004, MOL CELL ENDOCRINOL, V213, P121, DOI 10.1016/j.mce.2003.10.050; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jung N, 2000, EUR J BIOCHEM, V267, P6180, DOI 10.1046/j.1432-1327.2000.01692.x; Kakizawa T, 2001, J BIOL CHEM, V276, P9720, DOI 10.1074/jbc.M008531200; Kojima S, 1999, FEBS LETT, V446, P313, DOI 10.1016/S0014-5793(99)00234-3; Liebermann DA, 2003, BLOOD CELL MOL DIS, V31, P213, DOI 10.1016/S1079-9796(03)00160-8; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mariadason JM, 2000, CANCER RES, V60, P4561; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakayama K, 1999, J BIOL CHEM, V274, P24766, DOI 10.1074/jbc.274.35.24766; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Peng YW, 2003, J BIOL CHEM, V278, P8385, DOI 10.1074/jbc.M213156200; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Sun LH, 2003, MOL BIOL REP, V30, P249, DOI 10.1023/A:1026370726763; Takahashi S, 2001, CANCER RES, V61, P1187; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689; ZHAN QM, 1994, CANCER RES, V54, P2755; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang W, 2001, INT J ONCOL, V18, P749; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262	50	22	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1263	1272		10.1038/sj.onc.1210735	http://dx.doi.org/10.1038/sj.onc.1210735			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724474				2022-12-28	WOS:000253407000008
J	Mangold, U; Hayakawa, H; Coughlin, M; Munger, K; Zetter, BR				Mangold, U.; Hayakawa, H.; Coughlin, M.; Munger, K.; Zetter, B. R.			Antizyme, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor localize to centrosomes and modulate centriole amplification	ONCOGENE			English	Article						antizyme; antizyme inhibitor; centrosome; proteasome; genomic instability; cancer	ORNITHINE DECARBOXYLASE-ANTIZYME; CELL-CYCLE; PROTEIN; GROWTH; OVEREXPRESSION; DUPLICATION; CANCER; IDENTIFICATION; POLYAMINES; ANEUPLOIDY	The potential tumor suppressor antizyme and its endogenous inhibitor (antizyme inhibitor, AZI) have been implicated in the ubiquitin-independent proteasomal degradation of proteins involved in cell proliferation as well as in the regulation of polyamine levels. We show here that both antizyme and AZI concentrate at centrosomes and that antizyme preferentially associates with the maternal centriole. Interestingly, alterations in the levels of these proteins have opposing effects on centrosomes. Depletion of antizyme in various cell lines and primary cells leads to centrosome overduplication, whereas overexpression of antizyme reduces numerical centrosome abnormalities. Conversely, silencing of the antizyme inhibitor, AZI, results in a decrease of numerical centrosome abnormalities, whereas overexpression of AZI leads to centrosome overduplication. We further show that the numerical centrosome abnormalities are due to daughter centriole amplification. In summary, our results demonstrate that alterations in the antizyme/AZI balance cause numerical centrosomal defects and suggest a role for ubiquitin-independent proteasomal degradation in centrosome duplication.	[Mangold, U.; Zetter, B. R.] Childrens Hosp Boston, Program Vasc Biol, Boston, MA USA; [Mangold, U.; Zetter, B. R.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Hayakawa, H.; Munger, K.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Coughlin, M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Zetter, BR (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, 1 Blackfan Circle, Boston, MA 02115 USA.	bruce.zetter@childrens.harvard.edu	Loizides-Mangold, Ursula/I-9061-2014	Loizides-Mangold, Ursula/0000-0001-9233-2974; Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [R01CA037393, R01CA066980, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA066980, CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Choi KS, 2005, BIOCHEM BIOPH RES CO, V328, P206, DOI 10.1016/j.bbrc.2004.11.172; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fong LYY, 2003, CANCER RES, V63, P3945; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; Keren-Paz A, 2006, ONCOGENE, V25, P5163, DOI 10.1038/sj.onc.1209521; Kim SW, 2006, J CELL SCI, V119, P2853, DOI 10.1242/jcs.02966; Koike C, 1999, CANCER RES, V59, P6109; LANGE BMH, 1995, J CELL BIOL, V130, P919, DOI 10.1083/jcb.130.4.919; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Lin Y, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-15; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; Mitchell JLA, 1998, BIOCHEM J, V329, P453; Murai N, 2003, J BIOL CHEM, V278, P44791, DOI 10.1074/jbc.M308059200; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366; Sluder G, 2005, NAT REV MOL CELL BIO, V6, P743, DOI 10.1038/nrm1712; Tsou MFB, 2006, CURR OPIN CELL BIOL, V18, P74, DOI 10.1016/j.ceb.2005.12.008; Tsuji T, 2001, ONCOGENE, V20, P24, DOI 10.1038/sj.onc.1204051; Zou CZ, 2005, J CELL BIOL, V171, P437, DOI 10.1083/jcb.200506185	33	35	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					604	613		10.1038/sj.onc.1210685	http://dx.doi.org/10.1038/sj.onc.1210685			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667942				2022-12-28	WOS:000252674900005
J	Okuyama, T; Kurata, S; Tomimori, Y; Fukunishi, N; Sato, S; Osada, M; Tsukinoki, K; Jin, HF; Yamashita, A; Ito, M; Kobayashi, S; Hata, RI; Ikawa, Y; Katoh, I				Okuyama, T.; Kurata, S.; Tomimori, Y.; Fukunishi, N.; Sato, S.; Osada, M.; Tsukinoki, K.; Jin, H-F; Yamashita, A.; Ito, M.; Kobayashi, S.; Hata, R-I; Ikawa, Y.; Katoh, I.			p63(TP63) elicits strong trans-activation of the MFG-E8/lactadherin/BA46 gene through interactions between the TA and Delta N isoforms	ONCOGENE			English	Article						p63; MFG-E8; lactadherin; BA46; P53	MILK-FAT GLOBULE; SQUAMOUS-CELL CARCINOMA; P53 HOMOLOG P63; PROTEIN STABILITY; APOPTOTIC CELLS; STEM-CELLS; EXPRESSION; GLYCOPROTEIN; BINDING; CANCER	We report here that human MFGE8 encoding milk fat globule-EGF factor 8 protein (MFG-E8), also termed 46 kDa breast epithelial antigen and lactadherin, is transcriptionally activated by p63, or TP63, a p53 (TP53) family protein frequently overexpressed in head-and-neck squamous cell carcinomas, mammary carcinomas and so on. Despite that human MFG-E8 was originally identified as a breast cancer marker, and has recently been reported to provide peptides for cancer immunotherapy, its transcriptional control remains an open question. Observations in immunohistochemical analyses, a tetracycline-induced p63 expression system and keratinocyte cultures suggested a physiological link between p63 and MFGE8. By reporter assays with immediately upstream regions of MFGE8, we determined that the trans-activator (TA) isoforms of p63 activate MFGE8 transcription though a p53/p63 motif at -370, which was confirmed by a chromatin immunoprecipitation experiment. Upon siRNA-mediated p63 silencing in a squamous cell carinoma line, MFG-E8 production decreased to diminish Saos-2 cell adhesion. Interestingly, the Delta N-p63 isoform lacking the TA domain enhanced the MFGE8-activating function of TA-p63, if Delta N-p63 was dominant over TA-p63 as typically observed in undifferentiated keratinocytes and squamous cell carcinomas, implying a self-regulatory mechanism of p63 by the TA: Delta N association. MFG-E8 may provide a novel pathway of epithelial-nonepithelial cell interactions inducible by p63, probably in pathological processes.	[Jin, H-F; Yamashita, A.; Ito, M.; Katoh, I.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Microbiol, Yamanashi 4063898, Japan; [Okuyama, T.; Tomimori, Y.; Ikawa, Y.; Katoh, I.] RIKEN, Ikawa Lab, Wako, Saitama 35101, Japan; [Okuyama, T.; Kobayashi, S.] Kyoritsu Univ Pharm, Dept Mol Physiol, Tokyo, Japan; [Kurata, S.] Tokyo Med & Dent Univ, Inst Med Res, Dept Redox Response Cell Biol, Tokyo, Japan; [Kurata, S.; Tsukinoki, K.; Hata, R-I] Kanagawa Dent Coll, Oral Hlth Sci Res Ctr, Yokosuka, Kanagawa 238, Japan; [Sato, S.] Tokyo Med & Dent Univ, Dept Immune Regulat, Tokyo, Japan; [Osada, M.] Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo, Japan; [Jin, H-F; Ito, M.; Katoh, I.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Microbiol, Yamanashi, Japan; [Jin, H-F; Yamashita, A.; Katoh, I.] Tokyo Med & Dent Univ, Dept Hematol, Tokyo, Japan	University of Yamanashi; RIKEN; Keio University; Tokyo Medical & Dental University (TMDU); Kanagawa Dental College; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Yamanashi; Tokyo Medical & Dental University (TMDU)	Katoh, I (corresponding author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Microbiol, Yamanashi 4063898, Japan.	iyoko@yamanashi.ac.jp						Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Carmon L, 2002, J CLIN INVEST, V110, P453, DOI 10.1172/JCI200214071; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; DiRenzo J, 2002, CANCER RES, V62, P89; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Gailit J, 1997, EXP CELL RES, V232, P118, DOI 10.1006/excr.1997.3512; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2005, P NATL ACAD SCI USA, V102, P16886, DOI 10.1073/pnas.0508599102; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hoffmann Stephan, 2005, BMC Ophthalmol, V5, P16, DOI 10.1186/1471-2415-5-16; Hvarregaard J, 1996, EUR J BIOCHEM, V240, P628, DOI 10.1111/j.1432-1033.1996.0628h.x; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Koga F, 2003, BRIT J CANCER, V88, P740, DOI 10.1038/sj.bjc.6600764; Koistinen P, 1999, MATRIX BIOL, V18, P239, DOI 10.1016/S0945-053X(99)00022-0; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kruger W, 2000, BRIT J CANCER, V83, P874, DOI 10.1054/bjoc.2000.1404; Kurata S, 2004, J BIOL CHEM, V279, P50069, DOI 10.1074/jbc.M406322200; LAROCCA D, 1991, CANCER RES, V51, P4994; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Liu Y, 2005, CANCER GENE THER, V12, P304, DOI 10.1038/sj.cgt.7700785; Massion PP, 2003, CANCER RES, V63, P7113; MATHER IH, 1993, BIOCHEM MOL BIOL INT, V29, P545; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 2005, J INVEST DERMATOL, V125, P52, DOI 10.1111/j.0022-202X.2005.23801.x; Osada M, 2001, BIOCHEM BIOPH RES CO, V283, P1135, DOI 10.1006/bbrc.2001.4905; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Oshima K, 2002, EUR J BIOCHEM, V269, P1209, DOI 10.1046/j.1432-1033.2002.02758.x; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; PETERSON JA, 1990, HYBRIDOMA, V9, P221, DOI 10.1089/hyb.1990.9.221; Quade BJ, 2001, GYNECOL ONCOL, V80, P24, DOI 10.1006/gyno.2000.5953; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Shi JL, 2003, BLOOD, V101, P2628, DOI 10.1182/blood-2002-07-1951; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; Smith RA, 2004, ANN BIOMED ENG, V32, P635, DOI 10.1023/B:ABME.0000030230.81832.99; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; Watanabe T, 2005, CELL TISSUE RES, V321, P185, DOI 10.1007/s00441-005-1148-y; Wu GJ, 2005, CANCER RES, V65, P758; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	46	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					308	317		10.1038/sj.onc.1210646	http://dx.doi.org/10.1038/sj.onc.1210646			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637751				2022-12-28	WOS:000252256000006
J	Wu, A; Chen, J; Baserga, R				Wu, A.; Chen, J.; Baserga, R.			Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes	ONCOGENE			English	Article						IRS-1; c-myc; cyclin D1; rRNS	SIMIAN-VIRUS-40 T-ANTIGEN; GROWTH-FACTOR RECEPTOR; IGF-I RECEPTOR; BETA-CATENIN; TRANSLOCATION; IRS-1; TRANSFORMATION; INSULIN-RECEPTOR-SUBSTRATE-1; PATHWAY	The insulin receptor substrate-1 (IRS-1) is a docking protein of the insulin-like growth factor-1 (IGF-1) receptor and of the insulin receptor. IRS-1 sends a strong mitogenic, anti-apoptotic signal and plays an important role in cell transformation and cancer. IRS-1 translocates to nuclei of cells, where it increases the activity of the rDNA, c-myc and cyclin D1 promoters. We show, by chromatin immunoprecipitation, occupancy by IRS-1 of the same promoters. Both promoter activation and promoter occupancy are IGF-1-dependent. In cells that respond to IGF-1 but in which IRS-1 does not translocate to nuclei, promoter occupancy is absent and promoter activation is absent or much reduced. Transcriptional activation of c-myc and cyclin D1 promoters by nuclear IRS-1 does not occur with a mutant, inactive IRS-1 protein ( deletion of the phosphotyrosine-binding domain, PTB) and does not require PI3- kinase activity. Taken together, these results indicate a novel mechanism by which nuclear IRS-1 activates cell cycle genes.	[Wu, A.; Chen, J.; Baserga, R.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	b_lupo@mail.jci.tju.edu			NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NCI NIH HHS [CA08640, CA78890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Chang Q, 2002, CANCER RES, V62, P6035; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Cristofanelli B, 2000, ONCOGENE, V19, P3245, DOI 10.1038/sj.onc.1203664; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DeAngelis T, 2006, ONCOGENE, V25, P32, DOI 10.1038/sj.onc.1209013; Dearth RK, 2006, MOL CELL BIOL, V26, P9302, DOI 10.1128/MCB.00260-06; del Rincon SV, 2004, ONCOGENE, V23, P9269, DOI 10.1038/sj.onc.1208104; Drakas R, 2005, PROTEOMICS, V5, P132, DOI 10.1002/pmic.200400919; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Rowlands TM, 2003, P NATL ACAD SCI USA, V100, P11400, DOI 10.1073/pnas.1534601100; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wu A, 2005, J BIOL CHEM, V280, P2863, DOI 10.1074/jbc.M406138200	20	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					397	403		10.1038/sj.onc.1210636	http://dx.doi.org/10.1038/sj.onc.1210636			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17700539				2022-12-28	WOS:000252256000016
J	Fukata, M; Abreu, MT				Fukata, M.; Abreu, M. T.			Role of Toll-like receptors in gastrointestinal malignancies	ONCOGENE			English	Review						Toll-like receptor; cancer; stomach; intestine; colon; inflammation	INFLAMMATORY-BOWEL-DISEASE; INTESTINAL EPITHELIAL-CELLS; PROSTAGLANDIN E-2 SYNTHESIS; DEXTRAN SODIUM-SULFATE; HELICOBACTER-PYLORI; COLORECTAL-CANCER; CROHNS-DISEASE; COLON CARCINOGENESIS; ULCERATIVE-COLITIS; GERM-FREE	Mounting evidence supports the tenet that innate immune responses to luminal microbes participate in the development of gastrointestinal malignancies. The gastrointestinal tract is relatively unique in that it has evolved in the presence of diverse enteric micro. ora. Intestinal. ora is required to develop a normal adaptive immune response in the periphery. With the characterization of the innate immune system, we have begun to understand the adaptations the intestine has made to the microbiota. The interaction between the microbiota and the intestinal mucosa through Toll-like receptors (TLRs) is required to maintain intestinal homeostasis. In particular, intestinal epithelial cells and lamina propria mononuclear cells such as antigen-presenting cells and T cells must respond to breaches in the mucosal barrier by activating TLR-dependent pathways that result in increased epithelial proliferation, wound healing and recruitment of acute inflammatory cells. In the setting of chronic inflammation such as Helicobacter pylori (H. pylori) infection in the stomach or idiopathic inflammatory bowel disease, the process of repair may eventually result in carcinogenesis. The following review highlights human and animal data that support a role for innate immune responses and TLRs specifically in promoting gastrointestinal malignancies. Candidate pathways linking TLRs to gastrointestinal malignancies include activation of nuclear factor-kappa B and cyclooxygenase-2. Studying the link between innate immune signaling and gastrointestinal malignancies offers the possibility to identify novel ways to both prevent and treat gastrointestinal cancer.	[Fukata, M.; Abreu, M. T.] Mt Sinai Sch Med, Dept Med, Div Gastroenterol, Ctr Inflammatory Bowel Dis, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Abreu, MT (corresponding author), Mt Sinai Sch Med, Dept Med, Div Gastroenterol, Ctr Inflammatory Bowel Dis, New York, NY 10029 USA.	Maria.Abreu@mssm.edu		Abreu, Maria T./0000-0002-7294-0574	NATIONAL CANCER INSTITUTE [R01CA137869] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Abreu MT, 2005, J IMMUNOL, V174, P4453, DOI 10.4049/jimmunol.174.8.4453; Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652; Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522; Atherfold PA, 2006, BEST PRACT RES CL GA, V20, P813, DOI 10.1016/j.bpg.2006.04.003; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Baoprasertkul P, 2007, FISH SHELLFISH IMMUN, V22, P418, DOI 10.1016/j.fsi.2006.04.005; Bernstein CN, 2002, INFLAMM BOWEL DIS, V8, P356, DOI 10.1097/00054725-200209000-00007; Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355; Brand S, 2005, INFLAMM BOWEL DIS, V11, P645, DOI 10.1097/01.MIB.0000168372.94907.d2; Brittan M, 2002, J PATHOL, V197, P492, DOI 10.1002/path.1155; Brown SL, 2007, J CLIN INVEST, V117, P258, DOI 10.1172/JCI29159; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; Chang YJ, 2004, MOL PHARMACOL, V66, P1465, DOI 10.1124/mol.104.005199; CHOI PM, 1994, GUT, V35, P950, DOI 10.1136/gut.35.7.950; Chun KG, 2003, PHOTONIC NETW COMMUN, V6, P83, DOI 10.1023/A:1023642926131; Contasta I, 2006, CANCER BIOTHER RADIO, V21, P488, DOI 10.1089/cbr.2006.21.488; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Visser KE, 2005, CANCER IMMUNOL IMMUN, V54, P1143, DOI 10.1007/s00262-005-0702-5; De Vita F, 2001, J INTERF CYTOK RES, V21, P45, DOI 10.1089/107999001459150; Derdak Z, 2006, CARCINOGENESIS, V27, P956, DOI 10.1093/carcin/bgi335; Dove WF, 1997, CANCER RES, V57, P812; Drewitz DJ, 1997, AM J GASTROENTEROL, V92, P212; Du X, 2000, EUR CYTOKINE NETW, V11, P362; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I; Engle SJ, 2002, CANCER RES, V62, P6362; Erdman SE, 2003, AM J PATHOL, V162, P691, DOI 10.1016/S0002-9440(10)63863-1; Farinha P, 2005, J CLIN ONCOL, V23, P6370, DOI 10.1200/JCO.2005.05.011; Fass R, 2001, GUT, V48, P310, DOI 10.1136/gut.48.3.310; Fischer W, 2001, MOL MICROBIOL, V42, P1337, DOI 10.1046/j.1365-2958.2001.02714.x; Franchimont D, 2004, GUT, V53, P987, DOI 10.1136/gut.2003.030205; Frattini M, 2004, CLIN CANCER RES, V10, P4015, DOI 10.1158/1078-0432.CCR-04-0031; FUKATA M, 2005, AM J PHYSIOL-GASTR L, V288, pG105, DOI DOI 10.1152/AJPGI.00328.2004; FUKATA M, 2007, IN PRESS GASTROENTER; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Fukumoto S, 2003, WORLD J SURG, V27, P145, DOI 10.1007/s00268-002-6460-z; Furrie E, 2005, IMMUNOLOGY, V115, P565, DOI 10.1111/j.1365-2567.2005.02200.x; Gammon MD, 1997, J NATL CANCER I, V89, P1277, DOI 10.1093/jnci/89.17.1277; Garlanda C, 2007, CANCER RES, V67, P6017, DOI 10.1158/0008-5472.CAN-07-0560; Gazouli M, 2005, WORLD J GASTROENTERO, V11, P681, DOI 10.3748/wjg.v11.i5.681; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gunter MJ, 2006, CANCER EPIDEM BIOMAR, V15, P1126, DOI 10.1158/1055-9965.EPI-06-0042; Gupta RB, 2007, GASTROENTEROLOGY, V133, P1099, DOI 10.1053/j.gastro.2007.08.001; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; Haselkorn T, 2005, CANCER CAUSE CONTROL, V16, P781, DOI 10.1007/s10552-005-3635-6; Hausmann M, 2002, GASTROENTEROLOGY, V122, P1987, DOI 10.1053/gast.2002.33662; Helzlsouer KJ, 2006, EUR J CANCER, V42, P704, DOI 10.1016/j.ejca.2006.01.008; HILL MJ, 1971, LANCET, V1, P95; Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026; Hope ME, 2005, FEMS MICROBIOL LETT, V244, P1, DOI 10.1016/j.femsle.2005.01.029; Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Ishida I, 2002, J IMMUNOL, V169, P2069, DOI 10.4049/jimmunol.169.4.2069; Ishihara S, 2004, J IMMUNOL, V173, P1406, DOI 10.4049/jimmunol.173.2.1406; Itzkowitz SH, 2004, GASTROENTEROLOGY, V126, P1634, DOI 10.1053/j.gastro.2004.03.025; Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Jelavic TB, 2006, CLIN GENET, V70, P156, DOI 10.1111/j.1399-0004.2006.00651.x; Kado S, 2001, CANCER RES, V61, P2395; Kawahara T, 2001, INFECT IMMUN, V69, P4382, DOI 10.1128/IAI.69.7.4382-4389.2001; Kawahara Tsukasa, 2001, Journal of Medical Investigation, V48, P190; KELLY IMG, 1993, ABDOM IMAGING, V18, P366, DOI 10.1007/BF00201784; Kinoshita T, 1999, CANCER, V85, P2526, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LANGHOLZ E, 1992, GASTROENTEROLOGY, V103, P1444, DOI 10.1016/0016-5085(92)91163-X; LAQUEUR GL, 1981, J NATL CANCER I, V67, P1053; LEBLOND C. P., 1964, NAT CANCER INST MONOGR, V14, P119; Maggio-Price L, 2005, AM J PATHOL, V166, P1793, DOI 10.1016/S0002-9440(10)62489-3; Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI 10.1128/IAI.72.11.6446-6454.2004; Manju V, 2006, EUR J CANCER PREV, V15, P377, DOI 10.1097/00008469-200610000-00001; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Melmed G, 2003, J IMMUNOL, V170, P1406, DOI 10.4049/jimmunol.170.3.1406; Naik S, 2001, J PEDIATR GASTR NUTR, V32, P449, DOI 10.1097/00005176-200104000-00011; NOWACKI MR, 1993, FOLIA HISTOCHEM CYTO, V31, P77; Ohara T, 2006, INT J MOL MED, V18, P59; Oostenbrug LE, 2005, INFLAMM BOWEL DIS, V11, P567, DOI 10.1097/01.MIB.0000161305.81198.0f; Otte JM, 2004, GASTROENTEROLOGY, V126, P1054, DOI 10.1053/j.gastro.2004.01.007; Ouburg S, 2005, GUT, V54, P439; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Paulsen JE, 2006, INT J CANCER, V118, P540, DOI 10.1002/ijc.21416; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peter S, 2007, DIGESTION, V75, P25, DOI 10.1159/000101564; Pierik M, 2006, INFLAMM BOWEL DIS, V12, P1, DOI 10.1097/01.MIB.0000195389.11645.ab; Pomorski T, 2001, J BIOL CHEM, V276, P804, DOI 10.1074/jbc.M003819200; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rad R, 2007, GASTROENTEROLOGY, V133, P150, DOI 10.1053/j.gastro.2007.04.071; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Rao CV, 2002, CANCER RES, V62, P165; REDDY BS, 1975, CANCER RES, V35, P287; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Romano M, 1998, J BIOL CHEM, V273, P28560, DOI 10.1074/jbc.273.44.28560; Rumio C, 2004, AM J PATHOL, V165, P373, DOI 10.1016/S0002-9440(10)63304-4; Rumio C, 2006, J CELL PHYSIOL, V208, P47, DOI 10.1002/jcp.20632; Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010; Sawaoka H, 1998, PROSTAG LEUKOTR ESS, V59, P313, DOI 10.1016/S0952-3278(98)90079-5; Schmausser B, 2005, INT J MED MICROBIOL, V295, P179, DOI 10.1016/j.ijmm.2005.02.009; Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x; Schultz M, 1999, AM J PHYSIOL-GASTR L, V276, pG1461, DOI 10.1152/ajpgi.1999.276.6.G1461; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Sigel JE, 1999, AM J SURG PATHOL, V23, P651, DOI 10.1097/00000478-199906000-00003; Spechler SJ, 1999, GASTROENTEROLOGY, V117, P218, DOI 10.1016/S0016-5085(99)70571-8; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Suzuki M, 2003, INFECT IMMUN, V71, P3503, DOI 10.1128/IAI.71.6.3503-3511.2003; Suzuki R, 2006, CARCINOGENESIS, V27, P162, DOI 10.1093/carcin/bgi205; Suzuki R, 2005, HISTOL HISTOPATHOL, V20, P483, DOI 10.14670/HH-20.483; Swidsinski A, 1998, GASTROENTEROLOGY, V115, P281, DOI 10.1016/S0016-5085(98)70194-5; Tlaskalova-Hogenova H, 2004, IMMUNOL LETT, V93, P97, DOI 10.1016/j.imlet.2004.02.005; Torok HP, 2004, CLIN IMMUNOL, V112, P85, DOI 10.1016/j.clim.2004.03.002; Torok HP, 2004, GASTROENTEROLOGY, V127, P365, DOI 10.1053/j.gastro.2004.05.051; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wang XM, 2007, GASTROENTEROLOGY, V132, P551, DOI 10.1053/j.gastro.2006.11.040; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712; Xiao H, 2007, IMMUNITY, V26, P461, DOI 10.1016/j.immuni.2007.02.012	123	142	151	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					234	243		10.1038/sj.onc.1210908	http://dx.doi.org/10.1038/sj.onc.1210908			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176605	Green Accepted			2022-12-28	WOS:000252163600010
J	Budhram-Mahadeo, V; Irshad, S; Bowen, S; Lee, S; Samady, L; Tonini, G; Latchman, D				Budhram-Mahadeo, Vs; Irshad, S.; Bowen, S.; Lee, Sa; Samady, L.; Tonini, Gp; Latchman, Ds			Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells	ONCOGENE			English	Article						breast cancer; neuroblastoma; cyclin D1; Brn-3b; gene expression	RETINAL GANGLION-CELLS; NEURONAL CELLS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; GROWTH; DIFFERENTIATION; PROMOTER; SERUM; MICE	Brn-3b transcription factor enhances proliferation of neuroblastoma (NB) and breast cancer cell lines in vitro and increases the rate and size of in vivo tumour growth, whereas reducing Brn-3b slows growth, both in vitro and in vivo. Brn-3b is elevated in > 65% of breast cancer biopsies, and here we demonstrate that Brn-3b is also elevated in NB tumours. We show a significant correlation between Brn-3b and cyclin D1 (CD1) in breast cancers and NB tumours and cell lines. Brn-3b directly transactivates the CD1 promoter in co-transfection experiments, whereas electrophoretic mobility shift assay and chromatin immunoprecipitation assays demonstrate that Brn-3b protein binds to an octamer sequence located in the proximal CD1 promoter. Site-directed mutagenesis of this sequence resulted in loss of transactivation of the CD1 promoter by Brn-3b. Thus, Brn-3b may act to alter growth properties of breast cancer and NB cells by enhancing CD1 expression in these cells.	[Budhram-Mahadeo, Vs; Irshad, S.; Bowen, S.; Lee, Sa; Samady, L.; Latchman, Ds] UCL, Med Mol Biol Unit, Inst Child Hlth, London WC1N 1EH, England; [Tonini, Gp] Natl Inst Canc Res IST, Genoa, Italy	University of London; University College London; University of Genoa; IRCCS AOU San Martino IST	Budhram-Mahadeo, V (corresponding author), UCL, Med Mol Biol Unit, Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.	v.mahadeo@ich.ucl.ac.uk						ARNOLD A, 1991, COLD SPRING HARB SYM, V56, P93; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Budhram-Mahadeo V, 2001, INT J BIOCHEM CELL B, V33, P1027, DOI 10.1016/S1357-2725(01)00069-3; Budhram-Mahadeo VS, 2006, EXPERT OPIN THER TAR, V10, P15, DOI 10.1517/14728222.10.1.15; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; BUDHRAMMAHADEO V, 1995, NEUROSCI LETT, V185, P48, DOI 10.1016/0304-3940(94)11222-5; Dennis JH, 2001, ONCOGENE, V20, P4961, DOI 10.1038/sj.onc.1204491; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; Guo Y, 2005, ONCOGENE, V24, P2599, DOI 10.1038/sj.onc.1208326; Irshad S, 2004, J BIOL CHEM, V279, P21617, DOI 10.1074/jbc.M312506200; Israels E D, 2000, Oncologist, V5, P510, DOI 10.1634/theoncologist.5-6-510; Knudsen KE, 1999, CANCER RES, V59, P2297; Latchman DS, 1998, INT J BIOCHEM CELL B, V30, P1153, DOI 10.1016/S1357-2725(98)00090-9; LATCHMAN DS, 1998, GENE THER MOL BIOL, V2, P95; Lee SA, 2005, CANCER RES, V65, P3072, DOI 10.1158/0008-5472.CAN-04-2865; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Mu XQ, 2001, NUCLEIC ACIDS RES, V29, P4983, DOI 10.1093/nar/29.24.4983; Redeuilh G, 2002, ONCOGENE, V21, P5773, DOI 10.1038/sj.onc.1205753; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Samady L, 2004, CANCER BIOL THER, V3, P317, DOI 10.4161/cbt.3.3.698; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Smith MD, 1996, INT J CANCER, V67, P653; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiang MQ, 1998, DEV BIOL, V197, P155, DOI 10.1006/dbio.1998.8868; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; Xiang MQ, 1996, VISUAL NEUROSCI, V13, P955, DOI 10.1017/S0952523800009184; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	38	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					145	154		10.1038/sj.onc.1210621	http://dx.doi.org/10.1038/sj.onc.1210621			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17637757				2022-12-28	WOS:000252118700015
J	Cai, Z; Zhang, G; Zhou, Z; Bembas, K; Drebin, JA; Greene, MI; Zhang, H				Cai, Z.; Zhang, G.; Zhou, Z.; Bembas, K.; Drebin, J. A.; Greene, M. I.; Zhang, H.			Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185(her2/neu) and the EGFR-p185(her2/neu) complexes	ONCOGENE			English	Article						her2; Pertuzumab; heterodimer; 4D5	EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR; EXTRACELLULAR REGION; C-ERBB-2 ONCOGENE; BREAST; EXPRESSION; CANCER; P185NEU; PROTEIN; HER2	2C4 ( Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185(her2/neu), which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185(her2/neu) and ErbB3. In our studies of epidermal growth factor receptor ( EGFR)-p185(her2/neu) heterodimerization, we noted that 2C4 formed associations with the EGFR-p185(her2/neu) receptor complex. Our data argue against 2C4 as a universal heterodimerization blocker for p185(her2/neu), but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185(her2/neu) will emerge as the most potent targeted therapy.	[Cai, Z.; Zhang, G.; Zhou, Z.; Bembas, K.; Greene, M. I.; Zhang, H.] Univ Penn, Sch Med, Dept Pathol Lab Med, Philadelphia, PA 19104 USA; [Drebin, J. A.] Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Zhang, H (corresponding author), Univ Penn, Sch Med, Dept Pathol Lab Med, 3620 Hamilton Walk,252 John Morgan Bldg, Philadelphia, PA 19104 USA.	zhanghon@mail.med.upenn.edu		Zhang, Hongtao/0000-0001-9173-0049	NATIONAL CANCER INSTITUTE [P01CA089480] Funding Source: NIH RePORTER; NCI NIH HHS [5P01 CA89480, P01 CA089480-04, P01 CA089480] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; COHEN JA, 1989, ONCOGENE, V4, P81; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; KERN JA, 1990, CANCER RES, V50, P5184; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; LODATO RF, 1990, MODERN PATHOL, V3, P449; Mendoza N, 2002, CANCER RES, V62, P5485; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WADA T, 1990, ONCOGENE, V5, P489; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614	30	30	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3870	3874		10.1038/onc.2008.13	http://dx.doi.org/10.1038/onc.2008.13			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264138	Green Accepted			2022-12-28	WOS:000256904700011
J	Johnsen, JI; Segerstrom, L; Orrego, A; Elfman, L; Henriksson, M; Kagedal, B; Eksborg, S; Sveinbjornsson, B; Kogner, P				Johnsen, J. I.; Segerstrom, L.; Orrego, A.; Elfman, L.; Henriksson, M.; Kagedal, B.; Eksborg, S.; Sveinbjornsson, B.; Kogner, P.			Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo	ONCOGENE			English	Article						neuroblastoma; mTOR; rapamycin; CCI-779; MYCN; preclinical	C-KIT; CELL-PROLIFERATION; METASTATIC DISEASE; MTOR INHIBITORS; CYCLIN D1; N-MYC; ACTIVATION; RECEPTOR; PATHWAY; CANCER	Mammalian target of rapamycin (mTOR) has been shown to play an important function in cell proliferation, metabolism and tumorigenesis, and proteins that regulate signaling through mTOR are frequently altered in human cancers. In this study we investigated the phosphorylation status of key proteins in the PI3K/AKT/mTOR pathway and the effects of the mTOR inhibitors rapamycin and CCI-779 on neuroblastoma tumorigenesis. Significant expression of activated AKT and mTOR were detected in all primary neuroblastoma tissue samples investigated, but not in non-malignant adrenal medullas. mTOR inhibitors showed antiproliferative effects on neuroblastoma cells in vitro. Neuroblastoma cell lines expressing high levels of MYCN were significantly more sensitive to mTOR inhibitors compared to cell lines expressing low MYCN levels. Established neuroblastoma tumors treated with mTOR inhibitors in vivo showed increased apoptosis, decreased proliferation and inhibition of angiogenesis. Importantly, mTOR inhibitors induced downregulation of vascular endothelial growth factor A (VEGF-A) secretion, cyclin D1 and MYCN protein expression in vitro and in vivo. Our data suggest that mTOR inhibitors have therapeutic efficacy on aggressive MYCN amplified neuroblastomas.	[Johnsen, J. I.; Segerstrom, L.; Elfman, L.; Eksborg, S.; Sveinbjornsson, B.; Kogner, P.] Karolinska Inst, Dept Woman & Child Hlth, Childrens Canc Res Unit, S-17176 Stockholm, Sweden; [Orrego, A.] Karolinska Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden; [Henriksson, M.] Karolinska Inst, Dept Microbiol Tumor & Cellbiol, S-17176 Stockholm, Sweden; [Kagedal, B.] Linkoping Univ, Fac Hlth Sci, Div Clin Chem, S-58183 Linkoping, Sweden; [Sveinbjornsson, B.] Univ Tromso, Dept Cell Biol & Histol, Tromso, Norway	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Linkoping University; UiT The Arctic University of Tromso	Segerstrom, L (corresponding author), Karolinska Inst, Dept Woman & Child Hlth, Childrens Canc Res Unit, S-17176 Stockholm, Sweden.	lova.segerstrom@ki.se	Henriksson, Marie Arsenian/F-5010-2015	Kogner, Per/0000-0002-2202-9694; Johnsen, John Inge/0000-0003-1277-812X; Arsenian Henriksson, Marie/0000-0001-6376-7792; Eksborg, Staffan/0000-0001-7326-9471				Aguirre D, 2004, APOPTOSIS, V9, P797, DOI 10.1023/B:APPT.0000045781.46314.e2; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; COHEN PS, 1994, BLOOD, V84, P3465; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Davidoff AM, 2001, J PEDIATR SURG, V36, P30, DOI 10.1053/Jpsu.2001.19998; Dong JJ, 2005, CANCER RES, V65, P1961, DOI 10.1158/0008-5472.CAN-04-2501; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Eggert A, 2002, CANCER RES, V62, P1802; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Grimmer MR, 2006, CURR OPIN PEDIATR, V18, P634, DOI 10.1097/MOP.0b013e32801080fe; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Ho R, 2002, CANCER RES, V62, P6462; Jaboin J, 2002, CANCER RES, V62, P6756; Kagedal B, 2004, PIGM CELL RES, V17, P346, DOI 10.1111/j.1600-0749.2004.00153.x; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kim B, 2004, ONCOGENE, V23, P130, DOI 10.1038/sj.onc.1206924; Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399; Klos KS, 2006, CANCER RES, V66, P2028, DOI 10.1158/0008-5472.CAN-04-4559; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Lutz W, 1996, ONCOGENE, V13, P803; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Ponthan F, 2003, INT J CANCER, V104, P418, DOI 10.1002/ijc.10954; Ponthan F, 2007, CLIN CANCER RES, V13, P1036, DOI 10.1158/1078-0432.CCR-06-1908; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Segerstrom L, 2006, PEDIATR RES, V60, P576, DOI 10.1203/01.pdr.0000242494.94000.52; Singleton JR, 1996, CANCER RES, V56, P4522; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Uccini S, 2005, CLIN CANCER RES, V11, P380; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vitali R, 2003, INT J CANCER, V106, P147, DOI 10.1002/ijc.11187; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Yaari S, 2005, CLIN CANCER RES, V11, P4321, DOI 10.1158/1078-0432.CCR-04-2071; Yu QY, 2005, ONCOGENE, V24, P7114, DOI 10.1038/sj.onc.1208853	43	128	133	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2910	2922		10.1038/sj.onc.1210938	http://dx.doi.org/10.1038/sj.onc.1210938			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18026138				2022-12-28	WOS:000255502500012
J	Tsantoulis, PK; Kotsinas, A; Sfikakis, PP; Evangelou, K; Sideridou, M; Levy, B; Mo, L; Kittas, C; Wu, XR; Papavassiliou, AG; Gorgoulis, VG				Tsantoulis, P. K.; Kotsinas, A.; Sfikakis, P. P.; Evangelou, K.; Sideridou, M.; Levy, B.; Mo, L.; Kittas, C.; Wu, X-R; Papavassiliou, A. G.; Gorgoulis, V. G.			Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study	ONCOGENE			English	Article						fragile sites; DNA damage; cancer; nucleic acid repetitive sequences; preneoplastic lesions; replication stress	DNA-DAMAGE RESPONSE; INDUCED SENESCENCE; CANCER; TUMORIGENESIS; FLEXIBILITY; BREAKPOINTS; INSTABILITY; ACTIVATION; CHECKPOINT; BREAKAGE	Common fragile sites (CFSs) are regions of the genome prone to breakage by replication inhibitors ( extrinsic replication stress). Recently, we and others observed that oncogene-induced replication stress (RS) induces DNA damage from the earliest stages of cancer. Our aim was to perform a genome-wide analysis in precancerous and cancerous experimental models to examine whether allelic imbalance occurs within CFSs. Subsequently, CFSs sequence characteristics were assessed. We used a growth-factor-induced human skin hyperplasia and a H-ras-induced mouse hyperplastic urothelium as preneoplastic models, along with an inducible U2OS-CDT1(Tet-ON) cancer cell line model, all bearing established oncogene-induced RS stimuli. Human DNA was analysed with Affymetrix SNP microarrays, while mouse DNA was analysed with Nimblegen array CGH. We studied 56 aphidicolin-type CFSs and 1914 regions of control, nonfragile DNA. Our theoretical in silico analysis spanned 2.16 billion nonoverlapping bases on human chromosomes 1-22. Our results provide direct experimental evidence indicating that genomic alterations were more common within CFSs in epidermal and urothelial preneoplastic lesions as well as in cancer. CFSs were on average less flexible than nonfragile regions, contained more guanine-cytosine (GC) and Alu sequences. Importantly, regions with loss-of-heterozygosity were also less flexible and had a higher Alu percentage.	[Tsantoulis, P. K.; Kotsinas, A.; Evangelou, K.; Sideridou, M.; Kittas, C.; Gorgoulis, V. G.] Univ Athens, Sch Med, Dept Histol & Embryol, Mol Carcinogenesis Grp, GR-11527 Athens, Greece; [Sfikakis, P. P.] Univ Athens, Sch Med, Dept Propedeut & Internal Med 1, GR-11527 Athens, Greece; [Levy, B.] Columbia Univ, Coll Phys & Surg, Clin Cytogenet Lab, New York, NY USA; [Mo, L.; Wu, X-R] NYU, Sch Med, Dept Urol, New York, NY 10003 USA; [Papavassiliou, A. G.] Univ Athens, Sch Med, Dept Biochem, GR-11527 Athens, Greece	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; Columbia University; New York University; Athens Medical School; National & Kapodistrian University of Athens	Gorgoulis, VG (corresponding author), Antaiou 53 St, GR-11146 Athens, Greece.	papavas@med.uoa.gr; histoclub@ath.forthnet.gr	Evangelou, Konstantinos/AAG-5092-2020; Sfikakis, Petros/AAD-7289-2019; Gorgoulis, Vassilis/AAD-3630-2019; Tsantoulis, Petros/AAM-1653-2020; Karamouzis, Michalis/AAD-2860-2020; Tsantoulis, Petros/AAO-5211-2021	Evangelou, Konstantinos/0000-0002-2462-5748; Gorgoulis, Vassilis/0000-0001-9001-4112; Tsantoulis, Petros/0000-0003-3613-6682; Wu, Xue-Ru/0000-0001-6058-6291				Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104; Arlt MF, 2006, DNA REPAIR, V5, P1126, DOI 10.1016/j.dnarep.2006.05.010; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Ciullo M, 2002, HUM MOL GENET, V11, P2887, DOI 10.1093/hmg/11.23.2887; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Glover TW, 2006, CANCER LETT, V232, P4, DOI 10.1016/j.canlet.2005.08.032; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helmrich A, 2007, INT J CANCER, V120, P48, DOI 10.1002/ijc.22049; Helmrich A, 2006, GENOME RES, V16, P1222, DOI 10.1101/gr.5335506; HIRSCH B, 1991, HUM GENET, V87, P302; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456; Mishmar D, 1999, AM J HUM GENET, V64, P908, DOI 10.1086/302299; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Mo L, 2007, J CLIN INVEST, V117, P314, DOI 10.1172/JCI30062; Morelli C, 2002, ONCOGENE, V21, P7266, DOI 10.1038/sj.onc.1205573; Murnane JP, 2006, DNA REPAIR, V5, P1082, DOI 10.1016/j.dnarep.2006.05.030; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Olson WK, 1998, P NATL ACAD SCI USA, V95, P11163, DOI 10.1073/pnas.95.19.11163; Packer MJ, 2000, J MOL BIOL, V295, P71, DOI 10.1006/jmbi.1999.3236; SARAI A, 1989, BIOCHEMISTRY-US, V28, P7842, DOI 10.1021/bi00445a046; Smith DI, 2007, SEMIN CANCER BIOL, V17, P31, DOI 10.1016/j.semcancer.2006.10.003; Toledo F, 2000, NUCLEIC ACIDS RES, V28, P4805, DOI 10.1093/nar/28.23.4805; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wistuba II, 2000, CANCER RES, V60, P1949; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; Zlotorynski E, 2003, MOL CELL BIOL, V23, P7143, DOI 10.1128/MCB.23.20.7143-7151.2003	35	127	129	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3256	3264		10.1038/sj.onc.1210989	http://dx.doi.org/10.1038/sj.onc.1210989			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084328				2022-12-28	WOS:000256111400004
J	Ozeri-Galai, E; Schwartz, M; Rahat, A; Kerem, B				Ozeri-Galai, E.; Schwartz, M.; Rahat, A.; Kerem, B.			Interplay between ATM and ATR in the regulation of common fragile site stability	ONCOGENE			English	Article						fragile sites; replication stress; ATM; ATR; double strand breaks; Chk1	DNA-DAMAGE RESPONSE; ONCOGENE-INDUCED SENESCENCE; IONIZING-RADIATION; PREFERENTIAL TARGETS; PHOSPHORYLATION; REPLICATION; ACTIVATION; CHECKPOINT; BREAKS; RECOMBINATION	Common fragile sites are specific genomic loci that form constrictions and gaps on metaphase chromosomes under conditions that slow, but do not arrest, DNA replication. These sites have been shown to have a role in various chromosomal rearrangements in tumors. Different DNA damage response proteins were shown to regulate fragile site stability, including ataxia-telangiectasia and Rad3-related (ATR) and its effector Chk1. Here, we investigated the role of ataxia-telangiectasia mutated (ATM), the main transducer of DNA double-strand break (DSB) signal, in this regulation. We demonstrate that replication stress conditions, which induce fragile site expression, lead to DNA fragmentation and recruitment of phosphorylated ATM to nuclear foci at DSBs. We further show that ATM plays a role in maintaining fragile site stability, which is revealed only in the absence of ATR. However, the activation of ATM under these replication stress conditions is ATR independent. Following conditions that induce fragile site expression both ATR and ATM phosphorylate Chk1, suggesting that both proteins regulate fragile site expression probably via their effect on Chk1 activation. Our findings provide new insights into the interplay between ATR and ATM pathways in response to partial replication inhibition and in the regulation of fragile site stability.	[Ozeri-Galai, E.; Schwartz, M.; Rahat, A.; Kerem, B.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Kerem, B (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel.	kerem@cc.huji.ac.il		Schwartz, Michal/0000-0001-5442-0201				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Arlt MF, 2006, DNA REPAIR, V5, P1126, DOI 10.1016/j.dnarep.2006.05.010; Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bester AC, 2006, GENE THER, V13, P1057, DOI 10.1038/sj.gt.3302752; Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Cuadrado M, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-7; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Durkin SG, 2006, ONCOGENE, V25, P4381, DOI 10.1038/sj.onc.1209466; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; HECHT F, 1984, CLIN GENET, V26, P169; Hellman A, 2000, MOL CELL BIOL, V20, P4420, DOI 10.1128/MCB.20.12.4420-4427.2000; Ho GPH, 2006, MOL CELL BIOL, V26, P7005, DOI 10.1128/MCB.02018-05; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schwartz M, 2006, CANCER LETT, V232, P13, DOI 10.1016/j.canlet.2005.07.039; Schwartz M, 2005, GENE DEV, V19, P2715, DOI 10.1101/gad.340905; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Yoo HY, 2007, J BIOL CHEM, V282, P17501, DOI 10.1074/jbc.M701770200; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	46	47	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2109	2117		10.1038/sj.onc.1210849	http://dx.doi.org/10.1038/sj.onc.1210849			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17934520				2022-12-28	WOS:000254621300001
J	Jung, H; Lee, KP; Park, SJ; Park, JH; Jang, YS; Choi, SY; Jung, JG; Jo, K; Park, DY; Yoon, JH; Park, JH; Lim, DS; Hong, GR; Choi, C; Park, YK; Lee, JW; Hong, HJ; Kim, S; Park, YW				Jung, H.; Lee, K. P.; Park, S. J.; Park, J. H.; Jang, Y-s; Choi, S-Y; Jung, J-G; Jo, K.; Park, D. Y.; Yoon, J. H.; Park, J-H; Lim, D-S; Hong, G-R; Choi, C.; Park, Y-K; Lee, J. W.; Hong, H. J.; Kim, S.; Park, Y. W.			TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition	ONCOGENE			English	Article						TMPRSS4; invasion; metastasis; E-cadherin; EMT; serine protease	TRANSMEMBRANE SERINE PROTEASES; SURFACE PROTEOLYTIC-ENZYMES; BREAST-CANCER CELLS; MATRIX METALLOPROTEINASES; PLASMINOGEN-ACTIVATOR; E-CADHERIN; MATRIPTASE; EXPRESSION; PROSTATE; PROTEIN	TMPRSS4 is a novel type II transmembrane serine protease found at the cell surface that is highly expressed in pancreatic, colon and gastric cancer tissues. However, the biological functions of TMPRSS4 in cancer are unknown. Here we show, using reverse transcription PCR, that TMPRSS4 is highly elevated in lung cancer tissues compared with normal tissues and is also broadly expressed in a variety of human cancer cell lines. Knockdown of TMPRSS4 by small interfering RNA treatment in lung and colon cancer cell lines was associated with reduction of cell invasion and cell-matrix adhesion as well as modulation of cell proliferation. Conversely, the invasiveness, motility and adhesiveness of SW480 colon carcinoma cells were significantly enhanced by TMPRSS4 overexpression. Furthermore, overexpression of TMPRSS4 induced loss of E-cadherin-mediated cell-cell adhesion, concomitant with the induction of SIP1/ZEB2, an E-cadherin transcriptional repressor, and led to epithelial mesenchymal transition events, including morphological changes, actin reorganization and upregulation of mesenchymal markers. TMPRSS4-overexpressing cells also displayed markedly increased metastasis to the liver in nude mice upon intrasplenic injection. Taken together, these studies suggest that TMPRSS4 controls the invasive and metastatic potential of human cancer cells by facilitating an epithelial-mesenchymal transition; TMPRSS4 may be a potential therapeutic target for cancer treatment.	[Jung, H.; Lee, K. P.; Park, S. J.; Park, J. H.; Jang, Y-s; Choi, S-Y; Jung, J-G; Jo, K.; Hong, H. J.; Kim, S.; Park, Y. W.] Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, Taejon 305806, South Korea; [Lee, K. P.; Lim, D-S] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Park, D. Y.; Yoon, J. H.] Digital Genom Inc, Seoul, South Korea; [Park, J-H] Korea Canc Ctr Hosp, Dept Thorac Surg, Seoul, South Korea; [Hong, G-R; Park, Y-K] Chonnam Natl Univ, Sch Med, Dept Surg, Hwasun, South Korea; [Choi, C.] Chonnam Natl Univ, Sch Med, Dept Pathol, Hwasun, South Korea; [Lee, J. W.] Seoul Natl Univ, Coll Med, Inst Canc Res, Seoul, South Korea; [Lee, J. W.] Seoul Natl Univ, Coll Med, Dept Tumor Biol, Seoul, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST); National Cancer Center - Korea (NCC); Chonnam National University; Chonnam National University; Seoul National University (SNU); Seoul National University (SNU)	Kim, S (corresponding author), Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, 52 Eoeun Dong, Taejon 305806, South Korea.	semikim@kribb.re.kr; ywpark@kribb.re.kr	Lim, Dae-Sik/C-1599-2011; Lee, Jung Weon/AAC-1146-2020; Lee, Jung Weon/F-9149-2012	Lim, Dae-Sik/0000-0003-2356-7555; Lee, Jung Weon/0000-0003-2722-8200; Lee, Kwang-Pyo/0000-0003-0067-6898; Kim, Semi/0000-0001-8043-1465				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Aplin AE, 1998, PHARMACOL REV, V50, P197; Benaud CM, 2002, CLIN EXP METASTAS, V19, P639, DOI 10.1023/A:1020985632550; Berntzen G, 2005, J IMMUNOL METHODS, V298, P93, DOI 10.1016/j.jim.2005.01.002; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Del Rosso M, 2002, CLIN EXP METASTAS, V19, P193, DOI 10.1023/A:1015531321445; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Duffy MJ, 2002, BIOCHEM SOC T, V30, P207, DOI 10.1042/BST0300207; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Feltes CM, 2002, CANCER RES, V62, P6688; Forbs D, 2005, INT J ONCOL, V27, P1061; Galkin AV, 2004, PROSTATE, V61, P228, DOI 10.1002/pros.20094; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Kebebew E, 2005, ANN SURG, V242, P353, DOI 10.1097/sla.0000179623.87329.6b; Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268; Laferriere J, 2002, ANN NY ACAD SCI, V973, P562, DOI 10.1111/j.1749-6632.2002.tb04702.x; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Srikantan V, 2002, CANCER RES, V62, P6812; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Suzuki M, 2004, J BIOL CHEM, V279, P14899, DOI 10.1074/jbc.M313130200; Szabo R, 2003, THROMB HAEMOSTASIS, V90, P185, DOI 10.1160/TH03-02-0071; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; van Hengel J, 2007, BBA-MOL CELL RES, V1773, P78, DOI 10.1016/j.bbamcr.2006.08.033; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Wallrapp C, 2000, CANCER RES, V60, P2602; Xuan JA, 2006, CANCER RES, V66, P3611, DOI 10.1158/0008-5472.CAN-05-2983	44	119	132	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2635	2647		10.1038/sj.onc.1210914	http://dx.doi.org/10.1038/sj.onc.1210914			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17968309				2022-12-28	WOS:000255057000013
J	Stocklein, H; Smardova, J; Macak, J; Katzenberger, T; Holler, S; Wessendorf, S; Hutter, G; Dreyling, M; Haralambieva, E; Mader, U; Muller-Hermelink, HK; Rosenwald, A; Ott, G; Kalla, J				Stoecklein, H.; Smardova, J.; Macak, J.; Katzenberger, T.; Hoeller, S.; Wessendorf, S.; Hutter, G.; Dreyling, M.; Haralambieva, E.; Maeder, U.; Mueller-Hermelink, H. K.; Rosenwald, A.; Ott, G.; Kalla, J.			Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma	ONCOGENE			English	Article						diffuse large B-cell lymphoma; del(17p); TP53; HIC1	NON-HODGKINS-LYMPHOMA; COMPARATIVE GENOMIC HYBRIDIZATION; FUNCTIONAL ASSAY; BREAST-CANCER; P53 GENE; DNA HYPERMETHYLATION; DELETED REGION; MULTIPLE GENES; OVARIAN-CANCER; EXPRESSION	Deletions in the short arm of chromosome 17 (17p) involving the tumor suppressor TP53 occur in up to 20% of diffuse large B-cell lymphomas (DLBCLs). Although inactivation of both alleles of a tumor suppressor gene is usually required for tumor development, the overlap between TP53 deletions and mutations is poorly understood in DLBCLs, suggesting the possible existence of additional tumor suppressor genes in 17p. Using a bacterial artificial chromosome (BAC) and Phage 1 artificial chromosome (PAC) contig, we here de. ne a minimally deleted region in DLBCLs encompassing approximately 0.8MB telomeric to the TP53 locus. This genomic region harbors the tumor suppressor Hypermethylated in Cancer 1 (HIC1). Methylation-specific PCR demonstrated hypermethylation of HIC1 exon 1a in a substantial subset of DLBCLs, which is accompanied by simultaneous HIC1 deletion of the second allele in 90% of cases. In contrast, HIC1 inactivation by hypermethylation was rarely encountered in DLBCLs without concomitant loss of the second allele. DLBCL patients with complete inactivation of both HIC1 and TP53 may be characterized by an even inferior clinical course than patients with inactivation of TP53 alone, suggesting a functional cooperation between these two proteins. These findings strongly imply HIC1 as a novel tumor suppressor in a subset of DLBCLs.	[Ott, G.] Robert Bosch Krankenhaus, Dept Clin Pathol, D-70376 Stuttgart, Germany; [Stoecklein, H.; Katzenberger, T.; Hoeller, S.; Haralambieva, E.; Mueller-Hermelink, H. K.; Rosenwald, A.; Ott, G.; Kalla, J.] Univ Wurzburg, Inst Pathol, D-97070 Wurzburg, Germany; [Smardova, J.; Macak, J.] Masaryk Univ, Fac Med, Dept Pathol, Brno, Czech Republic; [Smardova, J.; Macak, J.] Fac Hosp Brno, Brno, Czech Republic; [Wessendorf, S.] Univ Ulm, Innere Med Klin 3, Ulm, Germany; [Hutter, G.; Dreyling, M.] Univ Munchen Grosshadern, Med Klin & Poliklin 2, Munich, Germany; [Maeder, U.] Univ Wurzburg, Interdisciplinary Canc Ctr, Wurzburg, Germany	Bosch; Robert Bosch Krankenhaus; University of Wurzburg; Masaryk University Brno; University Hospital Brno; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Wurzburg	Ott, G (corresponding author), Robert Bosch Krankenhaus, Dept Clin Pathol, Auerbachstr 110, D-70376 Stuttgart, Germany.	german.ott@rbk.de		Holler, Sylvia/0000-0001-9277-7076				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bea S, 2005, BLOOD, V106, P3183, DOI 10.1182/blood-2005-04-1399; Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240; Chen CM, 2004, GENE DEV, V18, P320, DOI 10.1101/gad.1162204; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; Dong SM, 2001, CLIN CANCER RES, V7, P1982; Duddy PM, 2000, J MOL DIAGN, V2, P139, DOI 10.1016/S1525-1578(10)60629-0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Haralambieva E, 2002, J PATHOL, V198, P163, DOI 10.1002/path.1197; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Ichikawa A, 1997, NEW ENGL J MED, V337, P529, DOI 10.1056/NEJM199708213370804; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Issa JPJ, 1997, CANCER RES, V57, P1678; Jaffe ES, 2001, WHO CLASSIFICATION T; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koduru PRK, 1997, BLOOD, V90, P4078, DOI 10.1182/blood.V90.10.4078; Konishi H, 2003, ONCOGENE, V22, P1892, DOI 10.1038/sj.onc.1206304; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; Lossos IS, 2005, J CLIN ONCOL, V23, P6351, DOI 10.1200/JCO.2005.05.012; Meinhold-Heerlein I, 2001, ONCOLOGY-BASEL, V60, P176, DOI 10.1159/000055316; Melki JR, 1999, CANCER RES, V59, P3730; Nenutil R, 2005, J PATHOL, V207, P251, DOI 10.1002/path.1838; Phillips NJ, 1996, CANCER RES, V56, P606; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Prowse AH, 2002, INT J CANCER, V99, P185, DOI 10.1002/ijc.10334; Rathi A, 2003, CLIN CANCER RES, V9, P3674; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Rudiger T, 1998, AM J SURG PATHOL, V22, P1184, DOI 10.1097/00000478-199810000-00003; Sankar M, 1998, LEUKEMIA, V12, P510, DOI 10.1038/sj.leu.2400973; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; SAXENA A, 1992, CANCER RES, V52, P6716; Schlegelberger B, 1999, BLOOD, V94, P3114; Schultz DC, 1996, CANCER RES, V56, P1997; Seitz S, 2001, J PATHOL, V194, P318, DOI 10.1002/1096-9896(200107)194:3<318::AID-PATH881>3.0.CO;2-4; Shaffer LG., 2005, INT SYSTEM HUMAN CYT; Smardova J, 2001, TUMOR BIOL, V22, P59; Stokke T, 2001, BRIT J CANCER, V85, P1900, DOI 10.1054/bjoc.2001.2164; Stokke T, 2000, INT J CANCER, V89, P313, DOI 10.1002/1097-0215(20000720)89:4<313::AID-IJC1>3.0.CO;2-D; von Bergh A, 2000, GENE CHROMOSOME CANC, V28, P14, DOI 10.1002/(SICI)1098-2264(200005)28:1<14::AID-GCC2>3.3.CO;2-O; Waha A, 2004, INT J CANCER, V110, P542, DOI 10.1002/ijc.20165; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Zettl A, 2000, AM J PATHOL, V157, P257, DOI 10.1016/S0002-9440(10)64536-1; Zhang QH, 2007, P NATL ACAD SCI USA, V104, P829, DOI 10.1073/pnas.0610590104	58	20	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2613	2625		10.1038/sj.onc.1210901	http://dx.doi.org/10.1038/sj.onc.1210901			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982487				2022-12-28	WOS:000255057000011
J	Cooper, WN; Dickinson, RE; Dallol, A; Grigorieva, EV; Pavlova, T; Hesson, LB; Bieche, I; Broggini, M; Maher, ER; Zabarovsky, ER; Clark, GJ; Latif, F				Cooper, W. N.; Dickinson, R. E.; Dallol, A.; Grigorieva, E. V.; Pavlova, T. V.; Hesson, L. B.; Bieche, I.; Broggini, M.; Maher, E. R.; Zabarovsky, E. R.; Clark, G. J.; Latif, F.			Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer	ONCOGENE			English	Article						RASSF2; breast cancer; lung cancer; epigenetic inactivation; nuclear localization signal	ISLAND PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR; CPG ISLAND; K-RAS; GENE; INACTIVATION; 3P21.3; REGION; IDENTIFICATION; OVARIAN	RASSF2 is a recently identified member of a class of novel tumour suppressor genes, all containing a ras-association domain. RASSF2 resides at 20p13, a region frequently lost in human cancers. In this report we investigated methylation status of the RASSF2 promoter CpG island in a series of breast, ovarian and non-small cell lung cancers (NSCLC). RASSF2 was frequently methylated in breast tumour cell lines (65%, 13/20) and in primary breast tumours (38%, 15/40). RASSF2 expression could be switched back on in methylated breast tumour cell lines after treatment with 5'-aza-2'deoxycytidine. RASSF2 was also frequently methylated in NSCLC tumours (44%, (22/50). The small number of corresponding normal breast and lung tissue DNA samples analysed were unmethylated. We also did not detect RASSF2 methylation in ovarian tumours (0/17). Furthermore no mutations were found in the coding region of RASSF2 in these ovarian tumours. We identified a highly conserved putative bipartite nuclear localization signal (NLS) and demonstrated that endogenous RASSF2 localized to the nucleus. Mutation of the putative NLS abolished the nuclear localization. RASSF2 suppressed breast tumour cell growth in vitro and in vivo, while the ability of NLS-mutant RASSF2 to suppress growth was much diminished. Hence we demonstrate that RASSF2 has a functional NLS that is important for its tumour suppressor gene function. Our data from this and a previous report indicate that RASSF2 is frequently methylated in colorectal, breast and NSCLC tumours. We have identified RASSF2 as a novel methylation marker for multiple malignancies and it has the potential to be developed into a valuable marker for screening several cancers in parallel using promoter hypermethylation profiles.	[Cooper, W. N.; Dickinson, R. E.; Dallol, A.; Hesson, L. B.; Maher, E. R.; Latif, F.] Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; [Grigorieva, E. V.; Pavlova, T. V.; Zabarovsky, E. R.] Karolinska Inst, MTC, Stockholm, Sweden; [Grigorieva, E. V.] Inst Mol Biol & Biophys SD RAMS, Novosibirsk, Russia; [Pavlova, T. V.] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow, Russia; [Bieche, I.] Ctr Rene Huguenin, INSERM, Lab Oncogenet E0017, St Cloud, France; [Broggini, M.] Ist Ric Farmacol Mario Negri, Mol Pharmacol Lab, Milan, Italy; [Clark, G. J.] Univ Louisville, Dept Med, JG Brown Canc Ctr, Mol Targets Grp, Louisville, KY 40292 USA	University of Birmingham; Karolinska Institutet; Russian Academy of Medical Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Louisville	Latif, F (corresponding author), Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	f.latif@bham.ac.uk	Dallol, Ashraf/H-8661-2012; Zabarovsky, Eugene R/A-6645-2010; broggini, massimo/AAA-6460-2020; Hesson, Luke/HDM-0311-2022; Bièche, Ivan/O-7399-2017; Grigorieva, Elvira/A-4937-2010; MAHER, EAMONN R/A-9507-2008	Dallol, Ashraf/0000-0002-8803-228X; Bièche, Ivan/0000-0002-2430-5429; Grigorieva, Elvira/0000-0003-2457-9179; MAHER, EAMONN R/0000-0002-6226-6918; BROGGINI, MASSIMO/0000-0002-8138-9358; Pavlova, Tatiana/0000-0002-2857-5696	Cancer Research UK [A7205] Funding Source: Medline; Breast Cancer Now [2005NOV13] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Breast Cancer Now		Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051; ALLEN NP, 2007, ONCOGENE; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Dallol A, 2005, CANCER RES, V65, P7653, DOI 10.1158/0008-5472.CAN-05-0247; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566; HESSON LB, 2007, ONCOGENE; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Lambros MBK, 2005, J PATHOL, V205, P29, DOI 10.1002/path.1681; Lerman MI, 2000, CANCER RES, V60, P6116; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Park HW, 2007, INT J CANCER, V120, P7, DOI 10.1002/ijc.22276; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; Schubbert S, 2007, CURR OPIN GENET DEV, V17, P15, DOI 10.1016/j.gde.2006.12.004; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Tommasi S, 2005, CANCER RES, V65, P92; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zhang Z, 2007, INT J CANCER, V120, P32, DOI 10.1002/ijc.22185	31	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1805	1811		10.1038/sj.onc.1210805	http://dx.doi.org/10.1038/sj.onc.1210805			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891178	Green Accepted			2022-12-28	WOS:000253962100017
J	Roelle, S; Grosse, R; Buech, T; Chubanov, V; Gudermann, T				Roelle, S.; Grosse, R.; Buech, T.; Chubanov, V.; Gudermann, T.			Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells	ONCOGENE			English	Article						Pyk2; Src; Ca2+; small cell lung cancer cells; neuropeptides	FOCAL ADHESION KINASE; RAS-BINDING DOMAIN; PROTEIN-KINASE; CA2+ MOBILIZATION; CLONAL GROWTH; RECEPTORS; GALANIN; PHOSPHORYLATION; RAFTK/PYK2; INVASION	Neuropeptide hormones like bombesin/gastrin-releasing peptide, galanin or bradykinin, acting via auto and paracrine growth loops, represent the principal mitogens of small cell lung cancer (SCLC). These mitogenic neuropeptides activate G(q/11)-coupled receptors which stimulate phospholipase C beta activity, followed by rises of the intracellular calcium concent ration ([Ca2+](i)) and activation of protein kinase C (PKC). We report here that proline-rich tyrosine kinase Pyk2 is highly expressed in SCLC cells and provides a functional link between neuropeptide-induced increases in [Ca2+](i) and tumor cell proliferation. Activation of Pyk2 and its association with Src kinases critically depends on the elevation of [Ca2+](i), but is independent of PKC. Src kinase activities are crucial for neuropeptide-mediated GTP-loading of Ras and activation of extracellular signal-regulated kinases in SCLC cells. Pyk2 and Src kinases essentially contribute to anchorage-independent proliferation of SCLC cells. Inhibition of either Pyk2 or Src kinases by lentiviral RNAi or pharmacological inhibition with PP2, respectively, attenuated basal and neuropeptide-elicited survival and proliferation of SCLC cells in liquid culture and in soft agar. Thus, neuropeptides stimulate anchorage-independent survival and proliferation of SCLC cells via pathways involving Pyk2 and Src kinases. Therefore, Ca2+-induced Pyk2/Src complex formation may be a rewarding molecular target for novel therapeutic strategies in SCLC cells.	[Roelle, S.; Buech, T.; Chubanov, V.; Gudermann, T.] Univ Marburg, Inst Pharmakol & Toxikol, D-35043 Marburg, Germany; [Grosse, R.] Univ Heidelberg, Inst Pharmakol, D-6900 Heidelberg, Germany	Philipps University Marburg; Ruprecht Karls University Heidelberg	Gudermann, T (corresponding author), Univ Marburg, Inst Pharmakol & Toxikol, Karl Von Frischstr 1, D-35043 Marburg, Germany.	guderman@staff.uni-marburg.de		Grosse, Robert/0000-0002-3380-5273				Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Beekman A, 1998, CANCER RES, V58, P910; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Cook SJ, 2006, CELL CALCIUM, V39, P101, DOI 10.1016/j.ceca.2005.10.014; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Jones K, 1999, TRENDS BIOTECHNOL, V17, P477, DOI 10.1016/S0167-7799(99)01379-7; Laskin J, 2003, JNCI-J NATL CANCER I, V95, P1099, DOI 10.1093/jnci/djg013; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lipinski CA, 2005, NEOPLASIA, V7, P435, DOI 10.1593/neo.04712; MABRY M, 1989, J CLIN INVEST, V84, P194, DOI 10.1172/JCI114140; MacKinnon AC, 1999, BRIT J CANCER, V80, P1026, DOI 10.1038/sj.bjc.6690458; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; Moore SM, 1998, CANCER RES, V58, P5239; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Rintoul RC, 2001, LANCET ONCOL, V2, P437, DOI 10.1016/S1470-2045(00)00421-6; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; SETHI T, 1991, CANCER RES, V51, P1674; SETHI T, 1992, CANCER RES, V52, pS2737; SETHI T, 1993, CANCER RES, V53, P5208; Seufferlein T, 1996, CANCER RES, V56, P3895; Seufferlein T, 1996, CANCER RES, V56, P5758; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Teti A, 2002, CALCIFIED TISSUE INT, V71, P293, DOI 10.1007/s00223-001-2071-1; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wei L, 2004, ONCOGENE, V23, P9052, DOI 10.1038/sj.onc.1208091; Wittau N, 2000, ONCOGENE, V19, P4199, DOI 10.1038/sj.onc.1203777; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	39	46	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1737	1748		10.1038/sj.onc.1210819	http://dx.doi.org/10.1038/sj.onc.1210819			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17906699				2022-12-28	WOS:000253962100009
J	Wang, P; Lushnikova, T; Odvody, J; Greiner, TC; Jones, SN; Eischen, CM				Wang, P.; Lushnikova, T.; Odvody, J.; Greiner, T. C.; Jones, S. N.; Eischen, C. M.			Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells	ONCOGENE			English	Article						Mdm2; Myc; p53; ARF; lymphoma chromosome	MYC-INDUCED LYMPHOMAGENESIS; BURKITTS-LYMPHOMA; DNA-DAMAGE; C-MYC; P53; ONCOGENE; OVEREXPRESSION; APOPTOSIS; PATHWAY; ARF	Mdm2, a regulator of the p53 tumor suppressor, is frequently overexpressed in lymphomas, including lymphomas that have inactivated p53. However, the biological consequences of Mdm2 overexpression in lymphocytes are not fully resolved. Here, we report that increased expression of Mdm2 in B cells augmented proliferation and reduced susceptibility to p53-dependent apoptosis, which was due to inhibition of p53 and suppression of p21 expression. Notably, developing and mature B cells from Mdm2 transgenic mice had an increased frequency of chromosomal/chromatid breaks and/or aneuploidy. This Mdm2-mediated genome instability occurred at a similar frequency as that in B cells overexpressing the oncogene c-Myc, but the chromosomal instability was not further enhanced when Mdm2 and c-Myc were overexpressed together. Elevated Mdm2 expression alone increased the occurrence of B-cell transformation in vivo and cooperated with c-Myc overexpression, resulting in an acceleration of B-cell lymphomagenesis. In addition, the frequency of p53 mutations was reduced, but not eliminated, in lymphomas arising in Mdm2/E mu-myc double transgenic mice. Therefore, increased Mdm2 expression facilitated B-cell lymphomagenesis, in part, through regulation of p53 by altering B-cell proliferation and susceptibility to apoptosis, and by inducing chromosomal instability.	[Wang, P.; Lushnikova, T.; Odvody, J.; Eischen, C. M.] Vanderbilt Univ, Ctr Med, Dept Pathol, Sch Med, Nashville, TN 37232 USA; [Greiner, T. C.] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68182 USA; [Jones, S. N.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA	Vanderbilt University; University of Nebraska System; University of Nebraska Medical Center; University of Massachusetts System; University of Massachusetts Worcester	Eischen, CM (corresponding author), Vanderbilt Univ, Ctr Med, Dept Pathol, Sch Med, MCN C3321,1161 21st Ave S, Nashville, TN 37232 USA.	eischen@vanderbilt.edu			NCI NIH HHS [CA098139, CA117935] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098139, R01CA117935] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Digweed M, 2004, DNA REPAIR, V3, P1207, DOI 10.1016/j.dnarep.2004.03.004; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; Ghobrial IM, 2005, BLOOD, V105, P3722, DOI 10.1182/blood-2004-10-3999; Gumy-Pause F, 2004, LEUKEMIA, V18, P238, DOI 10.1038/sj.leu.2403221; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; STRASSER A, 1993, ONCOGENE, V8, P1; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wang P, 2006, ONCOGENE, V25, P3708, DOI 10.1038/sj.onc.1209411; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wilda M, 2004, LEUKEMIA, V18, P584, DOI 10.1038/sj.leu.2403254; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	29	59	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1590	1598		10.1038/sj.onc.1210788	http://dx.doi.org/10.1038/sj.onc.1210788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828300				2022-12-28	WOS:000253815800011
J	Maekawa, T; Sano, Y; Shinagawa, T; Rahman, Z; Sakuma, T; Nomura, S; Licht, JD; Ishii, S				Maekawa, T.; Sano, Y.; Shinagawa, T.; Rahman, Z.; Sakuma, T.; Nomura, S.; Licht, J. D.; Ishii, S.			ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors	ONCOGENE			English	Article						ATF-2; GADD45 alpha; Maspin; p53; BRCA1; tumor suppressors	BRCA1; EXPRESSION; ELEMENT; BINDING; OCT-1; MICE	The activating transcription factor, ATF-2, is a target of p38 and JNK that are involved in stress-induced apoptosis. Heterozygous Atf-2 mutant ( Atf-2(+/-)) mice are highly prone to mammary tumors. The apoptosis-regulated gene GADD45 alpha and the breast cancer suppressor gene Maspin, both of which are known to be p53 target genes, are downregulated in the mammary tumors arisen in Atf-2(+/-) mice. Here, we have analysed how ATF-2 controls the transcription of GADD45a and Maspin. ATF-2 and p53 independently activate the GADD45a transcription. ATF-2 does not directly bind to the GADD45a promoter; instead, it is recruited via Oct-1 and NF-I. ATF-2 simultaneously binds to Oct-1, NF-I and breast cancer suppressor BRCA1 to activate transcription. With regard to Maspin, ATF-2 and p53 directly bind to different sites in the Maspin promoter to independently activate its transcription. Consistent with the observation that ATF-2 and p53 independently activate the transcription of Maspin and GADD45a is that the loss of one copy of p53 shortened the period required for mammary tumor development in Atf-2(+/-) mice. These studies suggest the functional link between the ATF-2 and the two tumor suppressors BRCA1 and p53.	[Maekawa, T.; Sano, Y.; Shinagawa, T.; Rahman, Z.; Ishii, S.] RIKEN, Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; [Sakuma, T.; Nomura, S.] Osaka Univ, Dept Pathol, Grad Sch Med, Suita, Osaka, Japan; [Licht, J. D.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	RIKEN; Osaka University; Northwestern University; Feinberg School of Medicine	Maekawa, T (corresponding author), RIKEN, Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	maekawa@rtc.riken.jp; sishii@rtc.riken.jp	Licht, Jonathan/AAL-9184-2020; Ishii, Shunsuke/A-5271-2016; Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369; Ishii, Shunsuke/0000-0002-6530-2478; Sakuma, Takahiko/0000-0002-9477-2196				Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Maekawa T, 1999, J BIOL CHEM, V274, P17813, DOI 10.1074/jbc.274.25.17813; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Osada S, 1996, J BIOL CHEM, V271, P3891; Takahashi S, 2001, CANCER RES, V61, P1187; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	23	58	60	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1045	1054		10.1038/sj.onc.1210727	http://dx.doi.org/10.1038/sj.onc.1210727			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700520				2022-12-28	WOS:000253136700003
J	Davis, E; Teng, H; Bilican, B; Parker, MI; Liu, B; Carriera, S; Goding, CR; Prince, S				Davis, E.; Teng, H.; Bilican, B.; Parker, M. I.; Liu, B.; Carriera, S.; Goding, C. R.; Prince, S.			Ectopic Tbx2 expression results in polyploidy and cisplatin resistance	ONCOGENE			English	Article						Tbx2; T-box factor; polyploidy; chromosomal instability	CELL-CYCLE; MITOTIC CATASTROPHE; DNA-DAMAGE; SENESCENCE; GENE; P53; REPRESSES; SUBSET; ARREST; DOMAIN	T-box factors play critical roles in embryonic development and have been implicated in cell cycle regulation and cancer. For example, Tbx2 can suppress senescence through a mechanism involving the repression of the cyclin-dependent kinase inhibitors, p19ARF and p21(WAF1/CIP1/SDII), and the Tbx2 gene is deregulated in melanoma, breast and pancreatic cancers. In this study, several transformed human lung. broblast cell lines were shown to downregulate Tbx2. To further investigate the role of Tbx2 in oncogenesis we therefore stably reexpressed Tbx2 in one such cell line. Compared to their parental cells, the resulting Tbx2-expressing cells are larger, with binucleate and lobular nuclei containing double the number of chromosomes. Moreover, these cells had an increase in frequency of several features of genomic instability such as chromosome missegregation, chromosomal rearrangements and polyploidy. While grossly abnormal, these cells still divide and give rise to cells that are resistant to the chemotherapeutic drug cisplatin. Furthermore, this is shown to be neither species nor cell type dependent, as ectopically expressing Tbx2 in a murine melanoma cell line also induce mitotic defects and polyploidy. These results have important implications for our understanding of the role of Tbx2 in tumorigenesis because polyploidy frequently precedes aneuploidy, which is associated with high malignancy and poor prognosis.	[Davis, E.; Prince, S.] Univ Cape Town, Dept Human Biol, Fac Hlth Sci,Div Cell Biol, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, Western Prov, South Africa; [Teng, H.; Parker, M. I.] Univ Cape Town, Fac Hlth Sci, Div Med Biochem, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, Western Prov, South Africa; [Bilican, B.; Liu, B.; Carriera, S.; Goding, C. R.] Marie Curie Res Inst, Signalling & Dev Lab, Surrey, England	University of Cape Town; University of Cape Town	Prince, S (corresponding author), Univ Cape Town, Dept Human Biol, Fac Hlth Sci,Div Cell Biol, Inst Infect Dis & Mol Med, Anzio Rd, ZA-7925 Cape Town, Western Prov, South Africa.	sharon.prince@uct.ac.za	Prince, Sharon/AFU-4911-2022	Prince, Sharon/0000-0002-6975-5255; Goding, Colin/0000-0002-1614-3909; Carreira, Suzanne/0000-0002-5077-5379				Andreassen PR, 2001, CANCER RES, V61, P7660; Baroja A, 1998, LIFE SCI, V62, P2275, DOI 10.1016/S0024-3205(98)00208-2; Bilican B, 2006, EXP CELL RES, V312, P2358, DOI 10.1016/j.yexcr.2006.03.033; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butz NV, 2004, GENE, V342, P67, DOI 10.1016/j.gene.2004.07.024; Carlson H, 2002, ONCOGENE, V21, P3827, DOI 10.1038/sj.onc.1205476; Carlson H, 2001, HUM MOL GENET, V10, P2403, DOI 10.1093/hmg/10.21.2403; Danesi R, 2003, PHARMACOL REV, V55, P57, DOI 10.1124/pr.55.1.4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fan WW, 2004, CANCER RES, V64, P5132, DOI 10.1158/0008-5472.CAN-04-0615; Huang XX, 2005, P NATL ACAD SCI USA, V102, P1065, DOI 10.1073/pnas.0409130102; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jerome-Majewska LA, 2005, DEV DYNAM, V234, P922, DOI 10.1002/dvdy.20575; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Naiche LA, 2005, ANNU REV GENET, V39, P219, DOI 10.1146/annurev.genet.39.073003.105925; NAMBA M, 1980, GANN, V71, P300; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Packham EA, 2003, HUM MOL GENET, V12, pR37, DOI 10.1093/hmg/ddg077; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PRIEST JH, 1977, MED CYTOGENETICS CEL, P118; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Prince S, 2003, PIGM CELL RES, V16, P26, DOI 10.1034/j.1600-0749.2003.00008.x; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; ROTHENBERG M, 1989, JNCI-J NATL CANCER I, V81, P907, DOI 10.1093/jnci/81.12.907; Sinclair CS, 2002, CANCER RES, V62, P3587; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; TENG H, 2007, J CELL BIOCH; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002	31	38	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					976	984		10.1038/sj.onc.1210701	http://dx.doi.org/10.1038/sj.onc.1210701			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700536				2022-12-28	WOS:000252946300009
J	Kramer, OH; Knauer, SK; Zimmermann, D; Stauber, RH; Heinzel, T				Kraemer, O. H.; Knauer, S. K.; Zimmermann, D.; Stauber, R. H.; Heinzel, T.			Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis	ONCOGENE			English	Article						VPA; HDAC inhibitor; hydroxyurea; caspase-3; CDKI p21/p27; chemotherapy resistance	ACUTE MYELOID-LEUKEMIA; TRANS-RETINOIC ACID; VALPROIC ACID; MEDIATED APOPTOSIS; DRUG-RESISTANCE; RECURRENT MENINGIOMAS; TUMOR-CELLS; P27(KIP1); MELANOMA; EXPRESSION	Therapy resistance represents a major problem for disease management in oncology. Histone deacetylase inhibitors (HDACi) have been shown to modulate the cell cycle, to induce apoptosis and to sensitize cancer cells for other chemotherapeutics. Our study shows that the HDACi valproic acid (VPA) and the ribonucleotide reductase inhibitor hydroxyurea (HU) potentiate the pro-apoptotic effects of each other towards several cancer cell lines. This correlates with the HU-induced degradation of the cyclin-dependent kinase inhibitors (CDKI) p21 and p27, mediated by the proteasome or caspase-3. Moreover, we found that caspase-3 activation is required for VPA induced apoptosis. Remarkably, p21 and p27 can confer resistance against VPA and HU. Both CDKI interact with caspase-3 and compete with other caspase-3 substrates. Hence, p21 and p27 may contribute to chemotherapy resistance as apoptosis inhibitors. Since the biological effects of VPA and HU could be achieved at concentrations used in current treatment protocols, the combined application of these compounds might be considered as a potential strategy for cancer treatment.	[Kraemer, O. H.; Heinzel, T.] Univ Jena, Inst Biochem & Biophys, Jena, Germany; [Knauer, S. K.; Stauber, R. H.] Univ Hosp Mainz, Mainz, Germany; [Zimmermann, D.] Inst Biomed Res, Frankfurt, Germany	Friedrich Schiller University of Jena; University Hospital Mainz	Kramer, OH (corresponding author), Univ Jena, Inst Biochem & Biophys, Jena, Germany.	Oliver.Kraemer@uni-jena.de; t.heinzel@uni-jena.de	Krämer, Oliver H/L-9266-2015; Heinzel, Thorsten/B-1013-2015; Knauer, Shirley K/E-7931-2012	Krämer, Oliver H/0000-0003-3973-045X; Knauer, Shirley K/0000-0003-4321-0924; Stauber, Roland/0000-0002-1341-4523				Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Boyle GM, 2005, PIGM CELL RES, V18, P160, DOI 10.1111/j.1600-0749.2005.00228.x; Bug G, 2005, CANCER, V104, P2717, DOI 10.1002/cncr.21589; Drexler HCA, 2003, CELL DEATH DIFFER, V10, P290, DOI 10.1038/sj.cdd.4401159; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS AL, 1985, INT J RADIAT BIOL, V48, P675, DOI 10.1080/09553008514551781; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Klisovic DD, 2003, INVEST OPHTH VIS SCI, V44, P2390, DOI 10.1167/iovs.02-1052; Knauer SK, 2006, EMBO REP, V7, P1259, DOI 10.1038/sj.embor.7400824; Koon HB, 2007, EXPERT REV ANTICANC, V7, P79, DOI 10.1586/14737140.7.1.79; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Kuendgen A, 2006, CANCER-AM CANCER SOC, V106, P112, DOI 10.1002/cncr.21552; La Porta CAM, 2007, CURR MED CHEM, V14, P387; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Maggio SC, 2004, CANCER RES, V64, P2590, DOI 10.1158/0008-5472.CAN-03-2631; Montefusco E, 2001, LEUKEMIA LYMPHOMA, V40, P671, DOI 10.3109/10428190109097666; Mouriaux F, 2000, INVEST OPHTH VIS SCI, V41, P2837; Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pantazis Panayotis, 1999, Neoplasia (New York), V1, P231, DOI 10.1038/sj.neo.7900025; Rosato RR, 2003, CANCER RES, V63, P3637; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Schrell UMH, 1997, J NEUROSURG, V86, P840, DOI 10.3171/jns.1997.86.5.0840; Schrell UMH, 1997, J NEUROSURG, V86, P845, DOI 10.3171/jns.1997.86.5.0845; Shin HJ, 2003, ONCOGENE, V22, P3853, DOI 10.1038/sj.onc.1206502; StCroix B, 1996, NAT MED, V2, P1204; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Szekeres T, 1997, CRIT REV CL LAB SCI, V34, P503, DOI 10.3109/10408369709006424; Van den Berg C, 1995, Cancer Treat Res, V78, P95; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	37	66	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					732	740		10.1038/sj.onc.1210677	http://dx.doi.org/10.1038/sj.onc.1210677			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653085				2022-12-28	WOS:000252884500002
J	Deniaud, A; el Dein, OS; Maillier, E; Poncet, D; Kroemer, G; Lemaire, C; Brenner, C				Deniaud, A.; el dein, O. Sharaf; Maillier, E.; Poncet, D.; Kroemer, G.; Lemaire, C.; Brenner, C.			Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis	ONCOGENE			English	Article						permeability transition; mitochondrion; cell death	ADENINE-NUCLEOTIDE TRANSLOCATOR; CELL-DEATH; INTRACELLULAR CA2+; RAT-LIVER; PORE; BAX; RECEPTOR; MECHANISM; CHANNEL; DRIVEN	The accumulation of Ca2+ in the mitochondrial matrix can stimulate oxidative phosphorylation, but can also, at high Ca2+ concentrations, transmit and amplify an apoptotic signal. Here, we characterized the capacity of physiological stimuli (for example, histamine and inositol-1,4,5-triphosphate) and inducers of endoplasmic reticulum (ER) stress (for example, A23187, thapsigargin and tunicamycin) to release Ca2+ from ER stores, induce mitochondrial Ca2+ accumulation, and trigger cell death in human cervix and colon carcinoma cell lines. Sustained Ca2+ accumulation in the mitochondrial matrix induced by ER stress triggered signs of proapoptotic mitochondrial alteration, namely permeability transition, dissipation of the electrochemical potential, matrix swelling, relocalization of Bax to mitochondria and the release of cytochrome c and apoptosis-inducing factor from mitochondria. In contrast, rapid and transient accumulation of Ca2+ induced by physiological stimuli failed to promote mitochondrial permeability transition and to affect cell viability. The specificity of this apoptosis pathway was validated in cells using a panel of pharmacological agents that chelate Ca2+ (BAPTA-AM) or inhibit inositol-1,4,5-trisphosphate receptor (IP3R; 2-aminoethoxydiphenyl borate), voltage-dependent anion channel (VDAC) (4,4'-diisothiocyanatostilbene-2,2'-disulfonate, NADH), the permeability transition pore (cyclosporin A and bongk-rekic acid), caspases (z-VAD-fmk) and protein synthesis (cycloheximide). Finally, we designed an original cell-free system in which we confronted purified mitochondria and ER vesicles, and identified IP3R, VDAC and the permeability transition pore as key proteins in the ER-triggered proapoptotic mitochondrial membrane permeabilization process.	[Deniaud, A.; el dein, O. Sharaf; Maillier, E.; Lemaire, C.; Brenner, C.] Univ Versailles, SQY, CNRS, UMR 8159, F-78035 Versailles, France; [Poncet, D.; Kroemer, G.] IGR, CNRS, UMR 8125, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Brenner, C (corresponding author), Univ Versailles, SQY, CNRS, UMR 8159, 45 Ave Etas Unis, F-78035 Versailles, France.	cbrenner@genetique.uvsq.fr	Poncet, Delphine A/A-7190-2016; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Deniaud, Aurelien/L-5093-2019	Poncet, Delphine A/0000-0003-0446-5262; KROEMER, Guido/0000-0002-9334-4405; Lemaire, Christophe/0000-0001-6316-8781				Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bathori G, 2006, J BIOL CHEM, V281, P17347, DOI 10.1074/jbc.M600906200; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bhanumathy CD, 2006, J BIOL CHEM, V281, P3722, DOI 10.1074/jbc.M509966200; BOCHNING D, 2003, NAT CELL BIOL, V5, P1051; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cianchi F, 2005, CLIN CANCER RES, V11, P6807, DOI 10.1158/1078-0432.CCR-05-0675; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Csordas G, 2006, J CELL BIOL, V174, P915, DOI 10.1083/jcb.200604016; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hajnoczky G, 2000, J BIOENERG BIOMEMBR, V32, P15, DOI 10.1023/A:1005504210587; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; Iwasaki H, 2001, RECEPTOR CHANNEL, V7, P429; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Korge P, 1999, EUR J BIOCHEM, V265, P273, DOI 10.1046/j.1432-1327.1999.00724.x; LAUQUIN GJM, 1976, BIOCHEMISTRY-US, V15, P2316, DOI 10.1021/bi00656a011; Le Bras M, 2005, HISTOL HISTOPATHOL, V20, P205, DOI 10.14670/HH-20.205; Le Bras M, 2006, CANCER RES, V66, P9143, DOI 10.1158/0008-5472.CAN-05-4407; LEE AC, 1994, J BIOL CHEM, V269, P30974; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Luo X, 2005, CELL DEATH DIFFER, V12, P1310, DOI 10.1038/sj.cdd.4401659; Madesh M, 2005, J CELL BIOL, V170, P1079, DOI 10.1083/jcb.200505022; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCDOWELL W, 1988, BIOCHIMIE, V70, P1535, DOI 10.1016/0300-9084(88)90290-8; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; PAULIK M, 1988, J BIOL CHEM, V263, P17738; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Petrosillo G, 2004, J BIOL CHEM, V279, P53103, DOI 10.1074/jbc.M407500200; Poncet D, 2003, APOPTOSIS, V8, P521, DOI 10.1023/A:1025546525894; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Risso A, 2002, MOL CELL BIOL, V22, P1926, DOI 10.1128/MCB.22.6.1926-1935.2002; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; THINNES FP, 1994, BIOL CHEM H-S, V375, P315, DOI 10.1515/bchm3.1994.375.5.315; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	59	437	450	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					285	299		10.1038/sj.onc.1210638	http://dx.doi.org/10.1038/sj.onc.1210638			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17700538				2022-12-28	WOS:000252256000004
J	Robb, L				Robb, L.			Cytokine receptors and hematopoietic differentiation	ONCOGENE			English	Review						hematopoietin receptor; hematopoiesis; lineage commitment	COLONY-STIMULATING FACTOR; ERYTHROPOIETIN RECEPTOR; MICE LACKING; DEFICIENT MICE; C-MPL; TARGETED DISRUPTION; GROWTH-FACTORS; G-CSF; SIGNAL-TRANSDUCTION; LINEAGE COMMITMENT	Colony- stimulating factors and other cytokines signal via their cognate receptors to regulate hematopoiesis. In many developmental systems, inductive signalling determines cell fate and, by analogy with this, it has been postulated that cytokines, signalling via their cognate receptors, may play an instructive role in lineage specification in hematopoiesis. An alternative to this instructive hypothesis is the stochastic or permissive hypothesis. The latter proposes that commitment to a particular hematopoietic lineage is an event that occurs independently of extrinsic signals. It predicts that the role of cytokines is to provide nonspecific survival and proliferation signals. In this review, we look at the role of cytokine receptor signalling in hematopoiesis and consider the evidence for both hypotheses. Data from experiments that genetically manipulate receptor gene expression in vitro or in vivo are reviewed. Experiments in which cytokine receptors were installed in multipotential cells showed that, in some cases, stimulation with the cognate ligand could lead to alterations in lineage output. The creation of genetically manipulated mouse strains demonstrated that cytokine receptors are required for expansion and survival of single lineages but did not reveal a role in lineage commitment. We conclude that hematopoietic differentiation involves mainly stochastic events, but that cytokine receptors also have some instructive role.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Robb, L (corresponding author), Walter & Eliza Hall Inst Med Res, IG Royal Parade, Melbourne, Vic 3050, Australia.	robb@wehi.edu.au			NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Barner M, 1998, CURR BIOL, V8, P669, DOI 10.1016/S0960-9822(98)70256-8; Behrmann I, 2004, J BIOL CHEM, V279, P35486, DOI 10.1074/jbc.M404202200; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; CarverMoore K, 1996, BLOOD, V88, P803; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Fox N, 2002, J CLIN INVEST, V110, P389, DOI 10.1172/JCI200215430; Frohlich A, 2007, BLOOD, V109, P2023, DOI 10.1182/blood-2006-05-021600; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Gainsford T, 2000, BLOOD, V95, P528, DOI 10.1182/blood.V95.2.528; Goldsmith MA, 1998, P NATL ACAD SCI USA, V95, P7006, DOI 10.1073/pnas.95.12.7006; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hisakawa H, 2001, BLOOD, V98, P3618, DOI 10.1182/blood.V98.13.3618; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Howard M, 1994, GUIDEBOOK CYTOKINES; ICHIHARA M, 1995, EMBO J, V14, P939, DOI 10.1002/j.1460-2075.1995.tb07075.x; Iwasaki-Arai J, 2003, J EXP MED, V197, P1311, DOI 10.1084/jem.20021843; Jegalian AG, 2002, BLOOD, V99, P2603, DOI 10.1182/blood.V99.7.2603; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; Kaushansky K, 2002, BLOOD, V99, P3573, DOI 10.1182/blood.V99.10.3573; Kaushansky K, 2006, NEW ENGL J MED, V354, P2034, DOI 10.1056/NEJMra052706; Kertesz N, 2004, DEV BIOL, V276, P101, DOI 10.1016/j.ydbio.2004.08.025; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; Kirby SL, 1996, P NATL ACAD SCI USA, V93, P9402, DOI 10.1073/pnas.93.18.9402; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; Liu FL, 1997, BLOOD, V90, P2583, DOI 10.1182/blood.V90.7.2583.2583_2583_2590; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Maki K, 1996, P NATL ACAD SCI USA, V93, P7172, DOI 10.1073/pnas.93.14.7172; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; MCARTHUR GA, 1994, BLOOD, V83, P972; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; METCALF D, 1982, J CELL PHYSIOL, V111, P275, DOI 10.1002/jcp.1041110308; Metcalf D, 1999, STEM CELLS, V17, P1, DOI 10.1002/stem.170001; Metcalf D, 1984, CLONAL CULTURE HEMOP; Nandurkar HH, 1997, BLOOD, V90, P2148; NICOLA M, 1996, SCI TECHNOL ENV PROT, V3, P3; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NISHINAKAMURA R, 1995, IMMUNITY, V2, P211, DOI 10.1016/1074-7613(95)90046-2; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PHARR PN, 1994, P NATL ACAD SCI USA, V91, P7482, DOI 10.1073/pnas.91.16.7482; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Richards MK, 2003, BLOOD, V102, P3562, DOI 10.1182/blood-2003-02-0593; Robb L, 1998, NAT MED, V4, P303, DOI 10.1038/nm0398-303; ROBB L, 1995, P NATL ACAD SCI USA, V92, P9565, DOI 10.1073/pnas.92.21.9565; Scott CL, 2000, EXP HEMATOL, V28, P1001, DOI 10.1016/S0301-472X(00)00504-X; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; Semerad CL, 1999, IMMUNITY, V11, P153, DOI 10.1016/S1074-7613(00)80090-4; Seymour JF, 1997, BLOOD, V90, P3037, DOI 10.1182/blood.V90.8.3037; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; Stoffel R, 1999, P NATL ACAD SCI USA, V96, P698, DOI 10.1073/pnas.96.2.698; Suzuki H, 1997, J EXP MED, V185, P499, DOI 10.1084/jem.185.3.499; Tamada T, 2006, P NATL ACAD SCI USA, V103, P3135, DOI 10.1073/pnas.0511264103; Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; WARE CB, 1995, DEVELOPMENT, V121, P1283; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu H, 1999, DEVELOPMENT, V126, P3597; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshida T, 1996, IMMUNITY, V4, P483, DOI 10.1016/S1074-7613(00)80414-8	84	96	98	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6715	6723		10.1038/sj.onc.1210756	http://dx.doi.org/10.1038/sj.onc.1210756			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934480	Bronze			2022-12-28	WOS:000250147000004
J	Nagy, Z; Tora, L				Nagy, Z.; Tora, L.			Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation	ONCOGENE			English	Review						TFTC; STAGA; ATAC; SAGA complexes; global histone acetylation; cofactors	TATA-BINDING PROTEIN; DEPENDENT GENE ACTIVATION; DROSOPHILA ADA2 HOMOLOGS; HUMAN STAGA COMPLEX; ACETYLTRANSFERASE COMPLEX; C-MYC; CHROMATIN-STRUCTURE; LYSINE ACETYLATION; POSTTRANSLATIONAL MODIFICATIONS; TAF(II)-CONTAINING COMPLEX	Transcription in eukaryotes is a tightly regulated, multistep process. Gene-specific transcriptional activators, several different co-activators and general transcription factors are necessary to access specific loci to allow precise initiation of RNA polymerase II transcription. As the dense chromatin folding of the genome does not allow the access of these sites by the huge multiprotein transcription machinery, remodelling is required to loosen up the chromatin structure for successful transcription initiation. In the present review, we summarize the recent evolution of our under standing of the function of two histone acetyl transferases ( ATs) from metazoan organisms: GCN5 and PCAF. Their overall structure and the multiprotein complexes in which they are carrying out their activities are discussed. Metazoan GCN5 and PCAF are subunits of at least two types of multiprotein complexes, one having a molecular weight of 2MDa ( SPT3-TAF9-GCN5 acetyl transferase/ TATA binding protein ( TBP)-free-TAF complex/ PCAF complexes) and a second type with about a size of 700 kDa ( ATAC complex). These complexes possess global histone acetylation activity and locus-specific co-activatorfunctions together with AT activity on non-histone substrates. Thus, their biological functions cover a wide range of tasks and render them indispensable for the normal function of cells. That deregulation of the global and/or specific AT activities of these complexes leads to the cancerous transformation of the cells highlights their importance in cellular processes. The possible effects of GCN5 and PCAF in tumorigenesis are also discussed.	IGBMC, CNRS, UMR 7104, Transcript Dept, Illkirch Graffenstaden, France; Univ Strasbourg 1, INSERM, U596, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), IGBMC, CNRS, UMR 7104, Transcript Dept, BP 10142-67404, Illkirch Graffenstaden, France.	laszlo@igbmc.u-strasbg.fr	Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Anafi M, 2000, MOL ENDOCRINOL, V14, P718, DOI 10.1210/me.14.5.718; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; Baker SP, 2007, ONCOGENE, V26, P5329, DOI 10.1038/sj.onc.1210603; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Barlev NA, 2003, MOL CELL BIOL, V23, P6944, DOI 10.1128/MCB.23.19.6944-6957.2003; Barrera LO, 2006, CURR OPIN CELL BIOL, V18, P291, DOI 10.1016/j.ceb.2006.04.002; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633; Boulton SJ, 2006, CELL CYCLE, V5, P1481, DOI 10.4161/cc.5.14.2930; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Carey M, 2006, MOL CELL, V24, P481, DOI 10.1016/j.molcel.2006.09.012; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Carre C, 2005, MOL CELL BIOL, V25, P8228, DOI 10.1128/MCB.25.18.8228-8238.2005; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Carruthers LM, 2000, J BIOL CHEM, V275, P37285, DOI 10.1074/jbc.M006801200; Cavusoglu N, 2003, PROTEOMICS, V3, P217, DOI 10.1002/pmic.200390030; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Ciurciu A, 2006, MOL CELL BIOL, V26, P9413, DOI 10.1128/MCB.01401-06; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Das BK, 1999, MOL CELL BIOL, V19, P6796; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Demeny MA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000316; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; Forsberg EC, 1997, BIOCHEMISTRY-US, V36, P15918, DOI 10.1021/bi971664x; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Georgieva S, 2000, MOL CELL BIOL, V20, P1639, DOI 10.1128/MCB.20.5.1639-1648.2000; Georgieva S, 2001, MOL CELL BIOL, V21, P5223, DOI 10.1128/MCB.21.15.5223-5231.2001; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Govind CK, 2007, MOL CELL, V25, P31, DOI 10.1016/j.molcel.2006.11.020; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guelman S, 2006, MOL CELL BIOL, V26, P871, DOI 10.1128/MCB.26.3.871-882.2006; Guelman S, 2006, MOL CELL BIOL, V26, P7178, DOI 10.1128/MCB.00130-06; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 2003, J BIOL CHEM, V278, P12310, DOI 10.1074/jbc.M211167200; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hassan AH, 2007, BIOCHEM J, V402, P125, DOI 10.1042/BJ20060907; Helmlinger D, 2006, PLOS BIOL, V4, P432, DOI 10.1371/journal.pbio.0040067; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Helmlinger D, 2006, TRENDS GENET, V22, P562, DOI 10.1016/j.tig.2006.07.010; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Imoberdorf RM, 2006, MOL CELL BIOL, V26, P1610, DOI 10.1128/MCB.26.5.1610-1616.2006; Jia L, 2006, MOL CELL BIOL, V26, P7331, DOI 10.1128/MCB.00581-06; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Johnson DG, 2006, CURR MOL MED, V6, P731; Kahata K, 2004, GENES CELLS, V9, P143, DOI 10.1111/j.1365-2443.2004.00706.x; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kikuchi H, 2005, GENE, V347, P83, DOI 10.1016/j.gene.2004.12.007; Kim SY, 2004, BIOGERONTOLOGY, V5, P305, DOI 10.1007/s10522-004-2568-x; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Krajewski WA, 1998, P NATL ACAD SCI USA, V95, P1540, DOI 10.1073/pnas.95.4.1540; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KURABE N, 2007, ONCOGENE; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kusch T, 2003, MOL CELL BIOL, V23, P3305, DOI 10.1128/MCB.23.9.3305-3319.2003; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Lebedeva LA, 2005, P NATL ACAD SCI USA, V102, P18087, DOI 10.1073/pnas.0509063102; Leriche M., 1926, MEM SOC GEOL NORD, V32, P365; Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Marmorstein R, 2001, CELL MOL LIFE SCI, V58, P693, DOI 10.1007/PL00000893; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Masumi A, 1999, MOL CELL BIOL, V19, P1810; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Morris SA, 2007, J BIOL CHEM, V282, P7632, DOI 10.1074/jbc.M607909200; Muratoglu S, 2003, MOL CELL BIOL, V23, P306, DOI 10.1128/MCB.23.1.306-321.2003; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Oishi H, 2006, J BIOL CHEM, V281, P20, DOI 10.1074/jbc.M510157200; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Pankotai T, 2005, MOL CELL BIOL, V25, P8215, DOI 10.1128/MCB.25.18.8215-8227.2005; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; Powell DW, 2004, MOL CELL BIOL, V24, P7249, DOI 10.1128/MCB.24.16.7249-7259.2004; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Qi D, 2004, MOL CELL BIOL, V24, P8080, DOI 10.1128/MCB.24.18.8080-8089.2004; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Rockx DAP, 2000, P NATL ACAD SCI USA, V97, P10503, DOI 10.1073/pnas.180169797; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sermwittayawong D, 2006, EMBO J, V25, P3791, DOI 10.1038/sj.emboj.7601265; Shamoo Y, 2003, CURR OPIN STRUC BIOL, V13, P206, DOI 10.1016/S0959-440X(03)00033-2; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Smith R, 1998, J MED SCREEN, V5, P5, DOI 10.1136/jms.5.1.5; Snijders PJF, 2006, J PATHOL, V208, P152, DOI 10.1002/path.1866; Soutoglou E, 2005, MOL CELL BIOL, V25, P4092, DOI 10.1128/MCB.25.10.4092-4104.2005; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stockinger EJ, 2001, NUCLEIC ACIDS RES, V29, P1524, DOI 10.1093/nar/29.7.1524; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Turner N, 2005, CURR OPIN PHARMACOL, V5, P388, DOI 10.1016/j.coph.2005.03.006; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; Verdone L, 2005, BIOCHEM CELL BIOL, V83, P344, DOI 10.1139/o05-041; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; Vlachonasios KE, 2003, PLANT CELL, V15, P626, DOI 10.1105/tpc.007922; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Winston F, 1998, COLD SPRING HARB SYM, V63, P553, DOI 10.1101/sqb.1998.63.553; Wolffe AP, 2001, CELL, V104, P631, DOI 10.1016/S0092-8674(02)01453-8; Wu PYJ, 2004, MOL CELL, V15, P199, DOI 10.1016/j.molcel.2004.06.005; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025	166	288	294	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5341	5357		10.1038/sj.onc.1210604	http://dx.doi.org/10.1038/sj.onc.1210604			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694077				2022-12-28	WOS:000248674300004
J	Maddika, S; Wiechec, E; Ande, SR; Poon, IK; Fischer, U; Wesselborg, S; Jans, DA; Schulze-Osthoff, K; Los, M				Maddika, S.; Wiechec, E.; Ande, S. R.; Poon, I. K.; Fischer, U.; Wesselborg, S.; Jans, D. A.; Schulze-Osthoff, K.; Los, M.			Interaction with PI3-kinase contributes to the cytotoxic activity of Apoptin	ONCOGENE			English	Article						anticancer drugs; apoptin; apoptosis; PI3-kinase	INDUCED CELL-DEATH; PHOSPHATIDYLINOSITOL 3-KINASE; T-CELLS; APOPTOSIS; ACTIVATION; BINDING; KINASE; PATHWAY; P85	Apoptin, a small protein from the chicken anemia virus, has attracted attention because of its specificity in killing tumor cells. Localization of apoptin in the nucleus of tumor cells has been shown to be vital for proapoptotic activity, however, targeted expression of apoptin in the nucleus of normal cells does not harm the cells, indicating that nuclear localization of apoptin is insufficient for its cytotoxicity. Here, we demonstrate for the first time that apoptin interacts with the SH3 domain of p85, the regulatory subunit of phosphoinositide 3-kinase (PI3-K), through its proline-rich region. Apoptin derivatives devoid of this proline-rich region do not interact with p85, are unable to activate PI3-K, and show impaired apoptosis induction. Moreover, apoptin mutants containing the proline-rich domain are sufficient to elevate PI3-K activity and to induce apoptosis in cancer cells. Downregulation of p85 leads to nuclear exclusion of apoptin and impairs cell death induction, indicating that interaction with the p85 PI3-K subunit essentially contributes to the cytotoxic activity of apoptin.	[Los, M.] BioApplicat Enterprises, Winnipeg, MB R2V 2N6, Canada; [Maddika, S.; Wiechec, E.; Ande, S. R.; Los, M.] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada; [Maddika, S.; Ande, S. R.; Los, M.] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB, Canada; [Wiechec, E.] Univ Aarhus, Inst Human Genet, Aarhus, Denmark; [Poon, I. K.; Jans, D. A.] Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Clayton, Vic 3168, Australia; [Fischer, U.; Schulze-Osthoff, K.] Univ Dusseldorf, Inst Mol Med, Dusseldorf, Germany; [Wesselborg, S.] Univ Tubingen, Dept Internal Med 1, Tubingen, Germany; [Los, M.] Univ Manitoba, Manitoba Inst Child Hlth, Winnipeg, MB, Canada; [Los, M.] Univ Manitoba, Dept Human Anat & Cell Biol, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba; Aarhus University; Monash University; Heinrich Heine University Dusseldorf; Eberhard Karls University of Tubingen; University of Manitoba; University of Manitoba	Los, M (corresponding author), BioApplicat Enterprises, Winnipeg, MB R2V 2N6, Canada.	mjelos@gmail.com	Schulze-Osthoff, Klaus/N-9025-2013; Ande, Sudharsana Rao/AAU-6950-2021	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Ande, Sudharsana Rao/0000-0001-8194-2902; Wesselborg, Sebastian/0000-0002-5236-942X; Los, Marek/0000-0001-9518-1411; Poon, Ivan/0000-0002-9119-7173; Jans, David/0000-0001-5115-4745	CIHR [81237, 82359] Funding Source: Medline	CIHR(Canadian Institutes of Health Research (CIHR))		Alvisi G, 2006, DRUG RESIST UPDATE, V9, P40, DOI 10.1016/j.drup.2006.02.003; Burek M, 2006, ONCOGENE, V25, P2213, DOI 10.1038/sj.onc.1209258; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Janssen K, 2007, ONCOGENE, V26, P1557, DOI 10.1038/sj.onc.1209923; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Maddika S, 2007, CELL PROLIFERAT, V40, P835, DOI 10.1111/j.1365-2184.2007.00475.x; Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Poon IH, 2005, CANCER RES, V65, P7059, DOI 10.1158/0008-5472.CAN-05-1370; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	19	38	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3060	3065		10.1038/sj.onc.1210958	http://dx.doi.org/10.1038/sj.onc.1210958			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059340	Green Published, Green Accepted			2022-12-28	WOS:000255681700013
J	Chung, SH; Weiss, RS; Frese, KK; Prasad, BVV; Javier, RT				Chung, S-H; Weiss, R. S.; Frese, K. K.; Prasad, B. V. V.; Javier, R. T.			Functionally distinct monomers and trimers produced by a viral oncoprotein	ONCOGENE			English	Article						adenovirus; E4-ORF1; monomer; PDZ; trimer	PAPILLOMAVIRUS E6 ONCOPROTEINS; STAPHYLOCOCCAL ALPHA-TOXIN; TUMOR-SUPPRESSOR PROTEIN; ADENOVIRUS E4-ORF1; EPITHELIAL-CELLS; PDZ DOMAINS; BINDING; POLARITY; OLIGOMERIZATION; VESICLES	While the process of homo-oligomer formation and disassembly into subunits represents a common strategy to regulate protein activity, reports of proteins in which the subunit and homo-oligomer perform independent functions are scarce. Tumorigenesis induced by the adenovirus E4-ORF1 oncoprotein depends on its binding to a select group of cellular PDZ proteins, including MUPP1, MAGI-1, ZO-2 and Dlg1. We report here that in cells E4-ORF1 exists as both a monomer and trimer and that monomers specifically bind and sequester MUPP1, MAGI-1 and ZO-2 within insoluble complexes whereas trimers specifically bind Dlg1 and promote its translocation to the plasma membrane. This work exposes a novel strategy wherein the oligomerization state of a protein not only determines the capacity to bind separate related targets but also couples the interactions to different functional consequences.	[Chung, S-H; Weiss, R. S.; Frese, K. K.; Javier, R. T.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Prasad, B. V. V.] Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Javier, RT (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza,Mail Stop 385, Houston, TX 77030 USA.	rjavier@bcm.tmc.edu	Chung, Sanghyuk/ABH-2697-2020	Prasad, B.V.Venkataram/0000-0002-1172-2071	NCI NIH HHS [T32 CA009197, R01 CA058541, T32 CA09197, CA58541] Funding Source: Medline; NIAID NIH HHS [AI36040, R01 AI036040, R37 AI036040] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009197, R01CA058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036040, R01AI036040] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; Chung SH, 2007, J VIROL, V81, P4787, DOI 10.1128/JVI.02855-06; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; Frese KK, 2006, EMBO J, V25, P1406, DOI 10.1038/sj.emboj.7601030; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Long JF, 2003, J MOL BIOL, V327, P203, DOI 10.1016/S0022-2836(03)00113-X; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Raffy S, 1999, BIOPHYS J, V76, P2072, DOI 10.1016/S0006-3495(99)77363-7; Ramachandran R, 2004, NAT STRUCT MOL BIOL, V11, P697, DOI 10.1038/nsmb793; Shin K, 2005, J CELL BIOL, V168, P705, DOI 10.1083/jcb.200408064; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	25	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1412	1420		10.1038/sj.onc.1210784	http://dx.doi.org/10.1038/sj.onc.1210784			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828302	Green Accepted			2022-12-28	WOS:000253548200008
J	Chan, BL; Ching, AK; To, KF; Leung, JK; Chen, S; Li, Q; Lai, PS; Tang, NS; Shaw, PC; Chan, JH; James, A; Lai, KN; Lim, PL; Lee, KH; Chui, YL				Chan, BC-L; Ching, AK-K; To, K-F; Leung, JC-K; Chen, S.; Li, Q.; Lai, PB-S; Tang, NL-S; Shaw, P-C; Chan, JY-H; James, A. E.; Lai, K-N; Lim, P-L; Lee, KK-H; Chui, Y-L			BRE is an antiapoptotic protein in vivo and overexpressed in human hepatocellular carcinoma	ONCOGENE			English	Article						BRE; antiapoptosis; tumorigenesis; human hepatocellular carcinoma; BRE-specific monoclonal antibody; Fas-mediated acute liver failure	ANTI-FAS ANTIBODY; CELL-CYCLE ENTRY; TRANSGENIC MICE; HEPATIC CARCINOGENESIS; SIGNALING PATHWAYS; BCL-2 FAMILY; APOPTOSIS; DEATH; EXPRESSION; PROLIFERATION	BRE binds to the cytoplasmic domains of tumor necrosis factor receptor-1 and Fas, and in cell lines can attenuate death receptor-initiated apoptosis by inhibiting t-BID-induced activation of the mitochondrial apoptotic pathway. Overexpression of BRE by transfection can also attenuate intrinsic apoptosis and promote growth of the transfected Lewis lung carcinoma line in mice. There is, however, a complete lack of in vivo data about the protein. Here, we report that by using our BRE-specific monoclonal antibody on the immunohistochemistry of 123 specimens of human hepatocellular carcinoma (HCC), significant differences in BRE expression levels between the paired tumoral and non-tumoral regions (P<2.2e-16) were found. Marked overexpression of BRE was detected in majority of the tumors, whereas most non-tumoral regions expressed the same low level of the protein as in normal livers. To investigate whether BRE overexpression could promote cell survival in vivo, liver-specific transgenic BRE mice were generated and found to be significantly resistant to Fas-mediated lethal hepatic apoptosis. The transgenic model also revealed post-transcriptional regulation of Bre level in the liver, which was not observed in HCC and non-HCC cell lines. Indeed, all cell lines analysed express high levels of BRE. In conclusion, BRE is antiapoptotic in vivo, and may promote tumorigenesis when overexpressed.	[Chan, BC-L; Ching, AK-K; Chen, S.; Li, Q.; Lim, P-L; Chui, Y-L] Chinese Univ Hong Kong, Clin Immunol Unit, Hong Kong, Hong Kong, Peoples R China; [Chan, BC-L; Ching, AK-K; Chen, S.; Li, Q.; Lim, P-L; Chui, Y-L] Clin Immunol Unit, Hong Kong, Hong Kong, Peoples R China; [To, K-F] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, State Key Lab Oncol S China, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Leung, JC-K; Lai, K-N] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; [Lai, PB-S] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Tang, NL-S] Chinese Univ Hong Kong, Dept Chem Pathol, Hong Kong, Hong Kong, Peoples R China; [Shaw, P-C] Chinese Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; [Chan, JY-H] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [James, A. E.] Chinese Univ Hong Kong, Lab Anim Serv Ctr, Hong Kong, Hong Kong, Peoples R China; [Lee, KK-H] Chinese Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Chui, Y-L] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital	Chui, YL (corresponding author), Chinese Univ Hong Kong, Clin Immunol Unit, Hong Kong, Hong Kong, Peoples R China.	yiuloonchui@cuhk.edu.hk	Lai, Kar Neng/C-4300-2009; Leung, Joseph Chi Kam/C-4338-2009; Lee, Kenneth Ka Ho/H-6698-2013; Tang, Nelson L/P-5018-2017; Lai, Paul BS/K-8556-2015	Lee, Kenneth Ka Ho/0000-0002-6520-304X; Tang, Nelson L/0000-0002-3607-5819; Lai, Paul BS/0000-0002-9469-6728; Chui, Yiu-Loon/0000-0002-3441-9729				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Bai L, 2005, AM J PATHOL, V166, P1523, DOI 10.1016/S0002-9440(10)62368-1; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Chan BCL, 2005, BIOCHEM BIOPH RES CO, V326, P268, DOI 10.1016/j.bbrc.2004.11.013; Chan BCL, 2002, INT J CANCER, V102, P492, DOI 10.1002/ijc.10773; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Ching AKK, 2000, INT IMMUNOL, V12, P1245, DOI 10.1093/intimm/12.9.1245; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; de la Coste A, 1999, CANCER RES, V59, P5017; De la Coste A, 1999, AM J PHYSIOL-GASTR L, V277, pG702, DOI 10.1152/ajpgi.1999.277.3.G702; Dive C, 1992, Semin Cancer Biol, V3, P417; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gu CH, 1998, FASEB J, V12, P1101, DOI 10.1096/fasebj.12.12.1101; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; KOHLER G, 1975, NATURE, V256, P497; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LI L, 1995, BIOCHEM BIOPH RES CO, V206, P764, DOI 10.1006/bbrc.1995.1108; Li Q, 2004, J BIOL CHEM, V279, P52106, DOI 10.1074/jbc.M408678200; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pierce RH, 2002, AM J PATHOL, V160, P1555, DOI 10.1016/S0002-9440(10)61101-7; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Tang MK, 2006, PROTEOMICS, V6, P2376, DOI 10.1002/pmic.200500603; Vail ME, 2001, CANCER RES, V61, P594; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu J, 2007, GUT, V56, P991, DOI 10.1136/gut.2006.097923; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhivotovsky B, 2006, CARCINOGENESIS, V27, P1939, DOI 10.1093/carcin/bgl035	39	34	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1208	1217		10.1038/sj.onc.1210733	http://dx.doi.org/10.1038/sj.onc.1210733			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704801				2022-12-28	WOS:000253407000003
J	Sauermann, M; Sahin, O; Sultmann, H; Hahne, F; Blaszkiewicz, S; Majety, M; Zatloukal, K; Fuzesi, L; Poustka, A; Wiemann, S; Arlt, D				Sauermann, M.; Sahin, Oe; Sueltmann, H.; Hahne, F.; Blaszkiewicz, S.; Majety, M.; Zatloukal, K.; Fuezesi, L.; Poustka, A.; Wiemann, S.; Arlt, D.			Reduced expression of vacuole membrane protein 1 affects the invasion capacity of tumor cells	ONCOGENE			English	Article						metastasis; invasion; detachment; initial cell-cell contact; cell junctions	GENE-EXPRESSION; E-CADHERIN; PROTEINS; CLASSIFICATION; CARCINOMA; PATTERNS; CANCER; FLOW	Vacuole membrane protein 1 (Vmp1) is described as a cancer-relevant cell cycle modulator, but the function of this protein and its mode of action in tumor progression are still unknown. In this study, we show that the VMP1 mRNA level is significantly reduced in kidney cancer metastases as compared to primary tumors. Further, VMP1 expression is also decreased in the invasive breast cancer cell lines HCC1954 and MDA-MB-231 as compared to the non-invasive cell lines MCF-12A, T-47D and MCF-7. We show for the first time that Vmp1 is a plasma membrane protein and an essential component of initial cell-cell contacts and tight junction formation. It interacts with the tight junction protein Zonula Occludens-1 and colocalizes in spots between neighboring HEK293 cells. Downregulation of VMP1 by RNAi results in loss of cell adherence, and increases the invasion capacity of the non-invasive kidney cancer cell line Caki-2. In conclusion, our findings establish Vmp1 to be a novel cell-cell adhesion protein and that its expression level determines the invasion and metastatic potential of cancer cells.	[Sauermann, M.; Sahin, Oe; Sueltmann, H.; Hahne, F.; Blaszkiewicz, S.; Majety, M.; Poustka, A.; Wiemann, S.; Arlt, D.] German Canc Res Ctr, Div Mol Genome Anal, DKFZ, D-69120 Heidelberg, Germany; [Zatloukal, K.] Med Univ Graz, Inst Pathol, Graz, Austria; [Fuezesi, L.] Univ Gottingen, Hosp Gottingen, Inst Pathol, Dept Gastroenteropathol, Gottingen, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Medical University of Graz; University of Gottingen	Arlt, D (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, DKFZ, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	d.arlt@dkfz.de	Wiemann, Stefan/E-4424-2013; Sültmann, Holger/E-4534-2013; Sahin, Özgür/F-4403-2014	Wiemann, Stefan/0000-0003-4683-3174; Sültmann, Holger/0000-0002-5257-8600; Sahin, Özgür/0000-0002-8033-7089				Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Arlt D, 2005, CANCER RES, V65, P7733, DOI 10.1158/0008-5472.CAN-05-0642; Benoliel AM, 2003, ANTICANCER RES, V23, P4891; Boer JM, 2001, GENOME RES, V11, P1861, DOI 10.1101/gr.184501; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Dusetti NJ, 2002, BIOCHEM BIOPH RES CO, V290, P641, DOI 10.1006/bbrc.2001.6244; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Martin TA, 2001, HISTOL HISTOPATHOL, V16, P1183, DOI 10.14670/HH-16.1183; Mehrle A, 2006, NUCLEIC ACIDS RES, V34, pD415, DOI 10.1093/nar/gkj139; Sahin O, 2007, P NATL ACAD SCI USA, V104, P6579, DOI 10.1073/pnas.0606827104; Sauermann M, 2007, J BIOMOL SCREEN, V12, P510, DOI 10.1177/1087057107301271; Starkuviene V, 2004, GENOME RES, V14, P1948, DOI 10.1101/gr.2658304; Sultmann H, 2005, CLIN CANCER RES, V11, P646; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R	16	41	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1320	1326		10.1038/sj.onc.1210743	http://dx.doi.org/10.1038/sj.onc.1210743			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724469				2022-12-28	WOS:000253407000016
J	Lewis, SM; Holcik, M				Lewis, S. M.; Holcik, M.			For IRES trans-acting factors, it is all about location	ONCOGENE			English	Editorial Material						translation regulation; RNA binding protein; subcellular localization; vincristine	TRANSLATION; STRESS	The translation of many proteins involved in transcription, cell cycle progression, apoptosis and cell survival is mediated by internal ribosome entry sites ( IRESs) present within the 5'-untranslated regions ( 5'-UTRs) of their messenger RNA molecules ( mRNAs). Several recent reports now demonstrate that the proteins controlling IRES-dependent translation initiation are regulated by their subcellular localization.	[Lewis, S. M.; Holcik, M.] Childrens Hosp Eastern Ontario, Res Inst, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada	University of Ottawa; Children's Hospital of Eastern Ontario	Holcik, M (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Apoptosis Res Ctr, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	martin@mgcheo.med.uottawa.ca	Lewis, Stephen/E-5533-2010; Holcik, Martin/A-9768-2008; Holcik, Martin/E-5372-2011; Holcik, Martin/AAC-6660-2019	Lewis, Stephen/0000-0001-9537-5822; Holcik, Martin/0000-0002-1922-5299				Baird SD, 2006, RNA, V12, P1755, DOI 10.1261/rna.157806; Dobbyn HC, 2008, ONCOGENE, V27, P1167, DOI 10.1038/sj.onc.1210723; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Lewis SM, 2007, MOL BIOL CELL, V18, P1302, DOI 10.1091/mbc.E06-06-0515; Lin JC, 2007, P NATL ACAD SCI USA, V104, P2235, DOI 10.1073/pnas.0611015104; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642	9	70	76	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1033	1035		10.1038/sj.onc.1210777	http://dx.doi.org/10.1038/sj.onc.1210777			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17767196				2022-12-28	WOS:000253136700001
J	Ying, H; Willingham, MC; Cheng, SY				Ying, H.; Willingham, M. C.; Cheng, S-Y			The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer	ONCOGENE			English	Article						thyroid carcinogenesis; SRC-3; apoptosis; cell cycles; thyroid hormone receptor mutant; mouse model of thyroid cancer	TRANSCRIPTIONAL ACTIVITY; HORMONE RESISTANCE; CELL-PROLIFERATION; SIGNALING PATHWAY; LIGAND-BINDING; BETA-RECEPTOR; GENE; CARCINOGENESIS; GROWTH; SRC-3	The molecular genetic events underlying thyroid carcinogenesis are not well understood. Mice harboring a dominant-negative mutant thyroid hormone receptor-beta (TR beta(PV/PV) mice) spontaneously develop follicular thyroid carcinoma similar to human cancer. The present study aimed to elucidate the role of the steroid receptor coactivator-3 (SRC-3) in thyroid carcinogenesis in vivo by using the offspring from the cross of TR beta(PV/PV) and SRC-3(-/-) mice. TR beta PV/PV mice deficient in SRC-3 (TRb beta(SRC)-S-PV/PV-3(-/-) mice) had significantly increased survival, decreased thyroid tumor growth, delayed tumor progression and lower incidence of distant metastasis as compared with TR beta(PV/PV) mice with SRC-3 (TR beta(SRC)-S-PV/PV-3(-/-) mice). Further, in vivo nd in vitro analyses of multiple signaling pathways indicated that SRC-3 deficiency could lead to (1) inhibition of cell cycle progression at the G(1)/S transition via controlling the expression of cell cycle regulators, such as E2F1; (2) induction of apoptosis by controlling the expression of the Bcl-2 and caspase-3 genes and (3) suppression of neovascularization and metastasis, at least in part, through modulating the vascular endothelial growth factor gene expression. Taken together, SRC-3 could play important roles through regulating multiple target genes and signaling pathways during thyroid carcinogenesis, understanding of which should direct future therapeutic options for thyroid cancer.	[Ying, H.; Cheng, S-Y] NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bldg 37,Room 5128,37 Convent Dr, Bethesda, MD 20892 USA.	chengs@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008752, ZIABC008752] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Gillenwater A M, 1997, Cancer Treat Res, V90, P149; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kato Y, 2006, ONCOGENE, V25, P2736, DOI 10.1038/sj.onc.1209299; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Kim CS, 2007, CARCINOGENESIS, V28, P932, DOI 10.1093/carcin/bgl231; Liao L, 2002, J STEROID BIOCHEM, V83, P3, DOI 10.1016/S0960-0760(02)00254-6; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; Louie MC, 2006, MOL CELL BIOL, V26, P3810, DOI 10.1128/MCB.26.10.3810-3823.2006; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; Olateju TO, 2006, ANN CLIN BIOCHEM, V43, P431, DOI 10.1258/000456306778904678; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yan J, 2006, ACTA PHARMACOL SIN, V27, P387, DOI 10.1111/j.1745-7254.2006.00315.x; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Ying H, 2005, MOL CELL BIOL, V25, P7687, DOI 10.1128/MCB.25.17.7687-7695.2005; Ying H, 2003, CANCER RES, V63, P5274; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	24	22	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					823	830		10.1038/sj.onc.1210680	http://dx.doi.org/10.1038/sj.onc.1210680			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653082				2022-12-28	WOS:000252884500011
J	Joo, CK; Kim, HS; Park, JY; Seomun, Y; Son, MJ; Kim, JT				Joo, C-K; Kim, H-S; Park, J-Y; Seomun, Y.; Son, M-J; Kim, J-T			Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways	ONCOGENE			English	Article						TGF-beta; EGFR; Src; ROS; NADPH oxidase; E-cadherin	PROTEIN-KINASE INHIBITORS; SMOOTH-MUSCLE-CELLS; TGF-BETA; EGF RECEPTOR; MESENCHYMAL TRANSITION; HYDROGEN-PEROXIDE; TYROSINE KINASES; GENE-EXPRESSION; MESANGIAL CELLS; C-SRC	Many of the signaling responses induced by transforming growth factor-beta (TGF-beta) are mediated by Smad proteins, but there is evidence that it can also signal independently of Smads. Here, we provide evidence that multiple signal pathways induced by TGF-beta 1-including Src family tyrosine kinases (SFKs), generation of reactive oxygen species (ROS), de novo protein synthesis and E-cadherin-dependent cell-cell interactions-transactivate the epidermal growth factor receptor (EGFR), which in turn regulates expression of c-Fos and c-Jun. Immunoprecipitation and immunofluorescence staining showed that EGFR was phosphorylated on tyrosine in response to TGF-beta 1. EGFR transactivation required the activation of SFKs and the production of ROS via NADPH oxidase, but was not dependent on metalloproteases or the release of EGF-like ligands. In addition, the production of ROS was dependent on signaling by specific SFKs as well as de novo protein synthesis. Stable transfection of E-cadherin into MDA-MB-231 cells as well as E-cadherin-blocking assays revealed that E-cadherin-mediated cell-cell interactions were also essential for EGFR transactivation. Finally, EGFR transactivation was involved in the expression of c-Fos and c-Jun via the extracellular signal-regulated kinase signaling cascade. Taken together our data suggest that ligand release-independent transactivation of EGFR may diversify early TGF-beta signaling and represent a novel pathway leading to TGF-beta-mediated gene expression.	[Joo, C-K; Kim, H-S; Park, J-Y; Seomun, Y.; Son, M-J; Kim, J-T] Catholic Univ Korea, Lab Visual Sci, Coll Med, Korea Eye Tissue & Gene Bank, Seoul 137040, South Korea; [Kim, J-T] KOCAT Inc, Bio Div, Seoul, South Korea	Catholic University of Korea	Kim, JT (corresponding author), Catholic Univ Korea, Lab Ophthalmol & Visual Sci, Coll Med, 505 Banpo Dong, Seoul 137040, South Korea.	superbio@kocat.com						Bahk YY, 2004, PROTEOMICS, V4, P3299, DOI 10.1002/pmic.200400980; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; CARMONOCUENCA I, 2005, J CELL PHYSL, V207, P322; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen HY, 1997, J CELL SCI, V110, P345; Chiu C, 2001, INT J MOL MED, V8, P251; Cucoranu I, 2005, CIRC RES, V97, P900, DOI 10.1161/01.RES.0000187457.24338.3D; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; FAN Z, 1994, J BIOL CHEM, V269, P27595; Ferguson KM, 2004, BIOCHEM SOC T, V32, P742, DOI 10.1042/BST0320742; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Frank GD, 2001, BIOCHEM BIOPH RES CO, V280, P1116, DOI 10.1006/bbrc.2001.4251; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hua H, 2003, J BIOL CHEM, V278, P33951, DOI 10.1074/jbc.M302823200; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; LAFON C, 1995, BBA-MOL CELL RES, V1266, P288, DOI 10.1016/0167-4889(95)00023-L; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; Levy DE, 1998, J MED CHEM, V41, P199, DOI 10.1021/jm970494j; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Murillo MM, 2005, ONCOGENE, V24, P4580, DOI 10.1038/sj.onc.1208664; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Park SK, 2001, BIOCHEM BIOPH RES CO, V284, P966, DOI 10.1006/bbrc.2001.5058; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RHEE SG, 2000, SCI STKE, pE1; Rocic P, 2005, CIRC RES, V97, P850, DOI 10.1161/01.RES.0000190403.87462.bf; Samarakoon R, 2005, J CELL PHYSIOL, V204, P236, DOI 10.1002/jcp.20279; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Sorescu D, 2001, FREE RADICAL BIO MED, V30, P603, DOI 10.1016/S0891-5849(00)00507-4; Takeda S, 2006, EMBO J, V25, P2388, DOI 10.1038/sj.emboj.7601131; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Uchiyama-Tanaka Y, 2002, KIDNEY INT, V62, P799, DOI 10.1046/j.1523-1755.2002.00537.x; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zuo X, 2001, ELECTROPHORESIS, V22, P1603, DOI 10.1002/1522-2683(200105)22:9<1603::AID-ELPS1603>3.0.CO;2-I; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	58	45	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					614	628		10.1038/sj.onc.1210649	http://dx.doi.org/10.1038/sj.onc.1210649			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17637750				2022-12-28	WOS:000252674900006
J	Sheehan, KM; Gulmann, C; Eichler, GS; Weinstein, JN; Barrett, HL; Kay, EW; Conroy, RM; Liotta, LA; Petricoin, EF				Sheehan, K. M.; Gulmann, C.; Eichler, G. S.; Weinstein, J. N.; Barrett, H. L.; Kay, E. W.; Conroy, R. M.; Liotta, L. A.; Petricoin, E. F., III			Signal pathway pro. ling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition	ONCOGENE			English	Article						proteomics; protein microarray; colon cancer; stroma; microdissection	PHASE PROTEIN MICROARRAYS; GENE-EXPRESSION PROFILES; TISSUE INHIBITORS; CELL-LINES; CANCER; FIBROBLASTS; PROGRESSION; GROWTH; METALLOPROTEINASES; METASTASIS	Molecular crosstalk, including reciprocal stimulation, is theorized to take place between epithelial cancer cells and surrounding non-neoplastic stromal cells. This is the rationale for stromal therapy, which could eliminate support of a cancer by its genetically stable stroma. Epithelial-stromal crosstalk is so far poorly documented in vivo, and cell cultures and animal experiments may not provide accurate models. The current study details stromal-epithelial signalling pathways in 35 human colon cancers, and compares them with matched normal tissues using quantitative proteomic microarrays. Lysates prepared from separately microdissected epithelium and stroma were analysed using antibodies against 61 cell signalling proteins, most of which recognize activated phospho-isoforms. Analyses using unsupervised and supervised statistical methods suggest that cell signalling pathway profiles in stroma and epithelium appear more similar to each other in tumours than in normal colon. This supports the concept that coordinated crosstalk occurs between epithelium and stroma in cancer and suggests epithelial-mesenchymal transition. Furthermore, the data herein suggest that it is driven by cell proliferation pathways and that, specifically, several key molecules within the mitogen-activated protein kinase pathway may play an important role. Given recent findings of epithelial-mesenchymal transition in therapy-resistant tumour epithelium, these findings could have therapeutic implications for colon cancer.	[Sheehan, K. M.; Gulmann, C.; Barrett, H. L.] Beaumont Hosp, Dept Pathol, Dublin 9, Ireland; [Sheehan, K. M.; Gulmann, C.] NIH, Natl Canc Inst, Canc Res Ctr, Pathol Lab,NCI FDA Clin Proteom Program, Bethesda, MD USA; [Sheehan, K. M.; Gulmann, C.; Barrett, H. L.; Kay, E. W.] Royal Coll Surgeons Ireland, Dept Pathol, Dublin 9, Ireland; [Eichler, G. S.; Weinstein, J. N.] NIH, Natl Canc Inst, Canc Res Ctr, Mol Pharmacol Lab, Bethesda, MD USA; [Conroy, R. M.] Royal Coll Surgeons Ireland, Dept Epidemiol, Dublin, Ireland; [Liotta, L. A.; Petricoin, E. F., III] George Mason Univ, Ctr Appl Proteom & Mol Med, Manassas, VA USA; [Petricoin, E. F., III] US FDA, NCI, Clin Proteom Program, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Royal College of Surgeons - Ireland; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal College of Surgeons - Ireland; George Mason University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Gulmann, C (corresponding author), Beaumont Hosp, Dept Pathol, Dublin 9, Ireland.	christian_gulmann@hotmail.com	Conroy, Ronan/C-6416-2008	Conroy, Ronan/0000-0001-5983-8682; Weinstein, John/0000-0001-9401-6908; Sheehan, Katherine/0000-0002-8969-3610	NATIONAL CANCER INSTITUTE [Z01BC007349] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAUJO RP, 2004, DRUG DISCOV TODAY TH, V1, P425, DOI DOI 10.1016/j.ddstr.2004.11.004; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Brigati C, 2002, CLIN EXP METASTAS, V19, P247, DOI 10.1023/A:1015587423262; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Derycke L, 2005, CANCER BIOTHER RADIO, V20, P579, DOI 10.1089/cbr.2005.20.579; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fend F, 1999, AM J PATHOL, V154, P61, DOI 10.1016/S0002-9440(10)65251-0; Gallagher PG, 2005, CANCER RES, V65, P4134, DOI 10.1158/0008-5472.CAN-04-0415; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Gulmann C, 2006, J PATHOL, V208, P595, DOI 10.1002/path.1958; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Kopfstein L, 2006, CELL MOL LIFE SCI, V63, P449, DOI 10.1007/s00018-005-5296-8; Lambert E, 2003, BIOCHEM J, V372, P767, DOI 10.1042/BJ20030187; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liotta LA, 2003, CANCER CELL, V3, P317, DOI 10.1016/S1535-6108(03)00086-2; Littlepage LE, 2005, CANCER CELL, V7, P499, DOI 10.1016/j.ccr.2005.05.019; Matrisian LM, 2001, CANCER RES, V61, P3844; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Notterman DA, 2001, CANCER RES, V61, P3124; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Sheehan KM, 2005, MOL CELL PROTEOMICS, V4, P346, DOI 10.1074/mcp.T500003-MCP200; Sun YJ, 2005, MOL CANCER THER, V4, P51; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Tomita T, 1996, DIS COLON RECTUM, V39, P1255, DOI 10.1007/BF02055119; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wulfkuhle JD, 2003, PROTEOMICS, V3, P2085, DOI 10.1002/pmic.200300591; Yang J, 2006, CANCER RES, V66, P4549, DOI 10.1158/0008-5472.CAN-05-3850; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	52	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					323	331		10.1038/sj.onc.1210647	http://dx.doi.org/10.1038/sj.onc.1210647			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621268				2022-12-28	WOS:000252256000008
J	Chen, R; Alvero, AB; Silasi, DA; Steffensen, KD; Mor, G				Chen, R.; Alvero, A. B.; Silasi, D-A; Steffensen, K. D.; Mor, G.			Cancers take their Toll - the function and regulation of Toll-like receptors in cancer cells	ONCOGENE			English	Review						ovarian cancer; Toll-like receptors; MyD88; inflammation; tissue repair; chemoresistance	NF-KAPPA-B; INFLAMMATION-ASSOCIATED CANCER; PROMOTES TUMOR-GROWTH; OVARIAN-CANCER; PROTEINS FAS; MURINE MODEL; APOPTOSIS; ACTIVATION; MACROPHAGES; CARCINOMA	Cancer could be deemed as an abnormal and uncontrolled tissue repair process. Therefore, it would not be surprising that factors that function in the tissue repair process, such as cytokines, chemokines, growth factors and Toll-like receptor (TLR) ligands, as well as growth signals for compensatory proliferation, would also be key factors in regulating and enhancing cancer progression. The TLR pathways, which play a critical role in tissue repair, are also key regulators in cancer progression as well as chemoresistance. TLRs serve as cell surface sensors that can initiate pathways leading to proliferation and chemoresistance; as well as mediators that are able to regulate the infiltrating immune cells to provide further support for cancer progression.	[Alvero, A. B.; Silasi, D-A; Mor, G.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, New Haven, CT 06520 USA; [Chen, R.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Steffensen, K. D.] Vejle Hosp, Dept Oncol, Vejle, Denmark	Yale University; Yale University; University of Southern Denmark; Lillebaelt Hospital	Mor, G (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, Reprod Immunol Unit, 333 Cedar St,FMB 301, New Haven, CT 06520 USA.	gil.mor@yale.edu		Dahl Steffensen, Karina/0000-0002-9217-3907; Alvero, Ayesha/0000-0002-6593-3595				Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Alvero AB, 2006, CANCER-AM CANCER SOC, V106, P599, DOI 10.1002/cncr.21633; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Barton GM, 2004, NAT IMMUNOL, V5, P472, DOI 10.1038/ni0504-472; Beachy PA, 2004, NATURE, V431, P402, DOI 10.1038/431402a; Ben-Hur H, 2000, EUR J GYNAECOL ONCOL, V21, P53; Ben-Hur H, 2000, EUR J GYNAECOL ONCOL, V21, P141; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; CHEN R, 2007, UNPUB J CLIN INVEST; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Ernst PB, 2001, DIGEST DIS, V19, P104, DOI 10.1159/000050663; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Gannot G, 2002, BRIT J CANCER, V86, P1444, DOI 10.1038/sj.bjc.6600282; Girling JE, 2007, IMMUNOL CELL BIOL, V85, P481, DOI 10.1038/sj.icb.7100086; Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Koff JL, 2006, J IMMUNOL, V177, P8693, DOI 10.4049/jimmunol.177.12.8693; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li QT, 2005, TRENDS IMMUNOL, V26, P318, DOI 10.1016/j.it.2005.04.003; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Menard S, 1997, CLIN CANCER RES, V3, P817; Mor G, 1998, J STEROID BIOCHEM, V67, P403, DOI 10.1016/S0960-0760(98)00143-5; Mor G, 2002, BIOCHEM PHARMACOL, V64, P1305, DOI 10.1016/S0006-2952(02)01267-4; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Pidgeon GP, 1999, BRIT J CANCER, V81, P1311, DOI 10.1038/sj.bjc.6694369; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Riman T, 2004, ACTA OBSTET GYN SCAN, V83, P783, DOI 10.1111/j.0001-6349.2004.00550.x; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Ruvkun G, 2001, SCIENCE, V294, P797, DOI 10.1126/science.1066315; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Schwartz Peter E, 2002, Cancer Treat Res, V107, P99; Sekizawa Akihiko, 2004, Medical Electron Microscopy, V37, P97; Shishodia S, 2002, J BIOCHEM MOL BIOL, V35, P28; Silasi Dan-Arin, 2006, Yale J Biol Med, V79, P153; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; Tsan MF, 2006, SEMIN CANCER BIOL, V16, P32, DOI 10.1016/j.semcancer.2005.07.004; Virchow R., 1863, KRANKHAFTEN GESCHWUL, P57; VIRSCHOW R, 1858, ARCH PATHOL ANAT KLI, V14, P1; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wiemer EAC, 2007, EUR J CANCER, V43, P1529, DOI 10.1016/j.ejca.2007.04.002; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	76	163	184	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					225	233		10.1038/sj.onc.1210907	http://dx.doi.org/10.1038/sj.onc.1210907			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176604				2022-12-28	WOS:000252163600009
J	Conroy, H; Marshall, NA; Mills, KHG				Conroy, H.; Marshall, N. A.; Mills, K. H. G.			TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours	ONCOGENE			English	Review						TLR ligand; regulatory T cell; dendritic cell; immunotherapeutic; cancer vaccine; antitumour immunity	REGULATORY T-CELLS; TOLL-LIKE RECEPTOR-2; THERAPEUTIC CANCER VACCINES; MEDIATED ANTITUMOR IMMUNITY; TRANSCRIPTION FACTOR FOXP3; GROWTH-FACTOR-BETA; DENDRITIC CELLS; TGF-BETA; METASTATIC MELANOMA; CUTTING EDGE	Toll-like receptor (TLR) agonists are potent activators of innate immune responses, activating dendritic cell (DC) maturation and inflammatory cytokine secretion by innate immune cells and as a consequence they promote adaptive immune response when coadministered with foreign antigens. There is also some evidence from mouse models that TLR ligands can help to break tolerance to self-antigens and promote immune responses to tumour antigens. Therefore, they have been exploited as adjuvants for tumour vaccines or as immunotherapeutics against cancer. Clinical evaluation of TLR agonists has resulted in a licensed immunotherapeutic for basal cell carcinoma, but there have also been disappointing results from clinical trials, with one pharmaceutical company recently halting its clinical programme. A major obstacle to the development of any active immunotherapeutic approach to cancer is the immunosuppressive environment of the growing tumour, including the induction of tolerogenic DCs and regulatory T (Treg) cells, which suppress the development of protective effector T-cell responses. This can be compounded by the use of TLR ligands as immunotherapeutics. A problem with TLR agonists that has not been fully appreciated is that they can generate suppressive as well as inflammatory responses in innate immune cells and can promote the induction of regulatory as well as effector T cells. This is part of a normal mechanism for limiting collateral damage during infection or sterile inflammation, but can constrain their ability to induce protective antitumour immunity, especially in the immune suppressed environment of the tumour. Alternatively, manipulating the TLR-activated innate immune responses to selectively blocking immunosuppressive arm, as well as that induced by the tumour, may hold the key to enhancing their efficacy as tumour immunotherapeutics and as adjuvants for cancer vaccines.	[Conroy, H.; Marshall, N. A.; Mills, K. H. G.] Trinity Coll Dublin, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin, Ireland	Trinity College Dublin	Mills, KHG (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin, Ireland.	kingston.mills@tcd.ie	Mills, Kingston H/F-5684-2013	Mills, Kingston H/0000-0003-3646-8222; Conroy, Helen/0000-0002-5857-2760				Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Akdis CA, 2003, EUR J IMMUNOL, V33, P2717, DOI 10.1002/eji.200323329; Alvaro T, 2005, CLIN CANCER RES, V11, P1467, DOI 10.1158/1078-0432.CCR-04-1869; Attia P, 2005, J CLIN ONCOL, V23, P6043, DOI 10.1200/JCO.2005.06.205; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Baratelli F, 2005, J IMMUNOL, V175, P1483, DOI 10.4049/jimmunol.175.3.1483; Bellone G, 2006, J IMMUNOL, V177, P3448, DOI 10.4049/jimmunol.177.5.3448; Beutner KR, 1999, J AM ACAD DERMATOL, V41, P1002, DOI 10.1016/S0190-9622(99)70261-6; Boccaccio GL, 1999, INT IMMUNOL, V11, P289, DOI 10.1093/intimm/11.2.289; Bourquin C, 2006, INT J CANCER, V118, P2790, DOI 10.1002/ijc.21681; Boyd AP, 2005, J IMMUNOL, V175, P730, DOI 10.4049/jimmunol.175.2.730; Brandau S, 2007, BIOMED PHARMACOTHER, V61, P299, DOI 10.1016/j.biopha.2007.05.004; Braun D, 2005, BLOOD, V106, P2375, DOI 10.1182/blood-2005-03-0979; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; Carreras J, 2006, BLOOD, V108, P2957, DOI 10.1182/blood-2006-04-018218; Chakraborty NG, 2004, HUM IMMUNOL, V65, P794, DOI 10.1016/j.humimm.2004.05.012; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen YJ, 2001, INT IMMUNOL, V13, P1013, DOI 10.1093/intimm/13.8.1013; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Crellin NK, 2005, J IMMUNOL, V175, P8051, DOI 10.4049/jimmunol.175.12.8051; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; den Haan JMM, 2007, J IMMUNOL, V178, P5429, DOI 10.4049/jimmunol.178.9.5429; Dercamp C, 2005, CANCER RES, V65, P8479, DOI 10.1158/0008-5472.CAN-05-1319; Espenschied J, 2003, J IMMUNOL, V170, P3401, DOI 10.4049/jimmunol.170.6.3401; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Foss F M, 2000, Clin Lymphoma, V1, P110, DOI 10.3816/CLM.2000.n.009; Frankel Arthur E, 2002, Cancer Chemother Biol Response Modif, V20, P301; Fricke I, 2006, IMMUNOL INVEST, V35, P459, DOI 10.1080/08820130600803429; Fu JL, 2007, GASTROENTEROLOGY, V132, P2328, DOI 10.1053/j.gastro.2007.03.102; FUJIMOTO S, 1975, IMMUNOL COMMUN, V4, P201, DOI 10.3109/08820137409055774; Gabrilovich DI, 1996, CELL IMMUNOL, V170, P101, DOI 10.1006/cimm.1996.0139; Garbi N, 2004, J IMMUNOL, V172, P5861, DOI 10.4049/jimmunol.172.10.5861; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Gilboa E, 2007, J CLIN INVEST, V117, P1195, DOI 10.1172/JCI31205; Golgher D, 2002, EUR J IMMUNOL, V32, P3267, DOI 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Heckelsmiller K, 2002, EUR J IMMUNOL, V32, P3235, DOI 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Higgins SC, 2003, J IMMUNOL, V171, P3119, DOI 10.4049/jimmunol.171.6.3119; Hirahara K, 2006, J IMMUNOL, V177, P4488, DOI 10.4049/jimmunol.177.7.4488; Hirano F, 2005, CANCER RES, V65, P1089; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Ichikawa HT, 2002, J IMMUNOL, V169, P2781, DOI 10.4049/jimmunol.169.5.2781; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jarnicki AG, 2006, J IMMUNOL, V177, P896, DOI 10.4049/jimmunol.177.2.896; JORDAN JT, 2007, CANC IMMUNOL THER; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; Katakura K, 2005, J CLIN INVEST, V115, P695, DOI 10.1172/JCI200522996; KIKKAWA F, 1993, EUR J CANCER, V29A, P1542, DOI 10.1016/0959-8049(93)90291-M; Knutson KL, 2005, CANCER IMMUNOL IMMUN, V54, P721, DOI 10.1007/s00262-004-0653-2; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Kreitman RJ, 2004, EXPERT OPIN BIOL TH, V4, P1115, DOI 10.1517/14712598.4.7.1115; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Kubo T, 2004, J IMMUNOL, V173, P7249, DOI 10.4049/jimmunol.173.12.7249; Kudo-Saito C, 2005, CLIN CANCER RES, V11, P4533, DOI 10.1158/1078-0432.CCR-04-2237; Kwon ED, 1997, P NATL ACAD SCI USA, V94, P8099, DOI 10.1073/pnas.94.15.8099; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lavelle EC, 2003, J IMMUNOL, V171, P2384, DOI 10.4049/jimmunol.171.5.2384; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lee DC, 2004, CANCER IMMUNOL IMMUN, V53, P275, DOI 10.1007/s00262-003-0432-5; Lin JT, 2006, LANCET, V368, P991, DOI 10.1016/S0140-6736(06)69294-5; Liu HY, 2006, P NATL ACAD SCI USA, V103, P7048, DOI 10.1073/pnas.0601554103; Liu VC, 2007, J IMMUNOL, V178, P2883, DOI 10.4049/jimmunol.178.5.2883; Livingston P O, 1989, Prog Clin Biol Res, V288, P309; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Lizee G, 2006, CLIN CANCER RES, V12, P4794, DOI 10.1158/1078-0432.CCR-06-0944; Marshall NA, 2004, BLOOD, V103, P1755, DOI 10.1182/blood-2003-07-2594; McGuirk P, 2002, TRENDS IMMUNOL, V23, P450, DOI 10.1016/S1471-4906(02)02288-3; Mellor AL, 2005, J IMMUNOL, V175, P5601, DOI 10.4049/jimmunol.175.9.5601; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Natarajan K, 2003, J INFECT DIS, V187, P914, DOI 10.1086/368173; Nava-Parada P, 2007, CANCER RES, V67, P1326, DOI 10.1158/0008-5472.CAN-06-3290; Netea MG, 2004, J IMMUNOL, V172, P3712, DOI 10.4049/jimmunol.172.6.3712; NORTH RJ, 1982, J EXP MED, V155, P1063, DOI 10.1084/jem.155.4.1063; Obermeier F, 2002, EUR J IMMUNOL, V32, P2084, DOI 10.1002/1521-4141(200207)32:7<2084::AID-IMMU2084>3.0.CO;2-Q; Oldenhove G, 2003, J EXP MED, V198, P259, DOI 10.1084/jem.20030654; Onizuka S, 1999, CANCER RES, V59, P3128; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Peng G, 2007, IMMUNITY, V27, P334, DOI 10.1016/j.immuni.2007.05.020; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Pinzon-Charry A, 2005, IMMUNOL CELL BIOL, V83, P451, DOI 10.1111/j.1440-1711.2005.01371.x; Qian C, 2007, BLOOD, V109, P3308, DOI 10.1182/blood-2006-08-040337; Ribas A, 2005, J CLIN ONCOL, V23, P8968, DOI 10.1200/JCO.2005.01.109; Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schmidt C, 2007, NAT BIOTECHNOL, V25, P825, DOI 10.1038/nbt0807-825; Sfondrini L, 2006, J IMMUNOL, V176, P6624, DOI 10.4049/jimmunol.176.11.6624; Shimizu J, 1999, J IMMUNOL, V163, P5211; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; Smyth MJ, 2000, NAT IMMUNOL, V1, P459, DOI 10.1038/82698; Somasundaram R, 2002, CANCER RES, V62, P5267; Sousa CRE, 2004, CURR OPIN IMMUNOL, V16, P21, DOI 10.1016/j.coi.2003.11.007; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Srivastava PK, 2006, CURR OPIN IMMUNOL, V18, P201, DOI 10.1016/j.coi.2006.01.009; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Toka FN, 2004, J VIROL, V78, P13082, DOI 10.1128/JVI.78.23.13082-13089.2004; Tormo D, 2006, CANCER RES, V66, P5427, DOI 10.1158/0008-5472.CAN-06-0399; Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003; Valenti R, 2006, CANCER RES, V66, P9290, DOI 10.1158/0008-5472.CAN-06-1819; Vicari AP, 2002, J EXP MED, V196, P541, DOI 10.1084/jem.20020732; Viguier M, 2004, J IMMUNOL, V173, P1444, DOI 10.4049/jimmunol.173.2.1444; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; WATANABE Y, 1987, J BIOL RESP MODIF, V6, P169; Weber J, 2007, ONCOLOGIST, V12, P864, DOI 10.1634/theoncologist.12-7-864; Wei S, 2005, CANCER RES, V65, P5020, DOI 10.1158/0008-5472.CAN-04-4043; Whitmore MM, 2004, CANCER RES, V64, P5850, DOI 10.1158/0008-5472.CAN-04-0063; Wilson SB, 2003, NAT REV IMMUNOL, V3, P211, DOI 10.1038/nri1028; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244; Woo EY, 2001, CANCER RES, V61, P4766; Xu SW, 2006, SURGERY, V140, P170, DOI 10.1016/j.surg.2006.03.006; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059; Zeytin HE, 2004, CANCER RES, V64, P3668, DOI 10.1158/0008-5472.CAN-03-3878; Zhou G, 2006, BLOOD, V107, P628, DOI 10.1182/blood-2005-07-2737; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806; Zwaveling S, 2002, J IMMUNOL, V169, P350, DOI 10.4049/jimmunol.169.1.350	134	140	153	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					168	180		10.1038/sj.onc.1210910	http://dx.doi.org/10.1038/sj.onc.1210910			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176598	Bronze			2022-12-28	WOS:000252163600003
J	Friedman, AD				Friedman, A. D.			Transcriptional control of granulocyte and monocyte development	ONCOGENE			English	Review						granulocyte; monocyte; differentiation; C/EBP alpha; PU.1	NF-KAPPA-B; BINDING-PROTEIN-ALPHA; HEMATOPOIETIC PROGENITOR CELLS; CCAAT DISPLACEMENT PROTEIN; C-JUN EXPRESSION; STIMULATING FACTOR-RECEPTOR; C/EBP FAMILY-MEMBERS; MYELOID STEM-CELLS; RETINOIC ACID; DNA-BINDING	PU.1 directs the hematopoietic stem cell to the lymphoid-myeloid progenitor ( LMP) and interacts with GATA-binding protein 1 to inhibit commitment to the megakaryocyte-erythroid progenitor. The CCAAT/ enhancerbinding protein ( C/ EBP)alpha then directs the LMP to the granulocyte- monocyte progenitor ( GMP) stage, while inhibiting lymphoid development via cross- inhibition of Pax5 and potentially other regulators. Increased PU. 1 activity favors monocytic commitment of the GMP. Induction of PU.1 by C/EBP alpha and interaction of PU.1 with c-Jun elevates PU. 1 activity. Zippering of C/ EBP alpha with c- Jun or c- Fos also contributes to monocyte lineage specification. An additional factor, potentially an Id1-regulated basic helix - loop - helix protein, may be required for the GMP to commit to the granulocyte lineage. Egr- 1, Egr- 2, Vitamin D Receptor, MafB/ c: Fos and PU. 1: interferon regulatory factor 8 complexes direct further monocytic maturation, while retinoic acid receptor ( RAR) and C/ EBP epsilon direct granulopoiesis. Both C/ EBP alpha and RARs induce C/ EBP epsilon, and PU.1 is also required, albeit at lower levels, for granulocytic maturation. HoxA10 and CAAT displacement protein act as transcriptional repressors to delay expression of terminal differentiation. Gfi-1 and Egr- 1,2/ Nab2 complexes repress each other to maintain myeloid lineage fidelity. NF-kappa B directly binds and cooperates with C/ EBP beta to induce the inflammatory response in mature myeloid cells and potentially also cooperates with C/ EBP alpha to regulate early myelopoiesis.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA	Johns Hopkins University	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Canc Res Bldg 1,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	afriedm2@jhmi.edu						Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Anderson K, 2007, BLOOD, V109, P3697, DOI 10.1182/blood-2006-05-026021; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; Arinobu Y, 2006, BLOOD, V108, p472A, DOI 10.1182/blood.V108.11.1656.1656; Aziz A, 2006, MOL CELL BIOL, V26, P6808, DOI 10.1128/MCB.00245-06; Bakri Y, 2005, BLOOD, V105, P2707, DOI 10.1182/blood-2004-04-1448; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Bastie JN, 2004, MOL ENDOCRINOL, V18, P2685, DOI 10.1210/me.2003-0412; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bei L, 2005, J BIOL CHEM, V280, P12359, DOI 10.1074/jbc.M408138200; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Bush TS, 2003, BLOOD, V101, P311, DOI 10.1182/blood.V101.1.311; Cadieux C, 2006, CANCER RES, V66, P9492, DOI 10.1158/0008-5472.CAN-05-4230; Cai DH, 2006, BLOOD, V108, p345A; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cammenga J, 2003, BLOOD, V101, P2206, DOI 10.1182/blood-2002-05-1546; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; Chih DY, 1997, BLOOD, V90, P2987, DOI 10.1182/blood.V90.8.2987; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; Chumakov AM, 2007, BLOOD, V109, P4209, DOI 10.1182/blood-2005-09-031963; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Cleaves R, 2004, ONCOGENE, V23, P716, DOI 10.1038/sj.onc.1207172; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Dahl R, 2007, J BIOL CHEM, V282, P6473, DOI 10.1074/jbc.M607613200; Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Dionne CJ, 2005, DEV BIOL, V280, P448, DOI 10.1016/j.ydbio.2005.01.027; DOUER D, 1982, J CLIN INVEST, V69, P1039, DOI 10.1172/JCI110507; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Endo M, 2006, J IMMUNOL, V176, P6245, DOI 10.4049/jimmunol.176.10.6245; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Friedman AD, 1996, CANCER RES, V56, P3250; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Fukuchi Y, 2006, EMBO J, V25, P3398, DOI 10.1038/sj.emboj.7601199; Ginhoux F, 2006, NAT IMMUNOL, V7, P265, DOI 10.1038/ni1307; Gombart AF, 2005, J LEUKOCYTE BIOL, V78, P1153, DOI 10.1189/jlb.0504286; Gombart AF, 2001, BLOOD, V97, P2561, DOI 10.1182/blood.V97.9.2561; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Grondin B, 2007, MOL CELL BIOL, V27, P2919, DOI 10.1128/MCB.00936-06; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963; Heavey B, 2003, EMBO J, V22, P3887, DOI 10.1093/emboj/cdg380; Hegde SP, 1999, BLOOD, V94, P1578, DOI 10.1182/blood.V94.5.1578.417k18_1578_1589; Henkel GW, 1999, BLOOD, V93, P2849; Himes SR, 2006, J IMMUNOL, V176, P2219, DOI 10.4049/jimmunol.176.4.2219; Hirai H, 2006, NAT IMMUNOL, V7, P732, DOI 10.1038/ni1354; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hsu CL, 2006, P NATL ACAD SCI USA, V103, P672, DOI 10.1073/pnas.0510304103; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HUANG G, 2007, IN PRESS NATURE GENE; Huang WQ, 2007, J BIOL CHEM, V282, P6629, DOI 10.1074/jbc.M607760200; Iwama A, 2002, J EXP MED, V195, P547, DOI 10.1084/jem.20011465; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Jankovic V, 2007, P NATL ACAD SCI USA, V104, P1260, DOI 10.1073/pnas.0607894104; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Kakar R, 2005, J LEUKOCYTE BIOL, V77, P120, DOI 10.1189/jlb.0704429; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kautz B, 2001, J BIOL CHEM, V276, P37868; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Khanna-Gupta A, 2001, P NATL ACAD SCI USA, V98, P8000, DOI 10.1073/pnas.141229598; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOEFFLER HP, 1984, CANCER RES, V44, P5624; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Krysinska H, 2007, MOL CELL BIOL, V27, P878, DOI 10.1128/MCB.01915-06; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; KUNSCH C, 1994, J IMMUNOL, V153, P153; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Laiosa CV, 2006, IMMUNITY, V25, P731, DOI 10.1016/j.immuni.2006.09.011; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Leeanansaksiri W, 2005, J IMMUNOL, V174, P7014, DOI 10.4049/jimmunol.174.11.7014; Lekstrom-Himes JA, 2001, STEM CELLS, V19, P125, DOI 10.1634/stemcells.19-2-125; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; LI JM, 1994, CELL GROWTH DIFFER, V5, P743; Liew CW, 2006, J BIOL CHEM, V281, P28296, DOI 10.1074/jbc.M602830200; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Lindsey S, 2007, J BIOL CHEM, V282, P2237, DOI 10.1074/jbc.M608642200; Liu HT, 2003, BLOOD, V101, P3885, DOI 10.1182/blood-2002-07-2212; Liu J, 2006, MOL CELL, V21, P467, DOI 10.1016/j.molcel.2005.12.020; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; Manz MG, 2001, BLOOD, V97, P3333, DOI 10.1182/blood.V97.11.3333; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; Meraro D, 1999, J IMMUNOL, V163, P6468; Miller M, 2003, J BIOL CHEM, V278, P15178, DOI 10.1074/jbc.M300417200; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; Moriguchi T, 2006, MOL CELL BIOL, V26, P5715, DOI 10.1128/MCB.00001-06; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Ortiz MA, 1999, P NATL ACAD SCI USA, V96, P2740, DOI 10.1073/pnas.96.6.2740; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; Papin S, 2003, J BIOL CHEM, V278, P48839, DOI 10.1074/jbc.M305166200; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Paz-Priel I, 2005, MOL CANCER RES, V3, P585, DOI 10.1158/1541-7786.MCR-05-0111; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; Porse BT, 2005, J EXP MED, V202, P85, DOI 10.1084/jem.20050067; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rangatia J, 2003, ONCOGENE, V22, P4760, DOI 10.1038/sj.onc.1206664; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rekhtman N, 2003, MOL CELL BIOL, V23, P7460, DOI 10.1128/MCB.23.21.7460-7474.2003; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SCOTT LM, 1992, BLOOD, V80, P1725; Sebastian T, 2006, CELL CYCLE, V5, P953, DOI 10.4161/cc.5.9.2733; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sharf R, 1997, J BIOL CHEM, V272, P9785; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Spain LM, 1999, J IMMUNOL, V163, P2681; Steidl U, 2006, NAT GENET, V38, P1269, DOI 10.1038/ng1898; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stopka T, 2005, EMBO J, V24, P3712, DOI 10.1038/sj.emboj.7600834; Suh HC, 2006, BLOOD, V107, P4308, DOI 10.1182/blood-2005-06-2216; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; Taghon T, 2002, BLOOD, V99, P1197, DOI 10.1182/blood.V99.4.1197; Tagoh H, 2006, EMBO J, V25, P1070, DOI 10.1038/sj.emboj.7600997; Tamura T, 2005, BLOOD, V106, P1938, DOI 10.1182/blood-2005-01-0080; Taschner S, 2007, BLOOD, V109, P971, DOI 10.1182/blood-2006-04-020552.7; Traver D, 2001, BLOOD, V98, P627, DOI 10.1182/blood.V98.3.627; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Tsujimura H, 2002, J IMMUNOL, V169, P1261, DOI 10.4049/jimmunol.169.3.1261; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Walkley CR, 2004, BLOOD, V103, P1286, DOI 10.1182/blood-2003-07-2391; Wang D, 2006, BLOOD, V108, P1223, DOI 10.1182/blood-2005-12-008763; Wang QF, 2003, ONCOGENE, V22, P2548, DOI 10.1038/sj.onc.1206360; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wang W, 2001, LEUKEMIA, V15, P779, DOI 10.1038/sj.leu.2402094; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Williamson EA, 1998, J BIOL CHEM, V273, P14796, DOI 10.1074/jbc.273.24.14796; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; YEAMANS C, 2007, IN PRESS BLOOD; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006; Zhang P, 2002, BLOOD, V99, P4406, DOI 10.1182/blood.V99.12.4406; Zou GM, 2005, P NATL ACAD SCI USA, V102, P13236, DOI 10.1073/pnas.0506218102; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	194	312	326	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6816	6828		10.1038/sj.onc.1210764	http://dx.doi.org/10.1038/sj.onc.1210764			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934488				2022-12-28	WOS:000250147000012
J	Goldfarb, AN				Goldfarb, A. N.			Transcriptional control of megakaryocyte development	ONCOGENE			English	Review						megakaryocyte; platelet; development; transcription factor	FAMILIAL PLATELET DISORDER; X-LINKED THROMBOCYTOPENIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; C-MYB; ADULT HEMATOPOIESIS; INHERITED MUTATION; DROSOPHILA HEMATOPOIESIS; LINEAGE COMMITMENT; GENE-EXPRESSION	Megakaryocytes are highly specialized cells that arise from a bipotent megakaryocytic- erythroid progenitor ( MEP). This developmental leap requires coordinated activation of megakaryocyte- specific genes, radical changes in cell cycle properties, and active prevention of erythroid differentiation. These programs result from upregulation of megakaryocyte- selective transcription factors, down-regulation of erythroid- selective transcription factors and ongoing mediation of common erythro- megakaryocytic transcription factors. Unlike most developmental programs, no single lineage- unique family of master regulators exerts executive control over the megakaryocytic plan. Rather, an assemblage of non- unique factors and signals converge to determine lineage and differentiation. In human megakaryopoiesis, hereditary disorders of platelet production have confirmed contributions from three distinct transcription factor families. Murine models have extended this repertoire to include multiple additional factors. At a mechanistic level, the means by which these non- unique factors collaborate in the establishment of a perfectly unique cell type remains a central question.	Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia	Goldfarb, AN (corresponding author), Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Pathol, Box 800904, Charlottesville, VA 22908 USA.	ang3x@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA100057, R56CA100057, R01CA093735] Funding Source: NIH RePORTER; NCI NIH HHS [CA93735, CA100057] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; BRETONGORIUS J, 1995, BLOOD, V85, P1805, DOI 10.1182/blood.V85.7.1805.bloodjournal8571805; Buijs A, 2001, BLOOD, V98, P2856, DOI 10.1182/blood.V98.9.2856; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Carpinelli MR, 2004, P NATL ACAD SCI USA, V101, P6553, DOI 10.1073/pnas.0401496101; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DOWTON SB, 1985, BLOOD, V65, P557; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Fossett N, 2003, P NATL ACAD SCI USA, V100, P11451, DOI 10.1073/pnas.1635050100; Freson K, 2002, HUM MOL GENET, V11, P147, DOI 10.1093/hmg/11.2.147; Freson K, 2001, BLOOD, V98, P85, DOI 10.1182/blood.V98.1.85; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Heller PG, 2005, BLOOD, V105, P4664, DOI 10.1182/blood-2005-01-0050; Ho CJ, 1996, J SYMB COMPUT, V21, P1, DOI 10.1006/jsco.1996.0001; Hock H, 2004, GENE DEV, V18, P2336, DOI 10.1101/gad.1239604; Hollanda LM, 2006, NAT GENET, V38, P807, DOI 10.1038/ng1825; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Kuhl C, 2005, MOL CELL BIOL, V25, P8592, DOI 10.1128/MCB.25.19.8592-8606.2005; Kundu M, 2002, BLOOD, V100, P2449, DOI 10.1182/blood-2002-04-1064; Kuo YH, 2006, CANCER CELL, V9, P57, DOI 10.1016/j.ccr.2005.12.014; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Liew CK, 2005, P NATL ACAD SCI USA, V102, P583, DOI 10.1073/pnas.0407511102; Liu YZ, 2006, CANCER CELL, V9, P249, DOI 10.1016/j.ccr.2006.03.012; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Ludlow LB, 1996, J BIOL CHEM, V271, P22076, DOI 10.1074/jbc.271.36.22076; Lulli V, 2006, CELL DEATH DIFFER, V13, P1064, DOI 10.1038/sj.cdd.4401811; Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399; Matheny CJ, 2007, EMBO J, V26, P1163, DOI 10.1038/sj.emboj.7601568; Mehaffey MG, 2001, BLOOD, V98, P2681, DOI 10.1182/blood.V98.9.2681; MICHIELS JJ, 2002, SEM VASC MED, V1, P1; Mukai HY, 2006, MOL CELL BIOL, V26, P7953, DOI 10.1128/MCB.00718-06; Muntean AG, 2005, BLOOD, V106, P1223, DOI 10.1182/blood-2005-02-0551; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Pang LY, 2006, BLOOD, V108, P2198, DOI 10.1182/blood-2006-04-019760; Phillips JD, 2007, BLOOD, V109, P2618, DOI 10.1182/blood-2006-06-022848; Putz G, 2006, ONCOGENE, V25, P929, DOI 10.1038/sj.onc.1209136; Raskind WH, 2000, BLOOD, V95, P2262, DOI 10.1182/blood.V95.7.2262.007k32_2262_2268; Raslova H, 2004, J CLIN INVEST, V114, P77, DOI 10.1172/JCI200421197; Sandberg ML, 2005, DEV CELL, V8, P153, DOI 10.1016/j.devcel.2004.12.015; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Stachura DL, 2006, BLOOD, V107, P87, DOI 10.1182/blood-2005-07-2740; Starck J, 2003, MOL CELL BIOL, V23, P1390, DOI 10.1128/MCB.23.4.1390-1402.2003; Stumpf M, 2006, P NATL ACAD SCI USA, V103, P18504, DOI 10.1073/pnas.0604494103; Sun LS, 2004, BLOOD, V103, P948, DOI 10.1182/blood-2003-07-2299; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Talebian L, 2007, BLOOD, V109, P11, DOI 10.1182/blood-2006-05-021188; Tracey WD, 2000, SEMIN CELL DEV BIOL, V11, P337, DOI 10.1006/scdb.2000.0186; Vyas P, 1999, BLOOD, V93, P2867; Walker LC, 2002, BRIT J HAEMATOL, V117, P878, DOI 10.1046/j.1365-2141.2002.03512.x; Waltzer L, 2003, EMBO J, V22, P6516, DOI 10.1093/emboj/cdg622; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; Xu G, 2006, LEUKEMIA, V20, P1002, DOI 10.1038/sj.leu.2404223; Yu CN, 2002, BLOOD, V100, P2040, DOI 10.1182/blood-2002-02-0387	60	36	36	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6795	6802		10.1038/sj.onc.1210762	http://dx.doi.org/10.1038/sj.onc.1210762			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934486				2022-12-28	WOS:000250147000010
J	Pina, C; Enver, T				Pina, C.; Enver, T.			Differential contributions of haematopoietic stem cells to foetal and adult haematopoiesis: insights from functional analysis of transcriptional regulators	ONCOGENE			English	Review						cell fate; self-renewal; foetal liver; bone marrow	ACUTE LYMPHOBLASTIC-LEUKEMIA; GONAD-MESONEPHROS REGION; YOLK-SAC HEMATOPOIESIS; ACUTE MYELOID-LEUKEMIA; CORE-BINDING FACTORS; SELF-RENEWAL; BONE-MARROW; MOUSE EMBRYO; DEFINITIVE HEMATOPOIESIS; MICE LACKING	An increasing number of molecules have been identified as candidate regulators of stem cell fates through their involvement in leukaemia or via post- genomic gene discovery approaches. A full understanding of the function of these molecules requires ( 1) detailed knowledge of the gene networks in which they participate and ( 2) an appreciation of how these networks vary as cells progress through the haematopoietic cell hierarchy. An additional layer of complexity is added by the occurrence of different haematopoietic cell hierarchies at different stages of ontogeny. Beyond these issues of cell context dependence, it is important from a mechanistic point of view to define the particular cell fate pathway impacted by any given regulator. Herein, we advance the notion that haematopoietic stem cells ( HSC), which sustain haematopoiesis throughout adult life and are specified in foetal life, have a minimal or late contribution to foetal haematopoiesis but instead largely proliferate during the foetal period. In light of this notion, we revisit published data on mouse knockouts of haematopoietically- affiliated transcription factors highlighting novel insights that may be gained from taking such a view.	Univ Oxford, MRC Mol Haematol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	Pina, C (corresponding author), Univ Oxford, MRC Mol Haematol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	cpina@gwmail.jr2.ox.ac.uk		Pina, Cristina/0000-0002-2575-6301	MRC [MC_U137973817] Funding Source: UKRI; Medical Research Council [MC_U137973817] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247; Adolfsson J, 2001, IMMUNITY, V15, P659, DOI 10.1016/S1074-7613(01)00220-5; Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Arai S, 2005, EMBO J, V24, P1863, DOI 10.1038/sj.emboj.7600654; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; Bowie MB, 2007, P NATL ACAD SCI USA, V104, P5878, DOI 10.1073/pnas.0700460104; Bowie MB, 2006, J CLIN INVEST, V116, P2808, DOI 10.1172/JCI28310; Bruno L, 2004, MOL CELL BIOL, V24, P741, DOI 10.1128/MCB.24.2.741-756.2004; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Collins EC, 2002, TRENDS MOL MED, V8, P436, DOI 10.1016/S1471-4914(02)02397-3; Cumano A, 2001, IMMUNITY, V15, P477, DOI 10.1016/S1074-7613(01)00190-X; Curtis DJ, 2004, BLOOD, V103, P3342, DOI 10.1182/blood-2003-09-3202; de Bruijn MFTR, 2000, EMBO J, V19, P2465, DOI 10.1093/emboj/19.11.2465; de Bruijn MFTR, 2004, ONCOGENE, V23, P4238, DOI 10.1038/sj.onc.1207763; de Bruijn MFTR, 2002, IMMUNITY, V16, P673, DOI 10.1016/S1074-7613(02)00313-8; de la Grange PB, 2006, BLOOD, V108, P2998, DOI 10.1182/blood-2006-05-022988; Delassus S, 1999, BLOOD, V94, P1495, DOI 10.1182/blood.V94.5.1495.417a08_1495_1503; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Erfurth F, 2004, LEUKEMIA, V18, P92, DOI 10.1038/sj.leu.2403200; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Ernst P, 2004, DEV CELL, V6, P437, DOI 10.1016/S1534-5807(04)00061-9; Forsberg EC, 2006, CELL, V126, P415, DOI 10.1016/j.cell.2006.06.037; Forsberg EC, 2005, PLOS GENET, V1, P281, DOI 10.1371/journal.pgen.0010028; Galan-Caridad JM, 2007, CELL, V129, P345, DOI 10.1016/j.cell.2007.03.014; Gekas C, 2005, DEV CELL, V8, P365, DOI 10.1016/j.devcel.2004.12.016; Godin I, 1999, J EXP MED, V190, P43, DOI 10.1084/jem.190.1.43; Godin I, 2002, NAT REV IMMUNOL, V2, P593, DOI 10.1038/nri857; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Heyworth C, 1999, GENE DEV, V13, P1847, DOI 10.1101/gad.13.14.1847; Hock H, 2006, CURR OPIN HEMATOL, V13, P1, DOI 10.1097/01.moh.0000190111.85284.8f; Hock H, 2004, GENE DEV, V18, P2336, DOI 10.1101/gad.1239604; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Iwasaki H, 2006, GENE DEV, V20, P3010, DOI 10.1101/gad.1493506; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kikuchi K, 2006, P NATL ACAD SCI USA, V103, P17852, DOI 10.1073/pnas.0603368103; Kingsley PD, 2004, BLOOD, V104, P19, DOI 10.1182/blood-2003-12-4162; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kumaravelu P, 2002, DEVELOPMENT, V129, P4891; Lacorazza HD, 2006, CANCER CELL, V9, P175, DOI 10.1016/j.ccr.2006.02.017; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Leroy H, 2005, LEUKEMIA, V19, P329, DOI 10.1038/sj.leu.2403614; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Lessard J, 2004, ONCOGENE, V23, P7199, DOI 10.1038/sj.onc.1207940; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Ling KW, 2004, J EXP MED, V200, P871, DOI 10.1084/jem.20031556; Mansson R, 2007, IMMUNITY, V26, P407, DOI 10.1016/j.immuni.2007.02.013; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; Medvinsky A, 1999, BLOOD, V94, P3613; Medvinsky AL, 1998, DEV COMP IMMUNOL, V22, P289, DOI 10.1016/S0145-305X(98)00007-X; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Miyamoto T, 2002, DEV CELL, V3, P137, DOI 10.1016/S1534-5807(02)00201-0; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Mueller BU, 2006, CURR OPIN HEMATOL, V13, P7, DOI 10.1097/01.moh.0000190110.08156.96; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Naito M, 1996, J LEUKOCYTE BIOL, V59, P133, DOI 10.1002/jlb.59.2.133; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; North T, 1999, DEVELOPMENT, V126, P2563; North TE, 2004, STEM CELLS, V22, P158, DOI 10.1634/stemcells.22-2-158; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477; Ohta H, 2002, J EXP MED, V195, P759, DOI 10.1084/jem.20011911; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osada H., 1997, Leukemia (Basingstoke), V11, P307; Ottersbach K, 2005, DEV CELL, V8, P377, DOI 10.1016/j.devcel.2005.02.001; Palis J, 2001, P NATL ACAD SCI USA, V98, P4528, DOI 10.1073/pnas.071002398; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2002, BLOOD, V99, P488, DOI 10.1182/blood.V99.2.488; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Porse BT, 2005, J EXP MED, V202, P85, DOI 10.1084/jem.20050067; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reynaud D, 2005, BLOOD, V106, P2318, DOI 10.1182/blood-2005-02-0557; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Rodrigues NP, 2005, BLOOD, V106, P477, DOI 10.1182/blood-2004-08-2989; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Rosenbauer F, 2005, BLOOD, V106, P1519, DOI 10.1182/blood-2005-02-0717; Samokhvalov IM, 2007, NATURE, V446, P1056, DOI 10.1038/nature05725; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Shojaei F, 2005, DEV CELL, V8, P651, DOI 10.1016/j.devcel.2005.03.004; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; Soneji S, 2007, ANN NY ACAD SCI, V1106, P30, DOI 10.1196/annals.1392.018; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Taoudi S, 2005, DEVELOPMENT, V132, P4179, DOI 10.1242/dev.01974; Tober J, 2007, BLOOD, V109, P1433, DOI 10.1182/blood-2006-06-031898; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Vander Lugt NM, 1994, GENE DEV, V8, P757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wilpshaar J, 2000, BLOOD, V96, P2100; Wilpshaar J, 2002, BLOOD, V100, P120, DOI 10.1182/blood.V100.1.120; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yoder MC, 1997, BLOOD, V89, P2176, DOI 10.1182/blood.V89.6.2176; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zeng H, 2004, EMBO J, V23, P4116, DOI 10.1038/sj.emboj.7600419; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006	129	17	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	47					6750	6765		10.1038/sj.onc.1210759	http://dx.doi.org/10.1038/sj.onc.1210759			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934483				2022-12-28	WOS:000250147000007
J	Baker, SP; Grant, PA				Baker, S. P.; Grant, P. A.			The SAGA continues: expanding the cellular role of a transcriptional co-activator complex	ONCOGENE			English	Review						SAGA; histone; modification; acetyl transferase; chromatin; transcription	MESSENGER-RNA EXPORT; TATA-BINDING PROTEIN; HISTONE ACETYLTRANSFERASE COMPLEX; NUCLEOTIDE EXCISION-REPAIR; HUMAN STAGA COMPLEX; IN-VIVO; SACCHAROMYCES-CEREVISIAE; NUCLEOSOME ACETYLATION; POLYMERASE-II; DNA-DAMAGE	Throughout the last decade, great advances have been made in our understanding of how DNA-templated cellular processes occur in the native chromatin environment. Proteins that regulate transcription, replication, DNA repair, mitosis and other processes must be targeted to specific regions of the genome and granted access to DNA, which is normally tightly packaged in the higher-order chromatin structure of eukaryotic nuclei. Massive multiprotein complexes have been discovered, which facilitate access to DNA and recruitment of downstream effectors through three distinct mechanisms: chemical modi. cation of histone amino-acid residues, ATP-dependent chromatin remodeling and histone exchange. The yeast Spt-Ada-Gcn5-Acetyl transferase ( SAGA) transcriptional co-activator complex regulates numerous cellular processes through coordination of multiple histone post-translational modi. cations. SAGA is known to generate and interact with a number of histone modi. cations, including acetylation, methylation, ubiquitylation and phosphorylation. Although best characterized for its role in regulating transcriptional activation, SAGA is also required for optimal transcription elongation, mRNA export and perhaps nucleotide excision repair. Here, we discuss findings from recent years that have elucidated the function of this 1.8-MDa complex in multiple cellular processes, and how misregulation of the homologous complexes in humans may ultimately play a role in development of disease.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Grant, PA (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	pag9n@virginia.edu			NCI NIH HHS [T32 CA009109, 5 T32 CA009109-30] Funding Source: Medline; NINDS NIH HHS [R01 NS049065, R01 NS049065-02, NS049065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altaf M, 2007, MUTAT RES-FUND MOL M, V618, P81, DOI 10.1016/j.mrfmmm.2006.09.009; Baker SP, 2005, CELL, V123, P361, DOI 10.1016/j.cell.2005.10.013; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Bu P, 2007, MOL CELL BIOL, V27, P3405, DOI 10.1128/MCB.00066-07; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Cabal GG, 2006, NATURE, V441, P770, DOI 10.1038/nature04752; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cleaver JE, 2000, J DERMATOL SCI, V23, P1, DOI 10.1016/S0923-1811(99)00088-2; Clements A, 2003, MOL CELL, V12, P461, DOI 10.1016/S1097-2765(03)00288-0; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; EISENMANN DM, 1994, GENETICS, V137, P647; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Ferreiro JA, 2006, NUCLEIC ACIDS RES, V34, P976, DOI 10.1093/nar/gkj501; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; GANSHEROFF LJ, 1995, GENETICS, V139, P523; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Govind CK, 2007, MOL CELL, V25, P31, DOI 10.1016/j.molcel.2006.11.020; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Ingvarsdottir K, 2005, MOL CELL BIOL, V25, P1162, DOI 10.1128/MCB.25.3.1162-1172.2005; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; Kinyamu HK, 2005, J MOL ENDOCRINOL, V34, P281, DOI 10.1677/jme.1.01680; Kohler A, 2006, MOL BIOL CELL, V17, P4228, DOI 10.1091/mbc.E06-02-0098; Kulesza CA, 2002, ONCOGENE, V21, P1411, DOI 10.1038/sj.onc.1205201; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Lee KK, 2005, MOL CELL BIOL, V25, P1173, DOI 10.1128/MCB.25.3.1173-1182.2005; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Lo WS, 2005, EMBO J, V24, P997, DOI 10.1038/sj.emboj.7600577; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MARCUS GA, 1996, MOL CELL BIOL, V3197, P16; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; McMahon SJ, 2005, P NATL ACAD SCI USA, V102, P8478, DOI 10.1073/pnas.0503493102; Mitra D, 2006, MOL CELL BIOL, V26, P4095, DOI 10.1128/MCB.01849-05; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Okuda M, 2007, J MOL BIOL, V365, P1047, DOI 10.1016/j.jmb.2006.10.039; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Powell DW, 2004, MOL CELL BIOL, V24, P7249, DOI 10.1128/MCB.24.16.7249-7259.2004; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Reeves WM, 2005, MOL CELL BIOL, V25, P9092, DOI 10.1128/MCB.25.20.9092-9102.2005; Ricci AR, 2002, MOL CELL BIOL, V22, P4033, DOI 10.1128/MCB.22.12.4033-4042.2002; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Shukla A, 2006, MOL CELL BIOL, V26, P3339, DOI 10.1128/MCB.26.9.3339-3352.2006; Shukla A, 2006, NUCLEIC ACIDS RES, V34, P6225, DOI 10.1093/nar/gkl844; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; van Hemert MJ, 2001, YEAST, V18, P889, DOI 10.1002/yea.739; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Wu PYJ, 2004, MOL CELL, V15, P199, DOI 10.1016/j.molcel.2004.06.005; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yu YC, 2005, P NATL ACAD SCI USA, V102, P8650, DOI 10.1073/pnas.0501458102	99	146	151	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5329	5340		10.1038/sj.onc.1210603	http://dx.doi.org/10.1038/sj.onc.1210603			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694076	Green Accepted, Bronze			2022-12-28	WOS:000248674300003
J	Baldwin, RM; Parolin, DAE; Lorimer, IAJ				Baldwin, R. M.; Parolin, D. A. E.; Lorimer, I. A. J.			Regulation of glioblastoma cell invasion by PKC iota and RhoB	ONCOGENE			English	Article						atypical PKC; RhoB; PI 3-kinase; PTEN; glioblastoma	PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN CYTOSKELETON; LUNG-CANCER; GROWTH; LAMBDA; PHOSPHORYLATION; SUPPRESSOR; EXPRESSION; MIGRATION	Glioblastoma multiforme is the most aggressive form of primary brain tumor and remains largely incurable, in large part, due to its highly invasive nature. The phosphoinositide (PI) 3-kinase pathway is often constitutively active in these tumors due to activating mutations in the epidermal growth factor receptor, or deletion/loss of function of the tumor suppressor PTEN. Protein kinase C type iota (PKC iota), a member of the atypical protein kinase C family, is activated by the PI 3-kinase pathway and is an important downstream mediator. Here, we have assessed the role of PKC iota in glioblastoma cell invasion. Depletion of PKC iota with RNA interference caused an increase in actin stress fibers and a decrease in cell motility and invasion. Gene expression microarray analysis of U87MG cells showed that PKC iota repressed expression of mRNA for RhoB, which has previously been shown to have a role in actin stress fiber formation. Western blot analysis showed that both PKC iota depletion and pharmacological inhibition of PKC iota caused an increase in the protein levels of RhoB, as did inhibition of PI 3-kinase. Expression of RhoB from a constitutive promoter caused changes in actin stress fibers and cell invasion that were similar to those seen with PKC iota depletion. These data show that PKC iota, activated as a consequence of aberrant upstream PI 3-kinase signaling, mediates glioblastoma cell motility and invasion, and that repression of RhoB is key downstream event in PKC iota signaling leading to enhanced cell motility. In addition, constitutive expression of RhoB repressed PKC iota activity, as assessed by its phosphorylation status on Thr555. PKC iota and RhoB are, therefore, mutually antagonistic, potentially creating a sensitive switch between invasive and non-invasive phenotypes.	[Baldwin, R. M.; Parolin, D. A. E.; Lorimer, I. A. J.] Ottawa Hlth Res Inst, Ottawa, ON, Canada; [Baldwin, R. M.; Lorimer, I. A. J.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Lorimer, I. A. J.] Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Lorimer, IAJ (corresponding author), Ottawa Hosp, Reg Canc Ctr, Ctr Canc Therapeut, 501 Smyth Rd,3rd Floor, Ottawa, ON K1H 8L6, Canada.	ilorimer@ohri.ca						Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Baldwin RM, 2006, ONCOGENE, V25, P2909, DOI 10.1038/sj.onc.1209312; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Cai XM, 2005, INT J CANCER, V117, P905, DOI 10.1002/ijc.21251; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Gerhard R, 2005, J BIOL CHEM, V280, P1499, DOI 10.1074/jbc.M406014200; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; Huang M, 2006, HISTOL HISTOPATHOL, V21, P213, DOI 10.14670/HH-21.213; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Jin ZJ, 2005, J BIOL CHEM, V280, P16045, DOI 10.1074/jbc.M413488200; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; Lambrechts A, 2004, INT J BIOCHEM CELL B, V36, P1890, DOI 10.1016/j.biocel.2004.01.024; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Messerschmidt A, 2005, J MOL BIOL, V352, P918, DOI 10.1016/j.jmb.2005.07.060; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Sang RL, 2007, CHEM BIOL DRUG DES, V69, P240, DOI 10.1111/j.1747-0285.2007.00502.x; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; Tamura M, 1999, CANCER RES, V59, P442; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Xu LJ, 2006, J BIOL CHEM, V281, P4457, DOI 10.1074/jbc.M510721200; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	37	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3587	3595		10.1038/sj.onc.1211027	http://dx.doi.org/10.1038/sj.onc.1211027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212741				2022-12-28	WOS:000256468500010
J	Lei, M; Erikson, R				Lei, M.; Erikson, Rl			Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint	ONCOGENE			English	Article						checkpoint; DNA damage; nontransformed cell	POLO-LIKE KINASE-1; PROGNOSTIC-SIGNIFICANCE; CANCER-THERAPY; EXPRESSION; POLO-LIKE-KINASE-1; DIFFERENTIATION; TELOMERASE; CARCINOMAS; INHIBITOR; POTENT	We previously reported that polo-like kinase 1 (Plk1) depletion by lentivirus-based RNA interference led to mitotic arrest and apoptosis in cancer cells, whereas normal diploid cell lines, hTERT-RPE1 and MCF10A, survived a similar level of depletion. To study homogeneous cell lines, we generated several Plk1-depleted hTERT-RPE1 and MCF10A clones that were derived from single cells depleted of Plk1. We found that in the longterm, Plk1 depletion slowed proliferation of hTERT-RPE1 cells, apparently due to attenuated progression through S phase. These cells had altered morphology and were elongated compared with control. In contrast, MCF10A clones with mild levels of depletion showed no obvious phenotype. They appeared to have normal proliferation rates with no cell-cycle arrest. However, one MCF10A clone, which was severely depleted of Plk1, although viable, showed sporadic G2/M arrest and apoptosis. This MCF10A clone and all the hTERT-RPE1 clones displayed evidence of DNA-damage checkpoint activation. These data further support the interpretation that cancer cell lines have a much greater requirement for Plk1 than normal nontransformed diploid cells.	[Lei, M.; Erikson, Rl] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Lei, M (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Biolabs Room 2048,16 Divin Ave, Cambridge, MA 02138 USA.	minglei@fas.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059172] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59172] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Angelis KJ, 1999, ELECTROPHORESIS, V20, P2133, DOI 10.1002/(SICI)1522-2683(19990701)20:10<2133::AID-ELPS2133>3.0.CO;2-Q; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736; GERDES J, 1984, J IMMUNOL, V133, P1710; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Rak DJ, 2006, EXP EYE RES, V82, P648, DOI 10.1016/j.exer.2005.09.002; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SOULE HD, 1990, CANCER RES, V50, P6075; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tsvetkov L, 2005, J BIOL CHEM, V280, P11943, DOI 10.1074/jbc.M413514200; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862	29	40	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					3935	3943		10.1038/onc.2008.36	http://dx.doi.org/10.1038/onc.2008.36			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18297112				2022-12-28	WOS:000257089000005
J	Liu, D; Evans, I; Britton, G; Zachary, I				Liu, D.; Evans, I.; Britton, G.; Zachary, I.			The zinc-finger transcription factor, early growth response 3, mediates VEGF-induced angiogenesis	ONCOGENE			English	Article						nuclear receptors; Nur77; protein kinase C; broblast growth factor	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION PATHWAY; FOCAL ADHESION KINASE; FACTOR EGR3; TYROSINE PHOSPHORYLATION; PROSTACYCLIN PRODUCTION; REGULATORY FACTORS; ACTIVATION; CELLS	Early growth response 3 (Egr3) is a member of a zinc-finger transcription factor subfamily, which we previously found to be strongly upregulated by vascular endothelial growth factor (VEGF)-A in an oligonucleotide microarray screen of endothelial cells. Here, we show that Egr3 is the predominant Egr family member upregulated by VEGF in endothelial cells at 45 min, and that VEGF induced a rapid increase in Egr-dependent transcriptional activation mediated via its major signalling receptor, VEGFR2/KDR, and the protein kinase C (PKC) pathway. VEGF-induced Egr3 gene expression was also mediated in part via a PKC-dependent activation of protein kinase D. Inhibition of Egr3 gene expression by RNA interference was effective in inhibiting basal and VEGF-induced Egr3 gene expression, and it also inhibited VEGF-mediated endothelial cell proliferation, migration and tubulogenesis. These findings indicate that Egr3 has an essential downstream role in VEGF-mediated endothelial functions leading to angiogenesis and may have particular relevance for adult angiogenic processes involved in vascular repair and neovascular disease.	[Liu, D.; Evans, I.; Britton, G.; Zachary, I.] UCL, BHF Labs, Dept Med, London WC1E 6JJ, England; [Liu, D.] UCL, Dept Med, Ark Therapeut Ltd, London, England	University of London; University College London; University of London; University College London	Zachary, I (corresponding author), UCL, BHF Labs, Dept Med, Rayne Bldg 5 Univ St, London WC1E 6JJ, England.	I.Zachary@ucl.ac.uk	Evans, Ian/C-8533-2009	Evans, Ian/0000-0002-0468-8274	British Heart Foundation [RG/06/003/21131] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Arkenbout EK, 2003, ARTERIOSCL THROM VAS, V23, P1535, DOI 10.1161/01.ATV.0000084639.16462.7A; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Carter JH, 2007, J IMMUNOL, V178, P3038, DOI 10.4049/jimmunol.178.5.3038; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; Inoue A, 2004, J MOL ENDOCRINOL, V32, P649, DOI 10.1677/jme.0.0320649; Jia HY, 2001, BIOCHEM BIOPH RES CO, V283, P164, DOI 10.1006/bbrc.2001.4761; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Levkovitz Y, 2001, J NEUROSCI, V21, P45, DOI 10.1523/JNEUROSCI.21-01-00045.2001; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Mercier G, 2001, MOL BRAIN RES, V97, P137, DOI 10.1016/S0169-328X(01)00311-4; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; O'Donovan KJ, 1998, J NEUROCHEM, V70, P1241; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Qin LL, 2006, J BIOL CHEM, V281, P32550, DOI 10.1074/jbc.M604853200; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Safford M, 2005, NAT IMMUNOL, V6, P472, DOI 10.1038/ni1193; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tourtellotte WG, 1998, NAT GENET, V20, P87, DOI 10.1038/1757; Tourtellotte WG, 2001, DEV BIOL, V232, P388, DOI 10.1006/dbio.2001.0202; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Xi HK, 2004, J IMMUNOL, V173, P340, DOI 10.4049/jimmunol.173.1.340; Xi HK, 2004, J IMMUNOL, V172, P964, DOI 10.4049/jimmunol.172.2.964; Xi HK, 2006, IMMUNITY, V24, P813, DOI 10.1016/j.immuni.2006.03.023; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	38	51	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					2989	2998		10.1038/sj.onc.1210959	http://dx.doi.org/10.1038/sj.onc.1210959			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059339				2022-12-28	WOS:000255681700006
J	Kim, S; Park, SY; Yong, H; Famulski, JK; Chae, S; Lee, JH; Kang, CM; Saya, H; Chan, GK; Cho, H				Kim, S.; Park, S-Y; Yong, H.; Famulski, J. K.; Chae, S.; Lee, J-H; Kang, C-M; Saya, H.; Chan, G. K.; Cho, H.			HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint	ONCOGENE			English	Article						HBV X; BubR1; chromosome instability; mitotic checkpoint	ANAPHASE-PROMOTING COMPLEX; CENTROSOME AMPLIFICATION; CHROMOSOMAL INSTABILITY; TUMOR-DEVELOPMENT; BUBR1; CELLS; ONCOPROTEIN; INHIBITION; REGULATOR; MAD2	Accurate chromosomal segregation is monitored by the mitotic checkpoint, and an increased rate of chromosomal missegregation leads to chromosomal instability (CIN). Here, we demonstrate that the HBV X protein (HBx) binds BubR1, a component of the mitotic checkpoint complex and co-localizes with BubR1 at the kinetochores. HBx binding to BubR1 attenuates the association between BubR1 and CDC20, an activator of the anaphase-promoting complex/cyclosome (APC/C) and induces slippage of mitotic arrest in the presence of microtubule poisons. In addition, HBx binding to BubR1 results in the accumulation of lagging chromosomes and chromosome bridges. In contrast, a C-terminally truncated HBx mutant (HBx(1-100)) fails to bind BubR1 and does not cause aberrant chromosomal segregation. This provides a novel mechanism for dysregulation of the mitotic checkpoint by a viral pathogen linking it to the accumulation of chromosomal instability in HBV-associated hepa tocarcinogenesis.	[Kim, S.; Park, S-Y; Yong, H.; Chae, S.; Lee, J-H; Cho, H.] Ajou Univ, Dept Biochem, Sch Med, Suwon 443721, Kyunggi Do, South Korea; [Famulski, J. K.; Chan, G. K.] Univ Alberta, Dept Oncol, Cross Canc Inst, Edmonton, AB, Canada; [Kang, C-M] Korea Inst Radiol & Med Sci, Seoul, South Korea; [Saya, H.] Keio Univ, Sch Med, Div Gene Regulat, Inst Adv Med Res, Tokyo, Japan	Ajou University; University of Alberta; Korea Institute of Radiological & Medical Sciences; Keio University	Cho, H (corresponding author), Ajou Univ, Dept Biochem, Sch Med, 5 Wonchon Dong, Suwon 443721, Kyunggi Do, South Korea.	gkc@ualberta.ca; hscho@ajou.ac.kr	Chan, Gordon/AAN-7784-2020; Saya, Hideyuki/J-4325-2013	Chan, Gordon/0000-0003-0497-9407; Cho, Hyeseong/0000-0002-4672-8887				Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Cotsiki M, 2004, P NATL ACAD SCI USA, V101, P947, DOI 10.1073/pnas.0308006100; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Forgues M, 2003, MOL CELL BIOL, V23, P5282, DOI 10.1128/MCB.23.15.5282-5292.2003; Fujii R, 2006, CANCER RES, V66, P9099, DOI 10.1158/0008-5472.CAN-06-1886; Gollin SM, 2004, CURR OPIN ONCOL, V16, P25, DOI 10.1097/00001622-200401000-00006; HENDERSON AS, 1988, CANCER GENET CYTOGEN, V30, P269, DOI 10.1016/0165-4608(88)90194-X; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kim S, 2007, J VIROL, V81, P1714, DOI 10.1128/JVI.01863-06; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee S, 2002, J BIOL CHEM, V277, P8730, DOI 10.1074/jbc.M108025200; Lin Y, 1997, CANCER RES, V57, P5137; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Madden CR, 2001, DIS MARKERS, V17, P153, DOI 10.1155/2001/571254; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood-2003-06-2158; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Yun C, 2004, MOL CANCER RES, V2, P159	28	57	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3457	3464		10.1038/sj.onc.1210998	http://dx.doi.org/10.1038/sj.onc.1210998			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193091				2022-12-28	WOS:000256309900010
J	Peak, JC; Jones, NP; Hobbs, S; Katan, M; Eccles, SA				Peak, J. C.; Jones, N. P.; Hobbs, S.; Katan, M.; Eccles, S. A.			Phospholipase C gamma 1 regulates the Rap GEF1-Rap1 signalling axis in the control of human prostate carcinoma cell adhesion	ONCOGENE			English	Article						phospholipase c gamma 1; rap GEF1; Rap1; adhesion	C-GAMMA-L; INTEGRIN ALPHA(2)BETA(1); ACTIVATION; RECEPTOR; REQUIREMENT; PLC-GAMMA-1; KINASES; COMPLEX; FAMILY; C3G	C gamma 1 (PLC gamma 1) is activated downstream of a variety of extracellular stimuli and has previously been implicated in the regulation of motility responses central to tumour cell invasion. In this study, we used a novel RNAi vector system to achieve conditional PLC gamma 1 knockdown in PC3LN3 human prostate carcinoma cells for further evaluation of PLC gamma 1 in tumour cell biology. Using this approach, we revealed a role for PLC gamma 1 in the regulation of PC3LN3 cell adhesion that appears to be independent of its effects on tumour cell chemotactic migration and spreading in response to extracellular matrix. Subsequent microarray analysis of PLC gamma 1-knockdown cells revealed Rap GEF1 mRNA to be decreased in response to PLC gamma 1 loss. This translated into a decrease in Rap GEF1 protein levels and a significant loss of Rap1 activity in PLC gamma 1-knockdown cells. Transient knockdown of Rap GEF1 caused a reduction in PC3LN3 adhesion while overexpression of Rap GEF1 rescued the PLC gamma 1 knockdown-induced adhesion defect. These data highlight control of the Rap GEF1-Rap1 molecular switch as a specific requirement for PLC gamma 1-mediated tumour cell adhesion.	[Eccles, S. A.] Canc Res UK Ctr Canc Therapeut, Inst Canc Res, McElwain Labs, Sutton SM2 5NG, Surrey, England; [Jones, N. P.; Katan, M.] Canc Res UK Ctr Cell & Mol Biol, Inst Canc Res, Sutton, Surrey, England	Cancer Research UK; University of London; Institute of Cancer Research - UK; Cancer Research UK; University of London; Institute of Cancer Research - UK	Eccles, SA (corresponding author), Canc Res UK Ctr Canc Therapeut, Inst Canc Res, McElwain Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	Sue.Eccles@icr.ac.uk			Cancer Research UK Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adams JC, 2001, CELL MOL LIFE SCI, V58, P371, DOI 10.1007/PL00000864; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Aydar E, 2006, CANCER LETT, V242, P245, DOI 10.1016/j.canlet.2005.11.011; Bernardi B, 2006, BLOOD, V107, P2728, DOI 10.1182/blood-2005-07-3023; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Choi JH, 2007, CELL SIGNAL, V19, P1784, DOI 10.1016/j.cellsig.2007.04.002; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; Han JW, 2006, CURR BIOL, V16, P1796, DOI 10.1016/j.cub.2006.08.035; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Jones NP, 2007, MOL CELL BIOL, V27, P5790, DOI 10.1128/MCB.00778-07; Jones NP, 2005, J CELL SCI, V118, P2695, DOI 10.1242/jcs.02374; Katagiri K, 2004, J BIOL CHEM, V279, P11875, DOI 10.1074/jbc.M310717200; Mamoune A, 2004, EXP CELL RES, V299, P91, DOI 10.1016/j.yexcr.2004.05.008; Manos EJ, 2001, ONCOGENE, V20, P2781, DOI 10.1038/sj.onc.1204379; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Nogami M, 2003, FEBS LETT, V536, P71, DOI 10.1016/S0014-5793(03)00013-9; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Piechulek T, 2005, J BIOL CHEM, V280, P38923, DOI 10.1074/jbc.M509396200; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Regunathan J, 2006, J IMMUNOL, V177, P5365, DOI 10.4049/jimmunol.177.8.5365; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shepard CR, 2007, ONCOGENE, V26, P3020, DOI 10.1038/sj.onc.1210115; Turner T, 1997, CLIN CANCER RES, V3, P2275; Tvorogov D, 2005, J CELL SCI, V118, P601, DOI 10.1242/jcs.01643; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang ZP, 2006, MOL CELL BIOL, V26, P2130, DOI 10.1128/MCB.26.6.2130-2145.2006; Wells A, 2000, ADV CANCER RES, V78, P31; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	30	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2008	27	20					2823	2832		10.1038/sj.onc.1210954	http://dx.doi.org/10.1038/sj.onc.1210954			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037957				2022-12-28	WOS:000255502500003
J	Szabova, L; Chrysovergis, K; Yamada, SS; Holmbeck, K				Szabova, L.; Chrysovergis, K.; Yamada, S. S.; Holmbeck, K.			MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease	ONCOGENE			English	Article						MT1-MMP; PyMT; mammary cancer; metastasis; collagen; proteolysis	MATRIX METALLOPROTEINASES; PERICELLULAR PROTEOLYSIS; EXTRACELLULAR-MATRIX; BREAST CARCINOMAS; CANCER INVASION; DEFICIENT MICE; MEMBRANE; EXPRESSION; CELLS; ANGIOGENESIS	Membrane-type I matrix metalloproteinase (MT1-MMP) is associated with multiple forms of cancer including mammary cancer. To directly evaluate the significance of MT1-MMP expression in tumor progression and metastasis using a genetically induced cancer model, we crossed MT1-MMP-deficient mice to MMTV-polyoma virus middle T-antigen (PyMT) mice. Expression of PyMT in the MT1-MMP-deficient background consistently resulted in hyperplasia of the mammary gland as seen in wild-type PyMT littermates. Following orthotopic transplantation of PyMT + glands into the cleared mammary fat pad of syngeneic recipient mice, MT1-MMP-deficient tumors were palpable earlier than wild-type tumors. Moreover, MT1-MMP-deficient tumors grew to the experimental end point size quicker than control tumors, but demonstrated markedly reduced ability to metastasize to the lungs of recipient mice. Accordingly, MT1-MMP deficient mice displayed an overall reduction in metastasis count of 50%. MT1-MMP was expressed solely in the stroma of PyMT-induced tumors and those metastatic nodules that formed in the lungs were devoid of MT1-MMP expression. Stromal fibbroblasts isolated from MT1-MMP-deficient tumors did not degrade type I collagen suggesting that efficient dissemination of tumor cells is dependent on stromal cell remodeling of the tumor environment. The data demonstrate directly that MT1-MMP-mediated proteolysis by stromal cells is important in the metastatic process.	[Szabova, L.; Chrysovergis, K.; Yamada, S. S.; Holmbeck, K.] Natl Inst Dent & Craniofacial Res, Matrix Metalloproteinase Unit, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Holmbeck, K (corresponding author), Natl Inst Dent & Craniofacial Res, Matrix Metalloproteinase Unit, Craniofacial & Skeletal Dis Branch, NIH, Bldg 30,Room 125,30 Convent Dr,MSC 4380, Bethesda, MD 20892 USA.	kenn.holmbeck@nih.gov		Holmbeck, Kenn/0000-0002-4472-3257	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000676] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andarawewa KL, 2003, CANCER RES, V63, P5844; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Bisson C, 2003, INT J CANCER, V105, P7, DOI 10.1002/ijc.11012; Blavier L, 2001, MOL BIOL CELL, V12, P1457, DOI 10.1091/mbc.12.5.1457; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Holmbeck K, 2003, J CELL BIOL, V163, P661, DOI 10.1083/jcb.200307061; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Itoh T, 1998, CANCER RES, V58, P1048; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; McCawley LJ, 2004, CANCER RES, V64, P6965, DOI 10.1158/0008-5472.CAN-04-0910; Murphy G, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar572; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Pedersen TX, 2005, CARCINOGENESIS, V26, P1233, DOI 10.1093/carcin/bgi065; Pendas AM, 2004, MOL CELL BIOL, V24, P5304, DOI 10.1128/MCB.24.12.5304-5313.2004; Polette M, 1996, VIRCHOWS ARCH, V428, P29; Polette M, 1997, CLIN EXP METASTAS, V15, P157, DOI 10.1023/A:1018404927753; Ricard-Blum S, 2005, PATHOL BIOL, V53, P430, DOI 10.1016/j.patbio.2004.12.024; Rosenthal EL, 2004, ARCH OTOLARYNGOL, V130, P943, DOI 10.1001/archotol.130.8.943; Seiki M, 2003, CANCER SCI, V94, P569, DOI 10.1111/j.1349-7006.2003.tb01484.x; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Szabova L, 2005, J CELL PHYSIOL, V205, P123, DOI 10.1002/jcp.20385; Tran KT, 2005, J DERMATOL SCI, V40, P11, DOI 10.1016/j.jdermsci.2005.05.001; Ueno H, 1997, CANCER RES, V57, P2055; Vizoso FJ, 2007, BRIT J CANCER, V96, P903, DOI 10.1038/sj.bjc.6603666; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Winkler MK, 2002, AM J PHYSIOL-LUNG C, V283, pL1, DOI 10.1152/ajplung.00489.2001; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97	38	64	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3274	3281		10.1038/sj.onc.1210982	http://dx.doi.org/10.1038/sj.onc.1210982			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18071307				2022-12-28	WOS:000256111400006
J	Colomba, A; Courilleau, D; Ramel, D; Billadeau, DD; Espinos, E; Delsol, G; Payrastre, B; Gaits-Iacovoni, F				Colomba, A.; Courilleau, D.; Ramel, D.; Billadeau, D. D.; Espinos, E.; Delsol, G.; Payrastre, B.; Gaits-Iacovoni, F.			Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas	ONCOGENE			English	Article						anaplastic large cell lymphomas; NPM-ALK; Rho GTPases; Vav3	RHO-GTPASES; TYROSINE KINASE; PROTEINS; EXPRESSION; IDENTIFICATION; PROLIFERATION; TRANSLOCATION; ASSOCIATION; INHIBITION; APOPTOSIS	The majority of anaplastic large cell lymphomas (ALCLs) express the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion protein, which is oncogenic due to its constitutive tyrosine kinase activity. Transformation by NPM-ALK not only increases proliferation, but also modifies cell shape and motility in both lymphoid and fibroblastic cells. We report that the Rac1 GTPase, a known cytoskeletal regulator, is activated by NPM-ALK in ALCL cell lines (Karpas 299 and Cost) and transfected cells (lymphoid Ba/F3 cells, NIH-3T3 fibroblasts). We have identified Vav3 as one of the exchange factors involved in Rac1 activation. Stimulation of Vav3 and Rac1 by NPM-ALK is under the control of Src kinases. It involves formation of a signaling complex between NPM-ALK, pp60(c-src), Lyn and Vav3, in which Vav3 associates with tyrosine 343 of NPM-ALK via its SH2 domain. Moreover, Vav3 is phosphorylated in NPM-ALK positive biopsies from patients suffering from ALCL, demonstrating the pathological relevance of this observation. The use of Vav3-specific shRNA and a dominant negative Rac1 mutant demonstrates the central role of GTPases in NPM-ALK elicited motility and invasion.	[Colomba, A.; Courilleau, D.; Ramel, D.; Espinos, E.; Delsol, G.; Payrastre, B.; Gaits-Iacovoni, F.] CHU Purpan, Ctr Physiopathol Toulouse Purpan, INSERM,U563, Dpt Oncogenese Signalisat & Innovat Theraperut, F-31024 Toulouse 3, France; [Colomba, A.; Courilleau, D.; Ramel, D.; Espinos, E.; Delsol, G.; Payrastre, B.; Gaits-Iacovoni, F.] Univ Toulouse III Paul Sabatier, IFR30, Toulouse, France; [Billadeau, D. D.] Mayo Clin, Coll Med, Div Dev Oncol Res, Rochester, MN USA; [Billadeau, D. D.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN USA	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Mayo Clinic; Mayo Clinic	Gaits-Iacovoni, F (corresponding author), CHU Purpan, Ctr Physiopathol Toulouse Purpan, INSERM,U563, Dpt Oncogenese Signalisat & Innovat Theraperut, BP 3028, F-31024 Toulouse 3, France.	frgaits@toulouse.inserm.fr	Espinos, Estelle/A-4661-2015	Espinos, Estelle/0000-0002-5693-8941; , Bernard/0000-0002-8693-0190; Colomba, Audrey/0000-0002-5612-8519; Gaits-Iacovoni, Frederique/0000-0002-9853-0442				Ambrogio C, 2005, BLOOD, V106, P3907, DOI 10.1182/blood-2005-03-1204; Amin HM, 2003, ONCOGENE, V22, P5399, DOI 10.1038/sj.onc.1206849; Armstrong F, 2004, ONCOGENE, V23, P6071, DOI 10.1038/sj.onc.1207813; Aznar S, 2004, CANCER LETT, V206, P181, DOI 10.1016/j.canlet.2003.08.035; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; Benard V, 2002, METHOD ENZYMOL, V345, P349; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Charvet C, 2005, J BIOL CHEM, V280, P15289, DOI 10.1074/jbc.M500275200; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Cho YJ, 2005, MOL CELL BIOL, V25, P5777, DOI 10.1128/MCB.25.13.5777-5785.2005; Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Crockett DK, 2004, ONCOGENE, V23, P2617, DOI 10.1038/sj.onc.1207398; Cussac D, 2004, BLOOD, V103, P1464; Cussac D, 2006, PROTEOMICS, V6, P3210, DOI 10.1002/pmic.200500647; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; Fawal M, 2006, BLOOD, V108, P2780, DOI 10.1182/blood-2006-04-014902; Fritz G, 2006, CURR CANCER DRUG TAR, V6, P1, DOI 10.2174/156800906775471752; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Genth H, 2006, FEBS LETT, V580, P3565, DOI 10.1016/j.febslet.2006.04.100; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Honorat JF, 2006, BLOOD, V107, P4130, DOI 10.1182/blood-2005-06-2421; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Lamant L, 2004, LEUKEMIA, V18, P1693, DOI 10.1038/sj.leu.2403464; Lamant L, 1996, BLOOD, V87, P284; Lamant L, 2007, BLOOD, V109, P2156, DOI 10.1182/blood-2006-06-028969; Lim MS, 2006, MOL CELL PROTEOMICS, V5, P1787, DOI 10.1074/mcp.R600005-MCP200; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Llorca O, 2005, EMBO J, V24, P1330, DOI 10.1038/sj.emboj.7600617; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Petit P, 2003, CELL MICROBIOL, V5, P761, DOI 10.1046/j.1462-5822.2003.00309.x; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; Thompson MA, 2005, HUM PATHOL, V36, P494, DOI 10.1016/j.humpath.2005.03.004; Titus B, 2005, CRIT REV EUKAR GENE, V15, P103, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.20; Zakaria S, 2004, J EXP MED, V199, P429, DOI 10.1084/jem.20031228; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	47	44	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2728	2736		10.1038/sj.onc.1210921	http://dx.doi.org/10.1038/sj.onc.1210921			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998938				2022-12-28	WOS:000255259500007
J	Huang, CC; Wang, JM; Kikkawa, U; Mukai, H; Shen, MR; Morita, I; Chen, BK; Chang, WC				Huang, C-C; Wang, J-M; Kikkawa, U.; Mukai, H.; Shen, M-R; Morita, I.; Chen, B-K; Chang, W-C			Calcineurin-mediated dephosphorylation of c-Jun Ser-243 is required for c-Jun protein stability and cell transformation	ONCOGENE			English	Article						calcineurin; c-jun; dephosphorylation; cell transformation	AP-1 ACTIVITY; DNA-BINDING; KINASE; PHOSPHORYLATION; TUMORIGENESIS; COOPERATION; EXPRESSION; REGULATOR	The proto-oncogene c-Jun plays an important role in regulating tumor progression. We previously reported that the serine/ threonine phosphatase calcineurin ( CaN, also called PP2B) dephosphorylates the C- terminus ( Ser- 243) of c- Jun, resulting in the increase in c- Jun and Sp1 interaction, and subsequent c- Jun- induced gene expression. Here, we demonstrate the interaction of c- Jun and CaN in the nucleus of living cells by fluorescence resonance energy transfer assay and that this interaction is mediated through the calmodulin- binding domain of CaN. Furthermore, c- Jun protein stability was altered by CaN- mediated dephosphorylation at the Ser- 243 site of c-Jun. The half-life of the c-Jun mutant, c-Jun-S243A was longer than that of the wild-type c- Jun. Moreover, silencing of endogenous CaN expression led to increased c- Jun ubiquitination and decreased stability. In 46% of clinical cervical tissue samples obtained from patients with cervical cancer, enhanced c- Jun and CaN expression, as well as decreased phospho-Ser-243 expression levels were detected. Our results suggest that CaN stabilizes c- Jun by dephosphorylating c-Jun at Ser-243 to enhance its tumorigenic ability.	[Wang, J-M; Chen, B-K] Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Biosignal Transduct, Tainan 701, Taiwan; [Huang, C-C; Wang, J-M; Shen, M-R; Chen, B-K; Chang, W-C] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; [Wang, J-M; Shen, M-R; Chen, B-K; Chang, W-C] Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct, Tainan 701, Taiwan; [Kikkawa, U.; Mukai, H.] Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 657, Japan; [Morita, I.] Tokyo Med & Dent Univ, Grad Sch, Dept Cellular Physiol Chem, Bunkyo Ku, Tokyo, Japan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Kobe University; Tokyo Medical & Dental University (TMDU)	Chen, BK (corresponding author), Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Biosignal Transduct, Tainan 701, Taiwan.	bkchen58@mail.ncku.edu.tw; wcchang@mail.ncku.edu.tw	wang, ju-ming/A-1875-2011	Mukai, Hideyuki/0000-0002-0167-8695				Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Chen BK, 2007, MOL BIOL CELL, V18, P1118, DOI 10.1091/mbc.E06-09-0797; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; GOTO S, 1987, CANCER-AM CANCER SOC, V60, P2948, DOI 10.1002/1097-0142(19871215)60:12<2948::AID-CNCR2820601217>3.0.CO;2-N; Hou Q, 2004, FEBS LETT, V577, P294, DOI 10.1016/j.febslet.2004.10.002; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Lakshmikuttyamma A, 2005, J CELL BIOCHEM, V95, P731, DOI 10.1002/jcb.20437; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nomura T, 2002, UROL RES, V30, P102, DOI 10.1007/s00240-002-0239-4; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; WONG WY, 1992, ONCOGENE, V7, P2077	22	27	29	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2422	2429		10.1038/sj.onc.1210888	http://dx.doi.org/10.1038/sj.onc.1210888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17952113				2022-12-28	WOS:000254844900007
J	Finckenstein, FG; Shahbazian, V; Davicioni, E; Ren, YX; Anderson, MJ				Finckenstein, F. Graf; Shahbazian, V.; Davicioni, E.; Ren, Y-X; Anderson, M. J.			PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis	ONCOGENE			English	Article						rhabdomyosarcoma; PAX-FKHR; MyoD; pangene	DNA-BINDING DOMAIN; ALVEOLAR RHABDOMYOSARCOMAS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; CELL-CYCLE; PAX3-FKHR; DIFFERENTIATION; MYOD; PROTEINS; IDENTIFICATION	Alveolar rhabdomyosarcomas (ARMS) escape terminal differentiation despite exhibiting a skeletal muscle phenotype. To understand the role of the ARMS-specific PAX-FKHR proteins in myogenesis, we characterized their regulation of MyoD expression and function. Reporter assays show that PAX-FKHR transactivate MyoD expression through its 258 bp core enhancer. Gel-shift assays confirm that PAX-FKHR bind to core enhancer sequences showing similarity to consensus PAX3/PAX-FKHR-binding sites. We show that while PAX3-FKHR activates the expression of endogenous MyoD and myogenin proteins in transduced NIH3T3 fibroblasts, it inhibits them from terminally differentiating as shown by low myogenin and myosin heavy chain expression, and lack of myotube formation. Attenuation of MyoD transcriptional activity via phosphorylation coupled to the lack of cell cycle arrest is the underlying mechanism for the differentiation block. Lastly, we show that fibroblast growth factor receptor signaling likely mediates the inhibition of differentiation by PAX3-FKHR. In a single experimental system we demonstrate that PAX3-FKHR can simultaneously induce myogenesis while preventing its completion. We propose a model whereby PAX-FKHR commit a yet undefined precursor cell to the myogenic lineage while at the same time inhibit terminal differentiation, thereby contributing to ARMS formation.	[Finckenstein, F. Graf; Shahbazian, V.; Ren, Y-X; Anderson, M. J.] Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA 90027 USA; [Davicioni, E.; Anderson, M. J.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA	Children's Hospital Los Angeles; University of Southern California	Anderson, MJ (corresponding author), Childrens Hosp Los Angeles, Saban Res Inst, Dept Pathol & Lab Med, 4650 Sunset Blvd,MS103, Los Angeles, CA 90027 USA.	manderson@chla.usc.edu		Davicioni, Elai/0000-0001-9136-099X				Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lang D, 2005, NATURE, V433, P884, DOI 10.1038/nature03292; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Liu LN, 1998, CELL GROWTH DIFFER, V9, P699; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; SCHMIDT D, 1986, VIRCHOWS ARCH A, V409, P183, DOI 10.1007/BF00708327; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958	27	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2004	2014		10.1038/sj.onc.1210835	http://dx.doi.org/10.1038/sj.onc.1210835			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922034				2022-12-28	WOS:000254359100005
J	Massimi, P; Shai, A; Lambert, P; Banks, L				Massimi, P.; Shai, A.; Lambert, P.; Banks, L.			HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background	ONCOGENE			English	Article						HPV E6; p53; PDZ; E6AP; proteasome	HUMAN-PAPILLOMAVIRUS E6; UBIQUITIN-PROTEIN LIGASE; LARGE TUMOR-SUPPRESSOR; MEDIATED DEGRADATION; ADENOVIRUS E4-ORF1; EPITHELIAL-CELLS; IN-VIVO; ONCOPROTEIN; TARGET; TYPE-16	Human papillomavirus(HPV) type 16 and 18 E6 proteins target many of their cellular substrates for proteasome-mediated degradation. In the case of p53, this is mediated by the E6AP ubiquitin ligase. However it is still unclear whether other E6 substrates, in particular those containing PDZ domains, are also degraded in a similar manner. To investigate this, we established an epithelial cell line from E6AP-null mice and used these cells as a background to perform E6-mediated in vivo degradation assays. We show that the PDZ domain-containing substrates of E6, including Scribble, MAGI-1 and MAGI-3, are all subject to E6-mediated degradation in these cells. Strikingly, we also found that p53 could be degraded by E6 within these cells in a proteasome-dependent manner. These results demonstrate that HPV-16 and -18 E6 can target substrates for degradation in a manner independent of the E6AP ubiquitin ligase.	[Massimi, P.; Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, TS, Italy; [Shai, A.; Lambert, P.] Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Wisconsin System; University of Wisconsin Madison	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, TS, Italy.	banks@icgeb.org			NCI NIH HHS [CA022443, CA098428] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443, R01CA098428] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Camus S, 2007, ONCOGENE, V26, P4059, DOI 10.1038/sj.onc.1210188; Cooper B, 2003, VIROLOGY, V306, P87, DOI 10.1016/S0042-6822(02)00012-0; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Grm HS, 2004, J GEN VIROL, V85, P2815, DOI 10.1099/vir.0.80035-0; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CH, 2004, J VIROL, V78, P12366, DOI 10.1128/JVI.78.22.12366-12377.2004; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shai A, 2007, CANCER RES, V67, P1626, DOI 10.1158/0008-5472.CAN-06-3344; Storrs CH, 2007, J VIROL, V81, P4080, DOI 10.1128/JVI.02545-06; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	29	69	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1800	1804		10.1038/sj.onc.1210810	http://dx.doi.org/10.1038/sj.onc.1210810			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17934525				2022-12-28	WOS:000253962100016
J	Warnock, LJ; Adamson, R; Lynch, CJ; Milner, J				Warnock, L. J.; Adamson, R.; Lynch, C. J.; Milner, J.			Crosstalk between site-specific modifications on p53 and histone H3	ONCOGENE			English	Article						p53 protein; histone H3; phosphorylation; acetylation; methylation	TUMOR-SUPPRESSOR PROTEIN; POSTTRANSLATIONAL MODIFICATIONS; LYSINE METHYLATION; DNA-DAMAGE; PHOSPHORYLATION; ACTIVATION; ACETYLATION; BINDING; REPAIR; TRANSCRIPTION	Previously, we have observed a link between p53 expression and histone H3 post-translational modifications. Here, we ask if specific post-translational modifications of p53 impact upon histone H3 modi. cations in a selective manner. We have also screened for internal co-operative effects within the repertoire of p53 modi. cations. Exogenous p53 constructs were expressed in HCT116 p53(-/-) cells. Four mutant p53 constructs were used, with single 'phosphorylation' mutations at serines 15 and 37 (S15A, S15D, S37A and S37D) and compared with exogenously expressed wild-type p53. The results showed that the replacement of serine 15 with either alanine (S15A) or aspartic acid (S15D) induced phosphorylation at S33P, S37P and S46P. In contrast, phosphorylation mutants p53(S37A) and p53(S37D) were not phosphorylated on S33. S46 phosphorylation appeared specifically enhanced by p53(S37D) relative to p53(S37A). Distal induction of S392 phosphorylation was observed for each of the p53 N-terminal phosphorylation mutants. Analysis of endogenous histone H3 (from the transfected cells) revealed loss of di-methylated K9 following expression of wild type and mutant p53 constructs. Expression of p53 (S15A), (S15D) and (S37A) selectively induced acetylation at K9 and K14. In contrast, wt p53 and p53(S37D) had no effect upon K9 or K14 acetylation. K18 acetylation status was unaffected throughout.	[Warnock, L. J.; Adamson, R.; Lynch, C. J.; Milner, J.] Univ York, YCR P53 Res Grp, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK	Warnock, LJ (corresponding author), Univ York, YCR P53 Res Grp, Dept Biol, Zone 2, York YO10 5DD, N Yorkshire, England.	ljw7@york.ac.uk	Lynch, Cian/AIC-5510-2022; Lynch, Christopher J./E-6875-2010; Lynch, Cian J/K-2191-2017	Lynch, Cian/0000-0003-0187-3527; Lynch, Christopher J./0000-0003-2453-5838; Lynch, Cian J/0000-0003-0187-3527				Allison SJ, 2003, CANCER RES, V63, P6674; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Morgunkova A, 2006, CELL CYCLE, V5, P1308, DOI 10.4161/cc.5.12.2820; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; Okorokov AL, 2006, EMBO J, V25, P5191, DOI 10.1038/sj.emboj.7601382; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; SCHAVOLT KL, 2007, ONCOGENE; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sims RJ, 2006, GENE DEV, V20, P2779, DOI 10.1101/gad.1468206; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Warnock LJ, 2005, FEBS J, V272, P1669, DOI 10.1111/j.1742-4658.2005.04589.x; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Zhang K, 2005, J CELL BIOCHEM, V96, P1137, DOI 10.1002/jcb.20615; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao RB, 2000, GENE DEV, V14, P981	28	12	13	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1639	1644		10.1038/sj.onc.1210787	http://dx.doi.org/10.1038/sj.onc.1210787			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17891183				2022-12-28	WOS:000253815800016
J	Wang, X; Pan, L; Feng, Y; Wang, Y; Han, Q; Han, L; Han, S; Guo, J; Huang, B; Lu, J				Wang, X.; Pan, L.; Feng, Y.; Wang, Y.; Han, Q.; Han, L.; Han, S.; Guo, J.; Huang, B.; Lu, J.			p300 plays a role in p16(INK4a) expression and cell cycle arrest	ONCOGENE			English	Article						p16; p300; Sp1; transcriptional regulation	GENE-EXPRESSION; SP1; TRANSCRIPTION; INHIBITOR; BINDING; PROTEIN; PROLIFERATION; SENESCENCE; RECRUITMENT; LOCUS	As a cyclin-dependent kinase inhibitor, p16(INK4a) plays a key role in cell cycle progression and cellular differentiation, and its expression is frequently altered in human cancers through epigenetically mediated transcriptional silencing. In this report, we demonstrate that p300 was able to induce cell cycle arrest, and this process was reversed by p16(INK4a) silencing by RNA interference in HeLa cells. We also show that p300 was involved in activation of p16(INK4a) expression in 293T cells. Specifically, p300 cooperated with Sp1 to stimulate both p16(INK4a) promoter activity and mRNA expression. Co-immunoprecipitation and mammalian two-hybrid assays revealed that p300 and Sp1 formed a complex through interaction between the Q domain of p300 and the N-terminal domain of Sp1. The chromatin immunoprecipitation assays verified that p300 was recruited to p16(INK4a) promoter, and the histone acetyltransferase domain of p300 participated in p16(INK4a) activation through inducing hyperacetylation of histone H4 at p16(INK4a) gene. These data suggest that p300 plays a critical role in transcriptional regulation of p16(INK4a) and in cell cycle arrest.	[Wang, X.; Pan, L.; Feng, Y.; Wang, Y.; Han, Q.; Han, L.; Han, S.; Huang, B.; Lu, J.] NE Normal Univ, Inst Cytol & Genet, Changchun 130024, Peoples R China; [Guo, J.] NE Normal Univ, Key Lab Appl Stat MOS, Changchun, Peoples R China	Northeast Normal University - China; Northeast Normal University - China	Lu, J (corresponding author), NE Normal Univ, Inst Cytol & Genet, 5268 Renmin St, Changchun 130024, Peoples R China.	luj809@nenu.edu.cn	Han, Songyan/D-8351-2012					Bond J, 2004, EXP CELL RES, V292, P151, DOI 10.1016/j.yexcr.2003.09.021; Chan HM, 2001, J CELL SCI, V114, P2363; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Deng QD, 2005, CANCER RES, V65, P8298, DOI 10.1158/0008-5472.CAN-05-0054; Gizard F, 2005, J CLIN INVEST, V115, P3228, DOI 10.1172/JCI22756; Han LP, 2006, BIOCHEM BIOPH RES CO, V348, P799, DOI 10.1016/j.bbrc.2006.07.147; Han SY, 2006, BIOCHEM J, V400, P439, DOI 10.1042/BJ20061085; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2005, CYTOKINE, V31, P46, DOI 10.1016/j.cyto.2005.03.001; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; RUAS M, 1998, BIOCHIM BIOPHYS ACTA, V115, pF177; RUMI M, 2003, EXP HEMATOL, V31, P355; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhao YM, 2005, J EXP BIOL, V208, P697, DOI 10.1242/jeb.01439	27	58	60	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2008	27	13					1894	1904		10.1038/sj.onc.1210821	http://dx.doi.org/10.1038/sj.onc.1210821			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906698	Bronze			2022-12-28	WOS:000254150600009
J	Rayter, S; Elliott, R; Travers, J; Rowlands, MG; Richardson, TB; Boxall, K; Jones, K; Linardopoulos, S; Workman, P; Aherne, W; Lord, CJ; Ashworth, A				Rayter, S.; Elliott, R.; Travers, J.; Rowlands, M. G.; Richardson, T. B.; Boxall, K.; Jones, K.; Linardopoulos, S.; Workman, P.; Aherne, W.; Lord, C. J.; Ashworth, A.			A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D	ONCOGENE			English	Article						PPM1D; chemical inhibitor; breast cancer	PHOSPHATASE PPM1D; CHK2 KINASE; WIP1; CANCER; IDENTIFICATION; AMPLIFICATION; EXPRESSION; VALIDATION; MECHANISM; TARGET	The PPM1D gene is aberrantly amplified in a range of common cancers and encodes a protein phosphatase that is a potential therapeutic target. However, the issue of whether inhibition of PPM1D in human tumour cells that overexpress this protein compromises their viability has not yet been fully addressed. We show here, using an RNA interference ( RNAi) approach, that inhibition of PPM1D can indeed reduce the viability of human tumour cells and that this effect is selective; tumour cell lines that overexpress PPM1D are sensitive to PPM1D inhibition whereas cell lines with normal levels are not. Loss of viability associated with PPM1D RNAi in human tumour cells occurs via the activation of the kinase P38. To identify chemical inhibitors of PPM1D, a high-throughput screening of a library of small molecules was performed. This strategy successfully identified a compound that selectively reduces viability of human tumour cell lines that overexpress PPM1D. As expected of a specific inhibitor, the toxicity to PPM1D overexpressing cell lines after inhibitor treatment is P38 dependent. These results further validate PPM1D as a therapeutic target and identify a proof-of-principle small molecule inhibitor.	[Rayter, S.; Elliott, R.; Richardson, T. B.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Travers, J.; Rowlands, M. G.; Boxall, K.; Jones, K.; Linardopoulos, S.; Workman, P.; Aherne, W.] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	Alan.Ashworth@icr.ac.uk	Lord, Christopher/AAX-7130-2021; Lord, Christopher J/B-3295-2012; Jones, Keith/R-7629-2016	Lord, Christopher J/0000-0002-3226-0515; Jones, Keith/0000-0002-9440-4094; Linardopoulos, Spiros/0000-0002-6600-400X	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		ARCHER S, 1982, J MED CHEM, V25, P220, DOI 10.1021/jm00345a006; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Brody LC, 2005, NEW ENGL J MED, V353, P949, DOI 10.1056/NEJMcibr052331; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Burns S, 2006, J BIOMOL SCREEN, V11, P822, DOI 10.1177/1087057106290992; Chen LW, 2006, CRIT CARE MED, V34, P142, DOI 10.1097/01.CCM.0000190621.48720.8C; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Collins I, 2006, NAT CHEM BIOL, V2, P689, DOI 10.1038/nchembio840; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fitzgerald CE, 2003, NAT STRUCT BIOL, V10, P764, DOI 10.1038/nsb949; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r; McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y; Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Oliva-Trastoy M, 2007, ONCOGENE, V26, P1449, DOI 10.1038/sj.onc.1209927; Proia DA, 2006, J BIOL CHEM, V281, P7089, DOI 10.1074/jbc.M511839200; Ryan AJ, 2003, J MED CHEM, V46, P3448, DOI 10.1021/jm0340896; Saito-Ohara F, 2003, CANCER RES, V63, P1876; SCANLON W, 1973, Patent No. 2245518; Schmid AC, 2004, BIOCHEM SOC T, V32, P348, DOI 10.1042/BST0320348; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; von Leoprechting A, 2004, J BIOMOL SCREEN, V9, P719, DOI 10.1177/1087057104268805; Warner G, 2004, CURR MED CHEM, V11, P721, DOI 10.2174/0929867043455693; Yamaguchi H, 2006, BIOCHEMISTRY-US, V45, P13193, DOI 10.1021/bi061356b; Yoda A, 2006, J BIOL CHEM, V281, P24847, DOI 10.1074/jbc.M600403200; Yu E, 2007, BREAST CANCER RES TR, V101, P269, DOI 10.1007/s10549-006-9304-y; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	39	72	72	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1036	1044		10.1038/sj.onc.1210729	http://dx.doi.org/10.1038/sj.onc.1210729			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700519				2022-12-28	WOS:000253136700002
J	Myatt, SS; Burchill, SA				Myatt, S. S.; Burchill, S. A.			The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38MAPK activity	ONCOGENE			English	Article						p38MAPK; EWS-Fli1; ROS; fenretinide; apoptosis; ESFT	PHASE-I TRIAL; RNA INTERFERENCE; N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED APOPTOSIS; SUSTAINED-ACTIVATION; ORAL FENRETINIDE; CANCER-CELLS; SOLID TUMORS; GROWTH; NEUROBLASTOMA; PHENOTYPE	The Ewing's sarcoma family of tumours (ESFT) are small round cell tumours characterized by the non-random EWS-ETS gene rearrangements. We have previously demonstrated that ESFT are highly sensitive to fenretinide-induced death, effected in part through a reactive oxygen species (ROS)-dependent pathway. Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG. This decrease in cell death was independent of the level of ROS produced following exposure to fenretinide, but was effected through EWSFli1-dependent modulation of p38(MAPK) activity. Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide- induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells. These data demonstrate that expression of EWS-Fli1 enhances fenretinide-induced cell death in ESFT and that this is effected at least in part through modulation of p38(MAPK) activity.	[Myatt, S. S.; Burchill, S. A.] St James Hosp, Candlelighters Childrens Can Res Lab, Canc Res UK Cllin Care, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Burchill, SA (corresponding author), St James Hosp, Candlelighters Childrens Can Res Lab, Canc Res UK Cllin Care, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	s.a.burchill@leeds.ac.uk						Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Boya P, 2003, ONCOGENE, V22, P6220, DOI 10.1038/sj.onc.1206827; Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96; BURCHILL SA, 1994, INT J CANCER, V57, P671, DOI 10.1002/ijc.2910570510; Chansky HA, 2004, J ORTHOPAED RES, V22, P910, DOI 10.1016/j.orthres.2003.12.008; Chiesa F, 2005, INT J CANCER, V115, P625, DOI 10.1002/ijc.20923; Corazzari M, 2005, BIOCHEM BIOPH RES CO, V331, P810, DOI 10.1016/j.bbrc.2005.03.184; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Dohjima T, 2003, MOL THER, V7, P811, DOI 10.1016/S1525-0016(03)00101-1; FORMELLI F, 1993, J CLIN ONCOL, V11, P2036, DOI 10.1200/JCO.1993.11.10.2036; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Huang SL, 2004, J BIOL CHEM, V279, P36490, DOI 10.1074/jbc.M401208200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kim HJ, 2006, ONCOGENE, V25, P2785, DOI 10.1038/sj.onc.1209303; Malone W, 2003, EXPERT OPIN INV DRUG, V12, P1829, DOI 10.1517/eoid.12.11.1829.21882; Matsunobu T, 2006, CANCER RES, V66, P803, DOI 10.1158/0008-5472.CAN-05-1972; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mittal V, 2004, NAT REV GENET, V5, P355, DOI 10.1038/nrg1323; Myatt SS, 2005, CLIN CANCER RES, V11, P3136, DOI 10.1158/1078-0432.CCR-04-2050; O'Donnell PH, 2002, LEUKEMIA, V16, P902, DOI 10.1038/sj.leu.2402485; Osone S, 2004, INT J CANCER, V112, P219, DOI 10.1002/ijc.20412; Pienta KJ, 1997, AM J CLIN ONCOL-CANC, V20, P36, DOI 10.1097/00000421-199702000-00008; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Simeone AM, 2005, CARCINOGENESIS, V26, P1000, DOI 10.1093/carcin/bgi038; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Villablanca JG, 2006, J CLIN ONCOL, V24, P3423, DOI 10.1200/JCO.2005.03.9271; Westerhout EM, 2005, NUCLEIC ACIDS RES, V33, P796, DOI 10.1093/nar/gki220; Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc.M409035200; Won JS, 2006, FREE RADICAL BIO MED, V40, P1875, DOI 10.1016/j.freeradbiomed.2006.01.035; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008-5472.CAN-05-1704; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Zanardi S, 2006, ENDOCR-RELAT CANCER, V13, P51, DOI 10.1677/erc.1.00938	41	18	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					985	996		10.1038/sj.onc.1210705	http://dx.doi.org/10.1038/sj.onc.1210705			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700534				2022-12-28	WOS:000252946300010
J	Mohr, A; Buneker, C; Gough, RP; Zwacka, RM				Mohr, A.; Bueneker, C.; Gough, R. P.; Zwacka, R. M.			MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release	ONCOGENE			English	Article						apoptosis; MnSOD; TRAIL; XIAP; Smac/DIABLO; colon cancer	MANGANESE SUPEROXIDE-DISMUTASE; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; REDOX GENE-THERAPY; PANCREATIC ADENOCARCINOMA; MATRIX METALLOPROTEINASES; ANTIOXIDANT ENZYMES; CONFERS RESISTANCE; OVEREXPRESSION; EXPRESSION	The mitochondrial enzyme manganese superoxide dismutase (MnSOD) has been shown to have two faces with regard to its role in tumor development. On the one side, it is well documented that overexpression of MnSOD slows down cancer cell growth, whereas on the other side MnSOD also has a metastasis-promoting activity. We set out to examine the role of MnSOD in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, thought to be a first-line tumor surveillance mechanism and failure to undergo apoptosis might contribute to metastasis formation. We show that overexpression of MnSOD at moderate levels is able to protect cells from TRAIL-induced apoptosis. While caspase-8 activation and Bid cleavage were not affected by MnSOD, we detected a marked decrease in caspase-3 activation pointing to a mitochondrial resistance mechanism. Indeed, we found that MnSOD-overexpressing cells showed reduced cytochrome c and no Smac/DIABLO release into the cytosol. The resulting lack of X-linked inhibitor of apoptosis (XIAP) inhibition by cytosolic Smac/DIABLO most likely caused the TRAIL resistance as RNAi against XIAP-rescued caspase-3 activity and TRAIL sensitivity. Our results show that reactive oxygen species are involved in TRAIL-induced Smac/DIABLO release and in TRAIL-triggered apoptosis. Hence, high levels of MnSOD, which decompose and neutralize these reactive oxygen species, might contribute to metastasis formation by allowing disseminated tumor cells to escape from TRAIL-mediated tumor surveillance. As part of TRAIL regimens, adjuvant treatment with XIAP inhibitors in the form of Smac/DIABLO mimetics or MnSOD inhibitors might be able to break TRAIL resistance of malignant tumor cells.	[Mohr, A.; Bueneker, C.; Gough, R. P.; Zwacka, R. M.] Natl Univ Ireland Univ Coll Galway, Mol Therapeut Grp, Natl Ctr Biomed Engn Sci, Galway, Ireland; [Bueneker, C.] Univ Ulm, Div Gene Therapy, Ulm, Germany	Ollscoil na Gaillimhe-University of Galway; Ulm University	Mohr, A (corresponding author), Natl Univ Ireland Univ Coll Galway, Mol Therapeut Grp, Natl Ctr Biomed Engn Sci, Univ Rd, Galway, Ireland.	andrea.mohr@nuigalway.ie; ralf.zwacka@nuigalway.ie		Zwacka, Ralf/0000-0003-2821-0387; Mohr, Andrea/0000-0002-4295-0341				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Behrend L, 2005, MOL CELL BIOL, V25, P7758, DOI 10.1128/MCB.25.17.7758-7769.2005; Braeuer SJ, 2006, MOL CANCER RES, V4, P715, DOI 10.1158/1541-7786.MCR-05-0231; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cullen JJ, 2003, CANCER RES, V63, P1297; Culotta VC, 2006, BBA-MOL CELL RES, V1763, P747, DOI 10.1016/j.bbamcr.2006.05.003; Davis AR, 2001, MOL BIOTECHNOL, V18, P63, DOI 10.1385/MB:18:1:63; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Duiker EW, 2006, EUR J CANCER, V42, P2233, DOI 10.1016/j.ejca.2006.03.018; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Izeradjene K, 2005, CANCER RES, V65, P7436, DOI 10.1158/0008-5472.CAN-04-2628; Izutani R, 1998, J GASTROENTEROL, V33, P816, DOI 10.1007/s005350050181; Janssen AML, 1999, J CANCER RES CLIN, V125, P327, DOI 10.1007/s004320050282; Kahl R, 2004, DRUG METAB REV, V36, P747, DOI 10.1081/DMR-200033488; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Lam EWN, 1997, CANCER RES, V57, P5550; Lee MW, 2002, CANCER LETT, V182, P75; Lewis A, 2005, CLIN EXP METASTAS, V22, P523, DOI 10.1007/s10585-005-4919-7; Li JJ, 1997, CANCER RES, V57, P1991; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Liotta L A, 1990, Semin Cancer Biol, V1, P99; Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773; Mantymaa P, 2000, BRIT J HAEMATOL, V108, P574, DOI 10.1046/j.1365-2141.2000.01852.x; Mohr A, 2005, ONCOGENE, V24, P2421, DOI 10.1038/sj.onc.1208432; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nozoe T, 2003, ONCOL REP, V10, P39; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Smirnov AS, 2001, CELL DEATH DIFFER, V8, P621, DOI 10.1038/sj.cdd.4400853; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Toh Y, 2000, INT J ONCOL, V17, P107; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; Vigneswaran N, 2005, INT J ONCOL, V26, P103; Wajant H, 2006, CANC TREAT, V130, P141; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698; Zwacka RM, 1998, HUM GENE THER, V9, P1381, DOI 10.1089/hum.1998.9.9-1381	46	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					763	774		10.1038/sj.onc.1210673	http://dx.doi.org/10.1038/sj.onc.1210673			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653087				2022-12-28	WOS:000252884500005
J	Ichikawa, T; Suenaga, Y; Koda, T; Ozaki, T; Nakagawara, A				Ichikawa, T.; Suenaga, Y.; Koda, T.; Ozaki, T.; Nakagawara, A.			TAp63-dependent induction of growth differentiation factor 15 (GDF15) plays a critical role in the regulation of keratinocyte differentiation	ONCOGENE			English	Article						TAp63; GDF15; keratinocyte; differentiation	TGF-BETA SUPERFAMILY; MACROPHAGE INHIBITORY CYTOKINE-1; PROSTATE-DERIVED FACTOR; CANCER CELL-GROWTH; EPIDERMAL MORPHOGENESIS; TARGET GENE; P53 HOMOLOG; P63; MEMBER; EXPRESSION	Since p63-deficient mice display severe defects in formation of epidermis, p63 has been considered to be a multi-isoform p53 family member essential for epidermal development. However, it is still unclear how p63 could contribute to keratinocyte differentiation. In the present study, we have found that TAp63 alpha is induced in association with the upregulation and a secretion of growth differentiation factor 15 (GDF15) during the keratinocyte differentiation of HaCaT cells bearing p53 mutation. Short interference RNA-mediated knockdown of the endogenous TAp63 resulted in a remarkable reduction of GDF15. Luciferase reporter assay and reverse transcription-PCR analysis demonstrated that enforced expression of TAp63 alpha significantly increases the luciferase activity driven by GDF15 promoter and the expression of GDF15. Consistent with these results, the proximal p53/p63-binding site within the GDF15 promoter region was required for the TAp63 alpha-mediated transcriptional activation of GDF15, and TAp63 alpha was recruited onto this site. Furthermore, siRNA-mediated knockdown of the endogenous GDF15 permitted cell growth and inhibited the expression of the differentiation markers such as keratin 10 and involucrin in response to differentiation stimuli. Taken together, our present results provide a novel insight into understanding the molecular mechanisms behind TAp63 alpha-mediated keratinocyte differentiation.	[Ichikawa, T.; Suenaga, Y.; Ozaki, T.; Nakagawara, A.] Chiba Canc Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Ichikawa, T.; Koda, T.] Hisamitsu Pharmaceut Co Inc, Res Ctr Funct Genom, Chiba, Japan; [Suenaga, Y.; Ozaki, T.; Nakagawara, A.] Chiba Univ, Grad Sch Med, Dept Mol Biol & Oncol, Chiba, Japan	Chiba Cancer Center; Hisamitsu Pharmaceutical Co Ltd; Chiba University	Nakagawara, A (corresponding author), Chiba Canc Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp		Suenaga, Yusuke/0000-0001-6902-5386				Agarwal MK, 2006, P NATL ACAD SCI USA, V103, P16278, DOI 10.1073/pnas.0607210103; Ago T, 2006, CIRC RES, V98, P294, DOI 10.1161/01.RES.0000207919.83894.9d; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bauskin AR, 2006, CANCER RES, V66, P4983, DOI 10.1158/0008-5472.CAN-05-4067; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, CELL TISSUE RES, V297, P103, DOI 10.1007/s004410051337; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; King KE, 2006, CARCINOGENESIS, V27, P53, DOI 10.1093/carcin/bgi200; Koster MI, 2007, CELL CYCLE, V6, P269, DOI 10.4161/cc.6.3.3792; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; Lambert JR, 2006, J CELL PHYSIOL, V208, P566, DOI 10.1002/jcp.20692; Lapi E, 2006, ONCOGENE, V25, P3628, DOI 10.1038/sj.onc.1209401; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nazarova N, 2004, INT J CANCER, V112, P951, DOI 10.1002/ijc.20510; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 2007, BIOCHEM BIOPH RES CO, V354, P913, DOI 10.1016/j.bbrc.2007.01.089; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Roninson IB, 2003, CANCER RES, V63, P2705; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Uchida K, 2003, J CELL BIOCHEM, V88, P394, DOI 10.1002/jcb.10327; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	35	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					409	420		10.1038/sj.onc.1210658	http://dx.doi.org/10.1038/sj.onc.1210658			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637746				2022-12-28	WOS:000252426100001
J	Raabe, EH; Laudenslager, M; Winter, C; Wasserman, N; Cole, K; LaQuaglia, M; Maris, DJ; Mosse, YP; Maris, JM				Raabe, E. H.; Laudenslager, M.; Winter, C.; Wasserman, N.; Cole, K.; LaQuaglia, M.; Maris, D. J.; Mosse, Y. P.; Maris, J. M.			Prevalence and functional consequence of PHOX2B mutations in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; PHOX2B; MYCN; neural crest; tumor suppressor gene	CENTRAL-HYPOVENTILATION-SYNDROME; HOMEOBOX GENE PHOX2B; HEREDITARY NEUROBLASTOMA; TRANSCRIPTION; PHENOTYPE; SHOWS	PHOX2B is a homeodomain-containing protein that is involved in the development of the peripheral nervous system and is the major disease gene for the rare congenital breathing disorder congenital central hypoventilation syndrome (CCHS). Germline PHOX2B alterations were also recently discovered in neuroblastoma cases with CCHS and/or Hirschsprung disease, but a comprehensive survey for mutational frequency and functional consequence has not been performed. We therefore studied a large panel of hereditary neuroblastomas to understand the frequency and functional effects of PHOX2B mutations. Three of 47 individuals with presumed genetic predisposition to neuroblastoma showed a germline PHOX2B mutation (6.4%). Mutations were also discovered in 2 of 30 human neuroblastoma-derived cell lines, but none of 86 primary tumors from patients with sporadically occurring neuroblastoma. The vast majority of primary tumors showed abundant PHOX2B mRNA expression relative to the remainder of the transcriptome. Consistent with its role as an important neurodevelopmental gene, forced overexpression of wild-type PHOX2B in neuroblastoma cell lines suppressed cell proliferation and synergized with all-trans retinoic acid to promote differentiation. Patient-derived mutant PHOX2B constructs retained the ability to suppress cellular proliferation, but were not able to promote differentiation or activate expression of a known PHOX2B target gene in vitro. These findings show that PHOX2B alterations are a rare cause of hereditary neuroblastoma, but disruption of this neurodevelopmental pathway can interfere with transcription-dependent terminal differentiation. These data also suggest that the genetics of neuroblastoma initiation are complex, and highlight genes involved in normal noradrenergic development as candidate predisposition genes.	[Raabe, E. H.; Laudenslager, M.; Winter, C.; Wasserman, N.; Cole, K.; LaQuaglia, M.; Maris, D. J.; Mosse, Y. P.; Maris, J. M.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Raabe, E. H.; Laudenslager, M.; Winter, C.; Wasserman, N.; Cole, K.; LaQuaglia, M.; Maris, D. J.; Mosse, Y. P.; Maris, J. M.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Maris, J. M.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Maris, JM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, ARC902A,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	maris@chop.edu		Raabe, Eric/0000-0002-9368-7037	NATIONAL CANCER INSTITUTE [R01CA087847, U10CA098543, R01CA078545] Funding Source: NIH RePORTER; NCI NIH HHS [U10-CA98543, R01-CA87847, R01-CA78545] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Atienza JM, 2006, J BIOMOL SCREEN, V11, P634, DOI 10.1177/1087057106289334; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Beiske K, 2005, CANCER LETT, V228, P229, DOI 10.1016/j.canlet.2005.02.053; DINGWALL C, 1991, BIOESSAYS, V13, P213, DOI 10.1002/bies.950130503; Dubreuil V, 2000, DEVELOPMENT, V127, P5191; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; Maris JM, 2002, CANCER RES, V62, P6651; Matera I, 2004, J MED GENET, V41, P373, DOI 10.1136/jmg.2003.015412; McConville C, 2006, AM J MED GENET A, V140A, P1297, DOI 10.1002/ajmg.a.31278; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527; Yang CY, 1998, J NEUROCHEM, V71, P1813; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311	18	114	117	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					469	476		10.1038/sj.onc.1210659	http://dx.doi.org/10.1038/sj.onc.1210659			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637745				2022-12-28	WOS:000252426100007
J	Howard, G; Eiges, R; Gaudet, F; Jaenisch, R; Eden, A				Howard, G.; Eiges, R.; Gaudet, F.; Jaenisch, R.; Eden, A.			Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice	ONCOGENE			English	Article						DNA hypomethylation; transposable elements; Notch1; T-cell lymphoma	DNA HYPOMETHYLATION; C-MYC; METHYLATION; GENE; TRANSCRIPTION; CHROMOSOME-1; EXPRESSION; INDUCTION; LEUKEMIA; CANCER	Genomewide DNA hypomethylation is a consistent finding in human tumors, but the importance of this change for human tumorigenesis remains an open question. We have previously reported that mice carrying a hypomorphic allele for the maintenance DNA methyltransferase (Dnmt1(chip/-)) are hypomethylated and develop thymic lymphomas, demonstrating that genomewide DNA hypomethylation can induce tumors. Hypomethylated cells exhibit inherent chromosomal instability, which is revealed in the lymphomas as a consistent trisomy of chromosome 15. We now report another aspect of the molecular basis for tumor development upon DNA hypomethylation. Seven out of 16 hypomethylation-induced lymphomas were found to contain an intracisternal A particle (IAP) somatic insertion in the middle of the Notch1 genomic locus, leading to generation of an oncogenic form of Notch1 in the tumors. This finding suggests that the molecular basis for hypomethylation-induced tumors in this model involves chromosomal instability events accompanied by activation of endogenous retroviral elements. Our findings validate the proposed role of DNA methylation in suppression of transposable elements in mammalian cells and demonstrate the importance of DNA methylation for normal cell function as well as the potential consequences of spontaneously occurring or chemically induced DNA hypomethylation.	[Howard, G.; Eiges, R.; Eden, A.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Anim & Cell Biol, IL-91904 Jerusalem, Israel; [Gaudet, F.; Jaenisch, R.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Gaudet, F.; Jaenisch, R.] MIT, Dept Biol, Cambridge, MA USA	Hebrew University of Jerusalem; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Eden, A (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Anim & Cell Biol, IL-91904 Jerusalem, Israel.	eden@vms.huji.ac.il		eiges, rachel/0000-0001-8139-0933				AnsariLari MA, 1996, BIOTECHNIQUES, V21, P34; BOEKE JD, 1997, COLD SPRING LAB, P343; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; Druker R, 2004, NUCLEIC ACIDS RES, V32, P5800, DOI 10.1093/nar/gkh914; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ehrlich M, 2003, CANCER GENET CYTOGEN, V141, P97, DOI 10.1016/S0165-4608(02)00668-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; JAHNER D, 1980, NATURE, V287, P456, DOI 10.1038/287456a0; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100; Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tsuda H, 2002, AM J PATHOL, V161, P859, DOI 10.1016/S0002-9440(10)64246-0; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zweidler-McKay PA, 2004, SEMIN CANCER BIOL, V14, P329, DOI 10.1016/j.semcancer.2004.04.012	29	232	239	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					404	408		10.1038/sj.onc.1210631	http://dx.doi.org/10.1038/sj.onc.1210631			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621273				2022-12-28	WOS:000252256000017
J	Krieg, AM				Krieg, A. M.			Toll-like receptor 9 (TLR9) agonists in the treatment of cancer	ONCOGENE			English	Review						PF-3512676; CpG ODN TLR9; toll-like receptor agonists; vaccine adjuvant	CPG-OLIGODEOXYNUCLEOTIDE; IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES; GENE-EXPRESSION; IFN-ALPHA; T-CELLS; VACCINATION; OLIGONUCLEOTIDE; MODULATION; GENERATION; INTERFERON	Although still early in clinical development, agonists of Toll-like receptor 9 (TLR9) have demonstrated potential for the treatment of cancer. TLR9 agonists directly induce activation and maturation of plasmacytoid dendritic cells and enhance differentiation of B cells into antibody-secreting plasma cells. Preclinical and early clinical data support the use of TLR9 agonists in patients with solid tumors and hematologic malignancies. In preclinical studies, TLR9 agonists have shown activity not only as monotherapy, but also in combination with multiple other therapies, including vaccines, antibodies, cellular therapies, other immunotherapies, antiangiogenic agents, radiotherapy, cryotherapy and some chemotherapies. Phase I and II clinical trials have indicated that these agents have antitumor activity as single agents and enhance the development of antitumor T-cell responses when used as therapeutic vaccine adjuvants. The activity and safety of these novel anticancer agents are being explored in a wide range of tumor types as part of a variety of therapeutic strategies with the goal of harnessing the immune response to fight cancer.	Coley Pharmaceut Grp Inc, Wellesley, MA 02481 USA	Coley Pharmaceutical Group	Krieg, AM (corresponding author), Coley Pharmaceut Grp Inc, Suite 101,93 Worcester St, Wellesley, MA 02481 USA.	akrieg@coleypharma.com	Krieg, Art/R-6166-2019; Krieg, Arthur M/K-8109-2019					Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Appay V, 2006, J IMMUNOL, V177, P1670, DOI 10.4049/jimmunol.177.3.1670; Baines J, 2003, CLIN CANCER RES, V9, P2693; Carpentier A, 2006, NEURO-ONCOLOGY, V8, P60, DOI 10.1215/S1522851705000475; Daftarian P, 2004, CANCER RES, V64, P5407, DOI 10.1158/0008-5472.CAN-04-0169; Damiano V, 2006, CLIN CANCER RES, V12, P577, DOI 10.1158/1078-0432.CCR-05-1943; Damiano V, 2007, P NATL ACAD SCI USA, V104, P12468, DOI 10.1073/pnas.0705226104; Davila E, 2003, CANCER RES, V63, P3281; Decker T, 2000, BLOOD, V95, P999, DOI 10.1182/blood.V95.3.999.003k10_999_1006; Droemann D, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-1; Friedberg JW, 2005, BLOOD, V105, P489, DOI 10.1182/blood-2004-06-2156; Gelman AE, 2006, IMMUNITY, V25, P783, DOI 10.1016/j.immuni.2006.08.023; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; HOFMANN MA, UNPUB SAFETY ACTIVIT; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jahrsdorfer B, 2005, J LEUKOCYTE BIOL, V77, P378, DOI 10.1189/jlb.0604373; Jahrsdorfer B, 2001, J LEUKOCYTE BIOL, V69, P81; KIM Y, 2004, ASH ANN M ABSTR, V104; KRIEG AM, 2006, CURR ONCOL REP, V5, P471; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Krieg Arthur M, 2004, Curr Oncol Rep, V6, P88, DOI 10.1007/s11912-004-0019-0; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Latz E, 2007, NAT IMMUNOL, V8, P772, DOI 10.1038/ni1479; Lebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530; Lee J, 2006, NAT CELL BIOL, V8, P1327, DOI 10.1038/ncb1500; LEONARD JP, 2007, IN PRESS CLIN CANC R; Li J, 2004, AM J PHYSIOL-LUNG C, V287, pL552, DOI 10.1152/ajplung.00436.2003; Link BK, 2006, J IMMUNOTHER, V29, P558, DOI 10.1097/01.cji.0000211304.60126.8f; MANEGOLD C, 2007, IN PRESS J CLIN ONCO; Milas L, 2004, CANCER RES, V64, P5074, DOI 10.1158/0008-5472.CAN-04-0926; Molenkamp BG, 2007, CLIN CANCER RES, V13, P2961, DOI 10.1158/1078-0432.CCR-07-0050; Pashenkov M, 2006, J CLIN ONCOL, V24, P5716, DOI 10.1200/JCO.2006.07.9129; Pedersen G, 2005, CLIN EXP IMMUNOL, V141, P298, DOI 10.1111/j.1365-2249.2005.02848.x; Platz J, 2004, J IMMUNOL, V173, P1219, DOI 10.4049/jimmunol.173.2.1219; READETT DRJ, 2007, 12 WORLD C LUNG CANC; Sabel MS, 2003, ONCOLOGIST, V8, P451, DOI 10.1634/theoncologist.8-5-451; Saikh KU, 2004, J IMMUNOL, V173, P7426, DOI 10.4049/jimmunol.173.12.7426; Siren J, 2005, J IMMUNOL, V174, P1932, DOI 10.4049/jimmunol.174.4.1932; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Thompson JA, 2004, J CLIN ONCOL, V22, p417S; TREFZER U, 2002, P AM SOC CLIN ONNCOL, V21; Van den Eertwegh AJ, 2006, J CLIN ONCOL, V24, p107S; VANOJIK H, 2002, ANN ONCOL, V13, P157; WEERATNA RD, 2004, J CLIN ONCOL S, V22, P699; Weigel BJ, 2003, CLIN CANCER RES, V9, P3105; Wooldridge James E., 2003, Current Opinion in Oncology, V15, P440, DOI 10.1097/00001622-200311000-00006; Wooldridge JE, 1997, BLOOD, V89, P2994, DOI 10.1182/blood.V89.8.2994; Wysocka M, 2004, BLOOD, V104, P4142, DOI 10.1182/blood-2004-03-1190	48	293	323	3	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					161	167		10.1038/sj.onc.1210911	http://dx.doi.org/10.1038/sj.onc.1210911			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176597				2022-12-28	WOS:000252163600002
J	Siddiqui, K; Del Valle, L; Morellet, N; Cui, J; Ghafouri, M; Mukerjee, R; Urbanska, K; Fan, S; Pattillo, CB; Deshmane, SL; Kiani, MF; Ansari, R; Khalili, K; Roques, BP; Reiss, K; Bouaziz, S; Amini, S; Srinivasan, A; Sawaya, BE				Siddiqui, K.; Del Valle, L.; Morellet, N.; Cui, J.; Ghafouri, M.; Mukerjee, R.; Urbanska, K.; Fan, S.; Pattillo, C. B.; Deshmane, S. L.; Kiani, M. F.; Ansari, R.; Khalili, K.; Roques, B. P.; Reiss, K.; Bouaziz, S.; Amini, S.; Srinivasan, A.; Sawaya, B. E.			Molecular mimicry in inducing DNA damage between HIV-1Vpr and the anticancer agent, cisplatin	ONCOGENE			English	Article						HIV-1; Vpr; DNA damage; chromosomal aberrations; cisplatin; necrosis	IMMUNODEFICIENCY-VIRUS TYPE-1; HISTONE H3 PHOSPHORYLATION; REGULATORY PROTEIN VPR; CELL-CYCLE; NMR STRUCTURE; TERMINAL DOMAIN; MICRONUCLEI FORMATION; VIRION INCORPORATION; GENE-EXPRESSION; ACCESSORY GENE	The human immunodeficiency virus type 1(HIV-1) viral protein R (vpr) gene is an evolutionarily conserved gene among the primate lentiviruses. Several functions are attributed to Vpr including the ability to cause cell death, cell cycle arrest, apoptosis and DNA damage. The Vpr domain responsible for DNA damage as well as the mechanism(s) through which Vpr induces this damage is unknown. Using site-directed mutagenesis, we identified the helical domain II within Vpr (aa 37-50) as the region responsible for causing DNA damage. Interestingly, Vpr D(37-50) failed to cause cell cycle arrest or apoptosis, to induce Ku70 or Ku80 and to suppress tumor growth, but maintained its capability to activate the HIV-1 LTR, to localize to the nucleus and to promote nonhomologous end-joining. In addition, our cytogenetic data indicated that helical domain II induced chromosomal aberrations, which mimicked those induced by cisplatin, an anticancer agent. This novel molecular mimicry function of Vpr might lead to its potential therapeutic use as a tumor suppressor.	[Del Valle, L.; Cui, J.; Ghafouri, M.; Mukerjee, R.; Urbanska, K.; Fan, S.; Deshmane, S. L.; Khalili, K.; Reiss, K.; Sawaya, B. E.] Temple Univ, Sch Med, Dept Neurosci, Philadelphia, PA 19122 USA; [Del Valle, L.; Cui, J.; Ghafouri, M.; Mukerjee, R.; Urbanska, K.; Fan, S.; Deshmane, S. L.; Khalili, K.; Reiss, K.; Sawaya, B. E.] Temple Univ, Sch Med, Ctr Neurovirol, Philadelphia, PA 19122 USA; [Siddiqui, K.; Amini, S.] Temple Univ, Coll Sci & Technol, Dept Biol, Philadelphia, PA 19122 USA; [Morellet, N.; Roques, B. P.; Bouaziz, S.] INSERM, Unite Pharmacol Chim & Genet, Paris 06, France; [Urbanska, K.] Jagiellonian Univ, Fac Biotechnol, Dept Cell Biol, Krakow, Poland; [Pattillo, C. B.; Kiani, M. F.; Ansari, R.] Temple Univ, Dept Mech Engn, Philadelphia, PA 19122 USA; [Srinivasan, A.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Institut National de la Sante et de la Recherche Medicale (Inserm); Jagiellonian University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University	Sawaya, BE (corresponding author), Temple Univ, Sch Med, Dept Neurosci, 1900 N 12th St, Philadelphia, PA 19122 USA.	sawaya@temple.edu	Del Valle, Luis/J-4085-2015; Pattillo, Christopher/J-9517-2012	Del Valle, Luis/0000-0003-3894-9206; Pattillo, Christopher/0000-0002-8017-067X; morellet, nelly/0000-0001-5076-8884; bouaziz, serge/0000-0001-7792-8307	NATIONAL CANCER INSTITUTE [R01CA095518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466, R01NS040673] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095518] Funding Source: Medline; NINDS NIH HHS [R01 NS040673-05, P01 NS036466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amini S, 2005, MOL CELL BIOL, V25, P8126, DOI 10.1128/MCB.25.18.8126-8138.2005; Amini S, 2004, J BIOL CHEM, V279, P46046, DOI 10.1074/jbc.M403792200; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Baumgartner BL, 2005, GENE DEV, V19, P2522, DOI 10.1101/gad.1373205; Claudio PP, 2006, J CELL PHYSIOL, V208, P602, DOI 10.1002/jcp.20698; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Gaynor EM, 2001, EXP CELL RES, V267, P243, DOI 10.1006/excr.2001.5247; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gougeon ML, 2003, NAT REV IMMUNOL, V3, P392, DOI 10.1038/nri1087; Gragerov A, 1998, VIROLOGY, V245, P323, DOI 10.1006/viro.1998.9138; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Huang MB, 2000, J NEUROVIROL, V6, P202, DOI 10.3109/13550280009015823; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Juan G, 1998, CYTOMETRY, V32, P71, DOI 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H; Kino T, 2002, J VIROL, V76, P9724, DOI 10.1128/JVI.76.19.9724-9734.2002; Labhart P, 1999, EUR J BIOCHEM, V265, P849, DOI 10.1046/j.1432-1327.1999.00805.x; Le Rouzic E, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-11; Mahalingam S, 1995, VIROLOGY, V214, P647, DOI 10.1006/viro.1995.0079; Mahalingam S, 1997, DNA CELL BIOL, V16, P137, DOI 10.1089/dna.1997.16.137; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; Majone F, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-45; Mameli G, 2007, J GEN VIROL, V88, P631, DOI 10.1099/vir.0.82487-0; McCray AN, 2006, MOL THER, V14, P647, DOI 10.1016/j.ymthe.2006.06.010; Morellet N, 2003, J MOL BIOL, V327, P215, DOI 10.1016/S0022-2836(03)00060-3; Muller C, 2005, CELL CYCLE, V4, P438, DOI 10.4161/cc.4.3.1565; Nakamura T, 2002, VIRUS RES, V90, P263, DOI 10.1016/S0168-1702(02)00230-7; Nishizawa M, 1999, VIROLOGY, V263, P313, DOI 10.1006/viro.1999.9905; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Pang S, 2001, CLIN CANCER RES, V7, P3567; Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sawaya BE, 1999, GENE THER, V6, P947, DOI 10.1038/sj.gt.3300907; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Sherman MP, 2002, VIROLOGY, V302, P95, DOI 10.1006/viro.2002.1576; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Shimura M, 1999, CANCER RES, V59, P2259; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; SIDDIQUI KM, 1988, MUTAT RES, V207, P179; Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000; Tachiwana H, 2006, CANCER RES, V66, P627, DOI 10.1158/0008-5472.CAN-05-3144; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wecker K, 2002, EUR J BIOCHEM, V269, P3779, DOI 10.1046/j.1432-1033.2002.03067.x; Zhou Y, 2000, J VIROL, V74, P6520, DOI 10.1128/JVI.74.14.6520-6527.2000; Zhou Y, 1998, VIROLOGY, V242, P414, DOI 10.1006/viro.1998.9028; Zhu QZ, 2001, CANCER RES, V61, P64; [No title captured]	53	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					32	43		10.1038/sj.onc.1210632	http://dx.doi.org/10.1038/sj.onc.1210632			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17653096				2022-12-28	WOS:000252118700004
J	Saunders, LR; Verdin, E				Saunders, L. R.; Verdin, E.			Sirtuins: critical regulators at the crossroads between cancer and aging	ONCOGENE			English	Review						sirtuins; cancer; lifespan; lysine acetylation	NF-KAPPA-B; FOXO TRANSCRIPTION FACTORS; REPLICATIVE LIFE-SPAN; CALORIE RESTRICTION; CELL-SURVIVAL; SIR2 HOMOLOG; HISTONE DEACETYLASE; DEPENDENT TRANSCRIPTION; ADP-RIBOSYLATION; MAMMALIAN-CELLS	Sirtuins ( SIRTs 1-7), or class III histone deacetylases ( HDACs), are protein deacetylases/ADP ribosyltransferases that target a wide range of cellular proteins in the nucleus, cytoplasm, and mitochondria for post-translational modi. cation by acetylation ( SIRT1, - 2, - 3 and - 5) or ADP ribosylation ( SIRT4 and - 6). The orthologs of sirtuins in lower organisms play a critical role in regulating lifespan. As cancer is a disease of aging, we discuss the growing implications of the sirtuins in protecting against cancer development. Sirtuins regulate the cellular responses to stress and ensure that damaged DNA is not propagated and that mutations do not accumulate. SIRT1 also promotes replicative senescence under conditions of chronic stress. By participating in the stress response to genomic insults, sirtuins are thought to protect against cancer, but they are also emerging as direct participants in the growth of some cancers. Here, we review the growing implications of sirtuins both in cancer prevention and as specific and novel cancer therapeutic targets.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes	Verdin, E (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, 1650 Owens St, San Francisco, CA 94158 USA.	everdin@gladstone.ucsf.edu	Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183				Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Aksoy P, 2006, BIOCHEM BIOPH RES CO, V349, P353, DOI 10.1016/j.bbrc.2006.08.066; Aksoy P, 2006, BIOCHEM BIOPH RES CO, V345, P1386, DOI 10.1016/j.bbrc.2006.05.042; Ando K, 2002, MICROSC RES TECHNIQ, V59, P293, DOI 10.1002/jemt.10207; ANISIMOV VN, 1988, CANCER LETT, V40, P77, DOI 10.1016/0304-3835(88)90264-9; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Ashraf N, 2006, BRIT J CANCER, V95, P1056, DOI 10.1038/sj.bjc.6603384; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Berrigan D, 2002, CARCINOGENESIS, V23, P817, DOI 10.1093/carcin/23.5.817; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chu F, 2005, CANCER RES, V65, P10183, DOI 10.1158/0008-5472.CAN-05-2002; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; de Nigris F, 2002, BRIT J CANCER, V87, P1479, DOI 10.1038/sj.bjc.6600636; DeGregori J, 2006, CURR MOL MED, V6, P739; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Ford E, 2006, GENE DEV, V20, P1075, DOI 10.1101/gad.1399706; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frye R, 2002, BRIT J CANCER, V87, P1479, DOI 10.1038/sj.bjc.6600635; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Fukuoka M, 2003, INT J MOL MED, V12, P503; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Fulda S, 2006, CANCER DETECT PREV, V30, P217, DOI 10.1016/j.cdp.2006.03.007; Funayama R, 2006, J CELL BIOL, V175, P869, DOI 10.1083/jcb.200604005; Furukawa-Hibi Y, 2005, ANTIOXID REDOX SIGN, V7, P752, DOI 10.1089/ars.2005.7.752; Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117; GLATT SJ, 2007, IN PRESS BIOL PSYCHI; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Han XJ, 2006, REJUV RES, V9, P69, DOI 10.1089/rej.2006.9.69; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Higami Y, 1997, AM J PATHOL, V151, P659; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Huffman DM, 2007, CANCER RES, V67, P417, DOI 10.1158/0008-5472.CAN-06-1244; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Inoue T, 2007, ONCOGENE, V26, P945, DOI 10.1038/sj.onc.1209857; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jackson MD, 2003, J BIOL CHEM, V278, P50985, DOI 10.1074/jbc.M306552200; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002; Kamel C, 2006, AGING CELL, V5, P81, DOI 10.1111/j.1474-9726.2006.00191.x; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kobayashi Y, 2005, INT J MOL MED, V16, P237; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; LENNOX RW, 1983, J BIOL CHEM, V258, P262; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Lim CS, 2006, MECH AGEING DEV, V127, P511, DOI 10.1016/j.mad.2006.02.001; Liszt G, 2005, J BIOL CHEM, V280, P21313, DOI 10.1074/jbc.M413296200; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mai V, 2003, CANCER RES, V63, P1752; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; McLure KG, 2004, MOL CELL BIOL, V24, P9958, DOI 10.1128/MCB.24.22.9958-9967.2004; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Niu HF, 2002, HEMATOL ONCOL, V20, P155, DOI 10.1002/hon.689; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Piva R, 2006, ANTIOXID REDOX SIGN, V8, P478, DOI 10.1089/ars.2006.8.478; POIRIER GG, 1980, CAN J BIOCHEM CELL B, V58, P509, DOI 10.1139/o80-069; Porcu M, 2005, TRENDS PHARMACOL SCI, V26, P94, DOI 10.1016/j.tips.2004.12.009; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rose G, 2003, EXP GERONTOL, V38, P1065, DOI 10.1016/S0531-5565(03)00209-2; Roth GS, 2001, ANN NY ACAD SCI, V928, P305; Rowinsky EK, 2006, SEMIN ONCOL, V33, P421, DOI 10.1053/j.seminoncol.2006.04.006; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64; Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200; Simbulan-Rosenthal CM, 2001, NEOPLASIA, V3, P179, DOI 10.1038/sj.neo.7900155; Singh P, 2006, ENDOCR-RELAT CANCER, V13, P653, DOI 10.1677/erc.1.00797; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Sommer M, 2006, CELL CYCLE, V5, P2005, DOI 10.4161/cc.5.17.3194; Stankovic-Valentin N, 2007, MOL CELL BIOL, V27, P2661, DOI 10.1128/MCB.01098-06; Strickler H D, 2001, Diabetes Technol Ther, V3, P263, DOI 10.1089/152091501300209633; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vainio H, 2002, EUR J CANCER PREV, V11, pS94; van der Heide LP, 2005, TRENDS BIOCHEM SCI, V30, P81, DOI 10.1016/j.tibs.2004.12.002; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Veer E, 2007, J BIOL CHEM, V282, P10841, DOI 10.1074/jbc.C700018200; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; WATERBOR JW, 1995, CANCER CAUSE CONTROL, V6, P267, DOI 10.1007/BF00051798; YAMAMOTO H, 1980, BIOCHEM BIOPH RES CO, V95, P474, DOI 10.1016/0006-291X(80)90762-7; Yang TL, 2006, AAPS J, V8, pE632, DOI 10.1208/aapsj080472; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang J, 2003, BIOESSAYS, V25, P808, DOI 10.1002/bies.10317; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	150	486	516	2	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5489	5504		10.1038/sj.onc.1210616	http://dx.doi.org/10.1038/sj.onc.1210616			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694089				2022-12-28	WOS:000248674300016
J	Vaquero, A; Sternglanz, R; Reinberg, D				Vaquero, A.; Sternglanz, R.; Reinberg, D.			NAD(+)-dependent deacetylation of H4 lysine 16 by class IIIHDACs	ONCOGENE			English	Review						H4K16Ac; SIRT1; SIRT2; SIRT3; HDAC; chromatin	NAD-DEPENDENT DEACETYLASE; YEAST HISTONE H4; REPLICATIVE LIFE-SPAN; ACETYL-COA SYNTHETASE; SILENT MATING LOCI; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; SIR2 HOMOLOG; CELL-CYCLE; METHYLTRANSFERASE ACTIVITY	Histone deacetylases ( HDACs) catalyse the removal of acetyl groups from the N-terminal tails of histones. All known HDACs can be categorized into one of four classes (I-IV). The class III HDAC or silencing information regulator 2 ( Sir2) family exhibits characteristics consistent with a distinctive role in regulation of chromatin structure. Accumulating data suggest that these deacetylases acquired new roles as genomic complexity increased, including deacetylation of non-histone proteins and functional diversification in mammals. However, the intrinsic regulation of chromatin structure in species as diverse as yeast and humans, underscores the pressure to conserve core functions of class III HDACs, which are also known as Sirtuins. One of the key factors that might have contributed to this preservation is the intimate relationship between some members of this group of proteins ( SirT1, SirT2 and SirT3) and deacetylation of a specific residue in histone H4, lysine 16 ( H4K16). Evidence accumulated over the years has uncovered a unique role for H4K16 in chromatin structure throughout eukaryotes. Here, we review the recent findings about the functional relationship between H4K16 and the Sir2 class of deacetylases and how that relationship might impact aging and diseases including cancerand diabetes.	NYU, Sch Med, Dept Biochem, Howard Hughes Med Inst,Smilow Res Ctr, New York, NY 10016 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; ICREA, Barcelona, Spain; CSIC, IBMB, Barcelona, Spain	Howard Hughes Medical Institute; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; ICREA; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Reinberg, D (corresponding author), NYU, Sch Med, Dept Biochem, Howard Hughes Med Inst,Smilow Res Ctr, 522 1st Ave,2nd Floor,Room 211, New York, NY 10016 USA.	reinbd01@med.nyu.edu	Vaquero, Alejandro/ABG-8634-2020; Vaquero, Alejandro/I-9845-2014	Vaquero, Alejandro/0000-0002-8735-4156; Reinberg, Danny/0000-0003-4288-2016	NIGMS NIH HHS [GM64844, GM28220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM028220, R01GM028220, R01GM064844] Funding Source: NIH RePORTER; ICREA Funding Source: Custom	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); ICREA(ICREA)		Agricola E, 2006, MOL MICROBIOL, V62, P1433, DOI 10.1111/j.1365-2958.2006.05451.x; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Ashraf N, 2006, BRIT J CANCER, V95, P1056, DOI 10.1038/sj.bjc.6603384; Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bell E, 2002, NAT REV IMMUNOL, V2, P148, DOI 10.1038/nri752; Belyaev ND, 1997, CHROMOSOMA, V106, P193, DOI 10.1007/s004120050239; Benson LJ, 2006, J BIOL CHEM, V281, P9287, DOI 10.1074/jbc.M512956200; Bernander R, 2003, MOL MICROBIOL, V48, P599, DOI 10.1046/j.1365-2958.2003.03414.x; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Calestagne-Morelli A, 2006, BIOCHEM CELL BIOL, V84, P518, DOI 10.1139/O06-067; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chiani F, 2006, NUCLEIC ACIDS RES, V34, P5426, DOI 10.1093/nar/gkl678; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Clapier CR, 2002, NUCLEIC ACIDS RES, V30, P649, DOI 10.1093/nar/30.3.649; CLARK T, 1983, J COMPUT CHEM, V4, P294, DOI 10.1002/jcc.540040303; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Ekwall K, 2005, TRENDS GENET, V21, P608, DOI 10.1016/j.tig.2005.08.009; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; Ford E, 2006, GENE DEV, V20, P1075, DOI 10.1101/gad.1399706; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Furuyama T, 2004, CURR BIOL, V14, P1812, DOI 10.1016/j.cub.2004.09.060; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Glowczewski L, 2004, MOL CELL BIOL, V24, P10180, DOI 10.1128/MCB.24.23.10180-10192.2004; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guarente L, 2005, MECH AGEING DEV, V126, P923, DOI 10.1016/j.mad.2005.03.013; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Halme A, 2004, CELL, V116, P405, DOI 10.1016/S0092-8674(04)00118-7; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Henikoff S, 2005, P NATL ACAD SCI USA, V102, P5308, DOI 10.1073/pnas.0501853102; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jasencakova Z, 2000, PLANT CELL, V12, P2087, DOI 10.1105/tpc.12.11.2087; Jazayeri A, 2004, P NATL ACAD SCI USA, V101, P1644, DOI 10.1073/pnas.0304797101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kume S, 2007, J BIOL CHEM, V282, P151, DOI 10.1074/jbc.M605904200; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lavender JS, 1994, CHROMOSOME RES, V2, P398, DOI 10.1007/BF01552799; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; Maas NL, 2006, MOL CELL, V23, P109, DOI 10.1016/j.molcel.2006.06.006; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Marmorstein R, 2004, BIOCHEM SOC T, V32, P904, DOI 10.1042/BST0320904; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Mellone BG, 2003, CURR BIOL, V13, P1748, DOI 10.1016/j.cub.2003.09.031; Meyer-Ficca ML, 2005, INT J BIOCHEM CELL B, V37, P920, DOI 10.1016/j.biocel.2004.09.011; Millar CB, 2006, COLD SPRING HARB SYM, V69, P193; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Nathan D, 2006, GENE DEV, V20, P966, DOI 10.1101/gad.1404206; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; O'Neill LP, 2006, NAT GENET, V38, P835, DOI 10.1038/ng1820; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pogribny IP, 2007, J NUTR, V137, p216S, DOI 10.1093/jn/137.1.216S; Polevoda B, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-5-reviews0006; Polo SE, 2006, CURR OPIN GENET DEV, V16, P104, DOI 10.1016/j.gde.2006.02.011; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rose G, 2003, EXP GERONTOL, V38, P1065, DOI 10.1016/S0531-5565(03)00209-2; Rosenberg MI, 2002, CELL, V109, P447, DOI 10.1016/S0092-8674(02)00732-8; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rougeulle C, 2004, MOL CELL BIOL, V24, P5475, DOI 10.1128/MCB.24.12.5475-5484.2004; Sakurada K, 1996, J BACTERIOL, V178, P5781, DOI 10.1128/jb.178.19.5781-5786.1996; Sandmeier JJ, 2002, GENETICS, V160, P877; Sarma K, 2005, NAT REV MOL CELL BIO, V6, P139, DOI 10.1038/nrm1567; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Scher MB, 2007, GENE DEV, V21, P920, DOI 10.1101/gad.1527307; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shankaranarayana GD, 2003, CURR BIOL, V13, P1240, DOI 10.1016/S0960-9822(03)00489-5; Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200; Shia WJ, 2006, GENE DEV, V20, P2507, DOI 10.1101/gad.1439206; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith CM, 2003, ANAL BIOCHEM, V316, P23, DOI 10.1016/S0003-2697(03)00032-0; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; Takata T, 2003, BIOCHEM BIOPH RES CO, V301, P250, DOI 10.1016/S0006-291X(02)03020-6; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tsang AW, 1998, J BIOL CHEM, V273, P31788, DOI 10.1074/jbc.273.48.31788; Tsuchiya M, 2006, AGING CELL, V5, P505, DOI 10.1111/j.1474-9726.2006.00240.x; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; van Leeuwen F, 2002, CURR OPIN CELL BIOL, V14, P756, DOI 10.1016/S0955-0674(02)00393-9; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; VAQUERO A, 2003, SCI AGING KNOWLEDGE, pRE4, DOI DOI 10.1126/SAGEKE.2003.14.RE4; VAQUERO A, UNPUB; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaquero Alejandro, 2006, P23; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wilson JM, 2006, EMBO REP, V7, P1247, DOI 10.1038/sj.embor.7400829; Xie JX, 1999, EMBO J, V18, P6448, DOI 10.1093/emboj/18.22.6448; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yu YC, 2005, P NATL ACAD SCI USA, V102, P8650, DOI 10.1073/pnas.0501458102; Zhang HY, 2005, CELL, V123, P219, DOI 10.1016/j.cell.2005.08.036; Zhou YG, 2005, CURR BIOL, V15, P1434, DOI 10.1016/j.cub.2005.06.057	167	217	227	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5505	5520		10.1038/sj.onc.1210617	http://dx.doi.org/10.1038/sj.onc.1210617			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694090				2022-12-28	WOS:000248674300017
J	Lakshmikuttyamma, A; Pastural, E; Takahashi, N; Sawada, K; Sheridan, DP; DeCoteau, JF; Geyer, CR				Lakshmikuttyamma, A.; Pastural, E.; Takahashi, N.; Sawada, K.; Sheridan, D. P.; DeCoteau, J. F.; Geyer, C. R.			Bcr-Abl induces autocrine IGF-1 signaling	ONCOGENE			English	Article						IGF-1; BCR-ABL; CML; autocrine signaling	GROWTH-FACTOR-I; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; FACTOR 1 RECEPTOR; HEMATOPOIETIC-CELLS; BETA-CATENIN; PHILADELPHIA-CHROMOSOME	Bcr-Abl oncogene is responsible for the initial phase of chronic myelogenous leukemia (CML), which is effectively treated by the Bcr-Abl inhibitor imatinib. Over time patients become resistant to treatment and progress to blast crisis, an event that is driven by additional genetic and epigenetic aberrations. Recently, we showed that Riz1 expression decreases in blast crisis and that re-expression of Riz1 inhibits IGF-1 expression. IGF-1 signaling is required in many stages of hematopoiesis and inappropriate activation of autocrine IGF-1 signaling may facilitate transformation to blast crisis. We observed that in 8 out of 11 matched CML patient biopsies the IGF-1 expression is elevated in blast crisis. We examined mechanisms used by CML blast crisis cell lines to activate IGF-1 expression. We found that Bcr-Abl activates autocrine IGF- 1 signaling using Hck and Stat5b. Inhibition of these signaling components using small molecule drugs or shRNA decreases proliferation and enhances apoptosis. Together, our study suggests that aberrant IGF- 1 signaling is an important event in blast crisis transformation and it provides a mechanism to explain the activity of IGF-1R and Hck inhibitors in blocking CML blast crisis phenotypes.	[Lakshmikuttyamma, A.; Pastural, E.; Sheridan, D. P.; DeCoteau, J. F.; Geyer, C. R.] Univ Saskatchewan, Genom Med & Pathobiol Res Grp, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; [Lakshmikuttyamma, A.; DeCoteau, J. F.] Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 5E5, Canada; [Pastural, E.; Geyer, C. R.] Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; [Sheridan, D. P.] Univ Saskatchewan, Dept Med, Saskatoon, SK S7N 5E5, Canada; [Takahashi, N.; Sawada, K.] Akita Univ, Sch Med, Akita 010, Japan	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; Akita University	Geyer, CR (corresponding author), Univ Saskatchewan, Genom Med & Pathobiol Res Grp, Dept Biochem, Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	ron.geyer@usask.ca	Lakshmikuttyamma, Ashakumary/K-7164-2019	Lakshmikuttyamma, Ashakumary/0000-0001-8580-7855				AKAHANE K, 1987, EXP HEMATOL, V15, P797; Barnes DJ, 2002, ACTA HAEMATOL-BASEL, V108, P180, DOI 10.1159/000065655; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Coluccia AML, 2007, EMBO J, V26, P1456, DOI 10.1038/sj.emboj.7601485; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Danielpour D, 2006, CYTOKINE GROWTH F R, V17, P59, DOI 10.1016/j.cytogfr.2005.09.007; Deutsch E, 2004, BRIT J CANCER, V91, P1735, DOI 10.1038/sj.bjc.6602190; DiNoto R, 1997, LEUKEMIA, V11, P1554; Doepfner KT, 2007, LEUKEMIA, V21, P1921, DOI 10.1038/sj.leu.2404813; Drexler HG, 1999, LEUKEMIA RES, V23, P207; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Guilhot F, 2007, BLOOD, V109, P4143, DOI 10.1182/blood-2006-09-046839; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; HIZUKA N, 1987, ENDOCRINOL JAPON, V34, P81; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; JOHNSON EW, 1992, J IMMUNOL, V148, P63; Jones HE, 2006, ENDOCR-RELAT CANCER, V13, pS45, DOI 10.1677/erc.1.01275; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; KURTZ A, 1988, P NATL ACAD SCI USA, V85, P7825, DOI 10.1073/pnas.85.20.7825; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; MERCHAV S, 1988, BRIT J HAEMATOL, V70, P267, DOI 10.1111/j.1365-2141.1988.tb02480.x; MERCHAV S, 1988, J CLIN INVEST, V81, P791, DOI 10.1172/JCI113385; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Nam S, 2007, MOL CANCER THER, V6, P1400, DOI 10.1158/1535-7163.MCT-06-0446; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Pastural E, 2007, ONCOGENE, V26, P1586, DOI 10.1038/sj.onc.1209959; PEPE MG, 1987, J CELL PHYSIOL, V133, P219, DOI 10.1002/jcp.1041330204; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; SANDERS M, 1993, EXP HEMATOL, V21, P25; Scherr M, 2006, BLOOD, V107, P3279, DOI 10.1182/blood-2005-08-3087; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schwartz GN, 1996, STEM CELLS, V14, P337, DOI 10.1002/stem.140337; Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHIMON I, 1995, LEUKEMIA RES, V19, P233, DOI 10.1016/0145-2126(94)00133-U; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; SPECCHIA G, 1992, BRIT J HAEMATOL, V80, P310, DOI 10.1111/j.1365-2141.1992.tb08138.x; Steller MA, 1996, CANCER RES, V56, P5087; Takahashi N, 2006, BLOOD, V108, p605A, DOI 10.1182/blood.V108.11.2134.2134; Tazzari PL, 2007, LEUKEMIA, V21, P886, DOI 10.1038/sj.leu.2404643; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang Y, 2005, J BIOL CHEM, V280, P10955, DOI 10.1074/jbc.M412808200; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; ZADIK Z, 1993, J PEDIATR ENDOCRINOL, V6, P79; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang ZH, 2006, MOL PHARMACOL, V69, P1510, DOI 10.1124/mol.106.023721; Zumkeller W, 1999, BLOOD, V94, P3653, DOI 10.1182/blood.V94.11.3653.423k42_3653_3657	72	34	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3831	3844		10.1038/onc.2008.8	http://dx.doi.org/10.1038/onc.2008.8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246120				2022-12-28	WOS:000256904700007
J	Brooke, GN; Parker, MG; Bevan, CL				Brooke, G. N.; Parker, M. G.; Bevan, C. L.			Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression	ONCOGENE			English	Article						androgen receptor; prostate cancer; co-activators; anti-androgens; SARMs	LIGAND-BINDING DOMAIN; MOLECULAR-MECHANISMS; CELL-GROWTH; WILD-TYPE; COREGULATORS; RECOGNITION; COFACTORS; MUTATION; LNCAP; FXXLF	Prostate tumour growth depends on androgens; hence treatment includes androgen ablation and anti-androgens. Eventually tumours progress and in approximately 30% of patients this is associated with mutation of the androgen receptor. Several receptor variants associated with advanced disease show promiscuous activation by other hormones and anti-androgens. Such loss of speci.city could promote receptor activation, hence tumour growth, in the absence of conventional ligands, explaining therapy failure. We aimed to elucidate mechanisms by which alternative ligands promote receptor activation. The three most commonly identified variants in tumours (with amino-acid substitutions H874Y, T877A and T877S) and wild-type receptor showed differences in co-activator recruitment dependent upon ligand and the interaction motif utilized. Co-expression and knockdown of co-activators that bind via leucine or phenylalanine motifs, combined with chromatin immunoprecipitation and quantitative PCR, revealed these preferences extend to co-activator recruitment in vivo and affect receptor activity at the transcriptional level, with subsequent effects on target gene regulation. The findings suggest that mutant receptors, activated by alternative ligands, drive growth via different mechanisms to androgenactivated wild-type receptor. Tumours may hence behave differently dependent upon any androgen receptor mutation present and what ligand is driving growth, as distinct subsets of genes may be regulated.	[Brooke, G. N.; Bevan, C. L.] Univ London Imperial Coll Sci Technol & Med, Androgen Signalling Lab, Dept Oncol, London W12 0NN, England; [Parker, M. G.] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England	Imperial College London; Imperial College London	Bevan, CL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Androgen Signalling Lab, Dept Oncol, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Brooke, Greg/C-9426-2013; Brooke, Greg/ABF-4859-2020; Bevan, Charlotte L/K-2276-2012; Bevan, Charlotte/T-7769-2019	Bevan, Charlotte L/0000-0002-7533-0552; Brooke, Greg/0000-0003-4501-4134	Medical Research Council Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541; Askew EB, 2007, J BIOL CHEM, V282, P25801, DOI 10.1074/jbc.M703268200; BERREVOETS CA, 1993, J STEROID BIOCHEM, V46, P731, DOI 10.1016/0960-0760(93)90313-L; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Callewaert L, 2004, MOL ENDOCRINOL, V18, P1438, DOI 10.1210/me.2003-0313; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; Dubbink HJ, 2004, MOL ENDOCRINOL, V18, P2132, DOI 10.1210/me.2003-0375; Duff J, 2005, MOL ENDOCRINOL, V19, P2943, DOI 10.1210/me.2005-0231; Estebanez-Perpina E, 2005, J BIOL CHEM, V280, P8060, DOI 10.1074/jbc.M407046200; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Gamble SC, 2007, ONCOGENE, V26, P1757, DOI 10.1038/sj.onc.1209967; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Goktas S, 1999, SEMIN ONCOL, V26, P162; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P4315; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Hsu CL, 2003, J BIOL CHEM, V278, P23691, DOI 10.1074/jbc.M211908200; Hu YC, 2004, J BIOL CHEM, V279, P33438, DOI 10.1074/jbc.M401781200; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kazmin D, 2006, MOL ENDOCRINOL, V20, P1201, DOI 10.1210/me.2005-0309; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; LI J, 2007, MOL ENDOCRINOL; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Linja MJ, 2004, CLIN CANCER RES, V10, P1032, DOI 10.1158/1078-0432.CCR-0990-3; Linja MJ, 2001, CANCER RES, V61, P3550; Lu S, 1997, CANCER RES, V57, P4511; Maki HE, 2006, PROSTATE, V66, P1391, DOI 10.1002/pros.20427; Marcelli M, 2000, CANCER RES, V60, P944; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McDonald S, 2000, CANCER RES, V60, P2317; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mestayer C, 2003, PROSTATE, V56, P192, DOI 10.1002/pros.10229; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Ozers MS, 2007, BIOCHEMISTRY-US, V46, P683, DOI 10.1021/bi061321b; Powell SM, 2004, ENDOCR-RELAT CANCER, V11, P117, DOI 10.1677/erc.0.0110117; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Segal S, 2006, EXPERT OPIN INV DRUG, V15, P377, DOI 10.1517/13543784.15.4.377; Steketee K, 2002, INT J CANCER, V100, P309, DOI 10.1002/ijc.10495; Taplin ME, 2007, NAT CLIN PRACT ONCOL, V4, P236, DOI 10.1038/ncponc0765; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; van de Wijngaart DJ, 2006, J BIOL CHEM, V281, P19407, DOI 10.1074/jbc.M602567200; VELDSCHOLTE J, 1994, J STEROID BIOCHEM, V49, P341, DOI 10.1016/0960-0760(94)90277-1; Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922	55	62	64	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					2941	2950		10.1038/sj.onc.1210955	http://dx.doi.org/10.1038/sj.onc.1210955			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18037956	Green Submitted			2022-12-28	WOS:000255681700001
J	Nakamura, K; Ichise, H; Nakao, K; Hatta, T; Otani, H; Sakagami, H; Kondo, H; Katsuki, M				Nakamura, K.; Ichise, H.; Nakao, K.; Hatta, T.; Otani, H.; Sakagami, H.; Kondo, H.; Katsuki, M.			Partial functional overlap of the three ras genes in mouse embryonic development	ONCOGENE			English	Article						H-Ras; N-Ras; K-Ras; gene targeting; knockout mice; transgenic mice	H-RAS; K-RAS; PLASMA-MEMBRANE; N-RAS; EXPRESSION; LOCALIZATION; PROTEIN; GROWTH; CELLS; MICE	In mammals, three ras genes, H-ras, N-ras and K-ras, encode homologous but distinct 21-kDa Ras proteins. We examined the in vivo functional relationship of the three ras genes in mouse embryonic development by investigating the phenotypes of mice deficient in one or multiple ras genes. H-ras(-/-) mice and N-ras(-/-) mice as well as a substantial proportion of H-ras(-/-)/N-ras(-/-) mice expressing only the K-ras gene were viable, while K-ras(-/-) mice were embryonically lethal, as have been reported previously. N-ras(-/-)/K-ras(+/-) mice died neonatally, while H-ras(-/-)/K-ras(-/-) embryos died much earlier than K-ras homozygous mutant fetuses. To further investigate the functional relationship of the ras genes in embryonic development, we introduced a human H-ras transgene into single or multiple ras mutant mice and found that the transgene rescued mice, including triple ras mutants, from embryonic lethality in association with correction of thin ventricular walls of the heart in null K-ras mutant mice. In situ hybridization revealed that the expression of the H-ras transgene on embryonic day E13.5 and E15.5 was more intense in major organs, including the heart, than those of endogenous ras genes. We therefore conclude that the functions of the ras genes are partially overlapping in mouse embryonic development.	[Nakamura, K.] Mitsubishi kagaku Inst Life Sci, Mouse Genome Technol Lab, Tokyo, Japan; [Ichise, H.] Univ Tokyo, Lab Gene Express & Regulat, Ctr Med Expt, Inst Med Sci,Minato Ku, Tokyo, Japan; [Nakao, K.] Ctr Dev Biol, Lab Anim Resources & Genet Engn, Chuo Ku, Kobe, Hyogo, Japan; [Hatta, T.; Otani, H.] Shimane Univ, Fac Med, Dept Anat, Izumo, Shimane, Japan; [Sakagami, H.; Kondo, H.] Tohoku Univ, Div Histol, Dept Cell Biol, Grad Sch Med Sci, Sendai, Miyagi 980, Japan; [Katsuki, M.] Natl Inst Basic Biol, Okazaki, Aichi 444, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); University of Tokyo; Shimane University; Tohoku University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Katsuki, M (corresponding author), Natl Inst Nat Sci, Minato Ku, Toranomon 4-3-13, Tokyo 1050001, Japan.	katsuki@nibb.ac.jp	Ichise, Hirotake/V-3536-2019	Ichise, Hirotake/0000-0002-3424-6637; zhong wei, he gui/0000-0002-3066-3564				Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Hancock JF, 2005, BIOCHEM J, V389, P1, DOI 10.1042/BJ20050231; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHER J, 1995, ONCOGENE, V11, P1639; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Manabe T, 2000, J NEUROSCI, V20, P2504; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; Perez de Castro I, 2003, CANCER RES, V63, P1615; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; SAITOH A, 1990, ONCOGENE, V5, P1195; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yamaguchi H, 1996, GENES CELLS, V1, P253, DOI 10.1046/j.1365-2443.1996.d01-238.x	30	29	30	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					2961	2968		10.1038/sj.onc.1210956	http://dx.doi.org/10.1038/sj.onc.1210956			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059342				2022-12-28	WOS:000255681700003
J	Persson, F; Winnes, M; Andren, Y; Wedell, B; Dahlenfors, R; Asp, J; Mark, J; Enlund, F; Stenman, G				Persson, F.; Winnes, M.; Andren, Y.; Wedell, B.; Dahlenfors, R.; Asp, J.; Mark, J.; Enlund, F.; Stenman, G.			High-resolution array CGH analysis of salivary gland tumors reveals fusion and amplification of the FGFR1 and PLAG1 genes in ring chromosomes	ONCOGENE			English	Article						array-CGH; gene amplification; fusion oncogene; FGFR1; PLAG1; salivary gland tumor	COMPARATIVE GENOMIC HYBRIDIZATION; DIFFERENTIAL EXPRESSION; PLEOMORPHIC ADENOMAS; IN-VITRO; CANCER; REARRANGEMENTS; TRANSLOCATION; DELETIONS; PROTEIN; BREAST	We have previously identified a subgroup of pleomorphic salivary gland adenomas with ring chromosomes of uncertain derivation. Here, we have used spectral karyotyping (SKY), fluorescence in situ hybridization (FISH) and high-resolution oligonucleotide array-CGH to determine the origin and content of these rings and to identify genes disrupted as a result of ring formation. Of 16 tumors with rings, 11 were derived from chromosome 8, 3 from chromosome 5 and 1 each from chromosomes 1, 6 and 9. Array-CGH revealed that 10/11 r(8) consisted of amplification of a 19Mb pericentromeric segment with recurrent breakpoints in FGFR1 in 8p12 and in PLAG1 in 8q12.1. Molecular analyses revealed that ring formation consistently generated novel FGFR1-PLAG1 gene fusions in which the 5'-part of FGFR1 is linked to the coding sequence of PLAG1. An alternative mechanism of PLAG1 activation was found in tumors with copy number gain of an intact PLAG1 gene. Rings derived from chromosomes 1, 5, 6 or 9 did not result in gene fusions, but rather resulted in losses indicative of the involvement of putative tumor suppressor genes on 8p, 5p, 5q and/or 6q. Our findings also reveal a novel mechanism by which FGFR1 contributes to oncogenesis and further illustrate the versatility of the FGFR1 and PLAG1 genes tumorigenesis.	[Persson, F.; Winnes, M.; Andren, Y.; Wedell, B.; Asp, J.; Enlund, F.; Stenman, G.] Sahlgrens Univ Hosp, Dept Pathol, Lundberg Lab Canc Res, SE-41345 Gothenburg, Sweden; [Dahlenfors, R.; Mark, J.] Cent Hosp Skovde, Dept Pathol, Skovde, Sweden	Sahlgrenska University Hospital	Stenman, G (corresponding author), Sahlgrens Univ Hosp, Dept Pathol, Lundberg Lab Canc Res, SE-41345 Gothenburg, Sweden.	goran.stenman@llcr.med.gu.se	Asp, Julia/AAE-5624-2019	Enlund, Fredrik/0000-0003-0030-9393				Abbott JJ, 2006, MODERN PATHOL, V19, P1512, DOI 10.1038/modpathol.3800695; Asp J, 2006, GENE CHROMOSOME CANC, V45, P820, DOI 10.1002/gcc.20346; Astrom AK, 1999, CANCER RES, V59, P918; Barrett MT, 2004, P NATL ACAD SCI USA, V101, P17765, DOI 10.1073/pnas.0407979101; Brennan C, 2004, CANCER RES, V64, P4744, DOI 10.1158/0008-5472.CAN-04-1241; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; EVESON JW, 2005, WHO CLASSIFICATION T, P254; Geurts JMW, 1997, CANCER RES, V57, P13; Gisselsson D, 1999, HUM GENET, V104, P315, DOI 10.1007/s004390050960; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; Hoffman MP, 2002, DEVELOPMENT, V129, P5767, DOI 10.1242/dev.00172; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; Johansson B, 2002, ACTA HAEMATOL-BASEL, V107, P76, DOI 10.1159/000046636; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kost-Alimova M, 2003, P NATL ACAD SCI USA, V100, P6622, DOI 10.1073/pnas.0430971100; Kost-Alimova M, 2007, SEMIN CANCER BIOL, V17, P19, DOI 10.1016/j.semcancer.2006.11.003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARK J, 1988, CANCER GENET CYTOGEN, V33, P229, DOI 10.1016/0165-4608(88)90033-7; Mark J, 1997, CANCER GENET CYTOGEN, V95, P9, DOI 10.1016/S0165-4608(96)00204-X; MARK J, 1983, ACTA PATH MICRO IM A, V91, P397; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; NORDKVIST A, 1994, GENE CHROMOSOME CANC, V10, P115, DOI 10.1002/gcc.2870100206; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Reis JS, 2006, CLIN CANCER RES, V12, P6652, DOI 10.1158/1078-0432.CCR-06-1164; Roijer E, 2002, AM J PATHOL, V160, P433, DOI 10.1016/S0002-9440(10)64862-6; Roumiantsev S, 2004, CANCER CELL, V5, P287, DOI 10.1016/S1535-6108(04)00053-4; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Sjogren H, 2000, CANCER RES, V60, P6832; Stenman G, 2005, SEMIN CANCER BIOL, V15, P224, DOI 10.1016/j.semcancer.2005.01.002; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Voz ML, 2004, ONCOGENE, V23, P179, DOI 10.1038/sj.onc.1207013; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84	38	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3072	3080		10.1038/sj.onc.1210961	http://dx.doi.org/10.1038/sj.onc.1210961			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059337				2022-12-28	WOS:000255681700015
J	Binda, O; Nassif, C; Branton, PE				Binda, O.; Nassif, C.; Branton, P. E.			SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins	ONCOGENE			English	Article						transcription; RBP1; BCAA; SIRT1; HDAC1; mSIN3A	CANDIDATE TUMOR-SUPPRESSOR; HISTONE DEACETYLASE COMPLEX; N-COR; COREPRESSOR COMPLEX; DNA-BINDING; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; GROWTH ARREST; CANCER-CELLS	Both RBP1 and the highly related protein BCAA play a role in the induction of growth arrest and cellular senescence via mechanisms involving transcriptional repression. While investigating the transcriptional repression activities of RBP1, we observed a genetic link between RBP1 and SIR2. Further work uncovered an interaction between RBP1 family proteins and the mammalian homologue of SIR2, SIRT1. Interestingly, the HDAC-dependent transcriptional repression domain of RBP1 proteins, termed R2, is necessary and sufficient for the interaction with SIRT1. In vitro and in vivo binding studies indicated that the p33(ING1b) and p33(ING2) subunits of the mSIN3A/HDAC1 complex are responsible for the recruitment of SIRT1 to the R2 domain. To investigate the biological relevance of this interaction, we used the sirtuin activator resveratrol and the sirtuin inhibitor sirtinol in transcriptional repression assays and demonstrated that SIRT1 activity negatively regulates R2-mediated transcriptional repression activity. We therefore propose a novel mechanism of class I HDAC regulation by a class III HDAC. Explicitly, SIRT1 is recruited by ING proteins and inhibits R2-associated mSIN3A/HDAC1 transcriptional repression activity.	[Binda, O.; Nassif, C.; Branton, P. E.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Branton, P. E.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; [Branton, P. E.] McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,Room 702,3655 Promenader Sir Wi, Montreal, PQ H3G 1Y6, Canada.	philip.branton@mcgill.ca	Binda, Olivier/A-5941-2009	Binda, Olivier/0000-0002-1539-0828				Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Binda O, 2006, MOL CELL BIOL, V26, P1917, DOI 10.1128/MCB.26.5.1917-1931.2006; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2005, MECH AGEING DEV, V126, P923, DOI 10.1016/j.mad.2005.03.013; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huang EY, 2000, GENE DEV, V14, P45; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kataoka H, 2003, CANCER RES, V63, P5785; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim S, 1999, MOL BIOL CELL, V10, P3125, DOI 10.1091/mbc.10.10.3125; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520; Laj A, 1999, MOL CELL BIOL, V19, P6632; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Lu RQ, 1999, J CELL PHYSIOL, V179, P297, DOI 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nikolaev AY, 2004, BIOCHEM BIOPH RES CO, V323, P1216, DOI 10.1016/j.bbrc.2004.08.227; North BJ, 2005, METHODS, V36, P338, DOI 10.1016/j.ymeth.2005.03.004; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Ota H, 2007, J MOL CELL CARDIOL, V43, P571, DOI 10.1016/j.yjmcc.2007.08.008; Parsons XH, 2003, P NATL ACAD SCI USA, V100, P1609, DOI 10.1073/pnas.0434064100; Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Qiu Y, 2006, MOL CELL, V22, P669, DOI 10.1016/j.molcel.2006.04.019; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Sasaki T, 2006, AGING CELL, V5, P413, DOI 10.1111/j.1474-9726.2006.00235.x; Sgambato A, 2001, MUTAT RES-GEN TOX EN, V496, P171, DOI 10.1016/S1383-5718(01)00232-7; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Takata T, 2003, BIOCHEM BIOPH RES CO, V301, P250, DOI 10.1016/S0006-291X(02)03020-6; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013; Wilson JM, 2006, EMBO REP, V7, P1247, DOI 10.1038/sj.embor.7400829; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	73	55	55	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3384	3392		10.1038/sj.onc.1211014	http://dx.doi.org/10.1038/sj.onc.1211014			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193082				2022-12-28	WOS:000256309900003
J	Lee, T; Langford, KJ; Askham, JM; Bruning-Richardson, A; Morrison, EE				Lee, T.; Langford, K. J.; Askham, J. M.; Bruning-Richardson, A.; Morrison, E. E.			MCAK associates with EB1	ONCOGENE			English	Article						EB1; MCAK; APC; microtubule	APC TUMOR-SUPPRESSOR; MICROTUBULE PLUS-END; MAMMALIAN-CELLS; PROTEIN; P150(GLUED); KINESIN; DEPOLYMERIZATION; POLYMERIZATION; DOMAINS	The microtubule ( MT)- associated protein EB1 localizes to and promotes growth at MT plus ends. The MT depolymerizing kinesin MCAK has also been reported to track growing MT plus ends. Here, we confirm that human MCAK colocalizes with EB1 at growing MT ends when expressed as a GFP fusion protein in transfected cells. We show that MCAK associates with the C- terminus of EB1 and EB3 but much less efficiently with RP1. EB1 associates with the N- terminal localization and regulatory domain in MCAK but not with the motor domain of the protein. The interaction is competitive with the binding of other EB1 ligands and does not require MTs. Knockdown of EB1 expression using siRNA impaired the ability of GFP- MCAK to localize to MT tips in transfected cells. We propose that MCAK is targeted to growing MT ends by EB1, that MCAK is held in an inactive conformation when associated with EB1 and that this could provide the basis for a mechanism that facilitates rapid switching between phases of MT growth and depolymerization.	[Lee, T.; Langford, K. J.; Askham, J. M.; Bruning-Richardson, A.; Morrison, E. E.] Univ Leeds, St James Univ Hosp, Leeds Inst Mol Med, Div Canc Med Res,CRUK Clin Ctr Leeds, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Morrison, EE (corresponding author), Univ Leeds, St James Univ Hosp, Leeds Inst Mol Med, Div Canc Med Res,CRUK Clin Ctr Leeds, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	e.e.morrison@leeds.ac.uk		Bruning-Richardson, Anke/0000-0002-9862-9805	Cancer Research UK Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Banks JD, 2004, CURR BIOL, V14, P2033, DOI 10.1016/j.cub.2004.10.049; Bu W, 2003, J BIOL CHEM, V278, P49721, DOI 10.1074/jbc.M306194200; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Draviam VM, 2006, EMBO J, V25, P2814, DOI 10.1038/sj.emboj.7601168; Ems-McClung SC, 2007, MOL BIOL CELL, V18, P282, DOI 10.1091/mbc.E06-08-0724; Hayashi I, 2005, MOL CELL, V19, P449, DOI 10.1016/j.molcel.2005.06.034; Helenius J, 2006, NATURE, V441, P115, DOI 10.1038/nature04736; Kinoshita K, 2006, J MUSCLE RES CELL M, V27, P107, DOI 10.1007/s10974-005-9045-2; Kline-Smith SL, 2004, MOL BIOL CELL, V15, P1146, DOI 10.1091/mbc.E03-08-0581; Knowlton AL, 2006, CURR BIOL, V16, P1705, DOI 10.1016/j.cub.2006.07.057; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; Lansbergen G, 2006, TRAFFIC, V7, P499, DOI 10.1111/j.1600-0854.2006.00400.x; Maney T, 2001, J BIOL CHEM, V276, P34753, DOI 10.1074/jbc.M106626200; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Moore AT, 2005, J CELL BIOL, V169, P391, DOI 10.1083/jcb.200411089; Moores CA, 2006, J CELL SCI, V119, P3905, DOI 10.1242/jcs.03224; Morrison EE, 2007, CELL MOL LIFE SCI, V64, P307, DOI 10.1007/s00018-007-6360-3; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Ohi R, 2007, CURR BIOL, V17, P953, DOI 10.1016/j.cub.2007.04.057; Riess NP, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-17; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; Watson P, 2006, J CELL SCI, V119, P2758, DOI 10.1242/jcs.02999	25	49	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2494	2500		10.1038/sj.onc.1210867	http://dx.doi.org/10.1038/sj.onc.1210867			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968321				2022-12-28	WOS:000254844900014
J	Montero-Conde, C; Martin-Campos, JM; Lerma, E; Gimenez, G; Martinez-Guitarte, JL; Combalia, N; Montaner, D; Matias-Guiu, X; Dopazo, J; de Leiva, A; Robledo, M; Mauricio, D				Montero-Conde, C.; Martin-Campos, J. M.; Lerma, E.; Gimenez, G.; Martinez-Guitarte, J. L.; Combalia, N.; Montaner, D.; Matias-Guiu, X.; Dopazo, J.; de Leiva, A.; Robledo, M.; Mauricio, D.			Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information	ONCOGENE			English	Article						anaplastic thyroid cancer; functional profile; molecular signature	DIFFUSE SCLEROSING VARIANT; DIFFERENTIATED CARCINOMAS; MESENCHYMAL TRANSITION; PAPILLARY CARCINOMA; MICROARRAY DATA; BREAST-CANCER; TGF-BETA; METASTASIS; OVEREXPRESSION; CONTRIBUTES	Undifferentiated and poorly differentiated thyroid tumors are responsible for more than half of thyroid cancer patient deaths in spite of their low incidence. Conventional treatments do not obtain substantial benefits, and the lack of alternative approaches limits patient survival. Additionally, the absence of prognostic markers for well-differentiated tumors complicates patient-specific treatments and favors the progression of recurrent forms. In order to recognize the molecular basis involved in tumor dedifferentiation and identify potential markers for thyroid cancer prognosis prediction, we analysed the expression profile of 44 thyroid primary tumors with different degrees of dedifferentiation and aggressiveness using cDNA microarrays. Transcriptome comparison of dedifferentiated and well-differentiated thyroid tumors identified 1031 genes with > 2-fold difference in absolute values and false discovery rate of <0.15. According to known molecular interaction and reaction networks, the products of these genes were mainly clustered in the MAPkinase signaling pathway, the TGF-beta signaling pathway, focal adhesion and cell motility, activation of actin polymerization and cell cycle. An exhaustive search in several databases allowed us to identify various members of the matrix metalloproteinase, melanoma antigen A and collagen gene families within the upregulated gene set. We also identified a prognosis classifier comprising just 30 transcripts with an overall accuracy of 95%. These findings may clarify the molecular mechanisms involved in thyroid tumor dedifferentiation and provide a potential prognosis predictor as well as targets for new therapies.	[Montero-Conde, C.; Robledo, M.] Spanish Natl Canc Ctr, Hereditary Endocrine Canc Grp Leader, CNIO, E-28029 Madrid, Spain; [Mauricio, D.] Arnau Vilanova Hosp, Dept Endocrinol, IRBLLEIDA, E-25198 Lleida, Spain; [Martin-Campos, J. M.] Santa Creu & Sant Pau Hosp, Res Inst, Barcelona, Spain; [Martin-Campos, J. M.] Univ Autonoma Barcelona, Biochem & Mol Biol Dept, Barcelona, Spain; [Lerma, E.] Santa Creu & Sant Pau Hosp, Pathol Serv, Barcelona, Spain; [Martinez-Guitarte, J. L.; Matias-Guiu, X.] Arnau Vilanova Hosp, IRBLLEIDA, Dept Pathol & Mol Genet, Lleida, Spain; [Montaner, D.; Dopazo, J.] CIPF, Bioinformat Dept, Valencia, Spain; [Dopazo, J.; Robledo, M.] CIBERER, Ctr Biomed Res Rare Dis, ISCIII, Lleida, Spain; [de Leiva, A.; Mauricio, D.] Santa Creu & Sant Pau Hosp, Dept Endocrinol & Nutr, Barcelona, Spain; [de Leiva, A.] CIBER, BBN, ISCIII, Lleida, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); University Hospital Arnau de Vilanova; Autonomous University of Barcelona; Institut de Recerca Biomedica - IRB Lleida; University Hospital Arnau de Vilanova; Prince Felipe Research Center; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Instituto de Salud Carlos III	Robledo, M (corresponding author), Spanish Natl Canc Ctr, Hereditary Endocrine Canc Grp Leader, CNIO, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	mrobledo@cnio.es	Martín-Campos, Jesús M./AAQ-5478-2021; Martinez-Guitarte, Jose-Luis/M-3990-2014; matias-guiu, xavier/C-3039-2009; Martín-Campos, Jesús Maria/AGJ-2586-2022; Lerma, Enrique/C-8498-2015; Robledo, Mercedes/O-2230-2013; Mauricio, Didac/B-7951-2009; Dopazo, Joaquin/A-9270-2014; Montero-Conde, Cristina/K-7349-2014; Montaner, David/A-9362-2014	Martinez-Guitarte, Jose-Luis/0000-0002-7722-864X; matias-guiu, xavier/0000-0002-7201-6605; Martín-Campos, Jesús Maria/0000-0003-0414-037X; Robledo, Mercedes/0000-0001-6256-5902; Mauricio, Didac/0000-0002-2868-0250; Dopazo, Joaquin/0000-0003-3318-120X; Montero-Conde, Cristina/0000-0002-4452-4469; de Leiva, Alberto/0000-0002-0419-6771; Montaner, David/0000-0002-2484-3278				Ain KB, 1999, SEMIN SURG ONCOL, V16, P64, DOI 10.1002/(SICI)1098-2388(199901/02)16:1<64::AID-SSU10>3.3.CO;2-L; Al-Shahrour F, 2006, NUCLEIC ACIDS RES, V34, pW472, DOI 10.1093/nar/gkl172; Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; Ambroise C, 2002, P NATL ACAD SCI USA, V99, P6562, DOI 10.1073/pnas.102102699; Benjamini Y, 2005, GENETICS, V171, P783, DOI 10.1534/genetics.104.036699; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; Burgdorf SK, 2006, J EXP CLIN CANC RES, V25, P201; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Croizet-Berger K, 2002, P NATL ACAD SCI USA, V99, P8277, DOI 10.1073/pnas.122187699; DELELLIS RA, 2004, WHO TUMORS ENDOCRINE; Duan ZF, 2003, CLIN CANCER RES, V9, P2778; FUJIMOTO Y, 1990, CANCER-AM CANCER SOC, V66, P2306, DOI 10.1002/1097-0142(19901201)66:11<2306::AID-CNCR2820661109>3.0.CO;2-P; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Glinsky GV, 2006, CELL CYCLE, V5, P1208, DOI 10.4161/cc.5.11.2796; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Lam AKY, 2006, ANN SURG ONCOL, V13, P176, DOI 10.1245/ASO.2006.03.062; Medina I, 2007, BIOINFORMATICS, V23, P390, DOI 10.1093/bioinformatics/btl602; Montaner D, 2006, NUCLEIC ACIDS RES, V34, pW486, DOI 10.1093/nar/gkl197; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Motti ML, 2005, CARCINOGENESIS, V26, P1021, DOI 10.1093/carcin/bgi050; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Onda M, 2004, ENDOCR-RELAT CANCER, V11, P843, DOI 10.1677/erc.1.00818; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; Randolph GW, 2002, THYROID, V12, P989, DOI 10.1089/105072502320908321; Rocha AS, 2003, HISTOPATHOLOGY, V42, P580, DOI 10.1046/j.1365-2559.2003.01642.x; SAKAMOTO A, 1983, CANCER, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Slettenaar VIF, 2006, ADV DRUG DELIVER REV, V58, P962, DOI 10.1016/j.addr.2006.03.012; Smith BR, 2006, THYROID, V16, P109, DOI 10.1089/thy.2006.16.109; Sobrinho-Simoes M, 2002, INT J SURG PATHOL, V10, P123, DOI 10.1177/106689690201000205; Sorrentino R, 2005, J CLIN ENDOCR METAB, V90, P928, DOI 10.1210/jc.2004-1518; Tang L, 2006, CLIN CANCER RES, V12, P3716, DOI 10.1158/1078-0432.CCR-06-0030; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Vini L, 2002, LANCET ONCOL, V3, P407, DOI 10.1016/S1470-2045(02)00787-8; Voigt C, 2000, FEBS LETT, V486, P208, DOI 10.1016/S0014-5793(00)02302-4; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zou M, 2005, BRIT J CANCER, V93, P1277, DOI 10.1038/sj.bjc.6602856	43	67	76	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1554	1561		10.1038/sj.onc.1210792	http://dx.doi.org/10.1038/sj.onc.1210792			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873908				2022-12-28	WOS:000253815800007
J	Harada, T; Chelala, C; Bhakta, V; Chaplin, T; Caulee, K; Baril, P; Young, BD; Lemoine, NR				Harada, T.; Chelala, C.; Bhakta, V.; Chaplin, T.; Caulee, K.; Baril, P.; Young, B. D.; Lemoine, N. R.			Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays	ONCOGENE			English	Article						pancreatic cancer; tissue microdissection; SNP array; genetic alterations; SKAP2/SCAP2	UNIPARENTAL DISOMY; TISSUE MICRODISSECTION; HOMOZYGOUS DELETIONS; GENETIC ALTERATIONS; HETEROZYGOSITY; ADENOCARCINOMA; HYBRIDIZATION; ABERRATIONS	To identify genomic abnormalities characteristic of pancreatic ductal adenocarcinoma (PDAC) in vivo, a panel of 27 microdissected PDAC specimens were analysed using high-density microarrays representing similar to 116000 single nucleotide polymorphism (SNP) loci. We detected frequent gains of 1q, 2, 3, 5, 7p, 8q, 11, 14q and 17q (>= 78% of cases), and losses of 1p, 3p, 6, 9p, 13q, 14q, 17p and 18q (>= 44%). Although the results were comparable with those from array CGH, regions of those genetic changes were defined more accurately by SNP arrays. Integrating the Ensembl public data, we have generated 'gene' copy number indices that facilitate the search for novel candidates involved in pancreatic carcinogenesis. Copy numbers in a subset of the genes were validated using quantitative real-time PCR. The SKAP2/SCAP2 gene (7p15.2), which belongs to the src family kinases, was most frequently (63%) amplified in our sample set and its recurrent overexpression (67%) was confirmed by reverse transcription-PCR. Furthermore, fluorescence in situ hybridization and in situ RNA hybridization analyses for this gene have demonstrated a significant correlation between DNA copy number and mRNA expression level in an independent sample set (P < 0.001). These findings indicate that the dysregulation of SKAP2/SCAP2, which is mostly caused by its increased gene copy number, is likely to be associated with the development of PDA C.	[Harada, T.; Chelala, C.; Bhakta, V.; Caulee, K.; Baril, P.; Lemoine, N. R.] Univ London, Ctr Mol Oncol, Inst Canc, Barts & London Sch Med & Dent,Canc Res UK, London EC1M 6BQ, England; [Chaplin, T.; Young, B. D.] Univ London, Ctr Med Oncol, Inst Canc, Barts & London Sch Med & Dent,Canc Res UK, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK; University of London; Queen Mary University London	Lemoine, NR (corresponding author), Univ London, Ctr Mol Oncol, Inst Canc, Barts & London Sch Med & Dent,Canc Res UK, Charterhouse Sq, London EC1M 6BQ, England.	nick.lemoine@cancer.org.uk		chelala, claude/0000-0002-2488-0669; BARIL, Patrick/0000-0001-8290-9899	Cancer Research UK [A6253, A6789, A6438] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Andersen CL, 2007, CARCINOGENESIS, V28, P38, DOI 10.1093/carcin/bgl086; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bignell GR, 2004, GENOME RES, V14, P287, DOI 10.1101/gr.2012304; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Calhoun ES, 2006, CANCER RES, V66, P7920, DOI 10.1158/0008-5472.CAN-06-0721; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Fitzgibbon J, 2005, CANCER RES, V65, P9152, DOI 10.1158/0008-5472.CAN-05-2017; Fujita M, 2007, J BIOL CHEM, V282, P5736, DOI 10.1074/jbc.M606175200; GRIFFIN CA, 1995, CANCER RES, V55, P2394; Harada T, 2007, BRIT J CANCER, V96, P373, DOI 10.1038/sj.bjc.6603563; Harada T, 2002, CANCER RES, V62, P835; Harada T, 2002, ONCOLOGY-BASEL, V62, P251, DOI 10.1159/000059573; Huang Jing, 2004, Human Genomics, V1, P287; Iacobuzio-Donahue CA, 2004, CANCER RES, V64, P871, DOI 10.1158/0008-5472.CAN-03-2756; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Janne PA, 2004, ONCOGENE, V23, P2716, DOI 10.1038/sj.onc.1207329; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Karhu R, 2006, GENE CHROMOSOME CANC, V45, P721, DOI 10.1002/gcc.20337; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Lips EH, 2007, J PATHOL, V212, P269, DOI 10.1002/path.2180; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Midorikawa Y, 2006, ONCOGENE, V25, P5581, DOI 10.1038/sj.onc.1209537; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Raghavan M, 2005, CANCER RES, V65, P375; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Saramaki OR, 2006, INT J CANCER, V119, P1322, DOI 10.1002/ijc.21976; TAKAHASHI T, 2003, J BIOL, P42225; Yamamoto G, 2007, AM J HUM GENET, V81, P114, DOI 10.1086/518809; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	32	101	106	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1951	1960		10.1038/sj.onc.1210832	http://dx.doi.org/10.1038/sj.onc.1210832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17952125	Green Accepted			2022-12-28	WOS:000254150600015
J	Denicourt, C; Legault, P; McNabb, FA; Rassart, E				Denicourt, C.; Legault, P.; McNabb, F-AC; Rassart, E.			Human and mouse cyclin D2 splice variants: transforming activity and subcellular localization	ONCOGENE			English	Article						truncated cyclin D2; transformation; splice variant	CELL-PROLIFERATION; KINASE ACTIVATION; DEPENDENT KINASE; PHASE ARREST; D1; EXPRESSION; PHOSPHORYLATION; GENE; OVEREXPRESSION; IDENTIFICATION	We have previously reported the identification of a novel 17 kDa truncated isoform of the cyclin D2 activated in 13% of the leukemias induced by the Graf. murine leukemia retrovirus. Retroviral integration in the Gris1 locus causes an alternative splicing of the mouse cyclin D2 gene and expression of a truncated protein of 159 amino acids that is detected at high levels in the Gris1 tumors and also in normal mouse tissues mainly the brain and ovaries. A truncated form of the cyclin D2 was also found in human. We show here that both mouse- and human-truncated cyclin D2 are able to transform primary mouse embryo fibroblasts (MEF) when co-expressed with an activated Ras protein. The truncated cyclin D2 localizes only to the cytoplasm of transfected cells. It has retained the ability to interact with cyclin-dependent kinases (CDKs), although it is a poor catalyst of pRb phosphorylation. Interestingly, the presence of a similar, alternatively spliced cyclin D2 mRNA was also detected in some human brain tumors.	[Denicourt, C.; Legault, P.; McNabb, F-AC; Rassart, E.] Univ Quebec, Dept Sci Biol, Mol Biol Lab, Montreal, PQ H3C 3P8, Canada	University of Quebec; University of Quebec Montreal	Rassart, E (corresponding author), Univ Quebec, Dept Sci Biol, Mol Biol Lab, Case Postale 8888, Montreal, PQ H3C 3P8, Canada.	Rassart.Eric@UQAM.ca		Denicourt, Catherine/0000-0001-8721-0163				Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Assoian Richard K., 1997, Cytokine and Growth Factor Reviews, V8, P165, DOI 10.1016/S1359-6101(97)00011-7; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartkova J, 1999, J PATHOL, V187, P573, DOI 10.1002/(SICI)1096-9896(199904)187:5<573::AID-PATH289>3.0.CO;2-H; Buschges R, 1999, BRAIN PATHOL, V9, P435; Denicourt C, 2003, J VIROL, V77, P37, DOI 10.1128/JVI.77.1.37-44.2003; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANNA Z, 1993, ONCOGENE, V8, P1661; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Lu FM, 2003, CANCER RES, V63, P7056; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Ortenblad A, 2002, INT J MANAG REV, V4, P87, DOI 10.1111/1468-2370.00078; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Schwartz MA, 2001, J CELL SCI, V114, P2553; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Susaki E, 2007, MOL CELL BIOL, V27, P4626, DOI 10.1128/MCB.00862-06; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Taieb F, 1996, BIOL CELL, V88, P99, DOI 10.1016/S0248-4900(97)83525-3; Teramoto N, 1999, INT J CANCER, V81, P543, DOI 10.1002/(SICI)1097-0215(19990517)81:4<543::AID-IJC7>3.3.CO;2-V; TREMBLAY PJ, 1992, J VIROL, V66, P1344, DOI 10.1128/JVI.66.3.1344-1353.1992; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	38	9	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1253	1262		10.1038/sj.onc.1210750	http://dx.doi.org/10.1038/sj.onc.1210750			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17873913				2022-12-28	WOS:000253407000007
J	Gal, A; Sjoblom, T; Fedorova, L; Imreh, S; Beug, H; Moustakas, A				Gal, A.; Sjoeblom, T.; Fedorova, L.; Imreh, S.; Beug, H.; Moustakas, A.			Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis	ONCOGENE			English	Article						epithelial-mesenchymal transition; metastasis; Smad; signal transduction; TGF beta; tumour suppression	TRANSFORMING GROWTH-FACTOR-BETA-1; TUMOR PROGRESSION; HUMAN CANCER; HA-RAS; METASTASIS; PLASTICITY; PATHWAY; TRANSDIFFERENTIATION; PROLIFERATION; INVASIVENESS	To better understand the dual, tumour-suppressive and tumour-promoting function of transforming growth factor-beta (TGF beta), we analysed mammary epithelial NMuMG cells in response to short and long-term TGFb exposure. NMuMG cells became proliferation-arrested and apoptotic after exposure to TGFb for 2-5 days, whereas surviving cells underwent epithelial-mesenchymal transition (EMT). After chronic TGFb exposure (2-3 weeks), however, NMuMG cells became resistant to proliferation arrest and apoptosis, showing sustained EMT instead (TD cells). EMT was fully reversed by a pharmacologic TGF beta-receptor-I kinase inhibitor or withdrawal of TGFb for 6-12 days. Interestingly, both cell cycle arresting/proapoptotic (Smads, p38 kinase) and antiapoptotic, proliferation and EMT-promoting signalling pathways (PI3K-PKB/Akt, ERK) were co-suppressed to low, but significant levels. Except for PI3K-Akt, TGF beta-dependent downregulation of these signalling pathways in transdifferentiated (TD) cells was fully reversed upon TGFb withdrawal, together with partial re-induction of proliferation arrest and apoptosis. Co-injection of non-tumorigenic NMuMG cells with tumour-forming CHO cells oversecreting exogenous TGF beta 1 (CHO-TGF beta 1) allowed outgrowth of epithelioid cells in CHO-TGF beta 1 cell-induced tumours. These epithelial islands enhanced CHO-TGF beta 1 tumour cell proliferation, possibly due to chemokines (for example, JE/MCP-1) secreted by NMuMG/TD cells. We conclude that suppression of antiproliferative, proapoptotic TGF beta signalling in TD cells may permit TGF beta-dependent proliferation, survival and EMT-enhancing signalling pathways to act at low levels. Thus, TGF beta may modulate its own signalling to facilitate switching from tumour suppression to tumour progression.	[Gal, A.; Beug, H.] Res Inst Mol Pathol, A-1030 Vienna, Austria; [Gal, A.; Sjoeblom, T.; Moustakas, A.] Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; [Sjoeblom, T.; Fedorova, L.] Karolinska Inst, Microbiol & Tumor Biol Ctr, Stockholm, Sweden	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Ludwig Institute for Cancer Research; Karolinska Institutet	Beug, H (corresponding author), Inst Mol Pathol, Dr A Moustakas, A-1030 Vienna, Austria.	beug@imp.univie.ac.at; aris.moustakas@LICR.uu.se		Gal, Annamaria/0000-0001-8171-1389	Austrian Science Fund (FWF) [F 2802] Funding Source: researchfish	Austrian Science Fund (FWF)(Austrian Science Fund (FWF))		Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; DALAL BI, 1993, AM J PATHOL, V143, P381; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; IVANOVIC V, 1995, NAT MED, V1, P282, DOI 10.1038/nm0495-282; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Piek E, 1999, J CELL SCI, V112, P4557; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Shim KS, 1999, CANCER-AM CANCER SOC, V85, P554, DOI 10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sjoblom T, 2001, CANCER RES, V61, P5778; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Waerner T, 2006, CANCER CELL, V10, P227, DOI 10.1016/j.ccr.2006.07.020	26	174	181	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1218	1230		10.1038/sj.onc.1210741	http://dx.doi.org/10.1038/sj.onc.1210741			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724470				2022-12-28	WOS:000253407000004
J	Gast, D; Riedle, S; Issa, Y; Pfeifer, M; Beckhove, P; Sanderson, MP; Arlt, M; Moldenhauer, G; Fogel, M; Kruger, A; Altevogt, P				Gast, D.; Riedle, S.; Issa, Y.; Pfeifer, M.; Beckhove, P.; Sanderson, M. P.; Arlt, M.; Moldenhauer, G.; Fogel, M.; Krueger, A.; Altevogt, P.			The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies	ONCOGENE			English	Article						cell migration; tumor growth; signaling; therapeutic antibodies	CELL-ADHESION MOLECULE; ACTIVATED PROTEIN-KINASES; MELANOMA PROGRESSION; MALIGNANT-MELANOMA; OVARIAN CARCINOMAS; NEURITE OUTGROWTH; L1 CD171; MIGRATION; METASTASIS; BINDING	L1 cell adhesion molecule (L1-CAM) is a transmembrane cell adhesion molecule involved in cell migration and axon guidance in the developing nervous system. L1 is also overexpressed in ovarian and endometrial carcinomas and is associated with a bad prognosis. In carcinoma cell lines, L1 overexpression augments cell motility, tumor growth in mice and induces expression of Erk-dependent genes. Here, we show that a mutation in the cytoplasmic portion of L1 (T1247A, S1248A) abrogates Erk activation, blocks cell migration on extracellular matrix proteins and did not augment tumor growth in non-obese diabetic/severe combined immuno-deficient mice. In cells expressing mutant L1, the induction of Erk-dependent genes such as beta 3-integrin, cathepsin-B and several transcription factors is eliminated and the invasive phenotype is abrogated. L1 antibodies showed similar effects. They prevented Erk activation and interfered with the Erk-dependent gene expression pattern. These findings provide a rationale for the mode of action of L1 antibodies and suggest that interference with L1 function could become a valuable target for therapy.	[Gast, D.; Riedle, S.; Issa, Y.; Pfeifer, M.; Beckhove, P.; Sanderson, M. P.; Moldenhauer, G.; Altevogt, P.] German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; [Arlt, M.; Krueger, A.] Tech Univ Munich, Inst Expt Oncol & Therapy, Munich, Germany; [Fogel, M.] Kaplan Med Ctr, Dept Pathol, Rehovot, Israel	Helmholtz Association; German Cancer Research Center (DKFZ); Technical University of Munich; Hebrew University of Jerusalem; Kaplan Medical Center	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, D010,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	P.Altevogt@dkfz.de	Sanderson, Michael/I-1674-2017	Sanderson, Michael/0000-0001-5362-486X				Allory Y, 2005, CLIN CANCER RES, V11, P1190; Arlt MJE, 2006, CANCER RES, V66, P936, DOI 10.1158/0008-5472.CAN-05-1818; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Brunner G, 1998, EXP CELL RES, V239, P301, DOI 10.1006/excr.1997.3877; Cheng L, 2005, J NEUROCHEM, V94, P1102, DOI 10.1111/j.1471-4159.2005.03254.x; Cheng L, 2005, J NEUROSCI, V25, P395, DOI 10.1523/JNEUROSCI.4097-04.2005; Colucci-D'Amato L, 2003, BIOESSAYS, V25, P1085, DOI 10.1002/bies.10355; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Gast D, 2005, INT J CANCER, V115, P658, DOI 10.1002/ijc.20869; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Huszar M, 2006, HUM PATHOL, V37, P1000, DOI 10.1016/j.humpath.2006.03.014; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Knogler K, 2007, CLIN CANCER RES, V13, P603, DOI 10.1158/1078-0432.CCR-06-1486; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meier F, 2006, INT J CANCER, V119, P549, DOI 10.1002/ijc.21880; MOLDENHAUER G, 1987, BRIT J CANCER, V56, P714, DOI 10.1038/bjc.1987.276; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; Primiano T, 2003, CANCER CELL, V4, P41, DOI 10.1016/S1535-6108(03)00169-7; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schmid RS, 2000, J NEUROSCI, V20, P4177; Senner V, 2002, GLIA, V38, P146, DOI 10.1002/glia.10058; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Silletti S, 2004, J BIOL CHEM, V279, P28880, DOI 10.1074/jbc.M404075200; Tang NF, 2006, J NEUROCHEM, V96, P1480, DOI 10.1111/j.1471-4159.2006.03649.x; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Thies A, 2002, EUR J CANCER, V38, P1708, DOI 10.1016/S0959-8049(02)00105-3	31	69	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1281	1289		10.1038/sj.onc.1210747	http://dx.doi.org/10.1038/sj.onc.1210747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17952127				2022-12-28	WOS:000253407000010
J	Beppu, H; Mwizerwa, ON; Beppu, Y; Dattwyler, MP; Lauwers, GY; Bloch, KD; Goldstein, AM				Beppu, H.; Mwizerwa, O. N.; Beppu, Y.; Dattwyler, M. P.; Lauwers, G. Y.; Bloch, K. D.; Goldstein, A. M.			Stromal inactivation of BMPRII leads to colorectal epithelial overgrowth and polyp formation	ONCOGENE			English	Article						bone morphogenetic proteins; BMPRII; nestin hamartomatous polyps; colorectal polyps; stromal-epithelial interactions	JUVENILE POLYPOSIS; CELLS; MYOFIBROBLASTS; SUPPRESSION; FIBROBLASTS; MUTATIONS; SIGNALS; GENE	Stromal - epithelial interactions play a central role in development and tumorigenesis. Bone morphogenetic protein ( BMP) signaling in the intestine is involved in both of these processes. Inactivation of BMP pathway genes in the epithelium is known to cause intestinal polyposis. However, the role of the intestinal stroma in polyp initiation is incompletely understood. We observed that conditional inactivation of the BMP type II receptor ( BMPRII) in the stroma leads to epithelial hyperplasia throughout the colon with increased epithelial cell proliferation. Mutant mice developed rectal bleeding and hamartomatous polyps in the colorectum. The polyps demonstrated increased proliferation of epithelial and mesenchymal cells in the mucosa with an expansion of the myofibroblast cell population. These results demonstrate that genetic mutations altering the BMP signaling pathway in the stromal microenvironment can lead to epithelial tumors in the colon.	[Mwizerwa, O. N.; Goldstein, A. M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA; [Beppu, H.; Beppu, Y.; Dattwyler, M. P.; Bloch, K. D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA 02114 USA; [Lauwers, G. Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Goldstein, AM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Surg, 55 Fruit St,Warren 1153, Boston, MA 02114 USA.	agoldstein@partners.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074352] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL074352] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adegboyega PA, 2002, ARCH PATHOL LAB MED, V126, P829; Batts LE, 2006, DEV DYNAM, V235, P1563, DOI 10.1002/dvdy.20741; Beppu H, 2005, GENESIS, V41, P133, DOI 10.1002/gene.20099; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Chen AL, 2005, SURGERY, V138, P382, DOI 10.1016/j.surg.2005.04.012; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Hogan B, 1994, MANIPULATING MOUSE E; Howe JR, 2004, J MED GENET, V41, P484, DOI 10.1136/jmg.2004.018598; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; LIU D, IN PRESS BLOOD; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Trumpp A, 1999, GENE DEV, V13, P3136, DOI 10.1101/gad.13.23.3136; van den Brink GR, 2004, NAT GENET, V36, P1038, DOI 10.1038/ng1004-1038; Wirtzfeld DA, 2001, ANN SURG ONCOL, V8, P319, DOI 10.1245/aso.2001.8.4.319	26	66	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1063	1070		10.1038/sj.onc.1210720	http://dx.doi.org/10.1038/sj.onc.1210720			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700526				2022-12-28	WOS:000253136700005
J	Faucherre, A; Taylor, GS; Overvoorde, J; Dixon, JE; den Hertog, J				Faucherre, A.; Taylor, G. S.; Overvoorde, J.; Dixon, J. E.; den Hertog, J.			Zebrafish pten genes have overlapping and non-redundant functions in tumorigenesis and embryonic development	ONCOGENE			English	Article						pten; zebrafish; tumorigenesis; development; proliferation; survival	LIPID PHOSPHATASE-ACTIVITY; LHERMITTE-DUCLOS-DISEASE; TUMOR-SUPPRESSOR PTEN; PROTEIN-KINASE B; SIGNALING PATHWAY; NEGATIVE REGULATION; GERMLINE MUTATIONS; CELL-SURVIVAL; CANCER-CELLS; PTEN/MMAC1	In human cancer, PTEN ( Phosphatase and TENsin homolog on chromosome 10, also referred to as MMAC1 and TEP1) is a frequently mutated tumor suppressor gene. We have used the zebrafish as a model to investigate the role of Pten in embryonic development and tumorigenesis. The zebrafish genome encodes two pten genes, ptena and ptenb. Here, we report that both Pten gene products from zebrafish are functional. Target-selected inactivation of ptena and ptenb revealed that Ptena and Ptenb have redundant functions in embryonic development, in that ptena-/- and ptenb-/- mutants did not show embryonic phenotypes. Homozygous single mutants survived as adults and they were viable and fertile. Double homozygous ptena-/- ptenb-/- mutants died at 5 days post fertilization with pleiotropic defects. These defects were rescued by treatment with the phosphatidylinositol-3-kinase inhibitor, LY294002. Double homozygous embryos showed enhanced cellular proliferation. In addition, cell survival was dramatically enhanced in embryos that lack functional Pten upon gamma-irradiation. Surprisingly, adult ptenb-/- zebrafish developed ocular tumors later in life, despite the expression of ptena in adult eyes. We conclude that whereas Ptena and Ptenb have redundant functions in embryonic development, they apparently do not have completely overlapping functions later in life. These pten mutant zebrafish represent a unique model to screen for genetic and/ or chemical suppressors of Pten loss-of-function.	[Faucherre, A.; Overvoorde, J.; den Hertog, J.] Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; [Taylor, G. S.; Dixon, J. E.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Taylor, G. S.; Dixon, J. E.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Taylor, G. S.; Dixon, J. E.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	den Hertog, J (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	j.denhertog@niob.knaw.nl		Faucherre, Adele/0000-0002-6099-3898				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Cole LK, 2001, DEV BIOL, V240, P123, DOI 10.1006/dbio.2001.0432; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Croushore JA, 2005, DEV DYNAM, V234, P911, DOI 10.1002/dvdy.20576; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Gregorieff A, 2004, EMBO J, V23, P1825, DOI 10.1038/sj.emboj.7600191; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marcus RC, 1999, VISUAL NEUROSCI, V16, P417, DOI 10.1017/S095252389916303X; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stokoe D, 2001, CURR BIOL, V11, pR502, DOI 10.1016/S0960-9822(01)00303-7; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Taylor GS, 2003, METHOD ENZYMOL, V366, P43; Westerfield M., 1995, GUIDE LAB USE ZEBRAF; Wienholds E, 2002, SCIENCE, V297, P99, DOI 10.1126/science.1071762; Wu ZX, 2007, TUMOR BIOL, V28, P9, DOI 10.1159/000097041; Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382	32	86	89	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1079	1086		10.1038/sj.onc.1210730	http://dx.doi.org/10.1038/sj.onc.1210730			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704803				2022-12-28	WOS:000253136700007
J	Morange, M				Morange, M.			The field of cancer research: an indicator of present transformations in biology	ONCOGENE			English	Review						cause; epigenetics; niche; post-genomics; stem cell	MALIGNANT-TUMORS; SOMATIC MUTATION; STEM-CELLS; EPIGENETICS; PARADIGM; HISTORY; PATHWAY; ORIGIN	'Biology and cancer research have developed together. Invariably, at each stage, the characteristics of the cancer cell have been ascribed to some defect in whatever branch of biology happens at the time to be fashionable and exciting; today, it is molecular genetics'. Tremendous transformations have occurred in cancer research since these few lines were written by John Cairns: the discovery of oncogenes and anti- oncogenes, and the successful development of 'magic bullets' targeting the proteins encoded by these oncogenes. Nevertheless, Cairns' message is still valid. In 1978, he observed the first attempts to apply the tools and concepts of molecular biology to cancer; today, this research. field reflects multiple and diverse efforts that go 'beyond' molecular biology by looking for explanations that have been left aside during its development, or by privileging new approaches, fully original or actively pursued in other fields of biological research. Because of this specific characteristic of cancer research, it is possible to use it as an indicator of trends in biological research in general.	[Morange, M.] ENS, Dept Biol, F-75230 Paris 056, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Morange, M (corresponding author), ENS, Dept Biol, 46 Rue Ulm, F-75230 Paris 056, France.	morange@biologie.ens.fr						Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Borczuk AC, 2007, ONCOGENE, V26, P610, DOI 10.1038/sj.onc.1209809; CAIRNS J, 1978, CANC SCI SOC, P63; Downward J, 2006, SCIENCE, V314, P433, DOI 10.1126/science.1134727; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ferres-Marco D, 2006, NATURE, V439, P430, DOI 10.1038/nature04376; Frantz S, 2005, NATURE, V437, P942, DOI 10.1038/437942a; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950; Kiberstis PA, 2006, SCIENCE, V312, P1157, DOI 10.1126/science.312.5777.1157; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; MANCHESTER KL, 1995, TRENDS CELL BIOL, V5, P384, DOI 10.1016/S0962-8924(00)89080-7; Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160; Marx J, 2003, SCIENCE, V301, P1308, DOI 10.1126/science.301.5638.1308; Morange M, 1997, J HIST BIOL, V30, P1, DOI 10.1023/A:1004255309721; Morange M, 2006, J BIOSCIENCES, V31, P537, DOI 10.1007/BF02708404; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Odling-Smee FJ, 2003, NICHE CONSTRUCTION N; Pelham RJ, 2006, P NATL ACAD SCI USA, V103, P19848, DOI 10.1073/pnas.0609635104; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Soto AM, 2004, BIOESSAYS, V26, P1097, DOI 10.1002/bies.20087; TRIOLO VA, 1965, CANCER RES, V25, P75; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; WEINBERG RA, 1982, CELL, V30, P3, DOI 10.1016/0092-8674(82)90003-4	37	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7607	7610		10.1038/sj.onc.1210583	http://dx.doi.org/10.1038/sj.onc.1210583			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17653097				2022-12-28	WOS:000251537800001
J	Bermudez, O; Marchetti, S; Pages, G; Gimond, C				Bermudez, O.; Marchetti, S.; Pages, G.; Gimond, C.			Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway	ONCOGENE			English	Article						ERK phosphatase DUSP6/MKP-3; mTOR; phosphorylation; degradation	ACTIVATED PROTEIN-KINASE; SPECIFICITY; MKP3; TRANSLATION; CANCER; MOTIF	MAP kinases phosphatases (MKPs) belong to the dual-specificity phosphatase family (DUSP) and dephosphorylate phosphothreonine and phosphotyrosine within MAP kinases. We had previously shown that DUSP6/MKP-3 was phosphorylated and degraded upon growth factor stimulation, in a MEK-dependent manner. Here we show that another pathway involved in growth factor signaling, the PI3K/mTOR signaling pathway, accounts for a part of the phosphorylation and degradation of DUSP6 induced by serum growth factors, as evidenced by experiments using pharmacological inhibitors of PI3 kinase and mammalian target of rapamycin (mTOR). Moreover, specific agonists of the mTOR pathway, such as amino acids or insulin/IGF-1, which do not activate extracellular signal regulated kinases (ERKs) in our cellular model, were also able to induce the phosphorylation and degradation of DUSP6. However, a basal activity of MEK was required for the mTOR pathway-mediated phosphorylation to occur. Mutagenesis studies identified serine 159 within DUSP6 as the target of the mTOR pathway. The ERK phosphatase DUSP6 may thus constitute a novel branch-point of the crosstalk between two major signaling pathways induced by growth factors, the MEK/ERK pathway and the PI3K/mTOR pathway.	[Bermudez, O.; Marchetti, S.; Pages, G.; Gimond, C.] Univ Nice Sophia Antipolis, CNRS, Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res,UMR 6543, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Gimond, C (corresponding author), Univ Nice Sophia Antipolis, CNRS, Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res,UMR 6543, 33 Ave Valombrose, F-06189 Nice, France.	gimond@unice.fr	Pages, Gilles/N-7135-2017; Marchetti, Sandrine/P-6479-2016	Marchetti, Sandrine/0000-0001-8326-5730; Gimond, Clotilde/0000-0003-1708-4629				Averous J, 2006, ONCOGENE, V25, P6423, DOI 10.1038/sj.onc.1209887; Avruch J, 2006, ONCOGENE, V25, P6361, DOI 10.1038/sj.onc.1209882; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Echevarria D, 2005, DEV BIOL, V277, P114, DOI 10.1016/j.ydbio.2004.09.011; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Jeffrey KL, 2007, NAT REV DRUG DISCOV, V6, P391, DOI 10.1038/nrd2289; Kawakami Y, 2003, NAT CELL BIOL, V5, P513, DOI 10.1038/ncb989; Kim M, 2004, MOL CELL BIOL, V24, P573, DOI 10.1128/MCB.24.2.573-583.2004; Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Li CY, 2007, DEVELOPMENT, V134, P167, DOI 10.1242/dev.02701; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; Marchetti S, 2004, J CELL PHYSIOL, V199, P441, DOI 10.1002/jcp.10465; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Smith TG, 2006, FEBS LETT, V580, P4242, DOI 10.1016/j.febslet.2006.06.081	22	60	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3685	3691		10.1038/sj.onc.1211040	http://dx.doi.org/10.1038/sj.onc.1211040			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223677				2022-12-28	WOS:000256659300005
J	Lee, YJ; Lee, HJ; Lee, JS; Jeoung, D; Kang, CM; Bae, S; Lee, SJ; Kwon, SH; Kang, D; Lee, YS				Lee, Y. J.; Lee, H. J.; Lee, J. S.; Jeoung, D.; Kang, C. M.; Bae, S.; Lee, S. J.; Kwon, S. H.; Kang, D.; Lee, Y. S.			A novel function for HSF1-induced mitotic exit failure and genomic instability through direct interaction between HSF1 and Cdc20	ONCOGENE			English	Article						HSF1; interaction with Cdc20; mitotic arrest; aneuploidy; inhibition of APC activity	SHOCK; DEPHOSPHORYLATION; EXPRESSION; FACTOR-1; CANCERS; MITOSIS; ROLES; CELLS	Although heat-shock factor (HSF) 1 is a known transcriptional factor of heat-shock proteins, other pathwayslike production of aneuploidy and increased protein stability of cyclin B1 have been proposed. In the present study, the regulatory domain of HSF1 (amino-acid sequence 212-380) was found to interact directly with the amino-acid sequence 106-171 of Cdc20. The association between HSF1 and Cdc20 inhibited the interaction between Cdc27 and Cdc20, the phosphorylation of Cdc27 and the ubiquitination activity of anaphase-promoting complex (APC). The overexpression of HSF1 inhibited mitotic exit and the degradations of cyclin B1 and securin, which resulted in production of aneuploidy and multinucleated cells, but regulatory domain-deficient HSF1 did not. Moreover, HSF1-overexpressing cells showed elevated levels of micronuclei and genomic alteration. The depletion of HSF1 from cells highly expressing HSF1 reduced nocodazole-mediated aneuploidy in cells. These findingss suggest a novel function of HSF1 frequently overexpressed in cancer cells, to inhibit APC/C activity by interacting with Cdc20, and to result in aneuploidy development and genomic instability.	[Lee, Y. J.; Lee, H. J.; Kang, C. M.; Bae, S.; Lee, Y. S.] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 139706, South Korea; [Lee, J. S.; Lee, S. J.] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea; [Jeoung, D.] Kangwon Natl Univ, Coll Nat Sci, Chunchon, South Korea; [Kwon, S. H.; Kang, D.] Korea basic Sci Inst, Chunchon Ctr, Chunchon, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Kangwon National University; Korea Basic Science Institute (KBSI)	Lee, YS (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Effect, 215-4 Gongneung Dong, Seoul 139706, South Korea.	yslee@kcch.re.kr	Lee, Yun-Sil/AAP-1378-2020	Lee, Yun-Sil/0000-0002-7538-8850				Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cen H, 2004, WORLD J GASTROENTERO, V10, P3122; Cross FR, 2003, DEV CELL, V4, P741, DOI 10.1016/S1534-5807(03)00119-9; HAHN GM, 1988, CANCER RES, V48, P1803; Hida K, 2005, CANCER RES, V65, P2507, DOI 10.1158/0008-5472.CAN-05-0002; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Ricaniadis N, 2001, EUR J SURG ONCOL, V27, P88, DOI 10.1053/ejso.1999.1018; Seo HR, 2006, J BIOL CHEM, V281, P17220, DOI 10.1074/jbc.M600062200; SHIN CR, 2003, CANC LETT, V201, P203; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200	17	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					2999	3009		10.1038/sj.onc.1210966	http://dx.doi.org/10.1038/sj.onc.1210966			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059335				2022-12-28	WOS:000255681700007
J	Vilgelm, A; Wei, JX; Piazuelo, MB; Washington, MK; Prassolov, V; El-Rifai, W; Zaika, A				Vilgelm, A.; Wei, J. X.; Piazuelo, M. B.; Washington, M. K.; Prassolov, V.; El-Rifai, W.; Zaika, A.			Delta Np73 alpha regulates MDR1 expression by inhibiting p53 function	ONCOGENE			English	Article						p73; p53; gastric tumor	P-GLYCOPROTEIN; P73 ISOFORMS; IN-VIVO; GASTRIC ADENOCARCINOMA; CLINICAL-RELEVANCE; GENE-EXPRESSION; POOR-PROGNOSIS; HUMAN TUMORS; CANCER; CELLS	The p73 protein is a transcription factor and member of the p53 protein family that expresses as a complex variety of isoforms. Delta Np73 alpha is an N-terminally truncated isoform of p73. We found that Delta Np73 protein is upregulated in human gastric carcinoma suggesting that DNp73 may play an oncogenic role in these tumors. Although it has been shown that DNp73a inhibits apoptosis and counteracts the effect of chemotherapeutic drugs, the underlying mechanism by which this p73 isoform contributes to chemotherapeutic drug response remains to be explored. We found that DNp73a upregulates MDR1 mRNA and p-glycoprotein (p-gp), which is involved in chemotherapeutic drug transport. This p-gp upregulation was accompanied by increased p-gp functional activity in gastric cancer cells. Our data suggest that upregulation of MDR1 by DNp73a is mediated by interaction with p53 at the MDR1 promoter.	[Vilgelm, A.; Wei, J. X.; El-Rifai, W.; Zaika, A.] Vanderbilt Univ, Med Ctr, Dept Surg & Canc Biol, Nashville, TN 37232 USA; [El-Rifai, W.; Zaika, A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Piazuelo, M. B.] Vanderbilt Univ, Med Ctr, Div Gastroenterol, Nashville, TN 37232 USA; [Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Vilgelm, A.; Prassolov, V.] Russian Acad Sci, VA Engelhardt Mol Biol Inst, Dept Cell Biol, Moscow 117901, Russia	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Zaika, A (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg & Canc Biol, 1255 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.	alex.zaika@vanderbilt.edu		Vilgelm, Anna/0000-0002-4446-913X	NATIONAL CANCER INSTITUTE [R21CA129655, R01CA138833, R01CA108956, P50CA095103] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA138833, R01 CA108956, P50 CA095103, R21 CA129655] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Choi JH, 2002, BRIT J CANCER, V86, P1578, DOI 10.1038/sj.bjc.6600305; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Guan M, 2005, J CLIN PATHOL, V58, P1175, DOI 10.1136/jcp.2005.026955; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; Hotta T, 1999, SURG TODAY, V29, P591, DOI 10.1007/BF02482982; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Johnson RA, 2005, J BIOL CHEM, V280, P13213, DOI 10.1074/jbc.M414646200; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lacueva FJ, 1998, HISTOPATHOLOGY, V32, P328; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; Tomkova K, 2006, ONCOGENE, V25, P6032, DOI 10.1038/sj.onc.1209610; Tomkova K, 2004, CANCER RES, V64, P6390, DOI 10.1158/0008-5472.CAN-04-2176; Uramoto H, 2004, CLIN CANCER RES, V10, P6905, DOI 10.1158/1078-0432.CCR-04-0290; VOLLRATH V, 1991, VIRCHOWS ARCH B, V60, P133, DOI 10.1007/BF02899538; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; WALLNER J, 1993, CANCER, V71, P667, DOI 10.1002/1097-0142(19930201)71:3<667::AID-CNCR2820710303>3.0.CO;2-6; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	30	33	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2170	2176		10.1038/sj.onc.1210862	http://dx.doi.org/10.1038/sj.onc.1210862			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952118	Green Accepted			2022-12-28	WOS:000254621300007
J	Freilinger, A; Rosner, M; Hanneder, M; Hengstschlager, M				Freilinger, A.; Rosner, M.; Hanneder, M.; Hengstschlaeger, M.			Ras mediates cell survival by regulating tuberin	ONCOGENE			English	Article						Ras; survival; tuberin; ERK; RSK	TUMOR-SUPPRESSOR GENE; RIBOSOMAL S6 KINASE; SCLEROSIS COMPLEX; 3-KINASE/AKT PATHWAY; HUMAN-DISEASE; TSC2; PRODUCT; GROWTH; PHOSPHORYLATION; APOPTOSIS	Mutational activation of Ras promotes oncogenesis by controlling cell cycle regulation and cell survival. Ras-mediated activation of both, the PI3K/AKT pathway and the MEK/ERK pathway, can trigger downregulation of the function of tuberin to block the activities of mTOR and p70S6K. Here we demonstrate that Ras-induced cell survival is accompanied by upregulation of p70S6K activity. Ras harbors the potential to negatively affect tuberin-induced apoptosis and p70S6K inactivation. These effects of Ras were found to depend on its potential to regulate the MEK/ERK pathway. Experiments using tuberin-negative fibroblasts revealed that the potential of Ras to counteract apoptosis depends on functional tuberin. Taken together, we provide evidence that the function of Ras to trigger inactivation of tuberin plays a major role in the regulation of cell survival upon mutational activation of the oncogene Ras. This is the first description of a functional interaction between the tumor suppressor tuberin and the oncogene Ras in regulating apoptosis.	[Hengstschlaeger, M.] Med Univ Vienna, Gen Hosp, A-1090 Vienna, Austria	Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Gen Hosp, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at						Adachi H, 2003, J UROLOGY, V170, P601, DOI 10.1097/01.ju.0000074621.74361.10; Arrebola F, 2005, APOPTOSIS, V10, P1317, DOI 10.1007/s10495-005-2718-x; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Ballif BA, 2005, P NATL ACAD SCI USA, V102, P667, DOI 10.1073/pnas.0409143102; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Freilinger A, 2006, ONCOGENE, V25, P6467, DOI 10.1038/sj.onc.1209660; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Knowles MA, 2003, CANCER RES, V63, P7652; Knowles MA, 2003, BIOCHEM SOC T, V31, P597, DOI 10.1042/BST0310597; Kolb TM, 2005, TOXICOL SCI, V88, P331, DOI 10.1093/toxsci/kfi310; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Wohlfart S, 2004, AM J PATHOL, V164, P1081, DOI 10.1016/S0002-9440(10)63195-1; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097	40	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2072	2083		10.1038/sj.onc.1210844	http://dx.doi.org/10.1038/sj.onc.1210844			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922028				2022-12-28	WOS:000254359100012
J	Siddiqui, IA; Malik, A; Adhami, VM; Asim, M; Hafeez, BB; Sarfaraz, S; Mukhtar, H				Siddiqui, I. A.; Malik, A.; Adhami, V. M.; Asim, M.; Hafeez, B. B.; Sarfaraz, S.; Mukhtar, H.			Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis	ONCOGENE			English	Article						EGCG; TRAIL; intrinsic pathway; extrinsic pathway; angiogenesis; metastasis	CANCER CELLS; PROTEASOME INHIBITOR; DEATH RECEPTOR-5; IN-VIVO; EXPRESSION; PATHWAY; GROWTH; (-)-EPIGALLOCATECHIN-3-GALLATE; CHEMOPREVENTION; MODULATION	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L) is a promising candidate for cancer therapy, however, emergence of drug resistance limits its potential use. Here, we report for the first time that epigallocatechin-3-gallate (EGCG), the major polyphenolic constituent of green tea, sensitizes TRAIL-resistant LNCaP cells to TRAIL-mediated apoptosis through modulation of intrinsic and extrinsic apoptotic pathways. When combined with EGCG, Apo2L/TRAIL exhibited enhanced apoptotic activity in LNCaP cells characterized by three major molecular events. First, apoptosis induction was accompanied by the upregulation of poly (ADP-ribose) polymerase cleavage and modulation of pro-and antiapoptotic Bcl2 family of proteins. A synergistic inhibition of inhibitors of apoptosis with concomitant increase in caspase cleavage was observed. Second, pretreatment of cells with EGCG resulted in modulation of death-inducing signaling cascade complex involving DR4/TRAIL R1, Fas-associated death domain and FLICE-inhibitory protein proteins. Last, we observed a synergistic inhibition in the invasion and migration of LNCaP cells. This effect was observed to be mediated through inhibition in the protein expression of vascular endothelial growth factor, uPA and angiopoietin 1 and 2. Further, the activity and protein expression of MMP-2, -3 and -9 and upregulation of TIMP1 in cells treated with a combination of EGCG and TRAIL was observed. These data might have implications for developing new strategies aimed at eliminating prostate cancer cells resistant to TRAIL.	[Siddiqui, I. A.; Malik, A.; Adhami, V. M.; Asim, M.; Hafeez, B. B.; Sarfaraz, S.; Mukhtar, H.] Univ Wisconsin, Med Sci Ctr B 25, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr B 25, Dept Dermatol, 1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Siddiqui, Imtiaz/B-6587-2009; Adhami, Vaqar/AAY-2837-2020	Adhami, Vaqar/0000-0002-2048-4570	NATIONAL CANCER INSTITUTE [R01CA120451, R01CA101039, R01CA078809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 101039, R01 CA 120451, R01 CA 78809] Funding Source: Medline; NIDDK NIH HHS [P50 DK065303-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adhami VM, 2007, CLIN CANCER RES, V13, P1611, DOI 10.1158/1078-0432.CCR-06-2269; Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Bettuzzi S, 2006, CANCER RES, V66, P1234, DOI 10.1158/0008-5472.CAN-05-1145; Bigelow RLH, 2006, ONCOGENE, V25, P1922, DOI 10.1038/sj.onc.1209227; Cantarella G, 2006, BRIT J CANCER, V94, P1428, DOI 10.1038/sj.bjc.6603092; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; de Bock CE, 2004, MED RES REV, V24, P13, DOI 10.1002/med.10054; Deeb D, 2004, MOL CANCER THER, V3, P803; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Gao S, 2005, MOL ENDOCRINOL, V19, P1792, DOI 10.1210/me.2004-0445; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hu HB, 2006, MOL CANCER THER, V5, P1873, DOI 10.1158/1535-7163.MCT-06-0063; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jian L, 2004, INT J CANCER, V108, P130, DOI 10.1002/ijc.11550; Koshida K, 2004, INT J UROL, V11, P1114, DOI 10.1111/j.1442-2042.2004.00961.x; Lakshmikanthan V, 2006, INT J CANCER, V119, P221, DOI 10.1002/ijc.21824; Lam WH, 2004, BIOORGAN MED CHEM, V12, P5587, DOI 10.1016/j.bmc.2004.08.002; Landis-Piwowar KR, 2005, INT J MOL MED, V15, P735; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Munshi A, 2002, CANCER CHEMOTH PHARM, V50, P46, DOI 10.1007/s00280-002-0465-z; Nencioni A, 2005, CLIN CANCER RES, V11, P4259, DOI 10.1158/1078-0432.CCR-04-2496; Ozawa F, 2001, CANCER LETT, V163, P71, DOI 10.1016/S0304-3835(00)00660-1; Qin J, 2007, BIOCHEM BIOPH RES CO, V354, P852, DOI 10.1016/j.bbrc.2007.01.003; Saleem M, 2006, P NATL ACAD SCI USA, V103, P14825, DOI 10.1073/pnas.0606747103; Schimmer AD, 2004, CANCER RES, V64, P7183, DOI 10.1158/0008-5472.CAN-04-1918; Siddiqui IA, 2006, MOL NUTR FOOD RES, V50, P130, DOI 10.1002/mnfr.200500113; Siddiqui IA, 2004, J CELL BIOCHEM, V91, P232, DOI 10.1002/jcb.10737; Siddiqui IA, 2007, ACTA PHARMACOL SIN, V28, P1392, DOI 10.1111/j.1745-7254.2007.00693.x; Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821; Thurston G, 2003, CELL TISSUE RES, V314, P61, DOI 10.1007/s00441-003-0749-6; Yamaguchi K, 2005, ONCOGENE, V24, P5868, DOI 10.1038/sj.onc.1208742; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1	33	168	170	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2055	2063		10.1038/sj.onc.1210840	http://dx.doi.org/10.1038/sj.onc.1210840			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17998943				2022-12-28	WOS:000254359100010
J	Katayama, K; Nakamura, A; Sugimoto, Y; Tsuruo, T; Fujita, N				Katayama, K.; Nakamura, A.; Sugimoto, Y.; Tsuruo, T.; Fujita, N.			FOXO transcription factor-dependent p15(INK4b) and p19(INK4d) expression	ONCOGENE			English	Article						Akt; FOXO; INK4	CYTOPLASMIC LOCALIZATION; GENE-EXPRESSION; CELL-LINES; PHOSPHORYLATION; AKT; INHIBITORS; P27(KIP1); BINDING; FKHR; INVOLVEMENT	FOXO (Forkhead box O) transcription factors are involved in cell-cycle arrest or apoptosis induction by transcripting cell-cycle inhibitor p27(KIP1) or apoptosis-related genes, respectively. Akt/protein kinase B promotes cell proliferation and suppresses apoptosis, in part, by phosphorylating FOXOs. Phosphorylated FOXOs could not exhibit transcriptional activity because of their nuclear export. Here we show that p15(INK4b) and p19(INK4d) transcription is associated with FOXO-mediated G(1) cell-cycle arrest. Inhibition of Akt signaling by PI3K inhibitors, a PDK1 inhibitor, or dominant-negative Akt transfection increased expression of p15(INK4b) and p19(INK4d) but not p16(INK4a) and p18(INK4c). Ectopic expression of wild type or active FOXO but not inactive form also increased p15(INK4b) and p19(INK4d) levels. FOXOs bound to promoter regions and induced transcription of these genes. No increase in the G1-arrested cell population, mediated by PI3K inhibitor LY294002, was observed in INK4b(-/-) or INK4d(-/-) murine embryonic fibroblasts. In summary, FOXOs are involved in G1 arrest caused by Akt inactivation via p15(INK4b) and p19(INK4d) transcription.	[Katayama, K.; Nakamura, A.; Sugimoto, Y.; Tsuruo, T.; Fujita, N.] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Expt Chemotherapy, Tokyo 1358550, Japan; [Katayama, K.; Sugimoto, Y.] Kyoritsu Univ Pharm, Dept Chemotherapy, Tokyo, Japan; [Nakamura, A.] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo, Japan	Japanese Foundation for Cancer Research; Keio University; University of Tokyo	Fujita, N (corresponding author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Expt Chemotherapy, Tokyo 1358550, Japan.	naoya.fujita@jfcr.or.jp	Katayama, Kazuhiro/AAH-2914-2019; Fujita, Naoya/A-7349-2010	Katayama, Kazuhiro/0000-0003-4232-7661; Fujita, Naoya/0000-0002-9631-9264				Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560-6568.2004; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Woods YL, 2002, BIOCHEM SOC T, V30, P391, DOI 10.1042/bst0300391; Zariwala M, 1996, ONCOGENE, V12, P451; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	29	54	56	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1677	1686		10.1038/sj.onc.1210813	http://dx.doi.org/10.1038/sj.onc.1210813			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17873901				2022-12-28	WOS:000253962100003
J	Zhu, S; Korzh, V; Gong, Z; Low, BC				Zhu, S.; Korzh, V.; Gong, Z.; Low, B. C.			RhoA prevents apoptosis during zebrafish embryogenesis through activation of Mek/Erk pathway	ONCOGENE			English	Article						RhoA; Mek/Erk; Bcl-2; apoptosis; embryogenesis; zebrafish	MAMMARY EPITHELIAL-CELLS; ACTIN DEPOLYMERIZATION; SIGNALING PATHWAY; BCL-2 EXPRESSION; PROTEIN-KINASE; SURVIVAL; DIFFERENTIATION; PROLIFERATION; METASTASIS; INHIBITION	RhoA small GTPase, as a key regulator for actin cytoskeletal rearrangement, plays pivotal roles during morphogenesis, cytokinesis, phagocytosis and cell migration, but little is known about its signaling mechanism that controls cell survival in vivo. Using zebrafish as a model, we show that non-overlapping antisense morpholinos that block either translation or splicing of rhoA lead to extensive apoptosis during embryogenesis, resulting in overall reduction of body size and body length. These defects are associated with reduced activation of growth-promoting Erk and decreased expression of anti-apoptotic bcl-2. Moreover, ectopic expression of rhoA, Mek or BCL-2 mRNA rescues such phenotypes. Consistently, combined suppression of RhoA and Mek/Erk or Bcl-2 pathways by sub-optimal dose of rhoA morpholino and pharmacological inhibitors for either Mek (U0126) or Bcl-2 (HA 14-1) can induce developmental abnormalities and enhanced apoptosis, similar to those caused by effective RhoA knockdown. Furthermore, U0126 abrogates the rescue by RhoA and MEK but not BCL-2. In contrast, HA 14-1 effectively abolishes all functional rescues by RhoA, MEK or BCL-2, supporting that RhoA prevents apoptosis by activation of Mek/ Erk pathway and requiring Bcl-2. These findings reveal an important genetic and functional relationship between RhoA with Mek/ Erk and Bcl-2 for cell survival control during embryogenesis.	[Zhu, S.; Korzh, V.; Low, B. C.] Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, Singapore 117543, Singapore; [Zhu, S.; Gong, Z.] Natl Univ Singapore, Dept Biol Sci, Mol Biol Lab, Singapore 117543, Singapore; [Korzh, V.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Low, BC (corresponding author), Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, 14 Sci Dr 4, Singapore 117543, Singapore.	dbslowbc@nus.edu.sg	Low, Boon Chuan/H-8049-2012; Korzh, Vladimir P/H-1596-2011; Low, Boon Chuan/AAU-7685-2021; Gong, Zhiyuan/H-8794-2012	Low, Boon Chuan/0000-0003-0756-096X; Korzh, Vladimir P/0000-0002-6580-7986; Low, Boon Chuan/0000-0003-0756-096X; Gong, Zhiyuan/0000-0002-9660-5260				Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Beis D, 2006, TRENDS CELL BIOL, V16, P105, DOI 10.1016/j.tcb.2005.12.001; Bijian K, 2005, AM J PHYSIOL-RENAL, V289, pF1313, DOI 10.1152/ajprenal.00106.2005; Blanco-Colio LM, 2002, ATHEROSCLEROSIS, V161, P17, DOI 10.1016/S0021-9150(01)00613-X; Cole LK, 2001, DEV BIOL, V240, P123, DOI 10.1006/dbio.2001.0432; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Corson LB, 2003, DEVELOPMENT, V130, P4527, DOI 10.1242/dev.00669; Del Re DP, 2007, J BIOL CHEM, V282, P8069, DOI 10.1074/jbc.M604298200; Deng X, 2001, J Natl Cancer Inst Monogr, P30; Doshi JM, 2006, J MED CHEM, V49, P7731, DOI 10.1021/jm060968r; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fromigue O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; Harms C, 2004, MOL CELL NEUROSCI, V25, P69, DOI 10.1016/j.mcn.2003.09.012; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Hong CC, 2006, CURR BIOL, V16, P1366, DOI 10.1016/j.cub.2006.05.046; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kobayashi K, 2004, J NEUROSCI, V24, P3480, DOI 10.1523/JNEUROSCI.0295-04.2004; Korichneva I, 1999, J CELL SCI, V112, P2521; Krens SFG, 2006, GENE EXPR PATTERNS, V6, P1019, DOI 10.1016/j.modgep.2006.04.008; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; McClintock JM, 2002, DEVELOPMENT, V129, P2339; McWhorter ML, 2003, J CELL BIOL, V162, P919, DOI 10.1083/jcb.200303168; Miyake H, 1999, BRIT J CANCER, V79, P1651, DOI 10.1038/sj.bjc.6690264; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Pinkas J, 2004, MOL CANCER RES, V2, P551; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; Rikitake Y, 2000, ARTERIOSCL THROM VAS, V20, P1006, DOI 10.1161/01.ATV.20.4.1006; Rios-Munoz W, 2005, J NEUROCHEM, V93, P1422, DOI 10.1111/j.1471-4159.2005.03129.x; Tahinci E, 2003, DEV BIOL, V259, P318, DOI 10.1016/S0012-1606(03)00206-9; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Wick W, 1998, FEBS LETT, V440, P419, DOI 10.1016/S0014-5793(98)01494-X; Wullimann MF, 2000, ANAT EMBRYOL, V202, P385, DOI 10.1007/s004290000115; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100; Zhao M, 2006, MOL PHARMACOL, V69, P66, DOI 10.1124/mol.105.016923; Zhu SZ, 2006, CELL SIGNAL, V18, P359, DOI 10.1016/j.cellsig.2005.05.019	42	36	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1580	1589		10.1038/sj.onc.1210790	http://dx.doi.org/10.1038/sj.onc.1210790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873909				2022-12-28	WOS:000253815800010
J	Buytaert, E; Matroule, JY; Durinck, S; Close, P; Kocanova, S; Vandenheede, JR; Witte, PA; Piette, J; Agostinis, P				Buytaert, E.; Matroule, J. Y.; Durinck, S.; Close, P.; Kocanova, S.; Vandenheede, J. R.; de Witte, P. A.; Piette, J.; Agostinis, P.			Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells	ONCOGENE			English	Article						photodynamic therapy; microarrays; p38(MAPK)	ACTIVATED PROTEIN-KINASE; PHOTODYNAMIC THERAPY; P38 MAPK; SIGNALING PATHWAYS; UP-REGULATION; ER STRESS; EXPRESSION; GENE; TRANSCRIPTION; INHIBITION	Photodynamic therapy (PDT) is an anticancer approach utilizing a light-absorbing molecule and visible light irradiation to generate, in the presence of O-2, cytotoxic reactive oxygen species, which cause tumor ablation. Given that the photosensitizer hypericin is under consideration for PDT treatment of bladder cancer we used oligonucleotide microarrays in the T24 bladder cancer cell line to identify differentially expressed genes with therapeutic potential. This study reveals that the expression of several genes involved in various metabolic processes, stress-induced cell death, autophagy, proliferation, inflammation and carcinogenesis is strongly affected by PDT and pinpoints the coordinated induction of a cluster of genes involved in the unfolded protein response pathway after endoplasmic reticulum stress and in antioxidant response. Analysis of PDT-treated cells after p38(MAPK) inhibition or silencing unraveled that the induction of an important subset of differentially expressed genes regulating growth and invasion, as well as adaptive mechanisms against oxidative stress, is governed by this stress-activated kinase. Moreover, p38(MAPK) inhibition blocked autonomous regrowth and migration of cancer cells escaping PDT-induced cell death. This analysis identifies new molecular effectors of the cancer cell response to PDT opening attractive avenues to improve the therapeutic efficacy of hypericin-based PDT of bladder cancer.	[Buytaert, E.; Kocanova, S.; Vandenheede, J. R.; Agostinis, P.] Catholic Univ Louvain, Fac Med, Dept Mol & Cell Biol, Brabant, Belgium; [Matroule, J. Y.; Close, P.; Piette, J.] Univ Liege, Lab Virol & Immunol, Liege, Belgium; [Durinck, S.] Catholic Univ Louvain, Dept Elect Engn, ESAT SCD, Brabant, Belgium; [de Witte, P. A.] Catholic Univ Louvain, Fac Pharm, Lab Pharmaceut Biol & Phytopharmacol, Brabant, Belgium	Universite Catholique Louvain; University of Liege; Universite Catholique Louvain; Universite Catholique Louvain	Agostinis, P (corresponding author), KULeuven, Dept Mol & Cell Biol, Herestr 49,Campus Gasthuisberg, B-3000 Louvain, Brabant, Belgium.	patrizia.agostinis@med.kuleuven.be	Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020	Agostinis, Patrizia/0000-0003-1314-2115; de Witte, Peter/0000-0002-9989-9567; CLOSE, PIERRE/0000-0002-8844-9616				Agostinis P, 2004, PHOTOCH PHOTOBIO SCI, V3, P721, DOI 10.1039/b315237e; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birney E, 2006, NUCLEIC ACIDS RES, V34, pD556, DOI 10.1093/nar/gkj133; Bostrom PJ, 2000, INT J CANCER, V88, P417, DOI 10.1002/1097-0215(20001101)88:3<417::AID-IJC14>3.3.CO;2-7; Buytaert E, 2006, FASEB J, V20, P756, DOI 10.1096/fj.05-4305fje; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Caristi S, 2005, J BIOL CHEM, V280, P14433, DOI 10.1074/jbc.M410725200; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; D'Hallewin MA, 2002, BJU INT, V89, P760, DOI 10.1046/j.1464-410X.2002.02690.x; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Elenitoba-Johnson KSJ, 2003, P NATL ACAD SCI USA, V100, P7259, DOI 10.1073/pnas.1137463100; Espel E, 2005, SEMIN CELL DEV BIOL, V16, P59, DOI 10.1016/j.semcdb.2004.11.008; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hashimoto S, 2000, CLIN EXP ALLERGY, V30, P48; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Hori O, 2006, MOL CELL BIOL, V26, P4257, DOI 10.1128/MCB.02055-05; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Johansson N, 2000, J CELL SCI, V113, P227; Kamuhabwa A, 2004, PHOTOCH PHOTOBIO SCI, V3, P772, DOI 10.1039/b315586b; Kocanova S, 2007, APOPTOSIS, V12, P731, DOI 10.1007/s10495-006-0016-x; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; LIN Z, 2004, MOL CELL PROTEOMICS, V820; Liu RY, 2000, J BIOL CHEM, V275, P21086, DOI 10.1074/jbc.M001281200; Lou H, 2006, MOL PHARMACOL, V69, P1662, DOI 10.1124/mol.105.019794; Ma YJ, 2004, J BIOL CHEM, V279, P13792, DOI 10.1074/jbc.M313724200; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Sanchez-Carbayo M, 2002, CANCER RES, V62, P6973; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Sengupta N, 2004, J R SOC PROMO HEALTH, V124, P228, DOI 10.1177/146642400412400520; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tsai PW, 2003, J BIOL CHEM, V278, P5750, DOI 10.1074/jbc.M204863200; Van de Putte M, 2005, BRIT J CANCER, V92, P1406, DOI 10.1038/sj.bjc.6602512; Verwanger T, 2002, INT J ONCOL, V21, P1353; Volanti C, 2004, ONCOGENE, V23, P8649, DOI 10.1038/sj.onc.1207871; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wild PJ, 2005, MOL CANCER THER, V4, P516, DOI 10.1158/1535-7163.MCT-04-0141; Wong S, 2004, LASER SURG MED, V35, P336, DOI 10.1002/lsm.20110; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	55	75	76	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1916	1929		10.1038/sj.onc.1210825	http://dx.doi.org/10.1038/sj.onc.1210825			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17952126	Green Published			2022-12-28	WOS:000254150600011
J	You, JS; Kang, JK; Lee, EK; Lee, JC; Lee, SH; Jeon, YJ; Koh, DH; Ahn, SH; Seo, DW; Lee, HY; Cho, EJ; Han, JW				You, J. S.; Kang, J. K.; Lee, E. K.; Lee, J. C.; Lee, S. H.; Jeon, Y. J.; Koh, D. H.; Ahn, S. H.; Seo, D-W; Lee, H. Y.; Cho, E-J; Han, J-W			Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells	ONCOGENE			English	Article						DNMT1; apicidin; histone modification; histone deacetylase inhibitor	CPG-BINDING-PROTEIN; TRANSCRIPTIONAL REPRESSION; DE-NOVO; MAMMALIAN DEVELOPMENT; CYTOSINE METHYLATION; GENE-EXPRESSION; BREAST-CANCER; DNMT1; ACTIVATION; CHROMATIN	Dysregulation of DN A methyltransferase (DNMT)1 expression is associated with cellular transformation, and inhibition of DNMT1 exerts antitumorigenic effects. Here, we report that DNMT1 abnormally expressed in HeLa cells is downregulated by a histone deacetylase (HDAC) inhibitor apicidin, which is correlated with induction of repressive histone modi. cations on the promoter site. Apicidin selectively represses the expression of DNMT1 among DNMTs in HeLa cells, independent of cell cycle arrest at G(0)/G(1). Furthermore, apicidin causes a significant reduction in the recruitment of RNA polymerase II into the promoter. Chromatin immunoprecipitation analysis shows that even though apicidin causes global hyperacetylation of histone H3 and H4, localized deacetylation ofhistone H3 and H4 occurs at the E2F binding site, which is accompanied by the recruitment of pRB and the replacement of P/CAF with HDAC1 into the sites. In addition, K4-trimethylated H3 on nucleosomes associated with the transcriptional start site is depleted following apicidin treatment, whereas repressive markers, K9- and K27-trimethylation of H3 are enriched on the site. The downregulation of DNMT 1 expression seems to require de novo protein synthesis, because the apicidin effect is antagonized by cycloheximide treatment. Moreover, knock down of DNMT1 with siRNA induces the apoptosis of HeLa cells, indicating that downregulation of DNMT might be a good strategy for therapeutics of human cervix cancer. Collectively, our findings will provide a mechanistic rationale for the use of HDAC inhibitors in cancer therapeutics.	[You, J. S.; Kang, J. K.; Lee, E. K.; Lee, J. C.; Lee, S. H.; Jeon, Y. J.; Koh, D. H.; Cho, E-J; Han, J-W] Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea; [Ahn, S. H.] Hanyang Univ, Div Mol & Life Sci, Ansan, South Korea; [Seo, D-W] Kangwon Natl Univ, Dept Mol Biosci, Chunchon, South Korea; [Lee, H. Y.] Konyang Univ, Coll Med, Dept Pharmacol, Taejon, South Korea	Sungkyunkwan University (SKKU); Hanyang University; Kangwon National University; Konyang University; Konyang University Hospital	Han, JW (corresponding author), Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, 300 Cheoncheon Dong, Suwon 440746, South Korea.	jhhan551@skku.edu	Cho, Eun-Jung/AAR-1785-2020; Kang, Jaeku/D-4933-2011; lee, jaecheol/AAS-3747-2020	Cho, Eun-Jung/0000-0002-6610-5329; Kang, Jaeku/0000-0002-8660-7940; lee, jaecheol/0000-0002-2070-7463; Seo, Dong-Wan/0000-0003-4971-834X; Ahn, Seong-Hoon/0000-0002-9174-4966				Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuino L, 2003, MOL CANCER THER, V2, P971; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Gupta A, 2003, CANCER RES, V63, P664; Han JW, 2000, CANCER RES, V60, P6068; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kim YK, 2006, CELL DEATH DIFFER, V13, P2033, DOI 10.1038/sj.cdd.4401915; Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kwon SH, 2002, J BIOL CHEM, V277, P2073, DOI 10.1074/jbc.M106699200; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lee BH, 2005, J BIOL CHEM, V280, P40749, DOI 10.1074/jbc.M505593200; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marsit CJ, 2006, CANCER RES, V66, P10621, DOI 10.1158/0008-5472.CAN-06-1687; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McCabe M, 2006, ONCOGENE, V25, P2727, DOI 10.1038/sj.onc.1209266; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nimmanapalli R, 2003, CANCER RES, V63, P5126; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Park JS, 1999, APPL ENVIRON MICROB, V65, P126; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Scott GK, 2002, MOL CANCER THER, V1, P385; SZYF M, 1991, J BIOL CHEM, V266, P10027; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xiong YN, 2005, CANCER RES, V65, P2684, DOI 10.1158/0008-5472.CAN-04-2843; Yan PS, 2003, CANCER RES, V63, P6178; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	63	57	61	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1376	1386		10.1038/sj.onc.1210776	http://dx.doi.org/10.1038/sj.onc.1210776			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828306				2022-12-28	WOS:000253548200004
J	Barzon, L; Trevisan, M; Masi, G; Pacenti, M; Sinigaglia, A; Macchi, V; Porzionato, A; De Caro, R; Favia, G; Iacobone, M; Palu, G				Barzon, L.; Trevisan, M.; Masi, G.; Pacenti, M.; Sinigaglia, A.; Macchi, V.; Porzionato, A.; De Caro, R.; Favia, G.; Iacobone, M.; Palu, G.			Detection of polyomaviruses and herpesviruses in human adrenal tumors	ONCOGENE			English	Article						adrenal gland neoplasms; herpesviruses; polyomaviruses; pheochromocytoma; adrenocortical carcinoma; hypercortisolism	EPSTEIN-BARR-VIRUS; GLUCOCORTICOID-RESPONSIVE ELEMENT; SARCOMA-ASSOCIATED HERPESVIRUS; TRANSGENIC MICE; CELL-LINES; JC VIRUS; HUMAN CYTOMEGALOVIRUS; CONTROL REGION; T-ANTIGEN; INFECTION	The presence of polyomaviruses and herpesviruses in adrenal tumors and their role in adrenal tumorigenesis has never been investigated, even though the adrenal gland seems to be a preferential site of infection by these viruses and adrenal steroid hormones have been shown to activate their replication. We examined in a large series of normal adrenal gland tissues (n = 20) and adrenal tumors (n = 107) the presence of herpesviruses and polyomaviruses sequences and gene expression, which were detected in a high proportion of both normal and neoplastic adrenal samples (overall, viruses were found in 15% normal adrenals, 27.8% benign adrenal tumors and 35.3% malignant tumors). The polyomaviruses SV40 and BK virus were more frequently found in malignant adrenal tumors, whereas herpesviruses, especially Epstein-Barr virus and human cytomegalovirus, were more frequently detected in functioning benign adrenocortical tumors, often as coinfection. Moreover, tumors from patients with severe hypercortisolism frequently showed herpesvirus coinfections at high viral genome copy number. Our study suggests that the adrenal gland could be a reservoir of infection for these viruses and that hormone overproduction by the adrenal gland could represent a trigger for virus reactivation. On the other hand, these viruses could also contribute to adrenal cell proliferation and tumorigenesis.	[Barzon, L.; Trevisan, M.; Masi, G.; Pacenti, M.; Sinigaglia, A.; Palu, G.] Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35121 Padua, Italy; [Macchi, V.; Porzionato, A.; De Caro, R.] Univ Padua, Dept Human Anat & Physiol, Padua, Italy; [Favia, G.; Iacobone, M.] Univ Padua, Dept Surg & Gastroenterol Sci, Padua, Italy	University of Padua; University of Padua; University of Padua	Barzon, L (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Via A Gabelli 63, I-35121 Padua, Italy.	luisa.barzon@unipd.it; giorgio.palu@unipd.it	Barzon, Luisa/K-7961-2016; Masi, Giulia/K-1577-2016; Iacobone, Maurizio/K-8714-2016; Macchi, Veronica/AAV-4514-2020; TREVISAN, MARTA/K-6591-2016	Barzon, Luisa/0000-0003-0720-8456; Masi, Giulia/0000-0001-9138-9186; Macchi, Veronica/0000-0003-2335-6897; Pacenti, Monia/0000-0002-9792-9195; TREVISAN, MARTA/0000-0002-3148-7240; sinigaglia, alessandro/0000-0002-2386-1757; Iacobone, Maurizio/0000-0002-6057-4642				Aita K, 2001, ARCH VIROL, V146, P2009, DOI 10.1007/s007050170048; AMSTEY MS, 1977, AM J OBSTET GYNECOL, V15, P159; Barzon I, 2005, EUR J ENDOCRINOL, V153, P629, DOI 10.1530/eje.1.02011; Barzon L, 2003, EUR J ENDOCRINOL, V149, P273, DOI 10.1530/eje.0.1490273; Barzon L, 2004, ENDOCR REV, V25, P1, DOI 10.1210/er.2002-0035; BAUER G, 1983, INT J CANCER, V31, P291, DOI 10.1002/ijc.2910310307; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Biasolo MA, 2003, J MED VIROL, V69, P220, DOI 10.1002/jmv.10285; Bloom DC, 1997, VIROLOGY, V236, P202, DOI 10.1006/viro.1997.8723; Boldorini R, 2005, AM J CLIN PATHOL, V124, P303, DOI 10.1309/RLB1PMV33RK7CGAX; Carbone M, 2005, CANCER RES, V65, P10120, DOI 10.1158/0008-5472.CAN-05-1911; Carbone M, 2003, CANCER RES, V63, P6125; Chang M, 2005, J VIROL, V79, P13538, DOI 10.1128/JVI.79.21.13538-13547.2005; Correa RM, 2004, J MED VIROL, V73, P583, DOI 10.1002/jmv.20129; Dahia PLM, 2006, CURR OPIN ONCOL, V18, P1, DOI 10.1097/01.cco.0000198017.45982.06; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; Flaegstad T, 1999, CANCER RES, V59, P1160; GLASER R, 1995, NEUROENDOCRINOLOGY, V62, P356, DOI 10.1159/000127025; Gratama JW, 1995, ADV CANCER RES, V67, P197, DOI 10.1016/S0065-230X(08)60714-9; Hornsby PJ, 2002, ENDOCR RES, V28, P777, DOI 10.1081/ERC-120017072; Hoshino Y, 1997, AIDS, V11, P1719, DOI 10.1097/00002030-199714000-00008; Isobe Y, 2004, CANCER RES, V64, P2167, DOI 10.1158/0008-5472.CAN-03-1562; KNECHT H, 1993, BLOOD, V82, P2937; KUPFER SR, 1990, J VIROL, V64, P1984, DOI 10.1128/JVI.64.5.1984-1990.1990; LATHEY JL, 1991, J VIROL, V65, P6371, DOI 10.1128/JVI.65.11.6371-6375.1991; Lee HS, 2004, CLIN CANCER RES, V10, P1698, DOI 10.1158/1078-0432.CCR-1122-3; Libe R, 2005, EUR J ENDOCRINOL, V153, P477, DOI 10.1530/eje.1.02004; Lopez-Rios F, 2004, LANCET, V364, P1157, DOI 10.1016/S0140-6736(04)17102-X; McNeese T, 2005, AM HIST, V40, P52; Mengoli C, 2004, J MED VIROL, V74, P78, DOI 10.1002/jmv.20149; MOENS U, 1994, J VIROL, V68, P2398, DOI 10.1128/JVI.68.4.2398-2408.1994; Moens U, 1999, J GEN VIROL, V80, P585, DOI 10.1099/0022-1317-80-3-585; MORHENN V, 1973, P NATL ACAD SCI USA, V70, P1088, DOI 10.1073/pnas.70.4.1088; NISHIYAMA Y, 1979, J VIROL, V31, P841, DOI 10.1128/JVI.31.3.841-844.1979; Podlech J, 1996, ARCH VIROL, V141, P1999, DOI 10.1007/BF01718210; Pomara G, 2006, EUR J HISTOCHEM, V50, P131; PULAKHANDAM U, 1990, AM J CLIN PATHOL, V93, P651, DOI 10.1093/ajcp/93.5.651; Razzaq F, 2002, HIV Med, V3, P212, DOI 10.1046/j.1468-1293.2002.00114.x; Ressetar HG, 1997, J NEUROVIROL, V3, P66, DOI 10.3109/13550289709015794; RESSETAR HG, 1993, MOL CHEM NEUROPATHOL, V20, P59, DOI 10.1007/BF03160070; SCHUSTER C, 1991, FEBS LETT, V284, P82, DOI 10.1016/0014-5793(91)80767-W; SCHUSTER C, 1991, MOL ENDOCRINOL, V5, P267, DOI 10.1210/mend-5-2-267; SERVENIUS B, 1994, CANCER RES, V54, P5198; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; TANAKA J, 1984, VIROLOGY, V136, P448, DOI 10.1016/0042-6822(84)90182-X; TANAKA J, 1984, J GEN VIROL, V65, P1757; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; TISCHLER AS, 1993, LAB INVEST, V68, P541; Watzinger F, 2004, J CLIN MICROBIOL, V42, P5189, DOI 10.1128/JCM.42.11.5189-5198.2004; Zoeteweij JP, 2002, J MED VIROL, V66, P378, DOI 10.1002/jmv.2155; ZUO FR, 1995, P NATL ACAD SCI USA, V92, P8586, DOI 10.1073/pnas.92.19.8586	51	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					857	864		10.1038/sj.onc.1210699	http://dx.doi.org/10.1038/sj.onc.1210699			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17684484				2022-12-28	WOS:000252884500015
J	Preet, A; Ganju, RK; Groopman, JE				Preet, A.; Ganju, R. K.; Groopman, J. E.			Delta(9)-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo	ONCOGENE			English	Article						tetrahydrocannabinol(THC); lung cancer; A549; migration; invasion; EGFR	FOCAL-ADHESION KINASE; CANNABINOID RECEPTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ANGIOGENESIS; ACTIVATION; EXPRESSION	Delta(9)-Tetrahydrocannabinol (THC) is the primary cannabinoid of marijuana and has been shown to either potentiate or inhibit tumor growth, depending on the type of cancer and its pathogenesis. Little is known about the activity of cannabinoids like THC on epidermal growth factor receptor-overexpressing lung cancers, which are often highly aggressive and resistant to chemotherapy. In this study, we characterized the effects of THC on the EGF-induced growth and metastasis of human non-small cell lung cancer using the cell lines A549 and SW-1573 as in vitro models. We found that these cells express the cannabinoid receptors CB1 and CB2, known targets for THC action, and that THC inhibited EGF-induced growth, chemotaxis and chemoinvasion. Moreover, signaling studies indicated that THC may act by inhibiting the EGF-induced phosphorylation of ERK1/2, JNK1/2 and AKT. THC also induced the phosphorylation of focal adhesion kinase at tyrosine 397. Additionally, in in vivo studies in severe combined immunodeficient mice, there was significant inhibition of the subcutaneous tumor growth and lung metastasis of A549 cells in THC-treated animals as compared to vehicle-treated controls. Tumor samples from THC-treated animals revealed antiproliferative and antiangiogenic effects of THC. Our study suggests that cannabinoids like THC should be explored as novel therapeutic molecules in controlling the growth and metastasis of certain lung cancers.	[Preet, A.; Ganju, R. K.; Groopman, J. E.] Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Groopman, JE (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu; jgroopma@bidmc.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA109527] Funding Source: NIH RePORTER; NCI NIH HHS [CA109527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2006, CLIN CANCER RES, V12, p4446S, DOI 10.1158/1078-0432.CCR-06-0623; Beckmann JD, 2001, J CELL PHYSIOL, V189, P171, DOI 10.1002/jcp.10013; Bifulco M, 2006, BRIT J PHARMACOL, V148, P123, DOI 10.1038/sj.bjp.0706632; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; CABRAL GA, 1987, ARCH TOXICOL, V60, P438, DOI 10.1007/BF00302387; CABRAL GA, 2006, CANCER RES, V66, P6615; CABRAL GA, 2006, CANCER CELL, V9, P301; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; CLARKE N, 1998, MOL CELL BIOL, V21, P4016; Derkinderen P, 2001, J BIOL CHEM, V276, P38289; Di Marzo V, 2006, ANNU REV MED, V57, P553, DOI 10.1146/annurev.med.57.011205.135648; Diaz-Laviada I, 2005, MINI-REV MED CHEM, V5, P619, DOI 10.2174/1389557054368808; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Ghosh S, 2006, MOL IMMUNOL, V43, P2169, DOI 10.1016/j.molimm.2006.01.005; Guzman M., 2006, BR JR CANC, V95, P204; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Hauck CR, 2001, CANCER RES, V61, P7079; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kogan NM, 2005, MINI-REV MED CHEM, V5, P941, DOI 10.2174/138955705774329555; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2006, ONCOGENE, V25, P5969, DOI 10.1038/sj.onc.1209588; Molina JR, 2006, CHEST, V130, P1211, DOI 10.1378/chest.130.4.1211; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; MUNSON AE, 1975, J NATL CANCER I, V55, P597, DOI 10.1093/jnci/55.3.597; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vaccani A, 2005, BRIT J PHARMACOL, V144, P1032, DOI 10.1038/sj.bjp.0706134; WILLIAMS R, 1993, J BIOL CHEM, V268, P18213; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697	38	108	109	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					339	346		10.1038/sj.onc.1210641	http://dx.doi.org/10.1038/sj.onc.1210641			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621270				2022-12-28	WOS:000252256000010
J	Wilson, JB; Yamamoto, K; Marriott, AS; Hussain, S; Sung, P; Hoatlin, ME; Mathew, CG; Takata, M; Thompson, LH; Kupfer, GM; Jones, NJ				Wilson, J. B.; Yamamoto, K.; Marriott, A. S.; Hussain, S.; Sung, P.; Hoatlin, M. E.; Mathew, C. G.; Takata, M.; Thompson, L. H.; Kupfer, G. M.; Jones, N. J.			FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3	ONCOGENE			English	Article						fanconi anemia; ATR; interstrand crosslinks; DNA repair; RAD51 paralog; replication restart; epistasis	DOUBLE-STRAND BREAKS; HAMSTER CELL MUTANTS; ANEMIA PATHWAY; HOMOLOGOUS RECOMBINATION; COMPLEMENTATION GROUP; ATAXIA-TELANGIECTASIA; MONOUBIQUITINATED FANCD2; CROSS-LINKS; REPAIR; GENE	Fanconi anemia (FA) is a human disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinks and other damages. Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group. Eight of the FA proteins, including FANCG, participate in a nuclear core complex that is required for the monoubiquitylation of FANCD2 and FANCI. FANCD2, like FANCD1/BRCA2, is not part of the core complex, and we previously showed direct BRCA2-FANCD2 interaction using yeast two-hybrid analysis. We now show in human and hamster cells that expression of FANCG protein, but not the other core complex proteins, is required for co-precipitation of BRCA2 and FANCD2. We also show that phosphorylation of FANCG serine 7 is required for its co-precipitation with BRCA2, XRCC3 and FANCD2, as well as the direct interaction of BRCA2-FANCD2. These results argue that FANCG has a role independent of the FA core complex, and we propose that phosphorylation of serine 7 is the signalling event required for forming a discrete complex comprising FANCD1/BRCA2-FANCD2-FANCG- XRCC3 (D1-D2-G-X3). Cells that fail to express either phospho-Ser7-FANCG, or full length BRCA2 protein, lack the interactions amongst the four component proteins. A role for D1-D2-G-X3 in homologous recombination repair (HRR) is supported by our finding that FANCG and the RAD51-paralog XRCC3 are epistatic for sensitivity to DNA crosslinking compounds in DT40 chicken cells. Our findings further define the intricate interface between FANC and HRR proteins in maintaining chromosome stability.	[Wilson, J. B.; Marriott, A. S.; Jones, N. J.] Univ Liverpool, Sch Biol Sci, Mol Oncol & Stem Cell Res Grp, Liverpool L69 7ZB, Merseyside, England; [Yamamoto, K.; Takata, M.] Kawasaki Med Sch, Dept Immunol & Med Genet, Okayama, Japan; [Hussain, S.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Sung, P.] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; [Hoatlin, M. E.] Oregon Hlth & Sci Univ, Div Biochem & Mol Biol, Portland, OR USA; [Mathew, C. G.] Oregon Hlth & Sci Univ, Div Biochem & Mol Biol, Portland, OR USA; [Thompson, L. H.] Lawrence Livermore Natl Lab, Biosci & Biotechnol Div, Livermore, CA USA; [Kupfer, G. M.] Yale Univ, Sch Med, Div Hematol Oncol, Dept Pediat, New Haven, CT USA	University of Liverpool; Kawasaki Medical School; University of Cambridge; Yale University; Oregon Health & Science University; Oregon Health & Science University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Yale University	Jones, NJ (corresponding author), Univ Liverpool, Sch Biol Sci, Mol Oncol & Stem Cell Res Grp, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	njjones@liv.ac.uk	Mathew, Christopher G/G-3434-2015; Jones, Nigel J/D-1997-2010	Mathew, Christopher G/0000-0003-4178-1838; Takata, Minoru/0000-0002-4926-3675				Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; Blom E, 2004, DNA REPAIR, V3, P77, DOI 10.1016/j.dnarep.2003.09.007; Bogliolo M, 2007, EMBO J, V26, P1340, DOI 10.1038/sj.emboj.7601574; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Busch DB, 1996, MUTAT RES-DNA REPAIR, V363, P209, DOI 10.1016/0921-8777(96)00014-6; Carreau M, 1999, MUTAT RES-DNA REPAIR, V435, P103, DOI 10.1016/S0921-8777(99)00041-5; Ciccia A, 2007, MOL CELL, V25, P331, DOI 10.1016/j.molcel.2007.01.003; Collins N, 2005, INT J HEMATOL, V82, P176, DOI 10.1532/IJH97.05108; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Goggins M, 1996, CANCER RES, V56, P5360; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; Gregory RC, 2003, SEMIN CANCER BIOL, V13, P77, DOI 10.1016/S1044-579X(02)00102-5; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Henry-Mowatt J, 2003, MOL CELL, V11, P1109, DOI 10.1016/S1097-2765(03)00132-1; Hinz JM, 2007, NUCLEIC ACIDS RES, V35, P3733, DOI 10.1093/nar/gkm315; Hinz JM, 2006, DNA REPAIR, V5, P875, DOI 10.1016/j.dnarep.2006.05.039; Hirano S, 2005, EMBO J, V24, P418, DOI 10.1038/sj.emboj.7600534; Ho GPH, 2006, MOL CELL BIOL, V26, P7005, DOI 10.1128/MCB.02018-05; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hussain S, 2004, HUM MOL GENET, V13, P1241, DOI 10.1093/hmg/ddh135; Hussain S, 2003, HUM MOL GENET, V12, P2503, DOI 10.1093/hmg/ddg266; Hussain S, 2006, DNA REPAIR, V5, P629, DOI 10.1016/j.dnarep.2006.02.007; Johnson MA, 2000, MUTAGENESIS, V15, P367, DOI 10.1093/mutage/15.4.367; Johnson MA, 1999, MUTAT RES-DNA REPAIR, V435, P271, DOI 10.1016/S0921-8777(99)00055-5; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lamerdin JE, 2004, MUTAGENESIS, V19, P237, DOI 10.1093/mutage/geh019; Levitus M, 2006, CELL ONCOL, V28, P3; Ling C, 2007, EMBO J, V26, P2104, DOI 10.1038/sj.emboj.7601666; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Lyakhovich A, 2007, CELL CYCLE, V6, P1019, DOI 10.4161/cc.6.9.4223; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Mi J, 2004, MOL CELL BIOL, V24, P8576, DOI 10.1128/MCB.24.19.8576-8585.2004; Mirchandani KD, 2006, EXP CELL RES, V312, P2647, DOI 10.1016/j.yexcr.2006.06.014; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Niedernhofer LJ, 2007, MOL CELL, V25, P487, DOI 10.1016/j.molcel.2007.02.002; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Ohashi A, 2005, J BIOL CHEM, V280, P14877, DOI 10.1074/jbc.M414669200; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Patel KJ, 2007, DNA REPAIR, V6, P885, DOI 10.1016/j.dnarep.2007.02.002; Qiao FY, 2004, J BIOL CHEM, V279, P46035, DOI 10.1074/jbc.M408323200; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Sarkaria JN, 1998, CANCER RES, V58, P4375; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240; Tebbs RS, 2005, DNA REPAIR, V4, P11, DOI 10.1016/j.dnarep.2004.06.013; Thacker J, 2005, CANCER LETT, V219, P125, DOI 10.1016/j.canlet.2004.08.018; Thompson LH, 2005, NAT GENET, V37, P921, DOI 10.1038/ng0905-921; Thompson LH, 2005, ENVIRON MOL MUTAGEN, V45, P128, DOI 10.1002/em.20109; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; Wiegant WW, 2006, MUTAT RES-FUND MOL M, V600, P79, DOI 10.1016/j.mrfmmm.2006.03.001; Wilson JB, 2001, CARCINOGENESIS, V22, P1939, DOI 10.1093/carcin/22.12.1939; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Yamada NA, 2004, J BIOL CHEM, V279, P23250, DOI 10.1074/jbc.M402247200; Yamamoto K, 2003, MOL CELL BIOL, V23, P5421, DOI 10.1128/MCB.23.15.5421-5430.2003; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; Yamashita YM, 2002, EMBO J, V21, P5558, DOI 10.1093/emboj/cdf534; Yang YG, 2005, CARCINOGENESIS, V26, P1731, DOI 10.1093/carcin/bgi134; Zhang NX, 2007, DNA REPAIR, V6, P1670, DOI 10.1016/j.dnarep.2007.06.002; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	80	69	75	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3641	3652		10.1038/sj.onc.1211034	http://dx.doi.org/10.1038/sj.onc.1211034			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212739				2022-12-28	WOS:000256659300001
J	McCracken, SRC; Ramsay, A; Heer, R; Mathers, ME; Jenkins, BL; Edwards, J; Robson, CN; Marquez, R; Cohen, P; Leung, HY				McCracken, S. R. C.; Ramsay, A.; Heer, R.; Mathers, M. E.; Jenkins, B. L.; Edwards, J.; Robson, C. N.; Marquez, R.; Cohen, P.; Leung, H. Y.			Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer	ONCOGENE			English	Article						prostate cancer; ERK5; MEK5	ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASES; MAP KINASE; DIFFERENTIAL EXPRESSION; ERK5; PROLIFERATION; MEK5; OVEREXPRESSION; IDENTIFICATION; BMK1/ERK5	Abnormal intracellular signaling contributes to carcinogenesis and may represent novel therapeutic targets. mitogen/extracellular signal-regulated kinase kinase-5 (MEK5) overexpression is associated with aggressive prostate cancer. In this study, we examined the role of extracellular signal-regulated kinase (ERK5, an MAPK and specific substrate for MEK5) in prostate cancer. ERK5 immunoreactivity was significantly upregulated in high-grade prostate cancer when compared to benign prostatic hyperplasia (P < 0.0001). Increased ERK5 cytoplasmic signals correlated closely with Gleason sum score (P < 0.0001), bony metastases (P = 0.0044) and locally advanced disease at diagnosis (P = 0.0023), with a weak association with shorter disease-specific survival (P = 0.036). A subgroup of patients showed strong nuclear ERK5 localization, which correlated with poor diseasespecific survival and, on multivariant analysis, was an independent prognostic factor (P < 0.0001). Analysis of ERK5 expression in matched tumor pairs (before and after hormone relapse, n = 26) revealed ERK5 nuclear expression was significantly associated with hormone-insensitive disease (P = 0.0078). Similarly, ERK5 protein expression was increased in an androgen-independent LNCaP subline. We obtained the following in vitro and in vivo evidence to support the above expression data: (1) cotransfection of ERK5wt and MEK5D constructs in PC3 cells results in predominant ERK5 nuclear localization, similar to that observed in aggressive clinical disease; (2) ERK5-overexpressing PC3 cells have enhanced proliferative, migrative and invasive capabilities in vitro (P < 0.0001), and were dramatically more efficient in forming tumors, with a shorter mean time for tumors to reach a critical volume of 1000 mm(3), in vivo (P < 0.0001); (3) the MEK1 inhibitor, PD184352, blocking ERK1/2 activation at low dose, did not suppress proliferation but did significantly decrease proliferation at a higher dose required to inhibit ERK5 activation. Taken together, our results establish the potential importance of ERK5 in aggressive prostate cancer.	[McCracken, S. R. C.; Heer, R.; Jenkins, B. L.; Robson, C. N.; Leung, H. Y.] Univ Newcastle, No Inst Canc Res, Urol Res Grp, Newcastle Upon Tyne, Tyne & Wear, England; [Ramsay, A.; Leung, H. Y.] Beatson Inst Canc Res, Canc Res UK Labs, Glasgow G61 1BD, Lanark, Scotland; [Ramsay, A.; Edwards, J.; Leung, H. Y.] Univ Glasgow, Sect Surg & Translat Res, Div Canc Sci & Mol Pathol, Glasgow, Lanark, Scotland; [Mathers, M. E.] Royal Victoria Infirm, Dept Cellular Pathol, Newcastle Upon Tyne, Tyne & Wear, England; [Marquez, R.; Cohen, P.] Univ Dundee, Med Res Council Protein, Phosphorylat Unit, Sch Life Sci, Dundee, Scotland	Newcastle University - UK; Beatson Institute; University of Glasgow; Newcastle University - UK; University of Dundee	Leung, HY (corresponding author), Glasgow Royal Infirm, Univ Sect Surg, Univ Tower Level 2, Glasgow G31 2ER, Lanark, Scotland.	h.leung@beatson.gla.ac.uk	Edwards, Joanne/J-1903-2015; Marquez, Rudi/F-4045-2014	Edwards, Joanne/0000-0002-7192-6906; Marquez, Rudi/0000-0001-9777-2012; Leung, Hing Y./0000-0002-3933-3975	Medical Research Council [MC_U127084348, G0500966] Funding Source: Medline; MRC [MC_U127084348, G0500966] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Armes JE, 1999, CANCER RES, V59, P2011; Barros JC, 2005, J CELL SCI, V118, P1663, DOI 10.1242/jcs.02308; Bartlett JMS, 2005, J PATHOL, V205, P522, DOI 10.1002/path.1735; Bouras T, 2001, CANCER RES, V61, P903; Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698; Buschbeck M, 2005, J BIOL CHEM, V280, P2659, DOI 10.1074/jbc.M412599200; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Carvajal-Vergara X, 2005, BLOOD, V105, P4492, DOI 10.1182/blood-2004-08-2985; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Dudderidge TJ, 2007, BRIT J CANCER, V96, P1384, DOI 10.1038/sj.bjc.6603718; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; Hayashi M, 2005, CANCER RES, V65, P7699, DOI 10.1158/0008-5472.CAN-04-4540; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kondoh K, 2006, MOL CELL BIOL, V26, P1679, DOI 10.1128/MCB.26.5.1679-1690.2006; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Okamoto M, 1997, ENDOCRINOLOGY, V138, P5071, DOI 10.1210/en.138.11.5071; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; Selcher JC, 2001, LEARN MEMORY, V8, P11, DOI 10.1101/lm.37001; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Terasawa K, 2003, GENES CELLS, V8, P263, DOI 10.1046/j.1365-2443.2003.00631.x; Uzgare AR, 2003, PROSTATE, V55, P128, DOI 10.1002/pros.10212; Wang X, 2005, MOL CELL BIOL, V25, P336, DOI 10.1128/MCB.25.1.336-345.2005; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	34	68	72	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					2978	2988		10.1038/sj.onc.1210963	http://dx.doi.org/10.1038/sj.onc.1210963			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18071319	Green Accepted			2022-12-28	WOS:000255681700005
J	Ho, LH; Read, SH; Dorstyn, L; Lambrusco, L; Kumar, S				Ho, L. H.; Read, S. H.; Dorstyn, L.; Lambrusco, L.; Kumar, S.			Caspase-2 is required for cell death induced by cytoskeletal disruption	ONCOGENE			English	Article						apoptosis; caspase-2 activation; Bid; Bax; initiator caspase; cytoskeleton	CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; MITOCHONDRIAL PERMEABILIZATION; CANCER-CELLS; DNA-DAMAGE; GENE CED-3; ACTIVATION; ENCODES; COMPLEX; STRESS	Caspase-2 is one of the most conserved caspases, yet its biological function remains a matter of controversy. In the present article we analysed mouse embryonic fibroblasts (MEFs) from caspase-2 knockout mice for their sensitivity to various apoptosis inducing agents. We found that cell death induced by drugs that disrupt cytoskeleton is significantly inhibited in Casp2(-/-) MEFs. These drugs included zoledronic acid, vincristine, cytochalasin D and paclitaxel. We demonstrate that MEFs lacking Casp2 show clonogenic survival following drug treatment, whereas all Casp2(-/-) MEFs die, indicating that caspase-2 is required for apoptosis induced by cytoskeletal disruption. We further found that caspase-2 mediates apoptosis via Piddosome, Bid and Bax activation, and cytochrome c release. In the absence of caspase-2, Bid and Bax activation, and cytochrome c release are significantly delayed following drug treatment. Our data provide strong support for a context-dependent function of caspase-2 in apoptosis.	[Ho, L. H.; Read, S. H.; Dorstyn, L.; Lambrusco, L.; Kumar, S.] Inst Med & Vet Sci, Div Haematol, Hanson Inst, Adelaide, SA 5000, Australia; [Kumar, S.] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide	Kumar, S (corresponding author), Inst Med & Vet Sci, Div Haematol, Hanson Inst, POB 14,Rundle Mall, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Kumar, Sharad/AAX-7787-2020; Dorstyn, Loretta/F-3673-2013	Kumar, Sharad/0000-0001-7126-9814; Dorstyn, Loretta/0000-0001-9886-0989				Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bonzon C, 2006, MOL BIOL CELL, V17, P2150, DOI 10.1091/mbc.E05-12-1107; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; Gourlay CW, 2005, NAT REV MOL CELL BIO, V6, P583, DOI 10.1038/nrm1682; Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9-90004-3; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Handrick R, 2006, RADIOTHER ONCOL, V80, P199, DOI 10.1016/j.radonc.2006.07.021; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Holleman A, 2005, BLOOD, V106, P1817, DOI 10.1182/blood-2004-11-4296; Kepp O, 2007, EMBO J, V26, P825, DOI 10.1038/sj.emboj.7601533; Kong JY, 2005, BIOCHEM CELL BIOL, V83, P608, DOI 10.1139/o05-066; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Marsden VS, 2004, J CELL BIOL, V165, P775, DOI 10.1083/jcb.200312030; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Mhaidat NM, 2007, MOL CANCER THER, V6, P752, DOI 10.1158/1535-7163.MCT-06-0564; Milleron RS, 2006, J BIOL CHEM, V281, P16991, DOI 10.1074/jbc.M512754200; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Panaretakis T, 2005, MOL BIOL CELL, V16, P3821, DOI 10.1091/mbc.E04-10-0862; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Shearwin-Whyatt L, 2001, BIOCHEM BIOPH RES CO, V282, P1114, DOI 10.1006/bbrc.2001.4699; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Shih YL, 2006, MICROBIOL MOL BIOL R, V70, P729, DOI 10.1128/MMBR.00017-06; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; THEIRAULT RL, 2003, EXPERT REV ANTICANC, V3, P157; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang YF, 2004, CANCER CHEMOTH PHARM, V54, P322, DOI 10.1007/s00280-004-0831-0; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Yeung BHY, 2006, J BIOL CHEM, V281, P11923, DOI 10.1074/jbc.M508533200; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191	49	99	100	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3393	3404		10.1038/sj.onc.1211005	http://dx.doi.org/10.1038/sj.onc.1211005			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193089				2022-12-28	WOS:000256309900004
J	Odgerel, T; Kikuchi, J; Wada, T; Shimizu, R; Futaki, K; Kano, Y; Furukawa, Y				Odgerel, T.; Kikuchi, J.; Wada, T.; Shimizu, R.; Futaki, K.; Kano, Y.; Furukawa, Y.			The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations	ONCOGENE			English	Article						FLT3 inhibitor; leukemia; cell cycle; CDC2; CDC25; bad	INTERNAL TANDEM DUPLICATION; TYROSINE KINASE INHIBITOR; ACUTE MYELOID-LEUKEMIA; SIGNAL-TRANSDUCTION; DEATH MACHINERY; BAD; PHOSPHORYLATION; PROTEIN; STAUROSPORINE; ACTIVATION	PKC412 is a staurosporine derivative that inhibits several protein kinases including FLT3, and is highly anticipated as a novel therapeutic agent for acute myeloblastic leukemia (AML) carrying FLT3 mutations. In this study, we show that PKC412 exerts differential cell cycle effects on AML cells depending on the presence of FLT3 mutations. PKC412 elicits massive apoptosis without markedly affecting cell cycle patterns in AML cell lines with FLT3 mutations (MV4-11 and MOLM13), whereas it induces G(2) arrest but not apoptosis in AML cell lines without FLT3 mutations (THP-1 and U937). In MV4-11 and MOLM13 cells, PKC412 inactivates Myt-1 and activates CDC25c, leading to the activation of CDC2. Activated CDC2 phosphorylates Bad at serine-128 and facilitates its translocation to the mitochondria, where Bad triggers apoptosis. In contrast, PKC412 inactivates CDC2 by inducing serine-216 phosphorylation and subsequent cytoplasmic sequestration of CDC25c in THP-1 and U937 cells. As a result, cells are arrested in the G2 phase of the cell cycle, but do not undergo apoptosis because Bad is not activated. The FLT3 mutation-dependent differential cell cycle effect of PKC412 is considered an important factor when PKC412 is combined with cell cycle-specific anticancer drugs in the treatment of cancer and leukemia.	[Odgerel, T.; Kikuchi, J.; Wada, T.; Shimizu, R.; Futaki, K.; Furukawa, Y.] Ctr Mol Med, Jichi Med Sch, Div Stem Cell Regulat, Shimotsuke, Tochigi 3290498, Japan	Jichi Medical University	Furukawa, Y (corresponding author), Ctr Mol Med, Jichi Med Sch, Div Stem Cell Regulat, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Begemann M, 1998, ANTICANCER RES, V18, P2275; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Furukawa Y, 2007, LEUKEMIA, V21, P1005, DOI 10.1038/sj.leu.2404593; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Galonek HL, 2006, NAT CELL BIOL, V8, P1317, DOI 10.1038/ncb1206-1317; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Green DR, 2006, CANCER CELL, V9, P328, DOI 10.1016/j.ccr.2006.05.004; Griffin JD, 2004, HEMATOL J, V5, pS188, DOI 10.1038/sj.thj.6200450; Ikegami Y, 1996, ARZNEIMITTEL-FORSCH, V46, P201; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kim KT, 2006, BRIT J HAEMATOL, V134, P500, DOI 10.1111/j.1365-2141.2006.06225.x; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Levis M, 2005, INT J HEMATOL, V82, P100, DOI 10.1532/IJH97.05079; Levis M, 2004, BLOOD, V104, P1145, DOI 10.1182/blood-2004-01-0388; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Neben K, 2005, ONCOGENE, V24, P1580, DOI 10.1038/sj.onc.1208344; Propper DJ, 2001, J CLIN ONCOL, V19, P1485, DOI 10.1200/JCO.2001.19.5.1485; Quentmeier H, 2003, LEUKEMIA, V17, P120, DOI 10.1038/sj.leu.2402740; Schmitt E, 2007, ONCOGENE, V26, P5851, DOI 10.1038/sj.onc.1210396; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yang XP, 2005, CANCER RES, V65, P7338, DOI 10.1158/0008-5472.CAN-04-2263; Yao Q, 2003, CLIN CANCER RES, V9, P4483; Yee KWH, 2004, BLOOD, V104, P4202, DOI 10.1182/blood-2003-10-3381; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	29	23	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3102	3110		10.1038/sj.onc.1210980	http://dx.doi.org/10.1038/sj.onc.1210980			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071308				2022-12-28	WOS:000255897600003
J	Shi, L; Itoh, F; Itoh, S; Takahashi, S; Yamamoto, M; Kato, M				Shi, L.; Itoh, F.; Itoh, S.; Takahashi, S.; Yamamoto, M.; Kato, M.			Ephrin-A1 promotes the malignant progression of intestinal tumors in Apc(min/+) mice	ONCOGENE			English	Article						ephrin-A1; intestinal adenoma; invasion Apc(min/+) mice	EPHA2 OVEREXPRESSION; COLORECTAL-CANCER; GENE-EXPRESSION; RECEPTOR; CARCINOMA; CELLS; TUMORIGENESIS; ANGIOGENESIS; METASTASIS; REGULATOR	The ephrin-A1 and EphA receptors are frequently highly expressed in different human cancers, suggesting that they may promote tumor development and progression. We generated transgenic mice carrying Fabpl(4xat-132) ephrin-A1, which express ephrin-A1 in the intestinal epithelial cells. Those mice were then mated with Apc(min/+) mice to produce the compound mice, which overexpress ephrin-A1 in the intestinal tumors of Apc(min/+) mice. We compared the number, size and histopathological features of the intestinal tumors in the Fabpl(4xat-132) ephrin-A1/Apc(min/+) compound mice with those of the Apc(min/+) mice. The compound mice showed an increased number of intestinal tumors, significantly in the large intestine, and developed more invasive tumors. Among the 20 mice of each type examined, 5 Apc(min/+) mice developed 5 invasive tumors, 1 invasive tumor in each mouse, in the proximal or middle portions of the small intestine. On the other hand, 14 out of 20 compound mice developed 29 invasive tumors and 16 of them were in the distal small intestine and the large intestine, where transgenic ephrin-A1 was highly expressed. These results suggested that the increased expression of ephrin-A1 accelerated the malignant progression of the intestinal adenoma to invasive tumors.	[Shi, L.; Itoh, F.; Itoh, S.; Kato, M.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Expt Pathol, Tsukuba, Ibaraki 3058575, Japan; [Takahashi, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Anat, Tsukuba, Ibaraki 3058575, Japan; [Takahashi, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Embryol, Tsukuba, Ibaraki 3058575, Japan; [Yamamoto, M.] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan; [Yamamoto, M.] Japan Sci & Technol Corp, ERATO Environm Response Project, Tsukuba, Ibaraki, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; Tohoku University; Japan Science & Technology Agency (JST)	Kato, M (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Expt Pathol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	mit-kato@md.tsukuba.ac.jp		Itoh, Susumu/0000-0002-7967-0730; Itoh, Fumiko/0000-0002-6134-5331				Abraham S, 2006, CLIN CANCER RES, V12, P353, DOI 10.1158/1078-0432.CCR-05-1505; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje; Coffman KT, 2003, CANCER RES, V63, P7907; DEBRUINE AP, 1993, INT J CANCER, V54, P765, DOI 10.1002/ijc.2910540510; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Flanagan JG, 1997, CELL, V90, P403; Hamamoto T, 2002, CANCER RES, V62, P5955; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Kataoka H, 2004, CANCER SCI, V95, P136, DOI 10.1111/j.1349-7006.2004.tb03194.x; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Liu DP, 2007, INT J ONCOL, V30, P865; LUONGO C, 1994, CANCER RES, V54, P5947; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Nakamura R, 2005, CANCER SCI, V96, P42, DOI 10.1111/j.1349-7006.2005.00007.x; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Parri M, 2005, J BIOL CHEM, V280, P34008, DOI 10.1074/jbc.M502879200; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Potla L, 2002, CANCER LETT, V175, P187, DOI 10.1016/S0304-3835(01)00613-9; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Simon TC, 1997, J BIOL CHEM, V272, P10652; Straume O, 2005, BRIT J CANCER, V93, P933, DOI 10.1038/sj.bjc.6602792; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Swatek Jaroslaw, 2000, Polish Journal of Pathology, V51, P127; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; Wang YJ, 2002, BIOCHEM BIOPH RES CO, V296, P214, DOI 10.1016/S0006-291X(02)00806-9; Wu D, 2004, GYNECOL ONCOL, V94, P312, DOI 10.1016/j.ygyno.2004.05.019; Xu F, 2005, ANTICANCER RES, V25, P2943; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zelinski DP, 2001, CANCER RES, V61, P2301	37	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3265	3273		10.1038/sj.onc.1210992	http://dx.doi.org/10.1038/sj.onc.1210992			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18246128				2022-12-28	WOS:000256111400005
J	Leder, A; McMenamin, J; Zhou, F; Moran, JL; Beier, D; Leder, P				Leder, A.; McMenamin, J.; Zhou, F.; Moran, J. L.; Beier, D. R.; Leder, P.			Genome-wide SNP analysis of Tg.AC transgenic mice reveals an oncogenic collaboration between v-Ha-ras and Ink4a, which is absent in p53 deficiency	ONCOGENE			English	Article						Tg.AC; SNP screen; ras; ink4a (cdkn2a); ink4b (cdkn2b); p53	TUMOR-SUPPRESSOR LOCUS; CELLULAR SENESCENCE; MOUSE; P16(INK4A); PATHWAYS; P16; RETINOBLASTOMA; INHIBITION; P15(INK4B); MUTATIONS	Oncogenesis is a progressive process often involving collaboration between various oncogenes and tumor suppressors. To identify those genes that collaborate with oncogenic ras, we took advantage of the Tg. AC transgenic mouse, a line that harbors the v- Ha- ras transgene and spontaneously develops an array of malignant tumors. By crossing Tg. AC mice on an inbred FVB background to other inbred strains, F1 mice were created that could be analysed using genome wide, single nucleotide polymorphism ( SNP) screens. Loss of heterozygosity ( LOH) in tumors and tumor cell lines marked a somatic event, possibly the inactivation of tumor suppressor gene( s). LOH could also represent DNA damage, a sign of genomic instability in the pretransformed cell. Nonetheless, the screens showed no evidence of such generalized genomic instability. Instead, they revealed a single region of LOH on chromosome 4 that occurred via somatic recombination/ gene conversion, generating a region of isoparental disomy. This LOH provided a clue that linked v- Ha- ras to the inactivation of the Ink4a locus in 25 of 32 tumor cell lines. This collaboration is seen regardless of tumor type or genetic background. In contrast, tumors that develop in bitransgenic mice bearing both the v- Ha- ras gene and a heterozygous mutant p53 allele tend to retain the Ink4a locus and instead lose the p53 wild- type allele. This suggests that different strategies can be selected to collaborate with v- Ha- ras in tumorigenesis.	[Leder, A.; McMenamin, J.; Zhou, F.; Leder, P.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Moran, J. L.; Beier, D. R.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Leder, P (corresponding author), Harvard Univ, Sch Med, Dept Genet, NRB 356B,77 Ave Louis Pasteur, Boston, MA 02115 USA.	leder@genetics.med.harvard.edu		Moran, Jennifer/0000-0002-5664-4716				Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Berger JH, 2007, CURR MOL MED, V7, P63, DOI 10.2174/156652407779940477; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Guan RJ, 1999, GASTROENTEROLOGY, V116, P1063, DOI 10.1016/S0016-5085(99)70009-0; Humble MC, 2005, ONCOGENE, V24, P8217, DOI 10.1038/sj.onc.1209000; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Leder A, 1997, BLOOD, V90, P1275, DOI 10.1182/blood.V90.3.1275.1275_1275_1282; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Moran JL, 2006, GENOME RES, V16, P436, DOI 10.1101/gr.4563306; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Uhrbom L, 2002, CANCER RES, V62, P5551	32	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2456	2465		10.1038/sj.onc.1210866	http://dx.doi.org/10.1038/sj.onc.1210866			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17952114				2022-12-28	WOS:000254844900010
J	Savio, MG; Rotondo, G; Maglie, S; Rossetti, G; Bender, JR; Pardi, R				Savio, M. G.; Rotondo, G.; Maglie, S.; Rossetti, G.; Bender, J. R.; Pardi, R.			COP1D, an alternatively spliced constitutive photomorphogenic-1 (COP1) product, stabilizes UV stress-induced c-Jun through inhibition of full-length COP1	ONCOGENE			English	Article						AP-1; transcription; ubiquitin ligase; alternative splicing; genotoxic stress	UBIQUITIN LIGASE COP1; TRANSCRIPTION FACTORS; NEGATIVE REGULATOR; P53; PROTEIN; KINASES; CELLS; TRANSACTIVATION; DEGRADATION; EXPRESSION	COP1 is an evolutionarily conserved RING-finger ubiquitin ligase acting within a Cullin- RING ligase ( CRL) complex that promotes polyubiquitination of c- Jun and p53. Stability of the above substrates is affected by post-translational changes priming the proteins for polyubiquitination and proteasome- dependent degradation. However, degradation of both substrates is controlled indirectly by signaling pathways affecting the E3 ligases involved in their polyubiquitination. Here, we report the identification of COP1D, a ubiquitously expressed splice variant of COP1 lacking a portion of a coiled- coil region involved in intermolecular associations. While being unable to associate with other components of the CRL complex, COP1D exerts a dominant- negative function over the full- length protein, due to its ability to heterodimerize with COP1 and sequester it from the enzymatically active complex. Ectopic expression of COP1D antagonizes the function of COP1, while its selective downregulation by RNA interference promotes more efficient degradation of c- Jun and p53 by the full- length protein. The COP1/ COP1D mRNA ratio is modulated by UV stress and a decreased COP1/ COP1D ratio correlates with elevated c- Jun, but not p53 protein levels in invasive ductal breast cancer. Thus, dynamic changes of the COP1/ COP1D ratio provide an additional level of regulation of the half-life of the substrates of this E3 ligase under homeostatic or pathological conditions.	[Savio, M. G.; Rotondo, G.; Maglie, S.; Rossetti, G.; Pardi, R.] Univ Vita Salute San Raffaele, Sch Med, DIBIT Sci Inst San Raffaele, Unit Leukocyte Biol, I-20132 Milan, Italy; [Bender, J. R.] Yale Univ, Sch Med, Sect Cardiovasc Med, Raymond & Beverly Sackler Fdn Cardiovasc Lab, New Haven, CT USA	Vita-Salute San Raffaele University; Yale University	Pardi, R (corresponding author), Univ Vita Salute San Raffaele, Sch Med, DIBIT Sci Inst San Raffaele, Unit Leukocyte Biol, I-20132 Milan, Italy.	pardi.ruggero@hsr.it	rossetti, grazisa/C-3722-2015	rossetti, grazisa/0000-0001-6361-311X; Rotondo, Giuseppe/0000-0001-7811-1753	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043331] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL43331] Funding Source: Medline	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bianchi E, 2003, J BIOL CHEM, V278, P19682, DOI 10.1074/jbc.M212681200; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Dornan D, 2004, CANCER RES, V64, P7226, DOI 10.1158/0008-5472.CAN-04-2601; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Dornan D, 2006, SCIENCE, V313, P1122, DOI 10.1126/science.1127335; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Koivusalo R, 2006, CANCER RES, V66, P11817, DOI 10.1158/0008-5472.CAN-06-2185; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Langer S, 2006, EUR J GYNAECOL ONCOL, V27, P345; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Subramanian C, 2004, P NATL ACAD SCI USA, V101, P6798, DOI 10.1073/pnas.0307964101; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; Tsuge T, 2001, MOL GENET GENOMICS, V265, P43, DOI 10.1007/s004380000396; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Yanagawa Y, 2004, GENE DEV, V18, P2172, DOI 10.1101/gad.1229504; Yi CL, 2005, TRENDS CELL BIOL, V15, P618, DOI 10.1016/j.tcb.2005.09.007; Yi CL, 2005, CANCER RES, V65, P5835, DOI 10.1158/0008-5472.CAN-05-0423	28	23	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2401	2411		10.1038/sj.onc.1210892	http://dx.doi.org/10.1038/sj.onc.1210892			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968316				2022-12-28	WOS:000254844900005
J	Tommiska, J; Bartkova, J; Heinonen, M; Hautala, L; Kilpivaara, O; Eerola, H; Aittomaki, K; Hofstetter, B; Lukas, J; von Smitten, K; Blomqvist, C; Ristimaki, A; Heikkila, P; Bartek, J; Nevanlinna, H				Tommiska, J.; Bartkova, J.; Heinonen, M.; Hautala, L.; Kilpivaara, O.; Eerola, H.; Aittomaki, K.; Hofstetter, B.; Lukas, J.; von Smitten, K.; Blomqvist, C.; Ristimaki, A.; Heikkila, P.; Bartek, J.; Nevanlinna, H.			The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer	ONCOGENE			English	Article						DNA damage response; triple-negative breast cancer; BRCA1/BRCA2 familial cancer; ATM defects; genetic instability	ONCOGENE-INDUCED SENESCENCE; DOUBLE-STRAND BREAKS; BRCA2 MUTATIONS; POLY(ADP-RIBOSE) POLYMERASE; HISTOPATHOLOGICAL FEATURES; ATAXIA-TELANGIECTASIA; ANTICANCER BARRIER; PROTEIN EXPRESSION; FAMILIES; TUMORS	The ataxia- telangiectasia- mutated ( ATM) kinase is a key transducer of DNA damage signals within the genome maintenance machinery and a tumour suppressor whose germline mutations predispose to familial breast cancer. ATM signalling is constitutively activated in early stages of diverse types of human malignancies and cell culture models in response to oncogene- induced DNA damage providing a barrier against tumour progression. As BRCA1 and BRCA2 are also components of the genome maintenance network and their mutations predispose to breast cancer, we have examined the ATM expression in human breast carcinomas of BRCA1/ 2 mutation carriers, sporadic cases and familial non- BRCA1/ 2 patients. Our results show that ATM protein expression is aberrantly reduced more frequently among BRCA1 ( 33%; P 0.0003) and BRCA2 ( 30%; P 0.0009) tumours than in non- BRCA1/ 2 tumours ( 10.7%). Furthermore, the non-BRCA1/ 2 tumours with reduced ATM expression were more often estrogen receptor ( ER) negative ( P 0.0002), progesterone receptor ( PR) negative ( P 0.004) and were of higher grade ( P 0.0004). In our series of 1013 non-BRCA1/ 2 cases, ATM was more commonly deficient ( 20%; P 0.0006) and p53 was overabundant ( 47%; P<0.0000000001) among the difficult- to- treat ER/ PR/ ERBB2- triple- negative subset of tumours compared with cases that expressed at least one of these receptors ( 10 and 16% of aberrant ATM and p53, respectively). We propose a model of conditional haploinsufficiency' for BRCA1/ 2 under conditions of enhanced DNA damage in precancerous lesions resulting in more robust activation and hence increased selection for inactivation or loss of ATM in tumours of BRCA1/ 2 mutation carriers, with implications for genomic instability and curability of diverse subsets of human breast cancer.	[Tommiska, J.; Hautala, L.; Kilpivaara, O.; Eerola, H.; Nevanlinna, H.] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00029 Helsinki, Finland; [Bartkova, J.; Hofstetter, B.; Lukas, J.; Bartek, J.] Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; [Bartkova, J.; Hofstetter, B.; Lukas, J.; Bartek, J.] Danish Canc Soc, Ctr Genotox Stress Res, Copenhagen, Denmark; [Heinonen, M.; Ristimaki, A.; Heikkila, P.] HUSLAB, Dept Pathol, Helsinki, Finland; [Heinonen, M.; Ristimaki, A.; Heikkila, P.] Univ Helsinki, Cent Hosp, Haartman Inst, FIN-00029 Helsinki, Finland; [Heinonen, M.; Ristimaki, A.] Univ Helsinki, Genome Scale Biol Program, Helsinki, Finland; [Eerola, H.; Blomqvist, C.] Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland; [Aittomaki, K.] Univ Helsinki, Cent Hosp, Dept Clin Genet, FIN-00029 Helsinki, Finland; [von Smitten, K.] Univ Helsinki, Cent Hosp, Dept Surg, FIN-00029 Helsinki, Finland; [Blomqvist, C.] Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden	University of Helsinki; Helsinki University Central Hospital; Danish Cancer Society; Danish Cancer Society; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Uppsala University; Uppsala University Hospital	Nevanlinna, H (corresponding author), Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, POB 700, FIN-00029 Helsinki, Finland.	jb@cancer.dk; heli.nevanlinna@hus.fi	Bartek, Jiri/G-5870-2014	Hautala, Laura/0000-0002-5501-2792; Nevanlinna, Heli/0000-0002-0916-2976; Blomqvist, Carl/0000-0003-3041-1938; Tommiska, Johanna/0000-0001-7958-8262; Lukas, Jiri/0000-0001-9087-506X				Angele S, 2003, HISTOPATHOLOGY, V43, P347, DOI 10.1046/j.1365-2559.2003.01713.x; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Eerola H, 2005, BREAST CANCER RES, V7, pR465, DOI 10.1186/bcr1025; Eerola H, 2005, BREAST CANCER RES, V7, pR93, DOI 10.1186/bcr953; Eerola H, 2000, EUR J CANCER, V36, P1143, DOI 10.1016/S0959-8049(00)00093-9; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Honrado E, 2005, MODERN PATHOL, V18, P1305, DOI 10.1038/modpathol.3800453; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kilpivaara O, 2005, INT J CANCER, V113, P575, DOI 10.1002/ijc.20638; Lassus H, 2004, GYNECOL ONCOL, V92, P31, DOI 10.1016/j.ygyno.2003.10.010; Lukas C, 2001, CANCER RES, V61, P4990; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Palacios J, 2003, CLIN CANCER RES, V9, P3606; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prokopcova J, 2007, BREAST CANCER RES TR, V104, P121, DOI 10.1007/s10549-006-9406-6; Pylkas K, 2007, CARCINOGENESIS, V28, P1040, DOI 10.1093/carcin/bgl237; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Syrjakoski K, 2000, J NATL CANCER I, V92, P1529, DOI 10.1093/jnci/92.18.1529; Tanner M, 2000, AM J PATHOL, V157, P1467, DOI 10.1016/S0002-9440(10)64785-2; Tommiska J, 2005, CLIN CANCER RES, V11, P5098, DOI 10.1158/1078-0432.CCR-05-0173; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, BRIT J CANCER, V84, P704, DOI 10.1054/bjoc.2000.1626; Vehmanen P, 1997, HUM MOL GENET, V6, P2309, DOI 10.1093/hmg/6.13.2309; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	41	86	90	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2501	2506		10.1038/sj.onc.1210885	http://dx.doi.org/10.1038/sj.onc.1210885			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17982490				2022-12-28	WOS:000254844900015
J	Shafiei, F; Rahnama, F; Pawella, L; Mitchell, MD; Gluckman, PD; Lobie, PE				Shafiei, F.; Rahnama, F.; Pawella, L.; Mitchell, M. D.; Gluckman, P. D.; Lobie, P. E.			DNMT3A and DNMT3B mediate autocrine hGH repression of plakoglobin gene transcription and consequent phenotypic conversion of mammary carcinoma cells	ONCOGENE			English	Article						DNA methylation; DNA methyltransferases; human growth hormone; plakoglobin; mammary carcinoma	HUMAN GROWTH-HORMONE; DNA METHYLTRANSFERASES DNMT3A; TUMOR-SUPPRESSOR GENES; GAMMA-CATENIN GENE; PROMOTER METHYLATION; COLON-CANCER; EXPRESSION; ACTIVATION; KINASE; IDENTIFICATION	Directed by microarray analyses, we report that autocrine human growth hormone (hGH) increased the mRNA and protein expression of DNA methyltransferase 1 (DNMT1), DNMT3A and DNMT3B in mammary carcinoma cells. Autocrine hGH stimulation of DNMT3A and DNMT3B expression was mediated by JAK2 and Src kinases, and treatment of mammary carcinoma cells with the DNMT inhibitor, 5'-aza-2'-deoxycytidine (AZA), abrogated autocrine hGH-stimulated cellular proliferation, apoptosis and anchorage-independent growth. AZA reversed the epitheliomesenchymal transition of mammary carcinoma cells induced by autocrine hGH, to an epithelioid morphology and abrogated cell migration stimulated by autocrine hGH. Autocrine hGH-stimulated hypermethylation of the first exon of the PLAKOGLOBIN gene and AZA abrogated the ability of autocrine hGH to repress plakoglobin gene transcription. Small interfering RNA (siRNA)-mediated depletion of the individual DNMT molecules did not release autocrine hGH repression of PLAKOGLOBIN promoter activity nor did individual DNMT depletion affect autocrine hGH-stimulated migration. However, concomitant siRNA-mediated depletion of both DNMT3A and DNMT3B abrogated hypermethylation of the PLAKOGLOBIN gene stimulated by autocrine hGH and subsequent repression of plakoglobin gene transcription and increased cell migration. Thus, the autocrine hGH-stimulated increases in DNMT3A and DNMT3B expression mediate repression of plakoglobin gene transcription by direct hypermethylation of its promoter and consequent phenotypic conversion of mammary carcinoma cells. Autocrine hGH, therefore, utilizes DNA methylation as a mechanism to exert its oncogenic effects in mammary carcinoma cells.	[Lobie, P. E.] Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland 1, New Zealand	University of Auckland; University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave, Auckland 1, New Zealand.	p.lobie@auckland.ac.nz	Mitchell, Murray/A-8639-2010	Mitchell, Murray/0000-0002-6167-7176				Bai SM, 2005, MOL CELL BIOL, V25, P751, DOI 10.1128/MCB.25.2.751-766.2005; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Breault JE, 2005, CLIN CANCER RES, V11, P557; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Fukunaga Y, 2005, CELL STRUCT FUNCT, V30, P25, DOI 10.1247/csf.30.25; Hausherr A, 2007, ONCOGENE, V26, P4987, DOI 10.1038/sj.onc.1210306; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jaenisch R, 1998, CIBA F SYMP, V214, P200; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Ling L, 2004, J BIOL CHEM, V279, P32737, DOI 10.1074/jbc.M400601200; Ling L, 2003, J BIOL CHEM, V278, P27301, DOI 10.1074/jbc.M302516200; MENG F, 2007, ONCOGENE        0709; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; Oka M, 2005, ONCOGENE, V24, P3091, DOI 10.1038/sj.onc.1208540; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Perry JK, 2006, GROWTH HORM IGF RES, V16, P277, DOI 10.1016/j.ghir.2006.09.006; Potter E, 2001, EUR J ENDOCRINOL, V145, P625, DOI 10.1530/eje.0.1450625; Rahnama F, 2006, ENDOCRINOLOGY, V147, P5275, DOI 10.1210/en.2006-0288; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; SERRANO J, 1993, J CHROMATOGR-BIOMED, V615, P203, DOI 10.1016/0378-4347(93)80334-Z; Shiina H, 2005, CANCER RES, V65, P2130, DOI 10.1158/0008-5472.CAN-04-3398; Sung J, 2005, CARCINOGENESIS, V26, P487, DOI 10.1093/carcin/bgh318; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Waters MJ, 1999, CLIN EXP PHARMACOL P, V26, P760, DOI 10.1046/j.1440-1681.1999.03129.x; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Yanagisawa Y, 2002, BBA-GENE STRUCT EXPR, V1577, P457, DOI 10.1016/S0167-4781(02)00482-7; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2005, CANCER RES, V65, P317; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200	44	34	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2602	2612		10.1038/sj.onc.1210917	http://dx.doi.org/10.1038/sj.onc.1210917			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17998942				2022-12-28	WOS:000255057000010
J	Uttamsingh, S; Bao, X; Nguyen, KT; Bhanot, M; Gong, J; Chan, JK; Liu, F; Chu, TT; Wang, LH				Uttamsingh, S.; Bao, X.; Nguyen, K. T.; Bhanot, M.; Gong, J.; Chan, JL-K; Liu, F.; Chu, T. T.; Wang, L-H			Synergistic effect between EGF and TGF-beta 1 in inducing oncogenic properties of intestinal epithelial cells	ONCOGENE			English	Article						EGF; TGF-beta 1; EMT; invasion; colony formation	GROWTH-FACTOR-BETA; ANCHORAGE-INDEPENDENT GROWTH; TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; TGF-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; CANCER-CELLS; TRANSFORMATION	Transforming growth factor (TGF)-beta 1 has a biphasic effect on rat intestinal epithelial (RIE) cells. By itself, TGF-beta 1 functions as a tumor suppressor by inhibiting the growth, migration and invasion of RIE cells. We show in this study that in conjunction with epidermal-growth factor (EGF), TGF-beta 1 helped to augment migration, invasion and anchorage-independent growth (AIG) compared to that by EGF alone. EGF plus TGF-beta 1 induced a dramatic morphological change characteristic of epithelial-mesenchymal transition (EMT). The mechanism for this enhanced effect of TGF-beta 1 and EGF on oncogenic properties was explored by analysis of EGF- and TGF-beta 1-mediated signaling pathways and complementary DNA arrays. TGF-beta 1 augmented EGF-mediated signaling of mitogen-activated protein kinase (MAPK) and AKT by enhancing and prolonging the activation of the former and prolonging the activation of the latter. Inhibition of MAPK, but not phosphoinositide-3 kinase (PI3K), abolished TGF-beta 1 plus EGF-induced EMT and down-regulation of E-cadherin at mRNA and protein levels. By contrast, cell migration and invasion were sensitive to inhibition of either MAPK or PI3 kinase. TGF-beta 1 plus EGF-induced AIG was significantly more resistant to inhibition of PI3K and MAPK compared to that induced by EGF alone. EGF and TGF-beta 1 synergistically induced the expression of a series of proteases including matrix metalloproteinase (MMP) 1 (collagenase), MMP3, MMP9, MMP10, MMP14 and cathepsin. Among them, the expression of MMP1, MMP3, MMP9 and MMP10 was MAPK dependent. Inhibition of the MMPs or cathepsin significantly blocked EGF plus TGF-beta 1-induced invasion, but had no effect on colony formation. Phospholipase C (PLC) and Cox2 induced by EGF plus TGF-beta 1 also played a significant role in invasion, whereas PLC was also important for colony formation. Our study reveals specific signaling functions and induction of genes differentially required for enhanced effect of EGF- and TGF-beta 1-induced oncogenic properties, and helps to explain the tumor-promoting effect of TGF-beta 1 in human cancer with elevated expression or activation of TGF-beta 1 and receptor protein tyrosine kinases.	[Uttamsingh, S.; Bao, X.; Nguyen, K. T.; Bhanot, M.; Gong, J.; Chan, JL-K; Wang, L-H] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; [Liu, F.] Rutgers State Univ, Ernest Mario Sch Pharm, Ctr Adv Biotechnol & Med, Piscataway, NJ USA; [Liu, F.] Rutgers State Univ, Ernest Mario Sch Pharm, Susan Lehman Cullman Lab Canc Res, Piscataway, NJ USA; [Chu, T. T.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.	lu-hai.wang@mssm.edu	Wang, Lu-Hai/E-3986-2010; Gong, Jianli/G-1212-2011		NATIONAL CANCER INSTITUTE [R01CA055054, R01CA029339] Funding Source: NIH RePORTER; NCI NIH HHS [CA29339, CA55054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSOIAN RK, 1989, ANAL BIOCHEM, V177, P95, DOI 10.1016/0003-2697(89)90020-1; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; Docherty NG, 2006, AM J PHYSIOL-RENAL, V290, pF1202, DOI 10.1152/ajprenal.00406.2005; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; JONG SMJ, 1987, ONCOGENE RES, V1, P7; Kizaka-Kondoh S, 2000, FEBS LETT, V466, P160, DOI 10.1016/S0014-5793(99)01784-6; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Stolz DB, 1997, J CELL PHYSIOL, V170, P57; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Uttamsingh S, 2003, J BIOL CHEM, V278, P18798, DOI 10.1074/jbc.M211522200; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang LH, 2004, MT SINAI J MED, V71, P361; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948	28	122	125	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2626	2634		10.1038/sj.onc.1210915	http://dx.doi.org/10.1038/sj.onc.1210915			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982486				2022-12-28	WOS:000255057000012
J	Bottley, G; Watherston, OG; Hiew, YL; Norrild, B; Cook, GP; Blair, GE				Bottley, G.; Watherston, O. G.; Hiew, Y-L; Norrild, B.; Cook, G. P.; Blair, G. E.			High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells	ONCOGENE			English	Article						HPV; E7; MHC class I; cervical cancer; NK cells	CERVICAL KERATINOCYTES; CHROMATIN REPRESSION; DOWN-REGULATION; HLA-E; COMPLEX; GENES; E6	High-risk human papillomavirus (HPV) is a major causative agent of cervical cancer and the E6 and E7 genes encode the major HPV oncoproteins. The E7 protein from high-risk HPV types alters cell cycle progression and represses genes encoding components of the antigen-presentation pathway, suggesting a role for E7 in tumour immune evasion. We show that knockdown of E7 expression in HPV16- and HPV18-transformed cervical carcinoma cells by RNA interference increased expression of major histocompatibility complex (MHC) class I at the cell surface and reduced susceptibility of these cells to natural killer (NK) cells. Tetracycline-regulated induction of HPV16 E7 resulted in reduced expression of cell surface MHC class I molecules and increased NK cell killing. Our results suggest that, for HPV-associated malignancies, reduced MHC class I expression is the result of an active immune evasion strategy that has evolved to assist viral replication.	[Bottley, G.; Watherston, O. G.; Hiew, Y-L; Blair, G. E.] Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England; [Norrild, B.] Univ Copenhagen, Panum Inst, Inst Cellular & Mol Med, DK-2200 Copenhagen, Denmark; [Cook, G. P.] St James Univ Hosp, Leeds Inst Mol Med, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Copenhagen; Saint James's University Hospital; University of Leeds	Blair, GE (corresponding author), Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Garstang Bldg Room, Leeds LS2 9JT, W Yorkshire, England.	g.e.blair@leeds.ac.uk	Blair, George Eric/A-5906-2008; Norrild, Bodil/C-1115-2009	Blair, George Eric/0000-0003-0440-1795; Cook, Graham/0000-0003-0223-3652	Medical Research Council Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abele R, 2006, FEBS LETT, V580, P1156, DOI 10.1016/j.febslet.2005.11.048; Berger AJ, 2002, AM J PATHOL, V161, P603, DOI 10.1016/S0002-9440(10)64215-0; Bottley G, 2005, VIROLOGY, V338, P297, DOI 10.1016/j.virol.2005.05.017; Bottley Graham, 2007, Methods Mol Med, V131, P221; Brady CS, 2000, TISSUE ANTIGENS, V55, P401, DOI 10.1034/j.1399-0039.2000.550502.x; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; CROMME FV, 1993, ONCOGENE, V8, P2969; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; Garcia-Lora A, 2003, EUR J IMMUNOGENET, V30, P177, DOI 10.1046/j.1365-2370.2003.00384.x; Georgopoulos NT, 2000, ONCOGENE, V19, P4930, DOI 10.1038/sj.onc.1203860; Hall AHS, 2003, J VIROL, V77, P6066, DOI 10.1128/JVI.77.10.6066-6069.2003; Hewitt EW, 2003, IMMUNOLOGY, V110, P163, DOI 10.1046/j.1365-2567.2003.01738.x; HOWLEY PM, 2007, FIELDS VIROLOGY, P2299; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kaznelson DW, 2004, VIROLOGY, V320, P301, DOI 10.1016/j.virol.2003.12.018; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Li H, 2006, BIOCHEM BIOPH RES CO, V349, P1315, DOI 10.1016/j.bbrc.2006.08.182; Marin R, 2003, IMMUNOGENETICS, V54, P767, DOI 10.1007/s00251-002-0526-9; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; O'Brien PM, 2003, TRENDS MICROBIOL, V11, P300, DOI 10.1016/S0966-842X(03)00145-8; Pett MR, 2006, P NATL ACAD SCI USA, V103, P3822, DOI 10.1073/pnas.0600078103; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Zhao BW, 2006, VIROLOGY, V352, P338, DOI 10.1016/j.virol.2006.04.036	27	46	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1794	1799		10.1038/sj.onc.1210798	http://dx.doi.org/10.1038/sj.onc.1210798			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17828295				2022-12-28	WOS:000253962100015
J	Kidokoro, T; Tanikawa, C; Furukawa, Y; Katagiri, T; Nakamura, Y; Matsuda, K				Kidokoro, T.; Tanikawa, C.; Furukawa, Y.; Katagiri, T.; Nakamura, Y.; Matsuda, K.			CDC20, a potential cancer therapeutic target, is negatively regulated by p53	ONCOGENE			English	Article						CDC20; p53; p21; therapeutic target; spindle checkpoint	GENE-EXPRESSION PROFILES; WIDE CDNA MICROARRAY; WILD-TYPE P53; CELL LUNG CANCERS; DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; NEOADJUVANT CHEMOTHERAPY; P53-DEPENDENT APOPTOSIS; MYELOID-LEUKEMIA; BREAST-CANCER	The p53 protein inhibits malignant transformation through direct and indirect regulation of transcription of many genes related to cell cycle, apoptosis and cellular senescence. A number of genes induced by p53 have been well characterized, but biological significance of genes whose expression was suppressed by p53 is still largely undisclosed. To clarify the roles of p53-suppressive genes in carcinogenesis, we analysed two data sets of whole-genome expression profiles, one for cells in which wildtype p53 was exogenously introduced and the other for a large number of clinical cancer tissues. Here, we identified CDC20 that was frequently upregulated in many types of malignancies and remarkably suppressed by ectopic introduction of p53. CDC20 expression was suppressed by genotoxic stresses in p53- and p21-dependent manners through CDE-CHR elements in the CDC20 promoter. Furthermore, small interference RNA (siRNA)-mediated silencing of p53 induced CDC20 expression in normal human dermal. broblast cells. As we expected, treatment of cancer cells with siRNA against CDC20 induced G(2)/M arrest and suppressed cell growth. Our results indicate that p53 inhibits tumor cell growth through the indirect regulation of CDC20 and that CDC20 might be a good potential therapeutic target for a broad spectrum of human cancer.	[Kidokoro, T.; Tanikawa, C.; Katagiri, T.; Nakamura, Y.; Matsuda, K.] Univ Tokyo, Ctr Human Genome, Inst Med Sci, Mol Med Lab, Tokyo 1088639, Japan; [Furukawa, Y.] Univ Tokyo, Ctr Human Genome, Inst Med Sci, Promot Genome Based Med Project, Tokyo, Japan	University of Tokyo; University of Tokyo	Kidokoro, T (corresponding author), Univ Tokyo, Ctr Human Genome, Inst Med Sci, Mol Med Lab, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	koichima@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012; Matsuda, Koichi/D-4597-2011	Matsuda, Koichi/0000-0001-7292-2686; Tanikawa, Chizu/0000-0003-4759-4793				Ashida S, 2004, CANCER RES, V64, P5963, DOI 10.1158/0008-5472.CAN-04-0020; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fung TK, 2005, SEMIN CELL DEV BIOL, V16, P335, DOI 10.1016/j.semcdb.2005.02.014; Hasegawa S, 2002, CANCER RES, V62, P7012; Hirota E, 2006, INT J ONCOL, V29, P799; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Jinawath N, 2004, ONCOGENE, V23, P6830, DOI 10.1038/sj.onc.1207886; Kaneta Y, 2002, JPN J CANCER RES, V93, P849, DOI 10.1111/j.1349-7006.2002.tb01328.x; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Kim JM, 2005, CLIN CANCER RES, V11, P473; Kitahara O, 2002, NEOPLASIA, V4, P295, DOI 10.1038/sj.neo.7900251; Kitahara O, 2001, CANCER RES, V61, P3544; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Matsuda K, 2002, CANCER RES, V62, P2883; Mondal G, 2007, CARCINOGENESIS, V28, P81, DOI 10.1093/carcin/bgl100; Nagayama S, 2002, CANCER RES, V62, P5859; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Nishidate T, 2004, INT J ONCOL, V25, P797; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Ochi K, 2004, INT J ONCOL, V24, P647; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okabe H, 2001, CANCER RES, V61, P2129; Okada K, 2003, INT J ONCOL, V23, P1615; Okutsu J, 2002, MOL CANCER THER, V1, P1035; Ono K, 2000, CANCER RES, V60, P5007; Roth JA, 2006, EXPERT OPIN BIOL TH, V6, P55, DOI 10.1517/14712598.6.1.55; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Soussi T, 2006, CLIN CANCER RES, V12, P62, DOI 10.1158/1078-0432.CCR-05-0413; St Clair S, 2004, MOL CELL, V16, P725; Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Taniwaki M, 2006, INT J ONCOL, V29, P567; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yamabuki T, 2006, INT J ONCOL, V28, P1375; Yi S, 2006, MOL CARCINOGEN, V45, P409, DOI 10.1002/mc.20231; Zaffaroni N, 2005, J CELL MOL MED, V9, P360, DOI 10.1111/j.1582-4934.2005.tb00361.x; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	50	156	165	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1562	1571		10.1038/sj.onc.1210799	http://dx.doi.org/10.1038/sj.onc.1210799			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873905				2022-12-28	WOS:000253815800008
J	Knoops, L; Hornakova, T; Royer, Y; Constantinescu, SN; Renauld, JC				Knoops, L.; Hornakova, T.; Royer, Y.; Constantinescu, S. N.; Renauld, J-C			JAK kinases overexpression promotes in vitro cell transformation	ONCOGENE			English	Article						interleukin-9; Janus kinases; transforming gene; overexpression	SURFACE EXPRESSION; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE DISORDERS; CONSTITUTIVE ACTIVATION; ERYTHROPOIETIN RECEPTOR; CYTOKINE RECEPTOR; HODGKINS LYMPHOMA; STAT PROTEINS; INTERLEUKIN-9; MUTATION	Constitutive activation of the JAK-STAT pathway is frequent in cancer and contributes to oncogenesis. Here, we took advantage of the Ba/F3 cell line, a murine proB cell line dependent on IL-3 for growth, to analyse mechanisms of constitutive STAT activation in vitro. Cytokine-independent and tumorigenic Ba/F3 cell lines were derived from a two-step selection process. Cells transfected with a defective IL-9 receptor acquire IL-9 responsiveness during a first step of selection, and progress after a second selection step to autonomously growing tumorigenic cells. Microarray analysis pointed to JAK1 overexpression as a key genetic event in this transformation. Overexpression of JAK1 not only increased the sensitivity to IL-9 but also allowed a second selection step toward cytokine-independent growth with constitutive STAT activation. This progression was dependent on a functional FERM and kinase JAK1 domain. Similar results were observed after JAK2, JAK3 and TYK2 overexpression. All autonomous cell lines showed an activation of STAT5, ERK1-2 and AKT but only TYK2-overexpressing cell lines showed a constitutive activation of STAT3. Thus, JAK overexpression can be considered as one of the oncogenic events leading to the constitutive activation of the JAK-STAT pathway.	[Knoops, L.; Hornakova, T.; Royer, Y.; Constantinescu, S. N.; Renauld, J-C] Univ Catholique Louvain, Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium; [Knoops, L.; Hornakova, T.; Royer, Y.; Constantinescu, S. N.; Renauld, J-C] Univ Catholique Louvain, Duve Inst, B-1200 Brussels, Belgium; [Knoops, L.] Clin Univ St Luc, Div Hematol, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Renauld, JC (corresponding author), Univ Catholique Louvain, Ludwig Inst Canc Res, Brussels Branch, Ave Hippocrate 74, B-1200 Brussels, Belgium.	renauld@bru.licr.org	Constantinescu, Stefan N/E-5277-2012; Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131; Constantinescu, Stefan N./0000-0002-8599-2699				Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Cochet O, 2006, CELL SIGNAL, V18, P449, DOI 10.1016/j.cellsig.2005.05.010; Demoulin JB, 2000, CANCER RES, V60, P3971; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; DRUEZ C, 1990, J IMMUNOL, V145, P2494; Fischer M, 2003, LEUKEMIA, V17, P2513, DOI 10.1038/sj.leu.2403123; Guiter C, 2004, BLOOD, V104, P543, DOI 10.1182/blood-2003-10-3545; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Joos S, 2000, CANCER RES, V60, P549; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; KELLEHER K, 1991, BLOOD, V77, P1436; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Knoops L, 2004, GROWTH FACTORS, V22, P207, DOI 10.1080/08977190410001720879; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; MERZ H, 1991, BLOOD, V78, P1311; Nagai H, 2003, J HUM GENET, V48, P65, DOI 10.1007/s100380300008; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Rawat R, 2000, BLOOD, V96, P3514; Renauld J.-C., 2003, CYTOKINE HDB, P347; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; Rucker FG, 2006, J CLIN ONCOL, V24, P3887, DOI 10.1200/JCO.2005.04.5450; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Staerk J, 2005, J BIOL CHEM, V280, P41893, DOI 10.1074/jbc.C500358200; Trikha M, 2003, CLIN CANCER RES, V9, P4653; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7	41	34	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1511	1519		10.1038/sj.onc.1210800	http://dx.doi.org/10.1038/sj.onc.1210800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873904				2022-12-28	WOS:000253815800002
J	Phillips, A; Blaydes, JP				Phillips, A.; Blaydes, J. P.			MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA	ONCOGENE			English	Article						p53; MDM2; mRNA export; breast cancer; eIF4E	SINGLE NUCLEOTIDE POLYMORPHISM; INITIATION-FACTOR EIF4E; TRANSLATION INITIATION; NEGATIVE REGULATION; GENE-EXPRESSION; P53 PATHWAY; MDM2; PROTEIN; ACTIVATION; TRANSPORT	Regulation of the synthesis, function and degradation of HDM2 (Mdm2 in mouse) plays a key role in controlling the abundance and activity of the transcription factor p53, with consequent implications for the proliferation and survival of normal and cancer cells. We have previously identified the regulation of export of HDM2 mRNA from the nucleus as a novel point of control of HDM2 synthesis. This process is dependent on the activity of the growth factor-regulated MAP-kinase kinases ( MEKs). Here, we provide evidence that the eIF4E kinase MNK1 is a key downstream effector of MEKs in this regulatory pathway. We show that HDM2 mRNA export in breast cancer cells is promoted by overexpressed eIF4E in a MEK- and MNK1-dependent manner, and inhibition of MNK1 suppresses endogenous HDM2 mRNA export pathways. This MNK1- and eIF4E-dependent HDM2 regulation occurs through sequences in the 30 untranslated region of HDM2 mRNA, and consequently HDM2 mRNA transcripts from both the constitutive P1 and inducible P2 promoters are regulated by this pathway. eIF4E is a known oncogene that is overexpressed in human tumours, including the majority of breast cancers. This pathway, therefore, may play an important role in the dysregulation of HDM2 oncoprotein expression that occurs in many human tumours.	[Phillips, A.; Blaydes, J. P.] Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Southampton SO16 6YD, Hants, England	University of Southampton	Blaydes, JP (corresponding author), Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Somers Res Bldg,MP824, Southampton SO16 6YD, Hants, England.	jpb1@soton.ac.uk	Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Bond GL, 2007, ONCOGENE, V26, P1317, DOI 10.1038/sj.onc.1210199; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Culjkovic B, 2006, J CELL BIOL, V175, P415, DOI 10.1083/jcb.200607020; Culjkovic B, 2007, CELL CYCLE, V6, P65, DOI 10.4161/cc.6.1.3688; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; HARVEY M, 1993, ONCOGENE, V8, P2457; Keene JD, 2003, NAT GENET, V33, P111, DOI 10.1038/ng0203-111; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Onel K, 2004, MOL CANCER RES, V2, P1; Phelps M, 2005, J BIOL CHEM, V280, P16651, DOI 10.1074/jbc.M412334200; Phelps M, 2003, CANCER RES, V63, P2616; Phillips A, 2006, ONCOGENE, V25, P4183, DOI 10.1038/sj.onc.1209451; Phillips A, 2006, FEBS LETT, V580, P300, DOI 10.1016/j.febslet.2005.12.026; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	36	35	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1645	1649		10.1038/sj.onc.1210785	http://dx.doi.org/10.1038/sj.onc.1210785			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828301	Green Accepted			2022-12-28	WOS:000253815800017
J	Cano, F; Drynan, LF; Pannell, R; Rabbitts, TH				Cano, F.; Drynan, L. F.; Pannell, R.; Rabbitts, T. H.			Leukaemia lineage specification caused by cell-specific Mll-Enl translocations	ONCOGENE			English	Article						MLL; leukaemia; translocation; translocator; mouse disease models	CHROMOSOMAL TRANSLOCATIONS; CRE-LOXP; GENE; 11Q23; RECOMBINATION	Chromosomal translocations involving the Mixed-Lineage Leukaemia (MLL) gene underlie many human leukaemias and MLL rearrangements are found in both acute myelogenous and acute lymphoblastic leukaemias. To assess the functionally relevant haematopoietic cell contexts for MLL fusions to be tumorigenic, we have generated different lines of mice in which de novo Mll-associated translocations occur. In these models, reciprocal chromosomal translocations occur by means of Cre-loxPmediated recombination (translocator mice) in different cells of the haematopoietic system (namely haematopoietic stem cells, semi-committed progenitors or committed T or B cells). Translocations between Mll and Enl cause myeloid neoplasias, initiating in stem cells or progenitors while no tumours arose when the translocation was restricted to the B-cell compartment. Despite the absence of tumorigenesis, Mll-Enl translocations did occur and Mll-Enl fusion mRNA was expressed in B-cell-restricted translocators. A permissive cellular environment is therefore required for oncogenicity of Mll-associated translocations since the occurrence of Mll-Enl does not promote unrestricted proliferation in all haematopoietic cellular contexts, consistent with a specific instructive role of the MLL-fusion proteins in leukaemogenesis.	[Rabbitts, T. H.] St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Therapeut, Leeds LS9 7TF, W Yorkshire, England; [Cano, F.; Drynan, L. F.; Pannell, R.; Rabbitts, T. H.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Saint James's University Hospital; University of Leeds; MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Therapeut, Wellcome Trust Brenner Bldg, Leeds LS9 7TF, W Yorkshire, England.	thr@leeds.ac.uk	Drynan, Lesley/V-2984-2019; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609	MRC [G0600914] Funding Source: UKRI; Medical Research Council [MC_U105178807, G0600914] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Bloomfield CD, 2002, GENE CHROMOSOME CANC, V33, P362, DOI 10.1002/gcc.10046; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; Drynan LF, 2005, EMBO J, V24, P3136, DOI 10.1038/sj.emboj.7600760; Felix CA, 2001, MED PEDIATR ONCOL, V36, P525, DOI 10.1002/mpo.1125; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; McCormack MP, 2003, MOL CELL BIOL, V23, P9003, DOI 10.1128/MCB.23.24.9003-9013.2003; Metzler M, 2006, ONCOGENE, V25, P3093, DOI 10.1038/sj.onc.1209636; Milne TA, 2005, CANCER RES, V65, P11367, DOI 10.1158/0008-5472.CAN-05-1041; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Pui CH, 2007, LEUKEMIA, V21, P593, DOI 10.1038/sj.leu.2404598; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; Pui Ching-Hon, 2002, Rev Clin Exp Hematol, V6, P161, DOI 10.1046/j.1468-0734.2002.00067.x; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4	21	15	16	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1945	1950		10.1038/sj.onc.1210818	http://dx.doi.org/10.1038/sj.onc.1210818			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906700				2022-12-28	WOS:000254150600014
J	Shin, DH; Li, SH; Chun, YS; Huang, LE; Kim, MS; Park, JW				Shin, D. H.; Li, S. H.; Chun, Y-S; Huang, L. E.; Kim, M-S; Park, J-W			CITED2 mediates the paradoxical responses of HIF-1 alpha to proteasome inhibition	ONCOGENE			English	Article						hIF-1 alpha; CITED2; proteasome inhibition; p300 co-activator	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; MELANOCYTE-SPECIFIC GENE; TRANSCRIPTIONAL ACTIVITY; PROTEIN; HIF-1; EXPRESSION; REGULATOR; P300/CBP; GROWTH; MRG1	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is destabilized via the ubiquitin-proteasome system. Thus HIF-1 alpha expression is robustly upregulated by proteasome inhibition, but paradoxically its activity is reduced. In the present study, we investigated the mechanism underlying the paradoxical response of HIF-1 alpha to proteasome inhibition. In both Hep3B and HEK293 cells, a proteasome inhibitor MG132 noticeably attenuated hypoxic induction of erythropoietin and VEGF mRNAs. MG132 inactivated HIF-1 alpha C-terminal transactivation domain (CAD), independently of factor inhibiting HIF-1 (FIH) and inhibited p300 recruitment by HIF-1 alpha. We next tested the possibility that CITED2 is involved in the HIF-1 inactivation. CITED2 was found to be degraded via the ubiquitin-proteasome system and thus was stabilized by proteasome inhibition. Both the activity and the p300 binding of HIF-1 alpha were inhibited by CITED2 expression and recovered by CITED2 siRNA in the presence of MG132. These results suggest that CITED2 is stabilized by proteasome inhibition and inactivates HIF-1 by interfering with the HIF-1 alpha-p300 interaction. This may be an important mode-of-action for proteasome inhibition-based cancer therapy.	[Shin, D. H.; Li, S. H.; Kim, M-S; Park, J-W] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 11079, South Korea; [Chun, Y-S] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul 11079, South Korea; [Chun, Y-S] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Huang, L. E.] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Utah System of Higher Education; University of Utah	Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, 28 Yongon Dong, Seoul 11079, South Korea.	parkjw@snu.ac.kr	Park, Jong-Wan/J-2758-2012	Huang, Eric/0000-0002-6444-1708				Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Birle DC, 2007, CANCER RES, V67, P1735, DOI 10.1158/0008-5472.CAN-06-2722; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Chou YT, 2006, J BIOL CHEM, V281, P18451, DOI 10.1074/jbc.M601720200; Chun YS, 2002, BIOCHEM J, V362, P71, DOI 10.1042/0264-6021:3620071; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kaluz S, 2006, MOL CELL BIOL, V26, P5895, DOI 10.1128/MCB.00552-06; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Sasabe E, 2007, INT J CANCER, V120, P268, DOI 10.1002/ijc.22294; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Xu B, 2007, DEV BIOL, V301, P130, DOI 10.1016/j.ydbio.2006.08.072; Yeo EJ, 2006, BLOOD, V107, P916, DOI 10.1182/blood-2005-06-2564; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799	22	31	32	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2008	27	13					1939	1944		10.1038/sj.onc.1210826	http://dx.doi.org/10.1038/sj.onc.1210826			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906695				2022-12-28	WOS:000254150600013
J	Wang, H; Mannava, S; Grachtchouk, V; Zhuang, D; Soengas, MS; Gudkov, AV; Prochownik, EV; Nikiforov, MA				Wang, H.; Mannava, S.; Grachtchouk, V.; Zhuang, D.; Soengas, M. S.; Gudkov, A. V.; Prochownik, E. V.; Nikiforov, M. A.			c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle	ONCOGENE			English	Article						myc; cell cycle; shRNA	S-PHASE CHECKPOINT; NEOPLASTIC PHENOTYPE; MELANOMA-CELLS; TARGET GENES; APOPTOSIS; REVEALS; SKIN; TUMORIGENESIS; INACTIVATION; SUPPRESSION	A major role for c-Myc in the proliferation of normal cells is attributed to its ability to promote progression through G(1) and into S phase of the cell cycle. The absolute requirement of c-Myc for cell cycle progression in human tumor cells has not been comprehensively addressed. In the present work, we used a lentiviral-based short hairpin RNA (shRNA) expression vector to stably reduce c-Myc expression in a large number of human tumor cell lines and in three different types of normal human cells. In all cases, cell proliferation was severely inhibited, with normal cells ultimately undergoing G(0)/G(1) growth arrest. In contrast, tumor cells demonstrated a much more variable cell cycle response with cells from several lines accumulating in S or G(2)/M phases. Moreover, in some tumor lines, the phase of cell cycle arrest caused by inhibition of c-Myc could be altered by depleting tumor suppressor protein p53 or its transcriptional target p21(CIP/WAF). Our data suggest that, as in the case of normal cells, c-Myc is essential for sustaining proliferation of human tumor cells. However its rate-limiting role in cell cycle control is variable and is reliant upon the status of other cell cycle regulators.	[Mannava, S.; Grachtchouk, V.; Zhuang, D.; Soengas, M. S.; Nikiforov, M. A.] Univ Michigan, Dept Dermatol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Wang, H.; Prochownik, E. V.] Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Pittsburgh, PA 15213 USA; [Gudkov, A. V.] Cleveland Clin, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44106 USA	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cleveland Clinic Foundation	Nikiforov, MA (corresponding author), Univ Michigan, Dept Dermatol, Ctr Comprehens Canc, 1150 W Med Ctr Dr,MS1 Room 6427, Ann Arbor, MI 48109 USA.	mikhailn@umich.edu	Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [R01 CA107237, R01 CA120244-05, R01 CA105033, R01-CA105033, R01 CA140624, R01-CA120244-A1, R01 CA120244, R01-CA078259, R01 CA078259] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105033, R01CA078259, R01CA140624, R01CA107237, R01CA120244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; Arvanitis C, 2006, SEMIN CANCER BIOL, V16, P313, DOI 10.1016/j.semcancer.2006.07.012; Athar M, 2006, EXP DERMATOL, V15, P667, DOI 10.1111/j.1600-0625.2006.00473.x; Baena E, 2005, P NATL ACAD SCI USA, V102, P7286, DOI 10.1073/pnas.0409260102; Bernard Sandra, 2006, V42, P329, DOI 10.1007/004; Bettess MD, 2005, MOL CELL BIOL, V25, P7868, DOI 10.1128/MCB.25.17.7868-7878.2005; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; Chen JP, 2001, J GASTROEN HEPATOL, V16, P22, DOI 10.1046/j.1440-1746.2001.02361.x; Citro G, 1998, CANCER RES, V58, P283; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 1999, MOL CELL BIOL, V19, P1; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Gottifredi V, 2005, SEMIN CELL DEV BIOL, V16, P355, DOI 10.1016/j.semcdb.2005.02.011; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hermeking H, 2003, CURR CANCER DRUG TAR, V3, P163, DOI 10.2174/1568009033481949; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Li F, 2006, CANCER RES, V66, P5608, DOI 10.1158/0008-5472.CAN-05-4242; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Malynn BA, 2000, GENE DEV, V14, P1390; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McGuffie EM, 2000, CANCER RES, V60, P3790; Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Paz MF, 2003, CANCER RES, V63, P1114; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Ponzielli R, 2005, EUR J CANCER, V41, P2485, DOI 10.1016/j.ejca.2005.08.017; Prathapam T, 2006, P NATL ACAD SCI USA, V103, P2695, DOI 10.1073/pnas.0511186103; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; Rothermund K, 2005, CANCER RES, V65, P2097, DOI 10.1158/0008-5472.CAN-04-2928; Sharma SV, 2006, CLIN CANCER RES, V12, p4392S, DOI 10.1158/1078-0432.CCR-06-0096; Oskarsson T, 2006, GENE DEV, V20, P2024, DOI 10.1101/gad.381206; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stark GR, 2006, MOL BIOTECHNOL, V32, P227, DOI 10.1385/MB:32:3:227; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; VITA M, SEMIN CANC BIOL, V16, P318; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Zhou ZQ, 2001, TRENDS CELL BIOL, V11, pS10, DOI 10.1016/S0962-8924(01)02121-3	54	106	110	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1905	1915		10.1038/sj.onc.1210823	http://dx.doi.org/10.1038/sj.onc.1210823			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906696	Green Accepted			2022-12-28	WOS:000254150600010
J	Wesolowska, A; Kwiatkowska, A; Slomnicki, L; Dembinski, M; Master, A; Sliwa, M; Franciszkiewicz, K; Chouaib, S; Kaminska, B				Wesolowska, A.; Kwiatkowska, A.; Slomnicki, L.; Dembinski, M.; Master, A.; Sliwa, M.; Franciszkiewicz, K.; Chouaib, S.; Kaminska, B.			Microglia-derived TGF-beta as an important regulator of glioblastoma invasion - an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor	ONCOGENE			English	Article						gliomas; TGF-beta signaling; RNA interference; invasion/cell motility; tumor-host interactions; microglia	GROWTH-FACTOR-BETA; HUMAN GLIOMA-CELLS; RNA INTERFERENCE; MESSENGER-RNA; IN-VIVO; TARGETED DISRUPTION; INDUCIBLE ELEMENTS; TUMOR PROGRESSION; MAMMALIAN-CELLS; CYCLOSPORINE-A	The invasion of tumor cells into brain tissue is a pathologic hallmark of malignant gliomas and contributes to treatment failures. Diffuse glioblastomas contain numerous microglial cells, which enhance the progression of gliomas; however, factors responsible for invasion-promoting role of microglia are unknown. Transforming growth factor-beta (TGF-beta) can enhance tumor growth, invasion, angiogenesis and immunosuppression. Antagonizing TGF-beta activity has been shown to inhibit tumor invasion in vitro and tumorigenicity, but a systemic inhibition or lack of TGF-beta signaling results in acute inflammation and disruption of immune system homeostasis. We developed plasmid-transcribed small hairpin RNAs (shRNAs) to downregulate the TGF-beta type II receptor (T beta IIR) expression, which effectively inhibited cytokine-induced signaling pathways and transcriptional responses in transiently transfected human glioblastoma cells. Silencing of T beta IIR abolished TGF-beta-induced glioblastoma invasiveness and migratory responses in vitro. Moreover, tumorigenicity of glioblastoma cells stably expressing T beta IIR shRNAs in nude mice was reduced by 50%. Microglia strongly enhanced glioma invasiveness in the co-culture system, but this invasion-promoting activity was lost in glioma cells stably expressing shT beta RII, indicating a crucial role of microglia-derived TGF-beta in tumor-host interactions. Our results demonstrate a successful targeting of TGF-beta-dependent invasiveness and tumorigenicity of glioblastoma cells by RNAi-mediated gene silencing.	[Wesolowska, A.; Kwiatkowska, A.; Slomnicki, L.; Dembinski, M.; Master, A.; Sliwa, M.; Kaminska, B.] M Nencki Inst Expt Biol, Dept Cell Biol, Lab Transcript Regulat, PL-002093 Warsaw, Poland; [Franciszkiewicz, K.; Chouaib, S.] Inst Gustave Roussy, Human Tumor Cytokines Lab, Villejuif, France	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; UNICANCER; Gustave Roussy	Kaminska, B (corresponding author), M Nencki Inst Expt Biol, Dept Cell Biol, Lab Transcript Regulat, 3 Pasteur St, PL-002093 Warsaw, Poland.	bozenakk@nencki.gov.pl	Chouaib, Salem/F-7939-2016; Kaminska, Bozena/H-4592-2011; Kaminska, Bozena/B-2915-2014	Kaminska, Bozena/0000-0002-2642-4616; Master, Adam/0000-0001-9391-8846				ALBINI A, 1987, CANCER RES, V47, P3239; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Badie B, 2001, MICROSC RES TECHNIQ, V54, P106, DOI 10.1002/jemt.1125; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hjelmeland MD, 2004, MOL CANCER THER, V3, P737; Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964; Jazag A, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni130; Jennings MT, 1998, J NEURO-ONCOL, V36, P123, DOI 10.1023/A:1005863419880; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIEFER R, 1994, NEUROSCI LETT, V166, P161, DOI 10.1016/0304-3940(94)90475-8; Kjellman C, 2000, INT J CANCER, V89, P251, DOI 10.1002/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Marie JC, 2006, IMMUNITY, V25, P441, DOI 10.1016/j.immuni.2006.07.012; Markovic DS, 2005, J NEUROPATH EXP NEUR, V64, P754, DOI 10.1097/01.jnen.0000178445.33972.a9; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Ogorelkova M, 2006, OLIGONUCLEOTIDES, V16, P2, DOI 10.1089/oli.2006.16.2; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Pardridge WM, 2004, EXPERT OPIN BIOL TH, V4, P1103, DOI 10.1517/14712598.4.7.1103; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Platten M, 2001, MICROSC RES TECHNIQ, V52, P401, DOI 10.1002/1097-0029(20010215)52:4<401::AID-JEMT1025>3.0.CO;2-C; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Praus M, 1999, GENE THER, V6, P227, DOI 10.1038/sj.gt.3300802; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Schlingensiepen KH, 2006, CYTOKINE GROWTH F R, V17, P129, DOI 10.1016/j.cytogfr.2005.09.002; Shah AH, 2002, CANCER RES, V62, P7135; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sliwa M, 2007, BRAIN, V130, P476, DOI 10.1093/brain/awl263; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Teicher BA, 2001, CANCER METAST REV, V20, P133, DOI 10.1023/A:1013177011767; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Watters JJ, 2005, J NEUROSCI RES, V81, P447, DOI 10.1002/jnr.20485; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Won JW, 1999, CANCER RES, V59, P1273; YAMADA N, 1995, INT J CANCER, V62, P386, DOI 10.1002/ijc.2910620405; YAMAMOTO M, 1994, CANCER RES, V54, P3329; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Ye L, 2006, INT J ONCOL, V29, P1149; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zawadzka M, 2005, GLIA, V49, P36, DOI 10.1002/glia.20092; Zupanska A, 2005, NEUROCHEM INT, V47, P430, DOI 10.1016/j.neuint.2005.05.010	61	183	188	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					918	930		10.1038/sj.onc.1210683	http://dx.doi.org/10.1038/sj.onc.1210683			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17684491				2022-12-28	WOS:000252946300004
J	Berenguer, C; Boudouresque, F; Dussert, C; Daniel, L; Muracciole, X; Grino, M; Rossi, D; Mabrouk, K; Figarella-Branger, D; Martin, PM; Ouafik, L				Berenguer, C.; Boudouresque, F.; Dussert, C.; Daniel, L.; Muracciole, X.; Grino, M.; Rossi, D.; Mabrouk, K.; Figarella-Branger, D.; Martin, P-M; Ouafik, L'Houcine			Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells	ONCOGENE			English	Article						prostate cancer; LNCaP cells; adrenomedullin; adrenomedullin receptors; neuroendocrine differentiation; LNCaP xenograft; androgen; regulation; cGMP-dependent protein kinase G	DEPENDENT PROTEIN-KINASE; CANCER CELLS; IN-VITRO; DIFFERENTIATION; GENE; ANGIOGENESIS; PROGRESSION; EXPRESSION; PEPTIDE; GROWTH	Neuroendocrine (NE) differentiation in prostate cancer (CaP) has been reported to be an early marker associated with the development of androgen independence. The mechanisms by which CaP acquires NE properties are poorly understood. In this study, a putative role of adrenomedullin (AM) in the NE differentiation was investigated. The expression of AM and AM receptors (calcitonin receptor-like receptor (CRLR)/receptor activity modifying protein-2 and -3 (RAMP2 and RAMP3) was evaluated after experimental manipulation of androgen status. Levels of AM mRNA and immunoreactive AM (ir-AM) increased four-to sevenfold in androgen-sensitive LNCaP cells after androgen withdrawal in vitro and in LNCaP xenograftsin animals after castration. Treatment of LNCaP cells with androgen analogue (dihydrotestosterone; 10(-9) M) prevented the increase in AM mRNA and ir-AM levels. Interestingly, the expression of CRLR, RAMP2 and RAMP3 is not regulated by androgen status. We demonstrate that in the presence of serum, AM is able to induce an NE phenotype in LNCaP cells via CRLR/ RAMP2 and RAMP3, which includes extension of neuritic processes and expression of the neuron-specific enolase (NSE), producing cGMP in a dose-dependent manner, which is mediated by a pertussis toxin-sensitive GTP-binding protein. 8-bromo-cGMP mimicked the effects of AM on cell differentiation. We demonstrate that AM induces a G-kinase I alpha translocation to the nucleus. The protein kinase G inhibitor KT-5823 inhibited the neurite outgrowth induced by both AM and 8-bromo-cGMP. In noncastrated animals, administration of AM enhanced expression of NSE and chromogranin A in LNCaP xenografts with a significant increase of NSE levels in serum and no changes in tumor growth. In castrated animals, intraperitoneal injection of AM resulted in a 240 +/- 18% ( P<0.001) increase in tumor volume 36 days after treatment, indicating that the nature of effect of AM in CaP depends on the presence or absence of endogenous androgen. Together, these results demonstrate that AM may function as a mediator of NE-like differentiation in culture as well as in vivo and indicate that its product ion may be important for tumor resurgence following androgen ablation.	[Berenguer, C.; Boudouresque, F.; Dussert, C.; Martin, P-M; Ouafik, L'Houcine] Univ Aix Marseille 2, Fac Med Secteur Nord, IFR Jean Roche, Expt Cancerol Lab, F-13916 Marseille 20, France; [Berenguer, C.; Boudouresque, F.; Dussert, C.; Martin, P-M; Ouafik, L'Houcine] INSERM E 359, Marseille, France; [Daniel, L.; Figarella-Branger, D.] Univ Aix Marseille 2, Fac Med, Lab Adhes & Signalisat EA3281, Marseille, France; [Muracciole, X.] Assistance Publ Hop Marseille, CHU Timone, Serv Radiotherapie, Marseille, France; [Grino, M.] INSERM, UMR 626, Marseille, France; [Rossi, D.] Assistance Publ Hop Marseille, CHU Nord, Serv Urol, Marseille, France; [Mabrouk, K.] CNRS, FRE 2738, Marseille, France; [Martin, P-M; Ouafik, L'Houcine] Assistance Publ Hop Marseille, CHU Nord, Lab Transfer Oncol Biol & Mol, Marseille, France	UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Ouafik, L (corresponding author), Univ Aix Marseille 2, Fac Med Secteur Nord, IFR Jean Roche, Expt Cancerol Lab, Bd Pierre Dramard, F-13916 Marseille 20, France.	lhoucine.ouafik@univmed.fr	Grino, Michel/GYD-8559-2022; Grino, Michel/O-5361-2017; Grino, Michel/M-7548-2017; Muracciole, Xavier/P-5640-2016; daniel, laurent/R-2826-2016	daniel, laurent/0000-0002-7539-0109; Ouafik, L'Houcine/0000-0002-4848-1232				Abasolo I, 2003, MOL CELL ENDOCRINOL, V199, P179, DOI 10.1016/S0303-7207(02)00229-0; Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; Chung TDK, 1999, PROSTATE, V38, P199; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Fernandez-Sauze S, 2004, INT J CANCER, V108, P797, DOI 10.1002/ijc.11663; GKONOS PJ, 1995, UROL RES, V23, P81, DOI 10.1007/BF00307937; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Kim J, 2002, CANCER RES, V62, P1549; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Nikitenko LL, 2006, BRIT J CANCER, V94, P1, DOI 10.1038/sj.bjc.6602832; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Rocchi P, 2001, CANCER RES, V61, P1196; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E	19	34	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					506	518		10.1038/sj.onc.1210656	http://dx.doi.org/10.1038/sj.onc.1210656			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637748				2022-12-28	WOS:000252426100011
J	Shen, Q; Uray, IP; Li, Y; Krisko, TI; Strecker, TE; Kim, HT; Brown, PH				Shen, Q.; Uray, I. P.; Li, Y.; Krisko, T. I.; Strecker, T. E.; Kim, H-T; Brown, P. H.			The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors	ONCOGENE			English	Article						AP-1 factor; proliferation arrest; cyclin D1; E2F factors; gene expression regulation; breast cancer cells	C-JUN; KINASE-ACTIVITY; BINDING-SITE; ACTIVATION; EXPRESSION; GENE; FOS; DIFFERENTIATION; OVEREXPRESSION; TRANSFORMATION	The activating protein-1 (AP-1) transcription factor transduces growth signals through signal transduction pathways to the nucleus, leading to the expression of genes involved in growth and malignant transformation in many cell types. We have previously shown that overexpression of a dominant negative form of the cJun proto-oncogene, a cJun dominant negative mutant (Tam67), blocks AP-1 transcriptional activity, induces a G(1) cell cycle block and inhibits breast cancer cell growth in vitro and in vivo. We found that AP-1 blockade by Tam67 in MCF-7 breast cancer cells downregulates cyclin D1 transcriptional activity by at least two mechanisms: by suppressing transcription at the known AP-1 binding site (-934/-928) and by suppressing growth factor-induced expression through suppressing E2F activation at the E2F-responsive site (-726/-719). AP-1 blockade also led to reduced expression of E2F1 and E2F2, but not E2F4, at the mRNA and protein levels. Chromatin immunoprecipitation and supershift assays demonstrated that AP-1 blockade caused decreased binding of E2F1 protein to the E2F site in the cyclin D1 promoter. We also found that Tam67 suppressed the expression of the E2F1 dimerizing partner, DP1 and E2F-upregulated cell cycle genes (cyclins E, A, B and D3) and enhanced the expression of E2F-downregulated cell cycle genes (cyclins G2 and I). Reduced expression of other E2F-regulated genes was also seen with AP-1 blockade and E2F suppression. Thus, the AP-1 factor regulates the expression of cyclin D and E2F (the latter in turn regulates E2F-downstream genes), leading to cell cycle progression and breast cancer cell proliferation.	[Shen, Q.; Uray, I. P.; Li, Y.; Krisko, T. I.; Strecker, T. E.; Kim, H-T; Brown, P. H.] Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA; [Shen, Q.; Uray, I. P.; Li, Y.; Krisko, T. I.; Strecker, T. E.; Kim, H-T; Brown, P. H.] Baylor Coll Med, Breast Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Brown, PH (corresponding author), Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Plaza,MS600, Houston, TX 77030 USA.	pbrown@breastcenter.tmc.edu	Krisko, Tibor/AAG-7595-2020	Krisko, Tibor/0000-0002-9414-5846; Shen, Qiang/0000-0002-1491-5434; Brown, Powel/0000-0002-3398-163X				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Botz J, 1996, MOL CELL BIOL, V16, P3401; BROWN PH, 1993, ONCOGENE, V8, P877; Bu X, 2005, ONCOGENE, V24, P2398, DOI 10.1038/sj.onc.1208466; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Han S, 2003, BREAST CANCER RES TR, V82, P11, DOI 10.1023/B:BREA.0000003843.53726.63; HERBER, 1994, ONCOGENE, V9, P2105; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Lavia P, 1999, BIOESSAYS, V21, P221; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Shah S, 2002, J BIOL CHEM, V277, P25313, DOI 10.1074/jbc.M203158200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen FH, 2006, TOXICOL LETT, V160, P185, DOI 10.1016/j.toxlet.2005.07.009; Shen Q, 2004, ONCOGENE, V23, P2454, DOI 10.1038/sj.onc.1207354; Shen Q, 2006, DEV BIOL, V295, P589, DOI 10.1016/j.ydbio.2006.03.042; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; Zhang SY, 2000, CANCER EPIDEM BIOMAR, V9, P395	26	92	94	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					366	377		10.1038/sj.onc.1210643	http://dx.doi.org/10.1038/sj.onc.1210643			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637753				2022-12-28	WOS:000252256000013
J	El-Omar, EM; Ng, MT; Hold, GL				El-Omar, E. M.; Ng, M. T.; Hold, G. L.			Polymorphisms in Toll-like receptor genes and risk of cancer	ONCOGENE			English	Review						gastric cancer; Helicobacter pylori; genetic polymorphisms; single nucleotide polymorphisms; Toll-like receptors; prostate cancer	HELICOBACTER-PYLORI INFECTION; SINGLE-NUCLEOTIDE POLYMORPHISMS; STOP CODON POLYMORPHISM; DUODENAL-ULCER DISEASE; ALLELE-SPECIFIC PCR; SEQUENCE VARIANTS; INNATE IMMUNITY; GASTRIC-CANCER; ATROPHIC GASTRITIS; EPITHELIAL-CELLS	Host genetic factors are emerging as key determinants of disease risk for many cancers. Identifying candidate genes is a major challenge that has to stem from a profound understanding of the pathophysiology of the disease. The Toll-like receptors are important members of the host's innate immune response and their genes have been found to be polymorphic. This genetic variation allows for a more intricate repertoire that enables the host to withstand microbial challenges. While this may be advantageous on a population level, there may be less favourable outcomes for individuals that harbour certain genotypes associated with excessive immune activation and inflammatory drive. The damage is often collateral and is manifest in organs where this chronic inflammation alters normal physiology. A classic example of this paradigm is the Helicobacter pylori-induced gastric cancer model. Another emerging model is prostate cancer where Toll-like receptor polymorphisms have also been found to play a role. In this review, we discuss polymorphisms in Toll-like receptors and give an insight into how they may influence risk of cancer.	[El-Omar, E. M.; Ng, M. T.; Hold, G. L.] Univ Aberdeen, Dept Med & Therapeut, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	El-Omar, EM (corresponding author), Univ Aberdeen, Dept Med & Therapeut, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.	e.el-omar@abdn.ac.uk	Hold, Georgina Louise/AAG-9923-2020; El-Omar, Emad/AAT-7780-2021	Hold, Georgina Louise/0000-0001-7573-3397; El-Omar, Emad/0000-0002-0011-3924				Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Backhed F, 2003, J INFECT DIS, V187, P829; Berghofer B, 2005, CLIN EXP ALLERGY, V35, P1147, DOI 10.1111/j.1365-2222.2005.02325.x; Bochud PY, 2007, AIDS, V21, P441, DOI 10.1097/QAD.0b013e328012b8ac; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; De Marzo AM, 2003, UROLOGY, V62, P55, DOI 10.1016/j.urology.2003.09.053; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; El-Omar EM, 2006, BEST PRACT RES CL GA, V20, P675, DOI 10.1016/j.bpg.2006.04.006; ElOmar EM, 1997, GASTROENTEROLOGY, V113, P15, DOI 10.1016/S0016-5085(97)70075-1; ELOMAR EM, 1995, GASTROENTEROLOGY, V109, P681, DOI 10.1016/0016-5085(95)90374-7; Franchimont D, 2004, GUT, V53, P987, DOI 10.1136/gut.2003.030205; Hamann L, 2005, J MOL MED, V83, P478, DOI 10.1007/s00109-005-0643-7; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; Hawn TR, 2007, EUR J IMMUNOL, V37, P2280, DOI 10.1002/eji.200737034; Hawn TR, 2005, P NATL ACAD SCI USA, V102, P10593, DOI 10.1073/pnas.0501165102; Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220; Higgins SC, 2003, J IMMUNOL, V171, P3119, DOI 10.4049/jimmunol.171.6.3119; Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026; Jelavic TB, 2006, CLIN GENET, V70, P156, DOI 10.1111/j.1399-0004.2006.00651.x; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kang TJ, 2001, FEMS IMMUNOL MED MIC, V31, P53, DOI 10.1111/j.1574-695X.2001.tb01586.x; Kawahara T, 2001, J Med Invest, V48, P167; Kawahara T, 2001, INFECT IMMUN, V69, P4382, DOI 10.1128/IAI.69.7.4382-4389.2001; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kutukculer N, 2007, BIOCHEM GENET, V45, P507, DOI 10.1007/s10528-007-9091-0; Lazarus R, 2004, AM J RESP CRIT CARE, V170, P594, DOI 10.1164/rccm.200404-491OC; Lazarus R, 2003, GENOMICS, V81, P85, DOI 10.1016/S0888-7543(02)00022-8; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Lorenz E, 2001, BIOTECHNIQUES, V31, P22, DOI 10.2144/01311bm01; Macarthur M, 2004, AM J PHYSIOL-GASTR L, V286, pG515, DOI 10.1152/ajpgi.00475.2003; Machado JC, 2003, GASTROENTEROLOGY, V125, P364, DOI 10.1016/S0016-5085(03)00899-0; Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI 10.1128/IAI.72.11.6446-6454.2004; Mockenhaupt FP, 2006, P NATL ACAD SCI USA, V103, P177, DOI 10.1073/pnas.0506803102; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pasare C, 2005, ADV EXP MED BIOL, V560, P11; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pierik M, 2006, INFLAMM BOWEL DIS, V12, P1, DOI 10.1097/01.MIB.0000195389.11645.ab; Pirie FJ, 2005, TISSUE ANTIGENS, V66, P125, DOI 10.1111/j.1399-0039.2005.00454.x; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Sanduleanu S, 2001, ALIMENT PHARM THERAP, V15, P1163, DOI 10.1046/j.1365-2036.2001.01029.x; Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x; Schroder NW, 2005, LANCET INFECT DIS, V5, P156, DOI 10.1016/S1473-3099(05)70023-2; Schroder NWJ, 2003, J MOL MED-JMM, V81, P368, DOI 10.1007/s00109-003-0443-x; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Su B, 2003, INFECT IMMUN, V71, P3496, DOI 10.1128/IAI.71.6.3496-3502.2003; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Sun JL, 2005, JNCI-J NATL CANCER I, V97, P525, DOI 10.1093/jnci/dji070; Tantisira K, 2004, GENES IMMUN, V5, P343, DOI 10.1038/sj.gene.6364096; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Yang IA, 2004, GENES IMMUN, V5, P41, DOI 10.1038/sj.gene.6364037; Zavros Y, 2002, GASTROENTEROLOGY, V122, P119, DOI 10.1053/gast.2002.30298; Zheng SL, 2004, CANCER RES, V64, P2918, DOI 10.1158/0008-5472.CAN-03-3280; Zhou XX, 2006, CANCER EPIDEM BIOMAR, V15, P862, DOI 10.1158/1055-9965.EPI-05-0874	61	173	185	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					244	252		10.1038/sj.onc.1210912	http://dx.doi.org/10.1038/sj.onc.1210912			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176606				2022-12-28	WOS:000252163600011
J	Abubaker, J; Bavi, P; Al-Harbi, S; Ibrahim, M; Siraj, AK; Al-Sanea, N; Abduljabbar, A; Ashari, LH; Alhomoud, S; Al-Dayel, F; Uddin, S; Al-Kuraya, KS				Abubaker, J.; Bavi, P.; Al-Harbi, S.; Ibrahim, M.; Siraj, A. K.; Al-Sanea, N.; Abduljabbar, A.; Ashari, L. H.; Alhomoud, S.; Al-Dayel, F.; Uddin, S.; Al-Kuraya, K. S.			Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population	ONCOGENE			English	Article						PIK3CA; MSI; PTEN; colorectal cancer	B-CELL LYMPHOMA; BREAST-CANCER; PHOSPHOINOSITIDE 3-KINASE; PTEN MUTATIONS; SAUDI-ARABIA; PATHWAY; GENE; EXPRESSION; PREVALENCE; CARCINOMAS	Activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT pathway results in an increase in cell proliferation and survival. Somatic mutations within the PI3K catalytic subunit, PIK3CA are common cause of increasing PI3K activity and are believed to be oncogenic in many cancer types. Few reports addressed the association between PIK3CA mutations and tumor progression specifically in microsatellite instable (MSI) colorectal cancer (CRC). In the present study, we have evaluated PIK3CA mutational status in a series of 410 Middle Eastern CRC and 13 colon cell lines to study the prevalence of PIK3CA mutations in MSI cases, PTEN expression in CRC and possibility of therapeutic targeting of this set of patients. PIK3CA mutations were found in four of the cell lines tested and 51 colorectal carcinomas (12.2%). Three of these four mutated cell lines were MSI. PTEN was inactivated in 66.1% of the CRC. Furthermore, we observed a strong association between PIK3CA mutations and MSI status (P = 0.0046) while PTEN loss was more frequent in microsatellite stable (MSS) CRC (P = 0.043). A high prevalence of genetic alterations in PI3K/AKT pathway in Saudi cohort of CRC, predominance of PIK3CA mutations in the MSI subgroup and their possible involvement in development/progression of this subset of CRC are some of the significant findings of our study.	[Abubaker, J.; Bavi, P.; Al-Harbi, S.; Ibrahim, M.; Siraj, A. K.; Uddin, S.; Al-Kuraya, K. S.] King Faisal Specialist Hosp & Res Ctr, Dept Human Canc Genom Res, King Fahad Natl Ctr Childrens Canc & Res, Riyadh 11211, Saudi Arabia; [Al-Sanea, N.; Abduljabbar, A.; Ashari, L. H.; Alhomoud, S.] King Faisal Specialist Hosp & Res Ctr, Dept Colorectal Surg, Riyadh 11211, Saudi Arabia; [Al-Dayel, F.] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Al-Kuraya, KS (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Human Canc Genom Res, King Fahad Natl Ctr Childrens Canc & Res, MBC 98-16,POB 3354, Riyadh 11211, Saudi Arabia.	kkuraya@kfshrc.edu.sa	Bavi, Prashant/B-2123-2009; Al-Sanea, Nasser AN/J-1565-2016	Bavi, Prashant/0000-0002-7711-2911; Al-Sanea, Nasser AN/0000-0002-6336-5942; Uddin, Shahab/0000-0003-1886-6710; Abubaker, Jehad/0000-0003-0681-7305				Abbott RT, 2003, MODERN PATHOL, V16, P607, DOI 10.1097/01.MP.0000067423.83712.74; Abubaker J, 2007, LEUKEMIA, V21, P2368, DOI 10.1038/sj.leu.2404873; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bavi P, 2006, CANCER EPIDEM BIOMAR, V15, P1708, DOI 10.1158/1055-9965.EPI-05-0972; Boland CR, 1998, CANCER RES, V58, P5248; Bose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525; Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; ELHAZMI MAF, 1995, J MED GENET, V32, P623, DOI 10.1136/jmg.32.8.623; Frattini M, 2005, CANCER RES, V65, P11227, DOI 10.1158/0008-5472.CAN-05-2780; Garcia Z, 2006, EMBO J, V25, P655, DOI 10.1038/sj.emboj.7600967; Isbister WH, 2000, AUST NZ J SURG, V70, P269, DOI 10.1046/j.1440-1622.2000.01805.x; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; Maruyama N, 2007, CLIN CANCER RES, V13, P408, DOI 10.1158/1078-0432.CCR-06-0267; Nassif NT, 2004, ONCOGENE, V23, P617, DOI 10.1038/sj.onc.1207059; Ollikainen M, 2007, INT J CANCER, V121, P915, DOI 10.1002/ijc.22768; Philp A J, 2000, Int J Surg Investig, V2, P267; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Toyota M, 2000, J GASTROENTEROL, V35, P727, DOI 10.1007/s005350070030; Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood-2006-04-016907; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011	32	74	77	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3539	3545		10.1038/sj.onc.1211013	http://dx.doi.org/10.1038/sj.onc.1211013			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18193083				2022-12-28	WOS:000256468500005
J	Miyamoto, D; Miyamoto, M; Takahashi, A; Yomogita, Y; Higashi, H; Kondo, S; Hatakeyama, M				Miyamoto, D.; Miyamoto, M.; Takahashi, A.; Yomogita, Y.; Higashi, H.; Kondo, S.; Hatakeyama, M.			Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors	ONCOGENE			English	Article						SHP-2; gain-of-function mutation; NIH3T3; solid tumor; oncogenic RAS	PROTEIN-TYROSINE-PHOSPHATASE; HELICOBACTER-PYLORI CAGA; CAUSE NOONAN-SYNDROME; JUVENILE MYELOMONOCYTIC LEUKEMIA; SOMATIC PTPN11 MUTATIONS; FACIO-CUTANEOUS SYNDROME; GROWTH-FACTOR RECEPTOR; GERMLINE MUTATIONS; LEUKEMOGENESIS; ACTIVATION	SHP-2 protein tyrosine phosphatase plays an important role in activation of the RAS-dependent signaling. Gain-of-function mutations in the PTPN11 gene, which encodes SHP-2, have been found in the leukemia-prone developmental disorder Noonan syndrome as well as sporadic childhood leukemias, indicating that SHP-2 is a bona. de human oncoprotein. However, the role of SHP-2 mutations in non-hematological malignancies remains obscure. Here, we screened for PTPN11 mutations in primary solid tumors and identified a 1520C > A mutation that causes threonine-507 to lysine (T507K) substitution in the phosphatase domain of SHP-2 in a case of hepatocellular carcinoma. T507K SHP-2 exhibited altered substrate specificity with slightly elevated basal phosphatase activity. Upon expression in NIH3T3 cells, T507K SHP-2 induced transformed foci, which was not observed with wild type, Noonan-specific or leukemia-specific SHP-2. Furthermore, NIH3T3 cells transformed by T507K SHP-2 showed anchorage-independent growth and developed tumors in nude mice. These results indicate that quantitative and/or qualitative alteration in phosphatase activity determines the transforming potential as well as target cell/tissue spectrum of individual SHP-2 mutants as oncoproteins. Although rare in solid tumors, the identified T507K SHP-2 represents a distinct class of SHP-2 mutants with oncogenic RAS-like transforming activity, which could contribute to the development of solid tumors.	[Hatakeyama, M.] Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan; [Miyamoto, D.; Miyamoto, M.; Kondo, S.] Hokkaido Univ, Grad Sch Med, Div Surg Oncol, Sapporo, Hokkaido 0600815, Japan	Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Higashi, Hideaki/F-6872-2012	Kanemitsu, Atsushi/0000-0002-4156-9522				Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Chen YY, 2006, GENE CHROMOSOME CANC, V45, P583, DOI 10.1002/gcc.20322; Choong K, 1999, J PEDIAT HEMATOL ONC, V21, P523, DOI 10.1097/00043426-199911000-00014; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Digilio MC, 2002, AM J HUM GENET, V71, P389, DOI 10.1086/341528; Gelb BD, 2006, HUM MOL GENET, V15, pR220, DOI 10.1093/hmg/ddl197; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Keilhack H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kosaki K, 2002, J CLIN ENDOCR METAB, V87, P3529, DOI 10.1210/jc.87.8.3529; Lauchle JO, 2006, PEDIATR BLOOD CANCER, V46, P579, DOI 10.1002/pbc.20644; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martinelli S, 2006, CANCER GENET CYTOGEN, V166, P124, DOI 10.1016/j.cancergencyto.2005.10.003; Mohi MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI 10.1016/j.gde.2006.12.011; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Roberts AE, 2007, NAT GENET, V39, P70, DOI 10.1038/ng1926; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Schubbert S, 2006, NAT GENET, V38, P331, DOI 10.1038/ng1748; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tartaglia M, 2006, AM J HUM GENET, V78, P279, DOI 10.1086/499925; Tartaglia M, 2004, BLOOD, V104, P307, DOI 10.1182/blood-2003-11-3876; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tartaglia M, 2007, NAT GENET, V39, P75, DOI 10.1038/ng1939; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006	37	76	80	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3508	3515		10.1038/sj.onc.1211019	http://dx.doi.org/10.1038/sj.onc.1211019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223690				2022-12-28	WOS:000256468500002
J	Hajji, N; Wallenborg, K; Vlachos, P; Nyman, U; Hermanson, O; Joseph, B				Hajji, N.; Wallenborg, K.; Vlachos, P.; Nyman, U.; Hermanson, O.; Joseph, B.			Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells	ONCOGENE			English	Article						NSCLC; apoptosis; HDAC inhibitor; AIF; Bcl-xL	HISTONE DEACETYLASE INHIBITORS; CANCER CELLS; ANTICANCER AGENTS; EXPRESSION; RESISTANT; BCL-2; AMPLIFICATION; THERAPY; PROTEIN; POINT	Commonly used regimens in cancer therapy rely on the induction of apoptotic cell death, and drug resistance can be attributed, at least in part, to a disabled apoptotic program. Non-small cell lung carcinomas (NSCLC), exhibit an intrinsic resistance to chemotherapy. Here, we show that co-treatment with etoposide (VP16) and the pan-histone deacetylase (HDAC) inhibitor trichostatin A (TSA), but not valproic acid (VPA), induced apoptotic cell death in drug-resistant NSCLC cells. Co-treatment, but not single treatment, with VP16 and TSA induced apoptosis in a caspase-dependent manner accompanied by a crucial decrease in Bcl-xL expression allowing Bax activation and subsequent initiation of the apoptosis inducingfactor (AIF)-dependent death pathway. Importantly, AIF proved to be required for the effects of TSA/VP16 as RNA knockdown of AIF resulted in a complete abolishment of TSA/VP16-induced apoptotic cell death in drug-resistant NSCLC cells. Our results thus provide evidence for the requirement of both caspase-dependent and caspase-independent apoptotic pathways in TSA/VP16-mediated death of drug-resistant NSCLC cells, and extend previous suggestions that HDAC inhibitors in combination with conventional chemotherapeutic drugs could be valuable in the treatment of NSCLC cancer and other malignancies in which Bcl-xL is overexpressed.	[Hajji, N.; Vlachos, P.; Nyman, U.; Joseph, B.] Karolinska Inst, Inst Environm Med, Div Toxicol & Neurotoxicol, SE-17177 Stockholm, Sweden; [Wallenborg, K.; Hermanson, O.] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Joseph, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol & Neurotoxicol, Box 210, SE-17177 Stockholm, Sweden.	bertrand.joseph@ki.se	hajji, nabil/AAV-1435-2020; Nyman, Ulrika/D-3708-2013; , Ola/AAF-5126-2021	Hermanson, Ola/0000-0001-9320-7921				Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Choi YH, 2005, INT J ONCOL, V27, P473; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Geng L, 2006, CANCER RES, V66, P11298, DOI 10.1158/0008-5472.CAN-06-0049; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Henderson C, 2003, DRUG RESIST UPDATE, V6, P247, DOI 10.1016/S1368-7646(03)00067-0; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Karczmarek-Borowska B, 2006, LUNG CANCER, V51, P61, DOI 10.1016/j.lungcan.2005.08.010; Komatsu N, 2006, ONCOL REP, V15, P187; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; La Thangue NB, 2004, J CHEMOTHERAPY, V16, P64, DOI 10.1179/joc.2004.16.Supplement-1.64; Lei XY, 2007, ACTA BIOCH BIOPH SIN, V39, P344, DOI 10.1111/j.1745-7270.2007.00286.x; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Pham NA, 2001, EXP CELL RES, V264, P345, DOI 10.1006/excr.2000.5148; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Rundall BK, 2005, SURGERY, V138, P360, DOI 10.1016/j.surg.2005.06.016; Schniewind Bodo, 2006, J Carcinog, V5, P25, DOI 10.1186/1477-3163-5-25; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Yu XD, 2002, J NATL CANCER I, V94, P504; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	36	50	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3134	3144		10.1038/sj.onc.1210976	http://dx.doi.org/10.1038/sj.onc.1210976			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071312				2022-12-28	WOS:000255897600006
J	Moulin, S; Llanos, S; Kim, SH; Peters, G				Moulin, S.; Llanos, S.; Kim, S-H; Peters, G.			Binding to nucleophosmin determines the localization of human and chicken ARF but not its impact on p53	ONCOGENE			English	Article						ARF; nucleophosmin; nucleolus; p53; MDM2; chicken embryo fibroblasts	TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; NUCLEOLAR LOCALIZATION; STABILIZES P53; NUCLEAR EXPORT; MDM2; P14(ARF); LOCUS; DEGRADATION; P19(ARF)	The ARF tumour suppressor gene encodes a small highly basic protein whose known functions are largely determined by the amino acids encoded within the first exon. In mammals, the protein incorporates additional residues specified by an alternative reading frame in the second exon of INK4a, but this arrangement does not apply to the chicken homologue. In exploring the intracellular localization of chicken p7(ARF), we found that while the FLAG- and HA- tagged versions localize in the nucleolus, in line with mammalian ARF, the GFP- tagged version is excluded from the nucleolus. Here we show that irrespective of the source or composition of the ARF fusion proteins, versions that accumulate in the nucleolus share the ability to bind to nucleophosmin ( NPM). Depletion of NPM with siRNA results in the re- location and destabilization of nucleolar forms of ARF but has little effect on the location or stability of a nucleoplasmic form of ARF. Importantly, knockdown of endogenous NPM does not impair the ability of ARF to bind to MDM2 and stabilize p53. These findings support the view that nucleolar localization determines the stability of ARF but not its primary function.	[Moulin, S.; Llanos, S.; Kim, S-H; Peters, G.] London Res Inst, Canc Res UK, Mol Oncol Lab, London WC2A 3PX, England	Cancer Research UK	Peters, G (corresponding author), London Res Inst, Canc Res UK, Mol Oncol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	gordon.peters@cancer.org.uk	Kim, Soo Hyun/ABG-8773-2020; , Susana/AAA-9282-2019	Kim, Soo Hyun/0000-0002-9394-1437; Llanos, Susana/0000-0002-8555-9326				Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; den Besten W, 2005, CELL CYCLE, V4, P1593; Enomoto T, 2006, J BIOL CHEM, V281, P18463, DOI 10.1074/jbc.M602788200; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kim SH, 2003, P NATL ACAD SCI USA, V100, P211, DOI 10.1073/pnas.0135557100; Kim SH, 2006, J CELL SCI, V119, P2435, DOI 10.1242/jcs.02989; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rodway H, 2004, ONCOGENE, V23, P6186, DOI 10.1038/sj.onc.1207854; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	31	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2382	2389		10.1038/sj.onc.1210887	http://dx.doi.org/10.1038/sj.onc.1210887			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968318				2022-12-28	WOS:000254844900003
J	Yu, PJ; Ferrari, G; Pirelli, L; Galloway, AC; Mignatti, P; Pintucci, G				Yu, P-J; Ferrari, G.; Pirelli, L.; Galloway, A. C.; Mignatti, P.; Pintucci, G.			Thrombin cleaves the high molecular weight forms of basic fibroblast growth factor (FGF-2): a novel mechanism for the control of FGF-2 and thrombin activity	ONCOGENE			English	Article						endothelial cells; inflammation; migration; proliferation; proteolysis; serine proteinases	ACTIVATED RECEPTORS; ENDOTHELIAL-CELLS; EXPRESSION; MIGRATION; TRANSLATION; METHYLATION; TRANSACTIVATION; ANGIOGENESIS; DIVERSITY; ISOFORMS	The fgf-2 gene encodes low molecular weight (LMW, 18 kDa) and high molecular weight (HMW, 22-24 kDa) forms that originate from alternative translation of a single mRNA and exhibit diverse biological functions. HMW fibroblast growth factor-2 (FGF-2) inhibits cell migration and induces cell transformation or growth arrest in a cell type-and dose-dependent fashion. Conversely, LMW FGF-2 upregulates both cell proliferation and migration in most cell types. Although transcriptional and translational regulation of HMW and LMW FGF-2 has been extensively investigated, little is known about post-translational control of their relative expression. Here we report that thrombin, a key coagulation factor and inflammatory mediator, cleaves HMW FGF-2 into an LMW FGF-2-like form that stimulates endothelial cell migration and proliferation. The effect of thrombin on these cell functions requires HMW FGF-2 cleavage. This post-translational control mechanism adds a novel level of complexity to the regulation of FGF-2, and links the activities of thrombin and FGF-2 in patho-physiological processes in which both molecules are expressed.	[Yu, P-J; Ferrari, G.; Pirelli, L.; Galloway, A. C.; Mignatti, P.; Pintucci, G.] NYU, Sch Med, Seymour Cohn Cardiovasc Res Lab, Dept Cardiothorac Surg, New York, NY 10016 USA; [Mignatti, P.] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University	Pintucci, G (corresponding author), NYU, Sch Med, Seymour Cohn Cardiovasc Res Lab, Dept Cardiothorac Surg, 530 1st Ave,NB-15W16, New York, NY 10016 USA.	pintug01@med.nyu.edu	Ferrari, Giovanni/A-3390-2009	Mignatti, Paolo/0000-0002-8157-457X; Galoway, Aubrey/0000-0001-5461-3820; Ferrari, Giovanni/0000-0002-8863-2496	NHLBI NIH HHS [5R01 HL70203-01, R01 HL070203] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arai T, 2005, J BIOL CHEM, V280, P5145, DOI 10.1074/jbc.M409234200; Balcaitis S, 2003, NEUROREPORT, V14, P2373, DOI 10.1097/00001756-200312190-00017; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BURGESS WH, 1991, CELL REGUL, V2, P87, DOI 10.1091/mbc.2.2.87; Claus P, 2004, NEUROSCI LETT, V360, P117, DOI 10.1016/j.neulet.2004.01.046; Coughlin SR, 2005, J THROMB HAEMOST, V3, P1800, DOI 10.1111/j.1538-7836.2005.01377.x; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Cucina A, 2002, CELL BIOCHEM FUNCT, V20, P39, DOI 10.1002/cbf.938; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; Ding L, 2002, J BIOL CHEM, V277, P31056, DOI 10.1074/jbc.M203658200; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Ferrari G, 2006, P NATL ACAD SCI USA, V103, P17260, DOI 10.1073/pnas.0605556103; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; Ishibashi T, 2003, ARTERIOSCL THROM VAS, V23, P681, DOI 10.1161/01.ATV.0000065194.00822.C7; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Klein S, 2000, J BIOL CHEM, V275, P3150, DOI 10.1074/jbc.275.5.3150; Klein S, 1996, J BIOL CHEM, V271, P22583, DOI 10.1074/jbc.271.37.22583; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; Malecki J, 2004, MOL BIOL CELL, V15, P801, DOI 10.1091/mbc.E03-08-0589; Mann KG, 2003, CHEST, V124, p1S, DOI 10.1378/chest.124.3_suppl.1S; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Ornitz DM, 2001, GENOME BIOL, V2; Papadimitriou E, 1997, AM J PHYSIOL-CELL PH, V272, pC1112, DOI 10.1152/ajpcell.1997.272.4.C1112; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Quarto N, 2005, GENE, V356, P49, DOI 10.1016/j.gene.2005.05.014; Rauch BH, 2005, J BIOL CHEM, V280, P17507, DOI 10.1074/jbc.M410848200; Rauch BH, 2004, CIRC RES, V94, P340, DOI 10.1161/01.RES.0000111805.09592.D8; Rickles FR, 2003, CHEST, V124, p58S, DOI 10.1378/chest.124.3_suppl.58S; Sharony R, 2006, AM J PHYSIOL-HEART C, V290, pH1651, DOI 10.1152/ajpheart.00530.2005; Sorensen V, 2006, BIOESSAYS, V28, P504, DOI 10.1002/bies.20405; Taverna S, 2003, J BIOL CHEM, V278, P51911, DOI 10.1074/jbc.M304192200; Touriol C, 2003, BIOL CELL, V95, P169, DOI 10.1016/S0248-4900(03)00033-9; Tsopanoglou NE, 1999, J BIOL CHEM, V274, P23969, DOI 10.1074/jbc.274.34.23969; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yu PJ, 2007, J CELL BIOCHEM, V100, P1100, DOI 10.1002/jcb.21116	40	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2594	2601		10.1038/sj.onc.1210899	http://dx.doi.org/10.1038/sj.onc.1210899			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17968311	Green Accepted			2022-12-28	WOS:000255057000009
J	Kadaja-Saarepuu, L; Laos, S; Jaeaeger, K; Viil, J; Balikova, A; Looke, M; Hansson, GC; Maimets, T				Kadaja-Saarepuu, L.; Laos, S.; Jaeaeger, K.; Viil, J.; Balikova, A.; Looke, M.; Hansson, G. C.; Maimets, T.			CD43 promotes cell growth and helps to evade FAS-mediated apoptosis in non-hematopoietic cancer cells lacking the tumor suppressors p53 or ARF	ONCOGENE			English	Article						leukosialin; sialophorin; FAS; colony formation; epithelial cell	NF-KAPPA-B; LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; ANTIBODY RECOGNIZING CD43; WISKOTT-ALDRICH SYNDROME; MONOCLONAL-ANTIBODY; COLON-CANCER; SIGNALING PATHWAYS; BETA-CATENIN; TF-1 CELLS; STEM-CELLS	CD43 is a highly glycosylated transmembrane protein expressed on the surface of most hematopoietic cells. Expression of CD43 has also been demonstrated in many human tumor tissues, including colon adenomas and carcinomas, but not in normal colon epithelium. The potential contribution of CD43 to tumor development is still not understood. Here, we show that overexpression of CD43 increases cell growth and colony formation in mouse and human cells lacking expression of either p53 or ARF (alternative reading frame) tumor-suppressor proteins. In addition, CD43 overexpression also lowers the detection of the FAS death receptor on the cell surface of human cancer cells, and thereby helps to evade FAS-mediated apoptosis. However, when both p53 and ARF proteins are present, CD43 overexpression activates p53 and suppresses colony formation due to induction of apoptosis. These observations suggest CD43 as a potential contributor to tumor development and the functional ARF-p53 pathway is required for the elimination of cells with aberrant CD43 expression.	[Kadaja-Saarepuu, L.; Jaeaeger, K.; Viil, J.; Balikova, A.; Looke, M.; Maimets, T.] Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia; [Laos, S.; Hansson, G. C.] Gothenburg Univ, Dept Med Biochem, Gothenburg, Sweden	University of Tartu; University of Gothenburg	Kadaja-Saarepuu, L (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, 23 Riia St, EE-51010 Tartu, Estonia.	lkadaja@ebc.ee	Hansson, Gunnar C./AAF-7324-2019; Hansson, Gunnar C/A-1236-2009; Maimets, Toivo/E-9268-2017; Jaager, Kersti/G-2786-2017	Hansson, Gunnar C./0000-0002-1900-1869; Hansson, Gunnar C/0000-0002-1900-1869; Maimets, Toivo/0000-0001-6461-3365; Jaager, Kersti/0000-0002-0503-9292				ABARZUA P, 1995, CANCER RES, V55, P3490; Andersson CX, 2004, BIOCHEM BIOPH RES CO, V316, P12, DOI 10.1016/j.bbrc.2004.02.011; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; BAECKSTROM D, 1995, J BIOL CHEM, V270, P13688, DOI 10.1074/jbc.270.23.13688; Bazil V, 1996, BLOOD, V87, P1272, DOI 10.1182/blood.V87.4.1272.bloodjournal8741272; Bazil V, 1997, STEM CELLS, V15, P13, DOI 10.1002/stem.5530150804; BAZIL V, 1997, STEM CELLS, V15, P18; Brown TJ, 1996, J BIOL CHEM, V271, P27686, DOI 10.1074/jbc.271.44.27686; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; Cermak L, 2002, J BIOL CHEM, V277, P7955, DOI 10.1074/jbc.M108048200; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; DRAGONE LL, 1995, P NATL ACAD SCI USA, V92, P626, DOI 10.1073/pnas.92.2.626; Esteller M, 2000, CANCER RES, V60, P129; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernandez-Rodriguez J, 2002, TUMOR BIOL, V23, P193, DOI 10.1159/000067252; He YW, 1999, J EXP MED, V190, P1903, DOI 10.1084/jem.190.12.1903; Hewitt RE, 2000, J PATHOL, V192, P446; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Kadaja L, 2004, ONCOGENE, V23, P2523, DOI 10.1038/sj.onc.1207359; Kyoizumi S, 2004, J IMMUNOL, V172, P7246, DOI 10.4049/jimmunol.172.12.7246; Laos S, 2006, INT J ONCOL, V28, P695; Layseca-Espinosa E, 2003, J LEUKOCYTE BIOL, V74, P1083, DOI 10.1189/jlb.0303095; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Mattioli I, 2004, BLOOD, V104, P3302, DOI 10.1182/blood-2004-04-1536; MAZARS R, 1991, ONCOGENE, V6, P1685; Misawa Y, 1996, EUR J IMMUNOL, V26, P2573, DOI 10.1002/eji.1830261106; Miura Y, 2001, BIOCHEM BIOPH RES CO, V288, P80, DOI 10.1006/bbrc.2001.5729; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; O'Connell J, 2000, ANN NY ACAD SCI, V910, P178; Onami TM, 2002, J IMMUNOL, V168, P6022, DOI 10.4049/jimmunol.168.12.6022; Ostberg JR, 1998, IMMUNOL TODAY, V19, P546, DOI 10.1016/S0167-5699(98)01343-7; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; Pimenidou A, 2004, ONCOL REP, V11, P327; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Santamaria M, 1996, CANCER RES, V56, P3526; Santana MA, 2000, J BIOL CHEM, V275, P31460, DOI 10.1074/jbc.M005231200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sikut R, 1999, INT J CANCER, V82, P52, DOI 10.1002/(SICI)1097-0215(19990702)82:1<52::AID-IJC10>3.0.CO;2-C; Sikut R, 1997, BIOCHEM BIOPH RES CO, V238, P612, DOI 10.1006/bbrc.1997.7334; von Reyher U, 1998, CANCER RES, V58, P526; Woodman RC, 1998, J EXP MED, V188, P2181, DOI 10.1084/jem.188.11.2181; Zhang K, 1997, CELL IMMUNOL, V176, P158, DOI 10.1006/cimm.1997.1085; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949; Ziprin P, 2004, BIOL CHEM, V385, P755, DOI 10.1515/BC.2004.092	51	17	20	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1705	1715		10.1038/sj.onc.1210802	http://dx.doi.org/10.1038/sj.onc.1210802			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891181				2022-12-28	WOS:000253962100006
J	Plans, V; Guerra-Rebollo, M; Thomson, TM				Plans, V.; Guerra-Rebollo, M.; Thomson, T. M.			Regulation of mitotic exit by the RNF8 ubiquitin ligase	ONCOGENE			English	Article						RNF8; ubiquitin ligase; cell cycle; mitosis	RING FINGER PROTEIN; CELL-CYCLE; CONJUGATING ENZYMES; CYTOKINESIS FAILURE; FHA DOMAIN; CHFR; CHECKPOINT; MECHANISMS; DMA1; LOCALIZATION	RNF8 is a ubiquitin ligase with a FHA domain near its N terminus, and a RING-finger domain at its C terminus, through which it recruits several ubiquitin-conjugating enzymes. In metazoans, only the mitotic checkpoint regulator CHFR shares this domain architecture. Here we show that RNF8 is a nuclear protein that follows a cell-cycle-dependent turnover, reaching its highest levels in mitosis, followed by a strong decline in late mitotic stages. Overexpression of RNF8 caused a delay in cytokinesis and the frequent appearance of aberrant mitotic figures. These effects were dependent on the ubiquitin ligase activity of RNF8, since they were significantly attenuated when a RING-finger mutant, inactive as an E3, was over-expressed. Depletion of RNF8 also caused a delay in the exit from the mitotic arrest induced by nocodazole, associated with a reduced turnover of the APC/C substrate cyclin B1. These observations suggest that RNF8 regulates the rate of exit from mitosis and cytokinesis.	[Plans, V.; Guerra-Rebollo, M.; Thomson, T. M.] CSIC, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, ES-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Thomson, TM (corresponding author), CSIC, Inst Biol Mol Barcelona, Dept Mol & Cellular Biol, C Jordi Girona 18-26, ES-08034 Barcelona, Spain.	titbmc@cid.csic.es	Guerra-Rebollo, Marta/H-3199-2015; Thomson, Timothy/Z-6271-2019	Guerra-Rebollo, Marta/0000-0002-3731-4527; Thomson, Timothy/0000-0002-4670-9440				Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831; Chaturvedi P, 2002, CANCER RES, V62, P1797; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Fraschini R, 2004, MOL BIOL CELL, V15, P3796, DOI 10.1091/mbc.E04-02-0094; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Guertin DA, 2002, DEV CELL, V3, P779, DOI 10.1016/S1534-5807(02)00367-2; Guertin DA, 2002, MICROBIOL MOL BIOL R, V66, P155, DOI 10.1128/MMBR.66.2.155-178.2002; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Ito K, 2001, EUR J BIOCHEM, V268, P2725, DOI 10.1046/j.1432-1327.2001.02169.x; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Mariatos G, 2003, CANCER RES, V63, P7185; Moore FL, 2003, P NATL ACAD SCI USA, V100, P538, DOI 10.1073/pnas.0234478100; Murone M, 1996, EMBO J, V15, P6605, DOI 10.1002/j.1460-2075.1996.tb01051.x; Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Plans V, 2006, J CELL BIOCHEM, V97, P572, DOI 10.1002/jcb.20587; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; Satoh A, 2003, CANCER RES, V63, P8606; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Takano Y, 2004, J BIOL CHEM, V279, P18926, DOI 10.1074/jbc.M309148200; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538	30	34	35	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1355	1365		10.1038/sj.onc.1210782	http://dx.doi.org/10.1038/sj.onc.1210782			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724460				2022-12-28	WOS:000253548200002
J	Simmons, MJ; Fan, G; Zong, WX; Degenhardt, K; White, E; Gelinas, C				Simmons, M. J.; Fan, G.; Zong, W-X; Degenhardt, K.; White, E.; Gelinas, C.			Bfl-1/A1 functions, similar to Mcl-1, as a selective tBid and Bak antagonist	ONCOGENE			English	Article						Bfl-1; A1; Bcl2a1; tBid; Bak; apoptosis	CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBER; NF-KAPPA-B; BH3 MIMETIC ABT-737; MITOCHONDRIAL-MEMBRANE; CONFORMATIONAL-CHANGE; APOPTOSIS; PROTEINS; SURVIVAL; HOMOLOG	The prosurvival Bcl-2-family member Bfl-1/A1 is a transcriptional target of nuclear factor-kappa B (NF-kappa B) that is overexpressed in many human tumors and is a means by which NF-kappa B inhibits apoptosis, but its mode of action is controversial. To better understand how Bfl-1 functions, we investigated its interaction with proapoptotic multidomain proteins Bax and Bak, and the BH3-only proteins Bid and tBid. We demonstrate that in living cells Bfl-1 selectively interacts with Bak and tBid, but not with Bax or Bid. Bfl-1/Bak interaction is functional as Bfl-1 suppressed staurosporine (STS)-induced apoptosis in wild-type and Bax-deficient cells, but not in Bak-/- cells. We also show that Bfl-1 blocks tumor necrosis factor-alpha (TNF alpha)-induced activation of Bax indirectly, via association with tBid. C-terminal deletion decreased Bfl-1's interaction with Bak and tBid and reduced its ability to suppress Bak- and tBid-mediated cell death. These data indicate that Bfl-1 utilizes different mechanisms to suppress apoptosis depending on the stimulus. Bfl-1 associates with tBid to prevent activation of proapoptotic Bax and Bak, and it also interacts directly with Bak to antagonize Bak- mediated cell death, similar to Mcl-1. Thus, part of the protective function of NF-kappa B is to induce Mcl-1-like activity by upregulating Bfl-1.	[Simmons, M. J.; Fan, G.; Zong, W-X; Degenhardt, K.; White, E.; Gelinas, C.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, CABM, Piscataway, NJ 08854 USA; [Fan, G.; Zong, W-X; Degenhardt, K.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Grad Program Biochem & Mol Biol, Piscataway, NJ 08854 USA; [White, E.] Rutgers State Univ, Dept Mol Biol & Biochem, New Brunswick, NJ 08903 USA; [White, E.; Gelinas, C.] Canc Inst New Jersey, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Gelinas, C (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, CABM, Room 137,679 Hoes Lane, Piscataway, NJ 08854 USA.	gelinas@cabm.rutgers.edu	White, Eileen/ABD-6745-2021; Fan, gaofeng/H-2996-2013	White, Eileen/0000-0003-2961-3065; Fan, gaofeng/0000-0002-6729-2867	NCI NIH HHS [CA083937, R01 CA083937, R37 CA053370-17, R37 CA053370, R37 CA053370-16] Funding Source: Medline; NIGMS NIH HHS [GM08360, T32 GM008360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, R01CA083937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cuconati A, 2002, J VIROL, V76, P4547, DOI 10.1128/JVI.76.9.4547-4558.2002; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Gelinas W, 2005, GENE DEV, V19, P1263, DOI 10.1101/gad.1326205; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Herold MJ, 2006, J BIOL CHEM, V281, P13663, DOI 10.1074/jbc.M600266200; Holmgreen SP, 1999, CELL DEATH DIFFER, V6, P525, DOI 10.1038/sj.cdd.4400519; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Kucharczak JF, 2005, CELL DEATH DIFFER, V12, P1225, DOI 10.1038/sj.cdd.4401684; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Letai A, 2006, CANCER CELL, V10, P343, DOI 10.1016/j.ccr.2006.10.014; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Somogyi RD, 2001, CELL DEATH DIFFER, V8, P785, DOI 10.1038/sj.cdd.4400879; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	41	58	58	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1421	1428		10.1038/sj.onc.1210771	http://dx.doi.org/10.1038/sj.onc.1210771			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724464	Green Accepted			2022-12-28	WOS:000253548200009
J	Lin, DI; Lessie, M; Gladden, AB; Bassing, C; Wagner, K; Diehl, J				Lin, D. I.; Lessie, M. D.; Gladden, A. B.; Bassing, C. H.; Wagner, K. U.; Diehl, J. A.			Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis	ONCOGENE			English	Article						CDK4; cyclin D1; FBX4; mammary gland; PD0332991	GENOMIC INSTABILITY; DEPENDENT KINASE; BREAST-CANCER; TUMORIGENESIS; HYPERPLASIA; EXPRESSION; ONCOGENE; CELLS; MICE; MYC	Cyclin D1 levels are maintained at steady state by phosphorylation-dependent nuclear export and polyubiquitination by SCFFBX4-alpha B (crystallin). Inhibition of cyclin D1 proteolysis has been implicated as a causative factor leading to its overexpression in breast and esophageal carcinomas; however, the contribution of stable cyclin D1 to the genesis of such carcinomas has not been evaluated. We therefore generated transgenic mice wherein expression of either wild-type or a stable cyclin D1 allele ( D1T286A) is regulated by MMTV-LTR. MMTV-D1T286A mice developed mammary adenocarcinomas at an increased rate relative to MMTV-D1 mice. Similar to human cancers that overexpress cyclin D1, D1T286A tumors were estrogen receptor-positive and exhibited estrogen-dependent growth. Collectively, these results suggest that temporal control of cyclin D1 subcellular localization and proteolysis is critical for maintenance of homeostasis within the mammary epithelium.	[Diehl, J. A.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Lin, D. I.; Lessie, M. D.; Gladden, A. B.; Diehl, J. A.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Bassing, C. H.] Univ Penn, Childrens Hosp, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Wagner, K. U.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Pathol & Microbiol, Omaha, NE 68182 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Nebraska System; University of Nebraska Medical Center	Diehl, J (corresponding author), Univ Penn, Abramson Family Canc Res Inst, 454 BRB 2 3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu		Wagner, Kay-Uwe/0000-0002-5081-0226; Lin, Douglas/0000-0003-0105-9760	NCI NIH HHS [CA11360, R01 CA111360, R01 CA125195-01A1, R01 CA111360-05, R01 CA125195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111360, R01CA125195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HENNIGHAUSEN L, 1994, CELL GROWTH DIFFER, V5, P607; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Ip M. M., 2000, METHODS MAMMARY GLAN; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lu FM, 2003, CANCER RES, V63, P7056; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Rowse GJ, 1998, CANCER RES, V58, P2675; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Utsumi T, 2000, INT J CANCER, V89, P39, DOI 10.1002/(SICI)1097-0215(20000120)89:1<39::AID-IJC7>3.0.CO;2-T; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012	26	60	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1231	1242		10.1038/sj.onc.1210738	http://dx.doi.org/10.1038/sj.onc.1210738			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724472	Green Accepted			2022-12-28	WOS:000253407000005
J	Thorslund, T; West, SC				Thorslund, T.; West, S. C.			BRCA2: a universal recombinase regulator	ONCOGENE			English	Review						tumour suppressor; RAD51; DMC1; DNA repair; genome instability; meiotic recombination	SUSCEPTIBILITY GENE BRCA2; HOMOLOGY-DIRECTED REPAIR; DNA STRAND EXCHANGE; CANCER SUSCEPTIBILITY; CAENORHABDITIS-ELEGANS; MEIOTIC CELLS; RADIATION HYPERSENSITIVITY; SYNAPTONEMAL COMPLEXES; RAD51-DNA FILAMENTS; NUCLEAR FOCI	Homologous recombination has a dual role in eukaryotic organisms. Firstly, it is responsible for the creation of genetic variability during meiosis by directing the formation of reciprocal crossovers that result in random combinations of alleles and traits. Secondly, in mitotic cells, it maintains the integrity of the genome by promoting the faithful repair of DNA double-strand breaks (DSBs). In vertebrates, it therefore plays a key role in tumour avoidance. Mutations in the tumour suppressor protein BRCA2 are associated with predisposition to breast and ovarian cancers, and loss of BRCA2 function leads to genetic instability. BRCA2 protein interacts directly with the RAD51 recombinase and regulates recombination-mediated DSB repair, accounting for the high levels of spontaneous chromosomal aberrations seen in BRCA2-defective cells. Recent observations indicate that BRCA2 also plays a critical role in meiotic recombination, this time through direct interactions with the meiosis-specific recombinase DMC1. The interactions of BRCA2 with RAD51 and DMC1 lead us to suggest that the BRCA2 tumour suppressor is a universal regulator of recombinase actions.	[Thorslund, T.; West, S. C.] Clare Hall Labs, London Res Inst, Canc Res UK, S Mimms EN6 3LD, Herts, England	Cancer Research UK	West, SC (corresponding author), Clare Hall Labs, London Res Inst, Canc Res UK, S Mimms EN6 3LD, Herts, England.	stephen.west@cancer.org.uk		Thorslund, Tina/0000-0001-9207-0070; West, Stephen/0000-0001-8848-9418				Atanassov BS, 2005, GENE CHROMOSOME CANC, V44, P429, DOI 10.1002/gcc.20255; Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; BENNETT CB, 1993, P NATL ACAD SCI USA, V90, P5613, DOI 10.1073/pnas.90.12.5613; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Davies OR, 2007, NAT STRUCT MOL BIOL, V14, P475, DOI 10.1038/nsmb1251; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Dray E, 2006, PLANT PHYSIOL, V140, P1059, DOI 10.1104/pp.105.075838; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Esashi F, 2007, NAT STRUCT MOL BIOL, V14, P468, DOI 10.1038/nsmb1245; Galkin VE, 2005, P NATL ACAD SCI USA, V102, P8537, DOI 10.1073/pnas.0407266102; Goggins M, 1996, CANCER RES, V56, P5360; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kinebuchi T, 2004, MOL CELL, V14, P363, DOI 10.1016/S1097-2765(04)00218-7; Kojic M, 2002, MOL CELL, V10, P683, DOI 10.1016/S1097-2765(02)00632-9; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Martin JS, 2005, MOL CELL BIOL, V25, P3127, DOI 10.1128/MCB.25.8.3127-3139.2005; McAllister KA, 2002, CANCER RES, V62, P990; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Neale MJ, 2006, NATURE, V442, P153, DOI 10.1038/nature04885; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Petalcorin MIR, 2007, P NATL ACAD SCI USA, V104, P8299, DOI [10.1073/pnas.0702805104, 10.1073/pnas.0702808104]; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Saeki H, 2006, P NATL ACAD SCI USA, V103, P8768, DOI 10.1073/pnas.0600298103; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; Sharan SK, 2004, DEVELOPMENT, V131, P131, DOI 10.1242/dev.00888; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Shivji MKK, 2006, NUCLEIC ACIDS RES, V34, P4000, DOI 10.1093/nar/gkl505; Siaud N, 2004, EMBO J, V23, P1392, DOI 10.1038/sj.emboj.7600146; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Takanami T, 2000, NUCLEIC ACIDS RES, V28, P4232, DOI 10.1093/nar/28.21.4232; Takata M, 2002, ONCOGENE, V21, P1130, DOI 10.1038/sj.onc.1205168; Tarsounas M, 1999, J CELL BIOL, V147, P207, DOI 10.1083/jcb.147.2.207; Tarsounas M, 2004, PHILOS T R SOC B, V359, P87, DOI 10.1098/rstb.2003.1368; Thorslund T, 2007, EMBO J, V26, P2915, DOI 10.1038/sj.emboj.7601739; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; YOSHIDA N, 1998, REC RES DEV FERMEN 1, V1, P1; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547	61	121	124	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2007	26	56					7720	7730		10.1038/sj.onc.1210870	http://dx.doi.org/10.1038/sj.onc.1210870			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066084				2022-12-28	WOS:000251537900002
J	Hodawadekar, SC; Marmorstein, R				Hodawadekar, S. C.; Marmorstein, R.			Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design	ONCOGENE			English	Review						histone acetyltransferases (HAT); histone deacetylases (HDAC); post-translational histone modifications	SIR2 HISTONE/PROTEIN DEACETYLASES; GCN5 TRANSCRIPTIONAL COACTIVATOR; SMALL-MOLECULE ACTIVATORS; CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; COENZYME-A; NICOTINAMIDE INHIBITION; CHROMATIN TRANSCRIPTION; CALORIE RESTRICTION; ANTITUMOR-ACTIVITY	The post-translational modi. cation of histones plays an important role in chromatin regulation, a process that insures the fidelity of gene expression and other DNA transactions. Of the enzymes that mediate post-translation modi. cation, the histone acetyltransferase ( HAT) and histone deacetylase ( HDAC) proteins that add and remove acetyl groups to and from target lysine residues within histones, respectively, have been the most extensively studied at both the functional and structural levels. Not surprisingly, the aberrant activity of several of these enzymes have been implicated in human diseases such as cancer and metabolic disorders, thus making them important drug targets. Significant mechanistic insights into the function of HATs and HDACs have come from the X-ray crystal structures of these enzymes both alone and in liganded complexes, along with associated enzymatic and biochemical studies. In this review, we will discuss what we have learned from the structures and related biochemistry of HATs and HDACs and the implications of these findings for the design of protein effectors to regulate gene expression and treat disease.	Univ Penn, Dept Chem, Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Marmorstein, R (corresponding author), Univ Penn, Dept Chem, Wistar Inst, 3601 Spruce St,Room 327, Philadelphia, PA 19104 USA.	marmor@wistar.org						Anekonda TS, 2006, J NEUROCHEM, V96, P305, DOI 10.1111/j.1471-4159.2005.03492.x; Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022; Avalos JL, 2004, MOL CELL, V13, P639, DOI 10.1016/S1097-2765(04)00082-6; Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200; Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074/jbc.M402839200; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Berndsen CE, 2007, BIOCHEMISTRY-US, V46, P623, DOI 10.1021/bi602513x; Biel M, 2005, ANGEW CHEM INT EDIT, V44, P3186, DOI 10.1002/anie.200461346; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Clements A, 2003, METHOD ENZYMOL, V371, P545; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Hoff KG, 2006, STRUCTURE, V14, P1231, DOI 10.1016/j.str.2006.06.006; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, COLD SPRING HARB SYM, V65, P297, DOI 10.1101/sqb.2000.65.297; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Jackson MD, 2003, J BIOL CHEM, V278, P50985, DOI 10.1074/jbc.M306552200; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Khan AN, 2006, J BIOL CHEM, V281, P11702, DOI 10.1074/jbc.M511482200; Kiviranta PH, 2006, J MED CHEM, V49, P7907, DOI 10.1021/jm060566j; Kobayashi Y, 2005, INT J MOL MED, V16, P237; Kumagai T, 2007, INT J CANCER, V121, P656, DOI 10.1002/ijc.22558; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; Liszt G, 2005, J BIOL CHEM, V280, P21313, DOI 10.1074/jbc.M413296200; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Manson MM, 2005, RECENT RESULTS CANC, V166, P257; Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564; Marmorstein R, 2001, CELL MOL LIFE SCI, V58, P693, DOI 10.1007/PL00000893; Marmorstein R, 2004, BIOCHEM SOC T, V32, P904, DOI 10.1042/BST0320904; Marmorstein R, 2001, STRUCTURE, V9, P1127, DOI 10.1016/S0969-2126(01)00690-6; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Moreth K, 2007, BIOCHEM J, V401, P659, DOI 10.1042/BJ20061239; Muraoka M, 1996, ONCOGENE, V12, P1565; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Nielsen TK, 2007, ACTA CRYSTALLOGR F, V63, P270, DOI 10.1107/S1744309107012377; Nielsen TK, 2005, J MOL BIOL, V354, P107, DOI 10.1016/j.jmb.2005.09.065; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Parthun MR, 2007, ONCOGENE, V26, P5319, DOI 10.1038/sj.onc.1210602; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Posakony J, 2004, J MED CHEM, V47, P2635, DOI 10.1021/jm030473r; Poux AN, 2003, BIOCHEMISTRY-US, V42, P14366, DOI 10.1021/bi035632n; Poux AN, 2002, P NATL ACAD SCI USA, V99, P14065, DOI 10.1073/pnas.222373899; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Sagar V, 2004, BIOORGAN MED CHEM, V12, P3383, DOI 10.1016/j.bmc.2004.03.070; Sanders BD, 2007, MOL CELL, V25, P463, DOI 10.1016/j.molcel.2006.12.022; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Schuetz A, 2007, STRUCTURE, V15, P377, DOI 10.1016/j.str.2007.02.002; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; Smith BC, 2007, J AM CHEM SOC, V129, P5802, DOI 10.1021/ja070162w; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101; Vanommeslaeghe K, 2005, BIOORGAN MED CHEM, V13, P3987, DOI 10.1016/j.bmc.2005.04.001; Varga-Weisz PD, 2006, CURR OPIN GENET DEV, V16, P151, DOI 10.1016/j.gde.2006.02.006; Varier RA, 2004, BIOCHEM PHARMACOL, V68, P1215, DOI 10.1016/j.bcp.2004.05.038; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Woodcock CL, 2006, CURR OPIN STRUC BIOL, V16, P213, DOI 10.1016/j.sbi.2006.02.005; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yan Y, 2002, NAT STRUCT BIOL, V9, P862, DOI 10.1038/nsb849; Zhang K, 2005, J CELL BIOCHEM, V96, P1137, DOI 10.1002/jcb.20615; Zhao KH, 2004, P NATL ACAD SCI USA, V101, P8563, DOI 10.1073/pnas.0401057101; Zheng YJ, 2004, METHOD ENZYMOL, V376, P188	93	179	184	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5528	5540		10.1038/sj.onc.1210619	http://dx.doi.org/10.1038/sj.onc.1210619			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694092				2022-12-28	WOS:000248674300019
J	Whiteman, EL; Liu, CJ; Fearon, ER; Margolis, B				Whiteman, E. L.; Liu, C-J; Fearon, E. R.; Margolis, B.			The transcription factor snail represses Crumbs3 expression and disrupts apico-basal polarity complexes	ONCOGENE			English	Article						Crumbs; Snail; apico-basal polarity; tight junction; epithelial to mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN; PROTEIN	In epithelial cells, the tight junction divides the plasma membrane into distinct apical and basolateral domains. Polarization is essential for epithelial cell function, and apico-basal cell polarity is lost during the epithelial to mesenchymal transition (EMT), a program of events characterized not only by loss of cell polarity, but also by enhanced cell motility and increased cell invasion. Among several apically localized protein complexes, the Crumbs and Par protein complexes have pivotal roles in control of epithelial polarity and apical membrane formation. Here, we demonstrate that the Snail transcriptional repressor antagonizes expression of the Crumbs polarity complex. We show that Snail abolishes localization of the Crumbs and Par complexes to the tight junction, decreases Crumbs complex protein levels and suppresses Crumbs3 transcription. Evidence that Snail acts directly to antagonize Crumbs3 promoter activity is presented. Strikingly, we note that reexpression of exogenous Crumbs3 in Snail- expressing Madin-Darby Canine Kidney cells partially restores cell-cell junctions. Moreover, we find that the EMT inducer transforming growth factor-beta elicits transcriptional repression of Crumbs3 and results in a measurable loss of Crumbs3 protein. Our findings provide new insights into the links between the transcriptional repression function of Snail and its role in antagonizing key apico-basal polarity factors during EMT.	[Margolis, B.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; [Fearon, E. R.] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; [Fearon, E. R.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Fearon, E. R.; Margolis, B.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Margolis, B.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 1528 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	bmargoli@umich.edu			NCI NIH HHS [T32 CA009676, 5-T32-CA09676] Funding Source: Medline; NIDDK NIH HHS [DK069605, R01 DK058208, P60 DK020572, 5-P60-DK20572, R01 DK058208-06, DK058208, R01 DK069605-04, R01 DK069605] Funding Source: Medline; NIGMS NIH HHS [F32 GM079906, 5-F32-GM07996] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, R01DK058208, R01DK069605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM079906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Hajra KM, 2002, CANCER RES, V62, P1613; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Straight SW, 2006, J BIOL CHEM, V281, P37738, DOI 10.1074/jbc.M607059200; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Whiteman EL, 2003, ENDOCRINOLOGY, V144, P3811, DOI 10.1210/en.2003-0480	12	131	137	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3875	3879		10.1038/onc.2008.9	http://dx.doi.org/10.1038/onc.2008.9			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246119	Green Accepted			2022-12-28	WOS:000256904700012
J	Asim, M; Siddiqui, IA; Hafeez, BB; Baniahmad, A; Mukhtar, H				Asim, M.; Siddiqui, I. A.; Hafeez, B. B.; Baniahmad, A.; Mukhtar, H.			Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells	ONCOGENE			English	Article						androgen receptor; casodex; invasion; prostate cancer; PP2; Src kinase	GROWTH-FACTOR-I; MOUSE MODEL; INHIBITION; ACTIVATION; RNA; PHOSPHORYLATION; COACTIVATOR-1; PROGRESSION; METASTASIS; EXPRESSION	Prostate cancer is one of the most prominent malignancies of elderly men in many Western countries including Europe and the United States with increasing trend worldwide. The growth of normal prostate as well as of prostate carcinoma cells depends on functional androgen receptor (AR) signaling. AR manifests the biological actions of androgens and its transcriptional activity is known to be influenced by signal transduction pathways. Here we show that Src, a nonreceptor tyrosine kinase, is overexpressed in androgen-independent prostate carcinoma C4-2 cells. Interestingly, the expression of Src was found to progressively increase (up to threefold) in transgenic adenocarcinoma of mouse prostate mice as a function of age and cancer progression. Blocking Src kinase function by a specific inhibitor, PP2, resulted in decreased AR transactivation function on two different reporters, mouse mammary tumor virus (MMTV) and prostate-specific antigen (PSA). Consistent with this, overexpression of a functional Src mutant also led to a dramatic decrease in AR transactivation potential in a hormone-dependent manner. Interference with Src function in C4-2 cells led to decreased recruitment of AR on the target gene PSA enhancer and also resulted in the abrogation of hormone-dependent PSA transcript induction. Src inhibition also led to a dramatic decrease in the cell invasion in addition to decreasing the cellular growth. We suggest that targeting Src kinase could be an effective strategy to inhibit prostate cancer growth and metastasis.	[Mukhtar, H.] Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Madison, WI 53706 USA; [Asim, M.; Baniahmad, A.] Univ Jena, Fac Med, Inst Human Genet & Anthropol, Jena, Germany; [Baniahmad, A.] Univ Kuopio, Dept Biosci, FIN-70211 Kuopio, Finland	University of Wisconsin System; University of Wisconsin Madison; Friedrich Schiller University of Jena; University of Eastern Finland	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Med Sci Ctr, 1300 Univ Ave,Med Sci Ctr 25B, Madison, WI 53706 USA.	aban@mti.uni-jena.de; hmukhtar@wisc.edu	Siddiqui, Imtiaz/B-6587-2009		NCI NIH HHS [R01 CA101039, R01CA101039, R01 CA120451, R01CA78809, R01 CA078809, R01CA120451] Funding Source: Medline; NIDDK NIH HHS [P50 DK065303, P50DK065303-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA120451, R01CA078809, R01CA101039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Baniahmad A, 2005, J STEROID BIOCHEM, V93, P89, DOI 10.1016/j.jsbmb.2004.12.012; BRINKMANN AO, 1992, J STEROID BIOCHEM, V41, P361, DOI 10.1016/0960-0760(92)90362-M; Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen S, 1998, MOL ENDOCRINOL, V12, P1558, DOI 10.1210/me.12.10.1558; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Dehm SM, 2007, MOL ENDOCRINOL, V21, P2855, DOI 10.1210/me.2007-0223; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Isaacs JT, 2000, JNCI-J NATL CANCER I, V92, P1367, DOI 10.1093/jnci/92.17.1367; Jenster G, 2000, J PATHOL, V191, P227; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Moehren U, 2007, MOL ENDOCRINOL, V21, P1039, DOI 10.1210/me.2006-0468; Notini AJ, 2005, J MOL ENDOCRINOL, V35, P547, DOI 10.1677/jme.1.01884; Perry JE, 1996, PROSTATE, P79; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Shah YM, 2005, MOL ENDOCRINOL, V19, P732, DOI 10.1210/me.2004-0298; Siddiqui IA, 2006, CARCINOGENESIS, V27, P833, DOI 10.1093/carcin/bgi323; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026	30	65	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3596	3604		10.1038/sj.onc.1211016	http://dx.doi.org/10.1038/sj.onc.1211016			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223692	Green Accepted			2022-12-28	WOS:000256468500011
J	Ben Sahra, I; Laurent, K; Loubat, A; Giorgetti-Peraldi, S; Colosetti, P; Auberger, P; Tanti, JF; Le Marchand-Brustel, Y; Bost, F				Ben Sahra, I.; Laurent, K.; Loubat, A.; Giorgetti-Peraldi, S.; Colosetti, P.; Auberger, P.; Tanti, J. F.; Le Marchand-Brustel, Y.; Bost, F.			The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level	ONCOGENE			English	Article						prostate cancer; type II diabetes; AMPK; cell cycle; cyclin D1; apoptosis	ACTIVATED PROTEIN-KINASE; PROSTATE-CANCER CELLS; DEPENDENT GROWTH; HIGH-GLUCOSE; APOPTOSIS; DEATH; AMPK; TUMORIGENICITY; OVEREXPRESSION; TRANSFORMATION	Metformin is a widely used antidiabetic agent, which regulates glucose homeostasis through inhibition of liver glucose production and an increase in muscle glucose uptake. Recent studies suggest that metformin may reduce the risk of cancer, but its mode of action in cancer remains not elucidated. We investigated the effect of metformin on human prostate cancer cell proliferation in vitro and in vivo. Metformin inhibited the proliferation of DU145, PC-3 and LNCaP cancer cells with a 50% decrease of cell viability and had a modest effect on normal prostate epithelial cell line P69. Metformin did not induce apoptosis but blocked cell cycle in G(0)/G(1). This blockade was accompanied by a strong decrease of cyclin D1 protein level, pRb phosphorylation and an increase in p27(kip) protein expression. Metformin activated the AMP kinase pathway, a fuel sensor signaling pathway. However, inhibition of the AMPK pathway using siRNA against the two catalytic subunits of AMPK did not prevent the antiproliferative effect of metformin in prostate cancer cells. Importantly, oral and intraperitoneal treatment with metformin led to a 50 and 35% reduction of tumor growth, respectively, in mice bearing xenografts of LNCaP. Similar, to the in vitro study, metformin led to a strong reduction of cyclin D1 protein level in tumors providing evidence for a mechanism that may contribute to the antineoplastic effects of metformin suggested by recent epidemiological studies.	[Ben Sahra, I.; Laurent, K.; Giorgetti-Peraldi, S.; Tanti, J. F.; Le Marchand-Brustel, Y.; Bost, F.] Univ Nice Sophia Antipolis, INSERM, U568, F-06204 Nice 03, France; [Ben Sahra, I.; Laurent, K.; Loubat, A.; Giorgetti-Peraldi, S.; Colosetti, P.; Auberger, P.; Tanti, J. F.; Le Marchand-Brustel, Y.; Bost, F.] Univ Nice Sophia Antipolis, IFR50, F-06204 Nice 03, France; [Loubat, A.] Fac Med Nice, INSERM, U638, F-06034 Nice, France; [Colosetti, P.; Auberger, P.] Fac Med Nice, INSERM, U526, F-06034 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Bost, F (corresponding author), Univ Nice Sophia Antipolis, INSERM, U568, Batiment ARCHIMED,151 Route St Antoine Ginestiere, F-06204 Nice 03, France.	bost@unice.fr	Colosetti, Pascal/ABH-4585-2020; AUBERGER, Patrick/G-1491-2013; BOST, Frederic/AAN-4691-2020	AUBERGER, Patrick/0000-0002-2481-8275; BOST, Frederic/0000-0003-4509-4701; Tanti, Jean-Francois/0000-0003-1782-1318; Colosetti, Pascal/0000-0002-5848-6053; Giorgetti-Peraldi, Sophie/0000-0002-2751-2618				Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; An D, 2006, DIABETOLOGIA, V49, P2174, DOI 10.1007/s00125-006-0338-9; Aouadi M, 2006, DIABETES, V55, P281, DOI 10.2337/diabetes.55.02.06.db05-0963; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bost F, 2000, METHOD ENZYMOL, V314, P342; CAMPBELL IW, 1985, HORM METAB RES, V15, P105; Chen Y, 1998, ONCOGENE, V16, P1913, DOI 10.1038/sj.onc.1201719; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Dagon Y, 2006, BIOCHEM BIOPH RES CO, V340, P43, DOI 10.1016/j.bbrc.2005.11.159; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; Denmeade SR, 2004, PROSTATE, V58, P211, DOI 10.1002/pros.10360; Detaille D, 2005, DIABETES, V54, P2179, DOI 10.2337/diabetes.54.7.2179; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Erlich S, 2006, BIOCHEM PHARMACOL, V72, P427, DOI 10.1016/j.bcp.2006.05.007; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Guigas B, 2006, DIABETES, V55, P865, DOI 10.2337/diabetes.55.04.06.db05-1178; Han EKH, 1998, PROSTATE, V35, P95, DOI 10.1002/(SICI)1097-0045(19980501)35:2<95::AID-PROS2>3.0.CO;2-F; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ibanez L, 2006, J CLIN ENDOCR METAB, V91, P2888, DOI 10.1210/jc.2006-0336; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim WH, 2007, CELL SIGNAL, V19, P791, DOI 10.1016/j.cellsig.2006.10.004; Libertini SJ, 2006, PROSTATE, V66, P70, DOI 10.1002/pros.20314; Lord JM, 2003, BRIT MED J, V327, P951, DOI 10.1136/bmj.327.7421.951; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Marchesini G, 2001, LANCET, V358, P893, DOI 10.1016/S0140-6736(01)06042-1; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Park C, 2006, MOL CANCER THER, V5, P3191, DOI 10.1158/1535-7163.MCT-06-0570; Perry JE, 1998, PROSTATE, V35, P117; Plymate SR, 1996, J CLIN ENDOCR METAB, V81, P3709, DOI 10.1210/jc.81.10.3709; Ruderman NB, 2003, ACTA PHYSIOL SCAND, V178, P435, DOI 10.1046/j.1365-201X.2003.01164.x; Schneider MB, 2001, GASTROENTEROLOGY, V120, P1263, DOI 10.1053/gast.2001.23258; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zhang Y, 2007, FRONT BIOSCI, V12, P4855, DOI 10.2741/2433; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	42	682	704	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3576	3586		10.1038/sj.onc.1211024	http://dx.doi.org/10.1038/sj.onc.1211024			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18212742				2022-12-28	WOS:000256468500009
J	Lopez-Serra, L; Ballestar, E; Ropero, S; Setien, F; Billard, LM; Fraga, MF; Lopez-Nieva, P; Alaminos, M; Guerrero, D; Dante, R; Esteller, M				Lopez-Serra, L.; Ballestar, E.; Ropero, S.; Setien, F.; Billard, L-M; Fraga, M. F.; Lopez-Nieva, P.; Alaminos, M.; Guerrero, D.; Dante, R.; Esteller, M.			Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins	ONCOGENE			English	Article						DNA methylation; epigenetics; methyl-CpG-binding domain proteins; tumor suppressor genes; RNA interference	HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; RETT-SYNDROME; TRANSCRIPTIONAL REPRESSION; CHROMOSOMAL-PROTEIN; CANCER-CELLS; MECP2; MBD2; IDENTIFICATION; ASSOCIATION	Methyl-cytosine-phosphate-guanine (CpG)-binding domain (MBD) proteins are bound to hypermethylated promoter CpG islands of tumor suppressor genes in human cancer cells, although a direct causal relationship at the genome-wide level between MBD presence and gene silencing remains to be demonstrated. To this end, we have inhibited the expression of MBD proteins in HeLa cells by short hairpin RNAs; and studied the functional consequences of MBD depletion using microarray-based expression analysis in conjunction with extensive bisulfite genomic sequencing and chromatin immunoprecipitation. The removal of MBDs results in a release of gene silencing associated witha loss of MBD occupancy in 5'-CpG islands without any change in the DNA methylation pattern. Our results unveil new targets for epigenetic inactivation mediated by MBDs in transformed cells, such as the cell adhesion protein gamma-parvin and the fibroblast growth factor 19, where we also demonstrate their bona. de tumor suppressor features. Our data support a fundamental role for MBD proteins in the direct maintenance of transcriptional repression of tumor suppressors and identify new candidate genes for epigenetic disruption in cancer cells.	[Esteller, M.] Spanish Natl Canc Res Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, Madrid, Spain; [Billard, L-M; Dante, R.] Ctr Leon Berard, INSERM, U590, Oncol Mol Lab, F-69373 Lyon, France; [Alaminos, M.] Univ Granada, Dept Histol, Granada, Spain; [Alaminos, M.] Fdn Hosp Clin, Granada, Spain; [Guerrero, D.] Ctr Invest Biomed, Serv Navarro Salud, Navarra, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; University of Granada; Servicio Navarro de Salud - Osasunbidea	Esteller, M (corresponding author), Spanish Natl Canc Res Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, C Melchor Fernandez Almagro 3, Madrid, Spain.	mesteller@cnio.es	Nieva, Pilar López/R-9516-2019; ALAMINOS, MIGUEL/N-9960-2016; Esteller, Manel/L-5956-2014; Ballestar, Esteban/ABG-8561-2020; Fraga, Mario F/H-7824-2017	Nieva, Pilar López/0000-0001-6369-2444; ALAMINOS, MIGUEL/0000-0003-4876-2672; Esteller, Manel/0000-0003-4490-6093; Fraga, Mario F/0000-0001-8450-2603; Ballestar, Esteban/0000-0002-1400-2440				Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200; Ballestar E, 2005, BIOCHEM CELL BIOL, V83, P374, DOI 10.1139/o05-035; Ballestar E, 2005, HUM GENET, V116, P91, DOI 10.1007/s00439-004-1200-0; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bernard D, 2006, ONCOGENE, V25, P1358, DOI 10.1038/sj.onc.1209179; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fatemi M, 2006, J CELL SCI, V119, P3033, DOI 10.1242/jcs.03099; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jordan C, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-36; Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021; Koizume S, 2002, NUCLEIC ACIDS RES, V30, P4770, DOI 10.1093/nar/gkf593; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Olski TM, 2001, J CELL SCI, V114, P525; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100	39	47	47	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3556	3566		10.1038/sj.onc.1211022	http://dx.doi.org/10.1038/sj.onc.1211022			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223687				2022-12-28	WOS:000256468500007
J	Chatterjee, A; Chang, X; Nagpal, JK; Chang, S; Upadhyay, S; Califano, J; Trink, B; Sidransky, D				Chatterjee, A.; Chang, X.; Nagpal, J. K.; Chang, S.; Upadhyay, S.; Califano, J.; Trink, B.; Sidransky, D.			Targeting human 8-oxoguanine DNA glycosylase to mitochondria protects cells from 2-methoxyestradiol-induced-mitochondria-dependent apoptosis	ONCOGENE			English	Article						hOGG1; mitochondria; 2-methoxyestradiol; Fas activation	BASE-EXCISION-REPAIR; FAS-MEDIATED APOPTOSIS; HUMAN LEUKEMIA-CELLS; OXIDATIVE STRESS; ESCHERICHIA-COLI; CANCER-CELLS; MAMMALIAN-CELLS; SUPEROXIDE-DISMUTASE; IONIZING-RADIATION; CELLULAR-SURVIVAL	2-Methoxyestradiol (2-ME), an endogenous estrogen metabolite of 17 beta-estradiol, is known to induce mitochondria-mediated apoptosis through several mechanisms. We sought to study the effect of mitochondrialy targeted hOGG1 (MTS-hOGG1) on HeLa cells exposed to 2-ME. MTS-hOGG1-expressing cells exposed to 2-ME showed increased cellular survival and had significantly less G(2)/M cell cycle arrest compared to vector-only-transfected cells. In addition, 2-ME exposure resulted in an increase in mitochondrial membrane potential, increased apoptosis, accompanied by higher activation of caspase-3, -9, cleavage of Bid to tBid and protein poly(ADP-ribose) polymerase (PARP) cleavage in HeLa cells lacking MTS-hOGG1. Fas inhibitors cerulenin or C75 inhibited 2-ME-induced caspase activation, PARP cleavage, apoptosis and reversed mitochondrial membrane hyperpolarization, thereby recapitulating the increased expression of MTS-hOGG1. Hence, MTS-hOGG1 plays an important protective role against 2-ME-mediated mitochondrial damage by blocking apoptosis induced through the Fas pathway.	[Chatterjee, A.; Chang, X.; Nagpal, J. K.; Chang, S.; Upadhyay, S.; Califano, J.; Trink, B.; Sidransky, D.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21231 USA	Johns Hopkins University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, 1550 Orleans St,Canc Res Bldg 2, Baltimore, MD 21231 USA.	dsidrans@jhmi.edu			NCI NIH HHS [5-PO1CA 77664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; ALLEY MC, 1988, CANCER RES, V48, P589; Audebert M, 2002, DNA REPAIR, V1, P497, DOI 10.1016/S1568-7864(02)00034-4; Banki K, 1999, J IMMUNOL, V162, P1466; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chatterjee A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-235; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHI NW, 1994, J BIOL CHEM, V269, P29984; CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Dhenaut A, 2001, ADV EXP MED BIOL, V500, P613; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Djavaheri-Mergny M, 2003, ANN NY ACAD SCI, V1010, P159, DOI 10.1196/annals.1299.026; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Druzhyna NM, 2005, J BIOL CHEM, V280, P21673, DOI 10.1074/jbc.m411531200; Druzhyna NM, 2003, GLIA, V42, P370, DOI 10.1002/glia.10230; Dubey RK, 1998, HYPERTENSION, V31, P522, DOI 10.1161/01.HYP.31.1.522; Fanizza C, 2007, TOXICOL IN VITRO, V21, P586, DOI 10.1016/j.tiv.2006.12.002; Fishel ML, 2003, CANCER RES, V63, P608; Gao N, 2005, ONCOGENE, V24, P3797, DOI 10.1038/sj.onc.1208530; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Gui Y, 2006, HYPERTENSION, V47, P271, DOI 10.1161/01.HYP.0000199656.99448.dc; Hagen T, 2004, BIOCHEM BIOPH RES CO, V322, P923, DOI 10.1016/j.bbrc.2004.07.204; Hazra TK, 2001, PROG NUCLEIC ACID RE, V68, P193; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; Ide H, 2004, BIOL PHARM BULL, V27, P480, DOI 10.1248/bpb.27.480; Itoh K, 2004, RHEUMATOLOGY, V43, P277, DOI 10.1093/rheumatology/keh039; Kachadourian R, 2001, ARCH BIOCHEM BIOPHYS, V392, P349, DOI 10.1006/abbi.2001.2455; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Lambert C, 2004, INT J CANCER, V108, P493, DOI 10.1002/ijc.11579; Lambert C, 2002, EUR J MED RES, V7, P404; LaVallee TM, 2003, CANCER RES, V63, P468; Li L, 2004, ANTICANCER RES, V24, P3983; Li L, 2004, ANTICANCER RES, V24, P873; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Mambo E, 2005, ONCOGENE, V24, P4496, DOI 10.1038/sj.onc.1208669; Mambo E, 2002, CANCER RES, V62, P1349; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; ModicaNapolitano JS, 1996, CANCER RES, V56, P544; Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001; Morgunov I, 1998, J BIOL CHEM, V273, P29540, DOI 10.1074/jbc.273.45.29540; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NABI ZF, 1986, CANCER, V58, P1461, DOI 10.1002/1097-0142(19861001)58:7<1461::AID-CNCR2820580714>3.0.CO;2-D; Pani G, 2000, CANCER RES, V60, P4654; Parlanti E, 2002, ONCOGENE, V21, P5204, DOI 10.1038/sj.onc.1205561; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Rachek LI, 2002, J BIOL CHEM, V277, P44932, DOI 10.1074/jbc.M208770200; Rachek LI, 2006, DIABETES, V55, P1022, DOI 10.2337/diabetes.55.04.06.db05-0865; Rachek LI, 2006, FREE RADICAL BIO MED, V40, P754, DOI 10.1016/j.freeradbiomed.2005.09.028; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rinne ML, 2005, NUCLEIC ACIDS RES, V33, P2859, DOI 10.1093/nar/gki601; Ruchko M, 2005, AM J PHYSIOL-LUNG C, V288, pL530, DOI 10.1152/ajplung.00255.2004; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; SEGALBENDIRDJIAN E, 1988, CANCER RES, V48, P4982; Shimada K, 2004, MOL CARCINOGEN, V39, P1, DOI 10.1002/mc.10158; Shokolenko IN, 2003, DNA REPAIR, V2, P471, DOI 10.1016/S1568-7864(03)00019-3; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Singh KK, 2001, NUCLEIC ACIDS RES, V29, P1381, DOI 10.1093/nar/29.6.1381; Srere P A, 1968, Biochem Soc Symp, V27, P11; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yang N, 2004, DNA REPAIR, V3, P1323, DOI 10.1016/j.dnarep.2004.04.014	77	7	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3710	3720		10.1038/onc.2008.3	http://dx.doi.org/10.1038/onc.2008.3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18246124				2022-12-28	WOS:000256659300008
J	Mathieu, J; Flexor, M; Lanotte, M; Besancon, F				Mathieu, J.; Flexor, M.; Lanotte, M.; Besancon, F.			A PARP-1/JNK1 cascade participates in the synergistic apoptotic effect of TNF alpha and all-trans retinoic acid in APL cells	ONCOGENE			English	Article						TNF alpha; apoptosis; ATRA; PARP-1	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; EWING SARCOMA-CELLS; POLY(ADP-RIBOSE) POLYMERASE; INDUCED ACTIVATION; JNK ACTIVATION; TUMOR-CELLS; IFN-GAMMA; DEATH; INDUCTION	When administrated by isolated limb perfusion, tumor necrosis factor alpha (TNF alpha) is an efficient antitumor agent that improves drug penetration and destroys angiogenic vessels. Moreover, the pronounced potentiation of TNF alpha-induced apoptosis by NF-kappa B inhibitors suggest that these compounds could enhance TNF alpha antitumor efficacy through direct induction of tumor cell apoptosis. Therefore, attempts at amplifying signaling pathways that mediate TNF alpha antitumor effects could help to design combination therapies improving its efficiency. We report that nanomolar concentrations of all-trans retinoic acid (ATRA) amplify TNF alpha-induced apoptosis in APL cells expressing a specific repressor of NF-kappa B activation. This effect is abolished by the pan-caspase inhibitor, Z-V AD-fmk and by caspase-8 and -9 inhibitors. Cell death is accompanied by a drop of mitochondrial potential and by poly (ADP-ribose) polymerase (PARP) activation. Using specific PARP-1 inhibitors and siRNAs, we show that PARP-1 is essential for the synergistic apoptotic effect and c-Jun N-terminal kinase 1 (JNK1) activation triggered by the ATRA/TNF alpha combination. JNK1 siRNAs reduce ATRA/TNF alpha-induced apoptosis, mitochondrial release of cytochrome c and caspase-9 activation. Altogether, these results identify a novel mechanism of PARP-1-induced apoptosis, in which JNK1 provides a link between PARP-1 activation and mitochondrial pathway of caspase-9 activation. This study also suggests that inclusion of nanomolar doses of ATRA could be clinically beneficial in amplifying TNF alpha-induced antitumor signals.	[Mathieu, J.; Lanotte, M.; Besancon, F.] Hop St Louis, INSERM, Unite 685, Inst Univ Hematol, F-75475 Paris 10, France; [Flexor, M.] Hop St Louis, AP HP, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP	Besancon, F (corresponding author), Hop St Louis, INSERM, Unite 685, Inst Univ Hematol, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	Francoise.Besancon@stlouis.inserm.fr						Abadie A, 2004, ONCOGENE, V23, P4911, DOI 10.1038/sj.onc.1207614; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; AMRAN D, 2007, BIOCHIM BIOPHYS ACTA, V1173, P1653; Boulares AH, 2001, J BIOL CHEM, V276, P38185; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kukekov NV, 2006, J BIOL CHEM, V281, P15517, DOI 10.1074/jbc.M601056200; LAINE A, 2005, SCI STKE, V281, pRE5; LANOTTE M, 1991, BLOOD, V77, P1080; Lejeune FJ, 2006, B CANC, V93, pE90; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Manna SK, 2000, ONCOGENE, V19, P2110, DOI 10.1038/sj.onc.1203547; Mathieu J, 2005, ONCOGENE, V24, P7145, DOI 10.1038/sj.onc.1208889; Mathieu J, 2006, INT J CANCER, V119, P1723, DOI 10.1002/ijc.21970; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; NAKAMURA J, 2003, NUCLEIC ACIDS RES, V31, P1; Nguewa PA, 2003, MOL PHARMACOL, V64, P1007, DOI 10.1124/mol.64.5.1007; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TOBLER A, 1987, BLOOD, V70, P1940; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; van Horssen R, 2006, ONCOLOGIST, V11, P397, DOI 10.1634/theoncologist.11-4-397; Van Molle W, 2002, IMMUNITY, V16, P685, DOI 10.1016/S1074-7613(02)00310-2; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; Xu Y, 2006, J BIOL CHEM, V281, P8788, DOI 10.1074/jbc.M508135200; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	36	15	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3361	3370		10.1038/sj.onc.1210997	http://dx.doi.org/10.1038/sj.onc.1210997			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18084321				2022-12-28	WOS:000256309900001
J	Torng, PL; Lee, YCG; Huang, CYF; Ye, JH; Lin, YS; Chu, YW; Huang, SC; Cohen, P; Wu, CW; Lin, CT				Torng, P-L; Lee, Y-CG; Huang, C-YF; Ye, J-H; Lin, Y-S; Chu, Y-W; Huang, S-C; Cohen, P.; Wu, C-W; Lin, C-T			Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma	ONCOGENE			English	Article						ovarian endometrioid carcinoma; invasion; suppressor; insulin-like growth factor binding protein-3	CANCER; STAGE; GENE; ADENOCARCINOMA; EXPRESSION	Metastasis and invasion occur in the majority of epithelial ovarian carcinoma at diagnosis. To delineate the molecular signature in ovarian cancer invasion, we established and characterized a human ovarian endometrioid carcinoma (EC) cell line OVTW59-P0 and its invasion-related sublines (P1-P4, in the order of increasing invasive activity). P4 showed faster migration and larger xenograft formation with metastasis than P0. By microarray analysis of different gene expression among P0-P4 sublines, one group of gene was found negatively correlated with cancer invasion. Among these genes, IGFBP-3 was identified as one of the most remarkably suppressed gene that showed lower gene expression in P4 than P0. Re-expression of IGFBP-3 in P4 effectively inhibited cell migration, invasion and metastasis, but did not affect cell proliferation. In 35 patients with EC tumors, low IGFBP-3 expression correlated clinically with higher tumor grade, advanced stage and poor survival. Our results provide evidence and indicate that IGFBP-3 plays an important role as an invasion-metastasis suppressor in ovarian EC.	[Lin, C-T] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10020, Taiwan; [Torng, P-L; Ye, J-H; Huang, S-C; Lin, C-T] Natl Taiwan Univ, Coll Med, Inst Pathol, Taipei 10020, Taiwan; [Cohen, P.] Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA 90024 USA; [Huang, C-YF; Lin, Y-S; Chu, Y-W; Wu, C-W] Natl Hlth Res Inst, Natl Hlth Canc Res, Taipei, Taiwan; [Lee, Y-CG] Taipei Med Univ, Grad Inst Med Informat, Taipei, Taiwan; [Torng, P-L; Huang, S-C] Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; University of California System; University of California Los Angeles; National Health Research Institutes - Taiwan; Taipei Medical University; National Taiwan University; National Taiwan University Hospital	Lin, CT (corresponding author), Natl Taiwan Univ Hosp, Dept Pathol, 7 Chung Shan S Rd, Taipei 10020, Taiwan.	ctl@ha.mc.ntu.edu.tw	Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937; TORNG, PAO-LING/0000-0002-6834-8295				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Bell KA, 2000, AM J SURG PATHOL, V24, P1465, DOI 10.1097/00000478-200011000-00002; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Goodman MT, 2003, CANCER, V97, P2648, DOI 10.1002/cncr.11347; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Jiang XX, 1998, CANCER RES, V58, P1707; Juan HF, 2002, ELECTROPHORESIS, V23, P2490, DOI 10.1002/1522-2683(200208)23:15<2490::AID-ELPS2490>3.0.CO;2-3; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katsaros D, 2001, EUR J CANCER, V37, P478, DOI 10.1016/S0959-8049(00)00423-8; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; LIN CT, 1993, LAB INVEST, V68, P716; Lu LG, 2006, CLIN CANCER RES, V12, P1208, DOI 10.1158/1078-0432.CCR-05-1801; McCluggage WG, 2002, HISTOPATHOLOGY, V40, P309, DOI 10.1046/j.1365-2559.2002.01384.x; McGuire WP, 1996, SEMIN ONCOL, V23, P40; Mishra S, 2004, MOL CELL BIOCHEM, V267, P83, DOI 10.1023/B:MCBI.0000049368.40558.0a; Oh SH, 2006, MOL CANCER THER, V5, P2685, DOI 10.1158/1535-7163.MCT-06-0142; Oh SH, 2006, CLIN CANCER RES, V12, P653, DOI 10.1158/1078-0432.CCR-05-1725; Ohwada M, 2001, CANCER CYTOPATHOL, V93, P376, DOI 10.1002/cncr.10137; Sayer RA, 2005, GYNECOL ONCOL, V96, P355, DOI 10.1016/j.ygyno.2004.10.012; Silha JV, 2006, ENDOCRINOLOGY, V147, P2112, DOI 10.1210/en.2005-1270; Simpson JL, 2002, ANN NY ACAD SCI, V955, P239, DOI 10.1111/j.1749-6632.2002.tb02785.x; Torng PL, 2004, GYNECOL ONCOL, V92, P559, DOI 10.1016/j.ygyno.2003.11.011; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wiley A, 2006, INT J GYNECOL CANCER, V16, P210, DOI 10.1111/j.1525-1438.2006.00299.x	25	59	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2137	2147		10.1038/sj.onc.1210864	http://dx.doi.org/10.1038/sj.onc.1210864			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952116	Green Published			2022-12-28	WOS:000254621300004
J	Camacho-Leal, P; Stanners, CP				Camacho-Leal, P.; Stanners, C. P.			The human carcinoembryonic antigen (CEA) GPI anchor mediates anoikis inhibition by inactivation of the intrinsic death pathway	ONCOGENE			English	Article						CEA; anoikis; molecular mechanism; caspases	HUMAN-TUMOR-MARKER; INTERCELLULAR-ADHESION MOLECULE; CYTOCHROME-C RELEASE; SIGNALING PATHWAY; CASPASE ACTIVATION; CELL-SURVIVAL; GENE FAMILY; INTEGRIN; DIFFERENTIATION; EXPRESSION	Human carcinoembryonic antigen (CEA) is a cell surface adhesion molecule member of the Immunoglobulin Superfamily (IgSF). Aberrant upregulation of CEA is a common feature found in a wide variety of human cancers such as colon, breast and lung. Previous in vitro and in vivo results have demonstrated that CEA can have tumorigenic effects including the inhibition of cell differentiation and anoikis, a specific type of apoptosis triggered by the absence of extracellular matrix-cell contacts. In the present work, we investigate the involvement of the caspase cascade in CEA-mediated inhibition of anoikis and the structural requirements for this signal. Expression of CEA and/or a chimeric protein consisting of the NCAM extracellular domain attached to the CEA-GPI anchor correlates with an early inactivation of caspase-9 and activation of the PI3-K/Akt survival pathway, and at later times, inactivation of caspase-8. The CEA-mediated caspase inactivation as well as activation of Akt was not observed by expression of a CEA molecule incapable of self-binding (DNCEA). These results suggest that the intrinsic caspase pathway is involved in the inhibitory effects of anoikis by CEA and this signal is dependent on the presence of self-adhesive extracellular domains and a CEA-GPI anchor.	[Camacho-Leal, P.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Stanners, CP (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	cliff.stanners@mcgill.ca						BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Camacho-Leal P, 2007, J CELL PHYSIOL, V211, P791, DOI 10.1002/jcp.20989; CHA YJ, 2001, EXP MOL MED, V33, P28492; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marconi A, 2004, J CELL SCI, V117, P5815, DOI 10.1242/jcs.01490; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Nollau P, 1997, CANCER RES, V57, P2354; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; Ordonez C, 2000, CANCER RES, V60, P3419; Ordonez C, 2007, J CELL PHYSIOL, V210, P757, DOI 10.1002/jcp.20887; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Rennebeck G, 2005, CANCER RES, V65, P11230, DOI 10.1158/0008-5472.CAN-05-2763; Rojas M, 1996, CELL GROWTH DIFFER, V7, P655; ROSENBERG M, 1993, CANCER RES, V53, P4938; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; Screaton RA, 2000, J CELL BIOL, V150, P613, DOI 10.1083/jcb.150.3.613; Soeth E, 2001, CLIN CANCER RES, V7, P2022; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P57; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Taheri M, 2003, J BIOL CHEM, V278, P14632, DOI 10.1074/jbc.M212500200; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Tiberio R, 2002, FEBS LETT, V524, P139, DOI 10.1016/S0014-5793(02)03040-5; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	39	29	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1545	1553		10.1038/sj.onc.1210789	http://dx.doi.org/10.1038/sj.onc.1210789			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17891182				2022-12-28	WOS:000253815800006
J	Dobbyn, HC; Hill, K; Hamilton, TL; Spriggs, KA; Pickering, BM; Coldwell, MJ; de Moor, CH; Bushell, M; Willis, AE				Dobbyn, H. C.; Hill, K.; Hamilton, T. L.; Spriggs, K. A.; Pickering, B. M.; Coldwell, M. J.; de Moor, C. H.; Bushell, M.; Willis, A. E.			Regulation of BAG-1 IRES-mediated translation following chemotoxic stress	ONCOGENE			English	Article						BAG-1; translation; IRES; internal ribosome entry; polypyrimidine tract binding protein	INTERNAL RIBOSOME ENTRY; TRACT-BINDING-PROTEIN; CELL-DEATH; HEAT-SHOCK; BREAST-CANCER; MESSENGER-RNA; EXPRESSION; INITIATION; GROWTH; APOPTOSIS	There are three major isoforms of BAG-1 in mammalian cells, termed BAG-1L ( p50), BAG-1M ( p46) and BAG-1S ( p36) that function as pro-survival proteins and are associated with tumorigenesis and chemoresistance. Initiation of BAG-1 protein synthesis can occur by both cap-dependent and cap-independent mechanisms and it has been shown that synthesis of BAG-1S is dependent upon the presence of an internal ribosome entry segment ( IRES) in the 5'-UTR of BAG-1 mRNA. We have shown previously that BAG-1 IRES-meditated initiation of translation requires two trans-acting factors poly ( rC) binding protein 1 ( PCBP1) and polypyrimidine tract binding protein ( PTB) for function. The former protein allows BAG-1 IRES RNA to attain a structure that permits binding of the ribosome, while the latter protein appears to be involved in ribosome recruitment. Here, we show that the BAG-1 IRES maintains synthesis of BAG-1 protein following exposure of cells to the chemotoxic drug vincristine but not to cisplatin and that this is brought about, in part, by the relocalization of PTB and PCBP1 from the nucleus to the cytoplasm.	[Dobbyn, H. C.; Hill, K.; Hamilton, T. L.; Spriggs, K. A.; Pickering, B. M.; Coldwell, M. J.; de Moor, C. H.; Bushell, M.; Willis, A. E.] Univ Nottingham, Sch Pharm, Chair Canc Cell Biol, Nottingham NG7 2RD, England	University of Nottingham	Willis, AE (corresponding author), Univ Nottingham, Sch Pharm, Chair Canc Cell Biol, Univ Pk, Nottingham NG7 2RD, England.	anne.willis@nottingham.ac.uk	de Moor, Cornelia/AAE-8043-2020	de Moor, Cornelia/0000-0001-8776-0085; Willis, Anne/0000-0002-1470-8531	Biotechnology and Biological Sciences Research Council [C14959, BBS/B/03556] Funding Source: Medline; Wellcome Trust [075802] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Back SH, 2002, J VIROL, V76, P2529, DOI 10.1128/JVI.76.5.2529-2542.2002; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Cato ACB, 2001, J STEROID BIOCHEM, V78, P379, DOI 10.1016/S0960-0760(01)00114-5; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Fraser CS, 1999, BIOCHEM J, V342, P519, DOI 10.1042/0264-6021:3420519; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Hague A, 2002, J PATHOL, V197, P60, DOI 10.1002/path.1076; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kamath RV, 2001, MOL BIOL CELL, V12, P3808, DOI 10.1091/mbc.12.12.3808; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Pickering BM, 2004, MOL CELL BIOL, V24, P5595, DOI 10.1128/MCB.24.12.5595-5605.2004; Pickering BM, 2003, NUCLEIC ACIDS RES, V31, P639, DOI 10.1093/nar/gkg146; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Qin XL, 2004, J BIOL CHEM, V279, P13721, DOI 10.1074/jbc.M312854200; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Takahashi A, 1997, BRAIN RES PROTOC, V1, P70, DOI 10.1016/S1385-299X(96)00013-X; Tang SC, 1999, J CLIN ONCOL, V17, P1710, DOI 10.1200/JCO.1999.17.6.1710; Townsend PA, 2003, CANCER RES, V63, P4150; Townsend PA, 2003, BBA-REV CANCER, V1603, P83, DOI 10.1016/S0304-419X(03)00002-7; Townsend PA, 2002, J PATHOL, V197, P51, DOI 10.1002/path.1081; Wang C, 2003, MOL BIOL CELL, V14, P2425, DOI 10.1091/mbc.E02-12-0818; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Xie JY, 2003, P NATL ACAD SCI USA, V100, P8776, DOI 10.1073/pnas.1432696100; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	34	52	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1167	1174		10.1038/sj.onc.1210723	http://dx.doi.org/10.1038/sj.onc.1210723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700523	Green Accepted			2022-12-28	WOS:000253136700016
J	Kurata, K; Yanagisawa, R; Ohira, M; Kitagawa, M; Nakagawara, A; Kamijo, T				Kurata, K.; Yanagisawa, R.; Ohira, M.; Kitagawa, M.; Nakagawara, A.; Kamijo, T.			Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; p53; noxa; mitochondria; apoptosis	WILD-TYPE P53; DNA-DAMAGE; IN-VIVO; P53-DEPENDENT APOPTOSIS; CYTOPLASMIC SEQUESTRATION; MOLECULAR-CLONING; EXPRESSION; DEATH; PROTEINS; GENE	In this study, we employed a panel of cell lines to determine whether p53-dependent cell death in neuroblastoma (NB) cells is caused by apoptotic cellular function, and we further studied the molecular mechanism of apoptosis induced via the p53-dependent pathway. We obtained evidence that a type of p53-dependent stress, doxorubicin (Doxo) administration, causes accumulation of p53 in the nucleus of NB cells and phosphorylation of several serine residues in both Doxo-sensitive and -resistant cell lines. Upregulation of p53-downstream molecules in cells and upregulation of Noxa in the mitochondrial fraction were observed only in Doxo-sensitive NB cells. Significance of Noxa in the Doxo-induced NB cell death was confirmed by Noxa-knockdown experiments. Mitochondrial dysfunction, including cytochrome-c release and membrane potential disregulation, occurred and resulted in the activation of the intrinsic caspase pathway. However, in the Doxo-resistant cells, the accumulation in the nucleus and phosphorylation of p53 did not induce p53-downstream p21(Cip1/Waf1) expression and the Noxa upregulation, resulting in the retention of the mitochondrial homeostasis. Taken together, these findings indicate that the p53 pathway seems to play a crucial role in NB cell death by Noxa regulation in mitochondria, and inhibition of the induction of p53-downstream effectors may regulate drug resistance of NB cells.	[Ohira, M.; Nakagawara, A.; Kamijo, T.] Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Kurata, K.; Yanagisawa, R.; Kamijo, T.] Shinshu Univ, Sch Med, Dept Pediat, Nagano, Japan; [Kitagawa, M.] Hamamatsu Univ Sch Med, Dept Biochem, Shizuoka, Japan	Chiba Cancer Center; Shinshu University; Hamamatsu University School of Medicine	Kamijo, T (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	tkamijo@chiba-cc.jp						Aleyasin H, 2004, J NEUROSCI, V24, P2963, DOI 10.1523/JNEUROSCI.0155-04.2004; Bell E, 2006, CELL CYCLE, V5, P2639, DOI 10.4161/cc.5.22.3443; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hempel G, 2002, CANCER CHEMOTH PHARM, V49, P133, DOI 10.1007/s00280-001-0392-4; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Hudson CD, 2005, J BIOL CHEM, V280, P11851, DOI 10.1074/jbc.M408679200; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; Keshelava N, 2001, CANCER RES, V61, P6185; Kiryu-Seo S, 2005, J NEUROSCI, V25, P1442, DOI 10.1523/JNEUROSCI.4041-04.2005; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lee SJ, 2005, J BIOL CHEM, V280, P5781, DOI 10.1074/jbc.M411224200; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Machida T, 2006, ONCOGENE, V25, P1931, DOI 10.1038/sj.onc.1209225; Matthay KK, 1998, J CLIN ONCOL, V16, P1256, DOI 10.1200/JCO.1998.16.4.1256; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Nakazawa Y, 2003, J BIOL CHEM, V278, P27888, DOI 10.1074/jbc.M300510200; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; ODA E, 2003, SCIENCE, V17, P1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohtani S, 2004, MOL CANCER THER, V3, P93; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Paull A, 2005, MOL VIS, V11, P328; Qin JZ, 2004, MOL CANCER THER, V3, P895; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, CANCER RES, V61, P8; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolff A, 2001, ONCOGENE, V20, P1307, DOI 10.1038/sj.onc.1204251; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200	37	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					741	754		10.1038/sj.onc.1210672	http://dx.doi.org/10.1038/sj.onc.1210672			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653088				2022-12-28	WOS:000252884500003
J	Borczuk, AC; Papanikolaou, N; Toonkel, RL; Sole, M; Gorenstein, LA; Ginsburg, ME; Sonett, JR; Friedman, RA; Powell, CA				Borczuk, A. C.; Papanikolaou, N.; Toonkel, R. L.; Sole, M.; Gorenstein, L. A.; Ginsburg, M. E.; Sonett, J. R.; Friedman, R. A.; Powell, C. A.			Lung adenocarcinoma invasion in TGFbRII-deficient cells is mediated by CCL5/RANTES	ONCOGENE			English	Article						lung adenocarcinoma; bronchioloalveolar carcinoma; neoplasm invasiveness; RANTES; TGF-beta; disease progression	FACTOR-BETA RECEPTOR; BREAST-CARCINOMA; GENE-EXPRESSION; CCL5 RANTES; CANCER; CCR5; METASTASIS; PROGRESSION; ANTAGONIST; ACTIVATION	Recently, we identified a lung adenocarcinoma signature that segregated tumors into three clades distinguished by histological invasiveness. Among the genes differentially expressed was the type II transforming growth factor-beta receptor (TGF beta RII), which was lower in adenocarcinoma mixed subtype and solid invasive subtype tumors compared with bronchioloalveolar carcinoma. We used a tumor cell invasion system to identify the chemokine CCL5 (RANTES, regulated on activation, normal T-cell expressed and presumably secreted) as a potential downstream mediator of TGF-beta signaling important for lung adenocarcinoma invasion. We specifically hypothesized that RANTES is required for lung cancer invasion and progression in TGFbRII-repressed cells. We examined invasion in TGFbRII-deficient cells treated with two inhibitors of RANTES activity, Met-RANTES and a CCR5 receptor-blocking antibody. Both treatments blocked invasion induced by TGFbRII knockdown. In addition, we examined the clinical relevance of the RANTES-CCR5 pathway by establishing an association of RANTES and CCR5 immunostaining with invasion and outcome in human lung adenocarcinoma specimens. Moderate or high expression of both RANTES and CCR5 was associated with an increased risk for death, P = 0.014 and 0.002, respectively. In conclusion, our studies indicate RANTES signaling is required for invasion in TGFbRII-deficient cells and suggest a role for CCR5 inhibition in lung adenocarcinoma prevention and treatment.	[Borczuk, A. C.] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; [Papanikolaou, N.; Toonkel, R. L.; Sole, M.; Powell, C. A.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; [Gorenstein, L. A.; Ginsburg, M. E.; Sonett, J. R.] Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; [Friedman, R. A.] Columbia Univ Coll Phys & Surg, Dept Biomed Informat, New York, NY 10032 USA; [Friedman, R. A.; Powell, C. A.] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Powell, CA (corresponding author), Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, 630 W,168th St,Box 91, New York, NY 10032 USA.	cap6@columbia.edu	BORCZUK, alain/AHA-5172-2022; Powell, Charles A/C-8663-2011; Borczuk, Alain/AAI-8226-2021; Borczuk, Alain/AFU-5278-2022	Powell, Charles A/0000-0003-3509-891X; Borczuk, Alain/0000-0001-6807-8064; Borczuk, Alain/0000-0001-6807-8064; toonkel, rebecca/0000-0001-8339-2107	NATIONAL CANCER INSTITUTE [R01CA120174] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA120174-02, 1R01CA120174, R01 CA120174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azenshtein E, 2002, CANCER RES, V62, P1093; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Biswas S, 2004, CANCER RES, V64, P4687, DOI 10.1158/0008-5472.CAN-03-3255; Borczuk AC, 2005, AM J RESP CRIT CARE, V172, P729, DOI 10.1164/rccm.200504-615OC; Borczuk Alain C, 2007, Proc Am Thorac Soc, V4, P127, DOI 10.1513/pats.200607-143JG; Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301; Culley FJ, 2006, J VIROL, V80, P8151, DOI 10.1128/JVI.00496-06; Fatkenheuer G, 2005, NAT MED, V11, P1170, DOI 10.1038/nm1319; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gustin JA, 2004, AM J PHYSIOL-CELL PH, V286, pC547, DOI 10.1152/ajpcell.00332.2002; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Jang SB, 2002, MOL CELLS, V14, P35; Luboshits G, 1999, CANCER RES, V59, P4681; Ma B, 2005, J CLIN INVEST, V115, P3460, DOI 10.1172/JCI24858; Moran CJ, 2002, CLIN CANCER RES, V8, P3803; Nakazaki Y, 2006, MOL THER, V14, P599, DOI 10.1016/j.ymthe.2006.04.014; Nissinen R, 2003, J RHEUMATOL, V30, P1928; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Remmelink M, 2005, INT J ONCOL, V26, P247; Sakurai H, 2004, AM J SURG PATHOL, V28, P198, DOI 10.1097/00000478-200402000-00007; Schwabe RF, 2003, AM J PHYSIOL-GASTR L, V285, pG949, DOI 10.1152/ajpgi.00215.2003; Vaday GG, 2006, PROSTATE, V66, P124, DOI 10.1002/pros.20306; van Deventer HW, 2005, CANCER RES, V65, P3374, DOI 10.1158/0008-5472.CAN-04-2616	24	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					557	564		10.1038/sj.onc.1210662	http://dx.doi.org/10.1038/sj.onc.1210662			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653092	Green Accepted			2022-12-28	WOS:000252426100016
J	Costoya, JA; Hobbs, RM; Pandolfi, PP				Costoya, J. A.; Hobbs, R. M.; Pandolfi, P. P.			Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation	ONCOGENE			English	Article						POZ and Kruppel-type zinc finger domains; transcriptional repression; cell cycle; cyclin-dependent kinases; PEST domains; ubiquitination	HEMATOPOIETIC STEM-CELLS; TRANSCRIPTIONAL REPRESSION; PROTEIN PLZF; DNA-BINDING; GERM-CELLS; EXPRESSION; GENE; PROLIFERATION; GROWTH	Acute promyelocytic leukemia is associated with chromosomal translocations that involve the RAR alpha gene and several distinct loci producing a variety of fusion proteins. One such fusion partner is promyelocytic leukemia zinc finger gene ( PLZF), a member of the POK ( POZ and Kruppel) family of transcriptional repressors that is a key developmental regulator, stem cell maintenance factor and tumor suppressor. Overexpression of PLZF has been shown to induce cell cycle arrest at the G(1) to S transition and repress the expression of key pro-proliferative genes such as CCNA2 and MYC. However, given this data suggesting an important growth inhibitory role for PLZF, relatively little is known regarding regulation of its activity. Here we show that the main cyclin-dependent kinase involved at the G1 to S transition ( CDK2) phosphorylates PLZF at two consensus sites found within PEST domains present in the hinge region of the protein. This phosphorylation triggers the ubiquitination and subsequent degradation of PLZF, which impairs PLZF transcriptional repression ability and antagonizes its growth inhibitory effects. This critical mechanism of PLZF regulation may thus be relevant for cell cycle progression during the development and the pathogenesis of human cancer.	[Costoya, J. A.; Hobbs, R. M.; Pandolfi, P. P.] Mem Sloan Kettering Canc Ctr, Dept Pathol, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Genet Program, NRB-1036E,330 Brookline Ave, Boston, MA 02215 USA.	ppandolf@bidmc.harvard.edu	Costoya, Jose A./B-2718-2009; Hobbs, Robin/I-2577-2014	Costoya, Jose A./0000-0003-3691-6419; Hobbs, Robin/0000-0002-3853-2614	NCI NIH HHS [CA-71692] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071692, R37CA071692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BONIFACINO JS, 2000, CURRENT PROTOCOLS CE; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Chao TT, 2007, BIOCHEM BIOPH RES CO, V358, P475, DOI 10.1016/j.bbrc.2007.04.157; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Costoya JA, 2001, CURR OPIN HEMATOL, V8, P212, DOI 10.1097/00062752-200107000-00006; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Filipponi D, 2007, MOL CELL BIOL, V27, P6770, DOI 10.1128/MCB.00479-07; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kang SI, 2003, J BIOL CHEM, V278, P51479, DOI 10.1074/jbc.M309237200; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Piazza F, 2004, MOL CELL BIOL, V24, P10456, DOI 10.1128/MCB.24.23.10456-10469.2004; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Senbonmatsu T, 2003, EMBO J, V22, P6471, DOI 10.1093/emboj/cdg637; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	31	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3789	3796		10.1038/onc.2008.7	http://dx.doi.org/10.1038/onc.2008.7			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246121				2022-12-28	WOS:000256904700003
J	Kawase, T; Ichikawa, H; Ohta, T; Nozaki, N; Tashiro, F; Ohki, R; Taya, Y				Kawase, T.; Ichikawa, H.; Ohta, T.; Nozaki, N.; Tashiro, F.; Ohki, R.; Taya, Y.			p53 target gene AEN is a nuclear exonuclease required for p53-dependent apoptosis	ONCOGENE			English	Article						p53; exonuclease; apoptosis; p53 phosphorylation	DNA-DAMAGE; NUCLEOLAR LOCALIZATION; CANDIDATE MEDIATOR; IONIZING-RADIATION; PHOSPHORYLATION; STRESS; ROLES; DEGRADATION; DOMAINS; POINT	DNA degradation is one of the biochemical hallmarks detected in apoptotic cells, and several nucleases have been reported to function cooperatively in this process. It has also been suggested that different sets of nucleases are activated by different stimuli, and induce distinct patterns of DNA degradation. Here we report that apoptosis-enhancing nuclease ( AEN) is a novel direct target gene of p53. AEN is induced by p53 with various DNA damage, and its expression is regulated by the phosphorylation status of p53. We demonstrate that AEN is a typical exonuclease with conserved exonuclease domains Exo I-III, and it targets both single- and double-stranded DNA and RNA. AEN induces apoptosis by itself, and the conserved domains are essential for both AEN nuclease activity and its apoptosis-inducing ability. AEN possesses nuclear and nucleolar localization signals, and it translocates from the nucleolus to nucleoplasm upon apoptosis induction. We also show the dislocation of nucleophosmin in conjunction with the translocation of AEN to the nucleoplasm, indicating the ability of AEN in nucleolus disruption. In addition, AEN is shown to be required for efficient DNA fragmentation in p53-dependent apoptosis. These results suggest that AEN is an important downstream mediator of p53 in apoptosis induction.	[Ohki, R.] Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; [Ichikawa, H.] Natl Canc Ctr, Res Inst, Canc Transcriptome Project, Tokyo 1040045, Japan; [Ohta, T.] Natl Canc Ctr, Res Inst, Ctr Med Genom, Tokyo 1040045, Japan; [Nozaki, N.] Kanagawa Dent Coll, Dept Biochem & Mol Biol, Kanagawa, Japan; [Kawase, T.; Tashiro, F.] Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Chiba, Japan; [Kawase, T.; Ohki, R.; Taya, Y.] Japan Sci & Technol Agcy, SORST, Chiba, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Kanagawa Dental College; Tokyo University of Science; Japan Science & Technology Agency (JST)	Ohki, R (corresponding author), Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rohki@gan2.res.ncc.go.jp			Direct For Mathematical & Physical Scien [1041698] Funding Source: National Science Foundation	Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Houseley J, 2006, NAT REV MOL CELL BIO, V7, P529, DOI 10.1038/nrm1964; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Karni-Schmidt O, 2007, ONCOGENE, V26, P3878, DOI 10.1038/sj.onc.1210162; Kawane K, 2006, NATURE, V443, P998, DOI 10.1038/nature05245; Kurki S, 2004, CELL CYCLE, V3, P976; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee JH, 2005, BIOCHEM BIOPH RES CO, V337, P39, DOI 10.1016/j.bbrc.2005.08.264; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; Ohki R, 2007, CANCER SCI, V98, P189, DOI 10.1111/j.1349-7006.2006.00375.x; Parrish JZ, 2006, CHROMOSOMA, V115, P89, DOI 10.1007/s00412-005-0038-0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rowland RRR, 2003, VIRUS RES, V95, P23, DOI 10.1016/S0168-1702(03)00161-8; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Samejima K, 2005, NAT REV MOL CELL BIO, V6, P677, DOI 10.1038/nrm1715; Schaetzlein S, 2007, CELL, V130, P863, DOI 10.1016/j.cell.2007.08.029; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; TOUNEKTI O, 1995, EXP CELL RES, V217, P506, DOI 10.1006/excr.1995.1116; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	40	51	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3797	3810		10.1038/onc.2008.32	http://dx.doi.org/10.1038/onc.2008.32			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264133				2022-12-28	WOS:000256904700004
J	McCormack, E; Bruserud, O; Gjertsen, BT				McCormack, E.; Bruserud, O.; Gjertsen, B. T.			Review: genetic models of acute myeloid leukaemia	ONCOGENE			English	Review						acute myelogenous leukaemia; mouse; transgenic; retroviral transduction; homologous recombination; genetics	PML-RAR-ALPHA; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; INTERNAL TANDEM DUPLICATION; RECEPTOR TYROSINE KINASE; BONE-MARROW-CELLS; ONCOGENIC K-RAS; TRANSGENIC MICE; FUSION GENE; RETINOIC ACID	The use of genetically engineered mice ( GEM) have been critical in understanding disease states such as cancer, and none more so than acute myelogenous leukaemia ( AML), a disease characterized by over 100 distinct chromosomal translocations. A substantial proportion of cases exhibiting recurrent reciprocal translocations at diagnosis, such as t( 8; 21) or t( 15; 17) have been exhaustively studied and are currently employed in clinical diagnosis. However, a definitive conclusion regarding the leukaemogenic potential of defined transgenes for this disease remains elusive. While it is increasingly apparent that a number of cooperating mutations are necessary to develop a leukaemic phenotype, the number of models reflecting these synergisms remains few. Furthermore, little emphasis has been paid to the effect of chromosomal translocations other than recurrent genetic abnormalities, with no models reflecting the multiple abnormalities observed in high-risk cases of AML accounting for 8-10% of adult AML. Here we review the differing technologies employed in generation of GEM of AML. We discuss the relevance of GEM AML from embryonic stem cell-mediated ( for example retinoic acid receptor-alpha fusions and AML1/ ETO) models; through to the valuable retroviral-mediated gene transfer models. The latter have been used to great effect in de. ning the transforming properties of chromosomal translocation products such as MLL ( found in 5 - 6% of all AML cases) and NUP98 ( denoting poor prognosis in therapy-related disease) and particularly when co-transduced with bad prognostic factors such as Flt3 mutations. Finally, we comment on the emergence of newer transduction technologies, which can regulate the level of expression to defined cell lineages in both primary murine and human xenografts, and discuss how combining multiple genetic modalities, more relevant models of this complex disease are being generated.	[McCormack, E.; Bruserud, O.; Gjertsen, B. T.] Univ Bergen, Haematol Sect, Inst Med, N-5021 Bergen, Norway	University of Bergen	Gjertsen, BT (corresponding author), Univ Bergen, Dept Internal Med, Haukeland Univ Hosp, Haematol Sect, N-5021 Bergen, Norway.	bjorn.gjertsen@med.uib.no	Gjertsen, Bjørn T/AAP-3281-2020; Gjertsen, Bjorn T/O-1542-2015; Cormack, Emmet Mc/D-2922-2012	Gjertsen, Bjørn T/0000-0001-9358-9704; Gjertsen, Bjorn T/0000-0001-9358-9704; Cormack, Emmet Mc/0000-0002-7621-4625				Bockamp E, 2002, PHYSIOL GENOMICS, V11, P115, DOI 10.1152/physiolgenomics.00067.2002; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Bruserud O, 2003, HAEMATOLOGICA, V88, P416; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chan IT, 2006, BLOOD, V108, P1708, DOI 10.1182/blood-2006-04-015040; Chan IT, 2004, CELL CYCLE, V3, P536; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Christianson SW, 1997, J IMMUNOL, V158, P3578; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; de Guzman CG, 2003, BLOOD CELL MOL DIS, V30, P201, DOI 10.1016/S1079-9796(03)00025-1; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Fenske TS, 2004, P NATL ACAD SCI USA, V101, P15184, DOI 10.1073/pnas.0400751101; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisolano JL, 2003, P NATL ACAD SCI USA, V100, P9506, DOI 10.1073/pnas.1531730100; GRISOLANO JL, 1994, P NATL ACAD SCI USA, V91, P8989, DOI 10.1073/pnas.91.19.8989; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Guillemin MC, 2002, J EXP MED, V196, P1373, DOI 10.1084/jem.20021129; Gurevich RM, 2004, BLOOD, V104, P1127, DOI 10.1182/blood-2003-10-3550; Harris N L, 2000, Hematol J, V1, P53, DOI 10.1038/sj.thj.6200013; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; JAENISCH R, 1980, CELL, V19, P181, DOI 10.1016/0092-8674(80)90399-2; Jaisser F, 2000, J AM SOC NEPHROL, V11, pS95; Kawagoe H, 2005, BLOOD, V106, P4278, DOI 10.1182/blood-2005-04-1674; Kelly LM, 2002, P NATL ACAD SCI USA, V99, P8283, DOI 10.1073/pnas.122233699; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kundu M, 2002, BLOOD, V100, P2449, DOI 10.1182/blood-2002-04-1064; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lee BH, 2005, ONCOGENE, V24, P7882, DOI 10.1038/sj.onc.1208933; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Marcucci G, 2007, J CLIN ONCOL, V25, P3337, DOI 10.1200/JCO.2007.10.8720; Mc Cormack E, 2005, LEUKEMIA, V19, P687, DOI 10.1038/sj.leu.2403670; McCormack E, 2007, MOL IMAGING, V6, P193, DOI 10.2310/7290.2007.00016; Minucci S, 2002, BLOOD, V100, P2989, DOI 10.1182/blood-2001-11-0089; Mrozek K, 2001, BEST PRACT RES CL HA, V14, P19, DOI 10.1053/beha.2000.0114; Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7; Mueller BU, 2006, BLOOD, V107, P3330, DOI 10.1182/blood-2005-07-3068; Muller U, 1999, MECH DEVELOP, V82, P3, DOI 10.1016/S0925-4773(99)00021-0; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Ono R, 2005, J CLIN INVEST, V115, P919, DOI 10.1172/JCI200522725; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Rhoades KL, 2000, BLOOD, V96, P2108; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Ryding ADS, 2001, J ENDOCRINOL, V171, P1, DOI 10.1677/joe.0.1710001; Sanz MA, 2005, ONCOLOGIST, V10, P806, DOI 10.1634/theoncologist.10-10-806; Scheller M, 1999, BLOOD, V94, P3764, DOI 10.1182/blood.V94.11.3764.423k03_3764_3771; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shankar DB, 2005, CANCER-AM CANCER SOC, V104, P1819, DOI 10.1002/cncr.21401; Shen SW, 2004, EXP HEMATOL, V32, P852, DOI 10.1016/j.exphem.2004.06.001; Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; So CW, 2004, BLOOD, V103, P3192, DOI 10.1182/blood-2003-10-3722; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Sohal J, 2003, BLOOD, V101, P3188, DOI 10.1182/blood-2002-06-1800; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Sukhai MA, 2004, ONCOGENE, V23, P665, DOI 10.1038/sj.onc.1207073; Testa G, 2000, EMBO REP, V1, P120, DOI 10.1093/embo-reports/kvd035; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Van der Weyden L, 2002, PHYSIOL GENOMICS, V11, P133, DOI 10.1152/physiolgenomics.00074.2002; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang ZG, 1998, SCIENCE, V279, P1547; Warner JK, 2005, LEUKEMIA, V19, P1794, DOI 10.1038/sj.leu.2403917; Westervelt P, 2003, BLOOD, V102, P1857, DOI 10.1182/blood-2002-12-3779; Wheatley K, 1999, BRIT J HAEMATOL, V107, P69, DOI 10.1046/j.1365-2141.1999.01684.x; Wunderlich M, 2006, BLOOD, V108, P1690, DOI 10.1182/blood-2005-12-012773; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yang R, 1999, BLOOD, V93, P2067; Yang YD, 2002, CANCER RES, V62, P2232; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yu YJ, 2001, NAT REV GENET, V2, P780, DOI 10.1038/35093564; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhu J, 2007, CANCER CELL, V12, P23, DOI 10.1016/j.ccr.2007.06.004	114	35	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3765	3779		10.1038/onc.2008.16	http://dx.doi.org/10.1038/onc.2008.16			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264136				2022-12-28	WOS:000256904700001
J	Tucker, LA; Zhang, Q; Sheppard, GS; Lou, P; Jiang, F; McKeegan, E; Lesniewski, R; Davidsen, SK; Bell, RL; Wang, J				Tucker, L. A.; Zhang, Q.; Sheppard, G. S.; Lou, P.; Jiang, F.; McKeegan, E.; Lesniewski, R.; Davidsen, S. K.; Bell, R. L.; Wang, J.			Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation	ONCOGENE			English	Article						MetAP2; transformation; proliferation; IHC	ANGIOGENESIS INHIBITOR; CLINICAL DEVELOPMENT; TNP-470 AGM-1470; GROWTH ARREST; AGENT TNP-470; TUMOR-GROWTH; FUMAGILLIN; PROTEIN; TARGET; CANCER	Methionine aminopeptidase-2 (MetAP2) processes N-terminal methionine from nascent cellular proteins. Inhibition of MetAP2 has been shown to block angiogenesis and suppress tumor growth in preclinical tumor models. However, the biological role of MetAP2 in cancer is not well understood. We examined the effect of three distinct chemical classes of MetAP2 inhibitors on the growth of a panel of human cancer cells in vitro. All MetAP2 inhibitors caused inhibition of tumor cell growth in both anchorage-dependent and, particularly, in anchorage-independent manner. These data prompted us to examine the possible roles of MetAP2 in cancers. Ectopic expression of MetAP2 in NIH-3T3 cells caused transformation, evidenced by the formation of foci in monolayer culture and growth of large colonies in soft agar. Overexpression of MetAP2 in an immortalized bronchial epithelial cell line NL20 accelerated growth. These phenotypes induced by the overexpression of MetAP2 were reversed by the treatment with MetAP2 inhibitors, indicating that the catalytic function of MetAP2 was essential. Accordingly, overexpression of a catalytically inactive MetAP2 resulted in growth retardation of HT1080 tumor cells, suggesting a dominant-negative role of the inactive MetAP2 mutant. Finally, we analysed the expression of MetAP2 in patient cancer samples by immunohistochemistry. Moderate-to-high staining was identified in the majority of breast, colon, lung, ovarian and prostate carcinomas examined. These data suggest that MetAP2 plays an important role in tumor cell growth and may contribute to tumorigenesis.	[Tucker, L. A.; Zhang, Q.; Sheppard, G. S.; Lou, P.; Jiang, F.; McKeegan, E.; Lesniewski, R.; Davidsen, S. K.; Bell, R. L.; Wang, J.] Abbott Labs, GPRD, Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories	Wang, J (corresponding author), Abbott Labs, GPRD, Canc Res, R47A,AP9-2124,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	jieyi.wang@abbott.com						Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009; Bernier SG, 2005, J CELL BIOCHEM, V95, P1191, DOI 10.1002/jcb.20493; Bradshaw RA, 2002, ESSAYS BIOCHEM, V38, P65, DOI 10.1042/bse0380065; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Castronovo V, 1996, EUR J CANCER, V32A, P2520, DOI 10.1016/S0959-8049(96)00388-7; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; Datta B, 2000, BIOCHIMIE, V82, P95, DOI 10.1016/S0300-9084(00)00383-7; Datta B, 1999, EXP CELL RES, V246, P376, DOI 10.1006/excr.1998.4313; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; Hannig G, 2006, INT J ONCOL, V28, P955; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Homsi J, 2007, EXPERT OPIN THER TAR, V11, P91, DOI 10.1517/14728222.11.1.91; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Kanno T, 2002, LAB INVEST, V82, P893, DOI 10.1097/01.LAB.0000020419.25365.C4; Kruger EA, 2000, EXPERT OPIN INV DRUG, V9, P1383, DOI 10.1517/13543784.9.6.1383; KUSAKA M, 1994, BRIT J CANCER, V69, P212, DOI 10.1038/bjc.1994.41; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Leszczyniecka M, 2006, ONCOGENE, V25, P3471, DOI 10.1038/sj.onc.1209383; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mieulet V, 2007, AM J PHYSIOL-CELL PH, V293, pC712, DOI 10.1152/ajpcell.00499.2006; Resh MD, 2004, SUB CELL BIOCHEM, V37, P217; Selvakumar P, 2004, CLIN CANCER RES, V10, P2771, DOI 10.1158/1078-0432.CCR-03-0218; Sheppard GS, 2006, J MED CHEM, V49, P3832, DOI 10.1021/jm0601001; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Varshavsky A, 2005, TRENDS BIOCHEM SCI, V30, P283, DOI 10.1016/j.tibs.2005.04.005; Vetro JA, 2005, J CELL BIOCHEM, V94, P656, DOI 10.1002/jcb.20285; Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D; Wang JY, 2003, CANCER RES, V63, P7861; Wang JY, 2003, BIOCHEMISTRY-US, V42, P5035, DOI 10.1021/bi020670c; WU SY, 1993, J BIOL CHEM, V268, P10796; Yang G, 2001, BIOCHEMISTRY-US, V40, P10645, DOI 10.1021/bi010806r; Yeh JRJ, 2006, P NATL ACAD SCI USA, V103, P10379, DOI 10.1073/pnas.0511313103; Yeh JRJ, 2000, P NATL ACAD SCI USA, V97, P12782, DOI 10.1073/pnas.97.23.12782; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427	37	32	37	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					3967	3976		10.1038/onc.2008.14	http://dx.doi.org/10.1038/onc.2008.14			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264137				2022-12-28	WOS:000257089000008
J	Wheeler, DL; Huang, S; Kruser, TJ; Nechrebecki, MM; Armstrong, EA; Benavente, S; Gondi, V; Hsu, KT; Harari, PM				Wheeler, D. L.; Huang, S.; Kruser, T. J.; Nechrebecki, M. M.; Armstrong, E. A.; Benavente, S.; Gondi, V.; Hsu, K-T; Harari, P. M.			Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members	ONCOGENE			English	Article						EGFR; cetuximab; acquired resistance	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; SQUAMOUS-CELL CARCINOMA; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; DOWN-REGULATION; CANCER-CELLS; GEFITINIB; EGFR; HYPOPHOSPHORYLATION	The epidermal growth factor receptor ( EGFR) is a central regulator of proliferation and progression in human cancers. Five EGFR inhibitors, two monoclonal antibodies and three TKIs, have recently gained FDA approval in oncology ( cetuximab, panitumumab, erlotinib, gefitinib and lapatinib). These strategies of EGFR inhibition demonstrate major tumor regressions in approximately 10-20% of advanced cancer patients. However, many tumors eventually manifest acquired resistance to treatment. In this study we established and characterized a model to study molecular mechanisms of acquired resistance to the EGFR monoclonal antibody cetuximab. Using high-throughput screening we examined the activity of 42 receptor tyrosine kinases in resistant tumor cells following chronic exposure to cetuximab. Cells developing acquired resistance to cetuximab exhibited increased steady-state EGFR expression secondary to alterations in trafficking and degradation. In addition, cetuximab-resistant cells manifested strong activation of HER2, HER3 and cMET. EGFR upregulation promoted increased dimerization with HER2 and HER3 leading to their transactivation. Blockade of EGFR and HER2 led to loss of HER3 and PI( 3) K/Akt activity. These data suggest that acquired resistance to cetuximab is accompanied by dysregulation of EGFR internalization/degradation and subsequent EGFR-dependent activation of HER3. Taken together these findings suggest a rationale for the clinical evaluation of combinatorial anti-HER targeting approaches in tumors manifesting acquired resistance to cetuximab.	[Wheeler, D. L.; Huang, S.; Kruser, T. J.; Nechrebecki, M. M.; Armstrong, E. A.; Benavente, S.; Gondi, V.; Hsu, K-T; Harari, P. M.] Univ Wisconsin, Ctr Comprehens Canc, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Harari, PM (corresponding author), Univ Wisconsin, Ctr Comprehens Canc, Dept Human Oncol, Sch Med & Publ Hlth, 600 Highland Ave, Madison, WI 53792 USA.	harari@humonc.wisc.edu	Wheeler, Deric/B-7175-2013; Kruser, Timothy/AAF-2155-2020; Benavente, Sergi/B-6470-2016	Wheeler, Deric/0000-0001-5915-3675; Kruser, Timothy/0000-0002-6006-2372; Benavente, Sergi/0000-0002-2700-3522	NATIONAL CANCER INSTITUTE [R01CA113448] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 113448-01, R01 CA113448, R01 CA113448-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; BENAVENTE S, 2004, AACR M ABSTRACTS, V2004, pA1230; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Christensen JG, 2003, CANCER RES, V63, P7345; Ciardiello F, 2004, CLIN CANCER RES, V10, P784, DOI 10.1158/1078-0432.CCR-1100-03; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Erjala K, 2006, CLIN CANCER RES, V12, P4103, DOI 10.1158/1078-0432.CCR-05-2404; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Furukawa M, 2007, DNA CELL BIOL, V26, P178, DOI 10.1089/dna.2006.0573; GONDI V, 2006, AACR M ABSTRACTS, V2006, pB294; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Han W, 2006, CANCER BIOL THER, V5, P1361, DOI 10.4161/cbt.5.10.3226; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Mendelsohn J, 2003, CANCER IMMUNOL IMMUN, V52, P342, DOI 10.1007/s00262-002-0354-7; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Reid A, 2007, EUR J CANCER, V43, P481, DOI 10.1016/j.ejca.2006.11.007; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Sequist LV, 2007, J CLIN ONCOL, V25, P587, DOI 10.1200/JCO.2006.07.3585; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	30	415	437	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3944	3956		10.1038/onc.2008.19	http://dx.doi.org/10.1038/onc.2008.19			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18297114	Green Accepted			2022-12-28	WOS:000257089000006
J	Courtois-Cox, S; Jones, SL; Cichowski, K				Courtois-Cox, S.; Jones, S. L.; Cichowski, K.			Many roads lead to oncogene-induced senescence	ONCOGENE			English	Review						senescence; DNA damage; heterochromatic foci; negative feedback; Ras; NF1; Raf; PTEN	DAMAGE SIGNALING PATHWAY; K-RAS ONCOGENE; CELLULAR SENESCENCE; IN-VIVO; HETEROCHROMATIN FORMATION; TYPE-1 NEUROFIBROMATOSIS; PREMATURE SENESCENCE; TUMOR SUPPRESSION; HUMAN-FIBROBLASTS; MOUSE MODELS	Oncogene-induced senescence is a mechanism of tumor suppression that restricts the progression of benign tumors. Important advances have been made toward elucidating the mechanisms that regulate this response; however, there is presently no unified model that integrates all current findings. DNA damage, replicative stress, reactive oxygen species, heterochromatin formation and negative feedback signaling networks have all been proposed to play an integral role in promoting senescence in response to various oncogenic insults. In all cases, these signals have been shown to function through Rb and p53, but utilize different intermediaries. Thus, it appears that senescence is not triggered by a single, linear series of events, but instead is regulated by a complex signaling network. Accordingly, multiple proteins may cooperate to establish a senescence response, but the limiting signal(s) may be dictated by the initiating genetic alteration and/or tissue type. This review will focus on integrating current models and will highlight data that provide new insight into the signals that function to suppress human tumor development.	[Courtois-Cox, S.] Harvard Univ, Dept Med, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Cichowski, K (corresponding author), Harvard Univ, Dept Med, Sch Med, 458c NRB,77 Louis Pasteur Ave, Boston, MA 02115 USA.	kcichowski@rics.bwh.harvard.edu						Adams PD, 2007, GENE, V397, P84, DOI 10.1016/j.gene.2007.04.020; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Brachmann SA, 2005, MOL CELL BIOL, V25, P2593, DOI 10.1128/MCB.25.7.2593-2606.2005; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brems H, 2007, NAT GENET, V39, P1120, DOI 10.1038/ng2113; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Frippiat C, 2000, EXP GERONTOL, V35, P733, DOI 10.1016/S0531-5565(00)00167-4; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hemann MT, 2007, GENE DEV, V21, P1, DOI 10.1101/gad.1514207; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Holtkamp N, 2004, ACTA NEUROPATHOL, V107, P159, DOI 10.1007/s00401-003-0797-8; Kim CFB, 2005, COLD SH Q B, V70, P241, DOI 10.1101/sqb.2005.70.037; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Kim R, 2006, CANCER BIOL THER, V5, P1429, DOI 10.4161/cbt.5.11.3456; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Meier F, 2005, FRONT BIOSCI-LANDMRK, V10, P2986, DOI 10.2741/1755; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Minamino T, 2003, CIRCULATION, V108, P2264, DOI 10.1161/01.CIR.0000093274.82929.22; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Ogawa K, 2005, ONCOL REP, V14, P1481; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Ray S, 2006, CANCER RES, V66, P6598, DOI 10.1158/0008-5472.CAN-05-3115; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Shaw AT, 2007, GENE DEV, V21, P694, DOI 10.1101/gad.1526207; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wu CW, 2004, NATURE, V432, P640, DOI 10.1038/nature03173; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Ye XF, 2007, MOL CELL, V27, P183, DOI 10.1016/j.molcel.2007.05.034	57	267	271	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2801	2809		10.1038/sj.onc.1210950	http://dx.doi.org/10.1038/sj.onc.1210950			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18193093				2022-12-28	WOS:000255502500001
J	Silva, FP; Hamamoto, R; Kunizaki, M; Tsuge, M; Nakamura, Y; Furukawa, Y				Silva, F. Pittella; Hamamoto, R.; Kunizaki, M.; Tsuge, M.; Nakamura, Y.; Furukawa, Y.			Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells	ONCOGENE			English	Article						SMYD3; methyltransferase; cancer	SET DOMAIN; HISTONE METHYLATION	Histone methylation is involved in the regulation of gene expression and DNA replication through alteration of chromatin structure. We earlier showed that SMYD3, a histone H3-lysine 4-specific methyltransferase, is frequently upregulated in human colorectal, liver and breast cancer compared to their matched non-cancerous cells, and that its activity is associated with the growth of these tumors. In the present study, we found that human cancer cells express both the full-length and a cleaved form of SMYD3 protein. Amino acid sequence analysis uncovered that the cleaved form lacks the 34 amino acids in the N-terminal region of the full-length protein. Interestingly, the cleaved protein and mutant protein containing substitutions at glycines 15 and 17, two highly conserved amino acids in the N-terminal region, revealed a higher histone methyltransferase (HMTase) activity compared to the full-length protein. Furthermore, the N-terminal region is responsible for the association with heat shock protein 90 alpha (HSP90 alpha). These data indicate that the N-terminal region plays an important role for the regulation of its methyltransferase activity and suggest that a structural change of the protein through the cleavage of the region or interaction with HSP90a may be involved in the modulation. These findings may help for a better understanding of the mechanisms that modulate the HMTase activity of SMYD3, and contribute to the development of novel anticancer drugs targeting SMYD3 methyltransferase activity.	[Furukawa, Y.] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, Tokyo 1088639, Japan; [Silva, F. Pittella; Hamamoto, R.; Kunizaki, M.; Tsuge, M.; Nakamura, Y.] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan	University of Tokyo; University of Tokyo	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Promot Genome Based Med Project,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	furukawa@ims.u-tokyo.ac.jp	Hamamoto, Ryuji/AAF-9600-2019; Silva, Fabio Pittella/B-2621-2013; Tsuge, Masataka/G-5246-2019	Hamamoto, Ryuji/0000-0002-2632-1334; Silva, Fabio Pittella/0000-0002-9644-7098; Tsuge, Masataka/0000-0001-7591-8287				Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x; Jacobs SA, 2002, NAT STRUCT BIOL, V9, P833, DOI 10.1038/nsb861; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Marmorstein R, 2003, TRENDS BIOCHEM SCI, V28, P59, DOI 10.1016/S0968-0004(03)00007-0; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; Tresaugues L, 2006, J MOL BIOL, V359, P1170, DOI 10.1016/j.jmb.2006.04.050; Tsuge M, 2005, NAT GENET, V37, P1104, DOI 10.1038/ng1638; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Zhang X, 2002, CELL, V111, P117, DOI 10.1016/S0092-8674(02)00999-6	18	47	50	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2008	27	19					2686	2692		10.1038/sj.onc.1210929	http://dx.doi.org/10.1038/sj.onc.1210929			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998933				2022-12-28	WOS:000255259500003
J	Endo, Y; Sakai, R; Ouchi, M; Onimatsu, H; Hioki, M; Kagawa, S; Uno, F; Watanabe, Y; Urata, Y; Tanaka, N; Fujiwara, T				Endo, Y.; Sakai, R.; Ouchi, M.; Onimatsu, H.; Hioki, M.; Kagawa, S.; Uno, F.; Watanabe, Y.; Urata, Y.; Tanaka, N.; Fujiwara, T.			Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation	ONCOGENE			English	Article						adenovirus; telomerase; dendritic cell; uric acid; danger signal	DENDRITIC CELLS; URIC-ACID; CANCER; PA28	Dendritic cells ( DCs) are the most potent antigen-presenting cells and acquire cellular antigens and danger signals from dying cells to initiate antitumor immune responses via direct cell- to- cell interaction and cytokine production. The optimal forms of tumor cell death for priming DCs for the release of danger signals are not fully understood. OBP- 301 ( Telomelysin) is a telomerase-specific replication- competent adenovirus that induces selective E1 expression and exclusively kills human cancer cells. Here, we show that OBP- 301 replication produced the endogenous danger signaling molecule, uric acid, in infected human tumor cells, which in turn stimulated DCs to produce interferon-gamma ( IFN-gamma) and interleukin 12 ( IL- 12). Subsequently, IFN-gamma release upregulated the endogenous expression of the proteasome activator PA28 in tumor cells and resulted in the induction of cytotoxic T- lymphocytes. Our data suggest that virus- mediated oncolysis might be the effective stimulus for immature DCs to induce specific activity against human cancer cells.	[Endo, Y.; Sakai, R.; Hioki, M.; Kagawa, S.; Uno, F.; Fujiwara, T.] Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama 7008558, Japan; [Endo, Y.; Sakai, R.; Hioki, M.; Kagawa, S.; Uno, F.; Tanaka, N.; Fujiwara, T.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg, Div Surg Oncol, Okayama, Japan; [Ouchi, M.; Onimatsu, H.; Watanabe, Y.; Urata, Y.] Oncolys BioPharma Inc, Tokyo, Japan	Okayama University; Okayama University; Oncolys BioPharma	Fujiwara, T (corresponding author), Okayama Univ Hosp, Ctr Gene & Cell Therapy, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp	Kagawa, Shunsuke/B-2189-2011	Kagawa, Shunsuke/0000-0002-3610-8211				Aliberti J, 2003, J IMMUNOL, V170, P5349, DOI 10.4049/jimmunol.170.11.5349; Bartholomae WC, 2004, J IMMUNOL, V173, P1012, DOI 10.4049/jimmunol.173.2.1012; Glantzounis GK, 2005, CURR PHARM DESIGN, V11, P4145, DOI 10.2174/138161205774913255; Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499; Hu DE, 2004, CANCER RES, V64, P5059, DOI 10.1158/0008-5472.CAN-04-1586; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Lenaerts L, 2006, ANTIVIR RES, V71, P172, DOI 10.1016/j.antiviral.2006.04.007; LINDENMANN J, 1967, J EXP MED, V126, P93, DOI 10.1084/jem.126.1.93; Manjili MH, 2005, IMMUNOBIOLOGY, V210, P295, DOI 10.1016/j.imbio.2005.04.002; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Sijts A, 2002, MOL IMMUNOL, V39, P165, DOI 10.1016/S0161-5890(02)00099-8; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Sun Y, 2002, CANCER RES, V62, P2875; Taki M, 2005, ONCOGENE, V24, P3130, DOI 10.1038/sj.onc.1208460; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Watanabe T, 2006, EXP CELL RES, V312, P256, DOI 10.1016/j.yexcr.2005.10.026	16	72	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2375	2381		10.1038/sj.onc.1210884	http://dx.doi.org/10.1038/sj.onc.1210884			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17982491	Green Submitted			2022-12-28	WOS:000254844900002
J	Ozen, M; Creighton, CJ; Ozdemir, M; Ittmann, M				Ozen, M.; Creighton, C. J.; Ozdemir, M.; Ittmann, M.			Widespread deregulation of microRNA expression in human prostate cancer	ONCOGENE			English	Article						prostate cancer; miRNA; microarray; EIF4EBP1	BREAST-CANCER; SIGNATURE; TARGETS; SEL1L	MicroRNAs (miRNAs) are small regulatory RNAs that can regulate gene expression by binding to mRNA sequences and repressing target-gene expression post-transcriptionally, either by inhibiting translation or promoting RNA degradation. We have analysed expression of 328 known and 152 novel human miRNAs in 10 benign peripheral zone tissues and 16 prostate cancer tissues using microarrays and found widespread, but not universal, downregulation of miRNAs in clinically localized prostate cancer relative to benign peripheral zone tissue. These findings have been verified by real-time RT-PCR assays on select miRNAs, including miR-125b, miR-145 and let-7c. The downregulated miRNAs include several with proven target mRNAs whose proteins have been previously shown to be increased in prostate cancer by immunohistochemistry, including RAS, E2F3, BCL-2 and MCL-1. Using a bioinformatics approach, we have identified additional potential mRNA targets of one of the miRNAs, (miR-125b) that are upregulated in prostate cancer and con firmed increased expression of one of these targets, EIF4EBP1, in prostate cancer tissues. Our findings indicate that changes in miRNA expression may have an important role in the biology of human prostate cancer.	[Ozen, M.; Ozdemir, M.; Ittmann, M.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Ozen, M.; Ozdemir, M.; Ittmann, M.] Michael E DeBakey Dept Vet Affairs, Med Ctr, Houston, TX USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Ittmann, M.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Ittmann, M (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	mittmann@bcm.tmc.edu	Jackson, Benjamin L/C-4297-2012	Ozen, Mustafa/0000-0002-6142-5294	NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA058204] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barberis MCP, 2006, HISTOPATHOLOGY, V48, P614, DOI 10.1111/j.1365-2559.2005.02274.x; Biunno I, 2006, J CELL PHYSIOL, V208, P23, DOI 10.1002/jcp.20574; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gorgoni Barbara, 2004, Briefings in Functional Genomics & Proteomics, V3, P125, DOI 10.1093/bfgp/3.2.125; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Marsit CJ, 2006, CANCER RES, V66, P10843, DOI 10.1158/0008-5472.CAN-06-1894; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Shingara J, 2005, RNA, V11, P1461, DOI 10.1261/rna.2610405; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; VOORHOEVE PM, 2006, BIOCHIM BIOPHYS ACTA, V1775, P274; Wang JH, 2006, PROSTATE, V66, P847, DOI 10.1002/pros.20389; Wu W, 2007, INT J CANCER, V120, P953, DOI 10.1002/ijc.22454	21	531	586	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1788	1793		10.1038/sj.onc.1210809	http://dx.doi.org/10.1038/sj.onc.1210809			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891175				2022-12-28	WOS:000253962100014
J	Falvella, FS; Spinola, M; Pignatiello, C; Noci, S; Conti, B; Pastorino, U; Carbone, A; Dragani, TA				Falvella, F. S.; Spinola, M.; Pignatiello, C.; Noci, S.; Conti, B.; Pastorino, U.; Carbone, A.; Dragani, T. A.			AZGP1 mRNA levels in normal human lung tissue correlate with lung cancer disease status	ONCOGENE			English	Article						genetic susceptibility; complex diseases; gene expression; inherited predisposition; lung neoplasms; microarray	DIFFERENTIAL GENE-EXPRESSION; SEGREGATION ANALYSIS; PROSTATE-CANCER; MICE; PREDISPOSITION; SUSCEPTIBILITY; EPITHELIUM; SMOKING	Evidence in animal models has suggested an association between susceptibility to lung tumorigenesis and geneexpression profiles in normal lung. Here, we compared RNA pools from normal lung tissue of lung adenocarcinoma patients (cases) or non-lung cancer patients (controls) by hybridization of whole-human genome expression arrays. Principal component analysis identified a gene-expression signature of 85 genes that distinguishes cases from controls as well as smokers from nonsmokers. Elevated mRNA levels of one of these genes, AZGP1, were significantly associated with disease status. These results support the hypothesis that differences in the gene-expression levels of the normal tissue may be predictive of genetic predisposition to lung cancer in humans.	[Falvella, F. S.; Spinola, M.; Pignatiello, C.; Noci, S.; Dragani, T. A.] Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Labs, I-20133 Milan, Italy; [Conti, B.; Pastorino, U.] Ist Nazl Tumori, Fdn IRCCS, Dept Thorac Surg, I-20133 Milan, Italy; [Carbone, A.] Ist Nazl Tumori, Fdn IRCCS, Dept Pathol, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Labs, Via G Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Carbone, Antonino/AAA-2217-2019; Pastorino, Ugo/C-2712-2017; Dragani, Tommaso A./K-4493-2016; Noci, Sara/E-5425-2017	Carbone, Antonino/0000-0003-2211-639X; Pastorino, Ugo/0000-0001-9974-7902; Dragani, Tommaso A./0000-0001-5915-4598; Noci, Sara/0000-0002-6227-3907	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857; Bing C, 2004, P NATL ACAD SCI USA, V101, P2500, DOI 10.1073/pnas.0308647100; CROFTS F, 1994, CARCINOGENESIS, V15, P2961, DOI 10.1093/carcin/15.12.2961; Dragani TA, 2003, CANCER RES, V63, P3011; Falvella FS, 2002, CARCINOGENESIS, V23, P1933, DOI 10.1093/carcin/23.11.1933; Fujiwara K, 2003, CANCER SCI, V94, P672, DOI 10.1111/j.1349-7006.2003.tb01501.x; Gariboldi M, 2003, CARCINOGENESIS, V24, P1819, DOI 10.1093/carcin/bgg133; Harvey BG, 2007, J MOL MED, V85, P39, DOI 10.1007/s00109-006-0103-z; Henshall SM, 2006, J NATL CANCER I, V98, P1420, DOI 10.1093/jnci/djj378; Hoover RN, 2000, NEW ENGL J MED, V343, P135, DOI 10.1056/NEJM200007133430210; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Larsen JE, 2006, CARCINOGENESIS, V27, P525, DOI 10.1093/carcin/bgi227; Riggs PK, 2005, MOL CARCINOGEN, V44, P122, DOI 10.1002/mc.20127; SELLERS TA, 1994, AM J MED GENET, V52, P308, DOI 10.1002/ajmg.1320520311; Spira A, 2004, P NATL ACAD SCI USA, V101, P10143, DOI 10.1073/pnas.0401422101; TADA T, 1991, J HISTOCHEM CYTOCHEM, V39, P1221, DOI 10.1177/39.9.1918940; Thum T, 2006, ENVIRON HEALTH PERSP, V114, P1655, DOI 10.1289/ehp.8861; Wu PF, 2004, EUR J CANCER, V40, P260, DOI 10.1016/j.ejca.2003.08.021	19	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1650	1656		10.1038/sj.onc.1210775	http://dx.doi.org/10.1038/sj.onc.1210775			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17724461				2022-12-28	WOS:000253815800018
J	Iwai, A; Hijikata, M; Hishiki, T; Isono, O; Chiba, T; Shimotohno, K				Iwai, A.; Hijikata, M.; Hishiki, T.; Isono, O.; Chiba, T.; Shimotohno, K.			Coiled-coil domain containing 85B suppresses the beta-catenin activityin a p53-dependent manner	ONCOGENE			English	Article						oncogenesis; Siah-1L; Wnt signal; tumor suppressor	P53; PATHWAY; TRANSCRIPTION; LOCALIZATION; ACCUMULATION; EXPRESSION; CANCER; TARGET; CELLS	Aberrant accumulation of beta-catenin is closely related to carcinogenesis. Mutations in the p53 gene are reported to induce the aberrant accumulation of beta-catenin in the absence of dysfunction in the glycogen synthase kinase 3 beta (GSK3 beta)-mediated degradation pathway, but the mechanism remains incompletely understood. Here, we show that human coiled-coil domain containing 85B (CCDC85B) is induced by p53 and regulates beta-catenin activity via interaction with the T-cell factor 4 in the nucleus. Moreover, CCDC85B enhances the degradation of beta-catenin and suppresses tumor cell growth. In conclusion, we revealed that CCDC85B-induced degradation of beta-catenin is independent of GSK3b and other p53-inducible products, Siah-1L, suggesting that CCDC85B constitutes the one of the frameworks of p53-induced multiple regulatory pathways for beta-catenin activity.	[Iwai, A.; Hijikata, M.; Hishiki, T.; Isono, O.; Shimotohno, K.] Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyoku, Kyoto 6068507, Japan; [Iwai, A.; Chiba, T.] Kyoto Univ, Dept Med, Div Gastroenterol & Hepatol, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyoku, Shogoin Kawara Cho 54, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp						Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Iwai A, 2004, ONCOGENE, V23, P7593, DOI 10.1038/sj.onc.1208016; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Lee TKW, 2002, CANCER CHEMOTH PHARM, V49, P78, DOI 10.1007/s00280-001-0376-4; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Park WS, 2001, J PATHOL, V193, P483; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tolwinski NS, 2001, DEVELOPMENT, V128, P2107; Watashi K, 2003, MOL CELL BIOL, V23, P7498, DOI 10.1128/MCB.23.21.7498-7509.2003; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3	22	14	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1520	1526		10.1038/sj.onc.1210801	http://dx.doi.org/10.1038/sj.onc.1210801			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873903				2022-12-28	WOS:000253815800003
J	Akbari, MR; Malekzadeh, R; Nasrollahzadeh, D; Amanian, D; Islami, F; Li, S; Zandvakili, I; Shakeri, R; Sotoudeh, M; Aghceli, K; Salahi, R; Pourshams, A; Semnani, S; Boffetta, P; Dawsey, SM; Ghadirian, P; Narod, SA				Akbari, M. R.; Malekzadeh, R.; Nasrollahzadeh, D.; Amanian, D.; Islami, F.; Li, S.; Zandvakili, I.; Shakeri, R.; Sotoudeh, M.; Aghceli, K.; Salahi, R.; Pourshams, A.; Semnani, S.; Boffetta, P.; Dawsey, S. M.; Ghadirian, P.; Narod, S. A.			Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma	ONCOGENE			English	Article						esophageal squamous cell carcinoma; Turkmen population; BRCA2; K3326X; Fanconi anemia pathway	POLYMORPHIC STOP CODON; FANCONI-ANEMIA; CANCER SUSCEPTIBILITY; BREAST-CANCER; GENETIC SUSCEPTIBILITY; PANCREATIC-CANCER; ALLELIC LOSS; CROSS-LINKS; DNA-BINDING; IRAN	The incidence of esophageal squamous cell carcinoma (ESCC) is very high among the Turkmen population of Iran. Family studies suggest a genetic component to the disease. Turkmen are ethnically homogenous and are well suited for genetic studies. A previous study from China suggested that BRCA2 might play a role in the etiology of ESCC. We screened for mutations in the coding region of the BRCA2 gene in the germline DNA of 197 Turkmen patients with ESCC. A nonsense variant, K3326X, was identified in 9 of 197 cases (4.6%) vs 2 of 254 controls (0.8%) (OR = 6.0, 95% CI = 1.3-28; P = 0.01). This mutation leads to the loss of the C-terminal domain of the BRCA2 protein, a part of the region of interaction with the FANCD2 protein. We observed nine other BRCA2 variants in single cases only, including two deletions, and seven missense mutations. Six of these were judged to be pathogenic. In total, a suspicious deleterious BRCA2 variant was identified in 15 of 197 ESCC cases (7.6%).	[Akbari, M. R.; Malekzadeh, R.; Nasrollahzadeh, D.; Amanian, D.; Islami, F.; Shakeri, R.; Sotoudeh, M.; Aghceli, K.; Pourshams, A.] Univ Tehran, Shariati Hosp, Digest Dis Res Ctr, Tehran 14114, Iran; [Akbari, M. R.; Li, S.; Zandvakili, I.; Narod, S. A.] Univ Toronto, Womens Coll Res Inst, Toronto, ON, Canada; [Akbari, M. R.] Univ Toronto, Fac Med, Inst Med Sci, Toronto, ON, Canada; [Semnani, S.] Golestan Univ Med Sci, Res Ctr Gastroentrol, Gorgan, Iran; [Boffetta, P.] Int Agcy Res Canc, F-69372 Lyon, France; [Dawsey, S. M.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; [Ghadirian, P.] Univ Montreal, CHUM Hotel Dieu, Epidemiol Res Unit Res Ctr, Montreal, PQ, Canada	Tehran University of Medical Sciences; University of Tehran; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; Golestan University of Medical Sciences; World Health Organization; International Agency for Research on Cancer (IARC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universite de Montreal	Narod, SA (corresponding author), Univ Tehran, Shariati Hosp, Digest Dis Res Ctr, Tehran 14114, Iran.	malek@ams.ac.ir	Boffetta, Paolo/AAI-7767-2021; Zandvakili, Inuk/P-7241-2019; Zandvakili, Inuk/C-8496-2011; Malekzadeh, Reza/U-1382-2017; Narod, Steven A/AAA-6112-2022; Semnani, Shahryar/N-2270-2016	Boffetta, Paolo/0000-0002-3811-2791; Zandvakili, Inuk/0000-0003-3409-0019; Malekzadeh, Reza/0000-0002-9820-6335; Semnani, Shahryar/0000-0002-8768-6142; Islami, Farhad/0000-0002-7357-5994; Malekzadeh, Reza/0000-0003-1043-3814; , Ramin/0000-0003-0487-3629; Pourshams, Akram/0000-0002-7950-3983	NATIONAL CANCER INSTITUTE [Z01CP000185] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akbari MR, 2006, INT J CANCER, V119, P1047, DOI 10.1002/ijc.21906; Alter BP, 2005, ARCH OTOLARYNGOL, V131, P635, DOI 10.1001/archotol.131.7.635; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Atanassov BS, 2005, GENE CHROMOSOME CANC, V44, P429, DOI 10.1002/gcc.20255; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; GHADIRIAN P, 1985, CANCER-AM CANCER SOC, V56, P2112, DOI 10.1002/1097-0142(19851015)56:8<2112::AID-CNCR2820560838>3.0.CO;2-3; Houghtaling S, 2005, HUM MOL GENET, V14, P3027, DOI 10.1093/hmg/ddi334; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hu N, 2004, ONCOGENE, V23, P852, DOI 10.1038/sj.onc.1207150; Hu N, 2003, CANCER DETECT PREV, V27, P132, DOI 10.1016/S0361-090X(03)00031-X; Hu N, 2002, CLIN CANCER RES, V8, P1121; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; HUSSAR DA, 2003, DRUG ADVISOR, V2, P1; Islami F, 2004, BRIT J CANCER, V90, P1402, DOI 10.1038/sj.bjc.6601737; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Li G, 2001, GENE CHROMOSOME CANC, V31, P390, DOI 10.1002/gcc.1158; Lowenfels AB, 2005, J CELL BIOCHEM, V95, P649, DOI 10.1002/jcb.20461; MAHBOUBI E, 1973, BRIT J CANCER, V28, P192, DOI 10.1038/bjc.1973.138; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Martin ST, 2005, ONCOGENE, V24, P3652, DOI 10.1038/sj.onc.1208411; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; McAllister KA, 2002, CANCER RES, V62, P990; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Morimatsu M, 1998, CANCER RES, V58, P3441; Narod SA, 2002, NAT REV CANCER, V2, P113, DOI 10.1038/nrc726; Offit K, 2003, JNCI-J NATL CANCER I, V95, P1548, DOI 10.1093/jnci/djg072; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; POUR P, 1974, CANCER-AM CANCER SOC, V33, P1649, DOI 10.1002/1097-0142(197406)33:6<1649::AID-CNCR2820330627>3.0.CO;2-0; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Rosenberg PS, 2003, BLOOD, V101, P822, DOI 10.1182/blood-2002-05-1498; Saidi F, 2000, BRIT J CANCER, V83, P1249, DOI 10.1054/bjoc.2000.1414; SCHOTTENFELD D, 1984, SEMIN ONCOL, V11, P92; Simard J, 2003, ENDOCR-RELAT CANCER, V10, P225, DOI 10.1677/erc.0.0100225; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240; Tian XX, 2005, CANCER RES, V65, P4747, DOI 10.1158/0008-5472.CAN-05-0018; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	46	61	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1290	1296		10.1038/sj.onc.1210739	http://dx.doi.org/10.1038/sj.onc.1210739			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724471				2022-12-28	WOS:000253407000011
J	Chan, KS; Sano, S; Kataoka, K; Abel, E; Carbajal, S; Beltran, L; Clifford, J; Peavey, M; Shen, J; DiGiovanni, J				Chan, K. S.; Sano, S.; Kataoka, K.; Abel, E.; Carbajal, S.; Beltran, L.; Clifford, J.; Peavey, M.; Shen, J.; DiGiovanni, J.			Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis	ONCOGENE			English	Article						stat3; epithelial carcinogenesis; malignant progression; angiogenesis and epithelial mesenchymal transition	GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN; ALTERED EXPRESSION; P-CADHERIN; MICE; ONCOGENESIS; METASTASIS; INITIATION; CANCER	Recently, our laboratory demonstrated that Stat3 is required for the de novo development of chemically-induced skin tumors. We have further investigated the role of Stat3 in epithelial carcinogenesis using mice in which the expression of a constitutively active/ dimerized form of Stat3 ( Stat3C) is targeted to the proliferative compartment of epidermis ( referred to as K5.Stat3C transgenic mice). Keratinocytes from K5. Stat3C mice showed increased survival following exposure to 7,12-dimethyl-benz[ a] anthracene ( DMBA) and enhanced proliferation following exposure to 12-O-tetradecanoylphorbol-13-acetate ( TPA). In two-stage chemical carcinogenesis experiments using DMBA as the tumor initiator and TPA as the promoter, K5. Stat3C mice developed skin tumors witha shorter latency and in much greater number compared to non-transgenic littermates. Remarkably, 100% of the skin tumors that developed in K5. Stat3C transgenic mice bypassed the premalignant stage and were initially diagnosed as carcinoma in situ which rapidly progressed to squamous cell carcinoma ( SCC). These tumors were highly vascularized, poorly differentiated and invasive and loss of expression of K10, filaggrin and E-cadherin was observed by 20 weeks. Finally, overexpression of Stat3C in a papilloma cell line led to enhanced cell migration and enhanced invasion through Matrigel in both the absence and presence of growth factors. In addition to its critical role in early stages of epithelial carcinogenesis, the current study reveals a novel role for Stat3 in driving malignant progression of skin tumors in vivo.	[Chan, K. S.; Sano, S.; Kataoka, K.; Abel, E.; Carbajal, S.; Beltran, L.; Peavey, M.; Shen, J.; DiGiovanni, J.] Univ Texas Dallas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; [Clifford, J.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem, Shreveport, LA 71105 USA	University of Texas System; University of Texas Dallas; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	DiGiovanni, J (corresponding author), Univ Texas Dallas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, 1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.	jdigiova@mdanderson.org	KATAOKA, Ken/B-1607-2011	Abel, Erika/0000-0001-8791-825X	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784, U01ES011047] Funding Source: NIH RePORTER; NCI NIH HHS [UO1 CA05345, CA16672] Funding Source: Medline; NHLBI NIH HHS [R01 HL074352] Funding Source: Medline; NIEHS NIH HHS [ES07784, U01 ES11047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cai SQ, 2005, J DERMATOL, V32, P354, DOI 10.1111/j.1346-8138.2005.tb00906.x; Cano A, 1996, INT J CANCER, V65, P254; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; Fuchs E, 1994, Princess Takamatsu Symp, V24, P290; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.0.CO;2-L; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; MILLER DR, 1987, CANCER RES, V47, P1935; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; RUGGERI B, 1992, AM J PATHOL, V140, P1179; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Tang MS, 2000, CANCER RES, V60, P5688; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545; Yang J, 2006, CANCER RES, V66, P4549, DOI 10.1158/0008-5472.CAN-05-3850; YUSPA SH, 1994, CANCER RES, V54, P1178; Zeigler ME, 1996, INVAS METAST, V16, P3	29	85	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1087	1094		10.1038/sj.onc.1210726	http://dx.doi.org/10.1038/sj.onc.1210726			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700521				2022-12-28	WOS:000253136700008
J	Williams, C; Edvardsson, K; Lewandowski, SA; Strom, A; Gustafsson, JA				Williams, C.; Edvardsson, K.; Lewandowski, S. A.; Stroem, A.; Gustafsson, J-A			A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells	ONCOGENE			English	Article						estrogen receptor; microarray; breast cancer; gene regulation	GENE-EXPRESSION; DOWN-REGULATION; IN-VITRO; ER-BETA; TARGET; PROLIFERATION; INTERLEUKIN-20; TRANSCRIPTION; ANGIOGENESIS; ESTRADIOL	Transcriptional effects of estrogen result from its activation of two estrogen receptor (ER) isoforms; ER alpha that drives proliferation and ER beta that is antiproliferative. Expression of ERb in xenograft tumors from the T47D breast cancer cell line reduces tumor growth and angiogenesis. If ERb can halt tumor growth, its introduction into cancers may be a novel therapeutic approach to the treatment of estrogen-responsive cancers. To assess the complete impact of ER beta on transcription, we have made a full transcriptome analysis of ER alpha- and ER beta-mediated gene regulation in T47D cell line with Tet-Off regulated ERb expression. Of the 35 000 genes and transcripts analysed, 4.1% (1434) were altered by ERa activation. Tet withdrawal and subsequent ER beta expression inhibited the ERa regulation of 998 genes and, in addition, altered expression of 152 non-ER alpha-regulated genes. ER alpha-induced and ER beta-repressed genes were involved in proliferation, steroid/xenobiotic metabolism and ion transport. The ER beta repressive effect was further confirmed by proliferation assays, where ER beta was shown to completely oppose the ER alpha-E2 induced proliferation. Additional analysis of ER beta with a mutated DNA-binding domain revealed that this mutant, at least for a quantity of genes, antagonizes ER alpha even more strongly than ER beta wt. From an examination of the genes regulated by ER alpha and ER beta, we suggest that introduction of ER beta may be an alternative therapeutic approach to the treatment of certain cancers.	[Williams, C.; Edvardsson, K.; Lewandowski, S. A.; Stroem, A.; Gustafsson, J-A] Karolinska Inst, Novum, Dept Biosci & Nutr, S-14157 Huddinge, Sweden	Karolinska Institutet	Williams, C (corresponding author), Karolinska Inst, Novum, Dept Biosci & Nutr, Halsovagen 7-9, S-14157 Huddinge, Sweden.	cecilia.williams@biosci.ki.se	Williams, Cecilia/A-6677-2009; Lewandowski, Sebastian A./K-2492-2019	Williams, Cecilia/0000-0002-0602-2062; Lewandowski, Sebastian A./0000-0002-5935-0211				Annicotte JS, 2005, ONCOGENE, V24, P8167, DOI 10.1038/sj.onc.1208950; Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI [10.1093/carcin/bci339, 10.1093/carcin/bgi339]; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Chen WY, 2006, ARTERIOSCL THROM VAS, V26, P2090, DOI 10.1161/01.ATV.0000232502.88144.6f; Esslimani-Sahla M, 2005, CLIN CANCER RES, V11, P3170, DOI 10.1158/1078-0432.CCR-04-2298; Frasor J, 2005, P NATL ACAD SCI USA, V102, P13153, DOI 10.1073/pnas.0502782102; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gougelet A, 2007, J STEROID BIOCHEM, V104, P110, DOI 10.1016/j.jsbmb.2007.03.002; Gustafsson JA, 2006, CLIMACTERIC, V9, P156, DOI 10.1080/14689360600734328; Hall JM, 2003, MOL ENDOCRINOL, V17, P792, DOI 10.1210/me.2002-0438; Hanstein B, 2004, EUR J ENDOCRINOL, V150, P243, DOI 10.1530/eje.0.1500243; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hartman J, 2006, CANCER RES, V66, P11207, DOI 10.1158/0008-5472.CAN-06-0017; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hsieh MY, 2006, GENES IMMUN, V7, P234, DOI 10.1038/sj.gene.6364291; Hsu YH, 2006, ARTHRITIS RHEUM-US, V54, P2722, DOI 10.1002/art.22039; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002-0206; Lo YL, 2005, INT J CANCER, V115, P276, DOI 10.1002/ijc.20855; Marshburn PB, 2004, AM J OBSTET GYNECOL, V191, P626, DOI 10.1016/j.ajog.2004.05.082; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Murphy LC, 2005, J MOL ENDOCRINOL, V34, P553, DOI 10.1677/jme.1.01688; Nikolova Z, 1998, J CELL SCI, V111, P2741; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Poola I, 2001, J STEROID BIOCHEM, V78, P459, DOI 10.1016/S0960-0760(01)00118-2; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Ricci MS, 1999, J BIOL CHEM, V274, P3430, DOI 10.1074/jbc.274.6.3430; Richter K, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-75; ROBERTS M, 1988, BIOCHEM BIOPH RES CO, V151, P306, DOI 10.1016/0006-291X(88)90594-3; Russo J, 2006, J STEROID BIOCHEM, V102, P89, DOI 10.1016/j.jsbmb.2006.09.004; Schaefer TM, 2005, J IMMUNOL, V175, P6509, DOI 10.4049/jimmunol.175.10.6509; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983; Tomasini R, 2005, ONCOGENE, V24, P8093, DOI 10.1038/sj.onc.1208951; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Wang F, 2006, J INVEST DERMATOL, V126, P1590, DOI 10.1038/sj.jid.5700310; Wang YH, 2005, BREAST CANCER RES, V7, pR220, DOI 10.1186/bcr975	49	182	187	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					1019	1032		10.1038/sj.onc.1210712	http://dx.doi.org/10.1038/sj.onc.1210712			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700529				2022-12-28	WOS:000252946300014
J	Okawa, ER; Gotoh, T; Manne, J; Igarashi, J; Fujita, T; Silverman, KA; Xhao, H; Mosse, YP; White, PS; Brodeur, GM				Okawa, E. R.; Gotoh, T.; Manne, J.; Igarashi, J.; Fujita, T.; Silverman, K. A.; Xhao, H.; Mosse, Y. P.; White, P. S.; Brodeur, G. M.			Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas	ONCOGENE			English	Article						neuroblastoma; 1p36; tumor suppressor gene; gene expression; CHD5; mutation	N-MYC AMPLIFICATION; HOMOZYGOUS DELETION; NERVOUS-SYSTEM; CHROMOSOME 1P; CELL-LINES; REGION; LOCI; IDENTIFICATION; CAMTA1; RIBOSOMAL-PROTEIN-L22	Neuroblastomas are characterized by 1p deletions, suggesting that a tumor suppressor gene (TSG) resides in this region. We have mapped the smallest region of deletion (SRD) to a 2Mb region of 1p36.31 using microsatellite and single nucleotide polymorphisms. We have identified 23 genes in this region, and we have analysed these genes for mutations and RNA expression patterns to identify candidate TSGs. W e sequenced the coding exons of these genes in 30 neuroblastoma cell lines. Although rare mutations were found in 10 of the 23 genes, none showed a pattern of genetic change consistent with homozygous inactivation. We examined the expression of these 23 genes in 20 neuroblastoma cell lines, and most showed readily detectable expression, and no correlation with 1p deletion. How ever, 7 genes showed uniformly low expression in the lines, and 2 genes (CHD5, RNF207) had virtually absent expression, consistent with the expected pattern for a TSG. Our mutation and expression analysis in neuroblastoma cell lines, combined with expression analysis in normal tissues, putative function and prior implication in neuroblastoma pathogenesis, suggests that the most promising TSG deleted from the 1p36 SRD is CHD5, but TNFRSF25, CAMTA1 and AJAP1 are also viable candidates.	[Okawa, E. R.; Gotoh, T.; Manne, J.; Igarashi, J.; Fujita, T.; Silverman, K. A.; Mosse, Y. P.; White, P. S.; Brodeur, G. M.] Univ Penn, Childrens Hosp Philadelphia, Div Oncol, Dept Pediat, Philadelphia, PA 19104 USA; [Xhao, H.] Childrens Hosp Philadelphia, Dept Pediat, Div Biostat & Data Management Core, Philadelphia, PA 19104 USA; [Xhao, H.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Brodeur, GM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, 3615 Civic Ctr Blvd,ARC Rm 902D, Philadelphia, PA 19104 USA.	brodeur@email.chop.edu			NCI NIH HHS [R01-CA039771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Brodeur G. M., 2006, PRINCIPLES PRACTICE, P933; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Chen YZ, 2001, GENE CHROMOSOME CANC, V31, P326, DOI 10.1002/gcc.1151; CHENG NC, 1995, ONCOGENE, V10, P291; Eggert A, 2002, EUR J CANCER, V38, P92, DOI 10.1016/S0959-8049(01)00347-1; Elia A, 2004, EUR J BIOCHEM, V271, P1895, DOI 10.1111/j.1432-1033.2004.04099.x; Fok V, 2006, RNA, V12, P872, DOI 10.1261/rna.2339606; GEHRING M, 1995, CANCER RES, V55, P5366; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Henrich KO, 2007, EUR J CANCER, V43, P607, DOI 10.1016/j.ejca.2006.09.023; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Katoh M, 2003, INT J ONCOL, V23, P1219; Maris JM, 1997, EUR J CANCER, V33, P1991, DOI 10.1016/S0959-8049(97)00279-7; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; MARTINSSON T, 1995, CANCER RES, V55, P5681; McDonald JM, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-35; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; OLIPHANT A, 2002, BIOTECHNIQUES S, V56, P60; Rozen S, 2000, Methods Mol Biol, V132, P365; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Steemers FJ, 2006, NAT METHODS, V3, P31, DOI 10.1038/NMETH842; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Thompson PM, 2001, CANCER RES, V61, P679; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102	40	69	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					803	810		10.1038/sj.onc.1210675	http://dx.doi.org/10.1038/sj.onc.1210675			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17667943				2022-12-28	WOS:000252884500009
J	Zhao, C; Inoue, J; Imoto, I; Otsuki, T; Iida, S; Ueda, R; Inazawa, J				Zhao, C.; Inoue, J.; Imoto, I.; Otsuki, T.; Iida, S.; Ueda, R.; Inazawa, J.			POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17	ONCOGENE			English	Article						multiple myeloma; POU2AF1; amplification TNFRSF17; array-CGH	CYCLIN D1 GENE; IDENTIFICATION; LYMPHOMA; PLASMA; OVEREXPRESSION; HYBRIDIZATION; ABNORMALITIES; BOB.1/OBF.1; ABERRATIONS; ACTIVATION	Multiple myeloma (MM), a progressive hematological neoplasm, is thought to result from multiple genetic events affecting the terminal plasma cell. However, genetic aberrations related to MM are seldom reported. Using our in-house array-based comparative genomic hybridization system to locate candidate target genes with following their expression analysis, we identified POU2AF1 at 11q23.1 as a probable amplification target in MM cell lines. POU2AF1 is a B-cell-specific transcriptional coactivator, which interacts with octamer-binding transcription factors Oct-1 and Oct-2, and augments their function. Downregulation of POU2AF1 expression by specific small-interfering RNA (siRNA) inhibited MM cell growth, whereas ectopic expression of POU2AF1 promoted growth of MM cells. Among putative transcriptional targets for POU2AF1, B-cell maturation factor, TNFRSF17, enhanced its transcription by POU2AF1, and POU2AF1 directly bound to an octamer site within the 50 region of TNFRSF17. Expression level of TNFRSF17 was closely correlated with that of POU2AF1 in cell lines and primary samples of MM, and decreasing TNFRSF17 expression by means of TNFRSF17 siRNA inhibited MM cell growth. Taken together, our results suggest that POU2AF1, when activated by amplification or other mechanisms, may contribute to progression of MM by accelerating growth of MM cells through direct transactivation of one of its target genes, TNFRSF17.	[Zhao, C.; Inoue, J.; Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; [Zhao, C.; Inazawa, J.] 21st Century Ctr Excellence Program Mol Destruct, Tokyo, Japan; [Inoue, J.; Imoto, I.; Inazawa, J.] Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Saitama, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo, Japan; [Otsuki, T.] Kawasaki Med Sch, Dept Hyg, Okayama, Japan; [Iida, S.; Ueda, R.] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Aichi, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); Kawasaki Medical School; Nagoya City University	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Zhao, Chen/D-8664-2012; Imoto, Issei/AAD-5799-2020					Brunner C, 2003, J EXP MED, V197, P1205, DOI 10.1084/jem.20022014; Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; Cigudosa JC, 1998, BLOOD, V91, P3007, DOI 10.1182/blood.V91.8.3007.3007_3007_3010; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; Cremer FW, 2005, CANCER GENET CYTOGEN, V161, P116, DOI 10.1016/j.cancergencyto.2005.02.015; Cremer FW, 2005, GENE CHROMOSOME CANC, V44, P194, DOI 10.1002/gcc.20231; Fonseca R, 2002, BLOOD, V100, P1417, DOI 10.1182/blood.V100.4.1417.h81602001417_1417_1424; Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876; Gonzalez MB, 2004, HAEMATOLOGICA, V89, P1213; Greiner A, 2000, AM J PATHOL, V156, P501, DOI 10.1016/S0002-9440(10)64754-2; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; Gutierrez NC, 2001, LEUKEMIA, V15, P840, DOI 10.1038/sj.leu.2402116; Hatzoglou A, 2000, J IMMUNOL, V165, P1322, DOI 10.4049/jimmunol.165.3.1322; Heckman CA, 2006, ONCOGENE, V25, P888, DOI 10.1038/sj.onc.1209127; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Hoechtlen-Vollmar W, 2000, BRIT J HAEMATOL, V109, P30, DOI 10.1046/j.1365-2141.2000.02007.x; Husson H, 2002, BLOOD, V99, P282, DOI 10.1182/blood.V99.1.282; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Inoue J, 2004, AM J PATHOL, V165, P71, DOI 10.1016/S0002-9440(10)63276-2; KABAT D, 1972, SCIENCE, V175, P134, DOI 10.1126/science.175.4018.134; Kim U, 2003, P NATL ACAD SCI USA, V100, P8868, DOI 10.1073/pnas.1033108100; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; LADANYI M, 1992, AM J PATHOL, V141, P949; Largo C, 2006, HAEMATOL-HEMATOL J, V91, P184; Lins K, 2003, EMBO J, V22, P2188, DOI 10.1093/emboj/cdg199; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Miura K, 2003, CANCER SCI, V94, P350, DOI 10.1111/j.1349-7006.2003.tb01445.x; Moreau LA, 2006, CLIN CANCER RES, V12, P5693, DOI 10.1158/1078-0432.CCR-06-1500; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Novak AJ, 2004, BLOOD, V103, P689, DOI 10.1182/blood-2003-06-2043; Robetorye RS, 2002, J MOL DIAGN, V4, P123, DOI 10.1016/S1525-1578(10)60693-9; Samardzic T, 2002, MOL CELL BIOL, V22, P8320, DOI 10.1128/MCB.22.23.8320-8331.2002; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; SCHUSCHEREBA ST, 2001, P SOC PHOTO-OPT INS, V2, P1; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Sonoki T, 1998, INT J HEMATOL, V68, P459; Standal T, 2004, HAEMATOLOGICA, V89, P174; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Teitell MA, 2003, TRENDS IMMUNOL, V24, P546, DOI 10.1016/j.it.2003.08.002; TRICOT G, 1995, BLOOD, V86, P4250, DOI 10.1182/blood.V86.11.4250.bloodjournal86114250; Yu X, 2001, IMMUNITY, V14, P157, DOI 10.1016/S1074-7613(09)00090-9; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	48	35	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					63	75		10.1038/sj.onc.1210637	http://dx.doi.org/10.1038/sj.onc.1210637			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17621271				2022-12-28	WOS:000252118700007
J	Rea, S; Xouri, G; Akhtar, A				Rea, S.; Xouri, G.; Akhtar, A.			Males absent on the first (MOF): from flies to humans	ONCOGENE			English	Review						MOF; MSL; histone acetyltransferase; H4K16; DNA damage; cancer	ACUTE MYELOID-LEUKEMIA; HISTONE ACETYLTRANSFERASE ACTIVITY; ZINC-FINGER PROTEIN; HEMATOPOIETIC STEM-CELLS; ACUTE MONOCYTIC LEUKEMIA; DROSOPHILA MSL COMPLEX; DOSAGE COMPENSATION; TRANSCRIPTIONAL REGULATION; H4 ACETYLATION; RECEPTOR COACTIVATOR	Histone modi. cations such as acetylation, methylation and phosphorylation have been implicated in fundamental cellular processes such as epigenetic regulation of gene expression, organization of chromatin structure, chromosome segregation, DNA replication and DNA repair. Males absent on the first ( MOF) is responsible for acetylating histone H4 at lysine 16 ( H4K16) and is a key component of the MSL complex required for dosage compensation in Drosophila. The human ortholog of MOF ( hMOF) has the same substrate specific city and recent purification of the human and Drosophila MOF complexes showed that these complexes were also highly conserved through evolution. Several studies have shown that loss of hMOF in mammalian cells leads to a number of different phenotypes; a G(2)/M cell cycle arrest, nuclear morphological defects, spontaneous chromosomal aberrations, reduced transcription of certain genes and an impaired DNA repair response upon ionizing irradiation. Moreover, hMOF is involved in ATM activation in response to DNA damage and acetylation of p53 by hMOF influences the cell's decision to undergo apoptosis instead of a cell cycle arrest. These data, highlighting hMOF as an important component of many cellular processes, as well as links between hMOF and cancer will be discussed.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Akhtar, A (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	akhtar@embl.de		Rea, Stephen/0000-0001-5797-5157				Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; ALLFREY VG, 1968, SCIENCE, V159, P314, DOI 10.1126/science.159.3812.314; Anderson JD, 2001, J MOL BIOL, V307, P977, DOI 10.1006/jmbi.2001.4528; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; Contzler R, 2006, BIOCHEM BIOPH RES CO, V350, P208, DOI 10.1016/j.bbrc.2006.09.030; Corona DFV, 2002, EMBO REP, V3, P242, DOI 10.1093/embo-reports/kvf056; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Deissler H, 2004, ONCOL REP, V11, P1281; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918; Favreau C, 2003, EXP CELL RES, V282, P14, DOI 10.1006/excr.2002.5669; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Hashimoto T, 1999, CANCER RES, V59, P5572; Hayes VM, 1999, BRAIN PATHOL, V9, P463, DOI 10.1111/j.1750-3639.1999.tb00535.x; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Iizuka M, 2006, MOL CELL BIOL, V26, P1098, DOI 10.1128/MCB.26.3.1098-1108.2006; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Katan-Khaykovich Y, 2005, EMBO J, V24, P2138, DOI 10.1038/sj.emboj.7600692; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kindle KB, 2005, MOL CELL BIOL, V25, P988, DOI 10.1128/MCB.25.3.988-1002.2005; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Leitao MM, 2004, GYNECOL ONCOL, V93, P301, DOI 10.1016/j.ygyno.2004.01.043; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; Lleonart ME, 2006, ONCOL REP, V16, P603; Lucchesi JC, 2005, ANNU REV GENET, V39, P615, DOI 10.1146/annurev.genet.39.073003.094210; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Mendjan S, 2007, CHROMOSOMA, V116, P95, DOI 10.1007/s00412-006-0089-x; MEYERS FJ, 1993, J NATL CANCER I, V85, P1856, DOI 10.1093/jnci/85.22.1856; MUNKS RJL, 1991, FEBS LETT, V284, P245, DOI 10.1016/0014-5793(91)80695-Y; Ohta K, 2007, BIOCHEM J, V402, P559, DOI 10.1042/BJ20061194; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Pardo PS, 2002, J BIOL CHEM, V277, P50860, DOI 10.1074/jbc.M203839200; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Prokocimer M, 2006, J STRUCT BIOL, V155, P351, DOI 10.1016/j.jsb.2006.02.016; Rea S, 2006, CURR TOP MICROBIOL, V310, P117; Reifnyder C, 1997, NAT GENET, V16, P109, DOI 10.1038/ng0597-109b; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Sanjuan R, 2001, MOL BIOL EVOL, V18, P330, DOI 10.1093/oxfordjournals.molbev.a003809; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shia WJ, 2005, J BIOL CHEM, V280, P11987, DOI 10.1074/jbc.M500276200; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Stedman W, 2004, J VIROL, V78, P12566, DOI 10.1128/JVI.78.22.12566-12575.2004; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Straub T, 2007, NAT REV GENET, V8, P47, DOI 10.1038/nrg2013; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; SUTTON WS, 1903, BIOL BULL, V4, P5; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Yamada T, 2004, EMBO J, V23, P1792, DOI 10.1038/sj.emboj.7600138; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430; Zong HL, 2005, FEBS LETT, V579, P3579, DOI 10.1016/j.febslet.2005.05.039	97	100	105	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5385	5394		10.1038/sj.onc.1210607	http://dx.doi.org/10.1038/sj.onc.1210607			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694080				2022-12-28	WOS:000248674300007
J	Munoz-Fontela, C; Garcia, MA; Garcia-Cao, I; Collado, M; Arroyo, J; Esteban, M; Serrano, M; Rivas, C				Munoz-Fontela, C; Garcia, MA; Garcia-Cao, I; Collado, M; Arroyo, J; Esteban, M; Serrano, M; Rivas, C			Resistance to viral infection of super p53 mice	ONCOGENE			English	Article						p53; vesicular stomatitis virus; vaccinia virus; tumor suppressor; antiviral activity; `super p53' mice	VESICULAR STOMATITIS-VIRUS; SV40-TRANSFORMED CELLS; ONCOLYTIC VIRUS; APOPTOSIS; ANTIGEN; INDUCTION; REPLICATION; ACTIVATION; CARCINOMA; PROTEINS	Induction of expression of the tumor suppressor p53 after interferon treatment has been recently demonstrated (Takaoka et al., 2003), suggesting an antiviral activity of the protein. In addition, a direct correlation between p53 levels and tumor resistance has been addressed by generating mice with an extra copy of p53 ('super p53' mice) (Garcia-Cao et al., 2002). Here, we show that vesicular stomatitis virus replication in mouse embryo fibroblasts derived from 'super p53' mice is impaired as a result of apoptosis induction via p53 activation. These findings unequivocally demonstrate an antiviral activity of p53, a process that may contribute to inhibit the spread of the virus in vivo.	Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, Madrid, Spain; CNIO, Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Centro Nacional de Investigaciones Oncologicas (CNIO)	Rivas, C (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, Plaza Ramon & Cajal SN, E-28040 Madrid, Spain.	mdcrivas@farm.ucm.es	Arroyo, Javier/E-9308-2016; Garcia, Maria Angel MA/I-5116-2016; Rivas, Carmen/AAB-6278-2019; Collado, Manuel/K-8140-2014; Serrano, Manuel/H-2634-2015; Rivas, Carmen/L-3162-2017	Arroyo, Javier/0000-0002-1971-1721; Garcia, Maria Angel MA/0000-0003-2003-3769; Rivas, Carmen/0000-0002-0518-7199; Collado, Manuel/0000-0002-0330-0880; Serrano, Manuel/0000-0001-7177-9312; Rivas, Carmen/0000-0002-0518-7199; ESTEBAN, MARIANO/0000-0003-0846-2827; Munoz-Fontela, Cesar/0000-0002-7725-2586				Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Clemens MJ, 2003, J INTERF CYTOK RES, V23, P277, DOI 10.1089/107999003766628124; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Gadaleta P, 2002, VIRUS RES, V86, P87, DOI 10.1016/S0168-1702(02)00049-7; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Giedlin MA, 2003, CANCER CELL, V4, P241, DOI 10.1016/S1535-6108(03)00251-4; GONZALO JA, 1994, EUR J IMMUNOL, V24, P48, DOI 10.1002/eji.1830240108; Humlova Z, 2002, J GEN VIROL, V83, P2821, DOI 10.1099/0022-1317-83-11-2821; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Kopecky SA, 2001, J VIROL, V75, P12169, DOI 10.1128/JVI.75.24.12169-12181.2001; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li M, 2000, J VIROL, V74, P7470, DOI 10.1128/JVI.74.16.7470-7477.2000; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Smith GL, 1997, IMMUNOL REV, V159, P137, DOI 10.1111/j.1600-065X.1997.tb01012.x; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Sur JH, 2003, VET PATHOL, V40, P512, DOI 10.1354/vp.40-5-512; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; WAGNER RR, 1996, FIELDS VIROLOGY	28	59	64	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3059	3062		10.1038/sj.onc.1208477	http://dx.doi.org/10.1038/sj.onc.1208477			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	17726827	Bronze			2022-12-28	WOS:000228649500016
J	Vercammen, E; Staal, J; Van den Broeke, A; Haegman, M; Vereecke, L; Schotte, P; Beyaert, R				Vercammen, E.; Staal, J.; Van den Broeke, A.; Haegman, M.; Vereecke, L.; Schotte, P.; Beyaert, R.			Prolonged exposure to IL-1 beta and IFN gamma induces necrosis of L929 tumor cells via a p38MAPK/NF-kappa B/NO-dependent mechanism	ONCOGENE			English	Article						interleukin-1; interferon; necrosis; nitric oxide; NF-kappa B	NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; IMMUNE-RESPONSE; P38 MAPK; DEATH; EXPRESSION; INTERLEUKIN-1	Interleukin-1 beta (IL-1 beta)is a cytokine that shares with tumor necrosis factor (TNF) the ability to initiate largely similar signaling pathways, leading to proinflammatory gene expression. In contrast to TNF, however, IL-1 beta is not believed to induce tumor cell death. Here we demonstrate that prolonged treatment with IL-1 beta, in combination with interferon-gamma (IFN gamma), is cytotoxic for L929 tumor cells. IL-1 beta/IFN gamma- induced cytotoxicity requires only minimal amounts of IL-1b and shows morphological features of necrosis. Although TNF induces a similar response, we could exclude a contribution of endogenous TNF production in the effect of IL-1 beta/IFN gamma. Cell death in response to IL-1 beta/IFN gamma is independent of caspases, but requires the IL-1 beta/IFN gamma- induced production of inducible nitric oxide synthase ( iNOS) and NO. Moreover, necrosis and iNOS/ NO production could be prevented by treatment of the cells with a p38 mitogen activated protein kinase ( p38MAPK) or I kappa B kinase beta inhibitor. Altogether, these findings demonstrate that prolonged exposure to IL-1 beta plus IFN gamma induces L929 tumor cell necrosis, via a p38MAPK and nuclear factor-kappa B ( NF-kappa B)- dependent signaling pathway, leading to the expression of iNOS and the production of toxic NO levels.	[Vercammen, E.; Staal, J.; Van den Broeke, A.; Haegman, M.; Vereecke, L.; Schotte, P.; Beyaert, R.] Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Zwijnaarde, Belgium; [Vercammen, E.; Staal, J.; Van den Broeke, A.; Haegman, M.; Vereecke, L.; Schotte, P.; Beyaert, R.] Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Beyaert, R (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Zwijnaarde, Belgium.	rudi.beyaert@dmbr.ugent.be	Beyaert, Rudi/B-2589-2009; Vereecke, Lars/H-6639-2016; Staal, Jens/B-7383-2008; Vereecke, Lars/ABH-2926-2020	Staal, Jens/0000-0003-2664-3357; Vereecke, Lars/0000-0002-1593-862X; Beyaert, Rudi/0000-0002-5704-582X; Haegman, Mira/0000-0002-4883-312X				BEYAERT R, 1993, J IMMUNOL, V151, P291; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Beyaert R, 2002, INT REV CYTOL, V214, P225; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Cnop M, 2005, DIABETES, V54, pS97, DOI 10.2337/diabetes.54.suppl_2.S97; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eizirik DL, 2001, DIABETOLOGIA, V44, P2115, DOI 10.1007/s001250100021; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; FRANSEN L, 1986, EUR J CANCER CLIN ON, V22, P419, DOI 10.1016/0277-5379(86)90107-0; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Huang H, 2004, MOL PHARMACOL, V66, P302, DOI 10.1124/mol.66.2.302; Itoh S, 1999, J IMMUNOL, V162, P7434; Janik JE, 1996, JNCI-J NATL CANCER I, V88, P44, DOI 10.1093/jnci/88.1.44; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Kim YJ, 2006, J NEUROSCI RES, V84, P1037, DOI 10.1002/jnr.21011; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Kobayashi T, 2004, MICROBES INFECT, V6, P1333, DOI 10.1016/j.micinf.2004.09.001; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Lejeune F J, 2006, Bull Cancer, V93, pE90; Lejeune Ferdy J, 2006, Cancer Immun, V6, P6; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Ricci MS, 2006, ONCOLOGIST, V11, P342, DOI 10.1634/theoncologist.11-4-342; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Saldeen J, 2004, EUR CYTOKINE NETW, V15, P47; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SMITH JW, 1992, J CLIN ONCOL, V10, P1141, DOI 10.1200/JCO.1992.10.7.1141; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANHAESEBROECK B, 1991, CANCER RES, V51, P2229; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; YAMADA K, 1993, DIABETES, V42, P1026, DOI 10.2337/diabetes.42.7.1026; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x	50	15	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3780	3788		10.1038/onc.2008.4	http://dx.doi.org/10.1038/onc.2008.4			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246123				2022-12-28	WOS:000256904700002
J	Falvella, FS; Colombo, F; Spinola, M; Campiglio, M; Pastorino, U; Dragani, TA				Falvella, F. S.; Colombo, F.; Spinola, M.; Campiglio, M.; Pastorino, U.; Dragani, T. A.			BHLHB3: a candidate tumor suppressor in lung cancer	ONCOGENE			English	Article						BHLHB2; DEC1; DEC2; SHARP-1; STRA13; lung cancer	E-BOX; DEC2; DIFFERENTIATION; EXPRESSION	BHLHB3 is a basic helix-loop-helix (bHLH) domain-containing protein that acts as a transcriptional repressor. We found that BHLHB3 transcript levels were low in three human lung cancer cell lines and downregulated in human lung adenocarcinomas as compared to normal lung tissue. BHLHB3 gene overexpression inhibited colony formation of A549, NCI-H520 and NCI-H596 lung cancer cells. The reduced colony growth was likely due to inhibition of cell proliferation as suggested by the downregulation of cyclin D1 (CCND1) expression in NCI-H520 cells transfected to overexpress the BHLHB3 gene; no evidence of apoptosis was observed. These results point to the potential role of the BHLHB3 protein as a tumor suppressor for lung cancer.	[Falvella, F. S.; Colombo, F.; Spinola, M.; Campiglio, M.; Dragani, T. A.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Labs, I-20133 Milan, Italy; [Pastorino, U.] Fdn IRCCS Ist Nazl Tumori, Unit Thorac Surg, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Dragani, TA (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Labs, Via G Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Colombo, Francesca/B-4617-2013; Dragani, Tommaso A./K-4493-2016; Colombo, Francesca/Q-5292-2019; Pastorino, Ugo/C-2712-2017	Colombo, Francesca/0000-0003-2015-4317; Dragani, Tommaso A./0000-0001-5915-4598; Colombo, Francesca/0000-0003-2015-4317; Pastorino, Ugo/0000-0001-9974-7902	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Azmi S, 2004, J BIOL CHEM, V279, P52643, DOI 10.1074/jbc.M409188200; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Berthet C, 2007, ONCOGENE, V26, P4469, DOI 10.1038/sj.onc.1210243; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; Falvella FS, 2007, LUNG CANCER, V56, P1, DOI 10.1016/j.lungcan.2006.11.008; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Li YX, 2003, J BIOL CHEM, V278, P16899, DOI 10.1074/jbc.M300596200; Noshiro M, 2004, GENES CELLS, V9, P317, DOI 10.1111/j.1356-9597.2004.00722.x; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949	12	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3761	3764		10.1038/sj.onc.1211038	http://dx.doi.org/10.1038/sj.onc.1211038			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223678				2022-12-28	WOS:000256659300014
J	Lee, J; Sung, YH; Cheong, C; Choi, YS; Jeon, HK; Sun, W; Hahn, WC; Ishikawa, F; Lee, HW				Lee, J.; Sung, Y. H.; Cheong, C.; Choi, Y. S.; Jeon, H. K.; Sun, W.; Hahn, W. C.; Ishikawa, F.; Lee, H-W			TERT promotes cellular and organismal survival independently of telomerase activity	ONCOGENE			English	Article						telomerase; telomerase activity; TERT; cell death; cellular protection	REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; MOUSE TELOMERASE; INDUCED-APOPTOSIS; NEURONAL DEATH; CANCER-CELLS; IN-VITRO; HTERT; MICE; INHIBITION	The expression level of the telomerase catalytic subunit (telomerase reverse transcriptase, TERT) positively correlates with cell survival after exposure to several lethal stresses. However, whether the protective role of TERT is independent of telomerase activity has not yet been clearly explored. Here, we genetically evaluated the protective roles of both TERT and telomerase activity against cell death induced by staurosporine (STS) and N-methyl-D-aspartic acid (NMDA). First generation (G1) TERT-deficient mouse embryonic fibroblasts (MEFs) displayed an increased sensitivity to STS, while TERT transgenic MEFs were more resistant to STS-induced apoptosis than wildtype. Deletion of the telomerase RNA component (TERC) failed to alter the sensitivity of TERT transgenic MEFs to STS treatment. Similarly, NMDA-induced excitotoxic cell death of primary neurons was suppressed by TERT, but not by TERC both in vitro and in vivo. Specifically, NMDA accelerated death of TERT-deficient mice, while TERT transgenic mice showed enhanced survival when compared with wild-type littermates after administration of NMDA. In addition, the transgenic expression of TERT protected motor neurons from apoptosis induced by sciatic nerve axotomy. These results indicate that telomerase activity is not essential for the protective function of TERT. This telomerase activity-independent TERT function may contribute to cancer development and aging independently of telomere lengthening.	[Sung, Y. H.; Choi, Y. S.; Jeon, H. K.; Lee, H-W] Yonsei Univ, Dept Biochem, Brain Korea Program 21, Seoul 120749, South Korea; [Lee, J.; Cheong, C.] Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Suwon, South Korea; [Sun, W.] Korea Univ, Coll Med, Brain Korea Program 21, Dept Anat, Seoul 136705, South Korea; [Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Hahn, W. C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Hahn, W. C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Ishikawa, F.] Kyoto Univ, Dept Gene Mech, Kyoto, Japan	Yonsei University; Sungkyunkwan University (SKKU); Korea University; Korea University Medicine (KU Medicine); Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kyoto University	Lee, HW (corresponding author), Yonsei Univ, Dept Biochem, Brain Korea Program 21, 134 Sinchon Dong, Seoul 120749, South Korea.	hwl@yonsei.ac.kr	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305; sun, woong/0000-0003-1792-4894	NIA NIH HHS [R01 AG23145] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG023145] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Boklan J, 2002, CANCER RES, V62, P2104; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Cerezo A, 2002, J CELL SCI, V115, P1305; Chen JL, 2003, GENE DEV, V17, P2747, DOI 10.1101/gad.1140303; Chung HK, 2005, CURR MOL MED, V5, P233, DOI 10.2174/1566524053586635; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Djebaili M, 2000, NEUROREPORT, V11, P2973, DOI 10.1097/00001756-200009110-00029; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; Erdmann N, 2004, P NATL ACAD SCI USA, V101, P6080, DOI 10.1073/pnas.0401580101; Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985; Folini M, 2005, EUR J CANCER, V41, P624, DOI 10.1016/j.ejca.2004.12.002; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Massard C, 2006, ONCOGENE, V25, P4505, DOI 10.1038/sj.onc.1209487; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Middleman EJ, 2006, MOL CELL BIOL, V26, P2146, DOI 10.1128/MCB.26.6.2146-2159.2006; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Perez-Navarro E, 2005, J NEUROCHEM, V92, P678, DOI 10.1111/j.1471-4159.2004.02904.x; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Seleznev K, 2006, J BIOL CHEM, V281, P22275, DOI 10.1074/jbc.M604330200; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Siegl-Cachedenier I, 2007, J CELL BIOL, V179, P277, DOI 10.1083/jcb.200704141; SOFIA RD, 1994, PHARMACOL RES, V29, P139, DOI 10.1016/1043-6618(94)80037-5; Sun W, 2003, J NEUROSCI, V23, P7298, DOI 10.1523/jneurosci.23-19-07298.2003; Sung YH, 2005, MOL CELLS, V19, P303; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yuan XM, 1999, GENES CELLS, V4, P563, DOI 10.1046/j.1365-2443.1999.00284.x; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje	49	114	119	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3754	3760		10.1038/sj.onc.1211037	http://dx.doi.org/10.1038/sj.onc.1211037			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223679				2022-12-28	WOS:000256659300013
J	Li, Y; Ozaki, T; Kikuchi, H; Yamamoto, H; Ohira, M; Nakagawara, A				Li, Y.; Ozaki, T.; Kikuchi, H.; Yamamoto, H.; Ohira, M.; Nakagawara, A.			A novel HECT-type E3 ubiquitin protein ligase NEDL1 enhances the p53-mediated apoptotic cell death in its catalytic activity-independent manner	ONCOGENE			English	Article						apoptosis; cisplatin; DNA damage; HECT-type E3 ubiquitin ligase; NEDL1; p53	GLYCOGEN-SYNTHASE KINASE-3-BETA; AMYOTROPHIC-LATERAL-SCLEROSIS; KINASE-I-EPSILON; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; DNA-BINDING; P53; NEUROBLASTOMA; DEGRADATION; NEURONS	NEDL1 (NEDD4-like ubiquitin protein ligase-1) is a newly identified HECT-type E3 ubiquitin protein ligase highly expressed in favorable neuroblastomas as compared with unfavorable ones. In this study, we found that NEDL1 cooperates with p53 to induce apoptosis. During cisplatin (CDDP)-mediated apoptosis in neuroblastoma SH-SY5Y cells, p53 was induced to accumulate in association with an increase in expression levels of NEDL1. Enforced expression of NEDL1 resulted in a decrease in number of G418-resistant colonies in SH-SY5Y and U2OS cells bearing wild-type p53, whereas NEDL1 had undetectable effect on p53-deficient H1299 and SAOS-2 cells. Similarly, enforced expression of NEDL1 increased number of U2OS cells with sub-G1 DNA content. Co-immunoprecipitation and in vitro binding assays revealed that NEDL1 binds to the COOH-terminal region of p53. Luciferase reporter assay showed that NEDL1 has an ability to enhance the transcriptional activity of p53. Small interfering RNA-mediated knockdown of the endogenous NEDL1 conferred the resistance of U2OS cells to adriamycin. It is noteworthy that NEDL1 enhanced pro-apoptotic activity of p53 in its catalytic activity-independent manner. Taken together, our present findings suggest that functional interaction of NEDL1 with p53 might contribute to the induction of apoptosis in cancerous cells bearing wild-type p53.	[Li, Y.; Ozaki, T.; Kikuchi, H.; Yamamoto, H.; Ohira, M.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan; [Li, Y.] Furukawa Elect Corp Ltd, Prod Technol Dev Ctr, Ichihara, Chiba, Japan	Chiba Cancer Center; Furukawa Electric	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; de Aguilar JLG, 2000, NEUROBIOL DIS, V7, P406, DOI 10.1006/nbdi.2000.0295; Di Lello P, 2006, MOL CELL, V22, P731, DOI 10.1016/j.molcel.2006.05.007; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ekegren T, 1999, ACTA NEUROL SCAND, V100, P317; Hetman M, 2000, J NEUROSCI, V20, P2567; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Kiryu-Seo S, 2005, J NEUROSCI, V25, P1442, DOI 10.1523/JNEUROSCI.4041-04.2005; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; Martin LJ, 2002, J NEUROBIOL, V50, P181, DOI 10.1002/neu.10026; Martin LJ, 2000, NEUROBIOL DIS, V7, P613, DOI 10.1006/nbdi.2000.0314; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Nakagawara A, 2004, CANCER LETT, V204, P213, DOI 10.1016/S0304-3835(03)00457-9; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Shaw P, 1996, ONCOGENE, V12, P921; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299	29	40	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3700	3709		10.1038/sj.onc.1211032	http://dx.doi.org/10.1038/sj.onc.1211032			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223681				2022-12-28	WOS:000256659300007
J	Chen, Z; Li, J; Li, QS; Fan, JQ; Dong, XM; Xu, JP; Wang, XM; Yang, GW; Yan, P; Wen, GZ; Zhang, YT; Niu, RG; Nan, PH; He, J; Zhou, HM				Chen, Z.; Li, J.; Li, Q. S.; Fan, J. Q.; Dong, X. M.; Xu, J. P.; Wang, X. M.; Yang, G. W.; Yan, P.; Wen, G. Z.; Zhang, Y. T.; Niu, R. G.; Nan, P. H.; He, J.; Zhou, H. M.			Suppression of PPN/MG61 attenuates Wnt/beta-catenin signaling pathway and induces apoptosis in human lung cancer	ONCOGENE			English	Article						lung cancer; PPN/MG61; apoptosis; wnt; diagnosis	MONOCLONAL-ANTIBODY; WNT; CELLS; GENE; INHIBITION; WINGLESS	Wingless and int homologue (Wnt) family proteins have been shown to have important roles in the decision of cell fate and behavior at multiple stages during the development and tumorigenesis. One of the Drosophila segment polarity genes, porcupine (porc) gene, encodes an evolutionarily conserved endoplasmic reticulum membrane protein involving in the post-translational processing of the Wnt family proteins. Here, we report that human homologue of Drosophila porc gene, PPN/MG61, was abundantly expressed in human cancer cell lines, but not in normal cells. We also found that PPN/MG61 was overexpressed in primary lung cancer tissue samples, compared to their matched normaltis sue samples. Furthermore, when we used small interfering RNA to knock down PPN/MG61 mRNA in lung cancer cells expressing the gene, we observed apoptosis induction, along with decreased activity of Wnt pathway in those lung cancer cells. These data suggest that PPN/MG61 may be a novel marker for human lung cancer and that post-translational modification of the Wnt signal molecules by PPN/MG61 may be important for the function of Wnt pathway in lung cancer.	[Chen, Z.; Li, J.; Li, Q. S.; Fan, J. Q.; Zhou, H. M.] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China; [Dong, X. M.; Xu, J. P.] Beijing ACCB Biotech Ltd, Beijing, Peoples R China; [Wang, X. M.; Yang, G. W.] Beijing Hosp Tradit Chinese Med, Beijing, Peoples R China; [Yan, P.] Hengxing Hosp, Internal Curat Dept Oncol, Baoding, Hebei, Peoples R China; [Wen, G. Z.; Zhang, Y. T.] Chengde N Hosp, Chengdu, Hebei, Peoples R China; [Niu, R. G.] Shanxi Tumor Hosp, Taiyuan, Shanxi, Peoples R China; [Nan, P. H.] Taigang Gen Hosp, Taiyuan, Shanxi, Peoples R China; [He, J.] Chinese Acad Med Sci, Canc Hosp, Beijing 100037, Peoples R China; [Zhou, H. M.] Tsinghua Univ, Yangtze Delta Reg Inst, Jiaxing, Zhejiang, Peoples R China	Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Tsinghua University	Zhou, HM (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, 1 Qinghuayuan, Beijing 100084, Peoples R China.	zhm-dbs@tsinghua.edu.cn						Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359-6101(00)00011-3; Caricasole A, 2002, GENE, V288, P147, DOI 10.1016/S0378-1119(02)00467-5; He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Katoh M, 2005, ONCOL REP, V14, P1583; Mazieres J, 2005, INT J CANCER, V117, P326, DOI 10.1002/ijc.21160; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; Mikami I, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-53; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Millar JBA, 2002, GENOME BIOL, V3; Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; Tanaka K, 2000, EUR J BIOCHEM, V267, P4300, DOI 10.1046/j.1432-1033.2000.01478.x; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Widelitz R, 2005, GROWTH FACTORS, V23, P111, DOI 10.1080/08977190500125746; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Winn RA, 2005, J BIOL CHEM, V280, P19625, DOI 10.1074/jbc.M409392200; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227; You L, 2004, CANCER RES, V64, P3474, DOI 10.1158/0008-5472.CAN-04-0115; Zhai L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/jbc.M403407200	26	20	20	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3483	3488		10.1038/sj.onc.1211006	http://dx.doi.org/10.1038/sj.onc.1211006			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193088				2022-12-28	WOS:000256309900013
J	Kim, JM; Kakusho, N; Yamada, M; Kanoh, Y; Takemoto, N; Masai, H				Kim, J. M.; Kakusho, N.; Yamada, M.; Kanoh, Y.; Takemoto, N.; Masai, H.			Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint	ONCOGENE			English	Article						Cdc7; DNA replication checkpoint; hydroxyurea; Chk1	HUMAN CDC7-RELATED KINASE; FORK PROTECTION COMPLEX; S-PHASE ARREST; FISSION YEAST; CELL-CYCLE; GENOTOXIC STRESS; SCHIZOSACCHAROMYCES-POMBE; EFFICIENT PROGRESSION; DAMAGE RESPONSE; PROTEIN-KINASE	Cdc7 kinase is evolutionarily conserved and is involved in initiation and progression of DNA replication. However, roles of Cdc7 in checkpoint responses remain largely unknown. In this study, we show that deletion of the Cdc7 genes in mouse embryonic stem (ES) cells abrogates hydroxyurea (HU)- or UV-induced activation of Chk1. HU-induced Chk1 activation is also impaired in human cancer cell lines in which Cdc7 is depleted by siRNA, and Cdc7-depleted cells are more sensitive to HU treatment. In contrast, ATR and Rad17 are relocated to chromatin in these cells following HU treatment, indicating that stalled DNA replication forks are detected normally. Cdc7-depleted cells exhibit defects in chromatin association and phosphorylation of Claspin, suggesting that Cdc7 exerts its effect at least partially through Claspin. Consistent with this prediction, Cdc7 interacts with and phosphorylates Claspin. We propose that Cdc7 is required for activation of the ATR-Chk1 checkpoint pathway through regulation of Cl aspin.	[Kim, J. M.; Kakusho, N.; Yamada, M.; Kanoh, Y.; Masai, H.] Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Bunkyo Ku, Tokyo 1138613, Japan; [Takemoto, N.] Tokyo Metropolitan Inst Med Sci, Cytokine Project, Bunkyo Ku, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	hmasai@rinshoken.or.jp						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, J BIOL CHEM, V280, P35337, DOI 10.1074/jbc.M506460200; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lee J, 2005, MOL BIOL CELL, V16, P5269, DOI 10.1091/mbc.E05-07-0671; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H, 2006, J BIOL CHEM, V281, P39249, DOI 10.1074/jbc.M608935200; Matsumoto S, 2005, J BIOL CHEM, V280, P42536, DOI 10.1074/jbc.M510575200; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Montagnoli A, 2004, CANCER RES, V64, P7110, DOI 10.1158/0008-5472.CAN-04-1547; Nedelcheva MN, 2005, J MOL BIOL, V347, P509, DOI 10.1016/j.jmb.2005.01.041; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Sclafani RA, 2000, J CELL SCI, V113, P2111; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Sommariva E, 2005, MOL CELL BIOL, V25, P2770, DOI 10.1128/MCB.25.7.2770-2784.2005; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tenca P, 2007, J BIOL CHEM, V282, P208, DOI 10.1074/jbc.M604457200; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200; Yoshizawa-Sugata N, 2007, J BIOL CHEM, V282, P2729, DOI 10.1074/jbc.M605596200; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhao H, 2003, MOL CELL BIOL, V23, P8395, DOI 10.1128/MCB.23.22.8395-8403.2003; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	51	74	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3475	3482		10.1038/sj.onc.1210994	http://dx.doi.org/10.1038/sj.onc.1210994			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18084324				2022-12-28	WOS:000256309900012
J	Ruddell, A; Kelly-Spratt, KS; Furuya, M; Parghi, SS; Kemp, CJ				Ruddell, A.; Kelly-Spratt, K. S.; Furuya, M.; Parghi, S. S.; Kemp, C. J.			p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis	ONCOGENE			English	Article						lymph node; lymphangiogenesis; metastasis; p53; p19/Arf	PROMOTES TUMOR-METASTASIS; GROWTH FACTOR-C; VEGF-C; MELANOMA METASTASIS; BREAST-CANCER; SKIN TUMORS; INDUCTION; CELLS; MICE; VASCULATURE	The ability of tumor cells to metastasize is increasingly viewed as an interaction between the primary tumor and host tissues. Deletion of the p19/Arf or p53 tumor suppressor genes accelerates malignant progression and metastatic spread of 7,12-dimethylbenz(a) anthracene (DMBA)/12-O-tetradecanoyl-phorbol-13-acetate (TPA)induced squamous cell carcinomas, providinga model system to address mechanisms of metastasis. Here, we show that benign pre-metastatic papillomas from wildtype mice trigger lymphangiogenesis within draining lymph nodes, whereas there is no growth of primary tumor lymphatic vessels. Lymph node lymphangiogenesis is greatly accelerated in papilloma-bearing p19/Arf- or p53-deficient mice, which coincides with the greater propensity of these tumors to progress to carcinomas and to metastasize. The extent of accumulation of B cells within the tumor-draininglymph nodes of wild-type mice predicted the level of lymph node lymphangiogenesis and metastatic potential. Arf or p53 deficiency strongly accelerated lymph node immune cell accumulation, in a manner that was associated with the extent of lymph node lymphatic sinus growth. This immune cell accumulation and lymph node lymphangiogenesis phenotype identifies host anti-tumor responses that could drive metastatic spread of cancers via the lymphatics.	[Ruddell, A.; Kelly-Spratt, K. S.; Furuya, M.; Parghi, S. S.; Kemp, C. J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,MS-C2-023,POB 19024, Seattle, WA 98109 USA.	aruddell@fhcrc.org		Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01-CA99517, R01-CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA099517, R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 2006, INT J CANCER, V119, P1755, DOI 10.1002/ijc.21899; Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Angeli V, 2006, IMMUNITY, V24, P203, DOI 10.1016/j.immuni.2006.01.003; Baldwin ME, 2002, BIOESSAYS, V24, P1030, DOI 10.1002/bies.10173; Brown DM, 2001, IMMUNOLOGY, V102, P486, DOI 10.1046/j.1365-2567.2001.01213.x; BURNS PA, 1991, ONCOGENE, V6, P2363; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Dadras SS, 2005, MODERN PATHOL, V18, P1232, DOI 10.1038/modpathol.3800410; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FARR A, 1993, J IMMUNOL, V150, P1160; Harrell MI, 2007, AM J PATHOL, V170, P774, DOI 10.2353/ajpath.2007.060761; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; IOACHIM HL, 2002, IOACHIMS LYMPH NODE; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kerjaschki D, 2005, J CLIN INVEST, V115, P2316, DOI 10.1172/JCI26354; Krishnan J, 2003, CANCER RES, V63, P713; LEPPINK DM, 1989, TRANSPLANTATION, V48, P874, DOI 10.1097/00007890-198911000-00032; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Nathanson SD, 2003, CANCER, V98, P413, DOI 10.1002/cncr.11464; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Roberts N, 2006, CANCER RES, V66, P2650, DOI 10.1158/0008-5472.CAN-05-1843; Ruddell A, 2003, AM J PATHOL, V163, P2233, DOI 10.1016/S0002-9440(10)63581-X; Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shimizu K, 2004, CANCER SCI, V95, P328, DOI 10.1111/j.1349-7006.2004.tb03211.x; Skelton D, 2001, GENE THER, V8, P1813, DOI 10.1038/sj.gt.3301586; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stacker SA, 2002, FASEB J, V16, P922, DOI 10.1096/fj.01-0945rev; Van den Eynden GG, 2006, BRIT J CANCER, V95, P1362, DOI 10.1038/sj.bjc.6603443; Wong SY, 2006, CELL CYCLE, V5, P812, DOI 10.4161/cc.5.8.2646	42	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3145	3155		10.1038/sj.onc.1210973	http://dx.doi.org/10.1038/sj.onc.1210973			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18059331				2022-12-28	WOS:000255897600007
J	Sasaki, H; Hayakawa, J; Terai, Y; Kanemura, M; Tanabe-Kimura, A; Kamegai, H; Seino-Noda, H; Ezoe, S; Matsumura, I; Kanakura, Y; Sakata, M; Tasaka, K; Ohmichi, M				Sasaki, H.; Hayakawa, J.; Terai, Y.; Kanemura, M.; Tanabe-Kimura, A.; Kamegai, H.; Seino-Noda, H.; Ezoe, S.; Matsumura, I.; Kanakura, Y.; Sakata, M.; Tasaka, K.; Ohmichi, M.			Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines	ONCOGENE			English	Article						ovarian cancer; estrogen; raloxifene; SRC-1	HEALTHY POSTMENOPAUSAL WOMEN; RANDOMIZED CONTROLLED-TRIAL; VASCULAR ENDOTHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; BREAST-CANCER; C-MYC; CYCLE PROGRESSION; RECEPTOR-ALPHA; PROTEIN-KINASE; GROWTH-FACTORS	Although there is growing evidence that estrogens promote tumor progression in epithelial ovarian cancer, the molecular mechanisms accounting for this are still unclear. Selective estrogen receptor modulators ( SERMs) mimic estrogen action in certain tissues while opposing it in others. The molecular mechanisms of the effects of SERMs such as raloxifene on the tumor progression of epithelial ovarian cancer are also still unclear. Here, we show that various genomic actions of estrogen differ from those of raloxifene in human ovarian cancer cell lines expressing estrogen receptor alpha (ER alpha). 17 beta-Estradiol (E2) induced the gene expression of c-Myc and IGF-1 and increased the binding of ER alpha to the AP1 site of the promoters of c-Myc and IGF-1. ER alpha silencing abolished the E2-stimulated c-Myc expression. E2 induced the recruitment of co-activators such as SRC-1, SRC-3 and CBP to the promoters of c-Myc and IGF-1, and SRC-1 silencing abolished both the E2-stimulated c-Myc expression and cell-cycle progression. In contrast, although raloxifene increased the binding of ER alpha to the AP1 site of the promoters of c-Myc and IGF-1, raloxifene had no effect on the gene expression of c-Myc or IGF-1. Raloxifene induced the recruitment of co-repressors such as HDAC2, N-CoR and SMRT to the promoter of IGF-1. Thus, the difference between the genomic actions exerted by estrogen and raloxifene in human ovarian cancer cell lines expressing ERa appear to be dependent on the recruitment of co-regulators.	[Sasaki, H.; Terai, Y.; Kanemura, M.; Tanabe-Kimura, A.; Kamegai, H.; Ohmichi, M.] Osaka Med Coll, Dept Obstet & Gynecol, Takatsuki, Osaka 5698686, Japan; [Hayakawa, J.; Seino-Noda, H.; Sakata, M.; Tasaka, K.] Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 565, Japan; [Ezoe, S.; Matsumura, I.; Kanakura, Y.] Osaka Univ, Sch Med, Dept Hematol & Oncol, Suita, Osaka 565, Japan	Osaka Medical College; Osaka University; Osaka University	Ohmichi, M (corresponding author), Osaka Med Coll, Dept Obstet & Gynecol, 2-7 Daigakutyou, Takatsuki, Osaka 5698686, Japan.	masa@gyne.med.osaka-u.ac.jp						Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Bardin A, 2004, CANCER RES, V64, P5861, DOI 10.1158/0008-5472.CAN-04-0552; BERNS EMJJ, 1992, INT J CANCER, V52, P218, DOI 10.1002/ijc.2910520211; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; CELANO P, 1989, BIOTECHNIQUES, V7, P942; Chow SN, 1996, INT SURG, V81, P152; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cunat S, 2004, GYNECOL ONCOL, V94, P25, DOI 10.1016/j.ygyno.2004.03.026; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; DUBIK D, 1992, ONCOGENE, V7, P1587; Girault I, 2003, CLIN CANCER RES, V9, P1259; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; HAMILTON TC, 1985, BIOCHEM PHARMACOL, V34, P2583, DOI 10.1016/0006-2952(85)90551-9; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hewitt SC, 2005, SCIENCE, V307, P1572, DOI 10.1126/science.1110345; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Hussein-Fikret S, 2005, MOL CELL ENDOCRINOL, V229, P149, DOI 10.1016/j.mce.2004.08.005; Kawagoe J, 2003, J BIOL CHEM, V278, P43363, DOI 10.1074/jbc.M304363200; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; Kimura A, 2004, ONCOGENE, V23, P4505, DOI 10.1038/sj.onc.1207582; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LACEY JV, 2002, JAMA-J AM MED ASSOC, V288, P3344; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P1302, DOI 10.1210/en.2003-0709; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P49, DOI 10.1210/en.2003-0792; Mawson A, 2005, MOL CELL ENDOCRINOL, V229, P161, DOI 10.1016/j.mce.2004.08.002; MURPHY LJ, 1991, J STEROID BIOCHEM, V40, P223, DOI 10.1016/0960-0760(91)90186-9; Neven P, 2002, GYNECOL ONCOL, V85, P388, DOI 10.1006/gyno.2001.6578; Oishi A, 2004, BIOCHEM BIOPH RES CO, V324, P193, DOI 10.1016/j.bbrc.2004.09.032; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VANDAM PA, 1994, J CLIN PATHOL, V47, P914, DOI 10.1136/jcp.47.10.914; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445; Webb Paul, 2003, Nucl Recept, V1, P4, DOI 10.1186/1478-1336-1-4; Weiss NS, 2001, LANCET, V358, P438, DOI 10.1016/S0140-6736(01)05669-0	38	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2737	2745		10.1038/sj.onc.1210926	http://dx.doi.org/10.1038/sj.onc.1210926			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18193094				2022-12-28	WOS:000255259500008
J	Toschi, A; Edelstein, J; Rockwell, P; Ohh, M; Foster, DA				Toschi, A.; Edelstein, J.; Rockwell, P.; Ohh, M.; Foster, D. A.			HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase	ONCOGENE			English	Article						phospholipase D; HIF alpha; VHL; survival; signals; apoptosis; hypoxia	TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTORS; HIPPEL-LINDAU PROTEIN; PHOSPHATIDIC-ACID; SURVIVAL SIGNALS; FIBRONECTIN MATRIX; MTOR; PATHWAY; D2; INHIBITION	Loss of the von Hippel-Lindau (VHL) tumor suppressor gene contributes to proliferative disorders including renal cell carcinoma. The consequence of VHL loss is increased levels of hypoxia-inducible factor-alpha (HIF alpha), which is targeted for proteolytic degradation by the VHL gene product pVHL. HIF is a transcription factor that increases the expression of factors critical for tumorigenesis in renal cell carcinoma. We report here another regulatory component of HIFa expression in renal cancer cells. Phospholipase D (PLD), which is commonly elevated in renal and other cancers, is required for elevated levels of both HIF1 alpha and HIF2 alpha in VHL-deficient renal cancer cells. The induction of both HIF1 alpha and HIF2 alpha by hypoxic mimetic conditions was also dependent on PLD in renal cancer cells with restored pVHL expression. The effect of PLD activity upon HIFa expression was at the level of translation. PLD activity also provides a survival signal that suppresses apoptosis induced by serum deprivation in the renal cancer cells. Suppression of HIF2 alpha has been shown to reverse tumorigenesis with renal cancer cells. The finding here that HIF2a expression is dependent on PLD in renal cancer cells suggests that targeting PLD signals may represent an alternative therapeutic strategy for targeting HIF2 alpha in renal cancers where HIF2 alpha is critical for tumorigenesis and elevated PLD activity is common.	[Toschi, A.; Edelstein, J.; Rockwell, P.; Foster, D. A.] CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; [Ohh, M.] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON, Canada	City University of New York (CUNY) System; Hunter College (CUNY); University of Toronto	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foster DA, 2003, MOL CANCER RES, V1, P789; Foster DA, 2006, CURR SIGNAL TRANSD T, V1, P295, DOI 10.2174/157436206778226941; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Foster David A, 2004, Expert Rev Anticancer Ther, V4, P691, DOI 10.1586/14737140.4.4.691; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hickey MM, 2006, CURR TOP DEV BIOL, V76, P217, DOI 10.1016/S0070-2153(06)76007-0; Hui L, 2005, J BIOL CHEM, V280, P35829, DOI 10.1074/jbc.M504192200; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ohh M, 2006, NEOPLASIA, V8, P623, DOI 10.1593/neo.06442; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rodrik V, 2005, MOL CELL BIOL, V25, P7917, DOI 10.1128/MCB.25.17.7917-7925.2005; Rodrik V, 2006, FEBS LETT, V580, P5647, DOI 10.1016/j.febslet.2006.09.013; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719; Zheng Y, 2006, J BIOL CHEM, V281, P15862, DOI 10.1074/jbc.M600660200; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	37	36	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2008	27	19					2746	2753		10.1038/sj.onc.1210927	http://dx.doi.org/10.1038/sj.onc.1210927			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998935				2022-12-28	WOS:000255259500009
J	Beach, S; Tang, H; Park, S; Dhillon, AS; Keller, ET; Kolch, W; Yeung, KC				Beach, S.; Tang, H.; Park, S.; Dhillon, A. S.; Keller, E. T.; Kolch, W.; Yeung, K. C.			Snail is a repressor of RK1P transcription in metastatic prostate cancer cells	ONCOGENE			English	Article						regulation of RKIP expression; EMT; prostate cancer metastasis	KINASE INHIBITOR PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN; UP-REGULATION; EXPRESSION; HYPERMETHYLATION	Diminished expression of the metastasis suppressor protein RKIP was previously reported in a number of cancers. The underlying mechanism remains unknown. Here, we show that the expression of RKIP negatively correlates with that of Snail zinc-transcriptional repressor, a key modulator of normal and neoplastic epithelial-mesenchymal transition (EMT) program. With a combination of loss-of-function and gain-of-function approaches, we showed that Snail repressed the expression of RKIP in metastatic prostate cancer cell lines. The effect of Snail on RKIP was on the level of transcriptional initiation and mediated by a proximal E-box on the RKIP promoter. Our results therefore suggest that RKIP is a novel component of the Snail transcriptional regulatory network important for the progression and metastasis of cancer.	[Beach, S.; Tang, H.; Park, S.; Yeung, K. C.] Univ Toledo, Coll Med, Dept Biochem & Canc Biol, Toledo, OH 43614 USA; [Keller, E. T.] Univ Michigan Hlth Syst, Ctr Comprehens Canc, Ann Arbor, MI USA; [Keller, E. T.; Kolch, W.] Univ Michigan Hlth Syst, Dept Urol, Ann Arbor, MI USA; [Dhillon, A. S.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Kolch, W.] Univ Glasgow, Sir Henry Wellcome Funct Genom Facil, Glasgow G12 8QQ, Lanark, Scotland	University System of Ohio; University of Toledo; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Beatson Institute; University of Glasgow	Yeung, KC (corresponding author), Univ Toledo, Coll Med, Dept Biochem & Canc Biol, Hlth Sci Campus,BHSB Room 469,3035 Arlington Ave, Toledo, OH 43614 USA.	kam.yeung@utoledo.edu	Keller, Evan T/M-1446-2016; Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021	Keller, Evan T/0000-0002-7592-7535; Kolch, Walter/0000-0001-5777-5016; Dhillon, Amardeep/0000-0002-6065-663X	NATIONAL CANCER INSTITUTE [R01CA098513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064767] Funding Source: NIH RePORTER; Cancer Research UK Funding Source: Medline; NCI NIH HHS [R01 CA098513-05, R01 CA098513] Funding Source: Medline; NIGMS NIH HHS [R01 GM064767, R01 GM64767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Cancer Research UK(Cancer Research UK); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Mulla F, 2006, J CLIN ONCOL, V24, P5672, DOI 10.1200/JCO.2006.07.5499; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Knight S.W., 2001, SCIENCE, V2, P2; Lee HC, 2006, GASTROENTEROLOGY, V131, P1208, DOI 10.1053/j.gastro.2006.07.012; Nakayama H, 1998, DEV BIOL, V199, P150, DOI 10.1006/dbio.1998.8914; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Schuierer MM, 2006, ONCOL REP, V16, P451; Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2; Zhang LZ, 2004, SURGERY, V136, P708, DOI 10.1016/j.surg.2003.12.013; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	31	136	148	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2243	2248		10.1038/sj.onc.1210860	http://dx.doi.org/10.1038/sj.onc.1210860			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952120	Green Accepted			2022-12-28	WOS:000254621300015
J	Morozov, VM; Massoll, NA; Vladimirova, OV; Maul, GG; Ishov, AM				Morozov, V. M.; Massoll, N. A.; Vladimirova, O. V.; Maul, G. G.; Ishov, A. M.			Regulation of c-met expression by transcription repressor Daxx	ONCOGENE			English	Article						Daxx; c-met; transcription; DNA methylation; histone acetylation; metastatic breast cancer	HEPATOCYTE GROWTH-FACTOR; FACTOR RECEPTOR; HGF RECEPTOR; FUNCTIONAL INTERACTIONS; EPITHELIAL-CELLS; SYNDROME PROTEIN; PROTOONCOGENE; INHIBITION; ACTIVATION; CANCER	The protooncogene c-met encodes the tyrosine kinase receptor for the hepatocyte growth factor/scatter factor (HGF/SF). While overexpression of c-met is documented in many types of tumors, the mechanism of c-met regulation remains elusive. Here, we demonstrate Daxx as a repressor of c-met transcription. The expression of c-met is elevated in Daxx knockout mouse cells and is reversed by Daxx reconstitution. C-met promoter analysis of Daxx(-/-) cells reveled changes in chromatin acetylation, but not in DNA methylation. Daxx binds to the mouse c-met promoter and Daxx-binding region is sufficient for transcription repression, while HDAC2 is associated with c-met promoter mostly in Daxx(+/+) cells, pointing to Daxx-dependent HDAC2 recruitment as a potential mechanism of c-met repression. HGF-induced cell mobility and invasion confirmed augmented activity of c-Met/HGF pathway in Daxx(-/-) cells. Finally, inverse correlation between Daxx and c-Met in cancer cell lines and in metastatic breast cancer specimens suggests potential function of Daxx as a c-met repressor during cancer progression.	[Morozov, V. M.; Ishov, A. M.] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Morozov, V. M.; Ishov, A. M.] Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; [Massoll, N. A.] Univ Florida, Dept Pathol, Gainesville, FL 32610 USA; [Massoll, N. A.] Univ Florida, Lab Med, Gainesville, FL 32610 USA; [Vladimirova, O. V.; Maul, G. G.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; The Wistar Institute	Ishov, AM (corresponding author), Univ Florida, Dept Anat & Cell Biol, 1376 Mowry Rd,Room 358, Gainesville, FL 32610 USA.	ishov@ufl.edu	Ishov, Alexander/E-4912-2010	Morozov, Viacheslav/0000-0002-4901-7722				Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boon EMJ, 2002, CANCER RES, V62, P5126; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Gambarotta G, 1996, ONCOGENE, V13, P1911; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Leroy C, 2006, ANN NY ACAD SCI, V1090, P188, DOI 10.1196/annals.1378.021; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Morotti A, 2002, ONCOGENE, V21, P4885, DOI 10.1038/sj.onc.1205622; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Ohiro Y, 2003, MOL CELL BIOL, V23, P322, DOI 10.1128/MCB.23.1.322-334.2003; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002; Seol DW, 1999, J BIOL CHEM, V274, P3565, DOI 10.1074/jbc.274.6.3565; Seol DW, 2000, ONCOGENE, V19, P1132, DOI 10.1038/sj.onc.1203404; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tang J, 2004, J BIOL CHEM, V279, P20369, DOI 10.1074/jbc.M401321200; Tzeng SL, 2006, J BIOL CHEM, V281, P15405, DOI 10.1074/jbc.M601807200; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100; Zhang XH, 2005, AM J PHYSIOL-RENAL, V288, pF16, DOI 10.1152/ajprenal.00318.2003; Zhang XH, 2003, AM J PHYSIOL-RENAL, V284, pF1216, DOI 10.1152/ajprenal.00426.2002; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	35	33	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2177	2186		10.1038/sj.onc.1210865	http://dx.doi.org/10.1038/sj.onc.1210865			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952115				2022-12-28	WOS:000254621300008
J	Kim, MS; Chang, X; Nagpal, JK; Yamashita, K; Baek, JH; Dasgupta, S; Wu, G; Osada, M; Woo, JH; Westra, WH; Trink, B; Ratovitski, EA; Moon, C; Sidransky, D				Kim, M. S.; Chang, X.; Nagpal, J. K.; Yamashita, K.; Baek, J. H.; Dasgupta, S.; Wu, G.; Osada, M.; Woo, J-H; Westra, W. H.; Trink, B.; Ratovitski, E. A.; Moon, C.; Sidransky, D.			The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth	ONCOGENE			English	Article						NMDAR2A; promoter hypermethylation; colon cancer; 5-aza-2'-deoxycytidine; tumor suppressor; biomarker	DISCS LARGE; PROMOTER METHYLATION; GENE-EXPRESSION; HUMAN HOMOLOG; LUNG-CANCER; HUMAN BRAIN; NMDA; HYPERMETHYLATION; BIOMARKER; PATTERNS	N-methyl-D-aspartate receptors (NMDARs) are the predominant excitatory neurotransmitter receptors in the mammalian brain. We found that among the three NMDARs examined (NMDAR1, NMDAR2A, NMDAR2B), only NMDAR2A was silenced in colorectal carcinoma (CRC) cell lines at basal line and reactivated by the demethylating agent, 5-aza-2'-deoxycytidine. NMDAR2A was expressed in normal colon epithelium, while expression was hardly detectable in colon cancer tissues. Promoter methylation of NMDAR2A was confirmed by bisulfite sequencing and combined bisulfite restriction analysis in the CRC cell lines and primary tumors. Quantitative methylation-specific PCR demonstrated NMDAR2A promoter hypermethylation in 82 of 100 primary human CRC, 15 of 100 normal corresponding epithelial tissues and 1 of 11 (9%) normal colon mucosa samples obtained from patients without cancer. Moreover, forced expression of full-length NMDAR2A in CRC cell lines induced apoptosis and almost abolished the ability of the cells to form colonies in culture, while NMDAR2A knockdown increased cell growth. Thus, NMDAR2A is commonly hypermethylated in primary human CRC and possesses tumor-suppressive activity.	[Kim, M. S.; Chang, X.; Nagpal, J. K.; Yamashita, K.; Dasgupta, S.; Wu, G.; Osada, M.; Woo, J-H; Trink, B.; Ratovitski, E. A.; Moon, C.; Sidransky, D.] Johns Hopkins Univ, Dept Otolaryngol, Head & Neck Canc Res Div, Baltimore, MD 21231 USA; [Baek, J. H.] Johns Hopkins Univ, Inst Cell Engn, Dept Med Genet, Baltimore, MD 21231 USA; [Westra, W. H.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sidransky, D (corresponding author), Johns Hopkins Univ, Dept Otolaryngol, Head & Neck Canc Res Div, 1550 Orleans St, Baltimore, MD 21231 USA.	dsidrans@jhmi.edu						Anegawa NJ, 2000, MOL BRAIN RES, V77, P163, DOI 10.1016/S0169-328X(00)00050-4; Azim AC, 1995, GENOMICS, V30, P613, DOI 10.1006/geno.1995.1286; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Choi SW, 2004, J ORAL PATHOL MED, V33, P533, DOI 10.1111/j.1600-0714.2004.00226.x; Ebert MPA, 2005, NEOPLASIA, V7, P771, DOI 10.1593/neo.05235; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Fang JY, 2004, CELL RES, V14, P217, DOI 10.1038/sj.cr.7290222; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Gonzalez-Cadavid NF, 2000, J ANDROL, V21, P566; Gruber AD, 1999, CANCER RES, V59, P5488; Haraguchi K, 2000, GENES CELLS, V5, P905, DOI 10.1046/j.1365-2443.2000.00374.x; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jeronimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747; Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608; KIM MS, 2007, IN PRESS CLIN CANC R; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Ludford-Menting MJ, 2002, J BIOL CHEM, V277, P4477, DOI 10.1074/jbc.M108479200; Mandelker DL, 2005, CANCER RES, V65, P4963, DOI 10.1158/0008-5472.CAN-04-3923; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Palmisano WA, 2000, CANCER RES, V60, P5954; Pillozzi S, 2002, LEUKEMIA, V16, P1791, DOI 10.1038/sj.leu.2402572; Rootwelt T, 1998, J NEUROCHEM, V71, P1544; Said SI, 1996, P NATL ACAD SCI USA, V93, P4688, DOI 10.1073/pnas.93.10.4688; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Saur D, 2002, AM J PHYSIOL-GASTR L, V282, pG349, DOI 10.1152/ajpgi.00226.2001; Schito AM, 1997, NEUROSCI LETT, V239, P49, DOI 10.1016/S0304-3940(97)00853-7; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Stepulak A, 2005, P NATL ACAD SCI USA, V102, P15605, DOI 10.1073/pnas.0507679102; Weaver KD, 2006, CANCER INVEST, V24, P35, DOI 10.1080/07357900500449546; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yanai H, 2000, GENES CELLS, V5, P815, DOI 10.1046/j.1365-2443.2000.00368.x	36	28	31	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					2045	2054		10.1038/sj.onc.1210842	http://dx.doi.org/10.1038/sj.onc.1210842			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922030				2022-12-28	WOS:000254359100009
J	Choi, D; Lee, SJ; Hong, S; Kim, IH; Kang, S				Choi, D.; Lee, S-J; Hong, S.; Kim, I-H; Kang, S.			Prohibitin interacts with RNF2 and regulates E2F1 function via dual pathways	ONCOGENE			English	Article						prohibitin; RNF2; E2F1; p16; cell cycle	RB; REPRESSION; SUPPRESSOR; P53	Prohibitin, a tumor suppresser protein, plays an important role in the transcriptional regulation of various genes involved in cell-cycle control and proliferation. Recent studies have reported that the growth-suppressive property of the prohibitin protein is exhibited in its physical interaction with E2F family proteins and its subsequent repression of their transcriptional activity. Herein, we report that prohibitin interacts with RING finger protein 2 (RNF2), a member of the PcG (polycomb-group) family of proteins, and that the two proteins regulate the activity of E2F1 via dual pathways: the direct, prohibitin-mediated pathway and the indirect, p16-mediated pathway of E2F1 transcriptional regulation. Co-immunoprecipitation experiments showed that endogenous prohibitin interacts with endogenous RNF2. Interestingly, the expressed amounts of RNF2 and prohibitin were interdependently affected at the post-translational level. Furthermore, the depletion of either endogenous RNF2 or prohibitin using the RNA interference technique increased the level of p16 protein expression, resulting in a decrease in the transcriptional activity of E2F1 via the p16-CDK4-Rb pathway. In addition, chromatin immunoprecipitation assays showed that RNF2 was recruited to E2F1-response promoters along with prohibitin to inhibit the transcriptional activity of E2F1. Cell proliferation was also regulated by the prohibitin-RNF2 interaction. These results suggest that the RNF2-prohibitin complex regulates the activity of E2F1 via dual pathways.	[Choi, D.; Lee, S-J; Hong, S.; Kim, I-H; Kang, S.] Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Korea University	Kang, S (corresponding author), Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	skang@korea.ac.kr						Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Kim H, 2004, J AM SOC NEPHROL, V15, P2042, DOI 10.1097/01.ASN.0000133490.00348.59; Lee SJ, 2005, BIOCHEM J, V389, P457, DOI 10.1042/BJ20041982; Lee SJ, 2001, FEBS LETT, V503, P61, DOI 10.1016/S0014-5793(01)02689-8; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; SATO T, 1993, GENOMICS, V17, P762, DOI 10.1006/geno.1993.1402; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sherr CJ, 2000, CANCER RES, V60, P3689; Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005; Zhu LA, 2005, EUR J CANCER, V41, P2415, DOI 10.1016/j.ejca.2005.08.009	18	44	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1716	1725		10.1038/sj.onc.1210806	http://dx.doi.org/10.1038/sj.onc.1210806			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17873902				2022-12-28	WOS:000253962100007
J	Hafner, N; Driesch, C; Gajda, M; Jansen, L; Kirchmayr, R; Runnebaum, IB; Durst, M				Hafner, N.; Driesch, C.; Gajda, M.; Jansen, L.; Kirchmayr, R.; Runnebaum, I. B.; Duerst, M.			Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts	ONCOGENE			English	Article						cervical cancer; HPV16; oncogene expression; physical state; integration	HUMAN-PAPILLOMAVIRUS TYPE-16; RISK HUMAN-PAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; IN-SITU HYBRIDIZATION; GENE-EXPRESSION; DNA-REPLICATION; E7 ONCOPROTEIN; MESSENGER-RNA; CANCER-CELLS; DIPS-PCR	Virus integration into the host genome is a characteristic step during cervical carcinogenesis. Experimental data provide evidence that integration could result in increased levels of oncogene (E6/E7) transcripts. This is the first study in which the level of viral transcripts is correlated to the physical state of the viral genome in cervical intraepithelial neoplasia (CIN) and cervical carcinomas (CxCa). Using the APOT-assayinteg rate-derived transcripts only were detected in 3/28 (11%) CIN and in 28/55 (51%) carcinomas, respectively. The remaining biopsies contained either episome-derived transcripts only or both mRNA species. SybrGreen real time reverse transcriptase-PCR assays were used to quantify viral gene expression for (i) all transcripts initiated from p97, (ii) full-length E6, (iii) E6*I and (iv) E5 transcripts (E6/E7) transcript levels showed a broad distribution but similar median values irrespective of histopathological grading and physical state of the viral genome. Biopsies with integrate-derived transcripts only generally lacked E5-specific mRNA. Our data do not support the hypothesis that HPV integration invariably results in high levels of oncogene transcripts. Instead, constitutive expression of oncogene transcripts rather than the level of expression appears to be decisive for transformation and the maintenance of the malignant phenotype.	[Hafner, N.; Driesch, C.; Jansen, L.; Runnebaum, I. B.; Duerst, M.] FSU Jena, Frauenklin, D-07743 Jena, Germany; [Gajda, M.] Klinikum Friedrich Schiller Univ, Inst Pathol, Jena, Germany; [Kirchmayr, R.] Gynakol Praxis, Ulm, Germany	Friedrich Schiller University of Jena	Durst, M (corresponding author), FSU Jena, Frauenklin, Bachstr 18, D-07743 Jena, Germany.	matthias.duerst@med.uni-jena.de	Häfner, Norman/B-6892-2012	Häfner, Norman/0000-0002-7012-483X				Alazawi W, 2002, CANCER RES, V62, P6959; Andersson S, 2006, INT J ONCOL, V29, P705; Arends MJ, 1998, J CLIN PATHOL, V51, P96, DOI 10.1136/jcp.51.2.96; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; De Marco L, 2007, J CLIN VIROL, V38, P7, DOI 10.1016/j.jcv.2006.09.008; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; Durst M, 1995, CANCER GENET CYTOGEN, V85, P105, DOI 10.1016/0165-4608(95)00155-7; DURST M, 1987, ONCOGENE, V1, P251; FALCINELLI C, 1993, J MED VIROL, V40, P261, DOI 10.1002/jmv.1890400402; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Hammerly C, 2022, LINGUIST INQ, V53, P823, DOI 10.1162/ling_a_00422; Hopman AHN, 2005, INT J CANCER, V115, P419, DOI 10.1002/ijc.20862; Itoshima T, 2000, CLIN CANCER RES, V6, P2851; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Klaes R, 1999, CANCER RES, V59, P6132; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Melsheimer P, 2004, CLIN CANCER RES, V10, P3059, DOI 10.1158/1078-0432.CCR-03-0565; Middleton K, 2003, J VIROL, V77, P10186, DOI 10.1128/JVI.77.19.10186-10201.2003; Molden T, 2005, CANCER EPIDEM BIOMAR, V14, P367, DOI 10.1158/1055-9965.EPI-04-0410; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Munoz N, 1992, IARC Sci Publ, P251; Nakagawa S, 2000, J MED VIROL, V62, P251, DOI 10.1002/1096-9071(200010)62:2<251::AID-JMV18>3.0.CO;2-V; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Peitsaro P, 2002, J CLIN MICROBIOL, V40, P886, DOI 10.1128/JCM.40.3.886-891.2002; Pett MR, 2004, CANCER RES, V64, P1359, DOI 10.1158/0008-5472.CAN-03-3214; Riethdorf S, 2001, INT J GYNECOL PATHOL, V20, P177, DOI 10.1097/00004347-200104000-00011; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; Rosty C, 2005, ONCOGENE, V24, P7094, DOI 10.1038/sj.onc.1208854; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SolinasToldo S, 1997, P NATL ACAD SCI USA, V94, P3854, DOI 10.1073/pnas.94.8.3854; Sotlar K, 2004, J MED VIROL, V74, P107, DOI 10.1002/jmv.20153; Van Tine BA, 2004, J VIROL, V78, P11172, DOI 10.1128/JVI.78.20.11172-11186.2004; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	44	94	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1610	1617		10.1038/sj.onc.1210791	http://dx.doi.org/10.1038/sj.onc.1210791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828299				2022-12-28	WOS:000253815800013
J	Cowling, VH; Cole, MD				Cowling, V. H.; Cole, M. D.			An N-Myc truncation analogous to c-Myc-S induces cell proliferation independently of transactivation but dependent on Myc homology box II	ONCOGENE			English	Article						c-Myc-S; Myc; transcriptional repression; transactivation; cell proliferation	TRANSFORMATION; TRANSCRIPTION; ASSOCIATION; RECRUITMENT; INHIBITORS; REPRESSES; MECHANISM; APOPTOSIS; COFACTOR; GROWTH	Myc promotes both normal cell proliferation and oncogenic transformation through the activation and repression of target genes. The c-Myc-S protein is a truncated form of c-Myc that is produced in some cells from translation initiation at an internal AUG codon. We report that c-Myc-S and a similar truncated form of N-MycWT can fully rescue the proliferation defect in myc-null fibroblasts, but rescue is dependent on the highly conserved Myc homology box II (MBII). Global gene expression studies show that the N-Myc equivalent of c-Myc-S is defective for virtually all transcriptional activation of Myc target genes but remains active for the majority of transcriptional repression. Repression by Myc-S is dependent on MBII, but it does not bind to several known nuclear cofactors. These data suggest that repression by Myc involves recruitment of a novel MBII-dependent cofactor.	[Cowling, V. H.; Cole, M. D.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; [Cowling, V. H.; Cole, M. D.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center	Cole, MD (corresponding author), Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pharmacol & Toxicol, 1 Med Ctr Dr,Rubin 6, Lebanon, NH 03756 USA.	mcole@dartmouth.edu		Cowling, Victoria/0000-0001-7638-4870	MRC [G0700240] Funding Source: UKRI; Medical Research Council [G0700240] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Benassayag C, 2005, MOL CELL BIOL, V25, P9897, DOI 10.1128/MCB.25.22.9897-9909.2005; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Cole MD, 2006, SEMIN CANCER BIOL, V16, P241, DOI 10.1016/j.semcancer.2006.08.003; Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Eisenman R N, 2000, Harvey Lect, V96, P1; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Hurlin PJ, 2006, SEMIN CANCER BIOL, V16, P265, DOI 10.1016/j.semcancer.2006.07.009; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Malynn BA, 2000, GENE DEV, V14, P1390; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Patel JH, 2007, J BIOL CHEM, V282, P5, DOI 10.1074/jbc.M609138200; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803	25	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1327	1332		10.1038/sj.onc.1210734	http://dx.doi.org/10.1038/sj.onc.1210734			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704800				2022-12-28	WOS:000253407000017
J	Radhakrishnan, SK; Bhat, UG; Halasi, M; Gartel, AL				Radhakrishnan, S. K.; Bhat, U. G.; Halasi, M.; Gartel, A. L.			P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents	ONCOGENE			English	Article						P-TEFb; ARC; flavopiridol; p53; phosphorylation; DNA-damaging agents	DEPENDENT PROTEIN-KINASE; TUMOR-CELLS; PHOSPHORYLATION; APOPTOSIS; DOXORUBICIN	Tumor suppressor p53 is stabilized in response to c-irradiation or treatment with DNA-damaging agents, and as a result p53 transcriptionally activates its targets leading to cell-cycle arrest or apoptosis. P-TEFb (positive transcription elongation factor b) inhibitors such as flavopiridol or 4-amino-6-hydrazino-7-b-d-ribofuranosyl-7H- pyrrolo[2,3-d]-pyrimidine-5-carboxamide (ARC) upregulate p53 protein levels, but inhibit the expression of its targets p21 and hdm2. DNA-damaging agents, doxorubicin and cisplatin are being used in combination with P-TEFb inhibitor flavopiridol in clinical trials for the treatment of some cancer patients. In this study, we found that P-TEFb inhibitors block the phosphorylation of p53 induced by doxorubicin. Furthermore, treatment of cells with P-TEFb inhibitors together with doxorubicin inhibits doxorubicin-induced binding of p53 to DNA and p53 transcriptional activity. These data suggest that P-TEFb inhibitors may antagonize the activation of p53 by DNA-damaging agents in tumors with wild-type p53.	[Radhakrishnan, S. K.; Bhat, U. G.; Halasi, M.; Gartel, A. L.] Univ Illinois, Dept Med, Coll Med, Chicago, IL 60612 USA; [Radhakrishnan, S. K.; Gartel, A. L.] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60680 USA; [Halasi, M.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, Coll Med, 840 S Wood St,Room 1041, Chicago, IL 60612 USA.	agartel@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bible KC, 2005, CLIN CANCER RES, V11, P5935, DOI 10.1158/1078-0432.CCR-04-2566; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Dunkern TR, 2003, DNA REPAIR, V2, P49, DOI 10.1016/S1568-7864(02)00185-4; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; Jack MT, 2004, J BIOL CHEM, V279, P15269, DOI 10.1074/jbc.M309917200; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Radhakrishnan SK, 2006, CELL CYCLE, V5, P519, DOI 10.4161/cc.5.5.2514; Radhakrishnan SK, 2006, CANCER RES, V66, P3264, DOI 10.1158/0008-5472.CAN-05-3940; Radhakrishnan SK, 2004, ONCOGENE, V23, P4173, DOI 10.1038/sj.onc.1207571; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, NAT CELL BIOL, V2, pE178, DOI 10.1038/35036427; Wang SW, 2004, J BIOL CHEM, V279, P25535, DOI 10.1074/jbc.M400944200; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343	19	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1306	1309		10.1038/sj.onc.1210737	http://dx.doi.org/10.1038/sj.onc.1210737			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724473				2022-12-28	WOS:000253407000013
J	Ammirante, M; Rosati, A; Gentilella, A; Festa, M; Petrella, A; Marzullo, L; Pascale, M; Belisario, MA; Leone, A; Turco, MC				Ammirante, M.; Rosati, A.; Gentilella, A.; Festa, M.; Petrella, A.; Marzullo, L.; Pascale, M.; Belisario, M. A.; Leone, A.; Turco, M. C.			The activity of hsp90 alpha promoter is regulated by NF-kappa B transcription factors	ONCOGENE			English	Article						hsp90 alpha; NF-kappa B; heat shock proteins	CELL APOPTOSIS; IKK; PROTEIN; HSP90	Heat-shock proteins ( HSP) 90 exert a relevant role in the survival and response to therapy of many neoplastic cell types. Here, we show that the promoter of hsp90 alpha gene, that encodes the inducible form of HSP90, is regulated by nuclear factor-kappa B (NF-kappa B) activity. Indeed, we found that NF-kappa B factors bound to one of the two putative consensus sequences present in the hsp90 alpha-flanking region; mutation of such motif hampered the phorbol-myristate-13-acetate-stimulated expression of a luciferase reporter gene under the control of the hsp90a promoter. Furthermore, the downmodulation of NF-kappa B ( p65) levels by a specific small interfering ( si) RNA resulted in reducing the levels of endogenous HSP90 alpha protein. These findings disclose a previously unrecognized mechanism that contributes to connect NF-kappa B factors and HSPs in cell defence machinery.	[Ammirante, M.; Rosati, A.; Gentilella, A.; Festa, M.; Petrella, A.; Marzullo, L.; Pascale, M.; Belisario, M. A.; Leone, A.; Turco, M. C.] Univ Salerno, Dept Pharmaceut Sci, I-84084 Fisciano, SA, Italy	University of Salerno	Turco, MC (corresponding author), Univ Salerno, Dept Pharmaceut Sci, Via Ponte Don Melillo, I-84084 Fisciano, SA, Italy.	mcturco@unisa.it	belisario, maria antonietta/B-4762-2012; Pascale, Maria/B-4273-2012; TURCO, Maria Caterina/AAC-5282-2022; Marzullo, Liberato/C-4408-2008; Gentilella, Antonio/AAA-9864-2020; Petrella, Antonello/E-7708-2012	TURCO, Maria Caterina/0000-0002-7835-359X; Marzullo, Liberato/0000-0001-6133-4483; PETRELLA, Antonello/0000-0002-6945-5295				Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Maiuri MC, 2004, AM J PATHOL, V165, P115, DOI 10.1016/S0002-9440(10)63280-4; Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood-2005-03-1158; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Pittet JF, 2005, J IMMUNOL, V174, P384, DOI 10.4049/jimmunol.174.1.384; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Richter K, 2007, NAT STRUCT MOL BIOL, V14, P90, DOI 10.1038/nsmb0207-90; Romano MF, 1999, BLOOD, V94, P4060, DOI 10.1182/blood.V94.12.4060.424k23_4060_4066; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	14	56	60	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1175	1178		10.1038/sj.onc.1210716	http://dx.doi.org/10.1038/sj.onc.1210716			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17724475				2022-12-28	WOS:000253136700017
J	Radhakrishnan, SK; Halasi, M; Bhat, UG; Kurmasheva, RT; Houghton, PJ; Gartel, AL				Radhakrishnan, S. K.; Halasi, M.; Bhat, U. G.; Kurmasheva, R. T.; Houghton, P. J.; Gartel, A. L.			Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells	ONCOGENE			English	Article						ARC; neuroblastoma; survivin; Mcl-1; Akt; N-myc	HIGH-RISK NEUROBLASTOMA; APOPTOSIS; TRANSPLANTATION; CHEMOTHERAPY; INHIBITOR; SURVIVAL; PROTEIN; EXPRESSION; REPRESSION; IRINOTECAN	We have previously described the identification of a nucleoside analog transcriptional inhibitor ARC (4-amino- 6-hydrazino-7-beta-D-ribofuranosyl-7H-pyrrolo[ 2,3-d]- pyrimidine-5-carboxamide) that was able to induce apoptosis in cancer cell lines of different origin. Here, we report the characterization of ARC on a panel of neuroblastoma cell lines. We found that these cell lines were more than 10-fold sensitive to ARC than to the well-known nucleoside analog DRB (5,6-dichloro-1-beta-Dribofuranosylbenzimidazole), and that ARC-induced apoptosis proceeds through mitochondrial injury. Also, we observed that ARC-mediated cell death was accompanied by caspase-3 cleavage and repression of antiapoptotic proteins such as Mcl-1 and survivin. Conversely, we found that overexpression of Mcl-1-protected neuroblastoma cell line NB-1691 from ARC-induced apoptosis. Furthermore, we found that while ARC inhibited the phosphorylation of Akt Ser-473 in multiple cancer cell lines, forced expression of myristoylated Akt promoted resistance to ARC-induced apoptosis in neuroblastoma cells. In addition, we observed that ARC was able to downregulate the protein levels of N-myc, a commonly amplified oncogene in neuroblastomas, and Akt protected N-myc from ARC-induced downregulation. These data suggest that ARC may antagonize different antiapoptotic pathways and induce apoptosis in neuroblastoma cells via multiple mechanisms. Overall, ARC could represent an attractive candidate for anticancer drug development against neuroblastomas.	[Radhakrishnan, S. K.; Bhat, U. G.; Gartel, A. L.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Radhakrishnan, S. K.; Gartel, A. L.] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60680 USA; [Halasi, M.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60680 USA; [Kurmasheva, R. T.; Houghton, P. J.] St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; St Jude Children's Research Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, 840 S Wood St,Room 1041, Chicago, IL 60612 USA.	agartel@uic.edu	Houghton, Peter/E-3265-2011	Radhakrishnan, Senthil/0000-0002-5211-9498	NCI NIH HHS [CA96696, CA23099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096696, P01CA023099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Castel V, 2001, MED PEDIATR ONCOL, V37, P537, DOI 10.1002/mpo.1248; Castel V, 2000, MED PEDIATR ONCOL, V35, P724, DOI 10.1002/1096-911X(20001201)35:6<724::AID-MPO53>3.0.CO;2-U; Castillo S, 2004, ATHEROSCLEROSIS SUPP, V5, P80, DOI 10.1016/S1567-5688(04)90347-4; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Donfrancesco A, 2004, ACTA PAEDIATR, V93, P6, DOI 10.0180/08035320310021165; DuBois SG, 1999, J PEDIAT HEMATOL ONC, V21, P181, DOI 10.1097/00043426-199905000-00005; Furman WL, 1999, J CLIN ONCOL, V17, P1815, DOI 10.1200/JCO.1999.17.6.1815; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Goldsby Robert E, 2004, Paediatr Drugs, V6, P107, DOI 10.2165/00148581-200406020-00004; Houghton PJ, 2002, J PEDIAT HEMATOL ONC, V24, P84, DOI 10.1097/00043426-200202000-00002; Imaizumi M, 2001, TOHOKU J EXP MED, V195, P73, DOI 10.1620/tjem.195.73; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kaneko M, 2002, J PEDIAT HEMATOL ONC, V24, P613, DOI 10.1097/00043426-200211000-00004; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Ma YH, 2003, MOL CANCER THER, V2, P73; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Newcomb EW, 2003, CELL CYCLE, V2, P243, DOI 10.4161/cc.2.3.357; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Peng J, 1998, COLD SPRING HARB SYM, V63, P365, DOI 10.1101/sqb.1998.63.365; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Radhakrishnan SK, 2006, CELL CYCLE, V5, P519, DOI 10.4161/cc.5.5.2514; Radhakrishnan SK, 2006, CANCER RES, V66, P3264, DOI 10.1158/0008-5472.CAN-05-3940; Radhakrishnan SK, 2005, CELL CYCLE, V4, P582, DOI 10.4161/cc.4.4.1583; Radhakrishnan SK, 2004, ONCOGENE, V23, P4173, DOI 10.1038/sj.onc.1207571; Thompson J, 1999, CLIN CANCER RES, V5, P3617; Thompson J, 2001, CANCER CHEMOTH PHARM, V47, P211, DOI 10.1007/s002800000235; Valteau-Couanet D, 2000, BONE MARROW TRANSPL, V25, P937, DOI 10.1038/sj.bmt.1702376; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042	31	16	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					694	699		10.1038/sj.onc.1210692	http://dx.doi.org/10.1038/sj.onc.1210692			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17724478				2022-12-28	WOS:000252674900013
J	Bae, SI; Cheriyath, V; Jacobs, BS; Reu, FJ; Borden, EC				Bae, S. I.; Cheriyath, V.; Jacobs, B. S.; Reu, F. J.; Borden, E. C.			Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL	ONCOGENE			English	Article						apoptosis; 5-AZAdC; IFNs; DR4; melanoma	TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION; CUTANEOUS MELANOMA; STIMULATED GENES; APOPTOSIS; HYPERMETHYLATION; IDENTIFICATION; XIAP; INHIBITOR; CARCINOMA	Human melanoma cell lines, SK-MEL-3 and SK-MEL-28, despite induction of the proapoptotic cytokine, Apo2L/TRAIL, did not undergo apoptosis in response to interferons ( IFN-alpha 2b or IFN-beta). Postulating that genes important for apoptosis induction by IFNs might be silenced by methylation, the DNA demethylating agent 5-aza-2'-deoxycytidine ( 5-AZAdC) was assessed. DR4 ( TRAIL-R1) was identified as one of the genes reactivated by 5-AZAdC with a > 3-fold increase in 8 of 10 melanoma cell lines. Pretreatment with 5-AZAdC sensitized SK-MEL-3 and SK-MEL-28 cells to apoptosis induced by IFN-a2b and IFN-b; methylation-specific PCR and bisulfite sequencing confirmed demethylation of 5'CpG islands of DR4 and flow cytometry showed an increase in DR4 protein on the cell surface. In cells with reactivated DR4, neutralizing mAB to TRAIL reduced apoptosis in response to IFN-b or Apo2L/TRAIL. To further confirm the role of DR4, it was expressed by retroviral vector in SK-MEL-3 and SK-MEL-28 cells with reversal of resistance to IFN-b and Apo2L/TRAIL. Thus, reexpressing DR4 by 5-AZAdC or retroviral transfection in melanoma cell in which promoter methylation had suppressed its expression, potentiated apoptosis by IFN-alpha 2b, IFN-beta and Apo2L/TRAIL. Reactivation of silenced proapoptotic genes by inhibitors of DNA methylation may enhance clinical response to IFNs or Apo2L/TRAIL.	[Bae, S. I.; Cheriyath, V.; Jacobs, B. S.; Reu, F. J.; Borden, E. C.] Cleveland Clin Fdn, Taussig Canc Ctr, Ctr Hematol & Oncol Mol Therapeut, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Borden, EC (corresponding author), Cleveland Clin Fdn, Taussig Canc Ctr, Ctr Hematol & Oncol Mol Therapeut, 9500 Euclid Ave,R 40, Cleveland, OH 44195 USA.	bordene@ccf.org		Reu, Frederic/0000-0003-1160-8030	NATIONAL CANCER INSTITUTE [R01CA090914] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 90914] Funding Source: Medline; NCRR NIH HHS [M01 RR-018390] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BORDEN EC, 2003, CANC MED, P830; Byun DS, 2003, CANCER RES, V63, P7068; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Esteller M, 2001, CANCER RES, V61, P3225; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Leaman DW, 2003, J INTERF CYTOK RES, V23, P745, DOI 10.1089/107999003772084860; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Pfeffer LM, 1998, CANCER RES, V58, P2489; Reu FJ, 2006, CANCER RES, V66, P2785, DOI 10.1158/0008-5472.CAN-05-2303; Reu FJ, 2006, J CLIN ONCOL, V24, P3771, DOI 10.1200/JCO.2005.03.4074; Spugnardi M, 2003, CANCER RES, V63, P1639; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227	23	55	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					490	498		10.1038/sj.onc.1210655	http://dx.doi.org/10.1038/sj.onc.1210655			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653094				2022-12-28	WOS:000252426100009
J	Meng, F; Wehbe-Janek, H; Henson, R; Smith, H; Patel, T				Meng, F.; Wehbe-Janek, H.; Henson, R.; Smith, H.; Patel, T.			Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes	ONCOGENE			English	Article						noncoding RNA; cytokine; liver cancer	CHOLANGIOCARCINOMA CELL-LINE; PROMOTER METHYLATION; CANCER-CELLS; KINASE; GROWTH; ACTIVATION; EXPRESSION; GENE; IDENTIFICATION; CONTRIBUTES	Interleukin-6 (IL-6) is overexpressed and contributes to tumor cell growth in cholangiocarcinoma. Enforced IL-6 production can alter the expression of specific microRNAs ( miRNAs) involved in tumor growth, and moreover can modulate expression of methylation-dependent genes. Thus, we assessed the methylation-dependent regulation of miRNA expression in human malignant cholangiocytes stably transfected to overexpress IL-6. The expression of the methyltransferases DNA methyltransferase enzyme-1 and HASJ4442 was increased by IL-6 overexpression, but was decreased by the methylation inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR). Expression pro. ling identified seven miRNAs that were significantly downregulated by IL-6 overexpression (<0.4-fold) and upregulated (>2- fold) by 5-aza-CdR. One of these, miR-370, is embedded in a CpG island. Although 5-aza-CdR increased miR-370 expression by 2.1-fold in malignant cells, the expression in nonmalignant cells was unchanged. The oncogene mitogen- activated protein kinase kinase kinase 8 (MAP3K8) was identified as a target of miR-370, and its expression was decreased by 5-aza-CdR in cholangiocarcinoma cells. Overexpression of IL-6 reduced miR-370 expression and reinstated MAP3K8 expression in vitro as well as in tumor cell xenografts in vivo. Thus, IL-6 may contribute to tumor growth by modulation of expression of selected miRNAs, such as miR-370. These studies de. ne a mechanism by which inflammation-associated cytokines can epigenetically modulate gene expression and directly contribute to tumor biology.	[Meng, F.; Patel, T.] Ohio State Univ, Med Ctr, Coll Med, Dept Internal Med, Columbus, OH 43210 USA; [Meng, F.; Wehbe-Janek, H.; Henson, R.; Smith, H.; Patel, T.] Texas A&M Univ, Coll Med, Syst Hlth Sci Ctr, Scott & White Clin,Dept Internal Med, Temple, TX 76508 USA	University System of Ohio; Ohio State University; Scott & White Medical Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Patel, T (corresponding author), Ohio State Univ, Med Ctr, Coll Med, Dept Internal Med, N2 Doan Hall,410 W 10th Ave, Columbus, OH 43210 USA.	tushar.patel@osumc.edu	patel, tushar/A-6382-2008		NIDDK NIH HHS [DK069370, R01 DK069370-02, R01 DK069370] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069370] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOKI M, 1993, J BIOL CHEM, V268, P22723; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Calin GA, 2006, ONCOGENE, V25, P6202, DOI 10.1038/sj.onc.1209910; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Meng F, 2006, J HEPATOL, V44, P1055, DOI 10.1016/j.jhep.2005.10.030; Meng FM, 2005, AM J PHYSIOL-CELL PH, V289, pC971, DOI 10.1152/ajpcell.00081.2005; OHARA R, 1995, J CELL SCI, V108, P97; OKADA K, 1994, J GASTROEN HEPATOL, V9, P462, DOI 10.1111/j.1440-1746.1994.tb01275.x; Park J, 1999, HEPATOLOGY, V30, P1128, DOI 10.1002/hep.510300522; Patel T, 2006, NAT CLIN PRACT GASTR, V3, P33, DOI 10.1038/ncpgasthep0389; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Tadlock L, 2001, HEPATOLOGY, V33, P43, DOI 10.1053/jhep.2001.20676; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Yamagiwa Y, 2003, HEPATOLOGY, V38, P158, DOI 10.1053/jhep.2003.50257	31	188	214	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					378	386		10.1038/sj.onc.1210648	http://dx.doi.org/10.1038/sj.onc.1210648			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621267				2022-12-28	WOS:000252256000014
J	Boyault, C; Sadoul, K; Pabion, M; Khochbin, S				Boyault, C.; Sadoul, K.; Pabion, M.; Khochbin, S.			HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination	ONCOGENE			English	Review						microtubule; actin; HSP90; virus; aggresome; transcription	HISTONE DEACETYLASE INHIBITORS; POSITIVE BREAST-CANCER; 2 CATALYTIC DOMAINS; LYSINE-ACETYLATION; GENE-EXPRESSION; DEUBIQUITINATING ENZYMES; MICROTUBULE ACETYLATION; GLUCOCORTICOID-RECEPTOR; TUBULIN DEACETYLASE; CHAPERONE FUNCTION	Histone deacetylase 6 ( HDAC6) is a unique enzyme with specific structural and functional features. It is actively or stably maintained in the cytoplasm and is the only member, within the histone deacetylase family, that harbors a full duplication of its deacetylase homology region followed by a specific ubiquitin-binding domain at the C-terminus end. Accordingly, this deacetylase functions at the heart of a cellular regulatory mechanism capable of coordinating various cellular functions largely relying on the microtubule network. Moreover, HDAC6 action as a regulator of the HSP90 chaperone activity adds to the multifunctionality of the protein, and allows us to propose a critical role for HDAC6 in mediating and coordinating various cellular events in response to different stressful stimuli.	Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Khochbin, S (corresponding author), Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, Domaine Merci, La Tronche, France.	khochbin@ujf-grenoble.fr	Khochbin, Saadi/M-8090-2013; Boyault, Cyril/K-3593-2014; Sadoul, Karin/N-2649-2013; 高, 雨莉/HGU-8187-2022	Khochbin, Saadi/0000-0002-0455-0857; Sadoul, Karin/0000-0001-7174-5016; Boyault, Cyril/0000-0001-9614-4292				Adachi N, 2002, J BIOL CHEM, V277, P35688, DOI 10.1074/jbc.M204640200; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Barlow AL, 2001, EXP CELL RES, V265, P90, DOI 10.1006/excr.2001.5162; Bershadsky AD, 2006, EUR J CELL BIOL, V85, P165, DOI 10.1016/j.ejcb.2005.11.001; Bertos NR, 2004, J BIOL CHEM, V279, P48246, DOI 10.1074/jbc.M408583200; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Boyault C, 2006, EMBO J, V25, P3357, DOI 10.1038/sj.emboj.7601210; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brush MH, 2004, J BIOL CHEM, V279, P7685, DOI 10.1074/jbc.M310997200; Cabrero JR, 2006, MOL BIOL CELL, V17, P3435, DOI 10.1091/mbc.E06-01-0008; Caron C, 2003, BIOESSAYS, V25, P58, DOI 10.1002/bies.10202; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Corcoran LJ, 2004, CURR BIOL, V14, P488, DOI 10.1016/j.cub.2004.03.003; Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425; Dihazi H, 2005, BIOL CHEM, V386, P895, DOI 10.1515/BC.2005.104; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Furumai R, 2002, CANCER RES, V62, P4916; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Goldberg AL, 2002, MOL IMMUNOL, V39, P147, DOI 10.1016/S0161-5890(02)00098-6; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hayashi Shin-ichi, 2006, Breast Cancer, V13, P123, DOI 10.2325/jbcs.13.123; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Hurst DR, 2006, BIOCHEM BIOPH RES CO, V348, P1429, DOI 10.1016/j.bbrc.2006.08.005; Iwabata H, 2005, PROTEOMICS, V5, P4653, DOI 10.1002/pmic.200500042; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Ling L, 2004, J BIOL CHEM, V279, P32737, DOI 10.1074/jbc.M400601200; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Marcus AI, 2006, CANCER RES, V66, P8838, DOI 10.1158/0008-5472.CAN-06-0699; Marcus AI, 2005, CANCER RES, V65, P3883, DOI 10.1158/0008-5472.CAN-04-3757; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Mosley AJ, 2006, BLOOD, V108, P3801, DOI 10.1182/blood-2006-03-013235; Murphy PJM, 2005, J BIOL CHEM, V280, P33792, DOI 10.1074/jbc.M506997200; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Nusinzon I, 2006, MOL CELL BIOL, V26, P3106, DOI 10.1128/MCB.26.8.3106-3113.2006; Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014; Romisch K, 2005, ANNU REV CELL DEV BI, V21, P435, DOI 10.1146/annurev.cellbio.21.012704.133250; Rumpf S, 2006, MOL CELL, V21, P261, DOI 10.1016/j.molcel.2005.12.014; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Sakuma T, 2006, INT J ONCOL, V29, P117; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Scroggins BT, 2007, MOL CELL, V25, P151, DOI 10.1016/j.molcel.2006.12.008; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; Shimazu T, 2007, J BIOL CHEM, V282, P4470, DOI 10.1074/jbc.M609745200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tong JJ, 2002, NUCLEIC ACIDS RES, V30, P1114, DOI 10.1093/nar/30.5.1114; Valenzuela-Fernandez A, 2005, MOL BIOL CELL, V16, P5445, DOI 10.1091/mbc.e05-04-0354; Verdel A, 2000, CURR BIOL, V10, P747, DOI 10.1016/S0960-9822(00)00542-X; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang Q, 2003, BIOCHEM BIOPH RES CO, V300, P253, DOI 10.1016/S0006-291X(02)02840-1; Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yoshida N, 2004, CANCER SCI, V95, P496, DOI 10.1111/j.1349-7006.2004.tb03239.x; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhang Y, 2006, J BIOL CHEM, V281, P2401, DOI 10.1074/jbc.C500241200; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024; Zou H, 2006, BIOCHEM BIOPH RES CO, V341, P45, DOI 10.1016/j.bbrc.2005.12.144	85	286	299	4	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	2007	26	37					5468	5476		10.1038/sj.onc.1210614	http://dx.doi.org/10.1038/sj.onc.1210614			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694087				2022-12-28	WOS:000248674300014
J	Frech, MS; Torre, KM; Robinson, GW; Furth, PA				Frech, M. S.; Torre, K. M.; Robinson, G. W.; Furth, P. A.			Loss of cyclin D1 in concert with deregulated estrogen receptor a expression induces DNA damage response activation and interrupts mammary gland morphogenesis	ONCOGENE			English	Article						ER alpha; cyclin D1; cyclin E; DNA damage; mammary gland	CARCINOMA IN-SITU; BREAST-CANCER; PRECANCEROUS BREAST; INSTABILITY; LESIONS; CELLS	We have previously shown that increased and deregulated estrogen receptor alpha expression in the mammary gland leads to the development of proliferative disease and cancer. To address the importance of cyclin D1 in ER alpha-mediated mammary tumorigenesis, we crossed ER alpha-overexpressing mice with cyclin D1 knockout mice. Mammary gland morphogenesis was completely interrupted in the ER alpha-overexpressing cyclin D1-deficient triple transgenic mice. In addition to a highly significant reduction in mammary epithelial cell proliferation, cyclin E was upregulated resulting in DNA damage checkpoint activation and apoptosis. This imbalance between proliferative and apoptotic rates in conjunction with remarkable structural defects and cellular disorganization in the terminal end buds interrupted ductal morphogenesis. Interestingly, the structure of the mammary fat pad was fundamentally altered by the consequences of overexpressing ERa in the epithelial cells in the absence of cyclin D1 illustrating how alterations in the epithelial compartment can impact surrounding stromal composition. Transplantation of embryonic ER alpha-overexpressing and cyclin D1-deficient mammary epithelium into the cleared fat pad of wild-type mice did not rescue the aberrant mammary gland phenotype indicating that it was intrinsic to the mammary epithelial cells. In conclusion, although cyclin D1 is not essential for proliferation of normal mammary epithelial cells, ER alpha-overexpressing cells are absolutely dependent on cyclin D1 for proliferation. This differential requirement for cyclin D1 in normal vs abnormal mammary epithelial cells supports the application of cyclin D1 inhibitors as therapeutic interventions in ER alpha-overexpressing breast cancers.	[Frech, M. S.; Torre, K. M.; Furth, P. A.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; [Robinson, G. W.] NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Frech, MS (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA.	msf25@georgetown.edu	Robinson, Gertraud/I-2136-2012		NATIONAL CANCER INSTITUTE [R01CA112176] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA112176, R01 CA112176, R01 CA112176-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Carthon BC, 2005, MOL CELL BIOL, V25, P1081, DOI 10.1128/MCB.25.3.1081-1088.2005; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; Deugnier MA, 2002, BREAST CANCER RES, V4, P224, DOI 10.1186/bcr459; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Frech MS, 2005, CANCER RES, V65, P681; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hinck L, 2005, BREAST CANCER RES, V7, P245, DOI 10.1186/bcr1331; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Minella AC, 2007, ONCOGENE, V26, P6948, DOI 10.1038/sj.onc.1210518; Oh YL, 2001, PATHOL INT, V51, P94, DOI 10.1046/j.1440-1827.2001.01173.x; Peng SY, 1998, J HEPATOL, V29, P281, DOI 10.1016/S0168-8278(98)80014-7; ROBINSON GW, 2000, METHODS MAMMARY GLAN, P301; Shoker BS, 1999, J PATHOL, V188, P237; Shoker BS, 2001, BRIT J CANCER, V84, P1064, DOI 10.1054/bjoc.2001.1705; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	23	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3186	3193		10.1038/sj.onc.1210974	http://dx.doi.org/10.1038/sj.onc.1210974			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071314	Green Accepted			2022-12-28	WOS:000255897600011
J	Jiao, W; Lin, HM; Datta, J; Braunschweig, T; Chung, JY; Hewitt, SM; Rane, SG				Jiao, W.; Lin, H-M; Datta, J.; Braunschweig, T.; Chung, J-Y; Hewitt, S. M.; Rane, S. G.			Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation	ONCOGENE			English	Article						RB; CDK; cancer; export; localization; differentiation	RING-FINGER DOMAIN; CELL-CYCLE; NUCLEAR EXPORT; BREAST-CANCER; GENE-PRODUCT; PHOSPHORYLATION; CDK4; EXPRESSION; MELANOMA; MECHANISM	Inactivation of the retinoblastoma (RB) tumor suppressor pathway, via elevated cyclin-dependent kinase (CDK) activity, is observed in majority of human cancers. Since CDK deregulation is evident in most cancer cells, pharmacological CDK inhibition has become an attractive therapeutic strategy in oncology. We recently showed that an oncogenic CDK4R24C mutation alters the subcellular localization of the normally nuclear RB phosphoprotein. Here, using 71 human cancer cell lines and over 300 primary human cancer tissues, we investigated whether changes in RB subcellular localization occur during human cancer progression. We uncover that diverse human cancers and their derived cell lines, particularly those with poor tumor differentiation, display significant cytoplasmic mislocalization of ordinarily nuclear RB. The nucleocytoplasmically distributed RB was derived via CDK-dependent and Exportin1-mediated nuclear export. Indeed, cytoplasmically mislocalized RB could be efficiently confined to the nucleus by pharmacologically reducing CDK activity or by inhibiting the Exportin1-mediated nuclear export pathway. Our observations uncover a post-translational CDK-dependent mechanism of RB inactivation and suggest that cytoplasmically localized RB may harbor a tumor promoting function. We propose that RB inactivation, via aberrant nucleocytoplasmic transport, may disrupt normal cell differentiation programs and accelerate the cancer process. These results are evidence that tumor cells modulate the protein transport machinery thereby making the protein transport process a viable therapeutic target.	[Lin, H-M; Rane, S. G.] NIDDKD, Diabet Branch, NIH, Bethesda, MD 20892 USA; [Jiao, W.; Lin, H-M; Datta, J.; Rane, S. G.] Lab Cell Regulat & Carcinogenesis, Bethesda, MD USA; [Braunschweig, T.; Chung, J-Y; Hewitt, S. M.] NCI, Pathol Lab, Tissue Array Res Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rane, SG (corresponding author), NIDDKD, Diabet Branch, NIH, CRC 5-5940,9000 Rockville Pike, Bethesda, MD 20892 USA.	ranes@mail.nih.gov	Chung, Joon-Yong/J-9177-2017; Braunschweig, Till/AAO-5725-2020	Chung, Joon-Yong/0000-0001-5041-5982; Braunschweig, Till/0000-0001-9166-2912; Datta, Jashodeep/0000-0003-2869-1571; Hewitt, Stephen/0000-0001-8283-1788	NATIONAL CANCER INSTITUTE [ZICBC010923, Z01BC010923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055107, ZIADK055107] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alkarain A, 2004, J MAMMARY GLAND BIOL, V9, P67, DOI 10.1023/B:JOMG.0000023589.00994.5e; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Braunschweig T, 2005, EXPERT REV PROTEOMIC, V2, P325, DOI 10.1586/14789450.2.3.325; Camphausen K, 2004, MOL CANCER THER, V3, P409; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Goodrich DW, 2006, ONCOGENE, V25, P5233, DOI 10.1038/sj.onc.1209616; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Jiao W, 2006, J BIOL CHEM, V281, P38098, DOI 10.1074/jbc.M605271200; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kastan MB, 2003, CELL, V112, P1, DOI 10.1016/S0092-8674(02)01281-3; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Khidr L, 2006, ONCOGENE, V25, P5210, DOI 10.1038/sj.onc.1209612; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Lu S, 1997, CANCER RES, V57, P4511; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; NORK TM, 1994, INVEST OPHTH VIS SCI, V35, P2682; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; STOKKE T, 1993, EXP CELL RES, V204, P147, DOI 10.1006/excr.1993.1019; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; WEINSTEIN JN, 1992, SCIENCE, V258, P447, DOI 10.1126/science.1411538; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yen A, 1997, EUR J CELL BIOL, V72, P159; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; Ziegler E. C., 2005, SCI STKE, pre6, DOI DOI 10.1126/STKE.2842005RE6; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	52	38	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3156	3164		10.1038/sj.onc.1210970	http://dx.doi.org/10.1038/sj.onc.1210970			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071317				2022-12-28	WOS:000255897600008
J	Leotoing, L; Meunier, L; Manin, M; Mauduit, C; Decaussin, M; Verrijdt, G; Claessens, F; Benahmed, M; Veyssiere, G; Morel, L; Beaudoin, C				Leotoing, L.; Meunier, L.; Manin, M.; Mauduit, C.; Decaussin, M.; Verrijdt, G.; Claessens, F.; Benahmed, M.; Veyssiere, G.; Morel, L.; Beaudoin, C.			Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell	ONCOGENE			English	Article						nucleophosmin/B23; androgen receptor; transcription and prostate cancer	NUCLEOLAR PROTEIN B23; MOUSE VAS-DEFERENS; IN-VITRO; GENE; ACTIVATION; PROMOTER; TRANSACTIVATION; DIFFERENTIATION; IDENTIFICATION; EXPRESSION	The promotion and progression of prostate cancer (PCa) are associated with androgen receptor (AR) signalling. AR functions are modulated by a variety of co-factors amongst which we identified the nucleophosmin (NPM/B23), a member of the histone chaperone family. Here, we show that NPM is overexpressed in PCa compared to normal adjacent tissues. AR and NPM interact in vitro and in vivo, and NPM is critical for androgen-dependent transcriptional activation in LNCaP cells as an anti-NPM siRNA downregulates transcription of a transfected androgen response element (ARE)-containing reporter promoter as well as expression of the endogenous androgen responsive prostate-specific antigen (PSA) gene. By investigating the effect of NPM on AR, we have also observed that NPM enhances AR binding to an ARE in vitro in electrophoretic gel mobility-shift assay experiments. Chromatin immunoprecipitation studies further demonstrated that both AR and NPM associate with AREs of the PSA gene in vivo. Altogether, our data suggest that the molecular histone chaperone NPM could regulate AR functions by promoting assembly of AR-containing regulatory complexes and that high levels of NPM might alter AR functions in PCa.	[Leotoing, L.; Manin, M.; Veyssiere, G.; Morel, L.; Beaudoin, C.] Univ Blaise Pascal Clermont Ferrand II, CNRS, UMR 6547, F-63177 Aubiere, France; [Meunier, L.; Mauduit, C.; Decaussin, M.; Benahmed, M.] Fac Med Lyon Sud, INSERM, U 407, Oullins, France; [Verrijdt, G.; Claessens, F.] Katholieke Univ Leuven, Mol Endocrinol Lab, Louvain, Belgium	Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); Institut National de la Sante et de la Recherche Medicale (Inserm); KU Leuven	Morel, L (corresponding author), Univ Blaise Pascal Clermont Ferrand II, CNRS, UMR 6547, 24 Ave Landais, F-63177 Aubiere, France.	laurent.morel@univ-bpclermont.fr	Claessens, Frank/M-8565-2016	Claessens, Frank/0000-0002-8676-7709; meunier, leo/0000-0001-8573-5687				Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; BOCKER T, 1995, MODERN PATHOL, V8, P226; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Darne CH, 1997, MOL CELL ENDOCRINOL, V132, P13, DOI 10.1016/S0303-7207(97)00116-0; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; FABRE S, 1994, J BIOL CHEM, V269, P5857; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Haelens A, 2007, CANCER RES, V67, P4514, DOI 10.1158/0008-5472.CAN-06-1701; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; Hu YC, 2004, J BIOL CHEM, V279, P33438, DOI 10.1074/jbc.M401781200; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kim J, 2003, NUCLEIC ACIDS RES, V31, P6741, DOI 10.1093/nar/gkg909; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Leotoing L, 2007, J MOL ENDOCRINOL, V39, P151, DOI 10.1677/JME-07-0021; Liu H, 2007, EMBO REP, V8, P394, DOI 10.1038/sj.embor.7400909; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; Melvin VS, 1999, STEROIDS, V64, P576, DOI 10.1016/S0039-128X(99)00036-7; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Ranganathan S, 1997, PROSTATE, V30, P263, DOI 10.1002/(SICI)1097-0045(19970301)30:4<263::AID-PROS6>3.0.CO;2-M; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Shatkina L, 2003, MOL CELL BIOL, V23, P7189, DOI 10.1128/MCB.23.20.7189-7197.2003; Subong ENP, 1999, PROSTATE, V39, P298; Swaminathan V, 2005, MOL CELL BIOL, V25, P7534, DOI 10.1128/MCB.25.17.7534-7545.2005; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Takemura M, 1999, J BIOCHEM-TOKYO, V125, P904, DOI 10.1093/oxfordjournals.jbchem.a022367; Verrijdt G, 2002, BIOCHEM J, V361, P97, DOI 10.1042/0264-6021:3610097; Volle DH, 2004, MOL ENDOCRINOL, V18, P888, DOI 10.1210/me.2003-0338; Wang L, 2005, PROSTATE, V63, P117, DOI 10.1002/pros.20170; Weng JJ, 2005, BIOCHEM BIOPH RES CO, V335, P826, DOI 10.1016/j.bbrc.2005.07.150	35	49	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2858	2867		10.1038/sj.onc.1210942	http://dx.doi.org/10.1038/sj.onc.1210942			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037965				2022-12-28	WOS:000255502500007
J	Muller, P; Hrstka, R; Coomber, D; Lane, DP; Vojtesek, B				Muller, P.; Hrstka, R.; Coomber, D.; Lane, D. P.; Vojtesek, B.			Chaperone-dependent stabilization and degradation of p53 mutants	ONCOGENE			English	Article						chaperones; p53 mutant; stabilization; degradation; CHIP	HISTONE DEACETYLASE INHIBITORS; LI-FRAUMENI-SYNDROME; HEAT-SHOCK PROTEINS; PROTEASOMAL DEGRADATION; MONOCLONAL-ANTIBODIES; WILD-TYPE; HSP90; CELLS; TUMOR; LIGASE	p53 missense mutant proteins commonly show increased stability compared to wild-type p53, which is thought to depend largely on the inability of mutant p53 to induce the ubiquitin ligase MDM2. However, recent work using mouse models has shown that the accumulation of mutant p53 occurs only in tumour cells, indicating that stabilization requires additional factors. To clarify the stabilization of p53 mutants in tumours, we analysed factors that affect their folding and degradation. Although all missense mutants that we studied are more stable than wild-type p53, the levels correlate with individual structural characteristics, which may be reflected in different gain-of-function properties. In the absence of Hsp90 activity, the less stable unfolded p53 mutants preferentially associate in a complex with Hsp70 and CHIP (carboxy terminus of Hsp70-interacting protein), and we show that CHIP is responsible for ubiquitination and degradation of these mutants. The demonstration of a complex interplay between Hsp90, Hsp70 and CHIP that regulate the stability of different p53 mutant proteins improves our understanding of the pro-tumorigenic effects of increased Hsp90 activity during multi-stage carcinogenesis. Understanding the roles of Hsp90, Hsp70 and CHIP in cancers may also provide an important avenue through which to target p53 to enhance treatment of human cancers.	[Muller, P.; Hrstka, R.; Vojtesek, B.] Masaryk Mem Canc Inst, Dept Clin & Expt Pathol, Brno 65653, Czech Republic; [Muller, P.; Coomber, D.; Lane, D. P.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Masaryk Memorial Cancer Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Vojtesek, B (corresponding author), Masaryk Mem Canc Inst, Dept Clin & Expt Pathol, Zluty Kopec 7, Brno 65653, Czech Republic.	vojtesek@mou.cz	Muller, Petr/AAK-5014-2021; Lane, David P/C-4920-2008; Muller, Petr/F-7762-2015; Hrstka, Roman/AAM-4430-2020; 高, 雨莉/HGU-8187-2022	Muller, Petr/0000-0002-8404-4494; Muller, Petr/0000-0002-8404-4494; Hrstka, Roman/0000-0002-6139-2664; Lane, David/0000-0003-0551-3545				Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barrette RW, 2006, CLIN VACCINE IMMUNOL, V13, P802, DOI 10.1128/CVI.00422-05; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; Blagosklonny MV, 2005, CANCER RES, V65, P7386, DOI 10.1158/0008-5472.CAN-04-3433; Blagosklonny MV, 2004, CELL CYCLE, V3, P1537, DOI 10.4161/cc.3.12.1278; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Esser C, 2004, BBA-MOL CELL RES, V1695, P171, DOI 10.1016/j.bbamcr.2004.09.020; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Milner J, 1997, PATHOL BIOL, V45, P797; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Nenutil R, 2005, J PATHOL, V207, P251, DOI 10.1002/path.1838; Nimmanapalli R, 2003, CANCER RES, V63, P5126; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; VOJTESEK B, 1993, BRIT J CANCER, V67, P1254, DOI 10.1038/bjc.1993.234; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Wang PL, 2001, ONCOGENE, V20, P2318, DOI 10.1038/sj.onc.1204316; Wang Y, 2007, BIOCHEM BIOPH RES CO, V356, P998, DOI 10.1016/j.bbrc.2007.03.076; Workman P, 2004, TRENDS MOL MED, V10, P47, DOI 10.1016/j.molmed.2003.12.005; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang Y, 2004, J BIOL CHEM, V279, P42545, DOI 10.1074/jbc.M314213200; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	41	133	138	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3371	3383		10.1038/sj.onc.1211010	http://dx.doi.org/10.1038/sj.onc.1211010			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18223694				2022-12-28	WOS:000256309900002
J	Ichimura, K; Vogazianou, AP; Liu, L; Pearson, DM; Backlund, LM; Plant, K; Baird, K; Langford, CF; Gregory, SG; Collins, VP				Ichimura, K.; Vogazianou, A. P.; Liu, L.; Pearson, D. M.; Backlund, L. M.; Plant, K.; Baird, K.; Langford, C. F.; Gregory, S. G.; Collins, V. P.			1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas	ONCOGENE			English	Article						microarray; array-CGH; methylation; astrocytoma; oligodendroglioma	COMPARATIVE GENOMIC HYBRIDIZATION; PHASE-III TRIAL; OLIGODENDROGLIAL TUMORS; ANAPLASTIC OLIGODENDROGLIOMA; EUROPEAN ORGANIZATION; GENETIC-ANALYSIS; HUMAN GLIOMAS; ARRAY-CGH; P73 GENE; 19Q LOSS	Astrocytic, oligodendroglial and mixed gliomas are the commonest gliomas in adults. They have distinct phenotypes and clinical courses, but as they exist as a continuous histological spectrum, differentiating them can be difficult. Co-deletions of total 1p and 19q are found in the majority of oligodendrogliomas and considered as a diagnostic marker and a prognostic indicator. The 1p status of astrocytomas has not yet been thoroughly examined. Using a chromosome 1 tile path array, we investigated 108 adult astrocytic tumours for copy number alterations. Total 1p deletions were rare (2%), however partial deletions involving 1p36 were frequently identified in anaplastic astrocytomas (22%) and glioblastomas (34%). Multivariate analysis showed that patients with total 1p deletions had significantly longer survival (P=0.005). In nine glioblastomas homozygous deletions at 1p36 were identified. No somatic mutations were found among the five genes located in the homozygously deleted region. However, the CpG island of TNFRSF9 was hypermethylated in 19% of astrocytic tumours and 87% of glioma cell lines. TNFRSF9 expression was upregulated after demethylation of glioma cell lines. Akt3 amplifications were found in four glioblastomas. Our results indicate that 1p deletions are common anaplastic astrocytomas and glioblastomas but are distinct from the 1p abnormalities in oligodendrogliomas.	[Ichimura, K.; Vogazianou, A. P.; Liu, L.; Pearson, D. M.; Plant, K.; Baird, K.; Collins, V. P.] Univ Cambridge, Dept Pathol, Div Mol Histopathol, Addenbrookes Hosp, Cambridge CB2 0QQ, England; [Backlund, L. M.] Karolinska Univ Hosp, Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Langford, C. F.; Gregory, S. G.] Wellcome Trust Sanger Inst, Cambridge, England; [Langford, C. F.; Gregory, S. G.] Duke Univ, Med Ctr, Duke Ctr Human Genet, Durham, NC USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Karolinska Institutet; Karolinska University Hospital; Wellcome Trust Sanger Institute; Duke University	Ichimura, K (corresponding author), Univ Cambridge, Dept Pathol, Div Mol Histopathol, Addenbrookes Hosp, Level 3,Lab Block,Box 231, Cambridge CB2 0QQ, England.	ki212@cam.ac.uk		Backlund, Magnus/0000-0003-0397-6538; Gregory, Simon/0000-0002-7805-1743	Cancer Research UK [A6618] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Alonso ME, 2001, INT J ONCOL, V19, P609; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; BIGNER SH, 1988, CANCER RES, V48, P405; Buckley PG, 2005, CANCER RES, V65, P2653, DOI 10.1158/0008-5472.CAN-04-3651; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Dong Z, 2004, BRIT J CANCER, V91, P1105, DOI 10.1038/sj.bjc.6602093; Felsberg J, 2004, BRAIN PATHOL, V14, P121, DOI 10.1111/j.1750-3639.2004.tb00044.x; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Gregory SG, 2006, NATURE, V441, P315, DOI 10.1038/nature04727; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Harden SV, 2003, J UROLOGY, V169, P1138, DOI 10.1097/01.ju.0000049627.90307.4d; Hashimoto K, 2004, MODERN PATHOL, V17, P617, DOI 10.1038/modpathol.3800107; Hashimoto N, 2003, CANCER-AM CANCER SOC, V97, P2254, DOI 10.1002/cncr.11322; He J, 2001, J NEUROPATH EXP NEUR, V60, P863, DOI 10.1093/jnen/60.9.863; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Homma T, 2006, J NEUROPATH EXP NEUR, V65, P846, DOI 10.1097/01.jnen.0000235118.75182.94; Ichimura K, 2006, ONCOGENE, V25, P1261, DOI 10.1038/sj.onc.1209156; Ichimura K, 2000, CANCER RES, V60, P417; Ichimura K, 2004, J NEURO-ONCOL, V70, P137, DOI 10.1007/s11060-004-2747-2; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; Idbaih A, 2005, ANN NEUROL, V58, P483, DOI 10.1002/ana.20607; Ino Y, 2000, J NEUROSURG, V92, P983, DOI 10.3171/jns.2000.92.6.0983; Iuchi T, 2002, GENE CHROMOSOME CANC, V35, P170, DOI 10.1002/gcc.10080; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; Kleihues P, 2000, PATHOLOGY GENETICS T; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Koschny R, 2002, CANCER GENET CYTOGEN, V135, P147, DOI 10.1016/S0165-4608(01)00650-1; Kros JM, 2007, J NEUROPATH EXP NEUR, V66, P545, DOI 10.1097/01.jnen.0000263869.84188.72; Liu L, 2005, J MOL MED, V83, P917, DOI 10.1007/s00109-005-0700-2; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Mueller W, 2002, AM J PATHOL, V161, P313, DOI 10.1016/S0002-9440(10)64183-1; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; Reifenberger G, 2003, J NEUROPATH EXP NEUR, V62, P111, DOI 10.1093/jnen/62.2.111; Schmidt EE, 1999, J NEUROPATH EXP NEUR, V58, P1170, DOI 10.1097/00005072-199911000-00007; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Thomas D, 2001, J CLIN ONCOL, V19, P509, DOI 10.1200/JCO.2001.19.2.509; Ueki K, 2002, CLIN CANCER RES, V8, P196; van den Bent MJ, 2006, J CLIN ONCOL, V24, P2715, DOI 10.1200/JCO.2005.04.6078; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Waerner T, 2001, CELL GROWTH DIFFER, V12, P201; Watanabe T, 2002, ACTA NEUROPATHOL, V104, P357, DOI 10.1007/s00401-002-0549-1; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Yanagisawa H, 2000, HUM MOL GENET, V9, P1433, DOI 10.1093/hmg/9.9.1433	47	66	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					2097	2108		10.1038/sj.onc.1210848	http://dx.doi.org/10.1038/sj.onc.1210848			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17934521	Green Accepted			2022-12-28	WOS:000254359100015
J	Gross, C; Dubois-Pot, H; Wasylyk, B				Gross, C.; Dubois-Pot, H.; Wasylyk, B.			The ternary complex factor Net/Elk-3 participates in the transcriptional response to hypoxia and regulates HIF-1 alpha	ONCOGENE			English	Article						siah-2; PHDs; egr-1; c-fos; VEGF	FACTOR NET; HIF-1; DOMAIN; RAS; INHIBITION; EXPRESSION; SYSTEM; CELLS; O-2	The ternary complex factor Net/Elk3 is downregulated in hypoxia and participates in the induction by hypoxia of several genes, including c-fos, vascular endothelial growth factor and egr-1. However, the global role of Net in hypoxia remains to be elucidated. We have identified, in a large-scale analysis of RNA expression using microarrays, more than 370 genes that are regulated by Net in hypoxia. In order to gain insights into the role of Net in hypoxia, we have analysed in parallel the genes regulated by HIF-1 alpha, the classical factor involved in the response to hypoxia. We identified about 190 genes that are regulated by HIF-1 alpha in hypoxia. Surprisingly, when we compare the genes induced by hypoxia that require either Net or HIF-1 alpha, the majority are the same (75%), suggesting that the functions of both factors are closely linked. Interestingly, in hypoxia, Net regulates the expression of several genes known to control HIF-1 alpha stability, including PHD2, PHD3 and Siah2, suggesting that Net regulates the stability of HIF-1 alpha. We found that inhibition of Net by RNAi leads to decreased HIF-1 alpha expression at the protein level in hypoxia. These results indicate that Net participates in the transcriptional response to hypoxia by regulation of HIF-1 alpha protein stability.	[Gross, C.; Dubois-Pot, H.; Wasylyk, B.] ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Aprelikova O, 2006, CANCER RES, V66, P5641, DOI 10.1158/0008-5472.CAN-05-3345; Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139; Brahimi-Horn C, 2001, TRENDS CELL BIOL, V11, pS32, DOI 10.1016/S0962-8924(01)02126-2; Buchwalter G, 2005, MOL CELL BIOL, V25, P10853, DOI 10.1128/MCB.25.24.10853-10862.2005; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Gross C, 2007, MOL CELL BIOL, V27, P4133, DOI 10.1128/MCB.01867-06; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Le Brigand K, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl485; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Nakamura N, 2004, J PHYS CONF SER, V2, P1, DOI 10.1088/1742-6596/2/1/001; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; van Riggelen J, 2005, J BIOL CHEM, V280, P3286, DOI 10.1074/jbc.M409915200; Zheng H, 2003, GENE DEV, V17, P2283, DOI 10.1101/gad.272503	22	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1333	1341		10.1038/sj.onc.1210736	http://dx.doi.org/10.1038/sj.onc.1210736			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704799				2022-12-28	WOS:000253407000018
J	Datta, A; Nicot, C				Datta, A.; Nicot, C.			Telomere attrition induces a DNA double-strand break damage signal that reactivates p53 transcription in HTLV-I leukemic cells	ONCOGENE			English	Article						telomere; p53; MDMX; HTLV-I; ATM; senescence	HOMOLOGOUS RECOMBINATION; INTERFERON-ALFA; MDMX; PHOSPHORYLATION; ZIDOVUDINE; LYMPHOMA; TAX; ATM; INACTIVATION; COMBINATION	Persistent inhibition of telomerase induces a severe telomere shortening in human T-cell leukemia virus type-1-infected cells which signals a DNA double-strand break damage response, formation of telomere dysfunction-induced foci and activates the ATM pathway. In turn, activation of ATM and its downstream effectors led to an increased phosphorylation and acetylation on specific residues of p53 known to be involved in transcriptional activation. Disruption of Mdm2-p53 complexes coupled with increased proteasomal degradation of MDMX further enhanced reactivation of p53 transcription, ultimately leading to senescence of tumor cells. Induction of senescence in these T-cells was associated with an increased expression of p21, p16 and activation of GSK3 beta. Our results support the cancer - aging model and demonstrate that the halt of aging in cancer cells can be reversed through reactivation of p53.	[Datta, A.; Nicot, C.] Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center	Nicot, C (corresponding author), Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, 3025 Wahl Hall W,3901 Rainbow Blvd, Kansas City, KS 66103 USA.	cnicot@kumc.edu		Datta, Abhik/0000-0002-3442-5774	NCI NIH HHS [R01 CA106258, R01CA106258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bellon M, 2006, INT J CANCER, V119, P2090, DOI 10.1002/ijc.22026; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; Chehab NH, 2000, GENE DEV, V14, P278; Datta A, 2006, BLOOD, V108, P1021, DOI 10.1182/blood-2006-01-0067; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Liu L, 1999, MOL CELL BIOL, V19, P1202; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matutes E, 2001, BRIT J HAEMATOL, V113, P779, DOI 10.1046/j.1365-2141.2001.02794.x; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Park HU, 2006, ONCOGENE, V25, P438, DOI 10.1038/sj.onc.1209059; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Ramos YFM, 2001, CANCER RES, V61, P1839; Sabbatini P, 2002, DNA CELL BIOL, V21, P519, DOI 10.1089/104454902320219077; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; White JD, 2001, LEUKEMIA LYMPHOMA, V40, P287, DOI 10.3109/10428190109057927	29	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1135	1141		10.1038/sj.onc.1210718	http://dx.doi.org/10.1038/sj.onc.1210718			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704807				2022-12-28	WOS:000253136700013
J	Elia, A; Constantinou, C; Clemens, MJ				Elia, A.; Constantinou, C.; Clemens, M. J.			Effects of protein phosphorylation on ubiquitination and stability of the translational inhibitor protein 4E-BP1	ONCOGENE			English	Article						calyculin A; eIF4E; protein degradation; protein phosphatases; protein synthesis	INITIATION-FACTOR 4E; NF-KAPPA-B; DNA-DAMAGING AGENT; MESSENGER-RNA; PHAS-I; DEPENDENT DEGRADATION; REPRESSOR 4E-BP1; CALYCULIN-A; CYCLIN D1; KINASE	The availability of the eukaryotic polypeptide chain initiation factor 4E (eIF4E) for protein synthesis is regulated by the 4E-binding proteins (4E-BPs), which act as inhibitors of cap-dependent mRNA translation. The ability of the 4E-BPs to sequester eIF4E is regulated by reversible phosphorylation at multiple sites. We show here that, in addition, 4E-BP1 is a substrate for polyubiquitination and that some forms of 4E-BP1 are simultaneously polyubiquitinated and phosphorylated. In Jurkat cells inhibition of proteasomal activity by MG132 enhances the level of hypophosphorylated, unmodified 4E-BP1 but only modestly increases the accumulation of high-molecular-weight, phosphorylated forms of 4E-BP1. In contrast, inhibition of protein phosphatase activity with calyculin A reduces the level of unmodified 4E-BP1 but strongly enhances the amount of phosphorylated, high-molecular-weight 4E-BP1. Turnover measurements in the presence of cycloheximide show that, whereas 4E-BP1 is normally a very stable protein, calyculin A decreases the apparent half-life of the normal-sized protein. Affinity chromatography on m(7)GTP-Sepharose indicates that the larger forms of 4E-BP1 bind very poorly to eIF4E. We suggest that the phosphorylation of 4E-BP1 may play a dual role in the regulation of protein synthesis, both reducing the affinity of 4E-BP1 for eIF4E and promoting the conversion of 4E-BP1 to alternative, polyubiquitinated forms.	[Elia, A.; Constantinou, C.; Clemens, M. J.] Univ London, Ctr Mol & Metab Signalling, Div Basic Med Sci, Translat Control Grp, London SW17 0RE, England	University of London	Clemens, MJ (corresponding author), Univ London, Ctr Mol & Metab Signalling, Div Basic Med Sci, Translat Control Grp, Cranmer Terrace, London SW17 0RE, England.	m.clemens@sgul.ac.uk	Elia, Androulla/AAE-6854-2021					Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Carroll M, 2006, MOL CELL BIOL, V26, P8586, DOI 10.1128/MCB.00955-06; Carter PS, 1999, ONCOGENE, V18, P4326, DOI 10.1038/sj.onc.1202890; Castellvi J, 2006, CANCER-AM CANCER SOC, V107, P1801, DOI 10.1002/cncr.22195; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Constantinou C, 2007, CELL DEATH DIFFER, V14, P576, DOI 10.1038/sj.cdd.4402045; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Cormier P, 2001, DEV BIOL, V232, P275, DOI 10.1006/dbio.2001.0206; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Fawcett J, 2001, J BIOL CHEM, V276, P11552, DOI 10.1074/jbc.M007988200; Fawcett J, 2001, ARCH BIOCHEM BIOPHYS, V385, P357, DOI 10.1006/abbi.2000.2160; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Graham B, 2005, CELL CYCLE, V4, P1342, DOI 10.4161/cc.4.10.2047; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Harhaj EW, 1997, J BIOL CHEM, V272, P5409, DOI 10.1074/jbc.272.9.5409; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hoover DS, 1997, CELL GROWTH DIFFER, V8, P1371; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Jeffrey IW, 2002, CANCER RES, V62, P2272; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Krappmann D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Le Bouffant R, 2006, J CELL BIOCHEM, V99, P126, DOI 10.1002/jcb.20856; Li BG, 2000, INT J BIOCHEM CELL B, V32, P677, DOI 10.1016/S1357-2725(00)00010-8; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; Lin SS, 2006, J BIOL CHEM, V281, P23003, DOI 10.1074/jbc.M602648200; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Murata T, 2006, J BIOL CHEM, V281, P20788, DOI 10.1074/jbc.M600563200; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nimmanapalli R, 2003, CANCER RES, V63, P7950; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Othumpangat S, 2005, J BIOL CHEM, V280, P25162, DOI 10.1074/jbc.M414303200; Othumpangat S, 2005, MOL CELL BIOCHEM, V279, P123, DOI 10.1007/s11010-005-8284-2; Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Proud CG, 2005, CELL DEATH DIFFER, V12, P541, DOI 10.1038/sj.cdd.4401588; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Ren Q, 2006, CANCER RES, V66, P5209, DOI 10.1158/0008-5472.CAN-05-4158; ROSENTHAL K, 1995, SEMIN AVIAN EXOT PET, V4, P1; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Salaun P, 2003, DEV BIOL, V255, P428, DOI 10.1016/S0012-1606(02)00099-4; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schneider R, 2005, INT J RADIAT ONCOL, V63, pS146, DOI 10.1016/j.ijrobp.2005.07.249; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Tilleray V, 2006, FEBS LETT, V580, P1766, DOI 10.1016/j.febslet.2006.02.030; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Torres C, 2003, EXP CELL RES, V290, P195, DOI 10.1016/S0014-4827(03)00309-4; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Walsh D, 2005, J VIROL, V79, P8057, DOI 10.1128/JVI.79.13.8057-8064.2005; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135	74	52	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					811	822		10.1038/sj.onc.1210678	http://dx.doi.org/10.1038/sj.onc.1210678			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653084				2022-12-28	WOS:000252884500010
J	Anderton, E; Yee, J; Smith, P; Crook, T; White, RE; Allday, MJ				Anderton, E.; Yee, J.; Smith, P.; Crook, T.; White, R. E.; Allday, M. J.			Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma	ONCOGENE			English	Article						apoptosis; Bim; Burkitt's lymphoma; EBV; EBNA3A; EBNA3C; MYC	NUCLEAR ANTIGEN 3C; HUMAN B-CELLS; HOMOZYGOUS DELETIONS; HISTONE DEACETYLASE; BH3-ONLY PROTEIN; DOWN-REGULATION; C-MYC; APOPTOSIS; P53; CTBP	Epstein-Barr virus (EBV) contributes to the development of several human cancers including the endemic form of Burkitt's lymphoma (BL). In culture, EBV induces the continuous proliferation of primary B cells as lymphoblastoid cell lines (LCLs) and if EBV-negative BL-derived cells are infected with EBV, latency-associated viral factors confer resistance to various inducers of apoptosis. Nuclear proteins EBNA3A and EBNA3C (but not EBNA3B) are necessary to establish LCLs and their expression may be involved in the resistance of BL cells to cytotoxic agents. We have therefore created recombinant EBVs from which each of the EBNA3 genes has been independently deleted, and revertant viruses in which the genes have been re-introduced into the viral genome. Infection of EBV-negative BL cells with this panel of EBVs and challenge with various cytotoxic drugs showed that EBNA3A and EBNA3C cooperate as the main determinants of both drug resistance and the downregulation of the proapoptotic Bcl-2- family member Bcl-2-interacting mediator of cell death (Bim). The regulation of Bim is predominantly at the level of RNA, with little evidence of post-translational Bim stabilization by EBV. In the absence of Bim, EBNA3A and EBNA3C appear to provide no survival advantage. The level of Bim is a critical regulator of B cell survival and reduced expression is a major determinant of lymphoproliferative disease in mice and humans; moreover, Bim is uniquely important in the pathogenesis of BL. By targeting this tumour-suppressor for repression, EBV significantly increases the likelihood of B lymphomagenesis in general, and BL in particular. Our results may also explain the selection pressure that gives rise to a subset of BL that retain expression of the EBNA3 proteins.	[Anderton, E.; Yee, J.; White, R. E.; Allday, M. J.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England; [Smith, P.; Crook, T.] Toby Robins Breast Canc Res Ctr, Inst Canc Res Breakthrough, London, England	Imperial College London; University of London; Institute of Cancer Research - UK	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England.	m.allday@imperial.ac.uk		White, Robert/0000-0002-5115-2173	Wellcome Trust Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission); Breast Cancer Now		ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; Alvi AJ, 2005, BLOOD, V105, P4484, DOI 10.1182/blood-2004-07-2713; Bain M, 1996, J VIROL, V70, P2481, DOI 10.1128/JVI.70.4.2481-2489.1996; Bornkamm GW, 2001, PHILOS T R SOC B, V356, P437, DOI 10.1098/rstb.2000.0781; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bourillot PY, 1998, J GEN VIROL, V79, P363, DOI 10.1099/0022-1317-79-2-363; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cludts I, 1998, J VIROL, V72, P1862, DOI 10.1128/JVI.72.3.1862-1869.1998; Clybouw C, 2005, J IMMUNOL, V175, P2968, DOI 10.4049/jimmunol.175.5.2968; Dang CV, 2005, CANCER CELL, V8, P177, DOI 10.1016/j.ccr.2005.08.005; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Epeldegui M, 2007, MOL IMMUNOL, V44, P934, DOI 10.1016/j.molimm.2006.03.018; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; Fruehling S, 1996, J VIROL, V70, P6216, DOI 10.1128/JVI.70.9.6216-6226.1996; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hickabottom M, 2002, J BIOL CHEM, V277, P47197, DOI 10.1074/jbc.M208116200; Jimenez-Ramirez C, 2006, J VIROL, V80, P11200, DOI 10.1128/JVI.00897-06; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; Kelly GL, 2006, P NATL ACAD SCI USA, V103, P14935, DOI 10.1073/pnas.0509988103; Kelly GL, 2005, J VIROL, V79, P10709, DOI 10.1128/JVI.79.16.10709-10717.2005; Knight JS, 2003, J VIROL, V77, P4261, DOI 10.1128/JVI.77.7.4261-4272.2003; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Leao M, 2007, J VIROL, V81, P248, DOI 10.1128/JVI.01096-06; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lindstrom MS, 2001, ONCOGENE, V20, P2171, DOI 10.1038/sj.onc.1204303; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; O'Nions F, 2004, ADV CANCER RES, V92, P119; O'Nions J, 2003, ONCOGENE, V22, P7181, DOI 10.1038/sj.onc.1206838; O'Nions J, 2006, J VIROL, V80, P12408, DOI 10.1128/JVI.01363-06; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Rosendorff A, 2004, J VIROL, V78, P367, DOI 10.1128/JVI.78.1.367-377.2004; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Wade M, 2000, MOL CELL BIOL, V20, P1344, DOI 10.1128/MCB.20.4.1344-1360.2000; White RE, 2003, J GEN VIROL, V84, P3393, DOI 10.1099/vir.0.19387-0; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Zimber-Strobl U, 2001, SEMIN CANCER BIOL, V11, P423, DOI 10.1006/scbi.2001.0409	46	140	143	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					421	433		10.1038/sj.onc.1210668	http://dx.doi.org/10.1038/sj.onc.1210668			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653091				2022-12-28	WOS:000252426100002
J	Kim, SI; Bresnick, EH				Kim, S-I; Bresnick, E. H.			Transcriptional control of erythropoiesis: emerging mechanisms and principles	ONCOGENE			English	Review						erythropoiesis; chromatin; transcription; epigenetic mark	LOCUS-CONTROL REGION; BETA-GLOBIN GENE; CREB-BINDING-PROTEIN; KRUPPEL-LIKE FACTOR; RNA-POLYMERASE-II; CHROMATIN-REMODELING COMPLEX; HISTONE ACETYLTRANSFERASE COMPLEXES; GATA FACTOR INTERPLAY; DNA-BINDING; FACTOR NF-E2	Transcriptional networks orchestrate fundamental biological processes, including hematopoiesis, in which hematopoietic stem cells progressively differentiate into specific progenitors cells, which in turn give rise to the diverse blood cell types. Whereas transcription factors recruit coregulators to chromatin, leading to targeted chromatin modification and recruitment of the transcriptional machinery, many questions remain unanswered regarding the underlying molecular mechanisms. Furthermore, how diverse cell type- specific transcription factors function cooperatively or antagonistically in distinct cellular contexts is poorly understood, especially since genes in higher eukaryotes commonly encompass broad chromosomal regions ( 100 kb and more) and are littered with dispersed regulatory sequences. In this article, we describe an important set of transcription factors and coregulators that control erythropoiesis and highlight emerging transcriptional mechanisms and principles. It is not our intent to comprehensively survey all factors implicated in the transcriptional control of erythropoiesis, but rather to underscore specific mechanisms, which have potential to be broadly relevant to transcriptional control in diverse systems.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Med Sci Ctr 385, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Med Sci Ctr 385, 1300 Univ Ave, Madison, WI 53706 USA.	ehbresni@wisc.edu		Kim, Shin-Il/0000-0002-7350-0087; Kim, Shin-Il/0000-0002-1742-3718	NIDDK NIH HHS [DK68634, DK55700, DK50107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK068634, R01DK050107, R01DK055700, R01DK068634] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Anderson KP, 2000, BLOOD, V95, P1652, DOI 10.1182/blood.V95.5.1652.005k23_1652_1655; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bank A, 2006, BLOOD, V107, P435, DOI 10.1182/blood-2005-05-2113; Bean TL, 1997, NUCLEIC ACIDS RES, V25, P2509, DOI 10.1093/nar/25.12.2509; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; Belakavadi M, 2006, REV PHYSIOL BIOCH P, V156, P23, DOI 10.1007/s10254-005-0002-7; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Bourquin JP, 2006, P NATL ACAD SCI USA, V103, P3339, DOI 10.1073/pnas.0511150103; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713; Bresnick EH, 2005, J CELL PHYSIOL, V205, P1, DOI 10.1002/jcp.20393; Bresnick EH, 2006, PROG NUCLEIC ACID RE, V81, P435, DOI 10.1016/S0079-6603(06)81011-1; Brown RC, 2002, MOL CELL BIOL, V22, P161, DOI 10.1128/MCB.22.1.161-170.2002; Bulger M, 2003, MOL CELL BIOL, V23, P5234, DOI 10.1128/MCB.23.15.5234-5244.2003; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2005, GENE DEV, V19, P2849, DOI 10.1101/gad.1364105; Cantor AB, 2005, SEMIN CELL DEV BIOL, V16, P117, DOI 10.1016/j.semcdb.2004.10.006; Cantor AB, 2002, MOL CELL BIOL, V22, P4268, DOI 10.1128/MCB.22.12.4268-4279.2002; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Casteel D, 1998, BLOOD, V91, P3193, DOI 10.1182/blood.V91.9.3193.3193_3193_3201; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chan WYI, 2007, BLOOD, V109, P1908, DOI 10.1182/blood-2006-05-023226; CHANG TC, 2007, ANN REV GENOMICS HUM; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Chen L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/pnas.212532399; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; Chen XY, 2004, MOL CELL BIOL, V24, P10416, DOI 10.1128/MCB.24.23.10416-10424.2004; Chen XY, 2001, MOL CELL BIOL, V21, P3118, DOI 10.1128/MCB.21.9.3118-3125.2001; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Chung YS, 2002, DEVELOPMENT, V129, P5511, DOI 10.1242/dev.00149; Coghill E, 2001, BLOOD, V97, P1861, DOI 10.1182/blood.V97.6.1861; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; Crispino JD, 2005, SEMIN CELL DEV BIOL, V16, P137, DOI 10.1016/j.semcdb.2004.11.002; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Crispino JD, 2001, GENE DEV, V15, P839, DOI 10.1101/gad.875201; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; Daftari P, 1999, ONCOGENE, V18, P5482, DOI 10.1038/sj.onc.1202916; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Dean A, 2006, TRENDS GENET, V22, P38, DOI 10.1016/j.tig.2005.11.001; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; Drissen R, 2005, MOL CELL BIOL, V25, P5205, DOI 10.1128/MCB.25.12.5205-5214.2005; Drissen R, 2004, GENE DEV, V18, P2485, DOI 10.1101/gad.317004; Ema M, 2003, GENE DEV, V17, P380, DOI 10.1101/gad.1049803; Emery DW, 2000, P NATL ACAD SCI USA, V97, P9150, DOI 10.1073/pnas.160159597; Emery DW, 2002, BLOOD, V100, P2012, DOI 10.1182/blood-2002-01-0219; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Forsberg EC, 1999, J BIOL CHEM, V274, P26850, DOI 10.1074/jbc.274.38.26850; Forsberg EC, 2000, BLOOD, V96, P334, DOI 10.1182/blood.V96.1.334.013k17_334_339; Forsberg EC, 1999, MOL CELL BIOL, V19, P5565; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Fujiwara Y, 2004, BLOOD, V103, P583, DOI 10.1182/blood-2003-08-2870; Garriga-Canut M, 2004, J BIOL CHEM, V279, P23597, DOI 10.1074/jbc.M313987200; Gering M, 2003, DEVELOPMENT, V130, P6187, DOI 10.1242/dev.00875; Gillemans N, 1998, GENE DEV, V12, P2863, DOI 10.1101/gad.12.18.2863; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Gottgens B, 2002, EMBO J, V21, P3039, DOI 10.1093/emboj/cdf286; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Grass JA, 2006, MOL CELL BIOL, V26, P7056, DOI 10.1128/MCB.01033-06; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Grewal SIS, 2007, NATURE, V447, P399, DOI 10.1038/nature05914; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hodge D, 2006, BLOOD, V107, P3359, DOI 10.1182/blood-2005-07-2888; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Hong W, 2005, EMBO J, V24, P2367, DOI 10.1038/sj.emboj.7600703; HROMAS R, 1993, BLOOD, V82, P2998; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Huebert DJ, 2006, METHODS, V40, P365, DOI 10.1016/j.ymeth.2006.07.032; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Hung HL, 2001, J BIOL CHEM, V276, P10715, DOI 10.1074/jbc.M007846200; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Im H, 2005, P NATL ACAD SCI USA, V102, P17065, DOI 10.1073/pnas.0506164102; Im Hogune, 2004, Methods Mol Biol, V284, P129; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Johnson KD, 2003, MOL CELL BIOL, V23, P6484, DOI 10.1128/MCB.23.18.6484-6493.2003; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Johnson KD, 2007, BLOOD, V109, P5230, DOI 10.1182/blood-2007-02-072983; Johnson KD, 2006, P NATL ACAD SCI USA, V103, P15939, DOI 10.1073/pnas.0604041103; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kapranov P, 2007, NAT REV GENET, V8, P413, DOI 10.1038/nrg2083; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; Katz SG, 2002, MOL CELL BIOL, V22, P3121, DOI 10.1128/MCB.22.9.3121-3128.2002; Kaushansky K, 2006, NEW ENGL J MED, V354, P2034, DOI 10.1056/NEJMra052706; Khandekar M, 2007, DEVELOPMENT, V134, P1703, DOI 10.1242/dev.001297; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kiekhaefer CM, 2004, J BIOL CHEM, V279, P7456, DOI 10.1074/jbc.M309750200; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kim SI, 2007, MOL CELL BIOL, V27, P4551, DOI 10.1128/MCB.00235-07; Kirmizis A, 2004, EXP BIOL MED, V229, P705, DOI 10.1177/153537020422900803; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Kong SM, 1997, MOL CELL BIOL, V17, P3955, DOI 10.1128/MCB.17.7.3955; Kooren J, 2007, J BIOL CHEM, V282, P16544, DOI 10.1074/jbc.M701159200; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Kung AL, 2000, GENE DEV, V14, P272; Lahlil R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004; Lamonica JM, 2006, BLOOD, V108, P3736, DOI 10.1182/blood-2006-07-032847; Landles C, 2003, MOL ENDOCRINOL, V17, P2418, DOI 10.1210/me.2003-0097; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Letting DL, 2004, P NATL ACAD SCI USA, V101, P476, DOI 10.1073/pnas.0306315101; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Levings PP, 2006, FEBS J, V273, P746, DOI 10.1111/j.1742-4658.2005.05107.x; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Liew CW, 2006, J BIOL CHEM, V281, P28296, DOI 10.1074/jbc.M602830200; Liew CK, 2005, P NATL ACAD SCI USA, V102, P583, DOI 10.1073/pnas.0407511102; Lin AC, 2004, J BIOL CHEM, V279, P55017, DOI 10.1074/jbc.M411240200; Ling JH, 2004, J BIOL CHEM, V279, P51704, DOI 10.1074/jbc.M404039200; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lopez RA, 2002, P NATL ACAD SCI USA, V99, P602, DOI 10.1073/pnas.022412699; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Lugus JJ, 2007, DEVELOPMENT, V134, P393, DOI 10.1242/dev.02731; Mahajan MC, 2005, P NATL ACAD SCI USA, V102, P15012, DOI 10.1073/pnas.0507596102; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; Martin J, 1990, ORGAN SCI, V1, P339, DOI 10.1287/orsc.1.4.339; Martowicz ML, 2005, J BIOL CHEM, V280, P1724, DOI 10.1074/jbc.M406038200; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Meier N, 2006, DEVELOPMENT, V133, P4913, DOI 10.1242/dev.02656; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; Mikkola HKA, 2006, DEVELOPMENT, V133, P3733, DOI 10.1242/dev.02568; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Minegishi N, 1999, BLOOD, V93, P4196, DOI 10.1182/blood.V93.12.4196.412k23_4196_4207; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOON AM, 1991, BLOOD, V77, P2272; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Munugalavadla V, 2005, MOL CELL BIOL, V25, P6747, DOI 10.1128/MCB.25.15.6747-6759.2005; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Nilson DG, 2006, EXP HEMATOL, V34, P705, DOI 10.1016/j.exphem.2006.02.018; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; O'Neill D, 1999, P NATL ACAD SCI USA, V96, P349, DOI 10.1073/pnas.96.2.349; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Oike Y, 1999, BLOOD, V93, P2771; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pal S, 2004, J BIOL CHEM, V279, P31348, DOI 10.1074/jbc.M403475200; Pal S, 2004, P NATL ACAD SCI USA, V101, P980, DOI 10.1073/pnas.0307612100; Pal S, 2006, J CELL BIOL, V174, P1047, DOI 10.1083/jcb.200603152; Patterson LJ, 2007, BLOOD, V109, P2389, DOI 10.1182/blood-2006-02-003087; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; Pilon AM, 2006, MOL CELL BIOL, V26, P4368, DOI 10.1128/MCB.02216-05; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRASAD KSS, 1995, J BIOL CHEM, V270, P11603, DOI 10.1074/jbc.270.19.11603; Prasad KSS, 1997, J BIOL CHEM, V272, P11457; Puthenveetil G, 2004, BLOOD, V104, P3445, DOI 10.1182/blood-2004-04-1427; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rekhtman N, 2003, MOL CELL BIOL, V23, P7460, DOI 10.1128/MCB.23.21.7460-7474.2003; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Rooke HM, 2006, BLOOD, V107, P3527, DOI 10.1182/blood-2005-10-4309; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Shyu YC, 2005, MOL CELL BIOL, V25, P10365, DOI 10.1128/MCB.25.23.10365-10378.2005; Simon E., 1892, Histoire naturelle des araignees, V1, P1; Stopka T, 2005, EMBO J, V24, P3712, DOI 10.1038/sj.emboj.7600834; Stumpf M, 2006, P NATL ACAD SCI USA, V103, P18504, DOI 10.1073/pnas.0604494103; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Szutorisz H, 2005, TRENDS BIOCHEM SCI, V30, P593, DOI 10.1016/j.tibs.2005.08.006; Szutorisz H, 2005, MOL CELL BIOL, V25, P1804, DOI 10.1128/MCB.25.5.1804-1820.2005; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Tewari R, 1998, EMBO J, V17, P2334, DOI 10.1093/emboj/17.8.2334; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; Travers A, 1999, P NATL ACAD SCI USA, V96, P13634, DOI 10.1073/pnas.96.24.13634; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Uhlmann T, 2007, J BIOL CHEM, V282, P2163, DOI 10.1074/jbc.M608451200; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Versaw WK, 1998, P NATL ACAD SCI USA, V95, P8756, DOI 10.1073/pnas.95.15.8756; Vieira KF, 2004, J BIOL CHEM, V279, P50350, DOI 10.1074/jbc.M408883200; Vyas P, 1999, DEVELOPMENT, V126, P2799; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Welch JJ, 2004, BLOOD, V104, P3136, DOI 10.1182/blood-2004-04-1603; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; Wozniak RJ, 2007, J BIOL CHEM, V282, P14665, DOI 10.1074/jbc.M700792200; XU Z, 2003, J DISTANCE ED TECHNO, V1, P1; Xu ZX, 2007, GENE DEV, V21, P942, DOI 10.1101/gad.1528507; Xu ZX, 2006, BIOCHEM J, V399, P297, DOI 10.1042/BJ20060873; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhao W, 2006, BLOOD, V107, P907, DOI 10.1182/blood-2005-06-2516; Zhou DW, 2006, J BIOL CHEM, V281, P16052, DOI 10.1074/jbc.M601182200; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200	270	72	75	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6777	6794		10.1038/sj.onc.1210761	http://dx.doi.org/10.1038/sj.onc.1210761			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934485				2022-12-28	WOS:000250147000009
J	Horn, S; Bergholz, U; Jucker, M; McCubrey, JA; Trumper, L; Stocking, C; Basecke, J				Horn, S.; Bergholz, U.; Juecker, M.; McCubrey, J. A.; Truemper, L.; Stocking, C.; Baesecke, J.			Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells	ONCOGENE			English	Article						leukemia; oncogenic transformation; phosphoinositide 3-kinase; signal transduction	ACUTE MYELOID-LEUKEMIA; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; ACUTE MYELOGENOUS LEUKEMIA; PIK3CA GENE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; HUMAN CANCER; IN-VIVO; C-MYC; CONSTITUTIVE PHOSPHORYLATION	Constitutive activation of the phosphoinositide 3-kinase ( PI3K)-AKT pathway is observed in up to 70% of acute myelogenous leukemia. To investigate the relevance of an intrinsic PI3K-AKT pathway activation in hematopoietic malignancies, we analysed the effect of point mutations in the catalytic ( p110 alpha) and regulatory ( p85 alpha) subunit of class IA PI3K. We demonstrated that mutations in the helical ( E542K, E545A) and kinase domain ( H1047R) of p110 alpha constitutively activate the PI3K-AKT pathway and lead to factor-independent growth of early hematopoietic cells. Proliferation and survival of the cells were inhibited in a time- and dose-dependent manner using either PI3K or AKT inhibitors. The mammalian target of rapamycin ( mTOR) was demonstrated to be important for mitogenic, but not antiapoptotic signaling of mutant p110a. In a syngenic mouse model, hematopoietic cells expressing mutated p110 alpha induced a leukemia-like disease characterized by anemia, neoplastic infiltration of hematopoietic organs and 90% mortality within 5 weeks, whereas activated mutants of the receptor tyrosine kinase c-KIT led to 100% mortality within 10 days. Our data show that point mutations in the p110 alpha subunit of class IA PI3K confer factor independence to hematopoietic cells in vitro and leukemogenic potential in vivo, but have lower transforming activity than a deregulated class III receptor tyrosine kinase.	[Horn, S.; Truemper, L.; Baesecke, J.] Univ Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany; [Bergholz, U.; Stocking, C.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Program Area Cellular Dysregulat, Mol Pathol Grp, D-2000 Hamburg, Germany; [Juecker, M.] Univ Med Ctr Hamburg Eppendorf, Dept Biochem & Mol Biol Cellular Signal Transduct, Hamburg, Germany; [McCubrey, J. A.] Univ Greenville, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC USA	University of Gottingen; Heinrich Pette Institute; University of Hamburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Basecke, J (corresponding author), Univ Gottingen, Dept Hematol & Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany.	jbaesec@gwdg.de		McCubrey, James/0000-0001-6027-3156				Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Billottet C, 2006, ONCOGENE, V25, P6648, DOI 10.1038/sj.onc.1209670; Borlado LR, 2000, FASEB J, V14, P895; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Bousquet M, 2005, BRIT J HAEMATOL, V131, P411, DOI 10.1111/j.1365-2141.2005.05784.x; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Cammenga J, 2005, BLOOD, V106, P3958, DOI 10.1182/blood-2005-02-0583; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Dutton A, 2005, J PATHOL, V205, P498, DOI 10.1002/path.1725; Frohling S, 2005, J CLIN ONCOL, V23, P6285, DOI 10.1200/JCO.2005.05.010; Gilliland DG, 2002, CURR OPIN HEMATOL, V9, P274, DOI 10.1097/00062752-200207000-00003; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hashimoto K, 2003, BLOOD, V101, P1094, DOI 10.1182/blood-2002-01-0177; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Hummerdal P, 2006, EUR J HAEMATOL, V77, P86, DOI 10.1111/j.0902-4441.2006.t01-1-EJH2605.x; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jucker M, 2002, LEUKEMIA, V16, P894, DOI 10.1038/sj.leu.2402484; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kornblau SM, 2006, BLOOD, V108, P2358, DOI 10.1182/blood-2006-02-003475; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; Luo JM, 2003, LEUKEMIA, V17, P1, DOI 10.1038/sj.leu.2402725; Malempati S, 2006, LEUKEMIA, V20, P1572, DOI 10.1038/sj.leu.2404317; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Min YH, 2004, CANCER RES, V64, P5225, DOI 10.1158/0008-5472.CAN-04-0174; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Muller CI, 2007, LEUKEMIA RES, V31, P27, DOI 10.1016/j.leukres.2006.04.011; Nyakern M, 2006, LEUKEMIA, V20, P230, DOI 10.1038/sj.leu.2404057; Philp AJ, 2001, CANCER RES, V61, P7426; Recher C, 2005, BLOOD, V105, P2527, DOI 10.1182/blood-2004-06-2494; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rudelius M, 2006, BLOOD, V108, P1668, DOI 10.1182/blood-2006-04-015586; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schade AE, 2006, BLOOD, V107, P4834, DOI 10.1182/blood-2005-08-3076; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shelton JG, 2004, CELL CYCLE, V3, P503; Shivakrupa R, 2003, CANCER RES, V63, P4412; STOCKING C, 1993, GROWTH FACTORS, V8, P197, DOI 10.3109/08977199309011023; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood-2006-04-016907; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	53	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4096	4106		10.1038/onc.2008.40	http://dx.doi.org/10.1038/onc.2008.40			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18317450				2022-12-28	WOS:000257325100009
J	Grady, WM; Parkin, RK; Mitchell, PS; Lee, JH; Kim, YH; Tsuchiya, KD; Washington, MK; Paraskeva, C; Willson, JKV; Kaz, AM; Kroh, EM; Allen, A; Fritz, BR; Markowitz, SD; Tewari, M				Grady, W. M.; Parkin, R. K.; Mitchell, P. S.; Lee, J. H.; Kim, Y-H; Tsuchiya, K. D.; Washington, M. K.; Paraskeva, C.; Willson, J. K. V.; Kaz, A. M.; Kroh, E. M.; Allen, A.; Fritz, B. R.; Markowitz, S. D.; Tewari, M.			Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer	ONCOGENE			English	Article						microRNA; epigenetic; colorectal cancer; colon cancer; methylation; apoptosis	OLIGONUCLEOTIDE ARRAYS; EXPRESSION PROFILES; COLON-CANCER; IDENTIFICATION; TARGETS; TUMOR; HYPERMETHYLATION; SIGNATURE; NEOPLASIA; MECHANISM	MicroRNAs are small, non-coding RNAs that influence gene regulatory networks by post-transcriptional regulation of specific messenger RNA targets. MicroRNA expression is dysregulated in human malignancies, frequently leading to loss of expression of certain microRNAs. We report that expression of hsa-miR-342, a microRNA encoded in an intron of the gene EVL, is commonly suppressed in human colorectal cancer. The expression of hsa-miR- 342 is coordinated with that of EVL and our results indicate that the mechanism of silencing is CpG island methylation upstream of EVL. We found methylation at the EVL/hsa-miR-342 locus in 86% of colorectal adenocarcinomas and in 67% of adenomas, indicating that it is an early event in colorectal carcinogenesis. In addition, we observed a higher frequency of methylation ( 56%) in histologically normal colorectal mucosa from individuals with concurrent cancer compared to mucosa from individuals without colorectal cancer ( 12%), suggesting the existence of a 'field defect' involving methylated EVL/hsa-miR-342. Furthermore, reconstitution of hsa-miR- 342 in the colorectal cancer cell line HT-29 induced apoptosis, suggesting that this microRNA could function as a proapoptotic tumor suppressor. In aggregate, these results support a novel mechanism for silencing intronic microRNAs in cancer by epigenetic alterations of cognate host genes.	[Grady, W. M.; Lee, J. H.; Kim, Y-H; Tsuchiya, K. D.; Kaz, A. M.; Tewari, M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Grady, W. M.; Kaz, A. M.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA; [Grady, W. M.; Kaz, A. M.] VA Puget Sound Healthcare Syst, Seattle, WA USA; [Parkin, R. K.; Mitchell, P. S.; Kroh, E. M.; Fritz, B. R.; Tewari, M.] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA; [Lee, J. H.; Kim, Y-H] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Seoul, South Korea; [Tsuchiya, K. D.] Seattle Childrens Hosp & Reg Med Ctr, Seattle, WA USA; [Washington, M. K.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Paraskeva, C.] Univ Bristol, Bristol, Avon, England; [Willson, J. K. V.] Univ Texas SW, Sch Med, Dallas, TX USA; [Allen, A.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; [Markowitz, S. D.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Markowitz, S. D.] Univ Hosp Cleveland, Cleveland, OH 44106 USA; [Markowitz, S. D.] Howard Hughes Med Inst, Cleveland, OH USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Fred Hutchinson Cancer Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Seattle Children's Hospital; Vanderbilt University; University of Bristol; University of Texas System; University of Texas Southwestern Medical Center Dallas; Fred Hutchinson Cancer Center; Case Western Reserve University; University Hospitals of Cleveland; Howard Hughes Medical Institute	Tewari, M (corresponding author), Fred Hutchinson Canc Res Ctr, Human Biol & Clin Res Div, 1100 Fairview Ave N,Mailstop D4-100, Seattle, WA 98109 USA.	mtewari@fhcrc.org		Mitchell, Patrick/0000-0001-8375-9060	NCI NIH HHS [P30 CA015704] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Grady WM, 2001, CANCER RES, V61, P900; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Kim YH, 2006, GENE CHROMOSOME CANC, V45, P781, DOI 10.1002/gcc.20341; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Michael MZ, 2003, MOL CANCER RES, V1, P882; Myohanen SK, 1998, CANCER RES, V58, P591; Notterman DA, 2001, CANCER RES, V61, P3124; Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104; Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340; Toyota M, 1999, CANCER RES, V59, P2307; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wijnhoven BPL, 2007, BRIT J SURG, V94, P23, DOI 10.1002/bjs.5673; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	29	228	246	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3880	3888		10.1038/onc.2008.10	http://dx.doi.org/10.1038/onc.2008.10			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264139				2022-12-28	WOS:000256904700013
J	Kim, MS; Chang, X; Yamashita, K; Nagpal, JK; Baek, JH; Wu, G; Trink, B; Ratovitski, EA; Mori, M; Sidransky, D				Kim, M. S.; Chang, X.; Yamashita, K.; Nagpal, J. K.; Baek, J. H.; Wu, G.; Trink, B.; Ratovitski, E. A.; Mori, M.; Sidransky, D.			Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma	ONCOGENE			English	Article						promoter methylation; DFNA5; colon cancer	CELLULAR RETINOL-BINDING-PROTEIN-1; DNA METHYLATION; HYPERMETHYLATION; EXPRESSION; IDENTIFICATION; INACTIVATION; CANCERS; ICERE-1; PROFILE	To identify novel methylated gene promoters, we compared differential RNA expression profiles of colorectal cancer (CRC) cell lines with or without treatment of 5-aza-2'-deoxycytidine (5-aza-dC). Out of 1776 genes that were initially 'absent (that is, silenced)' by gene expression array analysis, we selected 163 genes that were increased after 5-aza-dC treatment in at least two of three CRC cell lines. The microarray results were confirmed by Reverse Transcription-PCR, and CpG island of the gene promoters were amplified and sequenced for examination of cancer-specific methylation. Among the genes identified, the deafness, autosomal dominant 5 gene, DFNA5, promoter was found to be methylated in primary tumor tissues with high frequency (65%, 65/100). Quantitative methylation-specific PCR of DFNA5 clearly discriminated primary CRC tissues from normal colon tissues (3%, 3/100). The mRNA expression of DFNA5 in four of five colon cancer tissues was significantly downregulated as compared to normal tissues. Moreover, forced expression of full-length DFNA5 in CRC cell lines markedly decreased the cell growth and colony-forming ability whereas knockdown of DFNA5 increased cell growth in culture. Our data implicate DFNA5 as a novel tumor suppressor gene in CRC and a valuable molecular marker for human cancer.	[Kim, M. S.; Chang, X.; Yamashita, K.; Nagpal, J. K.; Trink, B.; Ratovitski, E. A.; Sidransky, D.] Johns Hopkins Univ, Head & Neck Canc Res Div, Dept Otolaryngol, Baltimore, MD 21231 USA; [Baek, J. H.] Johns Hopkins Univ, Inst Cell Engn, Dept Med Genet, Baltimore, MD 21231 USA; [Wu, G.] Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Detroit, MI USA; [Mori, M.] Kyushu Univ, Dept Surg Oncol, Med Inst Bioregulat, Beppu, Oita, Japan	Johns Hopkins University; Johns Hopkins University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Kyushu University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol & Otolaryngol, Div Head & Neck Canc Res Inst, Johns Hopkins Canc Res Bldg 2,1150 Orleans St, Baltimore, MD 21231 USA.	dsidran1@jhmi.edu						Akino K, 2007, CANCER SCI, V98, P88, DOI 10.1111/j.1349-7006.2006.00351.x; Brakenhoff RH, 1997, J IMMUNOL, V159, P4879; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Esteller M, 2002, CANCER RES, V62, P5902; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jeronimo C, 2004, J CLIN PATHOL, V57, P872, DOI 10.1136/jcp.2003.014555; Kim JM, 2005, CLIN CANCER RES, V11, P473; Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608; Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3; Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28; Luo LP, 2005, INT J CANCER, V115, P747, DOI 10.1002/ijc.20936; Masuda Yoshiko, 2006, J Hum Genet, V51, P652, DOI 10.1007/s10038-006-0004-6; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Scanlan Matthew J, 2004, Cancer Immun, V4, P1; Shutoh M, 2005, CANCER-AM CANCER SOC, V104, P1609, DOI 10.1002/cncr.21392; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Van Laer L, 1998, NAT GENET, V20, P194; VANCAMP G, 1995, HUM MOL GENET, V4, P2159; Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	24	131	141	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3624	3634		10.1038/sj.onc.1211021	http://dx.doi.org/10.1038/sj.onc.1211021			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223688				2022-12-28	WOS:000256468500014
J	Greif, PA; Tizazu, B; Krause, A; Kremmer, E; Bohlander, SK				Greif, P. A.; Tizazu, B.; Krause, A.; Kremmer, E.; Bohlander, S. K.			The leukemogenic CALM/AF10 fusion protein alters the subcellular localization of the lymphoid regulator Ikaros	ONCOGENE			English	Article						AF10; CALM/AF10; Ikaros; leukemia; translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DNA-BINDING PROTEINS; U937 CELL-LINE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LEUCINE-ZIPPER; FINGER; ISOFORMS; AF10	The t(10; 11)(p13; q14) translocation leads to the fusion of the CALM and AF10 genes. This translocation can be found as the sole cytogenetic abnormality in acute lymphoblastic leukemia, acute myeloid leukemia and in malignant lymphomas. The expression of CALM/AF10 in primary murine bone marrow cells results in the development of an aggressive leukemia in a murine bone marrow transplantation model. Using a yeast two-hybrid screen, we identified the lymphoid regulator Ikaros as an AF10 interacting protein. Interestingly, Ikaros is required for normal development of lymphocytes, and aberrant expression of Ikaros has been found in leukemia. In a murine model, the expression of a dominant negative isoform of Ikaros causes leukemias and lymphomas. The Ikaros interaction domain of AF10 was mapped to the leucine zipper domain of AF10, which is required for malignant transformation both by the CALM/AF10 and the MLL/AF10 fusion proteins. The interaction between AF10 and Ikaros was confirmed by GST pull down and co-immunoprecipitation. Coexpression of CALM/AF10 but not of AF10 alters the subcellular localization of Ikaros in murine fibroblasts. The transcriptional repressor activity of Ikaros is reduced by AF10. These results suggest that CALM/AF10 might interfere with normal Ikaros function, and thereby block lymphoid differentiation in CALM/AF10 positive leukemias.	[Bohlander, S. K.] Univ Munich, Dept Med 3, Klinikum Grosshadern, Med Klin 3, D-81377 Munich, Germany; [Kremmer, E.] GSF Forschungszentrum Umwelt & Gesundheit, Inst Mol Immunol, Munich, Germany; [Greif, P. A.; Tizazu, B.; Krause, A.; Bohlander, S. K.] Univ Munich, GSF, Clin Cooperat Grp Leukemia, D-81377 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Bohlander, SK (corresponding author), Univ Munich, Dept Med 3, Klinikum Grosshadern, Med Klin 3, Marchioninstr 25, D-81377 Munich, Germany.	sbohlan@gwdg.de	Krause, Alexandre/K-7221-2013	Greif, Philipp/0000-0002-3744-7936; Bohlander, Stefan/0000-0002-2202-9088				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Archangelo LF, 2006, ONCOGENE, V25, P4099, DOI 10.1038/sj.onc.1209438; Arco PGD, 2005, MOL CELL BIOL, V25, P2688, DOI 10.1128/MCB.25.7.2688-2697.2005; Bohlander SK, 2000, LEUKEMIA, V14, P93, DOI 10.1038/sj.leu.2401614; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Caudell D, 2007, CANCER RES, V67, P8022, DOI 10.1158/0008-5472.CAN-06-3749; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Deshpande AJ, 2006, CANCER CELL, V10, P363, DOI 10.1016/j.ccr.2006.08.023; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Gomez-del Arco P, 2004, MOL CELL BIOL, V24, P2797, DOI 10.1128/MCB.24.7.2797-2807.2004; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KOBAYASHI H, 1995, GENE CHROMOSOME CANC, V13, P217, DOI 10.1002/gcc.2870130312; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Linder B, 2001, EMBO REP, V2, P211, DOI 10.1093/embo-reports/kve039; Martin DGE, 2006, MOL CELL BIOL, V26, P7871, DOI 10.1128/MCB.00573-06; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Nietfeld W, 1996, IMMUNOL LETT, V49, P139, DOI 10.1016/0165-2478(95)02479-4; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Olivero S, 2000, BRIT J HAEMATOL, V110, P826, DOI 10.1046/j.1365-2141.2000.02297.x; Payne KJ, 2003, J IMMUNOL, V170, P3091, DOI 10.4049/jimmunol.170.6.3091; Payne KJ, 2001, J IMMUNOL, V167, P1867, DOI 10.4049/jimmunol.167.4.1867; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rebollo A, 2003, IMMUNOL CELL BIOL, V81, P171, DOI 10.1046/j.1440-1711.2003.01159.x; Ronni T, 2007, J BIOL CHEM, V282, P2538, DOI 10.1074/jbc.M605627200; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; ROWLEY JD, 1990, SEMIN HEMATOL, V27, P122; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Westman BJ, 2002, INT J BIOCHEM CELL B, V34, P1304, DOI 10.1016/S1357-2725(02)00070-5; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yoshida T, 2006, NAT IMMUNOL, V7, P382, DOI 10.1038/ni1314	47	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2008	27	20					2886	2896		10.1038/sj.onc.1210945	http://dx.doi.org/10.1038/sj.onc.1210945			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037964				2022-12-28	WOS:000255502500010
J	Tschan, MP; Reddy, VA; Ress, A; Arvidsson, G; Fey, MF; Torbett, BE				Tschan, M. P.; Reddy, V. A.; Ress, A.; Arvidsson, G.; Fey, M. F.; Torbett, B. E.			PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity	ONCOGENE			English	Article						PU.1; p53; p73; transcriptional repression	HEMATOPOIETIC STEM-CELLS; SELF-RENEWAL; FRIEND; GENE; EXPRESSION; ROLES; P73; PROGRESSION	The transcription factor PU.1 is essential for terminal myeloid differentiation, B- and T-cell development, erythropoiesis and hematopoietic stem cell maintenance. PU.1 functions as oncogene in Friend virus-induced erythroleukemia and as tumor suppressor in acute myeloid leukemias. Moreover, Friend virus-induced erythroleukemia requires maintenance of PU.1 expression and the disruption of p53 function greatly accelerates disease progression. It has been hypothesized that p53-mediated expression of the p21(Cip1) cell cycle inhibitor during differentiation of pre-erythroleukemia cells promotes selection against p53 function. In addition to the blockage of erythroblast differentiation provided by increased levels of PU.1, we propose that PU.1 alters p53 function. We demonstrate that PU.1 reduces the transcriptional activity of the p53 tumor suppressor family and thus inhibits activation of genes important for cell cycle regulation and apoptosis. Inhibition is mediated through binding of PU.1 to the DNA-binding and/or oligomerization domains of p53/p73 proteins. Lastly, knocking down endogenous PU.1 in p53 wild-type REH B-cell precursor leukemia cells leads to increased expression of the p53 target p21Cip1.	[Reddy, V. A.; Torbett, B. E.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; [Tschan, M. P.; Ress, A.; Arvidsson, G.; Fey, M. F.] Univ Bern, Dept Clin Res, Bern, Switzerland; [Fey, M. F.] Univ Hosp Bern, Dept Med Oncol, CH-3010 Bern, Switzerland	Scripps Research Institute; University of Bern; University of Bern; University Hospital of Bern	Torbett, BE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	betorbet@scripps.edu		Arvidsson, Gustav/0000-0001-7396-1820; Tschan, Mario P./0000-0001-5897-3647	NIAID NIH HHS [AI49165] Funding Source: Medline; NIDDK NIH HHS [DK49886] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049886] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Back J, 2004, BLOOD, V103, P3615, DOI 10.1182/blood-2003-11-4089; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Britschgi C, 2006, ONCOGENE, V25, P2030, DOI 10.1038/sj.onc.1209240; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Goldschneider D, 2005, J CELL SCI, V118, P1245, DOI 10.1242/jcs.01704; Houston IB, 2007, EXP HEMATOL, V35, P374, DOI 10.1016/j.exphem.2006.11.003; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; Jundt F, 2002, BLOOD, V99, P3060, DOI 10.1182/blood.V99.8.3060; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Miyake N, 2006, STEM CELLS, V24, P653, DOI 10.1634/stemcells.2005-0328; Moll UM, 2004, MOL CANCER RES, V2, P371; Moreau-Gachelin F, 2006, HAEMATOLOGICA, V91, P1644; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Pluta A, 2006, LEUKEMIA, V20, P757, DOI 10.1038/sj.leu.2404166; Prasher JM, 2001, ONCOGENE, V20, P2946, DOI 10.1038/sj.onc.1204395; Rimmele P, 2007, BLOOD, V109, P3007, DOI 10.1182/blood-2006-03-006718; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6	25	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3489	3493		10.1038/sj.onc.1211004	http://dx.doi.org/10.1038/sj.onc.1211004			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193090				2022-12-28	WOS:000256309900014
J	Porlan, E; Vidaurre, OG; Rodriguez-Pena, A				Porlan, E.; Vidaurre, O. G.; Rodriguez-Pena, A.			Thyroid hormone receptor-beta (TR beta 1) impairs cell proliferation by the transcriptional inhibition of cyclins D1, E and A2	ONCOGENE			English	Article						thyroid hormone receptor; cyclins; E2F-1; AP-1; nuclear receptors; cell cycle	NEGATIVE REGULATOR; E2F; SUPPRESSOR; GENE; RECRUITMENT; EXPRESSION; REPRESSION; MECHANISM; DEPENDS; PATHWAY	Thyroid hormone receptor-beta 1 (TR beta 1) belongs to the ligand-inducible transcription factor superfamily. We have previously described that stable TRb1 expression impairs fibroblast proliferation diminishing levels and activity of the main regulators of the G(1)/S transition. To unmask the underlying molecular mechanism of this action, we have investigated the expression of cyclin D1, E and A2 upon serum stimulation in TR beta 1 expressing cells, finding a strong downregulation of their mRNAs, concomitant with low protein levels. The inhibition of the transcriptional activation in response to serum of these cyclins is differently exerted. For cyclin D1, we demonstrate that TR beta 1 represses its promoter as a consequence of the downregulation of c-jun levels, diminished AP-1 activation and loss of c-jun recruitment to its binding sites on cyclin D1 promoter. For cyclin E and A2, it is the impairment of the cyclinD/Rb/E2F pathway by TR beta 1 that prevents the activation of these two E2F target genes. Indeed, recruitment of E2F-1 to cyclin A2 promoter could not be detected. In summary, we propose that apo-TR beta 1 exerts its antiproliferative action through a mechanism that could constitute a model by which other nuclear receptors may control cell division.	[Porlan, E.; Vidaurre, O. G.; Rodriguez-Pena, A.] Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Rodriguez-Pena, A (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	arodriguez@iib.uam.es	porlan, Eva/AAE-6561-2022	porlan, Eva/0000-0003-0934-9711; Rodriguez-Pena, Angeles/0000-0002-2515-4626				Barrera-Hernandez G, 1998, DNA CELL BIOL, V17, P743, DOI 10.1089/dna.1998.17.743; Benkoussa M, 2002, MOL CELL BIOL, V22, P4522, DOI 10.1128/MCB.22.13.4522-4534.2002; Bhat MK, 1997, J BIOL CHEM, V272, P28989, DOI 10.1074/jbc.272.46.28989; Botz J, 1996, MOL CELL BIOL, V16, P3401; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Chan IH, 2006, ONCOGENE, V25, P3576, DOI 10.1038/sj.onc.1209389; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; Deogracias R, 2004, MOL CELL NEUROSCI, V26, P470, DOI 10.1016/j.mcn.2004.03.007; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Hashimoto K, 2001, P NATL ACAD SCI USA, V98, P3998, DOI 10.1073/pnas.051454698; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Nygard M, 2003, MOL ENDOCRINOL, V17, P79, DOI 10.1210/me.2002-0107; O'Shea PJ, 2002, J ENDOCRINOL, V175, P553, DOI 10.1677/joe.0.1750553; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Porlan E, 2004, ONCOGENE, V23, P8756, DOI 10.1038/sj.onc.1208126; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Sanz-Gonzalez SM, 2004, BIOCHEM BIOPH RES CO, V317, P972, DOI 10.1016/j.bbrc.2004.03.143; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Yamaguchi K, 2005, J BIOL CHEM, V280, P32569, DOI 10.1074/jbc.M503201200; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	31	14	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2795	2800		10.1038/sj.onc.1210936	http://dx.doi.org/10.1038/sj.onc.1210936			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18037966				2022-12-28	WOS:000255259500015
J	Wierod, L; Rosseland, CM; Lindeman, B; Oksvold, MP; Grosvik, H; Skarpen, E; Huitfeldt, HS				Wierod, L.; Rosseland, C. M.; Lindeman, B.; Oksvold, M. P.; Grosvik, H.; Skarpen, E.; Huitfeldt, H. S.			Activation of the p53-p21(Cip1) pathway is required for CDK2 activation and S-phase entry in primary rat hepatocytes	ONCOGENE			English	Article						cyclin; nuclear translocation; PI3 kinase; DNA synthesis; primary liver cells	CYCLIN-DEPENDENT KINASE; WILD-TYPE P53; RETINOBLASTOMA PROTEIN; NUCLEAR ACCUMULATION; LIVER-REGENERATION; RESTRICTION POINT; DNA-DAMAGE; GROWTH; TUMOR; PHOSPHORYLATION	p53 plays a major role in the prevention of tumor development. It responds to a range of potentially oncogenic stresses by activating protective mechanisms, most notably cell-cycle arrest and apoptosis. The p53 gene is also induced during normal liver regeneration, and it has been hypothesized that p53 serve as a proliferative 'brake' to control excessive proliferation. However, it has lately been shown that p53 inhibition reduces hepatocyte growth factor-induced DNA synthesis of primary hepatocytes. Here we show that epidermal growth factor (EGF) activated p53 in a phosphatidylinositol-3 kinase-dependent way, and thus induced the cyclin-dependent kinase inhibitor p21(Cip1) in primary rat hepatocytes. p53 inactivation with a dominant-negative mutant (p53(V143A)) attenuated EGF-induced DNA synthesis and was associated with reduced CDK2 phosphorylation and retinoblastoma protein hyperphosphorylation. When p21(Cip1) was ectopically expressed in p53-inactivated cells, these effects were neutralized. In conclusion, our results demonstrate that in normal hepatocytes, EGF-induced expression of p53 is involved in regulating CDK2- and CDK4 activity, through p21(Cip1) expression.	[Wierod, L.; Rosseland, C. M.; Oksvold, M. P.; Grosvik, H.; Skarpen, E.; Huitfeldt, H. S.] Univ Oslo, Lab Toxicol Inst Pathol, Rikshosp Radiumhosp Med Ctr, Rikshosp Univ Hosp, N-0027 Oslo, Norway; [Wierod, L.; Rosseland, C. M.; Oksvold, M. P.; Grosvik, H.; Skarpen, E.; Huitfeldt, H. S.] Univ Oslo, Ctr Cellulare Stress Responses, Oslo, Norway; [Lindeman, B.] Norwegian Inst Publ Hlth, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; Norwegian Institute of Public Health (NIPH)	Wierod, L (corresponding author), Univ Oslo, Lab Toxicol Inst Pathol, Rikshosp Radiumhosp Med Ctr, Rikshosp Univ Hosp, N-0027 Oslo, Norway.	lene.wierod@medisin.uio.no						Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Arora V, 2000, DRUG METAB DISPOS, V28, P131; Bar J, 2005, CELL DEATH DIFFER, V12, P1578, DOI 10.1038/sj.cdd.4401677; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coutant A, 2002, HEPATOLOGY, V36, P1079, DOI 10.1053/jhep.2002.36160; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang WA, 2001, ACTA CRYSTALLOGR D, V57, P1162, DOI 10.1107/S090744490100926X; Fausto N, 1986, Symp Fundam Cancer Res, V39, P69; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Fujiwara Y, 2006, BIOCHEM BIOPH RES CO, V340, P560, DOI 10.1016/j.bbrc.2005.12.039; Gallant P, 1995, J CELL SCI, P21; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Ghosh AK, 2004, J BIOL CHEM, V279, P47455, DOI 10.1074/jbc.M403477200; HARPER JW, 1993, CELL, V75, P805; Hirota Y, 1996, JPN J CANCER RES, V87, P735, DOI 10.1111/j.1349-7006.1996.tb00286.x; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Ilyin GP, 2003, AM J PHYSIOL-GASTR L, V285, pG115, DOI 10.1152/ajpgi.00309.2002; Inoue Y, 2002, HEPATOLOGY, V36, P336, DOI 10.1053/jhep.2002.34942; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Monti P, 2002, ONCOGENE, V21, P1641, DOI 10.1038/sj.onc.1205250; Naderi S, 2005, MOL BIOL CELL, V16, P1527, DOI 10.1091/mbc.E04-06-0501; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Rosseland CM, 2005, HEPATOLOGY, V42, P200, DOI 10.1002/hep.20762; Saito A, 2005, J CEREBR BLOOD F MET, V25, P267, DOI 10.1038/sj.jcbfm.9600028; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Skarpen E, 2000, MOL CARCINOGEN, V28, P84, DOI 10.1002/1098-2744(200006)28:2<84::AID-MC4>3.0.CO;2-X; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMPSON NL, 1986, CANCER RES, V46, P3111; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	53	17	19	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2763	2771		10.1038/sj.onc.1210937	http://dx.doi.org/10.1038/sj.onc.1210937			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18026139	Bronze			2022-12-28	WOS:000255259500011
J	Fontaine, JF; Mirebeau-Prunier, D; Franc, B; Triau, S; Rodien, P; Houlgatte, R; Malthiery, Y; Savagner, F				Fontaine, J-F; Mirebeau-Prunier, D.; Franc, B.; Triau, S.; Rodien, P.; Houlgatte, R.; Malthiery, Y.; Savagner, F.			Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy	ONCOGENE			English	Article						thyroid tumours; microarray analysis; uncertain malignancy; classification	GENE-EXPRESSION PROFILES; FOLLICULAR VARIANT; OBSERVER VARIATION; CARCINOMA; CANCER; REARRANGEMENT; MUTATION; BENIGN; ASSOCIATION; DISCOVERY	Conventional histology failed to classify part of non-medullary thyroid lesions as either benign or malignant. The group of tumours of uncertain malignancy (T-UM) concerns either atypical follicular adenomas or the recently called 'tumours of uncertain malignant potential'. To re. ne this classification we analysed microarray data from 93 follicular thyroid tumours: 10 T-UM, 3 follicular carcinomas, 13 papillary thyroid carcinomas and 67 follicular adenomas, compared to 73 control thyroid tissue samples. The diagnosis potential of 16 selected genes was validated by real-time quantitative RT-PCR on 6 additional T-UM. The gene expression profiles in several groups were examined with reference to the mutational status of the RET/PTC, BRAF and RAS genes. A pathological score (histological and immunohistochemical) was estimate for each of the T-UM involved in the study. The correlation between the T-UM gene profiles and the pathological score allowed a separation of the samples in two groups of benign or malignant tumours. Our analysis confirms the heterogeneity of T-UM and highlighted the molecular similarities between some cases and true carcinomas. We demonstrated the ability of few marker genes to serve as diagnosis tools and the need of a T-UM pathological scoring.	[Fontaine, J-F; Mirebeau-Prunier, D.; Malthiery, Y.; Savagner, F.] CHU Angers, Biochim Lab, INSERM, U694, F-49033 Angers, France; [Fontaine, J-F; Mirebeau-Prunier, D.; Malthiery, Y.; Savagner, F.] Univ Angers, Fac Med, Angers, France; [Franc, B.] Univ Versailles, Hop Ambroise Pare, Serv Pathol, Fac Paris France Ouest, Boulogne, France; [Triau, S.] CHU Angers, Fed Pathol Cellulaire & Tissulaire, F-49033 Angers, France; [Rodien, P.] CHU Angers, Dept Endocrinol & Med Interne, F-49033 Angers, France; [Houlgatte, R.] INSERM, U533, Nantes, France; [Houlgatte, R.] Univ Nantes, Inst Thorax, Fac Med, F-44035 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes	Savagner, F (corresponding author), CHU Angers, Biochim Lab, INSERM, U694, 4 Rue Larrey, F-49033 Angers, France.	frsavagner@chu-angers.fr	Prunier, Delphine/K-3301-2015; Houlgatte, Remi/P-3020-2017; Rodien, Patrice/AAT-7909-2021; Fontaine, Jean-Fred/GNP-2904-2022	Fontaine, Jean-Fred/0000-0002-1101-4091				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Baris O, 2005, ONCOGENE, V24, P4155, DOI 10.1038/sj.onc.1208578; Baris O, 2004, J CLIN ENDOCR METAB, V89, P994, DOI 10.1210/jc.2003-031238; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bertucci F, 2003, INT J CANCER, V103, P565, DOI 10.1002/ijc.10867; de la Torre NG, 2006, ENDOCR-RELAT CANCER, V13, P931, DOI 10.1677/erc.1.01210; De Micco C, 1999, SURGERY, V126, P1200, DOI 10.1067/msy.2099.101428; Di Cristofaro J, 2006, HUM PATHOL, V37, P824, DOI 10.1016/j.humpath.2006.01.030; Du Villard J, 2000, ONCOGENE, V19, P4896, DOI 10.1038/sj.onc.1203852; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eszlinger M, 2006, J CLIN ENDOCR METAB, V91, P1934, DOI 10.1210/jc.2005-1620; Finley DJ, 2004, ANN SURG, V240, P425, DOI 10.1097/01.sla.0000137128.64978.bc; Finn SP, 2007, VIRCHOWS ARCH, V450, P249, DOI 10.1007/s00428-006-0348-5; Franc B, 2003, HUM PATHOL, V34, P1092, DOI 10.1016/S0046-8177(03)00403-9; GE YC, 2003, TEST, V12, P1, DOI DOI 10.1007/BF02595811; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Hirokawa M, 2002, AM J SURG PATHOL, V26, P1508, DOI 10.1097/00000478-200211000-00014; Hoffmann S, 2006, ENDOCRINE, V30, P129, DOI 10.1385/ENDO:30:1:129; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lacroix L, 2005, AM J PATHOL, V167, P223, DOI 10.1016/S0002-9440(10)62967-7; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Lubitz CC, 2005, SURGERY, V138, P1042, DOI 10.1016/j.surg.2005.09.009; Mazzanti C, 2004, CANCER RES, V64, P2898, DOI 10.1158/0008-5472.CAN-03-3811; Mirebeau-Prunier D, 2004, EUR J ENDOCRINOL, V150, P269, DOI 10.1530/eje.0.1500269; More E, 2003, J ENDOCRINOL, V176, P83, DOI 10.1677/joe.0.1760083; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; RHODEN KJ, 2003, J CLIN ENDOCR METAB, V91, P2414; Takahashi M, 2003, ONCOGENE, V22, P6810, DOI 10.1038/sj.onc.1206869; Williams ED, 2000, INT J SURG PATHOL, V8, P181, DOI 10.1177/106689690000800304; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	35	24	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2228	2236		10.1038/sj.onc.1210853	http://dx.doi.org/10.1038/sj.onc.1210853			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17968324				2022-12-28	WOS:000254621300013
J	Molli, PR; Singh, RR; Lee, SW; Kumar, R				Molli, P. R.; Singh, R. R.; Lee, S. W.; Kumar, R.			MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene	ONCOGENE			English	Article						NURD complex; chromatin remodeling centrosome; aneuploidy	SPORADIC BREAST-CANCER; CENTROSOME AMPLIFICATION; CELL-CYCLE; ESTROGEN-RECEPTOR; DOWN-REGULATION; MTA1 GENE; PROTEIN; INSTABILITY; EXPRESSION; COMPLEX	Metastasis-associated tumor antigen 1 (MTA1), a component of the nucleosome remodeling and deacetylating (NuRD) complex is routinely upregulated in several cancers. In the present study, we investigated the potential role of MTA1 in BRCA1 transcriptional repression and subsequent chromosomal instability. MTA1-NuRD complex was found to negatively regulate BRCA1 transcription by physically associating with an atypical estrogen-responsive element (ERE) on the BRCA1 promoter. Moreover, MTA1 and HDAC complex recruited to the ERE of BRCA1 promoter in an ER a-dependent manner. Accordingly, BRCA1 protein levels were enhanced by silencing of either MTA1 expression or by treatment with the specific histone deacetylase inhibitor trichostatin A. MTA1's strong repressive effects on BRCA1 expression was supported by our observation that cells stably overexpressing MTA1 showed centrosome amplification which has been long implicated as a phenotype for BRCA1 repression. Accordingly, overexpression of BRCA1 in cells stably over expressing MTA1 resulted in restoration of normal centrosome numbers. Together, these findings strongly implicate MTA1 in the transcriptional repression of BRCA1 leading to abnormal centrosome number and chromosomal instability.	[Molli, P. R.; Singh, R. R.; Kumar, R.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Lee, S. W.] Massachusetts Gen Hosp, Harvard Cutaneous Biol Res Ctr, Charlestown, MA USA; [Kumar, R.] Baylor Coll Med, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Massachusetts General Hospital; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746, R01CA098823] Funding Source: NIH RePORTER; NCI NIH HHS [CA 098823, R01 CA098823, U01 CA065746, R01 CA065746, CA65746, R01 CA098823-04, R01 CA065746-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagheri-Yarmand R, 2004, DEVELOPMENT, V131, P3469, DOI 10.1242/dev.01213; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Balasenthil S, 2006, HUM PATHOL, V37, P656, DOI 10.1016/j.humpath.2006.01.024; Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chen XW, 2006, EXPERT REV ANTICANC, V6, P187, DOI 10.1586/14737140.6.2.187; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Hamatsu T, 2003, ONCOL REP, V10, P599; Indraccolo S, 2006, EUR J CANCER, V42, P1475, DOI 10.1016/j.ejca.2006.01.057; Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x; Kanai M, 2003, MOL CELL BIOL, V23, P2451, DOI 10.1128/MCB.23.7.2451-2462.2003; Ko MJ, 2006, ONCOGENE, V25, P298, DOI 10.1038/sj.onc.1209028; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Martin MD, 2006, BREAST CANCER RES TR, V95, P7, DOI 10.1007/s10549-005-9016-8; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; Ouchi T, 2006, CANCER BIOL THER, V5, P470, DOI 10.4161/cbt.5.5.2845; Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.0.CO;2-3; Rosen EM, 2006, CANCER LETT, V236, P175, DOI 10.1016/j.canlet.2005.04.037; Simbulan-Rosenthal CM, 2001, NUCLEIC ACIDS RES, V29, P841, DOI 10.1093/nar/29.3.841; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Talukder AH, 2003, J BIOL CHEM, V278, P11676, DOI 10.1074/jbc.M209570200; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Yarden RI, 2006, MOL CANCER THER, V5, P1396, DOI 10.1158/1535-7163.MCT-05-0471	34	60	69	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					1971	1980		10.1038/sj.onc.1210839	http://dx.doi.org/10.1038/sj.onc.1210839			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922032	Green Accepted			2022-12-28	WOS:000254359100002
J	Ma, S; Lee, TK; Zheng, BJ; Chan, K; Guan, XY				Ma, S.; Lee, T. K.; Zheng, B-J; Chan, K. W.; Guan, X-Y			CD133(+) HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway	ONCOGENE			English	Article						HCC; CD133; survival; cancer stem cells; chemoresistance	ACUTE MYELOID-LEUKEMIA; PROSPECTIVE IDENTIFICATION; APOPTOSIS	The recent discovery of cancer stem cells (CSCs) has played a pivotal role in changing our view of carcinogenesis and chemotherapy. Based on this concept, CSCs are responsible for the formation and growth of neoplastic tissue and are naturally resistant to chemotherapy, explaining why traditional chemotherapies can initially shrinka tumor but fails to eradicate it in full, allowing eventual recurrence. Recently, we identified a CSC population in hepatocellular carcinoma (HCC) characterized by their CD133 phenotype. However, the molecular mechanism by which it escapes conventional therapies remains unknown. Here, we examined the sensitivity of these cells to chemotherapeutic agents (doxorubicin and fluorouracil) and the possible mechanistic pathway by which resistance may be regulated. Purified CD133(+) HCC cells isolated from human HCC cell line and xenograft mouse models survived chemotherapy in increased proportions relative to most tumor cells which lack the CD133 phenotype; the underlying mechanism of which required the preferential expression of survival proteins involved in the Akt/PKB and Bcl-2 pathway. Treatment of CD133(+) HCC cells with an AKT1 inhibitor, specific to the Akt/PKB pathway, significantly reduced the expression of the survival proteins that was normally expressed endogenously. In addition, treatment of unsorted HCC cells with both anticancer drugs in vitro significantly enriched the CD133(+) subpopulation. In conclusion, our results show that CD133(+) HCC cells contribute to chemoresistance through preferential activation of Akt/PKB and Bcl-2 cell survival response. Targeting of this specific survival signaling pathway in CD133(+) HCC CSCs may provide a novel therapeutic model for the disease.	[Ma, S.; Guan, X-Y] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Ma, S.; Chan, K. W.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Lee, T. K.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Zheng, B-J] Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong	Guan, XY (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Room L10-56,10-F Lab Block,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	; /A-3639-2009; Ma, Stephanie Kwai Yee/C-4766-2009; Guan, Xin-Yuan/A-3639-2009	Lee, Kin Wah/0000-0003-0682-322X; /0000-0003-1874-9805; Ma, Stephanie Kwai Yee/0000-0002-2029-7943; Guan, Xin-Yuan/0000-0002-4485-6017				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Fabregat I, 2007, LIVER INT, V27, P155, DOI 10.1111/j.1478-3231.2006.01409.x; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haraguchi N, 2006, STEM CELLS, V24, P506, DOI 10.1634/stemcells.2005-0282; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Suetsugi A, 2006, BIOCHEM BIOPH RES CO, V351, P820, DOI 10.1016/j.bbrc.2006.10.128; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yin SY, 2007, INT J CANCER, V120, P1444, DOI 10.1002/ijc.22476	29	611	657	2	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1749	1758		10.1038/sj.onc.1210811	http://dx.doi.org/10.1038/sj.onc.1210811			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891174				2022-12-28	WOS:000253962100010
J	Lee, SG; Su, ZZ; Emdad, L; Sarkar, D; Franke, TF; Fisher, PB				Lee, S-G; Su, Z-Z; Emdad, L.; Sarkar, D.; Franke, T. F.; Fisher, P. B.			Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling	ONCOGENE			English	Article						AEG-1; Ras; PI3K; Akt; apoptosis	RAPID SUBTRACTION HYBRIDIZATION; NF-KAPPA-B; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR PROGRESSION; HUMAN CANCER; AKT; APOPTOSIS; KINASE; PROTEIN	Astrocyte elevated gene-1 ( AEG-1) displays oncogenic properties. Its expression is elevated in diverse neoplastic states and it cooperates with Ha-ras to promote cellular transformation. Overexpression of AEG-1 augments invasion and anchorage-independent growth of transformed cells, while AEG-1 siRNA inhibits Ha-ras-mediated colony formation, supporting a potential functional role in tumorigenesis. Additionally, oncogenic Ha-ras induces AEG-1 expression through the phosphatidylinositol 3-kinase ( PI3K)-Akt signaling pathway. In the present study, we investigated whether AEG-1 could induce serum-independent cell growth, another property of oncogenes. Overexpression of AEG-1 inhibited serum starvation-induced apoptosis through activation of PI3K-Akt signaling, one of the effector pathways induced by activated Ras. AEG-1 also affected the phosphorylation state of Akt substrates that are implicated in apoptosis suppression, including glycogen synthase kinase 3 beta, c-Myc, murine double minute 2, p53, p21/ mda-6 and Bad. Additionally, AEG-1 blocked the activity of serum starvation-induced caspases. Taken together, these observations provide evidence that AEG-1 is an oncogene cooperating with Ha-ras as well as functioning as a downstream target gene of Ha-ras and may perform a central role in Ha-ras-mediated carcinogenesis. Activation of survival pathways may be one mechanism by which AEG-1 exerts its oncogenic properties.	[Lee, S-G; Su, Z-Z; Emdad, L.; Sarkar, D.; Fisher, P. B.] Columbia Univ Coll Phys & Surg, Dept Urol, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; [Emdad, L.; Fisher, P. B.] Columbia Univ Coll Phys & Surg, Dept Neurosurg, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; [Franke, T. F.] NYU, Sch Med, Dept Psychiat, New York, NY USA; [Fisher, P. B.] Columbia Univ Coll Phys & Surg, Dept Pathol, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; New York University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Urol, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA.	pbf1@columbia.edu	Lee, Seok-Geun/B-3408-2011	Lee, Seok-Geun/0000-0002-0060-5777	NINDS NIH HHS [5 P01 NS31492] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Britt DE, 2004, EXP CELL RES, V300, P134, DOI 10.1016/j.yexcr.2004.06.026; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Chen CM, 2001, J BIOL CHEM, V276, P38518, DOI 10.1074/jbc.M105702200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1984, MECHANISMS TUMOR PRO, P57; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060; Lauder A, 2001, MOL CELL BIOL, V21, P5797, DOI 10.1128/MCB.21.17.5797-5805.2001; Lebedeva IV, 2007, ONCOGENE, V26, P733, DOI 10.1038/sj.onc.1209813; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li YH, 2002, J INFRARED MILLIM W, V21, P1; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Ozes ON, 1999, NATURE, V401, P82; Rich JN, 2001, CANCER RES, V61, P3556; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Su ZZ, 2003, GENE, V306, P67, DOI 10.1016/S0378-1119(03)00404-9; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Sutherland HGE, 2004, EXP CELL RES, V294, P94, DOI 10.1016/j.yexcr.2003.11.020; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WHITE JA, 1992, EXP CELL RES, V203, P157, DOI 10.1016/0014-4827(92)90051-9; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	196	211	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1114	1121		10.1038/sj.onc.1210713	http://dx.doi.org/10.1038/sj.onc.1210713			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704808				2022-12-28	WOS:000253136700011
J	Gurzov, EN; Bakiri, L; Alfaro, JM; Wagner, EF; Izquierdo, M				Gurzov, E. N.; Bakiri, L.; Alfaro, J. M.; Wagner, E. F.; Izquierdo, M.			Targeting c-Jun and JunB proteins as potential anticancer cell therapy	ONCOGENE			English	Article						B16-F10 cancer cells; c-Jun; JunB; RNA interference; SP600125	APOPTOSIS-INDUCING FACTOR; N-TERMINAL KINASE; TRANSCRIPTION FACTOR AP-1; CHRONIC MYELOID-LEUKEMIA; OSTEO-SARCOMA VIRUS; DNA-BINDING; RNA INTERFERENCE; BREAST-CANCER; TUMOR-GROWTH; PROLIFERATION	The activating protein-1 transcription factor, in particular the Jun proteins play critical roles in the regulation of cell proliferation and tumor progression. To study the potential clinical relevance of interfering with JunB expression, we generated retroviruses expressing short hairpin RNA. Reduction of JunB levels causes increased proliferation and tumorigenicity in wild-type murine fibroblasts, whereas in c-Jun knockout cells p53-independent cell cycle arrest and apoptosis are induced. Using melanoma-derived B16-F10 cancer cells the combination of JunB knockdown and c-Jun/JNK inactivation leads to cell cycle arrest and apoptosis-inducing factor-dependent apoptosis. Furthermore, the combined treatment extends survival of mice inoculated with the tumor cells. These results indicate that in the absence of c-Jun, JunB can act as a tumor promoter and inactivation of both, c-Jun and JunB, could provide a valuable strategy for antitumor intervention.	[Gurzov, E. N.; Alfaro, J. M.; Izquierdo, M.] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, Dept Mol Biol, E-28049 Madrid, Spain; [Bakiri, L.; Wagner, E. F.] Res Inst Mol Pathol, A-1030 Vienna, Austria	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Izquierdo, M (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, Dept Mol Biol, E-28049 Madrid, Spain.	mizquierdo@cbm.uam.es	Bakiri, Latifa/N-5780-2014; Bakiri, Latifa/AAP-1674-2020	Wagner, Erwin F/0000-0001-7872-0196; bakiri, latifa/0000-0002-6300-2420; Gurzov, Esteban/0000-0003-4642-0273				Artus C, 2006, ONCOGENE, V25, P5741, DOI 10.1038/sj.onc.1209581; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOWDEN GT, 1994, CANCER RES, V54, pS1882; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Ennis BW, 2005, J PHARMACOL EXP THER, V313, P325, DOI 10.1124/jpet.104.078873; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Gurzov EN, 2006, GENE THER, V13, P1, DOI 10.1038/sj.gt.3302595; Joseloff E, 1997, MOL CARCINOGEN, V18, P26, DOI 10.1002/(SICI)1098-2744(199701)18:1<26::AID-MC4>3.0.CO;2-P; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Libermann TA, 2006, CURR GENE THER, V6, P17, DOI 10.2174/156652306775515501; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Marchetti P, 1996, J IMMUNOL, V157, P4830; Mariani O, 2007, CANCER CELL, V11, P361, DOI 10.1016/j.ccr.2007.02.007; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Rassidakis GZ, 2005, MODERN PATHOL, V18, P1365, DOI 10.1038/modpathol.3800419; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szremska AP, 2003, BLOOD, V102, P4159, DOI 10.1182/blood-2003-03-0915; Vleugel MM, 2006, HUM PATHOL, V37, P668, DOI 10.1016/j.humpath.2006.01.022; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Xia HHX, 2006, CANCER LETT, V241, P268, DOI 10.1016/j.canlet.2005.10.031; Yang MY, 2003, BLOOD, V101, P3205, DOI 10.1182/blood-2002-05-1598; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zhang WH, 2005, AM J CLIN PATHOL, V124, P11, DOI 10.1309/T1H2Y2CHWY7PD2BN	41	30	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					641	652		10.1038/sj.onc.1210690	http://dx.doi.org/10.1038/sj.onc.1210690			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667939				2022-12-28	WOS:000252674900008
J	Baker, SJ; Rane, SG; Reddy, EP				Baker, S. J.; Rane, S. G.; Reddy, E. P.			Hematopoietic cytokine receptor signaling	ONCOGENE			English	Review						hematopoiesis; cytokine receptors; Src kinases; JAKs; STATs	COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE-PHOSPHATASE; DNA-BINDING ACTIVITY; INTERLEUKIN-5 TRANSDUCE SIGNALS; C-TERMINAL DOMAINS; FACTOR GM-CSF; INTERFERON-ALPHA; ERYTHROPOIETIN RECEPTOR; SH2 DOMAIN; MOLECULAR-CLONING	Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are mediated by cytokines and their receptors. Proper culmination of these diverse pathways forms the basis for an orderly generation of different cell types. Recent studies conducted over the past 10 - 15 years have revealed that hematopoietic cytokine receptor signaling is largely mediated by a family of tyrosine kinases termed Janus kinases ( JAKs) and their downstream transcription factors termed STATs ( signal transducers and activators of transcription). Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders. This recent discovery, when coupled with the fact that STATs are activated by oncoproteins such as BCR-ABL, underscores the importance of the JAK- STAT pathway in both normal cellular development and disease states.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NIDDK, NIH, Diabet Branch, Bethesda, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	reddy@temple.edu	Reddy, E. Premkumar/F-6233-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080666] Funding Source: NIH RePORTER; NHLBI NIH HHS [5R01HL080666-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez JV, 2004, CANCER BIOL THER, V3, P1045, DOI 10.4161/cbt.3.11.1172; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DUHE RJ, 1995, J BIOL CHEM, V270, P23084, DOI 10.1074/jbc.270.39.23084; Durand C, 2005, HAEMATOLOGICA, V90, P100; EDER M, 1994, J BIOL CHEM, V269, P30173; Eilers A, 1996, CELL GROWTH DIFFER, V7, P833; Ema H, 2003, CURR OPIN GENET DEV, V13, P508, DOI 10.1016/j.gde.2003.08.011; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feener EP, 2004, MOL CELL BIOL, V24, P4968, DOI 10.1128/MCB.24.11.4968-4978.2004; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; Frank DA, 1996, LEUKEMIA, V10, P1724; Funakoshi-Tago M, 2006, EMBO J, V25, P4763, DOI 10.1038/sj.emboj.7601365; Gartsbein M, 2006, J CELL SCI, V119, P470, DOI 10.1242/jcs.02744; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Haan C, 2006, BIOCHEM PHARMACOL, V72, P1538, DOI 10.1016/j.bcp.2006.04.013; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HARPUR AG, 1992, ONCOGENE, V7, P1347; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; JUBINSKY PT, 1993, BLOOD, V81, P587; Kampa D, 2000, BIOCHEM BIOPH RES CO, V278, P175, DOI 10.1006/bbrc.2000.3757; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Khwaja A, 2006, BRIT J HAEMATOL, V134, P366, DOI 10.1111/j.1365-2141.2006.06206.x; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Lu XQ, 2007, MOL CELL BIOL, V27, P2166, DOI 10.1128/MCB.01234-06; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, J LEUKOCYTE BIOL, V57, P799, DOI 10.1002/jlb.57.5.799; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niu GL, 2001, CANCER RES, V61, P3276; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Pallen Catherine J., 1992, Current Opinion in Cell Biology, V4, P1000, DOI 10.1016/0955-0674(92)90132-V; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Rakesh K, 2005, BIOCHEM PHARMACOL, V70, P649, DOI 10.1016/j.bcp.2005.04.042; RANE SG, 1994, ONCOGENE, V9, P2415; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 2003, MOL BIOL CELL, V14, P1448, DOI 10.1091/mbc.E02-06-0342; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schindler C, 2000, ADV PHARMACOL, V47, P113; Seki Y, 2002, P NATL ACAD SCI USA, V99, P13003, DOI 10.1073/pnas.202477099; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; Tanaka T, 2005, IMMUNITY, V22, P729, DOI 10.1016/j.immuni.2005.04.008; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Ungureanu D, 2005, BLOOD, V106, P224, DOI 10.1182/blood-2004-11-4514; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Valentino L, 2006, BIOCHEM PHARMACOL, V71, P713, DOI 10.1016/j.bcp.2005.12.017; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Waiboci LW, 2007, J IMMUNOL, V178, P5058, DOI 10.4049/jimmunol.178.8.5058; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamada T, 2002, J BIOL CHEM, V277, P28830, DOI 10.1074/jbc.M201781200; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	130	201	214	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6724	6737		10.1038/sj.onc.1210757	http://dx.doi.org/10.1038/sj.onc.1210757			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934481				2022-12-28	WOS:000250147000005
J	Kang, J; Rychahou, PG; Ishola, TA; Mourot, JM; Evers, BM; Chung, DH				Kang, J.; Rychahou, P. G.; Ishola, T. A.; Mourot, J. M.; Evers, B. M.; Chung, D. H.			N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma	ONCOGENE			English	Article						angiogenesis; PI3K/Akt; MYCN; VEGF; neuroblastoma	ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR; TUMOR ANGIOGENESIS; MAMMALIAN TARGET; DOWN-REGULATION; C-MYC; CELLS; AMPLIFICATION; INHIBITION; PROGRESSION	Angiogenesis in neuroblastoma (NB) correlates with increased expression of vascular endothelial growth factor (VEGF) and a worse clinical outcome. Other cellular markers, such as Akt activation and MYCN amplification, are also associated with poor prognosis in NB; therefore, we sought to determine the role of N-myc in the regulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/ VEGF pathway. PI3K inhibition, using small-molecule inhibitors or phosphatase and tensin homolog adenovirus, led to decreased levels of VEGF mRNA and/or protein by reducing phosphorylation of Akt and mammalian target of rapamycin (mTOR), and attenuating hypoxia-inducible factor 1 alpha expression. Moreover, PI3K inhibition decreased levels of N-myc expression in MYCN-amplified cells. To further clarify the importance of N-myc as a target of PI3K in VEGF regulation, we inhibited N-myc expression by siRNA transfection. MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor. Interestingly, in cells with low-N-myc expression, MYCN siRNA reduction of VEGF secretion was only effective with MYCN overexpression or insulin-like growth factor-1 stimulation. Our results show that N-myc plays an important role in the PI3K-mediated VEGF regulation in NB cells. Targeting MYCN, as a novel effector of PI3K-mediated angiogenesis, has significant potential for the treatment of highly vascularized, malignant NB.	[Kang, J.; Rychahou, P. G.; Ishola, T. A.; Mourot, J. M.; Evers, B. M.; Chung, D. H.] Univ Texas Med Branch, Dept Surg, Galveston, TX 77555 USA; [Chung, D. H.] Univ Texas Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Chung, DH (corresponding author), Univ Texas Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	dhchung@utmb.edu		Rychahou, Piotr/0000-0001-7352-9122	NATIONAL CANCER INSTITUTE [R01CA104748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608, R01DK061470, R01DK048498] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104748, R01 CA104748-04] Funding Source: Medline; NIDDK NIH HHS [R01 DK61470, P01 DK35608, R01 DK048498-12, R01 DK061470, F31 DK079422, P01 DK035608, R01 DK48498, R01 DK048498, P01 DK035608-210001, R01 DK061470-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Beppu Y, 2005, CANCER RES, V65, P4775, DOI 10.1158/0008-5472.CAN-04-3332; Brodeur GM, 1990, BRAIN PATHOL, V1, P47, DOI 10.1111/j.1750-3639.1990.tb00638.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukuzawa M, 2002, J PEDIATR SURG, V37, P1747, DOI 10.1053/jpsu.2002.36712; Goodman LA, 1997, CLIN EXP METASTAS, V15, P130, DOI 10.1023/A:1018448710006; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Hatzi E, 2000, ADV EXP MED BIOL, V476, P239; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Kang JH, 2006, BIOCHEM BIOPH RES CO, V351, P192, DOI 10.1016/j.bbrc.2006.10.020; Kang JH, 2007, CANCER LETT, V253, P273, DOI 10.1016/j.canlet.2007.02.007; Kang J, 2006, ANTICANCER RES, V26, P1903; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kurmasheva RT, 2007, MOL CANCER THER, V6, P1620, DOI 10.1158/1535-7163.MCT-06-0646; Langer I, 2000, MED PEDIATR ONCOL, V34, P386, DOI 10.1002/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Marimpietri D, 2005, ONCOGENE, V24, P6785, DOI 10.1038/sj.onc.1208829; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789; Nara K, 2007, INT J ONCOL, V30, P1189; Oikawa T, 1996, EUR J PHARMACOL, V318, P93, DOI 10.1016/S0014-2999(96)00864-3; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Pession A, 1997, J PATHOL, V183, P339; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; POWIS G, 1994, CANCER RES, V54, P2419; RASCHELLA G, 1991, CANCER LETT, V56, P45, DOI 10.1016/0304-3835(91)90192-K; Ribatti D, 2002, INT J CANCER, V102, P351, DOI 10.1002/ijc.10742; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; von Rahden BHA, 2006, NEOPLASIA, V8, P702, DOI 10.1593/neo.06277; ZAIZEN Y, 1993, J PEDIATR SURG, V28, P766, DOI 10.1016/0022-3468(93)90321-B	40	81	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3999	4007		10.1038/onc.2008.15	http://dx.doi.org/10.1038/onc.2008.15			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18278068	Green Accepted			2022-12-28	WOS:000257089000011
J	Wagner, N; Michiels, JF; Schedl, A; Wagner, KD				Wagner, N.; Michiels, J. F.; Schedl, A.; Wagner, K-D			The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo	ONCOGENE			English	Article						cancer; endothelial cells; RNAi	TRANSCRIPTION FACTOR ETS-1; INDUCIBLE FACTOR-I; NESTIN EXPRESSION; ANGIOGENESIS; GENE; ACTIVATION; INTRON; KIDNEY; MOUSE	Vascularization is an important step in tumour growth. Although a variety of molecules, for example, VEGF, ETS-1 or nestin have been implicated in tumour angiogenesis, the molecular mechanisms of vessel formation are not fully characterized. We showed that the Wilms' tumour suppressor WT1 activates nestin during development. Here we tested whether WT1 might also be involved in tumour angiogenesis. Endothelial WT1 expression was detected in 95% of 113 tumours of different origin. To analyse the function of WT1 in endothelial cells, we used an RNAi approach in vitro and showed that inhibition of WT1 reduces cell proliferation, migration and endothelial tube formation. On a molecular level, WT1 silencing diminished expression of the ETS-1 transcription factor. WT1 and ETS-1 shared an overlapping expression in tumour endothelia. The ETS-1 promoter was stimulated approximately 10-fold by transient co-transfection of a WT1 expression construct and WT1 bound to the ETS-1 promoter in chromatin immunoprecipitation and electrophoretic mobility shift assays. Deletion of the identified WT1-binding site abolished stimulation of the ETS-1 promoter by WT1. These findings suggest that transcriptional activation of ETS-1 by the Wilms' tumour suppressor WT1 is a crucial step in tumour vascularization via regulation of endothelial cell proliferation and migration.	[Wagner, N.; Wagner, K-D] INSERM, U907, Fac Med, PACA, F-06107 Nice, France; [Wagner, N.; Michiels, J. F.; Schedl, A.; Wagner, K-D] Univ Nice Sophia Antipolis, Nice, France; [Michiels, J. F.] Univ Nice Sophia Antipolis, Dept Pathol, Nice, France; [Schedl, A.] INSERM, U636, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Wagner, KD (corresponding author), INSERM, U907, Fac Med, PACA, 28 Ave Valombrose, F-06107 Nice, France.	kwagner@unice.fr	Wagner, Kay-Dietrich/E-6119-2016; Schedl, Andreas/GOP-3427-2022; Schedl, Andreas/F-8823-2015	Wagner, Kay-Dietrich/0000-0001-5483-7760; Schedl, Andreas/0000-0001-9380-7396; Wagner, Nicole/0000-0002-2746-0707				Aihara M, 2004, LAB INVEST, V84, P1581, DOI 10.1038/labinvest.3700186; Amoh Y, 2005, CANCER RES, V65, P5352, DOI 10.1158/0008-5472.CAN-05-0821; Brown C, 2004, J BIOL CHEM, V279, P12794, DOI 10.1074/jbc.M308593200; Cheville JC, 2003, AM J SURG PATHOL, V27, P612, DOI 10.1097/00000478-200305000-00005; Cohen MM, 2006, AM J MED GENET A, V140A, P2013, DOI 10.1002/ajmg.a.31333; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Gao XB, 2005, DEVELOPMENT, V132, P5437, DOI 10.1242/dev.02095; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hasegawa Y, 2004, BIOCHEM BIOPH RES CO, V316, P52, DOI 10.1016/j.bbrc.2004.02.019; Hashiya N, 2004, CIRCULATION, V109, P3035, DOI 10.1161/01.CIR.0000130643.41587.DB; Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jorcyk CL, 1997, CELL MOL BIOL, V43, P211; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; Mikami S, 2006, CANCER SCI, V97, P875, DOI 10.1111/j.1349-7006.2006.00268.x; Mokry J, 2004, STEM CELLS DEV, V13, P658, DOI 10.1089/scd.2004.13.658; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Timar J, 2005, HISTOPATHOLOGY, V47, P67, DOI 10.1111/j.1365-2559.2005.02169.x; Wagner KD, 2003, FASEB J, V17, P1364, DOI 10.1096/fj.02-1065fje; Wagner KD, 2002, FASEB J, V16, P1117, DOI 10.1096/fj.01-0986fje; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Wagner N, 2004, J AM SOC NEPHROL, V15, P3044, DOI 10.1097/01.ASN.0000146687.99058.25; Wagner N, 2006, AM J PHYSIOL-REG I, V291, pR779, DOI 10.1152/ajpregu.00219.2006; WERNERT N, 1992, AM J PATHOL, V140, P119	27	76	78	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3662	3672		10.1038/sj.onc.1211044	http://dx.doi.org/10.1038/sj.onc.1211044			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212735				2022-12-28	WOS:000256659300003
J	Boisvert-Adamo, K; Aplin, AE				Boisvert-Adamo, K.; Aplin, A. E.			Mutant B-RAF mediates resistance to anoikis via Bad and Bim	ONCOGENE			English	Article						apoptosis; Bad; Bim; B-RAF; melanoma	BCL-2 FAMILY-MEMBERS; MELANOMA-CELLS; MULTIPLE-MYELOMA; EPITHELIAL-CELLS; SURVIVAL SIGNALS; CYCLIN D1; APOPTOSIS; DEATH; PHOSPHORYLATION; PATHWAY	Normal cells undergo anoikis when they lose adhesion to or encounter an inappropriate extracellular matrix. By contrast, oncogenic signaling in tumor cells enables resistance to anoikis, a trait that contributes to tumor progression. The B-RAF serine-threonine kinase is mutated in multiple cancers and functions as an oncogene in melanoma. Previously, we demonstrated that B-RAF and downstream mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling are necessary for protection from anoikis in mutant B-RAF-expressing melanoma cells. Regulation of Bcl-2 family members in melanoma and their role in B-RAF-mediated survival is poorly defined. Here, we provide evidence that B-RAFMEK signaling protects against anoikis through alterations in two proapoptotic Bcl-2 family proteins: Bcl-xL/Bcl-2-associated death promoter ( Bad) and Bcl-2-interacting mediator of cell death (Bim). B-RAF-MEK signaling regulates phosphorylation of the inhibitory serine-75 residue of Bad, and decreases Bad mRNA expression. RNA interference and overexpression experiments demonstrate that Bad contributes to the susceptibility of B-RAF-depleted cells to anoikis. Additionally, B-RAF-MEK signaling regulates the expression of Bim(EL), mainly through control of protein turnover. Increased BimEL levels induce apoptosis in suspended cells and are required for anoikis in B-RAF-depleted cells. Depletion of Bim together with Bad has an additive effect on protecting B-RAF knockdown cells from anoikis. Together, our data show that Bad and Bim are major B-RAF responsive proteins regulating apoptosis in melanoma cells.	[Boisvert-Adamo, K.; Aplin, A. E.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,MC-165, Albany, NY 12208 USA.	aplina@mail.amc.edu			NIGMS NIH HHS [R01 GM067893, GM067893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Amiri KI, 2004, CANCER RES, V64, P4912, DOI 10.1158/0008-5472.CAN-04-0673; Berenson JR, 2006, J CLIN ONCOL, V24, P937, DOI 10.1200/JCO.2005.03.2383; Bhatt KV, 2007, ONCOGENE, V26, P1056, DOI 10.1038/sj.onc.1209861; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Eisenmann KM, 2003, CANCER RES, V63, P8330; El Chami N, 2005, J CELL BIOL, V171, P651, DOI 10.1083/jcb.200507076; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Fukazawa H, 2004, MOL CANCER THER, V3, P1281; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jiang P, 2006, MOL CELL BIOL, V26, P9071, DOI 10.1128/MCB.01025-06; Kropff MH, 2005, LEUKEMIA RES, V29, P587, DOI 10.1016/j.leukres.2004.11.004; Letai A, 2005, J CLIN INVEST, V115, P2648, DOI 10.1172/JCI26250; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oliviero R, 1997, BIOCHEM J, V324, P75, DOI 10.1042/bj3240075; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Quadros MR, 2006, CANCER BIOL THER, V5, P498, DOI 10.4161/cbt.5.5.2567; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Troppmair J, 2003, BIOCHEM PHARMACOL, V66, P1341, DOI 10.1016/S0006-2952(03)00483-0; Wang PB, 2004, J BIOL CHEM, V279, P41280, DOI 10.1074/jbc.C400248200; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	40	78	80	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3301	3312		10.1038/sj.onc.1211003	http://dx.doi.org/10.1038/sj.onc.1211003			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18246127				2022-12-28	WOS:000256111400009
J	Cui, Y; Guadagno, TM				Cui, Y.; Guadagno, T. M.			B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells	ONCOGENE			English	Article						B-Raf(V600E); ERK; mps1; spindle checkpoint; melanoma	ACTIVATED PROTEIN-KINASE; B-RAF; ASSEMBLY CHECKPOINT; BRAF MUTATIONS; MAP KINASE; CENTROSOME DUPLICATION; CANCER; PATHWAY; MITOSIS; PHOSPHORYLATION	The B-Raf(V600E) mutant, found in 65% of human melanomas, drives constitutive activation of the extracellular signal-regulated kinase (ERK) pathway and is implicated in tumorigenesis. Recently, we showed that B-Raf is important for spindle formation and the mitotic spindle checkpoint arrest. In this study, we demonstrate that B-Raf(V600E) signaling deregulates the spindle checkpoint as a consequence of stabilizing monopolar spindle 1 (Mps1) levels in human melanoma cells. Upon introducing the B-Raf(V600E) mutant into wild-type B-Raf melanoma cells, Mps1 protein and activity increased 3- and 10-fold, respectively. In addition, Mps1 became hyperphosphorylated, which correlated with stabilization of Mps1 protein levels. In contrast, reduction of B-Raf by RNAi or inactivation of ERK by the MEK inhibitor U0126 resulted in a precipitous decline in Mps1 levels. Together, these results suggest that B-Raf signaling through ERK regulates the stability of Mps1. Finally, B-Raf(V600E) expression induces a mitotic delay due to promoting robust activation of the mitotic spindle checkpoint. These effects were dependent on the induction of Mps1 levels by oncogenic B-Raf(V600E) as shown by depleting Mps1 with short interfering RNA. Collectively, our findings implicate a new mechanism through which B-Raf(V600E) exerts its oncogenic effects in melanoma.	[Cui, Y.; Guadagno, T. M.] H Lee Moffitt Canc Ctr & Res Inst, Cutaneous Oncol Div, Mol Oncol Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Guadagno, TM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Cutaneous Oncol Div, Mol Oncol Program, Tampa, FL 33612 USA.	guadagnt@moffitt.usf.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062542] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62542] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Bastian BC, 1998, CANCER RES, V58, P2170; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Borysov SI, 2006, J BIOL CHEM, V281, P22586, DOI 10.1074/jbc.M601432200; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Eves EM, 2006, MOL CELL, V23, P561, DOI 10.1016/j.molcel.2006.07.015; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fukushima T, 2003, ONCOGENE, V22, P6455, DOI 10.1038/sj.onc.1206739; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoeflich MP, 2006, CANCER RES, V66, P999, DOI 10.1158/0008-5472.CAN-05-2720; Horne MM, 2003, J CELL BIOL, V161, P1021, DOI 10.1083/jcb.200304144; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jaspersen SL, 2004, DEV CELL, V7, P263, DOI 10.1016/j.devcel.2004.07.006; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kimura ET, 2003, CANCER RES, V63, P1454; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; Peeper DS, 2002, NAT CELL BIOL, V4, P148, DOI 10.1038/ncb742; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Satyamoorthy K, 2003, CANCER RES, V63, P756; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yuen ST, 2002, CANCER RES, V62, P6451; Zhao Y, 2006, CURR BIOL, V16, P1764, DOI 10.1016/j.cub.2006.07.058	41	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3122	3133		10.1038/sj.onc.1210972	http://dx.doi.org/10.1038/sj.onc.1210972			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071315				2022-12-28	WOS:000255897600005
J	Pan, Q; Zhu, YJ; Gu, BW; Cai, X; Bai, XT; Yun, HY; Zhu, J; Chen, B; Weng, L; Chen, Z; Xue, YQ; Chen, SJ				Pan, Q.; Zhu, Y-J; Gu, B-W; Cai, X.; Bai, X-T; Yun, H-Y; Zhu, J.; Chen, B.; Weng, L.; Chen, Z.; Xue, Y-Q; Chen, S-J			New fusion gene NUP98-IQCG identified in an acute T-lymphoid/myeloid leukemia with a t(3;11)(q29q13;p15)del(3)(q29) translocation	ONCOGENE			English	Article						NUP98-IQCG; fusion gene; acute T-lymphoid/myeloid leukemia	ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; PARTNER GENE; NUCLEAR-PORE; FG REPEATS; NUP98-HOXA9; LEUKEMOGENESIS; ABNORMALITIES; PROLIFERATION; DYSREGULATION	NUP98 has been involved in multiple recurrent chromosome rearrangements in leukemia. We identified a novel fusion between NUP98 and IQ motif containing G (IQCG) gene from a de novo acute T-lymphoid/myeloid leukemia harboring t(3;11)(q29q13;p15)del(3)(q29). IQCG has two putative coiled-coil domains and one IQ domain. The FG repeat from NUP98 and the coiled-coil domain from IQCG were retained in the fusion protein. We demonstrated that NUP98-IQCG could form homodimer, heterodimerize with NUP98 or IQCG, bind coactivators and/or co-repressors, and show transcriptional activity in vitro. Expression of NUP98-IQCG inhibited 32Dcl3 cell apoptosis induced by Ara-C, and partially blocked granulocyte differentiation induced by G-CSF. Colony-forming assay and serial replating assays indicated that NUP98-IQCG was able to stimulate proliferation, partially block differentiation of hematopoietic stem/progenitor cells but was unable to confer transformation alone. Taken together, our data indicate that newly identified NUP98-IQCG fusion protein may play an essential role in leukemogenesis, but by itself may not be sufficient to induce leukemia.	[Pan, Q.; Gu, B-W; Cai, X.; Bai, X-T; Yun, H-Y; Zhu, J.; Chen, B.; Weng, L.; Chen, Z.; Chen, S-J] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Med Genom, Shanghai Inst Hematol,Ruijin Hosp, Shanghai 200030, Peoples R China; [Zhu, Y-J; Xue, Y-Q] Soochow Univ, Affiliated Hosp 1, JiangSu Inst Hematol, Leukemia Res Unit, Suzhou, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Soochow University - China	Chen, SJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Med Genom, Shanghai Inst Hematol,Ruijin Hosp, 197,Ruijin Rd 2, Shanghai 200030, Peoples R China.	uujihsmc@public1.sz.js.cn; sjchen@stn.sh.cn		Yun, Haiyang/0000-0001-8714-205X				Bai XT, 2006, CANCER RES, V66, P4584, DOI 10.1158/0008-5472.CAN-05-3101; Chung KY, 2006, CANCER RES, V66, P11781, DOI 10.1158/0008-5472.CAN-06-0706; Gervais C, 2005, LEUKEMIA, V19, P145, DOI 10.1038/sj.leu.2403565; Gu BW, 2003, LEUKEMIA, V17, P1858, DOI 10.1038/sj.leu.2403036; Gurevich RM, 2004, BLOOD, V104, P1127, DOI 10.1182/blood-2003-10-3550; Iwasaki M, 2005, BLOOD, V105, P784, DOI 10.1182/blood-2004-04-1508; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lin YW, 2005, BLOOD, V106, P287, DOI 10.1182/blood-2004-12-4794; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Moore MAS, 2007, ANN NY ACAD SCI, V1106, P114, DOI 10.1196/annals.1392.019; Nakamura T, 2005, INT J HEMATOL, V82, P21, DOI 10.1532/IJH97.04160; Nebral K, 2005, CLIN CANCER RES, V11, P6489, DOI 10.1158/1078-0432.CCR-05-0150; Ohta H, 2007, EXP HEMATOL, V35, P817, DOI 10.1016/j.exphem.2007.02.012; Panagopoulos I, 2007, BRIT J HAEMATOL, V136, P294, DOI 10.1111/j.1365-2141.2006.06410.x; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Reader JC, 2007, LEUKEMIA, V21, P842, DOI 10.1038/sj.leu.2404579; Shaffer LG., 2005, INT SYSTEM HUMAN CYT; Slape C, 2004, LEUKEMIA LYMPHOMA, V45, P1341, DOI 10.1080/10428190310001659325; Takeda A, 2006, CANCER RES, V66, P6628, DOI 10.1158/0008-5472.CAN-06-0458; Tosi S, 2005, GENE CHROMOSOME CANC, V44, P225, DOI 10.1002/gcc.20233; van Zutven LJCM, 2006, GENE CHROMOSOME CANC, V45, P437, DOI 10.1002/gcc.20308; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Xu L, 2001, LEUKEMIA, V15, P1359, DOI 10.1038/sj.leu.2402205	25	23	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3414	3423		10.1038/sj.onc.1210999	http://dx.doi.org/10.1038/sj.onc.1210999			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18084320				2022-12-28	WOS:000256309900006
J	Schwab, R; Bussolari, R; Corvetta, D; Chayka, O; Santilli, G; Kwok, JMM; Amorotti, GF; Tonini, GP; Iacoviello, L; Bertorelle, R; Menin, C; Hubank, M; Calabretta, B; Sala, A				Schwab, R.; Bussolari, R.; Corvetta, D.; Chayka, O.; Santilli, G.; Kwok, J. M-M; Amorotti, G. F.; Tonini, G. P.; Iacoviello, L.; Bertorelle, R.; Menin, C.; Hubank, M.; Calabretta, B.; Sala, A.			Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk	ONCOGENE			English	Article						transcription; neuroblastoma; colon cancer; leukaemia; apoptosis	CHROMOSOMAL REGION; T-CELLS; APOPTOSIS; GENE; AMPLIFICATION	The B-MYB proto-oncogene is a transcription factor belonging to the MYB family that is frequently over-expressed or amplified in different types of human malignancies. While it is suspected that B-MYB plays a role in human cancer, there is still no direct evidence of its causative role. Looking for mutations of the B-MYB gene in human cell lines and primary cancer samples, we frequently isolated two nonsynonymous B-MYB polymorphic variants (rs2070235 and rs11556379). Compared to the wild-type protein, the B-MYB isoforms display altered conformation, impaired regulation of target genes and decreased antiapoptotic activity, suggesting that they are hypomorphic variants of the major allele. Importantly, the B-MYB polymorphisms are common; rs2070235 and rs11556379 are found, depending on the ethnic background, in 10-50% of human subjects. We postulated that, if B-MYB activity is important for transformation, the presence of common, hypomorphic variants might modify cancer risk. Indeed, the B-MYB polymorphisms are underrepresented in 419 cancer patients compared to 230 controls (odds ratio 0.53; (95%) confidence interval 0.385-0.755; P = 0.001). This data imply that a large fraction of the human population is carrier of B-MYB alleles that might be associated with a reduced risk of developing neoplastic disease.	[Schwab, R.; Corvetta, D.; Chayka, O.; Santilli, G.; Kwok, J. M-M; Hubank, M.; Sala, A.] UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England; [Bussolari, R.; Amorotti, G. F.; Calabretta, B.] Univ Modena & Reggio Emilia, Dept Biomed Sci, Modena, Italy; [Corvetta, D.] Univ Parma, Dipartimento Med Sperimentale, Sezione Biochim, Biochem Clin & Biochim Esercizio Fis, I-43100 Parma, Italy; [Tonini, G. P.] Natl Inst Canc Res, IST, Genoa, Italy; [Iacoviello, L.] Catholic Univ, John Paul II Ctr High Technol Res & Educ Biomed S, Lab Genet & Environm Epidemiol, Campobasso, Italy; [Bertorelle, R.; Menin, C.] IRCCS, IOV, Padua, Italy	University of London; University College London; Universita di Modena e Reggio Emilia; University of Parma; University of Genoa; IRCCS AOU San Martino IST; Catholic University of the Sacred Heart; IRCCS Istituto Oncologico Veneto (IOV)	Sala, A (corresponding author), UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N 1EH, England.	a.sala@ich.ucl.ac.uk	Bertorelle, Roberta/AAC-2357-2022; sala, arturo/C-4959-2008; Menin, Chiara/L-5770-2016; Iacoviello, Licia/AGX-7071-2022; Hubank, Michael JF/C-1837-2008; Siani, Alfonso/B-7925-2015; Iacoviello, Licia/K-4676-2016	Bertorelle, Roberta/0000-0002-4235-3862; Menin, Chiara/0000-0002-8907-772X; Iacoviello, Licia/0000-0003-0514-5885; Hubank, Michael JF/0000-0002-2901-0742; Iacoviello, Licia/0000-0003-0514-5885; Sala, Arturo/0000-0002-2841-7866				Ahlbory DR, 2005, ONCOGENE, V24, P7127, DOI 10.1038/sj.onc.1208869; Bar-Shira A, 2002, CANCER RES, V62, P6803; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Eckstein LA, 2005, INVEST OPHTH VIS SCI, V46, P782, DOI 10.1167/iovs.04-1022; Forozan F, 2000, CANCER RES, V60, P4519; Grassilli E, 1999, CANCER RES, V59, P2451; Iacoviello L, 1998, NEW ENGL J MED, V338, P79, DOI 10.1056/NEJM199801083380202; Imyanitov EN, 2004, CANCER LETT, V204, P3, DOI 10.1016/j.canlet.2003.09.026; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Masselink H, 2001, CANCER LETT, V171, P87, DOI 10.1016/S0304-3835(01)00631-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Raschella G, 1999, CANCER RES, V59, P3365; Sala A, 2005, EUR J CANCER, V41, P2479, DOI 10.1016/j.ejca.2005.08.004; Shepard JL, 2005, P NATL ACAD SCI USA, V102, P13194, DOI 10.1073/pnas.0506583102; SUGIMURA H, 1990, CANCER RES, V50, P1857; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tanner MM, 2000, CLIN CANCER RES, V6, P1833	19	9	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2929	2933		10.1038/sj.onc.1210947	http://dx.doi.org/10.1038/sj.onc.1210947			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18026132				2022-12-28	WOS:000255502500014
J	Lin, K; Rockliffe, N; Johnson, GG; Sherrington, PD; Pettitt, AR				Lin, K.; Rockliffe, N.; Johnson, G. G.; Sherrington, P. D.; Pettitt, A. R.			Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells	ONCOGENE			English	Article						p53; ATM; chronic lymphocytic leukaemia; Hsp90	ENDOTHELIAL GROWTH-FACTOR; GENE MUTATION STATUS; IN-VITRO; PURINE ANALOGS; HEAT-SHOCK-PROTEIN-90 HSP90; DISEASE PROGRESSION; PROTEIN EXPRESSION; ZAP-70 EXPRESSION; INDUCED APOPTOSIS; DRUG-RESISTANCE	In chronic lymphocytic leukaemia ( CLL), mutation/ deletion of TP53 is strongly associated with early disease progression, resistance to chemotherapy and short patient survival. Consequently, there is a pressing need to develop novel treatment protocols for this high- risk patient group. The present study was performed to evaluate Hsp90 inhibition as a possible therapeutic approach for such patients. Primary CLL cells of defined ataxia telangiectasia mutated ( ATM)/ p53 status were incubated with the Hsp90 inhibitor geldanamycin ( GA) and analysed by western blotting for the expression of p53, p21, MDM2 and Akt. GA downregulated overexpressed mutant p53 protein ( an oncogene) and upregulated wild- type ( wt) p53 ( a tumour suppressor). The upregulation of wt p53 by GA was independent of ATM and was accompanied by downregulation of Akt and the active form of MDM2, indicating a possible mechanism. GA also produced a p53/ ATM- independent increase in the levels of p21 - a potent inducer of cell- cycle arrest. In- vitro cytotoxicity studies showed that GA killed cultured CLL cells in a dose- and time- dependent fashion irrespective of their p53/ ATM status and more effectively than normal blood mononuclear cells. In summary, our findings reveal important consequences of inhibiting Hsp90 in CLL cells and strongly support the therapeutic evaluation of Hsp90 inhibitors in poor- prognosis patients with p53 defects.	[Lin, K.; Rockliffe, N.; Sherrington, P. D.; Pettitt, A. R.] Univ Liverpool, Dept Haematol, Sch Canc Studies, Div Haematol, Liverpool L69 3GA, Merseyside, England; [Lin, K.; Johnson, G. G.; Sherrington, P. D.; Pettitt, A. R.] Royal Liverpool & Broadgreen Univ Hosp Trust, Dept Haematol, Liverpool, Merseyside, England	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool	Pettitt, AR (corresponding author), Univ Liverpool, Dept Haematol, Sch Canc Studies, Div Haematol, 2nd Floor Duncan Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.	A.R.Pettitt@liverpool.ac.uk	lin, ke/GZM-8300-2022					BARTEK J, 1991, ONCOGENE, V6, P1699; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Carter A, 2006, LEUKEMIA, V20, P737, DOI 10.1038/sj.leu.2404120; Castro JE, 2005, BLOOD, V106, P2506, DOI 10.1182/blood-2005-03-1099; Catovsky D, 2004, BLOOD, V104, p8A, DOI 10.1182/blood.V104.11.13.13; Chen HJ, 2000, BLOOD, V96, P3181; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Choi HJ, 2006, GLYCOBIOLOGY, V16, P573, DOI 10.1093/glycob/cwj105; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cordone I, 1998, BLOOD, V91, P4342, DOI 10.1182/blood.V91.11.4342.411k39_4342_4349; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; ELROUBY S, 1993, BLOOD, V82, P3452; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; GINE E, 2005, LEUK LYMPHOMA S1, V46, pS89; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jones DT, 2004, BLOOD, V103, P1855, DOI 10.1182/blood-2003-05-1603; Jones DT, 2003, BLOOD, V101, P3174, DOI 10.1182/blood-2002-07-2143; Jones GG, 2004, ONCOGENE, V23, P1911, DOI 10.1038/sj.onc.1207318; Kamat CD, 2007, CANCER LETT, V249, P209, DOI 10.1016/j.canlet.2006.08.017; KIESER A, 1994, ONCOGENE, V9, P963; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lens D, 1997, BRIT J HAEMATOL, V99, P848, DOI 10.1046/j.1365-2141.1997.4723278.x; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Morabito F, 1997, HAEMATOLOGICA, V82, P16; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; Pettitt AR, 1999, BRIT J HAEMATOL, V105, P986, DOI 10.1046/j.1365-2141.1999.01448.x; Pettitt AR, 1999, BRIT J HAEMATOL, V106, P1049; Pettitt AR, 2000, BRIT J HAEMATOL, V109, P800, DOI 10.1046/j.1365-2141.2000.02068.x; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Rassenti LZ, 2004, NEW ENGL J MED, V351, P893, DOI 10.1056/NEJMoa040857; Romanov VV, 2005, ONCOGENE, V24, P6855, DOI 10.1038/sj.onc.1208895; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; SILBER R, 1994, BLOOD, V84, P3440; Smith V, 2005, CANCER CHEMOTH PHARM, V56, P126, DOI 10.1007/s00280-004-0947-2; Stankovic T, 2002, BLOOD, V99, P300, DOI 10.1182/blood.V99.1.300; STILGENBAUER S, 2005, LEUK LYMPHOMA S1, V46, pS6; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Thornton PD, 2004, HEMATOL J, V5, P47, DOI 10.1038/sj.thj.6200325; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; Valganon M, 2005, BRIT J HAEMATOL, V129, P53, DOI 10.1111/j.1365-2141.2005.05405.x; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9; Zhang Y, 2004, J BIOL CHEM, V279, P42545, DOI 10.1074/jbc.M314213200; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	76	57	58	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2445	2455		10.1038/sj.onc.1210893	http://dx.doi.org/10.1038/sj.onc.1210893			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17982489				2022-12-28	WOS:000254844900009
J	Corso, S; Migliore, C; Ghiso, E; De Rosa, G; Comoglio, PM; Giordano, S				Corso, S.; Migliore, C.; Ghiso, E.; De Rosa, G.; Comoglio, P. M.; Giordano, S.			Silencing the MET oncogene leads to regression of experimental tumors and metastases	ONCOGENE			English	Article						growth factor receptor; tumor progression; invasion; metastasis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; FACTOR-RECEPTOR; INVASIVE GROWTH; C-MET; TYROSINE KINASE; LENTIVIRAL VECTORS; CANCER METASTASIS; DOWN-REGULATION; GENE-TRANSFER	In spite of the established knowledge of the genetic alterations responsible for cancer onset, the genes promoting and maintaining the invasive/metastatic phenotype are still elusive. The MET proto-oncogene, encoding the tyrosine kinase receptor for hepatocyte growth factor (HGF), senses unfavorable micro-environmental conditions and drives cell invasion and metastasis. MET overexpression, often induced by tumor hypoxia, leads to constitutive activation of the receptor and correlates with poor prognosis. To establish the role of MET in different phases of tumor progression, we developed an inducible lentiviral delivery system of RNA interference. Silencing the endogenous MET gene, overexpressed in tumor cells, resulted in (i) impairment of the execution of the full invasive growth program in vitro, (ii) lack of tumor growth and (iii) decreased generation of experimental metastases in vivo. Notably, silencing MET in already established metastases led to their almost complete regression. This indicates that persistent expression of the MET oncogene is mandatory until the advanced phases of cancer progression.	[Corso, S.; Migliore, C.; Ghiso, E.; Comoglio, P. M.; Giordano, S.] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Div Mol Oncol, I-10060 Turin, Italy; [De Rosa, G.] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Unit Pathol, I-10060 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Giordano, S (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Div Mol Oncol, Str Prov 142, I-10060 Turin, Italy.	silvia.giordano@ircc.it	Giordano, Silvia/J-9858-2018	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; CORSO, Simona/0000-0002-5069-1503; Migliore, Cristina/0000-0003-3722-2814	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Christensen JG, 2003, CANCER RES, V63, P7345; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Corbel SY, 2002, CURR OPIN BIOTECH, V13, P448, DOI 10.1016/S0958-1669(02)00361-0; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FIXMAN ED, 1995, ONCOGENE, V10, P237; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galimi F, 2001, J IMMUNOL, V166, P1241, DOI 10.4049/jimmunol.166.2.1241; Gambarotta G, 1996, ONCOGENE, V13, P1911; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Patane S, 2006, CANCER RES, V66, P4750, DOI 10.1158/0008-5472.CAN-05-4422; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosario M, 2004, DEV CELL, V7, P3, DOI 10.1016/j.devcel.2004.06.015; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Skibinski G, 2001, IMMUNOLOGY, V102, P506, DOI 10.1046/j.1365-2567.2001.01186.x; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Taulli R, 2005, CANCER GENE THER, V12, P456, DOI 10.1038/sj.cgt.7700815; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Valabrega G, 2005, ONCOGENE, V24, P3002, DOI 10.1038/sj.onc.1208478; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; VANDEWOUDE GF, 1997, CIBA F SYMP, V212, P130; Vigna E, 2000, J GENE MED, V2, P308; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	64	103	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					684	693		10.1038/sj.onc.1210697	http://dx.doi.org/10.1038/sj.onc.1210697			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684486				2022-12-28	WOS:000252674900012
J	Bultman, SJ; Herschkowitz, JI; Godfrey, V; Gebuhr, TC; Yaniv, M; Perou, CM; Magnuson, T				Bultman, S. J.; Herschkowitz, J. I.; Godfrey, V.; Gebuhr, T. C.; Yaniv, M.; Perou, C. M.; Magnuson, T.			Characterization of mammary tumors from Brg1 heterozygous mice	ONCOGENE			English	Article						BRG1; SWF/SNF; breast cancer; haploin-sufficiency; genomic instability	SWI/SNF COMPLEX; CELL-CYCLE; CHROMATIN; EXPRESSION; CANCER; INACTIVATION; PROGRESSION; SUPPRESSOR	Mammalian SWI/SNF-related complexes have been implicated in cancer based on some of the subunits physically interacting with retinoblastoma (RB) and other proteins involved in carcinogenesis. Additionally, several subunits are mutated or not expressed in tumor-derived cell lines. Strong evidence for a role in tumorigenesis in vivo, however, has been limited to SNF5 mutations that result primarily in malignant rhabdoid tumors (MRTs) in humans and MRTs as well as other sarcomas in mice. We previously generated a null mutation of the Brg1 catalytic subunit in the mouse and reported that homozygotes die during embryogenesis. Here, we demonstrate that Brg1 heterozygotes are susceptible to mammary tumors that are fundamentally different than Snf5 tumors. First, mammary tumors are carcinomas not sarcomas. Second, Brg1(+/-) tumors arise because of haploinsufficiency rather than loss of heterozygosity. Third, Brg1(+/-) tumors exhibit genomic instability but not polyploidy based on array comparative genomic hybridization results. We monitored Brg1(+/-), Brm(-/-) double-mutant mice but did not observe any tumors resembling those from Snf5 mutants, indicating that the Brg1(+/-) and Snf5(+/-) tumor phenotypes do not differ simply because Brg1 has a closely related paralog whereas Snf5 does not. These findings demonstrate that BRG1 and SNF5 are not functionally equivalent but protect against cancer in different ways. We also demonstrate that Brg1(+/-) mammary tumors have relatively heterogeneous gene expression profiles with similarities and differences compared to other mouse models of breast cancer. The Brg1(+/-)expression profiles are not particularly similar to mammary tumors from Wap-T121 transgenic line where RB is perturbed. We were also unable to detect a genetic interaction between the Brg1(+/-) and Rb+/- tumor phenotypes. These latter findings do not support a BRG1-RB interaction in vivo.	[Bultman, S. J.; Herschkowitz, J. I.; Gebuhr, T. C.; Perou, C. M.; Magnuson, T.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Bultman, S. J.; Herschkowitz, J. I.; Gebuhr, T. C.; Perou, C. M.; Magnuson, T.] Univ N Carolina, Carolina Genome Sci Ctr, Chapel Hill, NC USA; [Godfrey, V.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Yaniv, M.] Inst Pasteur, Dept Dev Biol, Gene Express & Res Unit, Paris, France	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bultman, SJ (corresponding author), Univ N Carolina, Dept Genet, 103 Mason Farm Rd,4340B MBRB, Chapel Hill, NC 27599 USA.	Scott_Bultman@med.unc.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247	NICHD NIH HHS [R01 HD036655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD036655] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Dauvillier S, 2001, MECH DEVELOP, V101, P221, DOI 10.1016/S0925-4773(00)00560-8; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Guidi CJ, 2006, CANCER RES, V66, P8076, DOI 10.1158/0008-5472.CAN-06-1451; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071; Medina PP, 2004, GENE CHROMOSOME CANC, V41, P170, DOI 10.1002/gcc.20068; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Oesterreich S, 2001, BRIT J CANCER, V84, P493, DOI 10.1054/bjoc.2000.1606; Reisman DN, 2003, CANCER RES, V63, P560; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Simin K, 2004, PLOS BIOL, V2, P194, DOI 10.1371/journal.pbio.0020022; Snijders AM, 2005, GENOME RES, V15, P302, DOI 10.1101/gr.2902505; Wang Z, 2004, GENE DEV, V18, P3106, DOI 10.1101/gad.1238104; Yang TL, 2004, GENE CHROMOSOME CANC, V41, P250, DOI 10.1002/gcc.20080	17	126	130	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					460	468		10.1038/sj.onc.1210664	http://dx.doi.org/10.1038/sj.onc.1210664			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637742				2022-12-28	WOS:000252426100006
J	Haraguchi, K; Ohsugi, M; Abe, Y; Semba, K; Akiyama, T; Yamamoto, T				Haraguchi, K.; Ohsugi, M.; Abe, Y.; Semba, K.; Akiyama, T.; Yamamoto, T.			Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3 beta-mediated phosphorylation of beta-catenin	ONCOGENE			English	Article						Wnt; beta-catenin; GSK-3 beta; Ajuba; phosphorylation	LIM PROTEIN FHL2; CYCLIN D1; AXIN; CANCER; EMBRYOGENESIS; FIBROBLASTS; ACTIVATION; INTERACTS; NUCLEUS; CELLS	The Wnt signaling pathway is essential for embryonic development and carcinogenesis. Upon Wnt stimulation, beta-catenin is stabilized and associates with T-cell factor or lymphoid enhancing factor, thereby activating transcription of target genes. In the absence of Wnt stimulation, the level of beta-catenin is reduced via glycogen synthase kinase (GSK)-beta b-mediated phosphorylation and subsequent proteasome-dependent degradation. Here, we report the identification of Ajuba as a negative regulator of the Wnt signaling pathway. Ajuba is a member of LIM domain-containing proteins that contribute to cell fate determination and regulate cell proliferation and differentiation. We found that enforced expression of Ajuba destabilized beta-catenin and suppressed target gene expression. Ajuba promoted GSK-3 beta-mediated phosphorylation of beta-catenin by reinforcing the association between beta-catenin and GSK-3 beta. Furthermore, Wnt stimulation induced both accumulation of beta-catenin and destabilization of Ajuba. Our findings suggest that Ajuba is important for regulation of the Wnt signaling pathway.	[Haraguchi, K.; Ohsugi, M.; Abe, Y.; Yamamoto, T.] Univ Tokyo, Inst Med Sci, Div Oncol, Tokyo 1088639, Japan; [Semba, K.] Univ Tokyo, Inst Med Sci, Div Cell & Mol Biol, Tokyo 1088639, Japan; [Akiyama, T.] Univ Tokyo, Inst Mol & Cell Biol, Lab Mol & Genet Informat, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp	Ohsugi, Miho/AAY-9339-2020	Ohsugi, Miho/0000-0003-0288-3428; Abe, Yoshinori/0000-0003-3894-494X				Adachi S, 2004, CANCER RES, V64, P8496, DOI 10.1158/0008-5472.CAN-04-2254; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; CADIGAM KM, 1998, GENE DEV, V14, P156; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kanungo J, 2000, MOL BIOL CELL, V11, P3299, DOI 10.1091/mbc.11.10.3299; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Shibamoto S, 1998, GENES CELLS, V3, P659; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tago K, 2000, GENE DEV, V14, P1741; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200	26	44	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					274	284		10.1038/sj.onc.1210644	http://dx.doi.org/10.1038/sj.onc.1210644			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621269				2022-12-28	WOS:000252256000003
J	To-Ho, KW; Cheung, HW; Ling, MT; Wong, YC; Wang, X				To-Ho, K. W.; Cheung, H. W.; Ling, M-T; Wong, Y. C.; Wang, X.			MAD2 Delta C induces aneuploidy and promotes anchorage-independent growth in human prostate epithelial cells	ONCOGENE			English	Article						MAD2; mitotic; prostate epithelial cells; transformation	COMPARATIVE GENOMIC HYBRIDIZATION; NASOPHARYNGEAL CARCINOMA-CELLS; MITOTIC CHECKPOINT; CANCER-CELLS; CHROMOSOME MISSEGREGATION; PREMATURE ANAPHASE; MAMMALIAN-CELLS; SHORT TELOMERES; RAS MUTATION; MAD2 PROTEIN	The mitotic arrest deficient 2 (MAD2) is suggested to play a key role in a functional mitotic checkpoint because of its inhibitory effect on anaphase-promoting complex/cyclosome (APC/C) during mitosis. The binding of MAD2 to mitotic checkpoint regulators MAD1 and Cdc20 is thought to be crucial for its function and loss of which leads to functional inactivation of the MAD2 protein. However, little is known about the biological significance of this MAD2 mutant in human cells. In this study, we stably transfected a C-terminal-deleted MAD2 gene (MAD2 Delta C) into a human prostate epithelial cell line, Hpr-1 and studied its effect on chromosomal instability, cell proliferation, mitotic checkpoint control and soft agar colony-forming ability. We found that MAD2DC was able to induce aneuploidy through promoting chromosomal duplication, which was a result of an impaired mitotic checkpoint and cytokinesis, suggesting a crucial role of MAD2-mediated mitotic checkpoint in chromosome stability in human cells. In addition, the MAD2 Delta C-transfected cells displayed anchorage- independent growth in soft agar after challenged by 7,12-dimethylbenz[A]anthracene (DMBA), demonstrating a cancer-promoting effect of a defective mitotic checkpoint in human cells. Furthermore, the DMBA-induced transformation was accompanied by a complete loss of DNA damage-induced p53 response and activation of the MAPK pathway in MAD2 Delta C cells. These results indicate that a defective mitotic checkpoint alone is not a direct cause of tumorigenesis, but it may predispose human cells to carcinogen-induced malignant transformation. The evidence presented here provides a link between MAD2 inactivation and malignant transformation of epithelial cells.	[To-Ho, K. W.; Cheung, H. W.; Ling, M-T; Wong, Y. C.; Wang, X.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Wang, X (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, 1-F Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xhwang@hkucc.hku.hk						Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Bernardino J, 1997, CANCER GENET CYTOGEN, V96, P123, DOI 10.1016/S0165-4608(96)00258-0; Burds AA, 2005, P NATL ACAD SCI USA, V102, P11296, DOI 10.1073/pnas.0505053102; BUTZ K, 1995, ONCOGENE, V10, P927; Cheung BW, 2005, CANCER RES, V65, P1450, DOI 10.1158/0008-5472.CAN-04-0567; Cho ES, 2002, YONSEI MED J, V43, P145, DOI 10.3349/ymj.2002.43.2.145; Choo CK, 1999, PROSTATE, V40, P150, DOI 10.1002/(SICI)1097-0045(19990801)40:3<150::AID-PROS2>3.0.CO;2-7; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; DE AA, 2005, CURR BIOL, V15, P214; Deliveliotis C, 2003, WORLD J UROL, V21, P171, DOI 10.1007/s00345-003-0345-0; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Deng W, 2003, GENE CHROMOSOME CANC, V37, P92, DOI 10.1002/gcc.10190; Di Cristofaro J, 2006, HUM PATHOL, V37, P824, DOI 10.1016/j.humpath.2006.01.030; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; DOHNER H, 1992, GENE CHROMOSOME CANC, V5, P392, DOI 10.1002/gcc.2870050415; Eid MA, 1998, CANCER RES, V58, P2461; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fung MKL, 2006, BRIT J CANCER, V95, P475, DOI 10.1038/sj.bjc.6603284; Gioeli D, 1999, CANCER RES, V59, P279; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Haapala K, 2001, CANCER GENET CYTOGEN, V131, P74, DOI 10.1016/S0165-4608(01)00491-5; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Johannsdottir HK, 2004, ANTICANCER RES, V24, P2681; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Krishnan R, 1998, GENOMICS, V49, P475, DOI 10.1006/geno.1998.5233; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Luo XL, 2004, NAT STRUCT MOL BIOL, V11, P338, DOI 10.1038/nsmb748; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; OSAKA M, 1995, CANCER LETT, V91, P25, DOI 10.1016/0304-3835(94)03714-T; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Phillips JL, 2001, CANCER RES, V61, P8143; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; Stewart SL, 2004, CANCER RES, V64, P8177, DOI 10.1158/0008-5472.CAN-04-1702; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takahashi N, 1999, SOFTWARE STUDIES, V2, P55; Wang XH, 1998, CANCER RES, V58, P5019; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Webb HD, 1996, CANCER GENET CYTOGEN, V88, P126, DOI 10.1016/0165-4608(95)00305-3; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhao YF, 2006, CARCINOGENESIS, V27, P1692, DOI 10.1093/carcin/bgl037; Zitzelsberger H, 1996, CANCER GENET CYTOGEN, V90, P37, DOI 10.1016/0165-4608(96)00065-9	54	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					347	357		10.1038/sj.onc.1210633	http://dx.doi.org/10.1038/sj.onc.1210633			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621272				2022-12-28	WOS:000252256000011
J	Lavin, MF				Lavin, M. F.			ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks	ONCOGENE			English	Review						ATM; Mre11 complex; DNA double strand breaks; signal transduction; functional consequences	DEPENDENT NUCLEAR-DYNAMICS; IONIZING-RADIATION; REQUIRES ATM; DAMAGE RESPONSE; PROTEIN-KINASE; MRN COMPLEX; IN-VITRO; ACTIVATION; REPAIR; PHOSPHORYLATION	The recognition and repair of DNA double-strand breaks (DSBs) is a complex process that draws upon a multitude of proteins. This is not surprising since this is a lethal lesion if left unrepaired and also contributes to genome instability and the consequential risk of cancer and other pathologies. Some of the key proteins that recognize these breaks in DNA are mutated in distinct genetic disorders that predispose to agent sensitivity, genome instability, cancer predisposition and/or neurodegeneration. These include members of the Mre11 complex (Mre11/Rad50/Nbs1) and ataxia-telangiectasia (A-T) mutated (ATM), mutated in the human genetic disorder A-T. The mre11 (MRN) complex appears to be the major sensor of the breaks and subsequently recruits ATM where it is activated to phosphorylate in turn members of that complex and a variety of other proteins involved in cell-cycle control and DNA repair. The MRN complex is also upstream of ATM and ATR (A-T-mutated and rad3-related) protein in responding to agents that block DNA replication. To date, more than 30 ATM-dependent substrates have been identified in multiple pathways that maintain genome stability and reduce the risk of disease. We focus here on the relationship between ATM and the MRN complex in recognizing and responding to DNA DSBs.	Queensland Inst Med Res, Radiat Biol & Oncol Lab, Brisbane, Qld 4029, Australia; Univ Queensland, Fac Hlth Sci, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland	Lavin, MF (corresponding author), Queensland Inst Med Res, Radiat Biol & Oncol Lab, Brisbane, Qld 4029, Australia.	martin.lavin@qimr.edu.au	Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769				Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Agarwal S, 2006, DNA REPAIR, V5, P1075, DOI 10.1016/j.dnarep.2006.05.029; Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cerosaletti K, 2004, J BIOL CHEM, V279, P38813, DOI 10.1074/jbc.M404294200; Cerosaletti K, 2006, MOL CELL BIOL, V26, P1691, DOI 10.1128/MCB.26.5.1691-1699.2006; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2004, PLOS BIOL, V2, P600, DOI 10.1371/journal.pbio.0020110; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Difilippantonio S, 2007, J EXP MED, V204, P1003, DOI 10.1084/jem.20070319; Digweed M, 1999, BIOESSAYS, V21, P649, DOI 10.1002/(SICI)1521-1878(199908)21:8<649::AID-BIES4>3.0.CO;2-O; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Girard PM, 2000, CANCER RES, V60, P4881; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Hamer G, 2004, BIOL REPROD, V70, P1206, DOI 10.1095/biolreprod.103.024950; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Jiang XF, 2006, J BIOL CHEM, V281, P15741, DOI 10.1074/jbc.M513172200; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Krause DR, 2003, ONCOGENE, V22, P5927, DOI 10.1038/sj.onc.1206691; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Linding R, 2007, CELL, V129, P1415, DOI 10.1016/j.cell.2007.05.052; Lisby M, 2004, CURR BIOL, V14, pR994, DOI 10.1016/j.cub.2004.11.020; Livak F, 2004, IMMUNOL REV, V200, P23, DOI 10.1111/j.0105-2896.2004.00170.x; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lukas J, 2006, DNA REPAIR, V5, P591, DOI 10.1016/j.dnarep.2006.01.006; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McManus KJ, 2005, METHODS, V36, P351, DOI 10.1016/j.ymeth.2005.03.010; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nelms K, 1998, ADV EXP MED BIOL, V452, P37; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paulsen RD, 2007, DNA REPAIR, V6, P953, DOI 10.1016/j.dnarep.2007.02.015; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Powers JT, 2004, MOL CANCER RES, V2, P203; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Schroff KC, 2004, ADDICT BIOL, V9, P265, DOI 10.1080/13556210412331292596; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Stracker TH, 2007, NATURE, V447, P218, DOI 10.1038/nature05740; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Usui T, 2006, EXP CELL RES, V312, P2694, DOI 10.1016/j.yexcr.2006.06.013; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; WARD JF, 1985, RADIAT RES, V104, pS103, DOI 10.2307/3576637; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yuan SSF, 2002, TOXICOLOGY, V177, P123, DOI 10.1016/S0300-483X(02)00220-2; Zhang J, 2005, MOL CELL BIOL, V25, P9910, DOI 10.1128/MCB.25.22.9910-9919.2005; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	77	217	226	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7749	7758		10.1038/sj.onc.1210880	http://dx.doi.org/10.1038/sj.onc.1210880			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066087	Bronze			2022-12-28	WOS:000251537900005
J	Fleury, L; Gerus, M; Lavigne, AC; Richard-Foy, H; Bystricky, K				Fleury, L.; Gerus, M.; Lavigne, A. C.; Richard-Foy, H.; Bystricky, K.			Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells	ONCOGENE			English	Article						breast cancer; chromatin; ER alpha; PR; methylation	BONE MORPHOGENETIC PROTEIN-6; HISTONE DEACETYLASE INHIBITION; DNA METHYLATION; PROGESTERONE-RECEPTOR; PROSTATE-CANCER; COPY NUMBER; ALPHA; BINDING; PROGRESSION; PROMOTER	In breast cancer, approximately one-third of tumors express neither the estrogen receptor ( ER alpha) nor estrogen-regulated genes such as the progesterone receptor gene ( PR). Our study provides new insights into the mechanism allowing hormone-activated expression of ER alpha target genes silenced in ER alpha-negative mammary tumor cells. In cell lines derived from ER alpha-negative MDA-MB231 cells, stable expression of different levels of ER alpha from a transgene did not result in transcription of PR. A quantitative comparative analysis demonstrates that inhibiting DNA methyltransferases using 5-aza-2 '-deoxycytidine or specific disruption of DNMT1 by small interfering RNAs and treatment with the histone-deacetylase inhibitor trichostatin A enabled ER alpha-mediated hormone-dependent expression of endogenous PR. We show that demethylation of a CpG island located in the first exon of PR was a prerequisite for ER alpha binding to these regulatorysequences. Although not a general requirement, DNA demethylation is also necessary for derepression of a subset of ER alpha target genes involved in tumorigenesis. PR transcription did not subsist 4 days after removal of the DNA methyltransferase blocking agents, suggesting that hormone-induced expression of ER alpha target genes in ER alpha-negative tumor cells is transient. Our observations support a model where an epigenetic mark confers stable silencing by precluding ER alpha access to promoters.	[Fleury, L.; Gerus, M.; Lavigne, A. C.; Richard-Foy, H.; Bystricky, K.] Univ Toulouse, Lab Biol Mol Eucaryote, IBCG, F-31062 Toulouse, Midi Pyrenees, France; [Fleury, L.; Gerus, M.; Lavigne, A. C.; Richard-Foy, H.; Bystricky, K.] CNRS, UMR 5099, Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bystricky, K (corresponding author), Univ Toulouse, Lab Biol Mol Eucaryote, IBCG, 118 Route Narbonne, F-31062 Toulouse, Midi Pyrenees, France.	kerstin@ibcg.biotoul.fr	Bystricky, Kerstin/AAA-3003-2020; Lavigne, Anne-Claire/O-8805-2015; BYSTRICKY, Kerstin/B-8670-2009	Bystricky, Kerstin/0000-0001-6717-3721; BYSTRICKY, Kerstin/0000-0001-6717-3721				Ahram M, 2002, MOL CARCINOGEN, V33, P9, DOI 10.1002/mc.10019; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Balleine RL, 2000, GENE CHROMOSOME CANC, V29, P48, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1005>3.0.CO;2-O; Baron S, 2007, J BIOL CHEM, V282, P11732, DOI 10.1074/jbc.M610079200; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Giamarchi C, 1999, ONCOGENE, V18, P533, DOI 10.1038/sj.onc.1202317; GOODFELLOW PJ, 1995, J NATL CANCER I, V87, P1515, DOI 10.1093/jnci/87.20.1515; Hamdy FC, 1997, CANCER RES, V57, P4427; Heikinheimo AK, 1999, CANCER RES, V59, P5815; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kininis M, 2007, MOL CELL BIOL, V27, P5090, DOI 10.1128/MCB.00083-07; Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104; Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lande-Diner L, 2007, J BIOL CHEM, V282, P12194, DOI 10.1074/jbc.M607838200; Lazennec G, 1999, MOL ENDOCRINOL, V13, P969, DOI 10.1210/me.13.6.969; Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Metivier R, 2004, EMBO J, V23, P3653, DOI 10.1038/sj.emboj.7600377; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008; Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; TOUITOU I, 1991, J STEROID BIOCHEM, V40, P231, DOI 10.1016/0960-0760(91)90187-A; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Yang XW, 2001, CANCER RES, V61, P7025; Zhang M, 2007, J STEROID BIOCHEM, V105, P91, DOI 10.1016/j.jsbmb.2007.01.002	46	21	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4075	4085		10.1038/onc.2008.41	http://dx.doi.org/10.1038/onc.2008.41			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18317449				2022-12-28	WOS:000257325100007
J	Pearce, VP; Sherrell, J; Lou, Z; Kopelovich, L; Wright, WE; Shay, JW				Pearce, V. P.; Sherrell, J.; Lou, Z.; Kopelovich, L.; Wright, W. E.; Shay, J. W.			Immortalization of epithelial progenitor cells mediated by resveratrol	ONCOGENE			English	Article						telomerase; p53; progesterone; breast epithelial; aging	BREAST-CANCER CELLS; TELOMERASE ACTIVITY; IN-VITRO; P53 PROTEIN; ACTIVATION; EXPRESSION; NEUROBLASTOMA; LOCALIZATION; MAINTENANCE; SENESCENCE	Within the hierarchy of epithelial stem cells, normal progenitor cells may express regulated telomerase during renewal cycles of proliferation and differentiation. Discontinuous telomerase activity may promote increased renewal capacity of progenitor cells, while deregulated/ continuous telomerase activity may promote immortalization when differentiation and/ or senescent pathways are compromised. In the present work, we show that resveratrol activates, while progesterone inactivates, continuous telomerase activity within 24 h in subpopulations of human Li - Fraumeni syndrome- derived breast epithelial cells. Resveratrol results in immortalization of mixed progenitor cells with mutant p53, but not human epithelial cells with wild type p53. Our results demonstrate the potential for renewing progenitor cells with mutant p53 to immortalize after continuous telomerase expression when exposed to certain environmental compounds. Understanding the effects of telomerase modulators on endogenous telomerase activity in progenitor cells is relevant to the role of immortalization in the initiation and progression of cancer subtypes.	[Pearce, V. P.; Lou, Z.; Wright, W. E.; Shay, J. W.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Pearce, V. P.] Univ N Texas, Dept Pharmacol & Neurosci, UNT Hlth Sci Ctr Ft Worth, Ft Worth, TX USA; [Sherrell, J.] Univ Arizona, Sch Dent, Phoenix, AZ USA; [Kopelovich, L.] NCI, Div Canc Prevent, Bethesda, MD 20892 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of North Texas System; University of North Texas Health Science Center; University of Arizona; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shay, JW (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Jerry.Shay@UTSouthwestern.edu	Shay, Jerry W/F-7878-2011		DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005106] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R03CA075907, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA070907, P50 CA75907, N01CN43301, N01-CN43301, CN-05106] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bankfalvi A, 2004, MODERN PATHOL, V17, P1051, DOI 10.1038/modpathol.3800082; Bayne S, 2005, MOL CELL ENDOCRINOL, V240, P11, DOI 10.1016/j.mce.2005.05.009; Bhat KPL, 2002, ANN NY ACAD SCI, V957, P210, DOI 10.1111/j.1749-6632.2002.tb02918.x; Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Conneely OM, 2003, J MAMMARY GLAND BIOL, V8, P205, DOI 10.1023/A:1025952924864; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Dong CK, 2005, CRIT REV ONCOL HEMAT, V54, P85, DOI 10.1016/j.critrevonc.2004.12.005; Dong ZG, 2003, MUTAT RES-FUND MOL M, V523, P145, DOI 10.1016/S0027-5107(02)00330-5; Fridriksdottir AJR, 2005, J MAMMARY GLAND BIOL, V10, P61, DOI 10.1007/s10911-005-2541-6; Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111; Hahn WC, 2004, CANCER CELL, V6, P215, DOI 10.1016/j.ccr.2004.09.007; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lanzilli G, 2006, INT J ONCOL, V28, P641; Le Corre L, 2005, MOL NUTR FOOD RES, V49, P462, DOI 10.1002/mnfr.200400094; Lebeau J, 2002, ANTICANCER RES, V22, P2161; Leonhardt SA, 2002, EXP BIOL MED, V227, P969, DOI 10.1177/153537020222701104; Leslie KK, 2005, GYNECOL ONCOL, V96, P32, DOI 10.1016/j.ygyno.2004.09.057; Li XT, 2003, J BIOL CHEM, V278, P39261, DOI 10.1074/jbc.R300024200; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Masutomi K, 2003, CANCER LETT, V194, P163, DOI 10.1016/S0304-3835(02)00703-6; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Miloso M, 1999, NEUROSCI LETT, V264, P141, DOI 10.1016/S0304-3940(99)00194-9; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Petersen OW, 2003, CELL PROLIFERAT, V36, P33, DOI 10.1046/j.1365-2184.36.s.1.4.x; Rambhatla L., 2001, J BIOMED BIOTECHNOL, V1, P28, DOI DOI 10.1155/S1110724301000079; Saeki Y, 1997, J MOL MED-JMM, V75, P50, DOI 10.1007/s001090050086; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; Sun W, 1999, CANCER RES, V59, P6118; Tabata Y, 2002, J STEROID BIOCHEM, V82, P217, DOI 10.1016/S0960-0760(02)00157-7; Tanaka M, 1998, AM J PATHOL, V153, P1985, DOI 10.1016/S0002-9440(10)65712-4; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Wang Z, 2000, CANCER RES, V60, P5376; Williams CD, 2001, J CLIN ENDOCR METAB, V86, P3912, DOI 10.1210/jc.86.8.3912; Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X; Yu CC, 2001, BIOCHEM J, V355, P459, DOI 10.1042/0264-6021:3550459; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	47	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2365	2374		10.1038/sj.onc.1210886	http://dx.doi.org/10.1038/sj.onc.1210886			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968319	Green Accepted			2022-12-28	WOS:000254844900001
J	Wiencke, JK; Zheng, S; Morrison, Z; Yeh, RF				Wiencke, J. K.; Zheng, S.; Morrison, Z.; Yeh, R-F			Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells	ONCOGENE			English	Article						chromatin immunoprecipitation; histone methylation; histone acetylation; tiling array; homeobox; histone code	MAMMALIAN CHROMATIN; METHYLATION PATTERNS; DNA METHYLATION; STEM-CELLS; OTX2; H3; TRANSCRIPTION; LEUKEMIA; BRAIN; MEDULLOBLASTOMAS	Histone H3 lysine 9 trimethylation ( H3K9Me3) has been associated with transcriptional repression, but recent findings implicate this chromatin modi. cation in transcriptional activation and mRNA elongation by RNA polymerase II. Here, we applied immunoprecipitation ( IP) with a custom DNA tiling microarray containing many transcription factors important in development and cancer ( for example homeotic genes; N 683 total genes) to explore the relationship between H3K9Me3 and other histone modi. cations with the differential expression of genes. Cancer cell lines derived from different tissues ( 2 leukemia, 2 medulloblastoma) were characterized with IP antibodies to H3K9Me3, H3K4 dimethylation ( H3K4Me2) and H3K9 acetylation ( H3K9Ac). MV4- 11 is known to over-express the HOXA9 and MEIS1 genes, whereas D283 overexpresses the OTX2 homeobox gene. Gene expression was assessed by Affymetrix U133 array. Mapping the number and size of histone markings demonstrated significant colocalization of H3K9Ac and H3K4Me2 with H3K9Me3, indicating a pattern of putative 'activating' and 'repressive' markings. The median site size was 600 - 821 bp and 72 - 95% or 53 - 80% of chromatin signal sites were located within 1 kb or 500 bp of transcription start sites ( TSS), respectively. A relatively small number of genes displayed additional H3K9Me3 sites in the 50- region distant from the TSS. Comparing genes with modi. cation sites to those without sites in their promoters confirmed the positive associations of H3K9Ac and H3K4Me2 with gene expression and revealed that H3K9Me3 is associated with active genes rather than being a repressive marking as previously thought. The positive regulatory effect of all three types of modi. cations were quantitatively correlated with site size, and applied to absolute gene expression within a single cell line as well as relative expression among pairs of cell lines. Extended patterns of H3K9Me3 upstream of some genes ( for example HOXA9 and OTX2) may result from the action of multiple promoter elements. We found an inverse relationship between promoter DNA hypermethylation and H3K9Me3 in three studied genes ( HOXA9, TMS1, RASSF1A). The localization of H3K9Me3 downstream of the TSSs of expressed genes and not within promoter regions of hypermethylated and silenced genes is consistent with the proposed coupling of H3K9Me3 with RNA polymerase II. Our results indicate a need for revising aspects of the histone code involving H3 lysine methylation. Awareness of H3K9Me3 as a mark of gene activity, not repression, is especially important for the classification of human cancer using chromatin and histone profiles.	[Wiencke, J. K.; Zheng, S.; Morrison, Z.] Univ Calif San Francisco, Dept Neurol Surg, Lab Neuro & Mol Epidemiol Ambulatory Care, San Francisco, CA 94143 USA; [Yeh, R-F] Univ Calif San Francisco, Dept Epidemiol & Biostat, Ctr Bioinformat & Mol Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wiencke, JK (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Lab Neuro & Mol Epidemiol Ambulatory Care, AC-34,1 Irving St,Box 441, San Francisco, CA 94143 USA.	john.wiencke@ucsf.edu		Morrison, Zachary/0000-0001-9282-7248	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, R01ES006717] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06717, ES000002] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Acampora D, 2005, BRAIN RES BULL, V66, P410, DOI 10.1016/j.brainresbull.2005.02.005; Annabi B, 2005, J NEUROCHEM, V94, P906, DOI 10.1111/j.1471-4159.2005.03256.x; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Arslan MA, 2006, CURR CANCER DRUG TAR, V6, P623, DOI 10.2174/156800906778742479; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Boon K, 2005, CANCER RES, V65, P703; Boon K, 2003, ONCOGENE, V22, P7687, DOI 10.1038/sj.onc.1207043; Canaani E, 2004, BRIT J CANCER, V90, P756, DOI 10.1038/sj.bjc.6601639; Chomez P, 2001, CANCER RES, V61, P5544; de Haas T, 2006, J NEUROPATH EXP NEUR, V65, P176, DOI 10.1097/01.jnen.0000199576.70923.8a; Eissenberg JC, 2006, CURR OPIN GENET DEV, V16, P184, DOI 10.1016/j.gde.2006.02.004; Fossat N, 2005, DEV DYNAM, V233, P154, DOI 10.1002/dvdy.20287; Gregory RI, 2004, TRENDS CELL BIOL, V14, P695, DOI 10.1016/j.tcb.2004.10.002; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Kimura J, 2005, J NEUROSCI, V25, P5097, DOI 10.1523/JNEUROSCI.0239-05.2005; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383; Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005; Milne TA, 2005, CANCER RES, V65, P11367, DOI 10.1158/0008-5472.CAN-05-1041; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Nguyen CT, 2002, CANCER RES, V62, P6456; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Rath MF, 2006, J NEUROCHEM, V97, P556, DOI 10.1111/j.1471-4159.2006.03773.x; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Roh TY, 2006, P NATL ACAD SCI USA, V103, P15782, DOI 10.1073/pnas.0607617103; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tijink BM, 2006, CLIN CANCER RES, V12, P6064, DOI 10.1158/1078-0432.CCR-06-0910; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Vernay B, 2005, J NEUROSCI, V25, P4856, DOI 10.1523/JNEUROSCI.5158-04.2005; Wu R, 2005, MOL BIOL CELL, V16, P2872, DOI 10.1091/mbc.e04-11-0997; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Zhao W, 2005, J BIOCHEM, V137, P431, DOI 10.1093/jb/mvi048	42	74	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2412	2421		10.1038/sj.onc.1210895	http://dx.doi.org/10.1038/sj.onc.1210895			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968314				2022-12-28	WOS:000254844900006
J	Asangani, IA; Rasheed, SAK; Nikolova, DA; Leupold, JH; Colburn, NH; Post, S; Allgayer, H				Asangani, I. A.; Rasheed, S. A. K.; Nikolova, D. A.; Leupold, J. H.; Colburn, N. H.; Post, S.; Allgayer, H.			MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer	ONCOGENE			English	Article						pdcd4; miR-21; post-transcriptional regulation; invasion; CAM assay	GENE-EXPRESSION; MICRO-RNA; TRANSFORMATION; TRANSLATION; CELLS; INHIBITION; INITIATION; GROWTH; MA-3	Tumor-suppressor Pdcd4 inhibits transformation and invasion and is downregulated in cancers. So far, it has not been studied as to whether miRNAs, suppressing target expression by binding to the 3'-UTR, regulate Pdcd4 or invasion. The present study was conducted to investigate the regulation of Pdcd4, and invasion/intravasation, by miRNAs. A bioinformatics search revealed a conserved target-site for miR-21 within the Pdcd4-3'UTR at 228-249 nt. In 10 colorectal cell lines, an inverse correlation of miR-21 and Pdcd4-protein was observed. Transfection of Colo206f-cells with miR-21 significantly suppressed a luciferase-reporter containing the Pdcd4-3'-UTR, whereas transfection of RKO with anti-miR-21 increased activity of this construct. This was abolished when a construct mutated at the miR-21/nt228-249 target site was used instead. Anti-miR-21-transfected RKO cells showed an increase of Pdcd4-protein and reduced invasion. Moreover, these cells showed reduced intra-vasation and lung metastasis in a chicken-embryo-metastasis assay. In contrast, overexpression of miR-21 in Colo206f significantly reduced Pdcd4-protein amounts and increased invasion, while Pdcd4-mRNA was unaltered. Resected normal/tumor tissues of 22 colorectal cancer patients demonstrated an inverse correlation between miR-21 and Pdcd4-protein. This is the first study to show that Pdcd4 is negatively regulated by miR-21. Furthermore, it is the first report to demonstrate that miR-21 induces invasion/intravasation/metastasis.	[Asangani, I. A.; Rasheed, S. A. K.; Nikolova, D. A.; Leupold, J. H.; Allgayer, H.] Heidelberg Univ, Med Fac Mannheim, Dept Expt Surg & Mol Oncol Solid Tumors, Collaborat Unit,German Canc Res Ctr, D-68167 Mannheim, Germany; [Asangani, I. A.; Rasheed, S. A. K.; Nikolova, D. A.; Leupold, J. H.; Allgayer, H.] DKFZ Heidelberg, Mannheim, Germany; [Colburn, N. H.] NCI, Basic Res Lab, Gene Regulat Sect, Frederick, MD 21701 USA; [Post, S.] Heidelberg Univ, Med Fac Mannheim, Dept Surg, D-6800 Mannheim, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ruprecht Karls University Heidelberg	Allgayer, H (corresponding author), Heidelberg Univ, Med Fac Mannheim, Dept Expt Surg & Mol Oncol Solid Tumors, Collaborat Unit,German Canc Res Ctr, D-68167 Mannheim, Germany.	heike.allgayer@chir.ma.uni-heidelberg.de	Vickers, Michael M/E-4095-2010; Rasheed, Suhail Ahmed Kabeer/P-1257-2019	Rasheed, Suhail Ahmed Kabeer/0000-0002-7674-7560; asangani, irfan/0000-0001-5381-1702	NATIONAL CANCER INSTITUTE [ZIABC010026, Z01BC010026] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Goke R, 2004, ANN NY ACAD SCI, V1014, P220, DOI 10.1196/annals.1294.024; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; Lankat-Buttgereit B, 2004, MOL CELL ENDOCRINOL, V214, P149, DOI 10.1016/j.mce.2003.10.058; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200; Zijlstra A, 2002, CANCER RES, V62, P7083	39	1492	1621	6	205	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2128	2136		10.1038/sj.onc.1210856	http://dx.doi.org/10.1038/sj.onc.1210856			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17968323				2022-12-28	WOS:000254621300003
J	Denley, A; Kang, S; Karst, U; Vogt, PK				Denley, A.; Kang, S.; Karst, U.; Vogt, P. K.			Oncogenic signaling of class IPI3K isoforms	ONCOGENE			English	Article						PI3K; oncogenic transformation; signaling; Ras; MEK; inhibitor	ACUTE MYELOID-LEUKEMIA; PHOSPHOINOSITIDE 3-KINASE INHIBITORS; CATALYTIC SUBUNIT; CELL-PROLIFERATION; PI 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASES; MEDIATED PHOSPHORYLATION; PROTEASOMAL DEGRADATION; TRANSCRIPTION FACTOR; EMBRYONIC LETHALITY	The catalytic subunits of class I PI3Ks comprise four isoforms: p110 alpha, p110 beta, p110 delta and p110 gamma. Cancer-specific gain-of-function mutations in p110 alpha delta beta have been identified in various malignancies. Cancer-specific mutations in the non-alpha isoforms of class I PI3K have not yet been identified, however overexpression of either wild-type p110 beta, p110 gamma or p110 delta is sufficient to induce cellular transformation in chicken embryo fibroblasts. The mechanism whereby these non-a isoforms of class I mediate oncogenic signals is unknown. Here we show that potently transforming class I isoforms signal via Akt/mTOR, inhibit GSK3 beta and cause degradation of FoxO1. A functional Erk pathway is required for p110 gamma and p110 beta transformation but not for transformation by p110 delta or the H1047R mutant of p110 alpha. Transformation and signaling by p110 gamma and p110 beta are sensitive to loss of interaction with Ras, which acts as a membrane anchor. Mutations in the C2 domain of p110 delta reduce transformation, most likely by interfering with membrane association. Several small molecule inhibitors potently and specifically inhibit the oncogenic signaling and transformation of each of the class I PI3K, and, when used in combination with MEK inhibitors, can additively reduce the transformation induced by p110 beta and p110 gamma.	[Denley, A.; Kang, S.; Karst, U.; Vogt, P. K.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,BCC-239, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; Barber DF, 2005, NAT MED, V11, P933, DOI 10.1038/nm1291; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Billottet C, 2006, ONCOGENE, V25, P6648, DOI 10.1038/sj.onc.1209670; Blalock WL, 2003, LEUKEMIA, V17, P1058, DOI 10.1038/sj.leu.2402925; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bony C, 2001, J CELL BIOL, V152, P717, DOI 10.1083/jcb.152.4.717; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Dong JJ, 2005, CANCER RES, V65, P1961, DOI 10.1158/0008-5472.CAN-04-2501; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fan QW, 2006, CELL CYCLE, V5, P2301, DOI 10.4161/cc.5.20.3362; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hickey FB, 2006, J BIOL CHEM, V281, P2441, DOI 10.1074/jbc.M511173200; HOOSHMANDRAD R, 2000, J CELL SCI, V3, pP110; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kharas MG, 2004, BLOOD, V103, P4268, DOI 10.1182/blood-2003-07-2193; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kubota Y, 2004, LEUKEMIA, V18, P1438, DOI 10.1038/sj.leu.2403402; Leverrier Y, 2003, J BIOL CHEM, V278, P38437, DOI 10.1074/jbc.M306649200; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; McCubrey JA, 2001, CANCER DETECT PREV, V25, P375; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Okkenhaug K, 2002, SCIENCE, V297, P1031; Orme MH, 2006, NAT CELL BIOL, V8, P1298, DOI 10.1038/ncb1493; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; SKORSKI T, 1995, CANCER RES, V55, P2275; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Suire S, 2006, NAT CELL BIOL, V8, P1303, DOI 10.1038/ncb1494; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vogt PK, 2006, CELL CYCLE, V5, P946, DOI 10.4161/cc.5.9.2725; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Ward S, 2003, CHEM BIOL, V10, P207, DOI 10.1016/S1074-5521(03)00048-6; Ward SG, 2003, CURR OPIN PHARMACOL, V3, P426, DOI 10.1016/S1471-4892(03)00078-X; Yip SC, 2004, CELL MOTIL CYTOSKEL, V59, P180, DOI 10.1002/cm.20032; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	75	89	91	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2561	2574		10.1038/sj.onc.1210918	http://dx.doi.org/10.1038/sj.onc.1210918			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17998941				2022-12-28	WOS:000255057000006
J	Mantovani, G; Bondioni, S; Lania, AG; Rodolfo, M; Peverelli, E; Polentarutti, N; Rodriguez, TV; Ferrero, S; Bosari, S; Beck-Peccoz, P; Spada, A				Mantovani, G.; Bondioni, S.; Lania, A. G.; Rodolfo, M.; Peverelli, E.; Polentarutti, N.; Rodriguez, T. Veliz; Ferrero, S.; Bosari, S.; Beck-Peccoz, P.; Spada, A.			High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells	ONCOGENE			English	Article						melanomas; PKA; cAMP; R1/R2 ratio; proliferation	HL-60 LEUKEMIA-CELLS; RII-BETA-SUBUNIT; KINASE-A; MALIGNANT-MELANOMA; ADENYLYL CYCLASE; MUTATIONS; GROWTH; ALPHA; CAMP; DIFFERENTIATION	The cAMP-protein kinase A (PKA) pathway is the major signal transduction pathway involved in melanocyte-stimulating hormone receptor-mediated signaling and melanin production, whereas its role in the control of melanocyte proliferation is still controversial. In this study, we evaluated the effects of selective activation of the different PKA regulatory subunits type 1A (R1A) and type 2B (R2B) on melanocyte proliferation. Immunohistochemistry demonstrated that normal melanocytes lacked R1A protein whereas this subunit was highly expressed in all human melanomas studied (N = 20) and in six human melanoma cell lines. Pharmacological activation of the R2 subunits by the cAMP analogue 8-Cl-cAMP inhibited proliferation and increased caspase-3 activity by 68.77 +/- 10.5 and 72 +/- 9% respectively, in all cell lines with the exception of the only p53-mutated one. Similar effects were obtained by activating R2 subunits with other analogues and by silencing R1A expression. The antiproliferative and proapoptotic effects of 8-Cl-cAMP were comparable to those observed with commonly used antitumoral drugs. Moreover, 8-Cl-cAMP potentiated the effects of these drugs on both cell proliferation and caspase-3 activity. In conclusion, this study first reports that human melanomas are characterized by a high R1/R2 ratio and that pharmacological and genetic manipulations able to revert this unbalanced expression cause significant antiproliferative and proapoptotic effects in melanoma cells.	[Mantovani, G.; Bondioni, S.; Lania, A. G.; Peverelli, E.; Beck-Peccoz, P.; Spada, A.] Univ Milan, Dept Med Sci, Endocrine Unit, Fdn Policlin Osped Maggiore IRCCS, I-20122 Milan, Italy; [Rodolfo, M.] Ist Nazl Studio & Cura Tumori, IRCCS, Unit Melanoma Genet, I-20133 Milan, Italy; [Polentarutti, N.; Rodriguez, T. Veliz] IRCCS, Ist Clin Humanitas, Dept Immunol & Inflammat, Milan, Italy; [Ferrero, S.; Bosari, S.] AO San Paolo, Dept Med Surg & Dent, Pathol Unit, Milan, Italy; [Ferrero, S.; Bosari, S.] Fdn Osped Maggiore, IRCCS, Milan, Italy	University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Humanitas Research Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico	Spada, A (corresponding author), Univ Milan, Dept Med Sci, Endocrine Unit, Fdn Policlin Osped Maggiore IRCCS, Via F Sforza 35, I-20122 Milan, Italy.	anna.spada@unimi.it	rodolfo, monica/H-2671-2012; lania, andrea/AAA-9020-2019; Bosari, Silvano/K-7744-2016; Mantovani, Giovanna/A-2378-2014	rodolfo, monica/0000-0002-9196-0298; lania, andrea/0000-0002-5380-2141; Bosari, Silvano/0000-0002-9744-6951; Mantovani, Giovanna/0000-0002-9065-3886; Peverelli, Erika/0000-0002-4424-7895	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Cho YS, 2000, P NATL ACAD SCI USA, V97, P835, DOI 10.1073/pnas.97.2.835; Cho-Chung YS, 2005, ANN NY ACAD SCI, V1058, P76, DOI 10.1196/annals.1359.014; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CHOCHUNG YS, 1995, CRIT REV ONCOL HEMAT, V21, P2133; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DELUCA M, 1993, J CELL SCI, V105, P1079; Di Stasi D, 2005, INT J CANCER, V115, P224, DOI 10.1002/ijc.20885; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; HANDSCHIN JC, 1979, FEBS LETT, V106, P301, DOI 10.1016/0014-5793(79)80519-0; HUNT G, 1994, PIGM CELL RES, V7, P217, DOI 10.1111/j.1600-0749.1994.tb00052.x; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lania A, 2001, EUR J ENDOCRINOL, V145, P543, DOI 10.1530/eje.0.1450543; Lania AG, 2004, CANCER RES, V64, P9193, DOI 10.1158/0008-5472.CAN-04-1847; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Nesterova M, 1996, EUR J BIOCHEM, V235, P486, DOI 10.1111/j.1432-1033.1996.00486.x; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; Schwede F, 2000, BIOCHEMISTRY-US, V39, P8803, DOI 10.1021/bi000304y; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; TORTORA G, 1990, P NATL ACAD SCI USA, V87, P705, DOI 10.1073/pnas.87.2.705; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403	25	40	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2008	27	13					1834	1843		10.1038/sj.onc.1210831	http://dx.doi.org/10.1038/sj.onc.1210831			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906691				2022-12-28	WOS:000254150600003
J	Saito, Y; Nakagami, H; Kurooka, M; Takami, Y; Kikuchi, Y; Hayashi, H; Nishikawa, T; Tamai, K; Morishita, R; Azuma, N; Sasajima, T; Kaneda, Y				Saito, Y.; Nakagami, H.; Kurooka, M.; Takami, Y.; Kikuchi, Y.; Hayashi, H.; Nishikawa, T.; Tamai, K.; Morishita, R.; Azuma, N.; Sasajima, T.; Kaneda, Y.			Cold shock domain protein A represses angiogenesis and lymphangiogenesis via inhibition of serum response element	ONCOGENE			English	Article						antiangiogenesis; antilymphangiogenesis; gene therapy; endothelial cell serum response element	GROWTH-FACTOR-C; AMELIORATES SECONDARY LYMPHEDEMA; SUPPRESSES TUMOR-GROWTH; GM-CSF PROMOTER; HEMAGGLUTINATING VIRUS; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; NODE METASTASIS; ENVELOPE VECTOR; FACTOR GENE	Dual-targeted therapy for antiangiogenesis and antilymphangiogenesis represents a potentially effective strategy for the treatment of various malignancies. Therefore, the goal of the present study was to identify genes that encode inhibitors of both angiogenesis and lymphangiogenesis. Using a cDNA library obtained from Lewis lung carcinoma (LL/2), a candidate gene was identified by the evaluation of growth inhibition in aortic and lymphatic endothelial cells (EC) as that coding for the mouse cold shock domain protein A (mCSDA). Overexpression of mCSDA significantly repressed cell proliferation and c-fos promoter activity in aortic, venous and lymphatic ECs. CSDA is a DNA-binding protein that binds to the hypoxia response element (HRE). Furthermore, of importance, we revealed that CSDA could directly bind to the serum response element (SRE) sequence, resulting in the inhibition of SRE activity, which may lead to growth inhibition in ECs. In an LL/2-inoculated mouse model, tumor growth was significantly repressed in an mCSDA-injected group. Histopathological analysis revealed that expression of blood and lymphatic EC markers was significantly decreased in mCSDA-injected groups. In conclusion, these data suggest that expression of CSDA can repress angiogenesis and lymphangiogenesis via direct binding to SRE in addition to HRE.	[Saito, Y.; Nakagami, H.; Kurooka, M.; Takami, Y.; Kikuchi, Y.; Hayashi, H.; Nishikawa, T.; Tamai, K.; Kaneda, Y.] Osaka Univ, Grad Sch Med, Div Gen Therapy Sci, Suita, Osaka 5650871, Japan; [Saito, Y.; Azuma, N.] Asahikawa Med Univ, Dept Surg, Hokkaido, Japan; [Morishita, R.] Osaka Univ, Grad Sch Med, Div Clin Gene Therapy, Osaka, Japan	Osaka University; Asahikawa Medical College; Osaka University	Kaneda, Y (corresponding author), Osaka Univ, Grad Sch Med, Div Gen Therapy Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kaneday@gts.med.osaka-u.ac.jp	Nakagami, Hironori/GLU-0570-2022	Nakagami, Hironori/0000-0003-4494-3601				Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; Coles LS, 1996, NUCLEIC ACIDS RES, V24, P2311, DOI 10.1093/nar/24.12.2311; Coles LS, 2002, NUCLEIC ACIDS RES, V30, P4845, DOI 10.1093/nar/gkf615; Diamond P, 2001, J BIOL CHEM, V276, P7943, DOI 10.1074/jbc.M009836200; Folkman J, 2006, EXP CELL RES, V312, P594, DOI 10.1016/j.yexcr.2005.11.015; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Kaneda Y, 2002, MOL THER, V6, P219, DOI 10.1006/mthe.2002.0647; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karpanen T, 2001, CANCER RES, V61, P1786; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kobori M, 1998, GENES CELLS, V3, P459, DOI 10.1046/j.1365-2443.1998.00202.x; KUDO S, 1995, EUR J BIOCHEM, V231, P72; LORD BI, 1988, J CELL SCI, P231; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Nakagami H, 2005, ARTERIOSCL THROM VAS, V25, P2542, DOI 10.1161/01.ATV.0000190701.92007.6d; Nakagami H, 2001, HYPERTENSION, V37, P581, DOI 10.1161/01.HYP.37.2.581; Niki T, 2000, CLIN CANCER RES, V6, P2431; Nishikawa T, 2006, HUM GENE THER, V17, P470, DOI 10.1089/hum.2006.17.470; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pepper MS, 2001, CLIN CANCER RES, V7, P462; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Rikitake Y, 2000, ARTERIOSCL THROM VAS, V20, P1006, DOI 10.1161/01.ATV.20.4.1006; Saito Y, 2006, CIRCULATION, V114, P1177, DOI 10.1161/CIRCULATIONAHA.105.602953; Shannon MF, 2001, J LEUKOCYTE BIOL, V69, P21; Shannon MF, 1997, CRIT REV IMMUNOL, V17, P301, DOI 10.1615/CritRevImmunol.v17.i3-4.30; Shimamura M, 2004, GENE THER, V11, P1532, DOI 10.1038/sj.gt.3302323; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2000, RECENT RESULTS CANC, V157, P55; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Sund M, 2005, P NATL ACAD SCI USA, V102, P2934, DOI 10.1073/pnas.0500180102; Taniyama Y, 2001, GENE THER, V8, P181, DOI 10.1038/sj.gt.3301379; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	43	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1821	1833		10.1038/sj.onc.1210824	http://dx.doi.org/10.1038/sj.onc.1210824			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17934523				2022-12-28	WOS:000254150600002
J	Rashmi, R; Pillai, SG; Vijayalingam, S; Ryerse, J; Chinnadurai, G				Rashmi, R.; Pillai, S. G.; Vijayalingam, S.; Ryerse, J.; Chinnadurai, G.			BH3-only protein BIK induces caspase-independent cell death with autophagic features in Bcl-2 null cells	ONCOGENE			English	Article						BIK; Bcl-2; autophagy; Beclin-1; LC3	MALIGNANT GLIOMA-CELLS; FAMILY PROTEINS; DOWN-REGULATION; CANCER-CELLS; APOPTOSIS; BAX; EXPRESSION; SURVIVAL; REQUIREMENT; INDUCTION	The BH3-only protein BIK normally induces apoptotic cell death. Here, we have investigated the role of BCL-2 in BIK-induced cell death using Bcl-2(+/+) and Bcl-2(-/-) mouse embryo fibroblasts. Ectopic expression of BIK in Bcl-2(-/-) cells resulted in enhanced cell death compared to Bcl-2(-/-) cells. In these cells, while caspase-8 was activated, there was no significant activation of caspase-9 and 3. There was no detectable mitochondrial to cytosolic release of cytochrome-c. However, there was significant redistribution of AIF from mitochondria to the nucleus. The extent of BIK-induced cell death was augmented by treatment with the pancaspase inhibitor, zVAD-fmk. The Bcl- 2 null cells expressingB IK exhibited autophagic features such as cytosolic vacuoles, punctate distribution of LC3 and enhanced expression of Beclin-1. The survival of BIK-expressing Bcl-2(-/-) cells was enhanced in the presence of PI3 kinase inhibitors 3-methyladenine and Wortmannin and also by depletion of Atg5 and Beclin-1. Death of BIK-expressing Bcl-2(-/-) cells treated with zVAD-fmk was increased under caspase-8 depletion. Our results suggest enhanced expression of BIK in the Bcl- 2 deficient cells leads to cell death with autophagic features and the extent of such cell death could be increased by inhibition of caspases.	[Rashmi, R.; Pillai, S. G.; Vijayalingam, S.; Chinnadurai, G.] St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA; [Ryerse, J.] St Louis Univ, Hlth Sci Ctr, Dept Pathol, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu	Pillai, Sreeraj G/M-2369-2013; Pillai, Rashmi Ramachandran/B-8130-2012	Pillai, Sreeraj G/0000-0002-0285-0813; Pillai, Rashmi Ramachandran/0000-0002-1619-7763	NATIONAL CANCER INSTITUTE [R01CA033616, R01CA073803, R21CA116262] Funding Source: NIH RePORTER; NCI NIH HHS [CA-73803, CA-116262, R01 CA033616-27, R21 CA116262-01, R21 CA116262, R01 CA033616, R01 CA073803, R01 CA073803-08, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; BOYD JM, 1995, ONCOGENE, V11, P1921; Dai ZY, 2006, BIOCHEM BIOPH RES CO, V351, P455, DOI 10.1016/j.bbrc.2006.10.055; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Garcia N, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-93; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Naumann U, 2003, HUM GENE THER, V14, P1235, DOI 10.1089/104303403767740777; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Oppermann M, 2005, ONCOGENE, V24, P7369, DOI 10.1038/sj.onc.1208890; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025; Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Theodorakis P, 2002, CANCER RES, V62, P3373; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200; Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	31	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1366	1375		10.1038/sj.onc.1210783	http://dx.doi.org/10.1038/sj.onc.1210783			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17873911	Green Accepted			2022-12-28	WOS:000253548200003
J	Stevens, FE; Beamish, H; Warrener, R; Gabrielli, B				Stevens, F. E.; Beamish, H.; Warrener, R.; Gabrielli, B.			Histone deacetylase inhibitors induce mitotic slippage	ONCOGENE			English	Article						HDACi; centromere; mitosis; aurora B	CHROMOSOMAL PASSENGER COMPLEX; CENTROMERE PROTEIN INCENP; AURORA-B; SPINDLE CHECKPOINT; CENP-E; MICROTUBULE-ATTACHMENT; TUMOR-CELLS; SURVIVIN; MITOSIS; PHOSPHORYLATION	Chromosomal passenger proteins have emerged as key players in the regulation of mitosis and cytokinesis. Histone deacetylase inhibitors (HDACi) are a class of anticancer drugs that induce aberrant mitosis and can overcome the spindle assembly checkpoint. Here, we investigate the mechanism by which HDACi disrupt normal mitotic progression and checkpoint function. We demonstrate that HDACi treatment temporarily delays mitotic progression through prometaphase due to activation of the spindle assembly checkpoint. Despite failing to congress chromosomes to the metaphase plate, cells aberrantly segregate their chromosomes and exit mitosis to undergo a failed cytokinesis. We show that this premature exit from mitosis is a form of mitotic slippage. Chromosomal passenger proteins fail to accumulate at the centromere following HDACi treatment. This results in inadequate concentrations of chromosomal passenger proteins at the centromere, which are insufficient to regulate the phosphorylation of the kinetochore checkpoint component BubR1, and an inability to maintain the mitotic arrest. Thus, the centromeric accumulation of chromosomal passenger complex components is critical for regulating kinetochore but not centromeric processes, and failure of this accumulation underlies the HDACi-induced mitotic slippage.	[Stevens, F. E.; Beamish, H.; Warrener, R.; Gabrielli, B.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Res Immunol & Metab Med, Canc Biol Program, Brisbane, Qld 4102, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Res Immunol & Metab Med, Canc Biol Program, Brisbane, Qld 4102, Australia.	brianG@uq.edu.au	Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651; Stevens, Frankie/0000-0002-2556-473X				Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Aoyagi S, 2005, TRENDS CELL BIOL, V15, P565, DOI 10.1016/j.tcb.2005.09.003; Beardmore VA, 2004, J CELL SCI, V117, P4033, DOI 10.1242/jcs.01242; Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Delacour-Larose M, 2004, CELL CYCLE, V3, P1418, DOI 10.4161/cc.3.11.1203; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dowling M, 2005, CANCER BIOL THER, V4, P197, DOI 10.4161/cbt.4.2.1441; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kelly AE, 2007, DEV CELL, V12, P31, DOI 10.1016/j.devcel.2006.11.001; Klein UR, 2006, MOL BIOL CELL, V17, P2547, DOI 10.1091/mbc.E05-12-1133; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; Mao YH, 2005, J CELL BIOL, V170, P873, DOI 10.1083/jcb.200505040; Mollinari C, 2003, DEV CELL, V5, P295, DOI 10.1016/S1534-5807(03)00205-3; Morrow CJ, 2005, J CELL SCI, V118, P3639, DOI 10.1242/jcs.02487; Murata-Hori M, 2002, J CELL BIOL, V159, P45, DOI 10.1083/jcb.200207014; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Robbins AR, 2005, CELL CYCLE, V4, P717, DOI 10.4161/cc.4.5.1690; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Vagnarelli P, 2004, CHROMOSOMA, V113, P211, DOI 10.1007/s00412-004-0307-3; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X	38	71	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1345	1354		10.1038/sj.onc.1210779	http://dx.doi.org/10.1038/sj.onc.1210779			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828304				2022-12-28	WOS:000253548200001
J	Cheng, Z; Ke, Y; Ding, X; Wang, F; Wang, H; Ahmed, K; Liu, Z; Xu, Y; Aikhionbare, F; Yan, H; Liu, J; Xue, Y; Powell, M; Liang, S; Reddy, SE; Hu, R; Huang, H; Jin, C; Yao, X				Cheng, Z.; Ke, Y.; Ding, X.; Wang, F.; Wang, H.; Ahmed, K.; Liu, Z.; Xu, Y.; Aikhionbare, F.; Yan, H.; Liu, J.; Xue, Y.; Powell, M.; Liang, S.; Reddy, S. E.; Hu, R.; Huang, H.; Jin, C.; Yao, X.			Functional characterization of TIP60 sumoylation in UV-irradiated DNA damage response	ONCOGENE			English	Article						UV irradiation; DNA damage; TIP60; sumoylation; p53	HISTONE ACETYLTRANSFERASE; PROTEIN; P53; ACETYLATION; NUCLEAR; REPAIR	The histone acetyltransferase TIP60 regulates the DNA damage response following genotoxic stress by acetylating histone and remodeling chromatin. However, the molecular mechanisms underlying the TIP60-dependent response to UV-induced DNA damage remain poorly understood. To systematically analyse proteins that regulate TIP60 activity in response to UVirradiation, we performed a proteomic analysis of proteins selectively bound to TIP60 in response to UVirradiation using mass spectrometry and identified a novel regulatory mechanism by which TIP60 orchestrates transcriptional activation of p53-dependent checkpoint response in UV-irradiated cells. The initial step of this pathway involves UV-induced association of TIP60 with SUMO-conjugation enzymes and site-specific sumoylation of TIP60 at lysines 430 and 451 via Ubc9. This sumoylation initiates the relocation of TIP60 from nucleoplasm to the promyelocytic leukemia body, which is essential for the UV-irradiated DNA damage repair response via a p53-dependent pathway. Significantly, inhibition of TIP60 sumoylation by overexpression of non-sumoylatable mutant abrogates the p53-dependent DNA damage response, demonstrating the importance of TIP60 sumoylation in response to UV irradiation. Our biochemical characterization demonstrated that the sumoylation of TIP60 augments its acetyltransferase activity in vitro and in vivo. Thus, this study shed new light on the function and regulation of TIP60 activity in UV-irradiated DNA damage response.	[Cheng, Z.; Ke, Y.; Wang, F.; Wang, H.; Ahmed, K.; Liu, Z.; Yan, H.; Liu, J.; Jin, C.; Yao, X.] Hefei Natl Lab, Hefei, Peoples R China; [Ding, X.; Wang, F.; Aikhionbare, F.; Powell, M.; Reddy, S. E.] Morehouse Sch Med, Canc Biol Program, Atlanta, GA 30310 USA; [Ding, X.; Yao, X.] Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China; [Xu, Y.; Huang, H.] Zhejiang Univ, Dept Hematol, Hangzhou, Peoples R China; [Liang, S.] Hunan Normal Univ, Lab Protein chem, Changsha, Peoples R China; [Hu, R.] Fudan Univ, Dept Endocrinol, Shanghai 200433, Peoples R China	Morehouse School of Medicine; Beijing University of Chinese Medicine; Zhejiang University; Hunan Normal University; Fudan University	Yao, X (corresponding author), Univ Sci & Technol China, Lab Cell Dynam, Hefei 230026, Peoples R China.	yaoxb@ustc.edu.cn	Xue, Yu/G-5929-2011	Xue, Yu/0000-0002-9403-6869; Wang, Hongmei/0000-0002-5881-2488	NCRR NIH HHS [G-12-RR03034] Funding Source: Medline; NIDDK NIH HHS [DK56292] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Fang ZY, 2006, MOL CELL PROTEOMICS, V5, P1718; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fu CH, 2005, ONCOGENE, V24, P5401, DOI 10.1038/sj.onc.1208714; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SHELTER P, 2003, NATURE, V425, P188; Shieh SY, 2000, GENE DEV, V14, P289; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Zhou FF, 2005, FEBS LETT, V579, P3369, DOI 10.1016/j.febslet.2005.04.076	22	50	55	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					931	941		10.1038/sj.onc.1210710	http://dx.doi.org/10.1038/sj.onc.1210710			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17704809				2022-12-28	WOS:000252946300005
J	Peng, ZG; Zhou, MY; Huang, Y; Qiu, JH; Wang, LS; Liao, SH; Dong, S; Chen, GQ				Peng, Z. G.; Zhou, M. Y.; Huang, Y.; Qiu, J. H.; Wang, L. S.; Liao, S. H.; Dong, S.; Chen, G. Q.			Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1 alpha	ONCOGENE			English	Article						hypoxia-inducible factor-1 alpha (HIF-1 alpha); runt-related protein 1 (Runx1); protein-protein interaction; angiogenesis	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; LEUKEMIC-CELL DIFFERENTIATION; STIMULATING FACTOR-RECEPTOR; FUSION PROTEIN; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; OXYGEN-TENSION; ANGIOGENESIS; ALPHA; HEMATOPOIESIS	Angiogenesis and hematopoiesis are closely linked and interactive with each other, but few studies were given to identify possible links between angiogenesis-promoting proteins and hematopoiesis-related transcription factors. Here we investigated the potential relationship of oxygen-sensitive alpha-subunit of angiogenesis-related hypoxia-inducible factor-1 alpha (HIF-1 alpha) with Runt-related protein 1 (Runx1, also known as acute myeloid leukemia-1, AML-1), an important hematopoietic transcription factor. The results demonstrated that Runx1 and HIF-1 alpha proteins directly interacted with each other to a degree, in which Runt homology domain of Runx1 was mainly involved. Leukemia-related abnormal Runx1 fusion protein AML1-ETO, which fuses the N-terminal 177 amino acid residues of the Runx1 protein in frame to ETO (eight-twenty-one) protein, also interacted with HIF-1 alpha protein with greater ability than Runx1 itself. More intriguingly, Runx1 overexpression inhibited DNA-binding and transcriptional activity of HIF-1 protein with reduced expression of HIF-1-targeted genes such as vascular endothelial growth factor, while silence of Runx1 expression by specific small interfering RNA significantly increased transcriptional activity of HIF-1 protein, suggesting that Runx1 inhibited transcription-dependent function of HIF-1. Vice versa, HIF-1 alpha increased DNA-binding ability and transcriptional activity of Runx1 protein. All these data would shed new insight to understanding Runx1 and HIF-1 alpha-related hematopoietic cell differentiation and angiogenesis.	[Peng, Z. G.; Zhou, M. Y.; Liao, S. H.; Chen, G. Q.] Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Dept Pathophysiol, Shanghai Inst Biol Sci,Inst Hlth Sci, Shanghai 200025, Peoples R China; [Huang, Y.; Wang, L. S.; Chen, G. Q.] SJTU SM, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Dept Pathophysiol, Shanghai, Peoples R China; [Huang, Y.; Qiu, J. H.; Dong, S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Baylor College of Medicine	Chen, GQ (corresponding author), Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Dept Pathophysiol, Shanghai Inst Biol Sci,Inst Hlth Sci, 280 Chong Qing S Rd, Shanghai 200025, Peoples R China.	chengq@shsmu.edu.cn						Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Alberghini A, 2005, J BIOL CHEM, V280, P30120, DOI 10.1074/jbc.M500971200; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Desplat V, 2002, STEM CELLS, V20, P347, DOI 10.1634/stemcells.20-4-347; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Huang Y, 2003, LEUKEMIA, V17, P2065, DOI 10.1038/sj.leu.2403141; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Kilic M, 2007, ONCOGENE, V26, P2027, DOI 10.1038/sj.onc.1210008; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Kurokawa M, 2003, CANCER SCI, V94, P841, DOI 10.1111/j.1349-7006.2003.tb01364.x; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; Liu W, 2006, BLOOD, V107, P698, DOI 10.1182/blood-2005-03-1278; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Nguyen-Khac F, 2006, ONCOGENE, V25, P4840, DOI 10.1038/sj.onc.1209503; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; SONG LP, 2007, IN PRESS ONCOGENE; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Suda T, 2000, INT J HEMATOL, V71, P99; Werner MH, 1999, NAT MED, V5, P1356, DOI 10.1038/70920; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630	37	36	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					839	847		10.1038/sj.onc.1210676	http://dx.doi.org/10.1038/sj.onc.1210676			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17684492				2022-12-28	WOS:000252884500013
J	Liu, S; Vinall, RL; Tepper, C; Shi, XB; Xue, LR; Ma, AH; Wang, LY; Fitzgerald, LD; Wu, Z; Gandour-Edwards, R; White, RWD; Kung, HJ				Liu, S.; Vinall, R. L.; Tepper, C.; Shi, X-B; Xue, L. R.; Ma, A-H; Wang, L-Y; Fitzgerald, L. D.; Wu, Z.; Gandour-Edwards, R.; White, R. W. deVere; Kung, H-J			Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway	ONCOGENE			English	Article						H2-relaxin; GPCR; beta-catenin; Wnt; androgen receptor; prostate cancer	PROSTATE-CANCER CELLS; GLYCOGEN-SYNTHASE KINASE-3; INDEPENDENT GROWTH; NEUROENDOCRINE DIFFERENTIATION; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; COLON-CANCER; H2 RELAXIN; WNT; EXPRESSION	We have previously demonstrated that human H2-relaxin can mediate androgen-independent growth of LNCaP through a mechanism that involves the activation of the androgen receptor (AR) signaling pathway. The goal of the current study is to elucidate the mechanism(s) by which H2-relaxin causes activation of the AR pathway. Our data indicate that there is cross-talk between AR and components of the Wnt signaling pathway. Addition of H2-relaxin to LNCaP cells resulted in increased phosphorylation of protein kinase B (Akt) and inhibitory phosphorylation of glycogen synthase kinase-3 beta (GSK-3 beta) with subsequent cytoplasmic accumulation of beta-catenin. Immunoprecipitation and immunocytochemical studies demonstrated that the stabilized b-catenin formed a complex with AR, which was then translocated into the nucleus. Chromatin immunoprecipitation analysis determined that the AR/beta-catenin complex binds to the proximal region of the prostate-specific antigen promoter. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3b and translocation of beta-catenin/AR into the nucleus. Knockdown of beta-catenin levels using a beta-cateninspecific small interfering RNA inhibited H2-relaxin-induced AR activity. The combined data demonstrate that PI3K/Akt and components of the Wnt pathway can facilitate H2-relaxin-mediated activation of the AR pathway.	[Liu, S.; Vinall, R. L.; Tepper, C.; Shi, X-B; Xue, L. R.; Ma, A-H; Wang, L-Y; Fitzgerald, L. D.; Wu, Z.; Gandour-Edwards, R.; White, R. W. deVere; Kung, H-J] Univ Calif, Ctr Canc, Sacramento, CA USA; [Liu, S.; Tepper, C.; Ma, A-H; Wang, L-Y; Fitzgerald, L. D.; Wu, Z.; Kung, H-J] Univ Calif, Sch Med, Dept Biochem & Mol Med, Sacramento, CA USA; [Vinall, R. L.; Shi, X-B; Xue, L. R.; White, R. W. deVere] Univ Calif, Sch Med, Dept Urol, Sacramento, CA USA; [Gandour-Edwards, R.] Univ Calif, Sch Med, Dept Pathol, Sacramento, CA USA		White, RWD (corresponding author), Univ Calif Davis, Ctr Canc, UCDMC, Res 3,4645,2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013; Vinall, Ruth/L-7026-2019	Wang, Ling-Yu/0000-0002-1413-817X				Bartsch O, 2001, MOL HUM REPROD, V7, P799, DOI 10.1093/molehr/7.9.799; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cronauer MV, 2005, INT J ONCOL, V26, P1033; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Desai SJ, 2006, CANCER RES, V66, P10449, DOI 10.1158/0008-5472.CAN-06-2582; DESANTAGNESE P, 1996, CANCER, V78, P357; Dessauer CW, 2005, ANN NY ACAD SCI, V1041, P272, DOI 10.1196/annals.1282.040; DINJENS WNM, 1994, INT J CANCER, V56, P630, DOI 10.1002/ijc.2910560504; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Figueiredo KA, 2005, ANN NY ACAD SCI, V1041, P320, DOI 10.1196/annals.1282.051; Halls ML, 2005, ANN NY ACAD SCI, V1041, P288, DOI 10.1196/annals.1282.042; Halls ML, 2005, ANN NY ACAD SCI, V1041, P292, DOI 10.1196/annals.1282.043; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Huss WJ, 2004, PROSTATE, V60, P91, DOI 10.1002/pros.20032; Ivell R, 2002, SCIENCE, V295, P637, DOI 10.1126/science.1069234; Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344; Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Nguyen BT, 2003, MOL ENDOCRINOL, V17, P1075, DOI 10.1210/me.2002-0284; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Palejwala S, 1998, ENDOCRINOLOGY, V139, P1208, DOI 10.1210/en.139.3.1208; Pang S, 1997, CANCER RES, V57, P495; Polakis P, 2000, GENE DEV, V14, P1837; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Shi XB, 2004, BJU INT, V94, P996, DOI 10.1111/j.1464-410X.2004.05093.x; Silvertown JD, 2003, ENDOCRINOLOGY, V144, P3683, DOI 10.1210/en.2003-0248; Song SY, 2004, J CLIN GASTROENTEROL, V38, P252, DOI 10.1097/00004836-200403000-00011; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Truica CI, 2000, CANCER RES, V60, P4709; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Vinall RL, 2006, ONCOGENE, V25, P2082, DOI 10.1038/sj.onc.1209246; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yang X, 2006, ONCOGENE, V25, P3436, DOI 10.1038/sj.onc.1209366; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zhang Q, 2002, J CELL BIOCHEM, V85, P536, DOI 10.1002/jcb.10150	42	35	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					499	505		10.1038/sj.onc.1210671	http://dx.doi.org/10.1038/sj.onc.1210671			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653089				2022-12-28	WOS:000252426100010
J	Song, LP; Zhang, J; Wu, SF; Huang, Y; Zhao, Q; Cao, JP; Wu, YL; Wang, LS; Chen, GQ				Song, L-P; Zhang, J.; Wu, S-F; Huang, Y.; Zhao, Q.; Cao, J-P; Wu, Y-L; Wang, L-S; Chen, G-Q			Hypoxia-inducible factor-1 alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent	ONCOGENE			English	Article						leukemia; differentiation; HIF-1 alpha; C/EBP alpha	PHOSPHOLIPID SCRAMBLASE-1 GENE; TEL-ARNT FUSION; OXYGEN-TENSION; RETINOIC ACID; C/EBP-ALPHA; EXPRESSION; ARREST; TRANSLOCATION	Hypoxia or hypoxia mimetic has been shown to induce differentiation together with the accumulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein of myeloid leukemic cells and normal hematopoietic progenitors. To provide direct evidence for the role of HIF-1 alpha in acute myeloid leukemia (AML) cell differentiation and its mechanisms, we generated myeloid leukemic U937T transformants, in which HIF-1 alpha was tightly induced by tetracycline withdrawal. The results showed that the conditional HIF-1 alpha induction triggered granulocytic differentiation of these transformants, while the suppression of HIF-1 alpha expression by specific short hairpin RNAs (shRNAs) effectively inhibited hypoxia-induced differentiation of U937 cells, as evidenced by morphology, maturation-related antigens as well as expressions of myeloid differentiation signatures and hematopoietic cells- specific cytokine receptors. The specific shRNAs-inhibited expression of HIF-1 beta, an essential partner for transcription activity of HIF-1 alpha failed, while the inhibition of hematopoietic differentiation-critical CCAAT/enhancer-binding protein-a (C/EBPa) significantly eliminated HIF-1 alpha-mediated myeloid leukemic cell differentiation. Collectively, this work provided several lines of direct evidence for the role of HIF-1 alpha protein through its nontranscriptional activity in myeloid cell differentiation, in which C/EBP alpha elicitsa role as an effector downstream to HIF-1 alpha. These discoveries would shed new insights for understanding mechanisms underlying leukemogenesis and designing the new therapeutic strategy for differentiation induction of AML.	[Song, L-P; Zhang, J.; Wu, S-F; Zhao, Q.; Cao, J-P; Chen, G-Q] SJTU SM, Chinese Acad Sci, Grad Sch, Shanghai, Peoples R China; [Song, L-P; Zhang, J.; Wu, S-F; Zhao, Q.; Cao, J-P; Chen, G-Q] SJTU SM, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai, Peoples R China; [Huang, Y.; Wu, Y-L; Wang, L-S; Chen, G-Q] SJTU SM, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Dept Pathophysiol, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, GQ (corresponding author), Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Dept Pathophysiol, Shanghai 200025, Peoples R China.	chengq@shsmu.edu.cn						Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Chen GQ, 1997, BLOOD, V89, P3345; Cheng LRL, 2006, FOLIA PHONIATR LOGO, V58, P5, DOI 10.1159/000090474; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Hong SH, 2004, J BIOL CHEM, V279, P16996, DOI 10.1074/jbc.M311752200; Huang Y, 2006, ONCOGENE, V25, P6618, DOI 10.1038/sj.onc.1209677; Huang Y, 2003, LEUKEMIA, V17, P2065, DOI 10.1038/sj.leu.2403141; James SY, 1997, BIOCHEM PHARMACOL, V54, P625, DOI 10.1016/S0006-2952(97)00195-0; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Liu W, 2006, BLOOD, V107, P698, DOI 10.1182/blood-2005-03-1278; Mueller BU, 2006, CURR OPIN HEMATOL, V13, P7, DOI 10.1097/01.moh.0000190110.08156.96; Nguyen-Khac F, 2006, ONCOGENE, V25, P4840, DOI 10.1038/sj.onc.1209503; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Rosenbauer F, 2005, BLOOD, V106, P1519, DOI 10.1182/blood-2005-02-0717; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Scortegagna M, 2003, BLOOD, V102, P1634, DOI 10.1182/blood-2003-02-0448; SCOTT LM, 1992, BLOOD, V80, P1725; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Suh HC, 2006, BLOOD, V107, P4308, DOI 10.1182/blood-2005-06-2216; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630	25	48	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					519	527		10.1038/sj.onc.1210670	http://dx.doi.org/10.1038/sj.onc.1210670			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637739				2022-12-28	WOS:000252426100012
J	Chang, TW; Chen, CC; Chen, KY; Su, JH; Chang, JH; Chang, MC				Chang, T-W; Chen, C-C; Chen, K-Y; Su, J-H; Chang, J-H; Chang, M-C			Ribosomal phosphoprotein P0 interacts with GCIP and overexpression of P0 is associated with cellular proliferation in breast and liver carcinoma cells	ONCOGENE			English	Article						ribosomal P0; GCIP; DIP1/HHM; cyclin D1; breast cancer; hepatocellular carcinoma	GTPASE-ASSOCIATED DOMAIN; LOOP-HELIX PROTEIN; HUMAN HOMOLOG; EXPRESSION; P2; MAID; RNA; P1; HEPATOCARCINOGENESIS; COMPONENTS	The ribosomal acidic P0 protein, an essential component of the eukaryotic ribosomal stalk, was found to interact with the helix-loop-helix protein human Grap2 and cyclin D interacting protein (GCIP)/D-type cyclin-interacting protein 1/human homolog of MAID protein. Using in vivo and in vitro binding assays, we show that P0 can interact with the N and C termini of GCIP via its N-terminal 39-114 amino-acid residues. Although the P0-GCIP complex was detected mainly in cytoplasmic fraction, polysome pro. le analysis indicated that the P0-GCIP complex did not coelute with either polysomes or 60S ribosomes, suggesting that GCIP associates with the free form of P0 in the cytoplasm. Transfection of GCIP into MCF-7 cells resulted in decreased levels of pRb phosphorylation. Cotransfection of P0 with GCIP, however, resulted in GCIP-mediated reduction of pRb phosphorylation level which was repressed by P0. Furthermore, overexpression of P0 in breast cancer and hepatocellular cancer cell lines promoted cell growth and colony formation compared to control transfectants. Overexpression of P0 also increased cyclin D1 expression and phosphorylation of pRb at Ser780. Interestingly, P0 mRNA was overexpressed in 12 of 20 pairs of breast cancer/ normal breast specimens (60%). Together, these data indicate that P0 overexpression may cause tumorigenesis in breast and liver tissues at least in part by inhibiting GCIP-mediated tumor suppression.	[Chang, T-W; Chang, M-C] Natl Cheng Kung Univ, Coll Med, Basic Med Sci, Dept Biochem & Mol Biol, Tainan 704, Taiwan; [Chang, T-W] Natl Cheng Kung Univ, Coll Med, Dept Surg, Tainan 704, Taiwan; [Chen, C-C; Chen, K-Y; Chang, J-H; Chang, M-C] Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Biotechnol, Tainan 704, Taiwan; [Su, J-H] Chia Na Univ Pharm & Sci, Coll Med, Dept Biotechnol, Tainan, Taiwan; [Chang, J-H] Natl Cheng Kung Univ, Coll Med, Dept Parasitol, Tainan 704, Taiwan; [Chang, M-C] Natl Cheng Kung Univ, Coll Med, Basic Med Sci, Dept Biochem & Mol Biol, Tainan 704, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Chang, MC (corresponding author), Natl Cheng Kung Univ, Coll Med, Basic Med Sci, Dept Biochem & Mol Biol, 138 Sheng Li Rd, Tainan 704, Taiwan.	mcchang@mail.ncku.edu.tw		Chen, Kuanyu/0000-0001-9350-2699				BARNARD GF, 1992, CANCER RES, V52, P3067; Chang MS, 2000, BIOCHEM BIOPH RES CO, V279, P732, DOI 10.1006/bbrc.2000.3992; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; GRABOWSKI DT, 1992, CARCINOGENESIS, V13, P259, DOI 10.1093/carcin/13.2.259; Hosokawa Y, 1996, J LAB CLIN MED, V127, P246, DOI 10.1016/S0022-2143(96)90092-X; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kondoh N, 1999, CANCER RES, V59, P4990; Ma W, 2006, ONCOGENE, V25, P4207, DOI 10.1038/sj.onc.1209450; Ma WB, 2007, J CELL BIOCHEM, V100, P1376, DOI 10.1002/jcb.21140; Remacha M, 1995, BIOCHEM CELL BIOL, V73, P959, DOI 10.1139/o95-103; Shimizu T, 2002, NUCLEIC ACIDS RES, V30, P2620, DOI 10.1093/nar/gkf379; Sonnenberg-Riethmacher E, 2007, HEPATOLOGY, V45, P404, DOI 10.1002/hep.21461; Takami T, 2005, GASTROENTEROLOGY, V128, P1369, DOI 10.1053/j.gastro.2005.03.014; Tchorzewski M, 2003, INT J BIOCHEM CELL B, V35, P203, DOI 10.1016/S1357-2725(02)00133-4; Terai S, 2000, HEPATOLOGY, V32, P357, DOI 10.1053/jhep.2000.9092; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; Wu SB, 2005, CRYOBIOLOGY, V50, P71, DOI 10.1016/j.cryobiol.2004.11.001; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Yao Y, 2000, EXP CELL RES, V257, P22, DOI 10.1006/excr.2000.4884	20	41	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					332	338		10.1038/sj.onc.1210651	http://dx.doi.org/10.1038/sj.onc.1210651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621266				2022-12-28	WOS:000252256000009
J	Schon, MP; Schon, M				Schoen, M. P.; Schoen, M.			TLR7 and TLR8 as targets in cancer therapy	ONCOGENE			English	Review						TLR7; TLR8; skin cancer; imiquimod; imidazoquinolines; cancer immunity	IMIQUIMOD 5-PERCENT CREAM; BASAL-CELL-CARCINOMA; IMMUNE-RESPONSE MODIFIER; TOLL-LIKE RECEPTOR-7; MELANOMA IN-SITU; PLASMACYTOID DENDRITIC CELLS; VEHICLE-CONTROLLED TRIALS; ACTINIC KERATOSIS; DOUBLE-BLIND; TOPICAL APPLICATION	Small-molecule agonists at Toll-like receptor 7 (TLR7) and TLR8 have sparked a vivid interest in cancer research owing to their profound antitumoral activity. The lead compound of the imidazoquinoline family, imiquimod, is marketed as a topical formulation. It is efficacious against many primary skin tumors and cutaneous metastases. Using different imidazoquinoline species, distinct functions of TLR7 and TLR8 have been discovered. The predominant antitumoral mode of action of these agents is TLR7/8-mediated activation of the central transcription factor nuclear factor-kappa B, which leads to induction of proinflammatory cytokines and other mediators. Cutaneous dendritic cells are the primary responsive cell type and initiate a strong Th1-weighted antitumoral cellular immune response. Recent research has shown that dendritic cells themselves acquire direct antitumoral activity upon stimulation by imiquimod. In addition, there are a number of secondary effects on the molecular and cellular level that can be explained through the activation of TLR7/8. The proinflammatory activity of imiquimod, but not resiquimod, appears to be augmented by suppression of a regulatory mechanism, which normally limits inflammatory responses. This is achieved independently of TLR7/8 through interference with adenosine receptor signaling pathways. Finally, at higher concentrations imiquimod exerts Bcl-2- and caspase-dependent proapoptotic activity against tumor cells.	[Schoen, M. P.; Schoen, M.] Univ Wurzburg, Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, D-97078 Wurzburg, Germany; [Schoen, M. P.; Schoen, M.] Univ Wurzburg, Dept Dermatol, D-97078 Wurzburg, Germany	German Research Foundation (DFG); University of Wurzburg; University of Wurzburg	Schon, MP (corresponding author), Univ Wurzburg, Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, Versbacher Str 9, D-97078 Wurzburg, Germany.	michael.schoen@virchow.uni-wuerzburg.de						Ambach A, 2004, MOL IMMUNOL, V40, P1307, DOI 10.1016/j.molimm.2004.01.002; Barland CO, 2004, J INVEST DERMATOL, V122, P330, DOI 10.1046/j.0022-202X.2004.22203.x; Bath-Hextall F, 2004, BMJ-BRIT MED J, V329, P705, DOI 10.1136/bmj.38219.515266.AE; Berman B, 2003, BRIT J DERMATOL, V149, P59, DOI 10.1046/j.0366-077X.2003.05634.x; BERNSTEIN DI, 1995, VACCINE, V13, P72, DOI 10.1016/0264-410X(95)80014-5; BERSTEIN DI, 2000, J INFECT DIS, V183, P844; Bishop GA, 2001, CELL IMMUNOL, V208, P9, DOI 10.1006/cimm.2001.1769; Bong AB, 2002, DERMATOLOGY, V205, P135, DOI 10.1159/000063904; Bottrel RLA, 1999, ANTIMICROB AGENTS CH, V43, P856, DOI 10.1128/AAC.43.4.856; Brown VL, 2005, ARCH DERMATOL, V141, P985, DOI 10.1001/archderm.141.8.985; Buates S, 2001, ANTIMICROB AGENTS CH, V45, P1137, DOI 10.1128/AAC.45.4.1137-1142.2001; Burns RP, 2000, CLIN IMMUNOL, V94, P13, DOI 10.1006/clim.1999.4804; CHEN M, 1988, ANTIMICROB AGENTS CH, V32, P678, DOI 10.1128/AAC.32.5.678; Chong A, 2004, J Dermatolog Treat, V15, P118; Craft N, 2005, J IMMUNOL, V175, P1983, DOI 10.4049/jimmunol.175.3.1983; Deeths MJ, 2005, J AM ACAD DERMATOL, V52, P275, DOI 10.1016/j.jaad.2004.04.049; Dendorfer M, 2003, EUR J DERMATOL, V13, P80; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dockrell DH, 2001, J ANTIMICROB CHEMOTH, V48, P751, DOI 10.1093/jac/48.6.751; Dummer R, 2003, BRIT J DERMATOL, V149, P57, DOI 10.1046/j.0366-077X.2003.05630.x; Dummer R, 2003, DERMATOLOGY, V207, P116, DOI 10.1159/000070962; Fleming CJ, 2004, BRIT J DERMATOL, V151, P485, DOI 10.1111/j.1365-2133.2004.05983.x; Frotscher B, 2002, J INVEST DERMATOL, V119, P1059, DOI 10.1046/j.1523-1747.2002.19531.x; Geisse J, 2004, J AM ACAD DERMATOL, V50, P722, DOI 10.1016/j.jaad.2003.11.066; Gerster JF, 2005, J MED CHEM, V48, P3481, DOI 10.1021/jm049211v; Giannotti B, 2003, CLIN EXP DERMATOL, V28, P33, DOI 10.1046/j.1365-2230.28.s1.11.x; GIBSON SJ, 1995, J INTERF CYTOK RES, V15, P537, DOI 10.1089/jir.1995.15.537; Gibson SJ, 2002, CELL IMMUNOL, V218, P74, DOI 10.1016/S0008-8749(02)00517-8; Gollnick H, 2005, EUR J DERMATOL, V15, P374; Gollnick H, 2001, INT J STD AIDS, V12, P22, DOI 10.1258/0956462011916695; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Gorden KKB, 2006, J IMMUNOL, V177, P8164, DOI 10.4049/jimmunol.177.11.8164; Gorden KKB, 2006, J IMMUNOL, V177, P6584, DOI 10.4049/jimmunol.177.10.6584; Gorski KS, 2006, INT IMMUNOL, V18, P1115, DOI 10.1093/intimm/dxl046; Hadley G, 2006, J INVEST DERMATOL, V126, P1251, DOI 10.1038/sj.jid.5700264; HARRISON CJ, 1994, ANTIMICROB AGENTS CH, V38, P2059, DOI 10.1128/AAC.38.9.2059; HARRISON CJ, 1988, ANTIVIR RES, V10, P209, DOI 10.1016/0166-3542(88)90032-0; HEIL F, 2004, SCIENCE, V33, P2987; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hengge UR, 2004, DERMATOL SURG, V30, P1101, DOI 10.1111/j.1524-4725.2004.30335.x; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Hurwitz DJ, 2003, ARCH DERMATOL, V139, P1347, DOI 10.1001/archderm.139.10.1347; Imbertson LM, 1998, J INVEST DERMATOL, V110, P734, DOI 10.1046/j.1523-1747.1998.00174.x; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Jurk M, 2006, EUR J IMMUNOL, V36, P1815, DOI 10.1002/eji.200535806; Kamin A, 2005, J AM ACAD DERMATOL, V52, pS51, DOI 10.1016/j.jaad.2004.07.047; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Korman N, 2005, ARCH DERMATOL, V141, P467, DOI 10.1001/archderm.141.4.467; Lebwohl M, 2004, J AM ACAD DERMATOL, V50, P714, DOI 10.1016/j.jaad.2003.12.010; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Levy O, 2006, BLOOD, V108, P1284, DOI 10.1182/blood-2005-12-4821; Lonsdale-Eccles AA, 2006, BRIT J DERMATOL, V155, P215, DOI 10.1111/j.1365-2133.2006.07297.x; Lore K, 2003, J IMMUNOL, V171, P4320, DOI 10.4049/jimmunol.171.8.4320; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; MA Y, 2007, J IMMUNOL, V178, P36; MEGYERI K, 1995, MOL CELL BIOL, V15, P2207; Meyer T, 2003, BRIT J DERMATOL, V149, P9, DOI 10.1046/j.0366-077X.2003.05632.x; Miggin SM, 2006, J LEUKOCYTE BIOL, V80, P220, DOI 10.1189/jlb.1105672; Miller RL, 2002, INT IMMUNOPHARMACOL, V2, P443, DOI 10.1016/S1567-5769(01)00184-9; NAVI D, 2004, DERMATOL ONLINE, V10; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; Nishiya T, 2005, J BIOL CHEM, V280, P37107, DOI 10.1074/jbc.M504951200; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Palamara F, 2004, J IMMUNOL, V173, P3051, DOI 10.4049/jimmunol.173.5.3051; Patel GK, 2006, J AM ACAD DERMATOL, V54, P1025, DOI 10.1016/j.jaad.2006.01.055; Peres K, 2003, EUR J DERMATOL, V13, P413; Peris K, 2006, J AM ACAD DERMATOL, V55, P324, DOI 10.1016/j.jaad.2006.04.004; POPE BL, 1995, CELL IMMUNOL, V162, P333, DOI 10.1006/cimm.1995.1087; Prins RM, 2006, J IMMUNOL, V176, P157, DOI 10.4049/jimmunol.176.1.157; Prinz BM, 2004, TRANSPLANTATION, V77, P790, DOI 10.1097/01.TP.0000113445.02908.06; Qin JZ, 2006, J BIOL CHEM, V281, P21013, DOI 10.1074/jbc.M512908200; Ray CM, 2005, INT J DERMATOL, V44, P428, DOI 10.1111/j.1365-4632.2005.02582.x; Rechtsteiner G, 2005, J IMMUNOL, V174, P2476, DOI 10.4049/jimmunol.174.5.2476; REITER MJ, 1994, J LEUKOCYTE BIOL, V55, P234, DOI 10.1002/jlb.55.2.234; Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102; Roseeuw D, 2003, CLIN EXP DERMATOL, V28, P30, DOI 10.1046/j.1365-2230.28.s1.10.x; Sauder DN, 2003, ANTIMICROB AGENTS CH, V47, P3846, DOI 10.1128/AAC.47.12.3846-3852.2003; Schon M, 2007, CURR MED CHEM, V14, P681, DOI 10.2174/092986707780059625; Schon MP, 2006, J INVEST DERMATOL, V126, P1338, DOI 10.1038/sj.jid.5700286; Schon M, 2003, J NATL CANCER I, V95, P1138, DOI 10.1093/jnci/djg016; Schulze HJ, 2005, BRIT J DERMATOL, V152, P939, DOI 10.1111/j.1365-2133.2005.06486.x; Schwarz K, 2003, EUR J IMMUNOL, V33, P1465, DOI 10.1002/eji.200323919; SHACKLETON M, 2004, CANC IMMUN, V23, P9; Sidbury R, 2003, J INVEST DERMATOL, V121, P1205, DOI 10.1046/j.1523-1747.2003.12521.x; SIDKY YA, 1992, CANCER RES, V52, P3528; Smith KJ, 2001, DERMATOL SURG, V27, P561, DOI 10.1046/j.1524-4725.2001.00149.x; Stanley MA, 2002, CLIN EXP DERMATOL, V27, P571, DOI 10.1046/j.1365-2230.2002.01151.x; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Steinmann A, 2000, J AM ACAD DERMATOL, V43, P555, DOI 10.1067/mjd.2000.107954; Stephanou A, 2005, GROWTH FACTORS, V23, P177, DOI 10.1080/08977190500178745; Sterry W, 2002, BRIT J DERMATOL, V147, P1227, DOI 10.1046/j.1365-2133.2002.05069.x; Stockfleth E, 2002, ARCH DERMATOL, V138, P1498, DOI 10.1001/archderm.138.11.1498; Stockfleth E, 2001, BRIT J DERMATOL, V144, P1050, DOI 10.1046/j.1365-2133.2001.04197.x; Suchin KR, 2002, ARCH DERMATOL, V138, P1137, DOI 10.1001/archderm.138.9.1137; Sullivan TP, 2003, DERMATOL SURG, V29, P1181, DOI 10.1111/j.1524-4725.2003.29399.x; Suzuki H, 2000, J INVEST DERMATOL, V114, P135, DOI 10.1046/j.1523-1747.2000.00833.x; Szeimies RM, 2004, J AM ACAD DERMATOL, V51, P547, DOI 10.1016/j.jaad.2004.02.022; Thomsen LL, 2004, VACCINE, V22, P1799, DOI 10.1016/j.vaccine.2003.09.052; Tomai MA, 2000, CELL IMMUNOL, V203, P55, DOI 10.1006/cimm.2000.1673; Ugurel S, 2002, BRIT J DERMATOL, V147, P621, DOI 10.1046/j.1365-2133.2002.488811.x; Urosevic M, 2005, J NATL CANCER I, V97, P1143, DOI 10.1093/jnci/dji207; Urosevic M, 2004, CLIN CANCER RES, V10, P4959, DOI 10.1158/1078-0432.CCR-04-0193; Urosevic M, 2003, ARCH DERMATOL, V139, P1325, DOI 10.1001/archderm.139.10.1325; Vidal D, 2004, BRIT J DERMATOL, V151, P656, DOI 10.1111/j.1365-2133.2004.06094.x; Wagner TL, 1997, CYTOKINE, V9, P837, DOI 10.1006/cyto.1997.0239; Wagner TL, 1999, CELL IMMUNOL, V191, P10, DOI 10.1006/cimm.1998.1406; WEEKS CE, 1994, J INTERFERON RES, V14, P81, DOI 10.1089/jir.1994.14.81; Wille-Reece U, 2006, J EXP MED, V203, P1249, DOI 10.1084/jem.20052433; Wolf IH, 2003, ARCH DERMATOL, V139, P273, DOI 10.1001/archderm.139.3.273; Wolf IH, 2005, ARCH DERMATOL, V141, P510, DOI 10.1001/archderm.141.4.510; Zeitouni NC, 2005, BRIT J DERMATOL, V152, P376, DOI 10.1111/j.1365-2133.2005.06307.x; Zuber AK, 2004, VACCINE, V22, P1791, DOI 10.1016/j.vaccine.2003.10.051	114	230	252	3	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					190	199		10.1038/sj.onc.1210913	http://dx.doi.org/10.1038/sj.onc.1210913			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176600				2022-12-28	WOS:000252163600005
J	Avvakumov, N; Cote, J				Avvakumov, N.; Cote, J.			The MYST family of histone acetyltransferases and their intimate links to cancer	ONCOGENE			English	Review						MYST; histone acetyltransferase (HAT); chromatin modification; cancer	ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; TUMOR-SUPPRESSOR GENE; UV-INDUCED APOPTOSIS; ZINC-FINGER PROTEIN; MONOCYTIC LEUKEMIA; METASTASIS SUPPRESSOR-1; RECEPTOR COACTIVATOR; DEACETYLASE COMPLEX; ANDROGEN RECEPTOR	The histone acetyltransferases ( HATs) of the MYST family are highly conserved in eukaryotes and carry out a significant proportion of all nuclear acetylation. These enzymes function exclusively in multisubunit protein complexes whose composition is also evolutionarily conserved. MYST HATs are involved in a number of key nuclear processes and play critical roles in genespecific transcription regulation, DNA damage response and repair, as well as DNA replication. This suggests that anomalous activity of these HATs or their associated complexes can easily lead to severe cellular malfunction, resulting in cell death or uncontrolled growth and malignancy. Indeed, the MYST family HATs have been implicated in several forms of human cancer. This review summarizes the current understanding of these enzymes and their normal function, as well as their established and putative links to oncogenesis.	Univ Laval, Canc Res Ctr, Hotel Dieu, CHUQ, Quebec City, PQ G1R 2J6, Canada	Laval University	Cote, J (corresponding author), Univ Laval, Canc Res Ctr, Hotel Dieu, CHUQ, 9 McMahon St, Quebec City, PQ G1R 2J6, Canada.	Jacques.Cote@crhdq.ulaval.ca	Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X				Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Awasthi S, 2005, MOL CELL BIOL, V25, P6178, DOI 10.1128/MCB.25.14.6178-6198.2005; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Bertram MJ, 2001, GENE, V266, P111, DOI 10.1016/S0378-1119(01)00372-9; Bewersdorf J, 2006, P NATL ACAD SCI USA, V103, P18137, DOI 10.1073/pnas.0608709103; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chamberlin HM, 2000, DEVELOPMENT, V127, P713; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chang S, 2003, GENE DEV, V17, P2123, DOI 10.1101/gad.1117903; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; Collins HM, 2006, J BIOL CHEM, V281, P17124, DOI 10.1074/jbc.M602633200; Contzler R, 2006, BIOCHEM BIOPH RES CO, V350, P208, DOI 10.1016/j.bbrc.2006.09.030; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; DePamphilis ML, 2003, GENE, V310, P1, DOI 10.1016/S0378-1119(03)00546-8; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Eymin B, 2006, MOL CELL BIOL, V26, P4339, DOI 10.1128/MCB.02240-05; Fischer U, 1997, HUM MOL GENET, V6, P1817, DOI 10.1093/hmg/6.11.1817; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149; Grienenberger A, 2002, CURR BIOL, V12, P762, DOI 10.1016/S0960-9822(02)00814-X; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; Hobbs CA, 2006, CANCER RES, V66, P8116, DOI 10.1158/0008-5472.CAN-06-0359; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Iizuka M, 2006, MOL CELL BIOL, V26, P1098, DOI 10.1128/MCB.26.3.1098-1108.2006; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Knoops L, 2004, GROWTH FACTORS, V22, P207, DOI 10.1080/08977190410001720879; Kojima K, 2003, BRIT J HAEMATOL, V120, P271, DOI 10.1046/j.1365-2141.2003.04059.x; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; LAFON N, 2007, IN PRESS ONCOGENE; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Linggi BE, 2005, J CELL BIOCHEM, V96, P938, DOI 10.1002/jcb.20604; Liu Y, 2006, MOL CELL BIOL, V26, P8683, DOI 10.1128/MCB.00940-06; Lleonart ME, 2006, ONCOL REP, V16, P603; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200; Meehan WJ, 2003, CLIN EXP METASTAS, V20, P45, DOI 10.1023/A:1022542519586; Merson TD, 2006, J NEUROSCI, V26, P11359, DOI 10.1523/JNEUROSCI.2247-06.2006; Micci F, 2006, CANCER RES, V66, P107, DOI 10.1158/0008-5472.CAN-05-2485; Miotto B, 2006, GENE DEV, V20, P101, DOI 10.1101/gad.359506; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; Moore SDP, 2004, CANCER RES, V64, P5570, DOI 10.1158/0008-5472.CAN-04-0050; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; O'Connell S, 2001, J BIOL CHEM, V276, P43065, DOI 10.1074/jbc.M104294200; OHTA K, 2006, BIOCHEM J, V3, P3; Panagopoulos I, 2002, GENE CHROMOSOME CANC, V35, P372, DOI 10.1002/gcc.10131; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park JH, 2006, MOL CELL BIOL, V26, P4006, DOI 10.1128/MCB.02185-05; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; PHILLIPS DM, 1963, BIOCHEM J, V87, P258, DOI 10.1042/bj0870258; Radhakrishnan SK, 2006, BBA-REV CANCER, V1766, P53, DOI 10.1016/j.bbcan.2006.02.001; Raho G, 2007, ONCOGENE, V26, P5247, DOI 10.1038/sj.onc.1210335; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rozman M, 2004, GENE CHROMOSOME CANC, V40, P140, DOI 10.1002/gcc.20022; Russell M, 2006, EXP CELL RES, V312, P951, DOI 10.1016/j.yexcr.2006.01.020; Samant RS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-6; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Scott M, 2001, J CELL SCI, V114, P3455; Selleck W, 2005, MOL CELL BIOL, V25, P5535, DOI 10.1128/MCB.25.13.5535-5542.2005; Severinsen JE, 2006, MOL PSYCHIATR, V11, P1126, DOI 10.1038/sj.mp.4001885; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shimada Y, 1998, CYTOGENET CELL GENET, V83, P232, DOI 10.1159/000015188; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Shiseki M, 2003, CANCER RES, V63, P2373; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Sliva D, 1999, BIOCHEM BIOPH RES CO, V263, P149, DOI 10.1006/bbrc.1999.1083; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Stedman W, 2004, J VIROL, V78, P12566, DOI 10.1128/JVI.78.22.12566-12575.2004; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Thomas T, 2000, DEVELOPMENT, V127, P2537; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; Unoki M, 2006, J BIOL CHEM, V281, P34677, DOI 10.1074/jbc.M606296200; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; VAQUERO A, 2006, SCI AGING KNOWLEDGE, P20; Wang YM, 2006, J BIOL CHEM, V281, P11887, DOI 10.1074/jbc.M511309200; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zhang ZH, 2006, CLIN CANCER RES, V12, P6410, DOI 10.1158/1078-0432.CCR-06-1347; Zhou MI, 2005, P NATL ACAD SCI USA, V102, P11035, DOI 10.1073/pnas.0500757102	137	210	223	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5395	5407		10.1038/sj.onc.1210608	http://dx.doi.org/10.1038/sj.onc.1210608			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694081				2022-12-28	WOS:000248674300008
J	Banerjee, T; DuHadaway, JB; Gaspari, P; Sutanto-Ward, E; Munn, DH; Mellor, AL; Malachowski, WP; Prendergast, GC; Muller, AJ				Banerjee, T.; DuHadaway, J. B.; Gaspari, P.; Sutanto-Ward, E.; Munn, D. H.; Mellor, A. L.; Malachowski, W. P.; Prendergast, G. C.; Muller, A. J.			A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase	ONCOGENE			English	Article						IDO; INDO; tumoral immune tolerance; immunotherapy; targeted therapeutics; tryptophan	CANCER CHEMOPREVENTIVE ACTIVITY; SULFUR-CONTAINING PHYTOALEXINS; SSP PEKINENSIS CRUCIFERAE; TRYPTOPHAN CATABOLISM; DENDRITIC CELLS; T-CELLS; EXPRESSION; PREVENTION; CABBAGE; TOLERANCE	Agents that interfere with tumoral immune tolerance may be useful to prevent or treat cancer. Brassinin is a phytoalexin, a class of natural products derived from plants that includes the widely known compound resveratrol. Brassinin has been demonstrated to have chemopreventive activity in preclinical models but the mechanisms underlying its anticancer properties are unknown. Here, we show that brassinin and a synthetic derivative 5-bromo-brassinin (5-Br-brassinin) are bioavailable inhibitors of indoleamine 2,3-dioxygenase (IDO), a pro-toleragenic enzyme that drives immune escape in cancer. Like other known IDO inhibitors, both of these compounds combined with chemotherapy to elicit regression of autochthonous mammary gland tumors in MMTV-Neu mice. Furthermore, growth of highly aggressive melanoma isograft tumors was suppressed by single agent treatment with 5-Br-brassinin. This response to treatment was lost in athymic mice, indicating a requirement for active host T-cell immunity, and in IDO-null knockout mice, providing direct genetic evidence that IDO inhibition is essential to the antitumor mechanism of action of 5-Br-brassinin. The natural product brassinin thus provides the structural basis for a new class of compounds with in vivo anticancer activity that is mediated through the inhibition of IDO.	[DuHadaway, J. B.; Sutanto-Ward, E.; Prendergast, G. C.; Muller, A. J.] Lankenau Inst Med Res, Wynnewood, PA 19096 USA; [Banerjee, T.] NewLink Genet Corp, Ames, IA USA; [Gaspari, P.; Malachowski, W. P.] Bryn Mawr Coll, Dept Chem, Bryn Mawr, PA 19010 USA; [Munn, D. H.; Mellor, A. L.] Med Coll Georgia, Dept Med, Augusta, GA 30912 USA; [Munn, D. H.] Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; [Mellor, A. L.] Med Coll Georgia, Dept Med, Augusta, GA 30912 USA; [Prendergast, G. C.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; [Prendergast, G. C.; Muller, A. J.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Muller, A. J.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Bryn Mawr College; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Jefferson University; Jefferson University; Jefferson University	Muller, AJ (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	mullera@mlhs.org	Malachowski, Bill/AAD-7744-2022	Munn, David/0000-0002-7711-2858; Muller, Alexander/0000-0001-7854-6933; Malachowski, William/0000-0003-1215-3808	NATIONAL CANCER INSTITUTE [R01CA100123, R01CA109542, R01CA082222] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA109542, R01 CA100123, R01 CA82222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts DS, 1999, CANCER RES, V59, P4743; Baban B, 2004, J REPROD IMMUNOL, V61, P67, DOI 10.1016/j.jri.2003.11.003; Brandacher G, 2006, CLIN CANCER RES, V12, P1144, DOI 10.1158/1078-0432.CCR-05-1966; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Csomos P, 2006, BIOORG MED CHEM LETT, V16, P6273, DOI 10.1016/j.bmcl.2006.09.016; Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576; Gaspari P, 2006, J MED CHEM, V49, P684, DOI 10.1021/jm0508888; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hayaishi O, 1984, PROGR TRYPTOPHAN SER, P33; Hou DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925; Ino K, 2006, BRIT J CANCER, V95, P1555, DOI 10.1038/sj.bjc.6603477; MALABADI RB, 2005, S AFRICA NEWS PA MAR, V2, P3; MEHTA RG, 1995, CARCINOGENESIS, V16, P399, DOI 10.1093/carcin/16.2.399; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Mezencev R, 2003, NEOPLASMA, V50, P239; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Muller AJ, 2006, NAT REV CANCER, V6, P613, DOI 10.1038/nrc1929; MULLER K. O., 1958, AUSTRALIAN JOUR BIOL SCI, V11, P275; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583; Murillo G, 2001, NUTR CANCER, V41, P17, DOI 10.1207/S15327914NC41-1&amp;2_2; Okamoto A, 2005, CLIN CANCER RES, V11, P6030, DOI 10.1158/1078-0432.CCR-04-2671; Park EJ, 2002, CANCER METAST REV, V21, P231, DOI 10.1023/A:1021254725842; Pilatova M, 2005, LEUKEMIA RES, V29, P415, DOI 10.1016/j.leukres.2004.09.003; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Sabol M, 2000, BIOLOGIA, V55, P701; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; TAKASUGI M, 1988, B CHEM SOC JPN, V61, P285, DOI 10.1246/bcsj.61.285; TAKASUGI M, 1986, J CHEM SOC CHEM COMM, P1077, DOI 10.1039/c39860001077; THOMSON JA, 1993, IMMUNOLOGY, V78, P185	31	137	147	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2851	2857		10.1038/sj.onc.1210939	http://dx.doi.org/10.1038/sj.onc.1210939			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18026137				2022-12-28	WOS:000255502500006
J	Cangemi, R; Mensah, A; Albertini, V; Jain, A; Mello-Grand, M; Chiorino, G; Catapano, CV; Carbone, GM				Cangemi, R.; Mensah, A.; Albertini, V.; Jain, A.; Mello-Grand, M.; Chiorino, G.; Catapano, C. V.; Carbone, G. M.			Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer	ONCOGENE			English	Article						ETS transcription factor; ESE-3; prostate cancer; tumor suppressor; caspase-3; apoptosis	EPITHELIAL-CELLS; GENE-EXPRESSION; P53 PROMOTER; TARGET GENE; METHYLATION; INHIBITION; APOPTOSIS; SITE; DIFFERENTIATION; IDENTIFICATION	Deregulated expression of ETS transcription factors has emerged as an important event in prostate cancer pathogenesis. Here we show that the expression of epithelial-specific ETS (ESE)-3 factor is frequently reduced at the RNA and protein level in prostate cancer clinical samples compared to normal prostate. In PC3 and DU145 cells, ESE-3 was silenced by methylation of an evolutionarily conserved CpG site in its promoter and treatment with 5-aza-2'-deoxycytidine restored its expression. In a prostate epithelial cell transformation model, methylation of this site was inversely correlated with ESE-3 expression and occurred only in Ras-transformed and tumorigenic cells and not in normal and immortalized cells suggesting that ESE-3 silencing was functionally linked to oncogenic transformation. Consistent with a tumor suppressor function, re-expression of ESE-3 in prostate cancer cells inhibited clonogenic survival and induced apoptotic cell death. ESE-3 increased the level of procaspase-3, a key element in the apoptotic cascade. This effect was mediated at the transcriptional level by direct binding of ESE-3 to the caspase-3 promoter. Collectively, our findings implicate ESE-3 as a candidate tumor suppressor in prostate cancer. Decreased expression of ESE-3 may result in loss of important regulatory mechanisms in prostate epithelial cells and contribute to the pathogenesis of prostate cancer.	[Cangemi, R.; Mensah, A.; Albertini, V.; Jain, A.; Catapano, C. V.; Carbone, G. M.] Oncol Inst So Switzerland, Expt Oncol Lab, CH-6500 Bellinzona, Switzerland; [Mello-Grand, M.; Chiorino, G.] Lab Canc Genom, Fondo Edo Tempia, Biella, Italy	Institute of Oncology Research (IOR)	Carbone, GM (corresponding author), Oncol Inst So Switzerland, Expt Oncol Lab, CH-6500 Bellinzona, Switzerland.	pina.carbone@irb.unisi.ch	Chiorino, Giovanna/K-5037-2016	Chiorino, Giovanna/0000-0002-9502-6400; Catapano, Carlo V./0000-0002-7079-557X; Mensah, Afua Adjeiwaa/0000-0001-8113-3689; Jain, Aklank/0000-0001-5539-3225				Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Carbone GM, 2004, NUCLEIC ACIDS RES, V32, P4358, DOI 10.1093/nar/gkh744; Catapano CV, 2000, BIOCHEMISTRY-US, V39, P5126, DOI 10.1021/bi992185w; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Pei HP, 2005, CANCER RES, V65, P7205, DOI 10.1158/0008-5472.CAN-04-3566; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Pogribny IP, 2000, CANCER RES, V60, P588; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Schedin PJ, 2004, ONCOGENE, V23, P1766, DOI 10.1038/sj.onc.1207391; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tugores A, 2001, J BIOL CHEM, V276, P20397, DOI 10.1074/jbc.M010930200; Tummala R, 2006, J CELL BIOCHEM, V97, P766, DOI 10.1002/jcb.20685	26	49	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2877	2885		10.1038/sj.onc.1210953	http://dx.doi.org/10.1038/sj.onc.1210953			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037958				2022-12-28	WOS:000255502500009
J	Leister, P; Felten, A; Chasan, AI; Scheidtmann, KH				Leister, P.; Felten, A.; Chasan, A. I.; Scheidtmann, K. H.			ZIP kinase plays a crucial role in androgen receptor-mediated transcription	ONCOGENE			English	Article						androgen receptor; AATF/Che-1; co-activators; ZIP kinase/DAP like kinase	PROSTATE-CANCER; DLK/ZIP KINASE; NUCLEAR RECEPTORS; GENE-REGULATION; APOPTOSIS; PHOSPHORYLATION; INTERACTS; CHE-1; GROWTH; IDENTIFICATION	The androgen receptor (AR) is a ligand-dependent transcription factor that plays a crucial role in the development and homeostasis of the prostate and in prostate cancer. The transcriptional activity of AR is mediated by interaction with multiple co-activators, which serve in chromatin modi. cation or remodeling, or provide a link between specific and general transcription factors. We have identified zipper interacting protein (ZIP) kinase as a novel transcriptional co-activator of the AR. ZIP kinase enhanced expression of AR-responsive promotor/luciferase reporter constructs in a hormone-and kinase-dependent manner. Similar results were obtained for glucocorticoid receptor but not for progesterone receptor and estrogen receptor. Following hormone treatment, AR and ZIP kinase formed physical complexes and associated with the promoter and enhancer of the prostate-specific antigen gene, as revealed by chromatin immunoprecipitation. Strikingly, depletion of ZIP kinase by siRNA led to significant reduction of AR-mediated transactivation. The interaction of ZIP kinase with AR seems to be mediated in part by apoptosis antagonizing transcription factor and in part by direct binding. Interestingly, AR was not phosphorylated by ZIP kinase in vitro, suggesting that it phosphorylates other co-activators or chromatin proteins.	[Leister, P.; Felten, A.; Chasan, A. I.; Scheidtmann, K. H.] Univ Bonn, Genet Inst, D-53117 Bonn, Germany	University of Bonn	Scheidtmann, KH (corresponding author), Univ Bonn, Genet Inst, Romerstr 164,NRW, D-53117 Bonn, Germany.	kh.scheidtmann@uni-bonn.de		Imam Chasan, Achmet/0000-0001-5137-6890				Bruno T, 2002, CANCER CELL, V2, P387, DOI 10.1016/S1535-6108(02)00182-4; Bruno T, 2006, CANCER CELL, V10, P473, DOI 10.1016/j.ccr.2006.10.012; Burgdorf S, 2004, J BIOL CHEM, V279, P17524, DOI 10.1074/jbc.M313703200; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; Di Padova M, 2003, J BIOL CHEM, V278, P36496, DOI 10.1074/jbc.M306694200; Engemann H, 2002, NUCLEIC ACIDS RES, V30, P1408, DOI 10.1093/nar/30.6.1408; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Felten A, 2007, BIOL CHEM, V388, P569, DOI 10.1515/BC.2007.073; Gao S, 2006, J MOL ENDOCRINOL, V36, P463, DOI 10.1677/jme.1.01991; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Haystead TAJ, 2005, CELL SIGNAL, V17, P1313, DOI 10.1016/j.cellsig.2005.05.008; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kim J, 2004, J CELL BIOCHEM, V93, P233, DOI 10.1002/jcb.20228; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; Leister P., 2003, SIGNAL TRANSDUCTION, V3, P17, DOI [10.1002/sita.200300020, DOI 10.1002/SITA.200300020]; Lohrum M, 1996, ONCOGENE, V13, P2527; Lonard DM, 2006, CELL, V125, P411, DOI 10.1016/j.cell.2006.04.021; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Page G, 1999, FEBS LETT, V462, P187, DOI 10.1016/S0014-5793(99)01529-X; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Sato N, 2005, INT IMMUNOL, V17, P1543, DOI 10.1093/intimm/dxh331; Scheidtmann KH, 2007, SIGNAL TRANSDUCTION, V7, P248, DOI 10.1002/sita.200600112; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Thomas T, 2000, DEV BIOL, V227, P324, DOI 10.1006/dbio.2000.9915; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018	36	20	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3292	3300		10.1038/sj.onc.1210995	http://dx.doi.org/10.1038/sj.onc.1210995			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084323				2022-12-28	WOS:000256111400008
J	Sugimoto, K; Sasaki, M; Isobe, Y; Tsutsui, M; Suto, H; Ando, J; Tamayose, K; Ando, M; Oshimi, K				Sugimoto, K.; Sasaki, M.; Isobe, Y.; Tsutsui, M.; Suto, H.; Ando, J.; Tamayose, K.; Ando, M.; Oshimi, K.			Hsp90-inhibitor geldanamycin abrogates G(2) arrest in p53-negative leukemia cell lines through the depletion of Chk1	ONCOGENE			English	Article						Hsp90; geldanamycin; Chk1; G(2) arrest	DNA-DAMAGE; ANSAMYCINS CAUSES; PROTEIN-KINASE; TUMOR-CELLS; HSP90; CHECKPOINT; INHIBITION; APOPTOSIS; CYCLE; RADIOSENSITIZATION	Checkpoint protein Chk1 has been identified as an Hsp90 client. Treatment with 100 nM geldanamycin (GM) for 24 h markedly reduced the Chk1 amount in Jurkat and ML-1 leukemia cell lines. Because Chk1 plays a central role in G(2) checkpoint, we added GM to G(2)-arrested Jurkat and HL-60 cells pretreated with 50 nM doxorubicin for 24 h. GM slowly released both cell lines from doxorubicin-induced G(2) arrest into G(1) phase. GM also abrogated ICRF-193-induced decatenation G(2) checkpoint in Jurkat and HL-60 cells. Western blot analysis showed that addition of GM attenuates doxorubicin-and ICRF193-induced Chk1 phosphorylation at Ser345. GM, however, failed to abrogate G(2) arrest in p53-positive ML-1 cells maybe due to the p21 induction. GM released HeLa cells from doxorubicin-induced G(2) arrest but trapped them at M phase. Flow cytometric analysis showed that addition of GM converted doxorubicin-induced necrosis into apoptosis in Jurkat cells. Colony assay indicated that although GM has a weak cytotoxic effect as a single agent, it dramatically intensifies the cytotoxicity of doxorubicin and ICRF-193 in Jurkat and HL-60 cells. These results suggest that abrogation of G(2) checkpoint by GM may play a central role in sensitizing p53-negative tumor cells to DNA-damaging and decate-nation-inhibiting agents.	[Sugimoto, K.; Sasaki, M.; Isobe, Y.; Tsutsui, M.; Suto, H.; Ando, J.; Tamayose, K.; Ando, M.; Oshimi, K.] Juntendo Univ, Sch Med, Dept Internal Med, Div Hematol,Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Sugimoto, K (corresponding author), Juntendo Univ, Sch Med, Dept Internal Med, Div Hematol,Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.	ksugimot@med.juntendo.ac.jp						ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Bisht KS, 2003, CANCER RES, V63, P8984; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Bull EEA, 2004, CLIN CANCER RES, V10, P8077, DOI 10.1158/1078-0432.CCR-04-1212; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FAN SJ, 1995, CANCER RES, V55, P1649; Gorre ME, 2002, BLOOD, V100, P3041, DOI 10.1182/blood-2002-05-1361; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Jones DT, 2004, BLOOD, V103, P1855, DOI 10.1182/blood-2003-05-1603; Kawabe T, 2004, MOL CANCER THER, V3, P513; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kohn EA, 2003, CANCER RES, V63, P31; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Mesa RA, 2005, BLOOD, V106, P318, DOI 10.1182/blood-2004-09-3523; Minami Y, 2002, LEUKEMIA, V16, P1535, DOI 10.1038/sj.leu.2402558; Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood-2005-03-1158; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POWELL SN, 1995, CANCER RES, V55, P1643; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Srethapakdi M, 2000, CANCER RES, V60, P3940; Sugimoto K, 2000, BRIT J HAEMATOL, V110, P819, DOI 10.1046/j.1365-2141.2000.02304.x; Sugimoto K, 1998, BLOOD, V91, P1407, DOI 10.1182/blood.V91.4.1407; Sugimoto K, 2002, BRIT J HAEMATOL, V118, P229, DOI 10.1046/j.1365-2141.2002.03577.x; Tse AN, 2004, CANCER RES, V64, P6635, DOI 10.1158/0008-5472.CAN-04-0841; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M201233200	44	22	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3091	3101		10.1038/sj.onc.1210978	http://dx.doi.org/10.1038/sj.onc.1210978			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071310				2022-12-28	WOS:000255897600002
J	Hurst, CD; Tomlinson, DC; Williams, SV; Platt, FM; Knowles, MA				Hurst, C. D.; Tomlinson, D. C.; Williams, S. V.; Platt, F. M.; Knowles, M. A.			Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification	ONCOGENE			English	Article						E2F3; Rb; bladder cancer; 6p22 amplification	GENOME-WIDE ASSOCIATION; RETINOBLASTOMA PROTEIN; CELL-CYCLE; ALTERED EXPRESSION; COPY NUMBER; IN-VITRO; CANCER; PRB; PROLIFERATION; CARCINOMA	E2F3 and CDKAL1 are candidate genes from the 6p22 region frequently amplified in bladder cancer. Expression of E2F3 isoforms (E2F3a and b) and CDKAL1 were examined and modulated in 6p22-amplified bladder cell lines. Eight lines with amplification showed overexpression of both E2F3 isoforms and CDKAL1. shRNA-mediated knockdown of CDKAL1 had no effect on proliferation. Knockdown of E2F3a or E2F3b alone induced antiproliferative effects, with the most significant effect on proliferation being observed when both isoforms were knocked down together. As E2Fs interact with the Rb tumour suppressor protein, Rb expression was analysed. There was a striking relationship between 6p22.3 amplification, E2F3 overexpression and lack of Rb expression. This was also examined in primary bladder tumours. Array-CGH detected 6p22.3 amplification in 8/91 invasive tumours. Five were studied in more detail. Four showed 13q14.2 loss (including RB1) and expressed no Rb protein. In the fifth, 13q was unaltered but the CDKN2A locus was deleted. This tumour was negative for p16 and positive for Rb protein. As p16 is a negative regulator of the Rb pathway, its loss represents an alternative mechanism for inactivation. Indeed, a phospho-specific Rb antibody showed much Rb protein in a hyperphosphorylated (inactive) form. We conclude that inactivation of the Rb pathway is required in addition to E2F3 overexpression in this subset of bladder tumours.	[Hurst, C. D.; Tomlinson, D. C.; Williams, S. V.; Platt, F. M.; Knowles, M. A.] St James Univ Hosp, Sect Oncol, Canc Res UK Clin Ctr, Leeds Insts Mol Med, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St James Univ Hosp, Sect Oncol, Canc Res UK Clin Ctr, Leeds Insts Mol Med, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	m.a.knowles@leeds.ac.uk		Knowles, Margaret/0000-0002-9363-8657; Tomlinson, Darren/0000-0003-4134-7484	Cancer Research UK [C6228/A5433, A5433] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Blaveri E, 2005, CLIN CANCER RES, V11, P7012, DOI 10.1158/1078-0432.CCR-05-0177; Bruch J, 1998, GENE CHROMOSOME CANC, V23, P167, DOI 10.1002/(SICI)1098-2264(199810)23:2<167::AID-GCC10>3.0.CO;2-L; Bruch J, 2000, CANCER RES, V60, P4526; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Chapman EJ, 2005, CLIN CANCER RES, V11, P5740, DOI 10.1158/1078-0432.CCR-05-0411; Chatterjee SJ, 2004, J PATHOL, V203, P762, DOI 10.1002/path.1567; CHRISTIAN BJ, 1987, CANCER RES, V47, P6066; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; Cote RJ, 1998, CANCER RES, V58, P1090; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Frolov MV, 2001, GENE DEV, V15, P2146, DOI 10.1101/gad.903901; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; Humbert PO, 2000, GENE DEV, V14, P690; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; Le Frere-Belda MA, 2004, HUM PATHOL, V35, P817, DOI 10.1016/j.humpath.2004.01.019; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; Oeggerli M, 2006, ONCOGENE, V25, P6538, DOI 10.1038/sj.onc.1209946; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Olsson AY, 2007, ONCOGENE, V26, P1028, DOI 10.1038/sj.onc.1209854; Orlic M, 2006, GENE CHROMOSOME CANC, V45, P72, DOI 10.1002/gcc.20263; PAULIE S, 1983, INT J CANCER, V31, P297, DOI 10.1002/ijc.2910310308; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Prat E, 2001, UROLOGY, V57, P986, DOI 10.1016/S0090-4295(01)00909-8; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tomlinson D, 2007, ONCOGENE, V26, P5889, DOI 10.1038/sj.onc.1210399; Tomovska S, 2001, INT J ONCOL, V18, P1239; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Veltman JA, 2003, CANCER RES, V63, P2872; Wu QO, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-16; XU HJ, 1993, INT J CANCER, V53, P781, DOI 10.1002/ijc.2910530513; YEAGER T, 1995, CANCER RES, V55, P493; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	53	69	71	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2716	2727		10.1038/sj.onc.1210934	http://dx.doi.org/10.1038/sj.onc.1210934			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18037967	Green Accepted			2022-12-28	WOS:000255259500006
J	Wiesner, C; Winsauer, G; Resch, U; Hoeth, M; Schmid, JA; Van Hengel, J; Van Roy, F; Binder, BR; De Martin, R				Wiesner, C.; Winsauer, G.; Resch, U.; Hoeth, M.; Schmid, J. A.; Van Hengel, J.; Van Roy, F.; Binder, B. R.; De Martin, R.			alpha-Catulin, a Rho signalling component, can regulate NF-kappa B through binding to IKK-beta, and confers resistance to apoptosis	ONCOGENE			English	Article						Rho; alpha-catulin; IKK-beta; NF-kappa B	SERUM RESPONSE FACTOR; ENDOTHELIAL-CELLS; TRANSCRIPTION FACTORS; ADHESION COMPLEX; EPITHELIAL-CELLS; PROTEIN-RHO; CATENIN; ACTIVATION; ACTIN; IDENTIFICATION	Rho GTPases regulate diverse cellular functions including adhesion, cytokinesis and motility, as well as the activity of the transcription factors NF-kappa B, serum response factor and C/EBP. alpha-Catulin, an alpha-catenin-related protein that shares structural similarities with cytoskeletal linker proteins, facilitates Rho signalling by serving as a scaffold for the Rho-specific guanine nucleotide exchange factor Lbc. We report here that alpha-catulin also interacts with a key component of the NF-kappa B signalling pathway, namely the I kappa B kinase (IKK)-beta. In co-immunoprecipitations, alpha-catulin can bind IKK-beta and Lbc. Ectopic expression of alpha-catulin augmented NF-kappa B activity, promoted cell migration and increased resistance to apoptosis, whereas knockdown experiments showed the opposite effects. Together, these features suggest that alpha-catulin has tumorigenic potential.	[Wiesner, C.; Winsauer, G.; Resch, U.; Hoeth, M.; Schmid, J. A.; Binder, B. R.; De Martin, R.] Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria; [Van Hengel, J.; Van Roy, F.] Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; [Van Hengel, J.; Van Roy, F.] Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium	Medical University of Vienna; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	De Martin, R (corresponding author), Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, Lazarettg 19, A-1090 Vienna, Austria.	rainer.demartin@meduniwien.ac.at	van Roy, Frans M/C-6123-2009; Schmid, Johannes A./C-7659-2009	van Roy, Frans M/0000-0003-4358-1039; Schmid, Johannes A./0000-0002-6586-3507; Resch, Ulrike/0000-0002-8380-9555; Wiesner, Christoph/0000-0002-3281-0695				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; BEG AA, 1996, SCIENCE, V274, P784; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brock A. L., 2005, Molecular & Cellular Biomechanics, V2, P135; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Dutt P, 2004, CELL SIGNAL, V16, P201, DOI 10.1016/S0898-6568(03)00132-3; Ebner K, 2003, BLOOD, V102, P192, DOI 10.1182/blood-2002-12-3753; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Hippenstiel S, 2002, BIOCHEM PHARMACOL, V64, P971, DOI 10.1016/S0006-2952(02)01162-0; Hofer-Warbinek R, 2004, CELL DEATH DIFFER, V11, P1317, DOI 10.1038/sj.cdd.4401502; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Janssens B, 1999, BBA-GENE STRUCT EXPR, V1447, P341, DOI 10.1016/S0167-4781(99)00170-0; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Merdek KD, 2004, MOL CELL BIOL, V24, P2410, DOI 10.1128/MCB.24.6.2410-2422.2004; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park B, 2002, J BIOL CHEM, V277, P45361, DOI 10.1074/jbc.M202447200; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Surpili MJ, 2003, BIOCHEMISTRY-US, V42, P15369, DOI 10.1021/bi034575v; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHANG JC, 1995, J THORAC CARDIOV SUR, V109, P1059, DOI 10.1016/S0022-5223(95)70188-5; Zhang JS, 1998, GENOMICS, V54, P149, DOI 10.1006/geno.1998.5458; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	43	29	31	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2159	2169		10.1038/sj.onc.1210863	http://dx.doi.org/10.1038/sj.onc.1210863			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952117				2022-12-28	WOS:000254621300006
J	Fukunaga-Kalabis, M; Martinez, G; Telson, SM; Liu, ZJ; Balint, K; Juhasz, I; Elder, DE; Perbal, B; Herlyn, M				Fukunaga-Kalabis, M.; Martinez, G.; Telson, S. M.; Liu, Z-J; Balint, K.; Juhasz, I.; Elder, D. E.; Perbal, B.; Herlyn, M.			Downregulation of CCN3 expression as a potential mechanism for melanoma progression	ONCOGENE			English	Article						melanoma; CCN3; matricellular protein; matrix metalloproteinase	BREAST-CANCER CELLS; MATRIX-METALLOPROTEINASE; MALIGNANT-MELANOMA; INVASION; MIGRATION; GROWTH; LINES; GENE; PROLIFERATION; COMMUNICATION	Coculture of human melanocytes with keratinocytes upregulates CCN3, a matricellular protein critical to maintenance of normal homeostasis of melanocytes in the skin. CCN3 affects two fundamental features of melanocyte physiology: it inhibits melanocyte proliferation and stimulates their adhesion to the basement membrane. Here we report that expression of CCN3 is downregulated in advanced melanomas. Aggressive melanoma cell lines did not respond to treatment with CCN3 inducers, such as interleukin-1 beta (IL-beta), while less aggressive melanoma cell lines responded similarly to melanocytes. Immunostaining analyses revealed that CCN3 was present in melanoma cells close to the epidermal-dermal interface, but not in melanoma cells that had invaded deep into the dermis or had metastasized to lymph nodes. Contrary to our expectations, overexpression of CCN3 in 1205Lu metastatic melanoma cells did not affect their adhesion to collagen IV. However, CCN3 decreased the transcription and activation of matrix metalloproteinases and suppressed the invasion of 1205Lu melanoma cells. These results suggest that the lack of CCN3 in advanced melanoma cells contributes to their invasive phenotype. Whereas major matricellular proteins, such as osteopontin, tenascin or secreted protein acidic and rich in cysteine (SPARC), are strongly upregulated in melanoma cells; CCN3 is the first member of this family that is downregulated.	[Fukunaga-Kalabis, M.; Martinez, G.; Telson, S. M.; Liu, Z-J; Balint, K.; Herlyn, M.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; [Juhasz, I.] Univ Debrecen, Med & Hlth Sci Ctr, Dept Dermatol & Venerol, Debrecen, Hungary; [Elder, D. E.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Perbal, B.] Univ Paris 7D, Lab Oncol Virale & Mol, Paris, France	The Wistar Institute; University of Debrecen; University of Pennsylvania; UDICE-French Research Universities; Universite Paris Cite	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.org	Balint, Klara/ABB-8816-2021		NCI NIH HHS [R01 CA047159, CA76674, R01 CA080999, CA25874, CA80999, P30 CA010815, CA47159, R01 CA076674, P01 CA025874, CA10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025874, R01CA080999, R01CA076674, P30CA010815, R01CA047159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benini S, 2005, ONCOGENE, V24, P4349, DOI 10.1038/sj.onc.1208620; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; Denkert C, 2002, CLIN EXP METASTAS, V19, P79, DOI 10.1023/A:1013857325012; Fukunaga-Kalabis M, 2006, J CELL BIOL, V175, P563, DOI 10.1083/jcb.200602132; Gilles C, 1998, CANCER RES, V58, P5529; Glukhova L, 2001, CANCER GENET CYTOGEN, V130, P105, DOI 10.1016/S0165-4608(01)00477-0; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Haass NK, 2004, J MOL HISTOL, V35, P309; Haass NK, 2005, PIGM CELL RES, V18, P150, DOI 10.1111/j.1600-0749.2005.00235.x; HERLYN M, 1991, CANCER RES, V51, P4853; Hofmann UB, 1999, BRIT J CANCER, V81, P774, DOI 10.1038/sj.bjc.6690763; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Kalembeyi I, 2003, INT J CANCER, V105, P53, DOI 10.1002/ijc.11037; Kleer CG, 2004, NEOPLASIA, V6, P179, DOI 10.1593/neo.03316; Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555-005-1572-1; Lake AC, 2003, AM J PATHOL, V162, P219, DOI 10.1016/S0002-9440(10)63813-8; Laurent M, 2003, FASEB J, V17, P1919, DOI 10.1096/fj.02-1023fje; MAILLARDM, 2001, MOL PATHOL, V54, P275; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; Matic M, 2002, J INVEST DERMATOL, V118, P110, DOI 10.1046/j.0022-202x.2001.01623.x; McCallum L, 2006, BLOOD, V108, P1716, DOI 10.1182/blood-2006-04-016113; Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008-5472.CAN-05-2082; Perbal B, 2003, J CLIN PATHOL-MOL PA, V56, P80, DOI 10.1136/mp.56.2.80; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Planque N, 2006, J CELL BIOCHEM, V99, P105, DOI 10.1002/jcb.20887; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; Tanimura S, 2003, BIOCHEM BIOPH RES CO, V304, P801, DOI 10.1016/S0006-291X(03)00670-3; Welch DR, 2000, CANCER RES, V60, P1552; Zhou YW, 2005, J INVEST DERMATOL, V124, P1044, DOI 10.1111/j.0022-202X.2005.23680.x	35	58	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2552	2560		10.1038/sj.onc.1210896	http://dx.doi.org/10.1038/sj.onc.1210896			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17968313	Green Accepted			2022-12-28	WOS:000255057000005
J	Gallego, MA; Ballot, C; Kluza, J; Hajji, N; Martoriati, A; Castera, L; Cuevas, C; Formstecher, P; Joseph, B; Kroemer, G; Bailly, C; Marchetti, P				Gallego, M-A; Ballot, C.; Kluza, J.; Hajji, N.; Martoriati, A.; Castera, L.; Cuevas, C.; Formstecher, P.; Joseph, B.; Kroemer, G.; Bailly, C.; Marchetti, P.			Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway	ONCOGENE			English	Article						apoptosis; mitochondria; chemotherapy	CANCER-CELLS; MITOCHONDRIAL-DNA; LAMELLARIN-D; DEATH; INHIBITOR; CHEMOTHERAPY; TRANSLOCATION; COMBINATION; EXPRESSION; REDUCTION	Non-small cell lung carcinomas (NSCLCs) are typically resistant against apoptosis induced by standard chemotherapy. We evaluated the effects of the two potential antitumor agents of the lamellarin class on a highly apoptosis-resistant NSCLC cell line. Both the marine alkaloid lamellarin-D and its synthetic amino derivative PM031379 induced the activation of Bax, the mitochondrial release of cytochrome c and apoptosis-inducing factor (AIF), as well as the activation of caspase-3. However, only PM031379 triggered cell death and sign of nuclear apoptosis coupled to the nuclear translocation of AIF. Depletion of AIF with small interfering RNA or microinjection of a neutralizing anti-AIF antibody largely prevented PM031379-induced cytotoxicity, underscoring the essential contribution of AIF to NSCLC killing. Using NSCLC cells lacking mitochondrial DNA, we showed that the generation of mitochondrial reactive oxygen species (ROS) was crucial for the PM031379-induced translocation of AIF to the nucleus and subsequently cell death. Pretreatment of NSCLC cells with menadione, a mitochondrial ROS generator, was able to restore the deficient chemotherapy-induced apoptosis of NSCLC cells. Altogether, these data suggest that mitochondrial ROS generation is crucial for overriding the chemoresistance of NSCLC cells. Moreover, this study delineates the unique mechanism of action of lamellarins as potential anticancer agents.	[Gallego, M-A; Ballot, C.; Kluza, J.; Martoriati, A.; Castera, L.; Formstecher, P.; Bailly, C.; Marchetti, P.] Univ Lille 2, Fac Med, INSERM, Jean Pierre Aubert Res Ctr,U837, F-59045 Lille, France; [Hajji, N.; Joseph, B.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Cuevas, C.] PharmaMar, E-28770 Madrid, Spain; [Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Karolinska Institutet; PharmaMar; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Marchetti, P (corresponding author), Univ Lille 2, Fac Med, INSERM, Jean Pierre Aubert Res Ctr,U837, 1 Pl Verdun, F-59045 Lille, France.	philippe.marchetti@lille.inserm.fr	Kroemer, Guido/AAY-9859-2020; Kluza, Jérome/B-6312-2012; hajji, nabil/AAV-1435-2020; BAILLY, Christian/AAK-2799-2021; KROEMER, Guido/B-4263-2013	Kluza, Jérome/0000-0002-7346-1305; BAILLY, Christian/0000-0002-2973-9357; KROEMER, Guido/0000-0002-9334-4405; Martoriati, Alain/0000-0002-5684-1728; Castera, Laurent/0000-0002-0459-3400; MARCHETTI, Philippe/0000-0002-4663-6800; Joseph, Bertrand/0000-0001-5655-9979				Anderson CP, 1997, EUR J CANCER, V33, P2016, DOI 10.1016/S0959-8049(97)00203-7; Armand R, 2004, TOXICOL APPL PHARM, V196, P68, DOI 10.1016/j.taap.2003.12.001; Bailly Christian, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P363, DOI 10.2174/1568011043352939; Bartling B, 2004, EXP CELL RES, V298, P83, DOI 10.1016/j.yexcr.2004.04.007; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; Cande C, 2004, J CELL SCI, V117, P4461, DOI 10.1242/jcs.01356; Ekedahl J, 2003, CANCER BIOL THER, V2, P663; Engel RH, 2006, FRONT BIOSCI-LANDMRK, V11, P300, DOI 10.2741/1798; Facompre M, 2003, CANCER RES, V63, P7392; Fennell DA, 2005, CLIN CANCER RES, V11, P2097, DOI 10.1158/1078-0432.CCR-04-1482; Ferreira CG, 2001, ANN ONCOL, V12, P799, DOI 10.1023/A:1011167113067; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; Furre IE, 2005, CANCER RES, V65, P11051, DOI 10.1158/0008-5472.CAN-05-0510; Gabellini N, 2006, J CELL PHYSIOL, V207, P711, DOI 10.1002/jcp.20627; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Kang YH, 2004, INT J CANCER, V112, P385, DOI 10.1002/ijc.20424; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; Kluza J, 2006, CANCER RES, V66, P3177, DOI 10.1158/0008-5472.CAN-05-1929; Krishnaiah P, 2004, J NAT PROD, V67, P1168, DOI 10.1021/np030503t; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P., 1996, APOPTOSIS, V1, P119; Murahashi H, 2003, J LEUKOCYTE BIOL, V73, P399, DOI 10.1189/jlb.0702335; Nyman U, 2005, J BIOL CHEM, V280, P34159, DOI 10.1074/jbc.M500394200; O'Connor K, 2006, APOPTOSIS, V11, P1205, DOI 10.1007/s10495-006-6796-1; Okouoyo S, 2004, INT J CANCER, V108, P580, DOI 10.1002/ijc.11585; Park MT, 2005, BLOOD, V105, P1724, DOI 10.1182/blood-2004-07-2938; Park YC, 2005, LIFE SCI, V77, P2059, DOI 10.1016/j.lfs.2005.04.021; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Yang LL, 2003, CANCER RES, V63, P831; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhivotovsky B, 2003, SEMIN CANCER BIOL, V13, P125, DOI 10.1016/S1044-579X(02)00130-X	37	62	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					1981	1992		10.1038/sj.onc.1210833	http://dx.doi.org/10.1038/sj.onc.1210833			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17906690				2022-12-28	WOS:000254359100003
J	Julian, LM; Palander, O; Seifried, LA; Foster, JEG; Dick, FA				Julian, L. M.; Palander, O.; Seifried, L. A.; Foster, J. E. G.; Dick, F. A.			Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation	ONCOGENE			English	Article						cell cycle; retinoblastoma; E2F; apoptosis; transcription	CELL-CYCLE ARREST; E2F; PROTEINS; FAMILY; PROLIFERATION	The retinoblastoma protein (pRB) has the dual capability to negatively regulate both E2F-induced cell cycle entry and E2F1-induced apoptosis. In this report, we characterize a unique pRB-E2F1 interaction. Using mutagenesis to disrupt E2F1 binding, we find that the ability of pRB to regulate E2F1-induced apoptosis is diminished when this interaction is lost. Strikingly, this mutant form of pRB retains the ability to control E2F responsive cell cycle genes and blocks cell proliferation. These functional properties are the reciprocal of a previously described E2F binding mutant of pRB that interacts with E2F1, but lacks the ability to interact with other E2Fs. Our work shows that these distinct interactions allow pRB to separately regulate E2F-induced cell proliferation and apoptosis. This suggests a novel form of regulation whereby separate types of binding contacts between the same types of molecules can confer distinct functional outcomes.	[Julian, L. M.; Palander, O.; Seifried, L. A.; Foster, J. E. G.; Dick, F. A.] Univ Western Ontario, Dept Biochem, Childrens Hlth Res Inst, London, ON N6A 4L6, Canada	Western University (University of Western Ontario)	Dick, FA (corresponding author), Univ Western Ontario, Dept Biochem, Childrens Hlth Res Inst, 790 Commiss Rd E, London, ON N6A 4L6, Canada.	fdick@uwo.ca		Foster, Julia/0000-0002-6971-5683				Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dick FA, 2002, J VIROL, V76, P6224, DOI 10.1128/JVI.76.12.6224-6234.2002; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Johnson DG, 2006, CURR MOL MED, V6, P731; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Stevens C, 2003, CELL CYCLE, V2, P435, DOI 10.4161/cc.2.5.462; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000	16	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1572	1579		10.1038/sj.onc.1210803	http://dx.doi.org/10.1038/sj.onc.1210803			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17891180				2022-12-28	WOS:000253815800009
J	Vasilcanu, R; Vasilcanu, D; Rosengren, L; Natalishvili, N; Sehat, B; Yin, S; Girnita, A; Axelson, M; Girnita, L; Larsson, O				Vasilcanu, R.; Vasilcanu, D.; Rosengren, L.; Natalishvili, N.; Sehat, B.; Yin, S.; Girnita, A.; Axelson, M.; Girnita, L.; Larsson, O.			Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1	ONCOGENE			English	Article						PPP; IGF-1R; MDM2; beta-arrestin1; cancer	GROWTH-FACTOR-I; IGF-1 RECEPTOR; CYCLOLIGNAN PPP; BETA-ARRESTIN; CELL-GROWTH; MULTIPLE-MYELOMA; TYROSINE KINASE; UVEAL MELANOMA; TUMOR-GROWTH; MOUSE MODEL	The insulin-like growth factor 1 receptor (IGF-1R) is crucial for growth and survival of malignant cells. Experience in targeting IGF-1R in cancer models has shown that strategies promoting downregulation of the receptor are much more efficient in inducing apoptosis than those inhibiting the IGF-1R activity. Recently, we found that the cyclolignan picropodophyllin (PPP) inhibits phosphorylation of IGF-1R and activation of downstream signaling without interfering with the highly homologous insulin receptor (IR). Furthermore, PPP treatment caused strong regression of tumor grafts and prolonged survival of animals with systemic tumor disease. Here we demonstrate that PPP also downregulates the IGF-1R, whereas the IR and several other receptors were not affected. PPP-induced IGF-1R downregulation required expression of the MDM2 E3 ligase, which recently was found to ubiquitinate and cause degradation of the IGF-1R. In addition knockdown of beta-arrestin1, the adaptor molecule known to bridges MDM2 and IGF-1R, prevented downregulation of the receptor and significantly decreased PPP-induced cell death. All together these data suggest that PPP downregulates IGF-1R by interfering with the action of beta-arrestin1/MDM2 as well as the achieved receptor downregulation contributes to the apoptotic effect of PPP.	[Vasilcanu, R.; Vasilcanu, D.; Rosengren, L.; Natalishvili, N.; Sehat, B.; Yin, S.; Girnita, A.; Girnita, L.; Larsson, O.] Karolinska Inst, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; [Vasilcanu, R.; Vasilcanu, D.; Rosengren, L.; Natalishvili, N.; Sehat, B.; Yin, S.; Girnita, A.; Girnita, L.; Larsson, O.] Karolinska Univ Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; [Axelson, M.] Karolinska Univ Hosp, Dept Clin Chem, SE-17176 Stockholm, Sweden; [Axelson, M.] Karolinska Inst, Dept Clin Chem, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Larsson, O (corresponding author), Karolinska Inst, Dept Pathol & Oncol, CCK R8 04, SE-17176 Stockholm, Sweden.	Olle.Larsson@ki.se	Girnita, Leonard/A-4168-2008; Girnita, Ada/AAC-4518-2020	Girnita, Leonard/0000-0003-0280-9500; 				Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; Baserga R, 2004, EUR J CANCER, V40, P2013, DOI 10.1016/j.ejca.2004.06.015; Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; BUCHARDT O, 1986, J PHARM SCI, V75, P1076, DOI 10.1002/jps.2600751111; Catrina SB, 2005, BRIT J CANCER, V92, P1467, DOI 10.1038/sj.bjc.6602408; Colon E, 2007, ENDOCRINOLOGY, V148, P128, DOI 10.1210/en.2006-0835; Conti L, 2007, BLOOD, V109, P2496, DOI 10.1182/blood-2006-07-034231; GHOSH RN, 1994, J CELL SCI, V107, P2177; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Lee CT, 1996, CANCER RES, V56, P3038; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Loughran G, 2005, ONCOGENE, V24, P6185, DOI 10.1038/sj.onc.1208772; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; Menu E, 2006, BLOOD, V107, P655, DOI 10.1182/blood-2005-01-0293; Menu E, 2007, INT J CANCER, V121, P1857, DOI 10.1002/ijc.22845; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Razuvaev A, 2007, J VASC SURG, V46, P108, DOI 10.1016/j.jvs.2007.02.066; RESNICOFF M, 1994, CANCER RES, V54, P4848; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sehat B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000340; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; Tomizawa M, 2006, WORLD J GASTROENTERO, V12, P6531, DOI 10.3748/wjg.v12.i40.6531; Ulfarsson E, 2005, CLIN CANCER RES, V11, P4674, DOI 10.1158/1078-0432.CCR-05-0129; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065; Vasilcanu D, 2006, ONCOGENE, V25, P3186, DOI 10.1038/sj.onc.1209339; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Xie YT, 1999, CANCER RES, V59, P3588; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	42	64	68	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1629	1638		10.1038/sj.onc.1210797	http://dx.doi.org/10.1038/sj.onc.1210797			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828296				2022-12-28	WOS:000253815800015
J	Wu, L; Bernard-Trifilo, JA; Lim, Y; Lim, ST; Mitra, SK; Uryu, S; Chen, M; Pallen, CJ; Cheung, NKV; Mikolon, D; Mielgo, A; Stupack, DG; Schlaepfer, DD				Wu, L.; Bernard-Trifilo, J. A.; Lim, Y.; Lim, S-T; Mitra, S. K.; Uryu, S.; Chen, M.; Pallen, C. J.; Cheung, N-K V.; Mikolon, D.; Mielgo, A.; Stupack, D. G.; Schlaepfer, D. D.			Distinct FAK-Src activation events promote alpha 5 beta 1 and alpha 4 beta 1 integrin-stimulated neuroblastoma cell motility	ONCOGENE			English	Article						Src; FAK; alpha 4 integrin; alpha 5 integrin; motility; neuroblastoma	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; FIBRONECTIN MATRIX; MIGRATION; ALPHA; SUBUNIT; CANCER	Signals from. bronectin-binding integrins promote neural crest cell motility during development in part through protein-tyrosine kinase (PTK) activation. Neuroblastoma (NB) is a neural crest malignancy with high metastatic potential. We find that alpha 4 and alpha 5 integrins are present in late-stage NB tumors and cell lines derived thereof. To determine the signaling connections promoting either alpha 4 beta 1or alpha 5 beta 1-initiated NB cell motility, pharmacological, dominant negative and short-hairpin RNA (shRNA) inhibitory approaches were undertaken. shRNA knockdown revealed that alpha 5 beta 1-stimulated NB motility is dependent upon focal adhesion kinase (FAK) PTK, Src PTK and p130Cas adapter protein expression. Cell reconstitution showed that FAK catalytic activity is required for alpha 5 beta 1-stimulated Src activation in part through direct FAK phosphorylation of Src at Tyr-418. Alternatively, alpha 4 beta 1-stimulated NB cell motility is dependent upon Src and p130Cas but FAK is not essential. Catalytically inactive receptor protein-tyrosine phosphatase-alpha overexpression inhibited alpha 4 beta 1-stimulated NB motility and Src activation consistent with alpha 4-regulated Src activity occurringthr ough Src Tyr-529 dephosphorylation. In alpha 4 shRNA-expressingNB cells, alpha 4 beta 1-stimulated Src activation and NB cell motility were rescued by wild type but not cytoplasmic domain-truncated alpha 4 re-expression. These studies, supported by results using reconstituted fibroblasts, reveal that alpha 4 beta 1-mediated Src activation is mechanistically distinct from FAK-mediated Src activation during alpha 5 beta 1-mediated NB migration and support the evaluation of inhibitors to alpha 4, Src and FAK in the control of NB tumor progression.	[Wu, L.; Bernard-Trifilo, J. A.; Lim, Y.; Lim, S-T; Uryu, S.; Schlaepfer, D. D.] Scripps Res Inst, Dept Immunol, La Jolla, CA USA; [Chen, M.; Pallen, C. J.] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; [Chen, M.; Pallen, C. J.] Univ British Columbia, Child & Family Res Inst, Vancouver, BC V6T 1W5, Canada; [Cheung, N-K V.] Mem Sloan Kettering Canc Ctr, Dept Pediat Oncol, New York, NY 10021 USA; [Mikolon, D.; Mielgo, A.; Stupack, D. G.] Moores UCSD Canc Ctr, Dept Pathol, La Jolla, CA 92093 USA	Scripps Research Institute; University of British Columbia; Child & Family Research Institute; University of British Columbia; Memorial Sloan Kettering Cancer Center	Schlaepfer, DD (corresponding author), Moores UCSD Canc Ctr, Dept Reprod Med, 0803 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	dschlaepfer@ucsd.edu	; mostafavi-pour, zohreh/T-5588-2018	Lim, Steve/0000-0003-0323-8607; Pallen, Catherine/0000-0002-3576-5295; mostafavi-pour, zohreh/0000-0002-3779-177X	NATIONAL CANCER INSTITUTE [R01CA102310, R01CA075240, P01CA106450, R01CA107263, R29CA075240, R01CA087038] Funding Source: NIH RePORTER; NCI NIH HHS [CA106450, R01 CA102310-06, R01 CA087038, R01 CA087038-05, R29 CA075240, R01 CA102310, CA75240, P01 CA106450, CA102310, R01 CA075240-11, R01 CA075240, CA107263, CA87038, R01 CA107263] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Chen M, 2006, J BIOL CHEM, V281, P11972, DOI 10.1074/jbc.M600561200; Geng X, 2005, IMMUNOLOGY, V115, P347, DOI 10.1111/j.1365-2567.2005.02175.x; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hsia DA, 2005, MOL CELL BIOL, V25, P9700, DOI 10.1128/MCB.25.21.9700-9712.2005; Huttenlocher A, 2005, NAT CELL BIOL, V7, P336, DOI 10.1038/ncb0405-336; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; Kil SH, 1998, DEV BIOL, V202, P29, DOI 10.1006/dbio.1998.8985; Mattila E, 2005, NAT CELL BIOL, V7, P78, DOI 10.1038/ncb1209; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Na J, 2003, J CELL SCI, V116, P2333, DOI 10.1242/jcs.00445; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pinco KA, 2002, MOL BIOL CELL, V13, P3203, DOI 10.1091/mbc.02-05-0086; Rose DM, 2002, IMMUNOL REV, V186, P118, DOI 10.1034/j.1600-065X.2002.18611.x; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Testaz S, 2001, DEV DYNAM, V222, P127, DOI 10.1002/dvdy.1181; WU CY, 1995, J CELL SCI, V108, P821; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049	25	80	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1439	1448		10.1038/sj.onc.1210770	http://dx.doi.org/10.1038/sj.onc.1210770			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828307	Green Accepted			2022-12-28	WOS:000253548200011
J	Grochova, D; Vankova, J; Damborsky, J; Ravcukova, B; Smarda, J; Vojtesek, B; Smardova, J				Grochova, D.; Vankova, J.; Damborsky, J.; Ravcukova, B.; Smarda, J.; Vojtesek, B.; Smardova, J.			Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast	ONCOGENE			English	Article						p53; FASAY; transactivation; conformation; temperature-dependent mutants; discriminating mutants	CYTOPROTECTIVE AMINOTHIOL WR1065; WILD-TYPE P53; TUMOR-SUPPRESSOR; FUNCTIONAL ASSAY; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; MUTATION ANALYSIS; SENSITIVE MUTANT; HUMAN CANCERS; DNA-BINDING	The p53 gene is often mutated during cancer development. Frequency and functional consequences of these mutations vary in different tumor types. We analysed conformation and temperature dependency of 23 partially inactivating temperature-dependent (td) p53 mutants derived from various human tumors in yeast. We found considerable differences in transactivation capabilities and discriminative character of various p53 mutants. No correlations in transactivation rates and conformations of the td p53 proteins were detected. Amifostine-induced p53 reactivation occurred only in 13 of 23 td mutants, and this effect was temperature dependent and responsive element specific. The most of the p53 mutations (10/13) reactivated by amifostine were located in the part of the p53 gene coding for hydrophobic b-sandwich structure of the DNA-binding domain.	[Grochova, D.; Vankova, J.; Ravcukova, B.; Smardova, J.] Univ Hosp, Dept Pathol, Brno 62500, Czech Republic; [Grochova, D.; Vankova, J.; Damborsky, J.; Smardova, J.] Masaryk Univ, Fac Sci, CS-61137 Brno, Czech Republic; [Vojtesek, B.] Masaryk Memory Canc Inst, Dept Expt Oncol, Brno, Czech Republic	University Hospital Brno; Masaryk University Brno; Masaryk Memorial Cancer Institute	Smardova, J (corresponding author), Univ Hosp, Dept Pathol, Jihlavska 20, Brno 62500, Czech Republic.	janasmarda@seznam.cz	Damborsky, Jiri/H-3799-2012	Damborsky, Jiri/0000-0002-7848-8216				Acosta JC, 2003, MOL CANCER THER, V2, P893; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Di Como CJ, 1998, ONCOGENE, V16, P2527; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Lane DR, 2003, DRUG DISCOV TODAY, V8, P347, DOI 10.1016/S1359-6446(03)02669-2; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Maurici D, 2001, ONCOGENE, V20, P3533, DOI 10.1038/sj.onc.1204428; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; MILNER J, 1987, ONCOGENE, V1, P453; Nenutil R, 2005, J PATHOL, V207, P251, DOI 10.1002/path.1838; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Pataer A, 2006, CANCER GENE THER, V13, P806, DOI 10.1038/sj.cgt.7700960; Pavlova S, 2003, INT J ONCOL, V23, P121; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; SCHATZBERG AF, 1992, J CLIN PSYCHIAT, V53, P20; Selivanova G, 2007, ONCOGENE, V26, P2243, DOI 10.1038/sj.onc.1210295; Shiraishi K, 2004, J BIOL CHEM, V279, P348, DOI 10.1074/jbc.M310815200; Smardova J, 2005, DIFFERENTIATION, V73, P261, DOI 10.1111/j.1432-0436.2005.00028.x; Smardova J, 2004, ONCOL REP, V11, P923; Smardova J, 2001, TUMOR BIOL, V22, P59; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; Xirodimas DP, 1999, J BIOL CHEM, V274, P28042, DOI 10.1074/jbc.274.39.28042; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	40	21	21	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1243	1252		10.1038/sj.onc.1210748	http://dx.doi.org/10.1038/sj.onc.1210748			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724467				2022-12-28	WOS:000253407000006
J	Srinivasan, D; Sims, JT; Plattner, R				Srinivasan, D.; Sims, J. T.; Plattner, R.			Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival	ONCOGENE			English	Article						Abl kinases; breast cancer; proliferation; survival; transformation; STAT3	TYROSINE KINASE; INHIBITOR; APOPTOSIS; LEUKEMIA; PATHWAY; TARGETS; GENES; STAT1	Mutant Abl kinases ( such as BCR-Abl) drive the development of leukemia; however little is known regarding whether Abl kinases contribute to the development or progression of solid tumors. We recently demonstrated that endogenous Abl kinases ( c-Abl, Arg) are activated by deregulated ErbB receptors and Src kinases, and drive invasion of aggressive breast cancer cells. In this study, we examined whether activation of endogenous Abl kinases affects transformation, proliferation and survival, which are major contributors to breast cancer development and metastatic progression. Using a pharmacological inhibitor and RNAi, we demonstrate that activation of endogenous Abl kinases dramatically promotes breast cancer cell proliferation and anchorage-independent growth in serum, as well as survival following nutrient deprivation. Activation of Abl kinases mediates phosphorylation of STAT3, and promotes proliferation by accelerating G(1)-> S progression. Moreover, we identify IGF-1R as a novel upstream activator of endogenous Abl kinases, and demonstrate that Abl kinase activation is required for IGF-1-stimulated cell cycle progression in breast cancer cells. Since activation of Abl kinases affects multiple steps of breast cancer development and progression, Abl kinase inhibitors are likely to be effective agents for the treatment of breast cancers containing highly active Abl kinases.	[Srinivasan, D.; Sims, J. T.; Plattner, R.] Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA	University of Kentucky	Plattner, R (corresponding author), Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, 800 Rose St,Combs Res Bldg 209, Lexington, KY 40536 USA.	rplat2@uky.edu			NCI NIH HHS [R01 CA116784] Funding Source: Medline; NCRR NIH HHS [P20 RR20171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116784] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Buettner R, 2002, CLIN CANCER RES, V8, P945; Burkle A, 2005, FEBS J, V272, P4576, DOI 10.1111/j.1742-4658.2005.04864.x; Camirand A, 2005, BREAST CANCER RES, V7, pR570, DOI 10.1186/bcr1028; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Chernicky CL, 2002, J CLIN PATHOL-MOL PA, V55, P102, DOI 10.1136/mp.55.2.102; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kauffman EC, 2003, J UROLOGY, V169, P1122, DOI 10.1097/01.ju.0000051580.89109.4b; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Liliensiek SJ, 2006, EXP EYE RES, V83, P61, DOI 10.1016/j.exer.2005.11.007; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; Nagano K, 2006, ONCOGENE, V25, P493, DOI 10.1038/sj.onc.1208996; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; PENDERGAST AM, 2001, CHRONIC MYELOID LEUK, P19; Plattner R, 2003, CELL CYCLE, V2, P273, DOI 10.4161/cc.2.4.409; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Singer CF, 2004, ENDOCR-RELAT CANCER, V11, P861, DOI 10.1677/erc.1.00801; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; van Diest PJ, 2004, J CLIN PATHOL, V57, P675, DOI 10.1136/jcp.2003.010777; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Widschwendter A, 2002, CLIN CANCER RES, V8, P3065; Wu J, 1999, BRIT J CANCER, V79, P1572, DOI 10.1038/sj.bjc.6690250	33	86	90	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1095	1105		10.1038/sj.onc.1210714	http://dx.doi.org/10.1038/sj.onc.1210714			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700528				2022-12-28	WOS:000253136700009
J	Engelbert, D; Schnerch, D; Baumgarten, A; Wasch, R				Engelbert, D.; Schnerch, D.; Baumgarten, A.; Waesch, R.			The ubiquitin ligase APC(Cdh1) is required to maintain genome integrity in primary human cells	ONCOGENE			English	Article						Cdh1; anaphase-promoting complex; mitotic exit; genomic instability; ubiquitin-dependent proteolysis	ANAPHASE-PROMOTING COMPLEX; DNA-DAMAGE; CENTROSOME AMPLIFICATION; DEPENDENT PROTEOLYSIS; CYCLIN-E; INSTABILITY; OVEREXPRESSION; DEGRADATION; ACTIVATION; CHECKPOINT	Ensuring precise DNA replication and chromosome segregation is essential during cell division in order to provide genomic stability and avoid malignant growth. Proteolytic control of cell cycle regulators by the anaphase-promoting complex, activated by Cdh1 (APC(Cdh1)), is responsible for a stable G(1) phase after mitotic exit allowing accurate preparation for DNA replication in the following S phase. APCCdh1 target proteins are frequently upregulated in tumor cells and the inactivation of human Cdh1 might interfere with genome integrity by target stabilization. Here we show that APCCdh1 is required for maintaining genomic integrity in primary human cells. Lentiviral-delivered strong and stable suppression of Cdh1 by RNA interference (RNAi) causes aberrant accumulation of several APCCdh1 target proteins, such as cyclin A, B, Aurora A or Plk1, which control accurate and equal distribution of the genetic information to daughter cells. This induces a premature and prolonged S phase, mitotic-entry delay and defects in chromosome separation and cytokinesis. Cell cycle deregulation by stable knockdown of Cdh1 leads to activation of p53/p21 and genomic instability, which is further increased by codepletion of p53. Thus, stabilization of APCCdh1 targets may initiate aberrant DNA replication and chromosome separation, and trigger a p53 response by deregulating G(1) in primary human cells.	[Engelbert, D.; Schnerch, D.; Baumgarten, A.; Waesch, R.] Univ Freiburg, Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany	University of Freiburg	Wasch, R (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Hugstetter St 55, D-79106 Freiburg, Germany.	ralph.waesch@uniklinik-freiburg.de	Waesch, Ralph/F-6282-2019; Holt, Janet E/B-2415-2013					Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Cross FR, 2003, DEV CELL, V4, P741, DOI 10.1016/S1534-5807(03)00119-9; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Lehman NL, 2006, CELL CYCLE, V5, P1569, DOI 10.4161/cc.5.14.2925; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagao K, 2004, NATURE, V430, P1044, DOI 10.1038/nature02803; Naito Y, 2004, NUCLEIC ACIDS RES, V32, pW124, DOI 10.1093/nar/gkh442; Park KH, 2005, BREAST CANCER RES, V7, pR238, DOI 10.1186/bcr978; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Rape M, 2004, NATURE, V432, P588, DOI 10.1038/nature03023; Romero F, 2004, MOL CELL BIOL, V24, P2720, DOI 10.1128/MCB.24.7.2720-2733.2004; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; VEELKEN H, 1994, HUM GENE THER, V5, P1203, DOI 10.1089/hum.1994.5.10-1203; Wang CX, 2000, BLOOD, V96, P259, DOI 10.1182/blood.V96.1.259.013k36_259_263; Wang Q, 2003, ONCOGENE, V22, P1486, DOI 10.1038/sj.onc.1206224; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	46	92	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					907	917		10.1038/sj.onc.1210703	http://dx.doi.org/10.1038/sj.onc.1210703			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700535	Bronze			2022-12-28	WOS:000252946300003
J	Podar, K; Gouill, SL; Zhang, J; Opferman, JT; Zorn, E; Tai, YT; Hideshima, T; Amiot, M; Chauhan, D; Harousseau, JL; Anderson, KC				Podar, K.; Gouill, S. L.; Zhang, J.; Opferman, J. T.; Zorn, E.; Tai, Y-T; Hideshima, T.; Amiot, M.; Chauhan, D.; Harousseau, J-L; Anderson, K. C.			A pivotal role for Mcl-1 in Bortezomib-induced apoptosis	ONCOGENE			English	Article						Mcl-1; apoptosis; Bortezomib	PROTEASOME INHIBITOR PS-341; MULTIPLE-MYELOMA CELLS; DOWN-REGULATION; IN-VIVO; SURVIVAL; ACTIVATION; GROWTH; BCL-2; PROTEIN; DIFFERENTIATION	Bortezomib is a proteasome inhibitor for the treatment of relapsed/refractory multiple myeloma (MM). Mechanisms of resistance to Bortezomib are undefined. Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic protein, which protects tumor cells against spontaneous and chemotherapy-induced apoptosis. In MM, specific downregulation of Mcl-1 induces apoptosis. Here, we examined the role of Mcl-1 in Bortezomib- and doxorubicin-induced apoptosis. We demonstrate that Bortezomib, but not doxorubicin, triggers caspase-dependent generation of a 28 kDa Mcl-1 fragment, in several MM cell lines, including MM.1S cells. Conversely, transient transfection of MM.1S cells with a previously reported 28 kDa Mcl-1(128-350) fragment, but not with the Mcl-1(1-127) fragment, induces apoptosis. Therefore, both downregulation of full-length antiapoptotic Mcl-1, as well as Bortezomib- induced generation of Mcl-1(128-350) cleaved protein, contribute to MM cell apoptosis. To verify further these findings, we next compared effects triggered by Bortezomib, doxorubicin and melphalan in Mcl-1(wt/wt) and Mcl-1(Delta/null) murine embryonic fibroblasts (MEFs). Our results show that Bortezomib, but not doxorubicin or melphalan, triggers Mcl-1 cleavage in Mcl-1(wt/wt), but not Mcl-1(Delta/null) MEFs and induces sub-G(1) phase cells; caspase-3 and -9, and PARP cleavage as well as morphological signs of apoptosis. Taken together, these results support an important role of Mcl-1 and a Mcl-1 fragment in Bortezomib- induced cell death in general, and in MM in particular. To prevent relapse of MM in patients treated with Bortezomib, we therefore recommend the combination of Bortezomib with agents that induce MM cell death independent of Mcl-1.	[Podar, K.; Gouill, S. L.; Zhang, J.; Tai, Y-T; Hideshima, T.; Chauhan, D.; Anderson, K. C.] Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma CtrDept Med Oncol, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02215 USA; [Gouill, S. L.; Amiot, M.; Harousseau, J-L] CHU Nantes, Hotel Dieu, Serv Hematol Clin, F-44035 Nantes 01, France; [Gouill, S. L.; Amiot, M.] INSERM, U 0601, Inst Biol, Quai Moncousu 9, F-44035 Nantes 01, France; [Opferman, J. T.] St Jude Childrens Hosp, Dept Biochem, Memphis, TN 38105 USA; [Zorn, E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Ctr Hematol Oncol,Dept Med, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); St Jude Children's Research Hospital; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Podar, K (corresponding author), Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma CtrDept Med Oncol, Dana Farber Canc Inst,Dept Med Oncol, 44 Binney St, Boston, MA 02215 USA.	klaus_podar@dfci.harvard.edu; kenneth_anderson@dfci.harvard.edu	Podar, Klaus/ABD-1112-2020; Opferman, Joseph T/M-5331-2018; Amiot, Martine/K-9076-2015	Podar, Klaus/0000-0002-7414-3632; Opferman, Joseph T/0000-0002-1147-5621; le gouill, steven/0000-0001-9840-2128; Amiot, Martine/0000-0003-0428-7355	NATIONAL CANCER INSTITUTE [R01CA050947, P01CA078378] Funding Source: NIH RePORTER; NCI NIH HHS [R0 CA 50947, P0-1 CA 78378, P50 CA 10070] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; Chauhan D, 2005, MOL CANCER THER, V4, P686, DOI 10.1158/1535-7163.MCT-04-0338; Chauhan D, 2004, BLOOD, V104, P2458, DOI 10.1182/blood-2004-02-0547; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jang YM, 2004, FEBS LETT, V577, P483, DOI 10.1016/j.febslet.2004.10.053; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Le Gouill S, 2004, CELL CYCLE, V3, P1259; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; LeBlanc R, 2002, CANCER RES, V62, P4996; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; MAURER F, 1906, HDB VERGLEICHENDEN 1, V3, P1; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Opferman JT, 2006, CELL DEATH DIFFER, V13, P1260, DOI 10.1038/sj.cdd.4401978; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Orlowski RZ, 2005, BLOOD, V105, P3058, DOI 10.1182/blood-2004-07-2911; Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Podar K, 2004, CANCER RES, V64, P7500, DOI 10.1158/0008-5472.CAN-04-0124; Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood-2003-10-3527; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Rinkenberger JL, 2000, GENE DEV, V14, P23; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; ZAMAI L, 1993, CYTOMETRY, V14, P891, DOI 10.1002/cyto.990140807; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	46	105	111	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					721	731		10.1038/sj.onc.1210679	http://dx.doi.org/10.1038/sj.onc.1210679			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653083				2022-12-28	WOS:000252884500001
J	Spaner, DE; Foley, R; Galipeau, J; Bramson, J				Spaner, D. E.; Foley, R.; Galipeau, J.; Bramson, J.			Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies	ONCOGENE			English	Review						cancer immunotherapy; Toll-like receptors; hypoxia; glycolysis; adenosine; microenvironment	CHRONIC LYMPHOCYTIC-LEUKEMIA; REGULATORY T-CELLS; CANCER-THERAPY; B-CELLS; ADENOSINE RECEPTORS; MULTIPLE-MYELOMA; CYCLOOXYGENASE INHIBITORS; HEXOSAMINE BIOSYNTHESIS; NUCLEOSIDE TRANSPORTERS; DENDRITIC CELLS	It has long been noted that products of microorganisms have clinical activity against hematologic malignancies. Recent advances suggest that Toll-like receptors (TLRs) activated by ligands in the microbial preparations might account for some of this activity, and that defined TLR agonists might improve the clinical efficacy of this approach. A potentially important mechanism of action of TLR agonists is their ability to cause tumor cells to differentiate into a 'tolerized' state in which they become highly sensitive to cytotoxic effector cells and chemotherapeutic drugs. TLR agonists as single agents have strong activity against cutaneous leukemias and lymphomas but are not as effective against systemic disease. A possible reason for this discrepancy is the hypoxic internal tumor microenvironment, which promotes glycolytic metabolism, and the presence of suppressive cytokines, prostaglandins and nucleosides that prevent strong TLR signaling in cancer cells. Accordingly, concomitant use of agents to counter this intrinsic microenvironmental inhibition, together with TLR agonists, may prove to be an effective treatment strategy for the hematologic malignancies.	[Spaner, D. E.] Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Res Inst, Toronto, ON M4N 3M5, Canada; [Spaner, D. E.] Sunnybrook Reg Canc Ctr, Toronto, ON, Canada; [Spaner, D. E.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Spaner, D. E.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Foley, R.; Bramson, J.] McMaster Univ, Ctr Gene Therapeut, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Galipeau, J.] McGill Univ, Dept Med & Oncol, Sir Mortimer B Davis Jewish Gen Hosp, Montreal, PQ, Canada; [Galipeau, J.] McGill Univ, Dept Med & Oncol, Lady Davis Inst Med Res, Montreal, PQ, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; McMaster University; McGill University; Lady Davis Institute; McGill University	Spaner, DE (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Res Inst, S-116A,Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	david.spaner@swri.ca	Galipeau, Jacques/R-9909-2019	Galipeau, Jacques/0000-0002-9374-1996; Bramson, Jonathan/0000-0003-2874-6886				Al-Waili NS, 2005, MED SCI MONITOR, V11, pRA279; Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569; Blagosklonny MV, 2002, NAT REV CANCER, V2, P221, DOI 10.1038/nrc743; Blay J, 1997, CANCER RES, V57, P2602; Bogner C, 2003, EXP HEMATOL, V31, P218, DOI 10.1016/S0301-472X(02)01076-7; Bohle A, 2003, J UROLOGY, V170, P964, DOI 10.1097/01.ju.0000073852.24341.4a; Bohnhorst J, 2006, LEUKEMIA, V20, P1138, DOI 10.1038/sj.leu.2404225; Bouche C, 2004, ENDOCR REV, V25, P807, DOI 10.1210/er.2003-0026; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cairns R, 2006, MOL CANCER RES, V4, P61, DOI 10.1158/1541-7786.MCR-06-0002; Cann SAH, 2003, POSTGRAD MED J, V79, P672; Casale TB, 2006, ANN ALLERG ASTHMA IM, V97, P454, DOI 10.1016/S1081-1206(10)60934-9; Coors EA, 2006, EUR J DERMATOL, V16, P391; Corthals SL, 2006, BRIT J HAEMATOL, V132, P452, DOI 10.1111/j.1365-2141.2005.05893.x; Curiel TJ, 2007, J CLIN INVEST, V117, P1167, DOI 10.1172/JCI31202; Diebold SS, 2006, EUR J IMMUNOL, V36, P3256, DOI 10.1002/eji.200636617; Dudley ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882; Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Godaly G, 2005, CELL MICROBIOL, V7, P591, DOI 10.1111/j.1462-5822.2004.00489.x; Gomez G, 2003, INT J BIOCHEM CELL B, V35, P410, DOI 10.1016/S1357-2725(02)00177-2; GOODMAN MG, 1994, BLOOD, V84, P3457; GREEN H, 1973, SCIENCE, V182, P836, DOI 10.1126/science.182.4114.836; Gross BJ, 2005, J AM CHEM SOC, V127, P14588, DOI 10.1021/ja0555217; Harrison LI, 2007, J CLIN PHARMACOL, V47, P962, DOI 10.1177/0091270007303766; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Heyen JRR, 2000, MOL BRAIN RES, V77, P138, DOI 10.1016/S0169-328X(00)00042-5; Huang JB, 2007, CELL IMMUNOL, V245, P1, DOI 10.1016/j.cellimm.2007.03.006; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; Jager Dirk, 2007, Methods Mol Biol, V360, P319; Jahrsdorfer B, 2005, CLIN CANCER RES, V11, P1490, DOI 10.1158/1078-0432.CCR-04-1890; Jego G, 2006, LEUKEMIA, V20, P1130, DOI 10.1038/sj.leu.2404226; Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P39, DOI 10.1016/j.coi.2006.11.007; Kindzelskii AL, 2002, J CLIN INVEST, V110, P1801, DOI 10.1172/JCI200215973; King AE, 2006, TRENDS PHARMACOL SCI, V27, P416, DOI 10.1016/j.tips.2006.06.004; Kleef R, 2001, NEUROIMMUNOMODULAT, V9, P55, DOI 10.1159/000049008; Kloor D, 2004, TRENDS PHARMACOL SCI, V25, P294, DOI 10.1016/j.tips.2004.04.004; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Lasley RD, 1999, BASIC RES CARDIOL, V94, P199, DOI 10.1007/s003950050143; Le YY, 2004, J IMMUNOL, V173, P962, DOI 10.4049/jimmunol.173.2.962; Lee J, 2006, P NATL ACAD SCI USA, V103, P1828, DOI 10.1073/pnas.0510801103; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; LEVENTHAL BG, 1970, CANCER CHEMOTH REP 1, V54, P47; Levy O, 2006, J IMMUNOL, V177, P1956, DOI 10.4049/jimmunol.177.3.1956; Link BK, 2006, J IMMUNOTHER, V29, P558, DOI 10.1097/01.cji.0000211304.60126.8f; Llorente L, 2000, ARTHRITIS RHEUM, V43, P1790, DOI 10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2; Malissen B, 2005, NAT IMMUNOL, V6, P749, DOI 10.1038/ni0805-749; Mantovani A, 2006, LEUKEMIA, V20, P937, DOI 10.1038/sj.leu.2404229; Maratheftis CI, 2007, CLIN CANCER RES, V13, P1154, DOI 10.1158/1078-0432.CCR-06-2108; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Mathe G, 2001, BIOMED PHARMACOTHER, V55, P531, DOI 10.1016/S0753-3322(01)00138-X; Melillo G, 2006, MOL CANCER RES, V4, P601, DOI 10.1158/1541-7786.MCR-06-0235; Miggin SM, 2006, J LEUKOCYTE BIOL, V80, P220, DOI 10.1189/jlb.1105672; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Ohm JE, 2001, IMMUNOL RES, V23, P263, DOI 10.1385/IR:23:2-3:263; Olah Mark E, 2003, Mol Interv, V3, P370, DOI 10.1124/mi.3.7.370; Pascoe J, 2006, CURR OPIN ONCOL, V18, P325, DOI 10.1097/01.cco.0000228736.39885.e5; Peng SL, 2005, CURR OPIN IMMUNOL, V17, P230, DOI 10.1016/j.coi.2005.03.003; PETTIPHER ER, 1994, CYTOKINE, V6, P500, DOI 10.1016/1043-4666(94)90077-9; Pinhal-Enfield G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002-9440(10)63698-X; Podar K, 2007, CELL CYCLE, V6, P538, DOI 10.4161/cc.6.5.3922; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Richardson MA, 1999, ALTERN THER HEALTH M, V5, P42; Sala-Newby GB, 1999, J BIOL CHEM, V274, P17789, DOI 10.1074/jbc.274.25.17789; Sato A, 2004, P NATL ACAD SCI USA, V101, P16274, DOI 10.1073/pnas.0406268101; Sato S, 2002, INT IMMUNOL, V14, P783, DOI 10.1093/intimm/dxf046; Saunier EF, 2006, CURR CANCER DRUG TAR, V6, P565, DOI 10.2174/156800906778742460; Shi YH, 2007, CANCER RES, V67, P1823, DOI 10.1158/0008-5472.CAN-06-2381; Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685; Spaner DE, 2007, LEUKEMIA, V21, P53, DOI 10.1038/sj.leu.2404456; Spaner DE, 2006, LEUKEMIA, V20, P286, DOI 10.1038/sj.leu.2404061; Spaner DE, 2005, LEUKEMIA LYMPHOMA, V46, P935, DOI 10.1080/10428190500054426; Sprangers B, 2007, NAT CLIN PRACT ONCOL, V4, P404, DOI 10.1038/ncponc0848; STARNES CO, 1992, NATURE, V357, P11, DOI 10.1038/357011a0; Suleyman H, 2007, PHARMACOL REP, V59, P247; Sun WT, 2005, J BIOCHEM MOL BIOL, V38, P314; Sutinen J, 2007, ANTIVIR THER, V12, P97; Sutmuller RPM, 2006, TRENDS IMMUNOL, V27, P387, DOI 10.1016/j.it.2006.06.005; Takahashi HK, 2005, EUR J PHARMACOL, V512, P223, DOI 10.1016/j.ejphar.2005.01.046; Tergaonkar V, 2007, MOL CELL, V26, P158, DOI 10.1016/j.molcel.2007.04.006; Thompson KA, 1996, EUR J CLIN MICROBIOL, V15, P580, DOI 10.1007/BF01709367; Tiberio L, 2004, VACCINE, V22, P1515, DOI 10.1016/j.vaccine.2003.10.019; Tomic J, 2006, J IMMUNOL, V176, P3830, DOI 10.4049/jimmunol.176.6.3830; Tsung K, 2006, SURG ONCOL, V15, P25, DOI 10.1016/j.suronc.2006.05.002; von Ardenne M, 1970, Acta Biol Med Ger, V25, P671; Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901; Waltz E, 2007, NAT MED, V13, P516, DOI 10.1038/nm0507-516b; Wang HY, 2007, CURR OPIN IMMUNOL, V19, P217, DOI 10.1016/j.coi.2007.02.004; WICE BM, 1983, J BIOL CHEM, V258, P3134; Wolf NA, 2007, J NEUROIMMUNOL, V185, P115, DOI 10.1016/j.jneuroim.2007.02.001; Zeytin HE, 2004, CANCER RES, V64, P3668, DOI 10.1158/0008-5472.CAN-03-3878; ZINKERNAGEL RMG, 1996, SCIENCE, V272, P634; 2006, BLOOD, V108, pB3	100	16	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	2008	27	2					208	217		10.1038/sj.onc.1210905	http://dx.doi.org/10.1038/sj.onc.1210905			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176602				2022-12-28	WOS:000252163600007
J	Alcala, S; Klee, M; Fernandez, J; Fleischer, A; Pimental-Muinos, F				Alcala, S.; Klee, M.; Fernandez, J.; Fleischer, A.; Pimental-Muinos, Fx			A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release	ONCOGENE			English	Article						high-throughput screening; atypical cell death; apoptosis; permeability transition; phosphate carrier	PERMEABILITY TRANSITION-PORE; APOPTOSIS; PROTEIN; COMPLEXES; COMPONENT; GENES	Functional annotation of complex genomes requires the development of novel experimental platforms with increased capacity. Here, we describe a high-throughput system designed to identify cDNAs whose overexpression induces morphologically distinct cell death modalities. The methodology incorporates two robotized steps, and relies on coexpression of library clones with GFP to reveal the morphological features presented by the dying cells. By using this system we screened 135 000 cDNA clones and obtained 90 independent molecules. Interestingly, three death categories were identified, namely; apoptotic, vacuolated and autophagic. Among the pro-apoptotic clones, we found four members of the mitochondrial carrier family: the phosphate and adenine nucleotide (type 3) transporters, and the mitochondrial carrier homologs (MTCHs) 1 and 2. Expression of these molecules induced cytochrome c release and caspase-9-dependent death. One of them, the phosphate carrier, was able to interact with members of the permeability transition pore complex ANT1 and VDAC1, and its binding to ANT1 was stabilized in the presence of apoptotic activators. Depletion of this carrier by siRNA delayed cytochrome c mobilization and apoptosis. These results attribute a previously undescribed apoptotic function to the phosphate carrier and, more generally, suggest that a common property of various mitochondrial transporters was exploited during evolution to regulate apoptosis.	[Alcala, S.; Klee, M.; Fernandez, J.; Fleischer, A.; Pimental-Muinos, Fx] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Pimental-Muinos, F (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Miguel Unamuno, Salamanca 37007, Spain.	fxp@usal.es	Fleischer, Aarne/ABE-6966-2020; Pimentel-Muinos, Felipe/K-4557-2014	Fleischer, Aarne/0000-0003-4146-3303; Alcala, Sonia/0000-0002-7644-4973; Pimentel-Muinos, Felipe/0000-0002-0258-2855				Albayrak T, 2003, BIOCHEM BIOPH RES CO, V304, P772, DOI 10.1016/S0006-291X(03)00653-3; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Chanda SK, 2003, P NATL ACAD SCI USA, V100, P12153, DOI 10.1073/pnas.1934839100; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Faustin B, 2004, J BIOL CHEM, V279, P20411, DOI 10.1074/jbc.M314259200; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm S, 2004, NAT REV GENET, V5, P179, DOI 10.1038/nrg1291; Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005; Halestrap AP, 2004, NATURE, V430, DOI 10.1038/nature02816; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kiss-Toth E, 2004, CYTOKINE GROWTH F R, V15, P97, DOI 10.1016/j.cytogfr.2004.02.002; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Poncet D, 2006, J CELL BIOL, V174, P985, DOI 10.1083/jcb.200604069; Schobel S, 2006, INT J DEV NEUROSCI, V24, P141, DOI 10.1016/j.ijdevneu.2005.11.003; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Ting Adrian, 2005, Novartis Found Symp, V267, P219; Van Cruchten S, 2002, ANAT HISTOL EMBRYOL, V31, P214, DOI 10.1046/j.1439-0264.2002.00398.x; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Xu XM, 2002, J BIOL CHEM, V277, P48913, DOI 10.1074/jbc.M209613200; Yerushalmi GM, 2002, NEOPLASIA, V4, P510, DOI 10.1038/sj.neo.7900272; Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006	35	67	71	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					44	54		10.1038/sj.onc.1210600	http://dx.doi.org/10.1038/sj.onc.1210600			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17621274				2022-12-28	WOS:000252118700005
J	Argiropoulos, B; Humphries, RK				Argiropoulos, B.; Humphries, R. K.			Hox genes in hematopoiesis and leukemogenesis	ONCOGENE			English	Review						self-renewal; NUP98-HOX; Mll; leukemic stem cells	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; STEM-CELLS; HOMEOBOX GENES; SELF-RENEWAL; IN-VITRO; EXPRESSION PROFILE; UP-REGULATION; HOMEOTIC TRANSFORMATIONS; DIFFERENTIAL EXPRESSION	Gene expression analyses, gene targeting experiments and retroviral overexpression studies in the murine bone marrow transplantation model have provided strong correlative evidence for the involvement of clustered Hox genes in normal hematopoiesis. The data strongly support the hypothesis that the role of Hox genes in normal hematopoiesis is primarily at the level of hematopoietic stem cell function. A large body of evidence now links Hox genes to leukemic transformation including dysregulated HOX expression in leukemic patient samples, their involvement as oncogenic fusion proteins with NUP98 and their requirement for the oncogenicity of Mll fusions. In recent years, much attention has been devoted to the identification and characterization of leukemic stem cells. Given the documented role of Hox genes in hematopoiesis and leukemogenesis, we propose that Hox- dependent pathways are closely linked to the self-renewal program crucial to the origin and function of leukemic stem cells.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of British Columbia	Humphries, RK (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	khumphri@bccrc.ca		Humphries, Richard/0000-0003-0540-7005				Afonja O, 2000, LEUKEMIA RES, V24, P849, DOI 10.1016/S0145-2126(00)00059-X; Alcalay M, 2005, BLOOD, V106, P899, DOI 10.1182/blood-2005-02-0560; Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Bai XT, 2006, CANCER RES, V66, P4584, DOI 10.1158/0008-5472.CAN-05-3101; Bansal D, 2006, P NATL ACAD SCI USA, V103, P16924, DOI 10.1073/pnas.0604579103; Bergeron J, 2006, LEUKEMIA, V20, P1184, DOI 10.1038/sj.leu.2404187; Beslu N, 2004, BLOOD, V104, P2307, DOI 10.1182/blood-2004-04-1653; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bijl J, 2006, BLOOD, V108, P116, DOI 10.1182/blood-2005-06-2245; Bjornsson JM, 2003, MOL CELL BIOL, V23, P3872, DOI 10.1128/MCB.23.11.3872-3883.2003; Blair A, 1998, BLOOD, V92, P4325, DOI 10.1182/blood.V92.11.4325; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brun ACM, 2004, BLOOD, V103, P4126, DOI 10.1182/blood-2003-10-3557; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Calvo KR, 2002, ONCOGENE, V21, P4247, DOI 10.1038/sj.onc.1205516; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Cauwelier B, 2007, LEUKEMIA, V21, P121, DOI 10.1038/sj.leu.2404410; Cellot S, 2007, EXP HEMATOL, V35, P802, DOI 10.1016/j.exphem.2007.02.013; Chen F, 1997, DEV BIOL, V181, P186, DOI 10.1006/dbio.1996.8440; Chung KY, 2006, CANCER RES, V66, P11781, DOI 10.1158/0008-5472.CAN-06-0706; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Crump JG, 2006, DEVELOPMENT, V133, P2661, DOI 10.1242/dev.02435; Daser A, 2005, SEMIN CANCER BIOL, V15, P175, DOI 10.1016/j.semcancer.2005.01.007; Davidson AJ, 2003, NATURE, V425, P300, DOI 10.1038/nature01973; Davidson AJ, 2006, DEV BIOL, V292, P506, DOI 10.1016/j.ydbio.2006.01.003; De Braekeleer M, 2005, ANTICANCER RES, V25, P1931; Deshpande AJ, 2006, CANCER CELL, V10, P363, DOI 10.1016/j.ccr.2006.08.023; Dik WA, 2005, LEUKEMIA, V19, P1948, DOI 10.1038/sj.leu.2403891; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; Fine BM, 2004, BLOOD, V103, P1043, DOI 10.1182/blood-2003-05-1518; Fischbach NA, 2005, BLOOD, V105, P1456, DOI 10.1182/blood-2004-04-1583; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Ghannam G, 2004, J BIOL CHEM, V279, P866, DOI 10.1074/jbc.M307280200; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; GIAMPAOLO A, 1995, STEM CELLS, V13, P90; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Greer JM, 2000, NATURE, V403, P661, DOI 10.1038/35001077; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Hess JL, 2006, BLOOD, V108, P297, DOI 10.1182/blood-2005-12-5014; Hisa T, 2004, EMBO J, V23, P450, DOI 10.1038/sj.emboj.7600038; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; HORAN GSB, 1995, DEV BIOL, V169, P359, DOI 10.1006/dbio.1995.1150; HORAN GSB, 1995, GENE DEV, V9, P1667, DOI 10.1101/gad.9.13.1667; Horton SJ, 2005, CANCER RES, V65, P9245, DOI 10.1158/0008-5472.CAN-05-1691; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Imamura T, 2002, BRIT J HAEMATOL, V119, P119, DOI 10.1046/j.1365-2141.2002.03803.x; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Iwasaki M, 2005, BLOOD, V105, P784, DOI 10.1182/blood-2004-04-1508; Izon DJ, 1998, BLOOD, V92, P383, DOI 10.1182/blood.V92.2.383.414k41_383_393; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jin GA, 2007, BLOOD, V109, P3998, DOI 10.1182/blood-2006-08-041202; Kappen C, 2000, AM J HEMATOL, V65, P111, DOI 10.1002/1096-8652(200010)65:2<111::AID-AJH4>3.0.CO;2-Z; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kato Y, 2005, J EXP MED, V202, P169, DOI 10.1084/jem.20042541; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Ko KH, 2007, EXP HEMATOL, V35, P465, DOI 10.1016/j.exphem.2006.10.014; Kohlmann A, 2003, GENE CHROMOSOME CANC, V37, P396, DOI 10.1002/gcc.10225; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 2003, IMMUNITY, V18, P561, DOI 10.1016/S1074-7613(03)00090-6; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kumar AR, 2004, BLOOD, V103, P1823, DOI 10.1182/blood-2003-07-2582; Lam DH, 2001, LEUKEMIA, V15, P1689, DOI 10.1038/sj.leu.2402269; Lawrence HJ, 2005, BLOOD, V106, P3988, DOI 10.1182/blood-2005-05-2003; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lin YW, 2005, BLOOD, V106, P287, DOI 10.1182/blood-2004-12-4794; LUGT NMV, 1996, MECH DEVELOP, V58, P153; Mamo A, 2006, BLOOD, V108, P622, DOI 10.1182/blood-2005-06-2244; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Miller CT, 2004, DEVELOPMENT, V131, P2443, DOI 10.1242/dev.01134; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Moens CB, 2006, DEV BIOL, V291, P193, DOI 10.1016/j.ydbio.2005.10.032; MORETTI P, 1994, GENE, V144, P213, DOI 10.1016/0378-1119(94)90380-8; Morgado E, 2007, BLOOD, V109, P4020, DOI 10.1182/blood-2006-01-039586; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 2005, INT J HEMATOL, V82, P21, DOI 10.1532/IJH97.04160; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ohta H, 2007, EXP HEMATOL, V35, P817, DOI 10.1016/j.exphem.2007.02.012; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Ozeki K, 2004, BLOOD, V103, P1901, DOI 10.1182/blood-2003-06-1845; Palmqvist L, 2006, BLOOD, V108, P1030, DOI 10.1182/blood-2005-12-007005; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Pineault N, 2005, LEUKEMIA, V19, P636, DOI 10.1038/sj.leu.2403696; Pineault N, 2004, MOL CELL BIOL, V24, P1907, DOI 10.1128/MCB.24.5.1907-1917.2004; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Quentmeier H, 2004, LEUKEMIA LYMPHOMA, V45, P567, DOI 10.1080/10428190310001609942; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Satoh Y, 2004, J BIOL CHEM, V279, P24986, DOI 10.1074/jbc.M400407200; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Schreiner S, 2001, CANCER RES, V61, P6480; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; SHEN WF, 1992, EMBO J, V11, P983, DOI 10.1002/j.1460-2075.1992.tb05137.x; Shimamoto T, 1999, J EXP ZOOL, V283, P186; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Slape C, 2004, LEUKEMIA LYMPHOMA, V45, P1341, DOI 10.1080/10428190310001659325; So CW, 2004, BLOOD, V103, P3192, DOI 10.1182/blood-2003-10-3722; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Speleman F, 2005, LEUKEMIA, V19, P358, DOI 10.1038/sj.leu.2403657; Suemori H, 2000, DEV BIOL, V220, P333, DOI 10.1006/dbio.2000.9651; Taussig DC, 2005, BLOOD, V106, P4086, DOI 10.1182/blood-2005-03-1072; Thorington Richard W. Jr., 2002, Journal of Mammalian Evolution, V9, P99; Thornhill S, 1997, PHYS WORLD, V10, P17; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Tsutsumi S, 2003, CANCER RES, V63, P4882; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Uchida N, 2003, EXP HEMATOL, V31, P1338, DOI 10.1016/j.exphem.2003.09.001; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Wang GG, 2006, MOL CELL BIOL, V26, P3902, DOI 10.1128/MCB.26.10.3902-3916.2006; Wang GG, 2005, BLOOD, V106, P254, DOI 10.1182/blood-2004-12-4664; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Zakany J, 1997, P NATL ACAD SCI USA, V94, P13695, DOI 10.1073/pnas.94.25.13695; Zakany J, 1996, DEV BIOL, V176, P325, DOI 10.1006/dbio.1996.0137; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zhang XB, 2006, PLOS MED, V3, P687, DOI 10.1371/journal.pmed.0030173	140	356	367	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6766	6776		10.1038/sj.onc.1210760	http://dx.doi.org/10.1038/sj.onc.1210760			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934484				2022-12-28	WOS:000250147000008
J	Moniz, S; Verissimo, F; Matos, P; Brazao, R; Silva, E; Kotevelets, L; Chastre, E; Gespach, C; Jordan, P				Moniz, S.; Verissimo, F.; Matos, P.; Brazao, R.; Silva, E.; Kotevelets, L.; Chastre, E.; Gespach, C.; Jordan, P.			Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2	ONCOGENE			English	Article						cell cycle progression; EGF; ERK MAP kinase pathway; MEK1; WNK protein kinases	CROSS-CASCADE ACTIVATION; WNK KINASES; CYCLE ARREST; PHOSPHORYLATION; RAS; SPAK; MEK1; IDENTIFICATION; EXPRESSION; MUTATIONS	The recently identified subfamily of WNK protein kinases is characterized by a unique sequence variation in the catalytic domain and four related human WNK genes were identified. Here, we describe the cloning and functional analysis of the human family member WNK2. We show that the depletion of endogenous WNK2 expression by RNA interference in human cervical HeLa cancer cells led to the activation of the extracellular signal - regulated kinase ( ERK) 1/ 2 mitogen- activated protein kinases but, in contrast to the depletion of WNK1, had no effect on ERK5. Furthermore, expression of a kinase-dead WNK2- K207M mutant also activated ERK1/ 2 suggesting that WNK2 catalytic activity is required. Depletion of WNK2 expression increased G1/ S progression and potentiated the cellular response to low epidermal growth factor concentrations. The molecular mechanism of ERK1/ 2 activation in WNK2- depleted cells lies downstream of the Raf kinases and involves MEK1 phosphorylation at serine 298 in both HeLa and HT29 colon cancer cells. This modi. cation is linked to the upregulation of MEK1 activity toward ERK1/2. Together, these results provide evidence that WNK2 is involved in the modulation of growth factor - induced cancer cell proliferation through the MEK1/ERK1/2 pathway. The data identify WNK2 as a candidate tumor suppressor gene and suggest a coordinated activity of WNK kinases in the regulation of cell proliferation. ' in ' ' '	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; INSERM, U773, Ctr Rech Biomed Bichat Bequjon CRB3, Paris, France; Univ Paris 07, Paris, France; INSERM U673, Paris, France; Univ Paris 06, Fac Med, Lab Mol & Clin Oncol Solid Tumors, Paris, France	Instituto Nacional de Saude Dr. Ricardo Jorge; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Avenida,Padre Cruz, P-1649016 Lisbon, Portugal.	peter.jordan@insa.min-saude.pt	Jordan, Peter/G-9335-2012; CHASTRE, Eric/L-8446-2018; Matos, Paulo/F-5245-2012; Matos, Paulo/P-3012-2019	Jordan, Peter/0000-0002-1425-9211; CHASTRE, Eric/0000-0002-8993-1228; Matos, Paulo/0000-0002-9379-9696; Matos, Paulo/0000-0002-9379-9696				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gagnon KBE, 2006, MOL CELL BIOL, V26, P689, DOI 10.1128/MCB.26.2.689-698.2006; Gamba G, 2005, AM J PHYSIOL-RENAL, V288, pF245, DOI 10.1152/ajprenal.00311.2004; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hong CB, 2007, P NATL ACAD SCI USA, V104, P10974, DOI 10.1073/pnas.0700683104; Ito M, 2001, CANCER RES, V61, P2038; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kahle KT, 2004, CURR OPIN NEPHROL HY, V13, P557, DOI 10.1097/00041552-200409000-00012; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kostich M, 2002, GENOME BIOL, V3; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Li WQ, 2000, GENE DEV, V14, P895; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Matos P, 2005, EXP CELL RES, V305, P292, DOI 10.1016/j.yexcr.2004.12.029; Min XS, 2004, STRUCTURE, V12, P1303, DOI 10.1016/j.str.2004.04.014; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; Rodriguez-Viciana P, 2005, COLD SH Q B, V70, P461, DOI 10.1101/sqb.2005.70.044; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Verissimo F, 2006, ONCOGENE, V25, P4172, DOI 10.1038/sj.onc.1209449; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	46	64	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6071	6081		10.1038/sj.onc.1210706	http://dx.doi.org/10.1038/sj.onc.1210706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17667937				2022-12-28	WOS:000249277200010
J	Didier, C; Cavelier, C; Quaranta, M; Galcera, MO; Demur, C; Laurent, G; Manenti, S; Ducommun, B				Didier, C.; Cavelier, C.; Quaranta, M.; Galcera, M-O; Demur, C.; Laurent, G.; Manenti, S.; Ducommun, B.			G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress	ONCOGENE			English	Article						AML; G2/M checkpoint; chemoresistance; CDC25 phosphatase; CHK1 kinase	ACUTE MYELOID-LEUKEMIA; DNA-DAMAGE; IONIZING-RADIATION; CDC25 PHOSPHATASES; MAMMALIAN-CELLS; PROTEIN-KINASE; HUMAN CLASPIN; IN-VITRO; CHK1; RECOVERY	Acute myeloid leukemia ( AML) cells exposed to genotoxic agents arrest their cell cycle at the G2/M checkpoint and are inherently chemoresistant. To understand the mechanism of this chemoresistance, we compared the ability of immature CD34+ versus mature CD34- AML cell lines ( KG1a and U937, respectively) to recover from a DNA damage-induced cell cycle checkpoint in G2. Here, we report that KG1a cells have a more stringent G2/M checkpoint response than U937 cells. We show that in both cell types, the CDC25B phosphatase participates in the G2/M checkpoint recovery and that its expression is upregulated. Furthermore, we show that CHK1 inhibition by UCN-01 in immature KG1a cells allows checkpoint exit and induces sensitivity to genotoxic agents. Similarly, UCN-01 treatment potentializes genotoxic-induced inhibition of colony formation efficiency of primary leukemic cells from AML patients. Altogether, our results demonstrate that checkpoint stringency varies during the maturation process and indicate that targeting checkpoint mechanisms might represent an attractive therapeutic opportunity for chemoresistant immature AML cells.	[Didier, C.; Cavelier, C.; Quaranta, M.; Ducommun, B.] Univ Toulouse 3, CNRS, LBCMCP, UMR5088,IFR109,Inst Explorat Fonct Genomes, F-31062 Toulouse, France; [Galcera, M-O] Inst Henri Beaufour, IPSEN, F-91952 Les Ulis, France; [Demur, C.; Laurent, G.; Manenti, S.] CHU Purpan, Ctr Physiopathol Toulouse, INSERM, U563, Toulouse, France; [Demur, C.; Laurent, G.; Ducommun, B.] TSA, CHU Purpan, Serv Hematol, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, LBCMCP, UMR5088,IFR109,Inst Explorat Fonct Genomes, 118 Route Narbonne, F-31062 Toulouse, France.	ducommun@cict.fr	DUCOMMUN, Bernard/B-3208-2008; manenti, stephane/P-1518-2014; DIDIER, Christine O/P-2785-2014	manenti, stephane/0000-0002-4793-3196; DIDIER, Christine O/0000-0003-3979-0743; DUCOMMUN, Bernard/0000-0002-7126-8368				Amico D, 2003, BLOOD, V101, P4589, DOI 10.1182/blood-2002-07-2311; Bansal P, 2007, CANCER RES, V67, P3356, DOI 10.1158/0008-5472.CAN-06-3685; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Blagosklonny MV, 2006, LEUKEMIA, V20, P385, DOI 10.1038/sj.leu.2404075; Bouquet F, 2006, CELL CYCLE, V5, P1116, DOI 10.4161/cc.5.10.2799; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Brezak MC, 2005, MOL CANCER THER, V4, P1378, DOI 10.1158/1535-7163.MCT-05-0168; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Bugler B, 2006, MOL CANCER THER, V5, P1446, DOI 10.1158/1535-7163.MCT-06-0099; Chini C, 2006, ONCOGENE, V25, P4165, DOI 10.1038/sj.onc.1209447; Chini CCS, 2006, J BIOL CHEM, V281, P33276, DOI 10.1074/jbc.M604373200; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Clave E, 1997, LEUKEMIA, V11, P114, DOI 10.1038/sj.leu.2400528; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Fernandez-Vidal A, 2006, CANCER RES, V66, P7128, DOI 10.1158/0008-5472.CAN-05-2552; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Humbert O, 2002, J BIOL CHEM, V277, P18061, DOI 10.1074/jbc.M103451200; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; McManus KJ, 2005, MOL BIOL CELL, V16, P5013, DOI 10.1091/mbc.E05-01-0065; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Roberge M, 1998, CANCER RES, V58, P5701; Sampath D, 2006, BLOOD, V107, P2517, DOI 10.1182/blood-2005-08-3351; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; Shiloh Y, 2003, CELL CYCLE, V2, P116, DOI 10.4161/cc.2.2.342; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; van Vugt MATM, 2004, CELL CYCLE, V3, P1383, DOI 10.4161/cc.3.11.1248; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; WARTERS RL, 1995, MUTAT RES-DNA REPAIR, V336, P1, DOI 10.1016/0921-8777(94)00036-6; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002	40	30	32	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3811	3820		10.1038/sj.onc.1211041	http://dx.doi.org/10.1038/sj.onc.1211041			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18212737				2022-12-28	WOS:000256904700005
J	Caspi, M; Zilberberg, A; Eldar-Finkelman, H; Rosin-Arbesfeld, R				Caspi, M.; Zilberberg, A.; Eldar-Finkelman, H.; Rosin-Arbesfeld, R.			Nuclear GSK-3 beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner	ONCOGENE			English	Article						Wnt signalling; beta-catenin; GSK-3 beta; colorectal cancer; nucleus	GLYCOGEN-SYNTHASE KINASE-3; SUBCELLULAR-LOCALIZATION; NEGATIVE REGULATOR; EXPORT; INSULIN; AXIN; TRANSCRIPTION; PROTEOLYSIS; ACTIVATION; CELLS	beta-Catenin is the central signalling molecule of the canonical Wnt pathway, where it activates target genes in a complex with lymphoid enhancer factor/T-cell factor transcription factors in the nucleus. The regulation of beta-catenin activity is thought to occur via a cytoplasmatic multiprotein complex that includes the serine/threonine kinase glycogen synthase kinase-3 beta (GSK-3 beta) that phosphorylates beta-catenin, marking it for degradation by the proteasome. Here, we provide evidence showing that GSK-3 beta has a nuclear function in downregulating the activity of beta-catenin. Using colorectal cell lines that express a mutant form of beta-catenin, which cannot be phosphorylated by GSK-3 beta and ectopically expressed mutant beta-catenin protein, we show that nuclear GSK-3 beta functions in a mechanism that does not involve beta-catenin phosphorylation to reduce the levels of Wnt signalling. We show that GSK-3 beta enters the nucleus, forms a complex with beta-catenin and lowers the levels of beta-catenin/TCFdependent transcription in a mechanism that involves GSK-3 beta-Axin binding.	[Caspi, M.; Zilberberg, A.; Rosin-Arbesfeld, R.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Eldar-Finkelman, H.] Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Rosin-Arbesfeld, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	arina@tau.ac.il	Eldar-Finkelman, Hagit/AAF-8329-2019	Eldar-Finkelman, Hagit/0000-0002-8460-9686				Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Cong F, 2004, P NATL ACAD SCI USA, V101, P2882, DOI 10.1073/pnas.0307344101; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2007, DEV CELL, V12, P957, DOI 10.1016/j.devcel.2007.04.001; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; Liberman Z, 2005, J BIOL CHEM, V280, P4422, DOI 10.1074/jbc.M410610200; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Patel S, 2004, BIOCHEM SOC T, V32, P803, DOI 10.1042/BST0320803; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zilberberg A, 2004, J BIOL CHEM, V279, P17535, DOI 10.1074/jbc.M311292200	43	74	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3546	3555		10.1038/sj.onc.1211026	http://dx.doi.org/10.1038/sj.onc.1211026			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223684				2022-12-28	WOS:000256468500006
J	Eichele, K; Ramer, R; Hinz, B				Eichele, K.; Ramer, R.; Hinz, B.			Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells	ONCOGENE			English	Article						chemotherapeutics; cyclooxygenase-2; lipocalin-type prostaglandin D synthase; prostaglandins; peroxisome proliferator-activated receptor gamma; apoptosis	HUMAN NEUROGLIOMA CELLS; PHASE-II TRIAL; LUNG-CANCER; COLORECTAL-CANCER; EPITHELIAL-CELLS; UP-REGULATION; CELECOXIB; PROLIFERATION; EXPRESSION; DOCETAXEL	The role of cyclooxygenase-2 (COX-2) in cancer remains controversial. Using cervical carcinoma cells (HeLa), the present study investigates the involvement of COX-2 in apoptosis elicited by the chemotherapeutics paclitaxel, cisplatin and 5-fluorouracil. Each compound led to a profound induction of COX-2 expression and prostaglandin (PG) synthesis, accompanied by a substantial decrease of viability and enhanced apoptosis. Cells were significantly less sensitive to apoptotic death when either COX-2 expression or its activity was suppressed by smallinterfering RNA (siRNA) and by the selective COX-2 inhibitor NS-398, respectively. Experiments performed to clarify how COX-2 leads to apoptosis revealed a profound proapoptotic action of PGD2 and its dehydration product, 15-deoxy- D12,14 PGJ2 (15d-PGJ2). In line with these findings, chemotherapeutics-induced apoptosis was prevented by siRNA targeting lipocalin-type PGD synthase (L-PGDS), which catalyses the isomerization of PGH2 to PGD2. Moreover, apoptosis by chemotherapeutics, PGD2 and 15d-PGJ2 was suppressed by the peroxisome proliferator-activated receptor c (PPARc) antagonist, GW-9662 or PPARc siRNA. Finally, a COX-2-dependent apoptotic mechanism of all investigated chemotherapeutics was confirmed in human lung cancer cells (A549) as well as in another cervical carcinoma cell line (C33A). Collectively, this study suggests COX-2 induction and synthesis of L-PGDS-derived, PPARc-activating PGs as a decisive target by which several chemotherapeutics induce apoptosis. COX-2 is therefore suspected to sensitize cancer cells to apoptotic death under certain circumstances, suggesting that COX-2 inhibition during cancer therapy could diminish its efficacy.	[Eichele, K.; Ramer, R.; Hinz, B.] Univ Rostock, Inst Pharmacol & Toxicol, D-18057 Rostock, Germany	University of Rostock	Hinz, B (corresponding author), Univ Rostock, Inst Pharmacol & Toxicol, Schillingallee 70, D-18057 Rostock, Germany.	burkhard.hinz@med.uni-rostock.de						Altorki NK, 2003, J CLIN ONCOL, V21, P2645, DOI 10.1200/JCO.2003.07.127; Argiris A, 2006, INVEST NEW DRUG, V24, P203, DOI 10.1007/s10637-005-3259-4; Chen Q, 2004, ANAL BIOCHEM, V335, P253, DOI 10.1016/j.ab.2004.09.004; Chen YC, 2005, BBA-MOL CELL RES, V1743, P291, DOI 10.1016/j.bbamcr.2004.10.016; Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905; Csiki I, 2005, CLIN CANCER RES, V11, P6634, DOI 10.1158/1078-0432.CCR-05-0436; Danesi R, 2002, BRIT J CLIN PHARMACO, V53, P508, DOI 10.1046/j.1365-2125.2002.01579.x; Denkert C, 2003, ONCOGENE, V22, P8653, DOI 10.1038/sj.onc.1206920; Dommels YEM, 2003, CARCINOGENESIS, V24, P385, DOI 10.1093/carcin/24.3.385; Eichele K, 2006, PHARM RES-DORDR, V23, P90, DOI 10.1007/s11095-005-8815-2; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hinz B, 2004, MOL PHARMACOL, V66, P1643, DOI 10.1124/mol.104.002618; Hwang Daniel H., 2002, Neoplasia (New York), V4, P91, DOI 10.1038/sj.neo.7900226; Kim J, 2005, CANCER RES, V65, P6189, DOI 10.1158/0008-5472.CAN-04-4439; Lalier L, 2007, ONCOGENE, V26, P4999, DOI 10.1038/sj.onc.1210303; Maccarrone M, 2002, BIOCHEM J, V366, P137, DOI 10.1042/BJ20020438; Na HK, 2005, FEBS LETT, V579, P6279, DOI 10.1016/j.febslet.2005.09.094; Na HK, 2003, BIOCHEM PHARMACOL, V66, P1381, DOI 10.1016/S0006-2952(03)00488-X; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Nugent FW, 2005, LUNG CANCER, V48, P267, DOI 10.1016/j.lungcan.2004.11.004; Pan CX, 2005, ONCOLOGY-BASEL, V69, P63, DOI 10.1159/000087302; Ramer R, 2003, MOL PHARMACOL, V64, P1189, DOI 10.1124/mol.64.5.1189; Shen ZN, 2005, BIOCHEM BIOPH RES CO, V328, P375, DOI 10.1016/j.bbrc.2004.12.186; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Xu Z, 2006, CANCER RES, V66, P6657, DOI 10.1158/0008-5472.CAN-05-3624; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	27	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3032	3044		10.1038/sj.onc.1210962	http://dx.doi.org/10.1038/sj.onc.1210962			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18071320				2022-12-28	WOS:000255681700010
J	Yu, S; Wong, YC; Wang, XH; Ling, MT; Ng, CF; Chen, S; Chan, FL				Yu, S.; Wong, Y. C.; Wang, X. H.; Ling, M. T.; Ng, C. F.; Chen, S.; Chan, F. L.			Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer	ONCOGENE			English	Article						estrogen-related receptor; estrogen receptor-related; receptor; ERR beta; orphan nuclear receptor; tumor suppression; prostate cancer	PROLIFERATOR-ACTIVATED RECEPTOR; ANDROGEN RECEPTOR; GAMMA COACTIVATOR-1-ALPHA; TRANSCRIPTIONAL CONTROL; DNA-REPLICATION; MOUSE EMBRYOS; ERR-ALPHA; EXPRESSION; IDENTIFICATION; PGC-1-ALPHA	Recent studies indicate that estrogen-related receptors (ERRs) are involved in similar estrogen receptor (ER) regulatory pathways and play roles in energy and lipid metabolism. Here, we analysed the functional role of ERR beta in prostate cancer cell growth regulation in an androgen-sensitive and androgen-insensitive prostate cancer cell lines. ERR beta was expressed in normal human prostates, but exhibited a reduced expression in prostate cancer lesions. Stable ERR beta expression suppressed significantly cell proliferation and tumorigenicity of LNCaP and DU145 cells, accompanied by an S-phase suppression and increased p21 expression. Reporter and chromatin immunoprecipitation assays showed that ERRb could directly transactivate p21 gene promoter, which could be further enhanced by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha. Truncation analysis showed that ERR beta-mediated p21 transactivation and prostate cancer cell growth inhibition required intact DNA-binding domain and AF2 domains in ERR beta. Interestingly, ERR beta displayed a cell cycle associated downregulated expression pattern in ERR beta-transduced and non-transduced cells. Finally, we showed that ERR beta-mediated growth inhibition could be potentiated by an ERRb/gamma agonist DY131. Knockdown of ERR beta by RNA interference could reduce the DY131-induced growth inhibition in prostate cancer cells. Taken together, our findings indicate that ERR beta performs a tumor suppressing function in prostate cancer cells, and targeting ERR beta could be a potential therapeutic strategy for prostate cancer.	[Yu, S.; Chan, F. L.] Chinese Univ Hong Kong, Dept Anat, Shatin, Hong Kong, Peoples R China; [Wong, Y. C.; Wang, X. H.; Ling, M. T.] Univ Hong Kong, Dept Anat, Shatin, Hong Kong, Peoples R China; [Ng, C. F.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China; [Chen, S.] Beckman Res Inst City Hope, Dept Surg Res, Duarte, CA USA	Chinese University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; City of Hope; Beckman Research Institute of City of Hope	Chan, FL (corresponding author), Chinese Univ Hong Kong, Dept Anat, Basic Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	franky-chan@cuhk.edu.hk	Ng, Chi-Fai/E-5134-2011; Chi-fai, NG/AAV-8270-2021; Chan, Franky L./M-1043-2018	Ng, Chi-Fai/0000-0002-1723-9646; Chan, Franky L./0000-0003-0567-2052				Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Castet A, 2006, MOL ENDOCRINOL, V20, P1035, DOI 10.1210/me.2005-0227; Chan PSF, 1999, PROSTATE, V41, P99; Chen F, 1999, GENE, V228, P101, DOI 10.1016/S0378-1119(98)00619-2; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Fujimoto J, 2005, J STEROID BIOCHEM, V94, P67, DOI 10.1016/j.jsbmb.2004.12.030; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Griffiths K, 2000, Prostate, V45, P87, DOI 10.1002/1097-0045(20001001)45:2<87::AID-PROS2>3.0.CO;2-G; Ho E, 2004, ARCH BIOCHEM BIOPHYS, V428, P109, DOI 10.1016/j.abb.2004.01.009; Ho SM, 2004, J CELL BIOCHEM, V91, P491, DOI 10.1002/jcb.10759; Huang CY, 2005, MOL ENDOCRINOL, V19, P2915, DOI 10.1210/me.2005-0097; Huss JM, 2004, MOL CELL BIOL, V24, P9079, DOI 10.1128/MCB.24.20.9079-9091.2004; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Litvinov IV, 2006, P NATL ACAD SCI USA, V103, P15085, DOI 10.1073/pnas.0603057103; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Lu DS, 2001, CANCER RES, V61, P6755; Lui K, 2006, PROSTATE, V66, P1600, DOI 10.1002/pros.20429; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Mitsunaga K, 2004, MECH DEVELOP, V121, P237, DOI 10.1016/j.mod.2004.01.006; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Prins GS, 2006, ANN NY ACAD SCI, V1089, P1, DOI 10.1196/annals.1386.009; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Sharma MJ, 2003, EMBO J, V22, P6101, DOI 10.1093/emboj/cdg585; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Soriano FX, 2006, DIABETES, V55, P1783, DOI 10.2337/db05-0509; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Trapp T, 1996, J BIOL CHEM, V271, P9879, DOI 10.1074/jbc.271.17.9879; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vankoningsloo S, 2005, J LIPID RES, V46, P1133, DOI 10.1194/jlr.M400464-JLR200; Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Yu DD, 2005, BIOORG MED CHEM LETT, V15, P1311, DOI 10.1016/j.bmcl.2005.01.025; Yu SA, 2007, CANCER RES, V67, P4904, DOI 10.1158/0008-5472.CAN-06-3855; Zhang WH, 2002, MOL CELL ENDOCRINOL, V193, P1, DOI 10.1016/s0303-7207(02)00089-8; Zhou W, 2006, J CLIN ENDOCR METAB, V91, P569, DOI 10.1210/jc.2004-1957	45	60	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3313	3328		10.1038/sj.onc.1210986	http://dx.doi.org/10.1038/sj.onc.1210986			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18071305				2022-12-28	WOS:000256111400010
J	Balakrishnan, SK; Gross, DS				Balakrishnan, S. K.; Gross, D. S.			The tumor suppressor p53 associates with gene coding regions and co-traverses with elongating RNA polymerase II in an in vivo model	ONCOGENE			English	Article						p53; transcription elongation; RNA polymerase II; chromatin; acidic activator; yeast genetics	TRANSCRIPTIONAL ACTIVATION DOMAINS; FACTOR-BINDING-SITES; HEAT-SHOCK FACTOR; SACCHAROMYCES-CEREVISIAE; TARGET GENES; DNA-DAMAGE; YEAST; INITIATION; PROMOTER; COMPLEX	Sequence-specific transcriptional regulators function by stably binding cognate DNA sequences followed by recruitment of both general and specialized factors to target gene promoters. The tumor suppressor p53 mediates its antioncogenic effect on cells by functioning as a sequence specific regulator. p53 employs a secondary mechanism to suppress tumor formation by permeabilizing the outer mitochondrial membrane, thereby releasing pro-apoptotic factors. Here, we report a potential third biological function of p53: as a transcriptional elongation factor. Using chromatin immunoprecipitation, we demonstrate that human p53 robustly associates with RNA polymerase II (Pol II), but neither Pol I- nor Pol III-transcribed regions in the budding yeast, Saccharomyces cerevisiae. p53's association with open reading frames is mediated by its physical interaction with elongating Pol II, with which p53 travels in vivo and co-immunoprecipitates in vitro. When similarly expressed, the potent acidic activator VP16 cannot be crosslinked to Pol II coding regions. p53 levels comparable to those found in induced mammalian cells confer synthetic sickness or lethality in combination with deletions in genes encoding transcription elongation factors; p53 likewise confers hypersensitivity to the anti-elongation drug 6-azauracil. Collectively, our results indicate that p53 can physically interact with the transcription elongation complex and influence transcription elongation, and open up new avenues of investigation in mammalian cells.	[Balakrishnan, S. K.; Gross, D. S.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; [Balakrishnan, S. K.; Gross, D. S.] Feist Weiller Canc Ctr, Shreveport, LA USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Gross, DS (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	dgross@lsuhsc.edu						Blau J, 1996, MOL CELL BIOL, V16, P2044; Brown SA, 1998, EMBO J, V17, P3146, DOI 10.1093/emboj/17.11.3146; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; Di Lello P, 2006, MOL CELL, V22, P731, DOI 10.1016/j.molcel.2006.05.007; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; GROSS DS, 1993, EMBO J, V12, P3931, DOI 10.1002/j.1460-2075.1993.tb06071.x; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Kaeser MD, 2004, ONCOGENE, V23, P4007, DOI 10.1038/sj.onc.1207536; Kennedy BK, 2002, NAT REV MOL CELL BIO, V3, P41, DOI 10.1038/nrm704; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; LEE SW, 1993, MOL CELL BIOL, V13, P727, DOI 10.1128/MCB.13.2.727; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Mason PB, 2005, MOL CELL, V17, P831, DOI 10.1016/j.molcel.2005.02.017; Mattia M, 2007, MOL CELL BIOL, V27, P1309, DOI 10.1128/MCB.01520-06; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nourani A, 2003, J BIOL CHEM, V278, P19171, DOI 10.1074/jbc.C300036200; Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677; Proft M, 2006, MOL CELL, V23, P241, DOI 10.1016/j.molcel.2006.05.031; Saunders A, 2006, NAT REV MOL CELL BIO, V7, P557, DOI 10.1038/nrm1981; Schwabish MA, 2004, MOL CELL BIOL, V24, P10111, DOI 10.1128/MCB.24.23.10111-10117.2004; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; Venturi CB, 2000, MOL CELL BIOL, V20, P6435, DOI 10.1128/MCB.20.17.6435-6448.2000; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Zhao J, 2005, MOL CELL BIOL, V25, P8985, DOI 10.1128/MCB.25.20.8985-8999.2005	42	17	17	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2661	2672		10.1038/sj.onc.1210935	http://dx.doi.org/10.1038/sj.onc.1210935			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18026140				2022-12-28	WOS:000255259500001
J	French, CA; Ramirez, CL; Kolmakova, J; Hickman, TT; Cameron, MJ; Thyne, ME; Kutok, JL; Toretsky, JA; Tadavarthy, AK; Kees, UR; Fletcher, JA; Aster, JC				French, C. A.; Ramirez, C. L.; Kolmakova, J.; Hickman, T. T.; Cameron, M. J.; Thyne, M. E.; Kutok, J. L.; Toretsky, J. A.; Tadavarthy, A. K.; Kees, U. R.; Fletcher, J. A.; Aster, J. C.			BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells	ONCOGENE			English	Article						BRD3-NUT; t(15;19); t(9;15); NUT midline carcinoma	BROMODOMAIN PROTEIN; AGGRESSIVE CARCINOMA; S-PHASE; P-TEFB; REARRANGEMENT; INTERACTS; EXPORT; BINDS; CRM1	An unusual group of carcinomas, here termed nuclear protein in testis (NUT) midline carcinomas (NMC), are characterized by translocations that involve NUT, a novel gene on chromosome 15. In about 2/3rds of cases, NUT is fused to BRD4 on chromosome 19. Using a candidate gene approach, we identified two NMCs harboring novel rearrangements that result in the fusion of NUT to BRD3 on chromosome 9. The BRD3-NUT fusion gene encodes a protein composed of two tandem chromatin-binding bromodomains, an extra-terminal domain, a bipartite nuclear localization sequence, and almost the entirety of NUT that is highly homologous to BRD4-NUT. The function of NUT is unknown, but here we show that NUT contains nuclear localization and export sequences that promote nuclear-cytoplasmic shuttling via a leptomycin-sensitive pathway. In contrast, BRD3-NUT and BRD4-NUT are strictly nuclear, implying that the BRD moiety retains NUT in the nucleus via interactions with chromatin. Consistent with this idea, FRAP studies show that BRD4, BRD4-NUT and BRD3-NUT have significantly slower rates of lateral nuclear diffusion than that of NUT. To investigate the functional role of BRD-NUT fusion proteins in NMCs, we investigated the effects of siRNA-induced BRD3-NUT and BRD4-NUT withdrawal. Silencing of these proteins in NMC cell lines resulted in squamous differentiation and cell cycle arrest. Together, these data suggest that BRD-NUT fusion proteins contribute to carcinogenesis by associating with chromatin and interfering with epithelial differentiation.	[French, C. A.; Hickman, T. T.; Cameron, M. J.; Thyne, M. E.; Kutok, J. L.; Fletcher, J. A.; Aster, J. C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [French, C. A.; Hickman, T. T.; Cameron, M. J.; Thyne, M. E.; Kutok, J. L.; Fletcher, J. A.; Aster, J. C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA; [Ramirez, C. L.] Harvard Univ, Sch Med, Dept Biol, Cambridge, MA 02138 USA; [Ramirez, C. L.] Harvard Univ, Sch Med, Dept Biomed Sci, Cambridge, MA 02138 USA; [Kolmakova, J.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Toretsky, J. A.] Georgetown Univ, Lombardi Comprehens Canc Ctr & Pediat, Dept Oncol, Washington, DC 20057 USA; [Tadavarthy, A. K.] Allina Hosp & Clin, Minneapolis, MN USA; [Kees, U. R.] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Kees, U. R.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard University; Boston University; Georgetown University; Telethon Kids Institute; University of Western Australia; University of Western Australia	French, CA (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	Cfrench@partners.org		Ramirez, Cherie/0000-0002-0397-6872; Hickman, Tyler/0000-0003-2623-3251				Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Farina A, 2004, MOL CELL BIOL, V24, P9059, DOI 10.1128/MCB.24.20.9059-9069.2004; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; Haruki N, 2005, J MED GENET, V42, P558, DOI 10.1136/jmg.2004.029686; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002; MERTENS F, 2006, PEDIAT BLOOD CA 0102; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Ottinger M, 2006, J VIROL, V80, P10772, DOI 10.1128/JVI.00804-06; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029	15	286	348	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2237	2242		10.1038/sj.onc.1210852	http://dx.doi.org/10.1038/sj.onc.1210852			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17934517				2022-12-28	WOS:000254621300014
J	Li, Y; Lu, J; Cohen, D; Prochownik, EV				Li, Y.; Lu, J.; Cohen, D.; Prochownik, E. V.			Transformation, genomic instability and senescence mediated by platelet/megakaryocyte glycoprotein Ib alpha	ONCOGENE			English	Article						c-Myc; tetraploidy; aneuploidy; von Willebrand's factor	C-MYC TARGET; ONCOGENE-INDUCED SENESCENCE; HUMAN-CELLS; CANCER; GENES; OVEREXPRESSION; TUMORIGENESIS; ANEUPLOIDY; DEFECTS; GROWTH	GpIb alpha, a subunit of the von Willebrand factor receptor, functions during blood clotting to promote platelet adhesion and activation. GpIb alpha is widely expressed, is positively regulated by c-Myc and is essential for the promotion of c-Myc-mediated chromosomal instability. We now show that GpIba is also a classical oncoprotein in which its deregulated expression leads to transformation, reduced growth factor requirements, increased resistance to apoptosis, and, in primary cells, p53-dependent senescence. Finally, GpIb alpha also promotes double-stranded DNA breaks, and induces profound nuclear dysmorphology, indicating that, in addition to its direct transforming function, it displays genotoxicity at several distinct levels. These findings identify novel functions for GpIb alpha and pathways through which c-Myc mediates transformation and global genomic destabilization.	[Li, Y.; Lu, J.; Cohen, D.; Prochownik, E. V.] Childrens Hosp Pittsburgh, Rangos Res Ctr, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; [Prochownik, E. V.] Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Rangos Res Ctr, Hematol Oncol Sect, Room 8125,3460 5th Ave, Pittsburgh, PA 15213 USA.	procev@chp.edu			NATIONAL CANCER INSTITUTE [R01CA105033, R01CA078259] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA105033, R01CA078259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andalis AA, 2004, GENETICS, V167, P1109, DOI 10.1534/genetics.104.029256; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Asazuma N, 1997, BLOOD, V90, P4789, DOI 10.1182/blood.V90.12.4789.4789_4789_4798; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Canobbio H, 2004, CELL SIGNAL, V16, P1329, DOI 10.1016/j.cellsig.2004.05.008; Comai L, 2005, NAT REV GENET, V6, P836, DOI 10.1038/nrg1711; Dai KS, 2005, BLOOD, V106, P1975, DOI 10.1182/blood-2005-01-0440; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ekwall K, 1999, GENETICS, V153, P1153; Feng S, 1999, BLOOD, V93, P4256, DOI 10.1182/blood.V93.12.4256.412k33_4256_4263; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Goshima G, 2007, SCIENCE, V316, P417, DOI 10.1126/science.1141314; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Iarmarcovai G, 2006, TOXICOL LETT, V166, P1, DOI 10.1016/j.toxlet.2006.05.015; Kanaji T, 2004, BLOOD, V104, P3161, DOI 10.1182/blood-2004-03-0893; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Korkola JE, 2006, CANCER RES, V66, P820, DOI 10.1158/0008-5472.CAN-05-2445; Li Q, 1999, MOL CELL BIOL, V19, P5339; Li YJ, 2007, P NATL ACAD SCI USA, V104, P3490, DOI 10.1073/pnas.0610163104; Lopez J A, 1997, Curr Opin Hematol, V4, P323; Maines JZ, 2004, DEVELOPMENT, V131, P775, DOI 10.1242/dev.00932; Meek DW, 2000, PATHOL BIOL, V48, P246; Menssen A, 2007, CELL CYCLE, V6, P339, DOI 10.4161/cc.6.3.3808; Neiman PE, 2006, ONCOGENE, V25, P6325, DOI 10.1038/sj.onc.1209646; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Ozaki Y, 2005, J THROMB HAEMOST, V3, P1745, DOI 10.1111/j.1538-7836.2005.01379.x; Pierce SB, 2004, DEVELOPMENT, V131, P2317, DOI 10.1242/dev.01108; Prochownik EV, 2007, CELL CYCLE, V6, P1024, DOI 10.4161/cc.6.9.4161; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rogulski K, 2005, ONCOGENE, V24, P7524, DOI 10.1038/sj.onc.1208897; Rogulski KR, 2005, P NATL ACAD SCI USA, V102, P18968, DOI 10.1073/pnas.0507902102; Rothermund K, 2005, CANCER RES, V65, P2097, DOI 10.1158/0008-5472.CAN-04-2928; Saunders W, 2003, CANCER BIOL THER, V2, P253, DOI 10.4161/cbt.2.3.379; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Sedivy JM, 2007, CANCER CELL, V11, P389, DOI 10.1016/j.ccr.2007.04.014; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Storchova Z, 2006, NATURE, V443, P541, DOI 10.1038/nature05178; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Thorpe PH, 2007, TRENDS GENET, V23, P263, DOI 10.1016/j.tig.2007.03.016; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Weinstock DM, 2006, DNA REPAIR, V5, P1065, DOI 10.1016/j.dnarep.2006.05.028; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Zhou ZQ, 2001, TRENDS CELL BIOL, V11, pS10, DOI 10.1016/S0962-8924(01)02121-3	54	11	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1599	1609		10.1038/sj.onc.1210794	http://dx.doi.org/10.1038/sj.onc.1210794			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873907				2022-12-28	WOS:000253815800012
J	Fu, YN; Yeh, CL; Cheng, HY; Yang, CH; Tsai, SF; Huang, SF; Chen, YR				Fu, Y-N; Yeh, C-L; Cheng, Hh-Y; Yang, C-H; Tsai, S-F; Huang, S-F; Chen, Y-R			EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy	ONCOGENE			English	Article						EGFR; mutation; src; inhibitor; tyrosine phosphorylation	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; C-SRC; ACQUIRED-RESISTANCE; GEFITINIB TREATMENT; MUTATIONS; DOMAIN; ACTIVATION; PATTERNS; COMPLEX	Mutations in epidermal growth factor receptor (EGFR) kinase domain associate with clinical responses to EGFR inhibitors and are frequently observed in non-small cell lung cancer (NSCLC) patients in East Asian populations. Clinically identified EGFR mutations cause constitutive receptor activation. The activating mechanisms were unclear but appeared to be different among EGFR mutants. We found that EGFR mutants had different sensitivity to an Src inhibitor PP2. S768I and L861Q mutants were less sensitive to Src suppression than others. Mutation at tyrosine 869 (845) residue, an Src phosphorylation site, decreased the phosphorylation levels of wild-type EGFR and other mutants, but not that of S768I and L861Q mutants, suggesting that S768I and L861Q mutants became Src independent for their activation and biological functions. In contrast, cells expressing EGFR-L858R or exon 19 deletion mutants were more sensitive to PP2 than cells expressing wild-type EGFR. Interestingly, EGFR with exon 19-deletion/T790M double mutations, which was resistant to gefitinib, remained sensitive to PP2. Taken together, our data indicate that Src inhibitors might be effective in treating NSCLC harboring specific types of EGFR mutations.	[Fu, Y-N; Yeh, C-L; Cheng, Hh-Y; Yang, C-H; Tsai, S-F; Huang, S-F; Chen, Y-R] Natl Hlth Res Inst, Div Mol Genom Med, Zhunan Town 350, Miaoli Cty, Taiwan; [Tsai, S-F] Natl Yang Ming Univ, Inst Genet Genome Res Ctr, Taipei 112, Taiwan; [Huang, S-F] Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan	National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; Chang Gung Memorial Hospital	Chen, YR (corresponding author), Natl Hlth Res Inst, Div Mol Genom Med, 35 Keyan Rd, Zhunan Town 350, Miaoli Cty, Taiwan.	yrchen@nhri.org.tw	Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/CAF-2186-2022; Tsai, Shih-Feng/E-3997-2010; Chen, Yi-Rong/E-3991-2010; Huang, Shiu-Feng Kathy/E-3977-2010	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; 				Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Chou TY, 2005, CLIN CANCER RES, V11, P3750, DOI 10.1158/1078-0432.CCR-04-1981; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herbst RS, 2003, CLIN CANCER RES, V9, P5813; Hsieh MH, 2006, LUNG CANCER-J IASLC, V53, P311, DOI 10.1016/j.lungcan.2006.06.005; Huang SF, 2004, CLIN CANCER RES, V10, P8195, DOI 10.1158/1078-0432.CCR-04-1245; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Nakagawa K, 2003, ANN ONCOL, V14, P922, DOI 10.1093/annonc/mdg250; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Song LX, 2006, CANCER RES, V66, P5542, DOI 10.1158/0008-5472.CAN-05-4620; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	26	32	34	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					957	965		10.1038/sj.onc.1210684	http://dx.doi.org/10.1038/sj.onc.1210684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17653080				2022-12-28	WOS:000252946300007
J	Jones, L; Tilli, MT; Assefnia, S; Torre, K; Halama, ED; Parrish, A; Rosen, EM; Furth, PA				Jones, L. P.; Tilli, M. T.; Assefnia, S.; Torre, K.; Halama, E. D.; Parrish, A.; Rosen, E. M.; Furth, P. A.			Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ER alpha-negative and ER alpha-positive mammary preneoplasia and cancer	ONCOGENE			English	Article						breast cancer; mouse model; brca1; estrogen; ER alpha	INSULIN-RECEPTOR SUBSTRATE-2; SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; EPITHELIAL-CELLS; TRANSGENIC MICE; MOUSE MODEL; DUCTAL MORPHOGENESIS; TUMOR-FORMATION; GROWTH; PROGESTERONE	BRCA1 can regulate estrogen receptor-alpha (ER alpha) activity. This study tested the hypotheses that Brca1 loss in mammary epithelium alters the estrogenic growth response and that exposure to increased estrogen or ER alpha collaborates with Brca1 deficiency to accelerate preneoplasia and cancer development. Longer ductal extension was found in mammary glands of Brca1(f/f;MMTV-Cre) mice during puberty as compared to wild-type mice. Terminal end bud differentiation was impaired in Brca1 mutant mice with preservation of prolactin-induced alveolar differentiation. Exogenous estrogen stimulated an abnormal sustained increase in mammary epithelial cell proliferation and the appearance of ER alpha-negative preneoplasia in postpubertal Brca1 mutant mice. Carcinogenesis was investigated using Brca1(f/f;MMTV-Cre) mice hemizygous for p53. Exogenous estrogen increased the percentage of mice with multiple hyperplastic alveolar nodules. Targeted conditional ER alpha overexpression in mammary epithelial cells of mice that were Brca1 mutant and hemizygous for p53 increased the percentage of mice exhibiting multiple hyperplastic nodules, invasive mammary cancers and cancer multiplicity. Significantly more than half of the preneoplasia and cancers were ER alpha negative even as their initiation was promoted by ER alpha overexpression.	[Jones, L. P.; Tilli, M. T.; Assefnia, S.; Torre, K.; Halama, E. D.; Parrish, A.; Rosen, E. M.; Furth, P. A.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA	Georgetown University	Furth, PA (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA.	paf3@georgetown.edu			DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005024] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA112176, T32CA009686] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112176-05, T32 CA009686, R01 CA112176, 2T32CA09686-08, N01-CN-05024, R01CA08000] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Bachelier R, 2005, ONCOL REP, V14, P1117; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Cui XJ, 2003, ONCOGENE, V22, P6937, DOI 10.1038/sj.onc.1206803; Cullinane CA, 2005, INT J CANCER, V117, P988, DOI 10.1002/ijc.21273; Deans AJ, 2004, ONCOGENE, V23, P6136, DOI 10.1038/sj.onc.1207805; Decensi A, 2003, J MAMMARY GLAND BIOL, V8, P19, DOI 10.1023/A:1025779120649; Dembinski T. C., 1987, The mammary gland. Development, regulation, and function., P355; El Etreby MF, 1998, BREAST CANCER RES TR, V51, P149, DOI 10.1023/A:1006078032287; Fan SJ, 2002, CANCER RES, V62, P141; Fendrick JL, 1998, J MAMMARY GLAND BIOL, V3, P7, DOI 10.1023/A:1018766000275; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Frech MS, 2005, CANCER RES, V65, P681; FRECH MS, 2005, BREAST CANC ONLINE, V8; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Furuta S, 2006, CANCER CELL, V10, P13, DOI 10.1016/j.ccr.2006.05.022; Ginsburg E., 2000, METHODS MAMMARY GLAN, P147; Grimm SL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1520; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Jones LP, 2005, ONCOGENE, V24, P3554, DOI 10.1038/sj.onc.1208426; Krzysiek Jozef, 2003, Ginekol Pol, V74, P767; Liang YY, 2003, INT J ONCOL, V23, P369; Ma YX, 2006, MOL ENDOCRINOL, V20, P14, DOI 10.1210/me.2004-0488; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milewicz T, 2005, GROWTH HORM IGF RES, V15, P140, DOI 10.1016/j.ghir.2004.12.006; Poole AJ, 2006, SCIENCE, V314, P1467, DOI 10.1126/science.1130471; Raafat AM, 1999, ENDOCRINOLOGY, V140, P2570, DOI 10.1210/en.140.6.2570; Razandi M, 2004, MOL CELL BIOL, V24, P5900, DOI 10.1128/MCB.24.13.5900-5913.2004; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Ruan WF, 2005, ENDOCRINOLOGY, V146, P1170, DOI 10.1210/en.2004-1360; Shukla V, 2006, CANCER RES, V66, P7151, DOI 10.1158/0008-5472.CAN-05-4570; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	39	47	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					794	802		10.1038/sj.onc.1210674	http://dx.doi.org/10.1038/sj.onc.1210674			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653086	Green Accepted			2022-12-28	WOS:000252884500008
J	Han, SU; Kwak, TH; Her, KH; Cho, YH; Choi, C; Lee, HJ; Hong, S; Park, YS; Kim, YS; Kim, TA; Kim, SJ				Han, S-U; Kwak, T-H; Her, K. H.; Cho, Y-H; Choi, C.; Lee, H-J; Hong, S.; Park, Y. S.; Kim, Y-S; Kim, T-A; Kim, S-J			CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling	ONCOGENE			English	Article						carcinoembryonic antigen; TGF-beta; Smad3; gastric cancer	BILIARY GLYCOPROTEIN CD66A; CELL-ADHESION MOLECULE-1; HUMAN-TUMOR-MARKER; CARCINOEMBRYONIC ANTIGEN; CEA FAMILY; EXPRESSION; SMAD3; CANCER; TUMORIGENICITY; INHIBITOR	The carcinoembryonic antigen (CEAs) family consists of a large group of evolutionarily and structurally divergent glycoproteins. The transforming growth factor-beta (TGF-beta) signaling pathway has been implicated in the stimulation of CEA secretion in TGF-beta-sensitive colon cells, thereby possibly modulating cell adhesion and differentiation. However, the specific CEAs targeted by TGF-beta signaling or underlying mechanism of the expression of CEAs has not yet been clarified. In this study, we investigated the specific CEAs targeted by the TGF-beta signaling pathway. In nine human gastric cancer cell lines examined, TGF-beta-responsive cell lines showed positive expression of CEAs. Expression patterns of CEA proteins correlated well with the level of CEA (CEACAM5) and CEACAM6 transcripts in these cell lines, but CEACAM1 expression was not observed in all of these cells. To investigate the role of TGF-beta signaling in CEA expression, we selected two TGF-beta unresponsive gastric cancer cell lines; SNU638 cells that contain a mutation in the TGF-beta type II receptor and SNU484 cells that express low to undetectable level of the TGF-beta pathway intermediate protein, Smad3. Restoration of TGF-beta signaling in these cells induced expression of the CEAs and increased activity of both CEA (CEACAM5) and CEACAM6 promoters. CEA expression was observed in the epithelium of the stomach of wild-type mice, but was markedly decreased in Smad3 null mice. These findings suggest that CEA (CEACAM5) and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling.	[Han, S-U; Kwak, T-H; Her, K. H.; Cho, Y-H; Choi, C.; Lee, H-J; Hong, S.; Park, Y. S.; Kim, T-A; Kim, S-J] Natl Canc Inst, Lab Canc Biol & Genet, Natl Inst Hlth, Bethesda, MD 20892 USA; [Lee, H-J] KRIBB, Div Mol Therapeut, Taejon, South Korea; [Kim, Y-S] Hanyang Univ, Coll Med, Dept Biochem, Seoul 133791, South Korea; [Kim, S-J] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Lab Cell Regulat & Carcinogenesis, Inchon, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Hanyang University; Gachon University	Kim, SJ (corresponding author), Natl Canc Inst, Lab Canc Biol & Genet, Natl Inst Hlth, Bldg 37,Room 5046D,900 Rockville Pike, Bethesda, MD 20892 USA.	kims@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Bessa X, 2002, GASTROENTEROLOGY, V122, P1122, DOI 10.1053/gast.2002.32369; CHAKRABARTY S, 1998, CANCER RES, V48, P4059; Chang J, 1997, CANCER RES, V57, P2856; CHEVINSKY AH, 1991, SEMIN SURG ONCOL, V7, P162, DOI 10.1002/ssu.2980070309; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Han SU, 2004, ONCOGENE, V23, P1333, DOI 10.1038/sj.onc.1207259; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang J, 1999, J CELL SCI, V112, P4193; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; KAMMERER R, 1994, INT J CANCER, V57, P341, DOI 10.1002/ijc.2910570309; Kammerer R, 2001, J IMMUNOL, V166, P6537, DOI 10.4049/jimmunol.166.11.6537; Kammerer R, 1998, EUR J IMMUNOL, V28, P3664, DOI 10.1002/(SICI)1521-4141(199811)28:11<3664::AID-IMMU3664>3.0.CO;2-D; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Kim DY, 2000, J SURG ONCOL, V74, P185, DOI 10.1002/1096-9098(200007)74:3<185::AID-JSO4>3.3.CO;2-S; KIM J, 1992, INT J CANCER, V52, P718, DOI 10.1002/ijc.2910520509; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; Massague J, 2000, GENE DEV, V14, P627; MYEROFF LL, 1995, CANCER RES, V55, P5545; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Ordonez C, 2000, CANCER RES, V60, P3419; Park JG, 1997, INT J CANCER, V70, P443, DOI 10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Screaton RA, 2000, J CELL BIOL, V150, P613, DOI 10.1083/jcb.150.3.613; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zimmermann W, 1998, CELL ADHES COMMUN S, V5, P31	33	39	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					675	683		10.1038/sj.onc.1210686	http://dx.doi.org/10.1038/sj.onc.1210686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17653079				2022-12-28	WOS:000252674900011
J	Tomioka, N; Oba, S; Ohira, M; Misra, A; Fridlyand, J; Ishii, S; Nakamura, Y; Isogai, E; Hirata, T; Yoshida, Y; Todo, S; Kaneko, Y; Albertson, DG; Pinkel, D; Feuerstein, BG; Nakagawara, A				Tomioka, N.; Oba, S.; Ohira, M.; Misra, A.; Fridlyand, J.; Ishii, S.; Nakamura, Y.; Isogai, E.; Hirata, T.; Yoshida, Y.; Todo, S.; Kaneko, Y.; Albertson, D. G.; Pinkel, D.; Feuerstein, B. G.; Nakagawara, A.			Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature	ONCOGENE			English	Article						neuroblastoma; array-CGH; molecular signature; risk stratification; microarray	NEURO-BLASTOMA; EXPRESSION; INFANTS; TUMORS; GENE; AMPLIFICATION; HYBRIDIZATION; CHEMOTHERAPY; MICROARRAYS; SURVIVAL	Human neuroblastoma remains enigmatic because it often shows spontaneous regression and aggressive growth. The prognosis of advanced stage of sporadic neuroblastomas is still poor. Here, we investigated whether genomic and molecular signatures could categorize new therapeutic risk groups in primary neuroblastomas. We conducted microarray-based comparative genomic hybridization (array-CGH) with a DNA chip carrying 2464 BAC clones to examine genomic aberrations of 236 neuroblastomas and used in-house cDNA microarrays for gene-expression pro. ling. Array-CGH demonstrated three major genomic groups of chromosomal aberrations: silent (GGS), partial gains and/or losses (GGP) and whole gains and/or losses (GGW), which well corresponded with the patterns of chromosome 17 abnormalities. They were further classifi ed into subgroups with different outcomes. In 112 sporadic neuroblastomas, MYCN amplification was frequent in GGS (22%) and GGP (53%) and caused serious outcomes in patients. Sporadic tumors with a single copy of MYCN showed the 5-year cumulative survival rates of 89% in GGS, 53% in GGP and 85% in GGW. Molecular signatures also segregated patients into the favorable and unfavorable prognosis groups (P = 0.001). Both univariate and multivariate analyses revealed that genomic and molecular signatures were mutually independent, powerful prognostic indicators. Thus, combined genomic and molecular signatures may categorize novel risk groups and confer new clues for allowing tailored or even individualized medicine to patients with neuroblastoma.	[Tomioka, N.; Ohira, M.; Nakamura, Y.; Isogai, E.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Tomioka, N.; Misra, A.; Feuerstein, B. G.] Univ Calif San Francisco, Brain Tumor Res Ctr, Dept Neurol Surg, San Francisco, CA USA; [Tomioka, N.; Todo, S.] Hokkaido Univ, Sch Med, Dept Surg, Sapporo, Hokkaido 060, Japan; [Oba, S.; Ishii, S.] Nara Inst Sci & Technol, Grad Sch Informat Sci, Ikoma, Japan; [Fridlyand, J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Hirata, T.] Hisamitsu Pharmaceut Co Inc, Tokyo, Japan; [Yoshida, Y.] NGK Insulators Ltd, R&D Ctr, GENESHOT Project, Nagoya, Aichi, Japan; [Kaneko, Y.] Saitama Canc Ctr, Res Inst, Saitama, Japan; [Albertson, D. G.; Pinkel, D.; Feuerstein, B. G.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Albertson, D. G.; Pinkel, D.; Feuerstein, B. G.] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA USA	Chiba Cancer Center; University of California System; University of California San Francisco; Hokkaido University; Nara Institute of Science & Technology; University of California System; University of California San Francisco; Hisamitsu Pharmaceutical Co Ltd; NGK Insulators Ltd; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Feuerstein, Burt G/A-5186-2015	Feuerstein, Burt G/0000-0001-7276-8842; Ishii, Shin/0000-0001-9385-8230				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2001, MED PEDIATR ONCOL, V36, P157, DOI 10.1002/1096-911X(20010101)36:1<157::AID-MPO1038>3.0.CO;2-F; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Iehara T, 2006, BRIT J CANCER, V94, P1510, DOI 10.1038/sj.bjc.6603149; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kaneko M, 2002, J PEDIAT HEMATOL ONC, V24, P613, DOI 10.1097/00043426-200211000-00004; Levy IG, 2005, J NATL CANCER I, V97, P1105, DOI 10.1093/jnci/dji243; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Nakagawara A, 2004, PROG BRAIN RES, V146, P233, DOI 10.1016/S0079-6123(03)46015-9; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakagawara A, 1998, MED PEDIATR ONCOL, V31, P113, DOI 10.1002/(SICI)1096-911X(199808)31:2<113::AID-MPO14>3.0.CO;2-O; OBA S, 2006, IPSJ T BIOINFORMATIC, V47, P73; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; SAWADA T, 1984, LANCET, V2, P271; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tomioka N, 2003, GENE CHROMOSOME CANC, V36, P139, DOI 10.1002/gcc.10151; TONINI GP, 1993, STEM CELLS, V11, P276, DOI 10.1002/stem.5530110404; Vandesompele J, 1998, GENE CHROMOSOME CANC, V23, P141, DOI 10.1002/(SICI)1098-2264(199810)23:2<141::AID-GCC7>3.0.CO;2-2; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Woods WG, 2002, NEW ENGL J MED, V346, P1041, DOI 10.1056/NEJMoa012387	32	65	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					441	449		10.1038/sj.onc.1210661	http://dx.doi.org/10.1038/sj.onc.1210661			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637744				2022-12-28	WOS:000252426100004
J	Bourdeaut, F; Ribeiro, A; Paris, R; Pierron, G; Couturier, J; Peuchmaur, M; Delattre, O				Bourdeaut, F.; Ribeiro, A.; Paris, R.; Pierron, G.; Couturier, J.; Peuchmaur, M.; Delattre, O.			In neuroblastic tumours, Schwann cells do not harbour the genetic alterations of neuroblasts but may nevertheless share the same clonal origin	ONCOGENE			English	Article						Schwann cell; neuroblastoma; clonality; differentiation; X inactivation	PATCH SIZE; DIFFERENTIATION; GANGLIONEUROBLASTOMA; MATURATION	Neuroblastic tumours are composed of variable proportions of neuroblasts and Schwann cells. Whether both components share a common neoplastic origin is highly debated and discrepant results have been reported about the presence of tumour-related genetic alterations in Schwann cells. We have used X-methylation analysis and array-CGH to investigate contiguous Schwannian and neuroblastic areas in tumours with a nodular pattern. A skewed X inactivation was observed in four out of five stromal components. Interestingly, in these four cases, the X-inactivation profiles of the neuroblastic components were identical to the matched stromal areas. However, whereas all neuroblastic areas displayed chromosomal imbalances, no alteration was found in any Schwann cell components. Similarly, no alteration was observed in a series of 19 tumours with a single stroma-rich component, which occasionally exhibited a skewed X-inactivation pattern (3/17 informative tumours). Altogether, this indicates that most stroma-rich tumours display a polyclonal proliferation and that Schwann cells do not derive from neuroblasts. However, in tumours with both stroma-rich and -poor components, our results suggest that cells from both areas share a common progenitor.	[Bourdeaut, F.; Delattre, O.] Inst Curie, INSERM, Unite Genet & Biol Canc, Sect Rech,U830, F-75248 Paris 05, France; [Ribeiro, A.; Pierron, G.; Delattre, O.] Inst Curie, Unite Genet Somat, Paris, France; [Paris, R.; Peuchmaur, M.] Univ Paris 07, AP HP Hop R Debre, EA3102, Serv Patol, Paris, France; [Couturier, J.] Inst Curie, Cytogenet Unit, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Delattre, O (corresponding author), Inst Curie, INSERM, Unite Genet & Biol Canc, Sect Rech,U830, 26 Rue Ulm, F-75248 Paris 05, France.	olivier.delattre@curie.fr	, Bourdeaut/AAG-8494-2019	delattre, olivier/0000-0002-8730-2276				Ambros IM, 1996, NEW ENGL J MED, V334, P1505, DOI 10.1056/NEJM199606063342304; Ambros IM, 2001, MED PEDIATR ONCOL, V36, P163; Bhattacharyya I, 1999, ORAL SURG ORAL MED O, V88, P586, DOI 10.1016/S1079-2104(99)70090-9; Chen GL, 2007, BLOOD, V110, P1410, DOI 10.1182/blood-2006-09-018655; Coco S, 2005, J PATHOL, V207, P346, DOI 10.1002/path.1843; DUPIN E, 1990, P NATL ACAD SCI USA, V87, P1119, DOI 10.1073/pnas.87.3.1119; HAAS D, 1988, CANCER, V62, P815; Idbaih A, 2005, ANN NEUROL, V58, P483, DOI 10.1002/ana.20607; Jovanovic L, 2003, J CLIN ENDOCR METAB, V88, P3284, DOI 10.1210/jc.2002-021552; Kubota T, 1999, HUM GENET, V104, P49, DOI 10.1007/s004390050909; La Rosa P, 2006, BIOINFORMATICS, V22, P2066, DOI 10.1093/bioinformatics/btl359; Liu SQ, 2005, AM J PATHOL, V166, P891, DOI 10.1016/S0002-9440(10)62309-7; MERLO GR, 1991, BIOTECHNIQUES, V11, P166; Mora J, 2001, CANCER RES, V61, P6892; Nishihira H, 2000, J CLIN ONCOL, V18, P3012, DOI 10.1200/JCO.2000.18.16.3012; Novelli M, 2003, P NATL ACAD SCI USA, V100, P3311, DOI 10.1073/pnas.0437825100; Peuchmaur M, 2003, CANCER, V98, P2274, DOI 10.1002/cncr.11773; RANGECROFT L, 1978, ARCH DIS CHILD, V53, P815, DOI 10.1136/adc.53.10.815; Raskind WH, 1998, LEUKEMIA, V12, P108, DOI 10.1038/sj.leu.2400934; SUGIMOTO T, 1988, CANCER RES, V48, P2531; Tsai YC, 1996, CANCER RES, V56, P402	21	25	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					3066	3071		10.1038/sj.onc.1210965	http://dx.doi.org/10.1038/sj.onc.1210965			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18071318				2022-12-28	WOS:000255681700014
J	Clybouw, C; El Mchichi, B; Hadji, A; Portier, A; Auffredou, MT; Arnoult, D; Leca, G; Vazquez, A				Clybouw, C.; El Mchichi, B.; Hadji, A.; Portier, A.; Auffredou, M. T.; Arnoult, D.; Leca, G.; Vazquez, A.			TGF beta-mediated apoptosis of Burkitt's lymphoma BL41 cells is associated with the relocation of mitochondrial BimEL	ONCOGENE			English	Article						Bim; TGF beta; mitochondrial delocalization; apoptosis; lymphoma	BCL-2 FAMILY-MEMBER; HUMAN B-CELLS; BH3-ONLY PROTEINS; P38 MAPK; CASPASE-8 ACTIVATION; DEPENDENT APOPTOSIS; BH3 DOMAINS; T-CELLS; MCL-1; PHOSPHORYLATION	In this study, we showed that the transforming growth factor beta ( TGF beta)-mediated apoptosis of Burkitt's lymphoma BL41 cells is dependent on the BH3-only protein Bim. In contrast to what has been observed with other cell types, TGFb activation did not promote Bim upregulation in BL41 cells, but instead resulted in Bim release from the mitochondria. Indeed, Bim levels were high in healthy BL41 cells, in which they dimerized with the Bcl-2-like protein Mcl-1 at the mitochondrial surface. In healthy and TGF beta-activated BL41 cells, unlike in epithelial cells or hepatocytes, Bim did not associate with Bcl-2 or Bcl-xL. TGFb activation of BL41 cells triggered the p38-dependent activation of caspase-8, causing the cleavage of Mcl-1 and the transfer of Bim from the mitochondria to the cytoskeleton. In addition to mitochondrial activation, this relocation of Bim may facilitate the complete demise of a cell death that is beyond the commitment point to apoptosis and may represent a hallmark of the TGF beta-mediated apoptosis of human lymphoma B cells.	[Clybouw, C.; El Mchichi, B.; Hadji, A.; Portier, A.; Auffredou, M. T.; Arnoult, D.; Leca, G.; Vazquez, A.] Univ Paris Sud, Hop Paul Brousse, INSERM, U542, F-94807 Villejuif, Val De Marne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Vazquez, A (corresponding author), Univ Paris Sud, Hop Paul Brousse, INSERM, U542, Batiment,Lavoisier,14 Ave Paul Vaillant Couturier, F-94807 Villejuif, Val De Marne, France.	vazquez@vjf.inserm.fr	Arnoult, Damien/R-2032-2018					Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Clybouw C, 2005, J IMMUNOL, V175, P2968, DOI 10.4049/jimmunol.175.5.2968; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; El Mchichi B, 2007, CELL DEATH DIFFER, V14, P1826, DOI 10.1038/sj.cdd.4402187; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kobayashi S, 2007, J BIOL CHEM, V282, P18407, DOI 10.1074/jbc.M610010200; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; MAURER F, 1906, HDB VERGLEICHENDEN 1, V3, P1; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Mouhamad S, 2004, J IMMUNOL, V172, P2084, DOI 10.4049/jimmunol.172.4.2084; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ohgushi M, 2005, MOL CELL BIOL, V25, P10017, DOI 10.1128/MCB.25.22.10017-10028.2005; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	55	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3446	3456		10.1038/sj.onc.1211009	http://dx.doi.org/10.1038/sj.onc.1211009			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193085				2022-12-28	WOS:000256309900009
J	Gunther, HS; Schmidt, NO; Phillips, HS; Kemming, D; Kharbanda, S; Soriano, R; Modrusan, Z; Meissner, H; Westphal, M; Lamszus, K				Guenther, H. S.; Schmidt, N. O.; Phillips, H. S.; Kemming, D.; Kharbanda, S.; Soriano, R.; Modrusan, Z.; Meissner, H.; Westphal, M.; Lamszus, K.			Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria	ONCOGENE			English	Article						glioma; neural stem cell; neurosphere; microarray; pathway	TUMOR-INITIATING CELLS; BRAIN-TUMORS; MONOCLONAL-ANTIBODY; GROWTH-FACTOR; EXPRESSION; IDENTIFICATION; INHIBITION; PROFILES; PATHWAY; GENOME	Tumor cells with stem cell-like properties can be cultured from human glioblastomas by using conditions that select for the expansion of neural stem cells. We generated cell lines from glioblastoma specimens with the goal to obtain model systems for glioma stem cell biology. Unsupervised analysis of the expression profiles of nine cell lines established under neural stem cell conditions yielded two distinct clusters. Four cell lines were characterized by the expression of neurodevelopmental genes. They showed a multipotent differentiation profile along neuronal, astroglial and oligodendroglial lineages, grew spherically in vitro, expressed CD133 and formed highly invasive tumors in vivo. The other five cell lines shared expression signatures enriched for extracellular matrix-related genes, had a more restricted differentiation capacity, contained no or fewer CD133(+) cells, grew semiadherent or adherent in vitro and displayed reduced tumorigenicity and invasion in vivo. Our findings show that stable, multipotent glioblastoma cell lines with a full stem-like phenotype express neurodevelopmental genes as a distinctive feature, which may offer therapeutic targeting opportunities. The generation of another distinct cluster of cell lines showing similarly homogeneous pro. ling but restricted stem cell properties suggests that different phenotypes exist, each of which may lead to the typical appearance of glioblastoma.	[Guenther, H. S.; Schmidt, N. O.; Meissner, H.; Westphal, M.; Lamszus, K.] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Lab Brain Tumor Biol, D-20246 Hamburg, Germany; [Phillips, H. S.; Kharbanda, S.] Genentech Inc, Dept Tumor Biol & Angiogenesis, San Francisco, CA 94080 USA; [Kemming, D.] Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, Hamburg, Germany; [Soriano, R.; Modrusan, Z.] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; Roche Holding; Genentech; University of Hamburg; University Medical Center Hamburg-Eppendorf; Roche Holding; Genentech	Lamszus, K (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Lab Brain Tumor Biol, Martinistr 52, D-20246 Hamburg, Germany.	lamszus@uke.uni-hamburg.de	Schmidt, Nils Ole/D-5696-2014	Schmidt, Nils Ole/0000-0001-6910-8843				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Al-Shahrour F, 2006, NUCLEIC ACIDS RES, V34, pW472, DOI 10.1093/nar/gkl172; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Glaser T, 2004, FASEB J, V18, P112, DOI 10.1096/fj.04-1931fje; Gritti A, 1996, J NEUROSCI, V16, P1091; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Kageyama R, 1999, CELL RES, V9, P179, DOI 10.1038/sj.cr.7290016; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Kunkel P, 2001, CANCER RES, V61, P6624; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pilkington GJ, 2005, CELL PROLIFERAT, V38, P423, DOI 10.1111/j.1365-2184.2005.00358.x; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; Shih AH, 2006, NEOPLASIA, V8, P1072, DOI 10.1593/neo.06526; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Tunici P, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-25; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Zhang QB, 2006, CELL RES, V16, P909, DOI 10.1038/sj.cr.7310104	38	319	331	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2008	27	20					2897	2909		10.1038/sj.onc.1210949	http://dx.doi.org/10.1038/sj.onc.1210949			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037961				2022-12-28	WOS:000255502500011
J	Yoo, YG; Na, TY; Seo, HW; Seong, JK; Park, CK; Shin, YK; Lee, MO				Yoo, Y-G; Na, T-Y; Seo, H-W; Seong, J. K.; Park, C. K.; Shin, Y. K.; Lee, M-O			Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells	ONCOGENE			English	Article						HBx; metastasis-associated protein; histone deacetylase; hepatitis B virus; hypoxia-inducible factor-1 alpha	HISTONE DEACETYLASE INHIBITORS; INDUCIBLE FACTOR 1-ALPHA; HBX PROTEIN; HEPATOMA-CELLS; GROWTH-FACTOR; METASTASIS; ACETYLATION; GENE; HIF-1-ALPHA; ACTIVATION	Expression level of metastasis-associated protein 1 (MTA1) is closely related to tumor growth and metastasis in various cancers. Although increased expression level of MTA1 was observed in hepatocellular carcinoma (HCC), role of MTA1 complex containing histone deacetylase (HDAC) in hepatitis B virus (HBV)-associated hepatocarcinogenesis has not been studied. Here, we demonstrated that HBx strongly induced the expression of MTA1 and HDAC1 genes at transcription level. MTA1 and HDAC1/2 physically associated with hypoxia-inducible factor-1 alpha (HIF-1 alpha) in vivo in the presence of HBx, which was abolished by knockdown of MTA1 by short interfering RNA (siRNA). HBx induced deacetylation of the oxygen-dependent degradation domain of HIF-1 alpha, which was accompanied with dissociation of prolyl hydroxylases and von Hippel-Lindau tumor suppressor from HIF-1 alpha. These results indicate that HBx-induced deacetylation is important for proteasomal degradation of HIF-1 alpha. Further, we observed that protein levels of MTA1 and HDAC1 were increased in the liver of HBx-transgenic mice. Also, there was a higher expression of HDAC1 in HCC than in the adjacent non-tumorous cirrhotic nodules in 10 out of 12 human HBV-associated HCC specimens. Together, our data indicate a positive cross talk between HBx and the MTA1/HDAC complex in stabilizing HIF-1 alpha, which may play a critical role in angiogenesis and metastasis of HBV-associated HCC.	[Yoo, Y-G; Na, T-Y; Seo, H-W; Shin, Y. K.; Lee, M-O] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Yoo, Y-G; Na, T-Y; Seo, H-W; Lee, M-O] Seoul Natl Univ, Bio MAX Inst, Seoul 151742, South Korea; [Seong, J. K.] Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea; [Park, C. K.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center	Lee, MO (corresponding author), Seoul Natl Univ, Coll Pharm, San 56-1 Shillim Dong, Seoul 151742, South Korea.	molee@snu.ac.kr	Shin, Young Kee/C-8929-2011	Shin, Young Kee/0000-0003-0896-718X; Seong, Je Kyung/0000-0003-1177-6958				Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020; Arnesen T, 2005, FEBS LETT, V579, P6428, DOI 10.1016/j.febslet.2005.10.036; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Bilton R, 2006, TRENDS CELL BIOL, V16, P616, DOI 10.1016/j.tcb.2006.10.002; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Caron C, 2003, BIOESSAYS, V25, P58, DOI 10.1002/bies.10202; Chan DW, 2006, J PATHOL, V208, P372, DOI 10.1002/path.1901; Chang CC, 2006, JNCI-J NATL CANCER I, V98, P984, DOI 10.1093/jnci/djj242; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Cougot D, 2005, J CLIN VIROL, V34, pS75, DOI 10.1016/S1386-6532(05)80014-9; Fath DM, 2006, J BIOL CHEM, V281, P13612, DOI 10.1074/jbc.M600456200; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Frati A, 2002, J EXP CLIN CANC RES, V21, P321; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Hamatsu T, 2003, ONCOL REP, V10, P599; Huang GW, 2005, WORLD J GASTROENTERO, V11, P1705; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim SH, 2007, ONCOL REP, V17, P647; KONDO Y, 1991, HUM PATHOL, V22, P125, DOI 10.1016/0046-8177(91)90033-L; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Moon EJ, 2003, FASEB J, V17, P382, DOI 10.1096/fj.03-0153fje; Moon WS, 2004, HUM PATHOL, V35, P424, DOI 10.1016/j.humpath.2003.11.007; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Murray-Rust TA, 2006, FEBS LETT, V580, P1911, DOI 10.1016/j.febslet.2006.02.012; Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769; Ou DP, 2006, DIGEST LIVER DIS, V38, P262, DOI 10.1016/j.dld.2005.10.027; Pathil A, 2006, HEPATOLOGY, V43, P425, DOI 10.1002/hep.21054; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Wada H, 2006, LIVER INT, V26, P414, DOI 10.1111/j.1478-3231.2006.01243.x; Wang LH, 2007, CLIN CANCER RES, V13, P102, DOI 10.1158/1078-0432.CCR-06-1467; Wu BK, 2006, BIOCHEM BIOPH RES CO, V340, P916, DOI 10.1016/j.bbrc.2005.12.089; Yeo MG, 2005, MOL ENDOCRINOL, V19, P950, DOI 10.1210/me.2004-0209; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Yoo YG, 2004, FEBS LETT, V577, P121, DOI 10.1016/j.febslet.2004.10.004; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yu FL, 2005, J HEPATOL, V42, P520, DOI 10.1016/j.jhep.2004.11.031; Yun C, 2002, CANCER LETT, V184, P97, DOI 10.1016/S0304-3835(02)00187-8; Zhang XD, 2006, J LAB CLIN MED, V147, P58, DOI 10.1016/j.lab.2005.10.003	50	131	140	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3405	3413		10.1038/sj.onc.1211000	http://dx.doi.org/10.1038/sj.onc.1211000			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18264140				2022-12-28	WOS:000256309900005
J	Omerovic, J; Hammond, DE; Clague, MJ; Prior, IA				Omerovic, J.; Hammond, D. E.; Clague, M. J.; Prior, I. A.			Ras isoform abundance and signalling in human cancer cell lines	ONCOGENE			English	Article						Ras; siRNA; Akt; HGF; EGF	K-RAS; GROWTH-FACTOR; H-RAS; N-RAS; CARCINOMA-CELLS; ERK ACTIVITY; PROLIFERATION; ACTIVATION; PROTEINS; PATHWAY	The ubiquitously expressed major Ras isoforms: H-, K- and N-Ras, are highly conserved, yet exhibit different biological outputs. We have compared the relative efficiencies with which epidermal or hepatocyte growth factor activates Ras isoforms and the requirement for specific isoforms in the activation of downstream pathways. We find that the relative coupling efficiencies to each Ras isoform are conserved between stimuli. Furthermore, in both cases, inhibition of receptor endocytosis led to reduced N- and H- Ras activation, but K- Ras was unaffected. Acute knockdown of each isoform with siRNA allows endogenous Ras isoform function and abundance to be probed. This revealed that there is significant variation in the contribution of individual isoforms to total Ras across a panel of cancer cell lines although typically K >= N >= H. Intriguingly, cancer cell lines where a significant fraction of endogenous Ras is oncogenically mutated showed attenuated activation of canonical Ras effector pathways. We pro. led the contribution of each Ras isoform to the total Ras pool allowing interpretation of the effect of isoform-specific knockdown on signalling outcomes. In contrast to previous studies indicating preferential coupling of isoforms to Raf and PtdIns-3-kinase pathways, we find that endogenous Ras isoforms show no specific coupling to these major Ras pathways.	[Omerovic, J.; Hammond, D. E.; Clague, M. J.; Prior, I. A.] Univ Liverpool, Dept Physiol, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Prior, IA (corresponding author), Univ Liverpool, Dept Physiol, Crown St,POB 147, Liverpool L69 3BX, Merseyside, England.	iprior@liverpool.ac.uk	Clague, Michael J/A-7199-2008; Omerovic, Jasminka/D-4998-2017	Clague, Michael J/0000-0003-3355-9479; Hammond, Dean/0000-0002-6326-8739; Prior, Ian/0000-0002-4055-5161	Cancer Research UK [A6672] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BOS JL, 1989, CANCER RES, V49, P4682; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; ELHASHIR SM, 2001, NATURE, V411, P494; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Iida M, 1999, LEUKEMIA, V13, P585, DOI 10.1038/sj.leu.2401369; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Mitin NY, 2004, J BIOL CHEM, V279, P22353, DOI 10.1074/jbc.M312867200; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; *SANG, DAT WAS OBT WELLC TR; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Seufferlein T, 1999, GASTROENTEROLOGY, V116, P1441, DOI 10.1016/S0016-5085(99)70509-3; Sharpe CC, 2000, J AM SOC NEPHROL, V11, P1600, DOI 10.1681/ASN.V1191600; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VIERA AV, 1996, SCIENCE, V274, P2086; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271; Yip-Schneider MT, 2001, BIOCHEM BIOPH RES CO, V280, P992, DOI 10.1006/bbrc.2001.4243	34	73	75	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2008	27	19					2754	2762		10.1038/sj.onc.1210925	http://dx.doi.org/10.1038/sj.onc.1210925			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998936	Green Accepted			2022-12-28	WOS:000255259500010
J	Rao, PR; Makhijani, K; Shashidhara, LS				Rao, P. R.; Makhijani, K.; Shashidhara, L. S.			Human APC sequesters beta-catenin even in the absence of GSK-3 beta in a Drosophila model	ONCOGENE			English	Article						colon cancer; adenomatous polyposis coli; Shaggy/GSK-3 beta; Armadillo; Wnt; wingless	HOMEOTIC GENE; PHOSPHORYLATION; EXPRESSION; BINDING; COMPLEX	There have been conflicting reports on the requirement of GSK- 3 beta- mediated phosphorylation of the tumor suppressor adenomatous polyposis coli ( APC) vis-a-vis its ability to bind and degrade beta- catenin. Using a unique combination of loss of function for Shaggy/ GSK- 3 beta and a gain of function for human APC in Drosophila, we show that misexpressed human APC ( hAPC) can still sequester Armadillo/beta- catenin. In addition, human APC could suppress gain of Wnt/ Wingless phenotypes associated with loss of Shaggy/ GSK- 3 beta activity, suggesting that sequestered Armadillo/beta- catenin is non- functional. Based on these studies, we propose that binding per se of b- catenin by APC does not require phosphorylation by GSK- 3 beta.	[Rao, P. R.; Makhijani, K.; Shashidhara, L. S.] Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, PR (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	prashanth21676@gmail.com		Rao, Prashanth Ramesh/0000-0002-6877-6214; , Kalpana/0000-0001-7795-891X				Bajpai R, 2004, DEVELOPMENT, V131, P1007, DOI 10.1242/dev.00980; Bhandari P, 2001, ONCOGENE, V20, P6871, DOI 10.1038/sj.onc.1204849; BRAND AH, 1993, DEVELOPMENT, V118, P401; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Liu J, 2006, J MOL BIOL, V360, P133, DOI 10.1016/j.jmb.2006.04.064; Mohit P, 2003, DEVELOPMENT, V130, P1537, DOI 10.1242/dev.00393; Neumann CJ, 1997, DEVELOPMENT, V124, P871; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Seo E, 2007, BIOCHEM BIOPH RES CO, V357, P81, DOI 10.1016/j.bbrc.2007.03.117; Shashidhara LS, 1999, DEV BIOL, V212, P491, DOI 10.1006/dbio.1999.9341; SIMMONDS AJ, 1995, NATURE, V376, P424, DOI 10.1038/376424a0; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001; XU T, 1993, DEVELOPMENT, V117, P1223; Zilian O, 1999, DEVELOPMENT, V126, P5409	19	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2488	2493		10.1038/sj.onc.1210890	http://dx.doi.org/10.1038/sj.onc.1210890			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968317				2022-12-28	WOS:000254844900013
J	Martinez, I; Gardiner, AS; Board, KF; Monzon, FA; Edwards, RP; Khan, SA				Martinez, I.; Gardiner, A. S.; Board, K. F.; Monzon, F. A.; Edwards, R. P.; Khan, S. A.			Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells	ONCOGENE			English	Article						HPVs; microRNA; cervical cancer; oncogene	TUMOR-SUPPRESSOR; GENE-EXPRESSION; GENOMIC INSTABILITY; CANCER; LAMININ-5; P53; E6; PROTEIN; HPV; E7	Human papillomaviruses (HPVs) are involved in the pathogenesis of cancer of the cervix (CaCx). MicroRNA (miRNA) expression analysis using Ambion (Austin, TX, USA) arrays showed that three miRNAs were over-expressed and 24 underexpressed in cervical cell lines containing integrated HPV-16 DNA compared to the normal cervix. Furthermore, nine miRNAs were overexpressed and one underexpressed in integrated HPV-16 cell lines compared to the HPV-negative CaCx cell line C-33A. Based on microarray and/or quantitative realtime PCR and northern blot analyses, microRNA-218 (miR-218) was specifically underexpressed in HPV-positive cell lines, cervical lesions and cancer tissues containing HPV-16 DNA compared to both C-33A and the normal cervix. Expression of the E6 oncogene of high-risk HPV-16, but not that of low-risk HPV-6, reduced miR-218 expression, and conversely, RNA interference of E6/E7 oncogenes in an HPV-16-positive cell line increased miR-218 expression. We also demonstrate that the epithelial cell-specific marker LAMB3 is a target of miR-218. We also show that LAMB3 expression is increased in the presence of the HPV-16 E6 oncogene and this effect is mediated through miR-218. These findings may contribute to a better understanding of the molecular mechanisms involved in cervical carcinogenesis.	[Martinez, I.; Gardiner, A. S.; Board, K. F.; Khan, S. A.] Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; [Monzon, F. A.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; [Monzon, F. A.] Univ Pittsburgh, Sch Med, Ctr Pathol Informat, Pittsburgh, PA 15261 USA; [Edwards, R. P.] Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Khan, SA (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Room E 1240 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15261 USA.	khan@pitt.edu		Gardiner, Amy S./0000-0002-8179-4919	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F31DE019028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065100] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC016406] Funding Source: Medline; NIDCR NIH HHS [DE019028, F31 DE019028, F31 DE019028-01A1] Funding Source: Medline; NIGMS NIH HHS [T32 GM065100, 5T32GM065100] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alazawi W, 2002, CANCER RES, V62, P6959; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Calaluce R, 2004, NEOPLASIA, V6, P468, DOI 10.1593/neo.03499; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Culp TD, 2006, J VIROL, V80, P8940, DOI 10.1128/JVI.00724-06; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dallol A, 2002, CANCER RES, V62, P5874; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hebner CM, 2006, REV MED VIROL, V16, P83, DOI 10.1002/rmv.488; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kohlberger P, 2003, GYNECOL ONCOL, V89, P391, DOI 10.1016/S0090-8258(03)00086-6; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MANOS MM, 1994, J INFECT DIS, V170, P1096, DOI 10.1093/infdis/170.5.1096; Martinez I, 2007, EUR J CANCER, V43, P415, DOI 10.1016/j.ejca.2006.09.001; Massimi P, 1996, ONCOGENE, V12, P2325; Meissner JD, 1999, J GEN VIROL, V80, P1725, DOI 10.1099/0022-1317-80-7-1725; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Piboonniyom SO, 2003, CANCER RES, V63, P476; Skyldberg B, 1999, J NATL CANCER I, V91, P1882, DOI 10.1093/jnci/91.21.1882; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	33	276	306	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2575	2582		10.1038/sj.onc.1210919	http://dx.doi.org/10.1038/sj.onc.1210919			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17998940	Green Accepted, Bronze			2022-12-28	WOS:000255057000007
J	Chaigne-Delalande, B; Anies, G; Kramer, I; Genot, E				Chaigne-Delalande, B.; Anies, G.; Kramer, I.; Genot, E.			Nonadherent cells switch to a Rac-mediated, SHIP regulated, Akt activation mode for survival	ONCOGENE			English	Article						adhesion; anoikis; akt; rac; SHIP; survival	PROTEIN-KINASE B; INTEGRINS; PATHWAYS; MOTILITY; ADHESION; 3-KINASE; PHOSPHORYLATION; PI-3-KINASE; P130(CAS); ANOIKIS	Constitutively active Rac stimulates Akt activity in T lymphocytes cultured in suspension. This regulation contrasts with findings obtained in fibroblasts, endothelial or neuronal cells grown on substrate, where Akt stimulation occurs independently of Rac. We now show that V12Rac-mediated stimulation of Akt is not restricted to the hematopoietic lineage but is dependent on the adherence status of the cell. V12Rac-mediated stimulation of Akt as well as molecular association between Rac and Akt occurred exclusively in cells kept in suspension. Stimulation and complex formation are dependent on SHIP but in a manner that differs from its role in dephosphorylation of phosphoinositide lipids. Adherent cells lacking SHIP, but not those lacking PTEN, are able to activate Akt through the Rac pathway. Our data reveal the existence of a bona. de Rac to Akt signaling pathway, tightly regulated by SHIP and operational in suspended cells only. This pathway may point to an alternative survival signal that is called into action when cells lose contact with the substrate and/or with other cells.	[Chaigne-Delalande, B.; Anies, G.; Kramer, I.; Genot, E.] Univ Bordeaux 1, European Inst Chem & Biol, Pessac, France; [Chaigne-Delalande, B.; Anies, G.; Kramer, I.; Genot, E.] INSERM, U889, Bordeaux, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm)	Chaigne-Delalande, B (corresponding author), IECB, INSERT U441, 2 Rue Robert Escapit, F-33600 Pessac, France.	e.genot@iecb.u-bordeaux.fr	Genot, Elisabeth/G-8031-2014					Astoul E, 2001, TRENDS IMMUNOL, V22, P490, DOI 10.1016/S1471-4906(01)01973-1; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Grodzki ACG, 2003, BRAZ J MED BIOL RES, V36, P1101, DOI 10.1590/S0100-879X2003000800017; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; MARTE BM, 1997, CURR BIOL, V63, P3; Moreau V, 2003, MOL CELL BIOL, V23, P6809, DOI 10.1128/MCB.23.19.6809-6822.2003; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Song JX, 2004, NAT IMMUNOL, V5, P150, DOI 10.1038/ni1030; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7	33	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1876	1885		10.1038/sj.onc.1210830	http://dx.doi.org/10.1038/sj.onc.1210830			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906692				2022-12-28	WOS:000254150600007
J	Kwong, LN; Weiss, KR; Haigis, KM; Dove, WF				Kwong, L. N.; Weiss, K. R.; Haigis, K. M.; Dove, W. F.			Atm is a negative regulator of intestinal neoplasia	ONCOGENE			English	Article						gastrointestinal cancer; Atm; Apc; Blm; Lig4; modifier	ATAXIA-TELANGIECTASIA; CANCER PREDISPOSITION; GENOMIC INSTABILITY; TUMOR-FORMATION; TUMORIGENESIS; MOUSE; MICE; APC; PROGRESSION; ADENOMAS	The ataxia telangiectasia-mutated (ATM) gene has been implicated as an early barrier to the growth and progression of incipient solid tumors. Here, we show that germ-line nullizygosity for the mouse Atm gene significantly increases the proliferative index, net growth rate and multiplicity of intestinal adenomas in two distinct models of familial colon cancer: Apc(Min/+) and Apc(1638N/+). These effects of Atm deficiency are quantitatively different from deficiency for either of the genomic stability genes Bloom's syndrome helicase or DNA ligase 4, and the effect of Atm loss on tumor multiplicity is largely independent of the effect of ionizing radiation. Furthermore, the loss of heterozygosity rates at the adenomatous polyposis coli (Apc) locus are unaffected by Atm loss. Taken together, these data implicate the Atm gene product as a barrier to dysplastic growth in the early stages of intestinal tumor progression, independent of its effects on genomic stability.	[Kwong, L. N.; Weiss, K. R.; Haigis, K. M.; Dove, W. F.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dove, WF (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	dove@oncology.wisc.edu			NCI NIH HHS [T32 CA009135, R37CA63677, CA009135, R37 CA063677, R37 CA063677-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA063677, T32CA009135] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amos-Landgraf JM, 2007, P NATL ACAD SCI USA, V104, P4036, DOI 10.1073/pnas.0611690104; Bai AHC, 2004, INT J CANCER, V112, P846, DOI 10.1002/ijc.20485; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Grabsch H, 2006, CLIN CANCER RES, V12, P1494, DOI 10.1158/1078-0432.CCR-05-2105; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; Haigis KM, 2004, P NATL ACAD SCI USA, V101, P9769, DOI 10.1073/pnas.0403338101; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Luongo C, 1996, GENE CHROMOSOME CANC, V17, P194, DOI 10.1002/1098-2264(199611)17:3<194::AID-GCC2870170302>3.0.CO;2-E; Mann MB, 2005, HUM MOL GENET, V14, P813, DOI 10.1093/hmg/ddi075; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Sugai T, 2001, ONCOGENE, V20, P6095, DOI 10.1038/sj.onc.1204731; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397	26	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					1013	1018		10.1038/sj.onc.1210708	http://dx.doi.org/10.1038/sj.onc.1210708			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700532	Green Accepted			2022-12-28	WOS:000252946300013
J	Ciuffini, L; Castellani, L; Salvati, E; Galletti, S; Falcone, G; Alema, S				Ciuffini, L.; Castellani, L.; Salvati, E.; Galletti, S.; Falcone, G.; Alema, S.			Delineating v-Src downstream effector pathways in transformed myoblasts	ONCOGENE			English	Article						v-Src; myogenic differentiation; p38 MAPK; Ras-MEK signalling	SKELETAL-MUSCLE DIFFERENTIATION; SIGNALING PATHWAYS; MYOGENIC DIFFERENTIATION; CELL-TRANSFORMATION; GENE-EXPRESSION; FAMILY KINASES; MAP KINASE; RAS; P38; ACTIVATION	In this study, we delineate the intracellular signalling pathways modulated by a conditional v-Src tyrosine kinase that lead to unrestrained proliferation and block of differentiation of primary avian myoblasts. By inhibiting Ras-MAPK kinase and phosphatidylinositol 3-kinase with different means, we find that both pathways play crucial roles in controlling v-Src-sustained growth factor and anchorage independence for proliferation. The Ras-MAPK kinase pathway also contributes to block of differentiation independently of cell proliferation since inhibition of this pathway both in proliferating and growth-arrested v-Src-transformed myoblasts induces expression of muscle-specific genes, fusion into multinucleated myotubes and assembly of specialized contractile structures. Importantly, we find that the p38 MAPK pathway is inhibited by v-Src in myoblasts and its forced activation results in growth inhibition and expression of differentiation, indicating p38 MAPK as a critical target of v-Src in growth transformation and myogenic differentiation. Furthermore, we show that downregulation of p38 MAPK activation may occur via Ras-MAPK kinase, thus highlighting a cross-regulation between the two pathways. Finally, we report that the simultaneous inhibition of MAPK kinase and calpain, combined to activation of p38 MAPK, are sufficient to reconstitute largely the differentiation potential of v-Src-transformed myoblasts.	[Ciuffini, L.; Castellani, L.; Salvati, E.; Galletti, S.; Falcone, G.; Alema, S.] CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; [Castellani, L.] Univ Cassino, Dipartimento Sci Motor & Salute, I-03043 Cassino, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Cassino	Falcone, G (corresponding author), CNR, Ist Biol Cellulare, Via Ramarini 32, I-00016 Monterotondo, Italy.	gfalcone@ibc.cnr.it; alema@ibc.cnr.it	Falcone, Germana/A-3735-2016	Castellani, Loriana/0000-0002-8519-3504; Salvati, Erica/0000-0002-3373-7442; Falcone, Germana/0000-0002-3508-7623				Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Castellani L, 2006, J BIOL CHEM, V281, P15249, DOI 10.1074/jbc.M601390200; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FALCONE G, 1992, ONCOGENE, V7, P1913; Falcone G, 2003, ONCOGENE, V22, P8302, DOI 10.1038/sj.onc.1206915; Faust D, 2005, ONCOGENE, V24, P7941, DOI 10.1038/sj.onc.1208948; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Keren A, 2006, MOL CELL ENDOCRINOL, V252, P224, DOI 10.1016/j.mce.2006.03.017; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Li RH, 1996, P NATL ACAD SCI USA, V93, P7522, DOI 10.1073/pnas.93.15.7522; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Russo S, 1997, ONCOGENE, V14, P63, DOI 10.1038/sj.onc.1200805; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Sundaresan P, 2002, FEBS LETT, V528, P139, DOI 10.1016/S0014-5793(02)03277-5; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	44	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					528	539		10.1038/sj.onc.1210665	http://dx.doi.org/10.1038/sj.onc.1210665			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637741				2022-12-28	WOS:000252426100013
J	Shao, C; Folkard, M; Prise, KM				Shao, C.; Folkard, M.; Prise, K. M.			Role of TGF-beta 1 and nitric oxide in the bystander response of irradiated glioma cells	ONCOGENE			English	Article						targeted irradiation; bystander signaling; TGF-beta 1; nitric oxide; glioma	CHARGED-PARTICLE MICROBEAM; MEDIATED INTERCELLULAR COMMUNICATION; INDUCED GENOMIC INSTABILITY; GROWTH-FACTOR BETA-1; IONIZING-RADIATION; ALPHA-PARTICLES; HUMAN FIBROBLASTS; TGF-BETA; COUNTED PARTICLES; EPITHELIAL-CELLS	The radiation-induced bystander effect (RIBE) increases the probability of cellular response and therefore has important implications for cancer risk assessment following low-dose irradiation and for the likelihood of secondary cancers after radiotherapy. However, our knowledge of bystander signaling factors, especially those having long half-lives, is still limited. The present study found that, when a fraction of cells within a glioblastoma population were individually irradiated with helium ions from a particle microbeam, the yield of micronuclei (MN) in the nontargeted cells was increased, but these bystander MN were eliminated by treating the cells with either aminoguanidine (an inhibitor of inducible nitric oxide (NO) synthase) or anti-transforming growth factor beta 1 (anti-TGF-beta 1), indicating that NO and TGF-beta 1 are involved in the RIBE. Intracellular NO was detected in the bystander cells, and additional TGF-b1 was detected in the medium from irradiated T98G cells, but it was diminished by aminoguanidine. Consistent with this, an NO donor, diethylamine nitric oxide (DEANO), induced TGF-beta 1 generation in T98G cells. Conversely, treatment of cells with recombinant TGF-beta 1 could also induce NO and MN in T98G cells. Treatment of T98G cells with anti-TGF-beta 1 inhibited the NO production when only 1% of cells were targeted, but not when 100% of cells were targeted. Our results indicate that, downstream of radiation-induced NO, TGF-beta 1 can be released from targeted T98G cells and plays a key role as a signaling factor in the RIBE by further inducing free radicals and DNA damage in the nontargeted bystander cells.	[Prise, K. M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Shao, C.; Folkard, M.; Prise, K. M.] Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2RN, Middx, England; [Shao, C.] Fudan Univ, Inst Radiat Med, Shanghai 200433, Peoples R China	Queens University Belfast; University of Oxford; Fudan University	Prise, KM (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	k.prise@qub.ac.uk	Prise, Kevin/N-7872-2015	Prise, Kevin/0000-0001-6134-7946; Shao, Chunlin/0000-0001-9336-9912	Cancer Research UK [A7047] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Albertini RJ, 2000, MUTAT RES-REV MUTAT, V463, P111, DOI 10.1016/S1383-5742(00)00049-1; Arnold SF, 1999, RADIAT RES, V152, P487, DOI 10.2307/3580144; Ayache N, 2002, OSTEOARTHR CARTILAGE, V10, P344, DOI 10.1053/joca.2001.0499; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Barcellos-Hoff MH, 2005, SEMIN CANCER BIOL, V15, P138, DOI 10.1016/j.semcancer.2004.08.010; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; BLANCO FJ, 1995, J IMMUNOL, V154, P4018; Boerma M, 2002, INT J RADIAT BIOL, V78, P219, DOI 10.1080/09553000110094797; Burdak-Rothkamm S, 2007, ONCOGENE, V26, P993, DOI 10.1038/sj.onc.1209863; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; Folkard M, 1997, INT J RADIAT BIOL, V72, P387, DOI 10.1080/095530097143167; Gizatullina ZZ, 2003, BIOCHEM BIOPH RES CO, V304, P643, DOI 10.1016/S0006-291X(03)00654-5; Hamby ME, 2006, GLIA, V54, P566, DOI 10.1002/glia.20411; Han JX, 2006, RADIAT RES, V165, P283, DOI 10.1667/RR3516.1; Iyer R, 2000, CANCER RES, V60, P1290; Jobling ME, 2006, RADIAT RES, V166, P839, DOI 10.1667/RR0695.1; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Lewis DA, 2001, RADIAT RES, V156, P251, DOI 10.1667/0033-7587(2001)156[0251:PODDAN]2.0.CO;2; Limoli CL, 2000, ADV SPACE RES, V25, P2107, DOI 10.1016/S0273-1177(99)01062-5; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Lyng FM, 2006, RADIAT RES, V165, P400, DOI 10.1667/RR3527.1; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Matsumoto H, 2000, INT J RADIAT BIOL, V76, P1649; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Nesti LJ, 2007, J CELL BIOCHEM, V101, P348, DOI 10.1002/jcb.21180; Newman E, 2004, J BIOL CHEM, V279, P33547, DOI 10.1074/jbc.M403892200; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Schmidt A, 2003, CARDIOVASC RES, V58, P671, DOI 10.1016/S0008-6363(03)00322-5; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2005, INT J CANCER, V116, P45, DOI 10.1002/ijc.21003; Shao C, 2003, CANCER RES, V63, P8437; Shao CL, 2006, RADIAT RES, V166, P479, DOI 10.1667/RR3600.1; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2004, J RADIAT RES, V45, P97, DOI 10.1269/jrr.45.97; Shao CL, 2003, RADIAT ENVIRON BIOPH, V42, P183, DOI 10.1007/s00411-003-0202-y; Sokolov MV, 2005, ONCOGENE, V24, P7257, DOI 10.1038/sj.onc.1208886; Tartier L, 2007, CANCER RES, V67, P5872, DOI 10.1158/0008-5472.CAN-07-0188; Vodovotz Y, 1999, CANCER RES, V59, P2142; Yang HY, 2005, ONCOGENE, V24, P2096, DOI 10.1038/sj.onc.1208439; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	51	163	169	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					434	440		10.1038/sj.onc.1210653	http://dx.doi.org/10.1038/sj.onc.1210653			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17621264	Green Accepted			2022-12-28	WOS:000252426100003
J	Soulas-Sprauel, P; Rivera-Munoz, P; Malivert, L; Le Guyader, G; Abramowski, V; Revy, P; de Villartay, JP				Soulas-Sprauel, P.; Rivera-Munoz, P.; Malivert, L.; Le Guyader, G.; Abramowski, V.; Revy, P.; de Villartay, J-P			V(D)J and immunoglobulin class switch recombinations: a paradigm to study the regulation of DNA end-joining	ONCOGENE			English	Review						V(D)J recombination; class switch recombination; SCID; Artemis; Cernunnos; NHEJ	STRAND BREAK REPAIR; SEVERE COMBINED IMMUNODEFICIENCY; DEPENDENT PROTEIN-KINASE; COMBINED IMMUNE-DEFICIENCY; CYTIDINE DEAMINASE AID; LIGASE-IV COMPLEX; SACCHAROMYCES-CEREVISIAE; B-CELLS; HOMOLOGOUS RECOMBINATION; SOMATIC HYPERMUTATION	The immune system is the site of intense DNA damage/modification, which occur during the development and maturation of B and T lymphocytes. V(D)J recombination is initiated by the Rag1 and Rag2 proteins and the formation of a DNA double-strand break (DNA dsb). This DNA lesion is repaired through the use of the nonhomologous end-joining (NHEJ) pathway, several factors of which have been identified through the survey of immunodeficient conditions in humans and mice. Upon antigenic recognition in secondary lymphoid organs, mature B cells further diversify their repertoire through class switch recombination (CSR). CSR is a region-specific rearrangement process triggered by the activation-induced cytidine deaminase factor and also proceeds through the introduction of DNA dsb. However, unlike V(D)J recombination, CSR does not rely strictly on NHEJ for the repair of the DNA lesion. Instead, CSR, but not V(D)J recombination, requires the major factors of the DNA damage response. V(D)J recombination and CSR thus represent an interesting paradigm to study the regulation among the various DNA repair pathways.	Hop Necker Enfants Malad, INSERM, U768, F-75015 Paris, France; Univ Paris 05, Fac Med Rene Descartes, IFR94, Paris, France; Hop Necker Enfants Malad, AP HP, Serv Immunol & Hematol Pediat, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	de Villartay, JP (corresponding author), Hop Necker Enfants Malad, INSERM, U768, 149 Rue Sevres, F-75015 Paris, France.	devillar@necker.fr	Revy, Patrick/H-8137-2017; de Villartay, jean pierre/H-9353-2017	de Villartay, jean pierre/0000-0001-5987-0463; Revy, Patrick/0000-0003-0758-8022; Malivert, Laurent/0000-0002-0944-6573; Soulas-Sprauel, Pauline/0000-0002-2058-4811				Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Ahnesorg P, 2007, DNA REPAIR, V6, P190, DOI 10.1016/j.dnarep.2006.09.010; Aravind L, 1999, In Silico Biol, V1, P69; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Bassing CH, 2004, CELL CYCLE, V3, P149; Ben-Omran TI, 2005, AM J MED GENET A, V137A, P283, DOI 10.1002/ajmg.a.30869; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Bosma GC, 2002, J EXP MED, V196, P1483, DOI 10.1084/jem.20001871; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Callebaut I, 2006, J BIOL CHEM, V281, P13857, DOI 10.1074/jbc.C500473200; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Catalan N, 2003, J IMMUNOL, V171, P2504, DOI 10.4049/jimmunol.171.5.2504; CAVAZZANACALVO M, 1993, J CLIN INVEST, V91, P1214, DOI 10.1172/JCI116282; Cavero S, 2007, GENETICS, V175, P963, DOI 10.1534/genetics.106.067850; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Chen L, 2005, CANCER SCI, V96, P134, DOI 10.1111/j.1349-7006.2005.00019.x; Cook AJL, 2003, J IMMUNOL, V171, P6556, DOI 10.4049/jimmunol.171.12.6556; Corneo B, 2007, NATURE, V449, P483, DOI 10.1038/nature06168; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; Darroudi F, 2007, MUTAT RES-FUND MOL M, V615, P111, DOI 10.1016/j.mrfmmm.2006.11.029; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; Decottignies A, 2007, GENETICS, V176, P1403, DOI 10.1534/genetics.107.071621; Deshpande RA, 2007, DNA REPAIR, V6, P1507, DOI 10.1016/j.dnarep.2007.04.014; Drouet J, 2006, J BIOL CHEM, V281, P27784, DOI 10.1074/jbc.M603047200; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Enders A, 2006, J IMMUNOL, V176, P5060, DOI 10.4049/jimmunol.176.8.5060; Evans PM, 2006, HUM MOL GENET, V15, P1303, DOI 10.1093/hmg/ddl050; Fischer A, 2004, NAT IMMUNOL, V5, P23, DOI 10.1038/ni1023; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Geng LY, 2007, MOL CELL BIOL, V27, P2625, DOI 10.1128/MCB.02072-06; Gennery AR, 2005, CLIN IMMUNOL, V116, P246, DOI 10.1016/j.clim.2005.04.014; Goodarzi AA, 2006, EMBO J, V25, P3880, DOI 10.1038/sj.emboj.7601255; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Gu JF, 2007, NUCLEIC ACIDS RES, V35, P5755, DOI 10.1093/nar/gkm579; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Hentges P, 2006, J BIOL CHEM, V281, P37517, DOI 10.1074/jbc.M608727200; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Inagaki K, 2007, J VIROL, V81, P11304, DOI 10.1128/JVI.01225-07; Ishikawa H, 2006, J BIOCHEM, V140, P535, DOI 10.1093/jb/mvj183; Jankovic M, 2007, NAT IMMUNOL, V8, P801, DOI 10.1038/ni1498; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Kiefer K, 2007, P NATL ACAD SCI USA, V104, P2843, DOI 10.1073/pnas.0611359104; Kracker S, 2005, P NATL ACAD SCI USA, V102, P1584, DOI 10.1073/pnas.0409191102; Krempler A, 2007, CELL CYCLE, V6, P1682, DOI 10.4161/cc.6.14.4480; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lenain C, 2006, CURR BIOL, V16, P1303, DOI 10.1016/j.cub.2006.05.021; Li LY, 2005, J IMMUNOL, V174, P2420, DOI 10.4049/jimmunol.174.4.2420; Li LY, 1998, AM J HUM GENET, V62, P136, DOI 10.1086/301688; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Lu HH, 2007, J BIOL CHEM, V282, P11155, DOI 10.1074/jbc.M609904200; Lumsden JM, 2004, J EXP MED, V200, P1111, DOI 10.1084/jem.20041074; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Ma YM, 2005, J BIOL CHEM, V280, P33839, DOI 10.1074/jbc.M507113200; Mandel CR, 2006, NATURE, V444, P953, DOI 10.1038/nature05363; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Manis JP, 2002, IMMUNITY, V16, P607, DOI 10.1016/S1074-7613(02)00306-0; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nicolas N, 1996, EUR J IMMUNOL, V26, P1118, DOI 10.1002/eji.1830260524; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; Niewolik D, 2006, J BIOL CHEM, V281, P33900, DOI 10.1074/jbc.M606023200; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; Pan-Hammarstrom Q, 2005, J EXP MED, V201, P189, DOI 10.1084/jem.20040772; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; Peron S, 2007, J EXP MED, V204, P1207, DOI 10.1084/jem.20070087; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Poinsignon C, 2004, EUR J IMMUNOL, V34, P3146, DOI 10.1002/eji.200425455; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Povirk LF, 2007, J BIOL CHEM, V282, P3547, DOI 10.1074/jbc.M607745200; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Reina-San-Martin B, 2005, P NATL ACAD SCI USA, V102, P1590, DOI 10.1073/pnas.0406289102; Reina-San-Martin B, 2004, J EXP MED, V200, P1103, DOI 10.1084/jem.20041162; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Revy P, 2005, ADV IMMUNOL, V87, P237, DOI 10.1016/S0065-2776(05)87007-5; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rooney S, 2005, P NATL ACAD SCI USA, V102, P2471, DOI 10.1073/pnas.0409857102; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Roth DB, 2003, NAT REV IMMUNOL, V3, P656, DOI 10.1038/nri1152; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; Rush JS, 2004, INT IMMUNOL, V16, P549, DOI 10.1093/intimm/dxh057; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Sonoda E, 2006, DNA REPAIR, V5, P1021, DOI 10.1016/j.dnarep.2006.05.022; Soubeyrand S, 2006, J MOL BIOL, V358, P1200, DOI 10.1016/j.jmb.2006.02.061; Soulas-Sprauel P, 2007, J EXP MED, V204, P1717, DOI 10.1084/jem.20070255; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tsai CJ, 2007, P NATL ACAD SCI USA, V104, P7851, DOI 10.1073/pnas.0702620104; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; van Overbeek M, 2006, CURR BIOL, V16, P1295, DOI 10.1016/j.cub.2006.05.022; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; WU PY, 2007, J BIOL CHEM; Wuerffel RA, 1997, J IMMUNOL, V159, P4139; Wyman C, 2006, ANNU REV GENET, V40, P363, DOI 10.1146/annurev.genet.40.110405.090451; Yan CT, 2007, NATURE, V449, P478, DOI 10.1038/nature06020; Zha S, 2007, P NATL ACAD SCI USA, V104, P4518, DOI 10.1073/pnas.0611734104; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004	130	93	95	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7780	7791		10.1038/sj.onc.1210875	http://dx.doi.org/10.1038/sj.onc.1210875			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066091				2022-12-28	WOS:000251537900009
J	Mujtaba, S; Zeng, L; Zhou, MM				Mujtaba, S.; Zeng, L.; Zhou, M-M			Structure and acetyl-lysine recognition of the bromodomain	ONCOGENE			English	Review						bromodomain; chromatin remodeling; histone modification; lysine acetylation; transcriptional regulation	HISTONE H3; PROTEIN BRD4; P53 ACTIVITY; PHD FINGER; HIV-1 TAT; CHROMATIN; BINDING; RSC; METHYLATION; LIGAND	Histone lysine acetylation is central to epigenetic control of gene transcription. The bromodomain, found in chromatin-associated proteins and histone acetyltranferases, functions as the sole protein module known to bind acetyl-lysine motifs. Recent structural and functional analyses of bromodomains' recognition of lysine-acetylated peptides derived from major acetylation sites in histones and cellular proteins provide new insights into differences in ligand binding selectivity as well as unifying features of histone recognition by the bromodomains. These new findings highlight the functional importance of bromodomain/acetyl-lysine binding as a pivotal mechanism for regulating protein-protein interactions in histone-directed chromatin remodeling and gene transcription. These new studies also support the notion that functional diversity of a conserved bromodomain structural fold is achieved by evolutionary changes of structurally flexible amino-acid sequences in the ligand binding site such as the ZA and BC loops.	CUNY Mt Sinai Sch Med, Dept Struct & Chem Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Zhou, MM (corresponding author), CUNY Mt Sinai Sch Med, Dept Struct & Chem Biol, 1425 Madison Ave,Box 1677, New York, NY 10029 USA.	ming-ming.zhou@mssm.edu						ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Berger J, 2005, BIOCHEM SOC T, V33, P1537, DOI 10.1042/BST0331537; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Carey M, 2006, MOL CELL, V24, P481, DOI 10.1016/j.molcel.2006.09.012; CHUA P, 1995, MOL CELL BIOL, V15, P3685; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; Du J, 1998, GENETICS, V150, P987; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; Greenwald RJ, 2004, BLOOD, V103, P1475, DOI 10.1182/blood-2003-06-2116; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Hassan AH, 2006, J BIOL CHEM, V281, P18126, DOI 10.1074/jbc.M602851200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kasten M, 2004, EMBO J, V23, P1348, DOI 10.1038/sj.emboj.7600143; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Martinez-Campa C, 2004, MOL CELL, V15, P69, DOI 10.1016/j.molcel.2004.05.022; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Nakamura Y, 2007, J BIOL CHEM, V282, P4193, DOI 10.1074/jbc.M605971200; Neely KE, 2002, MOL GENET METAB, V76, P1, DOI 10.1016/S1096-7192(02)00014-8; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Qiu J, 2006, NATURE, V441, P143, DOI 10.1038/441143a; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sachchidanand, 2006, CHEM BIOL, V13, P81, DOI 10.1016/j.chembiol.2005.10.014; Schweiger MR, 2006, J VIROL, V80, P4276, DOI 10.1128/JVI.80.9.4276-4285.2006; Shen WQ, 2007, BIOCHEMISTRY-US, V46, P2100, DOI 10.1021/bi0611208; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Workman JL, 2006, GENE DEV, V20, P2009, DOI 10.1101/gad.1435706; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zeng L, 2005, J AM CHEM SOC, V127, P2376, DOI 10.1021/ja044885g; Zhou YG, 2005, CURR BIOL, V15, P1434, DOI 10.1016/j.cub.2005.06.057	62	292	299	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5521	5527		10.1038/sj.onc.1210618	http://dx.doi.org/10.1038/sj.onc.1210618			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694091				2022-12-28	WOS:000248674300018
J	Murr, R; Vaissiere, T; Sawan, C; Shukla, V; Herceg, Z				Murr, R.; Vaissiere, T.; Sawan, C.; Shukla, V.; Herceg, Z.			Orchestration of chromatin-based processes: mind the TRRAP	ONCOGENE			English	Review						TRRAP; HATs; histone acetylation; transcription; DNA repair; cancer	STRAND BREAK REPAIR; HISTONE ACETYLTRANSFERASE COMPLEX; NUCLEAR-RECEPTOR FUNCTION; EARLY EMBRYONIC LETHALITY; CELL-CYCLE PROGRESSION; DNA-DAMAGE RESPONSE; PIK-RELATED KINASES; HAT COFACTOR TRRAP; C-MYC; TRANSCRIPTIONAL ACTIVATION	Chromatin modi. cations at core histones including acetylation, methylation, phosphorylation and ubiquitination play an important role in diverse biological processes. Acetylation of specific lysine residues within the N terminus tails of core histones is arguably the most studied histone modi. cation; however, its precise roles in different cellular processes and how it is disrupted in human diseases remain poorly understood. In the last decade, a number of histone acetyltransferases ( HATs) enzymes responsible for histone acetylation, has been identified and functional studies have begun to unravel their biological functions. The activity of many HATs is dependent on HAT complexes, the multiprotein assemblies that contain one HAT catalytic subunit, adapter proteins, several other molecules of unknown function and a large protein called TRansformation/tRanscription domain-Associated Protein ( TRRAP). As a common component of many HAT complexes, TRRAP appears to be responsible for the recruitment of these complexes to chromatin during transcription, replication and DNA repair. Recent studies have shed new light on the role of TRRAP in HAT complexes as well as mechanisms by which it mediates diverse cellular processes. Thus, TRRAP appears to be responsible for a concerted and context-dependent recruitment of HATs and coordination of distinct chromatin-based processes, suggesting that its deregulation may contribute to diseases. In this review, we summarize recent developments in our understanding of the function of TRRAP and TRRAP-containing HAT complexes in normal cellular processes and speculate on the mechanism underlying abnormal events that may lead to human diseases such as cancer.	Int Agcy Res Canc, Epigenet Team, Mol Carcinogenesis & Biomarkers Grp, F-69008 Lyon, France; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA	World Health Organization; International Agency for Research on Cancer (IARC); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Herceg, Z (corresponding author), Int Agcy Res Canc, Epigenet Team, Mol Carcinogenesis & Biomarkers Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr	Vaissiere, Thomas/E-1121-2011	Murr, Rabih/0000-0002-3346-6590				Abrahamsson PA, 2004, EUR UROL SUPPL, V3, P3, DOI 10.1016/j.eursup.2004.09.001; Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Bienz M, 2003, NAT CELL BIOL, V5, P179, DOI 10.1038/ncb0303-179; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6; Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Choy JS, 2002, MOL CELL BIOL, V22, P8215, DOI 10.1128/MCB.22.23.8215-8225.2002; Cimbora DM, 2000, MOL CELL BIOL, V20, P5581, DOI 10.1128/MCB.20.15.5581-5591.2000; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Dumon-Jones V, 2003, CANCER RES, V63, P7263; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Etard C, 2005, MECH DEVELOP, V122, P545, DOI 10.1016/j.mod.2004.11.010; Fan WQ, 2004, MOL ENDOCRINOL, V18, P127, DOI 10.1210/me.2003-0110; Feng Y, 2003, CANCER RES, V63, P8726; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Frappart PO, 2005, NAT MED, V11, P538, DOI 10.1038/nm1228; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Gause M, 2006, MOL CELL BIOL, V26, P2347, DOI 10.1128/MCB.26.6.2347-2359.2006; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2005, CELL CYCLE, V4, P383, DOI 10.4161/cc.4.3.1546; Herceg Z, 2003, NUCLEIC ACIDS RES, V31, P7011, DOI 10.1093/nar/gkg902; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Iizuka M, 2006, MOL CELL BIOL, V26, P1098, DOI 10.1128/MCB.26.3.1098-1108.2006; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jazayeri A, 2004, P NATL ACAD SCI USA, V101, P1644, DOI 10.1073/pnas.0304797101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang XF, 2006, J BIOL CHEM, V281, P15741, DOI 10.1074/jbc.M513172200; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; KLUESZA CA, 2002, ONOCGENE, V21, P1411; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; Lin CM, 2003, CURR BIOL, V13, P1019, DOI 10.1016/S0960-9822(03)00382-8; Lin WC, 2006, CURR OPIN GENET DEV, V16, P137, DOI 10.1016/j.gde.2006.02.002; Liu L, 1999, MOL CELL BIOL, V19, P1202; Loizou JI, 2006, CELL CYCLE, V5, P696, DOI 10.4161/cc.5.7.2616; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Marks Paul A, 2004, Novartis Found Symp, V259, P269; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Memedula S, 2003, CURR BIOL, V13, P241, DOI 10.1016/S0960-9822(03)00048-4; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Myster SH, 2004, GENETICS, V166, P807, DOI 10.1534/genetics.166.2.807; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Oishi H, 2006, J BIOL CHEM, V281, P20, DOI 10.1074/jbc.M510157200; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Perry P, 2004, CELL CYCLE, V3, P1645; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Polakis P, 2000, GENE DEV, V14, P1837; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Robert F, 2006, MOL CELL BIOL, V26, P402, DOI 10.1128/MCB.26.2.402-412.2006; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMERDON MJ, 1982, J BIOL CHEM, V257, P13441; Smith CM, 2003, ANAL BIOCHEM, V316, P23, DOI 10.1016/S0003-2697(03)00032-0; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Unno A, 2005, BIOCHEM BIOPH RES CO, V327, P933, DOI 10.1016/j.bbrc.2004.12.095; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; van Attikum H, 2005, CELL CYCLE, V4, P1011, DOI 10.4161/cc.4.8.1887; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	144	116	116	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5358	5372		10.1038/sj.onc.1210605	http://dx.doi.org/10.1038/sj.onc.1210605			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694078				2022-12-28	WOS:000248674300005
J	Yang, XJ; Ullah, M				Yang, X-J; Ullah, M.			MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells	ONCOGENE			English	Review						lysine acetylation; MYST acetyltransferase; ING5; BR140; CBP; Runx1	ACUTE MYELOID-LEUKEMIA; ZINC-FINGER PROTEIN; HISTONE ACETYLTRANSFERASE COMPLEXES; TUMOR-SUPPRESSOR P33(ING1); ACUTE MONOCYTIC LEUKEMIA; GENE-EXPRESSION; PHD FINGER; TRANSCRIPTIONAL REGULATION; CAENORHABDITIS-ELEGANS; DOSAGE COMPENSATION	Genes of the human monocytic leukemia zinc-finger protein MOZ ( HUGO symbol, MYST3) and its paralog MORF ( MYST4) are rearranged in chromosome translocations associated with acute myeloid leukemia and/or benign uterine leiomyomata. Both proteins have intrinsic histone acetyltransferase activity and are components of quartet complexes with noncatalytic subunits containing the bromodomain, plant homeodomain-linked ( PHD) finger and proline-tryptophan-tryptophan-proline (PWWP)-containing domain, three types of structural modules characteristic of chromatin regulators. Although leukemia-derived fusion proteins such as MOZ-TIF2 promote self-renewal of leukemic stem cells, recent studies indicate that murine MOZ and MORF are important for proper development of hematopoietic and neurogenic progenitors, respectively, thereby highlighting the importance of epigenetic integrity in safeguarding stem cell identity.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Royal Victoria Hosp,Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Yang, XJ (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Royal Victoria Hosp,Dept Med, Room H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	xiang-jiao.yang@mcgill.ca						Antonchuk J, 2004, BLOOD, V104, P1306, DOI 10.1182/blood-2004-04-1522; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Chamberlin HM, 2000, DEVELOPMENT, V127, P713; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Chang S, 2003, GENE DEV, V17, P2123, DOI 10.1101/gad.1117903; Collins HM, 2006, J BIOL CHEM, V281, P17124, DOI 10.1074/jbc.M602633200; Crump JG, 2006, DEVELOPMENT, V133, P2661, DOI 10.1242/dev.02435; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; Goodman RH, 2000, GENE DEV, V14, P1553; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kindle KB, 2005, MOL CELL BIOL, V25, P988, DOI 10.1128/MCB.25.3.988-1002.2005; Kirito K, 2004, MOL CELL BIOL, V24, P6751, DOI 10.1128/MCB.24.15.6751-6762.2004; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kojima K, 2003, BRIT J HAEMATOL, V120, P271, DOI 10.1046/j.1365-2141.2003.04059.x; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lafon A, 2007, ONCOGENE, V26, P5373, DOI 10.1038/sj.onc.1210606; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Martin DGE, 2006, MOL CELL BIOL, V26, P3018, DOI 10.1128/MCB.26.8.3018-3028.2006; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Merson TD, 2006, J NEUROSCI, V26, P11359, DOI 10.1523/JNEUROSCI.2247-06.2006; Miller CT, 2004, DEVELOPMENT, V131, P2443, DOI 10.1242/dev.01134; Moore SDP, 2004, CANCER RES, V64, P5570, DOI 10.1158/0008-5472.CAN-04-0050; Nabirochkina E, 2002, MECH DEVELOP, V114, P119, DOI 10.1016/S0925-4773(02)00035-7; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; NUGYT AM, 2007, CIRC RES, V100, P425; Ohta K, 2007, BIOCHEM J, V402, P559, DOI 10.1042/BJ20061194; Oury F, 2006, SCIENCE, V313, P1408, DOI 10.1126/science.1130042; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Parthun MR, 2007, ONCOGENE, V26, P5319, DOI 10.1038/sj.onc.1210602; Pelletier N, 2003, METHODS, V31, P24, DOI 10.1016/S1046-2023(03)00084-7; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Perry J, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-6; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; Scott EK, 2001, CURR BIOL, V11, P99, DOI 10.1016/S0960-9822(01)00020-3; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taverna SD, 2006, MOL CELL, V24, P785, DOI 10.1016/j.molcel.2006.10.026; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Thomas T, 2000, DEVELOPMENT, V127, P2537; Thomas T, 2007, CELL CYCLE, V6, P696, DOI 10.4161/cc.6.6.4013; THOMPSON KA, 1994, BIOCHEM BIOPH RES CO, V198, P1143, DOI 10.1006/bbrc.1994.1162; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Wade PA, 2006, ENVIRON HEALTH PERSP, V114, pA140, DOI 10.1289/ehp.114-a140; Wang J, 2006, NATURE, V127, P1137; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 2007, EMBO REP, V8, P556, DOI 10.1038/sj.embor.7400977; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252	106	108	111	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5408	5419		10.1038/sj.onc.1210609	http://dx.doi.org/10.1038/sj.onc.1210609			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694082				2022-12-28	WOS:000248674300009
J	Du, J; Cai, X; Yao, J; Ding, X; Wu, Q; Pei, S; Jiang, K; Zhang, Y; Wang, W; Shi, Y; Lai, Y; Shen, J; Teng, M; Huang, H; Fei, Q; Reddy, ES; Zhu, J; Jin, C; Yao, X				Du, J.; Cai, X.; Yao, J.; Ding, X.; Wu, Q.; Pei, S.; Jiang, K.; Zhang, Y.; Wang, W.; Shi, Y.; Lai, Y.; Shen, J.; Teng, M.; Huang, H.; Fei, Q.; Reddy, E. S.; Zhu, J.; Jin, C.; Yao, X.			The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule attachment stability	ONCOGENE			English	Article						chromosome instability; mitosis; kinetochore-microtubule attachment; Hec1; NEK2A; phosphorylation	CELL-DIVISION; SPINDLE; MITOSIS; HEC1; PHOSPHORYLATION; CHROMOSOMES; CENTROSOME; INTERACTS; MOVEMENT; COMPLEX	Loss or gain of whole chromosome, the form of chromosome instability commonly associated with cancers is thought to arise from aberrant chromosome segregation during cell division. Chromosome segregation in mitosis is orchestrated by the interaction of kinetochores with spindle microtubules. Our studies show that NEK2A is a kinetochore-associated protein kinase essential for faithful chromosome segregation. However, it was unclear how NEK2A ensures accurate chromosome segregation in mitosis. Here we show that NEK2A-mediated Hec1 ( highly expressed in cancer) phosphorylation is essential for faithful kinetochore microtubule attachments in mitosis. Using phospho-specific antibody, our studies show that NEK2A phosphorylates Hec1 at Ser165 during mitosis. Although such phosphorylation is not required for assembly of Hec1 to the kinetochore, expression of non-phosphorylatable mutant Hec1(S165) perturbed chromosome congression and resulted in a dramatic increase in microtubule attachment errors, including syntelic and monotelic attachments. Our in vitro reconstitution experiment demonstrated that Hec1 binds to microtubule in low affinity and phosphorylation by NEK2A, which prevents aberrant kinetochore-microtubule connections in vivo, increases the affinity of the Ndc80 complex for microtubules in vitro. Thus, our studies illustrate a novel regulatory mechanism in which NEK2A kinase operates a faithful chromosome attachment to spindle microtubule, which prevents chromosome instability during cell division.	[Ding, X.; Wang, W.] Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China; [Du, J.; Cai, X.; Yao, J.; Wu, Q.; Pei, S.; Jiang, K.; Zhang, Y.; Shi, Y.; Lai, Y.; Shen, J.; Teng, M.; Jin, C.; Yao, X.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Peoples R China; [Cai, X.; Ding, X.; Wu, Q.; Jiang, K.; Reddy, E. S.; Yao, X.] Morehouse Sch Med, Canc Biol Program, Atlanta, GA 30310 USA; [Huang, H.] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China; [Fei, Q.; Zhu, J.] Shanghai Jiao Tong Univ, Shanghai Canc Inst, Canc Epigenet Program, Shanghai 200030, Peoples R China; [Yao, X.] Cellular Dynam, Hefei, Peoples R China	Beijing University of Chinese Medicine; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine; Zhejiang University; Shanghai Jiao Tong University	Ding, X (corresponding author), Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China.	xiading6@yahoo.com; jincj@ustc.edu.cn; yaoxb@ustc.edu.cn	Lai, Ying/E-5220-2015; PEI, SHANSHAN/D-8200-2016; Lai, YING/J-4019-2014	Lai, Ying/0000-0001-5347-5155; PEI, SHANSHAN/0000-0001-9619-2614; 	NCI NIH HHS [CA92080, CA132389, U56 CA092080, CA89019, P50 CA089019, P20 CA132389] Funding Source: Medline; NCRR NIH HHS [G12 RR003034, G-12-RR03034] Funding Source: Medline; NIDDK NIH HHS [R01 DK056292, DK56292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089019, P20CA132389] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; AULT JG, 1989, CHROMOSOMA, V98, P33, DOI 10.1007/BF00293332; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Ciferri C, 2005, J BIOL CHEM, V280, P29088, DOI 10.1074/jbc.M504070200; Ciferri C, 2007, FEBS LETT, V581, P2862, DOI 10.1016/j.febslet.2007.05.012; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fang L, 2007, CELL RES, V17, P664, DOI 10.1038/cr.2007.68; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fu GS, 2007, CELL RES, V17, P608, DOI 10.1038/cr.2007.55; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Ke YW, 2003, CELL RES, V13, P69, DOI 10.1038/sj.cr.7290152; Lampson MA, 2005, NAT CELL BIOL, V7, P93, DOI 10.1038/ncb1208; Liu D, 2007, J BIOL CHEM, V282, P21415, DOI 10.1074/jbc.M609026200; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nicklas R. B., 1971, Adv Cell Biol, V2, P225; NICKLAS RB, 1985, CHROMOSOMA, V92, P313, DOI 10.1007/BF00329815; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Storchova Z, 2006, NATURE, V443, P541, DOI 10.1038/nature05178; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518	25	56	61	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2008	27	29					4107	4114		10.1038/onc.2008.34	http://dx.doi.org/10.1038/onc.2008.34			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18297113	Green Accepted			2022-12-28	WOS:000257325100010
J	Zhou, G; Xie, TX; Zhao, M; Jasser, SA; Younes, MN; Sano, D; Lin, J; Kupferman, ME; Santillan, AA; Patel, V; Gutkind, JS; Ei-Naggar, AK; Emberley, ED; Watson, PH; Matsuzawa, SI; Reed, JC; Myers, JN				Zhou, G.; Xie, T-X; Zhao, M.; Jasser, S. A.; Younes, M. N.; Sano, D.; Lin, J.; Kupferman, M. E.; Santillan, A. A.; Patel, V.; Gutkind, J. S.; Ei-Naggar, A. K.; Emberley, E. D.; Watson, P. H.; Matsuzawa, S-I; Reed, J. C.; Myers, J. N.			Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity	ONCOGENE			English	Article						S100A7; psoriasin; beta-catenin; oral squamous cell carcinoma; head and neck squamous cell carcinoma	F-BOX PROTEIN; DEGRADATION PATHWAY; COLORECTAL-CANCER; PSORIASIN S100A7; C-MYC; EXPRESSION; COMPLEX; ACTIVATION; CALCIUM; SIAH-1	Overexpression of S100A7 (psoriasin), a small calcium-binding protein, has been associated with the development of psoriasis and carcinomas in different types of epithelia, but its precise functions are still unknown. Using human tissue specimens, cultured cell lines, and a mouse model, we found that S100A7 is highly expressed in preinvasive, well-differentiated and early staged human squamous cell carcinoma of the oral cavity (SCCOC), but little or no expression was found in poorly differentiated, later-staged invasive tumors. Interestingly, our results showed that S100A7 inhibits both SCCOC cell proliferation in vitro and tumor growth/invasion in vivo. Furthermore, we demonstrated that S100A7 is associated with the beta-catenin complex, and inhibits beta-catenin signaling by targeting beta-catenin degradation via a noncanonical mechanism that is independent of GSK3 beta-mediated phosphorylation. More importantly, our results also indicated that beta-catenin signaling negatively regulates S100A7 expression. Thus, this reciprocal negative regulation between S100A7 and beta-catenin signaling implies their important roles in tumor development and progression. Despite its high levels of expression in early stage SCCOC tumorigenesis, S100A7 actually inhibits SCCOC tumor growth/invasion as well as tumor progression. Downregulation of S100A7 in later stages of tumorigenesis increases beta-catenin signaling, leading to promotion of tumor growth and tumor progression.	[Zhou, G.; Xie, T-X; Zhao, M.; Jasser, S. A.; Younes, M. N.; Sano, D.; Lin, J.; Kupferman, M. E.; Santillan, A. A.; Myers, J. N.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Patel, V.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA; [Ei-Naggar, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Emberley, E. D.; Watson, P. H.] BC Canc Agcy, Deeley Res Ctr, Victoria, BC, Canada; [Matsuzawa, S-I; Reed, J. C.] Burnham Inst Med Res, La Jolla, CA USA; [Myers, J. N.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Texas System; UTMD Anderson Cancer Center; British Columbia Cancer Agency; Sanford Burnham Prebys Medical Discovery Institute; University of Texas System; UTMD Anderson Cancer Center	Myers, JN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd,Unit 441, Houston, TX 77030 USA.	jmyers@mdanderson.org	Gutkind, J. Silvio/A-1053-2009; Lin, Jing/I-3889-2013; Sano, Daisuke/R-6591-2018; Gutkind, J. Silvio/J-1201-2016	Lin, Jing/0000-0002-2563-5083; Sano, Daisuke/0000-0002-7686-4724; Gutkind, J. Silvio/0000-0002-5150-4482; Watson, Peter/0000-0002-1642-0638	NATIONAL CANCER INSTITUTE [P30CA016672, P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672, CA16672, CA69381] Funding Source: Medline; NIDCR NIH HHS [R01DE01461301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Alowami Salem, 2003, BMC Dermatol, V3, P1, DOI 10.1186/1471-5945-3-1; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; Di Nuzzo S, 2000, PHOTOCHEM PHOTOBIOL, V72, P374; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Emberley ED, 2005, CANCER RES, V65, P5696, DOI 10.1158/0008-5472.CAN-04-3927; Emberley ED, 2003, CLIN CANCER RES, V9, P2627; Emberley ED, 2003, CANCER RES, V63, P1954; Enerback C, 2002, CANCER RES, V62, P43; Filipek A, 2002, J BIOL CHEM, V277, P28848, DOI 10.1074/jbc.M203602200; Fukushima T, 2006, IMMUNITY, V24, P29, DOI 10.1016/j.immuni.2005.12.002; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; HOFFMANN HJ, 1994, J INVEST DERMATOL, V103, P370, DOI 10.1111/1523-1747.ep12395202; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krop I, 2005, CANCER RES, V65, P11326, DOI 10.1158/0008-5472.CAN-05-1523; Leygue E, 1996, CANCER RES, V56, P4606; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Martinsson H, 2005, EXP DERMATOL, V14, P161, DOI 10.1111/j.0906-6705.2005.00239.x; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MOOGLUTZ C, 1995, INT J CANCER, V63, P297, DOI 10.1002/ijc.2910630225; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin Patrice J, 2003, Cancer Treat Res, V115, P169; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Reischl J, 2007, J INVEST DERMATOL, V127, P163, DOI 10.1038/sj.jid.5700488; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; TAVAKKOL A, 1994, MOL BIOL REP, V20, P75, DOI 10.1007/BF00996356; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Watson PH, 1998, INT J BIOCHEM CELL B, V30, P567, DOI 10.1016/S1357-2725(97)00066-6; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Yigitbasi OG, 2004, CANCER RES, V64, P7977, DOI 10.1158/0008-5472.CAN-04-1477	37	44	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3527	3538		10.1038/sj.onc.1211015	http://dx.doi.org/10.1038/sj.onc.1211015			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223693				2022-12-28	WOS:000256468500004
J	Shahrzad, S; Shirasawa, S; Sasazuki, T; Rak, JW; Coomber, BL				Shahrzad, S.; Shirasawa, S.; Sasazuki, T.; Rak, J. W.; Coomber, B. L.			Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts	ONCOGENE			English	Article						hypoxia; antiangiogenic therapy; K-ras mutation; tumor microenvironment; metronomic cyclophosphamide	METASTATIC BREAST-CANCER; GROWTH-FACTOR RECEPTOR-2; HUMAN LIVER-MICROSOMES; MISMATCH-REPAIR GENES; TUMOR-CELL LINES; MICROSATELLITE INSTABILITY; ANTIANGIOGENIC THERAPY; ANGIOGENESIS; HYPOXIA; BEVACIZUMAB	Antiangiogenic therapies are promising approaches to cancer control, but the details of their effects on subsequent tumor progression are not fully understood. Such therapies have the potential to eventually generate extensive amounts of tumor ischemia, and we previously demonstrated that ischemic conditions induce K-ras mutations in cells with deficient mismatch repair (MMR) mechanisms. This suggested that similar effects on oncogene mutagenesis may accompany antiangiogenic therapy. To test this, MMR-deficient colorectal cancer cells (Dks-8) were xenografted into immune-deficient mice and treated with the antiangiogenic regimen of low-dose/metronomic cyclophosphamide for 2 weeks followed by a 2-week recovery period without therapy. This treatment resulted in transient tumor growth inhibition, increased hypoxia, and decreased microvessel density, and cancer cells from treated tumors acquired activating mutations of the K-ras oncogene (K-ras(G13D)). In vitro exposure of Dks-8 cells to the active metabolite of cyclophosphamide (4-hydroxycyclophosphamide) had no effect on the K-ras status, indicating that there was no direct action of this alkylating agent on K-ras mutagenesis. In addition, cells sorted from hypoxic regions of Dks-8 tumors were enriched in K-ras(G13D) mutants. Collectively, our studies suggest that increases in tumor hypoxia induced by antiangiogenic treatment may lead to K-ras mutation and consequently tumor progression, especially in susceptible individuals.	[Shahrzad, S.; Coomber, B. L.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; [Shirasawa, S.] Fukuoka Univ, Sch Med, Dept Cell Biol, Fukuoka 81401, Japan; [Sasazuki, T.] Int Med Ctr Japan, Res Inst, Tokyo, Japan; [Rak, J. W.] McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada	University of Guelph; Fukuoka University; National Center for Global Health & Medicine - Japan; McGill University	Coomber, BL (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.	bcoomber@uoguelph.ca						Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO;2-C; Bernhard EJ, 2000, CANCER RES, V60, P6597; BOS JL, 1989, CANCER RES, V49, P4682; BOYER JC, 1995, CANCER RES, V55, P6063; Browder T, 2000, CANCER RES, V60, P1878; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Brown JM, 2000, DRUG RESIST UPDATE, V3, P7, DOI 10.1054/drup.2000.0120; CHANG TKH, 1993, CANCER RES, V53, P5629; CHEN JZ, 1994, CURR OPIN IMMUNOL, V6, P313, DOI 10.1016/0952-7915(94)90107-4; DeLisser HM, 1997, AM J PATHOL, V151, P671; DEXTER DL, 1981, AM J MED, V71, P949, DOI 10.1016/0002-9343(81)90312-0; Emmenegger U, 2006, CANCER RES, V66, P1664, DOI 10.1158/0008-5472.CAN-05-2598; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Franco M, 2006, CANCER RES, V66, P3639, DOI 10.1158/0008-5472.CAN-05-3295; Galmarini Carlos Maria, 2003, Curr Opin Investig Drugs, V4, P1416; Gasparini G, 2005, NAT CLIN PRACT ONCOL, V2, P562, DOI 10.1038/ncponc0342; Halvarsson B, 2004, VIRCHOWS ARCH, V444, P135, DOI 10.1007/s00428-003-0922-z; HERMAN TS, 1989, CANCER RES, V49, P3338; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Janssen HL, 2005, HEAD NECK-J SCI SPEC, V27, P622, DOI 10.1002/hed.20223; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Jubb AM, 2006, NAT REV CANCER, V6, P626, DOI 10.1038/nrc1946; Kane MF, 1997, CANCER RES, V57, P808; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Koukourakis MI, 2000, INT J RADIAT ONCOL, V48, P545, DOI 10.1016/S0360-3016(00)00677-5; LIOTTA LA, 1974, CANCER RES, V34, P997; Miller KD, 2005, CLIN CANCER RES, V11, P3369, DOI 10.1158/1078-0432.CCR-04-1923; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Minamoto Toshinari, 2002, Expert Rev Mol Diagn, V2, P565, DOI 10.1586/14737159.2.6.565; Mitchell RJ, 2002, AM J EPIDEMIOL, V156, P885, DOI 10.1093/aje/kwf139; Motzer RJ, 2006, J CLIN ONCOL, V24, P5601, DOI 10.1200/JCO.2006.08.5415; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Perona R, 2004, BRIT J CANCER, V90, P573, DOI 10.1038/sj.bjc.6601552; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; RAK J, 1995, CANCER RES, V55, P4575; Rak JW, 2006, CANC DRUG DISC DEV, P67, DOI 10.1007/978-1-59745-035-5_4; Ren S, 1997, CANCER RES, V57, P4229; Rofstad EK, 2007, CLIN CANCER RES, V13, P1971, DOI 10.1158/1078-0432.CCR-06-1967; Shahrzad S, 2005, CANCER RES, V65, P8134, DOI 10.1158/0008-5472.CAN-05-0713; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; TAKAMIZAWA A, 1975, J MED CHEM, V18, P376, DOI 10.1021/jm00238a011; Toyooka S, 2003, ONCOL REP, V10, P1455; Varker KA, 2007, ANN SURG ONCOL, V14, P2367, DOI 10.1245/s10434-007-9389-5; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Yu JL, 2001, AM J PATHOL, V158, P1325, DOI 10.1016/S0002-9440(10)64083-7; Yu L, 1996, DRUG METAB DISPOS, V24, P1254; Yuan JL, 1998, MUTAT RES-FUND MOL M, V400, P439, DOI 10.1016/S0027-5107(98)00042-6; ZON G, 1984, J MED CHEM, V27, P466, DOI 10.1021/jm00370a008	56	15	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3729	3738		10.1038/sj.onc.1211031	http://dx.doi.org/10.1038/sj.onc.1211031			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223682				2022-12-28	WOS:000256659300010
J	Tsuruma, R; Ohbayashi, N; Kamitani, S; Ikeda, O; Sato, N; Muromoto, R; Sekine, Y; Oritani, K; Matsuda, T				Tsuruma, R.; Ohbayashi, N.; Kamitani, S.; Ikeda, O.; Sato, N.; Muromoto, R.; Sekine, Y.; Oritani, K.; Matsuda, T.			Physical and functional interactions between STAT3 and KAP1	ONCOGENE			English	Article						IL-6; STAT3; KAP1; transcriptional regulation; phosphorylation	ZINC-FINGER PROTEINS; TRANSCRIPTIONAL ACTIVATION; COREPRESSOR COMPLEX; SIGNAL TRANSDUCERS; PHOSPHORYLATION; ACETYLATION; PATHWAYS; TYROSINE; DOMAIN; FAMILY	Signal transducers and activators of transcription (STATs) mediate cell proliferation, differentiation and survival in immune responses, hematopoiesis, neurogenesis and other biological processes. For example, STAT3 has been reported to be constitutively activated in numerous cancer cells. To clarify the molecular mechanisms underlying the STAT activation, we performed yeast two-hybrid screening and identified KAP1/TIF1b as a novel STAT-binding partner. KAP1 is a universal corepressor protein for the Kruppel-associated box zinc-finger protein superfamily of transcriptional repressors. We found endogenous KAP1 associated with endogenous STAT3 in vivo. Importantly, small-interfering RNA-mediated reduction of KAP1 expression enhanced interleukin (IL)-6-induced STAT3-dependent transcription and gene expression. Furthermore, reduction of KAP1 expression resulted in the marked accumulation of STAT3 phosphorylated on Ser727 in the nucleus, a modi. cation that regulates its transcriptional activation. These results indicate that KAP1 may serve as a transcriptional regulator of the IL-6/STAT3 signaling pathway.	[Tsuruma, R.; Ohbayashi, N.; Kamitani, S.; Ikeda, O.; Sato, N.; Muromoto, R.; Sekine, Y.; Matsuda, T.] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; [Oritani, K.] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Osaka, Japan	Hokkaido University; Osaka University	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Muromoto, Ryuta/E-4203-2012; Sekine, Yuichi/S-8813-2019; Matsuda, Tadashi/A-3835-2012	Muromoto, Ryuta/0000-0002-7474-493X; Sekine, Yuichi/0000-0002-2861-603X; Matsuda, Tadashi/0000-0002-3089-3757				Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Herrmann A, 2004, J CELL SCI, V117, P339, DOI 10.1242/jcs.00833; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Ohbayashi N, 2007, BIOL PHARM BULL, V30, P1860, DOI 10.1248/bpb.30.1860; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Satou A, 2001, J BIOL CHEM, V276, P46562, DOI 10.1074/jbc.M104937200; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Sekine Y, 2007, ONCOGENE, V26, P6038, DOI 10.1038/sj.onc.1210426; Sekine Y, 2006, ONCOGENE, V25, P5801, DOI 10.1038/sj.onc.1209578; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	22	52	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3054	3059		10.1038/sj.onc.1210952	http://dx.doi.org/10.1038/sj.onc.1210952			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18037959	Green Submitted			2022-12-28	WOS:000255681700012
J	Cai, CQ; Peng, Y; Buckley, MT; Wei, J; Chen, F; Liebes, L; Gerald, WI; Pincus, MR; Osman, I; Lee, P				Cai, C. Q.; Peng, Y.; Buckley, M. T.; Wei, J.; Chen, F.; Liebes, L.; Gerald, W. I.; Pincus, M. R.; Osman, I.; Lee, P.			Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations	ONCOGENE			English	Article						EGFR; mutation; prostate cancer	CELL LUNG-CANCER; ONCOGENIC TRANSFORMATION; SOMATIC MUTATIONS; SIGNAL TRANSDUCER; EGFR MUTATIONS; KINASE DOMAIN; GEFITINIB; STAT3; INHIBITION; GENE	While epidermal growth factor receptor (EGFR) dysregulation is known to play a critical role in prostate carcinogenesis, there has been no direct evidence indicating EGFR mutations induce tumorigenesis in prostate cancer. We previously identified four novel EGFR somatic mutations in the EGFR tyrosine kinase domain of prostate cancer patients: G735S, G796S, E804G and R841K. In this study, we investigated the oncogenic potential of these somatic mutations by establishing stable clonal NIH3T3 cells expressing these four mutations and WT EGFR to determine their ability to increase cell proliferation and invasion. In the absence of the EGF ligand, cell proliferation was readily increased in G735S, G796S and E804G mutants compared to WT EGFR. The addition of EGF ligand greatly increased cell growth and transforming ability of these same EGFR mutants. Matrigel invasion assays showed enhanced invasion with G735S, G796S and E804G mutants. Western blot analysis showed that these EGFR mutations enhanced cell growth and invasion via constitutive and hyperactive tyrosine phosphorylation and led to the activation of mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3) and Akt pathways. Our findings demonstrate the oncogenic activation of three novel EGFR somatic missense mutations in prostate cancer. Molecules that regulate the mechanisms of their oncogenic activation represent novel targets for limiting tumor cell progression, and further elucidation of these mutations will have utility in prostate cancer treatment.	[Cai, C. Q.; Peng, Y.; Wei, J.; Chen, F.; Lee, P.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Buckley, M. T.; Liebes, L.; Osman, I.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Gerald, W. I.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Pincus, M. R.; Lee, P.] New York Harbor Healthcare Syst, New York, NY USA; [Pincus, M. R.] SUNY, Dept Pathol, New York, NY USA; [Osman, I.] NYU, Sch Med, Dept Urol, New York, NY 10003 USA	New York University; New York University; Memorial Sloan Kettering Cancer Center; State University of New York (SUNY) System; SUNY Community College; SUNY Maritime College; SUNY Optometry; New York University	Osman, I (corresponding author), NYU, Sch Med, Dept Urol & Med, 522 1st Ave,SML 405, New York, NY 10016 USA.	iman.osman@med.nyu.edu						Arteaga CL, 2006, CANCER CELL, V9, P421, DOI 10.1016/j.ccr.2006.05.014; Barton BE, 2004, MOL CANCER THER, V3, P11; Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Bellezza I, 2006, AM J PATHOL, V169, P2199, DOI 10.2353/ajpath.2006.060171; Choi SH, 2007, ONCOGENE, V26, P1567, DOI 10.1038/sj.onc.1209957; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Danielsen AJ, 2002, EXP CELL RES, V275, P9, DOI 10.1006/excr.2002.5494; DeMiguel F, 2002, PROSTATE, V52, P123, DOI 10.1002/pros.10110; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Douglas DA, 2006, FRONT BIOSCI-LANDMRK, V11, P2518, DOI 10.2741/1986; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang HF, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-2; Hubbard SR, 2005, CANCER CELL, V7, P287, DOI 10.1016/j.ccr.2005.04.004; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; Lee JW, 2005, CLIN CANCER RES, V11, P2879, DOI 10.1158/1078-0432.CCR-04-2029; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Nagahara H, 2005, CLIN CANCER RES, V11, P1368, DOI 10.1158/1078-0432.CCR-04-1894; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Ratan HL, 2003, BJU INT, V92, P890, DOI 10.1111/j.1464-410X.2003.04503.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; Shao H, 2003, CANCER RES, V63, P3923; Sherwood ER, 1998, BRIT J CANCER, V77, P855, DOI 10.1038/bjc.1998.142; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; USHIRO H, 1980, J BIOL CHEM, V255, P8363; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	34	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3201	3210		10.1038/sj.onc.1210983	http://dx.doi.org/10.1038/sj.onc.1210983			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18193092				2022-12-28	WOS:000255897600013
J	Geserick, P; Drewniok, C; Hupe, M; Haas, TL; Diessenbacher, P; Sprick, MR; Schon, MP; Henkler, F; Gollnick, H; Walczak, H; Leverkus, M				Geserick, P.; Drewniok, C.; Hupe, M.; Haas, T. L.; Diessenbacher, P.; Sprick, M. R.; Schoen, M. P.; Henkler, F.; Gollnick, H.; Walczak, H.; Leverkus, M.			Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis	ONCOGENE			English	Article						apoptosis; TRAIL; cFLIP; TRAIL-R1; TRAIL-R2; melanoma	NF-KAPPA-B; RECEPTOR-SELECTIVE MUTANTS; DOWN-REGULATION; DEATH RECEPTORS; UP-REGULATION; BCL-2 FAMILY; LIGAND; EXPRESSION; CASPASE-8; RESISTANCE	Death ligands such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and certain forms of CD95L are attractive therapeutic options for metastatic melanoma. Since knowledge about the regulation of death receptor sensitivity in melanoma is sparse, we have analysed these signaling pathways in detail. The loss of CD95 or TRAIL-R1, but not of TRAIL-R2, surface expression correlated with apoptosis sensitivity in a panel of melanoma cell lines. In contrast, the expression of proteins of the apical apoptosis signaling cascade (FADD, initiator caspases-8 and cFLIP) did not predict apoptosis sensitivity. Since both TRAIL-R1 and -R2 transmit apoptotic signals, we asked whether cFLIP, highly expressed in several of the cell lines tested, is sufficient to maintain resistance to TRAIL-R2-mediated apoptosis. Downregulation of cFLIP in TRAIL-R2-positive, TRAIL-resistant IGR cells dramatically increased TRAIL sensitivity. Conversely ectopic expression of cFLIP in TRAIL-sensitive, TRAIL-R2-expressing RPM-EP melanoma cells inhibited TRAIL- and CD95L- mediated cell death. Thus, modulation of cFLIP is sufficient to sensitize TRAIL-R2-expressing cells for TRAIL. Taken together, albeit expressing all proteins necessary for death receptor-mediated apoptosis, TRAIL-R1 negative melanoma cells cannot undergo TRAIL- or CD95L-induced apoptosis due to expression of cFLIP. Hence, cFLIP represents an attractive therapeutic target for melanoma treatment, especially in combination with TRAIL receptor agonists.	[Geserick, P.; Drewniok, C.; Hupe, M.; Diessenbacher, P.; Gollnick, H.; Leverkus, M.] Otto von Guericke Univ, Lab Expt Dermatol, Dept Dermatol & Venerol, D-39120 Magdeburg, Saxonia Anhalt, Germany; [Haas, T. L.; Sprick, M. R.; Walczak, H.] German Canc Res Ctr, Dept Apoptosis Regulat, D-6900 Heidelberg, Germany; [Sprick, M. R.] Acad Med Centrum UVA, Lab Expt Oncol & Radiat, Amsterdam, Netherlands; [Schoen, M. P.] Univ Wurzburg, DFG Res Ctr Expt Biomed, Rudolf Virchow Ctr, Wurzburg, Germany; [Schoen, M. P.] Univ Wurzburg, Dept Dermatol Venerol & Allergol, Wurzburg, Germany; [Henkler, F.] Univ Wurzburg, Med Policlin, Wurzburg, Germany	Otto von Guericke University; Helmholtz Association; German Cancer Research Center (DKFZ); University of Amsterdam; Academic Medical Center Amsterdam; German Research Foundation (DFG); University of Wurzburg; University of Wurzburg; University of Wurzburg	Leverkus, M (corresponding author), Otto von Guericke Univ, Lab Expt Dermatol, Dept Dermatol & Venerol, Leipziger St 44, D-39120 Magdeburg, Saxonia Anhalt, Germany.	leverkus@medizin.uni-magdeburg.de	Sprick, Martin R./I-7995-2019; Sprick, Martin R./A-8611-2008; Walczak, Henning/AAV-2214-2020	Sprick, Martin R./0000-0001-9691-7574; Sprick, Martin R./0000-0001-9691-7574; Walczak, Henning/0000-0002-6312-4591; Hupe, Mike/0000-0002-7735-2958; Haas, Tobias/0000-0003-2336-0263				Allen JD, 2005, CELL DEATH DIFFER, V12, P680, DOI 10.1038/sj.cdd.4401634; Bae SI, 2008, ONCOGENE, V27, P490, DOI 10.1038/sj.onc.1210655; Buchsbaum Donald J, 2007, Future Oncol, V3, P405, DOI 10.2217/14796694.3.4.405; BYERS HR, 1991, AM J PATHOL, V139, P423; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Diessenbacher P, 2008, J INVEST DERMATOL, V128, P1134, DOI 10.1038/sj.jid.5701141; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Fecker LF, 2006, J INVEST DERMATOL, V126, P1366, DOI 10.1038/sj.jid.5700192; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Golks A, 2006, J EXP MED, V203, P1295, DOI 10.1084/jem.20051556; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hamai A, 2006, ONCOGENE, V25, P7618, DOI 10.1038/sj.onc.1209738; Hymowitz SG, 2005, NAT CHEM BIOL, V1, P353, DOI 10.1038/nchembio1205-353; Ivanov VN, 2006, EXP CELL RES, V312, P4120, DOI 10.1016/j.yexcr.2006.09.019; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Karst AM, 2007, CELL MOL LIFE SCI, V64, P318, DOI 10.1007/s00018-006-6364-4; Kataoka T, 2005, CRIT REV IMMUNOL, V25, P31, DOI 10.1615/CritRevImmunol.v25.i1.30; Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200; Kimberley FC, 2004, CELL RES, V14, P359, DOI 10.1038/sj.cr.7290236; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Kurbanov BM, 2007, ONCOGENE, V26, P3364, DOI 10.1038/sj.onc.1210134; Lavrik I, 2003, CELL DEATH DIFFER, V10, P144, DOI 10.1038/sj.cdd.4401156; Leverkus M, 2000, CANCER RES, V60, P553; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; Meng XW, 2006, CURR OPIN CELL BIOL, V18, P668, DOI 10.1016/j.ceb.2006.10.008; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Naito M, 2004, MOL CELL BIOL, V24, P8418, DOI 10.1128/MCB.24.19.8418-8427.2004; Natoni A, 2007, BRIT J HAEMATOL, V139, P568, DOI 10.1111/j.1365-2141.2007.06852.x; Neise D, 2008, ONCOGENE, V27, P1387, DOI 10.1038/sj.onc.1210773; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Peltenburg LTC, 2005, CELL DEATH DIFFER, V12, P678, DOI 10.1038/sj.cdd.4401630; Peter ME, 2007, CELL, V129, P447, DOI 10.1016/j.cell.2007.04.031; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sprick MR, 2004, BBA-MOL CELL RES, V1644, P125, DOI 10.1016/j.bbamcr.2003.11.002; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Van der Sloot AM, 2006, P NATL ACAD SCI USA, V103, P8634, DOI 10.1073/pnas.0510187103; Wachter T, 2004, J BIOL CHEM, V279, P52824, DOI 10.1074/jbc.M409554200; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Zhang XD, 1999, CANCER RES, V59, P2747; Zhuang LQ, 2006, HUM PATHOL, V37, P1286, DOI 10.1016/j.humpath.2006.04.026	46	82	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3211	3220		10.1038/sj.onc.1210985	http://dx.doi.org/10.1038/sj.onc.1210985			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18084329				2022-12-28	WOS:000255897600014
J	Arany, PR; Rane, SG; Roberts, AB				Arany, P. R.; Rane, S. G.; Roberts, A. B.			Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition	ONCOGENE			English	Article						TGF-beta 1; Smad3; JNK MAPK; Ras; malignant transformation; farnesyl transferase inhibition	GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; KINASE; PROTEIN; GROWTH-FACTOR-BETA-1; PHOSPHORYLATION; MECHANISM; CELLS; OVEREXPRESSION; TRANSDUCTION	The ability of transforming growth factor-beta ( TGF- beta) to modulate various effects on distinct cell lineages has been a central feature of its multi- faceted nature. The purpose of this study was to access the effects of deletion of a key TGF- beta signal transducer, Smad3, on MAPK activation and v- Ras(Ha)- transformation of primary mouse embryonic. broblasts ( MEFs). We observe reduced TGF- beta 1 and v- ras(Ha) mediated activation of the JNK and ERK MAPK pathway upon ablation of Smad3. Further, Smad3-deficient MEFs demonstrate resistance to v- ras(Ha)- induced transformation while the absence of Smad3 results in increased inhibition of farnesyl transferase activity. Taken together, these observations demonstrate that the absence of Smad3 protects. broblasts from oncogenic transformation by ( i) augmenting farnesyl transferase inhibition and ( ii) suppressing the Ras - JNK MAPK pathway. These results provide new insights into the molecular mechanisms involved in v- Ras(Ha) oncogene- induced mesenchymal phenotypic transformation.	[Arany, P. R.; Rane, S. G.; Roberts, A. B.] NCI, NIH, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; [Rane, S. G.] NIDDK, NIH, Diabet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Arany, PR (corresponding author), Harvard Univ, Harvard Sch Dent Med, 188 Longwood Ave,REB 203, Boston, MA 02115 USA.	arany@fas.harvard.edu; ranes@mail.nih.gov	Arany, Praveen/S-5329-2019	Arany, Praveen/0000-0002-6116-2340	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055107, ZIADK055107, Z01DK055106, ZIADK055106] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arany PR, 2006, P NATL ACAD SCI USA, V103, P9250, DOI 10.1073/pnas.0602473103; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bost F, 1999, MOL CELL BIOL, V19, P1938; Brassard DL, 2002, EXP CELL RES, V273, P138, DOI 10.1006/excr.2001.5440; Byfield SD, 2004, TRENDS CELL BIOL, V14, P107; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; FILMUS J, 1992, ONCOGENE, V7, P521; Fong LG, 2006, SCIENCE, V311, P1621, DOI 10.1126/science.1124875; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Laping NJ, 2007, CLIN CANCER RES, V13, P3087, DOI 10.1158/1078-0432.CCR-06-1811; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Matsuura I, 2005, BIOCHEMISTRY-US, V44, P12546, DOI 10.1021/bi050560g; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Park BJ, 2000, CANCER RES, V60, P3031; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Radisky DC, 2007, J CELL BIOCHEM, V101, P830, DOI 10.1002/jcb.21186; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Santibanez JF, 2003, INT J CANCER, V107, P715, DOI 10.1002/ijc.11457; Santibanez JF, 2002, FEBS LETT, V520, P171, DOI 10.1016/S0014-5793(02)02760-6; Sekimoto G, 2007, CANCER RES, V67, P5090, DOI 10.1158/0008-5472.CAN-06-4629; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; Ventura JJ, 2004, MOL CELL, V15, P269, DOI 10.1016/j.molcel.2004.06.007; Vijayachandra K, 2003, CANCER RES, V63, P3447; Wisdom R, 2005, ONCOGENE, V24, P7043, DOI 10.1038/sj.onc.1208870; Yamagata H, 2005, CANCER RES, V65, P157; Yoshida K, 2005, AM J PATHOL, V166, P1029, DOI 10.1016/S0002-9440(10)62324-3; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7	44	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2507	2512		10.1038/sj.onc.1210889	http://dx.doi.org/10.1038/sj.onc.1210889			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17952112				2022-12-28	WOS:000254844900016
J	Chinen, Y; Taki, T; Nishida, K; Shimizu, D; Okuda, T; Yoshida, N; Kobayashi, C; Koike, K; Tsuchida, M; Hayashi, Y; Taniwaki, M				Chinen, Y.; Taki, T.; Nishida, K.; Shimizu, D.; Okuda, T.; Yoshida, N.; Kobayashi, C.; Koike, K.; Tsuchida, M.; Hayashi, Y.; Taniwaki, M.			Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA	ONCOGENE			English	Article						AML1/RUNX1; LAF4; T-cell acute lymphoblastic leukemia; MLL	ACUTE MYELOID-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; PROTEIN; MALIGNANCIES; BREAKPOINTS; RUNXI; HEMATOPOIESIS; AML1/RUNX1; TRANSCRIPT; MUTATIONS	The AML1 gene is frequently rearranged by chromosomal translocations in acute leukemia. We identified that the LAF4 gene on 2q11.2-12 was fused to the AML1 gene on 21q22 in a pediatric patient having T-cell acute lymphoblastic leukemia ( T-ALL) with t(2;21)(q11;q22) using the bubble PCR method for cDNA. The genomic break points were within intron 7 of AML1 and of LAF4, resulting in the in-frame fusion of exon 7 of AML1 and exon 8 of LAF4. The LAF4 gene is a member of the AF4/FMR2 family and was previously identified as a fusion partner of MLL in B-precursor ALL with t(2;11)(q11;q23), although AML1-LAF4 was in T-ALL. LAF4 is the first gene fused with both AML1 and MLL in acute leukemia. Almost all AML1 translocations except for TEL-AML1 are associated with myeloid leukemia; however, AML1-LAF4 was associated with T-ALL as well as AML1-FGA7 in t(4;21)(q28;q22). These findings provide new insight into the common mechanism of AML1 and MLL fusion proteins in the pathogenesis of ALL. Furthermore, we successfully applied bubble PCR to clone the novel AML1-LAF4 fusion transcript. Bubble PCR is a powerful tool for detecting unknown fusion transcripts as well as genomic fusion points.	[Chinen, Y.; Taki, T.; Taniwaki, M.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Lab Med, Kamigyo Ku, Kyoto 6028566, Japan; [Chinen, Y.; Nishida, K.; Shimizu, D.; Okuda, T.; Yoshida, N.; Taniwaki, M.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Hematol & Oncol, Kamigyo Ku, Kyoto 6028566, Japan; [Kobayashi, C.; Koike, K.; Tsuchida, M.] Ibaraki Childrens Hosp, Dept Pediat, Mito, Ibaraki, Japan; [Hayashi, Y.] Gunma Childrens Med Ctr, Gunma, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Gunma Children's Medical Centre	Taki, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Lab Med, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	taki-t@umin.net						Agerstam H, 2007, GENE CHROMOSOME CANC, V46, P635, DOI 10.1002/gcc.20442; Asou N, 2007, BLOOD, V109, P4023, DOI 10.1182/blood-2006-01-031781; Bruch J, 2003, GENE CHROMOSOME CANC, V37, P106, DOI 10.1002/gcc.10187; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Chan EM, 2005, BLOOD, V105, P4523, DOI 10.1182/blood-2004-07-2762; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERICKSON P, 1992, BLOOD, V80, P1825; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Hayashi Y, 2000, SEMIN HEMATOL, V37, P368, DOI 10.1016/S0037-1963(00)90017-9; Hiwatari M, 2003, ONCOGENE, V22, P2851, DOI 10.1038/sj.onc.1206389; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Isnard P, 2000, BLOOD, V96, P705; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kurokawa M, 2003, CANCER SCI, V94, P841, DOI 10.1111/j.1349-7006.2003.tb01364.x; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P9597, DOI 10.1073/pnas.150241797; Mikhail FM, 2004, GENE CHROMOSOME CANC, V39, P110, DOI 10.1002/gcc.10302; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nguyen TDT, 2006, GENE CHROMOSOME CANC, V45, P918, DOI 10.1002/gcc.20355; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Paulsson K, 2006, LEUKEMIA, V20, P224, DOI 10.1038/sj.leu.2404076; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Smith D R, 1992, PCR Methods Appl, V2, P21; Taketani T, 2002, CANCER RES, V62, P33; Taki T, 2006, CURR OPIN ONCOL, V18, P62, DOI 10.1097/01.cco.0000198972.69541.04; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; TANIWAKI M, 1994, BLOOD, V83, P2962, DOI 10.1182/blood.V83.10.2962.2962; VONBERGH AR, 2002, GENE CHROMOSOME CANC, V37, P106; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; ZHANG JG, 1995, BRIT J HAEMATOL, V90, P138, DOI 10.1111/j.1365-2141.1995.tb03392.x; Zhang YM, 2004, GENE CHROMOSOME CANC, V40, P365, DOI 10.1002/gcc.20050	41	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2249	2256		10.1038/sj.onc.1210857	http://dx.doi.org/10.1038/sj.onc.1210857			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17968322				2022-12-28	WOS:000254621300016
J	Kivi, N; Greco, D; Auvinen, P; Auvinen, E				Kivi, N.; Greco, D.; Auvinen, P.; Auvinen, E.			Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression	ONCOGENE			English	Article						HPV; papillomavirus; E5; microarray; cell adhesion; cell motility	HUMAN-PAPILLOMAVIRUS TYPE-16; GROWTH-FACTOR RECEPTOR; MATRIX METALLOPROTEINASES; CYCLE PROGRESSION; EPITHELIAL-CELLS; E7 GENE; TRANSFORMATION; IMMORTALIZATION; TRANSDUCTION; INVASION	We investigated the effects of the human papillomavirus type 16 E5 oncogene on cellular gene expression in human epithelial cells using cDNA microarray. In a genome-wide microarray assay, the expression of 179 genes was found to be significantly altered due to E5 expression. The expression of lamin A/C was downregulated at protein level. The expression of protein kinase C-delta and phosphoinositide-3-kinase proteins was found to be upregulated. We also observed increased motility of E5-expressing cells. We conclude that the E5 protein affects several cellular pathways involved in cell adhesion, cell motility and mitogenic signaling. These alterations may together lead to inhibition of apoptosis and facilitate the establishment of persistent infection in the epithelium.	[Kivi, N.; Auvinen, E.] Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; [Kivi, N.; Auvinen, E.] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; [Greco, D.; Auvinen, P.] Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Kivi, N (corresponding author), Univ Helsinki, Haartman Inst, Dept Virol, PO 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	niina.kivi@helsinki.fi	Auvinen, Petri/AAP-8117-2021; Greco, Dario/T-7113-2019; Auvinen, Petri/D-5044-2009	Greco, Dario/0000-0001-9195-9003; Auvinen, Petri/0000-0002-3947-4778; Auvinen, Eeva/0000-0002-2094-985X				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Auvinen E, 2004, ARCH VIROL, V149, P1745, DOI 10.1007/s00705-004-0325-8; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; Bravo IG, 2005, ARCH VIROL, V150, P231, DOI 10.1007/s00705-004-0420-x; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Buness A, 2005, BIOINFORMATICS, V21, P554, DOI 10.1093/bioinformatics/bti052; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CASTRONOVO V, 1993, INVAS METAST, V13, P1; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chen SL, 1996, ARCH VIROL, V141, P791, DOI 10.1007/BF01718155; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Czech MP, 2003, ANNU REV PHYSIOL, V65, P791, DOI 10.1146/annurev.physiol.65.092101.142522; DEMETER LM, 1992, CANCER RES, V52, P1561; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; Duerst RJ, 2003, VIRAL IMMUNOL, V16, P475, DOI 10.1089/088282403771926300; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fehrmann F, 2003, J VIROL, V77, P2819, DOI 10.1128/JVI.77.5.2819-2831.2003; Genther SM, 2003, J VIROL, V77, P2832, DOI 10.1128/JVI.77.5.2832-2842.2003; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; Ivetac I, 2005, MOL BIOL CELL, V16, P2218, DOI 10.1091/mbc.e04-09-0799; Kim SH, 2006, CELL MOL LIFE SCI, V63, P930, DOI 10.1007/s00018-005-5561-x; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Leykauf K, 2004, J GEN VIROL, V85, P1427, DOI 10.1099/vir.0.79844-0; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; MUNGER K, 1989, J VIROL, V63, P4417; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Rajeevan MS, 2001, J MOL DIAGN, V3, P26, DOI 10.1016/S1525-1578(10)60646-0; Sayama K, 2002, J BIOL CHEM, V277, P40390, DOI 10.1074/jbc.M112423200; Schreiber K, 2004, ONCOGENE, V23, P3972, DOI 10.1038/sj.onc.1207507; Shiomi T, 2003, CANCER METAST REV, V22, P145, DOI 10.1023/A:1023039230052; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Stoppler MC, 1996, VIROLOGY, V223, P251, DOI 10.1006/viro.1996.0475; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P10515; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Werner JA, 2002, CLIN EXP METASTAS, V19, P275, DOI 10.1023/A:1015531319087; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083; Zhang BY, 2002, J VIROL, V76, P220, DOI 10.1128/JVI.76.1.220-231.2002	55	51	53	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2532	2541		10.1038/sj.onc.1210916	http://dx.doi.org/10.1038/sj.onc.1210916			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982485				2022-12-28	WOS:000255057000003
J	Guirouilh-Barbat, J; Huck, S; Lopez, BS				Guirouilh-Barbat, J.; Huck, S.; Lopez, B. S.			S-phase progression stimulates both the mutagenic KU-independent pathway and mutagenic processing of KU-dependent intermediates, for nonhomologous end joining	ONCOGENE			English	Article						double strand break repair; nonhomologous end joining; S phase; genetic instability; cell cycle; mammalian cells	DOUBLE-STRAND BREAKS; MAMMALIAN-CELL CYCLE; HOMOLOGOUS RECOMBINATION; V(D)J RECOMBINATION; DNA-REPAIR; NHEJ; TRANSLOCATIONS; REARRANGEMENTS; INVOLVEMENT; STABILITY	We used intrachromosomal substrates to directly monitor the effect of the cell cycle on the efficiency and the accuracy of nonhomologous end joining (NHEJ) in mammalian cells. We show that both KU and KU-independent (KU-alt) pathways are efficient when maintaining cells in G(1)/S, in G(2)/M or during dynamic progression through S phase. In addition, the accuracy of NHEJ is barely altered when the cells are blocked in G(1)/S or in G(2)/M. However, progression through S phase increases the frequency of deletions, which is a hallmark of the KU-alt pathway. Moreover, we show that the intermediates that are generated by the KU-dependent end joining of non-fully complementary ends, and which contain mismatches, nicks or gap intermediates, are less accurately processed when the cells progress through S phase. In conclusion, both KU and KU-alt processes are active throughout the cell cycle, but the repair is more error prone during S phase, both by increasing the mutagenic KU-alt pathway and decreasing the accuracy of the repair of the intermediates generated by the KU-dependent pathway.	[Guirouilh-Barbat, J.; Huck, S.; Lopez, B. S.] Inst Radiobiol Cellulaire & Mol, DSV, UMR CEA,UMR 217, CNRS, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), Inst Radiobiol Cellulaire & Mol, DSV, UMR CEA,UMR 217, CNRS, 18 Route Panorama,BAT 05, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	guirouilh-barbat, josée/AAX-7140-2020; Lopez, Bernard S/O-7308-2017; guirouilh-barbat, josee/O-7286-2017	Lopez, Bernard S/0000-0001-5088-0155; guirouilh-barbat, josee/0000-0002-8845-7333				Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Ausubel F., 1999, CURRENT PROTOCOLS MO; Capp JP, 2007, NUCLEIC ACIDS RES, V35, P3551, DOI 10.1093/nar/gkm243; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Cohen PE, 2001, BIOESSAYS, V23, P996, DOI 10.1002/bies.1145; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; Honma M, 2003, ENVIRON MOL MUTAGEN, V42, P288, DOI 10.1002/em.10201; Honma M, 2007, DNA REPAIR, V6, P781, DOI 10.1016/j.dnarep.2007.01.004; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Saintigny Y, 2007, ONCOGENE, V26, P2769, DOI 10.1038/sj.onc.1210075; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; STAMATO TD, 1988, RADIAT RES, V115, P325, DOI 10.2307/3577168; Wang HC, 2003, NUCLEIC ACIDS RES, V31, P5377, DOI 10.1093/nar/gkg728; Weinstock DM, 2006, BLOOD, V107, P777, DOI 10.1182/blood-2005-06-2437; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	29	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1726	1736		10.1038/sj.onc.1210807	http://dx.doi.org/10.1038/sj.onc.1210807			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891177				2022-12-28	WOS:000253962100008
J	Enomoto, A; Kido, N; Ito, M; Morita, A; Matsumoto, Y; Takamatsu, N; Hosoi, Y; Miyagawa, K				Enomoto, A.; Kido, N.; Ito, M.; Morita, A.; Matsumoto, Y.; Takamatsu, N.; Hosoi, Y.; Miyagawa, K.			Negative regulation of MEKK1/2 signaling by Serine-Threonine kinase 38 (STK38)	ONCOGENE			English	Article						STK38; MEKK1; MEKK2; MAPKKK; signal transduction	ACTIVATED PROTEIN-KINASE; KAPPA-B ACTIVATION; N-TERMINAL KINASE; CELL LINE MOLT-4; MEK KINASE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MAP KINASES; JUN KINASES; JNK	Mitogen-activated protein kinases (MAPKs) are activated through the kinase cascades of MAPK, MAPK kinase (MAPKK) and MAPKK kinase (MAPKKK). MAPKKKs phosphorylate and activate their downstream MAPKKs, which in turn phosphorylate and activate their downstream MAPKs. MAPKKK proteins relay upstream signals through the MAPK cascades to induce cellular responses. However, the molecular mechanisms by which given MAPKKKs are regulated remain largely unknown. Here, we found that serine-threonine protein kinase 38, STK38, physically interacts with the MAPKKKs MEKK1 and MEKK2 (MEKK1/2). The carboxy terminus, including the catalytic domain, but not the amino terminus of MEKK1/2 was necessary for the interaction with STK38. STK38 inhibited MEKK1/2 activation without preventing MEKK1/2 binding to its substrate, SEK1. Importantly, STK38 suppressed the autophosphorylation of MEKK2 without interfering with MEKK2 dimer formation, and converted MEKK2 from its phosphorylated to its nonphosphorylated form. The negative regulation of MEKK1/2 was not due to its phosphorylation by STK38. On the other hand, stk38 short hairpin RNA enhanced sorbitol-induced activation of MEKK2 and phosphorylation of the downstream MAPKKs, MKK3/6. Taken together, our results indicate that STK38 negatively regulates the activation of MEKK1/2 by direct interaction with the catalytic domain of MEKK1/2, suggesting a novel mechanism of MEKK1/2 regulation.	[Enomoto, A.; Kido, N.; Matsumoto, Y.; Hosoi, Y.; Miyagawa, K.] Univ Tokyo, Grad Sch Med, Sect Radiol Biol, Ctr Dis Biol & Integrat Med,Bunkyo Ku, Tokyo 1130033, Japan; [Kido, N.] Univ Tokyo, Sch Med, Tokyo 113, Japan; [Ito, M.; Takamatsu, N.] Kitasato Univ, Sch Sci, Dept Biosci, Kanagawa, Japan; [Morita, A.] Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, Chiba, Japan; [Matsumoto, Y.] Tokyo Inst Technol, Nucl Reactors Res Lab, Dept Nucl Engn, Tokyo 152, Japan	University of Tokyo; University of Tokyo; Kitasato University; Tokyo University of Science; Tokyo Institute of Technology	Enomoto, A (corresponding author), Univ Tokyo, Grad Sch Med, Sect Radiol Biol, Ctr Dis & Integrat Med,Bunkyo Ku, 3-7-2001 Hongo, Tokyo 1130033, Japan.	aenomoto@m.u-tokyo.ac.jp	Morita, Akinori/D-1418-2011					Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Cheng J, 2005, MOL CELL BIOL, V25, P5955, DOI 10.1128/MCB.25.14.5955-5964.2005; Cheng JK, 2005, J BIOL CHEM, V280, P13477, DOI 10.1074/jbc.M414258200; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Enomoto A, 2000, CANCER LETT, V155, P137, DOI 10.1016/S0304-3835(00)00422-5; Enomoto A, 2003, INT J RADIAT BIOL, V79, P589, DOI 10.1080/09553000310001597273; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Guo ZJ, 2002, MOL CELL BIOL, V22, P5761, DOI 10.1128/MCB.22.16.5761-5768.2002; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hergovich A, 2006, NAT REV MOL CELL BIO, V7, P253, DOI 10.1038/nrm1891; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; ITOM, 1999, MOL CELL BIOL, V19, P7539; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Ryoo K, 2004, J BIOL CHEM, V279, P43589, DOI 10.1074/jbc.M404359200; Su B, 2001, J BIOL CHEM, V276, P14784, DOI 10.1074/jbc.M010134200; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; YAN MH, 1994, NATURE, V372, P798; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zhang DY, 2006, EMBO J, V25, P97, DOI 10.1038/sj.emboj.7600913	43	24	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1930	1938		10.1038/sj.onc.1210828	http://dx.doi.org/10.1038/sj.onc.1210828			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906693				2022-12-28	WOS:000254150600012
J	Gadir, N; Jackson, DN; Lee, E; Foster, DA				Gadir, N.; Jackson, D. N.; Lee, E.; Foster, D. A.			Defective TGF-beta signaling sensitizes human cancer cells to rapamycin	ONCOGENE			English	Article						rapamycin; mTOR; TGF-beta; PKC delta; cancer	GROWTH-FACTOR-BETA; KINASE-C-DELTA; MTOR; INHIBITION; SURVIVAL; RECEPTOR; ARREST; SMAD3; LINES; EXPRESSION	mTOR, the mammalian target of rapamycin, is a critical target of survival signals in many human cancers. In the absence of serum, rapamycin induces apoptosis in MDA-MB-231 human breast cancer cells. However, in the presence of serum, rapamycin induces G1 cell cycle arrest - indicating that a factor( s) in serum suppresses rapamycin-induced apoptosis. We report here that transforming growth factor-beta (TGF-beta) suppresses rapamycin-induced apoptosis in serum-deprived MDA-MB-231 cells in a protein kinase C delta (PKC delta)-dependent manner. Importantly, if TGF-beta signaling or PKCd was suppressed, rapamycin induced apoptosis rather than G1 arrest in the presence of serum. And, if cells were allowed to progress into S phase, rapamycin induced apoptosis in the presence of serum. BT-549 and MDA-MB-468 breast, and SW-480 colon cancer cells have defects in TGF-beta signaling and rapamycin induced apoptosis in these cells in the presence of either serum or TGF-beta. Thus, in the absence of TGF-beta signaling, rapamycin becomes cytotoxic rather than cytostatic. Importantly, this study provides evidence indicating that tumors with defective TGF-beta signaling - common in colon and pancreatic cancers - will be selectively sensitive to rapamycin or other strategies that target mTOR.	[Gadir, N.; Jackson, D. N.; Lee, E.; Foster, D. A.] CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Borel F, 2002, J CELL SCI, V115, P2829; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Fink SP, 2001, CANCER RES, V61, P256; Fink SP, 2003, ONCOGENE, V22, P1317, DOI 10.1038/sj.onc.1206128; Foster DA, 2006, CURR SIGNAL TRANSD T, V1, P295, DOI 10.2174/157436206778226941; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Foster David A, 2004, Expert Rev Anticancer Ther, V4, P691, DOI 10.1586/14737140.4.4.691; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Perillan PR, 2002, J BIOL CHEM, V277, P1974, DOI 10.1074/jbc.M107984200; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Popat S, 2005, EUR J CANCER, V41, P2060, DOI 10.1016/j.ejca.2005.04.039; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; van der Poel HG, 2003, UROL RES, V30, P380, DOI 10.1007/s00240-002-0282-1; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	34	43	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1055	1062		10.1038/sj.onc.1210721	http://dx.doi.org/10.1038/sj.onc.1210721			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700525				2022-12-28	WOS:000253136700004
J	Suprynowicz, FA; Disbrow, GL; Krawczyk, E; Simic, V; Lantzky, K; Schlegel, R				Suprynowicz, F. A.; Disbrow, G. L.; Krawczyk, E.; Simic, V.; Lantzky, K.; Schlegel, R.			HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells	ONCOGENE			English	Article						HPV-16 E5 oncoprotein; caveolin-1; ganglioside GM1	EPIDERMAL-GROWTH-FACTOR; E5 PROTEIN; EPITHELIAL-CELLS; PAPILLOMAVIRUS; EXPRESSION; LOCALIZATION; MICRODOMAINS; INHIBIT; SYNAPSE	High-risk human papillomaviruses ( HPVs), especially HPV-16, play a primary role in the pathogenesis of cervical cancer. HPV-16 encodes the E5, E6 and E7 oncoproteins. Although the biological functions of E5 are poorly understood, recent studies indicate that its expression correlates with papillomavirus oncogenicity. In this study we demonstrate that the HPV-16 E5 oncoprotein increases plasma membrane expression of caveolin-1, which is a constituent of lipid rafts and regulator of cell signaling, and that this phenotype is mediated by the C-terminal 10 amino acids of E5. Moreover, E5 ( but not mutant E5) induces a 23- to 40-fold increase in the lipid raft component, ganglioside GM1, on the cell surface and mediates a dramatic increase in caveolin-1/ GM1 association. Since gangliosides strongly inhibit cytotoxic T lymphocytes, block immune synapse formation and are expressed at high levels on the surface of many tumor cells, our results suggest a potential mechanism for immune evasion by the papillomaviruses. Additionally, surface gangliosides are known to enhance proliferative signaling by the epidermal growth factor ( EGF) receptor, providing a possible mechanistic basis for observations that EGF signaling is enhanced in E5-expressing cells. Finally, the upregulation of caveolin-1 and ganglioside GM1 at the plasma membrane of E5-expressing cervical cells provides potential new therapeutic targets and diagnostic markers for high-risk HPV infections.	[Suprynowicz, F. A.; Disbrow, G. L.; Krawczyk, E.; Simic, V.; Lantzky, K.; Schlegel, R.] Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20057 USA	Georgetown University	Schlegel, R (corresponding author), Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20057 USA.	schleger@georgetown.edu						Ashrafi GH, 2006, INT J CANCER, V119, P2105, DOI 10.1002/ijc.22089; Bacia K, 2004, BIOPHYS J, V87, P1034, DOI 10.1529/biophysj.104.040519; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; Bravo IG, 2005, ARCH VIROL, V150, P231, DOI 10.1007/s00705-004-0420-x; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cebo C, 2006, J IMMUNOL, V176, P864, DOI 10.4049/jimmunol.176.2.864; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Davis DM, 2004, TRENDS IMMUNOL, V25, P323, DOI 10.1016/j.it.2004.03.007; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Disbrow GL, 2005, J VIROL, V79, P5839, DOI 10.1128/JVI.79.9.5839-5846.2005; Disbrow GL, 2003, VIROLOGY, V311, P105, DOI 10.1016/S0042-6822(03)00129-6; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Frazer IH, 1996, CURR OPIN IMMUNOL, V8, P484, DOI 10.1016/S0952-7915(96)80035-5; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; Hao MM, 2004, J BIOL CHEM, V279, P14171, DOI 10.1074/jbc.M309793200; McKallip R, 1999, J IMMUNOL, V163, P3718; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Nishio M, 2005, INT J ONCOL, V26, P191; O'Brien PM, 2002, VIRUS RES, V88, P103, DOI 10.1016/S0168-1702(02)00123-5; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Riley RR, 2003, CANCER RES, V63, P4862; Rodriguez MI, 2000, ONCOGENE, V19, P3727, DOI 10.1038/sj.onc.1203718; Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016/j.virol.2005.04.002; Shurin GV, 2001, CANCER RES, V61, P363; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Sotgia F, 2002, MOL CELL BIOL, V22, P3905, DOI 10.1128/MCB.22.11.3905-3926.2002; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Suprynowicz FA, 2005, VIROLOGY, V332, P102, DOI 10.1016/j.virol.2004.11.011; Suprynowicz FA, 2006, PAPILLOMAVIRUS RESEARCH: FROM NATURAL HISTORY TO VACCINES AND BEYOND, P97; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Vyas YM, 2002, IMMUNOL REV, V189, P161, DOI 10.1034/j.1600-065X.2002.18914.x; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083	40	58	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1071	1078		10.1038/sj.onc.1210725	http://dx.doi.org/10.1038/sj.onc.1210725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704805	Bronze			2022-12-28	WOS:000253136700006
J	Hayes, NVL; Newsam, RJ; Baines, AJ; Gullick, WJ				Hayes, N. V. L.; Newsam, R. J.; Baines, A. J.; Gullick, W. J.			Characterization of the cell membrane-associated products of the Neuregulin 4 gene	ONCOGENE			English	Article						neuregulin 4; growth factor; tyrosine kinase	GROWTH-FACTOR; FACTOR-ALPHA; ISOFORMS; ACTIVATION; SYSTEM; FAMILY	The NRG4 gene is a member of a family of four genes that encode a class of epidermal growth factors. This gene has been reported to express a protein designated here as NRG4A1. We describe here a novel splice variant of the NRG4 gene, NRG4A2, which encodes a C-terminal region containing a predicted type I PDZ-binding peptide. Both NRG4A1 and NRG4A2 were shown to be expressed on the cell surface, as expected by the presence of a predicted transmembrane sequence, and were modified at a single N-linked glycosylation site in the extracellular domain. Significant stabilization of expression of both proteins was seen in the presence of the proteosome inhibitor MG-132 suggesting that they are normally degraded by this system. N-terminal cleavage was inhibited in both isotypes by the broad-spectrum matrix metalloproteinase inhibitor, galardin (GM 6001). A glycosylated, secreted form of NRG4A1 was detected in the cell medium which showed biological activity in two assays, phosphorylation of the HER4 receptor and stimulation of neurite formation in PC-12 cells stably expressing HER4. Transfection and expression of green fluorescent protein-tagged proteins and immunofluorescent staining with specific anti-peptide antibodies showed that NRG4A1 is localized to membrane ruffles, while NRG4A2 has a more punctate membrane distribution.	[Hayes, N. V. L.; Newsam, R. J.; Gullick, W. J.] Univ Kent, Res Sch Biosci, Canc Biol Lab, Canterbury CT2 7NJ, Kent, England; [Baines, A. J.] Univ Kent, Ctr Biomed Informat, Canterbury CT2 7NJ, Kent, England	University of Kent; University of Kent	Gullick, WJ (corresponding author), Univ Kent, Res Sch Biosci, Canc Biol Lab, Canterbury CT2 7NJ, Kent, England.	w.j.gullick@kent.ac.uk		Baines, Anthony/0000-0003-3068-7811				Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Carteron C, 2006, J CELL SCI, V119, P898, DOI 10.1242/jcs.02799; Dunn M, 2004, J PATHOL, V203, P672, DOI 10.1002/path.1561; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Harris BZ, 2001, J CELL SCI, V114, P3219; Harrison PJ, 2006, BIOL PSYCHIAT, V60, P132, DOI 10.1016/j.biopsych.2005.11.002; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; Hobbs SS, 2002, ONCOGENE, V21, P8442, DOI 10.1038/sj.onc.1205960; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; ROOBOL A, 1995, J CELL SCI, V108, P1477; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Tastet C, 2003, ELECTROPHORESIS, V24, P1787, DOI 10.1002/elps.200305400; Vaskovsky A, 2000, J NEUROCHEM, V74, P979, DOI 10.1046/j.1471-4159.2000.0740979.x; von Heijne G, 2006, NAT REV MOL CELL BIO, V7, P909, DOI 10.1038/nrm2063; Wakatsuki S, 2004, J NEUROCHEM, V89, P119, DOI 10.1046/j.1471-4159.2003.02303.x; Yamada K, 2000, GENE, V255, P15, DOI 10.1016/S0378-1119(00)00309-7	18	22	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					715	720		10.1038/sj.onc.1210689	http://dx.doi.org/10.1038/sj.onc.1210689			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684490	Green Accepted			2022-12-28	WOS:000252674900015
J	Verbrugge, I; de Vries, E; Tait, SWG; Wissink, EHJ; Walczak, H; Verheij, M; Borst, J				Verbrugge, I.; de Vries, E.; Tait, S. W. G.; Wissink, E. H. J.; Walczak, H.; Verheij, M.; Borst, J.			Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway	ONCOGENE			English	Article						apoptosis; DISC; ionizing radiation; mitochondria; TRAIL	IRRADIATION-INDUCED APOPTOSIS; DNA-DAMAGE; CELL-DEATH; CHEMOTHERAPEUTIC DRUGS; CASPASE-8 RECRUITMENT; GAMMA-RADIATION; LIGAND TRAIL; IN-VIVO; ACTIVATION; CD95	In many tumor cell types, ionizing radiation (IR) or DNA-damaging anticancer drugs enhance sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, which is of great clinical interest. We have investigated the molecular mechanism underlying the response to combined modality treatment in p53-mutant Jurkat T leukemic cells overexpressing Bcl-2. These cells are largely resistant to individual treatment with TRAIL or IR, but sensitive to combined treatment, in vitro as well as in vivo. We demonstrate that IR and DNA-damaging anticancer drugs enable TRAIL receptor-2 and CD95/Fas to bypass the mitochondrial pathway for effector caspase activation. This was validated by RNA interference for Bax and Bak and by overexpression of dominant-negative Caspase-9. Improved effector caspase activation was neither caused by altered expression of proapoptotic components nor by impaired activity of inhibitor of apoptosis proteins or nuclear factor-kappa B signaling. Rather, we found that pretreatment of cells with IR caused quantitative and qualitative changes in death receptor signaling. It strongly improved the capacity of ligand-bound receptors to recruit FADD and activate Caspase-8 and -10 in the death-inducing signaling complex, while c-FLIPL levels were unaffected.	[Verbrugge, I.; de Vries, E.; Tait, S. W. G.; Wissink, E. H. J.; Borst, J.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; [Walczak, H.] German Canc Res Ctr, Div Apoptosis Regulat, D-6900 Heidelberg, Germany; [Verheij, M.] Netherlands Canc Inst, Div Radiotherapy, Amsterdam, Netherlands	Netherlands Cancer Institute; Helmholtz Association; German Cancer Research Center (DKFZ); Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl	Verheij, Marcel/O-9652-2018; Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591; Tait, Stephen/0000-0001-7697-132X; Borst, Jannie/0000-0002-8043-5009				Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; Kitamura T, 1998, INT J HEMATOL, V67, P351; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARINI P, 2005, BMC CANC, V5; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Ramp U, 2003, BRIT J CANCER, V88, P1800, DOI 10.1038/sj.bjc.6600984; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Ravi R, 2002, CANCER RES, V62, P1583; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Singh TR, 2003, CANCER RES, V63, P5390; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XD, 2001, GENE DEV, V15, P2922; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Werner AB, 2004, J BIOL CHEM, V279, P28771, DOI 10.1074/jbc.M400268200; Wissink EHJ, 2006, RADIOTHER ONCOL, V80, P214, DOI 10.1016/j.radonc.2006.07.030; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	42	34	36	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					574	584		10.1038/sj.onc.1210696	http://dx.doi.org/10.1038/sj.onc.1210696			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684487				2022-12-28	WOS:000252674900002
J	Cascio, S; Bartella, V; Auriemma, A; Johannes, GJ; Russo, A; Giordano, A; Surmacz, E				Cascio, S.; Bartella, V.; Auriemma, A.; Johannes, G. J.; Russo, A.; Giordano, A.; Surmacz, E.			Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1 alpha	ONCOGENE			English	Article						breast cancer; HIF; hyperinsulinemia; leptin	TRANSCRIPTION FACTOR; GENE-EXPRESSION; FACTOR-I; RECEPTOR; OBESITY; PROMOTER; ACTIVATION; INSULIN; HIF-1-ALPHA; PATHWAYS	We reported previously that the obesity hormone leptin is overexpressed in breast cancer biopsies. Here, we investigated molecular mechanisms involved in this process, focusing on conditions that are associated with obesity, that is, hyperinsulinemia and induction of hypoxia. By using quantitative real-time PCR, immunofluorescent detection of proteins and enzyme-linked immunosorbent assays, we found that treatment of MCF-7 breast cancer cells with high doses of insulin or the hypoxia-mimetic agent CoCl2, or culturing the cells under hypoxic conditions significantly increased the expression of leptin mRNA and protein. Notably, the greatest leptin mRNA and protein expression were observed under combined hyperinsulinemia and hypoxia or hypoxia-mimetic treatments. Luciferase reporter assays suggested that increased leptin synthesis could be related to the activation of the leptin gene promoter. DNA affinity precipitation and chromatin immunoprecipitation experiments revealed that insulin, CoCl2 and/or hypoxia treatments augmented nuclear accumulation of hypoxia-inducible factor-1 alpha ( HIF-1 alpha) and increased its interaction with several upstream leptin regulatory sequences, especially with the proximal promoter containing four hypoxia-response elements and three GC-rich regions. By using reverse chromatin precipitation, we determined that loading of HIF-1 alpha on the proximal leptin promoter concurred with the recruitment of p300, the major HIF coactivator, suggesting that the HIF/p300 complex is involved in leptin transcription. The importance of HIF-1 alpha in insulin- and CoCl2-activated leptin mRNA and protein expression was confirmed using RNA interference.	[Cascio, S.; Bartella, V.; Giordano, A.; Surmacz, E.] Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Cascio, S.; Russo, A.] Univ Palermo, Sect Med Oncol, Dept Surg & Oncol Sci, Palermo, Italy; [Bartella, V.] Univ Calabria, Dept PharmacoBiol, I-87036 Cosenza, Italy; [Auriemma, A.] Univ Verona, Dept Oncol, I-37100 Verona, Italy; [Johannes, G. J.] Drexel Univ, Coll Med, Dept Pathol & Lab Med, Philadelphia, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Palermo; University of Calabria; University of Verona; Drexel University	Surmacz, E (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, 1900 N,12th St,Room 446, Philadelphia, PA 19122 USA.	surmacz@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cascio, Sandra/0000-0003-4234-0508				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Calle EE, 2004, ONCOGENE, V23, P6365, DOI 10.1038/sj.onc.1207751; Cascio S, 2007, J BIOL CHEM, V282, P3498, DOI 10.1074/jbc.M606244200; De Vos P, 1998, EUR J BIOCHEM, V253, P619, DOI 10.1046/j.1432-1327.1998.2530619.x; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eisenberg A, 2004, FEBS LETT, V565, P139, DOI 10.1016/j.febslet.2004.03.089; Garofalo C, 2006, CLIN CANCER RES, V12, P1447, DOI 10.1158/1078-0432.CCR-05-1913; Garofalo C, 2006, J CELL PHYSIOL, V207, P12, DOI 10.1002/jcp.20472; Garofalo C, 2004, CLIN CANCER RES, V10, P6466, DOI 10.1158/1078-0432.CCR-04-0203; Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078-0432.CCR-05-2690; Gonzalez RR, 2006, J BIOL CHEM, V281, P26320, DOI 10.1074/jbc.M601991200; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Grosfeld A, 2002, J BIOL CHEM, V277, P42953, DOI 10.1074/jbc.M206775200; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Ishikawa M, 2004, CLIN CANCER RES, V10, P4325, DOI 10.1158/1078-0432.CCR-03-0749; Klein S, 2002, GASTROENTEROLOGY, V123, P882, DOI 10.1053/gast.2002.35514; Losso JN, 2005, J AGR FOOD CHEM, V53, P3751, DOI 10.1021/jf0479719; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mason MM, 1998, ENDOCRINOLOGY, V139, P1013, DOI 10.1210/en.139.3.1013; Meissner U, 2003, BIOCHEM BIOPH RES CO, V303, P707, DOI 10.1016/S0006-291X(03)00401-7; Melzner I, 2002, J BIOL CHEM, V277, P45420, DOI 10.1074/jbc.M208511200; Miki N, 2004, J BIOL CHEM, V279, P15025, DOI 10.1074/jbc.M313186200; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Morelli C, 2004, ONCOGENE, V23, P7517, DOI 10.1038/sj.onc.1208014; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Porter GA, 2006, ANN SURG ONCOL, V13, P327, DOI 10.1245/ASO.2006.03.049; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Revillion F, 2006, CLIN CANCER RES, V12, P2088, DOI 10.1158/1078-0432.CCR-05-1904; Snoussi K, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-38; Surmacz E, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1638; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Wauters M, 2000, EUR J ENDOCRINOL, V143, P293, DOI 10.1530/eje.0.1430293; Zhong H, 1999, CANCER RES, V59, P5830	34	71	77	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					540	547		10.1038/sj.onc.1210660	http://dx.doi.org/10.1038/sj.onc.1210660			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653093				2022-12-28	WOS:000252426100014
J	Lee, JH; Paull, TT				Lee, J-H; Paull, T. T.			Activation and regulation of ATM kinase activity in response to DNA double-strand breaks	ONCOGENE			English	Review						ATM; MRN; DNA repair; checkpoints	TELANGIECTASIA MUTATED ATM; S-PHASE CHECKPOINT; FORKHEAD-ASSOCIATED DOMAIN; PROTEIN PHOSPHATASE 2A; ATAXIA-TELANGIECTASIA; DAMAGE RESPONSE; DEPENDENT PHOSPHORYLATION; IONIZING-RADIATION; MRE11 COMPLEX; HISTONE ACETYLTRANSFERASE	The ataxia-telangiectasia-mutated (ATM) protein kinase is rapidly and specifically activated in response to DNA double-strand breaks in eukaryotic cells. In this review, we summarize recent insights into the mechanism of ATM activation, focusing on the role of the Mre11/Rad50/Nbs1 (MRN) complexin this process. We also compare observations of the ATM activation process in different biological systems and highlight potential candidates for cellular factors that may participate in regulating ATM activity in human cells.	Univ Texas Austin, Dept Mol Genet & Microbiol, Inst Cell & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Paull, TT (corresponding author), Univ Texas Austin, Dept Mol Genet & Microbiol, Inst Cell & Mol Biol, 1 Univ Stn,A4800, Austin, TX 78712 USA.	tpaull@mail.utexas.edu	Lee, Jihoon/AAK-3497-2021	Lee, Jihoon/0000-0001-7387-935X; Paull, Tanya/0000-0002-2991-651X				Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Araujo FD, 2005, J VIROL, V79, P11382, DOI 10.1128/JVI.79.17.11382-11391.2005; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Becker E, 2006, BIOINFORMATICS, V22, P1289, DOI 10.1093/bioinformatics/btl075; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Bhaskara V, 2007, MOL CELL, V25, P647, DOI 10.1016/j.molcel.2007.01.028; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cerosaletti K, 2006, MOL CELL BIOL, V26, P1691, DOI 10.1128/MCB.26.5.1691-1699.2006; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Costanzo V, 2004, PLOS BIOL, V2, P600, DOI 10.1371/journal.pbio.0020110; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Difilippantonio S, 2007, J EXP MED, V204, P1003, DOI 10.1084/jem.20070319; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Guo CY, 2002, J BIOL CHEM, V277, P4839, DOI 10.1074/jbc.M110092200; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Kanu N, 2007, EMBO J, V26, P2933, DOI 10.1038/sj.emboj.7601733; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee JH, 2003, MOL CANCER RES, V1, P674; Lee J, 2007, J BIOL CHEM, V282, P28036, DOI 10.1074/jbc.M704635200; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; McConnell JL, 2007, ONCOGENE, V26, P6021, DOI 10.1038/sj.onc.1210406; Mochan TA, 2003, CANCER RES, V63, P8586; Moncalian G, 2004, J MOL BIOL, V335, P937, DOI 10.1016/j.jmb.2003.11.026; Nakada D, 2003, GENE DEV, V17, P1957, DOI 10.1101/gad.1099003; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Park BJ, 2005, CELL, V120, P209, DOI 10.1016/j.cell.2004.11.054; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Shirata N, 2005, J BIOL CHEM, V280, P30336, DOI 10.1074/jbc.M500976200; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2001, J BIOL CHEM, V276, P30133, DOI 10.1074/jbc.M103160200; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Stracker TH, 2007, NATURE, V447, P218, DOI 10.1038/nature05740; Sun YL, 2006, FEBS LETT, V580, P4353, DOI 10.1016/j.febslet.2006.06.092; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wu XH, 2004, GENE DEV, V18, P1305, DOI 10.1101/gad.1182804; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Young DB, 2005, J BIOL CHEM, V280, P27587, DOI 10.1074/jbc.M411689200; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	88	404	414	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2007	26	56					7741	7748		10.1038/sj.onc.1210872	http://dx.doi.org/10.1038/sj.onc.1210872			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066086				2022-12-28	WOS:000251537900004
J	Bhattacharyya, R; Noch, EK; Khalili, K				Bhattacharyya, R.; Noch, E. K.; Khalili, K.			A novel role of Rac1 GTPase in JCV T-antigen-mediated beta-catenin stabilization	ONCOGENE			English	Article						beta-catenin; T-antigen; JC virus; Rho; Wnt pathway; medulloblastoma	CELL-ADHESION; BRAIN-TUMORS; RHO; PROTEINS; UBIQUITINATION; LOCALIZATION; INVOLVEMENT; INTERACTS; BINDING; PATHWAY	Wnt signaling follows canonical and non-canonical pathways to regulate a variety of processes during cellular homeostasis and development. The large T-antigen (T-Ag) of the human neurotropic JC virus, has been shown to modulate the Wnt-signaling pathway via interaction with beta-catenin, one of the most important components of the canonical Wnt pathway. Here, we have identified an alternative non-canonical pathway that allows T-Ag to recruit Rac1 for stabilizing beta-catenin by inhibiting its ubiquitin-dependent proteasomal degradation. We demonstrate that inhibition of Rac1 by its dominant negative mutant, RacN17, abrogates T-Ag-mediated stabilization of b-catenin yet exhibits no impact on the transcriptional activity of b-catenin. Results from immunocytochemistry revealed that together with T-Ag, a pool of beta-catenin appears at the cell surface, particularly at the membrane ruffles where active Rac1 is positioned. Interestingly, cooperativity between T-Ag and beta-catenin leads to activation of Rac1, which in turn, stimulates its association with beta-catenin. These observations unravel the interplay between beta-catenin and Rac1 that is initiated by T-Ag and results in stabilization of beta-catenin and its presence in cell membrane ruffles.	[Bhattacharyya, R.; Noch, E. K.; Khalili, K.] Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19122 USA.	kkhalili@temple.edu						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Bachar-Dahan L, 2006, MOL BIOL CELL, V17, P2572, DOI 10.1091/mbc.E06-01-0052; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BUTEL JS, 1989, ANN NY ACAD SCI, V567, P104, DOI 10.1111/j.1749-6632.1989.tb16463.x; Gan DD, 2004, ONCOGENE, V23, P483, DOI 10.1038/sj.onc.1207018; Hwang SL, 2005, ACTA NEUROCHIR, V147, P551, DOI 10.1007/s00701-005-0515-5; Khalili K, 2006, ADV EXP MED BIOL, V577, P274; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Senadheera D, 2001, INT J MOL MED, V8, P127; Shackelford J, 2004, MOL CELL BIOL, V24, P5089, DOI 10.1128/MCB.24.12.5089-5093.2004; Shollar D, 2004, ONCOGENE, V23, P5459, DOI 10.1038/sj.onc.1207728; Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200; White MK, 2005, BRAIN RES REV, V50, P69, DOI 10.1016/j.brainresrev.2005.04.007; Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046	20	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7628	7636		10.1038/sj.onc.1210576	http://dx.doi.org/10.1038/sj.onc.1210576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17637758				2022-12-28	WOS:000251537800004
J	Denslow, SA; Wade, PA				Denslow, S. A.; Wade, P. A.			The human Mi-2/NuRD complex and gene regulation	ONCOGENE			English	Review						histone deacetylase; chromatin; transcriptional repression; chromatin remodeling	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; HISTONE DEACETYLASE; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; REMODELING COMPLEX; MI-2 AUTOANTIGEN; BINDING DOMAIN; MECP1 COMPLEX; PROTEINS	The Mi-2/(nu) under bar cleosome (r) under bar emodeling and (d) under bar eacetylase ( NuRD) complex is an abundant deacetylase complex with a broad cellular and tissue distribution. It is unique in that it couples histone deacetylation and chromatin remodeling ATPase activities in the same complex. A decade of research has uncovered a number of interesting connections between Mi-2/NuRD and gene regulation. The subunit composition of the enzyme appears to vary with cell type and in response to physiologic signals within a tissue. Here, we review the known subunits of the complex, their connections to signaling networks, and their association with cancer. In addition, we propose a working model that integrates the known biochemical properties of the enzyme with emerging models on how chromatin structure and modi. cation relate to gene activity.	NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wade, PA (corresponding author), NIEHS, Mol Carcinogenesis Lab, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	Wadep2@niehs.nih.gov	Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101965, ZIAES101965] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bagheri-Yarmand R, 2004, DEVELOPMENT, V131, P3469, DOI 10.1242/dev.01213; Ballestar E, 2001, EUR J BIOCHEM, V268, P5397, DOI 10.1046/j.0014-2956.2001.02480.x; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Brackertz M, 2006, NUCLEIC ACIDS RES, V34, P397, DOI 10.1093/nar/gkj437; Brackertz M, 2002, J BIOL CHEM, V277, P40958, DOI 10.1074/jbc.M207467200; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; Callen JP, 2006, CLIN DERMATOL, V24, P363, DOI 10.1016/j.clindermatol.2006.07.001; Cui YK, 2006, MOL ENDOCRINOL, V20, P2020, DOI 10.1210/me.2005-0063; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Feng Q, 2002, MOL CELL BIOL, V22, P536, DOI 10.1128/MCB.22.2.536-546.2002; Feng Q, 2001, GENE DEV, V15, P827; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; Fujita N, 2004, MOL ENDOCRINOL, V18, P2937, DOI 10.1210/me.2004-0258; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Fukaki H, 2006, PLANT J, V48, P380, DOI 10.1111/j.1365-313X.2006.02882.x; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hill CL, 2001, LANCET, V357, P96, DOI 10.1016/S0140-6736(00)03540-6; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Kaji K, 2006, NAT CELL BIOL, V8, P285, DOI 10.1038/ncb1372; Kaji K, 2007, DEVELOPMENT, V134, P1123, DOI 10.1242/dev.02802; Kon C, 2005, GENETICS, V169, P2087, DOI 10.1534/genetics.104.034595; Kumar R, 2003, CELL, V113, P142, DOI 10.1016/S0092-8674(03)00274-5; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Le Guezennec X, 2006, MOL CELL BIOL, V26, P843, DOI 10.1128/MCB.26.3.843-851.2006; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Manavathi B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200; Marhold J, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-20; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mishra SK, 2004, J BIOL CHEM, V279, P32709, DOI 10.1074/jbc.M402942200; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; von Zelewsky T, 2000, DEVELOPMENT, V127, P5277; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang HB, 2001, NUCLEIC ACIDS RES, V29, P2517, DOI 10.1093/nar/29.12.2517; Williams CJ, 2004, IMMUNITY, V20, P719, DOI 10.1016/j.immuni.2004.05.005; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178; Zhang H, 2006, GENE DEV, V20, P2943, DOI 10.1101/gad.1461706; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	67	348	358	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	2007	26	37					5433	5438		10.1038/sj.onc.1210611	http://dx.doi.org/10.1038/sj.onc.1210611			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694084				2022-12-28	WOS:000248674300011
J	Glozak, MA; Seto, E				Glozak, M. A.; Seto, E.			Histone deacetylases and cancer	ONCOGENE			English	Review						acetylation; deacetylation; cancer; HDAC; HDAC inhibitors	NF-KAPPA-B; TRANSCRIPTION FACTOR GATA-1; ACUTE MYELOID-LEUKEMIA; ZINC-FINGER PROTEIN; IN-VIVO; DNA-BINDING; CELL-SURVIVAL; DEPENDENT TRANSCRIPTION; REPRESS TRANSCRIPTION; PROSTATE-CANCER	Histone deacetylases ( HDACs) regulate the expression and activity of numerous proteins involved in both cancer initiation and cancer progression. By removal of acetyl groups from histones, HDACs create a non-permissive chromatin conformation that prevents the transcription of genes that encode proteins involved in tumorigenesis. In addition to histones, HDACs bind to and deacetylate a variety of other protein targets including transcription factors and other abundant cellular proteins implicated in control of cell growth, differentiation and apoptosis. This review provides a comprehensive examination of the transcriptional and post-translational mechanisms by which HDACs alter the expression and function of cancer-associated proteins and examines the general impact of HDAC activity in cancer.	H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Seto, E (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, SRB 23011,12902 Magnolia Dr, Tampa, FL 33612 USA.	ed.seto@mofitt.org						Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; ALTENBURG B C, 1976, Experimental Cell Research, V102, P223; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200; Annicotte JS, 2006, MOL CELL BIOL, V26, P7561, DOI 10.1128/MCB.00605-06; Augenlicht L, 2003, ONCOGENE, V22, P4983, DOI 10.1038/sj.onc.1206521; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cabrero JR, 2006, MOL BIOL CELL, V17, P3435, DOI 10.1091/mbc.E06-01-0008; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Caslini C, 2006, ONCOGENE, V25, P5446, DOI 10.1038/sj.onc.1209533; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Crazzolara R, 2002, BRIT J HAEMATOL, V119, P965, DOI 10.1046/j.1365-2141.2002.03955.x; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; GINSBURG E, 1973, P NATL ACAD SCI USA, V70, P2457, DOI 10.1073/pnas.70.8.2457; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hayakawa F, 2004, J LEUKOCYTE BIOL, V75, P529, DOI 10.1189/jlb.0603289; Hellebrekers DMEI, 2006, CANCER RES, V66, P10770, DOI 10.1158/0008-5472.CAN-06-1609; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Ho WC, 2005, CANCER RES, V65, P4273, DOI 10.1158/0008-5472.CAN-04-3494; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Huang XW, 2006, CANCER RES, V66, P9245, DOI 10.1158/0008-5472.CAN-06-0887; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Inoue Y, 2007, ONCOGENE, V26, P500, DOI 10.1038/sj.onc.1209826; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim SH, 2004, BIOCHEM BIOPH RES CO, V315, P964, DOI 10.1016/j.bbrc.2004.01.149; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lamonica JM, 2006, BLOOD, V108, P3736, DOI 10.1182/blood-2006-07-032847; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; McGarry LC, 2004, ONCOGENE, V23, P5284, DOI 10.1038/sj.onc.1207687; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Michaelis M, 2004, MOL PHARMACOL, V65, P520, DOI 10.1124/mol.65.3.520; Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088; Myzak MC, 2006, FASEB J, V20, P506, DOI 10.1096/fj.05-4785fje; Nadiminty N, 2006, P NATL ACAD SCI USA, V103, P7264, DOI 10.1073/pnas.0509808103; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Osada H, 2001, CANCER RES, V61, P8331; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Rampalli S, 2005, MOL CELL BIOL, V25, P8415, DOI 10.1128/MCB.25.19.8415-8429.2005; Reed-Inderbitzin E, 2006, ONCOGENE, V25, P5777, DOI 10.1038/sj.onc.1209591; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773; Roy S, 2007, J BIOL CHEM, V282, P4765, DOI 10.1074/jbc.M609588200; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Salto-Tellez M, 2006, ONCOGENE, V25, P7646, DOI 10.1038/sj.onc.1209739; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Scroggins BT, 2007, MOL CELL, V25, P151, DOI 10.1016/j.molcel.2006.12.008; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Simonsson M, 2006, J BIOL CHEM, V281, P39870, DOI 10.1074/jbc.M607868200; Song J, 2005, APMIS, V113, P264, DOI 10.1111/j.1600-0463.2005.apm_04.x; Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Wang R, 2005, J BIOL CHEM, V280, P11528, DOI 10.1074/jbc.M413930200; Wang YH, 2003, J BIOL CHEM, V278, P25568, DOI 10.1074/jbc.M212574200; Watabiki Y, 2003, J HIGH ENERGY PHYS; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Whetstine JR, 2005, MOL CELL, V18, P483, DOI 10.1016/j.molcel.2005.04.006; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Yamada N, 2006, INT J CANCER, V119, P1850, DOI 10.1002/ijc.22047; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Yang G, 2007, ONCOGENE, V26, P91, DOI 10.1038/sj.onc.1209760; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhang Y, 2006, J BIOL CHEM, V281, P2401, DOI 10.1074/jbc.C500241200; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	119	732	761	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5420	5432		10.1038/sj.onc.1210610	http://dx.doi.org/10.1038/sj.onc.1210610			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694083				2022-12-28	WOS:000248674300010
J	Al-Azawi, D; Mc Ilroy, M; Kelly, G; Redmond, AM; Bane, FT; Cocchiglia, S; Hill, ADK; Young, LS				Al-Azawi, D.; Mc Ilroy, M.; Kelly, G.; Redmond, A. M.; Bane, F. T.; Cocchiglia, S.; Hill, A. D. K.; Young, L. S.			Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer	ONCOGENE			English	Article						breast cancer; myc; SRC-1; tamoxifen resistance; Ets-2	CREB-BINDING-PROTEIN; ESTROGEN-RECEPTOR; EXPRESSION; PHOSPHORYLATION; ACTIVATION; GROWTH; COACTIVATORS; PATHWAYS; P300; ER81	Associations between p160 coactivator proteins and endocrine resistance have been described. Though thought to primarily interact with steroid receptors, the p160 proteins can also interact with non-nuclear receptor transcription factors including the MAP kinase effector proteins Ets. Here, we observed that in breast cancer cells resistant and insensitive to endocrine treatment, the growth factor EGF induced Ets-2 but not Ets-1 transcriptional regulation of the oncogene myc. Ets-2 regulation of myc was found to be reliant on the p160 proteins SRC-1 and SRC-3. In support of these molecular observations, strong associations were observed between the transcription factor, Ets-2 and its coactivator SRC-1 (P < 0.01) and the target gene myc (P < 0.0001) in a cohort of breast cancer patients with locally advanced disease. Expression of Ets-2, SRC-1 and c-Myc individually all associated with reduced disease-free survival (P < 0.001, P < 0.001 and P = 0.002 respectively). There was no association between SRC-3 and disease-free survival (P = 0.707). SRC-1 can utilize MAP kinase effector transcription factor Ets-2 to regulate the production of the oncogene myc. These signalling mechanisms maybe important in the development of steroid resistant/independent breast cancer.	[Al-Azawi, D.; Mc Ilroy, M.; Redmond, A. M.; Bane, F. T.; Cocchiglia, S.; Hill, A. D. K.; Young, L. S.] Royal Coll Surgeons Ireland, Dept Surg, Dublin 2, Ireland; [Al-Azawi, D.] Univ Coll Dublin, Sch Med & Med Sci, UCD Conway Inst, Dublin 2, Ireland; [Kelly, G.] Univ Coll Dublin, Sch Math Sci Stat & Actuarial Sci, Dublin 2, Ireland	Royal College of Surgeons - Ireland; University College Dublin; University College Dublin	Young, LS (corresponding author), Royal Coll Surgeons Ireland, Dept Surg Res, Lab 3, 4th Floor,York House,RCSI St Stephens Green, Dublin 2, Ireland.	lyoung@rcsi.ie	Hill, Arnold DK/F-8438-2011; McIlroy, Marie/D-6110-2012; Young, Leonie/D-5631-2012	McIlroy, Marie/0000-0002-0827-8096; Young, Leonie/0000-0002-4904-0367				BRONZERT DA, 1985, ENDOCRINOLOGY, V117, P1409, DOI 10.1210/endo-117-4-1409; BRUNNER N, 1993, CANCER RES, V53, P283; Carbone GM, 2004, NUCLEIC ACIDS RES, V32, P4358, DOI 10.1093/nar/gkh744; CHEVALLIER B, 1993, AM J CLIN ONCOL-CANC, V16, P223, DOI 10.1097/00000421-199306000-00006; Cosgrave N, 2006, J MOL ENDOCRINOL, V37, P377, DOI 10.1677/jme.1.02118; Cui YK, 2006, CANCER RES, V66, P5950, DOI 10.1158/0008-5472.CAN-05-3243; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Goel A, 2004, J BIOL CHEM, V279, P14909, DOI 10.1074/jbc.M400036200; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hutcheson IR, 2003, BREAST CANCER RES TR, V81, P81, DOI 10.1023/A:1025484908380; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; MCIIROY M, 2006, ENDOCR-RELAT CANCER, V13, P1135; McNeil CM, 2006, J STEROID BIOCHEM, V102, P147, DOI 10.1016/j.jsbmb.2006.09.028; Myers E, 2005, CLIN CANCER RES, V11, P2111, DOI 10.1158/1078-0432.CCR-04-1192; Nicholson RI, 2004, CLIN CANCER RES, V10, p346S, DOI 10.1158/1078-0432.CCR-031206; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shepherd T, 2001, J MAMMARY GLAND BIOL, V6, P129, DOI 10.1023/A:1009576801226; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218	27	49	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					3021	3031		10.1038/sj.onc.1210964	http://dx.doi.org/10.1038/sj.onc.1210964			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059336				2022-12-28	WOS:000255681700009
J	Mizuno, T; Yamasaki, N; Miyazaki, K; Tazaki, T; Koller, R; Oda, H; Honda, Z; Ochi, M; Wolff, L; Honda, H				Mizuno, T.; Yamasaki, N.; Miyazaki, K.; Tazaki, T.; Koller, R.; Oda, H.; Honda, Z-i; Ochi, M.; Wolff, L.; Honda, H.			Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice	ONCOGENE			English	Article						chronic myelogenous leukemia; blast crisis; transgenic mice; p210BCR/ABL; Notch1	CHRONIC MYELOGENOUS LEUKEMIA; RETROVIRAL INSERTIONAL MUTAGENESIS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL; MYELOPROLIFERATIVE DISEASE; CELL LEUKEMIA; BLAST CRISIS; GENE; CML	Chronic myelogenous leukemia (CML) is a hematopoietic disorder, which begins as indolent chronic phase but inevitably progresses to fatal blast crisis. p210BCR/ABL, a constitutively active tyrosine kinase, is responsible for disease initiation but molecular mechanism(s) underlying disease evolution remains largely unknown. To explore this process, we employed retroviral insertional mutagenesis to CML-exhibiting p210BCR/ABL transgenic mice (Tg). Virus infection induced acute lymphoblastic leukemia (ALL) in p210BCR/ABL Tg with a higher frequency and in a shorter latency than wild-type littermates, and inverse PCR detected two retrovirus common integration sites (CISs) in p210BCR/ABL Tg tumors. Interestingly, one CIS was the transgene itself, where retrovirus integrations induced upregulation of p210BCR/ABL and production of truncated BCR/ABL with an enhanced kinase activity. Another CIS was Notch1 gene, where retrovirus integrations resulted in overexpression of Notch1 and generation of Notch1 lacking the C-terminal region (Notch1DC) associated with stable expression of its activated product, C-terminal-truncated Notch intracellular domain (NICDDC). In addition, generation of Tg for both p210BCR/ABL and Notch1DC developed ALL in a shortened period with Stat5 activation, demonstrating the cooperative oncogenicity of Notch1DC/NICDDC with p210BCR/ABL involving Stat5-mediated pathway. These results demonstrated that overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induces acute leukemia in a transgenic model for CML.	[Mizuno, T.; Yamasaki, N.; Miyazaki, K.; Tazaki, T.; Honda, H.] Hiroshima Univ, Dept Dev Biol, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan; [Mizuno, T.; Ochi, M.] Hiroshima Univ, Sch Med, Dept Orthoped Surg, Hiroshima, Japan; [Koller, R.; Wolff, L.] NCI, Cellular Oncol Lab, Leukemogenesis Sect, Bethesda, MD 20892 USA; [Oda, H.] Tokyo Womens Med Univ, Dept Pathol, Tokyo, Japan; [Honda, Z-i] Univ Tokyo, Grad Sch Sci, Dept Allergy & Rheumatol, Fac Med, Tokyo 113, Japan	Hiroshima University; Hiroshima University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tokyo Women's Medical University; University of Tokyo	Honda, H (corresponding author), Hiroshima Univ, Dept Dev Biol, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	hhonda@hiroshima-u.ac.jp	Tazaki, Tatsuya/AAT-4215-2021	Tazaki, Tatsuya/0000-0001-9327-9749	NATIONAL CANCER INSTITUTE [ZIABC011027, Z01BC011027] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Honda H, 1997, BIOCHEM BIOPH RES CO, V234, P376, DOI 10.1006/bbrc.1997.6650; Huettner CS, 2003, BLOOD, V102, P3363, DOI 10.1182/blood-2003-03-0768; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ilagan Maria Xenia G, 2007, Cell, V128, P1246; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; Koschmieder S, 2005, BLOOD, V105, P324, DOI 10.1182/blood-2003-12-4369; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lin YW, 2006, BLOOD, V107, P2540, DOI 10.1182/blood-2005-07-3013; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Monsalve E, 2006, J IMMUNOL, V176, P5362, DOI 10.4049/jimmunol.176.9.5362; Nakamura T, 2005, CANCER SCI, V96, P7, DOI 10.1111/j.1349-7006.2005.00011.x; Niki M, 2004, J EXP MED, V200, P1689, DOI 10.1084/jem.20041306; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; Pane F, 2002, ONCOGENE, V21, P8652, DOI 10.1038/sj.onc.1206094; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Scherr M, 2006, BLOOD, V107, P3279, DOI 10.1182/blood-2005-08-3087; SHORE SK, 1994, J BIOL CHEM, V269, P5413; Shuai K, 1996, ONCOGENE, V13, P247; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wolff L, 2003, ONCOGENE, V22, P9265, DOI 10.1038/sj.onc.1207092; Wolff L, 2003, J VIROL, V77, P4965, DOI 10.1128/JVI.77.8.4965-4971.2003; Yamashita N, 2005, BRIT J HAEMATOL, V131, P495, DOI 10.1111/j.1365-2141.2005.05793.x; Ye D, 2006, BLOOD, V107, P4917, DOI 10.1182/blood-2005-10-4110; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	38	20	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3465	3474		10.1038/sj.onc.1211007	http://dx.doi.org/10.1038/sj.onc.1211007			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193087	Green Submitted, Bronze			2022-12-28	WOS:000256309900011
J	Olshavsky, NA; Groh, EM; Comstock, CES; Morey, LM; Wang, Y; Revelo, MP; Burd, C; Meller, J; Knudsen, KE				Olshavsky, N. A.; Groh, E. M.; Comstock, C. E. S.; Morey, L. M.; Wang, Y.; Revelo, M. P.; Burd, C.; Meller, J.; Knudsen, K. E.			Cyclin D3 action in androgen receptor regulation and prostate cancer	ONCOGENE			English	Article						cell cycle; prostatic adenocarcinoma; CDK; PSA and G1	VITAMIN-D-RECEPTOR; D-DEPENDENT KINASE; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; CELL-LINES; D1-DEPENDENT KINASE; BINDING DOMAIN; GROWTH-FACTOR; CO-REPRESSOR; G(1) PHASE	Prostate cancer (PCa) cell proliferation is dependent on activation of the androgen receptor (AR), a ligand-dependent transcription factor. AR activation controls G1-S phase progression through fostering enhanced translation of the D-type cyclins, which promote cell cycle progression through activation of CDK4/6. However, the D-type cyclins harbor additional, CDK4/6 kinase-independent, functions through manipulation of transcription factors, including AR. It was previously established that cyclins D1 and D3 have the potential to modulate AR, and with regard to cyclin D1, disruption of this function occurs in human tumors. Therefore, it was essential to interrogate cyclin D3 function in this tumor type. Here, we show that cyclin D3 is found in association with AR in PCa cells, as mediated through a conserved motif. Cyclin D3 functions to attenuate AR activity through defined mechanisms that include modulation of ligand-dependent conformational changes and modulation of chromatin binding activity. Accumulated cyclin D3 slows cell proliferation in AR-dependent cells, thus suggesting that androgen-induced D-type cyclin production serves to temper the mitogenic response to androgen. Supporting this hypothesis, it is shown that cyclin D3 expression is reduced in primary PCas as a function of tumor grade, and inversely correlates with the proliferative index. In total, these data identify cyclin D3 as a critical modulator of the androgen response, whose deregulation may foster unchecked AR activity in PCa.	[Olshavsky, N. A.; Groh, E. M.; Comstock, C. E. S.; Morey, L. M.; Wang, Y.; Knudsen, K. E.] Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Dept Cell & Canc Biol, Cincinnati, OH 45267 USA; [Revelo, M. P.] Univ Utah, Dept Pathol & Lab Med, Salt Lake City, UT USA; [Burd, C.] NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA; [Meller, J.; Knudsen, K. E.] Univ Cincinnati, Coll Med, UC Canc Ctr, Cincinnati, OH USA; [Meller, J.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Knudsen, K. E.] Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Knudsen, KE (corresponding author), Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Dept Cell & Canc Biol, 3125 Eden Ave,ML0521, Cincinnati, OH 45267 USA.	Karen.Knudsen@uc.edu	Meller, Jaroslaw/A-1971-2011; Duch, Wlodzislaw/A-2002-2011; Comstock, Clay/B-6122-2008	Meller, Jaroslaw/0000-0002-1162-8253; Duch, Wlodzislaw/0000-0001-7882-4729; Comstock, Clay/0000-0001-5867-1489; Burd, Craig/0000-0002-6899-6751; Knudsen, Karen/0000-0002-1301-890X	NATIONAL CANCER INSTITUTE [R01CA116777, T32CA117846, R01CA099996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER; NCI NIH HHS [CA099996, CA116777, T32 CA117846, T32-CA117846] Funding Source: Medline; NIEHS NIH HHS [T32-ES07250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAP W, 1995, CANCER RES, V55, P1351; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Braden WA, 2006, MOL CELL BIOL, V26, P7667, DOI 10.1128/MCB.00045-06; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Burd CJ, 2005, MOL ENDOCRINOL, V19, P607, DOI 10.1210/me.2004-0266; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Comstock CES, 2007, BRIT J CANCER, V96, P970, DOI 10.1038/sj.bjc.6603615; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fribourg AF, 2000, CELL GROWTH DIFFER, V11, P361; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Hedberg Y, 2002, ACTA ONCOL, V41, P175, DOI 10.1080/028418602753669562; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Jian YZ, 2005, BIOCHEM BIOPH RES CO, V335, P739, DOI 10.1016/j.bbrc.2005.07.141; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kato A, 1998, BIOCHEM BIOPH RES CO, V245, P70, DOI 10.1006/bbrc.1998.8377; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIESS M, 1995, ONCOGENE, V10, P159; Knudsen KE, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-15; Knudsen KE, 1999, CANCER RES, V59, P2297; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; LI J, 2007, MOL ENDOCRINOL; Lim J, 2000, MOL ENDOCRINOL, V14, P1187, DOI 10.1210/me.14.8.1187; Lim JTE, 2005, P NATL ACAD SCI USA, V102, P5156, DOI 10.1073/pnas.0501203102; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Miehlke S, 2002, DIGEST DIS SCI, V47, P1248, DOI 10.1023/A:1015358127751; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Parry D, 1999, MOL CELL BIOL, V19, P1775; Perry JE, 1998, PROSTATE, V35, P117; Peterson LF, 2005, MOL CELL BIOL, V25, P10205, DOI 10.1128/MCB.25.23.10205-10219.2005; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Petre-Draviam CE, 2005, ONCOGENE, V24, P431, DOI 10.1038/sj.onc.1208200; Petre-Draviam CE, 2003, CANCER RES, V63, P4903; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; Sarruf DA, 2005, MOL CELL BIOL, V25, P9985, DOI 10.1128/MCB.25.22.9985-9995.2005; SCHWARTZ GG, 1994, ANTICANCER RES, V14, P1077; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SKOWRONSKI RJ, 1993, ENDOCRINOLOGY, V132, P1952, DOI 10.1210/en.132.5.1952; Timchenko LT, 2006, J BIOL CHEM, V281, P32806, DOI 10.1074/jbc.M605701200; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wang GL, 2006, MOL CELL BIOL, V26, P2570, DOI 10.1128/MCB.26.7.2570-2582.2006; Wang GL, 2007, J BIOL CHEM, V282, P1468, DOI 10.1074/jbc.M608226200; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Zhuang SH, 1997, MOL CELL ENDOCRINOL, V126, P83, DOI 10.1016/S0303-7207(96)03974-3; Zong HL, 2007, MOL CELL BIOL, V27, P7125, DOI 10.1128/MCB.01753-06; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	69	23	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3111	3121		10.1038/sj.onc.1210981	http://dx.doi.org/10.1038/sj.onc.1210981			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18084330				2022-12-28	WOS:000255897600004
J	Ohmori, K; Endo, Y; Yoshida, Y; Ohata, H; Taya, Y; Enari, M				Ohmori, K.; Endo, Y.; Yoshida, Y.; Ohata, H.; Taya, Y.; Enari, M.			Monomeric but not trimeric clathrin heavy chain regulates p53-mediated transcription	ONCOGENE			English	Article						clathrin heavy chain; gene transcription; monomer; p53; tumor suppressor	UBIQUITIN LIGASE; TUMOR-SUPPRESSOR; MITOTIC SPINDLE; P53; PROTEIN; MDM2; IDENTIFICATION; DEGRADATION; EXPRESSION; SUPERHELIX	Tumor suppressor p53 protein is the transcription factor responsible for various genes including DNA repair, growth arrest, apoptosis and antiangiogenesis. Recently, we showed that clathrin heavy chain (CHC), which was originally identified as a cytosolic protein regulating endocytosis, is present in nuclei and functions as a coactivator for p53. Here, we determined the detailed p53-binding site of CHC and a CHC deletion mutant containing this region (CHC833-1406) behaved as a monomer in cells. Monomeric CHC833-1406 still had a higher ability to transactivate p53 than wild-type CHC although this CHC mutant no longer had endocytic function. Moreover, similar to wild-type CHC, monomeric CHC enhances p53-mediated transcription through the recruitment of histone acetyltransferase p300. Immunofluorescent microscopic analysis exhibited that CHC833-1406 is predominantly localized in nuclei, suggesting that there may be a certain regulatory domain for nuclear export in the C-terminus of CHC. Thus, the trimerization domain of CHC is not necessary for the transactivation of p53 target genes and these data provide further evidence that nuclear CHC plays a role distinct from clathrin-mediated endocytosis.	[Ohmori, K.; Endo, Y.; Yoshida, Y.; Ohata, H.; Taya, Y.; Enari, M.] Japan Sci & Technol Agcy, SORST, Chuo Ku, Tokyo 1040045, Japan; [Ohmori, K.; Endo, Y.; Yoshida, Y.; Ohata, H.; Taya, Y.; Enari, M.] Natl Canc Ctr, Res Inst, Div Radiol, Chuo Ku, Tokyo 1040045, Japan; [Ohmori, K.] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba, Japan	Japan Science & Technology Agency (JST); National Cancer Center - Japan; University of Tokyo	Enari, M (corresponding author), Natl Canc Ctr, Res Inst, Div Radiol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	ytaya@gan2.res.ncc.go.jp; menari@gan2.res.ncc.go.jp	Enari, Masato/E-5507-2014	Enari, Masato/0000-0003-4293-3848				Barth M, 2004, J CELL SCI, V117, P2051, DOI 10.1242/jcs.01062; Bourdon JC, 2003, CELL DEATH DIFFER, V10, P397, DOI 10.1038/sj.cdd.4401243; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CY, 2002, EMBO J, V21, P6072, DOI 10.1093/emboj/cdf594; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; ENARI M, 1953, GENE DEV, V20, P1087; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kim HL, 2000, EXP MOL MED, V32, P222, DOI 10.1038/emm.2000.36; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar S, 2006, MOL CELL ENDOCRINOL, V246, P147, DOI 10.1016/j.mce.2005.11.028; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 2003, CANCER RES, V63, P2596; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nakamura Y, 2006, CANCER SCI, V97, P633, DOI 10.1111/j.1349-7006.2006.00214.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Prives C, 1999, J PATHOL, V187, P112; Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502; Royle SJ, 2006, J CELL SCI, V119, P4071, DOI 10.1242/jcs.03192; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wakeham DE, 2003, EMBO J, V22, P4980, DOI 10.1093/emboj/cdg511; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Ziegler E. C., 2005, SCI STKE, pre6, DOI DOI 10.1126/STKE.2842005RE6	42	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2215	2227		10.1038/sj.onc.1210854	http://dx.doi.org/10.1038/sj.onc.1210854			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952123				2022-12-28	WOS:000254621300012
J	Hamer, PCDW; Van Tilborg, AAG; Eijk, PP; Sminia, P; Troost, D; Van Noorden, CJF; Ylstra, B; Leenstra, S				Hamer, P. C. De Witt; Van Tilborg, A. A. G.; Eijk, P. P.; Sminia, P.; Troost, D.; Van Noorden, C. J. F.; Ylstra, B.; Leenstra, S.			The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids	ONCOGENE			English	Article						glioma; primary cell culture; spheroid; comparative genomic hybridization; microarray	IN-VITRO; PRIMARY TUMORS; GLIOBLASTOMA; DELETIONS; LINES; HYBRIDIZATION	Screening of therapeutics relies on representative cancer models. The representation of human glioblastoma by in vitro cell culture models is questionable. We obtained genomic profiles by array comparative genomic hybridization of both short-and long-term primary cell and spheroid cultures, derived from seven glioblastomas and one anaplastic oligodendroglioma. Chromosomal copy numbers were compared between cell cultures and spheroids and related to the parental gliomas using unsupervised hierarchical clustering and correlation coefficient. In seven out of eight short-term cell cultures, the genomic profiles clustered further apart from their parental tumors than spheroid cultures. In four out of eight samples, the genetic changes in cell culture were substantial. T he average correlation coefficient between parental tumors and spheroid profiles was 0.89 (range: 0.79-0.97), whereas that between parental tumors and cell cultures was 0.62 (range: 0.10-0.96). In two out of three long-term cell cultures progressive genetic changes had developed, whereas the spheroid cultures were genetically stable. It is concluded that genomic profiles of primary cell cultures from glioblastoma are frequently deviant from parental tumor profiles, whereas spheroids are genetically more representative of the glioblastoma. This implies that glioma cell culture data have to be handled with the highest caution.	[Hamer, P. C. De Witt; Van Tilborg, A. A. G.; Leenstra, S.] Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, NL-1100 DD Amsterdam, Netherlands; [Van Tilborg, A. A. G.; Troost, D.] Univ Amsterdam, Acad Med Ctr, Dept Neuropathol, NL-1100 DD Amsterdam, Netherlands; [Eijk, P. P.; Ylstra, B.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Sect Micro Array Facil, Amsterdam, Netherlands; [Sminia, P.] Vrije Univ Amsterdam Med Ctr, Dept Radiat Oncol, Amsterdam, Netherlands; [Van Noorden, C. J. F.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam	Hamer, PCDW (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, Room H2-238,POB 22660, NL-1100 DD Amsterdam, Netherlands.	P.C.DeWittHamer@amc.nl	Ylstra, Bauke/D-2906-2012; van Tilborg, Angela/M-5704-2015; Sminia, Peter/P-3385-2014; De Witt Hamer, Philip/E-7630-2013	Ylstra, Bauke/0000-0001-9479-3010; van Tilborg, Angela/0000-0003-3968-5345; De Witt Hamer, Philip/0000-0003-2988-8544; Sminia, Peter/0000-0002-9531-5704				Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562; BIGNER SH, 1987, CANCER GENET CYTOGEN, V24, P163, DOI 10.1016/0165-4608(87)90094-X; BJERKVIG R, 1990, J NEUROSURG, V72, P463, DOI 10.3171/jns.1990.72.3.0463; Burton EC, 2002, CANCER RES, V62, P6205; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hartmann C, 1999, INT J ONCOL, V15, P975; IZUMOTO S, 1995, CANCER LETT, V97, P241, DOI 10.1016/0304-3835(95)03981-2; Koschny R, 2002, CANCER GENET CYTOGEN, V135, P147, DOI 10.1016/S0165-4608(01)00650-1; Kotliarov Y, 2006, CANCER RES, V66, P9428, DOI 10.1158/0008-5472.CAN-06-1691; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Loeper S, 2001, CYTOGENET CELL GENET, V94, P1, DOI 10.1159/000048773; Pandita A, 2004, GENE CHROMOSOME CANC, V39, P29, DOI 10.1002/gcc.10300; Smeets SJ, 2006, ONCOGENE, V25, P2558, DOI 10.1038/sj.onc.1209275; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Steilen-Gimbel H, 1999, CANCER GENET CYTOGEN, V113, P115, DOI 10.1016/S0165-4608(99)00013-8; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Voskoglou-Nomikos T, 2003, CLIN CANCER RES, V9, P4227; Wolff JEA, 1999, J CANCER RES CLIN, V125, P481, DOI 10.1007/s004320050305	21	154	157	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					2091	2096		10.1038/sj.onc.1210850	http://dx.doi.org/10.1038/sj.onc.1210850			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17934519				2022-12-28	WOS:000254359100014
J	Nuytten, M; Beke, L; Van Eynde, A; Ceulemans, H; Beullens, M; Van Hummelen, P; Fuks, F; Bollen, M				Nuytten, M.; Beke, L.; Van Eynde, A.; Ceulemans, H.; Beullens, M.; Van Hummelen, P.; Fuks, F.; Bollen, M.			The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing	ONCOGENE			English	Article						EZH2; gene silencing; NIPP1; polycomb group proteins; PRC2; transcriptional repression	POLYCOMB GROUP PROTEIN; PHOSPHATASE-1 REGULATOR NIPP1; BREAST EPITHELIAL-CELLS; EMBRYONIC STEM-CELLS; HISTONE H3; DEVELOPMENTAL REGULATORS; PROSTATE-CANCER; GROUP-COMPLEXES; TARGET GENES; KINASE MELK	EZH2 is a Polycomb group (PcG) protein that promotes the late-stage development of cancer by silencing a specific set of genes, at least in part through trimethylation of associated histone H3 on Lys 27 (H3K27). Nuclear inhibitor of protein phosphatase-1 (NIPP1) is a ubiquitously expressed transcriptional repressor that has binding sites for the EZH2 interactor EED. Here, we examine the contribution of NIPP1 to EZH2-mediated gene silencing. Studies on NIPP1-deficient cells disclose a widespread and essential role of NIPP1 in the trimethylation of H3K27 by EZH2, not only in the onset of this trimethylation during embryonic development, but also in the maintenance of this repressive mark in proliferating cells. Consistent with this notion, EZH2 and NIPP1 silence a common set of genes, as revealed by gene-expression pro. ling, and NIPP1 is associated with established Polycomb target genes and with genomic regions that are enriched in Polycomb targets. Furthermore, most NIPP1 target genes are trimethylated on H3K27 and the knockdown of either NIPP1 or EZH2 is often associated with a loss of this modi. cation. Our data reveal that NIPP1 is required for the global trimethylation of H3K27 and is implicated in gene silencing by EZH2.	[Nuytten, M.; Beke, L.; Van Eynde, A.; Ceulemans, H.; Beullens, M.; Bollen, M.] Katholieke Univ Leuven, Fac Med, Dept Mol Cell Biol, Lab Biosignaling & Therapeut, B-3000 Louvain, Belgium; [Van Hummelen, P.] VIB, Microarray Facil, Louvain, Belgium; [Fuks, F.] Free Univ Brussels, Fac Med, Lab Canc Epigenet, Louvain, Belgium	KU Leuven; Flanders Institute for Biotechnology (VIB)	Van Eynde, A (corresponding author), Katholieke Univ Leuven, Fac Med, Dept Mol Cell Biol, Lab Biosignaling & Therapeut, Campus Gasthuisberg,O&N1,Herestr 49, B-3000 Louvain, Belgium.	aleyde.vaneynde@med.kuleuven.be		Ceulemans, Hugo/0000-0002-7059-4399				Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Beullens M, 2002, J BIOL CHEM, V277, P19855, DOI 10.1074/jbc.M200847200; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Boudrez A, 2002, J BIOL CHEM, V277, P31834, DOI 10.1074/jbc.M204427200; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; FAUST C, 1995, DEVELOPMENT, V121, P273; Gray D, 2005, CANCER RES, V65, P9751, DOI 10.1158/0008-5472.CAN-04-4531; Isono K, 2005, GENE DEV, V19, P536, DOI 10.1101/gad.1284605; Jagiello I, 1997, J BIOL CHEM, V272, P22067, DOI 10.1074/jbc.272.35.22067; Jagiello I, 2000, J CELL SCI, V113, P3761; Jin QM, 1999, BIOCHEM J, V342, P13, DOI 10.1042/0264-6021:3420013; Jin QM, 2003, J BIOL CHEM, V278, P30677, DOI 10.1074/jbc.M302273200; Kirmizis A, 2004, EXP BIOL MED, V229, P705, DOI 10.1177/153537020422900803; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kirmizis A, 2003, MOL CANCER THER, V2, P113; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lin ML, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1650; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Ringrose L, 2007, CURR OPIN CELL BIOL, V19, P290, DOI 10.1016/j.ceb.2007.04.010; ROY N, 2007, BIOCH BIOPHYS ACTA; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Eynde A, 2004, MOL CELL BIOL, V24, P5863, DOI 10.1128/MCB.24.13.5863-5874.2004; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Vulsteke V, 2004, J BIOL CHEM, V279, P8642, DOI 10.1074/jbc.M311466200; Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472	47	60	62	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1449	1460		10.1038/sj.onc.1210774	http://dx.doi.org/10.1038/sj.onc.1210774			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724462				2022-12-28	WOS:000253548200012
J	Niemantsverdriet, M; Wagner, K; Visser, M; Backendorf, C				Niemantsverdriet, M.; Wagner, K.; Visser, M.; Backendorf, C.			Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character	ONCOGENE			English	Article						14-3-3 zeta siRNA; UV irradiation; c-Jun N-terminal kinase; p38-MAPK; E-cadherin; Oncomine	PROGNOSTIC MARKER; GAMMA-CATENIN; BETA-CATENIN; DNA-DAMAGE; E-CADHERIN; CANCER; EXPRESSION; CARCINOMA; 14-3-3-PROTEINS; IDENTIFICATION	14-3-3 proteins are relevant to cancer biology as they are key regulators of major cellular processes such as proliferation, differentiation, senescence and apoptosis. So far, the sigma isoform (14-3-3 sigma) has most directly been implicated in carcinogenesis and was recognized as a tumour-suppressor gene. The other six members of the mammalian 14-3-3 gene family likely behave as oncogenes, although direct evidence supporting this view is largely circumstantial. In this report, we show that knockdown of 14-3-3 zeta induces at least two isoform-specific phenotypes that are consistent with a potential oncogenic activity during tumorigenesis. Firstly, down-regulation of 14-3-3 zeta sensitized cells to stress-induced apoptosis and JNK/p38 signalling and secondly, it enforced cell-cell contacts and expression of adhesion proteins. Apparently, the zeta isoform restrains both cell adhesion and the cellular propensity for apoptosis, two activities that are also restrained during carcinogenesis. The assumption that 14-3-3 zeta has oncogenic properties was substantiated with a web-based meta-analysis (Oncomine), revealing that 14-3-3 zeta is overexpressed in various types of carcinomas. As the highly conserved human 14-3-3 gene family encodes proteins with either tumour-promoting or tumour-suppressing activities, we infer that the cellular balance between the various 14-3-3 isoforms is crucial for the proper functioning of cells.	[Niemantsverdriet, M.; Wagner, K.; Visser, M.; Backendorf, C.] Leiden Univ, Leiden Inst Chem, Mol Genet Lab, NL-2333 CC Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Backendorf, C (corresponding author), Leiden Univ, Leiden Inst Chem, Mol Genet Lab, Einsteinweg 55, NL-2333 CC Leiden, Netherlands.	backendo@chem.leidenuniv.nl						Arora S, 2005, MOL CARCINOGEN, V42, P97, DOI 10.1002/mc.20048; Balda MS, 2003, TRENDS CELL BIOL, V13, P310, DOI 10.1016/S0962-8924(03)00105-3; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buckley PG, 2002, HUM MOL GENET, V11, P3221, DOI 10.1093/hmg/11.25.3221; Burnworth B, 2006, ONCOGENE, V25, P4399, DOI 10.1038/sj.onc.1209474; Clairotte A, 2006, AM J CLIN PATHOL, V125, P119, DOI 10.1309/DKCLN4K2RK0V87YG; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Ghadimi BM, 2003, CLIN CANCER RES, V9, P1808; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hekman M, 2006, J BIOL CHEM, V281, P17321, DOI 10.1074/jbc.M600292200; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Jang JS, 2004, ONCOL RES, V14, P491, DOI 10.3727/0965040042380441; Jin YT, 2006, EMBO J, V25, P1207, DOI 10.1038/sj.emboj.7601010; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Niemantsverdriet M, 2005, EXP CELL RES, V310, P237, DOI 10.1016/j.yexcr.2005.07.016; Porter GW, 2006, SEMIN CANCER BIOL, V16, P193, DOI 10.1016/j.semcancer.2006.03.003; Rhodes DR, 2005, NAT GENET, V37, pS31, DOI 10.1038/ng1570; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; Tada K, 2000, CANCER, V88, P268, DOI 10.1002/(SICI)1097-0142(20000115)88:2<268::AID-CNCR4>3.0.CO;2-B; Takeuchi T, 2002, MOL CARCINOGEN, V35, P173, DOI 10.1002/mc.10088; Takihara Y, 2000, CARCINOGENESIS, V21, P2073, DOI 10.1093/carcin/21.11.2073; Tzivion G, 2006, SEMIN CANCER BIOL, V16, P203, DOI 10.1016/j.semcancer.2006.03.004; Ueda G, 2006, INT J ORAL MAX SURG, V35, P356, DOI 10.1016/j.ijom.2005.07.023; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Zang L, 2004, J PROTEOME RES, V3, P604, DOI 10.1021/pr034131l	31	78	84	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1315	1319		10.1038/sj.onc.1210742	http://dx.doi.org/10.1038/sj.onc.1210742			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704798				2022-12-28	WOS:000253407000015
J	Bader, AG; Vogt, PK				Bader, A. G.; Vogt, P. K.			Phosphorylation by Akt disables the anti-oncogenic activity of YB-1	ONCOGENE			English	Article						translation; p50; dbpb; NSEP1; PI3K; mRNA binding	BOX-BINDING PROTEIN-1; COLD-SHOCK DOMAIN; MESSENGER-RNA; CATALYTIC SUBUNIT; BREAST-CANCER; TRANSFORMATION; TRANSCRIPTION; 3-KINASE; KINASE	The Y box-binding protein 1 ( YB-1) is a DNA/ RNA-binding protein that regulates mRNA transcription and translation. It is a major component of free messenger ribonucleoprotein particles and, at higher concentrations, blocks protein synthesis. In chicken embryo fibroblasts, overexpression of YB-1 confers a specific resistance to oncogenic cellular transformation by phosphoinositide 3-kinase ( PI3K) or Akt/ PKB. Recent studies have identified ed YB-1 as a direct substrate of Akt. The functional significance of Akt-mediated phosphorylation remains largely unknown. We generated YB-1 mutants in the Akt phosphorylation consensus sequence to explore the effect of phosphorylated YB-1 in PI3K-induced transformation. In contrast to wild-type YB-1, the phosphomimetic S99E mutant no longer interferes with cellular transformation. This mutant has reduced affinity for the cap of mRNAs and fails to inhibit cap-dependent translation. The data suggest that phosphorylation by Akt disables the inhibitory activity of YB-1 and thereby enhances the translation of transcripts that are necessary for oncogenesis. Overexpression of wild-type YB-1 overrides inactivation by Akt and maintains inhibition of protein synthesis and resistance to transformation.	[Bader, A. G.; Vogt, P. K.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Bader, AG (corresponding author), Asuragen Inc, R&D, 2150 Woodward St, Austin, TX 78744 USA.	abader@asuragen.com	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Bader AG, 2005, MOL CELL BIOL, V25, P2095, DOI 10.1128/MCB.25.6.2095-2106.2005; Bader AG, 2006, CURR CANCER THER REV, V2, P31, DOI 10.2174/157339406775471786; Basaki Y, 2007, ONCOGENE, V26, P2736, DOI 10.1038/sj.onc.1210084; Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056; BOUVET P, 1995, J BIOL CHEM, V270, P28297; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kloks CPAM, 2002, J MOL BIOL, V316, P317, DOI 10.1006/jmbi.2001.5334; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590	19	48	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1179	1182		10.1038/sj.onc.1210719	http://dx.doi.org/10.1038/sj.onc.1210719			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704806				2022-12-28	WOS:000253136700018
J	Baldanzi, G; Cutrupi, S; Chianale, F; Gnocchi, V; Rainero, E; Porporato, P; Filigheddu, N; van Blitterswijk, WJ; Parolini, O; Bussolino, F; Sinigaglia, F; Graziani, A				Baldanzi, G.; Cutrupi, S.; Chianale, F.; Gnocchi, V.; Rainero, E.; Porporato, P.; Filigheddu, N.; van Blitterswijk, W. J.; Parolini, O.; Bussolino, F.; Sinigaglia, F.; Graziani, A.			Diacylglycerol kinase-alpha phosphorylation by Src on Y335 is required for activation, membrane recruitment and Hgf-induced cell motility	ONCOGENE			English	Article						hepatocyte growth factor; Src; diacylglycerol kinase; tyrosine kinase; signal transduction; cell migration	SUBTYPE-SPECIFIC TRANSLOCATION; TYROSINE PHOSPHORYLATION; PROCESSIVE PHOSPHORYLATION; PHOSPHATIDIC-ACID; T-LYMPHOCYTES; V-SRC; PROTEIN; DOMAINS; BINDING; SPECIFICITY	Diacylglycerol (DAG) kinases (Dgk), which phosphorylate DAG to generate phosphatidic acid, act as either positive or negative key regulators of cell signaling. We previously showed that Src mediates growth factors-induced activation of Dgk-alpha, whose activity is required for cell motility, proliferation and angiogenesis. Here, we demonstrate that both hepatocytes growth factor (HGF) stimulation and v-Src transformation induce tyrosine phosphorylation of Dgk-alpha on Y335, through a mechanism requiring its proline-rich C-terminal sequence. Moreover, we show that both proline-rich sequence and phosphorylation of Y335 of Dgk-alpha mediate: (i) its enzymatic activation, (ii) its ability to interact respectively with SH3 and SH2 domains of Src, (iii) its recruitment to the membrane. In addition, we show that phosphorylation of Dgk-alpha on Y335 is required for HGF-induced motility, while its constitutive recruitment at the membrane by myristylation is sufficient to trigger spontaneous motility in absence of HGF. Providing the first evidence that tyrosine phosphorylation of Dgk-alpha is required for growth-factors-induced activation and membrane recruitment, these findings underscore its relevance as a rheostat, whose activation is a threshold to elicit growth factors-induced migratory signaling.	[Baldanzi, G.; Chianale, F.; Gnocchi, V.; Rainero, E.; Porporato, P.; Sinigaglia, F.; Graziani, A.] Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy; [Baldanzi, G.; Parolini, O.] Ctr Di Ricerca E Menni, Fond Poliambulanza, Ist Osp, Brescia, Italy; [Cutrupi, S.] Univ Turin, Dept Human & Anim Biol, Turin, Italy; [Filigheddu, N.] Univ Amedeo Avogadro Piemonte Orientale, Dept Clin & Expt Med, Novara, Italy; [van Blitterswijk, W. J.] Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; [Bussolino, F.] Univ Turin, Inst Canc Res & Treatment IRCC, Turin, Italy; [Bussolino, F.] Univ Turin, Dept Oncol Sci, Turin, Italy	University of Eastern Piedmont Amedeo Avogadro; Fondazione Poliambulanza di Brescia; University of Turin; University of Eastern Piedmont Amedeo Avogadro; Netherlands Cancer Institute; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin	Graziani, A (corresponding author), Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, V Solaroli 17, I-28100 Novara, Italy.	graziani@med.unipmn.it	cutrupi, santina/AAC-4479-2022; Baldanzi, Gianluca/AAO-7673-2021; Filigheddu, Nicoletta/N-7219-2015; Bussolino, Federico/AES-3951-2022; PAROLINI, ORNELLA/ABI-7862-2020; Graziani, Andrea/AAB-6301-2022; PAROLINI, ORNELLA/C-7946-2013; Porporato, Paolo E./A-9932-2018; graziani, andrea/B-2554-2009; Bussolino, Federico/K-2500-2016	Baldanzi, Gianluca/0000-0002-1370-9903; Filigheddu, Nicoletta/0000-0002-3848-611X; PAROLINI, ORNELLA/0000-0002-5211-6430; Graziani, Andrea/0000-0002-6302-2317; PAROLINI, ORNELLA/0000-0002-5211-6430; Porporato, Paolo E./0000-0001-8519-1552; graziani, andrea/0000-0002-6302-2317; Bussolino, Federico/0000-0002-5348-1341; CUTRUPI, SANTINA/0000-0002-2358-5852; Rainero, Elena/0000-0003-1402-8701	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Alonso R, 2005, J BIOL CHEM, V280, P28439, DOI 10.1074/jbc.M501112200; Bacchiocchi R, 2005, BLOOD, V106, P2175, DOI 10.1182/blood-2005-01-0316; Baldanzi G, 2004, ONCOGENE, V23, P4828, DOI 10.1038/sj.onc.1207633; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Carrasco S, 2004, MOL BIOL CELL, V15, P2932, DOI 10.1091/mbc.E03-11-0844; Cipres A, 2003, J BIOL CHEM, V278, P35629, DOI 10.1074/jbc.M305635200; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Fukunaga-Takenaka R, 2005, GENES CELLS, V10, P311, DOI 10.1111/j.1365-2443.2005.00842.x; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Luo B, 2003, J BIOL CHEM, V278, P39542, DOI 10.1074/jbc.M307153200; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Nagaya H, 2002, MOL BIOL CELL, V13, P302, DOI 10.1091/mbc.01-05-0255; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Olenchock BA, 2006, NAT IMMUNOL, V7, P1174, DOI 10.1038/ni1400; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Sanjuan MA, 2003, J IMMUNOL, V170, P2877, DOI 10.4049/jimmunol.170.6.2877; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Santarius M, 2006, BIOCHEM J, V398, P1, DOI 10.1042/BJ20060565; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Yeo MG, 2006, MOL CELL BIOL, V26, P4399, DOI 10.1128/MCB.01147-05; Zha YY, 2006, NAT IMMUNOL, V7, P1166, DOI 10.1038/ni1394; Zhong XP, 2003, NAT IMMUNOL, V4, P882, DOI 10.1038/ni958; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	35	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					942	956		10.1038/sj.onc.1210717	http://dx.doi.org/10.1038/sj.onc.1210717			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700527				2022-12-28	WOS:000252946300006
J	de Bruijn, DRH; van Dijk, AHA; Willemse, MP; van Kessel, AG				de Bruijn, D. R. H.; van Dijk, A. H. A.; Willemse, M. P.; van Kessel, A. Geurts			The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4	ONCOGENE			English	Article						synovial sarcoma; SSX; LHX4; SS18-SSX; transcription regulation	CHRONIC MYELOGENOUS LEUKEMIA; KRUPPEL-ASSOCIATED BOX; CHROMOSOMAL LOCALIZATION; NUCLEAR-LOCALIZATION; ONCOPROTEIN SYT; FUSION TYPE; HOX GENE; EXPRESSION; TRANSLOCATION; IDENTIFICATION	As a result of the synovial sarcoma-associated t(X; 18) translocation, the SS18 gene on chromosome 18 is fused to either one of the three closely related SSX genes on the X chromosome. The SS18 protein is thought to act as a transcriptional co-activator, whereas the SSX proteins are thought to act as transcriptional corepressors. The main SSX-repression domain is located in its C terminus, a domain that is retained in the respective SS18-SSX fusion proteins. Both the SS18 and SSX proteins lack DNA-binding domains. Previously, we found that the SS18 and SS18-SSX fusion proteins may be tethered to DNA targets via the SS18-interacting protein AF10. Here, we set out to isolate proteins that interact with the SSX C-terminal repression domain using a yeast two-hybrid interaction trap. Of the positive clones isolated, two corresponded to the LIM homeobox protein LHX4, a DNA-binding protein that is involved in transcription regulation. An endogenous interaction was subsequently established in mammalian cells via colocalization and coimmunoprecipitation of the respective proteins. Interestingly, the LHX4 gene was previously found to be deregulated in various human leukemias. In addition, it was previously found that LIM homeobox proteins may bind to and activate the glycoprotein-alpha (CGA) promoter. Using LHX4 chromatin immunoprecipitation and CGA-promoter assays, we found that endogenous LHX4 binds to the CGA promoter and that LHX4-mediated CGA activation is enhanced by the SS18-SSX protein, but not by the SSX protein. Taken together, we conclude that this novel protein - protein interaction may have direct consequences for the (de) regulation of SSX and/or SS18-SSX target genes and, thus, for the development of human synovial sarcomas.	[de Bruijn, D. R. H.; van Dijk, A. H. A.; Willemse, M. P.; van Kessel, A. Geurts] Radboud Univ Nijmegen Med Ctr, Dept Human Genet 855, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Kessel, AG (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Human Genet 855, POB 9101, NL-6500 HB Nijmegen, Netherlands.	a.geurtsvankessel@antrg.umcn.nl	de Bruijn, D.R.H./L-4233-2015; van Kessel, Ad Geurts/A-2810-2010					Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Cronwright G, 2005, CANCER RES, V65, P2207, DOI 10.1158/0008-5472.CAN-04-1882; de Bruijn DRH, 2006, CANCER RES, V66, P9474, DOI 10.1158/0008-5472.CAN-05-3726; de Bruijn DRH, 2002, GENE CHROMOSOME CANC, V34, P285, DOI 10.1002/gcc.10073; de Bruijn DRH, 2001, CYTOGENET CELL GENET, V92, P310, DOI 10.1159/000056920; de Bruijn DRH, 2001, ONCOGENE, V20, P3281, DOI 10.1038/sj.onc.1204419; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; Dong WF, 1997, DNA CELL BIOL, V16, P671, DOI 10.1089/dna.1997.16.671; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; dos Santos NR, 2000, CANCER RES, V60, P1654; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Guillou L, 2004, J CLIN ONCOL, V22, P4040, DOI 10.1200/JCO.2004.11.093; Gure AO, 2002, INT J CANCER, V101, P448, DOI 10.1002/ijc.10634; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Howard PW, 2000, J BIOL CHEM, V275, P13336, DOI 10.1074/jbc.275.18.13336; Huntley S, 2006, GENOME RES, V16, P669, DOI 10.1101/gr.4842106; Ito T, 2004, LAB INVEST, V84, P1484, DOI 10.1038/labinvest.3700174; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kawai A, 2004, CANCER LETT, V204, P105, DOI 10.1016/j.canlet.2003.09.031; Kawamata N, 2002, ONCOGENE, V21, P4983, DOI 10.1038/sj.onc.1205628; Ladanyi M, 2002, CANCER RES, V62, P135; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Liu YB, 2002, BRAIN RES, V928, P147, DOI 10.1016/S0006-8993(01)03243-7; Machinis K, 2001, AM J HUM GENET, V69, P961, DOI 10.1086/323764; Mischo A, 2006, INT J CANCER, V118, P696, DOI 10.1002/ijc.21352; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Naka N, 2002, INT J CANCER, V98, P640, DOI 10.1002/ijc.10277; Perani M, 2003, ONCOGENE, V22, P8156, DOI 10.1038/sj.onc.1207031; Raetzman LT, 2002, DEVELOPMENT, V129, P4229; Richter K, 2003, HAEMATOLOGICA, V88, P1336; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; Saito T, 2006, CANCER RES, V66, P6919, DOI 10.1158/0008-5472.CAN-05-3697; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Taylor BJ, 2005, J IMMUNOTHER, V28, P564, DOI 10.1097/01.cji.0000175685.36239.e5; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Tureci O, 1996, CANCER RES, V56, P4766; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; Vogel MJ, 2006, GENOME RES, V16, P1493, DOI 10.1101/gr.5391806; Wu HK, 1997, BIOCHEM BIOPH RES CO, V233, P806, DOI 10.1006/bbrc.1997.6546; Wu HK, 1996, ONCOGENE, V12, P1205; Yamada S, 2003, INT J RELIAB APPL, V4, P1	56	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					653	662		10.1038/sj.onc.1210688	http://dx.doi.org/10.1038/sj.onc.1210688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667940				2022-12-28	WOS:000252674900009
J	Takeyama, K; Monti, S; Manis, JP; Dal Cin, P; Getz, G; Beroukhim, R; Dutt, S; Aster, JC; Alt, FW; Golub, TR; Shipp, MA				Takeyama, K.; Monti, S.; Manis, J. P.; Dal Cin, P.; Getz, G.; Beroukhim, R.; Dutt, S.; Aster, J. C.; Alt, F. W.; Golub, T. R.; Shipp, M. A.			Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas	ONCOGENE			English	Article						DNA damage; 53BP1; lymphoma; genetic abnormalities; high-density single nucleotide polymorphism array	CLASS-SWITCH RECOMBINATION; DNA-DAMAGE; HUMAN GENOME; PROTEIN 53BP1; BCL6; P53; SUPPRESS; BREAKS; TRANSLOCATIONS; TRANSCRIPTION	p53-Binding protein 1 (53BP1) encodes a critical checkpoint protein that localizes to sites of DNA double-strand breaks (DSBs) and participates in DSB repair. Mice that are 53bp1 deficient or hemizygous have an increased incidence of lymphoid malignancies. However, 53BP1 abnormalities in primary human tumors have not been described. By combining high-density single nucleotide polymorphism (HD SNP) array data and gene expression profiles, we found 9 of 63 newly diagnosed human diffuse large B-cell lymphomas (DLBCLs) with single copy loss of the chromosome 15q15 region including the 53BP1 locus; these nine tumors also had significantly lower levels of 53BP1 transcripts. 53BP1 single copy loss found with the HD SNP array platform was subsequently confirmed by fluorescence in situ hybridization. These studies highlight the role of 53BP1 copy loss in primary human DLBCLs and the value of integrative analyses in detecting this genetic lesion in human tumors.	[Takeyama, K.; Beroukhim, R.; Shipp, M. A.] Dana Fraber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Monti, S.; Getz, G.; Beroukhim, R.; Golub, T. R.] Broad Inst Massachusetts Inst Technol, Cambridge, MA USA; [Monti, S.; Getz, G.; Beroukhim, R.; Golub, T. R.] Harvard Univ, Cambridge, MA 02138 USA; [Manis, J. P.; Dutt, S.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; [Dal Cin, P.; Aster, J. C.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Alt, F. W.] Childrens Hosp, Howard Hughes Med Inst, CBR Inst Biomed Res, Boston, MA 02115 USA; [Alt, F. W.] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA; [Golub, T. R.] Dana Fraber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Shipp, MA (corresponding author), Dana Fraber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	margaret_shipp@dfci.harvard.edu			NCI NIH HHS [K08 CA122833-01A1, P01 CA92625, P01 CA092625, K08 CA122833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA122833, P01CA092625] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MM, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-19; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BEROUKHIM R, UNPUB GENOME WIDE AN; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697; Fodde R, 2002, SCIENCE, V298, P761, DOI 10.1126/science.1077707; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Polo JM, 2007, P NATL ACAD SCI USA, V104, P3207, DOI 10.1073/pnas.0611399104; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Takahashi H, 2006, CLIN CANCER RES, V12, P3265, DOI 10.1158/1078-0432.CCR-06-0076; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Wu XS, 2005, NAT IMMUNOL, V6, P964, DOI 10.1038/ni1005-964; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308	30	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					318	322		10.1038/sj.onc.1210650	http://dx.doi.org/10.1038/sj.onc.1210650			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17637749				2022-12-28	WOS:000252256000007
J	O'Neil, J; Look, AT				O'Neil, J.; Look, A. T.			Mechanisms of transcription factor deregulation in lymphoid cell transformation	ONCOGENE			English	Review						TAL1; NOTCH; PAX5; MLL; E2A; TEL-AML1	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING DOMAIN; C-MYC ONCOGENE; SITE-SPECIFIC DELETIONS; LIM-PROTEIN RBTN2; T-CELL; CHROMOSOMAL TRANSLOCATIONS; BURKITT-LYMPHOMA; HOMEOBOX GENE; NOTCH1 MUTATIONS	The most frequent targets of genetic alterations in human lymphoid leukemias are transcription factor genes with essential functions in blood cell development. TAL1, LYL1, HOX11 and other transcription factors essential for normal hematopoiesis are often misexpressed in the thymus in T- cell acute lymphoblastic leukemia ( T- ALL), leading to differentiation arrest and cell transformation. Recent advances in the ability to assess DNA copy number have led to the discovery that the MYB transcription factor oncogene is tandemly duplicated in T- ALL. The NOTCH1 gene, which is essential for key embryonic cell-fate decisions in multicellular organisms, was found to be activated by mutation in a large percentage of T- ALL patients. The gene encoding the FBW7 protein ubiquitin ligase, which regulates the turnover of the intracellular form of NOTCH ( ICN), is also mutated in T- ALL, resulting in stabilization of the ICN and activation of the NOTCH signaling pathway. In mature B- lineage ALL and Burkitt lymphoma, the MYC transcription factor oncogene is overexpressed due to translocation into the IG locus. PAX5, a transcription factor essential for B- lineage commitment, is inactivated in 32% of cases of B- progenitor ALL. Translocations resulting in oncogenic fusion transcription factors also occur frequently in this form of ALL. The most frequent transcription factor chimeric fusion, TEL- AML1, is an initiating event in B- progenitor ALL that acts by repressing transcription. Therefore, deregulated transcription and its consequent effects on key developmental pathways play a major role in the molecular pathogenesis of lymphoid malignancy. Once the full complement of cooperating mutations in transformed B- and T- progenitor cells is known, and the deregulated downstream pathways have been elucidated, it will be possible to identify vulnerable components and to target them with small- molecule inhibitors.	Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Look, AT (corresponding author), Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.	Thomas_Look@dfci.harvard.edu			NCI NIH HHS [CA109901] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA109901] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; Armstrong SA, 2005, J CLIN ONCOL, V23, P6306, DOI 10.1200/JCO.2005.05.047; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; ARNOLD A, 1983, NEW ENGL J MED, V309, P1593, DOI 10.1056/NEJM198312293092601; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Badiani PA, 1996, ONCOGENE, V13, P2205; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Ballerini P, 2002, BLOOD, V100, P991, DOI 10.1182/blood-2001-11-0093; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; Berger R, 2003, LEUKEMIA, V17, P1851, DOI 10.1038/sj.leu.2403061; BERNARD O, 1991, ONCOGENE, V6, P1477; Bernard OA, 2001, LEUKEMIA, V15, P1495, DOI 10.1038/sj.leu.2402249; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Bousquet M, 2007, BLOOD, V109, P3417, DOI 10.1182/blood-2006-05-025221; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Cave H, 1997, LEUKEMIA, V11, P1459, DOI 10.1038/sj.leu.2400798; Chan SM, 2007, BLOOD, V110, P278, DOI 10.1182/blood-2006-08-039883; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CROCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P6922, DOI 10.1073/pnas.80.22.6922; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Drynan LF, 2005, EMBO J, V24, P3136, DOI 10.1038/sj.emboj.7600760; DUBE ID, 1991, BLOOD, V78, P2996; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; EMANUEL BS, 1984, P NATL ACAD SCI-BIOL, V81, P2444, DOI 10.1073/pnas.81.8.2444; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Ferrando AA, 2000, SEMIN HEMATOL, V37, P381, DOI 10.1016/S0037-1963(00)90018-0; Ferrando AA, 2004, BLOOD, V103, P1909, DOI 10.1182/blood-2003-07-2577; Ferrando AA, 2003, SEMIN HEMATOL, V40, P274, DOI 10.1016/S0037-1963(03)00195-1; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FISCH P, 1992, ONCOGENE, V7, P2389; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; Hsu K, 2003, CANCER CELL, V4, P81, DOI 10.1016/S1535-6108(03)00192-2; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kees UR, 2003, LEUKEMIA, V17, P887, DOI 10.1038/sj.leu.2402892; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Lewis HD, 2007, CHEM BIOL, V14, P209, DOI 10.1016/j.chembiol.2006.12.010; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin YW, 2006, BLOOD, V107, P2540, DOI 10.1182/blood-2005-07-3013; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LU QA, 1995, MOL CELL BIOL, V15, P3786; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Malecki MJ, 2006, MOL CELL BIOL, V26, P4642, DOI 10.1128/MCB.01655-05; Malyukova A, 2007, CANCER RES, V67, P5611, DOI 10.1158/0008-5472.CAN-06-4381; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Mauvieux L, 2002, LEUKEMIA, V16, P2417, DOI 10.1038/sj.leu.2402709; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MCKEITHAN TW, 1986, P NATL ACAD SCI USA, V83, P6636, DOI 10.1073/pnas.83.17.6636; McLean TW, 1996, BLOOD, V88, P4252; MELLENTIN JD, 1990, GENE CHROMOSOME CANC, V2, P239, DOI 10.1002/gcc.2870020313; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Metzler M, 2006, ONCOGENE, V25, P3093, DOI 10.1038/sj.onc.1209636; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; Morrow M, 2007, ONCOGENE, V26, P4404, DOI 10.1038/sj.onc.1210227; Morrow M, 2004, BLOOD, V103, P3890, DOI 10.1182/blood-2003-10-3695; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; NEALE GAM, 1995, BLOOD, V86, P3060; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; O'Neil J, 2001, ONCOGENE, V20, P3897, DOI 10.1038/sj.onc.1204519; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Owens BM, 2006, BRIT J HAEMATOL, V132, P216, DOI 10.1111/j.1365-2141.2005.05850.x; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pearson R, 2000, EMBO J, V19, P6112, DOI 10.1093/emboj/19.22.6112; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; RAPPOLD GA, 1984, EMBO J, V3, P2951, DOI 10.1002/j.1460-2075.1984.tb02239.x; REEVES R, 1990, J BIOL CHEM, V265, P8573; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROBERTS CWM, 1995, AM J PATHOL, V146, P1089; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sabaawy HE, 2006, P NATL ACAD SCI USA, V103, P15166, DOI 10.1073/pnas.0603349103; SCHILLINGER M, 1993, MED MICROBIOL LETT, V2, P296; Sharma VM, 2006, MOL CELL BIOL, V26, P8022, DOI 10.1128/MCB.01091-06; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SHIMA EA, 1986, P NATL ACAD SCI USA, V83, P3439, DOI 10.1073/pnas.83.10.3439; Shirasawa S, 2000, NAT GENET, V24, P287, DOI 10.1038/73516; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Takeuchi S, 1997, LEUKEMIA, V11, P1220, DOI 10.1038/sj.leu.2400743; TAUB R, 1984, CELL, V37, P511, DOI 10.1016/0092-8674(84)90381-7; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Thompson CB, 1996, NATURE, V382, P492, DOI 10.1038/382492a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tsuzuki S, 2004, P NATL ACAD SCI USA, V101, P8443, DOI 10.1073/pnas.0402063101; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Van Vlierberghe P, 2006, BLOOD, V108, P3520, DOI 10.1182/blood-2006-04-019927; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WALDMANN TA, 1985, NEW ENGL J MED, V313, P776, DOI 10.1056/NEJM198509263131303; Wang JJ, 2000, P NATL ACAD SCI USA, V97, P3497, DOI 10.1073/pnas.97.7.3497; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson A, 2006, FEBS LETT, V580, P2860, DOI 10.1016/j.febslet.2006.03.024; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; Zeisig BB, 2003, ONCOGENE, V22, P1629, DOI 10.1038/sj.onc.1206104; Zhu YM, 2006, CLIN CANCER RES, V12, P3043, DOI 10.1158/1078-0432.CCR-05-2832; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	170	98	98	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6838	6849		10.1038/sj.onc.1210766	http://dx.doi.org/10.1038/sj.onc.1210766			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934490				2022-12-28	WOS:000250147000014
J	Pabst, T; Mueller, BU				Pabst, T.; Mueller, B. U.			Transcriptional dysregulation during myeloid transformation in AML	ONCOGENE			English	Review						CEBPA; RUNX1; PU.1; myeloid differentiation; AML	BINDING-PROTEIN-ALPHA; ACUTE-LYMPHOBLASTIC-LEUKEMIA; ACUTE-MYELOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FACTOR-C/EBP-ALPHA; CEBPA MUTATIONS; GRANULOCYTIC DIFFERENTIATION; POINT MUTATIONS; AML1/PEBP2-ALPHA-B GENE; PU.1 EXPRESSION	The current paradigm on leukemogenesis indicates that leukemias are propagated by leukemic stem cells. The genomic events and pathways involved in the transformation of hematopoietic precursors into leukemic stem cells are increasingly understood. This concept is based on genomic mutations or functional dysregulation of transcription factors in malignant cells of patients with acute myeloid leukemia ( AML). Loss of the CCAAT/ enhancer binding protein-alpha ( CEBPA) function in myeloid cells in vitro and in vivo leads to a differentiation block, similar to that observed in blasts from AML patients. CEBPA alterations in specific subgroups of AML comprise genomic mutations leading to dominant- negative mutant proteins, transcriptional suppression by leukemic fusion proteins, translational inhibition by activated RNA-binding proteins, and functional inhibition by phosphorylation or increased proteasomal- dependent degradation. The PU. 1 gene can be mutated or its expression or function can be blocked by leukemogenic fusion proteins in AML. Point mutations in the RUNX1/ AML1 gene are also observed in specific subtypes of AML, in addition to RUNX1 being the most frequent target for chromosomal translocation in AML. These data are persuasive evidence that impaired function of particular transcription factors contributes directly to the development of human AML, and restoring their function represents a promising target for novel therapeutic strategies in AML.	Univ Hosp Bern, Inst Med Oncol, CH-3010 Bern, Switzerland; Univ Hosp Bern, Dept Internal Med, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Pabst, T (corresponding author), Univ Hosp Bern, Inst Med Oncol, CH-3010 Bern, Switzerland.	thomas.pabst@insel.ch						Akasaka T, 2007, BLOOD, V109, P3451, DOI 10.1182/blood-2006-08-041012; Barjesteh van Waalwijk van Doorn-Khosrovani S, 2003, HEMATOL J, V4, P31; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Bienz M, 2005, CLIN CANCER RES, V11, P1416, DOI 10.1158/1078-0432.CCR-04-1552; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Chapiro E, 2006, BLOOD, V108, P3560, DOI 10.1182/blood-2006-03-010835; Chim CS, 2002, BRIT J HAEMATOL, V119, P988, DOI 10.1046/j.1365-2141.2002.03952.x; Cook WD, 2004, BLOOD, V104, P3437, DOI 10.1182/blood-2004-06-2234; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Ferrari-Amorotti G, 2006, BLOOD, V108, P1353, DOI 10.1182/blood-2006-01-011833; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Frohling S, 2005, GENE CHROMOSOME CANC, V42, P427, DOI 10.1002/gcc.20152; Frohling S, 2004, J CLIN ONCOL, V22, P624, DOI 10.1200/JCO.2004.06.060; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Harada H, 2003, BLOOD, V101, P673, DOI 10.1182/blood-2002-04-1010; Healy J, 2007, BLOOD, V109, P683, DOI 10.1182/blood-2006-02-003236; Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963; Helbling D, 2005, BLOOD, V106, P1369, DOI 10.1182/blood-2004-11-4392; Helbling D, 2004, P NATL ACAD SCI USA, V101, P13312, DOI 10.1073/pnas.0404731101; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Langabeer SE, 2002, GENE CHROMOSOME CANC, V34, P24, DOI 10.1002/gcc.10031; Lee YJ, 2006, BLOOD, V108, P2416, DOI 10.1182/blood-2006-02-003582; Lin LI, 2005, CLIN CANCER RES, V11, P1372, DOI 10.1158/1078-0432.CCR-04-1816; Liu HT, 2003, BLOOD, V101, P3885, DOI 10.1182/blood-2002-07-2212; Matsuno N, 2003, LEUKEMIA, V17, P2492, DOI 10.1038/sj.leu.2403160; McFie PJ, 2006, J BIOL CHEM, V281, P18069, DOI 10.1074/jbc.M512734200; Metcalf D, 2006, P NATL ACAD SCI USA, V103, P1486, DOI 10.1073/pnas.0510616103; Mizuki M, 2003, BLOOD, V101, P3164, DOI 10.1182/blood-2002-06-1677; Mueller BU, 2006, BRIT J CANCER, V94, P1918, DOI 10.1038/sj.bjc.6603198; Mueller BU, 2006, BLOOD, V107, P3330, DOI 10.1182/blood-2005-07-3068; Mueller BU, 2006, CURR OPIN HEMATOL, V13, P7, DOI 10.1097/01.moh.0000190110.08156.96; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Nagata C, 1999, Climacteric, V2, P6, DOI 10.3109/13697139909025557; Nanri T, 2006, BLOOD, V108, p543A, DOI 10.1182/blood.V108.11.1916.1916; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pabst T, 2006, BRIT J HAEMATOL, V133, P400, DOI 10.1111/j.1365-2141.2006.06057.x; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Parkin SE, 2002, J BIOL CHEM, V277, P23563, DOI 10.1074/jbc.M202184200; Pastinen T, 2004, SCIENCE, V306, P647, DOI 10.1126/science.1101659; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Porse BT, 2005, J EXP MED, V202, P85, DOI 10.1084/jem.20050067; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Preudhomme C, 2002, BLOOD, V100, P2717, DOI 10.1182/blood-2002-03-0990; Radomska HS, 2006, J EXP MED, V203, P371, DOI 10.1084/jem.20052242; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Roumier C, 2003, BLOOD, V101, P1277, DOI 10.1182/blood-2002-05-1474; Sellick G, 2005, LEUKEMIA, V19, P1276, DOI 10.1038/sj.leu.2403788; Shih LY, 2006, LEUKEMIA, V20, P604, DOI 10.1038/sj.leu.2404124; Silva FPG, 2003, ONCOGENE, V22, P538, DOI 10.1038/sj.onc.1206141; Skokowa J, 2006, NAT MED, V12, P1191, DOI 10.1038/nm1484; Smith ML, 2005, BRIT J HAEMATOL, V128, P318, DOI 10.1111/j.1365-2141.2004.05324.x; Smith ML, 2004, NEW ENGL J MED, V351, P2403, DOI 10.1056/NEJMoa041331; Snaddon J, 2003, GENE CHROMOSOME CANC, V37, P72, DOI 10.1002/gcc.10185; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Suraweera N, 2005, ONCOGENE, V24, P3678, DOI 10.1038/sj.onc.1208422; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wagner K, 2006, P NATL ACAD SCI USA, V103, P6338, DOI 10.1073/pnas.0508143103; Walter MJ, 2005, P NATL ACAD SCI USA, V102, P12513, DOI 10.1073/pnas.0504247102; Wang D, 2006, BLOOD, V108, P1223, DOI 10.1182/blood-2005-12-008763; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wouters BJ, 2007, BLOOD, V109, P389, DOI 10.1182/blood-2006-08-042325; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006; Zheng R, 2004, BLOOD, V103, P1883, DOI 10.1182/blood-2003-06-1978	78	85	90	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6829	6837		10.1038/sj.onc.1210765	http://dx.doi.org/10.1038/sj.onc.1210765			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934489				2022-12-28	WOS:000250147000013
J	Martin, M; Kettmann, R; Dequiedt, F				Martin, M.; Kettmann, R.; Dequiedt, F.			Class IIa histone deacetylases: regulating the regulators	ONCOGENE			English	Review						14-3-3; acetylation; chromatin; phosphatase; shuttling	MYOCYTE ENHANCER FACTOR-2; MEF2 TRANSCRIPTION FACTOR; CONTROLS CHONDROCYTE HYPERTROPHY; ORPHAN STEROID-RECEPTOR; NUCLEAR EXPORT; GENE-EXPRESSION; CRYSTAL-STRUCTURE; 14-3-3 PROTEINS; CO-REPRESSOR; CLASS-I	In the last decade, the identification of enzymes that regulate acetylation of histones and nonhistone proteins has revealed the key role of dynamic acetylation and deacetylation in various cellular processes. Mammalian histone deacetylases ( HDACs), which catalyse the removal of acetyl groups from lysine residues, are grouped into three classes, on the basis of similarity to yeast counterparts. An abundance of experimental evidence has established class IIa HDACs as crucial transcriptional regulators of various developmental and differentiation processes. In the past 5 years, a tremendous effort has been dedicated to characterizing the regulation of these enzymes. In this review, we summarize the latest discoveries in the field and discuss the molecular and structural determinants of class IIa HDACs regulation. Finally, we emphasize that comprehension of the mechanisms underlying class IIa HDAC functions is essential for potential therapeutic applications.	FUSAGx, Cellular & Mol Biol Unit, B-5030 Gembloux, Belgium	University of Liege	Dequiedt, F (corresponding author), FUSAGx, Cellular & Mol Biol Unit, B-5030 Gembloux, Belgium.	dequiedt.f@fsagx.ac.be		Dequiedt, Franck/0000-0003-1234-7477; Martin, Maud/0000-0003-0048-6437				Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004; Backs J, 2006, CIRC RES, V98, P15, DOI 10.1161/01.RES.0000197782.21444.8f; Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438; Bakin RE, 2004, J BIOL CHEM, V279, P51218, DOI 10.1074/jbc.M409271200; Basile V, 2006, J BIOL CHEM, V281, P2347, DOI 10.1074/jbc.M507712200; Berdeaux R, 2007, NAT MED, V13, P597, DOI 10.1038/nm1573; Berger I, 2003, J BIOL CHEM, V278, P17625, DOI 10.1074/jbc.M301646200; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bolger TA, 2005, J NEUROSCI, V25, P9544, DOI 10.1523/JNEUROSCI.1826-05.2005; Borghi S, 2001, J CELL SCI, V114, P4477; Bryant H, 2002, J VIROL, V76, P10290, DOI 10.1128/JVI.76.20.10290-10298.2002; Camins A, 2006, DRUG NEWS PERSPECT, V19, P453, DOI 10.1358/dnp.2006.19.8.1043961; Castet A, 2004, NUCLEIC ACIDS RES, V32, P1957, DOI 10.1093/nar/gkh524; Chakraborty S, 2006, J BIOL CHEM, V281, P35070, DOI 10.1074/jbc.M602474200; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040; Chang SR, 2005, P NATL ACAD SCI USA, V102, P8120, DOI 10.1073/pnas.0503275102; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chawla S, 2003, J NEUROCHEM, V85, P151, DOI 10.1046/j.1471-4159.2003.01648.x; Czubryt MP, 2004, RECENT PROG HORM RES, V59, P105, DOI 10.1210/rp.59.1.105; Dai YS, 2005, MOL CELL BIOL, V25, P9936, DOI 10.1128/MCB.25.22.9936-9948.2005; Davis FJ, 2003, J BIOL CHEM, V278, P20047, DOI 10.1074/jbc.M209998200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Deng XB, 2005, J BIOL CHEM, V280, P4894, DOI 10.1074/jbc.M411894200; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; Dequiedt F, 2006, MOL CELL BIOL, V26, P7086, DOI 10.1128/MCB.00231-06; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Ekwall K, 2005, TRENDS GENET, V21, P608, DOI 10.1016/j.tig.2005.08.009; Ellis JJ, 2003, MOL CELL BIOCHEM, V242, P153, DOI 10.1023/A:1021158216582; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fischler W, 2001, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2001/07/003; Franco PJ, 2003, MOL CELL ENDOCRINOL, V206, P1, DOI 10.1016/S0303-7207(03)00254-5; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gao CZ, 2006, FEBS LETT, V580, P5096, DOI 10.1016/j.febslet.2006.08.038; Ghisletti S, 2007, MOL CELL, V25, P57, DOI 10.1016/j.molcel.2006.11.022; Glaser KB, 2003, MOL CANCER THER, V2, P151; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Guo L, 2007, P NATL ACAD SCI USA, V104, P4297, DOI 10.1073/pnas.0608041104; Haberland M, 2007, MOL CELL BIOL, V27, P518, DOI 10.1128/MCB.01415-06; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Halkidou K, 2004, EUR UROL, V45, P382, DOI 10.1016/j.eururo.2003.10.005; Han AD, 2005, J MOL BIOL, V345, P91, DOI 10.1016/j.jmb.2004.10.033; Harrison BC, 2004, MOL CELL BIOL, V24, P10636, DOI 10.1128/MCB.24.24.10636-10649.2004; Harrison BC, 2006, MOL CELL BIOL, V26, P3875, DOI 10.1128/MCB.26.10.3875-3888.2006; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Heidenreich KA, 2004, MOL NEUROBIOL, V29, P155, DOI 10.1385/MN:29:2:155; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Huang EY, 2000, GENE DEV, V14, P45; Huynh KD, 2000, GENE DEV, V14, P1810; Huynh QK, 2006, ARCH BIOCHEM BIOPHYS, V450, P141, DOI 10.1016/j.abb.2006.02.014; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200; Jeong BC, 2004, MOL ENDOCRINOL, V18, P13, DOI 10.1210/me.2003-0065; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Kadoglou NP, 2004, CURR MED RES OPIN, V20, P419, DOI 10.1185/030079904125003143; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kao HY, 2000, GENE DEV, V14, P55; Karvonen U, 2006, EXP CELL RES, V312, P3165, DOI 10.1016/j.yexcr.2006.06.018; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kurtev V, 2004, J BIOL CHEM, V279, P24834, DOI 10.1074/jbc.M312300200; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Li XF, 2004, J BIOL CHEM, V279, P34201, DOI 10.1074/jbc.M405179200; Lin Q, 1998, DEVELOPMENT, V125, P4565; Linseman DA, 2003, J BIOL CHEM, V278, P41472, DOI 10.1074/jbc.M307245200; Liu F, 2004, J BIOL CHEM, V279, P34537, DOI 10.1074/jbc.M402475200; Liu YW, 2005, J CELL BIOL, V168, P887, DOI 10.1083/jcb.200408128; Lomonte P, 2004, J VIROL, V78, P6744, DOI 10.1128/JVI.78.13.6744-6757.2004; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Marmorstein R, 2004, BIOCHEM SOC T, V32, P904, DOI 10.1042/BST0320904; MARTIN M, IN PRESS PROTEIN PHO; Matthews SA, 2006, MOL CELL BIOL, V26, P1569, DOI 10.1128/MCB.26.4.1569-1577.2006; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2006, MOL BIOL CELL, V17, P438, DOI 10.1091/mbc.E05-07-0612; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; McKinsey TA, 2007, CARDIOVASC RES, V73, P667, DOI 10.1016/j.cardiores.2006.11.036; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakagawa Y, 2006, J MOL CELL CARDIOL, V41, P1010, DOI 10.1016/j.yjmcc.2006.08.010; Nielsen TK, 2005, J MOL BIOL, V354, P107, DOI 10.1016/j.jmb.2005.09.065; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; NUSINZON I, 2005, SCI STKE; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Pagan JK, 2007, J BIOL CHEM, V282, P15248, DOI 10.1074/jbc.M700246200; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Parra M, 2007, GENE DEV, V21, P638, DOI 10.1101/gad.1513107; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; Portal D, 2006, P NATL ACAD SCI USA, V103, P19278, DOI 10.1073/pnas.0609320103; Prima V, 2005, LEUKEMIA, V19, P806, DOI 10.1038/sj.leu.2403684; Puig-Kroger A, 2006, J CELL BIOCHEM, V98, P744, DOI 10.1002/jcb.20813; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Ranieri G., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P241, DOI 10.2174/1568008013341073; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sarvetnick N, 2003, CURR OPIN IMMUNOL, V15, P647, DOI 10.1016/j.coi.2003.09.019; Schneider A, 2004, J NEUROCHEM, V88, P1114, DOI 10.1046/j.1471-4159.2003.02228.x; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Shenoy G, 2003, STRUCT CHEM, V14, P3, DOI 10.1023/A:1021656723964; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Siggs OM, 2006, CURR OPIN IMMUNOL, V18, P175, DOI 10.1016/j.coi.2006.01.001; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Song K, 2006, CELL, V125, P453, DOI 10.1016/j.cell.2006.02.048; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Tong JJ, 2002, NUCLEIC ACIDS RES, V30, P1114, DOI 10.1093/nar/30.5.1114; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van der Linden AM, 2007, EMBO J, V26, P358, DOI 10.1038/sj.emboj.7601479; Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Verdin E, 2004, METHOD ENZYMOL, V377, P180; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Verma S, 2004, CAN J CARDIOL, V20, P1335; Visvikis-Siest S, 2006, CURR OPIN LIPIDOL, V17, P139, DOI 10.1097/01.mol.0000217895.67444.de; Wang AH, 2005, J BIOL CHEM, V280, P29117, DOI 10.1074/jbc.M500295200; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang H E, 2000, Prehosp Emerg Care, V4, P14, DOI 10.1080/10903120090941560; Wang JW, 2007, J NEUROSCI, V27, P574, DOI 10.1523/JNEUROSCI.5094-06.2007; Wang Qing, 2005, Curr Atheroscler Rep, V7, P235, DOI 10.1007/s11883-005-0012-6; Watabiki Y, 2003, J HIGH ENERGY PHYS; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Xing WB, 2006, CIRC RES, V98, P1089, DOI 10.1161/01.RES.0000218781.23144.3e; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x; Zhang AH, 2004, J BIOL CHEM, V279, P33799, DOI 10.1074/jbc.M403997200; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2001, P NATL ACAD SCI USA, V98, P7354, DOI 10.1073/pnas.131198498; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	182	183	188	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5450	5467		10.1038/sj.onc.1210613	http://dx.doi.org/10.1038/sj.onc.1210613			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694086				2022-12-28	WOS:000248674300013
J	Hara, T; Schwieger, M; Kazama, R; Okamoto, S; Minehata, K; Ziegler, M; Lohler, J; Stocking, C				Hara, T.; Schwieger, M.; Kazama, R.; Okamoto, S.; Minehata, K.; Ziegler, M.; Loehler, J.; Stocking, C.			Acceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells	ONCOGENE			English	Article						Meis1; Meis3; Icsbp; AML	SEQUENCE-BINDING-PROTEIN; HUMAN MYELOID LEUKEMIAS; TRANSCRIPTION FACTOR; HEMATOPOIETIC STEM; HOMEOBOX GENES; BXH-2 MICE; TRANSFORMATION; NUP98-HOXD13; COEXPRESSION; MUTATION	Identifying genetic pathways that cooperate in leukemo-genesis facilitates our understanding of the molecular mechanisms at play. Interferon consensus sequence-binding protein ( ICSBP) is a tumor suppressor, whose downregulation cooperates with BCR-ABL and NUP98-TOP1 gene products to accelerate leukemia induction in mouse models. Similarly, Meis1 synergizes with HoxA9 or NUP98-HOX ( but not NUP98-TOP1) fusion genes to promote the early onset of leukemia. To investigate whether Icsbp deficiency interacts with Meis1 or its family member Meis3, we transplanted Icsbp -/- bone marrow ( BM) cells after transduction with Meis1 or Meis3 retroviral vectors. Here, we show that enforced expression of Meis1 or Meis3 in Icsbp -/- BM cells induces a fatal, invasive myeloproliferative disease. Secondary mutations, such as activation of Mn1, led to the progression to acute myeloid leukemia in a few mice. Interestingly, expression of endogenous Meis1 and Meis3 mRNAs was repressed in the granulocytic progenitor population of Icsbp -/- mice. These results reveal a novel collaboration between Icsbp deficiency and Meis1/Meis3 in the acceleration of chronic myeloid leukemia-like disease.	[Hara, T.] Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Stem Cell Project Grp, Bunkyo Ku, Tokyo 1138613, Japan; [Schwieger, M.; Ziegler, M.; Loehler, J.; Stocking, C.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Mol Pathol Grp, D-2000 Hamburg, Germany	Tokyo Metropolitan Institute of Medical Science; Heinrich Pette Institute; University of Hamburg	Hara, T (corresponding author), Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Stem Cell Project Grp, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	thara@rinshoken.or.jp	Okamoto, Shiki/X-7274-2018	Okamoto, Shiki/0000-0002-2802-0527				Burchert A, 2004, BLOOD, V103, P3480, DOI 10.1182/blood-2003-08-2970; Diaz-Blanco E, 2007, LEUKEMIA, V21, P494, DOI 10.1038/sj.leu.2404549; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; Gurevich RM, 2006, EXP HEMATOL, V34, P1192, DOI 10.1016/j.exphem.2006.04.020; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; Pineault N, 2004, MOL CELL BIOL, V24, P1907, DOI 10.1128/MCB.24.5.1907-1917.2004; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Scheller M, 1999, BLOOD, V94, P3764, DOI 10.1182/blood.V94.11.3764.423k03_3764_3771; Schmidt M, 2004, BLOOD, V103, P4142, DOI 10.1182/blood-2003-01-0285; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Schmidt M, 2001, BLOOD, V97, P3648, DOI 10.1182/blood.V97.11.3648; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Serrano E, 2006, ACTA HAEMATOL-BASEL, V116, P77, DOI 10.1159/000093636; Slape C, 2007, CANCER RES, V67, P5148, DOI 10.1158/0008-5472.CAN-07-0075; Turcotte K, 2005, J EXP MED, V201, P881, DOI 10.1084/jem.20042170; Wang GG, 2006, MOL CELL BIOL, V26, P3902, DOI 10.1128/MCB.26.10.3902-3916.2006; Zhu CL, 2004, J BIOL CHEM, V279, P50874, DOI 10.1074/jbc.M405736200	25	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3865	3869		10.1038/sj.onc.1211043	http://dx.doi.org/10.1038/sj.onc.1211043			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18223676				2022-12-28	WOS:000256904700010
J	Humphries, MJ; Ohm, AM; Schaack, J; Adwan, TS; Reyland, ME				Humphries, M. J.; Ohm, A. M.; Schaack, J.; Adwan, T. S.; Reyland, M. E.			Tyrosine phosphorylation regulates nuclear translocation of PKC delta	ONCOGENE			English	Article						protein kinase C; tyrosine phosphorylation; apoptosis; nuclear localization; salivary gland	PROTEIN-KINASE-C; INDUCED APOPTOSIS; ACINAR-CELLS; ACTIVATION; CONSTRUCTION; SUPPRESSION; ETOPOSIDE; VECTORS	PKC delta is essential for apoptosis, but regulation of the proapoptotic function of this ubiquitous kinase is not well understood. Nuclear translocation of PKC delta is necessary and sufficient to induce apoptosis and is mediated via a C-terminal bipartite nuclear localization sequence. However, PKC delta is found predominantly in the cytoplasm of nonapoptotic cells, and the apoptotic signal that activates its nuclear translocation is not known. We show that in salivary epithelial cells, phosphorylation at specific tyrosine residues in the N-terminal regulatory domain directs PKC delta to the nucleus where it induces apoptosis. Analysis of each tyrosine residue in PKC delta by site-directed mutagenesis identified two residues, Y64 and Y155, as essential for nuclear translocation. Suppression of apoptosis correlated with suppressed nuclear localization of the Y -> F mutant proteins. Moreover, a phosphomimetic PKC delta Y64D/Y155D mutant accumulated in the nucleus in the absence of an apoptotic signal. Forced nuclear accumulation of PKC delta-Y64F and Y155F mutant proteins, by attachment of an SV40 nuclear localization sequence, fully reconstituted their ability to induce apoptosis, indicating that tyrosine phosphorylation per se is not required for apoptosis, but for targeting PKC delta to the nucleus. We propose that phosphorylation/dephosphorylation of PKC delta in the regulatory domain functions as a switch to promote cell survival or cell death.	[Humphries, M. J.; Ohm, A. M.; Schaack, J.; Adwan, T. S.; Reyland, M. E.] Hlth Sci Ctr, Aurora, CO 80045 USA; [Humphries, M. J.; Ohm, A. M.; Adwan, T. S.; Reyland, M. E.] Univ Colorado Denver, Sch Dent, Dept Craniofacial Biol, Program Cell & Dev Biol, Aurora, CO 80045 USA; [Schaack, J.] Univ Colorado Denver, Sch Med, Dept Microbiol, Aurora, CO USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Reyland, ME (corresponding author), Univ Colorado Denver, Sch Dent, Dept Craniofacial Biol, Program Cell & Dev Biol, 12801 E 17th Ave,Mail Stop 8120,POB 6511, Aurora, CO 80045 USA.	Mary.Reyland@uchsc.edu			NICHD NIH HHS [P01 HD038129, P0I HD038129] Funding Source: Medline; NIDCR NIH HHS [R01 DE015648, R01 DE015648-01, R01 DE015648-05, R01 DE015648-04] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD038129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015648] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Acs P, 2000, CARCINOGENESIS, V21, P887, DOI 10.1093/carcin/21.5.887; Anderson SM, 1999, CELL DEATH DIFFER, V6, P454, DOI 10.1038/sj.cdd.4400507; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Collazos A, 2006, MOL CELL BIOL, V26, P2247, DOI 10.1128/MCB.26.6.2247-2261.2006; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Limesand KH, 2003, CELL DEATH DIFFER, V10, P345, DOI 10.1038/sj.cdd.4401153; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Okhrimenko H, 2005, J BIOL CHEM, V280, P23643, DOI 10.1074/jbc.M501374200; Schaack J, 2001, VIROLOGY, V291, P101, DOI 10.1006/viro.2001.1211; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Tolcher AW, 2002, CLIN CANCER RES, V8, P2530; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zrachia A, 2002, J BIOL CHEM, V277, P23693, DOI 10.1074/jbc.M111658200	24	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3045	3053		10.1038/sj.onc.1210967	http://dx.doi.org/10.1038/sj.onc.1210967			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059334	Green Accepted			2022-12-28	WOS:000255681700011
J	Kaplan-Lefko, PJ; Sutherland, BW; Evangelou, AI; Hadsell, DL; Barrios, RJ; Foster, BA; DeMayo, F; Greenberg, NM				Kaplan-Lefko, P. J.; Sutherland, B. W.; Evangelou, A. I.; Hadsell, D. L.; Barrios, R. J.; Foster, B. A.; DeMayo, F.; Greenberg, N. M.			Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis	ONCOGENE			English	Article						IGF-1; prostate; transgenic; TRAMP; akt	FACTOR-I-RECEPTOR; TRANSGENIC MICE; BINDING PROTEIN-3; CANCER CELLS; STEM-CELLS; BREAST-CANCER; INSULIN; MOUSE; TUMORS; MODEL	The insulin-like growth factor-1 (IGF-1) signaling axis is important for cell growth, differentiation and survival and increased serum IGF is a risk factor for prostate and other cancers. To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells. This encodes a mature isoform of IGF-1 with decreased affinity for IGF binding proteins (IGFBP) due to a 3-amino acid deletion in the N terminus. Expression of IGF-1des was sufficient to cause hyperplastic lesions in all mice, however the well-differentiated lesions did not progress to adenocarcinoma within a year. Remarkably, crossing the PB-Des mice to an established model of prostate cancer delayed progression of organ-confined tumors and emergence of metastatic lesions in young mice. While dissemination of metastatic lesions was widespread in old bigenic mice we did not detect IGF-1des in poorly differentiated primary tumors or metastatic lesions. Expression of endogenous IGF-1 and levels of P-Akt and P-Erk were reduced independent of age. These data suggest that increased physiologic levels of IGF-1 facilitate the emergence of hyperplastic lesions while imposing a strong IGF-1-dependent differentiation block. Selection against IGF-1 action appears requisite for progression of localized disease and metastogenesis.	[Evangelou, A. I.; Greenberg, N. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Kaplan-Lefko, P. J.; Evangelou, A. I.; Hadsell, D. L.; DeMayo, F.; Greenberg, N. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Hadsell, D. L.] Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA; [Hadsell, D. L.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Barrios, R. J.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Foster, B. A.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; [Greenberg, N. M.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; [Greenberg, N. M.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Roswell Park Cancer Institute; Baylor College of Medicine; University of Washington; University of Washington Seattle	Greenberg, NM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.	ngreenberg@fhcrc.org	Hadsell, Darryl/GPF-9037-2022; DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	NCI NIH HHS [CA84296, CA82807, CA74589] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084296, R01CA082807, F32CA074589] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlen J, 2005, CLIN CANCER RES, V11, P206; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Chan JM, 2002, J NATL CANCER I, V94, P1099; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002-9440(10)65229-7; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1986, DOI 10.1210/jc.84.6.1986; Cunha G R, 1989, Cancer Treat Res, V46, P159; Damon SE, 2001, ENDOCRINOLOGY, V142, P21, DOI 10.1210/en.142.1.21; DiGiovanni J, 2000, CANCER RES, V60, P1561; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Evangelou AI, 2004, J CELL BIOCHEM, V91, P671, DOI 10.1002/jcb.10771; Forbes K, 2004, WORLD J UROL, V22, P67, DOI 10.1007/s00345-003-0395-3; Foulstone E, 2005, J PATHOL, V205, P145, DOI 10.1002/path.1712; Gingrich JR, 1996, CANCER RES, V56, P4096; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Hudson DL, 2004, PROSTATE CANCER P D, V7, P188, DOI 10.1038/sj.pcan.4500745; Huss WJ, 2005, CANCER RES, V65, P6640, DOI 10.1158/0008-5472.CAN-04-2548; Kaplan PJ, 1999, CANCER RES, V59, P2203; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Le Roith Derek, 2003, Exp Diabesity Res, V4, P205, DOI 10.1155/EDR.2003.205; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; MacGrogan D, 1997, SEMIN CANCER BIOL, V8, P11, DOI 10.1006/scbi.1997.0048; Majeed N, 2005, ONCOGENE, V24, P4736, DOI 10.1038/sj.onc.1208572; Mehrian-Shai R, 2007, P NATL ACAD SCI USA, V104, P5563, DOI 10.1073/pnas.0609139104; Nakamura M, 2004, CLIN CANCER RES, V10, P8434, DOI 10.1158/1078-0432.CCR-04-0430; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; Platz EA, 2005, CANCER CAUSE CONTROL, V16, P255, DOI 10.1007/s10552-004-3484-8; Plymate SR, 2004, PROSTATE, V61, P276, DOI 10.1002/pros.20099; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; Shaneyfelt T, 2000, J CLIN ONCOL, V18, P847, DOI 10.1200/JCO.2000.18.4.847; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Wu XC, 2003, CANCER RES, V63, P4936; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Yakar S, 2005, ENDOCR DEV, V9, P11, DOI 10.1159/000085718	47	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2008	27	20					2868	2876		10.1038/sj.onc.1210943	http://dx.doi.org/10.1038/sj.onc.1210943			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18026134				2022-12-28	WOS:000255502500008
J	Galie, M; Konstantinidou, G; Peroni, D; Scambi, I; Marchini, C; Lisi, V; Krampera, M; Magnani, P; Merigo, F; Montani, M; Boschi, F; Marzola, P; Orru, R; Farace, P; Sbarbati, A; Amici, A				Galie, M.; Konstantinidou, G.; Peroni, D.; Scambi, I.; Marchini, C.; Lisi, V.; Krampera, M.; Magnani, P.; Merigo, F.; Montani, M.; Boschi, F.; Marzola, P.; Orru, R.; Farace, P.; Sbarbati, A.; Amici, A.			Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice	ONCOGENE			English	Article						mammary carcinoma; reactive stromal cells; mesenchymal stem cells; angiogenesis; molecular signature; HER-2/neu	HUMAN ADIPOSE-TISSUE; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER CELLS; POSTNATAL NEOVASCULARIZATION; STROMAL FIBROBLASTS; ENDOTHELIAL-CELLS; BONE-MARROW; IN-VITRO; ANGIOGENESIS; IDENTIFICATION	Tumor microenvironment in carcinomas recruits mesenchymal cells with an abnormal proangiogenic and invasive phenotype. It is not clear whether mesenchymal tumor cells (MTCs) derive from the activation of mature fibroblasts or from their stem cell precursors. However, stromal cell activation in tumors resembles in several aspects the mesenchymal rearrangement which normally occurs during reparative processes such as wound healing. Mesenchymal stem cells (MSCs) play a crucial role in developmental and reparative processes and have extraordinary proangiogenic potential, on the basis of which they are thought to show great promise for the treatment of ischemic disorders. Here, we show that MTCs have proangiogenic potential and that they share the transcriptional expression of the best-known proangiogenic factors with MSCs. We also found that MTCs and MSCs have the same molecular signature for stemness-related genes, and that when co-implanted with cancer cells in syngeneic animals MSCs determine early tumor appearance, probably by favoring the angiogenic switch. Our data (1) reveal crucial aspects of the proangiogenic phenotype of MTCs, (2) strongly suggest their stem origin and (3) signal the risk of therapeutic use of MSCs in tumor-promoting conditions.	[Galie, M.; Peroni, D.; Scambi, I.; Magnani, P.; Merigo, F.; Boschi, F.; Marzola, P.; Farace, P.; Sbarbati, A.] Univ Verona, Dept Morphol & Biomed Sci, Anat & Histol Sect, I-37134 Verona, Italy; [Konstantinidou, G.; Marchini, C.; Montani, M.; Orru, R.; Amici, A.] Univ Camerino, Genet Immunizat Lab, Dept Mol Cellular & Anim Biol, Camerino, Macerata, Italy; [Lisi, V.; Krampera, M.] Univ Verona, Dept Clin & Expt Med, Haematol Sect, I-37134 Verona, Italy	University of Verona; University of Camerino; University of Verona	Galie, M (corresponding author), Univ Verona, Dept Morphol & Biomed Sci, Anat & Histol Sect, Via Grazie 8, I-37134 Verona, Italy.	mirco@anatomy.univr.it	Konstantinidou, Georgia/O-9192-2016; Farace, Paolo/AAK-4072-2020; KRAMPERA, MAURO/K-5596-2018	Konstantinidou, Georgia/0000-0001-9513-0286; Farace, Paolo/0000-0002-6051-2345; GALIE', Mirco/0000-0002-6441-8313; Peroni, Daniele/0000-0002-0862-266X; Amici, Augusto/0000-0002-4634-1500; KRAMPERA, Mauro/0000-0002-7280-2040; Marchini, Cristina/0000-0001-7692-8428; MARZOLA, Pasquina/0000-0001-6936-8901				Al Sayed AD, 2006, ACTA ONCOL, V45, P188, DOI 10.1080/02841860500513235; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Burns JS, 2005, CANCER RES, V65, P3126, DOI 10.1158/0008-5472.CAN-04-2218; Cao Y, 2005, BIOCHEM BIOPH RES CO, V332, P370, DOI 10.1016/j.bbrc.2005.04.135; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Dingli D, 2006, STEM CELLS, V24, P2603, DOI 10.1634/stemcells.2006-0136; Direkze NC, 2004, CANCER RES, V64, P8492, DOI 10.1158/0008-5472.CAN-04-1708; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Galie M, 2005, CARCINOGENESIS, V26, P1868, DOI 10.1093/carcin/bgi158; Galie M, 2005, NEOPLASIA, V7, P528, DOI 10.1593/neo.04730; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hayward SW, 2001, CANCER RES, V61, P8135; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Hung SC, 2005, CLIN CANCER RES, V11, P7749, DOI 10.1158/1078-0432.CCR-05-0876; Keith WN, 2004, ONCOGENE, V23, P5092, DOI 10.1038/sj.onc.1207762; Knutson KL, 2006, J IMMUNOL, V177, P1526, DOI 10.4049/jimmunol.177.3.1526; Krampera M, 2007, BONE, V40, P382, DOI 10.1016/j.bone.2006.09.006; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; McAlhany SJ, 2003, CANCER RES, V63, P5859; Miranville A, 2004, CIRCULATION, V110, P349, DOI 10.1161/01.CIR.0000135466.16823.D0; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Petersen OW, 2001, BREAST CANCER RES, V3, P213; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rigotti G, 2007, PLAST RECONSTR SURG, V119, P1409, DOI 10.1097/01.prs.0000256047.47909.71; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wolf D, 2005, JNCI-J NATL CANCER I, V97, P540, DOI 10.1093/jnci/dji088; Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008-5472.CAN-05-1702; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	46	95	103	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2542	2551		10.1038/sj.onc.1210920	http://dx.doi.org/10.1038/sj.onc.1210920			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17998939				2022-12-28	WOS:000255057000004
J	Garzia, L; D'Angelo, A; Amoresano, A; Knauer, SK; Cirulli, C; Campanella, C; Stauber, RH; Steegborn, C; Iolascon, A; Zollo, M				Garzia, L.; D'Angelo, A.; Amoresano, A.; Knauer, S. K.; Cirulli, C.; Campanella, C.; Stauber, R. H.; Steegborn, C.; Iolascon, A.; Zollo, M.			Phosphorylation of nm23-H1 by CKI induces its complex formation with h-prune and promotes cell motility	ONCOGENE			English	Article						h-prune; nm23; CKI; motility; IC261	NUCLEOSIDE DIPHOSPHATE KINASE; CASEIN KINASE-1; INHIBITORY-ACTIVITY; GLYCOGEN-SYNTHASE; GENE-EXPRESSION; BREAST-CANCER; BETA-CATENIN; PROTEIN; OVEREXPRESSION; BINDING	The combination of an increase in the cAMP-phosphodiesterase activity of h-prune and its interaction with nm23-H1 have been shown to be key steps in the induction of cellular motility in breast cancer cells. Here we present the molecular mechanisms of this interaction. The region of the nm23-h-prune interaction lies between S120 and S125 of nm23, where missense mutants show impaired binding; this region has been highly conserved throughout evolution, and can undergo serine phosphorylation by casein kinase I. Thus, the casein kinase I delta-epsilon specific inhibitor IC261 impairs the formation of the nm23-h-prune complex, which translates 'in vitro' into inhibition of cellular motility in a breast cancer cellular model. A competitive permeable peptide containing the region for phosphorylation by casein kinase I impairs cellular motility to the same extent as IC261. The identification of these two modes of inhibition of formation of the nm23-H1-h-prune protein complex pave the way toward new challenges, including translational studies using IC261 or this competitive peptide 'in vivo' to inhibit cellular motility induced by nm23-H1-h-prune complex formation during progression of breast cancer.	[Garzia, L.; D'Angelo, A.; Iolascon, A.; Zollo, M.] CEINGE, Ctr Ingn Genet & Biotecnol Avsnzate, I-80131 Naples, Italy; [Amoresano, A.; Cirulli, C.] Univ Naples Federico II, Complesso Univ Monte S Angelo, Dipartimento Chim Organ & Biochim, Naples, Italy; [Knauer, S. K.; Stauber, R. H.] Georg Speyer Haus, Frankfurt, Germany; [Campanella, C.] Univ Naples Federico II, Dipartimento Biol Struct & Funz, Naples, Italy; [Stauber, R. H.] Univ Hosp Mainz, Lab Mol Tumour Biol, Dept Otolaryngol, Mainz, Germany; [Steegborn, C.] Ruhr Univ Bochum, Dept Phys Chem, Bochum, Germany; [Zollo, M.] Univ Naples Federico II, Fac Sci Biotechnol, Dipartimento Biochim & Biotecnol Med, Naples, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Naples Federico II; University Hospital Mainz; Ruhr University Bochum; University of Naples Federico II	Zollo, M (corresponding author), CEINGE, Ctr Ingn Genet & Biotecnol Avsnzate, Via Comunale Margherita 482, I-80131 Naples, Italy.	zollo@ceinge.unina.it	Knauer, Shirley K/E-7931-2012; Iolascon, Achille/A-4461-2014	Knauer, Shirley K/0000-0003-4321-0924; AMORESANO, Angela/0000-0002-8386-655X; Stauber, Roland/0000-0002-1341-4523	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Biondi RM, 1996, FEBS LETT, V399, P183, DOI 10.1016/S0014-5793(96)01299-9; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; Crawford RM, 2005, BIOCHEM J, V392, P201, DOI 10.1042/BJ20050269; Crawford RM, 2006, MOL CELL BIOL, V26, P5921, DOI 10.1128/MCB.00315-06; D'Angelo A, 2004, CELL CYCLE, V3, P758; D'Angelo A, 2004, CANCER CELL, V5, P137, DOI 10.1016/S1535-6108(04)00021-2; ENGEL M, 1994, BIOCHEM BIOPH RES CO, V199, P1041, DOI 10.1006/bbrc.1994.1334; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; Forus A, 2001, ONCOGENE, V20, P6881, DOI 10.1038/sj.onc.1204874; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; GARZIA L, 2003, BIOTECHNIQUES, V384, P390; Garzia L, 2006, J BIOENERG BIOMEMBR, V38, P205, DOI 10.1007/s10863-006-9036-z; Heo YJ, 1997, J CHROMATOGR A, V781, P251; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Izeradjene K, 2004, CANCER RES, V64, P8036, DOI 10.1158/0008-5472.CAN-04-0762; KANTOR JD, 1993, CANCER RES, V53, P1971; Kim MS, 2002, BIOCHEM BIOPH RES CO, V291, P663, DOI 10.1006/bbrc.2002.6503; Kim YI, 2003, BIOCHEM BIOPH RES CO, V307, P281, DOI 10.1016/S0006-291X(03)01195-1; Knauer SK, 2005, ANAL CHEM, V77, P4815, DOI 10.1021/ac050413o; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Kobayashi T, 2006, MOL CELL BIOL, V26, P898, DOI 10.1128/MCB.26.3.898-911.2006; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P213; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; Li GB, 2004, J BIOL CHEM, V279, P15938, DOI 10.1074/jbc.M314116200; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MARIN O, 1994, EUR J BIOCHEM, V223, P647, DOI 10.1111/j.1432-1033.1994.tb19037.x; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; Middelhaufe S, 2007, BIOCHEM J, V407, P199, DOI 10.1042/BJ20070408; Mocan I, 2007, BIOCHEM J, V403, P149, DOI 10.1042/BJ20061141; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Pagano MA, 2004, BIOCHEM BIOPH RES CO, V321, P1040, DOI 10.1016/j.bbrc.2004.07.067; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Reymond A, 1999, ONCOGENE, V18, P7244, DOI 10.1038/sj.onc.1203140; Steeg PS, 2005, AM J PATHOL, V166, P1291, DOI 10.1016/S0002-9440(10)62348-6; STEEG PS, 1988, CANCER RES, V48, P6550; Tseng YH, 2001, CANCER RES, V61, P2071; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; Zhang BL, 2004, MOL CELL BIOL, V24, P6205, DOI 10.1128/MCB.24.14.6205-6214.2004; Zollo M, 2005, CLIN CANCER RES, V11, P199	47	39	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1853	1864		10.1038/sj.onc.1210822	http://dx.doi.org/10.1038/sj.onc.1210822			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906697				2022-12-28	WOS:000254150600005
J	Safina, A; Ren, MQ; Vandette, E; Bakin, AV				Safina, A.; Ren, M-Q; Vandette, E.; Bakin, A. V.			TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis	ONCOGENE			English	Article						angiogenesis; invasion; metastasis; MMP-9; TAK1; TGF-beta	GROWTH-FACTOR-BETA; NF-KAPPA-B; BREAST-CANCER CELLS; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR SMAD4; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; MESENCHYMAL TRANSITION; TRANSIENT ACTIVATION; SIGNAL-TRANSDUCTION	Transforming growth factor-beta 1 (TGF-beta 1) signaling in tumor cells has been implicated in tumor angiogenesis and metastasis by regulating matrix proteolysis. Although MMP-9/gelatinase-B is an important component of these TGF-b1 responses, the mechanism of its regulation is not well understood. Here, we present evidence that TGF-beta-activated protein kinase 1 (TAK1) is critical for TGF-beta regulation of MMP-9 and the metastatic potential of breast cancer cell line MDA-MB-231. We found that suppression of TAK1 signaling by dominant-negative (dn) TAK1 or RNA interference (siRNA) reduces expression of MMP-9 and tumor cell invasion, without growth inhibition in cell culture. The orthotopic xenograft studies in SCID mice showed that suppression of TAK1 signaling by Dn-TAK1 reduces tumor growth and formation of lung metastases. QJ; Dn-TAK1 reduced the proliferation Ki-67 index and neovasculature of orthotopic xenografts. TAK1-mediated regulation of MMP-9 involves NF-kappa B signaling. Dn-TAK1 reduces NF-kappa B transcriptional response and inhibition of NF-kappa B reduces expression of MMP-9 and activity of the MMP-9 promoter reporter. Together, these findings suggest that TAK1 contributes to TGF-beta 1-mediated tumor angiogenesis and metastasis via a mechanism involving the TAK1-NF-kappa B-MMP-9 pathway.	[Safina, A.; Ren, M-Q; Vandette, E.; Bakin, A. V.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Bakin, AV (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	andrei.bakin@roswellpark.org		Bakin, Andrei/0000-0002-7728-1969	NCI NIH HHS [R01 CA095263, CA 16056, R01 CA95263, P30 CA016056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA095263] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Azuma M, 1999, EXP CELL RES, V250, P213, DOI 10.1006/excr.1999.4503; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bakin AV, 2002, J CELL SCI, V115, P3193; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bitzer M, 2000, GENE DEV, V14, P187; Chantrain CF, 2004, CANCER RES, V64, P1675, DOI 10.1158/0008-5472.CAN-03-0160; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Dunker N, 2000, EUR J BIOCHEM, V267, P6982, DOI 10.1046/j.1432-1327.2000.01825.x; Farina AR, 1998, INT J CANCER, V75, P721; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang FY, 2000, INT J ENG SCI, V38, P275, DOI 10.1016/S0020-7225(99)00041-5; Iyer V, 2005, J CELL SCI, V118, P1185, DOI 10.1242/jcs.01708; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Johansson N, 2000, J CELL SCI, V113, P227; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ogata H, 2001, CANCER LETT, V172, P159, DOI 10.1016/S0304-3835(01)00648-6; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Safina A, 2007, ONCOGENE, V26, P2407, DOI 10.1038/sj.onc.1210046; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; SATO H, 1993, ONCOGENE, V8, P395; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; Tobe M, 2003, BIOORGAN MED CHEM, V11, P3869, DOI 10.1016/S0968-0896(03)00438-3; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Wang WS, 2005, J AM SOC NEPHROL, V16, P1371, DOI 10.1681/ASN.2004121070; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	50	72	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1198	1207		10.1038/sj.onc.1210768	http://dx.doi.org/10.1038/sj.onc.1210768			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17828308				2022-12-28	WOS:000253407000002
J	Michaloglou, C; Vredeveld, LCW; Mooi, WJ; Peeper, DS				Michaloglou, C.; Vredeveld, L. C. W.; Mooi, W. J.; Peeper, D. S.			BRAF(E600) in benign and malignant human tumours	ONCOGENE			English	Review						BRAF/B-RAF; melanoma; naevus/nevus; thyroid; senescence; cancer	ONCOGENE-INDUCED SENESCENCE; PAPILLARY THYROID-CARCINOMA; GENE-EXPRESSION PROFILES; FACIO-CUTANEOUS SYNDROME; HUMAN-MELANOMA CELLS; N-RAS MUTATIONS; V600E B-RAF; CONGENITAL MELANOCYTIC NEVI; KINASE SIGNALING PATHWAY; VERTICAL GROWTH-PHASE	Of the RAF family of protein kinases, BRAF is the only member to be frequently activated by mutation in cancer. A single amino acid substitution (V600E) accounts for the vast majority and results in constitutive activation of BRAF kinase function. Its expression is required to maintain the proliferative and oncogenic characteristics of BRAF(E600)-expressing human tumour cells. Although BRAF(E600) acts as an oncogene in the context of additional genetic lesions, in primary cells it appears to be associated rather with transient stimulation of proliferation. Eventually, BRAF(E600) signalling triggers cell cycle arrest with the hallmarks of cellular senescence, as is illustrated by several recent studies in cultured cells, animal models and benign human lesions. In this review, we will discuss recent advances in our understanding of the role of BRAF(E600) in benign and malignant human tumours and the implications for therapeutic intervention.	[Michaloglou, C.; Vredeveld, L. C. W.; Peeper, D. S.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; [Mooi, W. J.] Vrije Univ Amsterdam, Dept Pathol, Med Ctr, Amsterdam, Netherlands	Netherlands Cancer Institute; Vrije Universiteit Amsterdam	Peeper, DS (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	d.peeper@nki.nl	Peeper, Daniel/AAA-2430-2020					Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Baloch ZW, 2006, ADV ANAT PATHOL, V13, P69, DOI 10.1097/01.pap.0000213006.10362.17; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bauer J, 2007, J INVEST DERMATOL, V127, P179, DOI 10.1038/sj.jid.5700490; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004; Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446; Bennett DC, 2002, PIGM CELL RES, V15, P242, DOI 10.1034/j.1600-0749.2002.02036.x; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Brummer T, 2006, ONCOGENE, V25, P6262, DOI 10.1038/sj.onc.1209640; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Casula M, 2004, J CLIN ONCOL, V22, P286, DOI 10.1200/JCO.2004.07.112; Chan TL, 2003, CANCER RES, V63, P4878; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Christensen C, 2005, ONCOGENE, V24, P6292, DOI 10.1038/sj.onc.1208758; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Ciampi R, 2005, ENDOCR PATHOL, V16, P163, DOI 10.1385/EP:16:3:163; Ciampi R, 2005, ENDOCR PATHOL, V16, P99, DOI 10.1385/EP:16:2:099; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Cohen Y, 2004, CLIN CANCER RES, V10, P3444, DOI 10.1158/1078-0432.CCR-03-0562; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Collisson EA, 2003, CANCER RES, V63, P5669; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Raeve LE, 2006, BRIT J DERMATOL, V154, P485, DOI 10.1111/j.1365-2133.2005.07055.x; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Errico ME, 2003, ANTICANCER RES, V23, P2701; Eskandarpour M, 2005, INT J CANCER, V115, P65, DOI 10.1002/ijc.20873; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Feldser DM, 2007, CANCER CELL, V11, P461, DOI 10.1016/j.ccr.2007.02.026; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Goding CR, 2000, GENE DEV, V14, P1712; Goldstein NS, 2006, AM J CLIN PATHOL, V125, P146, DOI 10.1309/87BD0C6UCGUG126J; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; Goodall J, 2004, MOL CELL BIOL, V24, P2923, DOI 10.1128/MCB.24.7.2923-2931.2004; Gorden A, 2003, CANCER RES, V63, P3955; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gray-Schopfer VC, 2005, CANCER METAST REV, V24, P165, DOI 10.1007/s10555-005-5865-1; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Guldberg P, 1997, CANCER RES, V57, P3660; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446; Hingorani SR, 2003, CANCER RES, V63, P5198; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Hoeflich MP, 2006, CANCER RES, V66, P999, DOI 10.1158/0008-5472.CAN-05-2720; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Hussein MR, 2003, EUR J CANCER PREV, V12, P93, DOI 10.1097/00008469-200304000-00002; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Ichii-Nakato N, 2006, J INVEST DERMATOL, V126, P2111, DOI 10.1038/sj.jid.5700366; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Jackson S, 2005, CANCER EPIDEM BIOMAR, V14, P913, DOI 10.1158/1055-9965.EPI-04-0568; James MR, 2005, J INVEST DERMATOL, V125, P1252, DOI 10.1111/j.0022-202X.2005.23937.x; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kimura ET, 2003, CANCER RES, V63, P1454; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kramer BW, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-24; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Kumar R, 2003, CLIN CANCER RES, V9, P3362; KUWATA T, 1993, VIRCHOWS ARCH A, V423, P359, DOI 10.1007/BF01607148; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Landi MT, 2006, SCIENCE, V313, P521, DOI 10.1126/science.1127515; Lang J, 2003, HUM MUTAT, V21, P327, DOI 10.1002/humu.10188; LASSAM NJ, 1993, CANCER RES, V53, P2235; Laud K, 2003, CANCER RES, V63, P3061; Lee JW, 2005, APMIS, V113, P54, DOI 10.1111/j.1600-0463.2005.apm1130108.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Lima J, 2004, J CLIN ENDOCR METAB, V89, P4267, DOI 10.1210/jc.2003-032224; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MCGREGOR JM, 1993, BRIT J DERMATOL, V128, P606, DOI 10.1111/j.1365-2133.1993.tb00253.x; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; McPhillips F, 2006, CARCINOGENESIS, V27, P729, DOI 10.1093/carcin/bgi289; Meier F, 2007, BRIT J DERMATOL, V156, P1204, DOI 10.1111/j.1365-2133.2007.07821.x; Meier F, 2005, FRONT BIOSCI-LANDMRK, V10, P2986, DOI 10.2741/1755; Mercer K, 2005, CANCER RES, V65, P11493, DOI 10.1158/0008-5472.CAN-05-2211; Mesa C, 2006, CANCER RES, V66, P6521, DOI 10.1158/0008-5472.CAN-06-0739; Meyer P, 2003, INT J CANCER, V106, P78, DOI 10.1002/ijc.11199; Meyer Peter, 2003, J Carcinog, V2, P7, DOI 10.1186/1477-3163-2-7; Meyskens FL, 2001, PIGM CELL RES, V14, P148, DOI 10.1034/j.1600-0749.2001.140303.x; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Minoo P, 2006, J PATHOL, V210, P137, DOI 10.1002/path.2047; Miracco C, 2002, BRIT J DERMATOL, V146, P399, DOI 10.1046/j.1365-2133.2002.04600.x; Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; Miyamura Y, 2007, PIGM CELL RES, V20, P2, DOI 10.1111/j.1600-0749.2006.00358.x; Molhoek KR, 2005, J TRANSL MED, V3, P1, DOI 10.1186/1479-5876-3-39; MOOI WJ, 2006, NEW ENGL J MED, V355, P55; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Papp T, 2005, MELANOMA RES, V15, P401, DOI 10.1097/00008390-200510000-00008; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, LUNG CANCER, V4, P162; Rauen KA, 2006, AM J MED GENET A, V140A, P1681, DOI 10.1002/ajmg.a.31315; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Rotolo S, 2005, INT J CANCER, V115, P164, DOI 10.1002/ijc.20865; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Salvatore G, 2006, CLIN CANCER RES, V12, P1623, DOI 10.1158/1078-0432.CCR-05-2378; Schreck R, 2006, INT J CANCER, V119, P2261, DOI 10.1002/ijc.22144; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2003, ONCOGENE, V22, P5055, DOI 10.1038/sj.onc.1206809; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Straume O, 2002, AM J PATHOL, V161, P229, DOI 10.1016/S0002-9440(10)64174-0; Straume O, 2000, CLIN CANCER RES, V6, P1845; Sturm RA, 2002, MELANOMA RES, V12, P405, DOI 10.1097/00008390-200209000-00001; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sviderskaya EV, 2003, J NATL CANCER I, V95, P723, DOI 10.1093/jnci/95.10.723; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; Takata M, 2005, J INVEST DERMATOL, V125, P318, DOI 10.1111/j.0022-202X.2005.23812.x; Talve L, 1997, INT J CANCER, V74, P255, DOI 10.1002/(SICI)1097-0215(19970620)74:3<255::AID-IJC4>3.0.CO;2-Y; Thomas NE, 2006, J INVEST DERMATOL, V126, P1693, DOI 10.1038/sj.jid.5700458; Trotter MJ, 1997, J CUTAN PATHOL, V24, P265, DOI 10.1111/j.1600-0560.1997.tb00790.x; Trovisco V, 2006, HUM PATHOL, V37, P781, DOI 10.1016/j.humpath.2006.03.013; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; Uribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011; Van den Berg H, 1999, J MED GENET, V36, P799, DOI 10.1136/jmg.36.10.799; Vance KW, 2004, PIGM CELL RES, V17, P318, DOI 10.1111/j.1600-0749.2004.00164.x; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang YL, 1996, BRIT J DERMATOL, V134, P269; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Willmore-Payne C, 2006, HUM PATHOL, V37, P520, DOI 10.1016/j.humpath.2006.01.003; Willmore-Payne C, 2005, HUM PATHOL, V36, P486, DOI 10.1016/j.humpath.2005.03.015; WILSON RE, 1989, CANCER RES, V49, P711; Wong TH, 2005, PEPTIDES, V26, P1965, DOI 10.1016/j.peptides.2004.11.021; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Yang S, 2004, AM J SURG PATHOL, V28, P1452, DOI 10.1097/01.pas.0000141404.56839.6a; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Yeh AH, 2006, ONCOGENE, V25, P6574, DOI 10.1038/sj.onc.1209674; Zebisch A, 2006, CANCER RES, V66, P3401, DOI 10.1158/0008-5472.CAN-05-0115; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zuo H, 2007, PATHOL INT, V57, P12, DOI 10.1111/j.1440-1827.2007.02050.x; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	209	196	201	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					877	895		10.1038/sj.onc.1210704	http://dx.doi.org/10.1038/sj.onc.1210704			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17724477				2022-12-28	WOS:000252946300001
J	Rainey, MD; Black, EJ; Zachos, G; Gillespie, DAF				Rainey, M. D.; Black, E. J.; Zachos, G.; Gillespie, D. A. F.			Chk2 is required for optimal mitotic delay in response to irradiation-induced DNA damage incurred in G(2) phase	ONCOGENE			English	Article						Chk1; Chk2; DNA damage; G(2)/M checkpoint; mitosis; genome stability	IONIZING-RADIATION; TUMOR-SUPPRESSOR; CHECKPOINT KINASE; CELLS; ACTIVATION; ATM; CANCER; PHOSPHORYLATION; TUMORIGENESIS; INHIBITION	Whether Chk2 contributes to DNA damage- induced arrest in G(2) has been controversial. To investigate this issue further, we generated Chk2-deficient DT40 B-lymphoma cells by gene targeting and compared their cell cycle response to ionizing radiation (IR) with wildtype (WT) and isogenic Chk1-deficient counterparts. After moderate doses of IR (4 Gy), we find that Chk2(-/-) cells which are in G(1) or S phase at the time of irradiation arrest efficiently in G(2). In contrast, Chk2-/- cells which are in G(2) when DNA damage is incurred exhibit an impaired mitotic delay compared to WT, with the result that cells enter mitosis with damaged DNA as judged by the presence of numerous gamma-H2AX foci on condensed chromosomes. Impaired G(2) delay as the result of Chk2 deficiency can be detected at very low doses of radiation (0.1 Gy), and may allow division with spontaneous DNA damage, since a higher proportion of mitotic Chk2-/- cells bear spontaneous gamma-H2AX foci and damaged chromosomes during unperturbed growth compared to WT. The contribution of Chk2 to G(2)/M delay is epistatic to that of Chk1, since Chk1-/- cells exhibit no measurable mitotic delay at any radiation dose tested. We suggest that this function of Chk2 could contribute to tumour suppression, since cell division with low levels of spontaneous damage is likely to promote genetic instability and thus carcinogenesis.	[Gillespie, D. A. F.] Univ Glasgow, Fac Biomed & Life Sci, Glasgow G61 1BD, Lanark, Scotland; [Rainey, M. D.; Black, E. J.; Zachos, G.; Gillespie, D. A. F.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Glasgow; Beatson Institute	Gillespie, DAF (corresponding author), Univ Glasgow, Fac Biomed & Life Sci, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; Rainey, Michael/0000-0001-9777-873X				Ahn JY, 2000, CANCER RES, V60, P5934; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Lukas C, 2001, CANCER RES, V61, P4990; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiromizu T, 2006, GENES CELLS, V11, P477, DOI 10.1111/j.1365-2443.2006.00955.x; Skoufias DA, 2004, MOL CELL, V15, P977, DOI 10.1016/j.molcel.2004.08.018; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	28	37	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					896	906		10.1038/sj.onc.1210702	http://dx.doi.org/10.1038/sj.onc.1210702			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17684483				2022-12-28	WOS:000252946300002
J	Richard, S; Vogel, G; Huot, ME; Guo, T; Muller, WJ; Lukong, KE				Richard, S.; Vogel, G.; Huot, M-E; Guo, T.; Muller, W. J.; Lukong, K. E.			Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis	ONCOGENE			English	Article						Sam68; RNA binding; mammary tumorigenesis; Src; metastasis; signaling	MESENCHYMAL TRANSITION; TYROSINE KINASE; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; BREAST-CANCER; CELL-LINES; C-CBL; SRC; PROTEIN; GROWTH	The Src-associated substrate in mitosis Sam68 is a KH type RNA-binding protein known to be a substrate of numerous tyrosine kinases, and often referred to as a STAR ( signal transduction activator of RNA) protein. Herein, we observed that Sam68-null mice display mammary gland and the uterine development defects. Moreover, we report that Sam68 haploinsufficiency impedes mammary tumor onset in vivo driven by the potent mammary-targeted polyoma middle T-antigen (MMTV-PyMT) oncogene. The effect was cell autonomous as the Sam68 knockdown in PyMT-transformed cell lines also delayed tumorigenesis and metastasis formation in nude mice. Interestingly, tumor extracts isolated from PyMT/Sam68(+/-) mice compared with PyMT/Sam68(+/+) mice contained activated Src and FAK kinases. These findings suggest that Sam68 may be a modulator of tyrosine kinase activity in vivo and a signaling requirement for mammary tumorigenesis and metastasis.	[Richard, S.; Vogel, G.; Huot, M-E; Guo, T.; Lukong, K. E.] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; [Richard, S.; Vogel, G.; Huot, M-E; Guo, T.; Lukong, K. E.] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; [Richard, S.; Vogel, G.; Huot, M-E; Guo, T.; Muller, W. J.; Lukong, K. E.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Richard, S.; Vogel, G.; Huot, M-E; Guo, T.; Lukong, K. E.] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Muller, W. J.] McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ, Canada; [Muller, W. J.] McGill Univ, Dept Biochem, Montreal, PQ, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University	Richard, S (corresponding author), Lady Davis Inst Med Res, Segal Canc Ctr, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	stephane.richard@mcgill.ca						Andrechek ER, 2000, BREAST CANCER RES, V2, P211, DOI 10.1186/bcr56; Babic I, 2004, ONCOGENE, V23, P3781, DOI 10.1038/sj.onc.1207484; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; BUSA R, 2007, ONCOGENE; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Cohen LA, 2005, CURR CANCER DRUG TAR, V5, P629, DOI 10.2174/156800905774932798; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Fendrick JL, 1998, J MAMMARY GLAND BIOL, V3, P7, DOI 10.1023/A:1018766000275; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; Richard S, 2005, PLOS GENET, V1, P676, DOI 10.1371/journal.pgen.0010074; Schomberg DW, 1999, ENDOCRINOLOGY, V140, P2733, DOI 10.1210/en.140.6.2733; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344	36	65	69	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					548	556		10.1038/sj.onc.1210652	http://dx.doi.org/10.1038/sj.onc.1210652			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17621265				2022-12-28	WOS:000252426100015
J	Garofalo, M; Quintavalle, C; Di Leva, G; Zanca, C; Romano, G; Taccioli, C; Liu, CG; Croce, CM; Condorelli, G				Garofalo, M.; Quintavalle, C.; Di Leva, G.; Zanca, C.; Romano, G.; Taccioli, C.; Liu, C. G.; Croce, C. M.; Condorelli, G.			MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer	ONCOGENE			English	Article						microRNA; non-small cell lung cancer; apoptosis	CHRONIC LYMPHOCYTIC-LEUKEMIA; KINASE INHIBITOR P27(KIP1); PROTEIN EXPRESSION; INDUCED APOPTOSIS; KIT RECEPTOR; IN-VIVO; DEATH; GROWTH; P27; DIFFERENTIATION	To de. ne novel pathways that regulate susceptibility to tumor necrosis factor ( TNF)-related apoptosis-inducing ligand ( TRAIL) in non-small cell lung cancer (NSCLC), we have performed genome-wide expression pro. ling of microRNAs (miRs). We show that in TRAIL- resistant NSCLC cells, levels of different miRs are increased, and in particular, miR-221 and -222. We demonstrate that these miRs impair TRAIL- dependent apoptosis by inhibiting the expression of key functional proteins. Indeed, transfection with anti-miR-221 and -222 rendered CALU-1-resistant cells sensitive to TRAIL. Conversely, H460-sensitive cells treated with -221 and -222 pre-miRs become resistant to TRAIL. miR-221 and -222 target the 3'- UTR of Kit and p27(kip1) mRNAs, but interfere with TRAIL signaling mainly through p27kip1. In conclusion, we showthat high expression levels of miR-221 and -222 are needed to maintain the TRAIL- resistant phenotype, thus making these miRs as promising therapeutic targets or diagnostic tool for TRAIL resistance in NSCLC.	[Garofalo, M.; Quintavalle, C.; Zanca, C.; Romano, G.; Condorelli, G.] Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Garofalo, M.; Quintavalle, C.; Zanca, C.; Romano, G.; Condorelli, G.] IEOS, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy; [Garofalo, M.; Di Leva, G.; Taccioli, C.; Liu, C. G.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; [Condorelli, G.] Univ Naples Federico 2, Fac Sci Biotecnol, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Naples Federico II	Condorelli, G (corresponding author), Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	gecondor@unina.it	Taccioli, Cristian/ABC-3379-2020; Young, Richard A/F-6495-2012; Taccioli, Cristian/F-8801-2010; Condorelli, Gerolama/AAC-3472-2022	Taccioli, Cristian/0000-0003-2995-5612; Young, Richard A/0000-0001-8855-8647; Taccioli, Cristian/0000-0003-2995-5612; Condorelli, Gerolama/0000-0003-0177-8829; Di Leva, Gianpiero/0000-0001-6759-8682	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Fulda S, 2000, CANCER RES, V60, P3947; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Garofalo M, 2007, INT J CANCER, V120, P1215, DOI 10.1002/ijc.22495; Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Katayose Y, 1997, CANCER RES, V57, P5441; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Ovcharenko D, 2007, CANCER RES, V67, P10782, DOI 10.1158/0008-5472.CAN-07-1484; Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smirnova L, 2005, EUR J NEUROSCI, V21, P1469, DOI 10.1111/j.1460-9568.2005.03978.x; StCroix B, 1996, NAT MED, V2, P1204; Tamborini E, 2004, CLIN CANCER RES, V10, P8214, DOI 10.1158/1078-0432.CCR-04-1013; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Woltman AM, 2003, BLOOD, V101, P1439, DOI 10.1182/blood-2002-06-1688; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010	39	222	260	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3845	3855		10.1038/onc.2008.6	http://dx.doi.org/10.1038/onc.2008.6			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246122	Green Published			2022-12-28	WOS:000256904700008
J	Eliseev, RA; Dong, YF; Sampson, E; Zuscik, MJ; Schwarz, EM; O'Keefe, RJ; Rosier, RN; Drissi, MH				Eliseev, R. A.; Dong, Y-F; Sampson, E.; Zuscik, M. J.; Schwarz, E. M.; O'Keefe, R. J.; Rosier, R. N.; Drissi, M. H.			Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis	ONCOGENE			English	Article						Runx2; Bax; osteosarcoma; apoptosis	TUMOR-SUPPRESSOR; OSTEOBLAST DIFFERENTIATION; GASTRIC-CANCER; TRANSCRIPTIONAL ACTIVATOR; INDUCE APOPTOSIS; RUNX3; GROWTH; DEATH; EXPRESSION; PROTEINS	The Runx family of transcription factors regulate cell growth and differentiation, and control the expression of target genes involved in cell fate decisions. We examined the role of the bone-related member of this family, Runx2, in regulating apoptosis via modulation of the Bcl2 family of genes in the osteosarcoma cell line Saos2. Our data demonstrate that Runx2 directly binds to two Runx-specific regulatory elements on the human bax promoter thereby inducing Bax expression. Furthermore, bone morphogenetic protein-induced or vector-mediated expression of Runx2 resulted in upregulation of Bax expression, and subsequent increased sensitivity of Saos2 cells to apoptosis. Finally, the observed upregulation of Bax expression and increased apoptosis were Runx2 dependent as Runx2 loss of function abrogated these effects. Our study provides the first evidence for Bax as a direct target of Runx2, suggesting that Runx2 may act as a proapoptotic factor in osteosarcoma cells.	[Drissi, M. H.] Univ Connecticut, Ctr Hlth, Dept Orthopaed, New England Musculoskeletal Inst,MARB, Farmington, CT 06034 USA; [Eliseev, R. A.; Dong, Y-F; Sampson, E.; Zuscik, M. J.; Schwarz, E. M.; O'Keefe, R. J.; Rosier, R. N.] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Dept Orthopaed, Rochester, NY 14642 USA	University of Connecticut; University of Rochester	Drissi, MH (corresponding author), Univ Connecticut, Ctr Hlth, Dept Orthopaed, New England Musculoskeletal Inst,MARB, Suite 4048,263 Farmington Ave, Farmington, CT 06034 USA.	Drissi@UCHC.edu		drissi, hicham/0000-0002-3322-281X; Zuscik, Michael/0000-0003-0461-8708	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR052674] Funding Source: NIH RePORTER; NIAMS NIH HHS [R0-1 AR-052674-01, R01 AR052674] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antignani A, 2006, CURR OPIN CELL BIOL, V18, P685, DOI 10.1016/j.ceb.2006.10.004; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Barnes GL, 2003, CANCER RES, V63, P2631; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Drissi H, 2002, J CELL BIOCHEM, V86, P403, DOI 10.1002/jcb.10238; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fukuda N, 2006, ONCOGENE, V25, P3509, DOI 10.1038/sj.onc.1209393; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774-002-0408-0; Lee JS, 2006, J BONE MINER RES, V21, P921, DOI 10.1359/JBMR.060303; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIYASHITA T, 1995, CELL, V80, P293; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Noda M, 2006, J PHARMACOL SCI, V100, P211, DOI 10.1254/jphs.FMJ05004X6; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pratap J, 2003, CANCER RES, V63, P5357; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Torquati A, 2004, SURGERY, V136, P310, DOI 10.1016/j.surg.2004.05.005; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; van Wijnen AJ, 2004, ONCOGENE, V23, P4209, DOI 10.1038/sj.onc.1207758; Vogiatzi P, 2006, CANCER BIOL THER, V5, P371, DOI 10.4161/cbt.5.4.2748; Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404-200507000-00005; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	43	55	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3605	3614		10.1038/sj.onc.1211020	http://dx.doi.org/10.1038/sj.onc.1211020			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223689	Green Accepted			2022-12-28	WOS:000256468500012
J	Han, X; Saito, H; Miki, Y; Nakanishi, A				Han, X.; Saito, H.; Miki, Y.; Nakanishi, A.			A CRM1-mediated nuclear export signal governs cytoplasmic localization of BRCA2 and is essential for centrosomal localization of BRCA2	ONCOGENE			English	Article						breast cancer; BRCA2; nuclear export; centrosome; leptomycin B; microinjection	SUSCEPTIBILITY GENE BRCA2; CANCER SUSCEPTIBILITY; NUCLEOCYTOPLASMIC TRANSPORT; PHOSPHORYLATION; PROTEIN; GENOME; CRM1	Germ-line mutations of the BRCA2 gene cause inherited susceptibility to breast and ovarian cancers. BRCA2 contains two nuclear localization signals, predominantly localizes in the nucleus and plays significant roles in DNA double-strand break repair. Recently, we reported that BRCA2 localizes to the centrosomes during the S and early M phases of the cell cycle. In this study, for the first time, we identified a functional nuclear export sequence (NES1; (1383)DLSDLTFLEVA(1393)) in BRCA2. The green fluorescent protein (GFP)-NES1 fusion protein was localized in the cytoplasm and could be blocked by the chromosomal region maintenance 1-specific export inhibitor leptomycin B. Mutation of a leucine residue in the NES1 motif to alanine (L1384A) resulted in both cytoplasmic and nuclear localization of the GFP-NES1 fusion protein and a nuclear accumulation of ectopic full-length BRCA2-FLAG. Moreover, treatment of cells with leptomycin B decreased centrosomal localization of BRCA2. Finally, by microinjection of an anti-BRCA2 antibody into the cytoplasm of HeLa S3 cells, we found that depletion of normal BRCA2 proteins in the cytoplasm leads to centrosome amplification and binucleated cells. Our results suggest that disruption of the NES function by genetic changes results in deregulation of BRCA2 export, which ultimately leads to centrosome disorder.	[Han, X.; Miki, Y.] Tokyo Med & Dent Univ, Dept Mol Genet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; [Han, X.] Yanbiann Univ, Coll Med, Dept Prevent Med, Yanji, Peoples R China; [Saito, H.; Miki, Y.; Nakanishi, A.] Japanese Fdn Canc Res, Inst Canc, Dept Genet Diag, Tokyo 170, Japan; [Nakanishi, A.] Univ Tokyo, Inst Med Sci, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Yanbian University; Japanese Foundation for Cancer Research; University of Tokyo	Miki, Y (corresponding author), Tokyo Med & Dent Univ, Dept Mol Genet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	miki.mgen@mri.tmd.ac.jp						Bednenko J, 2003, TRAFFIC, V4, P127, DOI 10.1034/j.1600-0854.2003.00109.x; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Nakanishi A, 2007, BIOCHEM BIOPH RES CO, V355, P34, DOI 10.1016/j.bbrc.2007.01.100; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Thompson ME, 2005, J BIOL CHEM, V280, P21854, DOI 10.1074/jbc.M502676200; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu KJ, 2005, CANCER RES, V65, P417; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; Yano K, 2000, BIOCHEM BIOPH RES CO, V270, P171, DOI 10.1006/bbrc.2000.2392; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	21	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					2969	2977		10.1038/sj.onc.1210968	http://dx.doi.org/10.1038/sj.onc.1210968			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059333				2022-12-28	WOS:000255681700004
J	Kralova, J; Dvorak, M; Koc, M; Kral, V				Kralova, J.; Dvorak, M.; Koc, M.; Kral, V.			p38 MAPK plays an essential role in apoptosis induced by photoactivation of a novel ethylene glycol porphyrin derivative	ONCOGENE			English	Article						porphyrin; photoactivation; apoptosis; p38 MAPK; caspase; lysosome	CYTOCHROME-C RELEASE; ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION; MEDIATED PHOTODYNAMIC THERAPY; SIGNAL-REGULATED KINASE; CARCINOMA A431 CELLS; BID CLEAVAGE; SUBCELLULAR-LOCALIZATION; BCL-2 PHOSPHORYLATION; LYSOSOMAL PHOTODAMAGE	In this study, we provide evidence that photostimulation of various cancer cells preloaded with a new photosensitizing compound, tetrakis-meso-(4-ethyleneglycol- 2,3,5,6-tetra. fluorophenyl) porphyrin (PORF-TEG), results in rapid activation of the cell death machinery. PORF-TEG, although primarily localized in lysosomes, induces mitochondria-driven apoptosis. The induction of apoptosis is accompanied by immediate and sustained activation of p38 mitogen-activated protein kinase (MAPK) and transient activation of c-Jun N-terminal kinase (JNK). Conversely, the inhibition of p38 by PD 169316 or SB202190 and by the p38a dominant-negative mutant as well as the deletion of the p38a gene (MEFs-KO) protected cells from apoptosis, whereas inhibition of JNK did not. Activation of the p38 signaling pathway occurs upstream of caspase activation. In addition, preincubation of cells with scavengers of reactive oxygen species attenuated p38 and caspase activation and increased cell survival, thus connecting reactive oxygen species formation with the activation of the p38 pathway. Later events included degradation of Bcl-2, activation of tBid, and cleavage of Bad and Mcl-1. The data suggest a key role for p38 MAPK in PORF-TEG-photoinduced apoptosis.	[Kralova, J.; Dvorak, M.; Koc, M.] Acad Sci Czech Republic, Inst Mol Genet, Dept Mol Virol, CR-14220 Prague 4, Czech Republic; [Kral, V.] Inst Chem Technol, Dept Analyt Chem, CR-16628 Prague, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Chemistry & Technology, Prague	Kralova, J (corresponding author), Acad Sci Czech Republic, Inst Mol Genet, Dept Mol Virol, Videnska 1083, CR-14220 Prague 4, Czech Republic.	kralova@img.cas.cz	Dvorak, Michal/G-5861-2014; Kral, Vladimir/I-9518-2017; Dvořák, Michal/I-9939-2014; Kralova, Jarmila/G-3834-2014; Koc, Michal/D-1234-2014	Kral, Vladimir/0000-0001-5034-4184; Kralova, Jarmila/0000-0002-4735-8857; Koc, Michal/0000-0003-0928-4196				Ahmad N, 2000, J INVEST DERMATOL, V115, P1041, DOI 10.1046/j.1523-1747.2000.00147.x; Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; De Chiara G, 2006, J BIOL CHEM, V281, P21353, DOI 10.1074/jbc.M511052200; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hishita T, 2001, CANCER RES, V61, P2878; Hsieh YJ, 2003, J CELL PHYSIOL, V194, P363, DOI 10.1002/jcp.10273; Ichinose S, 2006, INT J ONCOL, V29, P349; Ishisaka R, 2001, J BIOCHEM-TOKYO, V129, P35, DOI 10.1093/oxfordjournals.jbchem.a002833; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Kessel D, 2000, PHOTOCHEM PHOTOBIOL, V71, P196, DOI 10.1562/0031-8655(2000)071<0196:DOTART>2.0.CO;2; Kessel D, 2002, PHOTOCH PHOTOBIO SCI, V1, P837, DOI 10.1039/b206046a; Kessel D, 1997, PHOTOCHEM PHOTOBIOL, V65, P422, DOI 10.1111/j.1751-1097.1997.tb08581.x; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Klotz LO, 1998, CANCER RES, V58, P4297; Kralova J, 2003, J MED CHEM, V46, P2049, DOI 10.1021/jm021060d; Lavie G, 1999, BRIT J CANCER, V79, P423, DOI 10.1038/sj.bjc.6690066; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matroule JY, 2001, ONCOGENE, V20, P4070, DOI 10.1038/sj.onc.1204546; Oh SH, 2004, TOXICOL APPL PHARM, V194, P221, DOI 10.1016/j.taap.2003.09.011; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; Saczko J, 2007, FOLIA BIOL-PRAGUE, V53, P7; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tong ZM, 2003, J PHOTOCH PHOTOBIO B, V71, P77, DOI 10.1016/j.jphotobiol.2003.08.001; Tong ZM, 2002, CANCER RES, V62, P5528; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Van Cruchten S, 2002, ANAT HISTOL EMBRYOL, V31, P214, DOI 10.1046/j.1439-0264.2002.00398.x; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Xue LY, 1999, CELL DEATH DIFFER, V6, P855, DOI 10.1038/sj.cdd.4400558; Yin L, 2005, J CELL BIOCHEM, V94, P433, DOI 10.1002/jcb.20277; Yu WP, 2001, CANCER RES, V61, P6569; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zhai DY, 2000, FEBS LETT, V472, P293, DOI 10.1016/S0014-5793(00)01471-X; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	48	50	51	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3010	3020		10.1038/sj.onc.1210960	http://dx.doi.org/10.1038/sj.onc.1210960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059338				2022-12-28	WOS:000255681700008
J	Nakayama, T; Hieshima, K; Arao, T; Jin, Z; Nagakubo, D; Shirakawa, AK; Yamada, Y; Fujii, M; Oiso, N; Kawada, A; Nishio, K; Yoshie, O				Nakayama, T.; Hieshima, K.; Arao, T.; Jin, Z.; Nagakubo, D.; Shirakawa, A-K; Yamada, Y.; Fujii, M.; Oiso, N.; Kawada, A.; Nishio, K.; Yoshie, O.			Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia	ONCOGENE			English	Article						adult T-cell leukemia; CCR4; Fra-2; JunD; c-Myb; MDM2; BCL-6	VIRUS TYPE-I; TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE ACTIVATION; CHEMOKINE RECEPTORS; NONCODING REGION; ATL CELLS; C-MYB; LYMPHOMA; GROWTH; GENE	Adult T-cell leukemia (ATL) is a mature CD4(+) T-cell malignancy etiologically associated with human T-cell leukemia virus type 1 (HTLV-1). Primary ATL cells frequently express CCR4 at high levels. Since HTLV-1 Tax does not induce CCR4 expression, transcription factor(s) constitutively active in ATL may be responsible for its strong expression. We identified an activator protein-1 (AP-1) site in the CCR4 promoter as the major positive regulatory element in ATL cells. Among the AP-1 family members, Fra-2, JunB and JunD are highly expressed in fresh primary ATL cells. Consistently, the Fra-2/JunB and Fra-2/JunD heterodimers strongly activated the CCR4 promoter in Jurkat cells. Furthermore, Fra-2 small interfering RNA (siRNA) or JunD siRNA, but not JunB siRNA, effectively reduced CCR4 expression and cell growth in ATL cells. Conversely, Fra-2 or JunD overexpression promoted cell growth in Jurkat cells. We identified 49 genes, including c-Myb, BCL-6 and MDM2, which were downregulated by Fra-2 siRNA in ATL cells. c-Myb, BCL-6 and MDM2 were also downregulated by JunD siRNA. As Fra-2, these proto-oncogenes were highly expressed in primary ATL cells but not in normal CD4(+) T cells. Collectively, aberrantly expressed Fra-2 in association with JunD may play a major role in CCR4 expression and oncogenesis in ATL.	[Nakayama, T.; Hieshima, K.; Jin, Z.; Nagakubo, D.; Shirakawa, A-K; Yoshie, O.] Kinki Univ, Sch Med, Dept Microbiol, Osaka 5898511, Japan; [Arao, T.; Nishio, K.] Kinki Univ, Sch Med, Dept Genome Sci, Osaka 5898511, Japan; [Yamada, Y.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Lab Med, Nagasaki 852, Japan; [Fujii, M.] Niigata Univ, Grad Sch Med & Dent Sci, Div Virol, Niigata, Japan; [Oiso, N.; Kawada, A.] Kinki Univ, Sch Med, Dept Dermatol, Osaka 5898511, Japan	Kindai University (Kinki University); Kindai University (Kinki University); Nagasaki University; Niigata University; Kindai University (Kinki University)	Yoshie, O (corresponding author), Kinki Univ, Sch Med, Dept Microbiol, 377-2 Ohono Higashi, Osaka 5898511, Japan.	o.yoshie@med.kindai.ac.jp	Kawada, Akira/AAQ-3460-2020; Oiso, Naoki/H-6540-2019; Hieshima, Kunio/AAF-7040-2019; Nagakubo, Daisuke/AAW-3621-2021	Oiso, Naoki/0000-0001-5593-6496; Hieshima, Kunio/0000-0002-7786-4646; Nagakubo, Daisuke/0000-0003-1213-1246; Yoshie, Osamu/0000-0003-4353-5809				Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; CESARMAN E, 1992, BLOOD, V80, P3205; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen F, 1999, INT IMMUNOL, V11, P677, DOI 10.1093/intimm/11.5.677; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Ferenczi K, 2002, J INVEST DERMATOL, V119, P1405, DOI 10.1046/j.1523-1747.2002.19610.x; Galonek HL, 2006, NAT CELL BIOL, V8, P1317, DOI 10.1038/ncb1206-1317; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Hata T, 1999, LEUKEMIA, V13, P215, DOI 10.1038/sj.leu.2401271; Hess JL, 2006, BLOOD, V108, P297, DOI 10.1182/blood-2005-12-5014; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847; Igarashi T, 2007, ONCOGENE, V26, P4749, DOI 10.1038/sj.onc.1210289; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Ishida T, 2003, CLIN CANCER RES, V9, P3625; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jones D, 2000, BLOOD, V96, P685; Karreth F, 2004, DEVELOPMENT, V131, P5717, DOI 10.1242/dev.01414; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; Kerl K, 2001, LAB INVEST, V81, P1693, DOI 10.1038/labinvest.3780382; Kim EJ, 2005, J CLIN INVEST, V115, P798, DOI 10.1172/JCI200524826; Matsubara Y, 2005, LEUKEMIA, V19, P482, DOI 10.1038/sj.leu.2403628; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Mori N, 1999, BLOOD, V93, P2360; Mori N, 2000, BLOOD, V95, P3915; Nagakubo D, 2007, INT J CANCER, V120, P1591, DOI 10.1002/ijc.22483; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Pasqualucci L, 2003, LEUKEMIA LYMPHOMA, V44, pS5, DOI 10.1080/10428190310001621588; Ramsay RG, 2003, EXPERT OPIN THER TAR, V7, P235; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shetzline SE, 2004, BLOOD, V104, P1833, DOI 10.1182/blood-2003-10-3577; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Yamada Y, 1996, LEUKEMIA LYMPHOMA, V21, P443, DOI 10.3109/10428199609093442; YAMAMOTO N, 1985, J GEN VIROL, V66, P1641, DOI 10.1099/0022-1317-66-8-1641; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505; Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9	47	45	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3221	3232		10.1038/sj.onc.1210984	http://dx.doi.org/10.1038/sj.onc.1210984			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18071306				2022-12-28	WOS:000256111400001
J	Sales, KJ; Boddy, SC; Jabbour, HN				Sales, K. J.; Boddy, S. C.; Jabbour, H. N.			F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells	ONCOGENE			English	Article						PGF(2 alpha); FP receptor; focal adhesions; morphology; migration; chemotaxis	GONADOTROPIN-RELEASING-HORMONE; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; N-TERMINAL KINASE; C-SRC; TYROSINE PHOSPHORYLATION; CYCLOOXYGENASE ENZYMES; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; EXPRESSION	Cellular adhesion to extracellular matrix is a central phenomenon for the maintenance of tissue integrity and cellular movement. Collectively, these processes are regulated by a fine- tuned balance between the formation and loosening of adhesive contacts, a process involving integrins, and the elevation and diminution of cytoplasmic signalling molecules. We demonstrate that prostaglandin ( PG) F-2 alpha stimulation rapidly increases the capacity of Ishikawa cells stably expressing the F- prostanoid receptor ( FPS) to adhere to vitronectin. Coincident with this elevation in matrix adhesion, we demonstrate a profound PGF(2 alpha)- induced alteration in cytoskeletal remodelling, characterized by polymerization of the actin cytoskeleton and recruitment of focal adhesion kinase at focal adhesions and enhanced cell migration. Moreover, we show that these PGF2a- induced alterations in adhesion and morphology on vitronectin and migration could be abolished by cultivating FPS cells in the presence of integrin alpha v beta 3 antibody or alpha v beta 3- directed tetrapeptide arg - gly - asp - ser or inhibition of FP receptor signalling with the FP receptor antagonist, chemical disruptors of the phospholipase C-beta, protein kinase A, c- Src and epidermal growth factor receptor kinase pathways or inhibition of the monomeric G proteins Rho, Rac and CDC42. These results reveal a mechanism by which prostanoids regulate cell movement, which may be relevant to pathologies of the endometrium.	[Sales, K. J.; Boddy, S. C.; Jabbour, H. N.] Queens Med Res Inst, MRC, MRC Human Reprod Sci Unit, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh	Jabbour, HN (corresponding author), Queens Med Res Inst, MRC, MRC Human Reprod Sci Unit, 47 Little France Crescent,Old Dalkeith Rd, Edinburgh EH16 4TJ, Midlothian, Scotland.	h.jabbour@hrsu.mrc.ac.uk		Sales, Kurt/0000-0002-9880-5143	Medical Research Council [MC_U127684438, U.1276.00.004.00002.01/2(61014)] Funding Source: Medline; MRC [MC_U127684438] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cruet S, 1999, GYNECOL ONCOL, V75, P254, DOI 10.1006/gyno.1999.5572; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davidson L, 2004, J BIOL CHEM, V279, P11906, DOI 10.1074/jbc.M310784200; Davidson L, 2004, J BIOL CHEM, V279, P1980, DOI 10.1074/jbc.M309827200; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fujino H, 2000, J BIOL CHEM, V275, P29907, DOI 10.1074/jbc.M003467200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Griffin BW, 1999, J PHARMACOL EXP THER, V290, P1278; Harris D, 2002, ENDOCRINOLOGY, V143, P1018, DOI 10.1210/en.143.3.1018; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Jabbour HN, 2005, ENDOCRINOLOGY, V146, P4657, DOI 10.1210/en.2005-0804; Jabbour HN, 2004, TRENDS ENDOCRIN MET, V15, P398, DOI 10.1016/j.tem.2004.08.006; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LESSEY BA, 1994, J CLIN ENDOCR METAB, V79, P643, DOI 10.1210/jc.79.2.643; Levi NL, 1998, MOL ENDOCRINOL, V12, P815, DOI 10.1210/me.12.6.815; Liapis H, 1997, HUM PATHOL, V28, P443, DOI 10.1016/S0046-8177(97)90033-2; LUMSDEN MA, 1983, BRIT J OBSTET GYNAEC, V90, P1135, DOI 10.1111/j.1471-0528.1983.tb06460.x; LUNDSTROM V, 1978, AM J OBSTET GYNECOL, V130, P640, DOI 10.1016/0002-9378(78)90320-4; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Sales KJ, 2004, MOL ENDOCRINOL, V18, P1533, DOI 10.1210/me.2004-0022; Sales KJ, 2005, CANCER RES, V65, P7707, DOI 10.1158/0008-5472.CAN-05-0101; Sales KJ, 2003, PROSTAG OTH LIPID M, V71, P97, DOI 10.1016/S1098-8823(03)00050-9; Sales KJ, 2004, J CLIN ENDOCR METAB, V89, P986, DOI 10.1210/jc.2003-031434; Sales KJ, 2003, REPRODUCTION, V126, P559, DOI 10.1530/rep.0.1260559; Sales KJ, 2007, ENDOCRINOLOGY, V148, P3635, DOI 10.1210/en.2006-1517; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SEGER R, 1994, J BIOL CHEM, V269, P25699; SINGH EJ, 1975, AM J OBSTET GYNECOL, V121, P1003, DOI 10.1016/0002-9378(75)90927-8; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007	43	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2466	2477		10.1038/sj.onc.1210883	http://dx.doi.org/10.1038/sj.onc.1210883			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968320	Green Accepted			2022-12-28	WOS:000254844900011
J	Perazzona, B; Lin, H; Sun, T; Wang, Y; Arlinghaus, R				Perazzona, B.; Lin, H.; Sun, T.; Wang, Y.; Arlinghaus, R.			Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects	ONCOGENE			English	Article						BCR-ABL; CML; BCR kinase-defective BCR	NEGATIVE REGULATOR; TYROSINE KINASE; GENE ENCODES; P160 BCR; C-ABL; ONCOPROTEIN; LEUKEMIA; TRANSFORMATION; EXPRESSION; PROTEIN	Bcr-Abl acquires its transforming ability through its upregulated Abl tyrosine kinase activity. Bcr is a phosphoprotein with a novel serine/threonine kinase activity encoded by its first exon. In chronic myelogenous leukemia (CML) cells, Bcr-Abl phosphorylates Bcr on tyrosine residues reducing its kinase activity. Overexpression of BCR in BCR-ABL + cells produces a phosphoserine form of Bcr, which inhibits the oncogenic effects of BCR-ABL. To investigate the inhibitory effects of Bcr on Bcr-Abl, we expressed BCR/GFP in TonB210 cells, which contain a tetracycline-inducible BCR-ABL. In nude mice injected with cell clones of TonB210/BCR/GFP, tumor formation was delayed, and tumors were 50% smaller compared with the TonB210/GFP. In addition, TonB210/BCR/GFP cells had little colony-forming ability in soft agar compared with TonB210/GFP cells. In contrast, a point mutant of BCR (Y360F), which disrupts its kinase activity, not only blocked Bcr's inhibitory effects but also enhanced the oncogenic effects of Bcr-Abl in a solid tumor model and in soft agar colony assays. Similar effects were observed with a second BCR kinase domain mutant, S354A. These results indicate that the inhibitory function of Bcr directed toward Bcr-Abl requires its kinase function.	[Perazzona, B.; Lin, H.; Sun, T.; Wang, Y.; Arlinghaus, R.] Univ Texas MD Anderson Canc Ctr, Unit 951, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Unit 951, Dept Mol Pathol, 7435 Fannin St, Houston, TX 77030 USA.	rarlingh@mdanderson.org			NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [CA49639, P01 CA049639, P01 CA049639-150024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Arlinghaus RB, 2002, ONCOGENE, V21, P8560, DOI 10.1038/sj.onc.1206083; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; GUO JQ, 1994, BLOOD, V83, P3629; Hawk N, 2002, CANCER RES, V62, P386; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; LI WJ, 1989, ONCOGENE, V4, P127; Lin F, 2001, ONCOGENE, V20, P1873, DOI 10.1038/sj.onc.1204409; Ling XY, 2003, CANCER RES, V63, P298; LIU J, 1996, MOL CELL BIOL, V3, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; Mahon GM, 2003, CURR BIOL, V13, P437, DOI 10.1016/S0960-9822(03)00090-3; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Moravcova J, 2005, NEOPLASMA, V52, P119; Nagar B, 2006, MOL CELL, V21, P787, DOI 10.1016/j.molcel.2006.01.035; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Ress A, 2005, EMBO REP, V6, P1095, DOI 10.1038/sj.embor.7400536; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942	23	3	4	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2208	2214		10.1038/sj.onc.1210851	http://dx.doi.org/10.1038/sj.onc.1210851			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17934518	Green Accepted			2022-12-28	WOS:000254621300011
J	Clark, J; Attard, G; Jhavar, S; Flohr, P; Reid, A; De-Bono, J; Eeles, R; Scardino, P; Cuzick, J; Fisher, G; Parker, MD; Foster, CS; Berney, D; Kovacs, G; Cooper, CS				Clark, J.; Attard, G.; Jhavar, S.; Flohr, P.; Reid, A.; De-Bono, J.; Eeles, R.; Scardino, P.; Cuzick, J.; Fisher, G.; Parker, M. D.; Foster, C. S.; Berney, D.; Kovacs, G.; Cooper, C. S.			Complex patterns of ETS gene alteration arise during cancer development in the human prostate	ONCOGENE			English	Article						prostate cancer; ERG; TMPRSS2; ERG fusion transcripts	IN-SITU HYBRIDIZATION; INTRAEPITHELIAL NEOPLASIA; RADICAL PROSTATECTOMY; CHROMOSOMAL-ANOMALIES; INDEPENDENT ORIGIN; TMPRSS2-ERG FUSION; EXPRESSION; CARCINOMA; HETEROGENEITY; SPECIMENS	An ERG gene 'break-apart' fluorescence in situ hybridization (FISH) assay has been used to screen whole-mount prostatectomy specimens for rearrangements at the ERG locus. In cancers containing ERG alterations the observed pattern of changes was often complex. Different categories of ERG gene alteration were found either together in a single cancerous region or within separate foci of cancer in the same prostate slice. In some cases the juxtaposition of particular patterns of ERG alterations suggested possible mechanisms of tumour progression. Prostates harbouring ERG alterations commonly also contained cancer that lacked rearrangements of the ERG gene. A single trans-urethral resection of the prostate specimen examined harboured both ERG and ETV1 gene rearrangements demonstrating that the observed complexity may, at least in part, be explained by multiple ETS gene alterations arising independently in a single prostate. In a search for possible precursor lesions clonal ERG rearrangements were found both in high grade prostatic intraepithelial neoplasia (PIN) and in atypical in situ epithelial lesions consistent with the diagnosis of low grade PIN. Our observations support the view that ERG gene alterations represent an initiating event that promotes clonal expansion initially to form regions of epithelial atypia. The complex patterns of ERG alteration found in prostatectomy specimens have important implications for the design of experiments investigating the clinical significance and mechanism of development of individual prostate cancers.	[Clark, J.; Attard, G.; Jhavar, S.; Flohr, P.; Reid, A.; De-Bono, J.; Eeles, R.; Parker, M. D.; Cooper, C. S.] Male Urol Canc Res Ctr, Inst Canc Res, Sutton SM2 5NG, Surrey, England; [Attard, G.; Reid, A.; De-Bono, J.; Eeles, R.] Royal Marsden NHS Trust Fdn Hosp, Sutton, Surrey, England; [Scardino, P.] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; [Cuzick, J.; Fisher, G.] Univ London, Wolfson Inst Prevent Med, London, England; [Foster, C. S.] Univ Liverpool, Dept Pathol, Royal Liverpool Univ Hosp, Liverpool L69 3BX, Merseyside, England; [Berney, D.] St Bartholomews Hosp, Orchid Tissue Lab, London, England; [Kovacs, G.] Heidelberg Univ, Fac Med, Mol Oncol Lab, Heidelberg, Germany	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Memorial Sloan Kettering Cancer Center; University of London; Queen Mary University London; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of London; Queen Mary University London; Ruprecht Karls University Heidelberg	Clark, J (corresponding author), Male Urol Canc Res Ctr, Inst Canc Res, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	jeremy.clark@icr.ac.uk		Berney, Daniel/0000-0001-5474-8696; Parker, Matthew/0000-0003-2999-3870; Eeles, Rosalind/0000-0002-3698-6241; de Bono, Johann S/0000-0002-2034-595X; Attard, Gerhardt/0000-0002-4811-7983	MRC [G0501019] Funding Source: UKRI; Cancer Research UK Funding Source: Medline; Medical Research Council [G0501019] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AIHARA M, 1994, UROLOGY, V43, P60, DOI 10.1016/S0090-4295(94)80264-5; Arora R, 2004, CANCER-AM CANCER SOC, V100, P2362, DOI 10.1002/cncr.20243; ATTARD G, 2007, ONCOGENE        0716; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; BRAWER MK, 1991, UROLOGY, V38, P103, DOI 10.1016/S0090-4295(05)80067-6; Cerveira N, 2006, NEOPLASIA, V8, P826, DOI 10.1593/neo.06427; Chen ME, 2000, CANCER, V89, P1800, DOI 10.1002/1097-0142(20001015)89:8<1800::AID-CNCR21>3.0.CO;2-D; Cheng L, 1998, J NATL CANCER I, V90, P233, DOI 10.1093/jnci/90.3.233; Chun FKH, 2007, EUR UROL, V51, P949, DOI 10.1016/j.eururo.2006.07.008; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Cuzick J, 2006, BRIT J CANCER, V95, P1186, DOI 10.1038/sj.bjc.6603411; Demichelis F, 2007, ONCOGENE, V26, P5692, DOI 10.1038/sj.onc.1210630; Djavan B, 1999, Tech Urol, V5, P139; Egevad L, 2006, MODERN PATHOL, V19, P180, DOI 10.1038/modpathol.3800522; EPSTEIN JI, 1995, AM J SURG PATHOL, V19, P873, DOI 10.1097/00000478-199508000-00002; Foster CS, 2000, PROSTATE, P4; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Foster CS, 2000, SCAND J UROL NEPHROL, V34, P19, DOI 10.1080/003655900750169284; GREENE DR, 1995, SEMIN SURG ONCOL, V11, P9, DOI 10.1002/ssu.2980110104; GRIGNON DJ, 1994, J CELL BIOCHEM, P267; Hermans KG, 2006, CANCER RES, V66, P10658, DOI 10.1158/0008-5472.CAN-06-1871; Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986; Jenkins RB, 1997, CANCER RES, V57, P524; Jhavar SG, 2005, J CLIN PATHOL, V58, P504, DOI 10.1136/jcp.2004.021808; KONISHI N, 1995, AM J PATHOL, V147, P1112; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; MCNEAL JE, 1988, PROSTATE, V13, P91, DOI 10.1002/pros.2990130202; McNeal JE, 1996, AM J SURG PATHOL, V20, P802, DOI 10.1097/00000478-199607000-00003; MILLER GJ, 1994, J UROLOGY, V152, P1709, DOI 10.1016/S0022-5347(17)32368-6; MIRCHANDANI D, 1995, AM J PATHOL, V147, P92; NAM RK, 2003, CANCER BIOL THER, V6, P40; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; QIAN JQ, 1995, CANCER RES, V55, P5408; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Sakai I, 2005, BJU INT, V96, P528, DOI 10.1111/j.1464-410X.2005.05678.x; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Srigley JR, 2000, ARCH PATHOL LAB MED, V124, P1034; Stephenson AJ, 2005, CANCER-AM CANCER SOC, V104, P290, DOI 10.1002/cncr.21157; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; VILLERS A, 1992, CANCER, V70, P2313, DOI 10.1002/1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Yoshimoto M, 2006, NEOPLASIA, V8, P465, DOI 10.1593/neo.06283; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	47	109	120	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					1993	2003		10.1038/sj.onc.1210843	http://dx.doi.org/10.1038/sj.onc.1210843			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922029				2022-12-28	WOS:000254359100004
J	Kanda, I; Nishimura, N; Nakatsuji, H; Yamamura, R; Nakanishi, H; Sasaki, T				Kanda, I.; Nishimura, N.; Nakatsuji, H.; Yamamura, R.; Nakanishi, H.; Sasaki, T.			Involvement of Rab13 and JRAB/MICAL-L2 in epithelial cell scattering	ONCOGENE			English	Article						Rab13; JRAB/MICAL-L2; cell scattering	SMALL G-PROTEINS; MDCK CELLS; ADHESION RECEPTORS; BINDING-PROTEINS; TIGHT JUNCTIONS; INTEGRIN BETA-1; OCCLUDIN; RHO; MEMBRANE; CADHERIN	Epithelial cell scattering recapitulates the first steps of carcinoma invasion/metastasis. While the balance between cell-cell adhesive activity and cell motility ultimately determines this process, its molecular mechanisms remain unclear. Adherence junctions and tight junctions (TJs) are primarily responsible for cell-cell adhesive activity and subjected to dynamic remodeling. We previously showed that Rab13 and its effector protein JRAB/MICAL-L2 mediate the endocytic recycling of the integral TJ protein occludin and the assembly of functional TJs. In this study, we examined the role of Rab13 and JRAB/MICAL-L2 in the scattering of Madin-Darby canine kidney (MDCK) cells in response to 12-O-tetradecanoylphorbol-13-acetate (TPA). Knockdown of Rab13 in canine MDCK cells suppressed the TPA-induced scattering, and this phenotype was restored by re-expression of human Rab13. During TPA-induced MDCK cell scattering, Rab13 was transiently activated and returned to its basal level, and both Rab13 and JRAB/MICAL-L2 were colocalized with F-actin at cell-cell contact sites and then accumulated at emerging lamellipodial structures. TPA-induced MDCK cell scattering was also inhibited by knockdown of canine JRAB/MICAL-L2 and rescued by re-expression of mouse JRAB/MICAL-L2. These results indicate that Rab13 and JRAB/MICAL-L2 are involved in epithelial cell scattering.	[Kanda, I.; Nishimura, N.; Nakatsuji, H.; Yamamura, R.; Sasaki, T.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Biochem, Tokushima 7708503, Japan; [Kanda, I.; Nakanishi, H.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Plast & Reconstruct Surg, Tokushima 7708503, Japan	Tokushima University; Tokushima University	Sasaki, T (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Biochem, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	sasaki@basic.med.tokushima-u.ac.jp	Nakanishi, Hiroyuki/AAD-9324-2020	Nakanishi, Hiroyuki/0000-0003-3982-3314; Nakanishi, Hiroyuki/0000-0002-9765-0266				Aijaz S, 2005, DEV CELL, V8, P777, DOI 10.1016/j.devcel.2005.03.003; Ashida S, 2006, CLIN CANCER RES, V12, P2767, DOI 10.1158/1078-0432.CCR-05-1995; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Bertet C, 2004, NATURE, V429, P667, DOI 10.1038/nature02590; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Braga VMM, 2005, CURR OPIN CELL BIOL, V17, P466, DOI 10.1016/j.ceb.2005.08.012; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; Chen X, 2006, CURR OPIN CELL BIOL, V18, P572, DOI 10.1016/j.ceb.2006.07.002; Clarke H, 2000, J CELL SCI, V113, P3187; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Di Giovanni S, 2005, J BIOL CHEM, V280, P2084, DOI 10.1074/jbc.M411975200; Di Giovanni S, 2006, EMBO J, V25, P4084, DOI 10.1038/sj.emboj.7601292; Hickson GRX, 2003, MOL BIOL CELL, V14, P2908, DOI 10.1091/mbc.E03-03-0160; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Jones MC, 2006, CURR OPIN CELL BIOL, V18, P549, DOI 10.1016/j.ceb.2006.08.003; Kimura Y, 1997, AM J PATHOL, V151, P45; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kusumi A, 1999, CURR OPIN CELL BIOL, V11, P582, DOI 10.1016/S0955-0674(99)00020-4; Li J, 2005, DEV CELL, V9, P663, DOI 10.1016/j.devcel.2005.09.012; Marzesco AM, 2002, MOL BIOL CELL, V13, P1819, DOI 10.1091/mbc.02-02-0029; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Morimoto S, 2005, J BIOL CHEM, V280, P2220, DOI 10.1074/jbc.M406906200; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Palacios F, 2003, J BIOL CHEM, V278, P17395, DOI 10.1074/jbc.M300998200; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Suzuki T, 2002, J BIOL CHEM, V277, P14933, DOI 10.1074/jbc.M111842200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Terai T, 2006, MOL BIOL CELL, V17, P2465, DOI 10.1091/mbc.E05-09-0826; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; Troyanovsky RB, 2006, MOL BIOL CELL, V17, P3484, DOI 10.1091/mbc.E06-03-0190; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Wells CD, 2006, CELL, V125, P535, DOI 10.1016/j.cell.2006.02.045; Yamamoto Y, 2003, BIOCHEM BIOPH RES CO, V308, P270, DOI 10.1016/S0006-291X(03)01358-5	42	27	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1687	1695		10.1038/sj.onc.1210812	http://dx.doi.org/10.1038/sj.onc.1210812			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891173				2022-12-28	WOS:000253962100004
J	Milliken, EL; Lozada, KL; Johnson, E; Landis, MD; Seachrist, DD; Whitten, I; Sutton, ALM; Abdul-Karim, FW; Keri, RA				Milliken, E. L.; Lozada, K. L.; Johnson, E.; Landis, M. D.; Seachrist, D. D.; Whitten, I.; Sutton, A. L. M.; Abdul-Karim, F. W.; Keri, R. A.			Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer	ONCOGENE			English	Article						breast cancer; mammary gland; ovarian steroids; p53; centrosome; aneuploidy	ELEVATED LUTEINIZING-HORMONE; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; RANDOMIZED-TRIALS; MENSTRUAL FACTORS; EPITHELIAL-CELLS; MICE DEFICIENT; TAMOXIFEN; RECEPTOR; RISK	Aneuploidy and genomic instability are common features of human cancers, including breast cancer; however, mechanisms by which such abnormalities develop are not understood. The exquisite dependence of the mammary gland on hormones for growth and development as well as hormonal contributions to breast cancer risk and progression suggest that tumorigenic mechanisms in the breast should be considered in the context of hormonal stimulation. We used transgenic mice that overexpress luteinizing hormone with subsequent ovarian hyperstimulation as a model to identify mechanisms involved in hormone-induced mammary cancer. Tumor pathology in these mice is highly variable, suggesting individual tumors undergo distinct initiating or promoting events. Supporting this notion, hormone-induced tumors display considerable chromosomal instability and aneuploidy, despite the presence of functional p53. The presence of extensive centrosome amplification in tumors and hyperplastic glands prior to tumor formation suggests that alterations in the ovarian hormonal milieu dysregulate the centrosome cycle in mammary epithelial cells, leading to aneuploidy and cancer.	[Milliken, E. L.; Lozada, K. L.; Johnson, E.; Landis, M. D.; Seachrist, D. D.; Whitten, I.; Sutton, A. L. M.; Keri, R. A.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Abdul-Karim, F. W.] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Abdul-Karim, F. W.] Univ Hosp Cleveland, Dept Pathol, Cleveland, OH 44106 USA; [Keri, R. A.] Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University	Keri, RA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd,10900 Euclid Ave, Cleveland, OH 44106 USA.	keri@case.edu	Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088; Sutton, Amelia/0000-0003-0493-0670	NCI NIH HHS [R01 CA090398, R01 CA090398-06A1, T32CA059366, CA090398, P30 CA043703, T32 CA059366, R01 CA090398-07] Funding Source: Medline; NIGMS NIH HHS [T32GM08056, T32 GM008803, T32 GM008056, T32GM08803, T32 GM007250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059366, R01CA090398, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250, T32GM008056, T32GM008803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Backlund MG, 2001, CANCER RES, V61, P6577; Baum M, 2002, LANCET, V359, P2131; Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y; Braakhuis BJM, 2003, CANCER RES, V63, P1727; BRINTON LA, 1988, CANCER INVEST, V6, P245, DOI 10.3109/07357908809080645; Buzdar AU, 2006, CANCER-AM CANCER SOC, V107, P472, DOI 10.1002/cncr.22042; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CHENG KC, 1993, ADV CANCER RES, V60, P121; Clarke M, 1998, LANCET, V351, P1451; Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Duesberg P, 2005, CELL ONCOL, V27, P293; Ewan KB, 2002, CANCER RES, V62, P5627; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Goepfert TM, 2002, CANCER RES, V62, P4115; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HSIEH CC, 1990, INT J CANCER, V46, P796, DOI 10.1002/ijc.2910460508; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; IRWIN KL, 1988, AM J EPIDEMIOL, V127, P1192, DOI 10.1093/oxfordjournals.aje.a114912; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Kero J, 2000, J CLIN INVEST, V105, P633, DOI 10.1172/JCI7716; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; KVALE G, 1988, CANCER-AM CANCER SOC, V62, P1625, DOI 10.1002/1097-0142(19881015)62:8<1625::AID-CNCR2820620828>3.0.CO;2-K; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mann RJ, 1999, ENDOCRINOLOGY, V140, P2592, DOI 10.1210/en.140.6.2592; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; MILLER CW, 1993, ONCOGENE, V8, P1815; Milliken EL, 2002, ENDOCRINOLOGY, V143, P3671, DOI 10.1210/en.2002-220228; Mohammad HP, 2003, ENDOCRINOLOGY, V144, P4626, DOI 10.1210/en.2003-0357; Pati D, 2004, CANCER RES, V64, P5608, DOI 10.1158/0008-5472.CAN-03-0629; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 2003, CANCER RES, V63, P1398; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200; Zell JA, 2002, LIFE SCI, V71, P2331, DOI 10.1016/S0024-3205(02)02045-3	47	8	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1759	1766		10.1038/sj.onc.1210815	http://dx.doi.org/10.1038/sj.onc.1210815			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891171	Green Accepted			2022-12-28	WOS:000253962100011
J	Liu, X; Mazanek, P; Dam, V; Wang, Q; Zhao, H; Guo, R; Jagannathan, J; Cnaan, A; Maris, JM; Hogarty, MD				Liu, X.; Mazanek, P.; Dam, V.; Wang, Q.; Zhao, H.; Guo, R.; Jagannathan, J.; Cnaan, A.; Maris, J. M.; Hogarty, M. D.			Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification	ONCOGENE			English	Article						neuroblastoma; CTNNB1/beta-catenin; MYC; MYCN; embryonal cancer	BETA-CATENIN; C-MYC; WNT; EXPRESSION; GENE; TARGET; ACTIVATION; MUTATIONS; MECHANISM; PATHWAY	Neuroblastoma (NB) is a frequently lethal tumor of childhood. MYCN amplification accounts for the aggressive phenotype in a subset while the majority have no consistently identified molecular aberration but frequently express MYC at high levels. We hypothesized that activated Wnt/beta-catenin (CTNNB1) signaling might account for this as MYC is a beta-catenin transcriptional target and multiple embryonal and neural crest malignancies have oncogenic alterations in this pathway. NB cell lines without MYCN amplification express higher levels of MYC and beta-catenin (with aberrant nuclear localization) than MYCN amplified cell lines. Evidence for aberrant beta-catenin-TCF transcriptional activity was demonstrated using expression profiles from 73 primary NBs. Findings included increased WNT ligands (WNT1, WNT6, WNT7A, WNT10B), DVL1 and TCF7 expression in high-risk NBs without MYCN amplification, consistent with canonical beta-catenin signaling. More directly, Patterns of Gene Expression and Gene Set Enrichment Analyses demonstrated beta-catenin target genes (for example, MYC, PPARD, NRCAM, CD44, TCF7) as coordinately upregulated in high-risk NBs without MYCN amplification in comparison to high-risk MYCN-amplified or intermediate-risk NBs, supporting pathway activation in this subset. Thus, high-risk NBs without MYCN amplification may deregulate MYC and other oncogenic genes via altered beta-catenin signaling providing a potential candidate pathway for therapeutic inhibition.	[Liu, X.; Mazanek, P.; Dam, V.; Wang, Q.; Jagannathan, J.; Cnaan, A.; Maris, J. M.; Hogarty, M. D.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Zhao, H.; Guo, R.; Cnaan, A.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Maris, J. M.; Hogarty, M. D.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Hogarty, MD (corresponding author), Childrens Hosp Philadelphia, Div Oncol, 9 N ARC 902C,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	hogartym@email.chop.edu			NATIONAL CANCER INSTITUTE [P01CA097323] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA97323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bellmeyer A, 2003, DEV CELL, V4, P827, DOI 10.1016/S1534-5807(03)00160-6; Blanc E, 2005, ONCOGENE, V24, P1277, DOI 10.1038/sj.onc.1208255; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; COHN SL, 1990, ONCOGENE, V5, P1821; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Kleber M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/jcb.200411095; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Manduchi E, 2000, BIOINFORMATICS, V16, P685, DOI 10.1093/bioinformatics/16.8.685; Maris JM, 2002, CANCER CELL, V2, P447, DOI 10.1016/S1535-6108(02)00206-4; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; SADEE W, 1987, CANCER RES, V47, P5207; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Thompson PM, 2001, CANCER RES, V61, P679; Voeller HJ, 1998, CANCER RES, V58, P2520; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4	34	87	90	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1478	1488		10.1038/sj.onc.1210769	http://dx.doi.org/10.1038/sj.onc.1210769			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724465				2022-12-28	WOS:000253548200015
J	Tan, M; Gu, Q; He, H; Pamarthy, D; Semenza, GL; Sun, Y				Tan, M.; Gu, Q.; He, H.; Pamarthy, D.; Semenza, G. L.; Sun, Y.			SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1 alpha ubiquitination and degradation	ONCOGENE			English	Article						E3 ligase; HIF-1; hypoxia; SAG; transcription; ubiquitination	HYPOXIA-INDUCIBLE FACTOR-1; TUMOR-SUPPRESSOR COMPLEX; PROTEIN; LIGASE; SAG; HYDROXYLATION; GROWTH; ACTIVATION; EXPRESSION; COMPONENT	SAG (sensitive to apoptosis gene) or ROC2/RBX2 is the second family member of ROC1/RBX1, a component of SCF (Skp1, Cullin, F-box protein) and VCB (von Hippel-Lindau (VHL), Cullin and Elongin B/C) E3 ubiquitin ligases. SAG protected cells from hypoxia-induced apoptosis when overexpressed. We report here that SAG was subjected to hypoxia induction at the levels of mRNA and protein. Hypoxia induction of SAG was largely HIF-1 alpha dependent. A consensus HIF-1-binding site, GCGTG was identified in the first intron of the SAG gene. In response to hypoxia, HIF-1 bound to this site and transactivated SAG expression. SAG transactivation required both the intact binding site in cis and HIF-1 alpha in trans. On the other hand, like its family member, ROC1, SAG promoted VHL-mediated HIF-1 alpha ubiquitination and degradation, which was significantly inhibited upon small interfering RNA silencing of SAG or ROC1. Furthermore, the endogenous HIF-1 alpha at both basal and hypoxia-induced levels was significantly increased upon SAG silencing. Finally, SAG forms in vivo complex with Cul-5 and VHL under hypoxia condition. These results suggest an HIF-1-SAG feedback loop in response to hypoxia, as follows: hypoxia induces HIF-1 to transactivate SAG. Induced SAG then promotes HIF-1 alpha ubiquitination and degradation. This feedback loop may serve as a cellular defensive mechanism to reduce potential cytotoxic effects of prolonged HIF-1 activation under hypoxia.	[Tan, M.; Gu, Q.; He, H.; Pamarthy, D.; Sun, Y.] Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med,Dept Pediat, Inst Cell Engn,Vasc Biol Program, Baltimore, MD USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med,Dept Med, Inst Cell Engn,Vasc Biol Program, Baltimore, MD USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med,Dept Oncol, Inst Cell Engn,Vasc Biol Program, Baltimore, MD USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med,Dept Radiat Oncol, Inst Cell Engn,Vasc Biol Program, Baltimore, MD USA	University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sun, Y (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, 4304 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287; Pamarthy, Deepika/0000-0003-2486-7437	NATIONAL CANCER INSTITUTE [R01CA111554, R01CA118762, R21CA116982] Funding Source: NIH RePORTER; NCI NIH HHS [CA111554, CA116982, CA118762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chanalaris A, 2003, J MOL CELL CARDIOL, V35, P257, DOI 10.1016/S0022-2828(03)00003-8; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; Felder CB, 1999, AAPS PHARMSCI, V1; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gu QY, 2007, CANCER RES, V67, P3616, DOI 10.1158/0008-5472.CAN-06-4020; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kim SY, 2003, BIOCHEM BIOPH RES CO, V301, P671, DOI 10.1016/S0006-291X(03)00018-4; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Sun Y, 2001, ANTIOXID REDOX SIGN, V3, P635, DOI 10.1089/15230860152542989; Swaroop M, 1999, FREE RADICAL BIO MED, V27, P193, DOI 10.1016/S0891-5849(99)00078-7; Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang GY, 2001, J CEREBR BLOOD F MET, V21, P722, DOI 10.1097/00004647-200106000-00010; Yi S, 2006, MOL CARCINOGEN, V45, P409, DOI 10.1002/mc.20231	25	61	63	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1404	1411		10.1038/sj.onc.1210780	http://dx.doi.org/10.1038/sj.onc.1210780			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828303				2022-12-28	WOS:000253548200007
J	Ehrhardt, H; Hacker, S; Wittmann, S; Maurer, M; Borkhardt, A; Toloczko, A; Debatin, KM; Fulda, S; Jeremias, I				Ehrhardt, H.; Haecker, S.; Wittmann, S.; Maurer, M.; Borkhardt, A.; Toloczko, A.; Debatin, K-M; Fulda, S.; Jeremias, I.			Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells	ONCOGENE			English	Article						caspase-8; p53; cytotoxic drugs; TRAIL; TRAIL-R1; TRAIL-R2	MUTANT P53; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; DEATH RECEPTORS; CANCER-CELLS; EXPRESSION; TRAIL; RESTORATION; THERAPY; PROLIFERATION	Apoptosis resistance is crucially involved in cancer development and progression, represents the leading cause for failure of anticancer therapy and is caused, for example, by downregulation of proapoptotic intracellular signaling molecules such as caspase-8. We found that the cytotoxic drugs methotrexate (MTX) and 5-fluorouracil (5-FU) were both able to sensitize resistant tumor cells for induction of apoptosis by p53-mediated upregulation of caspase-8. Increase in caspase-8 messenger RNA and protein expression disabled tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced proliferation and restored sensitivity toward TRAIL-induced apoptosis which was inhibited by transfection of p53 decoy oligonucleotides, p53 shRNA and caspase-8 shRNA. Upregulation of caspase-8 and sensitization toward TRAIL-induced apoptosis was found both in a broad panel of tumor cell lines with downregulated caspase-8 and in TRAIL-resistant primary tumor cells of children with acute leukemia. Taken together, we have identified caspase-8 as an important p53 target gene regulated by cytotoxic drugs. These findings highlight a new drug-induced modulation of physiological apoptosis pathways, which may be involved in successful anticancer therapy using MTX and 5-FU in leukemia and solid tumors over decades.	[Ehrhardt, H.; Wittmann, S.; Maurer, M.; Borkhardt, A.; Jeremias, I.] Univ Munich, Dr Von Haunerschen Kinderspital, Dept Hematol Oncol, D-80337 Munich, Germany; [Haecker, S.; Debatin, K-M; Fulda, S.] Klin Kinder & Jugendmed, Ulm, Germany; [Toloczko, A.; Jeremias, I.] GSF Res Ctr Environm & Hlth, Munich, Germany; [Ehrhardt, H.] Univ Munich, Dept Obstet & Gynecol, Div Neonatol, Munich, Germany	University of Munich; University of Munich	Jeremias, I (corresponding author), GSF Forschungszentrum Umwelt & Gesundheit, Abt Genvektoren, Marchioninistr 25, D-81377 Munich, Germany.	I.Jeremias@lrz.uni-muenchen.de	Ehrhardt, Harald/L-9007-2018; Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014; Jeremias, Irmela/Q-5934-2019; Jeremias, Irmela/C-6090-2015	Ehrhardt, Harald/0000-0003-4587-1734; Debatin, Klaus-Michael/0000-0002-8397-1886; Jeremias, Irmela/0000-0003-1773-7677; Fulda, Simone/0000-0002-0459-6417				Ashley DM, 2005, CANCER-AM CANCER SOC, V104, P1487, DOI 10.1002/cncr.21323; Baader E, 2005, CANCER RES, V65, P7888, DOI 10.1158/0008-5472.CAN-04-4278; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Ehrhardt H, 2004, LEUKEMIA, V18, P1406, DOI 10.1038/sj.leu.2403406; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002; Gomez-Lazaro M, 2004, J PHYSIOL BIOCHEM, V60, P287, DOI 10.1007/BF03167075; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; MILNER J, 1987, ONCOGENE, V1, P453; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ohnishi T, 1999, INT J RADIAT BIOL, V75, P1095; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232	31	53	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					783	793		10.1038/sj.onc.1210666	http://dx.doi.org/10.1038/sj.onc.1210666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17637740				2022-12-28	WOS:000252884500007
J	Venkatachalam, P; de Toledo, S; Pandey, B; Tephly, L; Carter, A; Little, J; Spitz, D; Azzam, E				Venkatachalam, P.; de Toledo, Sm; Pandey, Bn; Tephly, La; Carter, Ab; Little, Jb; Spitz, Dr; Azzam, Ei			Regulation of normal cell cycle progression by flavin-containing oxidases	ONCOGENE			English	Article						flavin-containing oxidases; NAD(P)H oxidase/nitric oxide synthase; reactive oxygen species; cellular proliferation/G1 checkpoint/G2 checkpoint; ATM/p53/p21(Waf1)/p38(MAPK)/cyclin D1	NORMAL HUMAN FIBROBLASTS; DOSE IONIZING-RADIATION; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; DIPHENYLENE IODONIUM; NADPH OXIDASE; FREE-RADICALS; DNA-SYNTHESIS; SUPEROXIDE; KINASE	Mechanisms underlying the role of reactive oxygen species (ROS) generated by flavin-containing oxidases in regulating cell cycle progression were examined in human and rodent fibroblasts. Incubation of confluent cell cultures with nontoxic/nonclastogenic concentrations of the flavoprotein inhibitor, diphenyleneiodonium (DPI), reduced nicotinamide adenine dinucleotide phosphate (NAD(P) H) oxidase activity and basal ROS levels, but increased proteolysis of cyclin D1, p21(Waf1) and phospho-p38(MAPK). When these cells were allowed to proliferate by subculture in DPI-free medium, an extensive G(1) delay was observed with concomitant activation of p53/p21(Waf1) signaling and reduced phosphorylation of mitogen-activated kinases. Compensation for decreased oxidant generation by simultaneous exposure to DPI and nontoxic doses of the ROS generators, gamma-radiation or t-butyl-hydroperoxide, attenuated the G(1) delay. Whereas the DPI-induced G(1) checkpoint was completely dependent on PHOX91, ATM and WAF1, it was only partially dependent on P53. Interestingly, G(1) to S progression was not affected when another flavin-containing enzyme, nitric oxide synthase, was inhibited nor was it associated with changes in mitochondrial membrane potential. Proliferating cells treated with DPI also experienced a significant but attenuated delay in G(2). We propose that ATM performs a critical function in mediating normal cellular proliferation that is regulated by nonphagocytic NAD(P)H oxidase enzymes activity, which may serve as a novel target for arresting cancer cells in G1.	[Venkatachalam, P.; de Toledo, Sm; Pandey, Bn; Azzam, Ei] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, Newark, NJ 07101 USA; [Tephly, La; Carter, Ab] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Med, Iowa City, IA USA; [Little, Jb] Harvard Univ, Sch Publ Hlth, Ctr Radiat Sci & Environm Hlth, Boston, MA 02115 USA; [Spitz, Dr] Univ Iowa, Holden Comprehens Canc Ctr, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Iowa City, IA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Iowa; Harvard University; Harvard T.H. Chan School of Public Health; University of Iowa	Azzam, E (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, 185 S Orange Ave,MSB F-451, Newark, NJ 07101 USA.	azzamei@umdnj.edu	Venkatachalam, Perumal/AAU-9320-2020	Venkatachalam, Perumal/0000-0003-2152-2003; Spitz, Douglas/0000-0002-1254-8765	NCI NIH HHS [CA92262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092262] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2002, CANCER LETT, V177, P111, DOI 10.1016/S0304-3835(01)00785-6; Ammendola R, 2002, ARCH BIOCHEM BIOPHYS, V397, P253, DOI 10.1006/abbi.2001.2641; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 1996, RADIAT RES, V146, P369, DOI 10.2307/3579298; Azzam EI, 2000, CANCER RES, V60, P2623; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BEGG AC, 1985, CYTOMETRY, V6, P620, DOI 10.1002/cyto.990060618; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cals-Grierson MM, 2004, NITRIC OXIDE-BIOL CH, V10, P179, DOI 10.1016/j.niox.2004.04.005; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; de Toledo SM, 2006, RADIAT RES, V166, P849, DOI 10.1667/RR0640.1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Esposito F, 2001, IUBMB LIFE, V52, P67, DOI 10.1080/15216540252774793; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; Frigo DE, 2006, MOL ENDOCRINOL, V20, P971, DOI 10.1210/me.2004-0075; Gordon DM, 2000, ESSAYS BIOCHEM, V36, P61, DOI 10.1042/bse0360061; Halliwell B, 1996, BIOCHEM SOC T, V24, P1023, DOI 10.1042/bst0241023; Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LI WG, 2001, J BIOL CHEM, V17, P17; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LITTLE JB, 1994, RADIAT RES, V140, P299, DOI 10.2307/3579106; Maki CG, 1996, CANCER RES, V56, P2649; Matsumoto H, 2007, J RADIAT RES, V48, P97, DOI 10.1269/jrr.06090; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Menon SG, 2003, CANCER RES, V63, P2109; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NAGASAWA H, 1995, CANCER RES, V55, P1842; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pandey BN, 2006, ANTIOXID REDOX SIGN, V8, P1253, DOI 10.1089/ars.2006.8.1253; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schulze-Osthoff Klaus, 1997, P239; Spitz DR, 2004, CANCER METAST REV, V23, P311, DOI 10.1023/B:CANC.0000031769.14728.bc; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TERASIMA T, 1963, SCIENCE, V140, P490, DOI 10.1126/science.140.3566.490; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	56	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					20	31		10.1038/sj.onc.1210634	http://dx.doi.org/10.1038/sj.onc.1210634			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17637756				2022-12-28	WOS:000252118700003
J	Parthun, MR				Parthun, M. R.			Hat1: the emerging cellular roles of a type B histone acetyltransferase	ONCOGENE			English	Review						histone; chromatin; acetylation; acetyltransferase; chromatin assembly	ASSEMBLY FACTOR-I; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; CHROMATIN REPLICATION; H4 ACETYLTRANSFERASE; NEGATIVE REGULATOR; ACETYLATION SITES; CRYSTAL-STRUCTURE; MAIZE EMBRYOS; HIR PROTEINS	Hat1 is the sole known example of a type B histone acetyltransferase. While it has long been presumed that type B histone acetyltransferases participate in the acetylation of newly synthesized histones during the process of chromatin assembly, definitive evidence linking these enzymes to this process has been scarce. This review will discuss recent results that have begun to shed light on the roles of Hat1 and also address several outstanding questions relating to the cellular function of this enzyme.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Parthun, MR (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 411 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	parthun.1@osu.edu			NIGMS NIH HHS [R01 GM062970, R01 GM62970] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062970] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; Ahmad A, 2001, NUCLEIC ACIDS RES, V29, P629, DOI 10.1093/nar/29.3.629; Ahmad S, 2000, IETE J RES, V46, P2, DOI 10.1080/03772063.2000.11416128; Ai X, 2004, MOL CELL, V14, P195, DOI 10.1016/S1097-2765(04)00184-4; Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Barman HK, 2006, BIOCHEM BIOPH RES CO, V345, P1547, DOI 10.1016/j.bbrc.2006.05.079; Benson LJ, 2007, J BIOL CHEM, V282, P836, DOI 10.1074/jbc.M607464200; Benson LJ, 2006, J BIOL CHEM, V281, P9287, DOI 10.1074/jbc.M512956200; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; DECKER RS, 1987, J BIOL CHEM, V262, P10863; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Eberharter A, 1996, FEBS LETT, V386, P75, DOI 10.1016/0014-5793(96)00401-2; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Furuyama T, 2006, P NATL ACAD SCI USA, V103, P6172, DOI 10.1073/pnas.0601686103; Gaillard PHL, 1997, EMBO J, V16, P6281, DOI 10.1093/emboj/16.20.6281; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GARCEA RL, 1980, J BIOL CHEM, V255, P1454; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Imhof A, 1999, BIOCHEMISTRY-US, V38, P13085, DOI 10.1021/bi9912490; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014; John S, 2000, GENE DEV, V14, P1196; Kaufman PD, 1998, MOL CELL BIOL, V18, P4793, DOI 10.1128/MCB.18.8.4793; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Krawitz DC, 2002, MOL CELL BIOL, V22, P614, DOI 10.1128/MCB.22.2.614-625.2002; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; Lim DA, 2006, MOL CELL NEUROSCI, V31, P131, DOI 10.1016/j.mcn.2005.10.005; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; LOPEZRODAS G, 1991, BIOCHEMISTRY-US, V30, P3728, DOI 10.1021/bi00229a020; LOUIE AJ, 1973, COLD SPRING HARB SYM, V38, P803, DOI 10.1101/SQB.1974.038.01.084; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Lusser A, 1999, NUCLEIC ACIDS RES, V27, P4427, DOI 10.1093/nar/27.22.4427; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; Makowski AM, 2001, J BIOL CHEM, V276, P43499, DOI 10.1074/jbc.C100549200; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; MINGARRO I, 1993, J BIOL CHEM, V268, P13248; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Park IK, 2002, BLOOD, V99, P488, DOI 10.1182/blood.V99.2.488; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pogribny IP, 2007, J NUTR, V137, p216S, DOI 10.1093/jn/137.1.216S; Poveda A, 2004, J BIOL CHEM, V279, P16033, DOI 10.1074/jbc.M314228200; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Qin S, 2006, MOL CELL BIOL, V26, P3649, DOI 10.1128/MCB.26.9.3649-3658.2006; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Seiden-Long IM, 2006, ONCOGENE, V25, P91, DOI 10.1038/sj.onc.1209005; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; Singer MS, 1998, GENETICS, V150, P613; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SURES I, 1980, BIOCHEMISTRY-US, V19, P943, DOI 10.1021/bi00546a019; Suter B, 2004, GENETICS, V167, P579, DOI 10.1534/genetics.103.024851; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Vermaak D, 1999, MOL CELL BIOL, V19, P5847; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; WIEGAND RC, 1981, J BIOL CHEM, V256, P4578; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Zhang K, 2005, J CELL BIOCHEM, V96, P1137, DOI 10.1002/jcb.20615; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	86	132	135	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5319	5328		10.1038/sj.onc.1210602	http://dx.doi.org/10.1038/sj.onc.1210602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694075				2022-12-28	WOS:000248674300002
J	Martin, D; Galisteo, R; Ji, Y; Montaner, S; Gutkind, JS				Martin, D.; Galisteo, R.; Ji, Y.; Montaner, S.; Gutkind, J. S.			An NF-kappa B gene expression signature contributes to Kaposi's sarcoma virus vGPCR-induced direct and paracrine neoplasia	ONCOGENE			English	Article						G proteins; signal transduction; G protein coupled receptors; angiosarcoma; endothelial cell; angiogenesis	PROTEIN-COUPLED-RECEPTOR; HERPESVIRUS; KSHV; CELL; CANCER; ANGIOGENESIS; SURVIVAL; PROMOTE	Kaposi's sarcoma (KS) is the most frequent AIDS-associated malignancy, etiologically linked to the infection with the human herpesvirus 8 (HHV-8/KSHV). This member of the gamma-herpesviridae family encodes 81 open reading frames, several bearing oncogenic potential. A constitutively active virally encoded G protein-coupled receptor (vGPCR) readily induces KS-like lesions when expressed in endothelial cells in vivo, and unmasks the oncogenic potential of other HHV-8 genes in a paracrine fashion. How vGPCR causes endothelial cell transformation is still not fully understood. Using full-genome microarray analysis we show here that the expression of nuclear factor-kappa B (NF-kappa B)regulated genes is a prominent feature triggered by vGPCR in cells expressing this viral oncogene and in cells exposed to vGPCR-induced secretions, thus mimicking its paracrine effect. Indeed, vGPCR activates the NF-kappa B pathway potently, and NF-kappa B activation is a hallmark of both human and experimental KS. Of interest, whereas constitutive NF-kappa B signaling is not sufficient to promote endothelial cells transformation, NF-kappa B function is strictly required for vGPCR-induced direct and paracrine neoplasia. Taken together, these results strongly support the role of NF-kappa B regulated genes in KS pathogenesis, thus providing the rationale for the development of novel mechanism-based therapies for this angioproliferative disease.	[Martin, D.; Galisteo, R.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, NIH, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA; [Ji, Y.; Montaner, S.] Univ Maryland, Dept Diagnost Sci & Pathol, Baltimore, MD 21201 USA; [Ji, Y.; Montaner, S.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, NIH, Oral & Pharyngeal Canc Branch, 30 Convent Dr,Bldg 30,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Abrams, William R/A-5782-2008; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Martin Izquierdo, Daniel/0000-0002-8880-9087	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Asou H, 1998, BLOOD, V91, P2475, DOI 10.1182/blood.V91.7.2475.2475_2475_2481; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126; Bower M, 2006, CURR OPIN INFECT DIS, V19, P14, DOI 10.1097/01.qco.0000200295.30285.13; Cesarman E, 2007, CURR TOP MICROBIOL, V312, P263; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hamilton TA, 2002, IMMUNOL RES, V25, P229, DOI 10.1385/IR:25:3:229; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Kanegane H, 1997, J INFECT DIS, V176, P254, DOI 10.1086/517260; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Montaner S, 2006, CANCER RES, V66, P168, DOI 10.1158/0008-5472.CAN-05-1026; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Morris K, 2003, LANCET ONCOL, V4, P5, DOI 10.1016/S1470-2045(03)00969-0; Mutlu AD, 2007, CANCER CELL, V11, P245, DOI 10.1016/j.ccr.2007.01.015; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Rezza G, 1999, J NATL CANCER I, V91, P1468, DOI 10.1093/jnci/91.17.1468; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; SCIACCA FL, 1994, J IMMUNOL, V153, P4816; Sodhi A, 2004, NAT REV MOL CELL BIO, V5, P998, DOI 10.1038/nrm1529; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	27	162	167	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1844	1852		10.1038/sj.onc.1210817	http://dx.doi.org/10.1038/sj.onc.1210817			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17934524				2022-12-28	WOS:000254150600004
